Effect	NN	O
of	IN	O
duloxetine	NN	O
on	IN	O
pain	NN	PA
,	,	O
function	NN	PH
,	,	O
and	CC	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
among	IN	O
patients	NNS	O
with	IN	O
chemotherapy-induced	JJ	O
painful	JJ	O
peripheral	JJ	O
neuropathy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	NNP	O
There	EX	O
are	VBP	O
no	DT	O
known	JJ	O
effective	JJ	O
treatments	NNS	O
for	IN	O
painful	JJ	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
duloxetine	NN	O
,	,	O
60	CD	O
mg	JJ	O
daily	RB	O
,	,	O
on	IN	O
average	JJ	PA
pain	NN	PA
severity	NN	PA
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
trial	NN	O
at	IN	O
8	CD	O
National	NNP	O
Cancer	NNP	O
Institute	NNP	O
(	(	O
NCI	NNP	O
)	)	O
-funded	VBD	O
cooperative	JJ	O
research	NN	O
networks	NNS	O
that	WDT	O
enrolled	VBD	O
231	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
25	CD	O
years	NNS	O
or	CC	O
older	JJR	O
being	VBG	O
treated	VBN	O
at	IN	O
community	NN	O
and	CC	O
academic	JJ	O
settings	NNS	O
between	IN	O
April	NNP	O
2008	CD	O
and	CC	O
March	NNP	O
2011	CD	O
.	.	O

Study	NNP	O
follow-up	NN	O
was	VBD	O
completed	VBN	O
July	NNP	O
2012	CD	O
.	.	O

Stratified	VBN	O
by	IN	O
chemotherapeutic	JJ	O
drug	NN	O
and	CC	O
comorbid	NN	O
pain	NN	O
risk	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
duloxetine	NN	O
followed	VBN	O
by	IN	O
placebo	NN	O
or	CC	O
placebo	NN	O
followed	VBN	O
by	IN	O
duloxetine	NN	O
.	.	O

Eligibility	NN	O
required	VBD	O
that	IN	O
patients	NNS	O
have	VBP	O
grade	VBN	O
1	CD	O
or	CC	O
higher	JJR	O
sensory	NN	O
neuropathy	JJ	O
according	VBG	O
to	TO	O
the	DT	O
NCI	NNP	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNS	O
and	CC	O
at	IN	O
least	JJS	O
4	CD	O
on	IN	O
a	DT	O
scale	NN	O
of	IN	O
0	CD	O
to	TO	O
10	CD	O
,	,	O
representing	VBG	O
average	JJ	O
chemotherapy-induced	JJ	O
pain	NN	O
,	,	O
after	IN	O
paclitaxel	NN	O
,	,	O
other	JJ	O
taxane	NN	O
,	,	O
or	CC	O
oxaliplatin	JJ	O
treatment	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
initial	JJ	O
treatment	NN	O
consisted	VBN	O
of	IN	O
taking	VBG	O
1	CD	O
capsule	JJ	O
daily	RB	O
of	IN	O
either	CC	O
30	CD	O
mg	NN	O
of	IN	O
duloxetine	NN	O
or	CC	O
placebo	NN	O
for	IN	O
the	DT	O
first	JJ	O
week	NN	O
and	CC	O
2	CD	O
capsules	NNS	O
of	IN	O
either	DT	O
30	CD	O
mg	NN	O
of	IN	O
duloxetine	NN	O
or	CC	O
placebo	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
additional	JJ	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
hypothesis	NN	O
was	VBD	O
that	IN	O
duloxetine	NN	O
would	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
decreasing	VBG	O
chemotherapy-induced	JJ	PA
peripheral	JJ	PA
neuropathic	JJ	PA
pain	NN	PA
.	.	O

Pain	NNP	PA
severity	NN	PA
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Brief	JJ	PA
Pain	NNP	PA
Inventory-Short	NNP	PA
Form	NNP	PA
average	NN	PA
pain	NN	PA
item	NN	PA
with	IN	O
0	CD	O
representing	VBG	O
no	DT	O
pain	NN	PA
and	CC	O
10	CD	O
representing	VBG	O
as	RB	O
bad	JJ	O
as	IN	O
can	MD	O
be	VB	O
imagined	VBN	O
.	.	O

RESULTS	JJ	O
Individuals	NNS	O
receiving	VBG	O
duloxetine	NN	O
as	IN	O
their	PRP$	O
initial	JJ	O
5-week	JJ	O
treatment	NN	O
reported	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
average	JJ	O
pain	NN	O
of	IN	O
1.06	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.72-1.40	NNP	O
)	)	O
vs	VBZ	O
0.34	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-0.66	NNP	O
)	)	O
among	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
;	:	O
effect	NN	O
size	NN	O
,	,	O
0.513	CD	O
)	)	O
.	.	O

The	DT	O
observed	JJ	O
mean	JJ	O
difference	NN	O
in	IN	O
the	DT	O
average	JJ	PA
pain	NN	PA
score	NN	PA
between	IN	O
duloxetine	NN	O
and	CC	O
placebo	NN	O
was	VBD	O
0.73	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.26-1.20	NN	O
)	)	O
.	.	O

Fifty-nine	JJ	O
percent	NN	O
of	IN	O
those	DT	O
initially	RB	O
receiving	VBG	O
duloxetine	NN	O
vs	FW	O
38	CD	O
%	NN	O
of	IN	O
those	DT	O
initially	RB	O
receiving	VBG	O
placebo	NN	O
reported	VBD	O
decreased	JJ	O
pain	NN	PA
of	IN	O
any	DT	O
amount	NN	O
.	.	O

CONCLUSION	NNP	O
AND	CC	O
RELEVANCE	NNP	O
Among	IN	O
patients	NNS	O
with	IN	O
painful	JJ	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
duloxetine	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
greater	JJR	O
reduction	NN	O
in	IN	O
pain	NN	PA
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00489411	NN	O
.	.	O

Need	NN	O
for	IN	O
insulin	NN	O
therapy	NN	O
in	IN	O
type	NN	O
II	NNP	O
diabetes	VBZ	O
mellitus	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

To	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
type	JJ	O
II	NNP	O
diabetes	VBZ	O
mellitus	NN	O
for	IN	O
whom	WP	O
insulin	NN	O
therapy	NN	O
is	VBZ	O
most	RBS	O
beneficial	JJ	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
in	IN	O
the	DT	O
general	JJ	O
medicine	NN	O
clinic	NN	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

Asymptomatic	NNP	O
,	,	O
obese	JJ	O
,	,	O
insulin-treated	JJ	O
patients	NNS	O
were	VBD	O
given	VBN	O
diet	JJ	O
and	CC	O
diabetes	VBZ	O
education	NN	O
and	CC	O
,	,	O
in	IN	O
half	NN	O
of	IN	O
these	DT	O
patients	NNS	O
,	,	O
insulin	JJ	O
therapy	NN	O
was	VBD	O
withdrawn	VBN	O
.	.	O

Over	IN	O
six	CD	O
months	NNS	O
,	,	O
patients	NNS	O
developing	VBG	O
hyperglycemic	JJ	PH
symptoms	NNS	PH
or	CC	PH
acetonemia	NN	PH
were	VBD	O
counted	VBN	O
as	IN	O
study	NN	O
failures	NNS	O
.	.	O

Failure	NN	PH
criteria	NNS	PH
developed	VBD	O
in	IN	O
13	CD	O
of	IN	O
25	CD	O
insulin-withdrawal	JJ	O
patients	NNS	O
,	,	O
at	IN	O
a	DT	O
median	NN	O
of	IN	O
four	CD	O
weeks	NNS	O
after	IN	O
withdrawal	NN	O
,	,	O
compared	VBN	O
with	IN	O
two	CD	O
of	IN	O
24	CD	O
control	NN	O
subjects	NNS	O
.	.	O

Elevated	VBN	PH
stimulated	VBD	PH
glucose	JJ	PH
levels	NNS	PH
predicted	VBD	O
the	DT	O
need	NN	O
for	IN	O
insulin	JJ	O
therapy	NN	O
.	.	O

Hyperglycemia	NNP	PH
worsened	VBD	O
in	IN	O
insulin-withdrawal	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
meet	VB	O
study	JJ	O
failure	NN	O
criteria	NNS	O
,	,	O
but	CC	O
it	PRP	O
improved	VBD	O
in	IN	O
control	NN	O
patients	NNS	O
.	.	O

Study	NNP	O
patients	NNS	O
were	VBD	O
insulin	JJ	O
deficient	NN	O
as	IN	O
shown	VBN	O
by	IN	O
low	JJ	O
baseline	NN	PH
C	NNP	PH
peptide	NN	PH
values	NNS	PH
(	(	O
0.43	CD	O
+/-	JJ	O
0.05	CD	O
nmol/L	NN	O
)	)	O
.	.	O

The	DT	O
prompt	JJ	O
metabolic	JJ	O
decompensation	NN	O
precipitated	VBN	O
by	IN	O
insulin	NN	O
withdrawal	NN	O
suggests	VBZ	O
that	IN	O
insulin-deficient	JJ	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
insulin	NN	O
therapy	NN	O
and	CC	O
may	MD	O
need	VB	O
it	PRP	O
to	TO	O
prevent	VB	O
symptomatic	JJ	PH
hyperglycemia	NN	PH
.	.	O

Short-term	JJ	O
effects	NNS	O
of	IN	O
prednisolone	NN	O
and	CC	O
dexamethasone	NN	O
on	IN	O
circulating	VBG	PH
concentrations	NNS	PH
of	IN	PH
leptin	NN	PH
and	CC	PH
sex	NN	PH
hormone-binding	JJ	PH
globulin	NN	PH
in	IN	O
children	NNS	O
being	VBG	O
treated	VBN	O
for	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
.	.	O

OBJECTIVE	NNP	O
Disturbances	NNPS	O
in	IN	O
body	NN	O
weight	JJ	O
regulation	NN	O
are	VBP	O
often	RB	O
encountered	VBN	O
during	IN	O
glucocorticoid	JJ	O
treatment	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
increased	JJ	O
insulin	NN	O
resistance	NN	O
and	CC	O
truncal	JJ	O
fat	NN	O
accumulation	NN	O
.	.	O

Children	NNP	O
were	VBD	O
investigated	VBN	O
who	WP	O
were	VBD	O
receiving	VBG	O
glucocorticoid	JJ	O
treatment	NN	O
for	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
(	(	O
ALL	DT	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
prednisolone	VB	O
or	CC	O
dexamethasone	VB	O
as	IN	O
part	NN	O
of	IN	O
induction	NN	O
of	IN	O
remission	NN	O
.	.	O

This	DT	O
randomization	NN	O
process	NN	O
provided	VBD	O
a	DT	O
suitable	JJ	O
opportunity	NN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
these	DT	O
two	CD	O
administered	VBD	O
steroid	NN	O
on	IN	O
surrogate	JJ	O
markers	NNS	O
of	IN	O
adipocyte	NN	O
activity	NN	O
(	(	O
leptin	NN	O
)	)	O
and	CC	O
hyperinsulinaemia/insulin	JJ	O
resistance	NN	O
(	(	O
SHBG	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
AND	CC	O
PATIENTS	NNP	O
Prospective	NNP	O
study	NN	O
over	IN	O
16	CD	O
weeks	NNS	O
of	IN	O
children	NNS	O
randomized	VBN	O
to	TO	O
receive	VB	O
prednisolone	NN	O
(	(	O
40	CD	O
mg/m2	NN	O
)	)	O
or	CC	O
dexamethasone	NN	O
(	(	O
6.5	CD	O
mg/m2	NN	O
)	)	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
MRC-ALL97/99	NNP	O
induction	NN	O
chemotherapy	NN	O
for	IN	O
ALL	NNP	O
.	.	O

Nineteen	NNP	O
children	NNS	O
(	(	O
8	CD	O
male	NN	O
,	,	O
11	CD	O
female	NN	O
)	)	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
5.9	CD	O
years	NNS	O
(	(	O
range	VB	O
2.6-13	CD	O
years	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

Main	NNP	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
body	JJ	PH
mass	NN	PH
index	NN	PH
(	(	PH
BMI	NNP	PH
)	)	PH
,	,	O
serum	JJ	PH
leptin	NN	PH
and	CC	PH
sex	NN	PH
hormone	NN	PH
binding	VBG	PH
globulin	NN	PH
(	(	PH
SHBG	NNP	PH
)	)	PH
.	.	O

RESULTS	NNP	O
Glucocorticoid	NNP	O
administration	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
increases	NNS	O
in	IN	O
BMI	NNP	PH
,	,	O
leptin	NN	PH
(	(	PH
corrected	VBN	PH
for	IN	PH
BMI	NNP	PH
)	)	PH
and	CC	PH
the	DT	PH
leptin	NN	PH
:	:	PH
SHBG	NNP	PH
ratio	NN	PH
and	CC	PH
lowering	NN	PH
of	IN	PH
SHBG	NNP	PH
.	.	O

Dose	NNP	O
for	IN	O
dose	NN	O
,	,	O
dexamethasone	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
potent	JJ	O
than	IN	O
prednisolone	NN	O
in	IN	O
altering	VBG	O
these	DT	O
parameters	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
glucocorticoid	NN	O
treatment	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
BMI	NNP	O
,	,	O
leptin	NN	O
and	CC	O
SHBG	NNP	O
.	.	O

The	DT	O
leptin	NN	O
:	:	O
SHBG	NNP	O
ratio	NN	O
increase	NN	O
indicates	VBZ	O
that	IN	O
this	DT	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
and	CC	O
sensitive	JJ	O
biochemical	JJ	O
marker	NN	O
of	IN	O
metabolic	JJ	O
change	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
glucocorticoid	JJ	O
treatment	NN	O
regimens	NNS	O
should	MD	O
be	VB	O
kept	VBN	O
as	RB	O
short	JJ	O
as	IN	O
possible	JJ	O
to	TO	O
avoid	VB	O
possible	JJ	O
detrimental	JJ	O
effects	NNS	O
associated	VBN	O
with	IN	O
increased	JJ	O
adiposity	NN	O
and	CC	O
insulin	NN	O
resistance	NN	O
.	.	O

Side	NNP	O
branch	NN	O
occlusion	NN	O
with	IN	O
everolimus-eluting	JJ	O
and	CC	O
paclitaxel-eluting	JJ	O
stents	NNS	O
:	:	O
three-year	JJ	O
results	NNS	O
from	IN	O
the	DT	O
SPIRIT	NNP	O
III	NNP	O
randomised	VBD	O
trial	NN	O
.	.	O

AIMS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
rates	NNS	O
of	IN	O
side	NN	O
branch	NN	O
occlusion	NN	O
and	CC	O
subsequent	JJ	O
periprocedural	JJ	O
MI	NNP	O
during	IN	O
everolimus-eluting	JJ	O
stent	NN	O
(	(	O
EES	NNP	O
)	)	O
and	CC	O
paclitaxel-eluting	JJ	O
stent	NN	O
(	(	O
PES	NNP	O
)	)	O
placement	NN	O
were	VBD	O
examined	VBN	O
in	IN	O
the	DT	O
randomised	JJ	O
SPIRIT	NNP	O
III	NNP	O
trial	NN	O
.	.	O

Periprocedural	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
following	VBG	O
drug-eluting	JJ	O
stent	JJ	O
placement	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
long-term	JJ	O
adverse	JJ	O
outcomes	NNS	O
.	.	O

Occlusion	NN	O
of	IN	O
side	NN	O
branches	NNS	O
may	MD	O
be	VB	O
an	DT	O
important	JJ	O
factor	NN	O
contributing	VBG	O
to	TO	O
periprocedural	JJ	O
MIs	NNP	O
.	.	O

Consecutive	JJ	O
procedural	JJ	O
angiograms	NNS	O
of	IN	O
patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
EES	NNP	O
(	(	O
n=669	NN	O
)	)	O
or	CC	O
PES	NNP	O
(	(	O
n=333	RB	O
)	)	O
were	VBD	O
analysed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
angiographic	JJ	O
core	NN	O
laboratory	NN	O
.	.	O

Side	NNP	O
branch	NN	O
occlusion	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
Thrombolysis	NN	O
In	IN	O
Myocardial	NNP	O
Infarction	NNP	O
(	(	O
TIMI	NNP	O
)	)	O
flow	NN	O
grade	VBD	O
0	CD	O
or	CC	O
1	CD	O
.	.	O

Clinical	JJ	O
outcomes	NNS	O
through	IN	O
three	CD	O
years	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
stent	NN	O
type	NN	O
and	CC	O
presence	NN	O
of	IN	O
side	NN	O
branch	NN	O
occlusion	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
total	NN	O
of	IN	O
2,048	CD	O
side	NN	O
branches	NNS	O
were	VBD	O
evaluated	VBN	O
(	(	O
EES	NNP	O
N=1,345	NNP	O
side	NN	O
branches	NNS	O
in	IN	O
688	CD	O
stented	JJ	O
lesions	NNS	O
,	,	O
PES	NNP	O
N=703	NNP	O
side	NN	O
branches	NNS	O
in	IN	O
346	CD	O
stented	JJ	O
lesions	NNS	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
compared	VBN	O
to	TO	O
those	DT	O
without	IN	O
transient	NN	O
or	CC	O
final	JJ	O
side	NN	O
branch	NN	O
occlusion	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
non-Q-wave	JJ	PH
MI	NNP	PH
(	(	PH
NQMI	NNP	PH
)	)	PH
rates	NNS	PH
in-hospital	JJ	O
(	(	O
9.0	CD	O
%	NN	O
vs.	FW	O
0.5	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

By	IN	O
multivariable	JJ	O
analysis	NN	O
side	NN	O
branch	NN	O
occlusion	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
NQMI	NNP	PH
(	(	O
OR	NNP	O
4.45	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
1.82	CD	O
,	,	O
10.85	CD	O
]	NN	O
)	)	O
.	.	O

Transient	NN	O
or	CC	O
final	JJ	O
side	NN	O
branch	NN	O
occlusion	NN	O
occurred	VBD	O
less	RBR	O
frequently	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
EES	NNP	O
compared	VBN	O
to	TO	O
PES	NNP	O
(	(	O
2.8	CD	O
%	NN	O
vs.	FW	O
5.2	CD	O
%	NN	O
,	,	O
p=0.009	NN	O
)	)	O
,	,	O
contributing	VBG	O
to	TO	O
the	DT	O
numerically	RB	O
lower	JJR	O
rates	NNS	PH
of	IN	PH
in-hospital	JJ	PH
NQMI	NNP	PH
with	IN	O
EES	NNP	O
arm	NN	O
compared	VBN	O
to	TO	O
PES	NNP	O
(	(	O
0.7	CD	O
%	NN	O
vs.	FW	O
2.3	CD	O
%	NN	O
,	,	O
p=0.05	NN	O
)	)	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
EES	NNP	O
rather	RB	O
than	IN	O
PES	NNP	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
develop	VB	O
side	JJ	PH
branch	NN	PH
occlusion	NN	PH
during	IN	O
stent	JJ	O
placement	NN	O
,	,	O
contributing	VBG	O
to	TO	O
lower	VB	O
rates	NNS	O
of	IN	O
periprocedural	JJ	O
MI	NNP	O
with	IN	O
EES	NNP	O
compared	VBN	O
to	TO	O
PES	NNP	O
.	.	O

Safety	NN	Ot
of	IN	O
ferumoxytol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
anemia	NN	O
and	CC	O
CKD	NNP	O
.	.	O

BACKGROUND	NNP	O
Iron	NNP	O
deficiency	NN	O
anemia	NN	O
is	VBZ	O
a	DT	O
common	JJ	O
complication	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
.	.	O

Currently	NNP	O
available	JJ	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
iron	NN	O
replacement	NN	O
therapies	NNS	O
have	VBP	O
either	DT	O
inconvenient	JJ	O
regimens	NNS	O
of	IN	O
administration	NN	O
or	CC	O
adverse	JJ	O
event	NN	O
profiles	NNS	O
that	WDT	O
limit	VBP	O
their	PRP$	O
utility	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

Ferumoxytol	NNP	O
is	VBZ	O
a	DT	O
novel	NN	O
,	,	O
semisynthetic	JJ	O
,	,	O
carbohydrate-coated	JJ	O
,	,	O
superparamagnetic	JJ	O
iron	NN	O
oxide	NN	O
nanoparticle	NN	O
that	WDT	O
is	VBZ	O
administered	VBN	O
IV	NNP	O
as	IN	O
an	DT	O
injection	NN	O
.	.	O

The	DT	O
main	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	Ot
of	IN	O
ferumoxytol	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
CKD	NNP	O
stages	VBZ	O
1	CD	O
to	TO	O
5	CD	O
and	CC	O
5D	CD	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Phase	NNP	O
3	CD	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
,	,	O
multicenter	NN	O
study	NN	O
of	IN	O
a	DT	O
single	JJ	O
510-mg	JJ	O
dose	NN	O
of	IN	O
ferumoxytol	JJ	O
versus	NN	O
saline	NN	O
as	IN	O
placebo	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
750	CD	O
patients	NNS	O
with	IN	O
CKD	NNP	O
stages	VBZ	O
1	CD	O
to	TO	O
5	CD	O
and	CC	O
5D	CD	O
.	.	O

INTERVENTION	NNP	O
An	DT	O
IV	NNP	O
injection	NN	O
of	IN	O
either	CC	O
17	CD	O
mL	NN	O
of	IN	O
ferumoxytol	NN	O
or	CC	O
saline	NN	O
placebo	NN	O
over	IN	O
17	CD	O
seconds	NNS	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
the	DT	O
alternate	NN	O
agent	NN	O
on	IN	O
day	NN	O
7	CD	O
.	.	O

OUTCOMES	NNP	O
&	CC	O
MEASUREMENTS	NNP	O
Descriptive	NNP	O
comparison	NN	O
of	IN	O
adverse	JJ	A
events	NNS	A
,	,	O
laboratory	NN	PH
tests	NNS	PH
,	,	PH
and	CC	PH
vital	JJ	PH
signs	NNS	PH
.	.	O

RESULTS	NNP	O
Of	IN	O
750	CD	O
randomly	NNS	O
assigned	VBD	O
patients	NNS	O
with	IN	O
CKD	NNP	O
,	,	O
60	CD	O
%	NN	O
were	VBD	O
not	RB	O
on	IN	O
dialysis	NN	O
therapy	NN	O
.	.	O

713	CD	O
patients	NNS	O
received	VBD	O
ferumoxytol	JJ	O
,	,	O
and	CC	O
711	CD	O
received	VBD	O
placebo	NN	O
.	.	O

There	EX	O
were	VBD	O
420	CD	O
adverse	JJ	A
events	NNS	A
reported	VBD	O
;	:	O
242	CD	O
in	IN	O
152	CD	O
patients	NNS	O
(	(	O
21.3	CD	O
%	NN	O
)	)	O
with	IN	O
ferumoxytol	NN	O
and	CC	O
178	CD	O
in	IN	O
119	CD	O
patients	NNS	O
(	(	O
16.7	CD	O
%	NN	O
)	)	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
incidence	NN	A
of	IN	A
related	JJ	A
adverse	JJ	A
events	NNS	A
was	VBD	O
5.2	CD	O
%	NN	O
with	IN	O
ferumoxytol	NN	O
and	CC	O
4.5	CD	O
%	NN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
related	JJ	O
adverse	JJ	A
events	NNS	A
after	IN	O
each	DT	O
treatment	NN	O
included	VBD	O
symptoms	NNS	A
related	VBN	O
to	TO	O
the	DT	O
injection/infusion	NN	A
site	NN	A
,	,	A
dizziness	NN	A
,	,	A
pruritus	NN	A
,	,	A
headache	NN	A
,	,	A
fatigue	NN	A
,	,	A
and	CC	A
nausea	NN	A
.	.	A

Serious	JJ	A
adverse	JJ	A
events	NNS	A
occurred	VBD	O
in	IN	O
21	CD	O
patients	NNS	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
after	IN	O
ferumoxytol	NN	O
and	CC	O
13	CD	O
patients	NNS	O
(	(	O
1.8	CD	O
%	NN	O
)	)	O
after	IN	O
placebo	NN	O
.	.	O

Serious	JJ	A
related	JJ	A
adverse	JJ	A
events	NNS	A
were	VBD	O
observed	VBN	O
in	IN	O
1	CD	O
patient	NN	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
meaningful	JJ	O
decrease	NN	O
in	IN	O
blood	NN	PH
pressure	NN	PH
after	IN	O
administration	NN	O
of	IN	O
ferumoxytol	NN	O
or	CC	O
placebo	NN	O
.	.	O

LIMITATIONS	NNP	O
Follow-up	NNP	O
was	VBD	O
7	CD	O
days	NNS	O
after	IN	O
each	DT	O
study	NN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Ferumoxytol	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	Ot
and	CC	O
has	VBZ	O
a	DT	O
safety	NN	Ot
profile	NN	Ot
similar	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
anemic	JJ	O
patients	NNS	O
with	IN	O
CKD	NNP	O
stages	VBZ	O
1	CD	O
to	TO	O
5	CD	O
and	CC	O
5D	CD	O
.	.	O

[	JJ	O
Efficacy	NNP	O
of	IN	O
naftopidil	NN	O
in	IN	O
patients	NNS	O
with	IN	O
overactive	JJ	O
bladder	NN	O
associated	VBN	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
:	:	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
to	TO	O
compare	VB	O
differences	NNS	O
in	IN	O
efficacy	NN	O
between	IN	O
morning	NN	O
and	CC	O
evening	VBG	O
medication	NN	O
]	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
100	CD	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
and	CC	O
overactive	JJ	O
bladder	NN	O
(	(	O
OAB	NNP	O
)	)	O
symptoms	NNS	O
(	(	O
BPH/OAB	NNP	O
)	)	O
,	,	O
enrolled	VBN	O
between	IN	O
June	NNP	O
2006	CD	O
to	TO	O
March	NNP	O
2008	CD	O
,	,	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
of	IN	O
morning	NN	O
medication	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
evening	VBG	O
medication	NN	O
(	(	O
E	NNP	O
)	)	O
groups	NNS	O
,	,	O
then	RB	O
50	CD	O
mg	NN	O
of	IN	O
naftopidil	NN	O
was	VBD	O
given	VBN	O
once	RB	O
a	DT	O
day	NN	O
after	IN	O
breakfast	NN	O
or	CC	O
supper	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
efficacy	NN	O
analysis	NN	O
on	IN	O
80	CD	O
patients	NNS	O
(	(	O
M	NNP	O
group	NN	O
;	:	O
43	CD	O
,	,	O
E	NNP	O
group	NN	O
;	:	O
37	CD	O
)	)	O
.	.	O

Naftopidil	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
overall	JJ	Ot
international	JJ	Ot
prostatic	JJ	Ot
symptom	NN	Ot
score	NN	Ot
;	:	O
from	IN	O
19.2?7.9	CD	O
to	TO	O
11.7?5.8	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
and	CC	O
from	IN	O
19.4?6.4	CD	O
to	TO	O
12.3?6.8	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
QOL	NNP	O
score	NN	O
from	IN	O
4.9?0.8	CD	O
to	TO	O
3.2?1.4	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
and	CC	O
from	IN	O
5.0?0.8	CD	O
to	TO	O
3.6?1.3	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
OAB	NNP	O
symptom	VBD	O
score	NN	O
from	IN	O
7.8?2.6	CD	O
to	TO	O
5.0?2.5	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
from	IN	O
8.6?2.9	CD	O
to	TO	O
5.8?	CD	O
3.3	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
M	NNP	O
group	NN	O
(	(	O
6.1	CD	O
%	NN	O
)	)	O
and	CC	O
E	NNP	O
group	NN	O
(	(	O
2.2	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
naftopidil	JJ	O
improves	NNS	O
storage	NN	O
symptoms	NNS	O
as	RB	O
well	RB	O
as	IN	O
voiding	VBG	O
symptoms	NNS	O
regardless	RB	O
of	IN	O
timing	NN	O
of	IN	O
administration	NN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
topical	JJ	O
azithromycin	NN	O
ophthalmic	JJ	O
solution	NN	O
1	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
posterior	JJ	O
blepharitis	NN	O
.	.	O

INTRODUCTION	NNP	O
Azithromycin	NNP	O
,	,	O
a	DT	O
broad-spectrum	JJ	O
antibiotic	JJ	O
with	IN	O
potent	JJ	O
anti-inflammatory	JJ	O
activities	NNS	O
,	,	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
effectively	RB	O
treat	VB	O
blepharitis	NN	PH
,	,	O
an	DT	O
inflammatory	JJ	O
disease	NN	O
of	IN	O
the	DT	O
eyelid	JJ	O
with	IN	O
abnormal	JJ	O
eyelid	JJ	O
flora	NN	O
as	IN	O
an	DT	O
etiologic	JJ	O
determinant	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	Ot
of	IN	O
topical	JJ	O
azithromycin	NN	O
ophthalmic	JJ	O
solution	NN	O
1	CD	O
%	NN	O
(	(	O
AzaSite	NNP	O
;	:	O
Inspire	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Inc	NNP	O
,	,	O
NC	NNP	O
,	,	O
USA	NNP	O
)	)	O
combined	VBD	O
with	IN	O
warm	JJ	O
compresses	NNS	O
(	(	O
azithromycin	JJ	O
group	NN	O
)	)	O
to	TO	O
warm	JJ	O
compresses	NNS	O
alone	RB	O
(	(	O
compress	JJ	O
group	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
posterior	JJ	O
blepharitis	NN	O
.	.	O

METHODS	NNP	O
Twenty-one	CD	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
posterior	JJ	O
blepharitis	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
azithromycin	NN	O
plus	CC	O
warm	JJ	O
compresses	NNS	O
(	(	O
10	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
compresses	VBZ	O
alone	RB	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
apply	VB	O
compresses	NNS	O
to	TO	O
each	DT	O
eye	NN	O
for	IN	O
5-10	JJ	O
minutes	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Each	DT	O
eye	NN	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
also	RB	O
received	VBD	O
azithromycin	JJ	O
solution	NN	O
(	(	O
1	CD	O
drop	NN	O
)	)	O
twice	RB	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
once	RB	O
daily	JJ	O
for	IN	O
the	DT	O
next	JJ	O
12	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
study	NN	O
initiation	NN	O
(	(	O
visit	IN	O
1	CD	O
)	)	O
and	CC	O
at	IN	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
visit	IN	O
2	CD	O
)	)	O
for	IN	O
the	DT	O
severity	NN	O
of	IN	O
five	CD	O
clinical	JJ	O
signs	NNS	O
:	:	O
eyelid	JJ	PH
debris	NN	PH
,	,	O
eyelid	JJ	PH
redness	NN	PH
,	,	O
eyelid	JJ	PH
swelling	NN	PH
,	,	O
meibomian	JJ	PH
gland	NN	PH
(	(	PH
MG	NNP	PH
)	)	PH
plugging	NN	PH
,	,	O
and	CC	O
the	DT	O
quality	NN	PH
of	IN	PH
MG	NNP	PH
secretion	NN	PH
.	.	O

At	IN	O
visit	NN	O
2	CD	O
,	,	O
patients	NNS	O
also	RB	O
rated	VBD	O
their	PRP$	O
degree	NN	O
of	IN	O
overall	JJ	Ot
symptomatic	JJ	Ot
relief	NN	Ot
.	.	O

RESULTS	NNP	O
Twenty	NNP	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

At	IN	O
visit	NN	O
2	CD	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	ME
improvements	NNS	ME
in	IN	O
MG	NNP	PH
plugging	NN	PH
,	,	O
MG	NNP	PH
secretions	NNS	PH
,	,	O
and	CC	O
eyelid	JJ	PH
redness	NN	PH
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
compress	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
,	,	O
MG	NNP	PH
plugging	VBG	PH
resolved	VBN	O
completely	RB	O
in	IN	O
three	CD	O
patients	NNS	O
and	CC	O
MG	NNP	PH
secretion	NN	PH
returned	VBD	PH
to	TO	PH
normal	JJ	PH
in	IN	O
two	CD	O
patients	NNS	O
;	:	O
no	DT	O
such	JJ	O
results	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
compress	NN	O
group	NN	O
.	.	O

Furthermore	RB	O
,	,	O
a	DT	O
higher	JJR	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
rated	VBD	O
overall	JJ	PH
symptomatic	JJ	PH
relief	NN	PH
as	IN	O
excellent	NN	O
or	CC	O
good	JJ	O
.	.	O

Visual	JJ	Ot
acuity	NN	Ot
measurements	NNS	Ot
and	CC	Ot
biomicroscopic	JJ	Ot
evaluation	NN	Ot
revealed	VBD	O
no	DT	Ot
ocular	JJ	Ot
safety	NN	Ot
issues	NNS	Ot
.	.	O

CONCLUSION	NNP	O
Azithromycin	NNP	O
ophthalmic	JJ	O
solution	NN	O
in	IN	O
combination	NN	O
with	IN	O
warm	JJ	O
compresses	NNS	O
provided	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
clinical	JJ	O
benefit	NN	O
than	IN	O
warm	JJ	O
compresses	NNS	O
alone	RB	O
in	IN	O
treating	VBG	O
the	DT	O
signs	NNS	PH
and	CC	PH
symptoms	NNS	PH
of	IN	PH
posterior	JJ	PH
blepharitis	NN	PH
.	.	O

A	DT	O
30-month	JJ	O
longitudinal	JJ	O
study	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	O
hygiene	NN	O
measures	NNS	O
on	IN	O
Streptococcus	NNP	PH
mutans	NNS	PH
and	CC	PH
approximal	JJ	PH
dental	JJ	PH
caries	NNS	PH
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	O
hygiene	NN	O
measures	NNS	O
on	IN	O
Streptococcus	NNP	PH
mutants	NNS	PH
and	CC	O
approximal	JJ	PH
dental	JJ	PH
caries	NNS	PH
were	VBD	O
evaluated	VBN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eighty-seven	JJ	O
13-year-old	JJ	O
individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
salivary	JJ	O
S.	NNP	PH
mutans	NNS	PH
(	(	O
greater	JJR	O
than	IN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/mL	NN	O
)	)	O
were	VBD	O
selected	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
distributed	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
initially	RB	O
received	VBD	O
professional	JJ	O
mechanical	JJ	O
tooth-cleaning	NN	O
,	,	O
tongue-scraping	NN	O
,	,	O
chlorhexidine	NN	O
treatment	NN	O
,	,	O
and	CC	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
concentrated	VBD	O
on	IN	O
the	DT	O
approximal	JJ	O
surfaces	NNS	O
most	RBS	O
colonized	VBN	O
by	IN	O
S.	NNP	O
mutans	NNS	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
given	VBN	O
four	CD	O
times	NNS	O
with	IN	O
intervals	NNS	O
of	IN	O
two	CD	O
days	NNS	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	O
single	JJ	O
treatment	NN	O
every	DT	O
six	CD	O
months	NNS	O
throughout	IN	O
the	DT	O
experimental	JJ	O
period	NN	O
.	.	O

The	DT	O
initial	JJ	O
treatment	NN	O
period	NN	O
for	IN	O
group	NN	O
II	NNP	O
,	,	O
also	RB	O
consisting	VBG	O
of	IN	O
four	CD	O
visits	NNS	O
,	,	O
included	VBD	O
the	DT	O
same	JJ	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
as	IN	O
for	IN	O
group	NN	O
I	PRP	O
.	.	O

The	DT	O
instructions	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
six	CD	O
months	NNS	O
.	.	O

Group	NNP	O
III	NNP	O
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
preventive	JJ	O
program	NN	O
provided	VBN	O
by	IN	O
the	DT	O
local	JJ	O
Dental	NNP	O
Health	NNP	O
Office	NNP	O
,	,	O
based	VBN	O
on	IN	O
mechanical	JJ	O
plaque	NN	O
control	NN	O
and	CC	O
topical	JJ	O
use	NN	O
of	IN	O
fluorides	NNS	O
and	CC	O
chlorhexidine	NN	O
at	IN	O
individualized	JJ	O
intervals	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
showed	VBD	O
a	DT	O
significant	JJ	O
immediate	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
saliva	NN	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
approximal	JJ	O
tooth	NN	O
surfaces	NNS	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
these	DT	O
variables	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
baseline	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
caries	NNS	PH
progression	NN	PH
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
selected	VBN	O
high-risk	JJ	O
individuals	NNS	O
in	IN	O
group	NN	O
I	PRP	O
developed	VBD	O
0.25	CD	O
new	JJ	O
manifest	NN	O
caries	NNS	O
lesions	NNS	O
approximally/year	VBP	O
,	,	O
compared	VBN	O
with	IN	O
0.27	CD	O
for	IN	O
all	DT	O
children	NNS	O
of	IN	O
the	DT	O
same	JJ	O
age	NN	O
group	NN	O
in	IN	O
the	DT	O
area	NN	O
.	.	O

Seventeen	JJ	O
individuals	NNS	O
had	VBD	O
approximal	JJ	O
surfaces	NNS	O
with	IN	O
consistently	RB	O
high	JJ	O
or	CC	O
consistently	RB	O
low	JJ	O
S.	NNP	O
mutans	NN	PH
levels	NNS	PH
.	.	O

Forty-six	CD	O
percent	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
high	JJ	O
values	NNS	O
developed	VBD	O
new	JJ	PH
or	CC	PH
progressive	JJ	PH
caries	NNS	PH
,	,	O
compared	VBN	O
with	IN	O
2	CD	O
%	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
low	JJ	O
values	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
:	:	O
neuropsychological	JJ	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
There	EX	O
has	VBZ	O
been	VBN	O
recent	JJ	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
cognitive	JJ	O
enhancing	VBG	O
drugs	NNS	O
,	,	O
such	JJ	O
as	IN	O
cholinesterase	NN	O
inhibitors	NNS	O
,	,	O
as	IN	O
a	DT	O
possible	JJ	O
treatment	NN	O
for	IN	O
executive	NN	ME
functioning	NN	ME
(	(	O
EF	NNP	O
)	)	O
deficits	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
tolerability	NN	Ot
,	,	Ot
safety	NN	Ot
,	,	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
donepezil	NN	O
on	IN	O
EF	NNP	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

METHOD	NNP	O
Thirty-four	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
age	NN	O
range	NN	O
8-17	CD	O
years	NNS	O
;	:	O
IQ	NNP	O
>	NNP	O
75	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
donepezil	NN	O
(	(	O
doses	NNS	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
open	JJ	O
label	NN	O
trial	NN	O
for	IN	O
placebo	NN	O
nonresponders	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effect	NN	O
of	IN	O
donepezil	NN	O
treatment	NN	O
on	IN	O
EF	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

Despite	IN	O
improvement	NN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
EF	NNP	O
measures	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
(	(	O
with	IN	O
gains	NNS	O
observed	VBN	O
for	IN	O
both	DT	O
the	DT	O
placebo	NN	O
and	CC	O
donepezil	NN	O
groups	NNS	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
donepezil	NN	O
may	MD	O
have	VB	O
limited	VBN	O
impact	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
ASD	NNP	O
.	.	O

Future	NNP	O
controlled	VBD	O
trials	NNS	O
may	MD	O
need	VB	O
to	TO	O
consider	VB	O
a	DT	O
longer	RBR	O
treatment	NN	O
period	NN	O
to	TO	O
detect	VB	O
significant	JJ	O
gains	NNS	O
on	IN	O
EF	NNP	O
measures	NNS	O
.	.	O

Predictors	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
and	CC	O
negative	JJ	O
caregiving	NN	O
experiences	NNS	O
in	IN	O
carers	NNS	O
of	IN	O
adolescents	NNS	O
with	IN	O
bulimia	NN	O
nervosa	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
exploratory	NN	O
study	NN	O
focuses	VBZ	O
on	IN	O
the	DT	O
mental	JJ	O
health	NN	O
(	(	O
MH	NNP	O
)	)	O
and	CC	O
caregiving	VBG	O
experience	NN	O
of	IN	O
carers	NNS	O
of	IN	O
adolescents	NNS	O
with	IN	O
Bulimia	NNP	O
Nervosa	NNP	O
(	(	O
BN	NNP	O
)	)	O
/Eating	VBG	O
Disorder	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
(	(	O
EDNOS	NNP	O
)	)	O
,	,	O
aiming	VBG	O
to	TO	O
determine	VB	O
:	:	O
levels	NNS	O
of	IN	O
MH	NNP	O
problems	NNS	O
in	IN	O
carers	NNS	O
and	CC	O
if	IN	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
predicts	NNS	O
carer	VBP	O
MH	NNP	O
status	NN	O
and	CC	O
which	WDT	O
factors	NNS	O
predict	VBP	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
.	.	O

METHOD	NNP	O
Hundred	NNP	O
and	CC	O
twelve	VB	O
carers	NNS	O
and	CC	O
68	CD	O
adolescents	NNS	O
with	IN	O
BN/EDNOS	NNP	O
completed	VBD	O
self-report	JJ	O
measures	NNS	O
(	(	O
General	NNP	O
Health	NNP	O
Questionnaire	NNP	O
,	,	O
Experience	NNP	O
of	IN	O
Caregiving	NNP	O
Inventory	NNP	O
,	,	O
Level	NNP	O
of	IN	O
Expressed	JJ	O
Emotion	NNP	O
,	,	O
Self-report	NNP	O
Family	NNP	O
Inventory	NNP	O
,	,	O
Inventory	NNP	O
of	IN	O
Interpersonal	NNP	O
Problems	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Over	IN	O
half	NN	O
of	IN	O
the	DT	O
carers	NNS	O
reported	VBD	O
some	DT	O
MH	NNP	A
problems	NNS	A
and	CC	O
a	DT	O
minority	NN	O
(	(	O
5.4	CD	O
%	NN	O
)	)	O
were	VBD	O
experiencing	VBG	O
considerable	JJ	O
difficulties	NNS	O
.	.	O

A	DT	PH
negative	JJ	PH
experience	NN	PH
of	IN	PH
caregiving	VBG	PH
predicted	VBN	O
carer	NN	O
MH	NNP	O
status	NN	O
.	.	O

Higher	JJR	PH
weekly	JJ	PH
contact	NN	PH
hours	NNS	PH
and	CC	PH
patient	JJ	PH
ratings	NNS	PH
of	IN	PH
expressed	VBN	PH
emotion	NN	PH
(	(	PH
EE	NNP	PH
)	)	PH
predicted	VBD	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
.	.	O

CONCLUSIONS	NNP	O
Interventions	NNPS	O
focusing	VBG	O
on	IN	O
reducing	VBG	O
EE	NNP	Ot
and	CC	O
contact	NN	Ot
hours	NNS	Ot
could	MD	O
prove	VB	O
beneficial	JJ	O
for	IN	O
both	DT	O
patient	NN	O
and	CC	O
caregiver	NN	O
outcomes	NNS	O
.	.	O

Right	RB	O
ventricular	JJ	O
function	NN	O
during	IN	O
high-frequency	JJ	O
oscillatory	JJ	O
ventilation	NN	O
in	IN	O
adults	NNS	O
with	IN	O
acute	JJ	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
mean	JJ	O
airway	JJ	O
pressure	NN	O
under	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation	NN	O
on	IN	O
right	JJ	O
ventricular	JJ	O
function	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Intensive	NNP	O
care	NN	O
unit	NN	O
of	IN	O
a	DT	O
tertiary	JJ	O
care	NN	O
hospital	NN	O
.	.	O

PATIENTS	NNP	O
Sixteen	NNP	O
consecutive	JJ	O
patients	NNS	O
within	IN	O
the	DT	O
first	JJ	O
48	CD	O
hrs	NN	O
of	IN	O
mainly	RB	O
pulmonary	JJ	O
acute	NN	O
respiratory	NN	O
distress	JJ	O
syndrome	NN	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
a	DT	O
6-hr-period	JJ	O
of	IN	O
protective	JJ	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
three	CD	O
1-hr	JJ	O
periods	NNS	O
of	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation	NN	O
(	(	O
+5	JJ	O
,	,	O
+10	NNP	O
,	,	O
+15	NNP	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
level	NN	O
determined	VBN	O
by	IN	O
adding	VBG	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
cm	NNS	O
H2O	NNP	O
to	TO	O
the	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
recorded	VBN	O
during	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Mean	NNP	ME
airway	JJ	ME
pressure	NN	ME
was	VBD	O
18?3	CD	O
cm	JJ	O
H2O	NNP	O
during	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
and	CC	O
was	VBD	O
increased	VBN	O
until	IN	O
33?3	CD	O
cm	NNS	O
H2O	NNP	O
at	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation+15	NN	O
.	.	O

Right	NNP	O
ventricular	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
transesophageal	JJ	O
echocardiography	NN	O
.	.	O

During	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
nine	CD	O
patients	NNS	O
presented	VBD	O
a	DT	O
right	JJ	O
ventricular	NN	O
dysfunction	NN	O
(	(	O
right	JJ	O
ventricular	NN	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
ratio	NN	O
>	NNP	O
0.6	CD	O
)	)	O
of	IN	O
whom	WP	O
four	CD	O
patients	NNS	O
had	VBD	O
a	DT	O
right	JJ	O
ventricular	NN	O
failure	NN	O
(	(	O
right	JJ	O
ventricular	NN	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
ratio	NN	O
>	NNP	O
0.9	CD	O
)	)	O
.	.	O

High-frequency	NNP	O
oscillatory	JJ	O
ventilation+10	NN	O
and	CC	O
+15	VB	O
further	RB	O
worsened	VBN	O
right	JJ	O
ventricular	NN	O
function	NN	O
,	,	O
resulting	VBG	O
in	IN	O
about	IN	O
a	DT	O
40	CD	O
%	NN	O
increase	NN	O
in	IN	O
right	JJ	O
ventricular	JJ	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
ratio	NN	O
and	CC	O
a	DT	O
30	CD	O
%	NN	O
increase	NN	O
in	IN	O
end-diastolic	JJ	O
eccentricity	NN	O
index	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
or	CC	O
high-frequency	NN	O
oscillatory	NN	O
ventilation+5	NN	O
periods	NNS	O
.	.	O

At	IN	O
high-frequency	JJ	O
oscillatory	NN	O
ventilation+15	NN	O
,	,	O
15	CD	O
patients	NNS	O
had	VBD	O
right	JJ	O
ventricular	JJ	O
dysfunction	NN	O
and	CC	O
nine	CD	O
had	VBD	O
right	JJ	O
ventricular	JJ	O
failure	NN	O
.	.	O

High-frequency	NNP	O
oscillatory	JJ	O
ventilation	NN	O
did	VBD	O
not	RB	O
improve	VB	O
oxygenation	NN	O
whatever	IN	O
the	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
level	NN	O
.	.	O

A	DT	O
significant	JJ	O
redistribution	NN	O
of	IN	O
tidal	JJ	O
variation	NN	O
to	TO	O
the	DT	O
posterior	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
lung	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
electrical	JJ	O
impedance	NN	O
tomography	NN	O
measurements	NNS	O
when	WRB	O
increasing	VBG	O
mean	VB	O
airway	JJ	O
pressure	NN	O
.	.	O

However	RB	O
,	,	O
this	DT	O
redistribution	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
presented	VBD	O
a	DT	O
worsening	NN	O
of	IN	O
right	JJ	O
ventricular	JJ	O
function	NN	O
(	(	O
right	JJ	O
ventricular	NN	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
increase	NN	O
>	VBD	O
40	CD	O
%	NN	O
)	)	O
at	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation+15	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
mainly	RB	O
pulmonary	JJ	O
acute	NN	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
,	,	O
using	VBG	O
high	JJ	O
mean	JJ	O
airway	NN	O
pressure	NN	O
under	IN	O
high-frequency	NN	O
oscillatory	JJ	O
ventilation	NN	O
can	MD	O
worsen	VB	O
right	JJ	O
ventricular	NN	O
function	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
protective	JJ	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
notably	RB	O
in	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
high-frequency	NN	O
oscillatory	NN	O
ventilation	NN	O
produced	VBD	O
less	JJR	O
alveolar	JJ	O
recruitment	NN	O
of	IN	O
the	DT	O
posterior	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
lungs	NNS	O
.	.	O

This	DT	O
study	NN	O
highlights	VBZ	O
the	DT	O
interest	NN	O
of	IN	O
monitoring	VBG	O
right	JJ	O
ventricular	JJ	O
function	NN	O
during	IN	O
high-frequency	JJ	O
oscillatory	JJ	O
ventilation	NN	O
.	.	O

The	DT	O
instruction	NN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
affects	NNS	O
auditory	JJ	PH
P3	NNP	PH
and	CC	PH
N1	NNP	PH
amplitudes	NNS	PH
.	.	PH

Often	NNP	O
subjects	VBZ	O
have	VBP	O
been	VBN	O
instructed	VBN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
lest	JJS	O
their	PRP$	O
evoked	JJ	O
EEG	NNP	O
potentials	NNS	O
should	MD	O
be	VB	O
distorted	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
these	DT	O
very	RB	O
instructions	NNS	O
have	VBP	O
any	DT	O
impact	NN	O
on	IN	O
P3	NNP	PH
amplitude	NN	PH
.	.	PH

Two	CD	O
tones	NNS	O
were	VBD	O
presented	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
and	CC	O
subjects	NNS	O
had	VBD	O
to	TO	O
count	VB	O
the	DT	O
high-pitched	JJ	O
tones	NNS	O
.	.	O

Half	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
instructed	VBN	O
not	RB	O
to	TO	O
blink	VB	O
,	,	O
whereas	IN	O
this	DT	O
instruction	NN	O
was	VBD	O
omitted	VBN	O
for	IN	O
the	DT	O
other	JJ	O
subjects	NNS	O
.	.	O

Target	NNP	O
tones	NNS	O
evoked	VBD	O
larger	JJR	O
P3s	NNP	PH
than	IN	O
non-targets	NNS	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
former	JJ	O
,	,	O
in	IN	O
particular	JJ	O
not	RB	O
in	IN	O
those	DT	O
subjects	NNS	O
that	WDT	O
actually	RB	O
blinked	VBD	O
rarely	RB	O
.	.	O

The	DT	O
groups	NNS	O
also	RB	O
differed	VBN	O
in	IN	O
their	PRP$	O
N1	NNP	PH
amplitudes	NNS	PH
.	.	PH

These	DT	O
findings	NNS	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
P3	NNP	O
studies	NNS	O
working	VBG	O
with	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
:	:	O
the	DT	O
harder	NN	O
some	DT	O
frequently	RB	O
blinking	JJ	O
subjects	NNS	O
try	VBP	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	NN	O
,	,	O
the	DT	O
smaller	JJR	O
might	MD	O
become	VB	O
their	PRP$	O
P3	NNP	PH
amplitudes	NNS	PH
.	.	PH

Omitting	VBG	O
the	DT	O
instruction	NN	O
and	CC	O
using	VBG	O
off-line	JJ	O
blink	NN	O
subtraction	NN	O
procedures	NNS	O
seems	VBZ	O
a	DT	O
viable	JJ	O
alternative	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
actually	RB	O
motivated	VBN	O
by	IN	O
discrepant	JJ	O
findings	NNS	O
on	IN	O
the	DT	O
effects	NNS	PH
of	IN	PH
the	DT	PH
preceding	VBG	PH
tone	NN	PH
sequence	NN	PH
on	IN	PH
P3	NNP	PH
.	.	O

These	DT	O
discrepancies	NNS	O
could	MD	O
be	VB	O
largely	RB	O
resolved	VBN	O
by	IN	O
the	DT	O
instructional	JJ	O
variable	NN	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
different	JJ	O
tone	NN	PH
intensities	NNS	PH
.	.	PH

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
subjects	NNS	O
who	WP	O
are	VBP	O
discouraged	VBN	O
from	IN	O
blinking	VBG	O
try	NN	O
to	TO	O
protect	VB	O
themselves	PRP	O
against	IN	O
the	DT	O
arousing	JJ	O
effects	NNS	O
of	IN	O
stimuli	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
psychological	JJ	O
intervention	NN	O
on	IN	O
quality	NN	PH
of	IN	PH
life	NN	PH
in	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
psychological	JJ	O
intervention	NN	O
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
quality	NN	PH
of	IN	PH
life	NN	PH
and	CC	O
behaviour	NN	ME
of	IN	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
breast	NN	O
cancer	NN	O
.	.	O

36	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
assigned	VBD	O
to	TO	O
surgery	VB	O
and	CC	O
systemic	VB	O
chemotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
psychological	JJ	O
intervention	NN	O
(	(	O
weekly	JJ	O
cognitive	VBP	O
individual	JJ	O
psychotherapy	NN	O
and	CC	O
bimonthly	JJ	O
family	NN	O
counselling	VBG	O
)	)	O
or	CC	O
standard	JJ	O
follow-up	NN	O
.	.	O

Personality	NNP	ME
(	(	ME
16-PF	JJ	ME
and	CC	ME
IIQ	NNP	ME
)	)	ME
,	,	O
quality	NN	PH
of	IN	PH
life	NN	PH
(	(	PH
FLIC	NNP	PH
)	)	PH
,	,	O
and	CC	O
depression	NN	ME
(	(	ME
BDI	NNP	ME
)	)	ME
scores	NNS	ME
were	VBD	O
the	DT	O
endpoints	NNS	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
at	IN	O
diagnosis	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
9	CD	O
months	NNS	O
after	IN	O
diagnosis	NN	O
.	.	O

Cognitive	JJ	O
psychotherapy	NN	O
and	CC	O
family	NN	O
counselling	NN	O
improved	VBD	O
both	DT	O
depression	NN	ME
and	CC	O
quality	NN	PH
of	IN	PH
life	NN	PH
indexes	NNS	PH
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Better	NNP	O
emotional	JJ	ME
coping	NN	ME
behaviours	NNS	ME
were	VBD	O
also	RB	O
revealed	VBN	O
by	IN	O
some	DT	O
changes	NNS	O
in	IN	O
personality	NN	O
traits	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

[	JJ	O
European	JJ	O
topic	NN	O
:	:	O
liver	NN	O
surgery	NN	O
II	NNP	O
--	:	O
regional	JJ	O
chemotherapy	NN	O
]	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
methods	NNS	O
of	IN	O
regional	JJ	O
chemotherapy	NN	O
are	VBP	O
exemplified	VBN	O
by	IN	O
657	CD	O
cases	NNS	O
of	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
liver	NN	O
only	RB	O
malignancies	VBZ	O
.	.	O

I	PRP	O
.	.	O

Adjuvant	JJ	O
portal	JJ	O
therapy	NN	O
of	IN	O
the	DT	O
liver	NN	O
with	IN	O
resection	NN	O
of	IN	O
the	DT	O
colorectal	JJ	O
primary	JJ	O
malignancy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
advantageous	JJ	O
for	IN	O
advanced	JJ	O
tumors	NNS	O
.	.	O

II	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
still	RB	O
unresolved	JJ	O
whether	IN	O
survival	NN	MO
is	VBZ	O
prolonged	VBN	O
by	IN	O
adjuvant	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
liver	NN	O
following	VBG	O
curative	JJ	O
resection	NN	O
of	IN	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
.	.	O

III	NNP	O
.	.	O

The	DT	O
median	JJ	MO
survival	NN	MO
time	NN	MO
(	(	MO
FUDR	NNP	MO
,	,	MO
pump	NN	MO
)	)	MO
is	VBZ	O
17	CD	O
months	NNS	O
for	IN	O
palliative	JJ	O
local	JJ	O
chemotherapy	NN	O
of	IN	O
unresectable	JJ	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
.	.	O

IV	NNP	O
.	.	O

Primary	NNP	O
non-resectable	JJ	O
liver	NN	O
malignancies	NNS	O
show	VBP	O
the	DT	O
best	JJS	O
results	NNS	O
after	IN	O
chemoembolisation	NN	O
(	(	O
Frankfurt	NNP	O
method	NN	O
)	)	O
.	.	O

Long-term	JJ	O
growth	NN	O
hormone	NN	O
treatment	NN	O
in	IN	O
growth	NN	O
hormone	NN	O
deficient	NN	O
adults	NNS	O
.	.	O

Growth	NNP	O
hormone	NN	O
treatment	NN	O
in	IN	O
GH-deficient	NNP	O
adults	NNS	O
has	VBZ	O
proved	VBN	O
beneficial	JJ	O
in	IN	O
recent	JJ	O
short-term	JJ	O
trials	NNS	O
,	,	O
but	CC	O
long-term	JJ	O
results	NNS	O
have	VBP	O
not	RB	O
yet	RB	O
been	VBN	O
reported	VBN	O
.	.	O

Thirteen	JJ	O
GH-deficient	JJ	O
adults	NNS	O
(	(	O
4	CD	O
females	NNS	O
,	,	O
9	CD	O
males	NNS	O
;	:	O
mean	FW	O
(	(	O
SEM	NNP	O
)	)	O
age	NN	O
26.4	CD	O
(	(	O
1.7	CD	O
)	)	O
years	NNS	O
)	)	O
,	,	O
who	WP	O
had	VBD	O
completed	VBN	O
4	CD	O
months	NNS	O
of	IN	O
GH	NNP	O
therapy	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
were	VBD	O
followed	VBN	O
,	,	O
for	IN	O
further	JJ	O
16.1	CD	O
(	(	O
0.8	CD	O
)	)	O
months	NNS	O
of	IN	O
uninterrupted	JJ	O
GH	NNP	O
therapy	NN	O
in	IN	O
an	DT	O
open	JJ	O
design	NN	O
.	.	O

A	DT	O
significant	JJ	O
mean	JJ	O
increase	NN	O
of	IN	O
1.3	CD	O
cm	NN	O
in	IN	O
linear	JJ	PH
height	NN	PH
was	VBD	O
recorded	VBN	O
,	,	O
whereas	IN	O
body	NN	PH
mass	NN	PH
index	NN	PH
remained	VBD	O
unchanged	JJ	O
.	.	O

Mean	JJ	Ot
muscle	NN	Ot
volume	NN	Ot
of	IN	Ot
the	DT	Ot
thigh	NN	Ot
,	,	O
estimated	VBN	O
by	IN	O
computerised	JJ	O
tomography	NN	O
,	,	O
increased	VBD	O
significantly	RB	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
initial	JJ	O
placebo	NN	O
period	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
slight	JJ	O
decrease	NN	O
was	VBD	O
recorded	VBN	O
in	IN	O
adipose	JJ	PH
tissue	NN	PH
volume	NN	PH
of	IN	PH
the	DT	PH
thigh	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.10	CD	O
)	)	O
and	CC	O
subscapular	JJ	PH
skinfold	NN	PH
thickness	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.10	CD	O
)	)	O
.	.	O

Still	RB	O
,	,	O
the	DT	O
muscle	NN	Ot
to	TO	Ot
fat	VB	Ot
ratio	NN	Ot
of	IN	Ot
the	DT	Ot
thigh	NN	Ot
was	VBD	O
significantly	RB	O
lower	JJR	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
normal	JJ	O
subjects	NNS	O
(	(	O
72.6/27.4	CD	O
vs	RB	O
77.9/22.1	CD	O
)	)	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	Ot
isometric	JJ	Ot
strength	NN	Ot
of	IN	Ot
the	DT	Ot
quadriceps	JJ	Ot
muscles	NNS	O
increased	VBD	O
significantly	RB	O
during	IN	O
long-term	JJ	O
GH	NNP	O
therapy	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
remained	VBD	O
lower	JJR	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
normal	JJ	O
subjects	NNS	O
(	(	O
1.66	CD	O
(	(	O
0.10	CD	O
)	)	O
vs	NN	O
2.13	CD	O
(	(	O
0.11	CD	O
)	)	O
Nm/kg	NNP	O
body	NN	O
weight	NN	O
)	)	O
.	.	O

Exercise	NN	PH
capacity	NN	PH
performed	VBN	O
on	IN	O
a	DT	O
bicycle	NN	O
ergometer	NN	O
increased	VBD	O
significantly	RB	O
after	IN	O
long-term	JJ	O
therapy	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
still	RB	O
did	VBD	O
not	RB	O
reach	VB	O
the	DT	O
values	NNS	O
seen	VBN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
(	(	O
22.5	CD	O
(	(	O
3.4	CD	O
)	)	O
vs	NN	O
37.4	CD	O
(	(	O
4.2	CD	O
)	)	O
watt.min.kg-1	NN	O
.	.	O

No	DT	O
adverse	JJ	A
reactions	NNS	A
were	VBD	O
recorded	VBN	O
during	IN	O
long-term	JJ	O
therapy	NN	O
and	CC	O
hemoglobin	NN	PH
A1c	NNP	PH
remained	VBD	O
unchanged	JJ	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
long-term	JJ	O
GH	NNP	O
replacement	NN	O
therapy	NN	O
in	IN	O
GH-deficient	NNP	O
adults	NNS	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
several	JJ	O
physiological	JJ	O
features	NNS	O
which	WDT	O
are	VBP	O
subnormal	JJ	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

Isoniazid	NNP	O
prophylaxis	NN	O
for	IN	O
tuberculosis	NN	O
in	IN	O
HIV	NNP	O
infection	NN	O
:	:	O
a	DT	O
meta-analysis	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
isoniazid	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
individuals	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

DESIGN	NNP	O
Meta-analysis	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

SETTING	NNP	O
Seven	NNP	O
trials	NNS	O
from	IN	O
Mexico	NNP	O
,	,	O
Haiti	NNP	O
,	,	O
the	DT	O
United	NNP	O
States	NNPS	O
,	,	O
Zambia	NNP	O
,	,	O
Uganda	NNP	O
and	CC	O
Kenya	NNP	O
.	.	O

PATIENTS	NNP	O
Individuals	NNP	O
free	JJ	O
from	IN	O
tuberculosis	NN	O
,	,	O
2367	CD	O
persons	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
2162	CD	O
in	IN	O
the	DT	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
Comparison	NNP	PH
of	IN	PH
isoniazid	NN	PH
with	IN	PH
placebo	NN	PH
or	CC	PH
no	DT	PH
prophylaxis	NN	PH
.	.	PH

METHODS	NNP	O
A	NNP	O
systematic	JJ	O
search	NN	O
of	IN	O
the	DT	O
literature	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
from	IN	O
1985	CD	O
to	TO	O
October	NNP	O
1997	CD	O
for	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
of	IN	O
isoniazid	JJ	O
prophylaxis	NN	O
in	IN	O
HIV-infected	JJ	O
persons	NNS	O
.	.	O

Two	CD	O
reviewers	NNS	O
evaluated	VBD	O
the	DT	O
relevance	NN	O
of	IN	O
each	DT	O
candidate	NN	O
study	NN	O
and	CC	O
the	DT	O
validity	NN	O
of	IN	O
eligible	JJ	O
trials	NNS	O
.	.	O

Studies	NNS	O
were	VBD	O
pooled	VBN	O
using	VBG	O
a	DT	O
random	JJ	O
effect	NN	O
model	NN	O
,	,	O
conducting	VBG	O
secondary	JJ	O
analyses	NNS	O
for	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
persons	NNS	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
follow-up	NN	O
in	IN	O
trials	NNS	O
varied	VBD	O
between	IN	O
0.4	CD	O
and	CC	O
3.2	CD	O
years	NNS	O
.	.	O

Pooling	VBG	O
all	DT	O
seven	CD	O
trials	NNS	O
,	,	O
a	DT	O
risk	NN	Ot
ratio	NN	Ot
was	VBD	O
found	VBN	O
for	IN	O
persons	NNS	O
treated	VBN	O
with	IN	O
isoniazid	NN	O
for	IN	O
developing	VBG	O
tuberculosis	NN	O
of	IN	O
0.58	CD	O
[	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
0.43-0.80	JJ	O
]	NN	O
and	CC	O
0.94	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.83-1.07	NNP	O
)	)	O
for	IN	O
death	NN	MO
.	.	O

In	IN	O
groups	NNS	O
of	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
persons	NNS	O
,	,	O
the	DT	O
risk	NN	Ot
ratio	NN	Ot
of	IN	Ot
tuberculosis	NN	Ot
was	VBD	O
0.40	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.24-0.65	NNP	O
)	)	O
and	CC	O
0.84	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.54-1.30	NNP	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
difference	NN	Ot
in	IN	Ot
the	DT	Ot
effectiveness	NN	Ot
of	IN	O
isoniazid	JJ	O
versus	NN	O
placebo	NN	O
between	IN	O
these	DT	O
groups	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
,	,	O
for	IN	O
the	DT	O
difference	NN	O
of	IN	O
summary	JJ	O
estimates	NNS	O
)	)	O
.	.	O

Consistency	NN	O
of	IN	O
results	NNS	O
was	VBD	O
found	VBN	O
across	IN	O
trials	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.10	CD	O
,	,	O
heterogeneity	NN	O
value	NN	O
)	)	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Prophylaxis	NNP	O
with	IN	O
isoniazid	JJ	O
reduces	NNS	O
the	DT	O
risk	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

The	DT	O
effect	NN	O
is	VBZ	O
restricted	VBN	O
to	TO	O
tuberculin	VB	O
skin	JJ	O
test-positive	JJ	O
persons	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
1-	JJ	O
and	CC	O
3-minute	JJ	O
lockout	NN	O
periods	NNS	O
during	IN	O
patient-controlled	JJ	O
sedation	NN	O
with	IN	O
midazolam	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
maximum	JJ	O
effect	NN	O
of	IN	O
midazolam	NN	O
injected	VBN	O
intravenously	RB	O
occurs	VBZ	O
in	IN	O
about	IN	O
3	CD	O
minutes	NNS	O
.	.	O

Patient-controlled	JJ	O
sedation	NN	O
carried	VBD	O
out	RP	O
with	IN	O
1-mg	JJ	O
increments	NNS	O
of	IN	O
midazolam	NN	O
at	IN	O
3-minute	JJ	O
intervals	NNS	O
provides	VBZ	O
comparable	JJ	O
conditions	NNS	O
to	TO	O
that	DT	O
of	IN	O
doctor-controlled	JJ	O
sedation	NN	O
carried	VBD	O
out	RP	O
with	IN	O
1-mg	JJ	O
increments	NNS	O
at	IN	O
1-minute	JJ	O
intervals	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
longer	JJR	O
duration	NN	O
taken	VBN	O
for	IN	O
the	DT	O
patients	NNS	O
to	TO	O
achieve	VB	O
satisfactory	JJ	O
sedation	NN	O
prior	RB	O
to	TO	O
surgery	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
out	RP	O
how	WRB	O
safe	JJ	O
it	PRP	O
would	MD	O
be	VB	O
to	TO	O
shorten	VB	O
the	DT	O
interval	NN	O
of	IN	O
increments	NNS	O
of	IN	O
midazolam	NN	O
to	TO	O
1	CD	O
minute	NN	O
in	IN	O
patient-controlled	JJ	O
sedation	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
26	CD	O
patients	NNS	O
undergoing	JJ	O
bilateral	JJ	O
lower	JJR	O
third	JJ	O
molar	JJ	O
surgery	NN	O
at	IN	O
two	CD	O
visits	NNS	O
had	VBD	O
patient-controlled	JJ	O
sedation	NN	O
with	IN	O
1	CD	O
mg	NNS	O
midazolam	JJ	O
increments	NNS	O
at	IN	O
1-minute	JJ	O
or	CC	O
3-minute	JJ	O
intervals	NNS	O
at	IN	O
one	CD	O
visit	NN	O
and	CC	O
the	DT	O
alternative	NN	O
at	IN	O
the	DT	O
other	JJ	O
visit	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
time	NN	O
taken	VBN	O
for	IN	O
patients	NNS	O
to	TO	O
achieve	VB	O
a	DT	O
degree	NN	PH
of	IN	PH
sedation	NN	PH
that	IN	O
they	PRP	O
thought	VBD	O
was	VBD	O
sufficient	JJ	O
to	TO	O
tolerate	VB	O
the	DT	O
surgery	NN	O
was	VBD	O
significantly	RB	O
longer	RBR	O
when	WRB	O
the	DT	O
increment	NN	O
interval	NN	O
was	VBD	O
3	CD	O
minutes	NNS	O
(	(	O
t	JJ	O
=	NNP	O
-4.8	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Both	DT	O
techniques	NNS	O
provided	VBD	O
good	JJ	O
operating	NN	Ot
conditions	NNS	Ot
,	,	O
stable	JJ	O
vital	JJ	PH
signs	NNS	PH
,	,	O
mild	NN	O
to	TO	O
moderate	VB	O
sedation	NN	O
,	,	O
without	IN	O
loss	NN	Ot
of	IN	Ot
verbal	JJ	Ot
contact	NN	Ot
.	.	Ot

CONCLUSION	VB	O
A	DT	O
significant	JJ	O
majority	NN	O
preferred	VBD	O
the	DT	O
sedation	NN	O
technique	NN	O
with	IN	O
1-minute	JJ	O
increment	NN	O
intervals	NNS	O
(	(	O
chi	VB	O
2	CD	O
=	JJ	O
4.6	CD	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
social	JJ	ME
functioning	NN	ME
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Imitation	NNP	O
is	VBZ	O
an	DT	O
early	JJ	O
skill	NN	O
thought	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
social	JJ	O
development	NN	O
,	,	O
leading	VBG	O
some	DT	O
to	TO	O
suggest	VB	O
that	IN	O
teaching	VBG	O
imitation	NN	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
should	MD	O
lead	VB	O
to	TO	O
improvements	NNS	O
in	IN	O
social	JJ	ME
functioning	NN	ME
.	.	O

This	DT	O
study	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
initiation	NN	O
of	IN	O
joint	JJ	ME
attention	NN	ME
and	CC	O
social-emotional	JJ	ME
functioning	NN	ME
in	IN	O
27	CD	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
the	DT	O
treatment	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
more	RBR	O
gains	NNS	O
in	IN	O
joint	JJ	ME
attention	NN	ME
initiations	NNS	ME
at	IN	O
post-treatment	JJ	O
and	CC	O
follow-up	JJ	O
and	CC	O
social-emotional	JJ	ME
functioning	NN	ME
at	IN	O
follow-up	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Although	IN	O
gains	NNS	ME
in	IN	ME
social	JJ	ME
functioning	NN	ME
were	VBD	O
associated	VBN	O
with	IN	O
treatment	NN	O
,	,	O
a	DT	O
mediation	NN	O
analysis	NN	O
did	VBD	O
not	RB	O
support	VB	O
imitation	NN	O
as	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
the	DT	O
intervention	NN	O
improves	VBZ	O
social	JJ	ME
functioning	NN	ME
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
synthetic	JJ	O
appeasing	VBG	O
pheromone	NN	O
on	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
synthetic	JJ	O
,	,	O
dog-appeasing	JJ	O
pheromone	NN	O
(	(	O
sDAP	NN	O
)	)	O
on	IN	O
the	DT	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

ANIMALS	$	O
46	CD	O
dogs	NNS	O
housed	VBN	O
in	IN	O
animal	NN	O
shelters	NNS	O
and	CC	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

PROCEDURES	NNP	O
Intensive	NNP	O
care	NN	O
unit	NN	O
cages	NNS	O
were	VBD	O
sprayed	VBN	O
with	IN	O
sDAP	JJ	O
solution	NN	O
or	CC	O
sham	NN	O
treated	VBN	O
with	IN	O
the	DT	O
carrier	NN	O
used	VBN	O
in	IN	O
the	DT	O
solution	NN	O
20	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

Dogs	NNS	O
(	(	O
n	JJ	O
=	NN	O
24	CD	O
and	CC	O
22	CD	O
in	IN	O
the	DT	O
sDAP	NN	O
and	CC	O
sham	JJ	O
treatment	NN	O
exposure	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
placed	VBN	O
in	IN	O
treated	JJ	O
cages	NNS	O
for	IN	O
30	CD	O
minutes	NNS	O
before	IN	O
and	CC	O
after	IN	O
surgery	NN	O
.	.	O

Indicators	NNS	O
of	IN	O
stress	NN	O
(	(	O
ie	NN	O
,	,	O
alterations	NNS	O
in	IN	O
behavioral	JJ	ME
,	,	ME
neuroendocrine	JJ	ME
,	,	ME
immune	JJ	ME
,	,	ME
and	CC	ME
acute-phase	JJ	ME
responses	NNS	ME
)	)	PH
were	VBD	O
evaluated	VBN	O
perioperatively	RB	O
.	.	O

Behavioral	JJ	PH
response	NN	PH
variables	NNS	PH
,	,	PH
salivary	JJ	PH
cortisol	NN	PH
concentration	NN	PH
,	,	PH
WBC	NNP	PH
count	NN	PH
,	,	PH
and	CC	PH
serum	JJ	PH
concentrations	NNS	PH
of	IN	PH
glucose	NN	PH
,	,	PH
prolactin	NN	PH
,	,	PH
haptoglobin	NN	PH
,	,	PH
and	CC	PH
C-reactive	JJ	PH
protein	NN	PH
were	VBD	O
analyzed	VBN	O
.	.	O

RESULTS	NNP	O
Behavioral	NNP	ME
response	NN	ME
variables	NNS	ME
and	CC	PH
serum	NN	PH
prolactin	NN	PH
concentration	NN	PH
were	VBD	O
influenced	VBN	O
by	IN	O
sDAP	NN	O
exposure	NN	O
.	.	O

Dogs	NNS	O
exposed	VBD	O
to	TO	O
sDAP	VB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
alertness	NN	ME
and	CC	ME
visual	JJ	ME
exploration	NN	ME
behaviors	NNS	ME
after	IN	O
surgery	NN	O
than	IN	O
were	VBD	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sham	VB	O
treatment	NN	O
.	.	O

Decreases	VBZ	O
in	IN	O
serum	NN	PH
prolactin	NN	PH
concentrations	NNS	PH
in	IN	O
response	NN	O
to	TO	O
perioperative	JJ	O
stress	NN	O
were	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sDAP	VB	O
,	,	O
compared	VBN	O
with	IN	O
findings	NNS	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
the	DT	O
sham	NN	O
treatment	NN	O
.	.	O

Variables	NNS	O
examined	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
,	,	O
immune	JJ	O
system	NN	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
sDAP	NN	O
appeared	VBD	O
to	TO	O
affect	VB	O
behavioral	JJ	ME
and	CC	ME
neuroendocrine	JJ	ME
perioperative	JJ	ME
stress	NN	ME
responses	NNS	ME
by	IN	O
modification	NN	O
of	IN	O
lactotropic	JJ	O
axis	NN	O
activity	NN	O
.	.	O

Use	NN	O
of	IN	O
sDAP	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
setting	NN	O
may	MD	O
improve	VB	O
the	DT	O
recovery	NN	Ot
and	CC	O
welfare	NN	O
of	IN	O
dogs	NNS	O
undergoing	VBG	O
surgery	NN	O
.	.	O

Virtual	JJ	O
reality	NN	O
intervention	NN	O
for	IN	O
older	JJR	O
women	NNS	O
with	IN	O
breast	NN	O
cancer	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
virtual	JJ	O
reality	NN	O
distraction	NN	O
intervention	NN	O
on	IN	O
chemotherapy-related	JJ	O
symptom	NN	PH
distress	NN	PH
levels	NNS	O
in	IN	O
16	CD	O
women	NNS	O
aged	VBD	O
50	CD	O
and	CC	O
older	JJR	O
.	.	O

A	DT	O
cross-over	JJ	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
answer	VB	O
the	DT	O
following	JJ	O
research	NN	O
questions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Is	VBZ	O
virtual	JJ	O
reality	NN	O
an	DT	O
effective	JJ	O
distraction	NN	O
intervention	NN	O
for	IN	O
reducing	VBG	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
levels	NNS	O
in	IN	O
older	JJR	O
women	NNS	O
with	IN	O
breast	NN	O
cancer	NN	O
?	.	O
(	(	O
2	CD	O
)	)	O
Does	NNP	O
virtual	JJ	O
reality	NN	O
have	VBP	O
a	DT	O
lasting	JJ	O
effect	NN	O
?	.	O
Chemotherapy	NN	O
treatments	NNS	O
are	VBP	O
intensive	JJ	O
and	CC	O
difficult	JJ	O
to	TO	O
endure	VB	O
.	.	O

One	CD	O
way	NN	O
to	TO	O
cope	VB	O
with	IN	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
is	VBZ	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
distraction	NN	O
.	.	O

For	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
head-mounted	JJ	O
display	NN	O
(	(	O
Sony	NNP	O
PC	NNP	O
Glasstron	NNP	O
PLM	NNP	O
-	:	O
S700	NN	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
display	VB	O
encompassing	VBG	O
images	NNS	O
and	CC	O
block	NN	O
competing	VBG	O
stimuli	NNS	O
during	IN	O
chemotherapy	JJ	O
infusions	NNS	O
.	.	O

The	DT	O
Symptom	NNP	PH
Distress	NNP	PH
Scale	NNP	PH
(	(	PH
SDS	NNP	PH
)	)	PH
,	,	O
Revised	VBN	PH
Piper	NNP	PH
Fatigue	NNP	PH
Scale	NNP	PH
(	(	PH
PFS	NNP	PH
)	)	PH
,	,	PH
and	CC	O
the	DT	O
State	NNP	ME
Anxiety	NNP	ME
Inventory	NNP	ME
(	(	ME
SAI	NNP	ME
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
symptom	JJ	O
distress	NN	O
.	.	O

For	IN	O
two	CD	O
matched	JJ	O
chemotherapy	NN	O
treatments	NNS	O
,	,	O
one	CD	O
pre-test	NN	O
and	CC	O
two	CD	O
post-test	JJ	O
measures	NNS	O
were	VBD	O
employed	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
the	DT	O
VR	NNP	O
distraction	NN	O
intervention	NN	O
during	IN	O
one	CD	O
chemotherapy	NN	O
treatment	NN	O
and	CC	O
received	VBD	O
no	DT	O
distraction	NN	O
intervention	NN	O
(	(	O
control	VB	O
condition	NN	O
)	)	O
during	IN	O
an	DT	O
alternate	JJ	O
chemotherapy	NN	O
treatment	NN	O
.	.	O

Analysis	NN	O
using	VBG	O
paired	VBN	O
t-tests	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	Ot
in	IN	O
the	DT	O
SAI	NNP	ME
(	(	O
p	JJ	O
=	NNP	O
0.10	CD	O
)	)	O
scores	NNS	O
immediately	RB	O
following	VBG	O
chemotherapy	NN	O
treatments	NNS	O
when	WRB	O
participants	NNS	O
used	VBD	O
VR	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
SDS	NNP	PH
or	CC	PH
PFS	NNP	PH
values	NNS	PH
.	.	O

There	EX	O
was	VBD	O
a	DT	O
consistent	JJ	O
trend	NN	O
toward	IN	O
improved	VBN	PH
symptoms	NNS	PH
on	IN	O
all	DT	O
measures	NNS	O
48	CD	O
h	NN	O
following	VBG	O
completion	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
intervention	NN	O
indicated	VBD	O
that	IN	O
women	NNS	O
thought	VBD	O
the	DT	O
head	NN	O
mounted	VBD	O
device	NN	O
was	VBD	O
easy	JJ	O
to	TO	O
use	VB	O
,	,	O
they	PRP	O
experienced	VBD	O
no	DT	O
cybersickness	NN	PH
,	,	O
and	CC	O
100	CD	O
%	NN	O
would	MD	O
use	VB	O
VR	NNP	O
again	RB	O
.	.	O

Primary	JJ	O
prophylaxis	NN	O
with	IN	O
pyrimethamine	NN	O
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
disease	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

Terry	NNP	O
Beirn	NNP	O
Community	NNP	O
Programs	NNP	O
for	IN	O
Clinical	NNP	O
Research	NNP	O
on	IN	O
AIDS	NNP	O
.	.	O

Pyrimethamine	NNP	O
,	,	O
25	CD	O
mg	NN	O
thrice	NN	O
weekly	RB	O
,	,	O
was	VBD	O
evaluated	VBN	O
as	IN	O
primary	JJ	O
prophylaxis	NN	O
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
(	(	O
TE	NNP	O
)	)	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
disease	NN	O
,	,	O
absolute	JJ	O
CD4	NNP	O
lymphocyte	NN	O
count	NN	O
of	IN	O
<	$	O
200/microL	CD	O
(	(	O
or	CC	O
prior	RB	O
AIDS-defining	NNP	O
opportunistic	JJ	O
infection	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
serum	NN	O
IgG	NNP	O
to	TO	O
Toxoplasma	NNP	O
gondii	NN	O
.	.	O

Leucovorin	NNP	O
was	VBD	O
coadministered	VBN	O
only	RB	O
for	IN	O
hematologic	JJ	O
toxicity	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
death	NN	MO
rate	NN	MO
among	IN	O
patients	NNS	O
receiving	VBG	O
pyrimethamine	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
,	,	O
2.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.3-4.8	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
,	,	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
factors	NNS	O
predictive	CD	O
of	IN	O
survival	NN	O
.	.	O

The	DT	O
TE	NNP	PH
event	NN	PH
rate	NN	PH
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Only	RB	O
1	CD	O
of	IN	O
218	CD	O
patients	NNS	O
taking	VBG	O
trimethoprim-sulfamethoxazole	JJ	O
but	CC	O
7	CD	O
of	IN	O
117	CD	O
taking	VBG	O
aerosolized	JJ	O
pentamidine	NN	O
for	IN	O
prophylaxis	NN	O
against	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
developed	VBD	O
TE	NNP	O
(	(	O
adjusted	VBN	O
RR	NNP	O
for	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
,	,	O
0.16	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-1.79	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.14	NNP	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
for	IN	O
HIV-infected	JJ	O
patients	NNS	O
receiving	VBG	O
trimethoprim-sulfamethoxazole	JJ	O
,	,	O
additional	JJ	O
prophylaxis	NN	O
for	IN	O
TE	NNP	O
appears	VBZ	O
unnecessary	JJ	O
.	.	O

Comparison	NNP	O
of	IN	O
maintenance	NN	O
treatment	NN	O
regimens	NNS	O
for	IN	O
first	JJ	O
central	JJ	O
nervous	JJ	O
system	NN	O
relapse	NN	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
.	.	O

A	DT	O
Pediatric	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

Eighty-seven	JJ	O
children	NNS	O
with	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
(	(	O
CNS	NNP	O
)	)	O
leukemia	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
induction	NN	O
intrathecal	JJ	O
chemotherapy	NN	O
(	(	O
ITC	NNP	O
)	)	O
and	CC	O
cranial	JJ	O
irradiation	NN	O
(	(	O
CRT	NNP	O
)	)	O
plus	CC	O
maintenance	NN	O
ITC	NNP	O
,	,	O
or	CC	O
induction	NN	O
ITC	NNP	O
and	CC	O
craniospinal	JJ	O
irradiation	NN	O
(	(	O
CSpRT	NNP	O
)	)	O
with	IN	O
no	DT	O
maintenance	NN	O
ITC	NNP	O
.	.	O

ITC	NNP	O
consisted	VBD	O
of	IN	O
six	CD	O
weekly	JJ	O
injections	NNS	O
of	IN	O
methotrexate	NN	O
,	,	O
hydrocortisone	NN	O
,	,	O
and	CC	O
arabinosylcytosine	NN	O
.	.	O

Also	RB	O
,	,	O
intensification	NN	O
of	IN	O
systemic	JJ	O
induction	NN	O
and	CC	O
maintenance	NN	O
chemotherapy	NN	O
was	VBD	O
given	VBN	O
.	.	O

CRT	NNP	O
+	NNP	O
ITC	NNP	O
was	VBD	O
given	VBN	O
as	IN	O
CRT	NNP	O
,	,	O
2400	CD	O
rad	NN	O
in	IN	O
12	CD	O
fractions	NNS	O
followed	VBN	O
by	IN	O
ITC	NNP	O
maintenance	NN	O
bimonthly	NN	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

Craniospinal	JJ	O
irradiation	NN	O
consisted	VBD	O
of	IN	O
CRT	NNP	O
+	NNP	O
1400	CD	O
rad	NN	O
in	IN	O
ten	JJ	O
fractions	NNS	O
to	TO	O
the	DT	O
spine	NN	O
.	.	O

Randomization	NN	O
was	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
CNS	NNP	O
leukemia	NN	O
occurred	VBD	O
at	IN	O
initial	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
(	(	O
ALL	DT	O
)	)	O
(	(	O
Stratum	NNP	O
I	PRP	O
,	,	O
15	CD	O
patients	NNS	O
)	)	O
,	,	O
during	IN	O
first	JJ	O
bone	NN	O
marrow	NN	O
(	(	O
BM	NNP	O
)	)	O
remission	NN	O
(	(	O
Stratum	NNP	O
II	NNP	O
,	,	O
49	CD	O
patients	NNS	O
)	)	O
,	,	O
simultaneous	JJ	O
with	IN	O
first	JJ	O
BM	NNP	O
relapse	NN	O
(	(	O
Stratum	NNP	O
III	NNP	O
,	,	O
12	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
during	IN	O
second	JJ	O
BM	NNP	O
remission	NN	O
(	(	O
Stratum	NNP	O
IV	NNP	O
,	,	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
follow-up	NN	O
for	IN	O
patients	NNS	O
who	WP	O
remain	VBP	O
at	IN	O
risk	NN	O
is	VBZ	O
15	CD	O
+	JJ	O
months	NNS	O
.	.	O

Eight	NNP	O
children	NNS	O
(	(	O
seven	CD	O
on	IN	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
,	,	O
one	CD	O
on	IN	O
CSpRT	NNP	O
)	)	O
developed	VBD	O
presumed	VBN	PH
therapy	RB	PH
related	VBN	PH
encephalopathy	NN	PH
.	.	PH

In	IN	O
Stratum	NNP	O
II	NNP	O
,	,	O
16	CD	O
of	IN	O
29	CD	O
(	(	O
55	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
experienced	VBD	O
adverse	JJ	PH
events	NNS	PH
:	:	PH
3	CD	O
deaths	NNS	PH
during	IN	PH
continuous	JJ	PH
complete	JJ	PH
remission	NN	PH
(	(	PH
CCR	NNP	PH
)	)	PH
and	CC	O
13	CD	O
relapses	NNS	PH
(	(	O
2	CD	O
CNS	NNP	O
,	,	O
1	CD	O
CNS	NNP	O
+	NNP	O
BM	NNP	O
,	,	O
1	CD	O
BM	NNP	O
+	NNP	O
testes	VBZ	O
,	,	O
and	CC	O
2	CD	O
testes	NNS	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
only	RB	O
5	CD	O
relapses	NNS	PH
in	IN	O
20	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
patients	NNS	O
on	IN	O
CSpRT	NNP	O
(	(	O
1	CD	O
CNS	NNP	O
,	,	O
1	CD	O
CNS	NNP	O
+	NNP	O
BM	NNP	O
,	,	O
1	CD	O
BM	NNP	O
,	,	O
and	CC	O
2	CD	O
testes	NNS	O
)	)	O
.	.	O

The	DT	O
children	NNS	O
on	IN	O
both	DT	O
regimens	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
sex	NN	O
,	,	O
race	NN	O
,	,	O
age	NN	O
at	IN	O
initial	JJ	O
ALL	NNP	O
diagnosis	NN	O
,	,	O
time	NN	PH
from	IN	PH
ALL	NNP	PH
diagnosis	NN	PH
to	TO	PH
first	JJ	PH
episode	NN	PH
of	IN	PH
CNS	NNP	PH
leukemia	NN	PH
,	,	PH
systemic	JJ	PH
therapy	NN	PH
both	DT	PH
before	IN	PH
and	CC	PH
after	IN	PH
CNS	NNP	PH
relapse	NN	PH
,	,	PH
and	CC	PH
number	NN	PH
of	IN	PH
blasts	NNS	PH
in	IN	PH
the	DT	PH
spinal	JJ	PH
fluid	NN	PH
at	IN	PH
diagnosis	NN	PH
of	IN	PH
CNS	NNP	PH
leukemia	NN	PH
.	.	PH

The	DT	O
conclusion	NN	O
is	VBZ	O
that	IN	O
children	NNS	O
with	IN	O
isolated	JJ	O
CNS	NNP	O
leukemia	NN	O
can	MD	O
achieve	VB	O
prolonged	JJ	PH
survival	NN	PH
with	IN	PH
aggressive	JJ	PH
therapy	NN	PH
,	,	O
and	CC	O
that	IN	O
CSpRT	NNP	PH
is	VBZ	PH
possibly	RB	PH
less	RBR	PH
toxic	JJ	PH
and	CC	O
more	RBR	O
likely	JJ	O
than	IN	O
is	VBZ	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
to	TO	O
prevent	VB	O
subsequent	JJ	PH
BM	NNP	PH
and	CC	PH
testicular	JJ	PH
relapse	NN	PH
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
subsequent	JJ	O
CNS	NNP	PH
relapse	NN	PH
(	(	O
P	NNP	O
=	NNP	O
0.7	CD	O
)	)	O
.	.	O

A	DT	O
possible	JJ	O
systemic	JJ	O
therapy	NN	O
effect	NN	O
of	IN	O
spinal	JJ	PH
irradiation	NN	PH
is	VBZ	O
postulated	VBN	O
to	TO	O
explain	VB	O
the	DT	O
superiority	NN	PH
of	IN	PH
CSpRT	NNP	PH
.	.	PH

Hypnosis	NNP	O
treatment	NN	O
for	IN	O
severe	JJ	PH
irritable	JJ	PH
bowel	NN	PH
syndrome	NN	PH
:	:	PH
investigation	NN	O
of	IN	O
mechanism	NN	O
and	CC	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
.	.	O

Hypnosis	NNP	O
improves	VBZ	O
irritable	JJ	PH
bowel	NN	PH
syndrome	NN	PH
(	(	O
IBS	NNP	O
)	)	O
,	,	O
but	CC	O
the	DT	O
mechanism	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

Possible	JJ	O
physiological	JJ	O
and	CC	O
psychological	JJ	O
mechanisms	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
two	CD	O
studies	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
received	VBD	O
seven	CD	O
biweekly	JJ	O
hypnosis	NN	O
sessions	NNS	O
and	CC	O
used	VBD	O
hypnosis	NN	O
audiotapes	NNS	O
at	IN	O
home	NN	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
and	CC	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
barostat	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
in	IN	O
18	CD	O
patients	NNS	O
(	(	O
study	VB	O
I	PRP	O
)	)	O
,	,	O
and	CC	O
treatment	NN	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
conductance	NN	O
,	,	O
finger	NN	O
temperature	NN	O
,	,	O
and	CC	O
forehead	JJ	O
electromyographic	JJ	O
activity	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
24	CD	O
patients	NNS	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
.	.	O

Somatization	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
depression	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

All	DT	PH
central	JJ	PH
IBS	NNP	PH
symptoms	NNS	PH
improved	VBN	O
substantially	RB	O
from	IN	O
treatment	NN	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

Rectal	JJ	PA
pain	NN	PA
thresholds	NNS	PA
,	,	O
rectal	JJ	PH
smooth	JJ	PH
muscle	NN	PH
tone	NN	PH
,	,	PH
and	CC	PH
autonomic	JJ	PH
functioning	NN	PH
(	(	PH
except	IN	PH
sweat	NN	PH
gland	VBP	PH
reactivity	NN	PH
)	)	PH
were	VBD	O
unaffected	VBN	O
by	IN	O
hypnosis	NN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
somatization	NN	ME
and	CC	ME
psychological	JJ	ME
distress	NN	ME
showed	VBD	O
large	JJ	O
decreases	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
hypnosis	NN	O
improves	NNS	O
IBS	NNP	O
symptoms	NNS	O
through	IN	O
reductions	NNS	O
in	IN	O
psychological	JJ	ME
distress	NN	ME
and	CC	ME
somatization	NN	ME
.	.	PH

Improvements	NNS	O
were	VBD	O
unrelated	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
physiological	JJ	O
parameters	NNS	O
measured	VBD	O
.	.	O

Environmental	JJ	O
enrichment	NN	O
as	IN	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
autism	NN	PH
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Enriched	NNP	O
sensorimotor	NN	O
environments	NNS	O
enable	JJ	O
rodents	NNS	O
to	TO	O
compensate	VB	O
for	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
neurological	JJ	O
challenges	NNS	O
,	,	O
including	VBG	O
those	DT	O
induced	VBN	O
in	IN	O
animal	JJ	O
models	NNS	O
of	IN	O
autism	NN	O
.	.	O

Given	VBN	O
the	DT	O
sensorimotor	NN	O
deficits	NNS	O
in	IN	O
most	JJS	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
we	PRP	O
attempted	VBD	O
to	TO	O
translate	VB	O
that	DT	O
approach	NN	O
to	TO	O
their	PRP$	O
treatment	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
3-12	JJ	O
year-old	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
sensorimotor	NN	O
enrichment	NN	O
group	NN	O
,	,	O
which	WDT	O
received	VBD	O
daily	RB	O
olfactory/tactile	JJ	O
stimulation	NN	O
along	IN	O
with	IN	O
exercises	NNS	O
that	WDT	O
stimulated	VBD	O
other	JJ	O
paired	JJ	O
sensory	JJ	O
modalities	NNS	O
,	,	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

We	PRP	O
administered	VBD	O
tests	NNS	O
of	IN	O
cognitive	JJ	O
performance	NN	O
and	CC	O
autism	NN	O
severity	NN	O
to	TO	O
both	DT	O
groups	NNS	O
at	IN	O
the	DT	O
initiation	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Severity	NNP	PH
of	IN	PH
autism	NN	PH
,	,	O
as	IN	O
assessed	VBN	O
with	IN	O
the	DT	O
Childhood	NNP	Ot
Autism	NNP	Ot
Rating	NNP	Ot
Scale	NNP	Ot
,	,	O
improved	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
controls	NNS	O
.	.	O

Indeed	RB	O
,	,	O
42	CD	O
%	NN	O
of	IN	O
the	DT	O
enriched	VBN	O
group	NN	O
and	CC	O
only	RB	O
7	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
had	VBD	O
what	WP	O
we	PRP	O
considered	VBD	O
to	TO	O
be	VB	O
a	DT	O
clinically	RB	O
significant	JJ	O
improvement	NN	O
of	IN	O
5	CD	O
points	NNS	O
on	IN	O
that	DT	O
scale	NN	O
.	.	O

Sensorimotor	NNP	O
enrichment	NN	O
also	RB	O
produced	VBD	O
a	DT	O
clear	JJ	Ot
improvement	NN	Ot
in	IN	Ot
cognition	NN	Ot
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
their	PRP$	O
Leiter-R	JJ	O
Visualization	NNP	O
and	CC	O
Reasoning	NNP	O
scores	NNS	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
average	JJ	O
scores	NNS	O
for	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
was	VBD	O
11.3	CD	O
points	NNS	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Finally	RB	O
,	,	O
69	CD	O
%	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
and	CC	O
31	CD	O
%	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
reported	VBD	O
improvement	NN	O
in	IN	O
their	PRP$	O
child	NN	O
over	IN	O
the	DT	O
6-month	JJ	O
study	NN	O
.	.	O

Environmental	JJ	O
enrichment	NN	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
ameliorating	VBG	Ot
some	DT	Ot
of	IN	Ot
the	DT	Ot
symptoms	NNS	Ot
of	IN	Ot
autism	NN	Ot
in	IN	O
children	NNS	O
.	.	O

Divalproex	NNP	O
sodium	NN	O
vs.	FW	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	ME
behaviours	NNS	ME
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Autism	NNP	O
is	VBZ	O
a	DT	O
neurodevelopmental	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
impairment	NN	O
in	IN	O
three	CD	O
core	NN	O
symptom	NN	O
domains	NNS	O
:	:	O
socialization	NN	O
,	,	O
communication	NN	O
,	,	O
and	CC	O
repetitive/stereotyped	VBD	O
behaviours	NNS	O
.	.	O

Other	JJ	O
associated	JJ	O
symptom	NN	O
domains	NNS	O
are	VBP	O
also	RB	O
affected	JJ	O
including	VBG	O
impulsivity/aggression	NN	O
,	,	O
self-injury	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
mood	NN	O
lability	NN	O
.	.	O

Divalproex	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
efficacy	NN	O
in	IN	O
treating	VBG	O
epilepsy	NN	O
,	,	O
bipolar	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
lability	NN	O
,	,	O
and	CC	O
impulsive	JJ	O
aggression	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	PH
,	,	PH
compulsive-like	JJ	PH
symptoms	NNS	PH
of	IN	PH
autism	NN	PH
spectrum	NN	PH
disorder	NN	PH
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirteen	JJ	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
participated	VBD	O
in	IN	O
an	DT	O
8-wk	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
divalproex	NN	O
sodium	NN	O
vs.	FW	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
group	NN	O
difference	NN	O
on	IN	O
improvement	NN	O
in	IN	O
repetitive	JJ	ME
behaviours	NNS	ME
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Children	NNP	ME
's	POS	ME
Yale-Brown	JJ	ME
Obsessive	NNP	ME
Compulsive	NNP	ME
Scale	NNP	ME
(	(	ME
C-YBOCS	NNP	ME
)	)	ME
(	(	O
p=0.037	NN	O
)	)	O
and	CC	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
(	(	O
d=1.616	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
preliminary	JJ	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	O
in	IN	O
treating	VBG	O
repetitive	JJ	ME
behaviours	NNS	ME
in	IN	O
ASD	NNP	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
specificity	NN	O
and	CC	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
comparing	VBG	O
induction	NN	O
chemotherapy	NN	O
versus	NN	O
induction	NN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
.	.	O

European	JJ	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
.	.	O

PURPOSE	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
European	NNP	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
(	(	O
ELCWP	NNP	O
)	)	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
to	TO	O
determine	VB	O
if	IN	O
maintenance	NN	O
chemotherapy	NN	O
with	IN	O
12	CD	O
courses	NNS	O
of	IN	O
etoposide	NN	O
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
vindesine	NN	O
(	(	O
3	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
3	CD	O
)	)	O
could	MD	O
improve	VB	O
progression-free	JJ	MO
survival	NN	MO
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
six	CD	O
courses	NNS	O
of	IN	O
induction	NN	O
chemotherapy	NN	O
with	IN	O
ifosfamide	NN	O
,	,	O
etoposide	RB	O
,	,	O
and	CC	O
an	DT	O
anthracycline	NN	O
(	(	O
doxorubicin	NN	O
or	CC	O
epirubicin	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
235	CD	O
eligible	JJ	O
patients	NNS	O
initially	RB	O
registered	VBD	O
,	,	O
91	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
maintenance	NN	O
therapy	NN	O
,	,	O
including	VBG	O
seven	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
no	RB	O
longer	RBR	O
responding	VBG	O
.	.	O

Among	IN	O
84	CD	O
randomized	JJ	O
responders	NNS	O
,	,	O
progression-free	JJ	MO
survival	NN	MO
was	VBD	O
significantly	RB	O
improved	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
by	IN	O
maintenance	NN	O
therapy	NN	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
(	(	O
maintenance	NN	O
v	IN	O
follow-up	JJ	O
)	)	O
of	IN	O
25	CD	O
versus	NNS	O
12	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
second	JJ	O
randomization	NN	O
,	,	O
but	CC	O
survival	NN	MO
was	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.10	NNP	O
)	)	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
of	IN	O
48	CD	O
and	CC	O
38	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
multi-variate	JJ	O
analysis	NN	O
that	WDT	O
took	VBD	O
into	IN	O
account	NN	PH
disease	NN	PH
extent	NN	PH
,	,	PH
maintenance	NN	PH
therapy	NN	PH
,	,	PH
Karnofsky	NNP	PH
performance	NN	PH
status	NN	PH
(	(	PH
PS	NNP	PH
)	)	PH
,	,	PH
and	CC	PH
absolute	JJ	PH
dose-intensity	NN	PH
(	(	PH
ADI	NNP	PH
)	)	PH
of	IN	PH
anthracycline	NN	PH
given	VBN	O
during	IN	O
induction	NN	O
,	,	O
limited	JJ	PH
disease	NN	PH
(	(	PH
LD	NNP	PH
)	)	PH
and	CC	PH
maintenance	NN	PH
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
independent	JJ	O
positive	JJ	O
predictors	NNS	O
of	IN	O
survival	NN	MO
.	.	MO

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	DT	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
responding	VBG	O
patients	NNS	O
is	VBZ	O
beneficial	JJ	O
in	IN	O
SCLC	NNP	O
.	.	O

RCT	NNP	O
of	IN	O
a	DT	O
manualized	JJ	O
social	JJ	O
treatment	NN	O
for	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
RCT	NNP	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
manualized	VBN	O
social	JJ	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
HFASDs	NNP	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
or	CC	O
wait-list	JJ	O
conditions	NNS	O
.	.	O

Treatment	NNP	O
included	VBD	O
instruction	NN	O
and	CC	O
therapeutic	JJ	O
activities	NNS	O
targeting	VBG	O
social	JJ	O
skills	NNS	O
,	,	O
face-emotion	NN	O
recognition	NN	O
,	,	O
interest	NN	O
expansion	NN	O
,	,	O
and	CC	O
interpretation	NN	O
of	IN	O
non-literal	JJ	O
language	NN	O
.	.	O

A	DT	O
response-cost	JJ	O
program	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
reduce	VB	O
problem	NN	O
behaviors	NNS	O
and	CC	O
foster	JJ	O
skills	NNS	O
acquisition	NN	O
.	.	O

Significant	NNP	O
treatment	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
five	CD	O
of	IN	O
seven	CD	O
primary	JJ	O
outcome	JJ	O
measures	NNS	O
(	(	O
parent	NN	ME
ratings	NNS	ME
and	CC	O
direct	JJ	O
child	NN	O
measures	NNS	O
)	)	O
.	.	O

Secondary	JJ	O
measures	NNS	O
based	VBN	O
on	IN	O
staff	NN	Ot
ratings	NNS	Ot
(	(	O
treatment	NN	O
group	NN	O
only	RB	O
)	)	O
corroborated	VBD	O
gains	NNS	O
reported	VBN	O
by	IN	O
parents	NNS	O
.	.	O

High	JJ	O
levels	NNS	O
of	IN	O
parent	NN	Ot
,	,	Ot
child	NN	Ot
and	CC	Ot
staff	NN	Ot
satisfaction	NN	Ot
were	VBD	O
reported	VBN	O
,	,	O
along	IN	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
treatment	NN	ME
fidelity	NN	ME
.	.	ME

Standardized	JJ	O
effect	NN	O
size	NN	O
estimates	NNS	O
were	VBD	O
primarily	RB	O
in	IN	O
the	DT	O
medium	NN	O
and	CC	O
large	JJ	O
ranges	NNS	O
and	CC	O
favored	VBD	O
the	DT	O
treatment	NN	O
group	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
three	CD	O
solutions	NNS	O
of	IN	O
ropivacaine/fentanyl	NN	O
for	IN	O
postoperative	JJ	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
Ropivacaine	NNP	O
,	,	O
0.2	CD	O
%	NN	O
,	,	O
is	VBZ	O
a	DT	O
new	JJ	O
local	JJ	O
anesthetic	JJ	O
approved	VBN	O
for	IN	O
epidural	JJ	O
analgesia	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
4	CD	O
microg/ml	NNS	O
fentanyl	JJ	O
improves	NNS	O
analgesia	VBP	O
from	IN	O
epidural	JJ	O
ropivacaine	NN	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
lower	JJR	O
concentration	NN	O
of	IN	O
ropivacaine-fentanyl	NN	O
may	MD	O
further	VB	O
improve	VB	O
analgesia	NN	O
or	CC	O
decrease	JJ	O
side	NN	A
effects	NNS	A
.	.	A

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blinded	JJ	O
manner	NN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
three	CD	O
solutions	NNS	O
:	:	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	VBD	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
,	,	O
or	CC	O
0.05	CD	O
%	NN	O
ropivacaine-1	JJ	O
microg	NN	O
fentanyl	NN	O
for	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
standardized	VBN	O
combined	JJ	O
epidural	JJ	O
and	CC	O
general	JJ	O
anesthesia	NN	O
.	.	O

Patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
settings	NNS	O
and	CC	O
adjustments	NNS	O
for	IN	O
the	DT	O
three	CD	O
solutions	NNS	O
were	VBD	O
standardized	VBN	O
to	TO	O
deliver	VB	O
equivalent	JJ	O
drug	NN	O
doses	NNS	O
.	.	O

Pain	NN	PA
scores	NNS	PA
(	(	PA
rest	NN	PA
,	,	PA
cough	NN	PA
,	,	PA
and	CC	PA
ambulation	NN	PA
)	)	PA
,	,	PA
side	JJ	PA
effects	NNS	PA
(	(	PA
nausea	NN	PA
,	,	PA
pruritus	NN	PA
,	,	PA
sedation	NN	PA
,	,	PA
motor	NN	PA
block	NN	PA
,	,	PA
hypotension	NN	PA
,	,	PA
and	CC	PA
orthostasis	NN	PA
)	)	PA
,	,	PA
and	CC	PA
patient-controlled	JJ	PA
epidural	JJ	PA
analgesia	NN	PA
consumption	NN	PA
were	VBD	O
measured	VBN	O
for	IN	O
48	CD	O
h.	JJ	O
RESULTS	NNP	O
All	NNP	O
three	CD	O
solutions	NNS	O
produced	VBD	O
equivalent	JJ	O
analgesia	NN	O
.	.	O

Motor	NNP	PH
block	NN	PH
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
(	(	O
30	CD	O
vs.	FW	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
more	JJR	O
intense	JJ	O
with	IN	O
the	DT	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	JJ	O
solution	NN	O
.	.	O

Other	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
equivalent	JJ	O
between	IN	O
solutions	NNS	O
and	CC	O
mild	NN	O
in	IN	O
severity	NN	A
.	.	A

A	DT	O
significantly	RB	O
smaller	JJR	O
volume	NN	O
of	IN	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	PH
microg	NN	PH
fentanyl	JJ	PH
solution	NN	PH
was	VBD	O
used	VBN	O
,	,	O
whereas	IN	O
the	DT	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
group	NN	O
used	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
amount	NN	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

CONCLUSIONS	NNP	O
Lesser	NNP	O
concentrations	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	JJ	O
provide	NN	O
comparable	JJ	O
analgesia	NN	O
with	IN	O
less	JJR	O
motor	NN	PH
block	NN	PH
despite	IN	O
the	DT	O
use	NN	O
of	IN	O
similar	JJ	O
amounts	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

This	DT	O
finding	NN	O
suggests	VBZ	O
that	IN	O
concentration	NN	O
of	IN	O
local	JJ	O
anesthetic	JJ	O
solution	NN	O
at	IN	O
low	JJ	O
doses	NNS	O
is	VBZ	O
a	DT	O
primary	JJ	O
determinant	NN	A
of	IN	A
motor	NN	A
block	NN	A
with	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Behavioral	NNP	ME
and	CC	ME
physiological	JJ	ME
effects	NNS	ME
of	IN	O
remifentanil	NN	O
and	CC	O
alfentanil	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
subjective	JJ	ME
and	CC	ME
psychomotor	JJ	ME
effects	NNS	ME
of	IN	O
remifentanil	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
authors	NNS	O
used	VBD	O
mood	NN	O
inventories	NNS	O
and	CC	O
psychomotor	NN	O
tests	NNS	O
to	TO	O
characterize	VB	O
the	DT	O
effects	NNS	O
of	IN	O
remifentanil	NN	O
in	IN	O
healthy	JJ	O
,	,	O
non-drug-abusing	JJ	O
volunteers	NNS	O
.	.	O

Alfentanil	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
comparator	NN	O
drug	NN	O
.	.	O

METHODS	NNP	O
Ten	NNP	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
an	DT	O
infusion	NN	O
of	IN	O
saline	NN	O
,	,	O
remifentanil	NN	O
,	,	O
or	CC	O
alfentanil	NN	O
for	IN	O
120	CD	O
min	NN	O
.	.	O

The	DT	O
age-	JJ	O
and	CC	O
weight-adjusted	JJ	O
infusions	NNS	O
(	(	O
determined	VBN	O
with	IN	O
STANPUMP	NNP	O
,	,	O
a	DT	O
computer	NN	O
modeling	VBG	O
software	NN	O
package	NN	O
)	)	O
were	VBD	O
given	VBN	O
to	TO	O
achieve	VB	O
three	CD	O
predicted	VBN	O
constant	JJ	O
plasma	NN	O
levels	NNS	O
for	IN	O
40	CD	O
min	NNS	O
each	DT	O
of	IN	O
remifentanil	NN	O
(	(	O
0.75	CD	O
,	,	O
1.5	CD	O
,	,	O
and	CC	O
3	CD	O
ng/ml	NN	O
)	)	O
and	CC	O
alfentanil	NN	O
(	(	O
16	CD	O
,	,	O
32	CD	O
,	,	O
and	CC	O
64	CD	O
ng/ml	NN	O
)	)	O
.	.	O

Mood	NN	O
forms	NNS	O
and	CC	O
psychomotor	NN	O
tests	NNS	O
were	VBD	O
completed	VBN	O
,	,	O
and	CC	O
miosis	NN	O
was	VBD	O
assessed	VBN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
infusions	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
analgesia	NN	O
was	VBD	O
tested	VBN	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
using	VBG	O
a	DT	O
cold-pressor	JJ	O
test	NN	O
.	.	O

RESULTS	NNP	O
Remifentanil	NNP	O
had	VBD	O
prototypic	VBN	ME
micro-like	JJ	ME
opioid	JJ	ME
subjective	JJ	ME
effects	NNS	ME
,	,	ME
impaired	JJ	ME
psychomotor	NN	ME
performance	NN	ME
,	,	ME
and	CC	ME
produced	VBD	ME
analgesia	NN	ME
.	.	O

Alfentanil	NNP	O
at	IN	O
the	DT	O
dose	JJ	O
range	NN	O
tested	VBD	O
had	VBD	O
more	RBR	O
mild	JJ	O
effects	NNS	O
on	IN	O
these	DT	O
measures	NNS	O
,	,	O
and	CC	O
the	DT	O
analgesia	NN	PH
data	NNS	O
indicated	VBD	O
that	IN	O
a	DT	O
40:1	CD	O
potency	NN	O
ratio	NN	O
,	,	O
rather	RB	O
than	IN	O
the	DT	O
20:1	CD	O
ratio	NN	O
we	PRP	O
used	VBD	O
,	,	O
may	MD	O
exist	VB	O
between	IN	O
remifentanil	NN	O
and	CC	O
alfentanil	NN	O
.	.	O

A	DT	O
psychomotor	NN	O
test	NN	O
administered	VBD	O
60	CD	O
min	NN	O
after	IN	O
the	DT	O
remifentanil	NN	O
infusion	NN	O
was	VBD	O
discontinued	VBN	O
showed	VBD	O
that	IN	O
the	DT	O
volunteers	NNS	O
were	VBD	O
still	RB	O
impaired	VBN	O
,	,	O
although	IN	O
they	PRP	O
reported	VBD	O
feeling	VBG	O
no	DT	O
drug	NN	O
effects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
notion	NN	O
that	IN	O
the	DT	O
pharmacodynamic	JJ	ME
effects	NNS	ME
of	IN	O
remifentanil	NN	O
are	VBP	O
extremely	RB	O
short-lived	JJ	O
after	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
no	DT	O
longer	RB	O
administered	VBN	O
must	MD	O
be	VB	O
questioned	VBN	O
given	VBN	O
our	PRP$	O
findings	NNS	O
that	IN	O
psychomotor	NN	ME
effects	NNS	ME
were	VBD	O
still	RB	O
apparent	JJ	O
1	CD	O
h	NN	O
after	IN	O
the	DT	O
infusion	NN	O
was	VBD	O
discontinued	VBN	O
.	.	O

Dexamethasone	NNP	O
effectively	RB	O
reduces	VBZ	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
a	DT	O
general	JJ	O
surgical	JJ	O
adult	NN	O
patient	JJ	O
population	NN	O
.	.	O

BACKGROUND	NNP	O
Postoperative	NNP	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
is	VBZ	O
still	RB	O
a	DT	O
common	JJ	O
and	CC	O
major	JJ	O
complication	NN	O
for	IN	O
surgical	JJ	O
patients	NNS	O
,	,	O
which	WDT	O
may	MD	O
delay	VB	O
post-anesthetic	JJ	O
care	NN	O
unit	NN	O
discharge	NN	O
,	,	O
prolong	JJ	O
hospital	NN	O
stay	NN	O
and	CC	O
thus	RB	O
increase	VB	O
the	DT	O
cost	NN	O
of	IN	O
hospitalization	NN	O
.	.	O

It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
PONV	NNP	O
is	VBZ	O
a	DT	O
multi-factorial	JJ	O
outcome	NN	O
and	CC	O
occurs	VBZ	O
more	RBR	O
often	RB	O
with	IN	O
general	JJ	O
anesthesia	NN	O
than	IN	O
with	IN	O
other	JJ	O
anesthetic	JJ	O
methods	NNS	O
.	.	O

Prophylactic	JJ	O
administration	NN	O
of	IN	O
antihistamines	NNS	O
,	,	O
antidopaminergics	NNS	O
,	,	O
anticholinergics	NNS	O
,	,	O
phenothiazines	NNS	O
,	,	O
serotonin	JJ	O
antagonist	NN	O
,	,	O
steroids	NNS	O
and	CC	O
even	RB	O
acupuncture	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

However	RB	O
,	,	O
expenses	NNS	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
a	DT	O
concern	NN	O
for	IN	O
clinical	JJ	O
doctors	NNS	O
.	.	O

The	DT	O
aim	NN	O
for	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
an	DT	O
agent	NN	O
that	WDT	O
is	VBZ	O
cost	RBS	O
effective	JJ	O
and	CC	O
side	JJ	O
effect	NN	O
free	JJ	O
(	(	O
or	CC	O
at	IN	O
least	JJS	O
with	IN	O
a	DT	O
low	JJ	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
)	)	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
PONV	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
700	CD	O
adult	NN	O
surgical	JJ	O
patients	NNS	O
who	WP	O
planned	VBD	O
to	TO	O
have	VB	O
surgery	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
double-blinded	JJ	O
,	,	O
randomized	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Group	NNP	O
P	NNP	O
received	VBD	O
the	DT	O
placebo	NN	O
(	(	O
0.9	CD	O
%	NN	O
normal	JJ	O
saline	JJ	O
2	CD	O
ml	NN	O
)	)	O
and	CC	O
Group	NNP	O
D	NNP	O
received	VBD	O
10	CD	O
mg	NNS	O
dexamethasone	RB	O
intravenously	RB	O
right	JJ	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
that	IN	O
during	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
1-8	JJ	O
h	NN	O
,	,	O
patients	NNS	O
in	IN	O
Group	NNP	O
D	NNP	O
reported	VBD	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
PONV	NNP	PH
(	(	O
24	CD	O
%	NN	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
Group	NNP	O
P	NNP	O
(	(	O
39	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
Group	NNP	O
D	NNP	O
also	RB	O
requested	VBD	O
less	JJR	O
rescue	JJ	O
anti-emetic	JJ	O
(	(	O
17	CD	O
%	NN	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
Group	NNP	O
P	NNP	O
(	(	O
30	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
phenomenon	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
the	DT	O
8-to-24-hour	JJ	O
interval	NN	O
(	(	O
PONV	NNP	O
4	CD	O
%	NN	O
vs.	FW	O
12	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
and	CC	O
rescue	VB	O
anti-emetic	JJ	O
3	CD	O
%	NN	O
vs.	FW	O
9	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
in	IN	O
Group	NNP	O
D	NNP	O
vs.	FW	O
Group	NNP	O
P	NNP	O
,	,	O
respectively	RB	O
.	.	O

)	)	O
CONCLUSIONS	IN	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
prophylactic	JJ	O
intravenous	JJ	O
administration	NN	O
of	IN	O
10	CD	O
mg	NNS	O
dexamethasone	VBP	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
preventing	VBG	O
PONV	NNP	O
in	IN	O
the	DT	O
general	JJ	O
surgical	JJ	O
adult	NN	O
patient	JJ	O
population	NN	O
.	.	O

Science	NN	O
to	TO	O
practice	NN	O
in	IN	O
underserved	JJ	O
communities	NNS	O
:	:	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
school	NN	O
mental	JJ	O
health	NN	O
programming	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
treatment	NN	O
program	NN	O
comprised	VBN	O
of	IN	O
several	JJ	O
components	NNS	O
based	VBN	O
on	IN	O
evidence-based	JJ	O
treatments	NNS	O
(	(	O
EBTs	NNP	O
)	)	O
for	IN	O
disruptive	JJ	O
behavior	NN	O
problems	NNS	O
delivered	VBN	O
to	TO	O
youth	VB	O
participating	VBG	O
in	IN	O
a	DT	O
school	NN	O
mental	JJ	O
health	NN	O
program	NN	O
in	IN	O
an	DT	O
underserved	JJ	O
community	NN	O
in	IN	O
the	DT	O
Appalachian	JJ	O
region	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
117	CD	O
children	NNS	O
in	IN	O
kindergarten	VBN	O
through	IN	O
6th	CD	O
grade	NN	O
including	VBG	O
91	CD	O
children	NNS	O
(	(	O
78	CD	O
%	NN	O
male	NN	O
)	)	O
from	IN	O
5	CD	O
schools	NNS	O
who	WP	O
were	VBD	O
consecutively	RB	O
referred	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
program	NN	O
and	CC	O
26	CD	O
children	NNS	O
(	(	O
73	CD	O
%	NN	O
male	NN	O
)	)	O
from	IN	O
3	CD	O
schools	NNS	O
in	IN	O
which	WDT	O
program	NN	O
implementation	NN	O
was	VBD	O
delayed	VBN	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

Treatment	NNP	O
outcome	NN	O
was	VBD	O
measured	VBN	O
via	IN	O
parent	NN	ME
and	CC	ME
teacher	JJ	ME
ratings	NNS	ME
of	IN	ME
child	NN	ME
symptoms	NNS	ME
and	CC	ME
functioning	VBG	ME
.	.	O

The	DT	O
treatment	NN	O
condition	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reduction	NN	O
in	IN	O
hyperactivity/impulsivity	NN	ME
and	CC	ME
early	JJ	ME
aggressive	JJ	ME
and	CC	ME
delinquent	JJ	ME
behavior	NN	ME
,	,	O
as	RB	O
well	RB	O
as	IN	O
significant	JJ	ME
improvement	NN	ME
in	IN	ME
several	JJ	ME
other	JJ	ME
functional	JJ	ME
domains	NNS	ME
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
EBTs	NNP	O
can	MD	O
retain	VB	O
their	PRP$	O
effectiveness	NN	Ot
when	WRB	O
transported	VBN	O
to	TO	O
a	DT	O
community	NN	O
context	NN	O
.	.	O

Family	RB	O
economic	JJ	O
empowerment	NN	O
and	CC	O
mental	JJ	O
health	NN	O
among	IN	O
AIDS-affected	JJ	O
children	NNS	O
living	VBG	O
in	IN	O
AIDS-impacted	JJ	O
communities	NNS	O
:	:	O
evidence	NN	O
from	IN	O
a	DT	O
randomised	JJ	O
evaluation	NN	O
in	IN	O
southwestern	JJ	O
Uganda	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
authors	NNS	O
examine	VBP	O
whether	IN	O
an	DT	O
innovative	JJ	O
family	NN	O
economic	JJ	O
empowerment	NN	O
intervention	NN	O
addresses	VBZ	O
mental	JJ	O
health	NN	O
functioning	NN	O
of	IN	O
AIDS-affected	JJ	O
children	NNS	O
in	IN	O
communities	NNS	O
heavily	RB	O
impacted	VBN	O
by	IN	O
HIV/AIDS	NNP	O
in	IN	O
Uganda	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
cluster	NN	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
consisting	VBG	O
of	IN	O
two	CD	O
study	NN	O
arms	NNS	O
,	,	O
a	DT	O
treatment	NN	O
condition	NN	O
(	(	O
n=179	JJ	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
condition	NN	O
(	(	O
n=118	JJ	O
)	)	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
family	NN	O
economic	JJ	O
empowerment	NN	O
intervention	NN	O
on	IN	O
children	NNS	O
's	POS	O
levels	NNS	O
of	IN	O
hopelessness	NN	O
and	CC	O
depression	NN	O
.	.	O

The	DT	O
intervention	NN	O
comprised	VBD	O
matched	JJ	O
children	NNS	O
savings	NNS	O
accounts	NNS	O
,	,	O
financial	JJ	O
management	NN	O
workshops	NNS	O
and	CC	O
mentorship	NN	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

RESULTS	NNP	O
Using	VBG	O
multivariate	JJ	O
analysis	NN	O
with	IN	O
several	JJ	O
socioeconomic	JJ	O
controls	NNS	O
,	,	O
the	DT	O
authors	NNS	O
find	VBP	O
that	IN	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
condition	NN	O
(	(	O
receiving	VBG	O
the	DT	O
intervention	NN	O
)	)	O
report	NN	O
significant	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
mental	JJ	ME
health	NN	ME
functioning	NN	ME
.	.	ME

Specifically	RB	O
,	,	O
the	DT	O
intervention	NN	O
reduces	VBZ	O
hopelessness	NN	ME
and	CC	ME
depression	NN	ME
levels	NNS	ME
.	.	ME

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
(	(	O
not	RB	O
receiving	VBG	O
the	DT	O
intervention	NN	O
)	)	O
report	NN	O
no	DT	O
changes	NNS	O
on	IN	O
both	DT	O
measures	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
children	NNS	O
with	IN	O
poor	JJ	O
mental	JJ	O
health	NN	O
functioning	VBG	O
living	NN	O
in	IN	O
communities	NNS	O
affected	VBN	O
by	IN	O
HIV/AIDS	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
innovative	JJ	O
family	NN	O
economic	JJ	O
empowerment	NN	O
interventions	NNS	O
.	.	O

As	IN	O
measures	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
functioning	NN	O
,	,	O
both	DT	O
hopelessness	NN	ME
and	CC	ME
depression	NN	ME
have	VBP	O
long-term	JJ	O
negative	JJ	O
psychosocial	NN	O
and	CC	O
developmental	JJ	O
impacts	NNS	O
on	IN	O
children	NNS	O
.	.	O

These	DT	O
findings	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
public	JJ	O
health	NN	O
programmes	NNS	O
intended	VBN	O
for	IN	O
long-term	JJ	O
care	NN	O
and	CC	O
support	NN	O
of	IN	O
children	NNS	O
living	VBG	O
in	IN	O
resource	JJ	O
poor	JJ	O
AIDS-impacted	JJ	O
communities	NNS	O
.	.	O

Effect	NN	O
of	IN	O
prophylactic	JJ	O
amiodarone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatic	JJ	O
valve	NNS	O
disease	NN	O
undergoing	VBG	O
valve	JJ	O
replacement	NN	O
surgery	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
single-dose	JJ	O
intravenous	JJ	O
amiodarone	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
valve	JJ	O
replacement	NN	O
surgery	NN	O
.	.	O

Maintenance	NN	O
of	IN	O
sinus	NN	O
rhythm	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
maintenance	NN	O
of	IN	O
fixed	JJ	O
ventricular	JJ	O
rate	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
especially	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
irritable	JJ	O
left	NN	O
or	CC	O
right	JJ	O
atrium	NN	O
because	IN	O
of	IN	O
enlargement	NN	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
with	IN	O
valvular	JJ	O
heart	NN	O
disease	NN	O
with	IN	O
or	CC	O
without	IN	O
AF	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
or	CC	O
the	DT	O
amiodarone	NN	O
group	NN	O
(	(	O
n=28	NN	O
)	)	O
received	VBD	O
amiodarone	NN	O
(	(	O
3	CD	O
mg/kg	NN	O
in	IN	O
100	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
)	)	O
and	CC	O
group	NN	O
II	NNP	O
or	CC	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
same	JJ	O
volume	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
.	.	O

The	DT	O
standardized	JJ	O
protocol	NN	O
for	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
was	VBD	O
maintained	VBN	O
for	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
.	.	O

AF	NNP	PH
occurred	VBD	O
in	IN	O
7.14	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
,	,	O
and	CC	O
in	IN	O
group	NN	O
II	NNP	O
,	,	O
28.57	CD	O
%	NN	O
(	(	O
P=0.035	NNP	O
)	)	O
;	:	O
ventricular	JJ	PH
tachycardia/fibrillation	NN	PH
was	VBD	O
observed	VBN	O
in	IN	O
21.43	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
46.43	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
P=0.089	NNP	O
)	)	O
after	IN	O
release	NN	O
of	IN	O
aortic	JJ	O
clamp	NN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
92.86	CD	O
%	NN	O
)	)	O
maintained	VBD	O
sinus	JJ	PH
rhythm	NN	PH
without	IN	PH
cardioversion	NN	PH
or	CC	PH
defibrillation	NN	PH
after	IN	O
release	NN	O
of	IN	O
aortic	JJ	O
cross	NN	O
clamp	NN	O
(	(	O
P=0.002	NNP	O
)	)	O
.	.	O

Defibrillation	NN	PH
or	CC	PH
cardio	NN	PH
version	NN	PH
was	VBD	O
needed	VBN	O
in	IN	O
7.14	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
28.57	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
P=0.078	NNP	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
prophylactic	JJ	O
intraoperative	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	O
decreased	VBD	O
post	NN	PH
bypass	NN	PH
arrhythmia	NN	PH
in	IN	O
this	DT	O
study	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Single	NNP	O
dose	NN	O
of	IN	O
intraoperative	JJ	O
amiodarone	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
decrease	VB	O
postoperative	JJ	O
arrhythmia	NN	O
in	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

A	DT	O
web-based	JJ	O
patient	NN	O
activation	NN	O
intervention	NN	O
to	TO	O
improve	VB	O
hypertension	NN	O
care	NN	O
:	:	O
study	NN	O
design	NN	O
and	CC	O
baseline	NN	O
characteristics	NNS	O
in	IN	O
the	DT	O
web	NN	O
hypertension	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
the	DT	O
known	JJ	O
health	NN	O
risks	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
many	JJ	O
hypertensive	JJ	O
patients	NNS	O
still	RB	O
have	VBP	O
uncontrolled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

Clinical	JJ	O
inertia	NN	O
,	,	O
the	DT	O
tendency	NN	O
of	IN	O
physicians	NNS	O
not	RB	O
to	TO	O
intensify	VB	O
treatment	NN	O
,	,	O
is	VBZ	O
a	DT	O
common	JJ	O
barrier	NN	O
in	IN	O
controlling	VBG	O
chronic	JJ	O
diseases	NNS	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
aimed	VBN	O
at	IN	O
determining	VBG	O
the	DT	O
impact	NN	O
of	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
ask	VB	O
providers	NNS	O
to	TO	O
make	VB	O
changes	NNS	O
to	TO	O
their	PRP$	O
care	NN	O
through	IN	O
tailored	VBN	O
feedback	NN	O
.	.	O

METHODS	NNP	O
Diagnosed	VBD	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
RCT	NNP	O
and	CC	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
intervention	NN	O
condition	NN	O
--	:	O
Web-based	JJ	O
hypertension	NN	O
feedback	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
self-report	NN	O
of	IN	O
health	NN	O
variables	NNS	O
and	CC	O
previous	JJ	O
BP	NNP	O
measurements	NNS	O
,	,	O
to	TO	O
prompt	VB	O
them	PRP	O
to	TO	O
ask	VB	O
questions	NNS	O
during	IN	O
their	PRP$	O
next	JJ	O
physician	NN	O
's	POS	O
visit	NN	O
about	IN	O
hypertension	NN	O
care	NN	O
(	(	O
2	CD	O
)	)	O
the	DT	O
control	NN	O
condition	NN	O
--	:	O
Web-based	JJ	O
preventive	JJ	O
health	NN	O
feedback	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
individual	NN	O
's	POS	O
self-report	NN	O
of	IN	O
receiving	VBG	O
preventive	JJ	O
care	NN	O
(	(	O
e.g.	UH	O
,	,	O
pap	JJ	O
testing	VBG	O
)	)	O
,	,	O
to	TO	O
prompt	VB	O
them	PRP	O
to	TO	O
ask	VB	O
questions	NNS	O
during	IN	O
their	PRP$	O
next	JJ	O
physician	NN	O
's	POS	O
visit	NN	O
about	IN	O
preventive	JJ	O
care	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
the	DT	O
study	NN	O
is	VBZ	O
change	VBN	PH
in	IN	PH
blood	NN	PH
pressure	NN	PH
and	CC	PH
change	NN	Ot
in	IN	Ot
the	DT	Ot
percentage	NN	Ot
of	IN	Ot
patients	NNS	Ot
in	IN	Ot
each	DT	Ot
group	NN	Ot
with	IN	Ot
controlled	VBN	Ot
blood	NN	Ot
pressure	NN	Ot
.	.	PH

CONCLUSION	NNP	O
Five	CD	O
hundred	VBD	O
participants	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
baseline	JJ	O
characteristics	NNS	O
include	VBP	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60.0	CD	O
years	NNS	O
;	:	O
57.6	CD	O
%	NN	O
female	NN	O
;	:	O
and	CC	O
77.6	CD	O
%	NN	O
white	JJ	O
.	.	O

Overall	JJ	O
37.7	CD	O
%	NN	O
participants	NNS	O
had	VBD	O
uncontrolled	VBN	O
blood	NN	O
pressure	NN	O
;	:	O
the	DT	O
mean	NN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
was	VBD	O
in	IN	O
the	DT	O
obese	JJ	O
range	NN	O
(	(	O
32.4	CD	O
)	)	O
and	CC	O
21.8	CD	O
%	NN	O
had	VBD	O
diabetes	NNS	O
.	.	O

By	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
become	VB	O
involved	VBN	O
in	IN	O
their	PRP$	O
own	JJ	O
care	NN	O
,	,	O
we	PRP	O
believe	VBP	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
web-based	JJ	O
intervention	NN	O
will	MD	O
improve	VB	O
blood	NN	PH
pressure	NN	PH
control	NN	PH
compared	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
who	WP	O
receive	VBP	O
web-based	JJ	O
preventive	JJ	O
messages	NNS	O
unrelated	VBN	O
to	TO	O
hypertension	NN	O
.	.	O

Anecortave	NNP	O
acetate	NN	O
treatment	NN	O
for	IN	O
retinal	JJ	O
angiomatous	JJ	O
proliferation	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
anecortave	JJ	O
acetate	JJ	O
treatment	NN	O
of	IN	O
retinal	JJ	O
angiomatous	JJ	O
proliferation	NN	O
(	(	O
RAP	NNP	O
)	)	O
,	,	O
a	DT	O
neovascular	JJ	O
form	NN	O
of	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
with	IN	O
specific	JJ	O
regard	NN	O
to	TO	O
inhibition	NN	PH
of	IN	PH
neovascularization	NN	PH
and	CC	PH
maintenance	NN	PH
of	IN	PH
vision	NN	PH
.	.	PH

METHODS	NNP	O
Thirty-four	JJ	O
patients	NNS	O
with	IN	O
RAP	NNP	O
with	IN	O
any	DT	O
stage	NN	O
of	IN	O
neovascularization	NN	O
were	VBD	O
randomized	VBN	O
1:1:1	CD	O
for	IN	O
treatment	NN	O
with	IN	O
three	CD	O
different	JJ	O
quantities	NNS	O
(	(	O
30	CD	O
mg	NN	O
,	,	O
15	CD	O
mg	NN	O
,	,	O
3	CD	O
mg	NN	O
)	)	O
of	IN	O
anecortave	NN	O
acetate	NN	O
sterile	JJ	O
suspension	NN	O
for	IN	O
juxtascleral	JJ	O
administration	NN	O
.	.	O

Best-corrected	JJ	PH
visual	JJ	PH
acuity	NN	PH
(	(	PH
Early	JJ	PH
Treatment	NNP	PH
Diabetic	NNP	PH
Retinopathy	NNP	PH
Study	NNP	PH
chart	NN	PH
)	)	PH
,	,	PH
intraocular	JJ	PH
pressure	NN	PH
measurement	NN	PH
,	,	PH
biomicroscopy	NN	PH
,	,	PH
funduscopy	NN	PH
,	,	PH
digital	JJ	PH
fluorescein	NN	PH
,	,	PH
and	CC	PH
indocyanine	NN	PH
green	JJ	PH
angiography	NN	PH
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

A	DT	O
6-month	JJ	O
retreatment	NN	O
interval	NN	O
was	VBD	O
established	VBN	O
for	IN	O
this	DT	O
study	NN	O
with	IN	O
a	DT	O
follow-up	NN	O
of	IN	O
12	CD	O
months	NNS	O
.	.	O

In	IN	O
selected	JJ	O
patients	NNS	O
optical	JJ	O
coherence	NN	O
tomography	NN	O
was	VBD	O
performed	VBN	O
.	.	O

The	DT	O
outcomes	NNS	O
were	VBD	O
mean	JJ	PH
changes	NNS	PH
in	IN	PH
visual	JJ	PH
acuity	NN	PH
and	CC	PH
lesion	NN	PH
size	NN	PH
at	IN	PH
1	CD	PH
year	NN	PH
.	.	PH

RESULTS	VB	O
The	DT	O
detachment	NN	PH
of	IN	PH
the	DT	PH
neurosensory	JJ	PH
retina	NN	PH
and	CC	PH
retinal	JJ	PH
pigment	NN	PH
epithelium	NN	PH
improved	VBN	O
in	IN	O
all	DT	O
eyes	NNS	O
,	,	O
but	CC	O
all	DT	O
neovascular	JJ	PH
lesions	NNS	PH
increased	VBD	PH
in	IN	PH
size	NN	PH
.	.	PH

Vision	NNP	PH
loss	NN	PH
occurred	VBD	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
study	NN	O
eyes	NNS	O
(	(	O
22	CD	O
out	IN	O
of	IN	O
34	CD	O
eyes	NNS	O
,	,	O
64.7	CD	O
%	NN	O
)	)	O
independent	JJ	O
of	IN	O
the	DT	O
concentration	NN	O
administered	VBD	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
posterior	JJ	O
juxtascleral	JJ	O
injection	NN	O
of	IN	O
anecortave	JJ	O
acetate	NN	O
reduces	NNS	O
capillary	JJ	PH
permeability	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
RAP	NNP	O
.	.	O

However	RB	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
improvement	NN	O
of	IN	O
the	DT	O
exudation	NN	O
there	EX	O
is	VBZ	O
a	DT	O
progression	NN	O
of	IN	O
neovascularization	NN	PH
and	CC	O
a	DT	O
significant	JJ	O
loss	NN	PH
of	IN	PH
vision	NN	PH
in	IN	O
all	PDT	O
these	DT	O
patients	NNS	O
.	.	O

Like	IN	O
other	JJ	O
monotherapeutic	JJ	O
methods	NNS	O
used	VBN	O
to	TO	O
treat	VB	O
this	DT	O
variant	NN	O
of	IN	O
neovascular	JJ	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
anecortave	VBP	O
acetate	JJ	O
alone	RB	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
benefit	VB	O
these	DT	O
patients	NNS	O
.	.	O

Future	JJ	O
studies	NNS	O
should	MD	O
investigate	VB	O
a	DT	O
combination	NN	O
form	NN	O
of	IN	O
therapy	NN	O
.	.	O

Clinical	JJ	O
hypnosis	NN	O
versus	NN	O
cognitive	JJ	O
behavioral	JJ	O
training	NN	O
for	IN	O
pain	NN	PA
management	NN	PA
with	IN	O
pediatric	JJ	O
cancer	NN	O
patients	NNS	O
undergoing	VBG	O
bone	NN	O
marrow	NN	O
aspirations	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
clinical	JJ	O
hypnosis	NN	O
versus	NN	O
cognitive	JJ	O
behavioral	NN	O
(	(	O
CB	NNP	O
)	)	O
coping	VBG	O
skills	NNS	O
training	VBG	O
in	IN	O
alleviating	VBG	O
the	DT	O
pain	NN	PA
and	CC	PA
distress	NN	PA
of	IN	O
30	CD	O
pediatric	JJ	O
cancer	NN	O
patients	NNS	O
(	(	O
age	NN	O
5	CD	O
to	TO	O
15	CD	O
years	NNS	O
)	)	O
undergoing	VBG	O
bone	NN	O
marrow	NN	O
aspirations	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
hypnosis	NN	O
,	,	O
a	DT	O
package	NN	O
of	IN	O
CB	NNP	O
coping	VBG	O
skills	NNS	O
,	,	O
and	CC	O
no	DT	O
intervention	NN	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
either	CC	O
hypnosis	NN	O
or	CC	O
CB	NNP	O
reported	VBD	O
less	JJR	O
pain	NN	PA
and	CC	PA
pain-related	JJ	ME
anxiety	NN	ME
than	IN	O
did	VBD	O
control	VB	O
patients	NNS	O
and	CC	O
less	JJR	O
pain	NN	PA
and	CC	PA
anxiety	NN	ME
than	IN	O
at	IN	O
their	PRP$	O
own	JJ	O
baseline	NN	O
.	.	O

Hypnosis	NNP	O
and	CC	O
CB	NNP	O
were	VBD	O
similarly	RB	O
effective	JJ	O
in	IN	O
the	DT	O
relief	NN	PH
of	IN	PH
pain	NN	PH
.	.	O

Results	NNP	O
also	RB	O
indicated	VBD	O
that	IN	O
children	NNS	O
reported	VBD	O
more	RBR	O
anxiety	NN	ME
and	CC	O
exhibited	VBD	O
more	RBR	O
behavioral	JJ	ME
distress	NN	ME
in	IN	O
the	DT	O
CB	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
hypnosis	NN	O
group	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
hypnosis	NN	O
and	CC	O
CB	NNP	O
coping	VBG	O
skills	NNS	O
are	VBP	O
effective	JJ	Ot
in	IN	O
preparing	VBG	O
pediatric	JJ	O
oncology	NN	O
patients	NNS	O
for	IN	O
bone	NN	O
marrow	NN	O
aspiration	NN	O
.	.	O

MDM2	NNP	O
and	CC	O
Ki-67	NNP	O
predict	NN	O
for	IN	O
distant	JJ	PH
metastasis	NN	PH
and	CC	O
mortality	NN	MO
in	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	O
and	CC	O
androgen	NN	O
deprivation	NN	O
for	IN	O
prostate	JJ	O
cancer	NN	O
:	:	O
RTOG	NNP	O
92-02	CD	O
.	.	O

PURPOSE	NNP	O
MDM2	NNP	O
regulates	VBZ	O
p53	NN	O
,	,	O
which	WDT	O
controls	VBZ	O
cell	NN	O
cycle	NN	O
arrest	NN	O
and	CC	O
apoptosis	NN	O
.	.	O

Both	DT	O
proteins	NNS	O
,	,	O
along	IN	O
with	IN	O
Ki-67	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
established	VBN	O
strong	JJ	O
determinant	NN	O
of	IN	O
metastasis	NN	O
,	,	O
have	VBP	O
shown	VBN	O
promise	NN	O
in	IN	O
predicting	VBG	O
the	DT	O
outcome	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
radiation	NN	O
therapy	NN	O
(	(	O
RT	NNP	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
short-term	JJ	O
androgen	NN	O
deprivation	NN	O
(	(	O
STAD	NNP	O
)	)	O
.	.	O

This	DT	O
report	NN	O
compares	VBZ	O
the	DT	O
utility	NN	O
of	IN	O
abnormal	JJ	O
expression	NN	O
of	IN	O
these	DT	O
biomarkers	NNS	O
in	IN	O
estimating	VBG	O
progression	NN	O
in	IN	O
a	DT	O
cohort	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
on	IN	O
RTOG	NNP	O
92-02	CD	O
.	.	O

PATIENTS	NNPS	O
AND	CC	O
METHODS	NNP	O
Adequate	NNP	O
tissue	NN	O
for	IN	O
immunohistochemistry	NN	O
was	VBD	O
available	JJ	O
for	IN	O
p53	NN	O
,	,	O
Ki-67	NNP	O
,	,	O
and	CC	O
MDM2	NNP	O
analyses	NNS	O
in	IN	O
478	CD	O
patient	JJ	O
cases	NNS	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
tumor	NN	PH
nuclei	NN	PH
staining	VBG	PH
positive	JJ	PH
(	(	O
PSP	NNP	O
)	)	O
was	VBD	O
quantified	VBN	O
manually	RB	O
or	CC	O
by	IN	O
image	NN	O
analysis	NN	O
,	,	O
and	CC	O
the	DT	O
per-sample	JJ	Ot
mean	JJ	Ot
intensity	NN	Ot
score	NN	Ot
(	(	PH
MIS	NNP	PH
)	)	PH
was	VBD	O
quantified	VBN	O
by	IN	O
image	NN	O
analysis	NN	O
.	.	O

Cox	NNP	O
regression	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
overall	JJ	MO
mortality	NN	MO
(	(	O
OM	NNP	O
)	)	O
,	,	O
and	CC	O
Fine	NNP	O
and	CC	O
Gray	NNP	O
's	POS	O
regressions	NNS	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
end	NN	O
points	NNS	O
of	IN	O
distant	JJ	PH
metastasis	NN	PH
(	(	PH
DM	NNP	PH
)	)	PH
and	CC	O
cause-specific	JJ	MO
mortality	NN	MO
(	(	MO
CSM	NNP	MO
)	)	MO
.	.	O

Results	NNS	O
In	IN	O
multivariate	JJ	O
analyses	NNS	O
that	WDT	O
adjusted	VBD	O
for	IN	O
all	DT	O
markers	NNS	O
and	CC	O
treatment	NN	O
covariates	NNS	O
,	,	O
MDM2	NNP	PH
overexpression	NN	PH
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
DM	NNP	PH
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
and	CC	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
,	,	O
and	CC	O
Ki-67	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
DM	NNP	PH
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
CSM	NNP	MO
(	(	O
P	NNP	O
=	NNP	O
.0007	NNP	O
)	)	O
,	,	O
and	CC	O
OM	NNP	MO
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

P53	NNP	PH
overexpression	NN	PH
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
OM	NNP	MO
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

When	WRB	O
considered	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
overexpression	NN	PH
of	IN	PH
both	DT	PH
Ki-67	NNP	PH
and	CC	PH
MDM2	NNP	PH
at	IN	O
high	JJ	O
levels	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	Ot
increased	VBN	Ot
failure	NN	Ot
rates	NNS	Ot
for	IN	O
all	DT	O
end	NN	O
points	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
for	IN	O
DM	NNP	O
,	,	O
CSM	NNP	O
,	,	O
and	CC	O
OM	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Combined	VBD	O
MDM2	NNP	PH
and	CC	O
Ki-67	NNP	PH
expression	NN	PH
levels	NNS	PH
were	VBD	O
independently	RB	O
related	VBN	O
to	TO	O
distant	JJ	PH
metastasis	NN	PH
and	CC	O
mortality	NN	MO
and	CC	O
,	,	O
if	IN	O
validated	VBN	O
,	,	O
could	MD	O
be	VB	O
considered	VBN	O
for	IN	O
risk	NN	O
stratification	NN	O
of	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
self-administered	JJ	O
vaginal	JJ	O
misoprostol	NN	O
versus	NN	O
placebo	NN	O
for	IN	O
cervical	JJ	O
ripening	VBG	O
prior	JJ	O
to	TO	O
operative	JJ	O
hysteroscopy	NN	O
using	VBG	O
a	DT	O
sequential	JJ	O
trial	NN	O
design	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
impact	NN	O
of	IN	O
1000-microgram	JJ	O
self-administered	JJ	O
vaginal	JJ	O
misoprostol	NN	O
versus	IN	O
self-administered	JJ	O
vaginal	JJ	O
placebo	NN	O
at	IN	O
home	NN	O
on	IN	O
preoperative	JJ	O
cervical	JJ	O
ripening	NN	O
in	IN	O
both	DT	O
premenopausal	NN	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
prior	RB	O
to	TO	O
outpatient	VB	O
resectoscopy	NN	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
sequential	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Norwegian	JJ	O
university	NN	O
teaching	VBG	O
hospital	NN	O
.	.	O

SAMPLE	NNP	O
Premenopausal	NNP	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
referred	VBD	O
to	TO	O
outpatient	VB	O
resectoscopy	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
women	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
either	DT	O
1000	CD	O
micrograms	NNS	O
of	IN	O
self-administered	JJ	O
vaginal	JJ	O
misoprostol	NN	O
or	CC	O
self-administered	JJ	O
vaginal	JJ	O
placebo	NN	O
the	DT	O
evening	NN	O
before	IN	O
outpatient	JJ	O
resectoscopy	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Preoperative	NNP	PH
cervical	JJ	PH
dilatation	NN	PH
,	,	O
acceptability	NN	Ot
and	CC	O
complications	NNS	A
.	.	O

RESULTS	NNP	O
(	(	O
a	DT	O
)	)	O
Intraoperative	JJ	O
findings	NNS	O
and	CC	O
distribution	NN	O
of	IN	O
cervical	JJ	O
dilatation	NN	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
median	JJ	O
(	(	O
range	NN	O
)	)	O
or	CC	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
b	NN	O
)	)	O
Acceptability	NN	Ot
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
completely	RB	O
acceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
;	:	O
fairly	RB	O
acceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
;	:	O
fairly	RB	O
unacceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
and	CC	O
completely	RB	O
unacceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
c	NN	O
)	)	O
Pain	NN	PA
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Pain	NNP	PA
was	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
score	NN	O
,	,	O
scale	JJ	O
ranges	NNS	O
from	IN	O
0	CD	O
(	(	O
no	DT	O
pain	NN	O
)	)	O
to	TO	O
10	CD	O
(	(	O
unbearable	JJ	O
pain	NN	O
)	)	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
median	JJ	O
(	(	O
range	NN	O
)	)	O
.	.	O

(	(	O
d	NN	O
)	)	O
Occurrence	NN	A
of	IN	A
adverse	JJ	A
effects	NNS	A
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
e	NN	O
)	)	O
Complications	NNPS	PH
,	,	O
given	VBN	O
as	IN	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

A	DT	O
first-in-man	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
feasibility	NN	Ot
of	IN	O
autologous	JJ	O
delipidated	VBN	O
high-density	NN	O
lipoprotein	NN	O
plasma	NN	O
infusions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
.	.	O

OBJECTIVES	CC	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
serial	JJ	O
autologous	JJ	O
infusions	NNS	O
of	IN	O
selective	JJ	O
high-density	NN	O
lipoprotein	NN	O
(	(	O
HDL	NNP	O
)	)	O
delipidated	VBD	O
plasma	NN	O
are	VBP	O
feasible	JJ	Ot
and	CC	O
well	RB	O
tolerated	VBN	Ot
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
(	(	O
ACS	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Low	NNP	O
HDL	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

Plasma	NNP	O
selective	JJ	O
delipidation	NN	O
converts	NNS	O
alphaHDL	VBP	O
to	TO	O
prebeta-like	JJ	O
HDL	NNP	O
,	,	O
the	DT	O
most	RBS	O
effective	JJ	O
form	NN	O
of	IN	O
HDL	NNP	O
for	IN	O
lipid	JJ	O
removal	NN	O
from	IN	O
arterial	JJ	O
plaques	NNS	O
.	.	O

METHODS	NNP	O
ACS	NNP	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
catheterization	NN	O
with	IN	O
>	NNP	O
or=1	VBP	O
nonobstructive	JJ	O
native	JJ	O
coronary	JJ	O
artery	NN	O
atheroma	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
7	CD	O
weekly	JJ	O
HDL	NNP	O
selective	NN	O
delipidated	VBD	O
or	CC	O
control	VB	O
plasma	JJ	O
apheresis/reinfusions	NNS	O
.	.	O

Patients	NNS	O
underwent	JJ	O
intravascular	JJ	PH
ultrasound	NN	PH
(	(	PH
IVUS	NNP	PH
)	)	PH
evaluation	NN	PH
of	IN	O
the	DT	O
target	NN	O
vessel	NN	O
during	IN	O
the	DT	O
catheterization	NN	O
for	IN	O
ACS	NNP	O
and	CC	O
up	RB	O
to	TO	O
14	CD	O
days	NNS	O
following	VBG	O
the	DT	O
final	JJ	O
apheresis/reinfusion	NN	O
session	NN	O
.	.	O

2-D	JJ	O
gel	JJ	O
electrophoresis	NN	O
of	IN	O
delipidated	JJ	O
plasmas	NN	O
established	VBN	O
successful	JJ	O
conversion	NN	O
of	IN	O
alphaHDL	NN	O
to	TO	O
prebeta-like	JJ	O
HDL	NNP	O
.	.	O

The	DT	O
trial	NN	O
was	VBD	O
complete	JJ	O
with	IN	O
28	CD	O
patients	NNS	O
randomized	VBN	O
.	.	O

RESULTS	NNP	O
All	DT	O
reinfusion	NN	O
sessions	NNS	O
were	VBD	O
tolerated	VBN	Ot
well	RB	O
by	IN	O
all	DT	O
patients	NNS	O
.	.	O

The	DT	O
levels	NNS	PH
of	IN	PH
prebeta-like	JJ	PH
HDL	NNP	PH
and	CC	PH
alphaHDL	NN	PH
in	IN	O
the	DT	O
delipidated	JJ	O
plasma	NN	O
converted	VBD	O
from	IN	O
5.6	CD	O
%	NN	O
to	TO	O
79.1	CD	O
%	NN	O
and	CC	O
92.8	CD	O
%	NN	O
to	TO	O
20.9	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
IVUS	NNP	O
data	NNS	O
demonstrated	VBD	O
a	DT	O
numeric	JJ	O
trend	NN	O
toward	IN	O
regression	NN	O
in	IN	O
the	DT	O
total	JJ	O
atheroma	NN	PH
volume	NN	PH
of	IN	O
-12.18	JJ	O
+/-	JJ	O
36.75	CD	O
mm	NN	O
(	(	O
3	CD	O
)	)	O
in	IN	O
the	DT	O
delipidated	JJ	O
group	NN	O
versus	VBD	O
an	DT	O
increase	NN	O
of	IN	O
total	JJ	PH
atheroma	JJ	PH
volume	NN	PH
of	IN	O
2.80	CD	O
+/-	JJ	O
21.25	CD	O
mm	NN	O
(	(	O
3	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.268	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
ACS	NNP	O
patients	NNS	O
,	,	O
serial	JJ	O
autologous	JJ	O
infusions	NNS	O
of	IN	O
selective	JJ	O
HDL	NNP	O
delipidated	VBD	O
plasma	NNS	O
are	VBP	O
clinically	RB	Ot
feasible	JJ	Ot
and	CC	O
well	RB	O
tolerated	VBN	Ot
.	.	Ot

This	DT	O
therapy	NN	O
may	MD	O
offer	VB	O
a	DT	O
novel	JJ	O
adjunct	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
presenting	VBG	O
with	IN	O
ACS	NNP	O
.	.	O

Further	NNP	O
study	NN	O
will	MD	O
be	VB	O
needed	VBN	O
to	TO	O
determine	VB	O
its	PRP$	O
ability	NN	O
to	TO	O
reduce	VB	O
clinical	JJ	PH
cardiovascular	JJ	PH
events	NNS	PH
.	.	PH

The	DT	O
effect	NN	O
of	IN	O
surgical	JJ	O
trauma	NN	O
and	CC	O
insulin	NN	O
on	IN	O
whole-body	NN	PH
protein	NN	PH
turnover	NN	PH
in	IN	O
parenterally-fed	JJ	O
undernourished	JJ	O
patients	NNS	O
.	.	O

Ten	CD	O
undernourished	JJ	O
patients	NNS	O
receiving	VBG	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
and	CC	O
undergoing	JJ	O
major	JJ	O
intestinal	JJ	O
surgery	NN	O
were	VBD	O
restarted	VBN	O
on	IN	O
intravenous	JJ	O
feeds	NNS	O
identical	JJ	O
to	TO	O
their	PRP$	O
pre-operative	JJ	O
regimens	NNS	O
within	IN	O
24	CD	O
h	NNS	O
of	IN	O
their	PRP$	O
operation	NN	O
.	.	O

Five	CD	O
,	,	O
chosen	VBN	O
at	IN	O
random	NN	O
,	,	O
received	VBD	O
post-operatively	RB	O
1-2	JJ	O
units	NNS	O
insulin/kg	VBP	O
body	NN	O
weight/24	JJ	O
h	NN	O
with	IN	O
their	PRP$	O
feed	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
five	CD	O
received	VBD	O
the	DT	O
feed	NN	O
only	RB	O
.	.	O

Pre-operatively	RB	O
,	,	O
and	CC	O
2	CD	O
h	NN	O
after	IN	O
commencing	VBG	O
their	PRP$	O
post-operative	JJ	O
feeds	NNS	O
,	,	O
rates	NNS	PH
of	IN	PH
whole-body	NN	PH
protein	NN	PH
synthesis	NN	PH
and	CC	PH
breakdown	NN	PH
were	VBD	O
measured	VBN	O
over	IN	O
a	DT	O
9-h	JJ	O
period	NN	O
following	VBG	O
intravenous	JJ	O
injection	NN	O
of	IN	O
a	DT	O
single	JJ	O
tracer	NN	O
dose	NN	O
of	IN	O
15N-glycine	JJ	O
by	IN	O
the	DT	O
ammonia	NN	O
and	CC	O
urea	JJ	O
end-product	NN	O
methods	NNS	O
.	.	O

During	IN	O
these	DT	O
9-h	CD	O
study	NN	O
periods	NNS	O
measurements	NNS	O
were	VBD	O
also	RB	O
made	VBN	O
of	IN	O
blood	NN	PH
glucose	NN	PH
,	,	O
plasma	JJ	PH
insulin	NN	PH
and	CC	PH
glucagon	NN	PH
,	,	O
urinary	JJ	PH
ammonia	NN	PH
,	,	O
nitrogen	NN	PH
,	,	O
creatinine	NN	PH
and	CC	O
3-methylhistidine	JJ	PH
.	.	O

Blood	NNP	PH
glucose	NN	PH
and	CC	O
plasma	JJ	PH
insulin	NN	PH
and	CC	PH
glucagon	NN	PH
concentrations	NNS	PH
rose	VBD	O
post-operatively	RB	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	O
was	VBD	O
given	VBN	O
,	,	O
but	CC	O
the	DT	O
increment	NN	O
in	IN	O
insulin	NN	PH
concentration	NN	PH
was	VBD	O
significantly	RB	O
greater	JJR	O
when	WRB	O
insulin	NN	O
was	VBD	O
given	VBN	O
.	.	O

Apparent	JJ	PH
nitrogen	NN	PH
balance	NN	PH
was	VBD	O
positive	JJ	O
pre-operatively	RB	O
and	CC	O
became	VBD	O
less	RBR	O
so	RB	O
post-operatively	RB	O
whether	IN	O
insulin	NN	O
was	VBD	O
given	VBN	O
or	CC	O
not	RB	O
.	.	O

Similarly	RB	O
,	,	O
post-operative	JJ	O
increments	NNS	O
in	IN	O
urinary	JJ	PH
excretion	NN	PH
of	IN	PH
ammonia	NN	PH
,	,	O
creatinine	NN	PH
and	CC	PH
3-methylhistidine	JJ	PH
were	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
addition	NN	O
of	IN	O
insulin	NN	O
.	.	O

Protein	NNP	PH
turnover	NN	PH
,	,	O
as	IN	O
estimated	VBN	O
by	IN	O
the	DT	O
ammonia	JJ	PH
end-product	NN	PH
method	NN	O
,	,	O
tended	VBD	O
to	TO	O
rise	VB	O
post-operatively	RB	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
increases	NNS	O
observed	VBD	O
with	IN	O
or	CC	O
without	IN	O
insulin	NN	O
.	.	O

The	DT	O
urea	JJ	O
end-product	NN	O
method	NN	O
suggested	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
change	NN	O
in	IN	O
whole-body	NN	PH
protein	NN	PH
turnover	NN	PH
after	IN	O
surgery	NN	O
,	,	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	O
was	VBD	O
given	VBN	O
.	.	O

This	DT	O
study	NN	O
does	VBZ	O
not	RB	O
support	VB	O
the	DT	O
clinical	JJ	O
use	NN	O
of	IN	O
insulin	NN	PH
as	IN	O
a	DT	O
means	NN	O
of	IN	O
modifying	VBG	O
protein	JJ	O
metabolic	JJ	O
losses	NNS	O
after	IN	O
major	JJ	O
surgery	NN	O
.	.	O

Approval	JJ	O
summary	NN	O
:	:	O
imatinib	JJ	O
mesylate	NN	PH
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
and/or	NN	O
unresectable	JJ	O
malignant	JJ	O
gastrointestinal	JJ	PH
stromal	JJ	PH
tumors	NNS	PH
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
application	NN	O
was	VBD	O
to	TO	O
fulfill	VB	O
a	DT	O
postmarketing	NN	O
commitment	NN	O
to	TO	O
provide	VB	O
long-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
data	NNS	O
on	IN	O
treatment	NN	O
with	IN	O
imatinib	JJ	PH
mesylate	NN	PH
(	(	O
Gleevec	NNP	O
;	:	O
Novartis	NNP	O
Pharmaceuticals	NNP	O
,	,	O
East	NNP	O
Hanover	NNP	O
,	,	O
NJ	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
CD117	NNP	O
(	(	O
+	NNP	O
)	)	O
unresectable	JJ	O
and/or	JJ	O
metastatic	JJ	O
malignant	JJ	O
gastrointestinal	JJ	O
stromal	NN	O
tumors	NNS	O
(	(	O
GISTs	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
this	DT	O
application	NN	O
also	RB	O
provides	VBZ	O
evidence	NN	O
to	TO	O
support	VB	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
label	NN	O
to	TO	O
allow	VB	O
for	IN	O
an	DT	O
escalation	NN	O
of	IN	O
imatinib	NN	O
dosing	VBG	O
to	TO	O
800	CD	O
mg/day	NN	O
for	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	O
disease	NN	O
on	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
.	.	O

Two	CD	O
open-label	JJ	O
,	,	O
controlled	VBN	O
,	,	O
multicenter	NN	O
,	,	O
intergroup	NN	O
,	,	O
international	JJ	O
,	,	O
randomized	JJ	O
phase	NN	O
III	NNP	O
studies	NNS	O
were	VBD	O
submitted	VBN	O
--	:	O
one	CD	O
conducted	VBN	O
by	IN	O
the	DT	O
European	JJ	O
Organization	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	PH
(	(	O
n	JJ	O
=	NNP	O
946	CD	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
by	IN	O
the	DT	O
Southwest	NNP	O
Oncology	NNP	PH
Group	NNP	O
(	(	O
n	JJ	O
=	NNP	O
746	CD	O
)	)	O
.	.	O

These	DT	O
studies	NNS	O
compared	VBN	O
400	CD	O
mg/day	NN	O
of	IN	O
imatinib	NN	O
with	IN	O
800	CD	O
mg/day	NN	O
of	IN	O
imatinib	NN	O
.	.	O

A	DT	O
combined	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
two	CD	O
studies	NNS	O
was	VBD	O
prospectively	RB	O
defined	VBN	O
and	CC	O
agreed	VBN	O
to	TO	O
by	IN	O
both	DT	O
groups	NNS	O
.	.	O

Both	DT	O
protocols	NNS	O
allowed	VBD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
400-mg/day	JJ	O
imatinib	NN	O
arm	NN	O
to	TO	O
cross	VB	O
over	IN	O
to	TO	O
800	CD	O
mg/day	NN	O
imatinib	NN	PH
at	IN	O
progression	NN	O
.	.	O

Objective	JJ	O
responses	NNS	O
were	VBD	O
achieved	VBN	O
in	IN	O
>	JJ	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
either	CC	O
imatinib	JJ	O
dose	NN	O
.	.	O

The	DT	O
median	JJ	O
progression-free	JJ	MO
survival	NN	MO
time	NN	MO
was	VBD	O
approximately	RB	O
20	CD	O
months	NNS	O
and	CC	O
the	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
time	NN	O
was	VBD	O
approximately	RB	O
49	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
combined	JJ	O
analysis	NN	O
,	,	O
347	CD	O
patients	NNS	O
crossed	VBN	O
over	IN	O
to	TO	O
800	CD	O
mg/day	NN	O
imatinib	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
progression	NN	O
.	.	O

The	DT	O
median	JJ	PH
OS	NNP	PH
time	NN	O
after	IN	O
crossover	NN	O
was	VBD	O
14.3	CD	O
months	NNS	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	A
events	NNS	A
(	(	A
AEs	NNP	A
)	)	A
were	VBD	O
fluid	JJ	O
retention	NN	O
,	,	O
nausea	NN	PH
,	,	O
fatigue	NN	PH
,	,	PH
skin	JJ	PH
rash	NN	PH
,	,	PH
gastrointestinal	JJ	PH
complaints	NNS	PH
,	,	O
and	CC	O
myalgia	NN	PH
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
laboratory	NN	O
abnormality	NN	PH
was	VBD	PH
anemia	VBN	PH
.	.	A

Most	JJS	O
often	RB	O
the	DT	O
AEs	NNP	PH
were	VBD	O
of	IN	O
mild-to-moderate	JJ	O
severity	NN	O
.	.	O

Fluid	NNP	O
retention	NN	O
events	NNS	O
and	CC	O
skin	JJ	O
rash	NN	O
were	VBD	O
numerically	RB	O
reported	VBN	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
800-mg/day	JJ	O
treatment	NN	O
cohort	NN	O
of	IN	O
patients	NNS	O
.	.	O

Effect	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
additional	JJ	O
insulin	NN	O
therapy	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
late	JJ	O
failure	NN	O
of	IN	O
sulphonylurea	JJ	O
therapy	NN	O
.	.	O

AIM	VB	O
The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
insulin	NN	PH
requirements	NNS	PH
and	CC	O
glycaemic	JJ	PH
control	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
receiving	VBG	O
exogenous	JJ	O
insulin	NN	O
due	JJ	O
to	TO	O
secondary	JJ	O
failure	NN	O
of	IN	O
maximum	NN	O
dose	JJ	O
sulphonylurea	JJ	O
therapy	NN	O
.	.	O

METHODS	VB	O
A	DT	O
single-centre	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
48	CD	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
late-term	JJ	O
failure	NN	O
following	VBG	O
at	IN	O
least	JJS	O
3	CD	O
years	NNS	O
of	IN	O
sulphonylurea	JJ	O
therapy	NN	O
requiring	VBG	O
additional	JJ	O
insulin	NN	O
therapy	NN	O
to	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
glycaemic	JJ	O
control	NN	O
and	CC	O
insulin	NN	O
requirements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
glycaemic	JJ	PH
response	NN	PH
rate	NN	PH
(	(	O
responders	NNS	O
being	VBG	O
predefined	VBN	O
as	IN	O
patients	NNS	O
who	WP	O
achieve	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
HbA1c	NNP	O
to	TO	O
less	JJR	O
than	IN	O
8	CD	O
%	NN	O
or	CC	O
a	DT	O
reduction	NN	O
by	IN	O
at	IN	O
least	JJS	O
15	CD	O
%	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
baseline	NN	O
values	NNS	O
)	)	O
and	CC	O
the	DT	O
daily	JJ	PH
insulin	NN	PH
dose	NN	PH
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Secondary	JJ	O
parameters	NNS	O
assessed	VBD	O
included	VBN	O
postprandial	JJ	PH
changes	NNS	PH
in	IN	PH
blood	NN	PH
glucose	NN	PH
,	,	PH
serum	JJ	PH
insulin	NN	PH
and	CC	PH
C-peptide	NNP	PH
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
significantly	RB	O
more	JJR	O
responders	NNS	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
20/24	CD	O
patients	NNS	O
vs.	FW	O
10/19	CD	O
patients	NNS	O
;	:	O
p	VB	O
<	$	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	PH
daily	JJ	PH
insulin	NN	PH
dose	NN	PH
after	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
16.4	CD	O
+/-	JJ	O
10.1	CD	O
IU	NNP	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
and	CC	O
22.4	CD	O
+/-	JJ	O
12.2	CD	O
IU	NNP	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

;	:	O
p	JJ	O
<	NNP	O
0.07	CD	O
)	)	O
.	.	O

Postprandial	JJ	PH
increases	NNS	PH
in	IN	PH
blood	NN	PH
glucose	NN	PH
,	,	O
insulin	NN	PH
and	CC	O
C-peptide	NNP	PH
were	VBD	O
consistently	RB	O
lower	JJR	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
the	DT	O
mean	JJ	PH
increase	NN	PH
in	IN	PH
2-h	JJ	PH
postprandial	JJ	PH
serum	NN	PH
insulin	NN	PH
remained	VBD	O
almost	RB	O
unchanged	JJ	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
compared	VBN	O
to	TO	O
an	DT	O
increase	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
29	CD	O
microU/ml	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
acarbose	NN	O
to	TO	O
sulphonylurea/insulin	VB	O
combination	NN	O
therapy	NN	O
can	MD	O
improve	VB	O
glycaemic	JJ	PH
control	NN	PH
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
.	.	O

Acarbose	NNP	O
may	MD	O
also	RB	O
reduce	VB	O
insulin	NN	PH
resistance	NN	PH
and	CC	PH
hyperinsulinaemia	NN	PH
.	.	PH

Efficacy	NN	O
of	IN	O
intravenous	JJ	O
granisetron	NN	O
to	TO	O
control	VB	O
nausea	NN	O
and	CC	O
vomiting	VBG	O
during	IN	O
multiple	JJ	O
cycles	NNS	O
of	IN	O
cisplatin-based	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
granisetron	NN	O
(	(	O
10	CD	O
micrograms/kg	NN	O
and	CC	O
40	CD	O
micrograms/kg	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
during	IN	O
a	DT	O
second	JJ	O
(	(	O
n	JJ	O
=	NNP	O
393	CD	O
)	)	O
and	CC	O
third	JJ	O
(	(	O
n	JJ	O
=	NNP	O
200	CD	O
)	)	O
cycle	NN	O
of	IN	O
chemotherapy	NN	O
in	IN	O
this	DT	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Granisetron	NNP	O
was	VBD	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
cisplatin	NN	O
chemotherapy	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
60	CD	O
mg/m2	NN	O
)	)	O
.	.	O

Total	JJ	Ot
control	NN	Ot
(	(	O
no	DT	PH
vomiting	NN	PH
,	,	O
no	DT	PH
retching	NN	PH
,	,	PH
no	DT	PH
nausea	NN	PH
,	,	PH
and	CC	PH
no	DT	PH
use	NN	PH
of	IN	PH
antiemetic	JJ	PH
rescue	NN	PH
medication	NN	PH
)	)	O
after	IN	O
the	DT	O
first	JJ	O
24	CD	O
hr	NN	O
following	VBG	O
chemotherapy	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
40	CD	O
%	NN	O
and	CC	O
49	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
10	CD	O
micrograms/kg	NN	O
group	NN	O
,	,	O
and	CC	O
in	IN	O
42	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
40	CD	O
micrograms/kg	NN	O
group	NN	O
.	.	O

Both	DT	O
dose	JJ	PH
levels	NNS	PH
of	IN	PH
granisetron	NN	PH
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
comparable	JJ	O
efficacy	NN	O
between	IN	O
the	DT	O
10	CD	O
micrograms/kg	NN	O
and	CC	O
40	CD	O
micrograms/kg	NN	O
doses	NNS	O
of	IN	O
granisetron	NN	O
in	IN	O
preventing	VBG	O
nausea	NN	PH
and	CC	PH
vomiting	VBG	PH
during	IN	O
repeat	NN	O
cycles	NNS	O
of	IN	O
high-dose	JJ	O
cisplatin-based	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
granisetron	VBZ	O
10	CD	O
micrograms/kg	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
remains	VBZ	O
effective	JJ	O
with	IN	O
repeat	NN	O
cycle	NN	O
use	NN	O
.	.	O

Chumnguh	NNP	O
thleum	NN	O
:	:	O
understanding	JJ	O
liver	NN	O
illness	NN	O
and	CC	O
hepatitis	NN	O
B	NNP	O
among	IN	O
Cambodian	JJ	O
immigrants	NNS	O
.	.	O

Cambodian	JJ	O
immigrants	NNS	O
are	VBP	O
over	IN	O
25	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
evidence	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
than	IN	O
the	DT	O
general	JJ	O
US	NNP	O
population	NN	O
.	.	O

Carriers	NNS	O
of	IN	O
HBV	NNP	O
are	VBP	O
over	IN	O
100	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
develop	VB	O
liver	RB	O
cancer	NN	O
than	IN	O
non-carriers	NNS	O
.	.	O

Liver	NNP	O
cancer	NN	O
incidence	NN	O
is	VBZ	O
the	DT	O
second	JJ	O
leading	JJ	O
cancer	NN	O
for	IN	O
Cambodian	JJ	O
men	NNS	O
and	CC	O
the	DT	O
sixth	JJ	O
for	IN	O
Cambodian	JJ	O
women	NNS	O
.	.	O

Despite	IN	O
this	DT	O
,	,	O
this	DT	O
underserved	JJ	O
population	NN	O
has	VBZ	O
received	VBN	O
very	RB	O
little	JJ	O
attention	NN	O
from	IN	O
health	NN	O
disparities	NNS	O
researchers	NNS	O
.	.	O

Culturally	NNP	O
and	CC	O
linguistically	RB	O
appropriate	JJ	O
interventions	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
increase	VB	O
hepatitis	NN	ME
B	NNP	ME
knowledge	NN	ME
,	,	O
serologic	JJ	Ot
testing	NN	Ot
,	,	O
and	CC	O
vaccination	NN	PH
among	IN	O
Cambodian	JJ	O
Americans	NNPS	O
.	.	O

Eight	NNP	O
group	NN	O
interviews	NNS	O
were	VBD	O
held	VBN	O
with	IN	O
Cambodian	JJ	O
American	JJ	O
men	NNS	O
(	(	O
48	CD	O
)	)	O
and	CC	O
women	NNS	O
(	(	O
49	CD	O
)	)	O
.	.	O

Focus	NNP	O
group	NN	O
discussion	NN	O
revealed	VBD	O
unanticipated	JJ	O
information	NN	O
about	IN	O
sociocultural	JJ	ME
influences	NNS	ME
on	IN	O
participants	NNS	ME
'	POS	ME
understanding	VBG	ME
about	IN	ME
hepatitis	NN	ME
B	NNP	ME
transmission	NN	ME
,	,	O
disease	NN	ME
course	NN	ME
,	,	O
and	CC	O
prevention	NN	ME
and	CC	ME
treatment	NN	ME
informed	VBN	O
by	IN	O
humoral	JJ	O
theories	NNS	O
underlying	VBG	O
Khmer	NNP	O
medicine	NN	O
,	,	O
by	IN	O
biomedicine	NN	O
,	,	O
and	CC	O
by	IN	O
migration	NN	O
experiences	NNS	O
.	.	O

Our	PRP$	O
findings	NNS	O
reveal	VBP	O
the	DT	O
value	NN	O
of	IN	O
qualitative	JJ	O
exploration	NN	O
to	TO	O
providing	VBG	O
cultural	JJ	O
context	NN	O
to	TO	O
biomedical	JJ	O
information	NN	O
--	:	O
a	DT	O
formula	NN	O
for	IN	O
effective	JJ	O
health	NN	O
promotion	NN	O
and	CC	O
practice	NN	O
.	.	O

Quality	NN	O
of	IN	O
individual	JJ	O
INR	NNP	O
control	NN	O
and	CC	O
the	DT	O
risk	NN	O
of	IN	O
stroke	NN	O
and	CC	O
bleeding	VBG	O
events	NNS	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
patients	NNS	O
:	:	O
a	DT	O
nested	JJ	O
case	NN	O
control	NN	O
analysis	NN	O
of	IN	O
the	DT	O
ACTIVE	NNP	O
W	NNP	O
study	NN	O
.	.	O

INTRODUCTION	NNP	O
Time	NNP	Ot
in	IN	Ot
therapeutic	JJ	Ot
range	NN	Ot
(	(	Ot
TTR	NNP	Ot
)	)	Ot
for	IN	O
international	JJ	O
normalized	JJ	O
ratio	NN	O
(	(	O
INR	NNP	O
)	)	O
is	VBZ	O
an	DT	O
accepted	JJ	O
quality	NN	O
measure	NN	O
of	IN	O
anticoagulation	NN	O
control	NN	O
in	IN	O
patient	JJ	O
populations	NNS	O
,	,	O
but	CC	O
its	PRP$	O
usefulness	NN	O
for	IN	O
predicting	VBG	O
stroke	NN	O
and	CC	O
bleeding	NN	O
in	IN	O
individuals	NNS	O
is	VBZ	O
not	RB	O
well	RB	O
understood	RB	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
nested	JJ	O
case	NN	O
control	NN	O
analysis	NN	O
among	IN	O
ACTIVE	NNP	O
W	NNP	O
study	NN	O
patients	NNS	O
,	,	O
cases	NNS	O
with	IN	O
stroke	NN	O
and	CC	O
cases	NNS	O
with	IN	O
bleeding	NN	O
were	VBD	O
separately	RB	O
matched	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Several	JJ	O
anticoagulation	NN	O
quality	NN	O
measures	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
overall	JJ	O
and	CC	O
in	IN	O
a	DT	O
time-dependent	JJ	O
manner	NN	O
.	.	O

RESULTS	CC	O
32	CD	O
cases	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
and	CC	O
234	CD	O
cases	NNS	O
with	IN	O
bleeding	NN	O
in	IN	O
the	DT	O
analysis	NN	O
were	VBD	O
matched	VBN	O
in	IN	O
a	DT	O
4:1	CD	O
ratio	NN	O
to	TO	O
122	CD	O
and	CC	O
865	CD	O
controls	NNS	O
,	,	O
respectively	RB	O
.	.	O

Follow-up	JJ	O
duration	NN	O
was	VBD	O
257?154days	CD	O
for	IN	O
the	DT	O
stroke	NN	O
analysis	NN	O
and	CC	O
222?146days	CD	O
for	IN	O
the	DT	O
bleeding	NN	O
analysis	NN	O
.	.	O

Compared	VBN	O
with	IN	O
their	PRP$	O
respective	NN	O
controls	NNS	O
,	,	O
the	DT	O
study	NN	O
mean	JJ	Ot
TTR	NNP	Ot
of	IN	O
both	DT	O
stroke	NN	O
cases	NNS	O
(	(	O
53.9	CD	O
%	NN	O
?25.1	NNP	O
vs	VBZ	O
63.4	CD	O
%	NN	O
?24.8	NN	O
;	:	O
p=0.055	CC	O
)	)	O
and	CC	O
bleeding	VBG	O
cases	NNS	O
(	(	O
56.2	CD	O
%	NN	O
?25.4	NNP	O
vs	VBZ	O
63.4	CD	O
%	NN	O
?26.8	NN	O
;	:	O
p	CC	O
<	VB	O
0.001	CD	O
)	)	O
was	VBD	O
lower	JJR	O
.	.	O

Time	NNP	O
below	IN	O
range	NN	O
for	IN	O
stroke	NN	O
and	CC	O
time	NN	O
above	IN	O
range	NN	O
for	IN	O
bleeding	VBG	O
were	VBD	O
only	RB	O
greater	JJR	O
in	IN	O
the	DT	O
last	JJ	O
month	NN	O
leading	VBG	O
up	RP	O
to	TO	O
the	DT	O
event	NN	O
,	,	O
not	RB	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
period	NN	O
.	.	O

Rather	CC	O
,	,	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
period	NN	O
bleeding	VBG	O
cases	NNS	O
spent	VBD	O
more	JJR	O
time	NN	O
below	IN	O
range	NN	O
than	IN	O
controls	NNS	O
(	(	O
26.8	CD	O
%	NN	O
?25.9	NNP	O
vs	VBZ	O
20.8	CD	O
%	NN	O
?24.0	NN	O
;	:	O
p=0.001	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
TTR	NNP	O
was	VBD	O
lower	JJR	O
in	IN	O
individual	JJ	O
AF	NNP	O
patients	NNS	O
with	IN	O
stroke	NN	O
or	CC	O
bleeding	NN	O
compared	VBN	O
with	IN	O
matched	JJ	O
controls	NNS	O
in	IN	O
ACTIVE	NNP	O
W.	NNP	O
Maintaining	VBG	O
a	DT	O
high	JJ	O
TTR	NNP	O
,	,	O
with	IN	O
equal	JJ	O
importance	NN	O
to	TO	O
avoid	VB	O
low	JJ	O
and	CC	O
high	JJ	O
INRs	NNP	O
,	,	O
is	VBZ	O
a	DT	O
relevant	JJ	O
goal	NN	O
of	IN	O
individual	JJ	O
patient	NN	O
treatment	NN	O
to	TO	O
prevent	VB	O
stroke	NN	O
and	CC	O
bleeding	NN	O
.	.	O

Early	JJ	O
combination	NN	O
disease-modifying	JJ	O
antirheumatic	JJ	O
drug	NN	O
therapy	NN	O
and	CC	O
tight	JJ	O
disease	NN	O
control	NN	O
improve	VB	O
long-term	JJ	Ot
radiologic	JJ	Ot
outcome	NN	Ot
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
the	DT	O
11-year	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Finnish	NNP	O
Rheumatoid	NNP	O
Arthritis	NNP	O
Combination	NNP	O
Therapy	NNP	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Early	NNP	O
treatment	NN	O
of	IN	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
retard	VB	O
the	DT	O
development	NN	PH
of	IN	PH
joint	JJ	PH
damage	NN	PH
for	IN	O
a	DT	O
period	NN	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	Ot
the	DT	Ot
radiologic	JJ	Ot
progression	NN	Ot
beyond	IN	O
that	DT	O
time	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
RA	NNP	O
initially	RB	O
treated	VBD	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
three	CD	O
disease-modifying	JJ	O
antirheumatic	JJ	O
drugs	NNS	O
(	(	O
DMARDs	NNP	O
)	)	O
or	CC	O
a	DT	O
single	JJ	O
DMARD	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
199	CD	O
patients	NNS	O
with	IN	O
early	JJ	O
active	JJ	O
RA	NNP	O
were	VBD	O
initially	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
methotrexate	NN	O
,	,	O
sulfasalazine	NN	O
,	,	O
and	CC	O
hydroxychloroquine	NN	O
with	IN	O
prednisolone	NN	O
(	(	O
FIN-RACo	NNP	O
)	)	O
,	,	O
or	CC	O
treatment	NN	O
with	IN	O
a	DT	O
single	JJ	O
DMARD	NNP	O
(	(	O
initially	RB	O
,	,	O
sulfasalazine	NN	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
prednisolone	NN	O
(	(	O
SINGLE	NNP	O
)	)	O
.	.	O

After	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
drug-treatment	JJ	O
strategy	NN	O
became	VBD	O
unrestricted	JJ	O
,	,	O
but	CC	O
still	RB	O
targeted	VBN	O
remission	NN	O
.	.	O

The	DT	O
radiographs	NN	Ot
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
were	VBD	O
analyzed	VBN	PH
by	IN	PH
using	VBG	PH
the	DT	PH
Larsen	NNP	PH
score	NN	PH
at	IN	O
baseline	NN	O
,	,	O
2	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
11	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
radiographs	NN	O
of	IN	O
large	JJ	O
joints	NNS	O
,	,	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Sixty-five	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
65	CD	O
in	IN	O
the	DT	O
SINGLE	NNP	O
group	NN	O
had	VBD	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
available	JJ	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
11	CD	O
years	NNS	O
in	IN	O
Larsen	NNP	PH
score	NN	PH
was	VBD	O
17	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
12	CD	O
to	TO	O
26	CD	O
)	)	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
group	NN	O
and	CC	O
27	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
22	CD	O
to	TO	O
33	CD	O
)	)	O
in	IN	O
the	DT	O
SINGLE	NNP	O
group	NN	O
(	(	O
P=0.037	NNP	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
87	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
74	CD	O
to	TO	O
94	CD	O
)	)	O
and	CC	O
72	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
58	CD	O
to	TO	O
84	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
the	DT	O
SINGLE	NNP	O
treatment	NN	O
arms	NNS	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
no	DT	O
erosive	JJ	PH
changes	NNS	PH
in	IN	O
large	JJ	O
joints	NNS	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Targeting	VBG	O
to	TO	O
remission	NN	O
with	IN	O
tight	JJ	O
clinical	JJ	O
controls	NNS	O
results	NNS	O
in	IN	O
low	JJ	O
radiologic	JJ	Ot
progression	NN	Ot
in	IN	O
most	JJS	O
RA	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
DMARDs	NNP	O
have	VBP	O
less	RBR	O
long-term	JJ	Ot
radiologic	NN	Ot
damage	NN	Ot
than	IN	O
do	VBP	O
those	DT	O
treated	VBN	O
initially	RB	O
with	IN	O
DMARD	NNP	O
monotherapy	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN18445519	NNP	O
.	.	O

[	JJ	O
Clinical	NNP	O
observation	NN	O
on	IN	O
acupuncture	NN	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
granules	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
clinical	JJ	O
therapeutic	JJ	A
effect	NN	A
of	IN	O
acupuncture	NN	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
and	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
intelligence	NN	PH
,	,	PH
daily	JJ	PH
life	NN	PH
and	CC	PH
social	JJ	PH
activity	NN	PH
ability	NN	PH
.	.	PH

METHODS	NNP	O
Eighty-four	JJ	O
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
,	,	O
28	CD	O
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
acupuncture	NN	O
at	IN	O
Baihui	NNP	O
(	(	O
GV	NNP	O
20	CD	O
)	)	O
,	,	O
Sishencong	NNP	O
(	(	O
EX-HN	NNP	O
1	CD	O
)	)	O
,	,	O
Dazhui	NNP	O
(	(	O
GV	NNP	O
14	CD	O
)	)	O
,	,	O
Guanyuan	NNP	O
(	(	O
CV	NNP	O
4	CD	O
)	)	O
,	,	O
etc	FW	O
.	.	O

and	CC	O
oral	JJ	O
administration	NN	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
;	:	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
,	,	O
and	CC	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
with	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
Aricept	NNP	O
.	.	O

The	DT	O
scores	NNS	Ot
for	IN	Ot
the	DT	Ot
Mini-Mental	JJ	Ot
State	NNP	Ot
Examination	NNP	Ot
(	(	Ot
MMSE	NNP	Ot
)	)	Ot
,	,	O
Ability	NNP	PH
of	IN	PH
Daily	NNP	PH
Life	NNP	PH
(	(	PH
ADL	NNP	PH
)	)	PH
and	CC	O
the	DT	A
therapeutic	JJ	A
effects	NNS	A
were	VBD	O
assessed	VBN	O
and	CC	O
compared	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
after	IN	O
treatment	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
scores	NNS	O
for	IN	O
MMSE	NNP	PH
and	CC	PH
ADL	NNP	PH
were	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
,	,	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
,	,	O
which	WDT	O
were	VBD	O
better	RBR	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
total	JJ	PH
effective	JJ	PH
rate	NN	PH
of	IN	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
71.4	CD	O
%	NN	O
in	IN	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
67.9	CD	O
%	NN	O
in	IN	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Acupuncture	NNP	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
has	VBZ	O
a	DT	O
significant	JJ	O
therapeutic	JJ	PH
effect	NN	PH
on	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
which	WDT	O
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
or	CC	O
Aricept	NNP	O
.	.	O

Comparative	NNP	O
dose	NN	O
efficacy	NN	Ot
study	NN	O
of	IN	O
atorvastatin	JJ	O
versus	NN	O
simvastatin	NN	O
,	,	O
pravastatin	NN	O
,	,	O
lovastatin	NN	O
,	,	O
and	CC	O
fluvastatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypercholesterolemia	NN	O
(	(	O
the	DT	O
CURVES	NNP	O
study	NN	O
)	)	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
8-week	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
comparative	JJ	O
dose	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
3-hydroxy-3-methylglutaryl	JJ	O
coenzyme	NN	O
A	NNP	O
(	(	O
HMG-CoA	NNP	O
)	)	O
reductase	NN	O
inhibitor	NN	O
atorvastatin	VBD	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
mg	NNS	O
compared	VBN	O
with	IN	O
simvastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
pravastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
lovastatin	VBZ	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
mg	NN	O
,	,	O
and	CC	O
fluvastatin	$	O
20	CD	O
and	CC	O
40	CD	O
mg.	NN	O
Investigators	NNS	O
enrolled	VBD	O
534	CD	O
hypercholesterolemic	JJ	O
patients	NNS	O
(	(	O
low-density	JJ	O
lipoprotein	NN	O
[	NNP	O
LDL	NNP	O
]	NNP	O
cholesterol	NN	O
>	NN	O
or	CC	O
=	$	O
160	CD	O
mg/dl	NN	O
[	VBD	O
4.2	CD	O
mmol/L	NN	O
]	NN	O
and	CC	O
triglycerides	NNS	O
<	VBP	O
or	CC	O
=	VBP	O
400	CD	O
mg/dl	NN	O
[	VBD	O
4.5	CD	O
mmol/L	NNS	O
]	RB	O
)	)	O
.	.	O

The	DT	O
efficacy	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
mean	JJ	O
percent	NN	O
change	NN	O
in	IN	O
plasma	NN	PH
LDL	NNP	PH
cholesterol	NN	PH
(	(	PH
primary	JJ	PH
)	)	PH
,	,	PH
total	JJ	PH
cholesterol	NN	PH
,	,	PH
triglycerides	NNS	PH
,	,	PH
and	CC	PH
high-density	NN	PH
lipoprotein	NN	PH
cholesterol	NN	PH
concentrations	NNS	PH
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
week	NN	O
8	CD	O
)	)	O
.	.	O

Atorvastatin	$	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
produced	VBN	O
greater	JJR	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.01	CD	O
)	)	O
reductions	NNS	O
in	IN	O
LDL	NNP	PH
cholesterol	NN	PH
,	,	O
-38	CD	O
%	NN	O
,	,	O
-46	CD	O
%	NN	O
,	,	O
and	CC	O
-51	NNP	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
the	DT	O
milligram	JJ	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
simvastatin	NN	O
,	,	O
pravastatin	NN	O
,	,	O
lovastatin	NN	O
,	,	O
and	CC	O
fluvastatin	NN	O
.	.	O

Atorvastatin	$	O
10	CD	O
mg	NN	O
produced	VBN	O
LDL	NNP	PH
cholesterol	NN	PH
reductions	NNS	O
comparable	JJ	O
to	TO	O
or	CC	O
greater	JJR	O
than	IN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.02	CD	O
)	)	O
simvastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
pravastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
lovastatin	CC	O
20	CD	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
and	CC	O
fluvastatin	$	O
20	CD	O
and	CC	O
40	CD	O
mg.	NN	O
Atorvastatin	NNP	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
produced	VBN	O
greater	JJR	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.01	CD	O
)	)	O
reductions	NNS	O
in	IN	O
total	JJ	PH
cholesterol	NN	PH
than	IN	O
the	DT	O
milligram	JJ	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
simvastatin	NN	O
,	,	O
pravastatin	NN	O
,	,	O
lovastatin	NN	O
,	,	O
and	CC	O
fluvastatin	NN	O
.	.	O

All	DT	O
reductase	NN	O
inhibitors	NNS	O
studied	VBD	O
had	VBD	O
similar	JJ	O
tolerability	NN	ME
.	.	Ot

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
persistent	JJ	O
elevations	NNS	O
in	IN	O
serum	NN	PH
transaminases	NNS	PH
or	CC	PH
myositis	NN	PH
.	.	A

Combination	NN	O
of	IN	O
sotalol	NN	O
and	CC	O
magnesium	NN	O
prevents	NNS	O
atrial	JJ	O
fibrillation	NN	O
after	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
.	.	O

BACKGROUND	NNP	O
Atrial	NNP	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
complication	NN	O
reported	VBD	O
in	IN	O
20	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
patients	NNS	O
after	IN	O
coronary	JJ	O
operations	NNS	O
.	.	O

Sotalol	NNP	O
alone	RB	O
and	CC	O
magnesium	VB	O
alone	RB	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
partially	RB	O
decrease	VB	O
the	DT	O
incidence	NN	O
of	IN	O
AF	NNP	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
these	DT	O
two	CD	O
pharmacological	JJ	O
agents	NNS	O
,	,	O
used	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
,	,	O
to	TO	O
reduce	VB	O
postoperative	JJ	PH
AF	NNP	PH
.	.	PH

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
seven	CD	O
consecutive	JJ	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
62	CD	O
+/-	JJ	O
11	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
sotalol	NN	O
alone	RB	O
(	(	O
80	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
starting	VBG	O
from	IN	O
the	DT	O
morning	NN	O
of	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
)	)	O
(	(	O
group	NN	O
S	NNP	O
)	)	O
,	,	O
magnesium	NN	O
alone	RB	O
(	(	O
1.5	CD	O
g	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
starting	VBG	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
just	RB	O
before	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
)	)	O
(	(	O
group	NN	O
M	NNP	O
)	)	O
,	,	O
both	DT	O
pharmacologic	JJ	O
agents	NNS	O
at	IN	O
the	DT	O
same	JJ	O
dosages	NNS	O
(	(	O
group	NN	O
S+M	NNP	O
)	)	O
,	,	O
or	CC	O
no	DT	O
antiarrhythmic	JJ	O
agents	NNS	O
(	(	O
group	NN	O
CTR	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
with	IN	O
an	DT	O
ejection	NN	O
fraction	NN	O
less	JJR	O
than	IN	O
0.40	CD	O
were	VBD	O
excluded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
incidence	NN	PH
of	IN	PH
postoperative	JJ	PH
AF	NNP	PH
was	VBD	O
11.8	CD	O
%	NN	O
(	(	O
6/51	CD	O
)	)	O
in	IN	O
the	DT	O
S	NNP	O
group	NN	O
,	,	O
14.8	CD	O
%	NN	O
(	(	O
8/54	CD	O
)	)	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
,	,	O
1.9	CD	O
%	NN	O
(	(	O
1/52	CD	O
)	)	O
in	IN	O
the	DT	O
S+M	NNP	O
group	NN	O
,	,	O
and	CC	O
38	CD	O
%	NN	O
(	(	O
19/50	CD	O
)	)	O
in	IN	O
the	DT	O
CTR	NNP	O
group	NN	O
.	.	O

The	DT	O
following	JJ	O
differences	NNS	O
were	VBD	O
significant	JJ	O
:	:	O
group	NN	O
CTR	NNP	O
versus	NN	O
groups	NNS	O
S	NNP	O
,	,	O
M	NNP	O
,	,	O
and	CC	O
S+M	NNP	O
with	IN	O
values	NNS	O
of	IN	O
p	NN	O
=	NN	O
0.002	CD	O
,	,	O
p	NN	O
=	VBD	O
0.007	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.0001	CD	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
group	NN	O
S+M	NNP	O
versus	NN	O
groups	NNS	O
S	NNP	O
and	CC	O
M	NNP	O
with	IN	O
p	JJ	O
=	$	O
0.04	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.01	CD	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Incidence	NNP	PH
of	IN	PH
AF	NNP	PH
after	IN	O
coronary	JJ	O
operation	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
sotalol	JJ	O
alone	NN	O
and	CC	O
magnesium	NN	O
alone	RB	O
;	:	O
more	RBR	O
importantly	RB	O
,	,	O
the	DT	O
incidence	NN	O
was	VBD	O
further	RBR	O
reduced	VBN	O
by	IN	O
combining	VBG	O
these	DT	O
agents	NNS	O
.	.	O

Reputation	NNP	O
management	NN	O
:	:	O
evidence	NN	O
for	IN	O
ability	NN	O
but	CC	O
reduced	JJ	O
propensity	NN	ME
in	IN	O
autism	NN	O
.	.	O

Previous	JJ	O
research	NN	O
has	VBZ	O
reported	VBN	O
that	IN	O
autistic	JJ	O
adults	NNS	O
do	VBP	O
not	RB	O
manage	VB	O
their	PRP$	O
reputation	NN	O
,	,	O
purportedly	RB	O
due	JJ	O
to	TO	O
problems	NNS	O
with	IN	O
theory	NN	O
of	IN	O
mind	NN	O
[	NNP	O
Izuma	NNP	O
,	,	O
Matsumoto	NNP	PH
,	,	O
Camerer	NNP	O
,	,	O
&	CC	O
Adolphs	NNP	PH
]	NNP	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
aimed	VBD	O
to	TO	O
test	VB	O
alternative	JJ	O
explanations	NNS	O
for	IN	O
this	DT	O
apparent	JJ	O
lack	NN	O
of	IN	O
reputation	NN	O
management	NN	O
.	.	O

Twenty	NNP	O
typical	JJ	O
and	CC	O
19	CD	O
autistic	JJ	O
adults	NNS	O
donated	VBD	O
to	TO	O
charity	NN	O
and	CC	O
to	TO	O
a	DT	O
person	NN	O
,	,	O
both	DT	O
when	WRB	O
alone	RB	O
and	CC	O
when	WRB	O
observed	VBN	O
.	.	O

In	IN	O
an	DT	O
additional	JJ	O
manipulation	NN	O
,	,	O
for	IN	O
half	NN	O
of	IN	O
the	DT	O
participants	NNS	O
,	,	O
the	DT	O
observer	NN	O
was	VBD	O
also	RB	O
the	DT	O
recipient	NN	O
of	IN	O
their	PRP$	O
donations	NNS	O
,	,	O
and	CC	O
participants	NNS	O
were	VBD	O
told	VBN	O
that	IN	O
this	DT	O
observer	NN	O
would	MD	O
subsequently	RB	O
have	VB	O
the	DT	O
opportunity	NN	O
to	TO	O
donate	VB	O
to	TO	O
them	PRP	O
(	(	O
motivation	NN	O
condition	NN	O
)	)	O
.	.	O

This	DT	O
manipulation	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
encourage	VB	O
an	DT	O
expectation	NN	O
of	IN	O
a	DT	O
reciprocal	JJ	O
tit-for-tat	NN	PH
strategy	NN	O
in	IN	O
the	DT	O
participant	NN	O
,	,	O
which	WDT	O
may	MD	O
motivate	VB	O
participants	NNS	O
to	TO	O
change	VB	O
their	PRP$	O
behavior	NN	O
to	TO	O
receive	VB	O
more	JJR	O
donations	NNS	O
.	.	O

The	DT	O
remaining	VBG	O
participants	NNS	O
were	VBD	O
told	VBN	O
that	IN	O
the	DT	O
person	NN	O
watching	NN	O
was	VBD	O
just	RB	O
observing	VBG	O
the	DT	O
procedure	NN	O
(	(	O
no	DT	O
motivation	NN	O
condition	NN	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
replicated	VBD	O
Izuma	NNP	PH
et	CC	O
al	NN	O
.	.	O

's	POS	O
finding	VBG	O
that	IN	O
autistic	JJ	O
adults	NNS	O
did	VBD	O
not	RB	O
donate	VB	O
more	JJR	O
to	TO	O
charity	NN	O
when	WRB	O
observed	VBN	O
.	.	O

Yet	CC	O
,	,	O
in	IN	O
the	DT	O
motivation	NN	O
condition	NN	O
,	,	O
both	DT	O
typical	JJ	O
and	CC	O
autistic	JJ	O
adults	NNS	O
donated	VBD	O
significantly	RB	O
more	RBR	O
to	TO	O
the	DT	O
observer	NN	O
when	WRB	O
watched	VBN	O
,	,	O
although	IN	O
this	DT	O
effect	NN	O
was	VBD	O
significantly	RB	O
attenuated	VBN	O
in	IN	O
autistic	JJ	O
individuals	NNS	O
.	.	O

Results	NNS	O
indicate	VBP	O
that	IN	O
,	,	O
while	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
may	MD	O
have	VB	O
the	DT	O
ability	NN	O
to	TO	O
think	VB	O
about	IN	O
reputation	NN	O
,	,	O
a	DT	O
reduced	JJ	O
expectation	NN	O
of	IN	O
reciprocal	JJ	O
behavior	NN	O
from	IN	O
others	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
they	PRP	O
engage	VBP	O
in	IN	O
reputation	NN	O
management	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
recombinant	JJ	O
alpha	JJ	O
2b-interferon	JJ	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
malignant	JJ	O
melanoma	NN	O
.	.	O

alpha-Interferon	NN	O
has	VBZ	O
antitumor	VBN	O
activity	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
malignancies	NNS	O
but	CC	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
unacceptable	JJ	O
toxic	JJ	A
side-effects	NNS	A
.	.	O

The	DT	O
routine	JJ	O
use	NN	O
of	IN	O
agents	NNS	O
potentially	RB	O
capable	JJ	O
of	IN	O
reducing	VBG	O
these	DT	O
side-effects	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
recommended	VBN	O
out	IN	O
of	IN	O
concern	NN	O
for	IN	O
possible	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
therapeutic	JJ	O
activity	NN	O
of	IN	O
interferon	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
alpha-interferon	JJ	O
given	VBN	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
to	TO	O
determine	VB	O
what	WP	O
effect	NN	O
,	,	O
if	IN	O
any	DT	O
,	,	O
indomethacin	NN	O
might	MD	O
have	VB	O
on	IN	O
the	DT	O
toxic	NN	A
,	,	O
immunomodulatory	NN	PH
,	,	O
and	CC	O
therapeutic	JJ	PH
properties	NNS	Ot
of	IN	O
interferon	NN	O
in	IN	O
this	DT	O
disease	NN	O
.	.	O

53	CD	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
performance	NN	O
status	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
alpha	JJ	O
2b-interferon	CD	O
,	,	O
20	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
i.v.	NN	O
,	,	O
5	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
10	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
s.c.	NN	O
three	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
either	RB	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NN	O
,	,	O
25	CD	O
mg	NN	O
orally	RB	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

The	DT	O
overall	JJ	Ot
major	JJ	Ot
response	NN	PH
rate	NN	PH
was	VBD	O
13	CD	O
%	NN	O
(	(	O
three	CD	O
complete	JJ	O
responders	NNS	O
and	CC	O
three	CD	O
partial	JJ	O
responders	NNS	O
among	IN	O
47	CD	O
evaluable	JJ	O
patients	NNS	O
)	)	O
and	CC	O
was	VBD	O
the	DT	O
same	JJ	O
on	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
mean	JJ	PH
maximal	JJ	PH
temperature	NN	PH
elevation	NN	PH
induced	VBN	O
by	IN	O
interferon	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
from	IN	O
102.1	CD	O
to	TO	O
100.7	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
by	IN	O
indomethacin	NN	O
,	,	O
but	CC	O
the	DT	O
incidence	NN	PH
and	CC	PH
severity	NN	PH
of	IN	PH
interferon-related	JJ	PH
fatigue	NN	PH
,	,	O
reduction	NN	PH
in	IN	PH
performance	NN	PH
status	NN	PH
,	,	O
headache	NN	PH
,	,	O
depression	NN	ME
,	,	O
confusion	NN	ME
,	,	O
elevations	NNS	PH
in	IN	PH
liver	JJ	PH
function	NN	PH
tests	NNS	PH
,	,	O
and	CC	O
myelosuppression	NN	PH
were	VBD	O
no	DT	O
different	JJ	O
in	IN	O
either	DT	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Indomethacin	NNP	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
frequency	NN	A
of	IN	A
dose	JJ	A
reductions	NNS	A
for	IN	A
toxic	JJ	A
side-effects	NNS	A
and	CC	O
did	VBD	O
not	RB	O
permit	VB	O
the	DT	O
administration	NN	Ot
of	IN	Ot
higher	JJR	Ot
interferon	NN	Ot
doses	NNS	Ot
.	.	O

Peripheral	NNP	PH
blood	VBD	PH
natural	JJ	PH
killer	NN	PH
activity	NN	PH
was	VBD	O
significantly	RB	O
enhanced	VBN	O
in	IN	O
patients	NNS	O
during	IN	O
maintenance	NN	O
therapy	NN	O
whether	IN	O
or	CC	O
not	RB	O
they	PRP	O
received	VBD	O
indomethacin	NN	O
.	.	O

Indomethacin	NNP	O
appeared	VBD	O
to	TO	O
inhibit	VB	O
augmentation	NN	PH
of	IN	PH
natural	JJ	PH
killer	NN	PH
activity	NN	PH
during	IN	O
high	JJ	O
dose	JJ	O
induction	NN	O
therapy	NN	O
.	.	O

Immunological	JJ	PH
changes	NNS	PH
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
response	NN	O
status	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
indomethacin	NN	O
can	MD	O
reduce	VB	O
the	DT	O
fever	NN	PH
associated	VBN	O
with	IN	O
interferon	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
its	PRP$	O
therapeutic	JJ	PH
or	CC	PH
chronic	JJ	PH
immunomodulatory	NN	PH
activities	NNS	PH
.	.	O

Since	IN	O
fever	NN	PH
is	VBZ	O
rarely	RB	O
the	DT	O
dose-limiting	JJ	O
toxicity	NN	O
of	IN	O
interferon	NN	O
,	,	O
indomethacin	NN	O
is	VBZ	O
of	IN	O
marginal	JJ	O
benefit	NN	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
receiving	VBG	O
interferon	NN	O
at	IN	O
the	DT	O
doses	NNS	O
outlined	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Assessing	VBG	O
the	DT	O
effect	NN	O
of	IN	O
CT	NNP	O
slice	NN	O
interval	NN	O
on	IN	O
unidimensional	JJ	Ot
,	,	Ot
bidimensional	JJ	Ot
and	CC	Ot
volumetric	JJ	Ot
measurements	NNS	Ot
of	IN	O
solid	JJ	O
tumours	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
study	VB	O
the	DT	O
magnitude	NN	Ot
of	IN	Ot
differences	NNS	Ot
in	IN	Ot
tumour	JJ	Ot
unidimensional	JJ	Ot
(	(	Ot
1D	CD	Ot
)	)	Ot
,	,	Ot
bidimensional	JJ	Ot
(	(	Ot
2D	CD	Ot
)	)	Ot
and	CC	Ot
volumetric	JJ	Ot
(	(	Ot
VOL	NNP	Ot
)	)	Ot
measurements	NNS	Ot
determined	VBN	O
from	IN	O
computed	VBN	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
images	VBZ	O
reconstructed	VBN	O
at	IN	O
5	CD	O
,	,	O
2.5	CD	O
and	CC	O
1.25	CD	O
mm	NN	O
slice	NN	O
intervals	NNS	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
118	CD	O
lesions	NNS	O
in	IN	O
lung	NN	O
,	,	O
liver	NN	O
and	CC	O
lymph	NN	O
nodes	NNS	O
were	VBD	O
selected	VBN	O
from	IN	O
30	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
early	JJ	O
phase	NN	O
clinical	JJ	O
trials	NNS	O
.	.	O

Each	DT	O
CT	NNP	O
scan	NN	O
was	VBD	O
reconstructed	VBN	O
at	IN	O
5	CD	O
,	,	O
2.5	CD	O
and	CC	O
1.25	CD	O
mm	NN	O
slice	NN	O
intervals	NNS	O
during	IN	O
the	DT	O
image	NN	O
acquisition	NN	O
.	.	O

Lesions	NNS	O
were	VBD	O
semi-automatically	RB	O
segmented	VBN	O
on	IN	O
each	DT	O
interval	JJ	O
image	NN	O
series	NN	O
and	CC	O
supervised	VBN	O
by	IN	O
a	DT	O
radiologist	NN	O
.	.	O

1D	CD	Ot
,	,	Ot
2D	CD	Ot
and	CC	Ot
VOL	NNP	Ot
were	VBD	O
computed	VBN	O
based	VBN	O
on	IN	O
the	DT	O
final	JJ	O
segmentation	NN	O
results	NNS	O
.	.	O

Average	JJ	O
measurement	JJ	O
differences	NNS	O
across	IN	O
different	JJ	O
slice	NN	O
intervals	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
linear	JJ	O
mixed-effects	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
models	NNS	O
.	.	O

RESULTS	NNP	O
Lesion	NNP	PH
diameters	NNS	PH
ranged	VBD	O
from	IN	O
6.1	CD	O
to	TO	O
80.1	CD	O
mm	NN	O
(	(	O
median	JJ	O
18.4	CD	O
mm	NN	O
)	)	O
.	.	O

The	DT	O
largest	JJS	O
difference	NN	O
was	VBD	O
seen	VBN	O
between	IN	O
1.25	CD	O
and	CC	O
5	CD	O
mm	NN	O
(	(	O
mean	JJ	O
difference	NN	O
of	IN	O
7.6	CD	O
%	NN	O
for	IN	O
1D	CD	O
[	JJ	O
P	NNP	O
<	NNP	O
0.0001	CD	O
]	NNP	O
,	,	O
13.1	CD	O
%	NN	O
for	IN	O
2D	CD	O
[	JJ	O
P	NNP	O
<	NNP	O
0.0001	CD	O
]	NNP	O
,	,	O
-5.7	NNP	O
%	NN	O
for	IN	O
VOL	NNP	O
[	NNP	O
P	NNP	O
=	VBD	O
0.0001	CD	O
]	NN	O
)	)	O
.	.	O

Mean	JJ	O
differences	NNS	O
between	IN	O
1.25	CD	O
and	CC	O
2.5	CD	O
mm	NNS	O
were	VBD	O
all	DT	O
within	IN	O
?3.5	NNP	O
%	NN	O
(	(	O
within	IN	O
?6	NNP	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
.	.	O

For	IN	O
VOL	NNP	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
larger	JJR	O
average	JJ	O
difference	NN	O
between	IN	O
measurements	NNS	O
on	IN	O
different	JJ	O
slice	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
smaller	JJR	O
lesions	NNS	O
(	(	O
<	$	O
10	CD	O
mm	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
larger	JJR	O
lesions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Different	NNP	O
slice	NN	O
intervals	NNS	O
may	MD	O
give	VB	O
different	JJ	O
1D	CD	O
,	,	O
2D	CD	O
and	CC	O
VOL	NNP	O
measurements	NNS	O
.	.	O

In	IN	O
clinical	JJ	O
practice	NN	O
,	,	O
it	PRP	O
would	MD	O
be	VB	O
prudent	JJ	O
to	TO	O
use	VB	O
the	DT	O
same	JJ	O
slice	NN	O
interval	NN	O
for	IN	O
consecutive	JJ	O
measurements	NNS	O
.	.	O

Long	JJ	O
term	NN	O
follow	VBP	O
up	IN	O
of	IN	O
patients	NNS	O
treated	VBN	O
for	IN	O
Helicobacter	NNP	PH
pylori	JJ	PH
infection	NN	PH
.	.	PH

BACKGROUND	NNP	O
Helicobacter	NNP	O
pylori	POS	O
infection	NN	O
induces	NNS	O
progressive	JJ	O
inflammatory	JJ	PH
changes	NNS	PH
in	IN	O
the	DT	O
gastric	JJ	O
mucosa	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
gastric	JJ	O
cancer	NN	O
.	.	O

Understanding	VBG	O
long	JJ	O
term	NN	O
effects	NNS	O
resulting	VBG	O
from	IN	O
the	DT	O
cure	NN	O
of	IN	O
this	DT	O
infection	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
design	VB	O
cancer	NN	O
prevention	NN	O
strategies	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
795	CD	O
adults	NNS	O
with	IN	O
preneoplastic	JJ	O
gastric	JJ	O
lesions	NNS	O
was	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
and/or	JJ	O
antioxidants	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
six	CD	O
years	NNS	O
of	IN	O
intervention	NN	O
,	,	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
were	VBD	O
offered	VBN	O
it	PRP	O
.	.	O

Gastric	JJ	O
biopsies	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
years	NNS	O
.	.	O

A	DT	O
histopathology	NN	PH
score	NN	PH
was	VBD	O
utilised	VBN	O
to	TO	O
document	VB	O
changes	NNS	O
in	IN	O
gastric	JJ	PH
lesions	NNS	PH
.	.	PH

Non-linear	JJ	O
mixed	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
cumulative	JJ	O
effect	NN	O
of	IN	O
H	NNP	O
pylori	JJ	O
clearance	NN	O
on	IN	O
histopathology	NN	PH
scores	NNS	PH
adjusted	VBN	O
for	IN	O
follow	VB	O
up	RP	O
time	NN	O
,	,	O
interventions	NNS	O
,	,	O
and	CC	O
confounders	NNS	O
.	.	O

RESULTS	NNP	O
Ninety	NNP	O
seven	CD	O
per	IN	O
cent	NN	O
of	IN	O
subjects	NNS	O
were	VBD	O
H	NNP	PH
pylori	JJ	PH
positive	JJ	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
.	.	O

Subjects	NNS	O
accumulated	JJ	O
1703	CD	O
person	NN	O
years	NNS	O
free	JJ	PH
of	IN	PH
infection	NN	PH
.	.	PH

A	DT	O
multivariate	NN	O
model	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
regression	NN	PH
in	IN	PH
histopathology	NN	PH
score	NN	PH
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
square	NN	O
of	IN	O
H	NNP	PH
pylori	FW	PH
negative	JJ	PH
time	NN	PH
.	.	PH

Subjects	NNS	O
who	WP	O
were	VBD	O
H	NNP	PH
pylori	JJ	PH
negative	JJ	O
had	VBD	O
14.8	CD	O
%	NN	O
more	JJR	O
regression	NN	PH
and	CC	O
13.7	CD	O
%	NN	O
less	JJR	O
progression	NN	PH
than	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	PH
of	IN	PH
healing	NN	PH
of	IN	PH
gastric	JJ	PH
lesions	NNS	PH
occurred	VBD	O
more	RBR	O
rapidly	RB	O
as	IN	O
years	NNS	A
free	JJ	A
of	IN	A
infection	NN	A
accumulated	VBN	O
,	,	O
and	CC	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
less	RBR	O
advanced	JJ	O
lesions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Preneoplastic	NNP	PH
gastric	JJ	PH
lesions	NNS	PH
regress	NN	O
at	IN	O
a	DT	O
rate	NN	O
equal	JJ	O
to	TO	O
the	DT	O
square	NN	O
of	IN	O
time	NN	O
in	IN	O
patients	NNS	O
rendered	JJ	O
free	JJ	O
of	IN	O
H	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
preneoplastic	JJ	O
gastric	JJ	O
lesions	NNS	O
should	MD	O
be	VB	O
treated	VBN	O
and	CC	O
cured	VBN	O
of	IN	O
their	PRP$	O
H	NNP	O
pylori	NN	O
infection	NN	O
.	.	O

Aztreonam	NNP	O
versus	NN	O
gentamicin	NN	O
for	IN	O
short-term	JJ	O
prophylaxis	NN	O
in	IN	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Short-term	NNP	O
antibiotic	JJ	O
prophylaxis	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
80	CD	O
patients	NNS	O
undergoing	JJ	O
biliary	JJ	O
or	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
g	NN	O
of	IN	O
aztreonam	NN	O
or	CC	O
80	CD	O
mg	NN	O
of	IN	O
gentamicin	NN	O
intravenously	RB	O
30	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
and	CC	O
8	CD	O
and	CC	O
16	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Of	IN	O
samples	NNS	O
taken	VBN	O
from	IN	O
the	DT	O
abdominal	JJ	O
cavity	NN	O
for	IN	O
bacteriologic	NN	O
study	NN	O
,	,	O
53	CD	O
%	NN	O
were	VBD	O
culture	NN	O
positive	JJ	O
.	.	O

Wound	IN	PH
infections	NNS	PH
developed	VBN	O
in	IN	O
two	CD	O
(	(	O
4.5	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
patients	NNS	O
receiving	VBG	O
aztreonam	NN	O
and	CC	O
in	IN	O
seven	CD	O
(	(	O
19.4	CD	O
%	NN	O
)	)	O
of	IN	O
36	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
gentamicin	NN	O
.	.	O

Staphylococcus	NNP	O
epidermidis	NN	O
and	CC	O
Enterobacter	NNP	O
species	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
sites	NNS	O
of	IN	O
wound	JJ	PH
infection	NN	PH
in	IN	O
the	DT	O
aztreonam	JJ	O
group	NN	O
;	:	O
Escherichia	NNP	O
coli	NNS	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Pseudomonas	NNP	O
aeruginosa	NN	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Enterobacter	NNP	O
species	NNS	O
,	,	O
Klebsiella	NNP	O
species	NNS	O
,	,	O
Enterococcus	NNP	O
faecalis	NN	O
,	,	O
and	CC	O
Aeromonas	NNP	O
hydrophila	NN	O
were	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
gentamicin	NN	O
group	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
aztreonam	NN	O
is	VBZ	O
safe	JJ	Ot
and	CC	Ot
effective	JJ	Ot
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
infections	NNS	O
following	VBG	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Improved	VBN	O
fibrinolysis	NN	O
after	IN	O
1-year	JJ	O
treatment	NN	O
with	IN	O
HMG	NNP	O
CoA	NNP	O
reductase	NN	O
inhibitors	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
different	JJ	O
statins	NNS	O
on	IN	O
the	DT	O
levels	NNS	O
of	IN	O
haemostatic	JJ	O
variables	NNS	O
reflecting	VBG	O
procoagulant	NN	O
and	CC	O
fibrinolytic	JJ	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
,	,	O
with	IN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
statins	VBZ	O
might	MD	O
beneficially	RB	O
modify	VB	O
these	DT	O
levels	NNS	O
.	.	O

Fifty-eight	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
atorvastatin	NN	O
(	(	O
n=28	JJ	O
)	)	O
or	CC	O
simvastatin	NN	O
(	(	O
n=30	JJ	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
20	CD	O
mg/day	NN	O
.	.	O

Fasting	VBG	Ot
blood	NN	Ot
samples	NNS	Ot
were	VBD	O
collected	VBN	O
before	IN	O
and	CC	O
after	IN	O
12-month	JJ	O
treatment	NN	O
for	IN	O
determinations	NNS	O
of	IN	O
fibrinogen	NN	PH
,	,	O
prothrombin	JJ	PH
fragment	NN	PH
1+2	CD	PH
(	(	PH
F1+2	NNP	PH
)	)	PH
,	,	PH
plasma	JJ	PH
D-dimer	NNP	PH
,	,	O
soluble	JJ	PH
tissue	NN	PH
factor	NN	PH
,	,	O
tissue	NN	PH
plasminogen	NN	PH
activator	NN	PH
(	(	PH
tPA	NN	PH
)	)	PH
antigen	NN	PH
,	,	O
tPA	NN	PH
activity	NN	PH
,	,	O
plasminogen	NN	PH
activator	NN	PH
inhibitor	JJ	PH
type-1	JJ	PH
activity	NN	PH
(	(	PH
PAI-1	NNP	PH
activity	NN	PH
)	)	PH
and	CC	O
serum	JJ	PH
D-dimer	NNP	PH
as	IN	PH
a	DT	PH
global	JJ	PH
test	NN	PH
of	IN	PH
fibrinolytic	JJ	PH
activity	NN	PH
.	.	O

In	IN	O
the	DT	O
total	JJ	O
population	NN	O
,	,	O
improved	VBN	PH
fibrinolytic	JJ	PH
activity	NN	PH
was	VBD	O
observed	VBN	O
after	IN	O
1	CD	O
year	NN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	PH
D-dimer	NNP	PH
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
tPA	JJ	PH
activity	NN	PH
(	(	O
P=.024	NNP	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	PH
in	IN	PH
tPA	NN	PH
antigen	NN	PH
(	(	O
P=.048	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
measured	JJ	O
coagulation	NN	O
variables	NNS	O
.	.	O

Separately	RB	O
examined	VBD	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
atorvastatin	NN	O
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	PH
in	IN	PH
serum	JJ	PH
D-dimer	NNP	PH
(	(	O
P=.005	NNP	O
)	)	O
,	,	O
a	DT	O
borderline	JJ	O
increase	NN	PH
in	IN	PH
tPA	JJ	PH
activity	NN	PH
(	(	O
P=.083	NNP	O
)	)	O
and	CC	O
a	DT	O
borderline	NN	O
reduction	NN	PH
in	IN	PH
tPA	NN	PH
antigen	NN	PH
(	(	O
P=.069	NNP	O
)	)	O
.	.	O

Within	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
a	DT	O
reduction	NN	PH
in	IN	PH
prothrombin	NN	PH
F1+2	NNP	PH
was	VBD	O
observed	VBN	O
(	(	O
P=.038	NNP	O
)	)	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
changes	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
global	JJ	PH
fibrinolysis	NN	PH
(	(	O
serum	JJ	O
D-dimer	NNP	O
,	,	O
P=.046	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	PH
profile	NN	PH
was	VBD	O
observed	VBN	O
after	IN	O
statin	NN	O
treatment	NN	O
,	,	O
most	RBS	O
pronounced	JJ	O
with	IN	O
atorvastatin	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
drugs	NNS	O
promote	VBP	O
a	DT	O
profibrinolytic	JJ	O
profile	NN	O
,	,	O
and	CC	O
may	MD	O
in	IN	O
part	NN	O
explain	VBP	O
the	DT	O
benefit	NN	O
of	IN	O
statin	NN	O
treatment	NN	O
rendered	VBN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CHD	NNP	O
.	.	O

Early	JJ	O
educational	JJ	O
intervention	NN	O
for	IN	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
infants	NNS	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
Infant	NNP	O
Health	NNP	O
and	CC	O
Development	NNP	O
Program	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
early	JJ	O
educational	JJ	O
intervention	NN	O
after	IN	O
discharge	NN	O
from	IN	O
the	DT	O
hospital	NN	O
on	IN	O
the	DT	O
health	NN	O
and	CC	O
developmental	JJ	O
status	NN	O
of	IN	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
(	(	O
<	CD	O
or	CC	O
=	VB	O
1500	CD	O
gm	NN	O
)	)	O
infants	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
trial	NN	O
,	,	O
with	IN	O
post	NN	O
hoc	NN	O
analysis	NN	O
.	.	O

SETTING	NN	O
Eight	NNP	O
sites	NNS	O
,	,	O
heterogeneous	JJ	O
for	IN	O
sociodemographic	JJ	O
and	CC	O
health	NN	O
care	NN	O
use	NN	O
.	.	O

PARTICIPANTS	NN	O
Infants	NNS	O
(	(	O
N	NNP	O
=	NNP	O
280	CD	O
)	)	O
born	VBN	O
weighing	VBG	O
<	NN	O
or	CC	O
=	NN	O
1500	CD	O
gm	NN	O
and	CC	O
selected	VBN	O
for	IN	O
the	DT	O
Infant	NNP	O
Health	NNP	O
and	CC	O
Development	NNP	O
Program	NNP	O
.	.	O

Eligibility	NNP	O
was	VBD	O
limited	VBN	O
primarily	RB	O
by	IN	O
geographic	JJ	O
distance	NN	O
from	IN	O
the	DT	O
day	NN	O
care	NN	O
center	NN	O
.	.	O

One	CD	O
third	WDT	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
(	(	O
INT	NNP	O
)	)	O
group	NN	O
and	CC	O
two	CD	O
thirds	NNS	O
to	TO	O
follow-up	JJ	O
only	RB	O
.	.	O

INTERVENTIONS	NNP	O
All	NNP	O
children	NNS	O
received	VBD	O
intensive	JJ	O
pediatric	NNS	O
and	CC	O
developmental	JJ	O
surveillance	NN	O
.	.	O

The	DT	O
INT	NNP	O
group	NN	O
received	VBD	O
home	NN	O
visits	NNS	O
and	CC	O
center-based	JJ	O
educational	JJ	O
interventions	NNS	O
until	IN	O
36	CD	O
months	NNS	O
of	IN	O
age	NN	O
(	(	O
corrected	VBN	O
for	IN	O
gestational	JJ	O
age	NN	O
when	WRB	O
final	JJ	O
assessments	NNS	O
were	VBD	O
completed	VBN	O
)	)	O
.	.	O

OUTCOMES	NNP	O
Cognitive	NNP	ME
development	NN	ME
(	(	ME
Stanford-Binet	JJ	ME
Intelligence	NNP	ME
Scale	NNP	ME
)	)	ME
,	,	PH
behavioral	JJ	ME
competence	NN	ME
(	(	ME
Achebach	NNP	ME
Child	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
)	)	ME
,	,	PH
and	CC	PH
health	NN	PH
status	NN	PH
(	(	PH
indexes	NNS	PH
summarizing	VBG	PH
reported	VBD	PH
morbidity	NN	PH
,	,	PH
the	DT	PH
Functional	NNP	PH
Status	NNP	PH
II	NNP	PH
(	(	PH
R	NNP	PH
)	)	PH
Scale	NNP	PH
,	,	PH
and	CC	PH
General	NNP	PH
Health	NNP	PH
Ratings	NNP	PH
Index	NNP	PH
)	)	PH
.	.	O

RESULTS	NNP	O
Cognitive	NNP	PH
development	NN	PH
scores	NNS	PH
were	VBD	O
7.2	CD	O
points	NNS	O
higher	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
in	IN	O
the	DT	O
INT	NNP	O
group	NN	O
,	,	O
after	IN	O
adjustment	NN	O
for	IN	O
baseline	NN	O
differences	NNS	O
in	IN	O
site	NN	O
,	,	O
sociodemographic	JJ	O
characteristics	NNS	O
,	,	O
and	CC	O
neonatal	JJ	PH
morbidity	NN	PH
,	,	O
and	CC	O
were	VBD	O
9.4	CD	O
points	NNS	O
higher	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.0003	CD	O
)	)	O
when	WRB	O
the	DT	O
29	CD	O
children	NNS	O
with	IN	O
significant	JJ	O
cerebral	JJ	O
palsy	NN	O
were	VBD	O
removed	VBN	O
.	.	O

No	DT	O
differences	NNS	O
in	IN	O
behavior	NN	PH
,	,	PH
serious	JJ	PH
morbidity	NN	PH
,	,	PH
functional	JJ	PH
status	NN	PH
,	,	PH
or	CC	PH
health	NN	PH
rating	NN	PH
were	VBD	O
found	VBN	O
overall	RB	O
.	.	O

The	DT	O
infants	NNS	O
in	IN	O
the	DT	O
INT	NNP	O
group	NN	O
who	WP	O
weighted	VBD	O
<	NNP	O
or	CC	O
=	VB	O
1000	CD	O
gm	NN	O
at	IN	O
birth	NN	O
had	VBD	O
significantly	RB	O
lower	JJR	PH
behavior	NN	PH
problem	NN	PH
scores	NNS	PH
but	CC	O
no	DT	O
differences	NNS	O
on	IN	O
other	JJ	O
outcomes	NNS	O
.	.	O

All	DT	O
children	NNS	O
in	IN	O
the	DT	O
INT	NNP	O
group	NN	O
had	VBD	O
slightly	RB	O
higher	JJR	O
rates	NNS	PH
of	IN	PH
less	JJR	PH
serious	JJ	PH
morbidity	NN	PH
.	.	PH

CONCLUSION	VB	O
The	DT	O
advantage	NN	O
conferred	VBN	O
by	IN	O
being	VBG	O
in	IN	O
the	DT	O
INT	NNP	O
group	NN	O
,	,	O
as	IN	O
previously	RB	O
reported	VBN	O
for	IN	O
heavier	JJR	O
infants	NNS	O
,	,	O
extends	VBZ	O
to	TO	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
children	NNS	O
,	,	O
supporting	VBG	O
the	DT	O
use	NN	O
of	IN	O
early	JJ	O
intervention	NN	O
in	IN	O
this	DT	O
group	NN	O
.	.	O

Effects	NNS	O
of	IN	O
weight	JJ	O
reduction	NN	O
interventions	NNS	O
by	IN	O
community	NN	O
pharmacists	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
a	DT	O
meal	JJ	O
replacement	NN	O
(	(	O
MR	NNP	O
)	)	O
program	NN	O
with	IN	O
a	DT	O
conventional	JJ	O
reduced-calorie	JJ	O
diet	NN	O
(	(	O
RCD	NNP	O
)	)	O
for	IN	O
weight	NN	PH
management	NN	PH
using	VBG	O
the	DT	O
pharmacy	NN	O
as	IN	O
the	DT	O
setting	NN	O
and	CC	O
the	DT	O
pharmacist	NN	O
as	IN	O
the	DT	O
point	NN	O
of	IN	O
contact	NN	O
for	IN	O
dietary	JJ	O
advice	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
open-label	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Travis	NNP	O
Pharmacy	NNP	O
in	IN	O
Shenandoah	NNP	O
,	,	O
Iowa	NNP	O
.	.	O

PATIENTS	NNP	O
Ninety-five	JJ	O
patients	NNS	O
from	IN	O
southwestern	JJ	O
iowa	NN	O
and	CC	O
southeastern	JJ	O
Nebraska	NNP	O
were	VBD	O
enrolled	VBN	O
,	,	O
of	IN	O
whom	WP	O
88	CD	O
were	VBD	O
considered	VBN	O
eligible	JJ	O
for	IN	O
comparison	NN	O
(	(	O
by	IN	O
continuing	VBG	O
through	IN	O
week	NN	O
2	CD	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
.	.	O

INTERVENTION	JJ	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
an	DT	O
MR	NNP	O
plan	NN	O
or	CC	O
a	DT	O
traditional	JJ	O
RCD	NNP	O
plan	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
a	DT	O
3-month	JJ	O
period	NN	O
of	IN	O
active	JJ	O
weight	JJ	O
loss	NN	O
and	CC	O
a	DT	O
10-week	JJ	O
period	NN	O
of	IN	O
weight	JJ	O
maintenance	NN	O
.	.	O

Patients	NNS	O
returned	VBD	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
follow-up	NN	O
with	IN	O
the	DT	O
pharmacist	NN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
13	CD	O
visits	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
Weight	NNP	PH
changes	NNS	PH
.	.	PH

RESULTS	NNP	O
During	IN	O
the	DT	O
active	JJ	O
weight	NN	O
loss	NN	O
phase	NN	O
,	,	O
the	DT	O
MR	NNP	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
and	CC	O
RCD	NNP	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
groups	NNS	O
lost	VBD	O
a	DT	O
significant	JJ	PH
amount	NN	PH
of	IN	PH
weight	NN	PH
,	,	O
although	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
error	NN	O
=	VBZ	O
4.90	CD	O
+/-	JJ	O
0.30	CD	O
kg	NN	O
MR	NNP	O
versus	NN	O
4.30	CD	O
+/-	JJ	O
0.30	CD	O
kg	NN	O
RCD	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.16	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
weight	NN	O
maintenance	NN	O
phase	NN	O
,	,	O
the	DT	O
MR	NNP	O
group	NN	O
lost	VBD	O
0.70	CD	O
+/-	JJ	O
0.40	CD	O
kg	NN	O
and	CC	O
the	DT	O
RCD	NNP	O
group	NN	O
lost	VBD	O
0.90	CD	O
+/-	JJ	O
0.40	CD	O
kg	NN	O
(	(	O
P	NNP	O
=	NNP	O
.60	NNP	O
)	)	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
waist	JJ	PH
circumference	NN	PH
,	,	PH
systolic	JJ	PH
and	CC	PH
diastolic	JJ	PH
blood	NN	PH
pressure	NN	PH
,	,	PH
and	CC	PH
triglyceride	NN	PH
levels	NNS	PH
.	.	PH

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
high-density	NN	PH
lipoprotein	NN	PH
cholesterol	NN	PH
or	CC	PH
low-density	NN	PH
lipoprotein	NNS	PH
cholesterol	NN	PH
levels	NNS	PH
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Successful	NNP	O
weight	VBD	PH
management	NN	PH
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
a	DT	O
pharmacy	NN	O
setting	NN	O
.	.	O

Both	DT	O
MR	NNP	O
and	CC	O
RCD	NNP	O
programs	NNS	O
were	VBD	O
effective	JJ	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
daily	JJ	O
versus	FW	O
weekly	JJ	O
administration	NN	O
of	IN	O
2-chlorodeoxyadenosine	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
hairy	JJ	O
cell	NN	O
leukemia	NN	O
:	:	O
a	DT	O
multicenter	NN	O
phase	NN	O
III	NNP	O
trial	NN	O
(	(	O
SAKK	NNP	O
32/98	CD	O
)	)	O
.	.	O

Daily	JJ	O
administration	NN	O
of	IN	O
2-chlorodeoxyadenosine	JJ	O
(	(	O
Cladribine	NNP	O
,	,	O
CDA	NNP	O
)	)	O
is	VBZ	O
a	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
hairy	NN	O
cell	NN	O
leukemia	NN	O
,	,	O
but	CC	O
may	MD	O
cause	VB	O
severe	JJ	O
neutropenia	NN	PH
and	CC	PH
neutropenic	JJ	PH
fever	NN	PH
.	.	O

This	DT	O
trial	NN	O
compared	VBN	O
toxicity	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
weekly	JJ	O
versus	NN	O
daily	RB	O
CDA	NNP	O
administration	NN	O
.	.	O

One	CD	O
hundred	VBD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
standard	NN	O
(	(	O
CDA	NNP	O
0.14	CD	O
mg/kg/day	JJ	O
day	NN	O
1-5	JJ	O
[	NNP	O
Arm	NNP	O
A	NNP	O
]	NN	O
)	)	O
or	CC	O
experimental	JJ	O
treatment	NN	O
(	(	O
CDA	NNP	O
0.14	CD	O
mg/kg/day	NN	O
once	RB	O
weekly	JJ	O
for	IN	O
5	CD	O
weeks	NNS	O
[	JJ	O
Arm	NNP	O
B	NNP	O
]	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
average	JJ	PH
leukocyte	JJ	PH
count	NN	PH
within	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
randomization	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
response	NN	PH
rates	NNS	PH
,	,	O
other	JJ	PH
acute	JJ	A
hematotoxicity	NN	A
,	,	O
acute	JJ	A
infection	NN	A
rate	NN	A
,	,	O
hospital	NN	Ot
admission	NN	Ot
,	,	O
remission	NN	Ot
duration	NN	Ot
,	,	O
event-free	JJ	MO
,	,	MO
and	CC	MO
overall	JJ	MO
survival	NN	MO
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
average	JJ	O
leukocyte	JJ	PH
count	NN	PH
.	.	O

Response	JJ	PH
rate	NN	PH
(	(	O
complete	JJ	O
+	NNP	O
partial	JJ	O
remission	NN	O
)	)	O
at	IN	O
week	NN	O
10	CD	O
was	VBD	O
78	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
64-88	CD	O
%	NN	O
)	)	O
in	IN	O
Arm	NNP	O
A	NNP	O
and	CC	O
68	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
54-80	CD	O
%	NN	O
)	)	O
in	IN	O
Arm	NNP	O
B	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.13	CD	O
)	)	O
.	.	O

Best	JJS	O
response	NN	PH
rates	NNS	PH
during	IN	O
follow-up	JJ	O
were	VBD	O
identical	JJ	O
(	(	O
86	CD	O
%	NN	O
)	)	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
grade	NN	PH
3+4	CD	PH
leukocytopenia	NN	PH
(	(	O
94	CD	O
%	NN	O
vs	NN	O
.	.	O

84	CD	O
%	NN	O
)	)	O
,	,	O
grade	VBD	PH
3+4	CD	PH
neutropenia	NN	PH
(	(	O
90	CD	O
%	NN	O
vs	NN	O
.	.	O

80	CD	O
%	NN	O
)	)	O
,	,	O
acute	JJ	PH
infection	NN	PH
(	(	O
44	CD	O
%	NN	O
vs	NN	O
.	.	O

40	CD	O
%	NN	O
)	)	O
,	,	O
hospitalization	NN	Ot
(	(	O
38	CD	O
%	NN	O
vs	NN	O
.	.	O

34	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
erythrocyte	JJ	PH
support	NN	PH
(	(	O
22	CD	O
%	NN	O
vs	NN	O
.	.	O

30	CD	O
%	NN	O
)	)	O
within	IN	O
10	CD	O
weeks	NNS	O
.	.	O

Overall	JJ	O
,	,	O
these	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
there	EX	O
are	VBP	O
no	DT	O
apparent	JJ	O
advantages	NNS	O
in	IN	O
toxicity	NN	Ot
and	CC	Ot
efficacy	NN	Ot
by	IN	O
giving	VBG	O
CDA	NNP	O
weekly	RB	O
rather	RB	O
than	IN	O
daily	RB	O
.	.	O

Activation	NN	O
and	CC	O
intermuscular	JJ	O
coherence	NN	O
of	IN	O
distal	JJ	O
arm	NN	O
muscles	NNS	O
during	IN	O
proximal	JJ	O
muscle	NN	O
contraction	NN	O
.	.	O

In	IN	O
the	DT	O
human	JJ	O
upper	JJ	O
extremity	NN	O
(	(	O
UE	NNP	O
)	)	O
,	,	O
unintended	JJ	O
effects	NNS	O
of	IN	O
proximal	JJ	O
muscle	NN	O
activation	NN	O
on	IN	O
muscles	NNS	O
controlling	VBG	O
the	DT	O
hand	NN	O
could	MD	O
be	VB	O
an	DT	O
important	JJ	O
aspect	NN	O
of	IN	O
motor	NN	O
control	NN	O
due	JJ	O
to	TO	O
the	DT	O
necessary	JJ	O
coordination	NN	O
of	IN	O
distal	NN	O
and	CC	O
proximal	JJ	O
segments	NNS	O
during	IN	O
functional	JJ	O
activities	NNS	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
concurrent	JJ	O
activation	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
on	IN	O
the	DT	O
coordination	NN	O
between	IN	O
hand	NN	O
muscles	NNS	O
performing	VBG	O
a	DT	O
grip	NN	O
task	NN	O
.	.	O

Eleven	NNP	O
healthy	JJ	O
subjects	NNS	O
performed	VBN	O
precision	NN	O
grip	NN	O
tasks	NNS	O
while	IN	O
a	DT	O
constant	JJ	O
extension	NN	O
or	CC	O
flexion	NN	O
moment	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
their	PRP$	O
elbow	NN	O
joints	NNS	O
,	,	O
inducing	VBG	O
a	DT	O
sustained	VBN	O
submaximal	JJ	O
contraction	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
to	TO	O
counter	VB	O
the	DT	O
applied	JJ	O
torque	NN	O
.	.	O

Activation	NNP	O
of	IN	O
four	CD	O
hand	NN	O
muscles	NNS	O
was	VBD	O
measured	VBN	O
during	IN	O
each	DT	O
task	NN	O
condition	NN	O
using	VBG	O
surface	NN	O
electromyography	NN	O
(	(	O
EMG	NNP	O
)	)	O
.	.	O

When	WRB	O
concurrent	JJ	O
activation	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
was	VBD	O
induced	VBN	O
,	,	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
activation	NN	PH
levels	NNS	PH
of	IN	PH
the	DT	PH
hand	NN	PH
muscles	NNS	PH
were	VBD	O
observed	VBN	O
,	,	O
with	IN	O
greater	JJR	O
effects	NNS	O
on	IN	O
the	DT	O
extrinsic	JJ	O
finger	NN	O
extensor	NN	O
(	(	O
23.2	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
extensor	NN	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.003	CD	O
)	)	O
than	IN	O
extrinsic	JJ	O
finger	NN	O
flexor	NN	O
(	(	O
14.2	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
flexor	JJ	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.130	CD	O
)	)	O
.	.	O

Elbow	NNP	PH
muscle	NN	PH
activation	NN	PH
also	RB	O
induced	VBD	O
involuntary	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
intrinsic	JJ	PH
thumb	NN	PH
flexor	NN	PH
activation	NN	PH
(	(	O
44.6	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
extensor	NN	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.005	CD	O
)	)	O
.	.	O

EMG-EMG	JJ	O
coherence	NN	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
elbow	JJ	PH
muscle	NN	PH
activation	NN	PH
significantly	RB	O
reduced	VBD	O
intermuscular	JJ	PH
coherence	NN	PH
between	IN	PH
distal	JJ	PH
muscle	NN	PH
pairs	NNS	PH
,	,	O
with	IN	O
its	PRP$	O
greatest	JJS	O
effects	NNS	O
on	IN	O
coherence	NN	O
in	IN	O
the	DT	O
?-band	NN	O
(	(	O
13-25	JJ	O
Hz	NNP	O
)	)	O
(	(	O
average	NN	O
of	IN	O
17	CD	O
%	NN	O
decrease	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
flexor	JJ	O
activation	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
evidence	NN	O
for	IN	O
involuntary	JJ	O
,	,	O
muscle-specific	JJ	O
interactions	NNS	O
between	IN	O
distal	NN	O
and	CC	O
proximal	JJ	O
UE	NNP	O
muscles	NNS	O
,	,	O
which	WDT	O
may	MD	O
contribute	VB	O
to	TO	O
UE	NNP	O
motor	NN	O
performance	NN	O
in	IN	O
health	NN	O
and	CC	O
disease	NN	O
.	.	O

Effect	NN	O
of	IN	O
antipsychotic	JJ	O
drugs	NNS	O
on	IN	O
cortical	JJ	PH
thickness	NN	PH
.	.	PH

A	DT	O
randomized	JJ	O
controlled	VBN	O
one-year	JJ	O
follow-up	NN	O
study	NN	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
and	CC	O
olanzapine	NN	O
.	.	O

BACKGROUND	NNP	O
Imaging	NNP	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
brain	NN	O
alterations	NNS	O
are	VBP	O
primary	JJ	O
to	TO	O
the	DT	O
full-blown	JJ	O
onset	NN	O
of	IN	O
schizophrenia	NN	O
and	CC	O
seem	VBP	O
to	TO	O
progress	VB	O
across	IN	O
time	NN	O
.	.	O

The	DT	O
potential	JJ	O
effects	NNS	Ot
of	IN	Ot
antipsychotic	JJ	Ot
medication	NN	Ot
on	IN	O
brain	NN	O
structure	NN	O
represent	VBP	O
a	DT	O
key	JJ	O
factor	NN	O
in	IN	O
understanding	VBG	O
brain	NN	O
changes	NNS	O
in	IN	O
psychosis	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
low	JJ	O
doses	NNS	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
and	CC	O
olanzapine	NN	O
on	IN	O
cortical	JJ	PH
thickness	NN	PH
.	.	O

METHOD	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	O
(	(	O
N=16	NNP	O
)	)	O
,	,	O
olanzapine	JJ	O
(	(	O
N=18	NNP	O
)	)	O
and	CC	O
low	JJ	O
doses	NNS	O
of	IN	O
haloperidol	NN	O
(	(	O
N=18	NNP	O
)	)	O
in	IN	O
cortical	JJ	O
thickness	NN	O
changes	NNS	O
during	IN	O
1-year	JJ	O
follow-up	JJ	O
period	NN	O
in	IN	O
a	DT	O
large	JJ	O
and	CC	O
heterogeneous	JJ	O
sample	NN	O
of	IN	O
schizophrenia	NN	O
spectrum	NN	O
patients	NNS	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
cortical	JJ	PH
thickness	NN	PH
changes	NNS	PH
and	CC	O
clinical	JJ	PH
and	CC	O
cognitive	JJ	ME
outcome	NN	ME
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

A	DT	O
group	NN	O
of	IN	O
45	CD	O
healthy	JJ	O
volunteers	NNS	O
was	VBD	O
also	RB	O
longitudinally	RB	O
evaluated	VBN	O
.	.	O

Magnetic	JJ	O
resonance	NN	O
imaging	VBG	O
brain	NN	O
scans	NNS	O
(	(	O
1.5T	CD	O
)	)	O
were	VBD	O
obtained	VBN	O
and	CC	O
images	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
BRAINS2	NNP	O
.	.	O

RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
of	IN	O
time	NN	O
(	(	O
F	NNP	O
(	(	O
1,47	CD	O
)	)	O
<	NN	O
1.66	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.204	CD	O
)	)	O
,	,	O
treatment	NN	O
group	NN	O
(	(	O
F	NNP	O
(	(	O
2,47	CD	O
)	)	O
<	NN	O
1.47	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.242	CD	O
)	)	O
or	CC	O
group-by-time	JJ	O
interaction	NN	O
(	(	O
F	NNP	O
(	(	O
2,47	CD	O
)	)	O
<	NN	O
1.82	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.174	CD	O
)	)	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
cortical	JJ	PH
thickness	NN	PH
variables	NNS	PH
.	.	PH

When	WRB	O
the	DT	O
group	NN	O
of	IN	O
healthy	JJ	O
controls	NNS	O
was	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analyses	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
of	IN	O
note	NN	O
that	IN	O
group-by-time	JJ	O
interaction	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
result	NN	O
for	IN	O
the	DT	O
frontal	JJ	O
lobe	NN	O
at	IN	O
trend	NN	O
level	NN	O
(	(	O
F	NNP	O
(	(	O
3,81	CD	O
)	)	O
=2.686	NN	O
;	:	O
P=0.052	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
Bonferroni	NNP	O
adjustment	NN	O
for	IN	O
multiple	JJ	O
comparisons	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
associations	NNS	O
between	IN	O
changes	NNS	PH
in	IN	PH
cortical	JJ	PH
thickness	NN	PH
and	CC	O
clinical	JJ	O
and	CC	O
cognitive	JJ	O
outcome	NN	O
.	.	O

CONCLUSIONS	NNP	O
Low	NNP	O
doses	NNS	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
,	,	O
and	CC	O
olanzapine	NN	O
seem	VBP	O
to	TO	O
equally	RB	O
affect	VB	O
gray	JJ	PH
matter	NN	PH
cortical	JJ	PH
thickness	NN	PH
,	,	PH
overall	JJ	PH
and	CC	PH
lobes	JJ	PH
,	,	O
at	IN	O
the	DT	O
medium-term	NN	O
(	(	O
1	CD	O
year	NN	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	O
effectiveness	NN	O
of	IN	O
treatments	NNS	O
was	VBD	O
not	RB	O
significantly	RB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
cortical	JJ	PH
thickness	NN	PH
.	.	O

A	DT	O
cost-benefit	JJ	Ot
comparison	NN	O
of	IN	O
intensive	JJ	O
diabetes	NNS	O
management	NN	O
with	IN	O
implantable	JJ	O
pumps	NNS	O
versus	IN	O
multiple	JJ	O
subcutaneous	JJ	O
injections	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
type	NN	O
I	PRP	O
diabetes	VBZ	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
if	IN	O
intraperitoneal	JJ	O
(	(	O
IP	NNP	O
)	)	O
insulin	NN	O
infusion	NN	O
via	IN	O
programmable	JJ	O
implantable	JJ	O
pumps	NNS	O
is	VBZ	O
a	DT	O
potential	JJ	O
alternative	NN	O
to	TO	O
subcutaneous	JJ	O
(	(	O
SC	NNP	O
)	)	O
insulin	NN	O
via	IN	O
multiple	JJ	O
injections	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
compared	VBN	O
the	DT	O
cost-benefits	NNS	Ot
of	IN	O
the	DT	O
two	CD	O
methods	NNS	O
using	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
6-month	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
in	IN	O
10	CD	O
adult	NN	O
type	NN	O
I	PRP	O
diabetic	JJ	O
patients	NNS	O
.	.	O

RESULTS	NNP	O
When	WRB	O
judged	VBN	O
on	IN	O
the	DT	O
last	JJ	O
month	NN	O
of	IN	O
IP	NNP	O
versus	NN	O
SC	NNP	O
periods	NNS	O
in	IN	O
the	DT	O
nine	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
metabolic	JJ	PH
data	NN	PH
showed	VBD	O
better	JJR	O
glycemic	JJ	PH
control	NN	PH
(	(	O
HbA1c	NNP	O
:	:	O
7.2	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
8.5	CD	O
+/-	JJ	O
0.7	CD	O
%	NN	O
SC	NNP	O
,	,	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
reduced	VBN	PH
glycemic	JJ	PH
fluctuations	NNS	PH
(	(	O
SD	NNP	O
of	IN	O
capillary	JJ	O
glucose	JJ	O
values	NNS	O
:	:	O
3.4	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
4.6	CD	O
+/-	JJ	O
0.2	CD	O
mM	NN	O
SC	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
fewer	JJR	O
mild	JJ	PH
hypoglycemic	JJ	PH
events	NNS	PH
(	(	O
5.7	CD	O
+/-	JJ	O
2.0	CD	O
IP	NNP	O
vs.	FW	O
10.0	CD	O
+/-	JJ	O
3.1	CD	O
events/month	JJ	O
SC	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Quality	NN	Ot
of	IN	Ot
life	NN	Ot
,	,	O
judged	VBN	O
by	IN	O
Diabetes	NNP	Ot
Control	NNP	Ot
and	CC	Ot
Complications	NNP	Ot
Trial	NNP	Ot
questionnaires	NNS	Ot
,	,	O
was	VBD	O
unaffected	VBN	O
by	IN	O
pump	NN	O
therapy	NN	O
.	.	O

Direct	JJ	Ot
costs	NNS	Ot
,	,	Ot
including	VBG	Ot
pump	JJ	Ot
acquisition	NN	Ot
,	,	Ot
implantation	NN	Ot
,	,	Ot
and	CC	Ot
follow-up	NN	Ot
,	,	O
were	VBD	O
2.6-fold	JJ	O
higher	JJR	O
with	IN	O
IP	NNP	O
than	IN	O
with	IN	O
SC	NNP	O
delivery	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
implantable	JJ	O
pump	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	Ot
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
,	,	O
equally	RB	O
accepted	VBN	Ot
,	,	O
but	CC	O
more	RBR	O
costly	JJ	Ot
than	IN	O
multiple	JJ	O
injections	NNS	O
and	CC	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
unsatisfactory	JJ	O
glycemic	JJ	PH
control	NN	PH
despite	IN	O
intensive	JJ	O
diabetes	NNS	O
management	NN	O
with	IN	O
SC	NNP	O
insulin	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
longer-term	JJ	O
,	,	O
larger-scale	JJ	O
,	,	O
and	CC	O
comparative	JJ	O
evaluation	NN	O
is	VBZ	O
required	VBN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
melatonin	NN	O
for	IN	O
sleep	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
,	,	O
or	CC	O
autism	NN	O
and	CC	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
melatonin	NN	O
on	IN	O
sleep	NN	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
(	(	O
FXS	NNP	O
)	)	O
.	.	O

METHODS	VB	O
A	DT	O
4-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
was	VBD	O
conducted	VBN	O
following	VBG	O
a	DT	O
1-week	JJ	O
baseline	NN	O
period	NN	O
.	.	O

Either	CC	O
melatonin	NN	O
,	,	O
3	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	O
was	VBD	O
given	VBN	O
to	TO	O
participants	NNS	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
alternated	VBD	O
for	IN	O
another	DT	O
2	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	PH
variables	NNS	PH
,	,	O
including	VBG	O
sleep	JJ	Ot
duration	NN	Ot
,	,	Ot
sleep-onset	JJ	Ot
time	NN	Ot
,	,	Ot
sleep-onset	JJ	Ot
latency	NN	Ot
time	NN	Ot
,	,	Ot
and	CC	Ot
the	DT	Ot
number	NN	Ot
of	IN	Ot
night	NN	Ot
awakenings	NNS	Ot
,	,	O
were	VBD	O
recorded	VBN	O
using	VBG	O
an	DT	O
Actiwatch	NN	O
and	CC	O
from	IN	O
sleep	JJ	O
diaries	NNS	O
completed	VBN	O
by	IN	O
parents	NNS	O
.	.	O

All	DT	O
participants	NNS	O
had	VBD	O
been	VBN	O
thoroughly	RB	O
assessed	VBN	O
for	IN	O
ASD	NNP	O
and	CC	O
also	RB	O
had	VBD	O
DNA	NNP	O
testing	VBG	O
for	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
FXS	NNP	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
were	VBD	O
successfully	RB	O
obtained	VBN	O
from	IN	O
the	DT	O
12	CD	O
of	IN	O
18	CD	O
subjects	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
11	CD	O
males	NNS	O
,	,	O
age	NN	O
range	NN	O
2	CD	O
to	TO	O
15.25	CD	O
years	NNS	O
,	,	O
mean	JJ	O
5.47	CD	O
,	,	O
SD	NNP	O
3.6	CD	O
)	)	O
.	.	O

Five	CD	O
participants	NNS	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
ASD	NNP	O
,	,	O
3	CD	O
for	IN	O
FXS	NNP	O
alone	RB	O
,	,	O
3	CD	O
for	IN	O
FXS	NNP	O
and	CC	O
ASD	NNP	O
,	,	O
and	CC	O
1	CD	O
for	IN	O
fragile	JJ	O
X	NNP	O
premutation	NN	O
.	.	O

Eight	CD	O
out	IN	O
of	IN	O
12	CD	O
had	VBD	O
melatonin	VBN	O
first	RB	O
.	.	O

The	DT	O
conclusions	NNS	O
from	IN	O
a	DT	O
nonparametric	JJ	O
repeated-measures	NNS	O
technique	NN	O
indicate	VBP	O
that	IN	O
mean	JJ	Ot
night	NN	Ot
sleep	NN	Ot
duration	NN	Ot
was	VBD	O
longer	RBR	O
on	IN	O
melatonin	NN	O
than	IN	O
placebo	NN	O
by	IN	O
21	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
mean	JJ	Ot
sleep-onset	JJ	Ot
latency	NN	Ot
was	VBD	O
shorter	JJR	O
by	IN	O
28	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
mean	VB	Ot
sleep-onset	JJ	Ot
time	NN	Ot
was	VBD	O
earlier	RB	O
by	IN	O
42	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
support	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
melatonin	NN	O
treatment	NN	O
for	IN	O
sleep	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
FXS	NNP	O
.	.	O

Humoral	NNP	O
immunity	NN	O
after	IN	O
kidney	NN	O
transplantation	NN	O
:	:	O
impact	NN	O
of	IN	O
two	CD	O
randomized	JJ	O
immunosuppressive	JJ	O
protocols	NNS	O
.	.	O

BACKGROUND	NNP	O
Controlling	NNP	O
alloimmune	JJ	O
humoral	JJ	O
response	NN	O
is	VBZ	O
a	DT	O
challenge	NN	O
in	IN	O
transplantation	NN	O
.	.	O

Few	JJ	O
studies	NNS	O
have	VBP	O
evaluated	VBN	O
the	DT	O
impact	NN	O
of	IN	O
maintenance	NN	O
immunosuppression	NN	O
on	IN	O
blood	NN	O
humoral	JJ	O
parameters	NNS	O
.	.	O

MATERIAL/METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
post-hoc	JJ	O
analysis	NN	O
on	IN	O
307	CD	O
kidney	NN	O
transplant	NN	O
recipients	NNS	O
included	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
tacrolimus/mycophenolate	NN	O
mofetil	NN	O
(	(	O
Tac/MMF	NNP	O
)	)	O
vs.	FW	O
cyclosporine/azathioprine	NN	O
(	(	O
CsA/AZA	NNP	O
)	)	O
,	,	O
both	DT	O
used	VBN	O
with	IN	O
antithymocyte	JJ	O
globulin	NN	O
induction	NN	O
and	CC	O
steroids	NNS	O
.	.	O

Humoral	JJ	O
parameters	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
D0	NNP	O
,	,	O
D15	NNP	O
,	,	O
and	CC	O
M12	NNP	O
.	.	O

RESULTS	NNP	O
IgG	NNP	PH
,	,	PH
IgA	NNP	PH
,	,	PH
and	CC	PH
IgM	NNP	PH
levels	NNS	PH
decreased	VBN	O
significantly	RB	O
as	RB	O
soon	RB	O
as	IN	O
D15	NNP	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
?35	CD	O
%	NN	O
,	,	O
?26	CD	O
%	NN	O
,	,	O
and	CC	O
?35	CD	O
%	NN	O
respectively	RB	O
,	,	O
vs.	FW	O
D0	NNP	O
)	)	O
.	.	O

At	IN	O
M12	NNP	O
,	,	O
although	IN	O
peripheral	JJ	O
B-cell	NNP	O
counts	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
Tac/MMF	NNP	O
regimen	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
IgG	NNP	O
,	,	O
IgA	NNP	O
,	,	O
and	CC	O
IgM	NNP	O
levels	NNS	O
than	IN	O
CsA/AZA	NNP	O
(	(	O
?5.9	CD	O
%	NN	O
,	,	O
?14.6	CD	O
%	NN	O
,	,	O
and	CC	O
?34	NNP	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Hypogammaglobulinemia	NNP	O
at	IN	O
D15	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
infections	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
HLA-sensitized	JJ	O
patients	NNS	O
decreased	VBN	O
in	IN	O
the	DT	O
Tac/MMF	NNP	O
group	NN	O
(	(	O
15.9	CD	O
%	NN	O
at	IN	O
D0	NNP	O
and	CC	O
6.7	CD	O
%	NN	O
at	IN	O
M12	NNP	O
,	,	O
p=0.02	NN	O
)	)	O
and	CC	O
remained	VBD	O
stable	JJ	O
in	IN	O
the	DT	O
CsA/AZA	NNP	O
group	NN	O
(	(	O
10.3	CD	O
%	NN	O
at	IN	O
D0	NNP	O
and	CC	O
8.9	CD	O
%	NN	O
at	IN	O
M12	NNP	O
,	,	O
p=0.5	NN	O
)	)	O
.	.	O

More	JJR	O
patients	NNS	O
sensitized	VBN	O
at	IN	O
baseline	NN	O
became	VBD	O
non-sensitized	JJ	O
at	IN	O
M12	NNP	O
with	IN	O
Tac/MMF	NNP	O
than	IN	O
with	IN	O
CsA/AZA	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
humoral	JJ	O
immunosuppression	NN	O
is	VBZ	O
better	RBR	O
with	IN	O
Tac/MMF	NNP	O
than	IN	O
with	IN	O
CsA/AZA	NNP	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
kidney	NN	O
transplantation	NN	O
.	.	O

Evidence	NN	O
for	IN	O
poorer	JJR	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
negative	JJ	O
trauma-related	JJ	O
cognitions	NNS	O
receiving	VBG	O
prolonged	JJ	O
exposure	NN	O
plus	CC	O
cognitive	JJ	O
restructuring	NN	O
:	:	O
implications	NNS	O
for	IN	O
treatment	NN	O
matching	NN	O
in	IN	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
.	.	O

In	IN	O
the	DT	O
current	JJ	O
article	NN	O
,	,	O
we	PRP	O
address	VBP	O
the	DT	O
existing	VBG	O
assumption	NN	O
in	IN	O
the	DT	O
literature	NN	O
on	IN	O
cognitive	JJ	O
behavioral	JJ	O
treatment	NN	O
of	IN	O
PTSD	NNP	O
that	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
negative	JJ	O
trauma-related	JJ	O
cognitions	NNS	O
would	MD	O
benefit	VB	O
more	RBR	O
from	IN	O
a	DT	O
treatment	NN	O
package	NN	O
that	WDT	O
includes	VBZ	O
exposure	NN	O
and	CC	O
cognitive	JJ	O
techniques	NNS	O
compared	VBN	O
with	IN	O
a	DT	O
treatment	NN	O
that	WDT	O
includes	VBZ	O
exposure	NN	O
only	RB	O
.	.	O

To	TO	O
test	VB	O
this	DT	O
assumption	NN	O
,	,	O
54	CD	O
PTSD	NN	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
prolonged	VB	O
exposure	NN	O
therapy	NN	O
or	CC	O
prolonged	JJ	O
exposure	NN	O
therapy	NN	O
plus	CC	O
cognitive	JJ	O
restructuring	NN	O
.	.	O

Contrary	NNP	O
to	TO	O
expectations	NNS	O
,	,	O
findings	NNS	O
revealed	VBD	O
that	IN	O
patients	NNS	O
characterized	VBN	O
by	IN	O
more	JJR	O
severe	JJ	O
pretreatment	NN	O
trauma-related	JJ	O
cognitions	NNS	O
(	(	O
and	CC	O
more	RBR	O
severe	JJ	O
pretreatment	NN	O
PTSD	NNP	O
symptoms	NNS	O
)	)	O
fared	VBD	O
slightly	RB	O
worse	JJR	O
in	IN	O
treatment	NN	O
combining	NN	O
exposure	NN	O
and	CC	O
cognitive	JJ	O
restructuring	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
relationship	NN	O
between	IN	O
pre-	NN	O
and	CC	O
post-treatment	JJ	ME
measures	NNS	ME
of	IN	ME
negative	JJ	ME
cognitions	NNS	ME
and	CC	PH
PTSD	NNP	PH
symptoms	NNS	PH
in	IN	O
the	DT	O
exposure	NN	O
alone	RB	O
group	NN	O
.	.	O

The	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
for	IN	O
examining	VBG	O
Person	NNP	O
X	NNP	O
Treatment	NNP	O
interactions	NNS	O
and	CC	O
the	DT	O
efficacy	NN	Ot
of	IN	O
combining	VBG	O
treatments	NNS	O
for	IN	O
PTSD	NNP	O
are	VBP	O
discussed	VBN	O
.	.	O

Lack	NN	O
of	IN	O
antihistamine	NN	O
properties	NNS	O
of	IN	O
single	JJ	O
dose	JJ	O
cinnarizine	NN	O
in	IN	O
man	NN	O
.	.	O

A	DT	O
simple	JJ	O
way	NN	O
to	TO	O
study	VB	O
a	DT	O
histamine	JJ	O
antagonist	NN	O
in	IN	O
man	NN	O
is	VBZ	O
to	TO	O
observe	VB	O
the	DT	O
effect	NN	O
it	PRP	O
has	VBZ	O
on	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
skin	JJ	O
reaction	NN	O
to	TO	O
intradermal	JJ	O
histamine	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
antihistamine	JJ	O
activity	NN	O
of	IN	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
75	CD	O
mg	NNS	O
cinnarizine	VBP	O
using	VBG	O
75	CD	O
mg	JJ	O
diphenhydramine	NN	O
as	IN	O
control	NN	O
,	,	O
both	DT	O
being	VBG	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
two	CD	O
groups	NNS	O
of	IN	O
5	CD	O
healthy	JJ	O
subjects	NNS	O
,	,	O
each	DT	O
group	NN	O
receiving	VBG	O
one	CD	O
of	IN	O
the	DT	O
active	JJ	O
treatments	NNS	O
or	CC	O
placebo	NN	O
randomly	RB	O
under	IN	O
blind	JJ	O
conditions	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
received	VBN	O
intradermal	JJ	O
injections	NNS	O
on	IN	O
the	DT	O
forearm	NN	O
of	IN	O
a	DT	O
0.05	CD	O
ml	NN	O
saline	JJ	O
solution	NN	O
containing	VBG	O
5	CD	O
micrograms	NNS	O
of	IN	O
histamine	NN	O
before	IN	O
and	CC	O
at	IN	O
different	JJ	O
times	NNS	O
after	IN	O
drug	NN	O
intake	NN	O
.	.	O

The	DT	O
histamine-induced	JJ	O
wheal	JJ	O
area	NN	O
was	VBD	O
measured	VBN	O
and	CC	O
,	,	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
the	DT	O
percent	NN	O
decrease	NN	O
of	IN	O
the	DT	O
wheal	JJ	PH
area	NN	PH
was	VBD	O
calculated	VBN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
diphenhydramine	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
inhibition	NN	Ot
of	IN	Ot
the	DT	Ot
histamine-induced	JJ	PH
wheal	NN	PH
size	NN	PH
at	IN	O
1.5	CD	O
h	NN	O
which	WDT	O
lasted	VBD	O
up	RB	O
to	TO	O
4	CD	O
h	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
reaching	VBG	O
maximum	JJ	O
inhibition	NN	O
at	IN	O
2.5	CD	O
h.	NN	O
After	IN	O
cinnarizine	NN	O
treatment	NN	O
no	DT	PH
significant	JJ	PH
decrease	NN	PH
of	IN	PH
the	DT	PH
histamine-induced	JJ	PH
wheal	JJ	PH
area	NN	PH
was	VBD	O
observed	VBN	O
at	IN	O
any	DT	O
time	NN	O
.	.	O

Dose	NNP	O
dependent	JJ	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	O
:	:	O
Michaelis-Menten	JJ	O
parameters	NNS	O
for	IN	O
its	PRP$	O
major	JJ	O
metabolic	JJ	O
pathways	NNS	O
.	.	O

Dose	NNP	O
Dependency	NNP	O
for	IN	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	O
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
,	,	O
3-methylxanthine	JJ	O
(	(	O
3-MX	JJ	O
)	)	O
;	:	O
1-methyluric	JJ	O
acid	NN	O
(	(	O
1-MU	JJ	O
)	)	O
;	:	O
1,3-dimethyluric	JJ	O
acid	NN	O
(	(	O
DMU	NNP	O
)	)	O
,	,	O
were	VBD	O
examined	VBN	O
by	IN	O
administering	VBG	O
three	CD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
250	CD	O
,	,	O
375	CD	O
,	,	O
500	CD	O
mg	NN	O
)	)	O
of	IN	O
theophylline	NN	O
to	TO	O
six	CD	O
healthy	JJ	O
adult	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
serum	NN	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
theophylline	NN	O
and	CC	O
the	DT	O
metabolites	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

Total	JJ	Ot
clearance	NN	Ot
of	IN	O
theophylline	NN	O
decreased	VBN	O
and	CC	O
its	PRP$	O
half	JJ	O
life	NN	O
increased	VBD	O
over	IN	O
the	DT	O
range	NN	O
of	IN	O
doses	NNS	O
administered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
dose	NN	O
related	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
fractional	JJ	O
recovery	NN	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
dose	NN	O
related	JJ	O
increase	NN	O
in	IN	O
fractional	JJ	ME
excretion	NN	ME
of	IN	ME
DMU	NNP	ME
and	CC	O
unchanged	JJ	O
theophylline	NN	O
(	(	O
p	JJ	O
<	NN	O
0.01	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.001	CD	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
dose	NN	O
related	VBN	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
renal	JJ	ME
clearance	NN	ME
of	IN	ME
3-MX	JJ	ME
,	,	O
1-MU	JJ	ME
and	CC	O
DMU	NNP	ME
,	,	O
indicating	VBG	O
linear	JJ	O
urinary	JJ	O
excretion	NN	O
kinetics	NNS	O
of	IN	O
the	DT	O
metabolites	NNS	O
.	.	O

Theophylline	NNP	ME
metabolic	JJ	ME
clearance	NN	ME
to	TO	ME
3-MX	JJ	ME
as	RB	O
well	RB	O
as	IN	O
to	TO	O
1-MU	CD	O
decreased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
but	CC	O
clearance	NN	O
to	TO	O
DMU	NNP	O
remained	VBD	O
unnaffected	JJ	O
by	IN	O
the	DT	O
size	NN	O
of	IN	O
dose	NN	O
.	.	O

The	DT	O
individual	JJ	O
Michaelis-Menten	NNP	Ot
parameters	NNS	Ot
Km	NNP	Ot
and	CC	Ot
Vmax	NNP	Ot
were	VBD	O
estimated	VBN	O
for	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
three	CD	O
different	JJ	O
single	JJ	O
doses	NNS	O
.	.	O

The	DT	O
Km	NNP	Ot
values	NNS	Ot
for	IN	Ot
theophylline	JJ	Ot
metabolism	NN	Ot
to	TO	Ot
3-MX	JJ	Ot
,	,	O
1-MU	JJ	ME
and	CC	O
DMU	NNP	ME
were	VBD	O
2.4+/-0.6	JJ	O
,	,	O
5.1+/-1.8+/-	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/L	NN	O
respectively	RB	O
and	CC	O
the	DT	O
Vmax	NNP	Ot
values	NNS	Ot
were	VBD	O
3.5+/-0.7	JJ	O
,	,	O
7.5+/-2.6	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/hr	NN	O
respectively	RB	O
.	.	O

The	DT	O
Km	NNP	Ot
values	NNS	Ot
for	IN	Ot
the	DT	Ot
N-demethylation	NNP	Ot
pathways	NNS	Ot
(	(	Ot
3MX	CD	Ot
and	CC	Ot
1-MU	JJ	Ot
)	)	Ot
were	VBD	O
lower	JJR	O
corresponding	VBG	O
to	TO	O
therapeutic	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
drug	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elimination	NN	O
kinetics	NNS	O
of	IN	O
theophylline	NN	O
is	VBZ	O
nonlinear	JJ	O
in	IN	O
the	DT	O
human	NN	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
of	IN	O
serum	JJ	PH
concenntrations	NNS	PH
and	CC	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
saturable	JJ	O
formation	NN	O
kinetics	NNS	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
previous	JJ	O
studies	NNS	O
we	PRP	O
did	VBD	O
n't	RB	O
find	VB	O
obvious	JJ	O
indication	NN	O
for	IN	O
nonlinear	JJ	O
formation	NN	O
of	IN	O
DMU	NNP	O
at	IN	O
therapeutic	JJ	O
concentration	NN	O
range	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
MRI	NNP	O
study	NN	O
of	IN	O
anti-herpes	NNS	O
virus	JJ	O
therapy	NN	O
in	IN	O
MS	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
the	DT	O
antiherpes	NNS	O
drug	NN	O
valacyclovir	NN	O
on	IN	O
MRI-evident	JJ	PH
lesions	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
MS	NNP	O
in	IN	O
a	DT	O
phase	NN	O
2	CD	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
It	PRP	O
has	VBZ	O
been	VBN	O
postulated	VBN	O
from	IN	O
virologic	JJ	O
studies	NNS	O
that	WDT	O
herpesvirus	VBP	O
infection	NN	O
could	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
progression	NN	O
of	IN	O
MS.	NNP	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
eligible	JJ	O
for	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
had	VBD	O
had	VBN	O
two	CD	O
or	CC	O
more	JJR	O
MS	JJ	O
relapses	NNS	O
in	IN	O
the	DT	O
2-year	JJ	O
period	NN	O
before	IN	O
enrollment	NN	O
.	.	O

Seventy	JJ	O
patients	NNS	O
with	IN	O
Expanded	NNP	O
Disability	NNP	O
Status	NNP	O
Scale	NNP	O
scores	NNS	O
of	IN	O
0	CD	O
to	TO	O
5.5	CD	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
1	CD	O
gram	NN	O
of	IN	O
valacyclovir	NN	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
34	CD	O
)	)	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
underwent	JJ	O
MRI	NNP	O
every	DT	O
fourth	JJ	O
week	NN	O
for	IN	O
32	CD	O
weeks	NNS	O
:	:	O
twice	RB	O
during	IN	O
pretreatment	NN	O
,	,	O
six	CD	O
times	NNS	O
during	IN	O
treatment	NN	O
,	,	O
and	CC	O
once	RB	O
after	IN	O
treatment	NN	O
.	.	O

Scoring	VBG	PH
of	IN	PH
neurologic	JJ	PH
disability	NN	PH
was	VBD	O
performed	VBN	O
at	IN	O
the	DT	O
start	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
number	NN	PH
of	IN	PH
new	JJ	PH
active	JJ	PH
MRI-evident	JJ	PH
lesions	NNS	PH
over	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
other	JJ	PH
MRI	NNP	PH
measures	NNS	PH
and	CC	O
clinical	JJ	PH
endpoints	NNS	PH
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
new	JJ	PH
active	JJ	PH
lesions	NNS	PH
+/-	JJ	O
SD	NNP	O
per	IN	O
patient	NN	O
during	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
valacyclovir	NN	O
was	VBD	O
11.9	CD	O
+/-	JJ	O
17.6	CD	O
and	CC	O
that	IN	O
during	IN	O
placebo	NN	O
treatment	NN	O
was	VBD	O
14.5	CD	O
+/-	JJ	O
21.4	CD	O
.	.	O

A	DT	O
protocol-planned	JJ	O
exploratory	NN	O
analysis	NN	O
stratified	VBD	O
patients	NNS	O
according	VBG	O
to	TO	O
baseline	NN	O
activity	NN	O
;	:	O
this	DT	O
analysis	NN	O
showed	VBD	O
that	IN	O
patients	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
disease	NN	O
activity	NN	O
in	IN	O
the	DT	O
valacyclovir	NN	O
treatment	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
developed	VBD	O
fewer	JJR	O
new	JJ	PH
active	JJ	PH
lesions	NNS	PH
per	IN	O
scan	JJ	O
than	IN	O
did	VBD	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
treatment	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
number	NN	O
(	(	O
Q	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
Q	NNP	O
(	(	O
3	CD	O
)	)	O
range	NN	O
)	)	O
of	IN	O
active	JJ	PH
lesions	NNS	PH
was	VBD	O
2.0	CD	O
(	(	O
1.38	CD	O
,	,	O
3.96	CD	O
)	)	O
in	IN	O
the	DT	O
valacyclovir	NN	O
treatment	NN	O
group	NN	O
and	CC	O
6.5	CD	O
(	(	O
2.63	CD	O
,	,	O
9.0	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
treatment	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Valacyclovir	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
formation	NN	O
of	IN	O
active	JJ	PH
lesions	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
MS	NNP	O
who	WP	O
had	VBD	O
two	CD	O
or	CC	O
more	JJR	O
relapses	NNS	O
during	IN	O
the	DT	O
previous	JJ	O
2-year	JJ	O
period	NN	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
disease	NN	O
activity	NN	O
who	WP	O
had	VBD	O
more	JJR	O
than	IN	O
one	CD	O
active	JJ	O
MRI-evident	JJ	O
lesion	NN	O
during	IN	O
4	CD	O
weeks	NNS	O
,	,	O
valacyclovir	FW	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduced	JJ	O
number	NN	O
of	IN	O
new	JJ	PH
active	JJ	PH
MRI-evident	JJ	PH
lesions	NNS	PH
and	CC	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
scans	NNS	O
free	JJ	O
of	IN	O
new	JJ	PH
active	JJ	PH
lesions	NNS	PH
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
exploratory	NN	O
subgroup	NN	O
analysis	NN	O
provide	VBP	O
support	NN	O
for	IN	O
further	JJ	O
studies	NNS	O
of	IN	O
antiherpes	NNS	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
MS	NNP	O
and	CC	O
high	JJ	O
levels	NNS	O
of	IN	O
MRI-evident	JJ	O
disease	NN	O
activity	NN	O
.	.	O

Involvement	NN	O
of	IN	O
cholecystokininA	NN	O
receptors	NNS	O
in	IN	O
transient	NN	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

OBJECTIVE	CC	O
Transient	NNP	PH
lower	JJR	PH
esophageal	NN	PH
sphincter	NN	PH
relaxations	NNS	PH
(	(	PH
TLESRs	NNP	PH
)	)	PH
are	VBP	O
the	DT	O
main	JJ	O
mechanism	NN	O
underlying	VBG	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
loxiglumide	NN	O
,	,	O
a	DT	O
specific	JJ	O
cholecystokininA	NN	O
(	(	O
CCKA	NNP	O
)	)	O
-receptor	NN	O
antagonist	NN	O
,	,	O
on	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
TLESRs	NNP	O
evoked	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
esophageal	JJ	O
manometry	NN	O
using	VBG	O
a	DT	O
10-lumen	JJ	O
sleeve	NN	O
assembly	NN	O
during	IN	O
placebo	NN	O
or	CC	O
loxiglumide	NN	O
(	(	O
10	CD	O
mg/kg/h	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
order	NN	O
.	.	O

Gastric	NNP	O
distension	NN	O
was	VBD	O
induced	VBN	O
by	IN	O
inflation	NN	O
of	IN	O
400	CD	O
ml	NN	O
of	IN	O
air	NN	O
.	.	O

RESULTS	VB	O
Basal	NNP	PH
lower	JJR	PH
esophageal	NN	PH
pressure	NN	PH
(	(	PH
LESP	NNP	PH
)	)	PH
and	CC	O
swallow-induced	JJ	PH
relaxation	NN	PH
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
loxiglumide	NN	O
.	.	O

Loxiglumide	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	PH
,	,	O
from	IN	O
11.5	CD	O
(	(	O
5.8-18.3	JJ	O
)	)	O
to	TO	O
6.0	CD	O
(	(	O
3.3-14.3	JJ	O
)	)	O
during	IN	O
the	DT	O
total	JJ	O
recording	JJ	O
period	NN	O
of	IN	O
1	CD	O
h	NN	O
,	,	O
and	CC	O
from	IN	O
5.5	CD	O
(	(	O
4.25-7.5	JJ	O
)	)	O
to	TO	O
2.0	CD	O
(	(	O
0.5-6.8	JJ	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
15	CD	O
min	NN	O
.	.	O

The	DT	O
number	NN	PH
of	IN	PH
common	JJ	PH
cavities	NNS	PH
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
loxiglumide	NN	O
,	,	O
from	IN	O
8.0	CD	O
(	(	O
4.0-20.0	JJ	O
)	)	O
to	TO	O
5.0	CD	O
(	(	O
2.0-7.8	JJ	O
)	)	O
.	.	O

TLESRs	NNP	PH
represented	VBD	O
the	DT	O
main	JJ	O
mechanism	NN	O
(	(	O
60	CD	O
%	NN	O
during	IN	O
placebo	NN	O
,	,	O
74	CD	O
%	NN	O
during	IN	O
loxiglumide	NN	O
)	)	O
underlying	VBG	O
common	JJ	O
cavities	NNS	O
,	,	O
followed	VBN	O
by	IN	O
swallow-induced	JJ	O
relaxation	NN	O
.	.	O

CONCLUSIONS	NNP	O
Loxiglumide	NNP	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	PH
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
swallow-related	JJ	O
relaxation	NN	O
of	IN	O
the	DT	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
,	,	O
suggesting	VBG	O
the	DT	O
involvement	NN	O
of	IN	O
CCKA	NNP	O
receptors	NNS	O
in	IN	O
the	DT	O
reflex	JJ	O
pathway	NN	O
mediating	VBG	O
TLESRs	NNP	O
.	.	O

Domperidone	NN	O
,	,	O
metoclopramide	NN	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

All	DT	O
give	JJ	O
symptomatic	JJ	Ot
improvement	NN	Ot
in	IN	Ot
gastroesophageal	JJ	Ot
reflux	NN	Ot
.	.	O

A	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
of	IN	O
two	CD	O
gastric	JJ	O
prokinetic	JJ	O
drugs	NNS	O
in	IN	O
23	CD	O
patients	NNS	O
with	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
a	DT	O
dual-isotope	JJ	O
mixed-meal	JJ	O
study	NN	O
of	IN	O
their	PRP$	O
gastric	JJ	O
emptying	NN	O
(	(	O
GE	NNP	O
)	)	O
.	.	O

Group	NNP	O
I	PRP	O
had	VBD	O
normal	JJ	O
GE	NNP	O
and	CC	O
group	NN	O
II	NNP	O
delayed	VBD	O
GE	NNP	O
.	.	O

Nine	NNP	O
gastrointestinal	JJ	O
symptoms	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
frequency	NN	O
and	CC	O
severity	NN	O
before	IN	O
treatment	NN	O
.	.	O

The	DT	O
trial	NN	O
had	VBD	O
three	CD	O
1-month	JJ	O
treatment	NN	O
periods	NNS	O
using	VBG	O
metoclopramide	RB	O
10	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
domperidone	NN	O
20	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
or	CC	O
placebo	NN	O
on	IN	O
a	DT	O
random	JJ	O
basis	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
reassessed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
month	NN	O
.	.	O

Taken	NNP	O
as	IN	O
a	DT	O
whole	NN	O
,	,	O
the	DT	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
symptomatic	JJ	PH
response	NN	PH
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
,	,	O
but	CC	O
patients	NNS	O
with	IN	O
delayed	JJ	O
or	CC	O
normal	JJ	O
GE	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
their	PRP$	O
symptomatic	JJ	O
response	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
complained	VBD	O
of	IN	O
side	NN	A
effects	NNS	A
with	IN	O
metoclopramide	NN	O
and	CC	O
three	CD	O
stopped	VBD	O
therapy	NN	O
before	IN	O
the	DT	O
1-month	JJ	O
course	NN	O
was	VBD	O
completed	VBN	O
.	.	O

Two	CD	O
patients	NNS	O
described	JJ	O
side	JJ	O
effects	NNS	O
with	IN	O
domperidone	NN	O
,	,	O
including	VBG	O
one	CD	O
woman	NN	O
with	IN	O
galactorrhea	NN	PH
after	IN	O
36	CD	O
h	NN	O
of	IN	O
treatment	NN	O
.	.	O

Three	CD	O
patients	NNS	O
on	IN	O
placebo	NN	O
also	RB	O
complained	VBD	O
of	IN	O
important	JJ	A
side	NN	A
effects	NNS	A
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
significant	JJ	O
placebo	NN	O
effect	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
symptomatic	JJ	Ot
improvement	NN	Ot
between	IN	O
placebo	NN	O
,	,	O
domperidone	NN	O
,	,	O
and	CC	O
metoclopramide	RB	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Exposure	NN	O
reduced	VBN	O
agoraphobia	NNS	O
but	CC	O
not	RB	O
panic	JJ	O
,	,	O
and	CC	O
cognitive	JJ	O
therapy	NN	O
reduced	VBD	O
panic	JJ	O
but	CC	O
not	RB	O
agoraphobia	RB	O
.	.	O

Earlier	JJR	O
studies	NNS	O
showed	VBD	O
that	IN	O
cognitive	JJ	O
therapy	NN	O
has	VBZ	O
anti-panic	JJ	O
effects	NNS	O
and	CC	O
exposure	NN	O
has	VBZ	O
anti-agoraphobic	JJ	O
effects	NNS	O
while	IN	O
other	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
agoraphobia	NN	O
is	VBZ	O
a	DT	O
secondary	JJ	O
complication	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
.	.	O

It	PRP	O
was	VBD	O
therefore	RB	O
hypothesized	VBN	O
that	IN	O
cognitive	JJ	O
therapy	NN	O
not	RB	O
only	RB	O
reduces	VBZ	O
panic	NN	O
but	CC	O
also	RB	O
agoraphobia	JJ	O
and	CC	O
that	IN	O
it	PRP	O
potentiates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
exposure	NN	O
in	IN	O
vivo	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
12	CD	O
severe	JJ	O
agoraphobics	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
4	CD	O
sessions	NNS	O
of	IN	O
cognitive	JJ	O
therapy	NN	O
followed	VBN	O
by	IN	O
8	CD	O
sessions	NNS	O
of	IN	O
cognitive	JJ	O
therapy	NN	O
combined	VBN	O
with	IN	O
in	IN	O
vivo	NN	O
exposure	NN	O
.	.	O

The	DT	O
other	JJ	O
12	CD	O
received	VBD	O
4	CD	O
sessions	NNS	O
of	IN	O
'associative	JJ	O
therapy	NN	O
'	''	O
,	,	O
a	DT	O
presumably	RB	O
inert	JJ	O
treatment	NN	O
that	WDT	O
controls	VBZ	O
for	IN	O
therapist	NN	O
attention	NN	O
,	,	O
followed	VBN	O
by	IN	O
8	CD	O
sessions	NNS	O
of	IN	O
in	IN	O
vivo	NN	O
exposure	NN	O
that	WDT	O
was	VBD	O
framed	VBN	O
in	IN	O
common	JJ	O
behavioral	JJ	O
terms	NNS	O
.	.	O

The	DT	O
initial	JJ	O
cognitive	JJ	O
therapy	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
panic	JJ	ME
frequency	NN	ME
,	,	O
while	IN	O
associative	JJ	O
therapy	NN	O
did	VBD	O
not	RB	O
affect	VB	O
panic	NN	O
.	.	O

Neither	CC	O
cognitive	JJ	O
therapy	NN	O
alone	RB	O
,	,	O
nor	CC	O
associate	JJ	O
therapy	NN	O
alone	RB	O
significantly	RB	O
reduced	VBN	O
depression	NN	ME
,	,	O
state	NN	ME
or	CC	ME
trait	NN	ME
anxiety	NN	ME
,	,	O
self-rated	JJ	ME
agoraphobia	NN	ME
or	CC	O
behavioral	JJ	ME
avoidance	NN	ME
.	.	O

After	IN	O
adding	VBG	O
exposure	NN	O
however	RB	O
,	,	O
these	DT	O
parameters	NNS	O
were	VBD	O
clearly	RB	O
and	CC	O
significantly	RB	O
reduced	VBN	O
.	.	O

Cognitive	JJ	O
therapy	NN	O
did	VBD	O
not	RB	O
potentiate	VB	O
exposure	NN	O
effects	NNS	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Effect	NN	O
of	IN	O
chronic	JJ	O
aerobic	JJ	O
exercise	NN	O
and	CC	O
progressive	JJ	O
relaxation	NN	O
on	IN	O
motor	NN	O
performance	NN	O
and	CC	O
affect	NN	O
following	VBG	O
acute	JJ	O
stress	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
10-week	JJ	O
aerobic	JJ	O
exercise	NN	O
and	CC	O
progressive	JJ	O
relaxation	NN	O
training	VBG	O
program	NN	O
on	IN	O
somatic	JJ	O
,	,	O
emotional	JJ	O
,	,	O
and	CC	O
behavioral	JJ	O
responses	NNS	O
to	TO	O
acute	VB	O
stress	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
quality	NN	O
of	IN	O
motor	NN	O
performance	NN	O
and	CC	O
affect	NN	O
,	,	O
were	VBD	O
examined	VBN	O
.	.	O

The	DT	O
participants	NNS	O
consisted	VBD	O
of	IN	O
60	CD	O
unfit	JJ	O
male	NN	O
university	NN	O
undergraduate	JJ	O
students	NNS	O
with	IN	O
no	DT	O
previous	JJ	O
training	NN	O
in	IN	O
stress	JJ	O
management	NN	O
who	WP	O
were	VBD	O
randomly	RB	O
and	CC	O
evenly	RB	O
assigned	VBD	O
to	TO	O
engage	VB	O
in	IN	O
one	CD	O
of	IN	O
four	CD	O
treatments	NNS	O
over	IN	O
10	CD	O
weeks	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
moderate	NN	O
aerobic	JJ	O
exercise	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
progressive	NN	O
relaxation	NN	O
,	,	O
(	(	O
c	NN	O
)	)	O
a	DT	O
placebo	NN	O
group	NN	O
that	WDT	O
engaged	VBD	O
in	IN	O
group	NN	O
discussion	NN	O
but	CC	O
did	VBD	O
experience	VB	O
acute	NN	O
stress	NN	O
,	,	O
and	CC	O
(	(	O
d	NN	O
)	)	O
a	DT	O
nonintervention	NN	O
control	NN	O
group	NN	O
that	WDT	O
did	VBD	O
not	RB	O
experience	VB	O
stress	NN	O
while	IN	O
performing	VBG	O
the	DT	O
motor	NN	O
task	NN	O
.	.	O

Acute	NNP	O
stress	NN	O
consisted	VBD	O
of	IN	O
losing	VBG	O
against	IN	O
a	DT	O
competitor	NN	O
of	IN	O
the	DT	O
opposite	JJ	O
sex	NN	O
on	IN	O
the	DT	O
criterion	NN	O
motor	NN	O
task	NN	O
while	IN	O
receiving	VBG	O
unpleasant	JJ	O
information	NN	O
about	IN	O
their	PRP$	O
performance	NN	O
over	IN	O
30	CD	O
preintervention	NN	O
and	CC	O
30	CD	O
postintervention	NN	O
trials	NNS	O
.	.	O

Analyses	NNS	O
indicated	VBD	O
that	IN	O
aerobic	JJ	O
exercisers	NNS	O
,	,	O
in	IN	O
comparisons	NNS	O
with	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
,	,	O
responded	VBD	O
to	TO	O
acute	VB	O
stress	NN	O
with	IN	O
more	RBR	O
positive	JJ	O
affect	NN	O
,	,	O
lower	JJR	PH
stressor	NN	PH
task	JJ	PH
heart	NN	PH
rate	NN	PH
,	,	PH
reduced	VBN	PH
systolic	JJ	PH
(	(	PH
but	CC	PH
not	RB	PH
diastolic	JJ	PH
)	)	PH
blood	NN	PH
pressure	NN	PH
,	,	O
and	CC	O
superior	JJ	O
motor	NN	ME
performance	NN	ME
.	.	O

Progressive	JJ	O
relaxation	NN	O
markedly	RB	O
reduced	VBD	O
systolic	JJ	ME
blood	NN	ME
pressure	NN	ME
but	CC	O
did	VBD	O
not	RB	O
favorably	RB	O
influence	JJ	O
performance	NN	O
or	CC	O
affect	VB	O
in	IN	O
response	NN	O
to	TO	O
acute	VB	O
stress	NN	O
.	.	O

Placebo	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
statistically	RB	O
similar	JJ	O
on	IN	O
all	DT	O
measures	NNS	O
.	.	O

The	DT	O
findings	NNS	O
indicated	VBD	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
chronic	JJ	O
aerobic	JJ	O
exercise	NN	O
as	IN	O
a	DT	O
strategy	NN	O
for	IN	O
improved	JJ	O
coping	NN	O
with	IN	O
acute	JJ	O
stress	NN	O
.	.	O

Effect	NN	O
of	IN	O
sport-tinted	JJ	O
contact	NN	O
lenses	NNS	O
for	IN	O
contrast	NN	O
enhancement	NN	O
on	IN	O
retinal	JJ	O
straylight	NN	O
measurements	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
tinted	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
CL	NNP	O
)	)	O
designed	VBN	O
for	IN	O
outdoor	JJ	O
sports	NNS	O
activity	NN	O
on	IN	O
the	DT	O
psychometric	JJ	O
determination	NN	O
of	IN	O
retinal	JJ	O
straylight	NN	O
using	VBG	O
the	DT	O
compensation	NN	O
comparison	NN	O
method	NN	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	O
emmetropic	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
fitted	VBN	O
with	IN	O
two	CD	O
different	JJ	O
tinted	VBN	O
Nike	NNP	O
Maxsight	NNP	O
(	(	O
Bausch	NNP	O
&	CC	O
Lomb	NNP	O
,	,	O
Rochester	NNP	O
,	,	O
NY	NNP	O
,	,	O
USA	NNP	O
)	)	O
CL	NNP	O
in	IN	O
one	CD	O
eye	NN	O
,	,	O
while	IN	O
the	DT	O
contralateral	JJ	O
eye	NN	O
was	VBD	O
fitted	VBN	O
with	IN	O
a	DT	O
clear	JJ	O
lens	NNS	O
made	VBN	O
of	IN	O
the	DT	O
same	JJ	O
material	NN	O
(	(	O
Optima	NNP	O
38	CD	O
,	,	O
Bausch	NNP	O
&	CC	O
Lomb	NNP	O
)	)	O
.	.	O

Three	CD	O
valid	JJ	O
straylight	NN	Ot
measurements	NNS	Ot
were	VBD	O
taken	VBN	O
on	IN	O
each	DT	O
eye	NN	O
before	IN	O
and	CC	O
a	DT	O
few	JJ	O
minutes	NNS	O
after	IN	O
lens	JJ	O
insertion	NN	O
,	,	O
when	WRB	O
lens	VBZ	O
stabilization	NN	O
had	VBD	O
occurred	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
subjects	NNS	O
'	POS	O
mean	NN	PH
straylight	NN	PH
values	NNS	PH
were	VBD	O
0.90	CD	O
+/-	JJ	O
0.09	CD	O
at	IN	O
baseline	NN	O
and	CC	O
0.95	CD	O
+/-	JJ	O
0.10	CD	O
with	IN	O
the	DT	O
clear	JJ	O
Optima	NNP	O
38	CD	O
CL	NNP	O
.	.	O

Straylight	NNP	Ot
values	NNS	Ot
were	VBD	O
0.97	CD	O
+/-	JJ	O
0.10	CD	O
and	CC	O
1.0	CD	O
+/-	JJ	O
0.10	CD	O
log	JJ	O
units	NNS	O
with	IN	O
the	DT	O
amber	NN	O
and	CC	O
grey-green	JJ	O
tinted	JJ	O
CL	NNP	O
,	,	O
respectively	RB	O
.	.	O

Differences	NNS	O
in	IN	O
straylight	NN	Ot
between	IN	O
baseline	NN	O
(	(	O
without	IN	O
CL	NNP	O
)	)	O
and	CC	O
with	IN	O
the	DT	O
clear	JJ	O
CL	NNP	O
in	IN	O
place	NN	O
were	VBD	O
neither	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.066	CD	O
)	)	O
nor	CC	O
was	VBD	O
there	EX	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
baseline	NN	O
and	CC	O
the	DT	O
amber	NN	O
CL	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.052	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
from	IN	O
baseline	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

Differences	NNS	O
in	IN	O
straylight	NN	O
with	IN	O
the	DT	O
clear	JJ	O
CL	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
were	VBD	O
also	RB	O
statistically	RB	O
different	JJ	O
from	IN	O
zero	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
showing	VBG	O
an	DT	O
increased	VBN	O
straylight	NN	PH
value	NN	PH
for	IN	O
the	DT	O
tinted	JJ	O
CL	NNP	O
.	.	O

These	DT	O
differences	NNS	O
were	VBD	O
variable	JJ	O
,	,	O
but	CC	O
consistent	JJ	O
for	IN	O
each	DT	O
subject	NN	O
,	,	O
thus	RB	O
those	DT	O
showing	VBG	O
higher	JJR	O
or	CC	O
lower	JJR	O
changes	NNS	O
with	IN	O
one	CD	O
tinted	JJ	O
lens	VBZ	O
tended	VBN	O
to	TO	O
show	VB	O
the	DT	O
same	JJ	O
trend	NN	O
with	IN	O
the	DT	O
second	JJ	O
lens	NNS	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
=	FW	O
0.736	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
increases	NNS	O
having	VBG	O
been	VBN	O
found	VBN	O
in	IN	O
straylight	JJ	O
values	NNS	O
with	IN	O
tinted	VBN	O
contact	NN	O
lenses	NNS	O
,	,	O
those	DT	O
changes	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
induce	VB	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
visual	JJ	O
function	NN	O
under	IN	O
photopic	NN	O
conditions	NNS	O
,	,	O
even	RB	O
for	IN	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
,	,	O
which	WDT	O
seems	VBZ	O
to	TO	O
increase	VB	O
straylight	JJ	O
values	NNS	O
more	RBR	O
significantly	RB	O
than	IN	O
the	DT	O
amber	JJ	O
CL	NNP	O
.	.	O

This	DT	O
difference	NN	O
between	IN	O
the	DT	O
tinted	JJ	O
CL	NNP	O
could	MD	O
suggest	VB	O
a	DT	O
wavelength	JJ	O
dependence	NN	O
of	IN	O
straylight	NN	O
values	NNS	O
,	,	O
although	IN	O
this	DT	O
should	MD	O
be	VB	O
investigated	VBN	O
further	JJ	O
by	IN	O
controlling	VBG	O
for	IN	O
pupil	NN	O
size	NN	O
and	CC	O
subjects	NNS	O
'	POS	O
pigmentation	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
using	VBG	O
neutral	JJ	O
density	NN	O
filters	NNS	O
.	.	O

Methotrexate	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
steroid-dependent	JJ	O
asthma	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
steroid	JJ	Ot
requirements	NNS	Ot
between	IN	O
placebo	NN	O
and	CC	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
corticosteroid-requiring	JJ	O
asthma	NN	O
.	.	O

Subjects	NNS	O
began	VBD	O
with	IN	O
a	DT	O
steroid	JJ	O
taper	NN	O
and	CC	O
then	RB	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
3-month	JJ	O
trial	NN	O
of	IN	O
drug	NN	O
or	CC	O
placebo	NN	O
therapy	NN	O
.	.	O

Subjects	NNS	O
received	VBD	O
15	CD	O
mg	NN	O
of	IN	O
MTX	NNP	O
a	DT	O
week	NN	O
or	CC	O
identical	JJ	O
placebo	NN	O
.	.	O

A	DT	O
1-month	JJ	O
washout	NN	O
period	NN	O
was	VBD	O
completed	VBN	O
before	IN	O
the	DT	O
crossover	NN	O
trial	NN	O
.	.	O

Symptom	NNP	PH
scores	NNS	PH
,	,	PH
peak	NN	PH
flow	NN	PH
rates	NNS	PH
,	,	PH
spirometry	NN	Ot
,	,	PH
and	CC	PH
beta-agonist	JJ	PH
frequency	NN	PH
were	VBD	O
closely	RB	O
monitored	VBN	O
.	.	O

Ten	CD	O
subjects	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
average	JJ	O
dose	NN	O
of	IN	O
prednisone	NN	O
during	IN	O
the	DT	O
placebo-treatment	JJ	O
period	NN	O
was	VBD	O
11.97	CD	O
mg/day	NN	O
compared	VBN	O
to	TO	O
8.37	CD	O
mg/day	NNS	O
while	IN	O
subjects	NNS	O
were	VBD	O
taking	VBG	O
MTX	NNP	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
30	CD	O
%	NN	O
reduction	NN	O
in	IN	O
daily	JJ	Ot
steroid	JJ	Ot
requirement	NN	Ot
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Symptom	JJ	PH
scores	NNS	PH
and	CC	O
spirometry	NN	Ot
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
crossover	NN	O
trials	NNS	O
,	,	O
and	CC	O
overall	JJ	O
clinical	JJ	O
status	NN	O
was	VBD	O
not	RB	O
altered	VBN	O
.	.	O

Complications	NNS	A
from	IN	A
MTX	NNP	A
were	VBD	O
mild	JJ	O
and	CC	O
included	VBD	O
anorexia	NN	A
,	,	A
alopecia	NN	A
,	,	A
and	CC	A
stomatitis	NN	A
.	.	O

All	DT	O
complications	NNS	A
resolved	VBN	O
with	IN	O
dose	JJ	O
reduction	NN	O
or	CC	O
when	WRB	O
MTX	NNP	O
was	VBD	O
stopped	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
subjects	NNS	O
withdrew	VBD	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
MTX	NNP	O
complications	NNS	O
.	.	O

Low-dose	JJ	O
MTX	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
steroid	JJ	Ot
requirement	NN	Ot
in	IN	O
this	DT	O
group	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
steroid-dependent	JJ	O
asthma	NN	O
.	.	O

This	DT	O
reduction	NN	Ot
in	IN	Ot
steroid	JJ	Ot
requirement	NN	Ot
was	VBD	O
obtained	VBN	O
without	IN	O
altering	VBG	O
clinical	JJ	O
status	NN	O
and	CC	O
without	IN	O
significant	JJ	O
complication	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	Ot
of	IN	O
indomethacin	NN	O
in	IN	O
uremic	JJ	PH
pericarditis	NN	PH
.	.	PH

To	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
indomethacin	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
uremic	JJ	O
pericarditis	NN	O
we	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
double	JJ	O
blind	NN	O
study	NN	O
in	IN	O
which	WDT	O
24	CD	O
patients	NNS	O
with	IN	O
endstage	NN	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
and	CC	O
pericarditis	NN	O
randomly	RB	O
received	VBD	O
indomethacin	JJ	O
,	,	O
25	CD	O
mg	NN	O
four	CD	O
times	NNS	O
daily	RB	O
,	,	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
for	IN	O
a	DT	O
3-week	JJ	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBN	O
peritoneal	JJ	O
or	CC	O
hemodialysis	NN	O
treatment	NN	O
concurrently	RB	O
with	IN	O
the	DT	O
study	NN	O
drug	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
placebo	NN	O
,	,	O
indomethacin	NN	O
produced	VBD	O
an	DT	O
immediate	JJ	O
and	CC	O
sustained	JJ	O
reduction	NN	PH
of	IN	PH
fever	NN	PH
in	IN	O
all	DT	O
but	CC	O
one	CD	O
patient	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
indomethacin	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
duration	NN	PA
of	IN	PA
chest	NN	PA
pain	NN	PA
(	(	O
mean	JJ	O
days	NNS	O
+/-	JJ	O
SE	NNP	O
:	:	O
placebo	NN	O
1.4	CD	O
+/-	JJ	O
0.6	CD	O
,	,	O
indomethacin	JJ	O
5.5	CD	O
+/-	JJ	O
3.3	CD	O
)	)	O
,	,	O
duration	NN	O
of	IN	O
pericardial	JJ	PH
friction	NN	PH
rub	NN	PH
(	(	O
placebo	JJ	O
10.3	CD	O
+/-	JJ	O
1.7	CD	O
,	,	O
indomethacin	JJ	O
16.0	CD	O
+/-	JJ	O
3.8	CD	O
)	)	O
,	,	O
or	CC	O
on	IN	O
the	DT	O
amount	NN	O
of	IN	O
pericardial	JJ	PH
effusion	NN	PH
.	.	PH

Further	NNP	O
,	,	O
indomethacin	NN	O
did	VBD	O
not	RB	O
diminish	VB	O
the	DT	O
need	NN	PH
for	IN	PH
invasive	JJ	PH
surgical	JJ	PH
procedures	NNS	PH
for	IN	O
relief	NN	O
of	IN	O
tamponade	NN	PH
(	(	O
three	CD	O
of	IN	O
13	CD	O
placebo	NN	O
patients	NNS	O
,	,	O
two	CD	O
of	IN	O
11	CD	O
indomethacin	JJ	O
patients	NNS	O
)	)	O
or	CC	O
result	NN	O
in	IN	O
decreased	JJ	O
mortality	NN	MO
rate	NN	MO
.	.	MO

Death	NNP	MO
(	(	O
not	RB	O
due	RB	O
to	TO	O
pericarditis	NN	O
)	)	O
occurred	VBD	O
in	IN	O
two	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
indomethacin	NN	O
and	CC	O
one	CD	O
patient	NN	O
who	WP	O
received	VBD	O
the	DT	O
placebo	NN	O
.	.	O

In	IN	O
our	PRP$	O
patients	NNS	O
pericarditis	VBP	O
encompassed	VBD	O
a	DT	O
wide	JJ	O
spectrum	NN	O
ranging	VBG	O
from	IN	O
a	DT	O
mild	JJ	PH
illness	NN	PH
of	IN	PH
several	JJ	PH
days	NNS	PH
duration	NN	PH
to	TO	O
a	DT	O
painful	JJ	PH
and	CC	PH
debilitating	JJ	PH
disease	NN	PH
lasting	JJ	PH
weeks	NNS	PH
and	CC	O
requiring	VBG	O
surgical	JJ	Ot
intervention	NN	Ot
.	.	O

Although	IN	O
the	DT	O
size	NN	O
of	IN	O
our	PRP$	O
population	NN	O
prohibits	VBZ	O
definitive	JJ	O
conclusions	NNS	O
,	,	O
it	PRP	O
would	MD	O
appear	VB	O
that	IN	O
,	,	O
except	IN	O
for	IN	O
fever	NN	O
,	,	O
the	DT	O
manifestations	NNS	O
and	CC	O
natural	JJ	O
history	NN	O
of	IN	O
this	DT	O
illness	NN	PH
are	VBP	O
unaffected	VBN	O
by	IN	O
indomethacin	NN	O
.	.	O

Can	MD	O
HMG	NNP	O
Co-A	NNP	O
reductase	NN	O
inhibitors	NNS	O
(	(	O
statins	NNS	O
)	)	O
slow	VBP	O
the	DT	O
progression	NN	O
of	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
?	.	O
The	DT	O
age-related	JJ	O
maculopathy	NN	O
statin	NN	O
study	NN	O
(	(	O
ARMSS	NNP	O
)	)	O
.	.	O

Age-related	JJ	O
macular	JJ	O
degeneration	NN	O
(	(	O
AMD	NNP	O
)	)	O
is	VBZ	O
responsible	JJ	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
visual	JJ	O
impairment	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
cholesterol-lowering	JJ	O
medications	NNS	O
,	,	O
HMG	NNP	O
Co-A	NNP	O
reductase	NN	O
inhibitors	NNS	O
or	CC	O
statins	NNS	O
,	,	O
in	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
AMD	NNP	O
or	CC	O
of	IN	O
delaying	VBG	O
its	PRP$	O
progression	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
fully	RB	O
investigated	VBN	O
.	.	O

A	DT	O
3-year	JJ	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
40	CD	O
mg	NN	O
simvastatin	NN	O
per	IN	O
day	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
subjects	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
of	IN	O
AMD	NNP	O
progression	NN	O
is	VBZ	O
described	VBN	O
.	.	O

This	DT	O
paper	NN	O
outlines	VBZ	O
the	DT	O
primary	JJ	O
aims	NNS	O
of	IN	O
the	DT	O
Age-Related	NNP	O
Maculopathy	NNP	O
Statin	NNP	O
Study	NNP	O
(	(	O
ARMSS	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
methodology	NN	O
involved	VBN	O
.	.	O

Standardized	NNP	O
clinical	JJ	O
grading	NN	O
of	IN	O
macular	JJ	O
photographs	NN	O
and	CC	O
comparison	NN	O
of	IN	O
serial	JJ	O
macular	JJ	O
digital	NN	O
photographs	NN	O
,	,	O
using	VBG	O
the	DT	O
International	NNP	O
grading	NN	O
scheme	NN	O
,	,	O
form	VB	O
the	DT	O
basis	NN	O
for	IN	O
assessment	NN	O
of	IN	O
primary	JJ	O
study	NN	O
outcomes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
macular	JJ	O
function	NN	O
is	VBZ	O
assessed	VBN	O
at	IN	O
each	DT	O
visit	NN	O
with	IN	O
detailed	JJ	O
psychophysical	JJ	O
measurements	NNS	O
of	IN	O
rod	NN	O
and	CC	O
cone	NN	O
function	NN	O
.	.	O

Information	NN	O
collected	VBN	O
in	IN	O
this	DT	O
study	NN	O
will	MD	O
assist	VB	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
the	DT	O
potential	JJ	O
value	NN	O
of	IN	O
HMG	NNP	O
Co-A	NNP	O
reductase	NN	O
inhibitors	NNS	O
(	(	O
statins	NNS	O
)	)	O
in	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
AMD	NNP	O
progression	NN	O
.	.	O

Modest	JJS	O
visceral	JJ	O
fat	NN	O
gain	NN	O
causes	VBZ	O
endothelial	JJ	O
dysfunction	NN	O
in	IN	O
healthy	JJ	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
fat	JJ	O
gain	NN	O
and	CC	O
its	PRP$	O
distribution	NN	O
on	IN	O
endothelial	JJ	PH
function	NN	PH
in	IN	O
lean	JJ	O
healthy	JJ	O
humans	NNS	O
.	.	O

BACKGROUND	NNP	O
Endothelial	NNP	PH
dysfunction	NN	PH
has	VBZ	O
been	VBN	O
identified	VBN	O
as	IN	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Whether	NNP	O
fat	JJ	O
gain	NN	O
impairs	NNS	O
endothelial	JJ	PH
function	NN	PH
is	VBZ	O
unknown	JJ	O
.	.	O

METHODS	VB	O
A	DT	O
randomized	NN	O
controlled	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fat	JJ	O
gain	NN	O
on	IN	O
endothelial	JJ	O
function	NN	O
.	.	O

Forty-three	JJ	O
normal-weight	JJ	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
recruited	VBN	O
(	(	O
mean	JJ	O
age	NN	O
29	CD	O
years	NNS	O
;	:	O
18	CD	O
women	NNS	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
gain	VB	O
weight	NN	O
(	(	O
approximately	RB	O
4	CD	O
kg	NNS	O
)	)	O
(	(	O
n=35	JJ	O
)	)	O
or	CC	O
to	TO	O
maintain	VB	O
weight	NN	O
(	(	O
n=8	JJ	O
)	)	O
.	.	O

Endothelial	JJ	PH
function	NN	PH
(	(	PH
brachial	JJ	PH
artery	NN	PH
flow-mediated	JJ	PH
dilation	NN	PH
[	NNP	PH
FMD	NNP	PH
]	NNP	PH
)	)	PH
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
fat	JJ	O
gain	NN	O
(	(	O
8	CD	O
weeks	NNS	O
)	)	O
,	,	O
and	CC	O
after	IN	O
weight	JJ	O
loss	NN	O
(	(	O
16	CD	O
weeks	NNS	O
)	)	O
for	IN	O
fat	JJ	O
gainers	NNS	O
and	CC	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	NN	O
(	(	O
8	CD	O
weeks	NNS	O
)	)	O
for	IN	O
weight	NN	O
maintainers	NNS	O
.	.	O

Body	NNP	O
composition	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
dual-energy	JJ	O
X-ray	JJ	O
absorptiometry	NN	O
and	CC	O
abdominal	JJ	O
computed	JJ	O
tomographic	JJ	O
scans	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
an	DT	O
average	JJ	O
weight	JJ	O
gain	NN	O
of	IN	O
4.1	CD	O
kg	NN	O
,	,	O
fat	JJ	O
gainers	NNS	O
significantly	RB	O
increased	VBD	O
their	PRP$	O
total	JJ	PH
,	,	PH
visceral	JJ	PH
,	,	PH
and	CC	PH
subcutaneous	JJ	PH
fat	NN	PH
.	.	PH

Blood	NNP	PH
pressure	NN	PH
and	CC	PH
overnight	JJ	PH
polysomnography	NN	PH
did	VBD	O
not	RB	O
change	NN	O
after	IN	O
fat	JJ	O
gain	NN	O
or	CC	O
loss	NN	O
.	.	O

FMD	NNP	PH
remained	VBD	O
unchanged	JJ	O
in	IN	O
weight	JJ	O
maintainers	NNS	O
.	.	O

FMD	NNP	PH
decreased	VBD	O
in	IN	O
fat	JJ	O
gainers	NNS	O
(	(	O
9.1+/-3	CD	O
%	NN	O
vs.	FW	O
7.8+/-3.2	CD	O
%	NN	O
,	,	O
p=0.003	NN	O
)	)	O
but	CC	O
recovered	VBD	O
to	TO	O
baseline	VB	O
when	WRB	O
subjects	NNS	O
shed	VBD	O
the	DT	O
gained	JJ	O
weight	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
decrease	NN	O
in	IN	O
FMD	NNP	PH
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
visceral	JJ	PH
fat	JJ	PH
gain	NN	PH
(	(	O
rho=-0.42	JJ	O
,	,	O
p=0.004	NN	O
)	)	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
subcutaneous	JJ	PH
fat	JJ	PH
gain	NN	PH
(	(	O
rho=-0.22	JJ	O
,	,	O
p=0.15	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
normal-weight	JJ	O
healthy	JJ	O
young	JJ	O
subjects	NNS	O
,	,	O
modest	JJ	O
fat	JJ	O
gain	NN	O
results	NNS	O
in	IN	O
impaired	JJ	O
endothelial	JJ	PH
function	NN	PH
,	,	O
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
changes	NNS	O
in	IN	O
blood	NN	PH
pressure	NN	PH
.	.	O

Endothelial	JJ	PH
function	NN	PH
recovers	NNS	O
after	IN	O
weight	JJ	O
loss	NN	O
.	.	O

Increased	VBN	O
visceral	JJ	O
rather	RB	O
than	IN	O
subcutaneous	JJ	O
fat	JJ	PH
predicts	NNS	O
endothelial	JJ	PH
dysfunction	NN	PH
.	.	O

(	(	O
Fat	JJ	O
Gain	NNP	O
and	CC	O
Cardiovascular	NNP	O
Disease	NNP	O
Mechanisms	NNP	O
;	:	O
NCT00589498	NNP	O
)	)	O
.	.	O

Levosulpiride	NNP	O
in	IN	O
functional	JJ	O
dyspepsia	NN	O
:	:	O
a	DT	O
multicentric	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

Abnormalities	NNS	O
in	IN	O
gastrointestinal	JJ	O
motility	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
a	DT	O
substantial	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
functional	JJ	O
dyspepsia	NN	O
,	,	O
supporting	VBG	O
the	DT	O
use	NN	O
of	IN	O
prokinetic	JJ	O
drugs	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
dyspeptic	JJ	O
symptoms	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
levosulpiride	NN	O
in	IN	O
short-term	JJ	O
treatment	NN	O
,	,	O
1298	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
multicentric	NN	O
study	NN	O
carried	VBD	O
out	IN	O
in	IN	O
45	CD	O
Italian	JJ	O
Gastroenterology	NNP	O
Departments	NNP	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
levosulpiride	NN	O
(	(	O
25	CD	O
mg	RB	O
tid	NN	O
)	)	O
,	,	O
domperidone	NN	O
(	(	O
10	CD	O
mg	RB	O
tid	NN	O
)	)	O
,	,	O
metoclopramide	RB	O
(	(	O
10	CD	O
mg	RB	O
tid	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
1	CD	O
tablet	NN	O
tid	NN	O
)	)	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
selected	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
:	:	O
a	DT	O
)	)	O
occurrence	NN	O
in	IN	O
the	DT	O
last	JJ	O
4	CD	O
weeks	NNS	O
of	IN	O
at	IN	O
least	JJS	O
5/10	CD	O
selected	VBN	O
symptoms	NNS	O
(	(	O
anorexia	NN	PH
,	,	PH
nausea	NN	PH
,	,	PH
vomiting	VBG	PH
,	,	PH
upper	JJ	PH
abdominal	JJ	PH
pain	NN	PH
,	,	PH
postprandial	JJ	PH
bloating	NN	PH
,	,	PH
abdominal	JJ	PH
fullness	NN	PH
,	,	PH
early	JJ	PH
satiety	NN	PH
,	,	PH
belching	NN	PH
,	,	PH
heartburn	NN	PH
,	,	PH
regurgitation	NN	PH
)	)	O
,	,	O
severity	NN	O
of	IN	O
which	WDT	O
should	MD	O
reach/exceed	VB	O
a	DT	O
total	JJ	O
score	NN	O
of	IN	O
8	CD	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
a	DT	O
specific	JJ	O
scale	NN	O
ranging	VBG	O
from	IN	O
0	CD	O
(	(	O
absent	NN	O
)	)	O
to	TO	O
3	CD	O
(	(	O
severe	JJ	O
)	)	O
;	:	O
b	VBN	O
)	)	O
normal	JJ	O
results	NNS	O
of	IN	O
routine	JJ	O
biochemical	NN	O
,	,	O
ultrasound	NN	O
and	CC	O
endoscopic	JJ	O
examinations	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
each	DT	O
patient	NN	O
subjectively	RB	O
evaluated	VBD	O
efficacy	NN	Ot
of	IN	O
treatment	NN	O
by	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
.	.	O

Significant	JJ	O
improvement	NN	O
was	VBD	O
recorded	VBN	O
for	IN	O
all	DT	O
symptoms	NNS	O
at	IN	O
days	NNS	O
10	CD	O
and	CC	O
28	CD	O
in	IN	O
all	DT	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
levosulpiride	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
superior	NN	O
to	TO	O
domperidone	VB	O
,	,	O
metoclopramide	NN	O
and	CC	O
placebo	VB	O
both	DT	O
in	IN	O
the	DT	O
overall	JJ	O
clinical	JJ	O
improvement	NN	O
scale	NN	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
symptoms	NNS	O
(	(	PA
postprandial	JJ	PH
bloating	NN	PH
,	,	O
epigastric	JJ	PA
pain	NN	PA
,	,	O
heartburn	NN	PH
)	)	O
.	.	O

Active	JJ	O
treatments	NNS	O
and	CC	O
placebo	NNS	O
were	VBD	O
comparable	JJ	O
as	RB	O
far	RB	O
as	IN	O
concerns	NNS	O
occurrence	IN	O
of	IN	O
side-effects	NNS	O
(	(	O
12-20	CD	O
%	NN	O
)	)	O
including	VBG	O
galactorrhoea	NN	PH
,	,	PH
breast	NN	PH
tenderness	NN	PH
and	CC	PH
menstrual	JJ	PH
changes	NNS	PH
.	.	O

Chemoradiation	NN	O
comparing	VBG	O
cisplatin	JJ	O
versus	NN	O
carboplatin	NN	O
in	IN	O
locally	RB	O
advanced	JJ	O
nasopharyngeal	JJ	O
cancer	NN	O
:	:	O
randomised	VBN	O
,	,	O
non-inferiority	NN	O
,	,	O
open	JJ	O
trial	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
single	JJ	O
centre	NN	O
,	,	O
open	JJ	O
labelled	VBD	O
,	,	O
randomised	VBD	O
non-inferiority	JJ	O
trial	NN	O
compared	VBN	O
concurrent	JJ	O
chemoradiotherapy	NN	O
with	IN	O
carboplatin	JJ	O
versus	JJ	O
standard	NN	O
concurrent	NN	O
chemoradiotherapy	NN	O
with	IN	O
cisplatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locoregionally	RB	O
advanced	JJ	O
nasopharyngeal	JJ	O
cancer	NN	O
(	(	O
NPC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
August	NNP	O
1999	CD	O
to	TO	O
December	NNP	O
2004	CD	O
,	,	O
206	CD	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
NPC	NNP	O
were	VBD	O
randomised	VBN	O
with	IN	O
101	CD	O
to	TO	O
cisplatin	VB	O
arm	NN	O
and	CC	O
105	CD	O
to	TO	O
carboplatin	VB	O
arm	NN	O
.	.	O

Planned	VBD	O
radiotherapy	NN	O
was	VBD	O
the	DT	O
same	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
toxicity	NN	PH
and	CC	O
survival	NN	MO
according	VBG	O
to	TO	O
the	DT	O
as-treated	JJ	O
principle	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
26.3	CD	O
months	NNS	O
(	(	O
range	VB	O
3-74.6	JJ	O
months	NNS	O
)	)	O
,	,	O
59	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
cisplatin	NN	O
arm	NN	O
completed	VBD	O
the	DT	O
planned	VBN	O
concurrent	NN	O
chemoradiation	NN	O
treatment	NN	O
,	,	O
compared	VBN	O
to	TO	O
73	CD	O
%	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
arm	NN	O
.	.	O

Forty-two	JJ	O
percent	NN	O
of	IN	O
cisplatin	NN	O
patients	NNS	O
completed	VBD	O
the	DT	O
3	CD	ME
cycles	NNS	ME
of	IN	ME
adjuvant	JJ	ME
therapy	NN	ME
compared	VBN	O
to	TO	O
70	CD	O
%	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
more	JJR	O
renal	JJ	PH
toxicity	NN	PH
,	,	O
leucopenia	NN	PH
,	,	O
and	CC	O
anaemia	NN	PH
in	IN	O
the	DT	O
cisplatin	NN	O
group	NN	O
,	,	O
and	CC	O
more	JJR	O
thrombocytopenia	NN	PH
in	IN	O
the	DT	O
carboplatin	NN	O
arm	NN	O
.	.	O

The	DT	O
3	CD	MO
year	NN	MO
disease	NN	MO
free	JJ	MO
survival	NN	MO
rates	NNS	MO
were	VBD	O
63.4	CD	O
%	NN	O
for	IN	O
the	DT	O
cisplatin	NN	O
group	NN	O
and	CC	O
60.9	CD	O
%	NN	O
for	IN	O
the	DT	O
carboplatin	NN	O
group	NN	O
(	(	O
p=0.9613	NN	O
)	)	O
(	(	O
HR	$	O
0.70	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
:	:	O
0.50-0.98	JJ	O
)	)	O
.	.	O

The	DT	O
3	CD	MO
year	NN	MO
overall	JJ	MO
survival	NN	MO
rates	NNS	MO
were	VBD	O
77.7	CD	O
%	NN	O
and	CC	O
79.2	CD	O
%	NN	O
for	IN	O
cisplatin	NN	O
and	CC	O
carboplatin	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
p=0.9884	NN	O
)	)	O
(	(	O
HR	$	O
0.83	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.63-1.010	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
concluded	VBD	O
that	IN	O
the	DT	O
tolerability	NN	Ot
of	IN	Ot
carboplatin	NN	Ot
based	VBN	Ot
regimen	NNS	Ot
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
cisplatin	NN	O
regimen	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
treatment	NN	O
efficacy	NN	O
of	IN	O
carboplatin	NN	O
arm	NN	O
is	VBZ	O
not	RB	O
different	JJ	O
from	IN	O
the	DT	O
standard	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
locoregional	JJ	O
advanced	JJ	O
stage	NN	O
NPC	NNP	O
.	.	O

Injection	NNP	O
sclerotherapy	NN	O
versus	NN	O
electrocoagulation	NN	O
in	IN	O
the	DT	O
management	NN	O
outcome	NN	O
of	IN	O
early	JJ	O
haemorrhoids	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
symptomatology	NN	O
of	IN	O
early	JJ	O
hemorrhoids	NNS	O
and	CC	O
to	TO	O
compare	VB	O
injection	NN	O
sclerotherapy	NN	O
(	(	O
IS	NNP	O
)	)	O
with	IN	O
electrocoagulation	NN	O
(	(	O
EC	NNP	O
)	)	O
in	IN	O
the	DT	O
management	NN	O
outcome	NN	O
of	IN	O
early	JJ	O
haemorrhoids	NNS	O
with	IN	O
respect	NN	O
to	TO	O
pain	VB	PA
during	IN	PA
the	DT	PA
procedure	NN	PA
,	,	O
reduction	NN	PH
in	IN	PH
bleeding	VBG	PH
per	IN	PH
rectum	NN	PH
,	,	O
and	CC	O
overall	JJ	Ot
patient	NN	Ot
satisfaction	NN	Ot
score	NN	Ot
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
102	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
experimental	JJ	O
study	NN	O
at	IN	O
the	DT	O
POF	NNP	O
Hospital	NNP	O
,	,	O
Wah	NNP	O
Cantt	NNP	O
from	IN	O
October	NNP	O
2004	CD	O
to	TO	O
June	NNP	O
2005	CD	O
.	.	O

A	DT	O
detailed	JJ	O
history	NN	O
was	VBD	O
taken	VBN	O
and	CC	O
proctoscopic	JJ	O
examination	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
Lottery	NNP	O
method	NN	O
)	)	O
.	.	O

One	CD	O
group	NN	O
was	VBD	O
subjected	VBN	O
to	TO	O
EC	NNP	O
and	CC	O
the	DT	O
other	JJ	O
to	TO	O
IS	NNP	O
.	.	O

In	IN	O
the	DT	O
EC	NNP	O
,	,	O
using	VBG	O
the	DT	O
EC	NNP	O
machine	NN	O
(	(	O
Wieda	NNP	O
,	,	O
China	NNP	O
)	)	O
,	,	O
direct	JJ	O
current	JJ	O
of	IN	O
10-20	JJ	O
mA	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
the	DT	O
submucosal	JJ	O
plane	NN	O
of	IN	O
each	DT	O
pile	NN	O
core	NN	O
for	IN	O
5-7	JJ	O
minutes	NNS	O
.	.	O

In	IN	O
the	DT	O
IS	NNP	O
1-2	JJ	O
ml	NN	O
of	IN	O
5	CD	O
%	NN	O
phenol	NN	O
in	IN	O
almond	NN	O
oil	NN	O
was	VBD	O
injected	VBN	O
in	IN	O
the	DT	O
same	JJ	O
plane	NN	O
in	IN	O
each	DT	O
pile	NN	O
core	NN	O
.	.	O

Pain	NN	PA
during	IN	PA
the	DT	PA
procedure	NN	PA
,	,	O
reduction	NN	PH
in	IN	PH
bleeding	VBG	PH
per	IN	PH
rectum	NN	PH
and	CC	O
overall	JJ	Ot
patient	NN	Ot
satisfaction	NN	Ot
,	,	O
were	VBD	O
studied	VBN	O
as	IN	O
outcome	JJ	O
measures	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
was	VBD	O
44	CD	O
years	NNS	O
,	,	O
86	CD	O
were	VBD	O
males	NNS	O
and	CC	O
16	CD	O
were	VBD	O
females	NNS	O
.	.	O

Two	CD	O
thirds	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
having	VBG	O
symptoms	NNS	O
for	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
.	.	O

A	DT	O
third	JJ	O
of	IN	O
patients	NNS	O
had	VBD	O
associated	VBN	O
local	JJ	PA
pain	NN	PA
while	IN	O
another	DT	O
third	JJ	O
had	VBD	O
associated	VBN	O
mucous	JJ	PH
discharge	NN	PH
.	.	O

Chronic	JJ	A
constipation	NN	A
was	VBD	O
present	JJ	O
in	IN	O
81	CD	O
%	NN	O
patients	NNS	O
.	.	O

Only	RB	O
24.5	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
positive	JJ	O
family	NN	O
history	NN	O
of	IN	O
haemorrhoids	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
electrocoagulation	NN	O
(	(	O
EC	NNP	O
)	)	O
group	NN	O
experienced	VBD	O
more	JJR	O
pain	NN	PA
during	IN	PA
the	DT	PA
procedure	NN	PA
than	IN	O
the	DT	O
injection	NN	O
sclerotherapy	NN	O
(	(	O
IS	NNP	O
)	)	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.000	CD	O
)	)	O
,	,	O
but	CC	O
EC	NNP	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
IS	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
reducing	VBG	O
the	DT	O
bleeding	NN	PH
per	IN	PH
rectum	NN	PH
(	(	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
,	,	O
and	CC	O
also	RB	O
significantly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
were	VBD	O
fully	RB	Ot
satisfied	VBN	Ot
with	IN	O
EC	NNP	O
than	IN	O
with	IN	O
IS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.04	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
EC	NNP	O
,	,	O
although	IN	O
more	RBR	O
painful	JJ	PA
,	,	O
is	VBZ	O
a	DT	O
safe	JJ	Ot
,	,	O
more	RBR	O
effective	JJ	Ot
and	CC	O
a	DT	O
highly	RB	Ot
satisfying	JJ	Ot
procedure	NN	O
for	IN	O
treating	VBG	O
early	JJ	O
hemorrhoids	NNS	O
.	.	O

Central	JJ	O
5-HT4	JJ	O
receptor	NN	O
binding	NN	O
as	IN	O
biomarker	NN	O
of	IN	O
serotonergic	JJ	O
tonus	NN	O
in	IN	O
humans	NNS	O
:	:	O
a	DT	O
[	$	O
11C	CD	O
]	NNP	O
SB207145	NNP	O
PET	NNP	O
study	NN	O
.	.	O

Identification	NNP	O
of	IN	O
a	DT	O
biomarker	NN	O
that	WDT	O
can	MD	O
inform	VB	O
on	IN	O
extracellular	JJ	O
serotonin	NN	O
(	(	O
5-HT	JJ	O
)	)	O
levels	NNS	O
in	IN	O
the	DT	O
brains	NNS	O
of	IN	O
living	NN	O
humans	NNS	O
would	MD	O
enable	VB	O
greater	JJR	O
understanding	NN	O
of	IN	O
the	DT	O
way	NN	O
brain	NN	O
circuits	NNS	O
are	VBP	O
modulated	VBN	O
by	IN	O
serotonergic	JJ	O
neurotransmission	NN	O
.	.	O

Substantial	JJ	O
evidence	NN	O
from	IN	O
studies	NNS	O
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
indicates	VBZ	O
an	DT	O
inverse	NN	O
relationship	NN	O
between	IN	O
central	JJ	O
5-HT	JJ	O
tonus	NN	O
and	CC	O
5-HT	JJ	O
type	NN	O
4	CD	O
receptor	NN	O
(	(	O
5-HT4R	JJ	O
)	)	O
density	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
5-HT4R	JJ	O
receptor	NN	O
density	NN	O
may	MD	O
be	VB	O
a	DT	O
biomarker	NN	O
marker	NN	O
for	IN	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
a	DT	O
3-week	JJ	O
administration	NN	O
of	IN	O
a	DT	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitor	NN	O
,	,	O
expected	VBN	O
to	TO	O
increase	VB	O
brain	NN	O
5-HT	JJ	O
levels	NNS	O
,	,	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decline	NN	O
in	IN	O
brain	NN	O
5-HT4R	JJ	O
binding	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
35	CD	O
healthy	JJ	O
men	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
3	CD	O
weeks	NNS	O
of	IN	O
oral	JJ	O
dosing	VBG	O
with	IN	O
placebo	NN	O
or	CC	O
fluoxetine	NN	O
,	,	O
40	CD	O
mg	NNS	O
per	IN	O
day	NN	O
.	.	O

Brain	VB	PH
5-HT4R	JJ	PH
binding	NN	PH
was	VBD	O
quantified	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
follow-up	JJ	O
with	IN	O
[	NNP	O
(	(	O
11	CD	O
)	)	O
C	NNP	O
]	NNP	O
SB207145	NNP	O
positron	NN	Ot
emission	NN	Ot
tomography	NN	Ot
(	(	O
PET	NNP	O
)	)	O
.	.	O

Three	CD	O
weeks	NNS	O
of	IN	O
intervention	NN	O
with	IN	O
fluoxetine	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
5.2	CD	O
%	NN	O
reduction	NN	O
in	IN	O
brain	NN	PH
5-HT4R	JJ	PH
binding	NN	PH
(	(	O
P=0.017	NNP	O
)	)	O
,	,	O
whereas	JJ	O
placebo	NN	O
intervention	NN	O
did	VBD	O
not	RB	O
change	VB	O
5-HT4R	JJ	O
binding	NN	O
(	(	O
P=0.52	NNP	O
)	)	O
.	.	O

Our	PRP$	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
model	NN	O
,	,	O
wherein	VBP	O
the	DT	O
5-HT4R	JJ	PH
density	NN	PH
adjusts	VBZ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
extracellular	JJ	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
demonstrate	NN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
in	IN	O
humans	NNS	O
that	IN	O
the	DT	O
imaging	NN	O
of	IN	O
central	JJ	O
5-HT4R	JJ	O
binding	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
in	IN	O
vivo	NN	O
biomarker	NN	O
of	IN	O
the	DT	O
central	JJ	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Metformin	NNP	O
does	VBZ	O
not	RB	O
enhance	VB	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
metformin	NN	O
pretreatment	NN	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
infertile	JJ	O
women	NNS	O
with	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
in	IN	O
an	DT	O
infertility	NN	O
clinic	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
placebo	NN	O
controlled	VBD	O
double-blind	NN	O
crossover	NN	O
study	NN	O
of	IN	O
3	CD	O
months	NNS	O
metformin	RB	O
(	(	O
1500	CD	O
mg	IN	O
day-1	NN	O
)	)	O
/placebo	NN	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	O
months	NNS	O
metformin/placebo	VBN	O
together	RB	O
with	IN	O
clomiphene	NN	O
(	(	O
50-100	JJ	O
mg	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
for	IN	O
three	CD	O
cycles	NNS	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
women	NNS	O
with	IN	O
PCOS	NNP	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
were	VBD	O
restoration	NN	PH
of	IN	PH
spontaneous	JJ	PH
menses	NNS	PH
,	,	PH
ovulation	NN	PH
induction	NN	PH
(	(	PH
spontaneous	JJ	PH
or	CC	PH
clomiphene	NN	PH
induced	VBN	PH
)	)	PH
and	CC	PH
pregnancy	NN	PH
.	.	PH

Secondary	JJ	PH
endpoints	NNS	PH
were	VBD	O
changes	NNS	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
related	VBN	O
to	TO	O
androgens	NNS	O
and	CC	O
insulin	NN	O
.	.	O

RESULTS	NNP	O
Twelve	NNP	O
women	NNS	O
completed	VBD	O
the	DT	O
metformin	NN	O
arm	NN	O
and	CC	O
14	CD	O
the	DT	O
placebo	NN	O
arm	NN	O
.	.	O

Spontaneous	JJ	PH
menstruation	NN	PH
resumed	VBD	O
in	IN	O
five	CD	O
metformin	NNS	O
treated	VBD	O
patients	NNS	O
and	CC	O
in	IN	O
six	CD	O
placebo	NN	O
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

No	NNP	O
women	NNS	O
given	VBN	O
metformin	NNS	O
spontaneously	RB	PH
ovulated	VBD	PH
,	,	O
although	IN	O
one	CD	O
patient	NN	O
given	VBN	O
placebo	NN	O
did	VBD	O
,	,	O
P=0.30	NNP	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
efficacy	NN	PH
of	IN	PH
clomiphene	NN	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
ovulation	NN	PH
being	VBG	PH
induced	VBN	PH
in	IN	O
five	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
metformin	NN	O
treated	VBN	O
women	NNS	O
and	CC	O
four	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
placebo	NN	O
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

Pregnancy	NN	PH
occurred	VBD	O
in	IN	O
three	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
women	NNS	O
given	VBN	O
metformin	NNS	O
and	CC	O
two	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
women	NNS	O
given	VBN	O
placebo	NNS	O
,	,	O
P=0.59	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Metformin	NNP	O
is	VBZ	O
not	RB	O
always	RB	O
beneficial	JJ	O
when	WRB	O
given	VBN	O
to	TO	O
clomiphene	VB	O
resistant	JJ	O
infertile	JJ	O
women	NNS	O
with	IN	O
PCOS	NNP	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Allopurinol	NNP	O
use	NN	O
yields	NNS	O
potentially	RB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
inflammatory	JJ	O
indices	NNS	O
in	IN	O
those	DT	O
with	IN	O
recent	JJ	O
ischemic	JJ	O
stroke	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Elevated	NNP	O
serum	NN	O
uric	JJ	O
acid	NN	O
level	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
poor	JJ	O
outcome	NN	O
and	CC	O
increased	VBD	O
risk	NN	O
of	IN	O
recurrent	NN	O
events	NNS	O
after	IN	O
stroke	NN	O
.	.	O

The	DT	O
xanthine	JJ	O
oxidase	NN	O
inhibitor	NN	O
allopurinol	NN	O
lowers	NNS	O
uric	JJ	O
acid	NN	O
but	CC	O
also	RB	O
attenuates	VBZ	O
expression	NN	O
of	IN	O
inflammatory	JJ	O
adhesion	NN	O
molecules	NNS	O
in	IN	O
murine	NN	O
models	NNS	O
,	,	O
reduces	NNS	O
oxidative	VBP	O
stress	NN	O
in	IN	O
the	DT	O
vasculature	NN	O
,	,	O
and	CC	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
allopurinol	JJ	O
alters	NNS	O
expression	NN	O
of	IN	O
inflammatory	NN	O
markers	NNS	O
after	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
effect	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
high-	NN	O
(	(	O
300	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
or	CC	O
low-	JJ	O
(	(	O
100	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
dose	NN	O
allopurinol	NN	O
on	IN	O
levels	NNS	O
of	IN	O
uric	JJ	O
acid	NN	O
and	CC	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
after	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
enrolled	VBD	O
50	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
(	(	O
17	CD	O
,	,	O
17	CD	O
,	,	O
and	CC	O
16	CD	O
in	IN	O
the	DT	O
high	JJ	O
,	,	O
low	JJ	O
,	,	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Mean	NNP	O
(	(	O
+/-SD	NNP	O
)	)	O
age	NN	O
was	VBD	O
70	CD	O
(	(	O
+/-13	JJ	O
)	)	O
years	NNS	O
.	.	O

Groups	NNP	O
had	VBD	O
similar	JJ	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Uric	NNP	PH
acid	NN	PH
levels	NNS	PH
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
both	DT	O
7	CD	O
days	NNS	O
and	CC	O
6	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
0.14	CD	O
mmol/L	NNS	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
P=0.002	NNP	O
)	)	O
.	.	O

Intercellular	JJ	PH
adhesion	NN	PH
molecule-1	JJ	PH
concentration	NN	PH
(	(	O
ng/mL	JJ	O
)	)	O
rose	VBD	O
by	IN	O
51.2	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
rose	VBD	O
slightly	RB	O
(	(	O
by	IN	O
10.6	CD	O
)	)	O
in	IN	O
the	DT	O
low-dose	JJ	O
allopurinol	NN	O
group	NN	O
,	,	O
but	CC	O
fell	VBD	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
2.6	CD	O
;	:	O
difference	NN	O
between	IN	O
groups	NNS	O
P=0.012	NNP	O
,	,	O
Kruskal-Wallis	NNP	O
test	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Allopurinol	NNP	O
treatment	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
attenuates	VBZ	O
the	DT	O
rise	NN	O
in	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
levels	NNS	O
seen	VBN	O
after	IN	O
stroke	NN	O
.	.	O

Uric	JJ	O
acid	NN	O
levels	NNS	O
were	VBD	O
lowered	VBN	O
with	IN	O
high	JJ	O
doses	NNS	O
.	.	O

These	DT	O
findings	NNS	O
support	NN	O
further	JJ	O
evaluation	NN	O
of	IN	O
allopurinol	NN	O
as	IN	O
a	DT	O
preventive	JJ	O
measure	NN	O
after	IN	O
stroke	NN	O
.	.	O

Screening	VBG	O
,	,	O
brief	JJ	O
intervention	NN	O
,	,	O
and	CC	O
referral	JJ	O
to	TO	O
treatment	NN	O
(	(	O
SBIRT	NNP	O
)	)	O
in	IN	O
a	DT	O
Polish	JJ	O
emergency	NN	O
department	NN	O
:	:	O
three-month	JJ	O
outcomes	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
A	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
screening	NN	O
,	,	O
brief	JJ	O
intervention	NN	O
,	,	O
and	CC	O
referral	JJ	O
to	TO	O
treatment	NN	O
(	(	O
SBIRT	NNP	O
)	)	O
for	IN	O
drinking	NN	O
and	CC	O
related	JJ	O
problems	NNS	O
among	IN	O
at-risk	JJ	O
and	CC	O
dependent	JJ	O
drinkers	NNS	O
was	VBD	O
conducted	VBN	O
in	IN	O
an	DT	O
emergency	NN	O
department	NN	O
(	(	O
ED	NNP	O
)	)	O
in	IN	O
Sosnowiec	NNP	O
,	,	O
Poland	NNP	O
,	,	O
among	IN	O
patients	NNS	O
ages	VBZ	O
18	CD	O
years	NNS	O
and	CC	O
older	JJR	O
.	.	O

METHOD	NNP	O
Data	NNP	O
were	VBD	O
collected	VBN	O
over	IN	O
a	DT	O
23-week	JJ	O
period	NN	O
,	,	O
from	IN	O
4:00	CD	O
PM	NNP	O
to	TO	O
midnight	VB	O
,	,	O
and	CC	O
resulted	VBD	O
in	IN	O
446	CD	O
patients	NNS	O
being	VBG	O
recruited	VBN	O
into	IN	O
the	DT	O
study	NN	O
(	(	O
90	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
screened	VBD	O
positive	JJ	O
)	)	O
and	CC	O
randomized	VBN	O
to	TO	O
three	CD	O
conditions	NNS	O
following	VBG	O
a	DT	O
two-stage	JJ	O
process	NN	O
:	:	O
screened	VBN	O
only	RB	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
,	,	O
assessed	VBN	O
(	(	O
n	JJ	O
=	NNP	O
152	CD	O
)	)	O
,	,	O
and	CC	O
received	VBN	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
assessment	NN	O
(	(	O
85	CD	O
%	NN	O
)	)	O
and	CC	O
intervention	NN	O
(	(	O
83	CD	O
%	NN	O
)	)	O
conditions	NNS	O
were	VBD	O
blindly	RB	O
reassessed	VBN	O
at	IN	O
3	CD	O
months	NNS	O
via	IN	O
a	DT	O
telephone	NN	O
interview	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
3-month	JJ	O
follow-up	NN	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
the	DT	O
proportion	NN	O
who	WP	O
were	VBD	O
positive	JJ	O
for	IN	O
at-risk	JJ	O
drinking	NN	O
,	,	O
the	DT	O
primary	JJ	O
outcome	NN	O
variable	NN	O
.	.	O

Both	DT	O
groups	NNS	O
also	RB	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
drinking	NN	ME
days	NNS	ME
per	IN	ME
week	NN	ME
,	,	O
drinks	NNS	ME
per	IN	ME
drinking	NN	ME
day	NN	ME
,	,	O
maximum	JJ	ME
drinks	NNS	ME
per	IN	ME
occasion	NN	ME
,	,	O
and	CC	O
negative	JJ	ME
consequences	NNS	ME
of	IN	ME
drinking	NN	ME
.	.	O

Using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
to	TO	O
control	VB	O
for	IN	O
baseline	NN	O
measures	NNS	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
no	DT	O
difference	NN	O
in	IN	O
outcome	JJ	O
measures	NNS	O
was	VBD	O
found	VBN	O
between	IN	O
intervention	NN	O
and	CC	O
assessment	JJ	O
conditions	NNS	O
.	.	O

Subgroup	NNP	O
analysis	NN	O
found	VBD	O
some	DT	O
significant	JJ	O
interactions	NNS	O
between	IN	O
intervention	NN	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
main	JJ	O
findings	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
from	IN	O
other	JJ	O
brief-intervention	NN	O
studies	NNS	O
in	IN	O
Western	JJ	O
cultures	NNS	O
,	,	O
findings	NNS	O
here	RB	O
also	RB	O
suggest	VBP	O
that	IN	O
intervention	NN	O
may	MD	O
have	VB	O
differential	JJ	O
benefits	NNS	O
for	IN	O
specific	JJ	O
subgroups	NNS	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
ED	NNP	O
,	,	O
an	DT	O
area	NN	O
of	IN	O
research	NN	O
that	WDT	O
may	MD	O
warrant	VB	O
additional	JJ	O
study	NN	O
of	IN	O
brief	JJ	O
intervention	NN	O
in	IN	O
the	DT	O
ED	NNP	O
setting	NN	O
.	.	O

Combined	VBN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
mediastinal	JJ	O
B-cell	NNP	O
lymphoma	NN	O
:	:	O
conventional	JJ	O
versus	NN	O
escalated	VBD	O
chemotherapy	NN	O
.	.	O

Treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
mediastinal	JJ	O
B-cell	NNP	O
lymphoma	NN	O
(	(	O
PMBCL	NNP	O
)	)	O
remains	VBZ	O
controversial	JJ	O
.	.	O

We	PRP	O
started	VBD	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	Ot
toxicity	NN	Ot
of	IN	O
a	DT	O
conventional	JJ	O
versus	NN	O
more	RBR	O
intensive	JJ	O
regimen	NNS	O
of	IN	O
combined	JJ	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiotherapy	NN	O
to	TO	O
the	DT	O
mediastinum	NN	O
with	IN	O
the	DT	O
mantle	NN	O
technique	NN	O
.	.	O

From	IN	O
1989	CD	O
to	TO	O
1997	CD	O
,	,	O
68	CD	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
previously	RB	O
untreated	VBN	O
PMBCL	NNP	O
,	,	O
aged	VBD	O
18-65	CD	O
years	NNS	O
and	CC	O
negative	JJ	O
for	IN	O
immunodeficiency	NN	O
virus	NN	O
test	NN	O
,	,	O
were	VBD	O
considered	VBN	O
candidates	NNS	O
to	TO	O
receive	VB	O
either	DT	O
conventional	JJ	O
chemotherapy	NN	O
with	IN	O
CEOP-Bleo	NNP	O
(	(	O
cyclophosphamide	VB	O
750	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
vincristine	JJ	O
1.4	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
prednisone	RB	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
70	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
and	CC	O
bleomycin	$	O
10	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
mega	JJ	O
CEOP-Bleo	NNP	O
(	(	O
cyclophosphamide	JJ	O
1000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
120	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
bleomycin	NN	O
at	IN	O
the	DT	O
same	JJ	O
doses	NNS	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
for	IN	O
six	CD	O
cycles	NNS	O
,	,	O
followed	VBN	O
by	IN	O
radiotherapy	NN	O
to	TO	O
the	DT	O
mediastinum	NN	O
with	IN	O
the	DT	O
mantle	NN	O
technique	NN	O
(	(	O
35-45	JJ	O
Gy	NNP	O
,	,	O
mean	VBP	O
38	CD	O
Gy	NNP	O
)	)	O
.	.	O

Complete	JJ	Ot
response	NN	Ot
(	(	Ot
CR	NNP	Ot
)	)	Ot
rates	NNS	Ot
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
:	:	O
64	CD	O
%	NN	O
[	CC	O
95	CD	O
percent	NN	O
confidence	NN	Ot
interval	NN	Ot
(	(	Ot
CI	NNP	Ot
)	)	Ot
:	:	Ot
58	CD	O
percent	NN	O
to	TO	O
70	CD	O
percent	NN	O
]	NN	O
for	IN	O
conventional	JJ	O
arm	NN	O
vs	NN	O
81	CD	O
percent	NN	O
(	(	O
95	CD	O
CI	NN	O
:	:	O
77-86	JJ	O
percent	NN	O
)	)	O
in	IN	O
the	DT	O
intensive	JJ	O
group	NN	O
(	(	O
p=0.2	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
failure-free	JJ	MO
survival	NN	MO
(	(	MO
FFS	NNP	MO
)	)	MO
and	CC	MO
overall	JJ	MO
survival	NN	MO
(	(	MO
OS	NNP	MO
)	)	MO
had	VBD	MO
statistical	JJ	MO
differences	NNS	MO
.	.	MO

At	IN	O
5	CD	O
years	NNS	O
,	,	O
actuarial	JJ	MO
FFS	NNP	MO
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
conventional	JJ	O
chemotherapy	NN	O
was	VBD	O
51	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
44-59	JJ	O
percent	NN	O
)	)	O
compared	VBN	O
to	TO	O
70	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
65-76	JJ	O
percent	NN	O
)	)	O
in	IN	O
the	DT	O
intensive	JJ	O
arm	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

OS	CC	MO
rates	NNS	MO
were	VBD	O
also	RB	O
different	JJ	O
:	:	O
54	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
48-57	JJ	O
percent	NN	O
)	)	O
vs	VBZ	O
70	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
65-76	JJ	O
percent	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Toxicity	NN	A
was	VBD	O
mild	JJ	O
and	CC	O
no	DT	O
therapy-related	JJ	MO
deaths	NNS	MO
were	VBD	O
observed	VBN	O
.	.	O

At	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
7.3	CD	O
years	NNS	O
,	,	O
no	DT	O
second	JJ	O
neoplasia	NN	PH
or	CC	PH
acute	NN	PH
leukemia	NN	PH
has	VBZ	O
been	VBN	O
observed	VBN	O
.	.	O

The	DT	PH
international	JJ	PH
prognostic	JJ	PH
index	NN	PH
was	VBD	O
not	RB	O
useful	JJ	O
to	TO	O
define	VB	O
clinical	JJ	O
risk	NN	O
in	IN	O
this	DT	O
selected	VBN	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
identified	VBN	O
pleural	JJ	PH
and	CC	PH
pericardial	JJ	PH
effusion	NN	PH
and	CC	PH
chemotherapy	NN	PH
regimen	NNS	PH
as	IN	O
prognostic	JJ	O
factors	NNS	O
influencing	VBG	O
FFS	NNP	MO
and	CC	MO
OS	NNP	MO
.	.	MO

We	PRP	O
feel	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
PMBCL	NNP	O
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
more	RBR	O
intensive	JJ	O
,	,	O
but	CC	O
not	RB	O
myeloablative	JJ	O
chemotherapy	NN	O
,	,	O
followed	VBN	O
by	IN	O
adjuvant	JJ	O
radiotherapy	NN	O
to	TO	O
achieve	VB	O
an	DT	O
improvement	NN	O
in	IN	O
outcome	NN	O
in	IN	O
this	DT	O
setting	NN	O
of	IN	O
patients	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
pleural	JJ	O
or	CC	O
pericardial	JJ	O
effusion	NN	O
are	VBP	O
considered	VBN	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
failure	NN	O
with	IN	O
the	DT	O
actual	JJ	O
programs	NNS	O
of	IN	O
treatment	NN	O
and	CC	O
probably	RB	O
will	MD	O
be	VB	O
considered	VBN	O
for	IN	O
experimental	JJ	O
therapeutic	JJ	O
approaches	NNS	O
.	.	O

Effect	NN	O
of	IN	O
pravastatin	NN	O
on	IN	O
cardiovascular	JJ	PH
events	NNS	PH
in	IN	O
women	NNS	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
:	:	O
the	DT	O
cholesterol	NN	O
and	CC	O
recurrent	JJ	O
events	NNS	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
pravastatin	NN	O
on	IN	O
recurrent	NN	PH
cardiovascular	JJ	PH
events	NNS	PH
in	IN	O
women	NNS	O
with	IN	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Little	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
lipid	JJ	O
lowering	VBG	O
in	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
in	IN	O
women	NNS	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
those	DT	O
with	IN	O
CHD	NNP	O
and	CC	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
,	,	O
576	CD	O
postmenopausal	NN	O
women	NNS	O
,	,	O
between	IN	O
3	CD	O
and	CC	O
20	CD	O
months	NNS	O
after	IN	O
MI	NNP	O
,	,	O
with	IN	O
a	DT	O
total	JJ	O
cholesterol	NN	O
level	NN	O
<	VBD	O
240	CD	O
mg/dl	NN	O
and	CC	O
a	DT	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
level	NN	O
115	CD	O
to	TO	O
174	CD	O
mg/dl	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
pravastatin	NN	O
40	CD	O
mg/day	NN	O
or	CC	O
matching	VBG	O
placebo	NN	O
for	IN	O
a	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
of	IN	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
combined	VBN	PH
coronary	JJ	PH
events	NNS	PH
(	(	PH
coronary	JJ	PH
death	NN	PH
,	,	PH
nonfatal	JJ	PH
MI	NNP	PH
,	,	PH
percutaneous	JJ	PH
transluminal	JJ	PH
coronary	NN	PH
angioplasty	NN	PH
[	NNP	PH
PTCA	NNP	PH
]	NNP	PH
or	CC	PH
coronary	JJ	PH
artery	NN	PH
bypass	NN	PH
graft	NN	PH
surgery	NN	PH
[	NNP	PH
CABG	NNP	PH
]	NNP	PH
)	)	PH
,	,	PH
the	DT	PH
primary	JJ	PH
trial	NN	PH
end	NN	PH
point	NN	PH
(	(	PH
coronary	JJ	PH
death	NN	PH
or	CC	PH
nonfatal	JJ	PH
MI	NNP	PH
)	)	PH
and	CC	PH
stroke	NN	PH
.	.	Ot

RESULTS	NNP	O
Women	NNP	O
treated	VBD	O
with	IN	O
pravastatin	NN	O
had	VBD	O
a	DT	O
risk	NN	PH
reduction	NN	PH
of	IN	O
43	CD	O
%	NN	O
for	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.035	CD	O
)	)	O
,	,	O
46	CD	O
%	NN	O
for	IN	O
combined	JJ	O
coronary	JJ	O
events	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
48	CD	O
%	NN	O
for	IN	O
PTCA	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.025	CD	O
)	)	O
,	,	O
40	CD	O
%	NN	O
for	IN	O
CABG	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.14	CD	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
for	IN	O
stroke	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

The	DT	O
3,583	CD	O
men	NNS	O
in	IN	O
the	DT	O
CARE	NNP	O
trial	NN	O
also	RB	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
risk	NN	PH
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	JJR	O
.	.	O

Pravastatin	NNP	O
improved	VBD	O
plasma	JJ	PH
lipids	NNS	PH
similarly	RB	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
risk	NN	PH
of	IN	PH
coronary	JJ	PH
events	NNS	PH
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
between	IN	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

Minor	JJ	O
differences	NNS	O
between	IN	O
men	NNS	O
and	CC	O
women	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
and	CC	O
treatment	NN	O
for	IN	O
MI	NNP	O
,	,	O
in	IN	O
general	JJ	O
,	,	O
conferring	VBG	O
a	DT	O
higher	JJR	O
risk	NN	O
status	NN	O
and	CC	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
CABG	NNP	O
in	IN	O
the	DT	O
women	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Pravastatin	NNP	O
led	VBD	O
to	TO	O
significant	JJ	O
early	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
post-MI	JJ	O
women	NNS	O
with	IN	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
.	.	O

Penetration	NN	ME
and	CC	ME
accumulation	NN	ME
of	IN	O
moxifloxacin	NN	O
in	IN	O
uterine	JJ	O
tissue	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
moxifloxacin	NN	O
penetrates	VBZ	O
the	DT	O
uterine	JJ	O
tissue	NN	O
and	CC	O
accumulates	NNS	O
at	IN	O
levels	NNS	O
sufficient	JJ	O
to	TO	O
eradicate	VB	PH
the	DT	PH
major	JJ	PH
pathogens	NNS	PH
causing	VBG	O
pelvic	JJ	O
inflammatory	JJ	O
disease	NN	O
(	(	O
PID	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
multicenter	NN	O
,	,	O
open-label	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
we	PRP	O
determined	VBD	O
the	DT	O
concentration	NN	O
of	IN	O
moxifloxacin	NN	O
in	IN	O
plasma	NN	O
and	CC	O
uterine	JJ	O
tissue	NN	O
after	IN	O
a	DT	O
single	JJ	O
,	,	O
400-mg	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
moxifloxacin	NN	O
.	.	O

Study	NN	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
for	IN	O
time	NN	O
of	IN	O
tissue	NN	O
sampling	NN	O
,	,	O
which	WDT	O
was	VBD	O
performed	VBN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
7	CD	O
,	,	O
or	CC	O
24	CD	O
hours	NNS	O
following	VBG	O
the	DT	O
moxifloxacin	JJ	O
infusion	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
43	CD	O
participants	NNS	O
,	,	O
40	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
tissue	VB	O
sampling	VBG	O
.	.	O

Moxifloxacin	NNP	PH
accumulated	VBD	PH
in	IN	PH
uterine	JJ	PH
tissue	NN	PH
and	CC	PH
concentrations	NNS	PH
were	VBD	O
highest	JJS	O
1	CD	O
hour	NN	O
after	IN	O
infusion	NN	O
in	IN	O
both	DT	O
plasma	NN	O
and	CC	O
tissue	NN	O
.	.	O

Tissue	NN	PH
to	TO	PH
plasma	VB	PH
ratios	NNS	PH
remained	VBD	O
between	IN	O
1.7	CD	O
and	CC	O
2.1	CD	O
for	IN	O
24	CD	O
hours	NNS	O
.	.	O

Moxifloxacin	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	Ot
and	CC	Ot
well	RB	Ot
tolerated	VBN	Ot
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
known	VBN	O
minimum	JJ	O
inhibitory	JJ	O
concentration	NN	O
data	NNS	O
,	,	O
the	DT	O
uterine	JJ	PH
tissue	NN	PH
concentrations	NNS	PH
of	IN	O
moxifloxacin	NN	O
achieved	VBN	O
over	IN	O
24	CD	O
hours	NNS	O
would	MD	O
be	VB	O
sufficient	JJ	O
to	TO	O
eradicate	VB	O
the	DT	O
range	NN	O
of	IN	O
bacterial	JJ	O
pathogens	NNS	O
responsible	JJ	O
for	IN	O
PID	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
cardiorespiratory	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
ketamine	NN	O
and	CC	O
propofol	NN	O
,	,	O
propofol	VB	O
alone	RB	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
ketamine	NN	O
and	CC	O
diazepam	NN	O
before	IN	O
and	CC	O
after	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
dogs	NNS	O
sedated	VBN	O
with	IN	O
acepromazine	NN	O
and	CC	O
oxymorphone	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
cardiorespiratory	JJ	PH
effects	NNS	PH
of	IN	O
IV	NNP	O
administration	NN	O
of	IN	O
propofol	NN	O
(	(	O
4	CD	O
mg/kg	NN	O
)	)	O
,	,	O
ketamine	JJ	O
hydrochloride	NN	O
and	CC	O
propofol	NN	O
(	(	O
2	CD	O
mg/kg	RB	O
each	DT	O
;	:	O
K-P	NNP	O
)	)	O
,	,	O
or	CC	O
ketamine	VB	O
hydrochloride	NN	O
(	(	O
5	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
diazepam	NN	O
(	(	O
0.2	CD	O
mg/kg	NN	O
;	:	O
K-D	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
(	(	O
IoA	NNP	O
)	)	O
in	IN	O
dogs	NNS	O
sedated	VBN	O
with	IN	O
acepromazine	JJ	O
maleate	NN	O
and	CC	O
oxymorphone	NN	O
hydrochloride	NN	O
.	.	O

ANIMALS	$	O
10	CD	O
healthy	JJ	O
adult	NN	O
Beagles	NNP	O
.	.	O

PROCEDURES	NNP	O
Each	DT	O
dog	NN	O
was	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
2	CD	O
of	IN	O
3	CD	O
treatments	NNS	O
(	(	O
1-week	JJ	O
interval	NN	O
)	)	O
.	.	O

For	IN	O
instrumentation	NN	O
prior	RB	O
to	TO	O
each	DT	O
treatment	NN	O
,	,	O
each	DT	O
dog	NN	O
was	VBD	O
anesthetized	VBN	O
with	IN	O
isoflurane	NN	O
.	.	O

After	IN	O
full	JJ	O
recovery	NN	O
,	,	O
acepromazine	NN	O
(	(	O
0.02	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
oxymorphone	NN	O
(	(	O
0.05	CD	O
mg/kg	NN	O
)	)	O
were	VBD	O
administered	VBN	O
IV	NNP	O
.	.	O

Fifteen	NNP	O
minutes	NNS	O
later	RB	O
(	(	O
before	IN	O
IoA	NNP	O
)	)	O
,	,	O
each	DT	O
dog	NN	O
received	VBD	O
treatment	NN	O
IV	NNP	O
with	IN	O
propofol	NN	O
,	,	O
K-P	NNP	O
,	,	O
or	CC	O
K-D.	NNP	O
Cardiorespiratory	NNP	PH
and	CC	PH
arterial	JJ	PH
blood	NN	PH
gas	NN	PH
variables	NNS	PH
were	VBD	O
assessed	VBN	O
before	RB	O
,	,	O
immediately	RB	O
after	IN	O
,	,	O
and	CC	O
5	CD	O
minutes	NNS	O
after	IN	O
IoA	NNP	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
findings	NNS	O
before	IN	O
IoA	NNP	O
,	,	O
dogs	NNS	O
receiving	VBG	O
the	DT	O
K-P	NNP	O
or	CC	O
K-D	NNP	O
treatment	NN	O
had	VBD	O
increased	VBN	O
cardiac	JJ	PH
output	NN	PH
,	,	PH
oxygen	NN	PH
delivery	NN	PH
,	,	PH
and	CC	PH
heart	NN	PH
rate	NN	PH
5	CD	O
minutes	NNS	O
after	IN	O
IoA	NNP	O
;	:	O
K-P	NNP	O
administration	NN	O
did	VBD	O
not	RB	O
change	VB	O
mean	JJ	PH
arterial	JJ	PH
blood	NN	PH
pressure	NN	PH
or	CC	PH
stroke	NN	PH
volume	NN	PH
and	CC	PH
decreased	JJ	PH
systemic	JJ	PH
vascular	JJ	PH
resistance	NN	PH
.	.	PH

Propofol	NNP	O
decreased	VBD	O
mean	JJ	PH
arterial	JJ	PH
blood	NN	PH
pressure	NN	PH
and	CC	O
systemic	JJ	PH
vascular	JJ	PH
resistance	NN	PH
immediately	RB	O
after	IN	O
IoA	NNP	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
heart	NN	PH
rate	NN	PH
,	,	O
cardiac	JJ	PH
output	NN	PH
,	,	O
or	CC	O
oxygen	NN	PH
delivery	NN	PH
.	.	O

All	DT	O
treatments	NNS	O
caused	VBD	O
some	DT	O
degree	NN	PH
of	IN	PH
apnea	NN	PH
,	,	PH
hypoventilation	NN	PH
,	,	PH
and	CC	PH
hypoxemia	NN	PH
(	(	O
Pao2	NNP	O
<	VBZ	O
80	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
In	IN	O
dogs	NNS	O
,	,	O
K-P	NNP	O
treatment	NN	O
maintained	VBD	O
mean	JJ	PH
arterial	JJ	PH
blood	NN	PH
pressure	NN	PH
better	RBR	O
than	IN	O
propofol	VB	O
alone	JJ	O
and	CC	O
increased	JJ	O
heart	NN	PH
rate	NN	PH
,	,	O
cardiac	JJ	PH
output	NN	PH
,	,	O
or	CC	O
oxygen	NN	PH
delivery	NN	PH
,	,	O
as	IN	O
did	VBD	O
the	DT	O
K-D	NNP	O
treatment	NN	O
.	.	O

Supplemental	JJ	O
100	CD	O
%	NN	O
oxygen	NN	O
should	MD	O
be	VB	O
provided	VBN	O
during	IN	O
IoA	NNP	O
with	IN	O
all	DT	O
3	CD	O
treatments	NNS	O
.	.	O

Transitions	NNS	O
during	IN	O
effective	JJ	O
treatment	NN	O
for	IN	O
cocaine-abusing	JJ	O
homeless	JJ	O
persons	NNS	O
:	:	O
establishing	VBG	O
abstinence	NN	O
,	,	O
lapse	NN	O
,	,	O
and	CC	O
relapse	NN	O
,	,	O
and	CC	O
reestablishing	VBG	O
abstinence	NN	O
.	.	O

Data	NNS	O
are	VBP	O
reported	VBN	O
on	IN	O
drug	NN	O
use	NN	O
among	IN	O
cocaine-dependent	JJ	O
homeless	NN	O
persons	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
day	NN	O
treatment	NN	O
only	RB	O
(	(	O
DT	NNP	O
,	,	O
n	JJ	O
=	NNP	O
69	CD	O
)	)	O
with	IN	O
day	NN	O
treatment	NN	O
plus	CC	O
abstinent-contingent	JJ	O
housing	NN	O
and	CC	O
work	NN	O
(	(	O
DT+	NNP	O
,	,	O
n	JJ	O
=	NNP	O
72	CD	O
)	)	O
.	.	O

Drug	NNP	PH
use	NN	PH
was	VBD	PH
measured	VBN	PH
with	IN	PH
multiple	JJ	PH
weekly	JJ	PH
urine	NN	PH
toxicologies	NNS	PH
.	.	PH

Compared	VBN	O
with	IN	O
DT	NNP	O
participants	NNS	O
,	,	O
more	JJR	O
DT+	JJ	O
participants	NNS	O
established	VBN	O
abstinence	NN	ME
,	,	ME
maintained	VBD	ME
abstinence	NN	ME
for	IN	ME
longer	JJR	ME
durations	NNS	ME
,	,	O
were	VBD	O
marginally	RB	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
lapse	VB	ME
,	,	O
and	CC	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
relapse	VB	ME
.	.	O

Of	IN	O
all	DT	O
participants	NNS	O
who	WP	O
established	VBD	O
abstinence	NN	O
and	CC	O
then	RB	O
relapsed	VBD	O
,	,	O
DT+	NNP	O
participants	NNS	O
relapsed	VBD	O
later	RB	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
reestablish	VB	ME
abstinence	NN	ME
.	.	Ot

These	DT	O
analyses	NNS	O
yield	VBP	O
information	NN	O
on	IN	O
the	DT	O
processes	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
manner	NN	O
in	IN	O
which	WDT	O
drug	NN	O
use	NN	O
changes	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
abstinent-contingent	JJ	O
housing	NN	O
and	CC	O
work	NN	O
.	.	O

Olanzapine	NNP	O
versus	NN	O
haloperidol	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	PH
disorder	NN	PH
:	:	O
an	DT	O
open	JJ	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
Conventional	NNP	O
neuroleptics	NNS	O
ameliorate	VBP	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
;	:	O
however	RB	O
,	,	O
they	PRP	O
are	VBP	O
known	VBN	O
to	TO	O
cause	VB	O
dyskinesias	NN	O
.	.	O

Atypical	JJ	O
neuroleptics	NNS	O
,	,	O
including	VBG	O
olanzapine	NN	O
,	,	O
may	MD	O
have	VB	O
less	JJR	O
risk	NN	O
for	IN	O
dyskinesia	NN	O
,	,	O
but	CC	O
their	PRP$	O
efficacy	NN	O
in	IN	O
autistic	JJ	O
disorder	NN	O
is	VBZ	O
not	RB	O
established	VBN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
open-label	JJ	O
olanzapine	NN	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
by	IN	O
using	VBG	O
haloperidol	NN	O
as	IN	O
a	DT	O
standard	JJ	O
comparator	NN	O
treatment	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
parallel	JJ	O
groups	NNS	O
design	NN	O
,	,	O
12	CD	O
children	NNS	O
with	IN	O
DSM-IV	NNP	O
autistic	JJ	O
disorder	NN	O
(	(	O
mean	JJ	O
age	NN	O
7.8+/-2.1	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
6	CD	O
weeks	NNS	O
of	IN	O
open	JJ	O
treatment	NN	O
with	IN	O
olanzapine	NN	O
or	CC	O
haloperidol	NN	O
.	.	O

Mean	NNP	O
final	JJ	O
dosages	NNS	O
were	VBD	O
7.9+/-2.5	JJ	O
mg/day	NN	O
for	IN	O
olanzapine	NN	O
and	CC	O
1.4+/-0.7	JJ	O
mg/day	NN	O
for	IN	O
haloperidol	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Clinical	NNP	ME
Global	NNP	ME
Impressions	NNP	ME
(	(	ME
CGI	NNP	ME
)	)	ME
and	CC	O
the	DT	ME
Children	NNP	ME
's	POS	ME
Psychiatric	NNP	ME
Rating	NNP	ME
Scale	NNP	ME
(	(	ME
CPRS	NNP	ME
)	)	ME
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
had	VBD	O
symptom	VBN	ME
reduction	NN	ME
.	.	O

Five	CD	O
of	IN	O
six	CD	O
in	IN	O
the	DT	O
olanzapine	NN	O
group	NN	O
and	CC	O
three	CD	O
of	IN	O
six	CD	O
in	IN	O
the	DT	O
haloperidol	NN	O
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
according	VBG	O
to	TO	O
the	DT	O
CGI	NNP	ME
Improvement	NNP	O
item	NN	O
.	.	O

Subjects	NNS	O
showed	VBD	O
improvement	NN	O
on	IN	O
the	DT	O
CPRS	NNP	ME
Autism	NNP	ME
Factor	NNP	ME
(	(	O
F1,9	NNP	O
=	NNP	O
24.4	CD	O
,	,	O
p	NN	O
=	NNP	O
.0008	NNP	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
included	VBD	O
drowsiness	NN	A
and	CC	A
weight	JJ	A
gain	NN	A
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
olanzapine	NN	O
is	VBZ	O
a	DT	O
promising	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Further	JJ	O
placebo-controlled	JJ	O
and	CC	O
long-term	JJ	O
studies	NNS	O
of	IN	O
olanzapine	NN	O
in	IN	O
autistic	JJ	O
disorder	NN	O
are	VBP	O
required	VBN	O
.	.	O

Combination	NNP	O
hydrocodone	NN	O
and	CC	O
ibuprofen	JJ	O
versus	NN	O
combination	NN	O
codeine	NN	O
and	CC	O
acetaminophen	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
with	IN	O
that	DT	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
Hydrocodone	NNP	O
7.5	CD	O
mg	NN	O
with	IN	O
ibuprofen	JJ	O
200	CD	O
mg	NN	O
is	VBZ	O
the	DT	O
only	JJ	O
approved	VBD	O
fixed-dose	JJ	O
combination	NN	O
analgesic	IN	O
containing	VBG	O
an	DT	O
opioid	NN	O
and	CC	O
ibuprofen	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
repeated-dose	JJ	O
,	,	O
active-comparator	JJ	O
,	,	O
4-week	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
,	,	O
469	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
1-tablet	JJ	O
(	(	O
n	JJ	O
=	NNP	O
156	CD	O
)	)	O
or	CC	O
2-tablet	JJ	O
(	(	O
n	JJ	O
=	NNP	O
153	CD	O
)	)	O
dose	NN	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
(	(	O
HI1	NNP	O
and	CC	O
HI2	NNP	O
,	,	O
respectively	RB	O
)	)	O
or	CC	O
a	DT	O
2-tablet	JJ	O
dose	NN	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
(	(	O
CA	NNP	O
,	,	O
n	RB	O
=	VBZ	O
160	CD	O
)	)	O
,	,	O
the	DT	O
active	JJ	O
comparator	NN	O
,	,	O
every	DT	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
measured	VBN	O
through	IN	O
pain	NN	PA
relief	NN	PA
scores	NNS	PA
,	,	O
number	NN	Ot
of	IN	Ot
daily	JJ	Ot
doses	NNS	Ot
of	IN	Ot
study	NN	Ot
medication	NN	Ot
,	,	O
number	NN	Ot
of	IN	Ot
daily	JJ	Ot
doses	NNS	Ot
of	IN	Ot
supplemental	JJ	Ot
analgesics	NNS	Ot
,	,	O
number	NN	Ot
of	IN	Ot
patients	NNS	Ot
who	WP	Ot
discontinued	VBD	Ot
therapy	NN	Ot
due	JJ	Ot
to	TO	Ot
an	DT	Ot
unsatisfactory	JJ	Ot
analgesic	JJ	Ot
response	NN	Ot
,	,	O
and	CC	O
global	JJ	O
assessment	NN	O
scores	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
469	CD	O
patients	NNS	O
,	,	O
255	CD	O
(	(	O
54.4	CD	O
%	NN	O
)	)	O
were	VBD	O
female	JJ	O
and	CC	O
214	CD	O
(	(	O
45.6	CD	O
%	NN	O
)	)	O
were	VBD	O
male	JJ	O
.	.	O

The	DT	O
mean	JJ	O
age	NN	O
was	VBD	O
51.1	CD	O
years	NNS	O
.	.	O

Types	NNS	O
of	IN	O
chronic	NN	O
pain	NN	O
included	VBD	O
back	RB	O
(	(	O
214	CD	O
;	:	O
45.6	CD	O
%	NN	O
)	)	O
,	,	O
arthritic	JJ	O
(	(	O
145	CD	O
;	:	O
30.9	CD	O
%	NN	O
)	)	O
,	,	O
other	JJ	O
musculoskeletal	NN	O
(	(	O
65	CD	O
;	:	O
13.9	CD	O
%	NN	O
)	)	O
,	,	O
cancer	NN	O
(	(	O
6	CD	O
;	:	O
1.3	CD	O
%	NN	O
)	)	O
,	,	O
diabetic	JJ	O
neuropathic	NN	O
(	(	O
3	CD	O
;	:	O
0.6	CD	O
%	NN	O
)	)	O
,	,	O
postherpetic	JJ	O
neuralgic	NN	O
(	(	O
5	CD	O
;	:	O
1.1	CD	O
%	NN	O
)	)	O
,	,	O
other	JJ	O
neurologic	NN	O
(	(	O
21	CD	O
;	:	O
4.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
other	JJ	O
unclassified	JJ	O
chronic	JJ	O
pain	NN	O
(	(	O
10	CD	O
;	:	O
2.1	CD	O
%	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
48	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
the	DT	O
study	NN	O
,	,	O
351	CD	O
(	(	O
74.8	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
opioid	JJ	O
or	CC	O
opioid-nonopioid	JJ	O
combination	NN	O
analgesics	NNS	O
.	.	O

The	DT	O
overall	JJ	PA
mean	JJ	PA
daily	JJ	PA
pain	NN	PA
relief	NN	PA
score	NN	PA
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2.25+/-0.89	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
1.98+/-0.87	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
or	CC	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
1.85+/-0.96	JJ	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	Ot
mean	JJ	Ot
number	NN	Ot
of	IN	Ot
daily	JJ	Ot
doses	NNS	Ot
of	IN	Ot
study	NN	Ot
medication	NN	Ot
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2.94+/-0.99	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
3.23+/-0.76	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
or	CC	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
3.26+/-0.75	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	Ot
mean	JJ	Ot
number	NN	Ot
of	IN	Ot
daily	JJ	Ot
doses	NNS	Ot
of	IN	Ot
supplemental	JJ	Ot
analgesics	NNS	Ot
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
0.24+/-0.49	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
0.34+/-0.58	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
or	CC	O
CA	NNP	O
group	NN	O
(	(	O
0.49+/-0.85	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
.	.	O

The	DT	O
number	NN	Ot
of	IN	Ot
patients	NNS	Ot
who	WP	Ot
discontinued	VBD	Ot
treatment	NN	Ot
due	JJ	Ot
to	TO	Ot
an	DT	Ot
unsatisfactory	JJ	Ot
analgesic	JJ	Ot
response	NN	Ot
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2	CD	O
;	:	O
1.3	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
12	CD	O
;	:	O
7.5	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

HI2	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
as	IN	O
measured	VBN	O
by	IN	O
pain	NN	PA
relief	NN	PA
scores	NNS	PA
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
,	,	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
,	,	O
and	CC	O
week	NN	O
3	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.008	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
;	:	O
daily	JJ	Ot
doses	NNS	Ot
of	IN	Ot
study	NN	Ot
medication	NN	Ot
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.019	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
=	NNP	O
0.011	CD	O
vs	NN	O
CA	NNP	O
)	)	O
;	:	O
daily	JJ	Ot
doses	NNS	Ot
of	IN	Ot
supplemental	JJ	Ot
analgesics	NNS	Ot
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.010	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
;	:	O
and	CC	O
global	JJ	Ot
assessment	NN	Ot
scores	NNS	Ot
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.018	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
,	,	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.005	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
,	,	O
and	CC	O
week	NN	O
4	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.013	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
=	NNP	O
0.023	CD	O
vs	NN	O
CA	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
in	IN	O
any	DT	O
efficacy	NN	Ot
variable	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
number	NN	A
of	IN	A
patients	NNS	A
experiencing	VBG	A
adverse	JJ	A
events	NNS	A
in	IN	O
the	DT	O
HI2	NNP	O
(	(	O
127	CD	O
;	:	O
83	CD	O
%	NN	O
)	)	O
,	,	O
HI1	NNP	O
(	(	O
124	CD	O
;	:	O
79.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
CA	NNP	O
(	(	O
129	CD	O
;	:	O
80.6	CD	O
%	NN	O
)	)	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mean	JJ	Ot
number	NN	Ot
of	IN	Ot
patients	NNS	Ot
who	WP	Ot
discontinued	VBD	Ot
treatment	NN	Ot
due	JJ	Ot
to	TO	Ot
adverse	JJ	Ot
events	NNS	Ot
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
40	CD	O
;	:	O
26.1	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
23	CD	O
;	:	O
14.7	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
either	DT	O
1-tablet	JJ	O
doses	NNS	O
of	IN	O
this	DT	O
combination	NN	O
or	CC	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
.	.	O

Moreover	RB	O
,	,	O
1-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
may	MD	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
.	.	O

Partial-area	JJ	O
method	NN	O
in	IN	O
bioequivalence	NN	O
assessment	NN	O
:	:	O
naproxen	NN	O
.	.	O

Regulatory	NNP	O
authorities	NNS	O
require	VBP	O
demonstration	NN	O
of	IN	O
bioequivalence	NN	O
through	IN	O
comparisons	NNS	O
of	IN	O
different	JJ	O
pharmacokinetic	JJ	O
parameters	NNS	O
,	,	O
the	DT	O
area	NN	PH
under	IN	PH
the	DT	PH
plasma	JJ	PH
concentration-time	JJ	PH
curve	NN	PH
(	(	PH
AUC	NNP	PH
)	)	PH
,	,	PH
the	DT	PH
maximum	JJ	PH
plasma	JJ	PH
concentration	NN	PH
(	(	PH
Cmax	NNP	PH
)	)	PH
,	,	O
and	CC	O
the	DT	PH
time	NN	PH
to	TO	PH
reach	VB	PH
peak	JJ	PH
concentration	NN	PH
(	(	Ot
Tmax	NNP	Ot
)	)	Ot
.	.	O

The	DT	O
applicability	NN	O
and	CC	O
validity	NN	O
of	IN	O
regulatory	JJ	O
requirements	NNS	O
have	VBP	O
been	VBN	O
widely	RB	O
criticized	VBN	O
on	IN	O
statistical	JJ	O
and	CC	O
clinical	JJ	O
relevance	NN	O
grounds	NNS	O
.	.	O

For	IN	O
most	JJS	O
noncomplicated	JJ	O
absorption	NN	O
models	NNS	O
,	,	O
the	DT	O
AUC	NNP	Ot
correlates	VBZ	O
well	RB	O
with	IN	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
nonlinear	JJ	O
models	NNS	O
of	IN	O
absorption	NN	O
,	,	O
in	IN	O
mechanisms	NN	O
involving	VBG	O
recycling	NN	O
of	IN	O
drugs	NNS	O
,	,	O
and	CC	O
for	IN	O
drugs	NNS	O
with	IN	O
long	JJ	O
half-life	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
total	JJ	O
AUC	NNP	Ot
(	(	O
from	IN	O
zero	CD	O
to	TO	O
infinity	NN	O
)	)	O
can	MD	O
give	VB	O
erroneous	JJ	O
and	CC	O
clinically	RB	O
irrelevant	JJ	O
results	NNS	O
since	IN	O
the	DT	O
area	NN	O
is	VBZ	O
mostly	RB	O
determined	VBN	O
by	IN	O
elimination	NN	O
phase	NN	O
or	CC	O
by	IN	O
recycling	VBG	O
.	.	O

The	DT	O
calculation	NN	O
of	IN	O
total	JJ	O
AUC	NNP	Ot
also	RB	O
involves	VBZ	O
prolonged	JJ	O
sampling	NN	O
,	,	O
adding	VBG	O
to	TO	O
the	DT	O
cost	NN	O
and	CC	O
risks	NNS	O
associated	VBN	O
with	IN	O
bioequivalence	NN	O
studies	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
Cmax	NNP	Ot
or	CC	O
Tmax	NNP	Ot
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
rate	NN	O
of	IN	O
absorption	NN	O
,	,	O
to	TO	O
correlate	VB	O
with	IN	O
clinical	JJ	O
relevance	NN	O
,	,	O
is	VBZ	O
widely	RB	O
criticized	VBN	O
on	IN	O
logical	JJ	O
,	,	O
technical	JJ	O
,	,	O
and	CC	O
statistical	JJ	O
grounds	NNS	O
.	.	O

For	IN	O
drugs	NNS	O
used	VBN	O
on	IN	O
a	DT	O
multiple-dose	JJ	O
basis	NN	O
,	,	O
Cmax	NNP	Ot
and	CC	O
Tmax	NNP	Ot
evaluations	NNS	O
become	VBP	O
redundant	JJ	O
since	IN	O
the	DT	O
average	JJ	O
plateau	NN	PH
concentration	NN	PH
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
these	DT	O
parameters	NNS	O
.	.	O

To	TO	O
resolve	VB	O
the	DT	O
drawbacks	NNS	O
in	IN	O
the	DT	O
traditional	JJ	O
methodology	NN	O
of	IN	O
bioequivalence	NN	O
evaluation	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
partial	JJ	O
areas	NNS	O
in	IN	O
lieu	NN	O
of	IN	O
total	JJ	O
AUC	NNP	Ot
,	,	O
Tmax	NNP	Ot
,	,	O
and	CC	O
Cmax	NNP	Ot
is	VBZ	O
suggested	VBN	O
.	.	O

This	DT	O
study	NN	O
investigates	VBZ	O
the	DT	O
logic	NN	O
and	CC	O
robustness	NN	O
of	IN	O
the	DT	O
partial-area	JJ	O
method	NN	O
in	IN	O
establishing	VBG	O
bioequivalence	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
5h	CD	Ot
AUC	NNP	Ot
is	VBZ	O
a	DT	O
more	RBR	O
relevant	JJ	O
parameter	NN	O
to	TO	O
establish	VB	O
naproxen	NNS	O
bioequivalence	NN	O
than	IN	O
AUCinf	NNP	Ot
.	.	O

We	PRP	O
recommend	VBP	O
against	IN	O
using	VBG	O
symmetrical	JJ	O
confidence	NN	O
intervals	NNS	O
and	CC	O
report	NN	O
excellent	JJ	O
agreement	NN	O
among	IN	O
several	JJ	O
methods	NNS	O
of	IN	O
calculating	VBG	O
confidence	NN	O
intervals	NNS	O
,	,	O
probability	NN	O
values	NNS	O
,	,	O
and	CC	O
nonparametric	JJ	O
tests	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
a	DT	O
single-point	JJ	Ot
short-term	JJ	Ot
AUC	NNP	Ot
is	VBZ	O
a	DT	O
better	JJR	O
indicator	NN	O
of	IN	O
the	DT	O
bioequivalence	NN	O
of	IN	O
generic	JJ	O
products	NNS	O
than	IN	O
the	DT	O
total	JJ	O
AUC	NNP	Ot
,	,	O
Cmax	NNP	Ot
,	,	O
and	CC	O
Tmax	NNP	Ot
as	IN	O
required	VBN	O
currently	RB	O
by	IN	O
the	DT	O
regulatory	JJ	O
authorities	NNS	O
.	.	O

Stress	NNP	O
reduction	NN	O
and	CC	O
analgesia	NN	O
in	IN	O
patients	NNS	O
exposed	VBN	O
to	TO	O
calming	VBG	O
music	NN	O
postoperatively	RB	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
OBJECTIVES	NNP	O
This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
,	,	O
first	RB	O
,	,	O
whether	IN	O
intra-	JJ	O
or	CC	O
postoperative	JJ	O
music	NN	O
therapy	NN	O
could	MD	O
influence	VB	O
stress	NN	ME
and	CC	O
immune	JJ	PH
response	NN	PH
during	IN	O
and	CC	O
after	IN	O
general	JJ	O
anaesthesia	NN	O
and	CC	O
second	JJ	O
,	,	O
if	IN	O
there	EX	O
was	VBD	O
a	DT	O
different	JJ	O
response	NN	O
between	IN	O
patients	NNS	O
exposed	VBN	O
to	TO	O
music	NN	O
intra-	NN	O
or	CC	O
postoperatively	RB	O
.	.	O

METHOD	NNP	O
Seventy-five	JJ	O
patients	NNS	O
undergoing	VBG	O
open	JJ	O
hernia	NN	O
repair	NN	O
as	IN	O
day	NN	O
care	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
:	:	O
intraoperative	JJ	O
music	NN	O
,	,	O
postoperative	JJ	O
music	NN	O
and	CC	O
silence	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

Anaesthesia	NNP	O
and	CC	O
postoperative	JJ	O
analgesia	NN	O
were	VBD	O
standardized	VBN	O
and	CC	O
the	DT	O
same	JJ	O
surgeon	NN	O
performed	VBD	O
all	PDT	O
the	DT	O
operations	NNS	O
.	.	O

Stress	NNP	PH
response	NN	PH
was	VBD	O
assessed	VBN	O
during	IN	O
and	CC	O
after	IN	O
surgery	NN	O
by	IN	O
determining	VBG	O
the	DT	O
plasma	NN	PH
cortisol	NN	PH
and	CC	O
blood	NN	PH
glucose	NN	PH
levels	NNS	PH
.	.	O

Immune	NNP	PH
function	NN	PH
was	VBD	O
evaluated	VBN	O
by	IN	O
studying	VBG	O
immunoglobulin	NN	PH
A	NNP	PH
(	(	PH
IgA	NNP	PH
)	)	PH
levels	NNS	PH
.	.	O

Patients	NNS	PA
'	POS	PA
postoperative	JJ	PA
pain	NN	PA
,	,	O
anxiety	NN	ME
,	,	O
blood	NN	PH
pressure	NN	PH
(	(	PH
BP	NNP	PH
)	)	PH
,	,	PH
heart	NN	PH
rate	NN	PH
(	(	PH
HR	NNP	PH
)	)	PH
and	CC	PH
oxygen	JJ	PH
saturation	NN	PH
were	VBD	O
also	RB	O
studied	VBN	O
as	IN	O
stress	NN	PH
markers	NNS	PH
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
the	DT	O
level	NN	PH
of	IN	PH
cortisol	NN	PH
in	IN	O
the	DT	O
postoperative	JJ	O
music	NN	O
group	NN	O
vs.	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
206	CD	O
and	CC	O
72	CD	O
mmol	NN	O
L	NNP	O
(	(	O
-1	NNP	O
)	)	O
decreases	VBZ	O
,	,	O
respectively	RB	O
)	)	O
after	IN	O
2	CD	O
h	NN	O
in	IN	O
the	DT	O
post	NN	O
anaesthesia	NN	O
care	NN	O
unit	NN	O
.	.	O

The	DT	O
postoperative	JJ	O
music	NN	O
group	NN	O
had	VBD	O
less	JJR	O
anxiety	NN	ME
and	CC	O
pain	NN	PA
and	CC	O
required	VBD	O
less	JJR	O
morphine	NN	Ot
after	IN	O
1	CD	O
h	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
postoperative	JJ	O
music	NN	O
group	NN	O
the	DT	O
total	JJ	O
requirement	NN	O
of	IN	O
morphine	NN	PH
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
intraoperative	JJ	O
music	NN	O
group	NN	O
reported	VBD	O
less	JJR	O
pain	NN	PA
after	IN	O
1	CD	O
h	NN	O
in	IN	O
the	DT	O
post	NN	O
anaesthesia	NN	O
care	NN	O
unit	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
IgA	NNP	PH
,	,	PH
blood	NN	PH
glucose	NN	PH
,	,	PH
BP	NNP	PH
,	,	PH
HR	NNP	PH
and	CC	PH
oxygen	NN	PH
saturation	NN	PH
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
intraoperative	JJ	O
music	NN	O
may	MD	O
decrease	VB	O
postoperative	JJ	O
pain	NN	O
,	,	O
and	CC	O
that	IN	O
postoperative	JJ	O
music	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
anxiety	NN	ME
,	,	O
pain	NN	PA
and	CC	O
morphine	NN	Ot
consumption	NN	Ot
.	.	O

Complementary	JJ	O
feeding	NN	O
with	IN	O
fortified	JJ	O
spread	NN	O
and	CC	O
incidence	NN	O
of	IN	O
severe	JJ	PH
stunting	VBG	PH
in	IN	O
6-	JJ	O
to	TO	O
18-month-old	JJ	O
rural	JJ	O
Malawians	NNPS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
growth	NN	Ot
and	CC	O
incidence	NN	O
of	IN	O
malnutrition	NN	PH
in	IN	O
infants	NNS	O
receiving	VBG	O
long-term	JJ	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
ready-to-use	NN	O
fortified	VBN	O
spread	NN	O
(	(	O
FS	NNP	O
)	)	O
or	CC	O
micronutrient-fortified	JJ	O
maize-soy	JJ	O
flour	NN	O
(	(	O
likuni	JJ	O
phala	NN	O
[	NNP	O
LP	NNP	O
]	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
single-blind	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Rural	JJ	O
Malawi	NNP	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
six-month-old	JJ	O
infants	NNS	O
.	.	O

INTERVENTION	NN	O
Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
year	NN	O
of	IN	O
daily	JJ	O
supplementation	NN	O
with	IN	O
71	CD	O
g	NN	O
of	IN	O
LP	NNP	O
(	(	O
282	CD	O
kcal	NN	O
)	)	O
,	,	O
50	CD	O
g	NN	O
of	IN	O
FS	NNP	O
(	(	O
FS50	NNP	O
)	)	O
(	(	O
256	CD	O
kcal	NN	O
)	)	O
,	,	O
or	CC	O
25	CD	O
g	NN	O
of	IN	O
FS	NNP	O
(	(	O
FS25	NNP	O
)	)	O
(	(	O
130	CD	O
[	RB	O
corrected	VBN	O
]	NNP	O
kcal	JJ	O
)	)	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Weight	NNP	PH
and	CC	PH
length	NN	PH
gains	NNS	PH
and	CC	O
the	DT	O
incidences	NNS	PH
of	IN	PH
severe	JJ	PH
stunting	NN	PH
,	,	O
underweight	JJ	PH
,	,	O
and	CC	O
wasting	VBG	PH
.	.	O

RESULTS	NNP	O
Mean	NNP	PH
weight	NN	PH
and	CC	PH
length	NN	PH
gains	NNS	PH
in	IN	O
the	DT	O
LP	NNP	O
,	,	O
FS50	NNP	O
,	,	O
and	CC	O
FS25	NNP	O
groups	NNS	O
were	VBD	O
2.37	CD	O
,	,	O
2.47	CD	O
,	,	O
and	CC	O
2.37	CD	O
kg	NN	O
(	(	O
P	NNP	O
=	NNP	O
.66	NNP	O
)	)	O
and	CC	O
12.7	CD	O
,	,	O
13.5	CD	O
,	,	O
and	CC	O
13.2	CD	O
cm	NN	O
(	(	O
P	NNP	O
=	NNP	O
.23	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
groups	NNS	O
,	,	O
the	DT	O
cumulative	JJ	O
12-month	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	PH
stunting	NN	PH
was	VBD	O
13.3	CD	O
%	NN	O
,	,	O
0.0	CD	O
%	NN	O
,	,	O
and	CC	O
3.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
,	,	O
of	IN	O
severe	JJ	O
underweight	NN	PH
was	VBD	O
15.0	CD	O
%	NN	O
,	,	O
22.5	CD	O
%	NN	O
,	,	O
and	CC	O
16.9	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.71	NNP	O
)	)	O
,	,	O
and	CC	O
of	IN	O
severe	JJ	PH
wasting	NN	PH
was	VBD	O
1.8	CD	O
%	NN	O
,	,	O
1.9	CD	O
%	NN	O
,	,	O
and	CC	O
1.8	CD	O
%	NN	O
(	(	O
P	NNP	O
>	NNP	O
.99	NNP	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
LP-supplemented	JJ	O
infants	NNS	O
,	,	O
those	DT	O
given	VBN	O
FS50	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
100	CD	O
g	NNS	O
more	JJR	O
weight	NN	PH
and	CC	O
0.8	CD	O
cm	NN	O
more	JJR	O
length	NN	PH
.	.	PH

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
baseline	NN	O
length	NN	O
and	CC	O
intervention	NN	O
(	(	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
;	:	O
in	IN	O
children	NNS	O
with	IN	O
below-median	JJ	O
length	NN	O
at	IN	O
enrollment	NN	O
,	,	O
those	DT	O
given	VBN	O
FS50	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
1.9	CD	O
cm	NNS	O
more	JJR	O
than	IN	O
individuals	NNS	O
receiving	VBG	O
LP	NNP	O
.	.	O

CONCLUSION	NNP	O
One-year-long	JJ	O
complementary	JJ	O
feeding	NN	O
with	IN	O
FS	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
a	DT	O
significantly	RB	O
larger	JJR	O
effect	NN	O
than	IN	O
LP	NNP	O
on	IN	O
mean	JJ	PH
weight	NN	PH
gain	NN	PH
in	IN	O
all	DT	O
infants	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
likely	JJ	O
to	TO	O
boost	VB	O
linear	JJ	PH
growth	NN	PH
in	IN	O
the	DT	O
most	RBS	O
disadvantaged	JJ	O
individuals	NNS	O
and	CC	O
,	,	O
hence	RB	O
,	,	O
decrease	VB	O
the	DT	O
incidence	NN	PH
of	IN	PH
severe	JJ	PH
stunting	NN	PH
.	.	O

Independent	NNP	O
prognostic	JJ	O
information	NN	O
provided	VBN	O
by	IN	O
sphygmomanometrically	RB	O
determined	VBN	O
pulse	JJ	PH
pressure	NN	PH
and	CC	O
mean	JJ	O
arterial	JJ	PH
pressure	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
relationship	NN	O
of	IN	O
baseline	NN	O
pulse	JJ	O
pressure	NN	O
and	CC	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
to	TO	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

BACKGROUND	NNP	O
Increased	VBD	O
conduit	NN	O
vessel	NN	O
stiffness	NN	O
increases	VBZ	O
pulse	JJ	O
pressure	NN	O
and	CC	O
pulsatile	NN	O
load	NN	O
,	,	O
potentially	RB	O
contributing	VBG	O
to	TO	O
adverse	VB	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

METHODS	NNP	O
Pulse	NNP	O
and	CC	O
mean	VB	O
arterial	JJ	O
pressure	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
mortality	NN	MO
,	,	O
adjusting	VBG	O
for	IN	O
other	JJ	O
modifiers	NNS	O
of	IN	O
risk	NN	O
,	,	O
using	VBG	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
analysis	NN	O
of	IN	O
data	NNS	O
collected	VBN	O
from	IN	O
6,781	CD	O
patients	NNS	O
randomized	VBN	O
into	IN	O
the	DT	O
Studies	NNPS	O
of	IN	O
Left	NNP	O
Ventricular	NNP	O
Dysfunction	NNP	O
trials	NNS	O
.	.	O

RESULTS	NNP	O
Pulse	NNP	PH
and	CC	PH
mean	VB	PH
arterial	JJ	PH
pressure	NN	PH
were	VBD	O
related	VBN	O
positively	RB	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
age	NN	O
,	,	O
ejection	NN	O
fraction	NN	O
and	CC	O
prevalence	NN	O
of	IN	O
diabetes	NNS	O
and	CC	O
hypertension	NN	O
and	CC	O
inversely	RB	O
to	TO	O
prior	VB	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
beta-adrenergic	JJ	O
blocking	NN	O
agent	NN	O
use	NN	O
.	.	O

Higher	JJR	PH
pulse	JJ	PH
pressure	NN	PH
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
prevalence	NN	O
of	IN	O
female	JJ	O
gender	NN	O
,	,	O
greater	JJR	O
calcium	NN	O
channel	NN	O
blocking	VBG	O
agent	NN	O
,	,	O
digoxin	NN	O
and	CC	O
diuretic	JJ	O
use	NN	O
,	,	O
lower	JJR	O
heart	NN	O
rate	NN	O
and	CC	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
reported	VBN	O
smoking	NN	O
history	NN	O
.	.	O

Higher	JJR	PH
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
heart	NN	O
rate	NN	O
,	,	O
lower	JJR	O
calcium	NN	O
channel	NN	O
blocker	NN	O
and	CC	O
digoxin	NN	O
use	NN	O
and	CC	O
lower	JJR	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
.	.	O

Over	IN	O
a	DT	O
61-month	JJ	O
follow-up	JJ	O
1,582	CD	O
deaths	NNS	MO
(	(	O
1,397	CD	O
cardiovascular	NN	O
)	)	O
occurred	VBD	O
.	.	O

In	IN	O
a	DT	O
multivariate	NN	O
analysis	NN	O
adjusting	VBG	O
for	IN	O
the	DT	O
above	JJ	O
covariates	NNS	O
and	CC	O
treatment	NN	O
assignment	NN	O
,	,	O
higher	JJR	O
pulse	JJ	PH
pressure	NN	PH
remained	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
total	JJ	MO
and	CC	MO
cardiovascular	JJ	MO
mortality	NN	MO
(	(	O
total	JJ	O
mortality	NN	O
relative	NN	O
risk	NN	O
,	,	O
1.05	CD	O
per	IN	O
10	CD	O
mm	NN	O
Hg	NNP	O
increment	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.01	CD	O
to	TO	O
1.10	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.02	CD	O
)	)	O
.	.	O

Mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
was	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
total	JJ	MO
and	CC	MO
cardiovascular	JJ	MO
mortality	NN	MO
(	(	O
total	JJ	O
mortality	NN	O
relative	NN	O
risk	NN	O
,	,	O
0.89	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.85	CD	O
to	TO	O
0.94	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
One	CD	O
noninvasive	JJ	O
blood	NN	O
pressure	NN	O
measurement	NN	O
provides	VBZ	O
two	CD	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
for	IN	O
survival	NN	MO
.	.	O

Increased	VBD	PH
conduit	NN	PH
vessel	NN	PH
stiffness	NN	PH
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
pulse	JJ	O
pressure	NN	O
,	,	O
may	MD	O
contribute	VB	O
to	TO	O
increased	VBN	O
mortality	NN	MO
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
,	,	O
independent	JJ	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
Selaginella	NNP	O
combined	VBD	O
with	IN	O
radiotherapy	NN	O
on	IN	O
nasopharyngeal	JJ	O
carcinoma	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
Chinese	JJ	O
herbal	JJ	O
medicine	NN	O
Selaginella-induced	NNP	O
radiosensitization	NN	O
of	IN	O
terminal	JJ	O
nasopharyngeal	JJ	O
carcinoma	NN	O
(	(	O
NPC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Totally	RB	O
180	CD	O
patients	NNS	O
with	IN	O
NPC	NNP	O
were	VBD	O
divided	VBN	O
equally	RB	O
into	IN	O
3	CD	O
groups	NNS	O
with	IN	O
the	DT	O
same	JJ	O
radiotherapeutic	JJ	O
protocols	NNS	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
received	VBD	O
radiotherapy	NN	O
alone	RB	O
,	,	O
those	DT	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
given	VBN	O
daily	JJ	O
Selaginella	NNP	O
(	(	O
30	CD	O
g	NN	O
)	)	O
prepared	VBD	O
into	IN	O
50	CD	O
ml	JJ	O
decoction	NN	O
during	IN	O
the	DT	O
entire	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	O
,	,	O
and	CC	O
those	DT	O
in	IN	O
group	NN	O
C	NNP	O
had	VBD	O
Selaginella	NNP	O
30	CD	O
g	JJ	O
daily	RB	O
in	IN	O
the	DT	O
late	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
complete	JJ	PH
remission	NN	PH
rate	NN	PH
of	IN	PH
nasopharyngeal	JJ	PH
primary	JJ	PH
lesions	NNS	PH
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
with	IN	O
also	RB	O
significantly	RB	O
higher	JJR	O
complete	JJ	O
remission	NN	PH
rates	NNS	PH
of	IN	PH
the	DT	PH
cervical	JJ	PH
lymph	NN	PH
nodes	NNS	PH
.	.	O

The	DT	O
acute	JJ	PH
toxicity	NN	PH
of	IN	PH
the	DT	PH
skin	NN	PH
and	CC	PH
mucous	JJ	PH
membrane	NN	PH
was	VBD	O
milder	RBR	O
in	IN	O
the	DT	O
latter	JJ	O
two	CD	O
groups	NNS	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Selaginella	NNP	O
may	MD	O
induce	VB	O
radiosensitization	NN	O
for	IN	O
terminal	JJ	O
NPC	NNP	O
and	CC	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

Treatment	NN	O
of	IN	O
recurrent	NN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
demonstrate	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
intranasal	JJ	O
furosemide	NN	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
the	DT	O
sodium	NN	O
chloride	NN	O
cotransporter	NN	O
channel	NN	O
at	IN	O
the	DT	O
basolateral	JJ	O
surface	NN	O
of	IN	O
the	DT	O
respiratory	JJ	O
epithelial	JJ	O
cell	NN	O
,	,	O
vs	VBZ	O
no	DT	O
therapeutic	JJ	O
intervention	NN	O
vs	NN	O
intranasal	NN	O
mometasone	NN	O
furoate	NN	O
,	,	O
a	DT	O
corticosteroid	NN	O
,	,	O
in	IN	O
preventing	VBG	O
relapses	NNS	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
prospective	NN	O
controlled	VBD	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
examined	VBN	O
every	DT	O
6	CD	O
months	NNS	O
during	IN	O
follow-up	NN	O
(	(	O
range	NN	O
,	,	O
1-9	JJ	O
years	NNS	O
)	)	O
.	.	O

PATIENTS	VB	O
One	CD	O
hundred	JJ	O
seventy	NN	O
patients	NNS	O
with	IN	O
bilateral	JJ	O
obstructive	CD	O
or	CC	O
minimally	RB	O
obstructive	JJ	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

INTERVENTION	NNP	O
All	DT	O
patients	NNS	O
were	VBD	O
surgically	RB	O
treated	VBN	O
in	IN	O
the	DT	O
ENT	NNP	O
Department	NNP	O
,	,	O
University	NNP	O
of	IN	O
Siena	NNP	O
Medical	NNP	O
School	NNP	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
surgery	NN	O
,	,	O
group	NN	O
1	CD	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
97	CD	O
)	)	O
started	VBD	O
treatment	NN	O
with	IN	O
intranasal	JJ	O
furosemide	NN	O
,	,	O
group	NN	O
2	CD	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
received	VBD	O
no	DT	O
therapeutic	JJ	O
treatment	NN	O
,	,	O
and	CC	O
group	NN	O
3	CD	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
were	VBD	O
treated	VBN	O
with	IN	O
mometasone	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Clinical	NNP	O
and	CC	O
instrumental	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Seventeen	NNP	O
(	(	O
17.5	CD	O
%	NN	O
)	)	O
of	IN	O
97	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
12	CD	O
(	(	O
30.0	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
and	CC	O
8	CD	O
(	(	O
24.2	CD	O
%	NN	O
)	)	O
of	IN	O
33	CD	O
patients	NNS	O
in	IN	O
group	NN	O
3	CD	O
experienced	VBD	O
nasal	JJ	PH
polyposis	NN	PH
relapses	NNS	PH
.	.	PH

We	PRP	O
noted	VBD	O
a	DT	O
prevalence	NN	O
of	IN	O
early-stage	JJ	PH
relapse	NN	PH
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
furosemide	NN	O
or	CC	O
mometasone	NN	O
,	,	O
whereas	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
treatment	NN	O
experienced	VBD	O
more	JJR	O
severe	JJ	O
grades	NNS	PH
of	IN	PH
chronic	JJ	PH
hyperplastic	JJ	PH
sinusitis	NN	PH
with	IN	PH
nasal	JJ	PH
polyposis	NN	PH
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
intranasal	NN	O
furosemide	JJ	O
represents	VBZ	O
a	DT	O
valid	JJ	O
therapeutic	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
method	NN	O
for	IN	O
the	DT	O
estimation	NN	PH
of	IN	PH
flunarizine	JJ	PH
area	NN	PH
under	IN	PH
the	DT	PH
curve	NN	PH
(	(	PH
AUC	NNP	PH
)	)	PH
and	CC	PH
maximum	JJ	PH
plasma	JJ	PH
concentration	NN	PH
(	(	PH
Cmax	NNP	PH
)	)	PH
.	.	PH

A	DT	O
limited	JJ	O
sampling	NN	O
model	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
flunarizine	NN	O
following	VBG	O
a	DT	O
30	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
in	IN	O
epileptic	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
receiving	VBG	O
phenytoin	NN	O
or	CC	O
carbamazepine	NN	O
or	CC	O
both	DT	O
,	,	O
to	TO	O
estimate	VB	PH
the	DT	PH
area	NN	PH
under	IN	PH
the	DT	PH
curve	NN	PH
(	(	PH
AUC	NNP	PH
)	)	PH
and	CC	PH
maximum	JJ	PH
plasma	JJ	PH
concentration	NN	PH
(	(	PH
Cmax	NNP	PH
)	)	PH
.	.	PH

The	DT	O
model	NN	O
was	VBD	O
developed	VBN	O
using	VBG	O
training	VBG	O
data	NNS	O
sets	NNS	O
from	IN	O
30	CD	O
,	,	O
20	CD	O
,	,	O
15	CD	O
,	,	O
or	CC	O
10	CD	O
patients	NNS	O
at	IN	O
one	CD	O
or	CC	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

The	DT	O
equations	NNS	O
describing	VBG	O
the	DT	O
models	NNS	O
for	IN	O
AUC	NNP	O
using	VBG	O
two	CD	O
time	NN	O
points	NNS	O
(	(	O
3	CD	O
and	CC	O
24h	CD	O
)	)	O
and	CC	O
Cmax	NNP	O
for	IN	O
the	DT	O
training	NN	O
data	NNS	O
set	NN	O
of	IN	O
30	CD	O
subjects	NNS	O
were	VBD	O
AUCpredicted	NNP	O
=	NNP	O
11.1	CD	O
C3h	NNP	O
+	VBD	O
121.4	CD	O
C24h	NNP	O
-	:	O
157	CD	O
(	(	O
r	NN	O
=	RB	O
0.80	CD	O
)	)	O
Cmax	NNP	O
(	(	O
predicted	VBN	O
)	)	O
=	$	O
0.036	CD	O
AUC	NNP	O
+	$	O
42.9	CD	O
(	(	O
r	NN	O
=	RB	O
0.74	CD	O
)	)	O
The	DT	O
model	NN	O
was	VBD	O
validated	VBN	O
on	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
flunarizine	JJ	O
orally	RB	O
.	.	O

The	DT	O
model	NN	O
provided	VBD	O
reasonably	RB	O
good	JJ	O
estimates	NNS	PH
for	IN	PH
both	DT	PH
AUC	NNP	PH
and	CC	O
Cmax	NNP	PH
.	.	O

The	DT	O
mean	NN	PH
predicted	VBD	PH
AUC	NNP	PH
of	IN	PH
flunarizine	NN	PH
was	VBD	O
1230	CD	O
+/-	JJ	O
717	CD	O
ng	JJ	O
h	NN	O
mL-1	NN	O
,	,	O
whereas	IN	O
the	DT	O
observed	JJ	PH
AUC	NNP	PH
was	VBD	O
1203	CD	O
+/-	JJ	O
900	CD	O
ng	JJ	O
h	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	Ot
of	IN	Ot
the	DT	Ot
prediction	NN	Ot
was	VBD	O
2	CD	O
%	NN	O
and	CC	O
precision	NN	O
was	VBD	O
28	CD	O
%	NN	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	PH
Cmax	NNP	PH
of	IN	PH
flunarizine	NN	PH
was	VBD	O
86	CD	O
+/-	JJ	O
32	CD	O
ng	JJ	O
mL-1	NN	O
as	IN	O
compared	VBN	O
to	TO	O
an	DT	O
observed	JJ	PH
mean	NN	PH
Cmax	NNP	PH
of	IN	O
90	CD	O
+/-	JJ	O
42	CD	O
ng	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	Ot
and	CC	Ot
precision	NN	Ot
of	IN	Ot
the	DT	Ot
prediction	NN	Ot
were	VBD	O
4	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
method	NN	O
described	VBD	O
here	RB	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
for	IN	O
flunarizine	NN	O
without	IN	O
detailed	JJ	O
pharmacokinetic	JJ	O
studies	NNS	O
.	.	O

Barriers	NNS	O
to	TO	O
hypertension	NN	O
care	NN	O
and	CC	O
control	NN	O
in	IN	O
young	JJ	O
urban	JJ	O
black	JJ	O
men	NNS	O
.	.	O

Barriers	NNS	O
to	TO	O
high	JJ	PH
blood	NN	PH
pressure	NN	PH
(	(	O
HBP	NNP	O
)	)	O
care	NN	O
and	CC	O
control	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
for	IN	O
>	$	O
30	CD	O
years	NNS	O
.	.	O

Few	JJ	O
reports	NNS	O
on	IN	O
barriers	NNS	O
,	,	O
however	RB	O
,	,	O
have	VBP	O
focused	VBN	O
on	IN	O
the	DT	O
young	JJ	O
black	JJ	O
man	NN	O
with	IN	O
HBP	NNP	O
,	,	O
the	DT	O
age/sex/race	NN	O
group	NN	O
with	IN	O
the	DT	O
highest	JJS	O
rates	NNS	O
of	IN	O
early	JJ	O
severe	JJ	O
and	CC	O
complicated	JJ	O
HBP	NNP	O
and	CC	O
the	DT	O
lowest	JJS	O
rates	NNS	O
of	IN	O
awareness	NN	O
,	,	O
treatment	NN	O
,	,	O
and	CC	O
control	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
comprehensive	JJ	O
care	NN	O
for	IN	O
hypertensive	JJ	O
young	JJ	O
urban	JJ	O
black	JJ	O
men	NNS	O
,	,	O
factors	NNS	O
potentially	RB	O
associated	VBN	O
with	IN	O
care	NN	O
and	CC	O
control	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
for	IN	O
the	DT	O
309	CD	O
enrolled	VBD	O
men	NNS	O
.	.	O

A	DT	O
majority	NN	O
of	IN	O
the	DT	O
men	NNS	O
encountered	VBD	O
a	DT	O
variety	NN	O
of	IN	O
barriers	NNS	O
including	VBG	O
economic	JJ	O
,	,	O
social	JJ	O
,	,	O
and	CC	O
lifestyle	JJ	O
obstacles	NNS	O
to	TO	O
adequate	VB	O
BP	NNP	O
care	NN	O
and	CC	O
control	NN	O
,	,	O
including	VBG	O
no	DT	PH
current	JJ	PH
HBP	NNP	PH
care	NN	PH
(	(	O
49	CD	O
%	NN	O
)	)	O
,	,	O
risk	NN	PH
of	IN	PH
alcoholism	NN	PH
(	(	O
62	CD	O
%	NN	O
)	)	O
,	,	O
use	NN	PH
of	IN	PH
illicit	NN	PH
drugs	NNS	PH
(	(	O
45	CD	O
%	NN	O
)	)	O
,	,	O
social	JJ	ME
isolation	NN	ME
(	(	O
47	CD	O
%	NN	O
)	)	O
,	,	O
unemployment	NN	ME
(	(	O
40	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
lack	NN	ME
of	IN	ME
health	NN	ME
insurance	NN	ME
(	(	O
51	CD	O
%	NN	O
)	)	O
.	.	O

Having	VBG	ME
health	NN	ME
insurance	NN	ME
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
7.20	CD	O
,	,	O
P	NNP	O
=	NNP	O
.00	NNP	O
)	)	O
and	CC	O
a	DT	O
negative	JJ	PH
urine	JJ	PH
drug	NN	PH
screen	NN	PH
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
.56	NNP	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
were	VBD	O
significant	JJ	O
predictors	NNS	O
of	IN	O
being	VBG	O
in	IN	O
HBP	NNP	O
care	NN	O
.	.	O

Low	JJ	A
alcoholism	NN	A
risk	NN	A
and	CC	O
employment	NN	PH
were	VBD	O
identified	VBN	O
as	IN	O
significant	JJ	O
predictors	NNS	O
of	IN	O
compliance	NN	O
with	IN	O
HBP	NNP	O
medication-taking	JJ	O
behavior	NN	O
.	.	O

Men	NNP	O
currently	RB	O
using	VBG	ME
illicit	JJ	ME
drugs	NNS	ME
were	VBD	O
2.64	CD	O
times	NNS	O
less	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
controlled	VBN	PH
BP	NNP	PH
compared	VBN	O
with	IN	O
their	PRP$	O
counterparts	NNS	O
who	WP	O
did	VBD	O
not	RB	O
use	VB	O
illicit	JJ	O
drugs	NNS	O
,	,	O
and	CC	O
men	NNS	O
currently	RB	O
taking	VBG	PH
HBP	NNP	PH
medication	NN	PH
were	VBD	O
63	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
have	VBP	O
controlled	VBN	PH
BP	NNP	PH
compared	VBN	O
with	IN	O
men	NNS	O
not	RB	O
taking	VBG	O
HBP	NNP	O
medication	NN	O
.	.	O

Comprehensive	JJ	O
interventions	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
address	VB	O
socioeconomic	JJ	O
and	CC	O
lifestyle	JJ	O
issues	NNS	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
barriers	NNS	O
to	TO	O
care	VB	O
and	CC	O
treatment	NN	O
,	,	O
if	IN	O
HBP	NNP	O
care	NN	O
is	VBZ	O
to	TO	O
be	VB	O
salient	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
this	DT	O
high	JJ	O
risk	NN	O
group	NN	O
.	.	O

Topical	JJ	O
treatment	NN	O
of	IN	O
alopecia	NN	O
areata	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
previously	RB	O
that	IN	O
alopecia	JJ	O
areata	NNS	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
dinitrochlorobenzene	NN	O
(	(	O
DNCB	NNP	O
)	)	O
and	CC	O
other	JJ	O
contact	NN	O
allergens	NNS	O
.	.	O

Whether	IN	O
these	DT	O
agents	NNS	O
work	NN	O
by	IN	O
inducing	VBG	O
immunologic	JJ	O
stimulation	NN	O
or	CC	O
simply	RB	O
a	DT	O
nonspecific	JJ	O
inflammatory	NN	O
reaction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
definitively	RB	O
demonstrated	VBN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
these	DT	O
two	CD	O
mechanisms	NNS	O
,	,	O
we	PRP	O
have	VBP	O
randomly	RB	O
studied	VBN	O
22	CD	O
patients	NNS	O
with	IN	O
alopecia	JJ	O
areata	NNS	O
to	TO	O
whom	WP	O
either	DT	O
DNCB	NNP	O
or	CC	O
croton	VB	O
oil	NN	O
was	VBD	O
applied	VBN	O
topically	RB	O
.	.	O

Sixty-three	JJ	O
percent	NN	O
of	IN	O
patients	NNS	O
without	IN	O
spontaneous	JJ	O
regrowth	NN	PH
of	IN	PH
hair	NN	PH
regrew	NNS	PH
hair	NN	PH
after	IN	O
DNCB	NNP	O
application	NN	O
.	.	O

None	NN	PH
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
croton	NN	O
oil	NN	O
regrew	VBD	PH
hair	NN	PH
when	WRB	O
treated	VBN	O
later	RB	O
with	IN	O
DNCB	NNP	O
.	.	O

Therefore	NNP	O
,	,	O
a	DT	O
proved	JJ	O
contact	NN	O
allergen	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
required	VBN	O
for	IN	O
therapeutic	JJ	O
success	NN	O
.	.	O

Patient	JJ	ME
acceptance	NN	ME
of	IN	O
the	DT	O
induced	JJ	O
contact	NN	O
dermatitis	NN	O
was	VBD	O
excellent	JJ	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
recent	JJ	O
data	NNS	O
on	IN	O
the	DT	O
mutagenicity	NN	O
of	IN	O
DNCB	NNP	O
to	TO	O
bacteria	NNS	O
,	,	O
other	JJ	O
contact	NN	O
allergens	NNS	O
for	IN	O
topical	JJ	O
immunotherapy	NN	O
are	VBP	O
being	VBG	O
sought	VBN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
stage-of-change	NN	O
oriented	VBN	O
smoking	VBG	O
cessation	NN	O
intervention	NN	O
in	IN	O
infertile	NN	O
and	CC	O
pregnant	JJ	O
women	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
stage-of-change	NN	O
oriented	VBN	O
smoking	VBG	O
cessation	NN	O
intervention	NN	O
for	IN	O
infertile	NN	O
and	CC	O
pregnant	JJ	O
women	NNS	O
,	,	O
compared	VBN	O
with	IN	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	CD	O
university	NN	O
teaching	VBG	O
hospitals	NNS	O
in	IN	O
Hamilton	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Infertile	NNP	O
women	NNS	O
at	IN	O
their	PRP$	O
first	JJ	O
visit	NN	O
to	TO	O
a	DT	O
tertiary	JJ	O
referral	JJ	O
infertility	NN	O
clinic	NN	O
(	(	O
n	JJ	O
=	NNP	O
94	CD	O
)	)	O
and	CC	O
new	JJ	O
patients	NNS	O
seeking	VBG	O
pre-natal	JJ	O
care	NN	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
who	WP	O
had	VBD	O
smoked	VBN	O
>	NNP	O
/=	$	O
3	CD	O
cigarettes	NNS	O
in	IN	O
the	DT	O
past	JJ	O
six	CD	O
months	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
three	CD	O
to	TO	O
five	CD	O
minute	NN	O
scripted	VBN	O
intervention	NN	O
and	CC	O
booklet	NN	O
specific	NN	O
to	TO	O
the	DT	O
woman	NN	O
's	POS	O
stage-of-change	NN	O
in	IN	O
the	DT	O
smoking	NN	O
continuum	NN	O
,	,	O
versus	JJ	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

Exhaled	VBN	O
carbon-monoxide	NN	O
(	(	O
CO	NNP	O
)	)	O
monitoring	NN	O
was	VBD	O
used	VBN	O
to	TO	O
validate	VB	O
exposure	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Delta	NNP	ME
stage-of-change	NN	ME
and	CC	ME
rate	NN	ME
of	IN	ME
maintained	VBN	ME
cessation	NN	ME
at	IN	O
12	CD	O
months	NNS	O
post	VBN	O
follow-up	JJ	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Intervention	NNP	O
and	CC	O
control	NN	O
were	VBD	O
similarly	RB	O
effective	JJ	O
for	IN	O
infertile	JJ	O
women	NNS	O
:	:	O
the	DT	O
rate	NN	ME
of	IN	ME
maintained	VBN	ME
cessation	NN	ME
rose	VBD	O
significantly	RB	O
from	IN	O
4	CD	O
%	NN	O
to	TO	O
24	CD	O
%	NN	O
over	IN	O
twelve	JJ	O
months	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	PH
delta	NN	PH
stage-of-change	NN	PH
0.28	CD	O
.	.	O

In	IN	O
prenatal	JJ	O
women	NNS	O
,	,	O
neither	CC	O
approach	NN	O
was	VBD	O
effective	JJ	O
.	.	O

Maintained	VBN	Ot
cessation	NN	Ot
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
from	IN	O
0	CD	O
to	TO	O
12	CD	O
months	NNS	O
(	(	O
19	CD	O
%	NN	O
to	TO	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mean	JJ	Ot
delta	JJ	Ot
stage-of-change	NN	Ot
declined	VBN	O
by	IN	O
-0.62	NNP	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
For	IN	O
infertile	JJ	O
women	NNS	O
,	,	O
basic	JJ	O
information	NN	O
describing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
fertility	NN	O
,	,	O
along	IN	O
with	IN	O
exhaled	JJ	O
CO	NNP	O
monitoring	NN	O
and	CC	O
a	DT	O
more	RBR	O
intensive	JJ	O
intervention	NN	O
were	VBD	O
both	DT	O
highly	RB	O
effective	JJ	O
.	.	O

In	IN	O
pregnant	JJ	O
women	NNS	O
neither	CC	O
approach	NN	O
was	VBD	O
beneficial	JJ	O
,	,	O
with	IN	O
some	DT	O
evidence	NN	O
of	IN	O
post-partum	JJ	O
relapse	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
valproate	NN	O
for	IN	O
aggression	NN	O
in	IN	O
youth	NN	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
study	VB	O
valproate	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
aggression	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
30	CD	O
subjects	NNS	O
(	(	O
20	CD	O
boys	NNS	O
,	,	O
10	CD	O
girls	NNS	O
)	)	O
6-20	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
PDD	NNP	O
and	CC	O
significant	JJ	O
aggression	NN	O
were	VBD	O
randomized	VBN	O
and	CC	O
received	VBN	O
treatment	NN	O
with	IN	O
valproate	NN	O
(	(	O
VPA	NNP	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
PBO	NNP	O
)	)	O
for	IN	O
8	CD	O
weeks	NNS	O
as	IN	O
outpatients	NNS	O
.	.	O

Mean	NNP	PH
VPA	NNP	PH
trough	IN	PH
blood	NN	PH
levels	NNS	PH
were	VBD	O
75.5	CD	O
mcg/mL	NNS	O
at	IN	O
week	NN	O
4	CD	O
and	CC	O
77.8	CD	O
mcg/mL	NN	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

RESULTS	VB	O
No	DT	O
treatment	NN	O
difference	NN	O
was	VBD	O
observed	VBN	O
statistically	RB	O
between	IN	O
VPA	NNP	O
and	CC	O
PBO	NNP	O
groups	NNS	O
.	.	O

The	DT	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
--	:	ME
Community	NNP	ME
Scale	NNP	ME
(	(	ME
ABC-C	NNP	ME
)	)	ME
Irritability	NNP	ME
subscale	NN	ME
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.65	CD	O
)	)	O
,	,	O
and	CC	O
CGI	NNP	ME
--	:	ME
Improvement	NNP	ME
(	(	O
p	JJ	O
=	NNP	O
0.16	CD	O
)	)	O
and	CC	O
OAS	NNP	ME
(	(	O
p	JJ	O
=	NNP	O
0.96	CD	O
)	)	O
were	VBD	O
secondary	JJ	O
outcome	NN	O
measures	NNS	O
.	.	O

Increased	VBN	A
appetite	NN	A
and	CC	A
skin	NN	A
rash	NN	A
were	VBD	O
significant	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Only	RB	O
1	CD	O
subject	NN	O
was	VBD	O
dropped	VBN	O
from	IN	O
the	DT	O
study	NN	O
owing	VBG	O
to	TO	O
side	VB	O
effects	NNS	O
,	,	O
notably	RB	O
a	DT	O
spreading	NN	A
skin	NN	A
rash	NN	A
,	,	O
which	WDT	O
then	RB	O
resolved	VBD	O
spontaneously	RB	O
.	.	O

Two	CD	O
subjects	NNS	O
receiving	VBG	O
VPA	NNP	O
developed	VBD	O
increased	VBN	O
serum	NN	A
ammonia	NN	A
levels	NNS	A
,	,	O
one	CD	O
with	IN	O
an	DT	O
associated	JJ	O
parent	NN	O
report	NN	O
of	IN	O
slurred	JJ	ME
speech	NN	ME
and	CC	ME
mild	JJ	ME
cognitive	JJ	ME
slowing	NN	ME
.	.	O

Poststudy	NNP	O
,	,	O
of	IN	O
16	CD	O
VPA	NNP	O
and	CC	O
PBO	NNP	O
subjects	NNS	O
receiving	VBG	O
VPA	NNP	O
,	,	O
10	CD	O
subjects	NNS	O
demonstrated	VBD	O
sustained	JJ	PH
response	NN	PH
,	,	O
4	CD	O
of	IN	O
whom	WP	O
later	RB	O
attempted	VBN	O
taper	NN	O
,	,	O
with	IN	O
significant	JJ	O
relapse	NN	ME
of	IN	ME
aggression	NN	ME
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
negative	JJ	O
findings	NNS	O
can	MD	O
not	RB	O
be	VB	O
viewed	VBN	O
as	IN	O
conclusive	JJ	O
,	,	O
partly	RB	O
owing	VBG	O
to	TO	O
the	DT	O
large	JJ	O
placebo	NN	O
response	NN	O
,	,	O
subject	JJ	O
heterogeneity	NN	O
,	,	O
and	CC	O
size	NN	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

Larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
expand	VB	O
upon	IN	O
these	DT	O
findings	NNS	O
.	.	O

Brief	JJ	O
Report	NNP	O
:	:	O
social	JJ	ME
disability	NN	ME
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
results	NNS	O
from	IN	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
trials	NNS	O
.	.	O

There	EX	O
is	VBZ	O
growing	VBG	O
interest	NN	O
in	IN	O
measuring	VBG	O
social	JJ	ME
disability	NN	ME
as	IN	O
a	DT	O
core	NN	O
element	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
medication	NN	O
trials	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
secondary	JJ	O
analysis	NN	O
on	IN	O
the	DT	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
Social	NNP	ME
Withdrawal	NNP	ME
subscale	JJ	ME
using	VBG	O
data	NNS	O
from	IN	O
two	CD	O
federally-funded	JJ	O
,	,	O
multi-site	JJ	O
,	,	O
randomized	JJ	O
trials	NNS	O
with	IN	O
risperidone	NN	O
.	.	O

Study	NNP	O
1	CD	O
included	VBD	O
52	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
placebo	VB	O
and	CC	O
49	CD	O
subjects	NNS	O
to	TO	O
risperidone	VB	O
under	IN	O
double-blind	JJ	O
conditions	NNS	O
.	.	O

Study	NNP	O
2	CD	O
included	VBD	O
49	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
risperidone	VB	O
only	RB	O
and	CC	O
75	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
risperidone	VB	O
plus	JJ	O
parent	NN	O
training	NN	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
all	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
(	(	O
effect	NN	O
sizes	VBZ	O
ranging	VBG	O
from	IN	O
0.42	CD	O
to	TO	O
0.65	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
Social	NNP	O
Withdrawal	NNP	O
subscale	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
measure	NN	O
of	IN	O
social	JJ	ME
disability	NN	ME
in	IN	O
acute	JJ	O
treatment	NN	O
trials	NNS	O
.	.	O

Phonophoresis	NNP	O
versus	NN	O
topical	JJ	O
application	NN	O
of	IN	O
ketoprofen	NN	O
:	:	O
comparison	NN	O
between	IN	O
tissue	NN	O
and	CC	O
plasma	NN	O
levels	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Over	IN	O
the	DT	O
last	JJ	O
few	JJ	O
decades	NNS	O
,	,	O
application	NN	O
of	IN	O
ultrasound	NN	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
to	TO	O
enhance	VB	O
transdermal	JJ	O
transport	NN	O
of	IN	O
several	JJ	O
drugs	NNS	O
,	,	O
a	DT	O
method	NN	O
referred	VBD	O
to	TO	O
as	IN	O
phonophoresis	NN	O
.	.	O

The	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
examine	VB	O
the	DT	O
influence	NN	O
of	IN	O
ultrasound	NN	O
on	IN	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
humans	NNS	O
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
concentrations	NNS	O
found	VBD	O
after	IN	O
continuous	JJ	O
and	CC	O
pulsed	JJ	O
application	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Twenty-six	NNP	O
patients	NNS	O
with	IN	O
knee	NN	O
disorders	NNS	O
requiring	VBG	O
arthroscopy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

Just	NNP	O
before	IN	O
surgery	NN	O
,	,	O
phonophoresis	NN	O
of	IN	O
a	DT	O
ketoprofen	NN	O
gel	NN	O
(	(	O
Fastum	NNP	O
gel	NN	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
group	NN	O
A	NNP	O
using	VBG	O
continuous	JJ	O
ultrasound	NN	O
(	(	O
1	CD	O
MHz	NNP	O
,	,	O
1.5	CD	O
W/cm2	NNP	O
,	,	O
for	IN	O
5	CD	O
minutes	NNS	O
)	)	O
.	.	O

Group	NNP	O
B	NNP	O
received	VBD	O
the	DT	O
same	JJ	O
treatment	NN	O
but	CC	O
with	IN	O
pulsed	JJ	O
ultrasound	NN	O
(	(	O
100	CD	O
Hz	NNP	O
,	,	O
20	CD	O
%	NN	O
duty	NN	O
cycle	NN	O
)	)	O
.	.	O

Group	NNP	O
C	NNP	O
received	VBD	O
5	CD	O
minutes	NNS	O
of	IN	O
sham	NN	O
ultrasound	NN	O
with	IN	O
the	DT	O
ketoprofen	NN	O
gel	NN	O
.	.	O

The	DT	O
ultrasound	JJ	O
head	NN	O
was	VBD	O
moved	VBN	O
over	IN	O
a	DT	O
10-cm2	JJ	O
area	NN	O
using	VBG	O
small	JJ	O
,	,	O
continuous	JJ	O
,	,	O
circular	JJ	O
movements	NNS	O
.	.	O

Biopsies	NNS	O
of	IN	O
adipose	JJ	O
tissue	NN	O
and	CC	O
synovial	JJ	O
tissue	NN	O
were	VBD	O
taken	VBN	O
during	IN	O
surgery	NN	O
to	TO	O
evaluate	VB	PH
the	DT	PH
local	JJ	PH
penetration	NN	PH
of	IN	PH
the	DT	PH
drug	NN	PH
.	.	O

Blood	NN	O
samples	NNS	O
also	RB	O
were	VBD	O
collected	VBN	O
to	TO	O
determine	VB	Ot
whether	IN	Ot
ketoprofen	NN	Ot
entered	VBD	Ot
the	DT	Ot
systemic	JJ	Ot
circulation	NN	Ot
.	.	O

RESULTS	VB	O
The	DT	O
concentration	NN	PH
of	IN	PH
ketoprofen	NN	PH
in	IN	O
plasma	NN	O
was	VBD	O
negligible	JJ	O
in	IN	O
all	DT	O
3	CD	O
groups	NNS	O
.	.	O

The	DT	O
concentration	NN	PH
of	IN	PH
ketoprofen	NN	PH
in	IN	O
synovial	JJ	O
tissue	NN	O
differed	VBD	O
from	IN	O
that	IN	O
in	IN	O
fat	JJ	O
tissue	NN	O
.	.	O

A	DT	O
difference	NN	O
in	IN	O
concentration	NN	PH
of	IN	PH
ketoprofen	NN	PH
in	IN	O
synovial	JJ	O
tissue	NN	O
was	VBD	O
found	VBN	O
between	IN	O
group	NN	O
C	NNP	O
and	CC	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

The	DT	O
concentration	NN	PH
of	IN	PH
ketoprofen	NN	PH
in	IN	PH
fat	JJ	PH
tissue	NN	PH
and	CC	PH
synovial	JJ	PH
tissue	NN	PH
was	VBD	O
consistently	RB	O
higher	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

DISCUSSION	NNP	O
AND	CC	O
CONCLUSION	NNP	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
phonophoresis	NN	O
of	IN	O
ketoprofen	NN	O
allows	VBZ	O
the	DT	O
attainment	NN	O
of	IN	O
higher	JJR	O
local	JJ	O
concentrations	NNS	O
,	,	O
whereas	JJ	O
systemic	JJ	O
exposure	NN	O
is	VBZ	O
lower	JJR	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
sham	VB	O
phonopheresis	NN	O
,	,	O
ultrasound	NN	O
can	MD	O
increase	VB	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
ketoprofen	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
7-day	JJ	O
and	CC	O
14-day	JJ	O
proton	NN	O
pump	IN	O
inhibitor-containing	JJ	O
triple	JJ	O
therapy	NN	O
for	IN	O
Helicobacter	NNP	PH
pylori	JJ	PH
eradication	NN	PH
:	:	O
neither	CC	O
treatment	NN	O
duration	NN	O
provides	VBZ	O
acceptable	JJ	O
eradication	NN	O
rate	NN	O
in	IN	O
Korea	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
Although	IN	O
triple	JJ	O
combination	NN	O
therapy	NN	O
containing	VBG	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
and	CC	O
two	CD	O
antibiotics	NNS	O
is	VBZ	O
considered	VBN	O
as	IN	O
a	DT	O
standard	JJ	O
regimen	NN	O
for	IN	O
the	DT	O
first-line	JJ	O
anti-Helicobacter	JJ	O
pylori	NN	O
treatment	NN	O
,	,	O
there	EX	O
are	VBP	O
still	RB	O
debates	NNS	O
on	IN	O
the	DT	O
ideal	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	Ot
of	IN	O
7-day	JJ	O
and	CC	O
14-day	JJ	O
PPI-containing	JJ	O
triple	NN	O
therapy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
multicenter	NN	O
,	,	O
prospective	JJ	O
manner	NN	O
.	.	O

After	IN	O
upper	JJ	O
gastrointestinal	JJ	O
endoscopy	NN	O
,	,	O
H.	NNP	O
pylori-infected	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
gastric	JJ	O
ulcer	NN	O
and/or	VBZ	O
a	DT	O
duodenal	JJ	O
ulcer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
PAC7	NNP	O
group	NN	O
(	(	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
or	CC	O
equivalent	JJ	O
dose	NN	O
of	IN	O
other	JJ	O
PPIs	NNP	O
,	,	O
amoxicillin	NN	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
clarithromycin	VBZ	O
500	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
7	CD	O
days	NNS	O
)	)	O
or	CC	O
to	TO	O
a	DT	O
PAC14	NNP	O
group	NN	O
(	(	O
the	DT	O
same	JJ	O
regimen	NN	O
as	IN	O
the	DT	O
PAC7	NNP	O
group	NN	O
but	CC	O
for	IN	O
14	CD	O
days	NNS	O
)	)	O
.	.	O

H.	NNP	O
pylori	NN	O
status	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
(	(	PH
13	CD	PH
)	)	PH
C	NNP	PH
urea	JJ	PH
breath	NN	PH
test	NN	O
5	CD	O
weeks	NNS	O
after	IN	O
anti-ulcer	JJ	O
treatment	NN	O
completion	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
598	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
;	:	O
337	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
PAC7	NNP	O
group	NN	O
and	CC	O
261	CD	O
to	TO	O
the	DT	O
PAC14	NNP	O
group	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
baseline	NN	O
characteristics	NNS	O
.	.	O

The	DT	O
eradication	NN	O
rates	NNS	O
of	IN	O
the	DT	O
PAC7	NNP	O
group	NN	O
were	VBD	O
not	RB	O
inferior	JJ	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
PAC14	NNP	O
group	NN	O
in	IN	O
both	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
71.2	CD	O
%	NN	O
vs.	FW	O
75.5	CD	O
%	NN	O
)	)	O
and	CC	O
per-protocol	JJ	O
analysis	NN	O
(	(	O
83.6	CD	O
%	NN	O
vs.	FW	O
86.6	CD	O
%	NN	O
)	)	O
.	.	O

Incidences	NNS	O
of	IN	O
adverse	JJ	A
events	NNS	A
were	VBD	O
comparable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
7-day	JJ	O
PPI-containing	JJ	O
triple	JJ	O
anti-H.	JJ	O
pylori	NN	O
therapy	NN	O
is	VBZ	O
not	RB	O
inferior	JJ	O
to	TO	O
the	DT	O
14-day	JJ	O
therapy	NN	O
,	,	O
neither	CC	O
treatment	NN	O
duration	NN	O
provides	VBZ	O
acceptable	JJ	O
eradication	NN	Ot
rate	NN	Ot
reaching	VBG	O
90	CD	O
%	NN	O
in	IN	O
per-protocol	JJ	O
analysis	NN	O
.	.	O

New	NNP	O
combination	NN	O
regimen	NNS	O
with	IN	O
higher	JJR	O
efficacy	NN	O
should	MD	O
be	VB	O
developed	VBN	O
as	IN	O
a	DT	O
first-line	JJ	O
eradication	NN	O
therapy	NN	O
for	IN	O
H.	NNP	O
pylori	NN	O
in	IN	O
Korea	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
menopausal	NN	O
symptoms	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
with	IN	O
either	DT	O
exemestane	NN	O
or	CC	O
tamoxifen	NN	O
in	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
report	NN	O
of	IN	O
a	DT	O
Tamoxifen	NNP	O
Exemestane	NNP	O
Adjuvant	NNP	O
Multicenter	NNP	O
trial	NN	O
substudy	NN	O
.	.	O

PURPOSE	NNP	O
Hormonal	NNP	O
breast	NN	O
cancer	NN	O
treatment	NN	O
increases	NNS	O
menopausal	VBP	PH
symptoms	NNS	PH
in	IN	O
women	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
differences	NNS	O
between	IN	O
the	DT	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
either	DT	O
adjuvant	JJ	O
tamoxifen	NN	O
or	CC	O
exemestane	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Ten	NNP	O
common	JJ	O
symptoms	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
self-report	JJ	O
questionnaire	NN	O
administered	VBD	O
to	TO	O
1,614	CD	O
consecutive	JJ	O
patients	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
every	DT	O
3	CD	O
months	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
of	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
early	JJ	O
hormone	NN	O
receptor-positive	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
categorized	VBN	O
as	IN	O
none	NN	O
,	,	O
mild	NN	O
,	,	O
moderate	JJ	O
,	,	O
or	CC	O
severe	RB	O
.	.	O

A	DT	O
hot	JJ	PH
flash	NN	PH
score	NN	PH
was	VBD	O
calculated	VBN	O
at	IN	O
each	DT	O
time	NN	O
point	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
repeated-measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
.	.	O

Each	DT	O
time	NN	O
period	NN	O
was	VBD	O
tested	VBN	O
repeatedly	RB	O
against	IN	O
the	DT	O
baseline	NN	O
;	:	O
an	DT	O
overall	JJ	O
P	NNP	O
value	NN	O
was	VBD	O
assigned	VBN	O
for	IN	O
each	DT	O
reported	VBN	O
symptom	NN	O
.	.	O

RESULTS	NNP	O
Compliance	NNP	O
was	VBD	O
excellent	JJ	O
,	,	O
with	IN	O
7,286	CD	O
questionnaires	NNS	O
analyzed	VBN	O
.	.	O

Baseline	NNP	O
symptom	JJ	PH
prevalence	NN	O
ranged	VBD	O
from	IN	O
2	CD	O
%	NN	O
(	(	O
vaginal	JJ	O
bleeding	NN	O
)	)	O
to	TO	O
60	CD	O
%	NN	O
to	TO	O
70	CD	O
%	NN	O
(	(	O
bone/muscle	NN	PH
aches	NNS	PH
and	CC	O
low	JJ	PH
energy	NN	PH
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
vaginal	JJ	PH
bleeding	NN	PH
,	,	PH
mood	NN	ME
alteration	NN	ME
,	,	PH
or	CC	PH
low	JJ	PH
energy	NN	PH
.	.	O

Patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
had	VBD	O
significantly	RB	O
more	RBR	O
vaginal	JJ	PH
discharge	NN	PH
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Exemestane	NN	O
patients	NNS	O
reported	VBD	O
more	RBR	O
bone/muscle	NN	PH
aches	NNS	PH
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
vaginal	JJ	PH
dryness	NN	PH
(	(	O
P	NNP	O
=	NNP	O
.0004	NNP	O
)	)	O
,	,	O
and	CC	O
difficulty	NN	PH
sleeping	NN	PH
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
hot	JJ	PH
flash	NN	PH
score	NN	PH
peaked	VBD	O
at	IN	O
3	CD	O
months	NNS	O
and	CC	O
decreased	JJ	O
thereafter	NN	O
.	.	O

At	IN	O
12	CD	O
months	NNS	O
,	,	O
patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
mean	JJ	O
hot	JJ	PH
flash	NN	PH
score	NN	PH
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
,	,	O
with	IN	O
daily	JJ	O
hot	JJ	PH
flashes	NNS	PH
increasing	VBG	O
from	IN	O
baseline	NN	O
by	IN	O
33	CD	O
%	NN	O
compared	VBN	O
with	IN	O
a	DT	O
7	CD	O
%	NN	O
increase	NN	O
from	IN	O
baseline	NN	O
with	IN	O
exemestane	NN	O
.	.	O

CONCLUSION	NNP	O
At	IN	O
12	CD	O
months	NNS	O
,	,	O
exemestane	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
fewer	JJR	O
hot	JJ	PH
flashes	NNS	PH
and	CC	O
less	JJR	O
vaginal	JJ	PH
discharge	NN	PH
than	IN	O
tamoxifen	NN	O
,	,	O
but	CC	O
with	IN	O
more	JJR	O
vaginal	JJ	PH
dryness	NN	PH
,	,	O
bone/muscle	NN	PH
aches	NNS	PH
,	,	O
and	CC	O
difficulty	NN	ME
sleeping	NN	ME
.	.	O

Symptoms	NNS	O
were	VBD	O
common	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	O
safety	NN	Ot
of	IN	O
nifedipine	NN	O
sustained	VBN	O
release	NN	O
with	IN	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
primary	JJ	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
in	IN	O
South	NNP	O
Korea	NNP	O
;	:	O
Korean	NNP	O
Raynaud	NNP	O
study	NN	O
(	(	O
KOARA	NNP	O
study	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	Ot
and	CC	O
safety	NN	Ot
of	IN	O
nifedipine	NN	O
sustained	VBN	O
release	NN	O
(	(	O
nifedipine	JJ	O
SR	NNP	O
)	)	O
compared	VBN	O
with	IN	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
as	IN	O
treatment	NN	O
for	IN	O
primary	JJ	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
(	(	O
RP	NNP	O
)	)	O
in	IN	O
Korea	NNP	O
.	.	O

Primary	NNP	O
RP	NNP	O
were	VBD	O
screened	VBN	O
and	CC	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
nifedipine	JJ	O
SR	NNP	O
group	NN	O
(	(	O
Group	NNP	O
N	NNP	O
)	)	O
or	CC	O
the	DT	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
group	NN	O
(	(	O
Group	NNP	O
G	NNP	O
)	)	O
in	IN	O
the	DT	O
ratio	NN	O
of	IN	O
2:1	CD	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
treatment	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

We	PRP	O
observed	VBD	O
the	DT	O
percent	NN	PH
improvement	NN	PH
of	IN	PH
the	DT	PH
RP	NNP	PH
attack	NN	PH
rate	NN	PH
between	IN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
8-week	JJ	O
treatment	NN	O
.	.	O

Ninety-three	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

The	DT	O
percent	NN	O
improvement	NN	O
in	IN	O
Group	NNP	O
N	NNP	O
was	VBD	O
50.1	CD	O
%	NN	O
at	IN	O
8	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
31.0	CD	O
%	NN	O
in	IN	O
Group	NNP	O
G	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

No	DT	O
serious	JJ	A
adverse	JJ	A
events	NNS	A
occurred	VBD	O
,	,	O
and	CC	O
almost	RB	A
adverse	JJ	A
events	NNS	A
were	VBD	A
mild	JJ	A
and	CC	O
improved	VBN	O
without	IN	O
specific	JJ	O
treatment	NN	O
.	.	O

nifedipine	JJ	O
SR	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	Ot
than	IN	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
for	IN	O
treatment	NN	O
of	IN	O
primary	JJ	O
RP	NNP	O
in	IN	O
Korean	JJ	O
patients	NNS	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
tolerable	JJ	Ot
with	IN	O
primary	JJ	O
RP	NNP	O
patients	NNS	O
.	.	O

Automatic	JJ	O
detection	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
in	IN	O
digital	JJ	O
color	NN	O
fundus	NN	O
photographs	NN	O
.	.	O

The	DT	O
robust	JJ	O
detection	NN	O
of	IN	O
red	JJ	Ot
lesions	NNS	Ot
in	IN	O
digital	JJ	O
color	NN	O
fundus	NN	O
photographs	NN	O
is	VBZ	O
a	DT	O
critical	JJ	O
step	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
automated	JJ	O
screening	VBG	O
systems	NNS	O
for	IN	O
diabetic	JJ	O
retinopathy	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
,	,	O
a	DT	O
novel	NN	O
red	JJ	O
lesion	NN	O
detection	NN	O
method	NN	O
is	VBZ	O
presented	VBN	O
based	VBN	O
on	IN	O
a	DT	O
hybrid	JJ	O
approach	NN	O
,	,	O
combining	VBG	O
prior	JJ	O
works	NNS	O
by	IN	O
Spencer	NNP	O
et	CC	O
al	NN	O
.	.	O

(	(	O
1996	CD	O
)	)	O
and	CC	O
Frame	NNP	O
et	NNP	O
al	NN	O
.	.	O

(	(	O
1998	CD	O
)	)	O
with	IN	O
two	CD	O
important	JJ	O
new	JJ	O
contributions	NNS	O
.	.	O

The	DT	O
first	JJ	O
contribution	NN	O
is	VBZ	O
a	DT	O
new	JJ	O
red	JJ	O
lesion	NN	O
candidate	NN	O
detection	NN	O
system	NN	O
based	VBN	O
on	IN	O
pixel	JJ	O
classification	NN	O
.	.	O

Using	VBG	O
this	DT	O
technique	NN	O
,	,	O
vasculature	NN	Ot
and	CC	Ot
red	JJ	Ot
lesions	NNS	Ot
are	VBP	O
separated	VBN	O
from	IN	O
the	DT	O
background	NN	O
of	IN	O
the	DT	O
image	NN	O
.	.	O

After	IN	O
removal	NN	O
of	IN	O
the	DT	O
connected	JJ	O
vasculature	NN	O
the	DT	O
remaining	VBG	O
objects	NNS	O
are	VBP	O
considered	VBN	O
possible	JJ	O
red	JJ	O
lesions	NNS	O
.	.	O

Second	NNP	O
,	,	O
an	DT	O
extensive	JJ	O
number	NN	O
of	IN	O
new	JJ	O
features	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
those	DT	O
proposed	VBN	O
by	IN	O
Spencer-Frame	NNP	O
.	.	O

The	DT	O
detected	JJ	O
candidate	NN	O
objects	NNS	O
are	VBP	O
classified	VBN	O
using	VBG	O
all	DT	O
features	NNS	O
and	CC	O
a	DT	O
k-nearest	JJ	O
neighbor	NN	O
classifier	NN	O
.	.	O

An	DT	O
extensive	JJ	O
evaluation	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
test	NN	O
set	NN	O
composed	VBN	O
of	IN	O
images	NNS	O
representative	NN	O
of	IN	O
those	DT	O
normally	RB	O
found	VBN	O
in	IN	O
a	DT	O
screening	NN	O
set	NN	O
.	.	O

When	WRB	O
determining	VBG	O
whether	IN	O
an	DT	O
image	NN	O
contains	VBZ	O
red	JJ	PH
lesions	NNS	PH
the	DT	O
system	NN	O
achieves	VBZ	O
a	DT	O
sensitivity	NN	Ot
of	IN	O
100	CD	O
%	NN	O
at	IN	O
a	DT	O
specificity	NN	O
of	IN	O
87	CD	O
%	NN	O
.	.	O

The	DT	O
method	NN	O
is	VBZ	O
compared	VBN	O
with	IN	O
several	JJ	O
different	JJ	O
automatic	JJ	O
systems	NNS	O
and	CC	O
is	VBZ	O
shown	VBN	O
to	TO	O
outperform	VB	O
them	PRP	O
all	DT	O
.	.	O

Performance	NNP	Ot
is	VBZ	O
close	RB	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
human	JJ	O
expert	NN	O
examining	VBG	O
the	DT	O
images	NNS	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
.	.	O

Tailored	NNP	O
,	,	O
iterative	JJ	O
,	,	O
printed	JJ	O
dietary	JJ	O
feedback	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
group	NN	O
education	NN	O
in	IN	O
improving	VBG	O
dietary	JJ	O
behaviours	NNS	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	VBN	O
control	NN	O
trial	NN	O
in	IN	O
middle-aged	JJ	O
adults	NNS	O
with	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

BACKGROUND	NNP	O
Tailored	NNP	O
nutrition	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
non-tailored	JJ	O
materials	NNS	O
in	IN	O
changing	VBG	O
dietary	JJ	O
behaviours	NNS	O
,	,	O
particularly	RB	O
fat	JJ	O
intake	NN	O
and	CC	O
fruit	NN	O
and	CC	O
vegetable	JJ	O
intake	NN	O
.	.	O

But	CC	O
further	JJ	O
research	NN	O
examining	VBG	O
efficacy	NN	O
of	IN	O
tailored	JJ	O
nutrition	NN	O
education	NN	O
in	IN	O
comparison	NN	O
to	TO	O
other	JJ	O
nutrition	JJ	O
education	NN	O
methods	NNS	O
and	CC	O
across	IN	O
a	DT	O
wider	NN	O
range	NN	O
of	IN	O
dietary	JJ	O
behaviours	NNS	O
is	VBZ	O
needed	VBN	O
.	.	O

The	DT	O
Stages	NNPS	O
to	TO	O
Healthy	NNP	O
Eating	NNP	O
Patterns	NNP	O
Study	NNP	O
(	(	O
STEPs	NNP	O
)	)	O
was	VBD	O
an	DT	O
intervention	NN	O
study	NN	O
,	,	O
in	IN	O
middle-aged	JJ	O
adults	NNS	O
with	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
printed	VBN	O
,	,	O
tailored	VBN	O
,	,	O
iterative	JJ	O
dietary	JJ	O
feedback	NN	O
delivered	VBN	O
by	IN	O
mail	NN	O
in	IN	O
improving	VBG	O
short-term	JJ	O
dietary	JJ	O
behaviour	NN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
saturated	JJ	O
fat	NN	O
,	,	O
fruit	NN	O
,	,	O
vegetable	JJ	O
and	CC	O
grain	NN	O
and	CC	O
cereal	NN	O
intake	NN	O
.	.	O

METHODS	NNP	O
STEPs	NNP	O
was	VBD	O
a	DT	O
3-month	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
a	DT	O
pre	NN	O
and	CC	O
post-test	JJ	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
experimental	JJ	O
conditions	NNS	O
:	:	O
1	CD	O
)	)	O
tailored	VBN	O
,	,	O
iterative	JJ	O
,	,	O
printed	JJ	O
dietary	JJ	O
feedback	NN	O
(	(	O
TF	NNP	O
)	)	O
with	IN	O
three	CD	O
instalments	NNS	O
mail-delivered	JJ	O
over	IN	O
a	DT	O
3-month	JJ	O
period	NN	O
that	WDT	O
were	VBD	O
re-tailored	VBN	O
to	TO	O
most	RBS	O
recent	JJ	O
assessment	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
,	,	O
intention	NN	O
to	TO	O
change	VB	O
and	CC	O
assessment	NN	O
of	IN	O
self-adequacy	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
.	.	O

Tailoring	VBG	O
for	IN	O
dietary	JJ	O
intake	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
data	NNS	O
from	IN	O
a	DT	O
validated	JJ	O
63-item	JJ	O
combination	NN	O
FFQ	NNP	O
designed	VBN	O
for	IN	O
the	DT	O
purpose	JJ	O
2	CD	O
)	)	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
sessions	NNS	O
(	(	O
GE	NNP	O
)	)	O
:	:	O
consisting	NN	O
of	IN	O
two	CD	O
90-minute	JJ	O
dietitian-led	JJ	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
sessions	NNS	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
a	DT	O
wait-listed	JJ	O
control	NN	O
(	(	O
C	NNP	O
)	)	O
group	NN	O
who	WP	O
completed	VBD	O
the	DT	O
dietary	JJ	O
measures	NNS	O
and	CC	O
socio-demographic	JJ	O
questionnaires	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
3-months	JJ	O
later	NN	O
.	.	O

Dietary	NNP	O
outcome	NN	O
measures	NNS	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
saturated	JJ	ME
fat	JJ	ME
intake	NN	ME
(	(	ME
g	NN	ME
)	)	ME
,	,	O
and	CC	O
the	DT	O
intake	NN	ME
of	IN	ME
fruit	NN	ME
(	(	ME
serves	NNS	ME
)	)	ME
,	,	ME
vegetables	NNS	ME
(	(	ME
serves	NNS	ME
)	)	ME
,	,	ME
grain	NN	ME
and	CC	ME
cereals	NNS	ME
as	IN	O
total	JJ	ME
and	CC	ME
wholegrain	NN	ME
(	(	ME
serves	NNS	ME
)	)	ME
were	VBD	O
collected	VBN	O
using	VBG	O
7-day	JJ	O
estimated	VBN	O
dietary	JJ	O
records	NNS	O
.	.	O

Descriptive	JJ	O
statistics	NNS	O
,	,	O
paired	VBD	O
t-tests	NNS	O
and	CC	O
general	JJ	O
linear	JJ	O
models	NNS	O
adjusted	VBN	O
for	IN	O
baseline	NN	O
dietary	JJ	O
intake	NN	O
,	,	O
age	NN	O
and	CC	O
gender	NN	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
different	JJ	O
nutrition	NN	O
interventions	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
TF	NNP	O
group	NN	O
reported	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
increase	NN	O
in	IN	O
fruit	JJ	ME
intake	NN	ME
(	(	O
0.3	CD	O
serves/d	NN	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
GE	NNP	O
and	CC	O
the	DT	O
C	NNP	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
intervention	NN	O
groups	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
total	JJ	ME
saturated	JJ	ME
fat	JJ	ME
intake	NN	ME
.	.	O

GE	NNP	O
also	RB	O
had	VBD	O
a	DT	O
within-group	JJ	O
increase	NN	O
in	IN	O
mean	JJ	ME
vegetable	JJ	ME
intake	NN	ME
after	IN	O
3	CD	O
months	NNS	O
,	,	O
but	CC	O
this	DT	O
increase	NN	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
changes	NNS	O
in	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
printed	VBN	O
,	,	O
tailored	VBN	O
,	,	O
iterative	JJ	O
dietary	JJ	O
feedback	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
in	IN	O
improving	VBG	O
the	DT	O
short-term	JJ	O
fruit	NN	O
intake	VB	O
behaviour	NN	O
,	,	O
and	CC	O
as	IN	O
effective	JJ	O
in	IN	O
improving	VBG	O
saturated	VBN	O
fat	JJ	O
intake	NN	O
of	IN	O
middle-aged	JJ	O
adults	NNS	O
with	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

This	DT	O
showed	VBD	O
that	IN	O
a	DT	O
low-level	JJ	O
dietary	JJ	O
intervention	NN	O
could	MD	O
achieve	VB	O
modest	JJ	O
dietary	JJ	O
behaviour	NN	O
changes	NNS	O
that	WDT	O
are	VBP	O
of	IN	O
public	JJ	O
health	NN	O
significance	NN	O
.	.	O

Sunlight	JJ	O
exposure	NN	O
or	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
vitamin	JJ	O
D-deficient	JJ	O
non-western	JJ	O
immigrants	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

UNLABELLED	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
is	VBZ	O
very	RB	O
common	JJ	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
vitamin	NN	O
D	NNP	O
800	CD	O
IU/day	NNP	O
or	CC	O
100,000	CD	O
IU/3	JJ	O
months	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
.	.	O

Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
in	IN	O
improving	VBG	O
vitamin	NN	O
D	NNP	O
status	NN	O
and	CC	O
lowering	VBG	O
parathyroid	JJ	O
hormone	NN	O
levels	NNS	O
.	.	O

INTRODUCTION	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
(	(	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
<	VBD	O
25	CD	O
nmol/l	NN	O
)	)	O
is	VBZ	O
common	JJ	O
among	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
.	.	O

METHODS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
(	(	O
3	CD	O
)	)	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
advice	NN	O
is	VBZ	O
similar	JJ	O
with	IN	O
regard	NN	O
to	TO	O
serum	VB	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
concentrations	NNS	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
in	IN	O
11	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
The	DT	O
Netherlands	NNP	O
.	.	O

Non-western	JJ	O
immigrants	NNS	O
,	,	O
aged	VBN	O
18-65	CD	O
years	NNS	O
(	(	O
n	JJ	O
=	NNP	O
232	CD	O
)	)	O
and	CC	O
serum	$	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
<	$	O
25	CD	O
nmol/l	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
advice	NN	O
for	IN	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
6	CD	O
months	NNS	O
(	(	O
March-September	NNP	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
,	,	O
during	IN	O
treatment	NN	O
(	(	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
(	(	O
12	CD	O
months	NNS	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
multilevel	JJ	O
regression	NN	O
modelling	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intention-to-treat	JJ	O
analysis	NN	O
included	VBD	O
211	CD	O
persons	NNS	O
.	.	O

Baseline	NNP	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
was	VBD	O
22.5	CD	O
?	.	O
11.1	CD	O
nmol/l	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
mean	VBP	O
serum	JJ	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
increased	VBD	O
to	TO	O
53	CD	O
nmol/l	NNS	O
with	IN	O
800	CD	O
IU/day	NNP	O
,	,	O
to	TO	O
50.5	CD	O
nmol/l	NNS	O
with	IN	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
,	,	O
and	CC	O
to	TO	O
29.1	CD	O
nmol/l	NNS	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
(	(	O
supplementation	NN	O
vs	FW	O
sunshine	NN	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Serum	NNP	O
PTH	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
groups	NNS	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
more	RBR	O
in	IN	O
the	DT	O
supplementation	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
advised	JJ	O
sunlight	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
physical	JJ	O
performance	NN	O
and	CC	O
functional	JJ	O
limitations	NNS	O
.	.	O

CONCLUSION	NNP	O
Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
treating	VBG	O
vitamin	NN	O
D	NNP	O
deficiency	NN	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

Eltrombopag	NNP	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
(	(	O
RAISE	NNP	O
)	)	O
:	:	O
a	DT	O
6-month	JJ	O
,	,	O
randomised	VBN	O
,	,	O
phase	VB	O
3	CD	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
an	DT	O
oral	JJ	O
thrombopoietin	NN	O
receptor	NN	O
agonist	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
response	NN	PH
to	TO	O
once	RB	O
daily	JJ	O
eltrombopag	NNS	O
versus	VBP	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
immune	JJ	O
thrombocytopenia	NN	O
during	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
undertook	VBD	O
a	DT	O
phase	NN	O
3	CD	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
adults	NNS	O
with	IN	O
previously	RB	O
treated	VBN	O
immune	JJ	O
thrombocytopenia	NN	O
of	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
'	POS	O
duration	NN	O
who	WP	O
had	VBD	O
baseline	NN	O
platelet	NN	O
counts	VBZ	O
lower	JJR	O
than	IN	O
30,000	CD	O
per	IN	O
?L	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
(	(	O
in	IN	O
a	DT	O
2:1	CD	O
ratio	NN	O
)	)	O
treatment	NN	O
with	IN	O
local	JJ	O
standard	NN	O
of	IN	O
care	NN	O
plus	CC	O
50	CD	O
mg	NN	O
eltrombopag	NN	O
or	CC	O
matching	VBG	O
placebo	JJ	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
centrally	RB	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
schedule	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
baseline	JJ	O
platelet	NN	O
count	NN	O
(	(	O
?	.	O
15,000	CD	O
per	IN	O
?L	NN	O
)	)	O
,	,	O
use	NN	O
of	IN	O
treatment	NN	O
for	IN	O
immune	JJ	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
splenectomy	JJ	O
status	NN	O
.	.	O

Patients	NNS	O
,	,	O
investigators	NNS	O
,	,	O
and	CC	O
those	DT	O
assessing	VBG	O
data	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
allocation	NN	O
.	.	O

Dose	JJ	O
modifications	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
platelet	NN	PH
response	NN	PH
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
response	NN	O
to	TO	O
treatment	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
platelet	NN	O
count	NN	O
of	IN	O
50,000-400,000	CD	O
per	IN	O
?L	NN	O
)	)	O
weekly	NN	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
weeks	NNS	O
and	CC	O
at	IN	O
least	JJS	O
once	RB	O
every	DT	O
4	CD	O
weeks	NNS	O
thereafter	RB	O
;	:	O
the	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
odds	NNS	PH
of	IN	PH
response	NN	PH
to	TO	O
eltrombopag	VB	O
versus	NN	O
placebo	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00370331	NNP	O
.	.	O

FINDINGS	NNP	O
Between	NNP	O
Nov	NNP	O
22	CD	O
,	,	O
2006	CD	O
,	,	O
and	CC	O
July	NNP	O
31	CD	O
,	,	O
2007	CD	O
,	,	O
197	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
groups	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
135	CD	O
eltrombopag	NN	O
,	,	O
62	CD	O
placebo	NN	O
)	)	O
.	.	O

106	CD	O
(	(	O
79	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
responded	VBD	O
to	TO	O
treatment	NN	O
at	IN	O
least	JJS	O
once	RB	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
compared	VBN	O
with	IN	O
17	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
odds	NNS	O
of	IN	O
responding	VBG	O
were	VBD	O
greater	JJR	O
in	IN	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
throughout	IN	O
the	DT	O
6-month	JJ	O
treatment	NN	O
period	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
8?2	CD	O
,	,	O
99	CD	O
%	NN	O
CI	NNP	O
3?59-18?73	CD	O
;	:	O
p	CC	O
<	VB	O
0?0001	CD	O
)	)	O
.	.	O

37	CD	O
(	(	O
59	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
reduced	VBD	PH
concomitant	JJ	PH
treatment	NN	PH
versus	NN	O
ten	NN	O
(	(	O
32	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?016	NN	O
)	)	O
.	.	O

24	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
needed	VBN	O
rescue	NN	Ot
treatment	NN	Ot
compared	VBN	O
with	IN	O
25	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?001	NN	O
)	)	O
.	.	O

Three	NNP	O
(	(	O
2	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
had	VBD	O
thromboembolic	JJ	O
events	NNS	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
patients	NNS	O
on	IN	O
placebo	NN	O
.	.	O

Nine	NNP	O
(	(	O
7	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
and	CC	O
two	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
mild	VBN	O
increases	NNS	O
in	IN	O
alanine	JJ	O
aminotransferase	NN	O
concentration	NN	O
,	,	O
and	CC	O
five	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
(	(	O
vs	IN	O
none	NN	O
allocated	VBN	O
to	TO	O
placebo	VB	O
)	)	O
had	VBD	O
increases	NNS	O
in	IN	O
total	JJ	O
bilirubin	NN	O
.	.	O

Four	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
patients	NNS	O
taking	VBG	O
placebo	NN	O
had	VBD	O
serious	JJ	A
bleeding	VBG	A
events	NNS	A
,	,	O
compared	VBN	O
with	IN	O
one	CD	O
(	(	O
<	VB	O
1	CD	O
%	NN	O
)	)	O
patient	NN	O
treated	VBN	O
with	IN	O
eltrombopag	NN	O
.	.	O

INTERPRETATION	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
effective	JJ	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
could	MD	O
be	VB	O
particularly	RB	O
beneficial	JJ	O
for	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
not	RB	O
responded	VBN	O
to	TO	O
splenectomy	VB	O
or	CC	O
previous	JJ	O
treatment	NN	O
.	.	O

These	DT	O
benefits	NNS	O
should	MD	O
be	VB	O
balanced	VBN	O
with	IN	O
the	DT	O
potential	JJ	O
risks	NNS	O
associated	VBN	O
with	IN	O
eltrombopag	JJ	O
treatment	NN	O
.	.	O

FUNDING	NN	O
GlaxoSmithKline	NNP	O
.	.	O

A	DT	O
high	JJ	O
intake	NN	O
of	IN	O
trans	NNS	O
fatty	JJ	O
acids	NNS	O
has	VBZ	O
little	JJ	O
effect	NN	O
on	IN	O
markers	NNS	PH
of	IN	PH
inflammation	NN	PH
and	CC	PH
oxidative	JJ	PH
stress	NN	PH
in	IN	O
humans	NNS	O
.	.	O

Consumption	NN	O
of	IN	O
industrial	JJ	O
trans	NNS	O
fatty	JJ	O
acids	NNS	O
(	(	O
iTFA	NN	O
)	)	O
increases	VBZ	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
decreases	VBZ	O
HDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
is	VBZ	O
strongly	RB	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
changes	NNS	O
in	IN	O
circulating	VBG	O
cholesterol	NN	O
can	MD	O
not	RB	O
explain	VB	O
the	DT	O
entire	JJ	O
effect	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
studied	VBD	O
whether	IN	O
iTFA	NN	O
and	CC	O
conjugated	VBD	O
linoleic	JJ	O
acid	NN	O
(	(	O
CLA	NNP	O
)	)	O
affect	VBP	O
markers	NNS	PH
of	IN	PH
inflammation	NN	PH
and	CC	PH
oxidative	JJ	PH
stress	NN	PH
.	.	O

Sixty-one	CD	O
healthy	JJ	O
adults	NNS	O
consumed	VBD	O
each	DT	O
of	IN	O
3	CD	O
diets	NNS	O
for	IN	O
3	CD	O
wk	NN	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Diets	NNS	O
were	VBD	O
identical	JJ	O
except	IN	O
for	IN	O
7	CD	O
%	NN	O
of	IN	O
energy	NN	O
provided	VBN	O
by	IN	O
oleic	JJ	O
acid	NN	O
(	(	O
control	VB	O
diet	NN	O
)	)	O
,	,	O
iTFA	JJ	O
,	,	O
or	CC	O
CLA	NNP	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
3	CD	O
wk	NN	O
,	,	O
we	PRP	O
measured	VBD	O
plasma	JJ	O
inflammatory	JJ	O
markers	NNS	O
IL-6	NNP	O
,	,	O
C-reactive	NNP	O
protein	NN	O
,	,	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
receptors	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
(	(	O
TNF-RI	NNP	O
and	CC	O
-RII	NNP	O
)	)	O
,	,	O
monocyte	JJ	O
chemotactic	JJ	O
protein-1	NN	O
and	CC	O
E-selectin	NNP	O
,	,	O
and	CC	O
urinary	JJ	O
8-iso-PGF	NN	O
(	(	O
2?	CD	O
)	)	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
lipid	JJ	O
peroxidation	NN	O
.	.	O

Consumption	NN	O
of	IN	O
iTFA	NN	O
caused	VBD	O
4	CD	O
%	NN	O
lower	JJR	O
TNF-RI	NNP	O
concentrations	NNS	O
and	CC	O
6	CD	O
%	NN	O
higher	JJR	O
E-selectin	JJ	O
concentrations	NNS	O
compared	VBN	O
with	IN	O
oleic	JJ	O
acid	NN	O
(	(	O
control	NN	O
)	)	O
and	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
other	JJ	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

CLA	NNP	O
did	VBD	O
not	RB	O
significantly	RB	O
affect	JJ	O
inflammatory	NN	O
markers	NNS	O
.	.	O

The	DT	O
urine	JJ	O
concentration	NN	O
of	IN	O
8-iso-PGF	JJ	O
(	(	O
2?	CD	O
)	)	O
[	NN	O
geometric	JJ	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
]	NN	O
was	VBD	O
greater	JJR	O
after	IN	O
the	DT	O
iTFA	NN	O
[	VBZ	O
0.54	CD	O
(	(	O
0.48	CD	O
,	,	O
0.60	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
]	NN	O
and	CC	O
the	DT	O
CLA	NNP	O
[	NNP	O
1.2	CD	O
(	(	O
1.1	CD	O
,	,	O
1.3	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
]	NNP	O
diet	VBZ	O
periods	NNS	O
than	IN	O
after	IN	O
the	DT	O
control	NN	O
period	NN	O
[	VBD	O
0.45	CD	O
(	(	O
0.41	CD	O
,	,	O
0.50	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
]	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
high	JJ	O
intakes	NNS	O
of	IN	O
iTFA	NN	O
and	CC	O
CLA	NNP	O
did	VBD	O
not	RB	O
substantially	RB	O
affect	JJ	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
but	CC	O
they	PRP	O
increased	VBD	O
the	DT	O
urine	JJ	O
8-iso-PGF	JJ	O
(	(	O
2?	CD	O
)	)	O
concentration	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
this	DT	O
plays	VBZ	O
a	DT	O
major	JJ	O
role	NN	O
in	IN	O
the	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
iTFA	JJ	O
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
CVD	NNP	O
.	.	O

However	RB	O
,	,	O
more	JJR	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
the	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Wheelchair	NNP	O
skills	VBZ	O
training	NN	O
to	TO	O
improve	VB	O
confidence	NN	ME
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
wheelchair	NN	O
skills	NNS	O
training	VBG	O
on	IN	O
confidence	NN	ME
in	IN	O
older	JJR	O
adults	NNS	O
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

DESIGN	NNP	O
Parallel	NNP	O
group	NN	O
,	,	O
single-blind	JJ	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Research	NNP	O
laboratory	NN	O
in	IN	O
a	DT	O
rehabilitation	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
N=20	NNP	O
)	)	O
who	WP	O
were	VBD	O
community-living	JJ	O
older	JJR	O
adults	NNS	O
at	IN	O
least	JJS	O
65	CD	O
years	NNS	O
old	JJ	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
70y	CD	O
)	)	O
,	,	O
50	CD	O
%	NN	O
women	NNS	O
,	,	O
and	CC	O
who	WP	O
had	VBD	O
no	DT	O
experience	NN	O
of	IN	O
using	VBG	O
a	DT	O
wheelchair	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n=10	JJ	O
)	)	O
group	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
two	CD	O
1-hour	JJ	O
training	NN	O
sessions	NNS	O
that	WDT	O
followed	VBD	O
the	DT	O
Wheelchair	NNP	O
Skills	NNP	O
Training	NNP	O
Program	NNP	O
(	(	O
WSTP	NNP	O
)	)	O
protocol	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
single	JJ	O
socialization	NN	O
contact	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
Wheelchair	NNP	ME
Use	NNP	ME
Confidence	NNP	ME
Scale-Manual	JJ	ME
(	(	ME
WheelCon-M	NNP	ME
)	)	ME
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	ME
confidence	NN	ME
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
.	.	O

The	DT	O
WheelCon-M	NNP	O
is	VBZ	O
a	DT	O
self-report	JJ	O
questionnaire	NN	O
that	WDT	O
comprises	VBZ	O
65	CD	O
items	NNS	O
in	IN	O
6	CD	O
conceptual	JJ	O
areas	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
1-way	JJ	O
between-groups	JJ	O
analysis	NN	O
of	IN	O
covariance	NN	O
revealed	VBD	O
a	DT	O
significant	JJ	ME
difference	NN	ME
in	IN	O
postintervention	NN	Ot
WheelCon-M	JJ	Ot
scores	NNS	Ot
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
F1,17=10.9	NNP	O
,	,	O
P=.004	NNP	O
)	)	O
after	IN	O
controlling	VBG	O
for	IN	O
baseline	JJ	O
WheelCon-M	JJ	O
scores	NNS	O
.	.	O

A	DT	O
large	JJ	O
effect	NN	ME
size	NN	ME
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
partial	JJ	O
?	.	O
(	(	O
2	CD	O
)	)	O
=.39	NN	O
)	)	O
.	.	O

Secondary	JJ	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
WSTP	NNP	O
had	VBD	O
greater	JJR	O
effects	NNS	O
on	IN	O
confidence	NN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
maneuvering	VBG	O
around	IN	O
the	DT	O
physical	JJ	O
environment	NN	O
,	,	O
knowledge	NN	O
and	CC	O
problem	NN	O
solving	NN	O
,	,	O
advocacy	NN	O
,	,	O
and	CC	O
managing	VBG	O
emotions	NNS	O
than	IN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
performing	VBG	O
activities	NNS	O
and	CC	O
behaving	VBG	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

CONCLUSION	NNP	O
Two	CD	O
1-hour	JJ	O
WSTP	NNP	O
sessions	NNS	O
improve	VBP	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

Training	VBG	O
referential	JJ	O
communicative	JJ	O
skills	NNS	O
to	TO	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
reports	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
referential	JJ	O
communication	NN	O
training	NN	O
in	IN	O
individuals	NNS	O
formally	RB	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
20	CD	O
children	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
M	NNP	O
age	NN	O
=	VBD	O
14.3	CD	O
yr.	NN	O
,	,	O
SD	NNP	O
=	NNP	O
4.2	CD	O
;	:	O
6	CD	O
girls	NNS	O
,	,	O
14	CD	O
boys	NNS	O
)	)	O
in	IN	O
the	DT	O
role	NN	O
of	IN	O
speakers	NNS	O
and	CC	O
20	CD	O
control	NN	O
children	NNS	O
,	,	O
who	WP	O
acted	VBD	O
as	IN	O
listeners	NNS	O
.	.	O

They	PRP	O
were	VBD	O
all	DT	O
enrolled	VBN	O
in	IN	O
mainstream	JJ	O
compulsory	NN	O
education	NN	O
.	.	O

Inclusion/exclusion	NNP	O
criteria	NNS	O
were	VBD	O
defined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
ASD	NNP	O
,	,	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
additional	JJ	O
or	CC	O
associated	JJ	O
disability	NN	O
,	,	O
previous	JJ	O
training	NN	O
in	IN	O
referential	JJ	O
communication	NN	O
,	,	O
and	CC	O
any	DT	O
drug	NN	O
treatment	NN	O
.	.	O

Speakers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
(	(	O
trained	JJ	O
vs	NN	O
untrained	VBD	O
)	)	O
.	.	O

Linguistic	JJ	PH
age	NN	PH
,	,	ME
cognitive	JJ	PH
level	NN	PH
and	CC	PH
autistic	JJ	PH
symptoms	NNS	PH
were	VBD	O
analyzed	VBN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
the	DT	O
Peabody	NNP	ME
Picture	NNP	ME
Vocabulary	NNP	ME
Test	NNP	ME
(	(	ME
PPVT	NNP	ME
)	)	ME
,	,	ME
the	DT	ME
Wechsler	NNP	ME
Intelligence	NNP	ME
Scale	NNP	ME
(	(	ME
WISC-R	NNP	ME
or	CC	ME
WAIS-III	NNP	ME
)	)	ME
,	,	ME
and	CC	ME
the	DT	ME
Autistic	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
(	(	ME
ABC	NNP	ME
)	)	ME
.	.	ME

Communicative	JJ	ME
abilities	NNS	ME
were	VBD	O
analyzed	VBN	O
through	IN	O
two	CD	O
indexes	NNS	O
related	VBN	O
to	TO	O
message	VB	O
complexity	NN	O
and	CC	O
self-regulation	NN	O
.	.	O

The	DT	O
trained	JJ	O
group	NN	O
was	VBD	O
trained	VBN	O
in	IN	O
referential	JJ	O
communication	NN	O
tasks	NNS	O
(	(	O
task	NN	O
analysis	NN	O
,	,	O
role	NN	O
taking	NN	O
,	,	O
and	CC	O
task	JJ	O
evaluation	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
untrained	JJ	O
group	NN	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
communicative	JJ	O
game	NN	O
but	CC	O
without	IN	O
any	DT	O
specific	JJ	O
communicative	JJ	O
training	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
complexity	NN	PH
of	IN	PH
emitted	JJ	PH
messages	NNS	PH
had	VBD	O
improved	VBN	O
statistically	RB	O
significantly	RB	O
in	IN	O
the	DT	O
trained	JJ	O
group	NN	O
as	IN	O
an	DT	O
effect	NN	O
of	IN	O
training	NN	O
.	.	O

Ecological	JJ	O
referential	JJ	O
communication	NN	O
is	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
appropriate	JJ	O
paradigm	NN	O
for	IN	O
studying	VBG	O
the	DT	O
communicative	JJ	O
process	NN	O
and	CC	O
its	PRP$	O
products	NNS	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
develop	VB	O
and	CC	O
implement	VB	O
a	DT	O
training	NN	O
program	NN	O
focused	VBN	O
on	IN	O
those	DT	O
skills	NNS	O
in	IN	O
which	WDT	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
are	VBP	O
most	RBS	O
deficient	JJ	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	O
versus	NN	O
conventional-dose	JJ	O
antibiotic	JJ	O
treatment	NN	O
of	IN	O
bacteriuria	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
single-dose	JJ	O
antibiotic	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacteriuria	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
non-catheterized	JJ	O
elderly	JJ	O
women	NNS	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
conventional	JJ	O
7-10	JJ	O
day	NN	O
courses	NNS	O
of	IN	O
antibiotic	JJ	O
therapy	NN	O
.	.	O

Thirty-one	JJ	O
women	NNS	O
received	VBD	O
single-dose	JJ	O
treatment	NN	O
and	CC	O
22	CD	O
conventional-dose	JJ	O
treatment	NN	O
.	.	O

The	DT	O
cure	NN	Ot
rates	NNS	Ot
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
single-dose	JJ	O
treatments	NNS	O
were	VBD	O
52	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
cure	NN	Ot
rates	NNS	Ot
for	IN	O
the	DT	O
conventional-dose	JJ	O
treatments	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
were	VBD	O
59	CD	O
%	NN	O
and	CC	O
52	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
place	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
single-dose	JJ	O
antibiotic	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
selected	VBN	O
elderly	JJ	O
women	NNS	O
with	IN	O
bacteriuria	NN	O
,	,	O
but	CC	O
larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Anticholinergic	NNP	O
drugs	NNS	O
:	:	O
effects	NNS	O
on	IN	O
oxygen	NN	PH
consumption	NN	PH
and	CC	PH
energy	NN	PH
expenditure	NN	PH
.	.	O

Premedication	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
affect	VB	O
both	DT	O
oxygen	NN	PH
consumption	NN	PH
(	(	O
VO2	NNP	O
)	)	O
and	CC	O
energy	NN	PH
expenditure	NN	PH
(	(	O
EE	NNP	O
)	)	O
.	.	O

The	DT	O
metabolic	JJ	O
responses	NNS	O
to	TO	O
anticholinergic	VB	O
drugs	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
effects	NNS	O
of	IN	O
anticholinergic	JJ	O
drugs	NNS	O
on	IN	O
VO2	NNP	O
and	CC	O
EE	NNP	O
(	(	O
calculated	VBN	O
from	IN	O
the	DT	O
measured	VBN	O
rates	NNS	O
of	IN	O
VO2	NNP	O
and	CC	O
carbon	NN	O
dioxide	NN	O
production	NN	O
[	NNP	O
VCO2	NNP	O
]	NN	O
:	:	O
EE	NNP	O
[	NNP	O
kcal/d	NNP	O
]	NNP	O
=	VBD	O
3.581	CD	O
x	NNP	O
VO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
+	VBD	O
1.448	CD	O
x	NNP	O
VCO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
-	:	O
32.4	CD	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
six	CD	O
healthy	JJ	O
female	NN	O
volunteers	NNS	O
.	.	O

They	PRP	O
were	VBD	O
given	VBN	O
intramuscular	JJ	O
atropine	NN	O
(	(	O
15	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
glycopyrrolate	NN	O
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
scopolamine	NN	O
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
in	IN	O
a	DT	O
random	JJ	O
double-blind	JJ	O
cross-over	NN	O
design	NN	O
.	.	O

The	DT	O
consecutive	JJ	O
sessions	NNS	O
were	VBD	O
at	IN	O
least	JJS	O
1	CD	O
wk	JJ	O
apart	RB	O
for	IN	O
each	DT	O
subject	NN	O
.	.	O

VO2	NNP	PH
and	CC	PH
EE	NNP	PH
were	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
indirect	JJ	O
calorimetry	NN	O
(	(	O
Deltatrac	NNP	O
)	)	O
.	.	O

Cardiovascular	JJ	PH
responses	NNS	PH
were	VBD	O
assessed	VBN	O
using	VBG	O
standard	JJ	O
noninvasive	JJ	O
monitoring	NN	O
.	.	O

Plasma	NNP	PH
drug	NN	PH
concentrations	NNS	PH
were	VBD	O
analyzed	VBN	O
using	VBG	O
a	DT	O
sensitive	JJ	O
modification	NN	O
of	IN	O
radioreceptor	NN	O
assay	NN	O
.	.	O

Subjective	JJ	O
responses	NNS	O
were	VBD	O
measured	VBN	O
with	IN	O
visual	JJ	PH
analog	NN	PH
scale	NN	PH
(	(	PH
VAS	NNP	PH
)	)	PH
.	.	O

Atropine	NNP	O
and	CC	O
glycopyrrolate	NN	O
induced	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
heart	NN	PH
rate	NN	PH
with	IN	O
a	DT	O
simultaneous	JJ	O
decrease	NN	O
in	IN	O
pressure	NN	PH
rate	NN	PH
quotient	NN	PH
(	(	PH
PRQ	NNP	PH
)	)	PH
,	,	O
while	IN	O
scopolamine	NN	O
caused	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
heart	NN	PH
rate	NN	PH
with	IN	O
a	DT	O
simultaneous	JJ	O
increase	NN	PH
in	IN	PH
PRQ	NNP	PH
.	.	O

Scopolamine	NNP	O
significantly	RB	O
decreased	VBD	O
both	DT	O
VO2	NNP	PH
and	CC	PH
EE	NNP	PH
,	,	O
whereas	JJ	O
glycopyrrolate	NN	O
increased	VBD	O
VO2	NNP	PH
.	.	O

Atropine	NNP	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
metabolic	JJ	PH
variables	NNS	PH
.	.	O

Only	RB	O
scopolamine	NN	O
induced	JJ	O
sedation	NN	PH
in	IN	O
this	DT	O
study	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
atropine	NN	O
,	,	O
glycopyrrolate	NN	O
,	,	O
and	CC	O
scopolamine	NN	O
differ	NN	O
not	RB	O
only	RB	O
in	IN	O
their	PRP$	O
cardiovascular	NN	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
effects	NNS	O
,	,	O
but	CC	O
also	RB	O
in	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
metabolism	NN	O
.	.	O

Anti-angiogenic	JJ	O
effect	NN	O
of	IN	O
tamoxifen	NN	O
combined	VBN	O
with	IN	O
epirubicin	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

Vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
A	NNP	O
(	(	O
VEGF-A	NNP	O
)	)	O
and	CC	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
VEGFR2	NNP	O
)	)	O
are	VBP	O
the	DT	O
key	JJ	O
factors	NNS	O
mediating	VBG	O
neo-vascularization	NN	O
.	.	O

They	PRP	O
are	VBP	O
often	RB	O
coexpressed	VBN	O
in	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Sex	NNP	O
steroids	NNS	O
may	MD	O
stimulate	VB	O
angiogenesis	NN	O
via	IN	O
the	DT	O
estrogen	NN	O
receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
pathway	RB	O
.	.	O

We	PRP	O
investigated	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	O
to	TO	O
epirubicin	VB	O
versus	NN	O
epirubicin	FW	O
alone	RB	O
on	IN	O
VEGF	NNP	O
and	CC	O
VEGFR2	NNP	O
expression	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
VEGF	NNP	PH
and	CC	PH
VEGFR2	NNP	PH
was	VBD	O
assessed	VBN	O
on	IN	O
tissue	NN	O
microarray	NN	O
by	IN	O
immunohistochemistry	NN	O
at	IN	O
baseline	JJ	O
conditions	NNS	O
and	CC	O
after	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
191	CD	O
patients	NNS	O
with	IN	O
T2-4	NNP	O
N0-1	NNP	O
breast	NN	O
cancer	NN	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
four	CD	O
cycles	NNS	O
of	IN	O
single	JJ	O
agent	NN	O
epirubicin	NN	O
versus	NN	O
epirubicin	NN	O
plus	CC	O
tamoxifen	NN	O
as	IN	O
primary	JJ	O
systemic	JJ	O
treatment	NN	O
.	.	O

Epirubicin	NNP	O
alone	RB	O
failed	VBD	O
to	TO	O
induce	VB	O
changes	NNS	PH
in	IN	PH
VEGF	NNP	PH
expression	NN	PH
(	(	O
P	NNP	O
=	NNP	O
0.54	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	O
to	TO	O
epirubicin	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
VEGF	NNP	PH
expression	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

As	IN	O
a	DT	O
consequence	NN	O
,	,	O
baseline	NN	PH
VEGF	NNP	PH
had	VBD	O
a	DT	O
negative	JJ	O
prognostic	JJ	O
role	NN	O
in	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
epirubicin	JJ	O
alone	RB	O
but	CC	O
not	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
epirubicin	JJ	O
plus	CC	O
tamoxifen	JJ	O
(	(	O
interaction	JJ	O
test	NN	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

VEGFR2	NNP	PH
expression	NN	PH
increased	VBD	O
at	IN	O
residual	JJ	O
tumor	NN	O
histology	NN	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
,	,	O
with	IN	O
a	DT	O
lesser	JJR	O
extent	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
tamoxifen	JJ	O
plus	CC	O
epirubicin	JJ	O
.	.	O

Decrease	NNP	O
in	IN	O
VEGFR2	NNP	PH
expression	NN	PH
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
response	NN	PH
rate	NN	PH
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	O
to	TO	O
epirubicin	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
suppression	NN	Ot
of	IN	Ot
a	DT	Ot
key	JJ	Ot
angiogenic	JJ	Ot
pathway	NN	Ot
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
a	DT	O
potential	JJ	O
synergism	NN	O
of	IN	O
these	DT	O
two	CD	O
drugs	NNS	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
early	JJ	O
discharge	NN	O
after	IN	O
uncomplicated	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Out	IN	O
of	IN	O
383	CD	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
patients	NNS	O
aged	VBN	O
below	IN	O
70	CD	O
years	NNS	O
,	,	O
252	CD	O
(	(	O
66	CD	O
%	NN	O
)	)	O
were	VBD	O
judged	VBN	O
after	IN	O
the	DT	O
third	JJ	O
day	NN	O
in	IN	O
hospital	NN	O
to	TO	O
have	VB	O
had	VBN	O
uncomplicated	VBN	O
infarctions	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
at	IN	O
random	NN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
of	IN	O
which	WDT	O
was	VBD	O
given	VBN	O
treatment	NN	O
for	IN	O
8	CD	O
days	NNS	O
and	CC	O
the	DT	O
other	JJ	O
for	IN	O
15	CD	O
days	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mortality	NN	MO
,	,	O
morbidity	NN	Ot
or	CC	O
incapacity	NN	PH
for	IN	PH
work	NN	PH
could	MD	O
be	VB	O
detected	VBN	O
during	IN	O
the	DT	O
three-month	JJ	O
period	NN	O
of	IN	O
follow-up	NN	O
.	.	O

The	DT	O
findings	NNS	O
thus	RB	O
support	VBP	O
previous	JJ	O
conclusions	NNS	O
that	WDT	O
early	RB	O
discharge	VBP	O
from	IN	O
hospital	NN	O
after	IN	O
uncomplicated	JJ	O
MI	NNP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
the	DT	O
patient	NN	O
than	IN	O
later	RB	O
discharge	NN	O
.	.	O

Low	JJ	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
in	IN	O
anxiety	NN	ME
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
between-patient	JJ	O
trial	NN	O
comparing	VBG	O
two	CD	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
(	(	O
15	CD	O
and	CC	O
30	CD	O
mg	NN	O
)	)	O
with	IN	O
placebo	NN	O
,	,	O
each	DT	O
given	VBN	O
once	RB	O
daily	JJ	O
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
92	CD	O
outpatients	NNS	O
affected	VBN	O
by	IN	O
generalized	JJ	O
anxiety	NN	O
disorders	NNS	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
month	NN	O
,	,	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

After	IN	O
1-week	JJ	O
washout	NN	O
period	NN	O
47	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
ketazolam	VB	O
15	CD	O
mg	NN	O
,	,	O
and	CC	O
45	CD	O
to	TO	O
placebo	VB	O
for	IN	O
15	CD	O
days	NNS	O
(	(	O
first	JJ	O
period	NN	O
)	)	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
this	DT	O
period	NN	O
,	,	O
if	IN	O
the	DT	O
patient	NN	O
experienced	VBD	O
a	DT	O
decrease	NN	O
on	IN	O
the	DT	O
total	JJ	PH
Hamilton	NNP	PH
Anxiety	NNP	PH
Rating	NNP	PH
Scale	NNP	PH
(	(	PH
HAM-A	NNP	PH
)	)	PH
of	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
of	IN	O
basal	NN	O
value	NN	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
kept	VBN	O
unchanged	JJ	O
for	IN	O
a	DT	O
further	JJ	O
15	CD	O
days	NNS	O
,	,	O
otherwise	RB	O
15	CD	O
mg	NN	O
of	IN	O
ketazolam	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
previous	JJ	O
treatment	NN	O
(	(	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Anxiety	NN	O
was	VBD	O
rated	VBN	O
after	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
with	IN	O
the	DT	O
Italian	JJ	ME
HAM-A	NNP	ME
scale	NN	ME
and	CC	O
with	IN	O
a	DT	O
4-point	JJ	ME
scale	NN	ME
(	(	ME
patient	NN	ME
's	POS	ME
assessment	NN	ME
)	)	ME
.	.	ME

Seventy-eight	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
first	JJ	O
period	NN	O
and	CC	O
75	CD	O
the	DT	O
whole	NN	O
study	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
period	NN	O
the	DT	O
percentage	NN	O
of	IN	O
responders	NNS	O
was	VBD	O
almost	RB	O
identical	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
but	CC	O
during	IN	O
the	DT	O
second	JJ	O
period	NN	O
a	DT	O
further	JJ	O
slight	NN	O
improvement	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
early	JJ	O
placebo	NN	O
responders	NNS	O
,	,	O
while	IN	O
the	DT	O
HAM-A	NNP	Ot
score	NN	Ot
of	IN	O
patients	NNS	O
on	IN	O
ketazolam	NNS	O
continued	VBN	O
to	TO	O
improve	VB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Likewise	VB	O
a	DT	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
difference	NN	O
between	IN	O
treatments	NNS	O
was	VBD	O
observed	VBN	O
,	,	O
on	IN	O
the	DT	O
4-point	JJ	Ot
scale	NN	Ot
,	,	O
in	IN	O
the	DT	O
population	NN	O
as	IN	O
a	DT	O
whole	NN	O
(	(	O
end	NN	O
of	IN	O
first	JJ	O
period	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
responder	NN	O
patients	NNS	O
(	(	O
end	JJ	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Tolerability	NN	Ot
was	VBD	O
good	JJ	O
,	,	O
except	IN	O
in	IN	O
1	CD	O
patient	NN	O
on	IN	O
placebo	NN	O
,	,	O
who	WP	O
was	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
severe	JJ	PH
headache	NN	PH
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	O
fatty	JJ	O
acid	NN	O
ethyl	NN	O
esters	NNS	O
increases	VBZ	O
large	JJ	O
and	CC	O
small	JJ	O
artery	NN	O
elasticity	NN	PH
in	IN	O
obese	JJ	O
adults	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
.	.	O

Increased	VBN	O
arterial	JJ	O
stiffness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
enhanced	JJ	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
obese	JJ	O
individuals	NNS	O
.	.	O

Whether	NNP	O
n3	JJ	O
fatty	RB	O
acid	JJ	O
ethyl	NN	O
ester	NN	O
(	(	O
FAEE	NNP	O
)	)	O
supplementation	NN	O
improves	VBZ	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
obese	JJ	O
participants	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
carry	VB	O
out	RP	O
a	DT	O
12-wk	JJ	O
randomized	NN	O
,	,	O
single-blind	JJ	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
25	CD	O
%	NN	O
energy	NN	O
deficit	NN	O
weight	VBD	O
loss	NN	O
diet	NN	O
alone	RB	O
(	(	O
WL	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
WL	NNP	O
plus	CC	O
4	CD	O
g/d	NN	O
Omacor	NNP	O
(	(	O
46	CD	O
%	NN	O
EPA	NNP	O
and	CC	O
38	CD	O
%	NN	O
DHA	NNP	O
)	)	O
supplementation	NN	O
(	(	O
WL+FAEE	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
on	IN	O
arterial	JJ	O
elasticity	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Large	NNP	PH
(	(	PH
C1	NNP	PH
)	)	PH
and	CC	PH
small	JJ	PH
artery	NN	PH
elasticity	NN	PH
(	(	PH
C2	NNP	PH
)	)	PH
were	VBD	O
measured	VBN	O
by	IN	O
pulse	JJ	O
contour	NN	O
analysis	NN	O
of	IN	O
the	DT	O
radial	JJ	O
artery	NN	O
.	.	O

WL	NNP	O
alone	RB	O
reduced	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
in	IN	O
all	DT	O
)	)	O
body	NN	PH
weight	NN	PH
(	(	O
-3	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
cardiac	JJ	O
output	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
TG	NNP	O
concentration	NN	O
(	(	O
-25	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
homeostasis	NN	O
model	NN	O
assessment	NN	O
(	(	O
HOMA	NNP	O
)	)	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	VBD	PH
plasma	NN	PH
HDL	NNP	PH
cholesterol	NN	PH
(	(	O
+9	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	NN	O
(	(	O
+18	CD	O
%	NN	O
)	)	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
WL	NNP	O
alone	RB	O
did	VBD	O
not	RB	O
alter	VB	O
C1	NNP	O
and	CC	O
C2	NNP	O
.	.	O

The	DT	O
WL+FAEE	NNP	O
intervention	NN	O
significantly	RB	O
reduced	VBN	O
body	NN	O
weight	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	PH
(	(	O
-8	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	PH
(	(	O
-5	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
pulse	JJ	PH
pressure	NN	PH
(	(	O
-5	CD	O
%	NN	O
)	)	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
-8	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	PH
TG	NNP	PH
concentration	NN	PH
(	(	O
-36	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
HOMA	NNP	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	JJ	PH
stroke	NN	PH
volume	NN	PH
(	(	O
+3	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
+6	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	JJ	O
concentrations	NNS	O
(	(	O
+28	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
C1	NNP	O
(	(	O
+20	NNP	O
%	NN	O
)	)	O
and	CC	O
C2	NNP	O
(	(	O
+22	NNP	O
%	NN	O
)	)	O
artery	NN	O
elasticity	NN	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
systolic	JJ	PH
blood	NN	PH
pressure	NN	PH
,	,	O
heart	NN	PH
rate	NN	PH
,	,	O
plasma	NN	PH
TGs	NNP	PH
,	,	O
C1	NNP	PH
,	,	O
and	CC	O
C2	NNP	PH
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
WL+FAEE	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
WL	NNP	O
group	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	O
FAEEs	NNP	O
improves	VBZ	O
C1	NNP	PH
and	CC	O
C2	NNP	PH
independently	RB	O
of	IN	O
weight	JJ	PH
loss	NN	PH
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Blood	NNP	PH
purification	NN	PH
for	IN	O
critical	JJ	O
care	NN	O
medicine	NN	O
:	:	O
endotoxin	NN	O
adsorption	NN	O
.	.	O

Many	JJ	O
kinds	NNS	O
of	IN	O
blood	NN	O
purifying	VBG	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
since	IN	O
1979	CD	O
when	WRB	O
plasma	JJ	O
exchange	NN	O
with	IN	O
hollow-fiber	JJ	O
membranes	NNS	O
was	VBD	O
developed	VBN	O
.	.	O

These	DT	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
not	RB	O
only	RB	O
to	TO	O
the	DT	O
removal	NN	O
of	IN	O
toxic	JJ	O
substances	NNS	O
,	,	O
but	CC	O
also	RB	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
objective	JJ	O
diseases	NNS	O
and	CC	O
the	DT	O
removal	NN	O
of	IN	O
the	DT	O
factors	NNS	O
relating	VBG	O
to	TO	O
the	DT	O
associated	VBN	O
inflammation	NN	O
.	.	O

This	DT	O
article	NN	O
summarizes	VBZ	O
these	DT	O
methods	NNS	O
and	CC	O
their	PRP$	O
efficacies	NNS	O
for	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
,	,	O
especially	RB	O
those	DT	O
with	IN	O
severe	JJ	O
sepsis	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
endotoxin	NN	O
,	,	O
the	DT	O
main	JJ	O
cause	NN	O
of	IN	O
sepsis	NN	O
,	,	O
from	IN	O
the	DT	O
circulation	NN	O
using	VBG	O
polymyxin	NN	O
B	NNP	O
immobilized	VBD	O
fiber	NN	O
,	,	O
charcoal	NN	O
hemoperfusion	NN	O
,	,	O
and	CC	O
plasma	NN	O
or	CC	O
whole	JJ	O
blood	NN	O
exchange	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
proinflammatory	NN	O
cytokines	NNS	O
,	,	O
eicosanoides	NNS	O
,	,	O
and	CC	O
coagulative	JJ	O
factors	NNS	O
from	IN	O
the	DT	O
circulation	NN	O
in	IN	O
the	DT	O
human	JJ	O
body	NN	O
.	.	O

Continuous	JJ	O
hemofiltration	NN	O
or	CC	O
hemodiafiltration	NN	O
is	VBZ	O
the	DT	O
representative	JJ	O
technology	NN	O
.	.	O

The	DT	O
efficacy	NN	Ot
of	IN	O
these	DT	O
methods	NNS	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
but	CC	O
several	JJ	O
issues	NNS	O
remain	VBP	O
unresolved	JJ	O
.	.	O

All	DT	O
methods	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
sepsis	NN	O
are	VBP	O
discussed	VBN	O
with	IN	O
reference	NN	O
to	TO	O
treatment	NN	O
indications	NNS	Ot
,	,	O
efficacy	NN	Ot
,	,	O
and	CC	O
outcome	JJ	O
parameters	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
clinical	JJ	O
results	NNS	O
of	IN	O
endotoxin	JJ	O
removal	NN	O
with	IN	O
polymyxin	NN	O
B	NNP	O
immobilized	JJ	O
fiber	NN	O
are	VBP	O
summarized	VBN	O
in	IN	O
this	DT	O
article	NN	O
.	.	O

A	DT	O
randomised	JJ	O
open	JJ	O
multicentre	NN	O
comparative	JJ	O
trial	NN	O
of	IN	O
lamotrigine	NN	O
and	CC	O
carbamazepine	NN	O
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
or	CC	O
recurrent	JJ	O
epilepsy	NN	O
.	.	O

The	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
lamotrigine	NN	O
and	CC	O
carbamazepine	NN	O
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
untreated	JJ	O
,	,	O
newly	RB	O
diagnosed	VBN	O
or	CC	O
recurrent	JJ	O
partial	JJ	O
and/or	NN	O
generalised	VBD	O
tonic-clonic	JJ	O
seizures	NNS	O
,	,	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
open	JJ	O
,	,	O
multicentre	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
24	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
oral	JJ	O
lamotrigine	NN	O
100	CD	O
mg	NN	O
(	(	O
LTG	NNP	O
100	CD	O
,	,	O
n	RB	O
=	VBZ	O
115	CD	O
)	)	O
or	CC	O
200	CD	O
mg	NN	O
(	(	O
LTG	NNP	O
200	CD	O
,	,	O
n	RB	O
=	VBZ	O
111	CD	O
)	)	O
or	CC	O
carbamazepine	$	O
600	CD	O
mg	NN	O
(	(	O
CBZ	NNP	O
600	CD	O
,	,	O
n	RB	O
=	VBZ	O
117	CD	O
)	)	O
.	.	O

Efficacy	NN	Ot
measurements	NNS	Ot
were	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
,	,	O
although	IN	O
the	DT	O
higher	JJR	O
lamotrigine	NN	O
dose	NN	O
was	VBD	O
possibly	RB	O
most	RBS	O
effective	JJ	O
,	,	O
with	IN	O
60.4	CD	O
%	NN	O
completing	VBG	O
seizure	NN	O
free	JJ	O
compared	VBN	O
with	IN	O
51.3	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
54.7	CD	O
%	NN	O
(	(	O
CBZ	NNP	O
600	CD	O
)	)	O
.	.	O

Both	DT	O
dosage	NN	O
regimens	NNS	O
of	IN	O
lamotrigine	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	Ot
.	.	Ot

More	JJR	O
patients	NNS	O
on	IN	O
CBZ	NNP	O
600	CD	O
reported	VBD	O
adverse	JJ	A
experiences	NNS	A
,	,	O
66	CD	O
%	NN	O
versus	IN	O
53	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
58	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
,	,	O
and	CC	O
of	IN	O
these	DT	O
a	DT	O
greater	JJR	O
proportion	NN	O
were	VBD	O
attributed	VBN	O
to	TO	O
CBZ	NNP	O
600	CD	O
treatment	NN	O
,	,	O
53	CD	O
%	NN	O
versus	IN	O
23	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
28	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
the	DT	O
CBZ	NNP	O
600	CD	O
group	NN	O
required	VBD	O
a	DT	O
change	NN	O
in	IN	O
dose	NN	O
,	,	O
47	CD	O
%	NN	O
versus	IN	O
20	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
17	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
or	CC	O
withdrew	$	O
completely	RB	O
due	JJ	O
to	TO	O
adverse	JJ	A
experiences	NNS	A
,	,	O
10.3	CD	O
%	NN	O
versus	IN	O
4.3	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
4.5	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	A
experience	NN	A
leading	VBG	O
to	TO	O
withdrawal	VB	O
was	VBD	O
rash	NN	A
,	,	O
with	IN	O
approximately	RB	O
double	JJ	O
the	DT	O
proportion	NN	O
of	IN	O
reports	NNS	O
occurring	VBG	O
in	IN	O
patients	NNS	O
on	IN	O
CBZ	NNP	O
600	CD	O
(	(	O
5.1	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
lamotrigine	NN	O
(	(	O
1.7	CD	O
%	NN	O
on	IN	O
LTG	NNP	O
100	CD	O
and	CC	O
2.7	CD	O
%	NN	O
on	IN	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

Overall	JJ	O
lamotrigine	NN	O
appeared	VBD	O
equally	RB	O
effective	JJ	O
but	CC	O
better	RB	O
tolerated	VBD	O
compared	VBN	O
with	IN	O
carbamazepine	NN	O
.	.	O

Unpacking	VBG	O
attitude	JJ	O
certainty	NN	O
:	:	O
attitude	NN	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
.	.	O

Attitude	NNP	O
certainty	NN	O
has	VBZ	O
been	VBN	O
the	DT	O
subject	NN	O
of	IN	O
considerable	JJ	O
attention	NN	O
in	IN	O
the	DT	O
attitudes	NNS	O
and	CC	O
persuasion	NN	O
literature	NN	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
identifies	VBZ	O
2	CD	O
aspects	NNS	O
of	IN	O
attitude	NN	O
certainty	NN	O
and	CC	O
provides	VBZ	O
evidence	NN	O
for	IN	O
the	DT	O
distinctness	NN	O
of	IN	O
the	DT	O
constructs	NNS	O
.	.	O

Specifically	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
attitude	JJ	O
certainty	NN	O
can	MD	O
be	VB	O
conceptualized	VBN	O
,	,	O
and	CC	O
empirically	RB	O
separated	VBN	O
,	,	O
in	IN	O
terms	NNS	O
of	IN	O
attitude	NN	O
clarity	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	WDT	O
one	CD	O
knows	VBZ	O
what	WP	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
)	)	O
and	CC	O
attitude	JJ	O
correctness	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	IN	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
correct	JJ	O
or	CC	O
valid	JJ	O
)	)	O
.	.	O

Experiment	JJ	O
1	CD	O
uses	NNS	O
factor	NN	O
analysis	NN	O
and	CC	O
correlational	JJ	O
data	NNS	O
to	TO	O
provide	VB	O
evidence	NN	O
for	IN	O
viewing	VBG	O
attitude	JJ	ME
clarity	NN	ME
and	CC	O
attitude	NN	ME
correctness	NN	ME
as	IN	O
separate	JJ	O
constructs	NNS	O
.	.	O

Experiments	NNS	O
2	CD	O
and	CC	O
3	CD	O
demonstrate	NN	O
that	WDT	O
attitude	VBP	ME
clarity	NN	ME
and	CC	O
attitude	NN	ME
correctness	NN	ME
can	MD	O
have	VB	O
distinct	JJ	O
antecedents	NNS	O
(	(	O
repeated	VBN	O
expression	NN	O
and	CC	O
consensus	NN	O
feedback	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Experiment	JJ	O
4	CD	O
reveals	NNS	O
that	IN	O
these	DT	O
constructs	NNS	O
each	DT	O
play	VBP	ME
an	DT	ME
independent	JJ	ME
role	NN	ME
in	IN	ME
persuasion	NN	ME
and	CC	ME
resistance	NN	ME
situations	NNS	ME
.	.	O

As	IN	O
clarity	NN	O
and	CC	O
correctness	JJ	O
increase	NN	O
,	,	O
attitudes	VBZ	ME
become	VBP	ME
more	RBR	ME
resistant	JJ	ME
to	TO	O
counterattitudinal	JJ	O
persuasive	JJ	O
messages	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
existing	VBG	O
attitude	NN	O
strength	NN	O
literature	NN	O
.	.	O

Benefits	NNS	O
of	IN	O
adding	VBG	O
fluticasone	NN	O
propionate/salmeterol	NN	O
to	TO	O
tiotropium	VB	O
in	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
COPD	NNP	O
.	.	O

BACKGROUND	NNP	O
Combining	NNP	O
maintenance	NN	O
medications	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
may	MD	O
improve	VB	O
outcomes	NNS	O
in	IN	O
COPD	NNP	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
fluticasone/salmeterol	NN	O
(	(	O
FSC	NNP	O
)	)	O
(	(	O
250/50	CD	O
mcg	NN	O
twice	RB	O
daily	RB	O
)	)	O
when	WRB	O
added	VBN	O
to	TO	O
tiotropium	VB	O
(	(	O
18	CD	O
mcg	NN	O
once	RB	O
daily	RB	O
)	)	O
(	(	O
TIO	NNP	O
)	)	O
in	IN	O
subjects	NNS	O
with	IN	O
symptomatic	JJ	O
moderate	NN	O
to	TO	O
severe	VB	O
COPD	NNP	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
24-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
,	,	O
multi-center	NN	O
study	NN	O
.	.	O

Subjects	VBZ	O
40	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
cigarette	NN	O
smoking	VBG	O
history	NN	O
?10	JJ	O
pack-years	NNS	O
and	CC	O
with	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
COPD	NNP	O
and	CC	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
?40	NN	O
to	TO	O
?	.	O
80	CD	O
%	NN	O
of	IN	O
predicted	VBN	O
normal	JJ	O
and	CC	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
/FVC	NN	O
of	IN	O
?0.70	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Following	VBG	O
a	DT	O
4-week	JJ	O
treatment	NN	O
with	IN	O
open-label	JJ	O
TIO	NNP	O
18	CD	O
mcg	NN	O
once	RB	O
daily	JJ	O
,	,	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
to	TO	O
either	VB	O
the	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
250/50	CD	O
DISKUS	NNP	O
twice	RB	O
daily	RB	O
or	CC	O
matching	VBG	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
AM	NNP	O
pre-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
included	VBD	O
other	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
,	,	O
rescue	NN	O
albuterol	NN	O
use	NN	O
,	,	O
health	NN	O
status	NN	O
and	CC	O
exacerbations	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
to	TO	O
TIO	NNP	O
significantly	RB	O
improved	VBD	O
lung	JJ	O
function	NN	O
indices	NNS	O
including	VBG	O
AM	NNP	O
pre-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
2	CD	O
h	NN	O
post-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
AM	NNP	O
pre-dose	JJ	O
FVC	NNP	O
,	,	O
2	CD	O
h	NN	O
post-dose	JJ	O
FVC	NNP	O
and	CC	O
AM	NNP	O
pre-dose	JJ	O
IC	NNP	O
compared	VBN	O
with	IN	O
TIO	NNP	O
alone	RB	O
.	.	O

Furthermore	RB	O
,	,	O
this	DT	O
combination	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
TIO	VB	O
alone	RB	O
in	IN	O
reducing	VBG	O
rescue	NN	Ot
albuterol	NN	Ot
use	NN	Ot
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
health	NN	O
status	NN	O
or	CC	O
COPD	NNP	O
exacerbations	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
to	TO	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
treated	VBD	O
with	IN	O
TIO	NNP	O
significantly	RB	O
improves	VBZ	O
lung	JJ	O
function	NN	O
without	IN	O
increasing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

NCT00784550	NNP	O
.	.	O

Effect	NN	O
of	IN	O
daily	JJ	O
etidronate	NN	O
on	IN	O
the	DT	O
osteolysis	NN	O
of	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Progressive	NNP	O
bone	NN	O
disease	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
frequently	RB	O
leads	VBZ	O
to	TO	O
osteolysis	VB	O
,	,	O
bone	NN	O
resorption	NN	O
,	,	O
pathologic	JJ	O
fractures	NNS	O
,	,	O
vertebral	JJ	O
compression	NN	O
,	,	O
and	CC	O
hypercalcemia	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	NN	O
study	NN	O
in	IN	O
173	CD	O
newly	RB	O
diagnosed	VBN	O
multiple	JJ	O
myeloma	NN	O
patients	NNS	O
of	IN	O
etidronate	JJ	O
disodium	NN	O
(	(	O
EHDP	NNP	O
)	)	O
,	,	O
a	DT	O
diphosphonate	NN	O
compound	NN	O
that	WDT	O
reduces	VBZ	O
bone	NN	O
resorption	NN	O
by	IN	O
inhibiting	VBG	O
osteoclastic	JJ	O
activity	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
oral	JJ	O
EHDP	NNP	O
5	CD	O
mg/kg/d	NN	O
or	CC	O
placebo	NN	O
until	IN	O
death	NN	O
or	CC	O
discontinuation	NN	O
due	JJ	O
to	TO	O
intolerance	VB	O
or	CC	O
refusal	VB	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
vertebral	JJ	O
deformity	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
vertebral	JJ	O
index	NN	O
as	RB	O
well	RB	O
as	IN	O
height	NN	O
.	.	O

The	DT	O
frequency	NN	PH
of	IN	PH
pathologic	JJ	PH
fractures	NNS	PH
,	,	Ot
hypercalcemia	NN	PH
,	,	Ot
and	CC	Ot
bone	NN	Ot
pain	NN	Ot
was	VBD	O
regularly	RB	O
assessed	VBN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
size	NN	O
and	CC	O
number	NN	O
of	IN	O
osteolytic	JJ	O
lesions	NNS	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
melphalan	JJ	O
and	CC	O
prednisone	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
days	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
as	IN	O
the	DT	O
primary	JJ	O
chemotherapy	NN	O
for	IN	O
their	PRP$	O
disease	NN	O
.	.	O

Although	IN	O
the	DT	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
height	JJ	PH
loss	NN	PH
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
arms	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.98	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
bone	NN	PH
pain	NN	PH
,	,	PH
episodes	NNS	PH
of	IN	PH
hypercalcemia	NN	PH
,	,	PH
or	CC	PH
development	NN	PH
of	IN	PH
pathologic	JJ	PH
fractures	NNS	PH
.	.	PH

Patients	NNS	O
on	IN	O
EHDP	NNP	O
showed	VBD	O
less	JJR	O
deterioration	NN	PH
in	IN	PH
their	PRP$	PH
vertebral	JJ	PH
index	NN	PH
,	,	O
but	CC	O
this	DT	O
difference	NN	O
only	RB	O
approached	VBD	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
.07	NNP	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
EHDP	NNP	O
therapy	NN	O
used	VBN	O
in	IN	O
this	DT	O
dosage	NN	O
schedule	NN	O
does	VBZ	O
not	RB	O
have	VB	O
a	DT	O
clinically	RB	O
significant	JJ	O
impact	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Bevacizumab	NNP	O
compared	VBN	O
with	IN	O
macular	JJ	O
laser	NN	O
grid	JJ	O
photocoagulation	NN	O
for	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
in	IN	O
branch	JJ	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

INTRODUCTION	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
outcome	NN	O
of	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
treated	VBN	O
with	IN	O
intravitreal	JJ	O
injections	NNS	O
of	IN	O
bevacizumab	NN	O
and	CC	O
macular	JJ	O
grid	NN	O
laser	NN	O
photocoagulation	NN	O
(	(	O
GLP	NNP	O
)	)	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
perfused	JJ	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
eyes	NNS	O
of	IN	O
30	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
secondary	JJ	O
to	TO	O
nonischemic	JJ	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
GLP	NNP	O
group	NN	O
or	CC	O
to	TO	O
intravitreal	VB	O
bevacizumab	NN	O
(	(	O
IB	NNP	O
)	)	O
group	NN	O
.	.	O

Complete	NNP	PH
ophthalmologic	JJ	PH
examinations	NNS	PH
were	VBD	O
performed	VBN	O
just	RB	O
before	IN	O
GLP	NNP	O
and	CC	O
IB	NNP	O
injection	NN	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
.	.	O

Changes	NNS	O
in	IN	O
logarithm	NN	PH
of	IN	PH
minimum	JJ	PH
angle	NN	PH
of	IN	PH
resolution	NN	PH
(	(	PH
logMAR	JJ	PH
)	)	PH
best-corrected	JJ	PH
visual	JJ	PH
acuity	NN	PH
(	(	PH
BCVA	NNP	PH
)	)	PH
,	,	PH
central	JJ	PH
macular	JJ	PH
thickness	NN	PH
(	(	PH
CMT	NNP	PH
)	)	PH
shown	VBN	PH
by	IN	PH
optical	JJ	PH
coherence	NN	PH
tomography-3	NN	PH
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	PH
BCVA	NNP	PH
(	(	PH
logMAR	NN	PH
)	)	PH
and	CC	PH
CMT	NNP	PH
were	VBD	O
,	,	O
respectively	RB	O
,	,	O
0.89	CD	O
+/-	JJ	O
0.13	CD	O
and	CC	O
650	CD	O
+/-	JJ	O
140	CD	O
microm	NN	O
for	IN	O
the	DT	O
GLP	NNP	O
group	NN	O
,	,	O
0.87	CD	O
+/-	JJ	O
0.16	CD	O
and	CC	O
690	CD	O
+/-	JJ	O
120	CD	O
microm	NN	O
for	IN	O
the	DT	O
IB	NNP	O
group	NN	O
.	.	O

After	IN	O
the	DT	O
treatment	NN	O
,	,	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
in	IN	O
the	DT	O
GLP	NNP	O
group	NN	O
,	,	O
BCVA	NNP	PH
had	VBD	O
improved	VBN	O
by	IN	O
0.19	CD	O
,	,	O
0.22	CD	O
,	,	O
0.21	CD	O
,	,	O
and	CC	O
0.20	CD	O
logMAR	NN	O
,	,	O
CMT	NNP	PH
had	VBD	O
decreased	VBN	O
by	IN	O
40	CD	O
%	NN	O
,	,	O
41.3	CD	O
%	NN	O
,	,	O
40.5	CD	O
%	NN	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
.	.	O

In	IN	O
the	DT	O
IB	NNP	O
group	NN	O
,	,	O
BCVA	NNP	PH
had	VBD	O
improved	VBN	O
by	IN	O
0.31	CD	O
,	,	O
0.32	CD	O
,	,	O
0.30	CD	O
,	,	O
and	CC	O
0.31	CD	O
logMAR	NN	PH
and	CC	O
CMT	NNP	PH
had	VBD	O
decreased	VBN	O
by	IN	O
59.5	CD	O
%	NN	O
,	,	O
59	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
,	,	O
and	CC	O
60.3	CD	O
%	NN	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
bevacizumab	NN	O
had	VBD	O
better	JJR	O
BCVA	NNP	PH
and	CC	O
lower	JJR	O
CMT	NNP	PH
values	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Intravitreal	NNP	O
bevacizumab	NN	O
injection	NN	O
improves	VBZ	O
BCVA	NNP	PH
and	CC	O
reduces	NNS	O
CMT	NNP	PH
more	JJR	O
than	IN	O
GLP	NNP	O
.	.	O

Intravitreal	NNP	O
bevacizumab	JJ	O
injection	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
primary	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
secondary	JJ	O
to	TO	O
perfused	VBN	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

Emotional	JJ	ME
reactivity	NN	ME
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
among	IN	O
persons	NNS	O
with	IN	O
borderline	JJ	O
personality	NN	O
features	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
emotional	JJ	ME
reactivity	NN	ME
of	IN	O
persons	NNS	O
with	IN	O
heightened	JJ	O
borderline	NN	O
personality	NN	O
(	(	O
BP	NNP	O
)	)	O
features	VBZ	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
in	IN	O
the	DT	O
laboratory	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
BP	NNP	O
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
and	CC	O
controls	NNS	O
with	IN	O
low	JJ	O
levels	NNS	O
of	IN	O
BP	NNP	O
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
44	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
writing	NN	ME
(	(	O
negative	JJ	O
evaluation/academic	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
personal	JJ	ME
characteristics	NNS	ME
as	RB	O
well	RB	O
as	IN	O
social	JJ	ME
rejection	NN	ME
(	(	ME
negative	JJ	ME
evaluation/social	JJ	ME
rejection	NN	ME
)	)	ME
.	.	O

Hypothesis	$	O
1	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
,	,	O
but	CC	O
not	RB	O
low-BP	JJ	O
controls	NNS	O
,	,	O
would	MD	O
show	VB	O
greater	JJR	O
emotional	JJ	ME
reactivity	NN	ME
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
(	(	O
writing	VBG	O
)	)	O
stressor	NN	O
.	.	O

Hypothesis	$	O
2	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
would	MD	O
specifically	RB	O
show	VB	O
greater	JJR	O
reactivity	NN	ME
of	IN	ME
shame-	JJ	ME
and	CC	ME
anger-related	JJ	ME
emotions	NNS	ME
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
stressor	NN	O
.	.	O

Findings	NNS	O
indicated	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
showed	VBD	O
heightened	VBN	ME
emotional	JJ	ME
reactivity	NN	ME
to	TO	O
the	DT	O
social	JJ	O
rejection	NN	O
stressor	NN	O
but	CC	O
not	RB	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation	NN	O
stressor	NN	O
,	,	O
but	CC	O
the	DT	O
opposite	JJ	O
pattern	NN	O
occurred	VBD	O
for	IN	O
controls	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
evidence	NN	O
for	IN	O
heightened	JJ	ME
reactivity	NN	ME
of	IN	ME
irritability	NN	ME
,	,	ME
distress	NN	ME
,	,	ME
and	CC	ME
shame	NN	ME
for	IN	O
the	DT	O
high-BP	JJ	O
group	NN	O
,	,	O
specifically	RB	O
in	IN	O
the	DT	O
social	JJ	O
rejection	NN	O
condition	NN	O
.	.	O

Nutrient	JJ	O
retention	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
fed	VBN	O
standard	JJ	O
infant	NN	O
formulas	NN	O
.	.	O

Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
compare	VB	PH
nitrogen	NN	PH
,	,	PH
mineral	NN	PH
,	,	PH
and	CC	PH
zinc	NN	PH
balance	NN	PH
in	IN	O
preterm	JJ	O
infants	NNS	O
fed	VBN	O
standard	JJ	O
infant	NN	O
formulas	NNS	O
,	,	O
Similac	NNP	O
With	IN	O
Iron	NNP	O
and	CC	O
Similac	NNP	O
With	IN	O
Whey	NNP	O
+	NNP	O
Iron	NNP	O
.	.	O

Nitrogen	NNP	PH
and	CC	PH
magnesium	NN	PH
balances	NNS	PH
were	VBD	O
similar	JJ	O
during	IN	O
both	DT	O
feeds	NNS	O
,	,	O
and	CC	O
met	VBD	O
estimated	VBN	O
fetal	JJ	O
requirements	NNS	O
.	.	O

Infants	NNS	O
absorbed	VBD	O
and	CC	O
retained	VBD	O
(	(	O
milligrams	FW	O
per	IN	O
kilogram	FW	O
per	IN	O
day	NN	O
)	)	O
more	JJR	O
calcium	NN	PH
,	,	PH
phosphorus	NN	PH
,	,	PH
and	CC	PH
zinc	NN	PH
when	WRB	O
fed	VBN	O
Similac	NNP	O
With	IN	O
Iron	NNP	O
.	.	O

However	RB	O
,	,	O
retention	NN	PH
of	IN	PH
calcium	NN	PH
,	,	PH
phosphorus	NN	PH
(	(	PH
both	DT	PH
formulas	NN	PH
)	)	PH
,	,	PH
and	CC	PH
zinc	NN	PH
(	(	O
Similac	NNP	O
With	IN	O
Whey	NNP	O
+	NNP	O
Iron	NNP	O
)	)	O
was	VBD	O
inadequate	JJ	O
to	TO	O
meet	VB	O
estimated	JJ	O
fetal	JJ	O
requirements	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
important	JJ	O
in	IN	O
the	DT	O
rapidly	RB	O
growing	VBG	O
preterm	JJ	O
infant	NN	O
,	,	O
who	WP	O
is	VBZ	O
already	RB	O
at	IN	O
risk	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
rickets	NNS	O
and	CC	O
zinc	NN	O
deficiency	NN	O
and	CC	O
may	MD	O
be	VB	O
fed	VBN	O
either	DT	O
formula	NN	O
on	IN	O
discharge	NN	O
from	IN	O
the	DT	O
newborn	JJ	O
nursery	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
sclerotherapy	NN	O
with	IN	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
for	IN	O
the	DT	O
emergency	NN	O
control	NN	PH
of	IN	PH
bleeding	VBG	PH
from	IN	O
esophageal	JJ	O
varices	NNS	O
.	.	O

We	PRP	O
compared	VBN	O
two	CD	O
procedures	NNS	O
for	IN	O
the	DT	O
emergency	NN	O
treatment	NN	O
of	IN	O
bleeding	VBG	PH
esophageal	JJ	O
varices	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
blood	VB	O
transfusion	NN	O
and	CC	O
vasoactive	JJ	O
drugs	NNS	O
.	.	O

We	PRP	O
randomly	VBP	O
assigned	VBD	O
101	CD	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
of	IN	O
the	DT	O
liver	NN	O
and	CC	O
bleeding	VBG	O
esophageal	JJ	O
varices	NNS	O
to	TO	O
undergo	VB	O
either	DT	O
emergency	NN	O
sclerotherapy	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Four	CD	O
patients	NNS	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	O
and	CC	O
12	CD	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
did	VBD	O
not	RB	O
actually	RB	O
undergo	VBP	O
those	DT	O
procedures	NNS	O
,	,	O
but	CC	O
all	DT	O
analyses	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
.	.	O

Total	JJ	MO
mortality	NN	MO
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
;	:	O
the	DT	O
relative	JJ	MO
risk	NN	MO
of	IN	MO
death	NN	MO
for	IN	O
staple	JJ	O
transection	NN	O
as	IN	O
compared	VBN	O
with	IN	O
sclerotherapy	NN	O
was	VBD	O
0.88	CD	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.51	CD	O
to	TO	O
1.54	CD	O
)	)	O
.	.	O

Mortality	NN	MO
at	IN	O
six	CD	O
weeks	NNS	O
was	VBD	O
44	CD	O
percent	NN	O
among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	O
and	CC	O
35	CD	O
percent	NN	O
among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
.	.	O

Complication	NN	PH
rates	NNS	PH
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

An	DT	O
interval	NN	PH
of	IN	PH
five	CD	PH
days	NNS	PH
without	IN	PH
bleeding	NN	PH
was	VBD	O
achieved	VBN	O
in	IN	O
88	CD	O
percent	NN	O
of	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
and	CC	O
in	IN	O
62	CD	O
percent	NN	O
of	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	O
after	IN	O
a	DT	O
single	JJ	O
injection	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
82	CD	O
percent	NN	O
after	IN	O
three	CD	O
injections	NNS	O
.	.	O

In	IN	O
only	RB	O
2	CD	O
of	IN	O
the	DT	O
11	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
a	DT	O
third	JJ	O
sclerotherapy	NN	O
injection	NN	O
was	VBD	O
bleeding	VBG	PH
controlled	VBN	PH
for	IN	O
more	JJR	O
than	IN	O
five	CD	O
days	NNS	O
,	,	O
and	CC	O
9	CD	O
died	VBD	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
is	VBZ	O
as	RB	O
safe	JJ	Ot
as	IN	Ot
sclerotherapy	NN	Ot
for	IN	O
the	DT	O
emergency	NN	PH
treatment	NN	PH
of	IN	PH
bleeding	VBG	PH
esophageal	JJ	O
varices	NNS	O
and	CC	O
that	IN	O
it	PRP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
a	DT	O
single	JJ	O
sclerotherapy	NN	O
procedure	NN	O
.	.	O

We	PRP	O
currently	RB	O
recommend	VBP	O
surgery	NN	O
after	IN	O
two	CD	O
injection	NN	O
treatments	NNS	O
have	VBP	O
failed	VBN	O
.	.	O

Effect	NN	O
of	IN	O
recombinant	JJ	O
adenovirus-p53	NN	O
combined	VBN	O
with	IN	O
radiotherapy	NN	O
on	IN	O
long-term	JJ	PH
prognosis	NN	PH
of	IN	O
advanced	JJ	O
nasopharyngeal	JJ	O
carcinoma	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
centrally	RB	O
assess	VB	O
the	DT	O
safety	NN	Ot
,	,	Ot
efficacy	NN	Ot
,	,	Ot
and	CC	Ot
6-year	JJ	Ot
follow-up	NN	Ot
of	IN	O
recombinant	JJ	O
adenovirus-p53	JJ	O
(	(	O
rAd-p53	NN	O
)	)	O
combined	VBN	O
with	IN	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
nasopharyngeal	JJ	O
carcinoma	NN	O
(	(	O
NPC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
on	IN	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
in	IN	O
42	CD	O
patients	NNS	O
with	IN	O
NPC	NNP	O
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
40	CD	O
patients	NNS	O
with	IN	O
NPC	NNP	O
treated	VBD	O
with	IN	O
RT	NNP	O
alone	RB	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
,	,	O
rAd-p53	NN	O
was	VBD	O
intratumorally	RB	O
injected	VBN	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Concurrent	NNP	O
RT	NNP	O
(	(	O
70	CD	O
Gy	NNP	O
in	IN	O
35	CD	O
fractions	NNS	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
the	DT	O
nasopharyngeal	JJ	O
tumor	NN	O
and	CC	O
neck	NN	O
lymph	NN	O
node	NN	O
.	.	O

Patients	NNS	O
and	CC	O
tumors	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	A
events	NNS	A
and	CC	A
responses	NNS	A
.	.	A

RESULTS	NNP	O
rAd-p53-specific	JJ	PH
p53	NN	PH
mRNA	NN	PH
was	VBD	O
detected	VBN	O
in	IN	O
postinjection	NN	O
of	IN	O
rAd-p53	JJ	O
biopsies	NNS	O
from	IN	O
16	CD	O
(	(	O
94.1	CD	O
%	NN	O
)	)	O
of	IN	O
17	CD	O
patients	NNS	O
.	.	O

Upregulation	NN	O
of	IN	O
p21/WAF1	NN	PH
and	CC	PH
Bax	NNP	PH
and	CC	O
downregulation	NN	O
of	IN	O
vascular	JJ	PH
endothelial	JJ	PH
growth	NN	PH
factor	NN	PH
were	VBD	O
observed	VBN	O
in	IN	O
postinjection	NN	O
tumor	NN	O
biopsy	NN	O
.	.	O

Complete	JJ	PH
response	NN	PH
rate	NN	PH
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
was	VBD	O
observed	VBN	O
at	IN	O
2.73	CD	O
times	NNS	O
that	WDT	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
RT	NNP	O
alone	RB	O
(	(	O
66.7	CD	O
%	NN	O
v	JJ	O
24.4	CD	O
%	NN	O
)	)	O
.	.	O

Six-year	JJ	O
follow-up	JJ	O
data	NN	O
showed	VBD	O
that	IN	O
rAd-p53	JJ	O
significantly	RB	O
increased	VBD	O
the	DT	O
5-year	JJ	PH
locoregional	JJ	PH
tumor	NN	PH
control	NN	PH
rate	NN	PH
by	IN	O
25.3	CD	O
%	NN	O
for	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
treated	VBD	O
with	IN	O
irradiation	NN	O
(	(	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
.	.	O

The	DT	O
5-year	JJ	MO
overall	JJ	MO
survival	NN	MO
rate	NN	MO
and	CC	MO
5-year	JJ	MO
disease-free	JJ	MO
survival	NN	MO
rate	NN	MO
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
were	VBD	O
7.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.34	NNP	O
)	)	O
and	CC	O
11.7	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.21	NNP	O
)	)	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
RT	NNP	O
alone	RB	O
.	.	O

No	DT	O
dose-limiting	JJ	A
toxicity	NN	A
or	CC	O
adverse	JJ	O
events	NNS	O
appeared	VBD	O
,	,	O
except	IN	O
for	IN	O
transient	NN	PH
fever	NN	PH
after	IN	O
rAd-p53	JJ	O
administration	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
,	,	O
rAd-p53	NN	O
was	VBD	O
safe	JJ	PH
and	CC	PH
biologically	RB	PH
active	JJ	PH
.	.	O

Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
rAd-p53	JJ	O
improves	NNS	O
radiotherapeutic	JJ	O
tumor	NN	O
control	NN	O
and	CC	O
survival	JJ	O
rate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
.	.	O

Development	NNP	O
of	IN	O
an	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
auditory	NN	PH
processing	NN	PH
disorders	NNS	PH
.	.	O

OBJECTIVE	CC	O
One	CD	O
type	NN	O
of	IN	O
test	NN	O
commonly	RB	O
used	VBD	O
to	TO	O
examine	VB	O
auditory	JJ	O
processing	NN	O
disorders	NNS	O
(	(	O
APD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
(	(	O
LPFST	NNP	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
there	EX	O
are	VBP	O
various	JJ	O
versions	NNS	O
.	.	O

In	IN	O
LPFSTs	NNP	O
,	,	O
a	DT	O
monaural	JJ	O
,	,	O
low-redundancy	JJ	O
speech	NN	O
sample	NN	O
is	VBZ	O
distorted	VBN	O
by	IN	O
using	VBG	O
filtering	VBG	O
to	TO	O
modify	VB	O
its	PRP$	O
frequency	NN	O
content	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
richness	NN	O
of	IN	O
the	DT	O
neural	JJ	O
pathways	NNS	O
in	IN	O
the	DT	O
auditory	NN	O
system	NN	O
and	CC	O
the	DT	O
redundancy	NN	O
of	IN	O
acoustic	JJ	O
information	NN	O
in	IN	O
spoken	JJ	O
language	NN	O
,	,	O
a	DT	O
normal	JJ	O
listener	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
recognize	VB	O
speech	NN	O
even	RB	O
when	WRB	O
parts	NNS	O
of	IN	O
the	DT	O
signal	NN	O
are	VBP	O
missing	VBG	O
,	,	O
whereas	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
often	RB	O
impaired	VBN	O
in	IN	O
listeners	NNS	O
with	IN	O
APD	NNP	O
.	.	O

One	CD	O
limitation	NN	O
of	IN	O
the	DT	O
various	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
LPFST	NNP	O
is	VBZ	O
that	IN	O
they	PRP	O
are	VBP	O
carried	VBN	O
out	IN	O
using	VBG	O
a	DT	O
constant	JJ	O
level	NN	O
of	IN	O
low-pass	JJ	O
filtering	NN	O
(	(	O
e.g	NN	O
.	.	O

a	DT	O
fixed	JJ	O
1kHz	CD	O
corner	NN	O
frequency	NN	O
)	)	O
which	WDT	O
makes	VBZ	O
them	PRP	O
prone	VB	O
to	TO	O
ceiling	NN	O
and	CC	O
floor	NN	O
effects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
counter	VB	O
these	DT	O
effects	NNS	O
by	IN	O
modifying	VBG	O
the	DT	O
LPFST	NNP	O
using	VBG	O
a	DT	O
computer-based	JJ	O
adaptive	JJ	O
procedure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	O
of	IN	O
normal-hearing	JJ	O
participants	NNS	O
of	IN	O
varying	VBG	O
ages	NNS	O
on	IN	O
the	DT	O
test	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
preliminary	JJ	O
study	NN	O
,	,	O
33	CD	O
adults	NNS	O
and	CC	O
30	CD	O
children	NNS	O
(	(	O
aged	VBN	O
8-11	CD	O
years	NNS	O
)	)	O
with	IN	O
no	DT	O
known	JJ	O
history	NN	O
of	IN	O
listening	VBG	O
difficulties	NNS	O
were	VBD	O
tested	VBN	O
.	.	O

The	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test	NNP	O
(	(	O
UCAST	NNP	O
)	)	O
platform	NN	O
was	VBD	O
used	VBN	O
to	TO	O
administer	VB	O
a	DT	O
four-alternative	JJ	O
forced-choice	JJ	O
adaptive	JJ	O
test	NN	O
that	WDT	O
altered	VBD	O
a	DT	O
low-pass	JJ	O
filter	NN	O
(	(	O
LPF	NNP	O
)	)	O
to	TO	O
track	VB	O
the	DT	O
corner	NN	O
frequency	NN	O
at	IN	O
which	WDT	O
participants	NNS	O
correctly	RB	O
identified	VBN	O
a	DT	O
certain	JJ	O
percentage	NN	O
of	IN	O
the	DT	O
word	NN	O
stimuli	NN	O
.	.	O

RESULTS	NNP	O
Findings	NNP	O
on	IN	O
the	DT	O
University	NNP	Ot
of	IN	Ot
Canterbury	NNP	Ot
Adaptive	NNP	Ot
Speech	NNP	Ot
Test-Filtered	NNP	Ot
Words	NNP	Ot
(	(	Ot
UCAST-FW	NNP	Ot
)	)	Ot
indicated	VBD	O
a	DT	O
significant	JJ	PH
maturational	JJ	PH
effect	NN	PH
.	.	O

Adult	NN	O
participants	NNS	O
performed	VBD	O
significantly	RB	O
better	RBR	O
on	IN	O
the	DT	O
UCAST-FW	NNP	Ot
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
child	NN	O
participants	NNS	O
.	.	O

The	DT	O
UCAST-FW	JJ	O
test	NN	O
was	VBD	O
reliable	JJ	O
over	IN	O
repeated	JJ	O
administrations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
An	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
such	JJ	O
as	IN	O
the	DT	O
UCAST-FW	NNP	Ot
is	VBZ	O
sensitive	JJ	O
to	TO	O
maturational	JJ	PH
changes	NNS	PH
in	IN	PH
auditory	NN	PH
processing	NN	PH
ability	NN	PH
.	.	O

Randomized	VBN	O
controlled	VBD	O
study	NN	O
of	IN	O
customized	JJ	O
preventive	JJ	O
medicine	NN	O
reminder	NN	O
letters	NNS	O
in	IN	O
a	DT	O
community	NN	O
practice	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
customized	JJ	O
,	,	O
family-oriented	JJ	O
reminder	NN	O
letters	NNS	O
in	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
seek	VB	O
appropriate	JJ	O
preventive	JJ	O
services	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
computer-generated	JJ	O
,	,	O
customized	JJ	O
letters	NNS	O
explaining	VBG	O
recommended	VBD	O
preventive	JJ	O
procedures	NNS	O
for	IN	O
each	DT	O
family	NN	O
member	NN	O
.	.	O

A	DT	O
second	JJ	O
group	NN	O
received	VBD	O
a	DT	O
form	JJ	O
letter	NN	O
listing	NN	O
recommendations	NNS	O
for	IN	O
all	DT	O
preventive	JJ	O
procedures	NNS	O
for	IN	O
all	DT	O
age	NN	O
and	CC	O
sex	NN	O
groups	NNS	O
.	.	O

A	DT	O
third	JJ	O
group	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
received	VBD	O
no	DT	O
letters	NNS	O
.	.	O

SETTING	VBG	O
A	DT	O
private	JJ	O
medical	JJ	O
centre	NN	O
,	,	O
without	IN	O
university	NN	O
affiliation	NN	O
,	,	O
in	IN	O
rural	JJ	O
Quebec	NNP	O
.	.	O

PARTICIPANTS	NN	O
From	IN	O
8770	CD	O
patients	NNS	O
who	WP	O
met	VBD	O
study	NN	O
criteria	NNS	O
,	,	O
719	CD	O
families	NNS	O
were	VBD	O
randomly	RB	O
selected	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
1971	CD	O
of	IN	O
1998	CD	O
patients	NNS	O
in	IN	O
these	DT	O
families	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	PH
Family	NNP	PH
Received	NNP	PH
Index	NNP	PH
is	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
all	DT	O
procedures	NNS	O
for	IN	O
which	WDT	O
a	DT	O
family	NN	O
was	VBD	O
overdue	JJ	O
that	IN	O
they	PRP	O
received	VBD	O
.	.	O

The	DT	O
Family	JJ	PH
End-of-study	NNP	PH
Up-to-date	NNP	PH
Index	NNP	PH
is	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
procedures	NNS	O
for	IN	O
which	WDT	O
the	DT	O
family	NN	O
was	VBD	O
eligible	JJ	O
and	CC	O
for	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
up-to-date	JJ	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
Family	NNP	PH
Received	NNP	PH
Index	NNP	PH
for	IN	O
families	NNS	O
mailed	VBN	O
customized	JJ	O
letters	NNS	O
was	VBD	O
more	RBR	O
than	IN	O
double	RB	O
the	DT	O
index	NN	O
for	IN	O
patients	NNS	O
not	RB	O
mailed	VBN	O
letters	NNS	O
(	(	O
Kruskal-Wallis	NNP	O
P	NNP	O
=	NNP	O
.0139	NNP	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
Family	NNP	PH
End-of-study	NNP	PH
Up-to-date	NNP	PH
indices	NNS	PH
also	RB	O
demonstrated	VBD	O
that	IN	O
families	NNS	O
of	IN	O
patients	NNS	O
sent	JJ	O
customized	JJ	O
letters	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
up-to-date	JJ	O
than	IN	O
families	NNS	O
not	RB	O
sent	VBD	O
letters	NNS	O
(	(	O
Kruskal-Wallis	NNP	O
P	NNP	O
=	NNP	O
.0054	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
appeared	VBD	O
between	IN	O
the	DT	O
number	NN	O
of	IN	O
preventive	JJ	O
measures	NNS	O
received	VBN	O
by	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
form-letter	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
a	DT	O
clinically	RB	O
small	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
value	NN	O
to	TO	O
customizing	VBG	O
reminder	NN	O
letters	NNS	O
.	.	O

Endobronchial	JJ	O
ultrasonography-guided	JJ	O
transbronchial	JJ	O
needle	JJ	O
aspiration	NN	O
increases	VBZ	O
the	DT	O
diagnostic	JJ	Ot
yield	NN	Ot
of	IN	O
peripheral	JJ	O
pulmonary	JJ	O
lesions	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
diagnostic	JJ	PH
yield	NN	PH
of	IN	O
endobronchial	JJ	O
ultrasonography	NN	O
(	(	O
EBUS	NNP	O
)	)	O
-guided	VBD	O
transbronchial	JJ	O
needle	JJ	O
aspiration	NN	O
(	(	O
TBNA	NNP	O
)	)	O
for	IN	O
peripheral	JJ	O
pulmonary	JJ	O
lesions	NNS	O
(	(	O
PPLs	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
impact	NN	O
of	IN	O
TBNA	NNP	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
is	VBZ	O
adjacent	JJ	O
to	TO	O
lesions	NNS	O
remains	VBZ	O
to	TO	O
be	VB	O
determined	VBN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
PPLs	NNP	O
and	CC	O
positive	JJ	O
EBUS	NNP	O
findings	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
classified	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
EBUS	NNP	O
conventional	JJ	O
diagnostic	JJ	O
procedures	NNS	O
(	(	O
CDPs	NNP	O
)	)	O
group	NN	O
(	(	O
103	CD	O
patients	NNS	O
)	)	O
,	,	O
both	DT	O
transbronchial	JJ	O
biopsy	NN	O
(	(	O
TBB	NNP	O
)	)	O
and	CC	O
bronchial	JJ	O
washing	NN	O
(	(	O
BW	NNP	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

In	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
99	CD	O
patients	NNS	O
)	)	O
,	,	O
TBNA	NNP	O
,	,	O
TBB	NNP	O
,	,	O
and	CC	O
BW	NNP	O
were	VBD	O
performed	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	PH
yield	NN	PH
in	IN	O
each	DT	O
group	NN	O
was	VBD	O
compared	VBN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
patients	NNS	O
(	(	O
94	CD	O
in	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
and	CC	O
88	CD	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
)	)	O
were	VBD	O
analyzed	VBN	O
.	.	O

The	DT	O
yield	NN	Ot
in	IN	Ot
the	DT	Ot
EBUS-TBNA	JJ	Ot
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
78.4	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
(	(	O
60.6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.015	CD	O
)	)	O
.	.	O

Cases	NNS	O
in	IN	O
which	WDT	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
located	VBN	O
within	IN	O
the	DT	O
lesions	NNS	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	RBR	PH
diagnostic	JJ	PH
yield	NN	PH
(	(	O
78.3	CD	O
%	NN	O
)	)	O
than	IN	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
them	PRP	O
(	(	O
47.2	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Concerning	VBG	O
the	DT	O
three	CD	O
different	JJ	O
techniques	NNS	O
,	,	O
TBNA	NNP	O
showed	VBD	O
the	DT	O
highest	JJS	PH
diagnostic	JJ	PH
yield	NN	PH
(	(	O
62.5	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
TBB	NNP	O
(	(	O
48.9	CD	O
%	NN	O
)	)	O
and	CC	O
to	TO	O
BW	NNP	O
(	(	O
19.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
diagnostic	JJ	PH
yield	NN	PH
of	IN	PH
TBNA	NNP	PH
remained	VBD	O
unchanged	JJ	O
even	RB	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
.	.	O

No	DT	O
additional	JJ	O
adverse	JJ	A
effects	NNS	A
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Applying	NNP	O
TBNA	NNP	O
to	TO	O
EBUS-guided	NNP	O
CDPs	NNP	O
further	RBR	O
increased	VBD	O
the	DT	O
diagnostic	JJ	PH
yield	NN	PH
of	IN	O
PPLs	NNP	O
without	IN	O
additional	JJ	O
risk	NN	O
.	.	O

The	DT	O
diagnostic	JJ	Ot
advantage	NN	Ot
of	IN	O
TBNA	NNP	O
became	VBD	O
more	RBR	O
obvious	JJ	O
if	IN	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinicaltrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00626587	NN	O
.	.	O

Epidural	JJ	O
fentanyl-bupivacaine	JJ	O
compared	VBN	O
with	IN	O
clonidine-bupivacaine	NN	O
for	IN	O
analgesia	NN	O
in	IN	O
labour	NN	O
.	.	O

Alpha-adrenergic	JJ	O
agonists	NNS	O
produce	VBP	O
pain	NN	PA
relief	NN	PA
through	IN	O
an	DT	O
opioid	JJ	O
independent	JJ	O
mechanism	NN	O
and	CC	O
may	MD	O
be	VB	O
alternatives	NNS	O
to	TO	O
opioids	NNS	O
for	IN	O
combination	NN	O
with	IN	O
local	JJ	O
anaesthetics	NNS	O
for	IN	O
analgesia	NN	O
during	IN	O
labour	NN	O
.	.	O

We	PRP	O
studied	VBD	O
41	CD	O
pregnant	JJ	O
women	NNS	O
.	.	O

Epidural	JJ	O
block	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
75	CD	O
microg	NNS	O
clonidine	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
50	CD	O
microg	NNS	O
fentanyl	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
combined	VBN	O
with	IN	O
0.125	CD	O
%	NN	O
bupivacaine	NN	O
(	(	O
10	CD	O
mL	NN	O
)	)	O
.	.	O

Maternal	JJ	PH
vital	JJ	PH
parameters	NNS	PH
were	VBD	O
measured	VBN	O
.	.	O

Analgesia	NNP	PA
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
;	:	O
sedation	NN	PH
was	VBD	O
scored	VBN	O
using	VBG	O
a	DT	O
five-point	JJ	O
scale	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
maternal	JJ	PH
vital	JJ	PH
parameters	NNS	PH
,	,	PH
fetal	JJ	PH
heart	NN	PH
rate	NN	PH
(	(	PH
FHR	NNP	PH
)	)	PH
or	CC	PH
Apgar	NNP	PH
scores	NNS	PH
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Analgesia	NNP	O
lasted	VBD	O
longer	RBR	O
in	IN	O
the	DT	O
bupivacaine-clonidine	JJ	O
group	NN	O
(	(	O
139.4	CD	O
+/-	JJ	O
31	CD	O
min	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
bupivacaine-fentanyl	JJ	O
group	NN	O
(	(	O
127.9	CD	O
+/-	JJ	O
48	CD	O
min	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
.	.	O

Additional	JJ	PA
analgesic	JJ	PA
requirement	NN	PA
was	VBD	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
fentanyl-bupivacaine	JJ	O
group	NN	O
and	CC	O
total	JJ	O
bupivacaine	NN	O
requirement	NN	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
clonidine-bupivacaine	JJ	O
group	NN	O
(	(	O
22.5	CD	O
+/-	JJ	O
12.5	CD	O
mg	NN	O
vs.	FW	O
30.9	CD	O
+/-	JJ	O
12.8	CD	O
mg	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

This	DT	O
small	JJ	O
study	NN	O
confirms	VBZ	O
that	IN	O
this	DT	O
combination	NN	O
of	IN	O
bupivacaine	NN	O
and	CC	O
clonidine	NN	O
provides	VBZ	O
satisfactory	JJ	PA
analgesia	NN	PA
for	IN	O
first-stage	JJ	O
labour	NN	O
,	,	O
and	CC	O
of	IN	O
longer	JJR	O
duration	NN	Ot
than	IN	O
bupivacaine-fentanyl	NN	O
.	.	O

Safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
oral	JJ	O
DMSA	NNP	O
therapy	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
part	NN	O
B	NNP	O
-	:	O
behavioral	JJ	O
results	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
dimercapto	NN	O
succinic	JJ	O
acid	NN	O
(	(	O
DMSA	NNP	O
)	)	O
therapy	NN	O
on	IN	O
the	DT	O
behavioural	JJ	O
symptoms	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
ages	VBZ	O
3-8	JJ	O
years	NNS	O
.	.	O

METHODS	NNP	O
Phase	NNP	O
1	CD	O
involved	VBD	O
65	CD	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
received	VBD	O
one	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
(	(	O
3	CD	O
days	NNS	O
)	)	O
.	.	O

Participants	NNS	O
who	WP	O
had	VBD	O
high	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
were	VBD	O
selected	VBN	O
to	TO	O
continue	VB	O
on	IN	O
to	TO	O
phase	VB	O
2	CD	O
.	.	O

In	IN	O
phase	NN	O
2	CD	O
,	,	O
49	CD	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
design	NN	O
to	TO	O
receive	VB	O
an	DT	O
additional	JJ	O
6	CD	O
rounds	NNS	O
of	IN	O
either	DT	O
DMSA	NNP	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
receiving	VBG	O
one	CD	O
round	NN	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
on	IN	O
all	PDT	O
the	DT	O
assessment	JJ	O
measures	NNS	O
.	.	O

For	IN	O
the	DT	O
seven	CD	O
round	NN	O
group	NN	O
,	,	O
the	DT	O
degree	NN	O
of	IN	O
improvement	NN	PH
on	IN	O
the	DT	O
assessment	NN	Ot
measures	NNS	Ot
could	MD	O
be	VB	O
partially	RB	O
explained	VBN	O
by	IN	O
a	DT	O
regression	NN	O
analysis	NN	O
based	VBN	O
on	IN	O
excretion	NN	PH
of	IN	PH
toxic	JJ	PH
metals	NNS	PH
and	CC	PH
changes	NNS	PH
in	IN	PH
glutathione	NN	PH
(	(	O
adjusted	VBN	O
R2	NNP	O
of	IN	O
0.28-0.75	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.02	CD	O
in	IN	O
all	DT	O
cases	NNS	O
)	)	O
.	.	O

One	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
had	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
as	IN	O
seven	CD	O
rounds	NNS	O
.	.	O

The	DT	O
assessment	JJ	O
measures	NNS	O
correlated	VBN	O
reasonably	RB	O
with	IN	O
one	CD	O
another	DT	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.60-0.87	NN	O
)	)	O
and	CC	O
even	RB	O
better	JJR	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.63-0.94	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
both	DT	O
one	CD	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	O
therapy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
reasonably	RB	O
safe	JJ	Ot
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
have	VBP	O
high	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
,	,	O
and	CC	O
possibly	RB	O
helpful	JJ	O
in	IN	O
reducing	VBG	O
some	DT	O
of	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
autism	NN	O
in	IN	O
those	DT	O
children	NNS	O
.	.	O

Effect	NN	O
of	IN	O
simvastatin	NN	O
on	IN	O
hemostasis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
.	.	O

BACKGROUNDS/AIMS	NNP	O
Elevated	NNP	O
triglyceride	NN	O
levels	NNS	O
seem	VBP	O
to	TO	O
predispose	VB	O
to	TO	O
the	DT	O
earlier	JJR	O
development	NN	O
and	CC	O
accelerated	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

In	IN	O
our	PRP$	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
whether	IN	O
simvastatin	JJ	O
treatment	NN	O
affects	NNS	O
coagulation	NN	PH
and	CC	PH
fibrinolysis	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
39	CD	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
and	CC	O
peripheral	JJ	O
artery	NN	O
sclerosis	NN	O
,	,	O
treated	VBD	O
for	IN	O
90	CD	O
days	NNS	O
with	IN	O
either	DT	O
simvastatin	NN	O
(	(	O
40	CD	O
mg	NNS	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Plasma	NNP	PH
lipids	NNS	PH
,	,	PH
glucose	JJ	PH
homeostasis	NN	PH
markers	NNS	PH
and	CC	O
hemostasic	JJ	PH
variables	NNS	PH
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Simvastatin	NNP	O
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
administered	VBN	O
to	TO	O
these	DT	O
patients	NNS	O
reduced	VBD	O
plasma	JJ	PH
levels/activity	NN	PH
of	IN	PH
fibrinogen	NN	PH
(	(	O
from	IN	O
3.5	CD	O
?	.	O
0.4	CD	O
to	TO	O
2.8	CD	O
?	.	O
0.3	CD	O
g/l	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
factor	NN	O
VII	NNP	O
(	(	O
from	IN	O
144.2	CD	O
?	.	O
16.9	CD	O
to	TO	O
112.5	CD	O
?	.	O
14.0	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
(	(	O
from	IN	O
76.9	CD	O
?	.	O
13.5	CD	O
to	TO	O
50.2	CD	O
?	.	O
9.2	CD	O
ng/ml	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
without	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
von	NN	O
Willebrand	NNP	O
factor	NN	O
levels	NNS	O
,	,	O
and	CC	O
tended	VBD	O
to	TO	O
prolong	VB	O
the	DT	O
prothrombin	NN	O
and	CC	O
partial	JJ	O
thromboplastin	NN	O
times	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
statin	NN	O
treatment	NN	O
produces	VBZ	O
a	DT	O
multidirectional	JJ	O
effect	NN	O
on	IN	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
and	CC	O
that	IN	O
this	DT	O
treatment	NN	O
may	MD	O
bring	VB	O
some	DT	O
benefits	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
.	.	O

Omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
supplementation	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
evidence	NN	O
that	IN	O
fatty	JJ	O
acid	JJ	O
deficiencies	NNS	O
or	CC	O
imbalances	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
childhood	VB	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
6-week	JJ	O
pilot	NN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
1.5	CD	O
g/d	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
(	(	O
.84	JJ	O
g/d	NN	O
eicosapentaenoic	NN	O
acid	NN	O
,	,	O
.7	NNP	O
g/d	NN	O
docosahexaenoic	NN	O
acid	NN	O
)	)	O
supplementation	NN	O
in	IN	O
13	CD	O
children	NNS	O
(	(	O
aged	VBN	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
)	)	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
(	(	ME
ABC	NNP	ME
)	)	ME
at	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
observed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	PH
and	CC	PH
stereotypy	NN	PH
,	,	O
each	DT	O
with	IN	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
.	.	O

Repeated-measures	NNS	O
ANOVA	NNP	O
indicated	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superiority	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
over	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	PH
.	.	PH

No	DT	O
clinically	RB	O
relevant	JJ	O
adverse	JJ	A
effects	NNS	A
were	VBD	O
elicited	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Variations	NNS	O
in	IN	O
EEG	NNP	PH
discharges	NNS	PH
predict	VBP	O
ADHD	NNP	O
severity	NN	O
within	IN	O
individual	JJ	O
Smith-Lemli-Opitz	JJ	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
examine	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
EEG	NNP	O
abnormalities	NNS	O
in	IN	O
Smith-Lemli-Opitz	NNP	O
syndrome	NN	O
(	(	O
SLOS	NNP	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
relationship	NN	O
between	IN	O
interictal	JJ	O
epileptiform	NN	O
discharges	NNS	O
(	(	O
IEDs	NNP	O
)	)	O
and	CC	O
within-subject	JJ	O
variations	NNS	O
in	IN	O
attentional	JJ	O
symptom	NN	O
severity	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
for	IN	O
SLOS	NNP	O
,	,	O
we	PRP	O
performed	VBD	O
cross-sectional	JJ	O
and	CC	O
repeated-measure	JJ	O
observational	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
relationship	NN	O
between	IN	O
EEG	NNP	O
findings	NNS	O
and	CC	O
cognitive/behavioral	JJ	O
factors	NNS	O
on	IN	O
23	CD	O
children	NNS	O
(	(	O
aged	VBN	O
4-17	CD	O
years	NNS	O
)	)	O
.	.	O

EEGs	NNP	O
were	VBD	O
reviewed	VBN	O
for	IN	O
clinical	JJ	O
abnormalities	NNS	O
,	,	O
including	VBG	O
IEDs	NNP	O
,	,	O
by	IN	O
readers	NNS	O
blinded	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
behavioral	NN	O
symptoms	NNS	O
.	.	O

Between-group	JJ	O
differences	NNS	O
in	IN	O
baseline	JJ	O
characteristics	NNS	O
of	IN	O
participants	NNS	O
with	IN	O
and	CC	O
without	IN	O
IEDs	NNP	O
were	VBD	O
analyzed	VBN	O
.	.	O

Within-subject	JJ	O
analyses	NNS	O
examined	VBD	O
the	DT	O
association	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
IEDs	NNP	O
and	CC	O
changes	NNS	O
in	IN	O
attention-deficit/hyperactivity	NN	PH
disorder	NN	PH
(	(	PH
ADHD	NNP	PH
)	)	PH
symptoms	NNS	PH
.	.	PH

RESULTS	NNP	O
Of	IN	O
85	CD	O
EEGs	NNP	O
,	,	O
43	CD	O
(	(	O
51	CD	O
%	NN	O
)	)	O
were	VBD	O
abnormal	JJ	PH
,	,	O
predominantly	RB	O
because	IN	O
of	IN	O
IEDs	NNP	O
.	.	O

Only	RB	O
one	CD	O
subject	NN	O
had	VBD	O
documented	VBN	O
clinical	JJ	A
seizures	NNS	A
.	.	A

IEDs	NNP	O
clustered	VBD	O
in	IN	O
13	CD	O
subjects	NNS	O
(	(	O
57	CD	O
%	NN	O
)	)	O
,	,	O
whereas	$	O
9	CD	O
subjects	NNS	O
(	(	O
39	CD	O
%	NN	O
)	)	O
had	VBD	O
EEGs	NNP	O
consistently	RB	O
free	JJ	O
of	IN	O
IEDs	NNP	O
.	.	O

While	IN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
group	NN	O
differences	NNS	O
in	IN	O
sex	NN	ME
,	,	ME
age	NN	ME
,	,	ME
intellectual	JJ	ME
disability	NN	ME
,	,	ME
language	NN	ME
level	NN	ME
,	,	ME
or	CC	ME
baseline	VB	ME
ADHD	NNP	ME
symptoms	NNS	ME
,	,	ME
autistic	JJ	ME
symptoms	NNS	ME
tended	VBD	O
to	TO	O
be	VB	O
more	RBR	O
prevalent	JJ	O
in	IN	O
the	DT	O
IED	NNP	O
group	NN	O
(	(	O
according	VBG	O
to	TO	O
Autism	NNP	ME
Diagnostic	NNP	ME
Observation	NNP	ME
Schedule-2	NNP	ME
criteria	NNS	ME
)	)	ME
.	.	O

Within	JJ	O
individuals	NNS	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
IEDs	NNP	O
on	IN	O
a	DT	O
particular	JJ	O
EEG	NNP	O
predicted	VBD	O
,	,	O
on	IN	O
average	NN	O
,	,	O
a	DT	O
27	CD	O
%	NN	O
increase	NN	O
in	IN	O
ADHD	NNP	ME
symptom	NN	ME
severity	NN	ME
.	.	ME

CONCLUSIONS	NNP	O
Epileptiform	NNP	O
discharges	NNS	O
are	VBP	O
common	JJ	O
in	IN	O
SLOS	NNP	O
,	,	O
despite	IN	O
a	DT	O
relatively	RB	O
low	JJ	O
prevalence	NN	O
of	IN	O
epilepsy	NN	O
.	.	O

Fluctuations	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
epileptiform	NN	O
discharges	NNS	O
within	IN	O
individual	JJ	O
children	NNS	O
with	IN	O
a	DT	O
developmental	JJ	O
disability	NN	O
syndrome	NN	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
fluctuations	NNS	O
in	IN	O
ADHD	NNP	O
symptomatology	NN	O
,	,	O
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
clinical	JJ	O
seizures	NNS	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
using	VBG	O
testosterone	NN	O
undecanoate	NN	O
with	IN	O
injectable	JJ	O
norethisterone	JJ	O
enanthate	NN	O
:	:	O
effect	NN	O
on	IN	O
anthropometric	NN	O
,	,	O
metabolic	JJ	O
and	CC	O
biochemical	JJ	O
parameters	NNS	O
.	.	O

Testosterone	CD	O
administered	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
progestogens	NNS	O
in	IN	O
male	JJ	O
contraception	NN	O
induces	NNS	O
reversible	JJ	O
oligo-azoospermia	JJ	O
,	,	O
but	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
body	NN	O
composition	NN	O
and	CC	O
metabolism	NN	O
are	VBP	O
less	RBR	O
known	JJ	O
.	.	O

We	PRP	O
analysed	VBD	O
anthropometric	JJ	O
and	CC	O
metabolic	JJ	O
parameters	NNS	O
in	IN	O
five	CD	O
groups	NNS	O
of	IN	O
10	CD	O
males	NNS	O
:	:	O
four	CD	O
receiving	VBG	O
testosterone	NN	O
undecanoate	NN	O
(	(	O
TU	NNP	O
:	:	O
1000	CD	O
mg	NN	O
)	)	O
plus	CC	O
norethisterone	JJ	O
enanthate	NN	O
(	(	O
NETE	NNP	O
:	:	O
200	CD	O
mg	NN	O
)	)	O
at	IN	O
different	JJ	O
intervals	NNS	O
(	(	O
every	DT	O
8	CD	O
weeks	NNS	O
:	:	O
NETE-8	JJ	O
;	:	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-12	NN	O
;	:	O
every	DT	O
6	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-6/12	JJ	O
;	:	O
every	DT	O
6	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
TU	NNP	O
plus	CC	O
placebo	JJ	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-6/12/0	NNP	O
)	)	O
and	CC	O
one	CD	O
placebo	NN	O
(	(	O
NETE-0/0	NNP	O
)	)	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Body	NNP	PH
mass	NN	PH
index	NN	PH
(	(	PH
BMI	NNP	PH
)	)	PH
and	CC	PH
waist	JJ	PH
circumference	NN	PH
did	VBD	PH
not	RB	PH
change	VB	PH
in	IN	O
any	DT	O
groups	NNS	O
except	IN	O
for	IN	O
the	DT	O
NETE-8	NNP	O
in	IN	O
which	WDT	O
BMI	NNP	PH
increased	VBD	PH
significantly	RB	PH
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

Lean	JJ	PH
body	NN	PH
mass	NN	PH
(	(	PH
MAMC	NNP	PH
or	CC	PH
AMA	NNP	PH
)	)	PH
increased	VBD	PH
significantly	RB	PH
in	IN	O
the	DT	O
highest	JJS	O
hormonal	JJ	O
dose	NN	O
groups	NNS	O
(	(	O
p	JJ	O
=	NN	O
0.04	CD	O
,	,	O
NETE-6/12	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.004	CD	O
,	,	O
NETE-8	NNP	O
)	)	O
.	.	O

No	UH	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
glucose	JJ	PH
levels	NNS	PH
,	,	PH
insulin	NN	PH
sensitivity	NN	PH
index	NN	PH
and	CC	PH
lipid	JJ	PH
profile	NN	PH
as	RB	O
well	RB	O
as	IN	O
in	IN	O
biochemical	JJ	PH
and	CC	PH
cell	NN	PH
count	NN	PH
parameters	NNS	PH
in	IN	O
any	DT	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
NETE	NNP	O
and	CC	O
TU	NNP	O
for	IN	O
48	CD	O
weeks	NNS	O
were	VBD	O
not	RB	O
accompanied	VBN	O
by	IN	O
any	DT	O
metabolic	JJ	PH
changes	NNS	PH
and	CC	PH
any	DT	PH
adverse	JJ	A
effects	NNS	A
.	.	O

The	DT	O
weight	JJ	PH
gain	NN	PH
of	IN	O
the	DT	O
highest	JJS	O
NETE	JJ	O
plus	CC	O
TU	JJ	O
dosage	NN	O
was	VBD	O
mainly	RB	O
because	IN	O
of	IN	O
gain	NN	O
in	IN	O
muscle	NN	O
mass	NN	O
.	.	O

Can	MD	O
acupuncture	VB	O
ease	VB	O
the	DT	O
symptoms	NNS	PH
of	IN	PH
menopause	NN	PH
?	.	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
2-group	JJ	O
clinical	JJ	O
study	NN	O
,	,	O
acupuncture	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
menopausal	NN	PH
hot	JJ	PH
flushes	NNS	PH
,	,	O
sleep	JJ	PH
disturbances	NNS	PH
,	,	O
and	CC	O
mood	NN	ME
changes	NNS	ME
.	.	O

The	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
consisted	VBD	O
of	IN	O
specific	JJ	O
acupuncture	NN	O
body	NN	O
points	NNS	O
related	VBN	O
to	TO	O
menopausal	VB	PH
symptoms	NNS	PH
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	O
treatment	NN	O
consisted	VBN	O
of	IN	O
a	DT	O
treatment	NN	O
designated	VBN	O
as	IN	O
a	DT	O
general	JJ	O
tonic	NN	O
specifically	RB	O
designed	VBN	O
to	TO	O
benefit	VB	O
the	DT	O
flow	NN	O
of	IN	O
Ch'i	NNP	O
(	(	O
energy	NN	O
)	)	O
.	.	O

Results	NNS	O
from	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
mean	JJ	PH
monthly	JJ	PH
hot	JJ	PH
flush	NN	PH
severity	NN	PH
for	IN	O
site-specific	JJ	O
acupuncture	NN	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
change	NN	PH
in	IN	PH
severity	NN	PH
from	IN	O
baseline	NN	O
over	IN	O
the	DT	O
treatment	NN	O
phase	NN	O
.	.	O

Sleep	JJ	PH
disturbances	NNS	PH
in	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
declined	VBD	O
over	IN	O
the	DT	O
study	NN	O
.	.	O

Mood	NNP	ME
changes	NNS	ME
in	IN	O
both	DT	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
and	CC	O
the	DT	O
comparison	NN	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
the	DT	O
third	JJ	O
month	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Acupuncture	NNP	O
using	VBG	O
menopausal-specific	JJ	O
sites	NNS	O
holds	VBZ	O
promise	NN	O
for	IN	O
nonhormonal	JJ	O
relief	NN	PH
of	IN	PH
hot	JJ	PH
flushes	NNS	PH
and	CC	PH
sleep	JJ	PH
disturbances	NNS	PH
.	.	O

First-line	JJ	O
cisplatin	NN	O
with	IN	O
docetaxel	NN	O
or	CC	O
vinorelbine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
:	:	O
a	DT	O
quality	NN	O
of	IN	O
life	NN	O
directed	VBN	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
of	IN	O
Gruppo	NNP	O
Oncologico	NNP	O
Italia	NNP	O
Meridionale	NNP	O
.	.	O

BACKGROUND	NNP	O
Quality	NNP	ME
of	IN	ME
life	NN	ME
(	(	ME
QoL	NNP	ME
)	)	ME
has	VBZ	O
gained	VBN	O
greater	JJR	O
importance	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
metastatic	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
due	JJ	O
to	TO	O
the	DT	O
palliative	JJ	O
nature	NN	O
of	IN	O
treatment	NN	O
.	.	O

Docetaxel	NNP	O
(	(	O
DCT	NNP	O
)	)	O
and	CC	O
cisplatin	NN	O
(	(	O
CDDP	NNP	O
)	)	O
doublet	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
to	TO	O
a	DT	O
better	JJR	O
QoL	NNP	O
than	IN	O
the	DT	O
weekly	JJ	O
vinorelbine	NN	O
(	(	O
VNR	NNP	O
)	)	O
and	CC	O
CDDP	NNP	O
regimen	NNS	O
.	.	O

Recently	RB	O
a	DT	O
newer	NN	O
more	RBR	O
tolerated	JJ	O
schedule	NN	O
of	IN	O
the	DT	O
VNR/CDDP	NNP	O
regimen	NN	O
has	VBZ	O
been	VBN	O
published	VBN	O
and	CC	O
is	VBZ	O
widely	RB	O
employed	VBN	O
in	IN	O
medical	JJ	O
practice	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
these	DT	O
regimens	NNS	O
on	IN	O
patients	NNS	O
'	POS	O
QoL	NNP	O
as	RB	O
well	RB	O
as	IN	O
symptoms	NNS	PH
control	NN	PH
and	CC	O
type	NN	O
and	CC	O
grading	VBG	O
chemo-related	JJ	O
side-effects	NNS	PH
has	VBZ	O
been	VBN	O
compared	VBN	O
prospectically	RB	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
received	VBD	O
CDDP	NNP	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
plus	CC	O
DCT	NNP	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
every	DT	O
weeks	NNS	O
(	(	O
arm	IN	O
A	NNP	O
)	)	O
or	CC	O
CDDP	$	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
plus	CC	O
VNR	NNP	O
30	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
day	NN	O
1	CD	O
and	CC	O
8	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
(	(	O
arm	NN	O
B	NNP	O
)	)	O
.	.	O

G-CSF	NNP	O
and/or	JJ	O
EPO	NNP	O
were	VBD	O
employed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Health-related	JJ	ME
QoL	NNP	ME
was	VBD	O
assessed	VBN	O
at	IN	O
entry	NN	O
and	CC	O
after	IN	O
every	DT	O
cycle	NN	O
by	IN	O
the	DT	O
EORTC-QLQ-C30	NNP	O
and	CC	O
LC13	NNP	ME
questionnaires	NNS	ME
,	,	O
toxicity	NN	PH
by	IN	O
the	DT	O
NCI-NCCN	NNP	O
CTC	NNP	O
vs	NN	O
2	CD	O
,	,	O
and	CC	O
intent-to-treat	JJ	O
objective	JJ	PH
response	NN	PH
by	IN	O
the	DT	O
Recist	NNP	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
QoL	NNP	PH
questionnaires	NNS	PH
were	VBD	O
completed	VBN	O
by	IN	O
37	CD	O
pts	NNS	O
(	(	O
88	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
and	CC	O
39	CD	O
pts	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
one	NN	O
.	.	O

Baseline	JJ	O
mean	JJ	O
scores	NNS	O
and	CC	O
rates	NNS	O
at	IN	O
which	WDT	O
pts	NNS	O
failed	VBD	O
to	TO	O
complete	VB	O
QoL	NNP	O
assessment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Global	NNP	ME
health	NN	ME
status	NN	ME
of	IN	O
the	DT	O
EORTC	NNP	PH
QLQ-C30	NNP	PH
scale	NN	PH
and	CC	O
specific	JJ	O
symptoms	NNS	O
control	NN	O
(	(	O
LC13	NNP	O
module	NN	O
)	)	O
improved	VBD	O
during	IN	O
treatment	NN	O
without	IN	O
any	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Emotional	JJ	ME
functioning	NN	ME
remained	VBD	O
stable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
during	IN	O
treatment	NN	O
,	,	O
whereas	JJ	O
physical	JJ	ME
and	CC	O
role	NN	ME
improved	VBN	O
slightly	RB	O
.	.	O

In	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
14	CD	O
pts	NNS	O
(	(	O
33	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CL	NNP	O
24-40	CD	O
%	NN	O
)	)	O
had	VBD	O
PR	NNP	O
,	,	O
and	CC	O
10	CD	O
(	(	O
24	CD	O
%	NN	O
)	)	O
SD	NNP	O
for	IN	O
a	DT	O
57	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

In	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
12	CD	O
pts	NNS	O
(	(	O
27	CD	O
%	NN	O
)	)	O
achieved	VBD	O
PR	NNP	PH
,	,	O
18	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
SD	VBZ	O
a	DT	O
68	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

Differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Median	JJ	PH
time-to-progression	NN	PH
was	VBD	O
4.2	CD	O
months	NNS	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
and	CC	O
4.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
one	CD	O
,	,	O
and	CC	O
median	JJ	MO
overall	JJ	MO
survival	NN	MO
was	VBD	O
12.1	CD	O
(	(	O
range	VB	O
1-26+	JJ	O
months	NNS	O
)	)	O
and	CC	O
12.5	CD	O
months	NNS	O
(	(	O
range	VB	O
1-28+	JJ	O
months	NNS	O
)	)	O
for	IN	O
DCT/CDDP	NNP	O
and	CC	O
VNR/CDDP	NNP	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Febrile	NNP	PH
neutropenia	JJ	PH
rate	NN	PH
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
(	(	O
p=0.02	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
G3-4	NNP	O
anemia	NN	PH
(	(	O
p=0.005	NN	O
)	)	O
and	CC	O
G-CSF/EPO	NNP	O
use	NN	O
(	(	O
p=0.019	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Global	NNP	PH
and	CC	PH
specific	JJ	PH
health-related	JJ	PH
QoL	NNP	PH
data	NNS	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
.	.	O

Efficacy	NN	Ot
measures	NNS	Ot
,	,	O
overall	JJ	O
response	NN	PH
rate	NN	PH
,	,	O
time-to-progression	NN	PH
and	CC	O
overall	JJ	MO
survival	NN	MO
were	VBD	O
equivalent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

However	RB	O
,	,	O
severe	JJ	PH
anemia	NN	PH
and	CC	O
febrile	JJ	PH
neutropenia	NN	PH
are	VBP	O
statistically	RB	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
than	IN	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
one	NN	O
.	.	O

These	DT	O
data	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
treatment	NN	O
decision-making	NN	O
for	IN	O
pts	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
and	CC	O
for	IN	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
trials	NNS	O
with	IN	O
chemotherapy	NN	O
plus	CC	O
biologics	NNS	O
.	.	O

Can	MD	O
incentives	VB	O
undermine	JJ	O
intrinsic	JJ	ME
motivation	NN	ME
to	TO	O
participate	VB	O
in	IN	O
epidemiologic	JJ	O
surveys	NNS	O
?	.	O
Response	JJ	O
rates	NNS	O
to	TO	O
surveys	NNS	O
are	VBP	O
decreasing	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	O
tickets	NNS	O
as	IN	O
incentives	NNS	O
in	IN	O
an	DT	O
epidemiologic	JJ	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
self-administered	JJ	O
questionnaire	NN	O
was	VBD	O
sent	VBN	O
to	TO	O
parents	NNS	O
in	IN	O
the	DT	O
municipality	NN	O
of	IN	O
Stockholm	NNP	O
,	,	O
Sweden	NNP	O
,	,	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
in	IN	O
a	DT	O
study	NN	O
addressing	VBG	O
stress	NN	O
in	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
cancer	NN	O
.	.	O

A	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
450	CD	O
parents	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
incentive	JJ	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
no	DT	O
incentive	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
a	DT	O
promised	JJ	O
incentive	NN	O
of	IN	O
one	CD	O
lottery	NN	O
ticket	NN	O
to	TO	O
be	VB	O
received	VBN	O
upon	IN	O
reply	NN	O
;	:	O
(	(	O
c	NN	O
)	)	O
a	DT	O
promised	JJ	O
incentive	NN	O
of	IN	O
one	CD	O
lottery	NN	O
ticket	NN	O
to	TO	O
be	VB	O
received	VBN	O
upon	IN	O
reply	NN	O
and	CC	O
an	DT	O
additional	JJ	O
lottery	NN	O
ticket	NN	O
upon	IN	O
reply	NN	O
within	IN	O
1	CD	O
week	NN	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	ME
rate	NN	ME
across	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
65.3	CD	O
%	NN	O
.	.	O

The	DT	O
response	NN	ME
rate	NN	ME
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
(	(	O
69.3	CD	O
%	NN	O
)	)	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
one	CD	O
plus	CC	O
one	CD	O
lottery	NN	O
ticket	NN	O
group	NN	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
a	DT	O
survival	JJ	MO
analysis	NN	MO
,	,	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
response	NN	O
curves	NNS	O
was	VBD	O
significant	JJ	O
by	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
having	VBG	O
a	DT	O
shorter	JJR	O
time	NN	O
to	TO	O
response	NN	O
than	IN	O
the	DT	O
incentive	NN	O
group	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	O
tickets	NNS	O
as	IN	O
incentives	NNS	O
to	TO	O
increase	VB	ME
participation	NN	ME
in	IN	O
a	DT	O
mail	NN	Ot
questionnaire	NN	Ot
among	IN	O
parents	NNS	O
may	MD	O
be	VB	O
less	RBR	O
valuable	JJ	O
or	CC	O
even	RB	O
harmful	JJ	O
.	.	O

Incentives	NNS	O
may	MD	O
undermine	VB	O
motivation	NN	ME
in	IN	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
intrinsic	JJ	O
motivation	NN	O
of	IN	O
the	DT	O
respondents	NNS	O
is	VBZ	O
already	RB	O
high	JJ	O
.	.	O

Augmented	VBN	O
soft	JJ	O
tissue	NN	O
mobilization	NN	O
vs	IN	O
natural	JJ	O
history	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
lateral	JJ	O
epicondylitis	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
augmented	JJ	O
soft	JJ	O
tissue	NN	O
mobilization	NN	O
(	(	O
ASTM	NNP	O
)	)	O
on	IN	O
the	DT	O
treatment	NN	O
of	IN	O
lateral	JJ	O
epicondylitis	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
randomized	VBD	O
clinical	JJ	O
study	NN	O
assessed	VBD	O
27	CD	O
subjects	NNS	O
(	(	O
12	CD	O
men	NNS	O
and	CC	O
15	CD	O
women	NNS	O
)	)	O
with	IN	O
lateral	JJ	O
epicondylitis	NN	O
and	CC	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
received	VBD	O
ASTM	NNP	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
received	VBN	O
advice	NN	O
on	IN	O
the	DT	O
natural	JJ	O
evolution	NN	O
of	IN	O
lateral	JJ	O
epicondylitis	NN	O
,	,	O
computer	NN	O
ergonomics	NNS	O
,	,	O
and	CC	O
stretching	VBG	O
exercises	NNS	O
.	.	O

Patient-rated	JJ	O
outcome	NN	O
was	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
using	VBG	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
and	CC	O
the	DT	O
Patient-Rated	JJ	O
Tennis	NNP	O
Elbow	NNP	O
Evaluation	NNP	O
.	.	O

The	DT	O
function	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
pain-free	JJ	PA
grip	NN	PA
strength	NN	PA
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
showed	VBD	O
improvements	NNS	PA
in	IN	PA
pain-free	JJ	PA
grip	NN	PA
strength	NN	PA
,	,	O
visual	JJ	PH
analog	NN	PH
scale	NN	PH
,	,	O
and	CC	O
Patient-Rated	JJ	PH
Tennis	NNP	PH
Elbow	NNP	PH
Evaluation	NNP	PH
.	.	O

Sample	NNP	O
size	NN	O
for	IN	O
larger	JJR	O
future	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
was	VBD	O
116	CD	O
participants	NNS	O
.	.	O

CONCLUSION	VB	O
A	NNP	O
larger	JJR	O
study	NN	O
investigating	VBG	O
the	DT	O
same	JJ	O
hypothesis	NN	O
is	VBZ	O
warranted	VBN	O
to	TO	O
detect	VB	O
difference	NN	O
in	IN	O
the	DT	O
effects	NNS	O
of	IN	O
these	DT	O
treatments	NNS	O
strategies	NNS	O
.	.	O

The	DT	O
study	NN	O
design	NN	O
is	VBZ	O
feasible	JJ	O
,	,	O
and	CC	O
minor	JJ	O
improvements	NNS	O
will	MD	O
help	VB	O
to	TO	O
minimize	VB	O
the	DT	O
potential	JJ	O
bias	NN	O
.	.	O

Impact	NN	O
of	IN	O
a	DT	O
controlled	VBN	O
heated	VBN	O
breathing	VBG	O
tube	NN	O
humidifier	NN	O
on	IN	O
sleep	JJ	PH
quality	NN	PH
during	IN	O
CPAP	NNP	O
therapy	NN	O
in	IN	O
a	DT	O
cool	JJ	O
sleeping	NN	O
environment	NN	O
.	.	O

There	EX	O
are	VBP	O
conflicting	VBG	O
data	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
a	DT	O
heated	VBN	O
humidifier	NN	O
to	TO	O
nasal	RB	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
(	(	O
CPAP	NNP	O
)	)	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
obstructive	JJ	O
sleep	JJ	O
apnoea	NN	O
syndrome	NN	O
(	(	O
OSAS	NNP	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
heated	JJ	O
humidification	NN	O
on	IN	O
sleep	JJ	PH
quality	NN	PH
and	CC	O
treatment	NN	A
side-effects	NNS	A
for	IN	O
patients	NNS	O
who	WP	O
prefer	VBP	O
a	DT	O
cold	JJ	O
bedroom	NN	O
environment	NN	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

A	DT	O
randomised	JJ	O
,	,	O
controlled	VBD	O
crossover	RB	O
trial	NN	O
involving	VBG	O
19	CD	O
patients	NNS	O
with	IN	O
a	DT	O
first-ever	JJ	O
diagnosis	NN	O
of	IN	O
OSAS	NNP	O
measured	VBD	O
the	DT	O
effect	NN	O
of	IN	O
conventional	JJ	O
heated	JJ	O
humidification	NN	O
added	VBD	O
to	TO	O
CPAP	NNP	O
compared	VBN	O
with	IN	O
a	DT	O
controlled	VBN	O
heated	VBN	O
breathing	VBG	O
tube	NN	O
humidifier	NN	O
(	(	O
ThermoSmart	NNP	O
(	(	O
R	NNP	O
)	)	O
;	:	O
Fisher	NNP	O
and	CC	O
Paykel	NNP	O
Healthcare	NNP	O
,	,	O
Auckland	NNP	O
,	,	O
New	NNP	O
Zealand	NNP	O
)	)	O
on	IN	O
sleep	JJ	PH
quality	NN	PH
.	.	PH

During	IN	O
the	DT	O
night	NN	O
in	IN	O
the	DT	O
sleep	JJ	O
laboratory	NN	O
at	IN	O
a	DT	O
mean	JJ	O
room	NN	O
temperature	NN	O
of	IN	O
14	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
less	JJR	O
condensation	NN	Ot
formed	VBN	O
with	IN	O
the	DT	O
controlled	VBN	O
heated	VBD	O
breathing	VBG	O
tube	NN	O
humidifier	NN	O
(	(	O
1.9	CD	O
mL	NN	O
versus	NN	O
35.3	CD	O
mL	NN	O
)	)	O
in	IN	O
the	DT	O
delivery	NN	O
system	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
total	JJ	PH
sleep	JJ	PH
time	NN	PH
,	,	PH
time	NN	PH
spent	VBN	PH
in	IN	PH
sleep	JJ	PH
stages	NNS	PH
3	CD	PH
and	CC	PH
4	CD	PH
,	,	PH
and	CC	PH
rapid	JJ	PH
eye	NN	PH
movement	NN	PH
sleep	JJ	PH
phases	NNS	PH
were	VBD	O
significantly	RB	O
longer	RBR	O
and	CC	O
the	DT	O
overall	JJ	A
side-effect	JJ	A
score	NN	A
was	VBD	O
lower	JJR	O
than	IN	O
with	IN	O
conventional	JJ	O
heated	JJ	O
humidification	NN	O
.	.	O

Patients	NNS	O
on	IN	O
nasal	JJ	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
desiring	VBG	O
a	DT	O
cool	JJ	O
bedroom	NN	O
temperature	NN	O
could	MD	O
benefit	VB	O
from	IN	O
controlled	VBN	O
heated	VBN	O
breathing	VBG	O
tube	JJ	O
humidification	NN	O
technology	NN	O
(	(	O
with	IN	O
inputs	NNS	O
from	IN	O
ambient	JJ	O
temperature	NN	O
,	,	O
set	VBN	O
pressure	NN	O
and	CC	O
flow	NN	O
)	)	O
.	.	O

Use	NNP	O
of	IN	O
the	DT	O
electrothermal	JJ	O
bipolar	JJ	O
vessel	NN	O
system	NN	O
(	(	O
EBVS	NNP	O
)	)	O
in	IN	O
laparoscopic	JJ	O
adrenalectomy	NN	O
:	:	O
a	DT	O
prospective	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Since	IN	O
laparoscopic	NN	O
adrenalectomy	NN	O
(	(	O
LA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
adopted	VBN	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adrenal	JJ	O
diseases	NNS	O
,	,	O
the	DT	O
development	NN	O
of	IN	O
technology	NN	O
for	IN	O
vascular	JJ	O
control	NN	O
and	CC	O
dissection	NN	O
manoeuvres	NNS	O
,	,	O
amongst	VBZ	O
other	JJ	O
things	NNS	O
,	,	O
may	MD	O
play	VB	O
a	DT	O
pivotal	JJ	O
role	NN	O
in	IN	O
its	PRP$	O
further	JJ	O
improvement	NN	O
.	.	O

We	PRP	O
report	VBP	O
our	PRP$	O
experience	NN	O
with	IN	O
the	DT	O
electrothermal	JJ	O
bipolar	JJ	O
vessel	NN	O
sealing	NN	O
(	(	O
EBVS	NNP	O
)	)	O
device	NN	O
for	IN	O
LA	NNP	O
.	.	O

METHODS	NNP	O
From	IN	O
January	NNP	O
2004	CD	O
to	TO	O
January	NNP	O
2006	CD	O
,	,	O
50	CD	O
patients	NNS	O
(	(	O
pts	NNS	O
)	)	O
undergoing	VBG	O
LA	NNP	O
were	VBD	O
selected	VBN	O
and	CC	O
randomized	VBN	O
for	IN	O
use	NN	O
of	IN	O
the	DT	O
EBVS	NNP	O
(	(	O
25	CD	O
pts	NNS	O
,	,	O
group	NN	O
A	NNP	O
)	)	O
versus	IN	O
the	DT	O
UltraSonic	NNP	O
Shears	NNP	O
(	(	O
USS	NNP	O
)	)	O
device	NN	O
(	(	O
25	CD	O
pts	NNS	O
,	,	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Age	NNP	O
,	,	O
sex	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
previous	JJ	O
surgery	NN	O
and	CC	O
associated	VBN	O
diseases	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
main	JJ	O
surgical	JJ	O
parameters	NNS	O
collected	VBN	O
for	IN	O
each	DT	O
patient	NN	O
(	(	O
pt	NN	O
)	)	O
concerned	VBD	O
operative	JJ	O
time	NN	O
,	,	O
major	JJ	O
and	CC	O
minor	JJ	O
complications	NNS	O
,	,	O
conversion	NN	O
rate	NN	O
,	,	O
blood	NN	O
loss	NN	O
,	,	O
hospital	JJ	O
stay	NN	O
and	CC	O
histology	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	MO
mortality	NN	MO
in	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
right	JJ	O
adrenalectomy	NN	O
mean	VB	Ot
operative	JJ	Ot
time	NN	Ot
(	(	Ot
OpT	NNP	Ot
)	)	Ot
was	VBD	O
51.8	CD	O
mins	NNS	O
(	(	O
range	VB	O
40-90	JJ	O
mins	NNS	O
)	)	O
and	CC	O
68.6	CD	O
mins	NNS	O
(	(	O
range	VB	O
50-130	NNP	O
mins	NNS	O
)	)	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
left	JJ	Ot
adrenalectomy	JJ	Ot
mean	JJ	Ot
OpT	NNP	Ot
was	VBD	O
72.2	CD	O
mins	NNS	O
(	(	O
range	VB	O
55-100	NNP	O
mins	NNS	O
)	)	O
and	CC	O
94	CD	O
mins	NNS	O
(	(	O
range	VB	O
65-140	NNP	O
mins	NNS	O
)	)	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	PH
blood	NN	PH
loss	NN	PH
was	VBD	O
83	CD	O
ml	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
210	CD	O
ml	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Complications	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	Ot
hospital	NN	Ot
stay	NN	Ot
was	VBD	O
2.9	CD	O
and	CC	O
3.1	CD	O
days	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
EBVS	NNP	O
in	IN	O
LA	NNP	O
may	MD	O
provide	VB	O
a	DT	O
significantly	RB	O
short	JJ	PH
operating	NN	PH
time	NN	PH
and	CC	PH
blood	NN	PH
loss	NN	PH
.	.	O

Untoward	NNP	O
effects	NNS	O
of	IN	O
fenfluramine	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

Several	JJ	O
recent	JJ	O
studies	NNS	O
have	VBP	O
described	VBN	O
the	DT	O
benefits	NNS	O
of	IN	O
fenfluramine	NN	O
for	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
infantile	JJ	O
autism	NN	O
.	.	O

No	DT	O
large	JJ	O
surveys	NNS	O
of	IN	O
side	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
drug	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
untoward	JJ	O
effects	NNS	O
of	IN	O
fenfluramine	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
12	CD	O
subjects	NNS	O
were	VBD	O
systematically	RB	O
studied	VBN	O
.	.	O

Medication	NNP	O
was	VBD	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
trained	VBN	O
in	IN	O
monitoring	VBG	O
untoward	JJ	O
effects	NNS	O
.	.	O

These	DT	O
observations	NNS	O
were	VBD	O
compiled	VBN	O
in	IN	O
detailed	JJ	O
daily	JJ	O
notes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
four	CD	O
cases	NNS	O
describing	VBG	O
unusual	JJ	O
effects	NNS	O
found	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
170	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
fenfluramine	NN	O
are	VBP	O
also	RB	O
reported	VBN	O
.	.	O

In	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
drug	NN	O
listlessness	NN	O
,	,	O
food	NN	ME
refusal	NN	ME
,	,	O
and	CC	O
stomach	NN	PH
upset	NN	PH
were	VBD	O
frequently	RB	O
seen	VBN	O
.	.	O

A	DT	O
different	JJ	O
pattern	NN	O
of	IN	O
untoward	JJ	A
effects	NNS	A
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
final	JJ	O
14	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Irritability	NNP	ME
,	,	ME
agitation	NN	ME
,	,	ME
and	CC	ME
crying	VBG	ME
along	RB	ME
with	IN	ME
continued	VBN	ME
food	NN	ME
refusal	NN	ME
were	VBD	O
noted	VBN	O
.	.	O

The	DT	O
subjects	NNS	O
lost	VBD	O
2.1	CD	O
%	NN	O
of	IN	O
body	NN	PH
weight	NN	PH
during	IN	O
active	JJ	O
drug	NN	O
phase	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
rebound	NN	PH
weight	NN	PH
gain	NN	PH
during	IN	O
the	DT	O
subsequent	JJ	O
placebo	NN	O
phase	NN	O
.	.	O

A	DT	O
thorough	JJ	O
understanding	NN	O
of	IN	O
fenfluramine	NN	O
's	POS	O
side	NN	O
effects	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
is	VBZ	O
necessary	JJ	O
so	RB	O
as	IN	O
to	TO	O
differentiate	VB	O
them	PRP	O
from	IN	O
the	DT	O
multiple	NN	O
symptoms	NNS	O
inherent	NN	O
in	IN	O
the	DT	O
syndrome	NN	O
of	IN	O
autism	NN	O
.	.	O

Impact	NN	O
of	IN	O
different	JJ	O
platelet	NN	O
glycoprotein	NN	O
IIb/IIIa	NNP	O
receptor	NN	O
inhibitors	NNS	O
among	IN	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
:	:	O
:	:	O
Do	VB	O
Tirofiban	NNP	O
and	CC	O
ReoPro	NNP	O
Give	NNP	O
Similar	NNP	O
Efficacy	NNP	O
Outcomes	NNP	O
Trial	NNP	O
(	(	O
TARGET	NNP	O
)	)	O
1-year	JJ	O
follow-up	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
platelet	NN	O
glycoprotein	NN	O
IIb/IIIa	NNP	O
receptor	NN	O
inhibitor	NN	O
abciximab	NN	O
,	,	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
early	JJ	O
and	CC	O
late	JJ	O
outcomes	NNS	O
among	IN	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
unknown	JJ	O
whether	IN	O
small-molecule	JJ	O
agents	NNS	O
confer	VBP	O
similar	JJ	O
benefits	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
In	IN	O
18	CD	O
countries	NNS	O
,	,	O
4809	CD	O
patients	NNS	O
undergoing	VBG	O
PCI	NNP	O
with	IN	O
stent	JJ	O
implantation	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
tirofiban	VB	O
or	CC	O
abciximab	VB	O
.	.	O

At	IN	O
the	DT	O
time	NN	O
of	IN	O
enrollment	NN	O
,	,	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
diabetes	NNS	O
status	NN	O
.	.	O

As	IN	O
compared	VBN	O
with	IN	O
non-diabetic	JJ	O
patients	NNS	O
,	,	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
(	(	O
n=1117	NN	O
)	)	O
showed	VBD	O
similar	JJ	O
30-day	JJ	O
ischemic	JJ	O
outcomes	NNS	O
,	,	O
an	DT	O
increased	JJ	O
incidence	NN	PH
of	IN	PH
any	DT	PH
target	NN	PH
vessel	NN	PH
revascularization	NN	PH
(	(	PH
TVR	NNP	PH
)	)	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
10.3	CD	O
%	NN	O
versus	IN	O
7.8	CD	O
%	NN	O
;	:	O
P=	NNP	O
0.008	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
higher	JJR	MO
1-year	JJ	MO
mortality	NN	MO
(	(	O
2.5	CD	O
%	NN	O
versus	IN	O
1.6	CD	O
%	NN	O
;	:	O
P=0.056	NNP	O
)	)	O
.	.	O

Among	IN	O
diabetic	JJ	O
patients	NNS	O
randomized	VBN	O
to	TO	O
tirofiban	VB	O
(	(	O
n=560	NN	O
)	)	O
,	,	O
the	DT	O
incidence	NN	MO
of	IN	MO
death	NN	MO
,	,	O
myocardial	JJ	PH
infarction	NN	PH
(	(	PH
MI	NNP	PH
)	)	PH
,	,	PH
or	CC	O
urgent	JJ	PH
TVR	NNP	PH
at	IN	O
30	CD	O
days	NNS	O
was	VBD	O
6.2	CD	O
%	NN	O
,	,	O
and	CC	O
among	IN	O
those	DT	O
randomized	VBN	O
to	TO	O
abciximab	VB	O
(	(	O
n=557	NN	O
)	)	O
it	PRP	O
was	VBD	O
5.4	CD	O
%	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
1.16	CD	O
;	:	O
P=0.540	NNP	O
)	)	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
composite	NN	O
of	IN	O
death	NN	MO
,	,	O
MI	NNP	O
,	,	O
or	CC	O
any	DT	O
TVR	NNP	PH
occurred	VBD	O
in	IN	O
15.7	CD	O
%	NN	O
and	CC	O
in	IN	O
16.9	CD	O
%	NN	O
of	IN	O
tirofiban	NN	O
and	CC	O
abciximab	NN	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
HR	NNP	O
0.93	CD	O
;	:	O
P=0.610	NNP	O
)	)	O
.	.	O

Any	DT	O
TVR	NNP	PH
occurred	VBD	O
in	IN	O
9.5	CD	O
%	NN	O
and	CC	O
11.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
HR	NNP	O
0.84	CD	O
;	:	O
P=	NNP	O
0.366	CD	O
)	)	O
.	.	O

The	DT	O
1-year	JJ	MO
mortality	NN	MO
was	VBD	O
2.1	CD	O
%	NN	O
in	IN	O
the	DT	O
tirofiban	NN	O
group	NN	O
and	CC	O
2.9	CD	O
%	NN	O
in	IN	O
the	DT	O
abciximab	NN	O
group	NN	O
(	(	O
HR	NNP	O
0.74	CD	O
;	:	O
P=	NNP	O
0.436	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Among	IN	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
PCI	NNP	O
,	,	O
tirofiban	NN	O
and	CC	O
abciximab	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
comparable	JJ	O
event	NN	O
rates	NNS	O
,	,	O
including	VBG	O
similar	JJ	O
rates	NNS	O
of	IN	O
6-month	JJ	O
TVR	NNP	O
and	CC	O
1-year	JJ	O
mortality	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
non-glycoprotein	JJ	O
IIb/IIIa	NNP	O
properties	NNS	O
of	IN	O
abciximab	NNS	O
do	VBP	O
not	RB	O
translate	VB	O
into	IN	O
a	DT	O
discernible	JJ	O
long-term	JJ	O
clinical	JJ	O
benefit	NN	O
among	IN	O
diabetic	JJ	O
patients	NNS	O
.	.	O

Locomoting-to-reach	NN	O
:	:	O
information	NN	O
variables	NNS	O
and	CC	O
control	NN	O
strategies	NNS	O
for	IN	O
nested	JJ	O
actions	NNS	O
.	.	O

Locomoting-to-reach	NNP	O
is	VBZ	O
a	DT	O
basic	JJ	O
perception/action	NN	O
behavior	NN	O
that	WDT	O
requires	VBZ	O
visual	JJ	O
information	NN	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
locomotion	NN	O
and	CC	O
reaching	VBG	O
components	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
visual	JJ	O
information	NN	O
and	CC	O
the	DT	O
control	NN	O
strategies	NNS	O
used	VBN	O
to	TO	O
guide	VB	O
both	PDT	O
the	DT	O
head	NN	O
and	CC	O
the	DT	O
hand	NN	O
on	IN	O
approach	NN	O
to	TO	O
a	DT	O
target	NN	O
in	IN	O
a	DT	O
locomotion-to-reach	JJ	O
task	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
participants	NNS	O
were	VBD	O
required	VBN	O
to	TO	O
locomote	VB	O
in	IN	O
the	DT	O
dark	NN	O
to	TO	O
a	DT	O
lit	NN	O
target	NN	O
in	IN	O
three	CD	O
different	JJ	O
conditions	NNS	O
:	:	O
monocular	JJ	O
vision/target	NN	O
with	IN	O
image	NN	O
size	NN	O
,	,	O
binocular	JJ	O
vision/target	NN	O
with	IN	O
image	NN	O
size	NN	O
,	,	O
and	CC	O
binocular	JJ	O
vision/point-light	JJ	O
target	NN	O
(	(	O
without	IN	O
image	NN	O
size	NN	O
)	)	O
.	.	O

In	IN	O
task	NN	O
one	CD	O
,	,	O
participants	NNS	O
brought	VBD	O
their	PRP$	O
eyes	NNS	O
to	TO	O
the	DT	O
target	NN	O
.	.	O

In	IN	O
task	NN	O
two	CD	O
,	,	O
participants	NNS	O
brought	VBD	O
their	PRP$	O
outstretched	JJ	O
hand	NN	O
to	TO	O
the	DT	O
target	NN	O
.	.	O

Movement	JJ	PH
trajectories	NNS	PH
for	IN	O
both	DT	O
tasks	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Results	NNP	O
show	VBP	O
that	IN	O
participants	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
accurate	JJ	Ot
when	WRB	Ot
binocular	JJ	Ot
information	NN	Ot
was	VBD	Ot
present	JJ	Ot
.	.	O

In	IN	O
both	DT	O
tasks	NNS	O
,	,	O
participants	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
use	VB	O
a	DT	O
proportional	JJ	O
rate	NN	O
control	NN	O
strategy	NN	O
rather	RB	O
than	IN	O
a	DT	O
constant	JJ	O
?	.	O
strategy	NN	O
.	.	O

In	IN	O
the	DT	O
walk-to-reach	NN	O
task	NN	O
,	,	O
they	PRP	O
used	VBD	O
monocular	JJ	O
and/or	NN	O
binocular	NN	O
?	.	O
information	NN	O
to	TO	O
guide	VB	O
the	DT	O
head	NN	O
and	CC	O
then	RB	O
switched	VBD	O
to	TO	O
using	VBG	O
relative	JJ	O
disparity	NN	O
?	.	O
to	TO	O
guide	VB	O
the	DT	O
hand	NN	O
to	TO	O
final	JJ	O
target	NN	O
acquisition	NN	O
,	,	O
switching	VBG	O
when	WRB	O
the	DT	O
hand	NN	O
centric	NN	O
?	.	O
became	VBD	O
less	JJR	O
than	IN	O
the	DT	O
head	NN	O
centric	JJ	O
?.	NNP	O
Dynamical	NNP	O
models	NNS	O
of	IN	O
the	DT	O
information	NN	O
and	CC	O
control	NN	O
strategies	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
perform	VB	O
simulations	NNS	O
that	WDT	O
were	VBD	O
found	VBN	O
to	TO	O
fit	VB	O
the	DT	O
data	NN	O
well	RB	O
.	.	O

The	DT	O
conclusion	NN	O
is	VBZ	O
that	IN	O
proportional	JJ	O
rate	NN	O
control	NN	O
is	VBZ	O
used	VBN	O
sequentially	RB	O
with	IN	O
head	NN	O
centric	NN	O
,	,	O
then	RB	O
hand-centric	JJ	O
?-based	JJ	O
information	NN	O
,	,	O
using	VBG	O
at	IN	O
each	DT	O
moment	NN	O
the	DT	O
?	.	O
with	IN	O
the	DT	O
smallest	JJS	O
value	NN	O
.	.	O

Direct	JJ	O
evidence	NN	O
for	IN	O
spinal	JJ	O
cord	NN	O
involvement	NN	O
in	IN	O
placebo	NN	O
analgesia	NN	O
.	.	O

Placebo	NNP	O
analgesia	NN	O
is	VBZ	O
a	DT	O
prime	JJ	O
example	NN	O
of	IN	O
the	DT	O
impact	NN	O
that	WDT	O
psychological	JJ	O
factors	NNS	O
have	VBP	O
on	IN	O
pain	NN	O
perception	NN	O
.	.	O

We	PRP	O
used	VBD	O
functional	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
of	IN	O
the	DT	O
human	JJ	O
spinal	JJ	O
cord	NN	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
placebo	VBZ	O
analgesia	JJ	O
results	NNS	O
in	IN	O
a	DT	O
reduction	NN	O
of	IN	O
nociceptive	JJ	O
processing	NN	O
in	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
.	.	O

In	IN	O
line	NN	O
with	IN	O
behavioral	JJ	O
data	NNS	O
that	WDT	O
show	VBP	O
decreased	VBN	O
pain	NN	PA
responses	NNS	PA
under	IN	O
placebo	NN	O
,	,	O
pain-related	JJ	PA
activity	NN	PA
in	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
is	VBZ	O
strongly	RB	O
reduced	VBN	O
under	IN	O
placebo	NN	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
direct	JJ	O
evidence	NN	O
for	IN	O
spinal	JJ	O
inhibition	NN	O
as	IN	O
one	CD	O
mechanism	NN	O
of	IN	O
placebo	NN	O
analgesia	NN	O
and	CC	O
highlight	NN	O
that	WDT	O
psychological	JJ	O
factors	NNS	O
can	MD	O
act	VB	O
on	IN	O
the	DT	O
earliest	JJS	O
stages	NNS	O
of	IN	O
pain	NN	O
processing	NN	O
in	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
Picture	NNP	O
Exchange	NNP	O
Communication	NNP	O
System	NNP	O
(	(	O
PECS	NNP	O
)	)	O
training	NN	O
for	IN	O
teachers	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
pragmatic	JJ	O
,	,	O
group	NN	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
expert	JJ	O
training	NN	O
and	CC	O
consultancy	NN	O
for	IN	O
teachers	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Picture	NNP	O
Exchange	NNP	O
Communication	NNP	O
System	NNP	O
(	(	O
PECS	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
DESIGN	NNP	O
Group	NNP	O
randomised	VBD	O
,	,	O
controlled	VBN	O
trial	NN	O
(	(	O
3	CD	O
groups	NNS	O
:	:	O
immediate	JJ	O
treatment	NN	O
,	,	O
delayed	VBN	O
treatment	NN	O
,	,	O
no	DT	O
treatment	NN	O
)	)	O
.	.	O

PARTICIPANTS	$	O
84	CD	O
elementary	JJ	O
school	NN	O
children	NNS	O
,	,	O
mean	JJ	O
age	NN	O
6.8	CD	O
years	NNS	O
.	.	O

TREATMENT	VB	O
A	DT	O
2-day	JJ	O
PECS	NNP	O
workshop	NN	O
for	IN	O
teachers	NNS	O
plus	CC	O
6	CD	O
half-day	JJ	O
,	,	O
school-based	JJ	O
training	NN	O
sessions	NNS	O
with	IN	O
expert	JJ	O
consultants	NNS	O
over	IN	O
5	CD	O
months	NNS	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Rates	NNPS	O
of	IN	O
:	:	O
communicative	JJ	ME
initiations	NNS	ME
,	,	ME
use	NN	ME
of	IN	ME
PECS	NNP	ME
,	,	ME
and	CC	ME
speech	NN	ME
in	IN	ME
the	DT	ME
classroom	NN	ME
;	:	ME
Autism	NNP	ME
Diagnostic	NNP	ME
Observation	NNP	ME
Schedule-Generic	NNP	ME
(	(	ME
ADOS-G	NNP	ME
)	)	ME
domain	NN	ME
scores	NNS	ME
for	IN	ME
Communication	NNP	ME
and	CC	ME
Reciprocal	NNP	ME
Social	NNP	ME
Interaction	NNP	ME
;	:	ME
scores	NNS	ME
on	IN	ME
formal	JJ	ME
language	NN	ME
tests	NNS	ME
.	.	O

RESULTS	NNP	O
Controlling	VBG	O
for	IN	O
baseline	NN	O
age	NN	O
,	,	O
developmental	JJ	ME
quotient	NN	ME
(	(	ME
DQ	NNP	ME
)	)	ME
and	CC	ME
language	NN	ME
;	:	ME
rates	NNS	ME
of	IN	ME
initiations	NNS	ME
and	CC	ME
PECS	NNP	ME
usage	NN	ME
increased	VBD	O
significantly	RB	O
immediately	RB	O
post-treatment	JJ	O
(	(	O
Odds	NNP	O
Ratio	NNP	O
(	(	O
OR	NNP	O
)	)	O
of	IN	O
being	VBG	O
in	IN	O
a	DT	O
higher	JJR	O
ordinal	JJ	O
rate	NN	O
category	NN	O
2.72	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
1.22-6.09	JJ	O
,	,	O
p	JJ	O
<	NNP	O
.05	NNP	O
and	CC	O
OR	NNP	O
3.90	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.75-8.68	CD	O
)	)	O
,	,	O
p	JJ	O
<	NNP	O
.001	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
increases	NNS	O
in	IN	O
frequency	NN	ME
of	IN	ME
speech	NN	ME
,	,	ME
or	CC	ME
improvements	NNS	ME
in	IN	ME
ADOS-G	NNP	ME
ratings	NNS	ME
or	CC	ME
language	NN	ME
test	NN	ME
scores	NNS	ME
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
indicate	VBP	O
modest	JJ	O
effectiveness	NN	O
of	IN	O
PECS	NNP	O
teacher	NN	O
training/consultancy	NN	O
.	.	O

Rates	NNS	O
of	IN	O
pupils	NNS	O
'	POS	O
initiations	NNS	O
and	CC	O
use	NN	O
of	IN	O
symbols	NNS	O
in	IN	O
the	DT	O
classroom	NN	O
increased	VBD	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
improvement	NN	O
in	IN	O
other	JJ	O
areas	NNS	O
of	IN	O
communication	NN	O
.	.	O

TREATMENT	NNP	O
effects	NNS	O
were	VBD	O
not	RB	O
maintained	VBN	O
once	RB	O
active	JJ	O
intervention	NN	O
ceased	VBD	O
.	.	O

Long	JJ	O
term	NN	O
response	NN	O
to	TO	O
therapy	NN	O
of	IN	O
chronic	JJ	O
anti-HBe-positive	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
poor	JJ	O
independent	JJ	O
of	IN	O
type	NN	O
and	CC	O
schedule	NN	O
of	IN	O
interferon	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
response	NN	PH
rate	NN	PH
to	TO	PH
alpha	VB	PH
interferon	NN	PH
(	(	PH
IFN	NNP	PH
)	)	PH
of	IN	O
chronic	JJ	O
anti-HBe-positive	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
variable	JJ	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
type	NN	O
,	,	O
dose	NN	O
,	,	O
and	CC	O
schedule	NN	O
of	IN	O
IFN	NNP	O
,	,	O
and	CC	O
type	NN	O
and	CC	O
frequency	NN	O
of	IN	O
posttreatment	NN	O
monitoring	NN	O
,	,	O
influence	VB	O
the	DT	O
response	NN	O
rate	NN	O
.	.	O

METHODS	NNP	O
Seventy-two	JJ	O
consecutive	JJ	O
anti-HBe-positive	JJ	O
chronic	NN	O
hepatitis	NN	O
B	NNP	O
patients	NNS	O
(	(	O
59	CD	O
male	NN	O
and	CC	O
13	CD	O
female	NN	O
,	,	O
median	JJ	O
age	NN	O
41	CD	O
yr	NN	O
)	)	O
stratified	VBN	O
by	IN	O
sex	NN	O
and	CC	O
histology	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
arms	NNS	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
(	(	O
A	DT	O
)	)	O
received	VBD	O
10	CD	O
million	CD	O
units	NNS	O
alpha-N1	JJ	O
IFN	NNP	O
i.m	NN	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
24	CD	O
wk	NN	O
(	(	O
total	JJ	O
dose	NN	O
:	:	O
720	CD	O
million	CD	O
units	NNS	O
)	)	O
;	:	O
21	CD	O
(	(	O
B	NNP	O
)	)	O
received	VBD	O
9	CD	O
million	CD	O
units	NNS	O
alpha-2a	JJ	O
IFN	NNP	O
i.m	NN	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
4	CD	O
wk	NN	O
,	,	O
followed	VBN	O
by	IN	O
18	CD	O
million	CD	O
units	NNS	O
for	IN	O
12	CD	O
wk	NN	O
and	CC	O
9	CD	O
million	CD	O
units	NNS	O
for	IN	O
8	CD	O
wk	NN	O
(	(	O
972	CD	O
million	CD	O
units	NNS	O
)	)	O
;	:	O
24	CD	O
(	(	O
C	NNP	O
)	)	O
received	VBD	O
2	CD	O
alpha-2a	JJ	O
IFN	NNP	O
courses	NNS	O
(	(	O
9	CD	O
million	CD	O
units	NNS	O
i.m	RB	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
16	CD	O
and	CC	O
12	CD	O
wk	NN	O
separated	VBN	O
by	IN	O
a	DT	O
6-month	JJ	O
interval	NN	O
[	$	O
756	CD	O
million	CD	O
units	NNS	O
]	NNP	O
)	)	O
.	.	O

Primary	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
normal	JJ	PH
ALT	NNP	PH
and	CC	O
serum	VB	PH
HBV-DNA	NNP	PH
levels	NNS	PH
below	IN	O
10	CD	O
pg/ml	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
therapy	NN	O
and	CC	O
sustained	VBN	O
response	NN	O
by	IN	O
normal	JJ	PH
ALT	NNP	PH
(	(	O
tested	VBN	O
monthly	RB	O
)	)	O
,	,	O
undetectable	JJ	PH
HBV-DNA	NN	PH
and	CC	O
IgM	NNP	O
anti-HBc	NN	O
(	(	O
<	JJ	O
7	CD	O
I.U	NNP	O
.	.	O

Paul	NNP	O
Ehrlich	NNP	O
Institute	NNP	O
)	)	O
(	(	O
tested	VBN	O
every	DT	O
3	CD	O
months	NNS	O
)	)	O
during	IN	O
the	DT	O
posttreatment	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
,	,	O
12	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
13	CD	O
patients	NNS	O
from	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
and	CC	O
C	NNP	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
responders	NNS	O
.	.	O

At	IN	O
the	DT	O
18-month	JJ	O
follow-up	JJ	O
,	,	O
two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
only	RB	O
one	CD	O
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
maintained	VBD	O
the	DT	O
response	NN	O
.	.	O

Overall	NNP	O
,	,	O
after	IN	O
34	CD	O
months	NNS	O
(	(	O
median	JJ	O
posttreatment	NN	O
follow-up	NN	O
)	)	O
,	,	O
three	CD	O
patients	NNS	O
were	VBD	O
long	JJ	O
term	NN	O
responders	NNS	O
,	,	O
whereas	NNS	O
three	CD	O
showed	VBD	O
a	DT	O
sustained	VBN	O
remission	NN	Ot
after	IN	O
relapse	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
rate	NN	PH
of	IN	PH
long	JJ	PH
term	NN	PH
response	NN	PH
to	TO	O
interferon	VB	O
of	IN	O
anti-HBe-positive	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
poor	JJ	O
,	,	O
independent	JJ	O
of	IN	O
IFN	NNP	O
type	NN	O
,	,	O
dose	VB	O
,	,	O
or	CC	O
schedule	NN	O
;	:	O
the	DT	O
more	RBR	O
stringent	JJ	O
the	DT	O
monitoring	NN	O
,	,	O
the	DT	O
higher	JJR	O
the	DT	O
relapse	NN	O
rate	NN	O
.	.	O

Pharmacokinetics	NNS	Ot
and	CC	A
tolerance	NN	Ot
of	IN	O
single-	JJ	O
and	CC	O
multiple-dose	JJ	O
oral	JJ	O
or	CC	O
intravenous	JJ	O
linezolid	NNS	O
,	,	O
an	DT	O
oxazolidinone	NN	O
antibiotic	JJ	O
,	,	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
tolerance	NN	PH
of	IN	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
linezolid	NN	O
,	,	O
an	DT	O
oxazolidinone	NN	O
antibiotic	JJ	O
,	,	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
following	VBG	O
single-	JJ	O
and	CC	O
multiple-dose	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
two	CD	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
dose-escalating	JJ	O
trials	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
exposed	VBN	O
either	RB	O
to	TO	O
oral	JJ	O
(	(	O
375	CD	O
,	,	O
500	CD	O
or	CC	O
625	CD	O
mg	NN	O
)	)	O
or	CC	O
intravenous	JJ	O
(	(	O
500	CD	O
or	CC	O
625	CD	O
mg	NN	O
)	)	O
linezolid	VBD	O
or	CC	O
placebo	VB	O
twice	JJ	O
daily	RB	O
.	.	O

Serial	JJ	Ot
blood	NN	Ot
and	CC	Ot
urine	JJ	Ot
samples	NNS	Ot
were	VBD	O
obtained	VBN	O
after	IN	O
the	DT	O
first-	JJ	O
and	CC	O
multiple-dose	JJ	O
administrations	NNS	O
for	IN	O
up	IN	O
to	TO	O
18	CD	O
days	NNS	O
.	.	O

Non-compartmental	JJ	O
pharmacokinetic	JJ	PH
analyses	NNS	PH
were	VBD	O
used	VBN	O
to	TO	O
describe	VB	O
the	DT	O
disposition	NN	O
of	IN	O
linezolid	JJ	O
.	.	O

RESULTS	NNP	O
Plasma	NNP	Ot
linezolid	JJ	Ot
concentrations	NNS	Ot
and	CC	Ot
area	NN	Ot
under	IN	Ot
the	DT	Ot
concentration-time	JJ	Ot
curves	NNS	Ot
increased	VBD	O
proportionally	RB	O
with	IN	O
dose	JJ	O
irrespective	NN	O
of	IN	O
the	DT	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

Plasma	NNP	Ot
linezolid	JJ	Ot
concentrations	NNS	Ot
remained	VBN	O
above	IN	O
the	DT	O
MIC90	NNP	O
for	IN	O
susceptible	JJ	O
target	NN	O
pathogens	NNS	O
(	(	O
4.0	CD	O
mg/L	NN	O
)	)	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
12	CD	O
h	NN	O
dosing	VBG	O
interval	NN	O
.	.	O

Mean	JJ	Ot
clearance	NN	Ot
,	,	Ot
half-life	JJ	Ot
and	CC	Ot
volume	NN	Ot
of	IN	Ot
distribution	NN	Ot
were	VBD	O
similar	JJ	O
irrespective	NN	O
of	IN	O
dose	NN	O
for	IN	O
both	DT	O
the	DT	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
routes	NNS	O
.	.	O

Linezolid	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	PH
and	CC	O
the	DT	O
frequency	NN	A
of	IN	A
drug-related	JJ	A
adverse	JJ	A
events	NNS	A
was	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
linezolid	JJ	O
and	CC	O
placebo	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
and	CC	O
intravenous	JJ	O
linezolid	JJ	O
exhibit	NN	O
linear	JJ	Ot
pharmacokinetics	NNS	Ot
,	,	O
with	IN	O
concentrations	NNS	O
remaining	VBG	O
above	IN	O
the	DT	O
target	NN	Ot
MIC90	NNP	Ot
for	IN	O
most	JJS	O
of	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBD	O
a	DT	O
twice-daily	JJ	O
schedule	NN	O
for	IN	O
linezolid	JJ	O
and	CC	O
demonstrate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
converting	VBG	O
from	IN	O
intravenous	JJ	O
to	TO	O
oral	JJ	O
dosing	NN	O
without	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
.	.	O

Pretreatment	NN	O
and	CC	O
co-administration	NN	O
of	IN	O
oral	JJ	O
anti-diabetic	JJ	O
agent	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
or	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
.	.	O

AIM	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
result	NN	O
of	IN	O
pretreatment	NN	O
and	CC	O
concomitant	NN	O
use	NN	O
of	IN	O
metformin	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
(	(	O
CC	NNP	O
)	)	O
and	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
done	VBN	O
in	IN	O
the	DT	O
Dhaka	NNP	O
Medical	NNP	O
College	NNP	O
and	CC	O
Hospital	NNP	O
and	CC	O
the	DT	O
Infertility	NNP	O
Care	NNP	O
and	CC	O
Research	NNP	O
Centre	NNP	O
,	,	O
Dhaka	NNP	O
,	,	O
Bangladesh	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
165	CD	O
infertile	JJ	O
patients	NNS	O
with	IN	O
CC-resistant	JJ	O
PCOS	NNP	O
who	WP	O
attended	VBD	O
for	IN	O
treatment	NN	O
were	VBD	O
the	DT	O
target	NN	O
population	NN	O
for	IN	O
this	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
groups	NNS	O
A	DT	O
and	CC	O
B	NNP	O
were	VBD	O
given	VBN	O
metformin	NNS	O
and	CC	O
group	NN	O
C	NNP	O
was	VBD	O
the	DT	O
control	NN	O
.	.	O

Along	IN	O
with	IN	O
metformin	NN	O
,	,	O
group	NN	O
A	NNP	O
received	VBD	O
CC	NNP	O
and	CC	O
group	NN	O
B	NNP	O
received	VBD	O
rFSH	NN	O
.	.	O

Group	NNP	O
C	NNP	O
was	VBD	O
treated	VBN	O
with	IN	O
only	RB	O
rFSH	NN	O
.	.	O

Metformin	NNP	O
was	VBD	O
given	VBN	O
1500	CD	O
mg	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Afterwards	NNS	O
CC	NNP	O
or	CC	O
rFSH	VB	O
were	VBD	O
added	VBN	O
for	IN	O
induction	NN	O
of	IN	O
ovulation	NN	O
along	IN	O
with	IN	O
metformin	NN	O
.	.	O

Six	NNP	O
ovulatory	JJ	O
cycles	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

Treatment	NNP	O
was	VBD	O
terminated	VBN	O
when	WRB	O
there	EX	O
was	VBD	O
no	DT	O
response	NN	O
with	IN	O
maximum	JJ	O
dose	NN	O
of	IN	O
CC	NNP	O
and	CC	O
rFSH	NN	O
or	CC	O
after	IN	O
six	CD	O
ovulatory	JJ	O
cycles	NNS	O
without	IN	O
pregnancy	NN	O
or	CC	O
after	IN	O
achieving	VBG	O
pregnancy	NN	O
.	.	O

A	DT	O
P-value	NNP	O
of	IN	O
<	NNP	O
0.5	CD	O
was	VBD	O
considered	VBN	O
as	IN	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
Ovulation	NNP	O
(	(	O
89.09	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
54.55	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
group	NN	O
B.	NNP	O
Ovulation	NNP	O
(	(	O
74.55	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
29.09	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
also	RB	O
satisfactory	JJ	O
in	IN	O
group	NN	O
C	NNP	O
but	CC	O
a	DT	O
dose	NN	O
of	IN	O
rFSH	JJ	O
requirement	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.000	CD	O
)	)	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
both	DT	O
ovulation	NN	O
and	CC	O
pregnancy	NN	PH
rate	NN	PH
were	VBD	O
much	RB	O
lower	JJR	O
than	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
(	(	O
27.27	CD	O
%	NN	O
and	CC	O
12.73	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
metformin	NN	O
increases	VBZ	O
the	DT	O
response	NN	O
of	IN	O
ovulation-inducing	JJ	O
agents	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
safely	RB	O
in	IN	O
PCOS	NNP	O
.	.	O

Torasemide	NNP	O
versus	NN	O
furosemide	NN	O
in	IN	O
cirrhosis	NN	O
:	:	O
a	DT	O
long-term	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
long-term	JJ	O
therapy	NN	O
(	(	O
70	CD	O
days	NNS	O
)	)	O
with	IN	O
torasemide	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
loop	NN	O
diuretic	JJ	O
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
furosemide	NN	O
(	(	O
50	CD	O
mg/day	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
administered	VBN	O
in	IN	O
association	NN	O
with	IN	O
spironolactone	NN	O
(	(	O
200	CD	O
mg/day	NN	O
)	)	O
in	IN	O
28	CD	O
nonazotemic	JJ	O
cirrhotic	JJ	O
patients	NNS	O
with	IN	O
controlled	JJ	O
ascites	NNS	O
.	.	O

The	DT	O
treatments	NNS	O
did	VBD	O
not	RB	O
modify	VB	O
creatinine	JJ	PH
clearance	NN	PH
and	CC	O
exhibited	VBD	O
a	DT	O
similar	JJ	O
effect	NN	O
on	IN	O
body	NN	PH
weight	NN	PH
,	,	PH
urinary	JJ	PH
volume	NN	PH
,	,	O
and	CC	O
fractional	JJ	PH
excretion	NN	PH
of	IN	PH
uric	JJ	PH
acid	NN	PH
,	,	PH
sodium	NN	PH
,	,	PH
and	CC	PH
chloride	NN	PH
.	.	O

The	DT	O
effect	NN	O
of	IN	O
torasemide	NN	O
on	IN	O
fractional	JJ	PH
potassium	NN	PH
excretion	NN	PH
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
furosemide	NN	O
.	.	O

Torasemide	VB	O
showed	VBD	O
higher	JJR	O
sparing	VBG	Ot
effect	NN	Ot
than	IN	O
furosemide	NN	O
on	IN	O
calcium	NN	PH
,	,	PH
inorganic	JJ	PH
phosphate	NN	PH
,	,	PH
and	CC	PH
magnesium	NN	PH
excretion	NN	PH
and	CC	O
stronger	JJR	O
action	NN	O
on	IN	O
free	JJ	PH
water	NN	PH
clearance	NN	PH
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
serum	NN	PH
parameters	NNS	PH
were	VBD	O
induced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
.	.	O

Two	CD	O
episodes	NNS	O
of	IN	O
hepatic	JJ	PH
encephalopathy	NN	PH
occurred	VBD	O
in	IN	O
the	DT	O
torasemide	NN	O
group	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
its	PRP$	O
effects	NNS	PH
on	IN	PH
sodium	NN	PH
and	CC	PH
water	NN	PH
excretion	NN	PH
and	CC	O
on	IN	PH
other	JJ	PH
urinary	JJ	PH
parameters	NNS	PH
,	,	O
torasemide	NN	O
can	MD	O
represent	VB	O
an	DT	O
alternative	JJ	O
tool	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
ascites	NNS	O
.	.	O

Gemcitabine	NNP	O
and	CC	O
split-dose	JJ	O
paclitaxel	NN	O
or	CC	O
docetaxel	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
activity	NN	Ot
and	CC	Ot
toxicity	NN	Ot
of	IN	O
split-dose	JJ	O
paclitaxel	NN	O
or	CC	O
docetaxel	NN	O
in	IN	O
combination	NN	O
with	IN	O
gemcitabine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
who	WP	O
had	VBD	O
previously	RB	O
received	VBN	O
anthracyclines	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
gemcitabine	NN	O
1,250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
paclitaxel	VB	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
3-h	JJ	O
infusion	NN	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
GP1	NNP	O
)	)	O
;	:	O
gemcitabine	$	O
1,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
paclitaxel	VB	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
1-h	JJ	O
infusion	NN	O
on	IN	O
Days	NNP	O
1	CD	O
and	CC	O
8	CD	O
(	(	O
GP2	NNP	O
)	)	O
;	:	O
gemcitabine	$	O
1,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
docetaxel	VB	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
1-h	JJ	O
infusion	NN	O
on	IN	O
Days	NNP	O
1	CD	O
and	CC	O
8	CD	O
(	(	O
GD	NNP	O
)	)	O
.	.	O

Cycles	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
3	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
204	CD	O
patients	NNS	O
evaluable	JJ	O
for	IN	O
response	NN	O
assessment	NN	O
,	,	O
the	DT	O
response	NN	PH
rates	NNS	PH
were	VBD	O
48.6	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
52.2	CD	O
%	NN	O
for	IN	O
GP2	NNP	O
,	,	O
and	CC	O
52.3	CD	O
%	NN	O
for	IN	O
GD	NNP	O
.	.	O

Median	JJ	Ot
response	NN	Ot
duration	NN	Ot
,	,	O
time	NN	Ot
to	TO	Ot
treatment	NN	Ot
failure	NN	Ot
,	,	O
and	CC	O
time	NN	Ot
to	TO	Ot
progression	NN	Ot
(	(	Ot
TTP	NNP	Ot
)	)	Ot
were	VBD	O
similar	JJ	O
in	IN	O
each	DT	O
arm	NN	O
.	.	O

Median	JJ	O
TTP	NNP	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
and	CC	O
GD	NNP	O
was	VBD	O
7.5	CD	O
,	,	O
7.0	CD	O
and	CC	O
7.4	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

For	IN	O
the	DT	O
208	CD	O
patients	NNS	O
evaluable	JJ	O
for	IN	O
safety	NN	Ot
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3/4	CD	O
toxicity	NN	Ot
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
neutropaenia	RB	PH
,	,	O
with	IN	O
64	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
,	,	O
and	CC	O
68	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
,	,	O
and	CC	O
GD	NNP	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
4	CD	O
neutropaenia	NN	PH
,	,	O
grade	VBD	O
3/4	CD	O
anaemia	NN	PH
,	,	O
febrile	JJ	PH
neutropaenia	NN	PH
,	,	O
and	CC	O
diarrhoea	NNS	PH
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
docetaxel	NN	O
arm	NN	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
use	NN	O
of	IN	O
intravenous	JJ	O
antibiotics	NNS	O
and	CC	O
blood	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
study	NN	O
confirmed	VBD	O
the	DT	O
high	JJ	O
activity	NN	O
of	IN	O
gemcitabine-taxane	JJ	O
combinations	NNS	O
in	IN	O
MBC	NNP	O
.	.	O

Split-dose	JJ	O
paclitaxel	NN	O
had	VBD	O
similar	JJ	O
activity	NN	O
and	CC	O
toxicity	NN	Ot
to	TO	O
the	DT	O
3-weekly	JJ	O
administration	NN	O
.	.	O

The	DT	O
split-dose	JJ	O
docetaxel	NN	O
regimen	NNS	O
had	VBD	O
similar	JJ	O
activity	NN	O
to	TO	O
the	DT	O
paclitaxel	NN	O
combinations	NNS	O
though	IN	O
associated	VBN	O
with	IN	O
higher	JJR	O
toxicity	NN	O
.	.	O

Virtual	JJ	O
reality	NN	O
for	IN	O
acute	NN	O
pain	NN	O
reduction	NN	O
in	IN	O
adolescents	NNS	O
undergoing	VBG	O
burn	NN	O
wound	NN	O
care	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Effective	NNP	O
pain	NN	O
management	NN	O
remains	VBZ	O
a	DT	O
challenge	NN	O
for	IN	O
adolescents	NNS	O
during	IN	O
conscious	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
procedures	NNS	O
.	.	O

Virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
shows	VBZ	O
promise	NN	O
as	IN	O
a	DT	O
non-pharmacological	JJ	O
adjunct	NN	O
in	IN	O
reducing	VBG	O
pain	NN	O
.	.	O

AIMS	VB	O
This	DT	O
study	NN	O
assessed	VBD	O
off-the-shelf	JJ	O
VR	NNP	O
for	IN	O
(	(	O
1	CD	O
)	)	O
its	PRP$	O
effect	NN	O
on	IN	O
reducing	VBG	O
acute	JJ	O
pain	NN	O
intensity	NN	O
during	IN	O
adolescent	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
in	IN	O
a	DT	O
busy	JJ	O
hospital	NN	O
setting	NN	O
.	.	O

METHODS	NNP	O
Forty-one	CD	O
adolescents	NNS	O
(	(	O
11-17	CD	O
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

Acute	NNP	O
pain	NN	O
outcomes	NNS	O
including	VBG	O
adolescent	JJ	O
self-report	NN	O
,	,	O
nursing	VBG	O
staff	NN	O
behavioral	JJ	O
observation	NN	O
,	,	O
caregiver	NN	O
observation	NN	O
and	CC	O
physiological	JJ	O
measures	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

Length	NNP	O
of	IN	O
procedure	NN	O
times	NNS	O
and	CC	O
adolescent	JJ	O
reactions	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
to	TO	O
inform	VB	O
clinical	JJ	O
utility	NN	O
.	.	O

RESULTS	NNP	O
Nursing	JJ	O
staff	NN	O
reported	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
pain	NN	PH
scores	NNS	PH
during	IN	O
dressing	VBG	O
removal	NN	O
,	,	O
and	CC	O
significantly	RB	O
less	JJR	O
rescue	JJ	PH
doses	NNS	PH
of	IN	PH
Entonox	NNP	PH
given	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
standard	JJ	O
distraction	NN	O
.	.	O

For	IN	O
all	DT	O
other	JJ	O
pain	NN	O
outcomes	NNS	O
and	CC	O
length	NN	O
of	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
lower	JJR	O
pain	NN	Ot
scores	NNS	Ot
and	CC	Ot
treatment	NN	Ot
times	NNS	Ot
for	IN	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Despite	IN	O
only	RB	O
minimal	JJ	O
pain	NN	O
reduction	NN	O
achieved	VBD	O
using	VBG	O
off-the-shelf	JJ	O
VR	NNP	O
,	,	O
other	JJ	O
results	NNS	O
from	IN	O
this	DT	O
trial	NN	O
and	CC	O
previous	JJ	O
research	NN	O
on	IN	O
younger	JJR	O
children	NNS	O
with	IN	O
burns	NNS	O
suggest	VBP	O
a	DT	O
customized	JJ	O
,	,	O
adolescent	JJ	O
and	CC	O
hospital	JJ	O
friendly	JJ	O
device	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
pain	NN	O
reduction	NN	O
.	.	O

Parenteral	NNP	O
amino	NN	O
acid	NN	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
in	IN	O
premature	JJ	O
infants	NNS	O
.	.	O

BACKGROUND	NNP	O
Aggressive	NNP	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
PN	NNP	O
)	)	O
including	VBG	O
amino	JJ	O
acids	NNS	O
is	VBZ	O
recommended	VBN	O
for	IN	O
low-birth-weight	JJ	O
infants	NNS	O
to	TO	O
prevent	VB	O
energy	NN	O
and	CC	O
protein	NN	O
deficit	NN	O
.	.	O

Their	PRP$	O
impact	NN	O
on	IN	O
acid-base	JJ	O
homeostasis	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
examined	VBN	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
impact	NN	O
of	IN	O
dose	NN	O
and	CC	O
duration	NN	O
of	IN	O
parenteral	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
with	IN	O
cysteine	NN	O
,	,	O
on	IN	O
acid-base	JJ	O
parameters	NNS	O
in	IN	O
122	CD	O
low-birth-weight	JJ	O
infants	NNS	O
.	.	O

Premature	NN	O
infants	NNS	O
<	VBP	O
or=32	JJ	O
weeks	NNS	O
,	,	O
<	NNP	O
or=1850	MD	O
g	VB	O
,	,	O
and	CC	O
receiving	VBG	O
parenteral	JJ	O
amino	NN	O
acids	NNS	O
at	IN	O
1.5	CD	O
g/kg/d	NN	O
for	IN	O
an	DT	O
extended	JJ	O
period	NN	O
(	(	O
>	JJ	O
24	CD	O
hours	NNS	O
)	)	O
,	,	O
or	CC	O
3	CD	O
g/kg/d	NN	O
for	IN	O
a	DT	O
short	JJ	O
(	(	O
5	CD	O
hour	NN	O
)	)	O
,	,	O
extended	VBD	O
(	(	O
24	CD	O
hour	NN	O
)	)	O
,	,	O
or	CC	O
prolonged	VBN	O
(	(	O
3-5	JJ	O
days	NNS	O
)	)	O
duration	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Data	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
age	NN	O
0-3	JJ	O
days	NNS	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
or	CC	O
,	,	O
when	WRB	O
clinically	RB	O
stable	JJ	O
,	,	O
age	NN	O
3-5	JJ	O
days	NNS	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

Data	NNS	O
from	IN	O
30	CD	O
infants	NNS	O
,	,	O
matched	VBN	O
for	IN	O
birth	NN	O
weight	NN	O
and	CC	O
gestational	JJ	O
age	NN	O
,	,	O
receiving	VBG	O
PN	NNP	O
during	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
after	IN	O
birth	NN	O
were	VBD	O
also	RB	O
obtained	VBN	O
.	.	O

Acidosis	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
pH	NN	O
<	$	O
7.25	CD	O
.	.	O

RESULTS	JJ	O
Acidosis	NNP	A
was	VBD	O
evident	JJ	O
in	IN	O
all	DT	O
infants	NNS	O
between	IN	O
2	CD	O
and	CC	O
5	CD	O
days	NNS	O
after	IN	O
birth	NN	O
.	.	O

Infants	NNS	O
with	IN	O
large	JJ	O
patent	NN	O
ductus	NN	O
arteriosus	NN	O
(	(	O
PDA	NNP	O
)	)	O
exhibited	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
lower	JJR	PH
pH	NN	PH
early	RB	O
,	,	O
had	VBD	O
higher	JJR	O
blood	NN	PH
urea	JJ	PH
nitrogen	NN	PH
levels	NNS	PH
(	(	O
26	CD	O
+/-	JJ	O
9	CD	O
vs	NN	O
18	CD	O
+	NN	O
8	CD	O
mg/dL	NN	O
;	:	O
p	CC	O
<	NNP	O
.05	NNP	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
greater	JJR	PH
weight	JJ	PH
loss	NN	PH
(	(	O
approximately	RB	O
17	CD	O
%	NN	O
of	IN	O
birth	NN	O
weight	NN	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
infants	NNS	O
without	IN	O
PDA	NNP	O
.	.	O

Gestational	NNP	PH
age	NN	PH
,	,	O
weight	JJ	PH
loss	NN	PH
,	,	O
and	CC	O
patent	NN	PH
ductus	NN	PH
arteriosus	NN	PH
accounted	VBD	O
for	IN	O
65	CD	O
%	NN	O
of	IN	O
variance	NN	O
in	IN	O
acidosis	NN	O
.	.	O

CONCLUSIONS	NNP	O
Low-birth-weight	JJ	O
infants	NNS	O
develop	VB	O
metabolic	JJ	O
acidosis	NN	O
between	IN	O
2	CD	O
and	CC	O
5	CD	O
days	NNS	O
after	IN	O
birth	NN	O
,	,	O
irrespective	NN	O
of	IN	O
dose	NN	O
and	CC	O
duration	NN	O
of	IN	O
parenteral	JJ	O
amino	NN	O
acid	JJ	O
administration	NN	O
.	.	O

Careful	JJ	O
management	NN	O
of	IN	O
parenteral	JJ	O
fluids	NNS	O
and	CC	O
comorbidities	NNS	O
may	MD	O
lower	VB	O
the	DT	O
incidence	NN	O
of	IN	O
acidosis	NN	O
and	CC	O
promote	NN	O
protein	NN	O
accretion	NN	O
.	.	O

An	DT	O
exploratory	NN	O
,	,	O
pragmatic	JJ	O
,	,	O
cluster	NN	O
randomised	VBD	O
trial	NN	O
of	IN	O
practice	NN	O
nurse	JJ	O
training	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
asthma	JJ	O
action	NN	O
plans	NNS	O
.	.	O

INTRODUCTION	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
feasibility	NN	Ot
of	IN	O
improving	VBG	O
asthma	JJ	O
management	NN	O
-	:	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
implementation	NN	O
of	IN	O
individualised	JJ	O
asthma	JJ	O
action	NN	O
plans	NNS	O
(	(	O
AAPs	NNP	O
)	)	O
for	IN	O
poorly-controlled	JJ	O
adult	NN	O
asthma	NN	O
patients	NNS	O
-	:	O
by	IN	O
providing	VBG	O
training	NN	O
in	IN	O
asthma-focused	JJ	O
clinical	JJ	O
and	CC	O
communication	NN	O
skills	NNS	O
for	IN	O
practice	NN	O
nurses	NNS	O
who	WP	O
deliver	VBP	O
asthma	JJ	O
clinics	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
pragmatic	JJ	O
,	,	O
cluster	NN	O
randomised	VBD	O
trial	NN	O
with	IN	O
an	DT	O
intervention	NN	O
(	(	O
an	DT	O
interactive	JJ	O
seminar	NN	O
)	)	O
delivered	VBD	O
at	IN	O
practice	NN	O
level	NN	O
(	(	O
n=13	JJ	O
practices	NNS	O
;	:	O
6=intervention	CD	O
,	,	O
7=control	CD	O
)	)	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
assessed	VBN	O
against	IN	O
patient	JJ	PH
outcomes	NNS	PH
:	:	PH
routinely	RB	PH
available	JJ	PH
asthma	JJ	PH
outcome	NN	PH
measures	NNS	PH
(	(	PH
beta2-agonist	JJ	Ot
prescription	NN	Ot
rate	NN	Ot
and	CC	PH
number	NN	Ot
of	IN	Ot
oral	JJ	Ot
steroid	NN	Ot
courses	NNS	Ot
)	)	PH
for	IN	O
asthma	NN	O
patients	NNS	O
identified	VBN	O
as	IN	O
being	VBG	O
poorly-controlled	JJ	O
from	IN	O
practice	NN	O
records	NNS	O
;	:	O
and	CC	O
questionnaire	VB	Ot
data	NNS	Ot
-	:	PH
Mini	NNP	PH
Asthma	NNP	PH
Quality	NNP	PH
of	IN	PH
Life	NNP	PH
Questionnaire	NNP	PH
(	(	PH
AQLQ	NNP	PH
)	)	PH
and	CC	PH
the	DT	PH
Asthma	NNP	PH
Control	NNP	PH
Questionnaire	NNP	PH
(	(	PH
ACQ	NNP	PH
)	)	PH
-	:	O
from	IN	O
a	DT	O
subset	NN	O
of	IN	O
consenting	VBG	O
patients	NNS	O
.	.	O

Data	NNP	O
was	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

ANALYSISs	NN	O
:	:	O
Routine	NNP	O
data	NN	O
was	VBD	O
analysed	VBN	O
for	IN	O
629	CD	O
patients	NNS	O
.	.	O

236	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
patients	NNS	O
consented	VBD	O
to	TO	O
provide	VB	O
questionnaire	NN	O
data	NNS	O
at	IN	O
baseline	NN	O
,	,	O
with	IN	O
75	CD	O
%	NN	O
returning	VBG	O
questionnaires	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

After	IN	O
adjustment	NN	O
for	IN	O
baseline	NN	O
and	CC	O
practice	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
at	IN	O
followup	NN	O
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
practices	NNS	O
on	IN	O
the	DT	O
Mini	NNP	PH
AQLQ	NNP	PH
only	RB	O
(	(	O
p=0.03	NN	O
)	)	O
.	.	O

Estimates	NNS	O
for	IN	O
subsequent	JJ	O
sample	NN	O
sizes	NNS	O
to	TO	O
inform	VB	O
future	JJ	O
trials	NNS	O
of	IN	O
asthma	JJ	O
training	NN	O
were	VBD	O
identified	VBN	O
.	.	O

CONCLUSION	NNP	O
Training	NNP	O
designed	VBD	O
to	TO	O
support	VB	O
practice	NN	O
nurses	NNS	O
in	IN	O
implementing	VBG	O
individualised	JJ	O
AAPs	NNP	O
impacted	VBD	O
on	IN	O
one	CD	O
patient	NN	O
outcome	NN	O
only	RB	O
.	.	O

This	DT	O
disappointing	JJ	O
outcome	NN	O
may	MD	O
have	VB	O
been	VBN	O
due	JJ	O
to	TO	O
many	JJ	O
different	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
outcome	JJ	O
measure	NN	O
limitations	NNS	O
,	,	O
data	NNS	O
collection	NN	O
problems	NNS	O
,	,	O
and	CC	O
underestimating	VBG	O
the	DT	O
complexity	NN	O
of	IN	O
supporting	VBG	O
practice	NN	O
nurses	NNS	O
in	IN	O
behaviour	JJ	O
change	NN	O
.	.	O

Effect	NN	O
of	IN	O
light-cured	JJ	O
filled	VBN	O
sealant	NN	O
on	IN	O
shear	JJ	O
bond	NN	O
strength	NN	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
a	DT	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
.	.	O

INTRODUCTION	NNP	O
Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
highly	RB	O
filled	VBN	O
light-cured	JJ	O
sealant	NN	O
(	(	O
HFLCS	NNP	O
)	)	O
on	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
strength	NN	O
and	CC	O
bond	NN	O
failure	NN	O
site	NN	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
(	(	O
RMGIC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
freshly	RB	O
extracted	VBD	O
maxillary	JJ	O
premolars	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
(	(	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
.	.	O

In	IN	O
all	DT	O
groups	NNS	O
,	,	O
the	DT	O
teeth	NNS	O
were	VBD	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
for	IN	O
20	CD	O
seconds	NNS	O
,	,	O
and	CC	O
RMGIC	NNP	O
(	(	O
Fuji	NNP	O
Ortho	NNP	O
LC	NNP	O
,	,	O
GC	NNP	O
Europe	NNP	O
,	,	O
Leuven	NNP	O
,	,	O
Belgium	NNP	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
bracket	NN	O
bonding	NN	O
.	.	O

In	IN	O
groups	NNS	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
the	DT	O
brackets	NNS	O
were	VBD	O
bonded	VBN	O
directly	RB	O
to	TO	O
etched	VB	O
enamel	JJ	O
surfaces	NNS	O
;	:	O
in	IN	O
groups	NNS	O
2	CD	O
and	CC	O
4	CD	O
,	,	O
the	DT	O
etched	JJ	O
enamel	NN	O
was	VBD	O
covered	VBN	O
with	IN	O
HFLCS	NNP	O
(	(	O
Pro	NNP	O
Seal	NNP	O
,	,	O
Reliance	NNP	O
Orthodontic	NNP	O
Products	NNP	O
,	,	O
Itasca	NNP	O
,	,	O
Ill	NNP	O
)	)	O
.	.	O

Groups	$	O
1	CD	O
and	CC	O
2	CD	O
received	VBD	O
metal	JJ	O
brackets	NNS	O
,	,	O
and	CC	O
groups	NNS	O
3	CD	O
and	CC	O
4	CD	O
had	VBD	O
ceramic	JJ	O
brackets	NNS	O
.	.	O

The	DT	O
specimens	NNS	O
were	VBD	O
stored	VBN	O
in	IN	O
distilled	JJ	O
water	NN	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
24	CD	O
hours	NNS	O
and	CC	O
subsequently	RB	O
tested	VBN	O
in	IN	O
shear	JJ	O
mode	NN	O
with	IN	O
a	DT	O
universal	JJ	O
testing	NN	O
machine	NN	O
.	.	O

After	IN	O
debonding	VBG	O
,	,	O
the	DT	O
teeth	NNS	O
and	CC	O
the	DT	O
brackets	NNS	O
were	VBD	O
examined	VBN	O
under	IN	O
a	DT	O
stereomicroscope	NN	O
(	(	O
model	JJ	O
SMZ-1B	NNP	O
,	,	O
Nikon	NNP	O
,	,	O
Osaka	NNP	O
,	,	O
Japan	NNP	O
)	)	O
at	IN	O
20-times	JJ	O
magnification	NN	O
to	TO	O
assess	VB	O
the	DT	O
residual	JJ	O
adhesive	NN	O
on	IN	O
the	DT	O
tooth	NN	O
surfaces	NNS	O
.	.	O

RESULTS	NNP	O
Interaction	NNP	O
between	IN	O
HFLCS	NNP	O
and	CC	O
bracket	NN	O
type	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
HFLCS	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
the	DT	O
shear	JJ	Ot
bond	NN	Ot
values	NNS	Ot
of	IN	Ot
either	DT	Ot
metal	NN	Ot
or	CC	Ot
ceramic	JJ	Ot
brackets	NNS	Ot
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Shear	JJ	Ot
bond	NN	Ot
values	NNS	Ot
of	IN	Ot
the	DT	Ot
ceramic	JJ	Ot
brackets	NNS	Ot
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
metal	JJ	O
brackets	NNS	O
independent	JJ	O
of	IN	O
HFLCS	NNP	O
application	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
bond	NN	Ot
failure	NN	Ot
modes	VBZ	Ot
in	IN	O
the	DT	O
4	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
HFLCS	NNP	O
application	NN	O
on	IN	O
enamel	NN	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
bond	NN	Ot
strength	NN	Ot
values	NNS	Ot
and	CC	O
the	DT	O
bond	NN	Ot
failure	NN	Ot
modes	NNS	Ot
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
RMGIC	NNP	O
.	.	O

RESULTS	NNP	O
Interaction	NNP	O
between	IN	O
HFLCS	NNP	O
and	CC	O
bracket	NN	O
type	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
HFLCS	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
the	DT	O
shear	JJ	Ot
bond	NN	Ot
values	NNS	Ot
of	IN	Ot
either	DT	Ot
metal	NN	Ot
or	CC	Ot
ceramic	JJ	Ot
brackets	NNS	Ot
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Shear	JJ	Ot
bond	NN	Ot
values	NNS	Ot
of	IN	Ot
the	DT	Ot
ceramic	JJ	Ot
brackets	NNS	Ot
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
metal	JJ	O
brackets	NNS	O
independent	JJ	O
of	IN	O
HFLCS	NNP	O
application	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
bond	NN	O
failure	NN	O
modes	VBZ	O
in	IN	O
the	DT	O
4	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
HFLCS	NNP	O
application	NN	O
on	IN	O
enamel	NN	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
bond	NN	O
strength	NN	O
values	NNS	O
and	CC	O
the	DT	O
bond	NN	O
failure	NN	O
modes	NNS	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
RMGIC	NNP	O
.	.	O

Selected	VBN	O
polymorphisms	NNS	O
of	IN	O
GSTP1	NNP	O
and	CC	O
TERT	NNP	O
were	VBD	O
associated	VBN	O
with	IN	O
glioma	NN	O
risk	NN	O
in	IN	O
Han	NNP	O
Chinese	NNP	O
.	.	O

BACKGROUND	NNP	O
Current	NNP	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
a	DT	O
majority	NN	O
of	IN	O
the	DT	O
inherited	JJ	O
risks	NNS	O
play	VBP	O
a	DT	O
major	JJ	O
role	NN	O
in	IN	O
glioma	JJ	O
susceptibility	NN	O
,	,	O
and	CC	O
glioma	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
the	DT	O
co-inheritance	NN	O
of	IN	O
multiple	JJ	O
low-risk	JJ	O
variants	NNS	O
.	.	O

These	DT	O
variants	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
through	IN	O
association	NN	O
studies	NNS	O
including	VBG	O
such	JJ	O
as	IN	O
genome-wide	JJ	O
association	NN	O
studies	NNS	O
(	(	O
GWAS	NNP	O
)	)	O
,	,	O
which	WDT	O
has	VBZ	O
led	VBN	O
the	DT	O
glioma	NN	O
epidemiology	NN	O
researchers	NNS	O
to	TO	O
focus	VB	O
on	IN	O
identifying	VBG	O
potential	JJ	O
disease-causing	JJ	O
factors	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
evaluated	VBD	O
and	CC	O
validated	VBD	O
10	CD	O
tag	NN	O
single	JJ	O
nucleotide	JJ	O
polymorphisms	NN	O
(	(	O
tSNPs	NN	O
)	)	O
in	IN	O
seven	CD	O
genes	NNS	O
associated	VBN	O
with	IN	O
glioma	NN	O
susceptibility	NN	O
in	IN	O
a	DT	O
Han	NNP	O
Chinese	NNP	O
population	NN	O
,	,	O
including	VBG	O
301	CD	O
glioma	NN	O
cases	NNS	O
and	CC	O
302	CD	O
controls	NNS	O
,	,	O
using	VBG	O
a	DT	O
multiplexed	JJ	O
single	JJ	O
nucleotide	NN	O
polymorphism	NN	O
(	(	O
SNP	NNP	O
)	)	O
MassEXTEND	NNP	O
assay	NN	O
.	.	O

We	PRP	O
ascertained	VBD	O
the	DT	O
genotypic	NN	O
frequencies	NNS	O
for	IN	O
each	DT	O
tSNP	NN	O
in	IN	O
control	NN	O
subjects	NNS	O
were	VBD	O
within	IN	O
Hardy-Weinberg	NNP	O
equilibrium	NN	O
(	(	O
HWE	NNP	O
)	)	O
using	VBG	O
an	DT	O
exact	JJ	O
test	NN	O
,	,	O
and	CC	O
then	RB	O
compared	VBN	O
the	DT	O
genotype	NN	O
and	CC	O
allele	JJ	O
frequencies	NNS	O
of	IN	O
glioma	NN	O
patients	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
using	VBG	O
the	DT	O
?2	JJ	O
test	NN	O
.	.	O

We	PRP	O
then	RB	O
applied	VBD	O
three	CD	O
genetic	JJ	O
models	NNS	O
(	(	O
dominant	JJ	O
,	,	O
recessive	JJ	O
,	,	O
and	CC	O
additive	JJ	O
)	)	O
using	VBG	O
PLINK	NNP	O
software	NN	O
to	TO	O
assess	VB	O
the	DT	O
association	NN	O
of	IN	O
each	DT	O
tSNP	NN	O
with	IN	O
glioma	NN	O
risk	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
identified	VBD	O
two	CD	O
tSNPs	NN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
glioma	NN	O
susceptibility	NN	O
(	(	O
rs1695	NN	O
,	,	O
GSTP1	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.019	CD	O
;	:	O
rs2853676	NN	O
,	,	O
TERT	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
,	,	O
which	WDT	O
we	PRP	O
confirmed	VBD	O
using	VBG	O
dominant	NN	O
and	CC	O
additive	JJ	O
model	NN	O
analyses	NNS	O
.	.	O

The	DT	O
genotype	NN	O
&	CC	O
ldquo	NN	O
;	:	O
GA	NNP	O
&	CC	O
rdquo	NN	O
;	:	O
for	IN	O
rs1695	NN	O
was	VBD	O
recognized	VBN	O
to	TO	O
be	VB	O
a	DT	O
protective	JJ	O
genotype	NN	O
for	IN	O
glioma	NN	O
(	(	O
OR	NNP	O
,	,	O
0.67	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.47-0.96	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.027	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
genotype	NN	O
&	CC	O
ldquo	NN	O
;	:	O
AG	NNP	O
&	CC	O
rdquo	NN	O
;	:	O
for	IN	O
rs2853676	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
risk	NN	O
genotype	NN	O
for	IN	O
glioma	NN	O
(	(	O
OR	NNP	O
,	,	O
1.50	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.05-2.15	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
,	,	O
and	CC	O
those	DT	O
from	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
suggest	VBP	O
potential	JJ	O
genetic	JJ	O
contributes	NNS	O
for	IN	O
GSTP1	NNP	O
and	CC	O
TERT	NNP	O
in	IN	O
glioma	NN	O
development	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
fluconazole	JJ	O
after	IN	O
treatment	NN	O
of	IN	O
cryptococcal	JJ	O
meningitis	NN	O
in	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
.	.	O

California	NNP	O
Collaborative	NNP	O
Treatment	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
relapse	NN	O
after	IN	O
primary	JJ	O
treatment	NN	O
for	IN	O
cryptococcal	JJ	O
meningitis	NN	O
remains	VBZ	O
high	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
controlled	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
fluconazole	NN	O
.	.	O

At	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
all	DT	O
participants	NNS	O
had	VBD	O
sterile	JJ	O
cultures	NNS	O
of	IN	O
cerebrospinal	JJ	O
fluid	NN	O
,	,	O
blood	NN	O
,	,	O
and	CC	O
urine	JJ	O
after	IN	O
following	VBG	O
a	DT	O
standardized	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
for	IN	O
culture-proved	JJ	O
cryptococcal	JJ	O
meningitis	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
take	VB	O
either	DT	O
fluconazole	NN	O
or	CC	O
placebo	NN	O
as	IN	O
maintenance	NN	O
therapy	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
fluconazole	NN	O
was	VBD	O
100	CD	O
mg	JJ	O
daily	RB	O
in	IN	O
the	DT	O
first	JJ	O
phase	NN	O
of	IN	O
study	NN	O
and	CC	O
200	CD	O
mg	NNS	O
daily	RB	O
in	IN	O
the	DT	O
second	JJ	O
phase	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
84	CD	O
patients	NNS	O
initially	RB	O
enrolled	VBD	O
,	,	O
16	CD	O
(	(	O
19	CD	O
percent	NN	O
)	)	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
silent	JJ	O
,	,	O
persistent	JJ	O
infection	NN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
cultures	NNS	O
that	WDT	O
became	VBD	O
positive	JJ	O
after	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
;	:	O
7	CD	O
other	JJ	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NNS	O
shortly	RB	O
after	IN	O
entry	NN	O
.	.	O

Of	IN	O
the	DT	O
remaining	VBG	O
61	CD	O
patients	NNS	O
,	,	O
10	CD	O
of	IN	O
27	CD	O
assigned	VBN	O
to	TO	O
placebo	VB	O
(	(	O
37	CD	O
percent	NN	O
)	)	O
and	CC	O
1	CD	O
of	IN	O
34	CD	O
assigned	VBN	O
to	TO	O
fluconazole	VB	O
(	(	O
3	CD	O
percent	NN	O
)	)	O
had	VBD	O
a	DT	O
recurrence	NN	PH
of	IN	PH
cryptococcal	JJ	PH
infection	NN	PH
at	IN	PH
any	DT	PH
site	NN	PH
(	(	O
difference	NN	O
in	IN	O
risk	NN	O
,	,	O
34	CD	O
percent	NN	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
15	CD	O
to	TO	O
53	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
11	CD	O
recurrent	NN	O
infections	NNS	O
,	,	O
7	CD	O
were	VBD	O
detected	VBN	O
in	IN	O
urine	NN	O
obtained	VBN	O
after	IN	O
prostatic	JJ	O
massage	NN	O
.	.	O

There	EX	O
were	VBD	O
four	CD	O
recurrent	NN	PH
meningeal	NN	PH
infections	NNS	PH
in	IN	O
the	DT	O
patients	NNS	O
taking	VBG	O
placebo	NN	O
,	,	O
but	CC	O
none	NN	O
in	IN	O
those	DT	O
taking	VBG	O
fluconazole	JJ	O
(	(	O
mean	JJ	O
duration	NN	O
of	IN	O
follow-up	NN	O
,	,	O
164	CD	O
days	NNS	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

In	IN	O
multivariate	NN	O
analyses	NNS	O
,	,	O
the	DT	O
best	JJS	O
predictors	NNS	O
of	IN	O
recurrence-free	JJ	MO
survival	NN	MO
were	VBD	O
fluconazole	JJ	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
13.2	CD	O
)	)	O
,	,	O
a	DT	O
lower	JJR	O
serum	NN	O
cryptococcal-antigen	NN	O
titer	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
1.2	CD	O
)	)	O
,	,	O
and	CC	O
more	JJR	O
prolonged	JJ	O
primary	JJ	O
therapy	NN	O
with	IN	O
flucytosine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.09	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
1.1	CD	O
)	)	O
.	.	O

Survival	NNP	MO
and	CC	O
toxicity	NN	Ot
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
maintenance-treatment	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
,	,	O
silent	JJ	O
persistent	JJ	O
infection	NN	O
is	VBZ	O
common	JJ	O
after	IN	O
clinically	RB	O
successful	JJ	O
treatment	NN	O
for	IN	O
cryptococcal	JJ	O
meningitis	NN	O
.	.	O

Maintenance	NNP	O
therapy	NN	O
with	IN	O
fluconazole	NN	O
is	VBZ	O
highly	RB	O
effective	JJ	O
in	IN	O
preventing	VBG	O
recurrent	JJ	O
cryptococcal	JJ	O
infection	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
evolutional	JJ	Ot
process	NN	Ot
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
different	JJ	O
language	NN	O
therapeutic	JJ	O
interventions	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
analyze	VB	O
and	CC	O
compare	VB	O
the	DT	ME
extension	NN	ME
and	CC	ME
the	DT	ME
speed	NN	ME
of	IN	ME
the	DT	ME
evolutional	JJ	ME
process	NN	ME
of	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
in	IN	O
direct	JJ	O
and	CC	O
indirect	JJ	O
interventions	NNS	O
as	IN	O
opposed	VBN	O
to	TO	O
only	RB	O
indirect	VB	O
intervention	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
design	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
sample	NN	O
was	VBD	O
composed	VBN	O
of	IN	O
11	CD	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
Autism	NNP	O
(	(	O
n=6	NN	O
)	)	O
and	CC	O
Asperger	NNP	O
syndrome	VBP	O
(	(	O
n=5	NN	O
)	)	O
by	IN	O
a	DT	O
multidisciplinary	JJ	O
team	NN	O
,	,	O
that	WDT	O
attended	VBD	O
specialized	JJ	O
speech-language	JJ	O
pathology	NN	O
therapy	NN	O
at	IN	O
the	DT	O
institution	NN	O
were	VBD	O
the	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

These	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
Therapy	NNP	O
Group	NNP	O
(	(	O
TG	NNP	O
)	)	O
-	:	O
composed	VBN	O
by	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
both	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
intervention	NN	O
;	:	O
and	CC	O
Orientation	NNP	O
Group	NNP	O
(	(	O
OG	NNP	O
)	)	O
-	:	O
constituted	VBN	O
by	IN	O
five	CD	O
subjects	NNS	O
receiving	VBG	O
exclusively	RB	O
indirect	JJ	O
intervention	NN	O
.	.	O

It	PRP	O
was	VBD	O
used	VBN	O
the	DT	O
Autism	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
(	(	ME
ABC	NNP	ME
)	)	ME
to	TO	O
interview	NN	O
the	DT	O
mothers	NNS	O
,	,	O
and	CC	O
the	DT	O
Sample	NNP	ME
of	IN	ME
Vocal	NNP	ME
Behavior	NNP	ME
(	(	ME
SVB	NNP	ME
)	)	ME
,	,	O
in	IN	O
three	CD	O
occasions	NNS	O
:	:	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
intervention	NN	O
process	NN	O
(	(	O
time	NN	O
0	CD	O
)	)	O
,	,	O
six	CD	O
months	NNS	O
later	RB	O
(	(	O
time	NN	O
1	CD	O
)	)	O
and	CC	O
12	CD	O
months	NNS	O
later	RB	O
(	(	O
time	NN	O
2	CD	O
)	)	O
.	.	O

RESULTS	VB	O
It	PRP	O
was	VBD	O
observed	VBN	O
greater	JJR	O
speed	NN	Ot
and	CC	Ot
extension	NN	Ot
in	IN	Ot
the	DT	Ot
evolutional	JJ	Ot
process	NN	Ot
of	IN	O
the	DT	O
TG	NNP	O
Group	NNP	O
,	,	O
both	DT	O
in	IN	O
the	DT	O
analysis	NN	O
of	IN	O
the	DT	O
Autism	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
(	(	ME
total	JJ	ME
and	CC	ME
partial	JJ	ME
scores	NNS	ME
)	)	ME
and	CC	O
the	DT	O
Sample	NNP	O
of	IN	O
Vocal	NNP	O
Behavior	NNP	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
item	NN	O
Full	NNP	O
Language	NNP	O
.	.	O

The	DT	O
performance	NN	O
of	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
was	VBD	O
considered	VBN	O
more	RBR	O
positive	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
that	DT	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

There	EX	O
was	VBD	O
greater	JJR	O
evolution	NN	Ot
in	IN	O
younger	JJR	O
children	NNS	O
and	CC	O
with	IN	O
normal	JJ	O
,	,	O
mild	JJ	O
,	,	O
and	CC	O
moderate	JJ	O
adaptive	JJ	ME
functioning	NN	ME
.	.	O

CONCLUSION	VB	O
The	DT	O
tendency	NN	O
towards	NNS	O
better	RBR	O
performance	NN	ME
of	IN	O
the	DT	O
children	NNS	O
attending	VBG	O
direct	JJ	O
and	CC	O
indirect	JJ	O
intervention	NN	O
showed	VBD	O
that	IN	O
this	DT	O
association	NN	O
is	VBZ	O
fundamental	JJ	O
in	IN	O
the	DT	O
therapeutic	JJ	O
process	NN	O
of	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
vacuum-compression	NN	PH
therapy	NN	PH
on	IN	O
healing	NN	O
of	IN	O
diabetic	JJ	PH
foot	NN	PH
ulcers	NNS	PH
:	:	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
vacuum-compression	NN	PH
therapy	NN	PH
(	(	PH
VCT	NNP	PH
)	)	PH
for	IN	O
the	DT	O
healing	NN	O
of	IN	O
diabetic	JJ	PH
foot	NN	PH
ulcers	NNS	PH
.	.	O

Eighteen	NNP	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
foot	JJ	PH
ulcers	NNS	PH
were	VBD	O
recruited	VBN	O
through	IN	O
simple	JJ	O
nonprobability	NN	O
sampling	VBG	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
experimental	JJ	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
,	,	O
the	DT	O
foot	NN	PH
ulcer	JJ	PH
surface	NN	PH
area	NN	PH
was	VBD	O
estimated	VBN	O
stereologically	RB	O
,	,	O
based	VBN	O
on	IN	O
Cavalieri	NNP	O
's	POS	O
principle	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
VCT	NNP	Ot
in	IN	O
addition	NN	O
to	TO	O
conventional	JJ	PH
therapy	NN	PH
for	IN	O
10	CD	O
sessions	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
only	RB	O
conventional	JJ	Ot
therapy	NN	Ot
,	,	O
including	VBG	O
debridement	NN	Ot
,	,	Ot
blood	NN	Ot
glucose	NNS	Ot
control	NN	Ot
agents	NNS	Ot
,	,	O
systemic	JJ	Ot
antibiotics	NNS	Ot
,	,	O
wound	IN	Ot
cleaning	VBG	Ot
with	IN	Ot
normal	JJ	Ot
saline	NN	Ot
,	,	O
offloading	VBG	Ot
(	(	O
pressure	NN	O
relief	NN	O
)	)	O
,	,	O
and	CC	O
daily	RB	PH
wound	JJ	PH
dressings	NNS	PH
.	.	O

The	DT	O
mean	JJ	O
foot	NN	PH
ulcer	JJ	PH
surface	NN	PH
area	NN	PH
decreased	VBD	O
from	IN	O
46.88	CD	O
+/-	JJ	O
9.28	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
35.09	CD	O
+/-	JJ	O
4.09	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
from	IN	O
46.62	CD	O
+/-	JJ	O
10.03	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
42.89	CD	O
+/-	JJ	O
8.1	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
experimental	JJ	O
group	NN	O
significantly	RB	O
improved	VBN	O
in	IN	O
measures	NNS	PH
of	IN	PH
foot	NN	PH
ulcer	JJ	PH
surface	NN	PH
area	NN	PH
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.024	CD	O
)	)	O
.	.	O

VCT	NNP	Ot
enhances	VBZ	O
diabetic	JJ	PH
foot	NN	PH
ulcer	NN	PH
healing	VBG	PH
when	WRB	O
combined	VBN	O
with	IN	O
appropriate	JJ	O
wound	NN	O
care	NN	O
.	.	O

Economic	NNP	O
burden	NN	O
of	IN	O
childhood	NN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
estimate	VB	O
the	DT	O
associations	NNS	O
between	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
diagnoses	NNS	O
and	CC	O
service	NN	Ot
use	NN	Ot
,	,	Ot
caregiver	NN	Ot
time	NN	Ot
,	,	O
and	CC	O
cost	NN	Ot
outcomes	NNS	Ot
.	.	O

METHODS	NNP	O
We	PRP	O
used	VBD	O
national	JJ	O
data	NNS	O
from	IN	O
the	DT	O
Medical	NNP	O
Expenditure	NNP	O
Panel	NNP	O
Survey	NNP	O
linked	VBD	O
to	TO	O
the	DT	O
National	NNP	O
Health	NNP	O
Interview	NNP	O
Survey	NNP	O
and	CC	O
a	DT	O
study-specific	JJ	O
survey	NN	O
to	TO	O
estimate	VB	O
the	DT	O
annual	JJ	Ot
utilization	NN	Ot
and	CC	Ot
costs	NNS	Ot
for	IN	O
health	NN	O
care	NN	O
,	,	O
school	NN	O
,	,	O
ASD-related	JJ	O
therapy	NN	O
,	,	O
family-coordinated	JJ	O
services	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
caregiver	NN	O
time	NN	O
in	IN	O
children	NNS	O
aged	VBD	O
3	CD	O
to	TO	O
17	CD	O
years	NNS	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
parent-reported	JJ	O
ASD	NNP	O
.	.	O

Regression	NNP	O
analyses	VBZ	O
estimated	VBN	O
the	DT	O
association	NN	O
between	IN	O
ASD	NNP	O
diagnosis	NN	O
and	CC	O
cost	NN	Ot
,	,	O
controlling	VBG	O
for	IN	O
child	NN	O
gender	NN	O
,	,	O
age	NN	O
,	,	O
race/ethnicity	NN	O
,	,	O
insurance	NN	O
status	NN	O
,	,	O
household	JJ	O
income	NN	O
,	,	O
country	NN	O
region	NN	O
and	CC	O
urban/rural	JJ	O
classification	NN	O
,	,	O
and	CC	O
non-ASD-related	JJ	O
illnesses	NNS	O
.	.	O

RESULTS	NNP	O
Children	NNP	O
with	IN	O
parent-reported	JJ	O
ASD	NNP	O
had	VBD	O
higher	JJR	PH
levels	NNS	PH
of	IN	PH
health	NN	PH
care	NN	PH
office	NN	PH
visits	NNS	PH
and	CC	O
prescription	NN	O
drug	NN	O
use	NN	O
compared	VBN	O
with	IN	O
children	NNS	O
without	IN	O
ASD	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

A	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
children	NNS	O
in	IN	O
the	DT	O
ASD	NNP	O
group	NN	O
used	VBD	O
special	JJ	O
educational	JJ	O
services	NNS	O
(	(	O
76	CD	O
%	NN	O
vs.	FW	O
7	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

After	IN	O
adjusting	VBG	O
for	IN	O
child	JJ	O
demographic	JJ	O
characteristics	NNS	O
and	CC	O
non-ASD-associated	JJ	O
illnesses	NNS	O
,	,	O
ASD	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
$	$	O
3020	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
$	$	O
1017-	CD	O
$	$	O
4259	CD	O
)	)	O
higher	JJR	O
health	NN	O
care	NN	O
costs	NNS	O
and	CC	O
$	$	O
14,061	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
$	$	O
4390-	JJ	O
$	$	O
24,302	CD	O
)	)	O
higher	JJR	O
aggregate	JJ	O
non-health	NNS	O
care	NN	O
costs	NNS	O
,	,	O
including	VBG	O
$	$	O
8610	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
$	$	O
6595-	JJ	O
$	$	O
10,421	CD	O
)	)	O
higher	JJR	O
school	NN	O
costs	NNS	O
.	.	O

In	IN	O
adjusted	JJ	O
analyses	NNS	O
,	,	O
parents	NNS	O
who	WP	O
reported	VBD	O
that	IN	O
their	PRP$	O
child	NN	O
had	VBD	O
ASD	NNP	O
did	VBD	O
not	RB	Ot
have	VB	Ot
significantly	RB	Ot
higher	JJR	Ot
out-of-pocket	NN	Ot
costs	NNS	Ot
or	CC	O
spend	VB	O
more	JJR	O
time	NN	O
on	IN	O
caregiving	VBG	O
activities	NNS	O
compared	VBN	O
with	IN	O
control	NN	O
parents	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
economic	JJ	O
burden	NN	O
associated	VBN	O
with	IN	O
ASD	NNP	O
is	VBZ	O
substantial	JJ	O
and	CC	O
can	MD	O
be	VB	O
measured	VBN	O
across	IN	O
multiple	JJ	O
sectors	NNS	O
of	IN	O
our	PRP$	O
society	NN	O
.	.	O

Previous	JJ	O
analyses	NNS	O
that	WDT	O
focused	VBD	O
on	IN	O
health	NN	O
care	NN	O
underestimated	VBD	O
this	DT	O
economic	JJ	O
burden	NN	O
,	,	O
particularly	RB	O
for	IN	O
school	NN	O
systems	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
live	JJ	O
and	CC	O
videotape	JJ	O
ratings	NNS	O
:	:	O
clomipramine	NN	O
and	CC	O
haloperidol	NN	O
in	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
live	JJ	O
ratings	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
videotapes	NNS	O
and	CC	O
compared	VBN	O
response	NN	O
to	TO	O
clomipramine	VB	O
with	IN	O
response	NN	O
to	TO	O
haloperidol	VB	O
in	IN	O
8	CD	O
subjects	NNS	O
,	,	O
mean	JJ	O
age	NN	O
5.62	CD	O
years	NNS	O
,	,	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
autism	NN	O
.	.	O

They	PRP	O
were	VBD	O
consecutive	JJ	O
admissions	NNS	O
to	TO	O
a	DT	O
pilot	NN	O
study	NN	O
of	IN	O
clomipramine	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
or	CC	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
haloperidol	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
.	.	O

Live	JJ	O
ratings	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
pre-treatment	JJ	O
placebo	NN	O
baseline	NN	O
period	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
period	NN	O
on	IN	O
the	DT	O
CPRS	NNP	O
and	CC	O
the	DT	O
CGI	NNP	O
and	CC	O
were	VBD	O
videotaped	VBN	O
.	.	O

Employing	VBG	O
the	DT	O
same	JJ	O
instruments	NNS	O
,	,	O
these	DT	O
videotapes	NNS	O
were	VBD	O
rated	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
who	WP	O
did	VBD	O
not	RB	O
know	VB	O
the	DT	O
subjects	NNS	O
and	CC	O
were	VBD	O
blind	NNS	O
to	TO	O
study	VB	O
design	NN	O
,	,	O
treatment	NN	O
,	,	O
and	CC	O
study	NN	O
phase	NN	O
.	.	O

Ratings	NNS	Ot
of	IN	Ot
videotapes	NNS	Ot
significantly	RB	O
differed	VBN	O
from	IN	O
live	JJ	Ot
ratings	NNS	Ot
.	.	O

A	DT	O
treatment	NN	O
effect	NN	O
for	IN	O
haloperidol	NN	O
was	VBD	O
detected	VBN	O
only	RB	O
on	IN	O
live	JJ	Ot
ratings	NNS	Ot
and	CC	O
not	RB	O
on	IN	O
ratings	NNS	Ot
of	IN	Ot
videotapes	NNS	Ot
.	.	O

No	DT	O
treatment	NN	O
effect	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
clomipramine	NN	O
in	IN	O
either	CC	O
live	JJ	Ot
or	CC	O
videotape	JJ	Ot
ratings	NNS	Ot
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
investigating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
porcine	NN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

OBJECTIVES	CC	O
A	DT	O
recent	JJ	O
patient	NN	O
series	NN	O
reported	VBD	O
the	DT	O
incidental	JJ	O
findings	NNS	O
of	IN	O
improved	VBN	O
social	JJ	O
and	CC	O
language	NN	O
skills	NNS	O
in	IN	O
3	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
secretin	NN	O
,	,	O
a	DT	O
peptide	NN	O
hormone	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subsequent	JJ	O
study	NN	O
did	VBD	O
not	RB	O
find	VB	O
evidence	NN	O
for	IN	O
a	DT	O
drug	NN	O
effect	NN	O
.	.	O

Parents	NNS	O
are	VBP	O
seeking	VBG	O
treatment	NN	O
with	IN	O
secretin	JJ	O
despite	IN	O
the	DT	O
absence	NN	O
of	IN	O
empirical	JJ	O
investigations	NNS	O
demonstrating	VBG	O
amelioration	NN	O
in	IN	O
autism	NN	O
symptomology	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
more	RBR	O
precisely	RB	O
measure	VB	O
the	DT	O
effects	NNS	O
of	IN	O
secretin	NN	O
,	,	O
this	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
porcine	NN	O
secretin	NN	O
on	IN	O
12	CD	O
autistic	JJ	O
children	NNS	O
through	IN	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
on	IN	O
objective	JJ	ME
language	NN	ME
and	CC	ME
on	IN	ME
social	JJ	ME
,	,	ME
neuropsychological	JJ	ME
,	,	ME
and	CC	ME
gastrointestinal	JJ	PH
measures	NNS	PH
to	TO	O
evaluate	VB	O
drug	NN	O
effects	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
over	IN	O
a	DT	O
16-week	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
significant	JJ	O
differences	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
on	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
dependent	JJ	O
variables	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
on	IN	O
measures	NNS	ME
of	IN	ME
positive	JJ	ME
affect	NN	ME
and	CC	ME
activity	NN	ME
level	NN	ME
following	VBG	O
secretin	JJ	O
infusion	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
autistic	JJ	O
children	NNS	O
did	VBD	O
not	RB	O
demonstrate	VB	O
the	DT	O
improvements	NNS	O
described	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
retrospective	JJ	O
report	NN	O
.	.	O

Cost-effectiveness	NN	Ot
of	IN	O
cognitive-behavioral	JJ	O
group	NN	O
therapy	NN	O
for	IN	O
dysfunctional	JJ	O
fear	NN	O
of	IN	O
progression	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Anxiety	NNP	ME
and	CC	O
fear	NN	ME
are	VBP	O
often	RB	O
associated	VBN	O
with	IN	O
chronic	JJ	O
conditions	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
.	.	O

This	DT	O
paper	NN	O
targets	VBZ	O
the	DT	O
cost-effectiveness	JJ	Ot
analysis	NN	Ot
of	IN	O
a	DT	O
cognitive-behavioral	JJ	O
group	NN	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
client-centered	JJ	O
,	,	O
supportive-experiential	JJ	O
group	NN	O
therapy	NN	O
(	(	O
SET	NNP	O
)	)	O
in	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
dysfunctional	JJ	O
fear	NN	O
of	IN	O
progression	NN	O
.	.	O

An	DT	O
incremental	JJ	O
cost-effectiveness	JJ	Ot
analysis	NN	Ot
was	VBD	O
performed	VBN	O
using	VBG	O
data	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
among	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
inpatient	JJ	O
rehabilitation	NN	O
.	.	O

The	DT	O
means	NNPS	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
,	,	O
incremental	JJ	Ot
cost-effectiveness	JJ	Ot
graphic	NN	Ot
and	CC	Ot
acceptability	NN	Ot
curve	NN	Ot
were	VBD	O
obtained	VBN	O
from	IN	O
1,000	CD	O
bootstrap	NN	O
replications	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
174	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
economic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
estimated	JJ	O
means	VBZ	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
of	IN	O
direct	JJ	Ot
costs	NNS	Ot
and	CC	O
reduction	NN	ME
of	IN	ME
fear	NN	ME
of	IN	ME
progression	NN	ME
were	VBD	O
<	JJ	O
euro	JJ	O
>	NN	O
9,045.03	CD	O
[	JJ	O
6,359.07	CD	O
;	:	O
12,091.87	CD	O
]	NN	O
and	CC	O
1.41	CD	O
[	JJ	O
0.93	CD	O
;	:	O
1.92	CD	O
]	NN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
SET	NNP	O
and	CC	O
<	NNP	O
euro	VBP	O
>	$	O
6,682.78	CD	O
[	JJ	O
4,998.09	CD	O
;	:	O
8,440.95	CD	O
]	NN	O
and	CC	O
1.44	CD	O
[	JJ	O
1.02	CD	O
;	:	O
1.09	CD	O
]	NN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
CBT	NNP	O
.	.	O

The	DT	O
incremental	JJ	Ot
cost-effectiveness	JJ	Ot
ratio	NN	Ot
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
amounts	NNS	O
to	TO	O
minus	NNS	O
<	NNP	O
euro	VBP	O
>	$	O
78,741.66	CD	O
[	NNP	O
-154,987.20	NNP	O
;	:	O
110,486.32	CD	O
]	NN	O
for	IN	O
an	DT	O
additional	JJ	O
unit	NN	O
of	IN	O
effect	NN	O
.	.	O

Given	VBN	O
the	DT	O
acceptability	NN	Ot
curve	NN	Ot
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
92.4	CD	O
%	NN	O
chance	NN	O
that	IN	O
the	DT	O
CBT	NNP	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
SET	NNP	O
,	,	O
is	VBZ	O
cost-effective	JJ	Ot
without	IN	O
the	DT	O
need	NN	O
of	IN	O
additional	JJ	O
costs	NNS	O
to	TO	O
payers	NNS	O
.	.	O

Our	PRP$	O
main	JJ	O
result	NN	O
is	VBZ	O
the	DT	O
superior	JJ	O
cost-effectiveness	NN	Ot
of	IN	O
the	DT	O
cognitive-behavioral	JJ	O
intervention	NN	O
program	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
non-directive	JJ	O
encounter	NN	O
group	NN	O
for	IN	O
our	PRP$	O
sample	NN	O
of	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
anxiety	NN	ME
.	.	O

[	JJ	Ot
Effect	NNP	Ot
analysis	NN	Ot
on	IN	O
non-and-low	JJ	O
response	NN	O
infants	NNS	O
after	IN	O
revaccinated	VBN	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
booster	NN	PH
immunization	NN	PH
effect	NN	PH
to	TO	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
after	IN	O
3	CD	O
doses	NNS	O
HepB	NNP	O
immunization	NN	O
.	.	O

METHODS	NNP	O
Non-and-low	JJ	O
response	NN	O
infants	NNS	O
born	VBN	O
in	IN	O
2004	CD	O
2005	CD	O
administered	VBD	O
3	CD	O
doses	NNS	O
of	IN	O
HepB	NNP	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
6	CD	O
months	NNS	O
in	IN	O
Guangzhou	NNP	O
,	,	O
Beijing	NNP	O
and	CC	O
Zhejiang	NNP	O
were	VBD	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
randomly	RB	O
,	,	O
and	CC	O
boosted	VBD	O
3	CD	O
dose	NN	O
of	IN	O
4	CD	O
different	JJ	O
types	NNS	O
of	IN	O
HepB	NNP	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
GMC	NNP	O
of	IN	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
before	IN	O
booster	NN	O
)	)	O
,	,	O
group	NN	O
B	NNP	O
(	(	O
after	IN	O
1	CD	O
dose	JJ	O
booster	NN	O
)	)	O
and	CC	O
group	NN	O
C	NNP	O
(	(	O
after	IN	O
3	CD	O
dose	JJ	O
booster	NN	O
)	)	O
were	VBD	O
18.66	CD	O
mIUml	NN	O
,	,	O
88.82	CD	O
mIU/ml	NN	O
,	,	O
178.24	CD	O
mIU/ml	NN	O
respectively	RB	O
;	:	O
the	DT	O
proportion	NN	O
of	IN	O
non-responders	NNS	O
in	IN	O
three	CD	O
groups	NNS	O
were	VBD	O
20.4	CD	O
%	NN	O
,	,	O
9.1	CD	O
%	NN	O
,	,	O
1.9	CD	O
%	NN	O
respectively	RB	O
.	.	O

In	IN	O
103	CD	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
,	,	O
proportion	NN	PH
of	IN	PH
titers	NNS	PH
of	IN	O
more	JJR	O
than	IN	O
100	CD	O
mIU/ml	NN	O
of	IN	O
group	NN	O
B	NNP	O
and	CC	O
group	NN	O
C	NNP	O
were	VBD	O
61.2	CD	O
%	NN	O
and	CC	O
84.5	CD	O
%	NN	O
,	,	O
and	CC	O
there	RB	O
was	VBD	O
statistical	JJ	O
significant	JJ	O
difference	NN	O
(	(	O
chi2	JJ	O
=	NN	O
14.13	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
GMC	NNP	O
after	IN	O
3	CD	O
doses	NNS	O
revaccination	NN	O
with	IN	O
four	CD	O
kinds	NNS	O
of	IN	O
HepB	NNP	O
,	,	O
included	VBD	O
5	CD	O
microg	NN	O
HepB-Y	NNP	O
,	,	O
10	CD	O
microg	NN	O
HepB-Y	NNP	O
,	,	O
l0	JJ	O
microg	NN	O
HepB-CHO	NNP	O
,	,	O
10	CD	O
microg	JJ	O
HepB-HY	NNP	O
were	VBD	O
168.8	CD	O
mJU/ml	NN	O
,	,	O
174.7	CD	O
mIU/ml	NN	O
,	,	O
184.9	CD	O
mIU/ml	NN	O
,	,	O
182.9	CD	O
mIU/ml	NN	O
respectively	RB	O
.	.	O

Proportion	NN	PH
of	IN	PH
titers	NNS	PH
of	IN	O
more	JJR	O
than	IN	O
100	CD	O
mIU/ml	NNS	O
for	IN	O
four	CD	O
kinds	NNS	O
HepB	NNP	O
were	VBD	O
79.0	CD	O
%	NN	O
,	,	O
85.7	CD	O
%	NN	O
,	,	O
88.2	CD	O
%	NN	O
and	CC	O
84.6	CD	O
%	NN	O
respectively	RB	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
chi2	JJ	O
=	NN	O
0.75	CD	O
,	,	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
There	EX	O
were	VBD	O
no	DT	O
different	JJ	O
of	IN	O
seroconversion	NN	PH
rate	NN	PH
between	IN	O
study	NN	O
population	NN	O
received	VBD	O
1	CD	O
dose	NN	O
and	CC	O
3	CD	O
dose	JJ	O
booster	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
high	JJ	O
titer	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
3	CD	O
dose	JJ	O
booster	NN	O
.	.	O

The	DT	O
four	CD	O
kinds	NNS	O
of	IN	O
HepB	NNP	O
,	,	O
including	VBG	O
5	CD	O
microg	JJ	O
HepB-Y,10	NNP	O
microg	NN	O
HepB-Y	NNP	O
,	,	O
10	CD	O
microg	NN	O
HepB-CHO	NNP	O
,	,	O
10	CD	O
microg	NN	O
HepB-HY	NNP	O
had	VBD	O
the	DT	O
same	JJ	O
immunization	NN	O
effect	NN	O
after	IN	O
3	CD	O
doses	NNS	O
revaccination	NN	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
6	CD	O
months	NNS	O
to	TO	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
.	.	O

Pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
YM17E	NNP	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	DT	O
:	:	O
cholesterol	NN	O
acyl	NN	O
transferase	NN	O
,	,	O
and	CC	O
serum	VB	PH
cholesterol	NN	PH
levels	NNS	PH
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
single	JJ	O
and	CC	O
repeat	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
of	IN	O
YM17E	NNP	O
,	,	O
a	DT	O
novel	JJ	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	NNP	O
(	(	O
CoA	NNP	O
)	)	O
:	:	O
cholesterol	NN	O
acyltransferase	NN	O
,	,	O
in	IN	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
pharmacokinetic	JJ	Ot
profile	NN	Ot
,	,	Ot
tolerability	NN	Ot
and	CC	Ot
effect	NN	Ot
of	IN	Ot
the	DT	Ot
drug	NN	Ot
on	IN	Ot
serum	NN	Ot
cholesterol	NN	Ot
.	.	Ot

In	IN	O
the	DT	O
single	JJ	O
administration	NN	O
study	NN	O
,	,	O
YM17E	NNP	O
was	VBD	O
administered	VBN	O
after	IN	O
a	DT	O
meal	NN	O
to	TO	O
two	CD	O
groups	NNS	O
of	IN	O
subjects	NNS	O
(	(	O
each	DT	O
containing	VBG	O
six	CD	O
subjects	NNS	O
taking	VBG	O
the	DT	O
drug	NN	O
and	CC	O
three	CD	O
taking	VBG	O
placebo	NN	O
)	)	O
receiving	VBG	O
3	CD	O
,	,	O
60	CD	O
and	CC	O
300	CD	O
mg	NN	O
or	CC	O
15	CD	O
,	,	O
60	CD	O
and	CC	O
450	CD	O
mg	NN	O
YM17E	NNP	O
,	,	O
respectively	RB	O
.	.	O

Plasma	NNP	PH
concentrations	NNS	PH
of	IN	O
unchanged	JJ	O
drug	NN	O
following	VBG	O
single	JJ	O
oral	JJ	O
administration	NN	O
at	IN	O
3-300	JJ	O
mg	NN	O
after	IN	O
a	DT	O
meal	NN	O
increased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
plasma	NN	PH
concentrations	NNS	PH
after	IN	O
administration	NN	O
of	IN	O
450	CD	O
mg	NNS	O
were	VBD	O
almost	RB	O
the	DT	O
same	JJ	O
as	IN	O
after	IN	O
300	CD	O
mg	NN	O
.	.	O

Unchanged	VBD	O
YM17E	NNP	O
was	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
urine	NN	O
after	IN	O
single	JJ	O
administration	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
it	PRP	O
was	VBD	O
excreted	VBN	O
via	IN	O
the	DT	O
bile	NN	O
or	CC	O
urine	NN	O
after	IN	O
metabolism	NN	O
.	.	O

Five	CD	O
active	JJ	O
metabolites	NNS	O
(	(	O
M1	NNP	O
,	,	O
M2-a	NNP	O
,	,	O
M2-b	NNP	O
,	,	O
M3	NNP	O
and	CC	O
M4	NNP	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
plasma	NN	O
at	IN	O
concentrations	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unchanged	JJ	O
YM17E	NNP	O
.	.	O

Their	PRP$	O
plasma	JJ	PH
concentrations	NNS	PH
increased	VBD	O
in	IN	O
a	DT	O
slightly	RB	O
greater	JJR	O
than	IN	O
dose-dependent	JJ	O
manner	NN	O
from	IN	O
3	CD	O
to	TO	O
300	CD	O
mg	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
food	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
received	VBD	O
150	CD	O
mg	NNS	O
YM17E	VBN	O
in	IN	O
both	DT	O
the	DT	O
fasted	VBN	O
and	CC	O
post-prandial	JJ	O
states	NNS	O
.	.	O

The	DT	O
AUC	NNP	Ot
and	CC	Ot
Cmax	NNP	Ot
after	IN	O
fasting	VBG	O
were	VBD	O
closely	RB	O
similar	JJ	O
to	TO	O
those	DT	O
after	IN	O
a	DT	O
meal	NN	O
,	,	O
showing	VBG	O
that	IN	O
bioavailability	NN	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
food	NN	O
intake	NN	O
.	.	O

In	IN	O
the	DT	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
test	JJ	O
drug	NN	O
at	IN	O
150	CD	O
mg	NN	O
or	CC	O
300	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	RB	O
6	CD	O
each	DT	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
3	CD	O
)	)	O
twice	RB	O
a	DT	O
day	NN	O
(	(	O
after	IN	O
breakfast	NN	O
and	CC	O
after	IN	O
dinner	NN	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

On	IN	O
days	NNS	O
1	CD	O
and	CC	O
7	CD	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
YM17E	NNP	O
once	RB	O
a	DT	O
day	NN	O
(	(	O
after	IN	O
breakfast	NN	O
)	)	O
for	IN	O
evaluation	NN	O
of	IN	O
pharmacokinetic	JJ	O
properties	NNS	O
.	.	O

After	IN	O
repeated	VBN	O
oral	JJ	O
administration	NN	O
of	IN	O
150	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	PH
concentrations	NNS	PH
reached	VBD	O
steady	JJ	O
state	NN	O
by	IN	O
day	NN	O
5	CD	O
(	(	O
mean	JJ	O
Cmin	NNP	O
48.6	CD	O
ng.ml-1	NN	O
)	)	O
.	.	O

After	IN	O
repeated	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	PH
concentrations	NNS	PH
prior	RB	O
to	TO	O
each	DT	O
daily	JJ	O
morning	NN	O
dose	NN	O
increased	VBD	O
up	RB	O
to	TO	O
the	DT	O
5th	JJ	O
day	NN	O
(	(	O
mean	JJ	O
Cmin	NNP	O
166.6	CD	O
ng.ml-1	NN	O
)	)	O
and	CC	O
then	RB	O
tended	VBD	O
to	TO	O
decrease	VB	O
until	IN	O
the	DT	O
7th	JJ	O
day	NN	O
.	.	O

No	DT	O
significant	JJ	PH
signs	NNS	PH
,	,	PH
symptoms	NNS	PH
or	CC	PH
changes	NNS	PH
in	IN	PH
serum	NN	PH
cholesterol	NN	PH
levels	NNS	PH
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
single	JJ	O
and	CC	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
studies	NNS	O
at	IN	O
150	CD	O
mg	NN	O
b.d	NN	O
.	.	O

Although	IN	O
statistical	JJ	O
analysis	NN	O
was	VBD	O
not	RB	O
conducted	VBN	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
subjects	NNS	O
,	,	O
all	DT	O
subjects	NNS	O
receiving	VBG	O
repeated	VBD	O
oral	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
showed	VBD	O
a	DT	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
serum	NN	PH
cholesterol	NN	PH
level	NN	O
on	IN	O
day	NN	O
7	CD	O
,	,	O
but	CC	O
also	RB	O
the	DT	O
simultaneous	JJ	O
occurrence	NN	O
of	IN	O
diarrhoea	NN	A
.	.	O

Effect	NN	O
of	IN	O
micronutrient	NN	O
supplement	NN	O
on	IN	O
health	NN	PH
and	CC	PH
nutritional	JJ	PH
status	NN	PH
of	IN	O
schoolchildren	NNS	O
:	:	O
study	NN	O
design	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
supplementation	NN	O
with	IN	O
a	DT	O
micronutrient-fortified	JJ	O
beverage	NN	O
improves	VBZ	O
micronutrient	JJ	O
status	NN	O
and	CC	O
physical	JJ	O
and	CC	O
mental	JJ	O
development	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
schoolchildren	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
middle-income	JJ	O
students	NNS	O
in	IN	O
two	CD	O
residential	JJ	O
schools	NNS	O
that	WDT	O
catered	VBD	O
to	TO	O
children	NNS	O
from	IN	O
a	DT	O
semi-urban	JJ	O
population	NN	O
near	IN	O
Hyderabad	NNP	O
,	,	O
India	NNP	O
.	.	O

Included	NNP	O
were	VBD	O
869	CD	O
children	NNS	O
who	WP	O
were	VBD	O
6	CD	O
to	TO	O
16	CD	O
y	NN	O
of	IN	O
age	NN	O
in	IN	O
grades	NNS	O
1	CD	O
to	TO	O
10	CD	O
.	.	O

Because	IN	O
children	NNS	O
at	IN	O
each	DT	O
grade	NN	O
were	VBD	O
distributed	VBN	O
across	IN	O
two	CD	O
classrooms	NNS	O
(	(	O
clusters	NNS	O
)	)	O
and	CC	O
were	VBD	O
homogeneous	JJ	O
,	,	O
each	DT	O
grade	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
consist	VB	O
of	IN	O
a	DT	O
matched	JJ	O
pair	NN	O
.	.	O

There	EX	O
were	VBD	O
thus	RB	O
10	CD	O
pairs	NNS	O
available	JJ	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Classes	NNS	O
in	IN	O
each	DT	O
grade	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
micronutrient-enriched	JJ	O
beverage	NN	O
or	CC	O
a	DT	O
placebo	NN	O
without	IN	O
added	JJ	O
micronutrients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
double	RB	O
blinded	VBN	O
and	CC	O
the	DT	O
duration	NN	O
was	VBD	O
14	CD	O
mo	NN	O
,	,	O
with	IN	O
supervised	JJ	O
feeding	NN	O
of	IN	O
the	DT	O
micronutrient-enriched	JJ	O
beverage	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
micronutrients	NNS	O
on	IN	O
the	DT	O
outcome	NN	PH
variables	NNS	PH
growth	NN	PH
,	,	PH
biochemical	JJ	PH
status	NN	PH
,	,	O
mental	JJ	ME
function	NN	ME
,	,	O
and	CC	O
bone	NN	PH
health	NN	PH
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
number	NN	O
of	IN	O
matched	JJ	O
pairs	NNS	O
varied	VBD	O
between	IN	O
seven	CD	O
and	CC	O
eight	CD	O
,	,	O
and	CC	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
treatment	NN	O
group	NN	O
ranged	VBD	O
from	IN	O
32	CD	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
bone	NN	O
heath	NN	O
to	TO	O
177	CD	O
for	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
power	NN	O
of	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
ranged	VBD	O
from	IN	O
74	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
and	CC	O
was	VBD	O
adequate	NN	O
for	IN	O
successful	JJ	O
pairing	NN	O
.	.	O

The	DT	O
effect	NN	O
assessed	VBD	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
supplementation	NN	O
showed	VBD	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
beneficial	JJ	Ot
.	.	O

CONCLUSIONS	NNP	O
Designing	VBG	O
an	DT	O
intervention	NN	O
,	,	O
choosing	VBG	O
outcome	NN	O
variables	NNS	O
,	,	O
and	CC	O
implementing	VBG	O
the	DT	O
protocol	NN	O
in	IN	O
a	DT	O
typical	JJ	O
Indian	JJ	O
school	NN	O
setting	VBG	O
were	VBD	O
achieved	VBN	O
.	.	O

Mouth	NNP	O
closing	NN	O
device	NN	O
(	(	O
chinstrap	NN	O
)	)	O
reduces	VBZ	O
mouth	JJ	PH
leak	NN	PH
during	IN	O
nasal	JJ	O
CPAP	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Mouth	NNP	O
leak	VBP	O
occasionally	RB	O
complicates	VBZ	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
(	(	O
CPAP	NNP	O
)	)	O
therapy	NN	O
,	,	O
which	WDT	O
leads	VBZ	O
to	TO	O
discomfort	VB	O
.	.	O

While	IN	O
a	DT	O
chinstrap	NN	O
prevents	VBZ	O
the	DT	O
mouth	NN	O
from	IN	O
opening	VBG	O
during	IN	O
sleep	NN	O
,	,	O
its	PRP$	O
efficacy	NN	O
in	IN	O
diminishing	VBG	O
mouth	NN	O
leak	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Fifteen	NNP	O
patients	NNS	O
with	IN	O
mouth	JJ	O
leak	JJ	O
complaining	NN	O
of	IN	O
mouth	NN	O
dryness	NN	O
and	CC	O
nasal	JJ	O
obstruction	NN	O
underwent	JJ	O
two	CD	O
consecutive	JJ	O
overnight	JJ	O
polysomnographies	NNS	O
,	,	O
one	CD	O
with	IN	O
a	DT	O
chinstrap	NN	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Cephalometry	NN	PH
with	IN	O
and	CC	O
without	IN	O
a	DT	O
chinstrap	NN	O
was	VBD	O
randomly	RB	O
performed	VBN	O
on	IN	O
six	CD	O
patients	NNS	O
.	.	O

RESULTS	NNP	O
With	IN	O
the	DT	O
chinstrap	NN	O
,	,	O
both	DT	O
mouth	FW	PH
leak	NN	PH
and	CC	O
the	DT	Ot
arousal	NN	Ot
index	NN	Ot
decreased	VBD	O
significantly	RB	O
,	,	O
from	IN	O
(	(	O
mean+/-SD	JJ	O
)	)	O
42.9+/-23.5	CD	O
to	TO	O
23.8+/-13.3	CD	O
%	NN	O
of	IN	O
total	JJ	PH
sleep	JJ	PH
time	NN	PH
(	(	O
TST	NNP	O
)	)	O
,	,	O
and	CC	O
from	IN	O
33.4+/-18.6	JJ	O
to	TO	O
23.6+/-9.3/sleep	JJ	O
hour	NN	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
snoring	VBG	PH
time	NN	PH
showed	VBD	O
a	DT	O
concomitant	JJ	O
increase	NN	O
from	IN	O
6.7+/-14.3	JJ	O
to	TO	O
24.0+/-13.2	CD	O
%	NN	O
of	IN	O
TST	NNP	O
.	.	O

The	DT	O
arousal	JJ	PH
index	NN	PH
was	VBD	O
significantly	RB	O
higher	JJR	O
during	IN	O
leak	JJR	O
periods	NNS	O
,	,	O
and	CC	O
its	PRP$	O
changes	NNS	O
correlated	VBN	O
positively	RB	O
with	IN	O
changes	NNS	O
in	IN	O
mouth	NN	PH
leak	NN	PH
.	.	O

Cephalometric	JJ	PH
measures	NNS	PH
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
anterior	JJ	PH
lower	JJR	PH
facial	JJ	PH
height	NN	PH
.	.	O

CONCLUSIONS	VB	O
The	DT	O
chinstrap	NN	O
,	,	O
by	IN	O
closing	VBG	O
the	DT	O
mouth	NN	O
during	IN	O
CPAP	NNP	O
,	,	O
reduces	VBZ	O
mouth	JJ	O
leak	NN	O
and	CC	O
therefore	RB	O
the	DT	O
arousal	NN	O
index	NN	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

Nevertheless	NNP	O
,	,	O
the	DT	O
indices	NNS	O
remained	VBD	O
unacceptably	RB	O
high	JJ	O
.	.	O

The	DT	O
chinstrap	NN	O
may	MD	O
also	RB	O
increase	VB	O
snoring	NN	O
and	CC	O
,	,	O
in	IN	O
rare	JJ	O
cases	NNS	O
,	,	O
can	MD	O
worsen	VB	O
the	DT	O
respiratory	NN	O
disturbance	NN	O
index	NN	O
.	.	O

Consideration	NN	O
of	IN	O
these	DT	O
potential	JJ	O
effects	NNS	O
is	VBZ	O
important	JJ	O
before	IN	O
instituting	VBG	O
regular	JJ	O
home	NN	O
use	NN	O
of	IN	O
the	DT	O
chinstrap	NN	O
.	.	O

Acute	NNP	O
intravenous	JJ	O
L-arginine	JJ	O
infusion	NN	O
decreases	VBZ	O
endothelin-1	JJ	PH
levels	NNS	PH
and	CC	O
improves	VBZ	O
endothelial	JJ	PH
function	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
angina	JJ	O
pectoris	NN	O
and	CC	O
normal	JJ	O
coronary	JJ	O
arteriograms	NNS	O
:	:	O
correlation	NN	O
with	IN	O
asymmetric	JJ	O
dimethylarginine	NN	PH
levels	NNS	PH
.	.	PH

BACKGROUND	NNP	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
asymmetric	JJ	PH
dimethylarginine	NN	PH
(	(	PH
ADMA	NNP	PH
)	)	PH
levels	NNS	PH
could	MD	O
be	VB	O
elevated	VBN	O
and	CC	O
influence	VB	O
endothelin-1	JJ	PH
and	CC	O
nitric	JJ	PH
oxide	NN	PH
release	NN	PH
and	CC	PH
action	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	O
syndrome	NN	O
X	NNP	O
(	(	O
CSX	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
whether	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
L-arginine	NNP	O
would	MD	O
improve	VB	O
endothelial	JJ	PH
function	NN	PH
in	IN	O
these	DT	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Nine	NNP	O
patients	NNS	O
with	IN	O
CSX	NNP	O
and	CC	O
14	CD	O
control	NN	O
subjects	NNS	O
underwent	VBD	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
L-arginine	NNP	O
(	(	O
0.125	CD	O
g/min	NN	O
)	)	O
or	CC	O
saline	NN	O
for	IN	O
120	CD	O
minutes	NNS	O
.	.	O

Sixty	NNP	O
minutes	NNS	O
after	IN	O
L-arginine	NNP	O
or	CC	O
saline	JJ	O
infusions	NNS	O
,	,	O
an	DT	O
intravenous	JJ	O
insulin	NN	O
bolus	NN	O
(	(	O
0.1	CD	O
U/kg	NNP	O
)	)	O
combined	VBD	O
with	IN	O
a	DT	O
euglycemic	JJ	O
clamp	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Basal	NNP	PH
ADMA	NNP	PH
and	CC	O
endothelin-1	JJ	PH
levels	NNS	PH
were	VBD	O
higher	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
infusion	NN	O
,	,	O
compared	VBN	O
with	IN	O
saline	NN	O
,	,	O
L-arginine	JJ	O
infusion	NN	O
increased	VBD	O
basal	JJ	PH
forearm	NN	PH
blood	NN	PH
flow	NN	PH
,	,	O
nitrite	JJ	PH
and	CC	PH
nitrate	JJ	PH
(	(	PH
NOx	NNP	PH
)	)	PH
,	,	O
and	CC	O
forearm	NN	PH
cGMP	NN	PH
release	NN	O
and	CC	O
decreased	VBD	O
endothelin-1	NN	PH
.	.	O

After	IN	O
insulin	NN	O
bolus	NN	O
,	,	O
during	IN	O
saline	NN	O
,	,	O
insulin-induced	JJ	PH
NOx	NNP	PH
,	,	O
endothelin-1	JJ	PH
,	,	O
and	CC	O
forearm	NN	PH
cGMP	NN	PH
release	NN	O
was	VBD	O
almost	RB	O
abolished	VBN	O
.	.	O

Conversely	RB	O
,	,	O
L-arginine	NNP	O
restored	VBD	O
a	DT	O
physiological	JJ	O
profile	NN	O
of	IN	O
all	DT	O
endothelial	JJ	Ot
variables	NNS	Ot
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
.	.	O

In	IN	O
control	NN	O
subjects	NNS	O
,	,	O
compared	VBN	O
with	IN	O
saline	JJ	O
infusion	NN	O
,	,	O
L-arginine	JJ	O
infusion	NN	O
did	VBD	O
not	RB	O
modify	VB	O
any	DT	O
parameter	NN	O
.	.	O

ADMA	NNP	PH
levels	NNS	PH
were	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
basal	JJ	O
endothelin-1	JJ	PH
levels	NNS	PH
and	CC	O
negatively	RB	O
correlated	VBN	O
with	IN	O
insulin-induced	JJ	ME
incremental	JJ	ME
levels	NNS	PH
of	IN	PH
NOx	NNP	PH
and	CC	ME
forearm	NN	PH
cGMP	NN	PH
release	NN	ME
.	.	O

CONCLUSIONS	NNP	O
Plasma	NNP	PH
ADMA	NNP	PH
levels	NNS	PH
are	VBP	O
increased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
,	,	O
and	CC	O
they	PRP	O
are	VBP	O
correlated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
endothelin-1	JJ	PH
and	CC	O
reductions	NNS	O
in	IN	O
insulin-induced	JJ	O
increments	NNS	O
in	IN	O
plasma	NN	PH
NOx	NNP	PH
and	CC	PH
cGMP	NN	PH
,	,	O
effects	NNS	O
that	WDT	O
are	VBP	O
reversed	VBN	O
by	IN	O
intravenous	JJ	O
L-arginine	NNP	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
increased	VBD	O
ADMA	NNP	PH
levels	NNS	PH
play	VBP	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
abnormal	JJ	O
vascular	JJ	O
reactivity	NN	O
that	WDT	O
is	VBZ	O
observed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
ulinastatin	NN	O
on	IN	O
inflammatory	JJ	PH
responses	NNS	PH
induced	VBN	O
by	IN	O
oesophagectomy	JJ	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
ulinastatin	NN	O
(	(	O
UTI	NNP	O
)	)	O
on	IN	O
the	DT	O
inflammatory	JJ	PH
responses	NNS	PH
induced	VBN	O
by	IN	O
oesophagectomy	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
patients	NNS	O
with	IN	O
esophageal	JJ	O
cancer	NN	O
(	(	O
without	IN	O
serious	JJ	O
hypertension	NN	O
,	,	O
heart	NN	O
disease	NN	O
,	,	O
or	CC	O
respiratory	JJ	O
function	NN	O
impairment	NN	O
,	,	O
including	VBG	O
34	CD	O
men	NNS	O
and	CC	O
6	CD	O
women	NNS	O
aged	VBD	O
46	CD	O
to	TO	O
70	CD	O
years	NNS	O
)	)	O
scheduled	VBD	O
for	IN	O
oesophagectomy	JJ	O
via	IN	O
left	JJ	O
thoracotomy	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
control	NN	O
group	NN	O
(	(	O
n=20	CC	O
)	)	O
and	CC	O
UTI	NNP	O
group	NN	O
(	(	O
n=20	RB	O
)	)	O
.	.	O

Anesthesia	NNP	O
induction	NN	O
and	CC	O
perioperative	JJ	O
management	NN	O
followed	VBD	O
the	DT	O
same	JJ	O
protocols	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
in	IN	O
UTI	NNP	O
group	NN	O
,	,	O
patients	NNS	O
received	VBD	O
5000	CD	O
U/kg	NNP	O
UTI	NNP	O
while	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
given	VBN	O
the	DT	O
same	JJ	O
volume	NN	O
of	IN	O
saline	NN	O
.	.	O

Before	IN	O
operation	NN	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
,	,	O
10	CD	O
min	NN	O
after	IN	O
recovery	NN	O
of	IN	O
two-lung	JJ	O
ventilation	NN	O
(	(	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
,	,	O
and	CC	O
24	CD	O
h	NN	O
(	(	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
)	)	O
and	CC	O
48	CD	O
h	NN	O
(	(	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
)	)	O
after	IN	O
operation	NN	O
,	,	O
the	DT	O
venous	JJ	O
blood	NN	O
sample	NN	O
was	VBD	O
taken	VBN	O
from	IN	O
the	DT	O
internal	JJ	O
jugular	NN	O
vein	NN	O
and	CC	O
the	DT	O
plasma	NN	O
was	VBD	O
separated	VBN	O
and	CC	O
stored	VBN	O
at	IN	O
-70	NNP	O
degrees	NNS	O
C	NNP	O
for	IN	O
later	JJR	O
analysis	NN	O
of	IN	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
with	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

The	DT	O
bronchoalveoar	NN	O
lavage	NN	O
fluid	NN	O
(	(	O
BAFL	NNP	O
)	)	O
was	VBD	O
also	RB	O
collected	VBN	O
at	IN	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
for	IN	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
detection	NN	O
.	.	O

RESULTS	NNP	O
IL-6	JJ	PH
,	,	PH
IL-8	JJ	PH
levels	NNS	PH
in	IN	PH
the	DT	PH
plasma	NN	PH
and	CC	PH
BALF	NNP	PH
collected	VBD	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
increased	VBD	PH
significantly	RB	PH
as	IN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
samples	NNS	O
collected	VBN	O
at	IN	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
peak	JJ	PH
concentration	NN	PH
inplasma	NN	PH
and	CC	PH
BALF	NNP	PH
samples	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

IL-6	JJ	PH
and	CC	O
IL-8	JJ	PH
levels	NNS	O
in	IN	O
the	DT	O
UTI	NNP	O
group	NN	O
were	VBD	O
significantly	RB	PH
lower	JJR	PH
than	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
during	IN	O
the	DT	O
time	NN	O
points	NNS	O
of	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Inflammatory	NNP	O
responses	VBZ	O
occur	VBP	O
during	IN	O
and	CC	O
after	IN	O
oesophagectomy	NN	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
inhibited	VBN	O
with	IN	O
UTI	NNP	O
.	.	O

A	DT	O
psychological	JJ	O
intervention	NN	O
reduces	NNS	O
inflammatory	JJ	PH
markers	NNS	PH
by	IN	O
alleviating	VBG	O
depressive	JJ	ME
symptoms	NNS	ME
:	:	O
secondary	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
test	VB	O
experimentally	RB	O
whether	IN	O
a	DT	O
psychological	JJ	O
intervention	NN	O
reduces	NNS	O
depression-related	JJ	O
symptoms	NNS	O
and	CC	O
markers	NNS	O
of	IN	O
inflammation	NN	O
among	IN	O
cancer	NN	O
patients	NNS	O
and	CC	O
to	TO	O
test	VB	O
one	CD	O
mechanism	NN	O
for	IN	O
the	DT	O
intervention	NN	O
effects	NNS	O
.	.	O

Depression	NNP	O
and	CC	O
inflammation	NN	O
are	VBP	O
common	JJ	O
among	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Data	NNP	O
suggest	NN	O
that	IN	O
inflammation	NN	O
can	MD	O
contribute	VB	O
to	TO	O
depressive	VB	ME
symptoms	NNS	ME
,	,	O
although	IN	O
the	DT	O
converse	NN	O
remains	VBZ	O
untested	JJ	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
newly	RB	O
diagnosed	VBN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
with	IN	O
clinically	RB	O
significant	JJ	O
depressive	JJ	O
symptoms	NNS	O
were	VBD	O
evaluated	VBN	O
and	CC	O
randomized	VBN	O
to	TO	O
psychological	JJ	O
intervention	NN	O
with	IN	O
assessment	NN	O
or	CC	O
assessment	NN	O
only	RB	O
study	VBD	O
arms	NNS	O
.	.	O

The	DT	O
intervention	NN	O
spanned	VBD	O
12	CD	O
months	NNS	O
,	,	O
with	IN	O
assessments	NNS	O
at	IN	O
baseline	NN	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Mixed-effects	NNS	O
modeling	VBG	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
intervention	NN	O
reduced	VBD	O
self-reported	JJ	ME
depressive	NN	ME
symptoms	NNS	ME
(	(	O
Center	NNP	O
for	IN	O
Epidemiological	NNP	O
Studies	NNPS	O
Depression	NNP	O
scale	NN	O
,	,	O
Profile	NNP	O
of	IN	O
Mood	NNP	O
States	NNPS	O
Depression	NNP	O
and	CC	O
Fatigue	NNP	O
subscales	NNS	O
,	,	O
and	CC	O
Medical	NNP	O
Outcomes	NNP	O
Study-Short	NNP	O
Form	NNP	O
36	CD	O
Bodily	NNP	O
Pain	NNP	O
subscale	NN	O
)	)	O
and	CC	O
immune	JJ	PH
cell	NN	PH
numbers	NNS	PH
that	WDT	O
are	VBP	O
elevated	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
inflammation	NN	O
(	(	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
,	,	O
neutrophil	JJ	O
count	NN	O
,	,	O
and	CC	O
helper/suppressor	VB	O
ratio	NN	O
)	)	O
.	.	O

Mediation	NN	O
analyses	NNS	O
tested	VBD	O
whether	IN	O
change	NN	ME
in	IN	ME
depressive	JJ	ME
symptoms	NNS	ME
,	,	O
pain	NN	PA
,	,	O
or	CC	O
fatigue	NN	PH
predicted	VBN	O
change	NN	PH
in	IN	PH
white	JJ	PH
blood	NN	PH
cell	NN	PH
count	NN	PH
,	,	O
neutrophil	JJ	PH
count	NN	PH
,	,	PH
or	CC	O
the	DT	O
helper/suppressor	NN	PH
ratio	NN	PH
.	.	O

RESULTS	VB	O
The	DT	O
intervention	NN	O
reduced	VBD	O
significantly	RB	O
depressive	JJ	ME
symptoms	NNS	ME
,	,	O
pain	NN	PA
,	,	O
fatigue	NN	PH
,	,	O
and	CC	O
inflammation	NN	PH
markers	NNS	PH
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
intervention	NN	O
effect	NN	O
on	IN	O
inflammation	NN	PH
was	VBD	O
mediated	VBN	O
by	IN	O
its	PRP$	O
effect	NN	O
on	IN	O
depressive	NN	O
symptoms	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
experiment	NN	O
to	TO	O
test	VB	O
whether	IN	O
psychological	JJ	O
treatment	NN	O
effective	JJ	O
in	IN	O
reducing	VBG	O
depressive	JJ	ME
symptoms	NNS	ME
would	MD	O
also	RB	O
reduce	VB	O
indicators	NNS	O
of	IN	O
inflammation	NN	O
.	.	O

Data	NNP	O
show	NN	O
that	IN	O
the	DT	O
intervention	NN	O
reduced	VBD	O
directly	RB	O
depressive	JJ	ME
symptoms	NNS	ME
and	CC	O
reduced	VBN	O
indirectly	RB	O
inflammation	NN	PH
.	.	O

Psychological	JJ	O
treatment	NN	O
may	MD	O
treat	VB	O
effectively	RB	O
depressive	JJ	PA
symptoms	NNS	PA
,	,	O
pain	NN	PA
,	,	O
and	CC	O
fatigue	NN	PA
among	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Therapy	NNP	Ot
effect	NN	Ot
of	IN	O
either	CC	O
paclitaxel	NN	O
or	CC	O
cyclophosphamide	JJ	O
combination	NN	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
epithelial	JJ	O
ovarian	JJ	O
cancer	NN	O
and	CC	O
relation	NN	O
to	TO	O
TP53	NNP	O
gene	NN	O
status	NN	O
.	.	O

Cell	NNP	O
death	NN	O
after	IN	O
treatment	NN	O
with	IN	O
chemotherapy	NN	O
is	VBZ	O
exerted	VBN	O
by	IN	O
activation	NN	O
of	IN	O
apoptosis	NN	O
,	,	O
and	CC	O
the	DT	O
p53	NN	O
protein	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
actively	RB	O
participate	VB	O
in	IN	O
this	DT	O
process	NN	O
.	.	O

This	DT	O
recent	JJ	O
focus	NN	O
on	IN	O
TP53	NNP	PH
status	NN	PH
as	IN	O
a	DT	O
possible	JJ	O
determinant	NN	O
of	IN	O
cancer	NN	O
therapy	NN	O
response	NN	O
has	VBZ	O
raised	VBN	O
the	DT	O
question	NN	O
of	IN	O
whether	IN	O
or	CC	O
not	RB	O
mutations	NNS	O
in	IN	O
the	DT	O
TP53	NNP	O
gene	NN	O
have	VBP	O
an	DT	O
influence	NN	O
on	IN	O
paclitaxel	NN	O
therapy	NN	O
.	.	O

The	DT	O
TP53	NNP	PH
status	NN	PH
has	VBZ	O
been	VBN	O
analysed	VBN	O
at	IN	O
the	DT	O
DNA	NNP	O
level	NN	O
in	IN	O
tumours	NNS	O
from	IN	O
45	CD	O
ovarian	JJ	O
cancer	NN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
paclitaxel	NN	O
and	CC	O
cisplatin	NN	O
or	CC	O
cyclophosphamide	NN	O
and	CC	O
cisplatin	NN	O
.	.	O

Therapy	NNP	Ot
response	NN	Ot
was	VBD	O
obtained	VBN	O
for	IN	O
38	CD	O
patients	NNS	O
with	IN	O
clinically	RB	O
evaluable	JJ	O
disease	NN	O
after	IN	O
initial	JJ	O
surgery	NN	O
.	.	O

The	DT	O
positive	JJ	PH
response	NN	PH
rate	NN	PH
to	TO	O
the	DT	O
paclitaxel/cisplatin	NN	O
therapy	NN	O
was	VBD	O
85	CD	O
%	NN	O
vs	JJ	O
61	CD	O
%	NN	O
for	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
cyclophosphamide/cisplatin	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
relapse-free	JJ	MO
survival	NN	MO
in	IN	O
favour	NN	O
of	IN	O
paclitaxel/cisplatin	NN	O
chemotherapy	NN	O
was	VBD	O
found	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
33	CD	O
tumour	NN	O
samples	NNS	O
(	(	O
73	CD	O
%	NN	O
)	)	O
had	VBD	O
detectable	JJ	O
sequence	NN	PH
alterations	NNS	PH
in	IN	PH
the	DT	PH
TP53	NNP	PH
gene	NN	PH
.	.	PH

When	WRB	O
relapse-free	JJ	MO
survival	NN	MO
was	VBD	O
estimated	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
with	IN	O
TP53	NNP	PH
alterations	NNS	PH
in	IN	O
their	PRP$	O
tumours	NNS	O
,	,	O
a	DT	O
significant	JJ	O
better	RBR	O
outcome	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
group	NN	O
was	VBD	O
found	VBN	O
compared	VBN	O
with	IN	O
the	DT	O
patient	NN	O
group	NN	O
receiving	VBG	O
cyclophosphamide	NN	O
and	CC	O
cisplatin	NN	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

We	PRP	O
did	VBD	O
not	RB	O
observe	VB	O
an	DT	O
association	NN	O
between	IN	O
TP53	NNP	PH
tumour	NN	PH
status	NN	PH
and	CC	O
prognosis	NN	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
paclitaxel/cisplatin	JJ	O
combination	NN	O
treatment	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
effect	NN	O
of	IN	O
this	DT	O
therapy	NN	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
this	DT	O
parameter	NN	O
.	.	O

Prognostic	JJ	O
value	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
clearance	NN	O
in	IN	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
with	IN	O
high	JJ	O
preoperative	JJ	O
CEA	NNP	O
levels	NNS	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
determined	VBD	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
carcinoembryonic	JJ	O
antigen	NN	O
(	(	O
CEA	NNP	O
)	)	O
clearance	NN	O
after	IN	O
tumor	NN	O
resection	NN	O
with	IN	O
serial	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
levels	NNS	O
in	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1994	CD	O
and	CC	O
2004	CD	O
,	,	O
we	PRP	O
retrospectively	RB	O
reviewed	VBD	O
122	CD	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
whose	WP$	O
serum	JJ	PH
CEA	NNP	PH
levels	NNS	PH
were	VBD	O
measured	VBN	O
on	IN	O
the	DT	O
preoperative	JJ	O
day	NN	O
and	CC	O
postoperative	JJ	O
days	NNS	O
7	CD	O
and	CC	O
30	CD	O
.	.	O

Patients	NNS	O
with	IN	O
preoperative	JJ	O
CEA	NNP	O
levels	NNS	O
<	VBP	O
5.0	CD	O
ng/ml	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

An	DT	O
exponential	JJ	O
trend	NN	O
line	NN	O
was	VBD	O
drawn	VBN	O
using	VBG	O
the	DT	O
three	CD	O
CEA	NNP	O
values	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
categorized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
based	VBN	O
on	IN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
values	NNS	O
calculated	VBN	O
through	IN	O
trend	NN	O
line	NN	O
,	,	O
which	WDT	O
indicates	VBZ	O
the	DT	O
correlation	NN	O
coefficient	NN	O
between	IN	O
exponential	JJ	O
graph	NN	O
and	CC	O
measured	VBD	O
CEA	NNP	PH
values	NNS	PH
:	:	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
1	CD	O
:	:	O
0.9	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
1.0	CD	O
)	)	O
,	,	O
nearly	RB	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
2	CD	O
:	:	O
0.5	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
0.9	CD	O
)	)	O
,	,	O
and	CC	O
randomized	JJ	O
clearance	NN	O
group	NN	O
(	(	O
group	NN	O
3	CD	O
:	:	O
0.5	CD	O
<	NN	O
or	CC	O
=	VB	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

We	PRP	O
then	RB	O
analyzed	VBD	O
the	DT	O
CEA	NNP	O
clearance	NN	O
pattern	NN	O
as	IN	O
a	DT	O
prognostic	JJ	O
indicator	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
57	CD	O
months	NNS	O
,	,	O
the	DT	O
5-year	JJ	MO
overall	JJ	MO
survival	NN	MO
was	VBD	O
62.3	CD	O
%	NN	O
vs.	FW	O
48.1	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
and	CC	O
the	DT	O
5-year	JJ	MO
disease-free	JJ	MO
survival	NN	MO
was	VBD	O
58.6	CD	O
%	NN	O
vs.	FW	O
52.7	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
among	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.027	CD	O
,	,	O
respectively	RB	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
rectal	JJ	O
cancer	NN	O
.	.	O

For	IN	O
those	DT	O
with	IN	O
stage	NN	O
II	NNP	O
rectal	NN	O
cancer	NN	O
,	,	O
the	DT	O
5-year	JJ	MO
overall	JJ	MO
survival	NN	MO
rate	NN	MO
of	IN	O
group	NN	O
1	CD	O
was	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
groups	NNS	O
2	CD	O
and	CC	O
3	CD	O
(	(	O
88.8	CD	O
%	NN	O
vs.	FW	O
74.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
postoperative	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	O
clearance	NN	O
is	VBZ	O
a	DT	O
useful	JJ	O
prognostic	JJ	O
determinant	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
randomized	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	PH
clearance	NN	PH
after	IN	O
tumor	NN	O
resection	NN	O
should	MD	O
be	VB	O
regarded	VBN	O
as	IN	O
having	VBG	O
the	DT	O
possibility	NN	O
of	IN	O
a	DT	O
persistent	JJ	O
CEA	NNP	O
source	NN	O
and	CC	O
may	MD	O
require	VB	O
consideration	NN	O
of	IN	O
intensive	JJ	O
follow-up	NN	O
or	CC	O
adjuvant	JJ	O
therapy	NN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
patient	JJ	O
education	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
vs	NN	O
patient	JJ	O
education	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
hip	JJ	O
osteoarthritis	NN	O
:	:	O
a	DT	O
single	JJ	O
blind	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
patient	JJ	O
education	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
with	IN	O
that	DT	O
of	IN	O
patient	JJ	O
education	NN	O
alone	RB	O
for	IN	O
the	DT	O
management	NN	PA
of	IN	PA
pain	NN	PA
in	IN	O
patients	NNS	O
with	IN	O
hip	NN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blind	IN	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Recruitment	NNP	O
of	IN	O
patients	NNS	O
from	IN	O
hospitals	NNS	O
,	,	O
primary	JJ	O
health	NN	O
care	NN	O
and	CC	O
advertisement	NN	O
,	,	O
Oslo	NNP	O
,	,	O
Norway	NNP	O
.	.	O

PARTICIPANTS	NNP	O
109	CD	O
patients	NNS	O
with	IN	O
radiographic	JJ	O
and	CC	O
symptomatic	JJ	O
hip	NN	O
OA	NNP	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
symptoms	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Patient	NNP	O
education	NN	O
(	(	O
PE	NNP	O
)	)	O
.	.	O

Patient	JJ	O
education	NN	O
and	CC	O
supervised	VBN	O
exercise	NN	O
(	(	O
PE+SE	NNP	O
)	)	O
.	.	O

PRIMARY	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
pain	NN	PA
subscale	NN	PA
of	IN	PA
the	DT	PA
Western	NNP	PA
Ontario	NNP	PA
and	CC	O
McMaster	NNP	PA
Universities	NNP	PA
Osteoarthritis	NNP	PA
Index	NNP	PA
(	(	PA
WOMAC	NNP	PA
pain	NN	PA
)	)	PA
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
between	IN	O
group	NN	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	PA
pain	NN	PA
over	IN	O
the	DT	O
16-month	JJ	O
follow-up	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
secondary	JJ	O
outcome	NN	O
WOMAC	NNP	PH
physical	JJ	PH
function	NN	PH
(	(	O
P=0.011	NNP	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PE+SE	NNP	O
compared	VBN	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
PE	NNP	O
only	RB	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	PH
stiffness	NN	PH
,	,	O
the	DT	O
SF-36	JJ	O
subscales	NNS	O
or	CC	O
the	DT	O
activity	NN	O
scale	NN	O
.	.	O

The	DT	O
effect	NN	O
sizes	VBZ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
WOMAC	NNP	PA
pain	NN	PA
were	VBD	O
-0.26	NNP	O
(	(	O
0.11	CD	O
,	,	O
-0.64	NN	O
)	)	O
,	,	O
-0.35	NNP	O
(	(	O
0.07	CD	O
,	,	O
-0.77	NN	O
)	)	O
,	,	O
and	CC	O
-0.30	NNP	O
(	(	O
0.15	CD	O
,	,	O
-0.75	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
WOMAC	NNP	PH
physical	JJ	PH
function	NN	PH
-0.29	NNP	O
(	(	O
0.09	CD	O
,	,	O
-0.67	NN	O
)	)	O
,	,	O
-0.48	NNP	O
(	(	O
-0.06	NNP	O
,	,	O
-0.91	NNP	O
)	)	O
,	,	O
and	CC	O
-0.47	NNP	O
(	(	O
-0.02	NNP	O
,	,	O
-0.93	NNP	O
)	)	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
both	DT	O
PE	NNP	O
and	CC	O
SE	NNP	O
.	.	O

All	DT	O
patients	NNS	O
attended	VBD	O
the	DT	O
three-session	JJ	O
PE	NNP	O
program	NN	O
,	,	O
and	CC	O
75	CD	O
%	NN	O
performed	VBN	O
?16	JJ	O
sessions	NNS	O
of	IN	O
the	DT	O
12-week	JJ	O
SE	NNP	O
program	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
study	NN	O
could	MD	O
not	RB	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
reduction	NN	O
over	IN	O
time	NN	O
between	IN	O
PE+SE	NNP	O
vs	NNP	O
PE	NNP	O
alone	RB	O
.	.	O

Adding	VBG	O
SE	NNP	O
to	TO	O
PE	NNP	O
may	MD	O
improve	VB	O
physical	JJ	O
function	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
possible	JJ	O
benefit	NN	O
is	VBZ	O
unknown	JJ	O
as	IN	O
the	DT	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
around	IN	O
the	DT	O
mean	JJ	O
difference	NN	O
were	VBD	O
wide	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinical	NNP	O
Trials	NNP	O
NCT00319423	NNP	O
.	.	O

Moclobemide	NNP	O
,	,	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depression	NN	PH
.	.	O

Moclobemide	NNP	O
was	VBD	O
compared	VBN	O
with	IN	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
episodes	NNS	O
in	IN	O
75	CD	O
outpatients	NNS	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
moclobemide	NN	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
was	VBD	O
300	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
increased	VBN	O
to	TO	O
600	CD	O
mg.	NNS	O
Imipramine	NNP	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
was	VBD	O
given	VBN	O
in	IN	O
a	DT	O
dosage	NN	O
starting	VBG	O
with	IN	O
33	CD	O
mg	NNS	O
and	CC	O
gradually	RB	O
increased	VBD	O
to	TO	O
100	CD	O
mg/day	NN	O
in	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
further	RB	O
increased	VBN	O
;	:	O
25	CD	O
patients	NNS	O
received	VBD	O
placebo	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Hamilton	NNP	PH
Rating	NNP	PH
Scale	NNP	PH
for	IN	PH
Depression	NNP	PH
,	,	O
the	DT	O
overall	JJ	O
assessment	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
the	DT	O
Zung	NNP	Ot
Self-rating	NNP	Ot
Scale	NNP	Ot
,	,	O
and	CC	O
clearly	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
active	JJ	O
drugs	NNS	O
.	.	O

Moclobemide	NNP	O
was	VBD	O
better	RBR	Ot
tolerated	VBN	Ot
than	IN	O
imipramine	NN	O
,	,	O
and	CC	O
was	VBD	O
almost	RB	O
comparable	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
this	DT	O
respect	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
application	NN	O
of	IN	O
irradiated	JJ	O
drug-containing	JJ	O
porcine-cornea	NN	O
to	TO	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
]	FW	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
a	DT	O
new	JJ	O
method	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
.	.	O

METHODS	NNP	O
Fifty-five	JJ	O
cases	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
(	(	O
in	IN	O
88	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Thirty	NNP	O
cases	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
49	CD	O
eyes	NNS	O
were	VBD	O
transplanted	VBN	O
with	IN	O
irradiated	JJ	O
drug-containing	NN	O
(	(	O
ofloxacin	UH	O
,	,	O
acetyl	JJ	O
cysteine	NN	O
and	CC	O
reduced	JJ	O
glutathione	NN	O
)	)	O
porcine-cornea	NN	O
.	.	O

25	CD	O
cases	NNS	O
in	IN	O
control	NN	O
group	NN	O
with	IN	O
39	CD	O
eyes	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
routine	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Thirty-two	JJ	O
eyes	NNS	Ot
were	VBD	Ot
rescued	VBN	Ot
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
65.3	CD	O
%	NN	O
.	.	O

But	CC	O
only	RB	O
17	CD	O
eyes	NNS	Ot
were	VBD	Ot
saved	VBN	Ot
in	IN	O
control	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
43.59	CD	O
%	NN	O
,	,	O
indicating	VBG	O
significant	JJ	O
difference	NN	O
of	IN	O
the	DT	O
cure	NN	Ot
rate	NN	Ot
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiated	VBD	O
drug-containing	JJ	O
porcine-cornea	NN	O
might	MD	O
well	RB	O
be	VB	O
an	DT	O
ideal	JJ	O
therapeutic	JJ	O
material	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
.	.	O

[	RB	O
Dexmedetomidine	NNP	O
use	NN	O
for	IN	O
postoperative	JJ	PH
adrenergic	JJ	PH
analgesia	NN	PH
and	CC	PH
sedation	NN	PH
in	IN	O
abdominal	JJ	O
surgery	NN	O
]	NN	O
.	.	O

Comparative	NNP	O
study	NN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
and	CC	O
sedation	NN	O
with	IN	O
trimeperidine	NN	O
and	CC	O
dexmedetomidine	NN	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
haemodynamics	NNS	O
and	CC	O
vegetative	VBP	O
nervous	JJ	O
system	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Assessment	NNP	O
of	IN	O
analgesia	NN	O
and	CC	O
sedation	NN	O
during	IN	O
vagotonia	NN	O
(	(	O
first	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
and	CC	O
hypokinetic	JJ	O
type	NN	O
of	IN	O
haemodynamics	NNS	O
(	(	O
second	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
was	VBD	O
carried	VBN	O
out	RP	O
with	IN	O
visual	JJ	PH
analogue	NN	PH
scale	NN	PH
(	(	PH
VAS	NNP	PH
)	)	PH
and	CC	O
Richmond	NNP	PH
scale	NN	PH
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
showed	VBD	O
that	IN	O
dexmedetomidine	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	Ot
and	CC	Ot
safer	JJR	Ot
than	IN	O
trimeperidine	NN	O
for	IN	O
analgesia	NN	PH
and	CC	PH
sedation	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
spontaneous	JJ	O
breathing	NN	O
after	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Dexmedetomidine	NNP	O
use	NN	O
allows	VBZ	O
keeping	VBG	O
optimal	JJ	O
type	NN	O
of	IN	O
haemodynamics	NNS	O
and	CC	O
vegetative	VBP	O
nervous	JJ	O
system	NN	O
parameters	NNS	O
on	IN	O
first	JJ	O
day	NN	O
of	IN	O
postoperative	JJ	O
period	NN	O
.	.	O

Butorphanol	NNP	O
and	CC	O
meperidine	NN	O
compared	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
ureteral	JJ	O
colic	NN	O
.	.	O

Pain	NNP	O
relief	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
81	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ureteral	JJ	O
colic	NN	O
and	CC	O
the	DT	O
confirmed	JJ	O
presence	NN	O
of	IN	O
a	DT	O
calculus	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
intramuscular	JJ	O
2	CD	O
and	CC	O
4	CD	O
mg.	NN	O
butorphanol	NN	O
and	CC	O
80	CD	O
mg.	NNS	O
meperidine	NN	O
was	VBD	O
used	VBN	O
.	.	O

Pain	NNP	PA
intensity	NN	PA
and	CC	O
pain	NN	PA
relief	NN	PA
were	VBD	O
evaluated	VBN	O
at	IN	O
half	JJ	O
hour	NN	O
and	CC	O
hourly	JJ	O
intervals	NNS	O
for	IN	O
4	CD	O
hours	NNS	O
.	.	O

A	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
analgesically	RB	O
equivalent	JJ	O
to	TO	O
80	CD	O
mg.	NNS	O
meperidine	NN	O
,	,	O
while	IN	O
a	DT	O
4	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
80	CD	O
mg.	JJ	O
meperidine	NN	O
and	CC	O
2	CD	O
mg.	NN	O
butorphanol	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
up	RB	O
to	TO	O
2	CD	O
doses	NNS	O
of	IN	O
analgesic	JJ	O
medication	NN	O
when	WRB	O
necessary	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	A
of	IN	A
side	JJ	A
effects	NNS	A
among	IN	O
treatments	NNS	O
.	.	O

One	CD	O
patient	NN	O
had	VBD	O
visual	JJ	PH
hallucinations	NNS	PH
after	IN	O
a	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	O
,	,	O
possibly	RB	O
owing	VBG	O
to	TO	O
its	PRP$	O
antagonistic	JJ	O
activity	NN	O
to	TO	O
significant	JJ	O
narcotic	JJ	O
experience	NN	O
given	VBN	O
previously	RB	O
at	IN	O
another	DT	O
hospital	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
other	JJ	O
evidence	NN	O
of	IN	O
toxicity	NN	A
with	IN	O
butorphanol	NN	O
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	Ot
,	,	Ot
effective	JJ	Ot
and	CC	Ot
wall	RB	Ot
tolerated	JJ	Ot
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ureteral	JJ	O
colic	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
place	NN	O
of	IN	O
narcotics	NNS	O
.	.	O

Long-term	JJ	O
use	NN	O
of	IN	O
Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
study	NN	O
.	.	O

Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
,	,	O
AR-C68397AA	NNP	O
)	)	O
is	VBZ	O
a	DT	O
novel	JJ	O
dual	JJ	O
D2	NNP	O
dopamine	NN	O
receptor	NN	O
,	,	O
beta2-adrenoceptor	JJ	O
agonist	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
investigated	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

The	DT	O
slowly	RB	O
progressive	JJ	O
nature	NN	O
of	IN	O
this	DT	O
disease	NN	O
means	VBZ	O
that	IN	O
patients	NNS	O
will	MD	O
require	VB	O
ongoing	JJ	O
therapeutic	JJ	O
management	NN	O
for	IN	O
many	JJ	O
years	NNS	O
,	,	O
or	CC	O
even	RB	O
decades	NNS	O
.	.	O

With	IN	O
such	JJ	O
long-term	JJ	O
treatment	NN	O
,	,	O
the	DT	O
safety	NN	O
profile	NN	O
of	IN	O
new	JJ	O
agents	NNS	O
will	MD	O
be	VB	O
of	IN	O
paramount	JJ	O
importance	NN	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
the	DT	O
large-scale	JJ	O
assessment	NN	O
of	IN	O
sibenadet	NN	O
,	,	O
a	DT	O
12-month	JJ	O
safety	NN	O
study	NN	O
has	VBZ	O
been	VBN	O
conducted	VBN	O
.	.	O

Following	VBG	O
completion	NN	O
of	IN	O
a	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
,	,	O
435	CD	O
adults	NNS	O
with	IN	O
stable	JJ	O
,	,	O
symptomatic	JJ	O
,	,	O
smoking-related	JJ	O
COPD	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
500	CD	O
microg	NN	O
sibenadet	NN	O
or	CC	O
placebo	NN	O
delivered	VBN	O
via	IN	O
pressurized	VBN	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
(	(	O
pMDI	NN	O
)	)	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
52	CD	O
weeks	NNS	O
.	.	O

Sibenadet	NNP	O
therapy	NN	O
was	VBD	O
generally	RB	O
well	RB	Ot
tolerated	VBN	Ot
,	,	O
with	IN	O
the	DT	O
only	JJ	O
notable	JJ	PH
differences	NNS	PH
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	PH
of	IN	PH
tremor	NN	PH
and	CC	PH
taste	NN	PH
of	IN	PH
treatment	NN	PH
(	(	O
16.9	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
and	CC	O
14.5	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
in	IN	O
the	DT	O
sibenadet	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
total	NN	O
of	IN	O
79	CD	O
patients	NNS	O
with	IN	O
serious	JJ	A
adverse	JJ	A
events	NNS	A
(	(	O
SAEs	NNP	O
)	)	O
,	,	O
43	CD	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
sibenadet	NN	O
pMDI	NN	O
group	NN	O
and	CC	O
36	CD	O
(	(	O
24.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

No	DT	O
clinically	RB	PH
significant	JJ	PH
abnormal	JJ	PH
laboratory	NN	PH
values	NNS	PH
or	CC	O
overall	JJ	PH
differences	NNS	PH
between	IN	O
treatment	NN	O
groups	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Similarly	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	PH
clinically	RB	PH
significant	JJ	PH
differences	NNS	PH
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
for	IN	O
cardiac	JJ	PH
variables	NNS	PH
,	,	PH
or	CC	PH
in	IN	PH
vital	JJ	PH
signs	NNS	PH
.	.	PH

The	DT	O
secondary	JJ	O
variables	NNS	O
showed	VBD	O
no	DT	PH
notable	JJ	PH
differences	NNS	PH
with	IN	O
respect	NN	O
to	TO	O
lung	NN	PH
function	NN	PH
,	,	PH
exacerbations	NNS	PH
or	CC	PH
health-related	JJ	PH
quality	NN	PH
of	IN	PH
life	NN	PH
.	.	PH

Due	NNP	O
to	TO	O
the	DT	O
effective	JJ	O
beta2-agonist	NN	O
properties	NNS	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
sibenadet	NN	O
group	NN	O
did	VBD	O
,	,	O
however	RB	O
,	,	O
report	NN	O
reduced	VBD	Ot
rescue	JJ	Ot
medication	NN	Ot
usage	NN	Ot
at	IN	Ot
all	DT	Ot
timepoints	NNS	Ot
.	.	O

While	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
,	,	O
overall	JJ	O
,	,	O
sibenadet	JJ	O
therapy	NN	O
was	VBD	O
well	RB	Ot
tolerated	VBN	Ot
,	,	O
the	DT	O
lack	NN	Ot
of	IN	Ot
sustained	JJ	Ot
benefit	NN	Ot
reported	VBD	O
in	IN	O
large-scale	JJ	Ot
clinical	JJ	Ot
efficacy	NN	Ot
studies	NNS	Ot
means	VBZ	O
that	IN	O
sibenadet	NN	O
development	NN	O
will	MD	O
not	RB	O
be	VB	O
continued	VBN	O
.	.	O

The	DT	O
relationship	NN	O
of	IN	O
alexithymia	NN	O
to	TO	O
emotional	JJ	O
dysregulation	NN	O
within	IN	O
an	DT	O
alcohol	NN	O
dependent	JJ	O
treatment	NN	O
sample	NN	O
.	.	O

Difficulties	NNS	O
regulating	VBG	O
emotions	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
the	DT	O
development	NN	O
,	,	O
maintenance	NN	O
,	,	O
and	CC	O
recovery	NN	O
from	IN	O
alcohol	NN	O
problems	NNS	O
.	.	O

One	CD	O
construct	NN	O
thought	NN	O
to	TO	O
impede	VB	O
the	DT	O
regulation	NN	O
of	IN	O
emotion	NN	O
is	VBZ	O
alexithymia	JJ	O
.	.	O

Alexithymia	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
difficulties	NNS	O
identifying	VBG	O
,	,	O
differentiating	VBG	O
and	CC	O
expressing	VBG	O
feelings	NNS	O
,	,	O
a	DT	O
limited	JJ	O
imagination	NN	O
and	CC	O
fantasy	JJ	O
life	NN	O
,	,	O
and	CC	O
an	DT	O
externally-oriented	JJ	O
thinking	NN	O
style	NN	O
(	(	O
e.g.	UH	O
,	,	O
prefer	VBP	O
talking	VBG	O
about	IN	O
daily	JJ	O
activities	NNS	O
rather	RB	O
than	IN	O
feelings	NNS	O
)	)	O
.	.	O

Given	VBN	O
that	IN	O
poor	JJ	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
predict	VB	O
posttreatment	NN	O
levels	NNS	O
of	IN	O
alcohol	NN	O
use	NN	O
,	,	O
and	CC	O
that	IN	O
several	JJ	O
defining	VBG	O
characteristics	NNS	O
of	IN	O
alexithymia	JJ	O
bear	JJ	O
similarity	NN	O
to	TO	O
deficits	NNS	O
in	IN	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
alexithymia	NN	O
may	MD	O
predict	VB	O
poorer	JJR	O
alcohol	NN	O
treatment	NN	O
outcomes	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
first	RB	O
examined	VBD	O
the	DT	O
relationship	NN	O
of	IN	O
alexithymia	NN	O
to	TO	O
several	JJ	O
other	JJ	O
emotion	NN	ME
regulation	NN	ME
measures	NNS	ME
and	CC	O
then	RB	O
investigated	VBD	O
the	DT	O
impact	NN	O
of	IN	O
alexithymia	NN	O
on	IN	O
attrition	NN	O
and	CC	O
alcohol	NN	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
(	(	O
N=77	NNP	O
)	)	O
enrolled	VBD	O
in	IN	O
a	DT	O
12-week	JJ	O
cognitive-behavioral	JJ	O
intervention	NN	O
for	IN	O
alcohol	NN	O
dependence	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
higher	JJR	O
scores	NNS	O
on	IN	O
alexithymia	NN	O
were	VBD	O
associated	VBN	O
poorer	JJR	ME
emotion	NN	ME
regulation	NN	ME
skills	NNS	ME
,	,	O
fewer	JJR	ME
percent	NN	ME
days	NNS	ME
abstinent	NN	ME
,	,	O
greater	JJR	ME
alcohol	NN	ME
dependence	NN	ME
severity	NN	ME
,	,	O
and	CC	O
several	JJ	ME
high-risk	JJ	ME
drinking	NN	ME
situations	NNS	ME
.	.	O

Alexithymia	NNP	O
was	VBD	O
unrelated	JJ	O
to	TO	O
attrition	NN	O
and	CC	O
to	TO	O
level	NN	O
of	IN	O
alcohol	NN	O
consumption	NN	O
at	IN	O
posttreatment	NN	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
construct	NN	O
of	IN	O
alexithymia	NN	O
is	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
several	JJ	O
theoretically-related	JJ	O
constructs	NNS	O
(	(	O
e.g.	NN	O
,	,	O
emotion	NN	O
regulation	NN	O
,	,	O
mindfulness	NN	O
)	)	O
but	CC	O
demonstrated	VBD	O
a	DT	O
limited	JJ	O
relationship	NN	O
to	TO	O
drinking	VBG	O
outcomes	NNS	O
in	IN	O
those	DT	O
seeking	VBG	O
treatment	NN	O
for	IN	O
alcohol	NN	O
dependence	NN	O
.	.	O

Short-term	JJ	O
fluoxetine	NN	O
monotherapy	NN	O
for	IN	O
bipolar	JJ	O
type	NN	O
II	NNP	O
or	CC	O
bipolar	JJ	O
NOS	NNP	O
major	JJ	O
depression	NN	O
-	:	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
.	.	O

OBJECTIVES	CC	O
Current	NNP	O
guidelines	NNS	O
for	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
bipolar	JJ	O
type	NN	O
II	NNP	O
(	(	O
BP	NNP	O
II	NNP	O
)	)	O
major	JJ	O
depressive	JJ	O
episode	NN	O
(	(	O
MDE	NNP	O
)	)	O
recommend	VBP	O
using	VBG	O
either	CC	O
a	DT	O
mood	NN	O
stabilizer	NN	O
alone	RB	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
a	DT	O
mood	NN	O
stabilizer	NN	O
plus	CC	O
a	DT	O
selective	JJ	O
serotonin	NN	O
re-uptake	NN	O
inhibitor	NN	O
(	(	O
SSRI	NNP	O
)	)	O
.	.	O

This	DT	O
recommendation	NN	O
is	VBZ	O
the	DT	O
result	NN	O
of	IN	O
concern	NN	O
over	IN	O
antidepressant-induced	JJ	O
manic	JJ	O
switch	NN	O
episodes	NNS	O
.	.	O

However	RB	O
,	,	O
recent	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
manic	JJ	O
switch	NN	O
rate	NN	O
may	MD	O
be	VB	O
low	JJ	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
during	IN	O
SSRI	NNP	O
therapy	NN	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
relapse-prevention	NN	O
study	NN	O
of	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
37	CD	O
patients	NNS	O
received	VBD	O
open-label	JJ	O
fluoxetine	NN	O
20	CD	O
mg	NN	O
every	DT	O
day	NN	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
(	(	O
HAM-D	NNP	O
17	CD	O
)	)	O
rating	NN	O
and	CC	O
the	DT	O
Young	NNP	O
Mania	NNP	O
Rating	NNP	O
(	(	O
YMR	NNP	O
)	)	O
scale	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
of	IN	O
23	CD	O
patients	NNS	O
(	(	O
48	CD	O
%	NN	O
)	)	O
who	WP	O
completed	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
fluoxetine	NN	O
treatment	NN	O
showed	VBD	O
a	DT	O
HAM-D	JJ	PH
17	CD	PH
reduction	NN	PH
of	IN	O
>	NN	O
or	CC	O
=50	CD	O
%	NN	O
,	,	O
while	IN	O
14	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
all	DT	O
treated	JJ	O
patients	NNS	O
had	VBD	O
>	VBN	O
or	CC	O
=50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
baseline	JJ	O
HAM-D	JJ	O
17	CD	O
score	NN	O
.	.	O

Using	VBG	O
a	DT	O
conservative	JJ	O
YMR	NNP	PH
score	NN	PH
of	IN	PH
>	NN	PH
or	CC	PH
=8	VB	PH
to	TO	O
identify	VB	O
hypomanic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
patients	NNS	O
with	IN	O
YMR	NNP	O
score	NN	O
>	NN	O
or	CC	O
=8	NN	O
during	IN	O
fluoxetine	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
seen	VBN	O
during	IN	O
the	DT	O
screen	NN	O
and	CC	O
baseline	JJ	O
period	NN	O
.	.	O

Only	RB	O
three	CD	O
patients	NNS	O
(	(	O
7.3	CD	O
%	NN	O
)	)	O
had	VBD	O
symptoms	NNS	O
suggestive	JJ	O
of	IN	O
hypomania	NN	PH
,	,	O
and	CC	O
only	RB	O
one	CD	O
patient	NN	O
stopped	VBD	O
treatment	NN	O
because	IN	O
of	IN	O
a	DT	O
rapid	JJ	ME
mood	NN	ME
swing	VBG	ME
into	IN	ME
depression	NN	ME
.	.	O

LIMITATIONS	NNP	O
Fluoxetine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
of	IN	O
20	CD	O
mg	NNS	O
everyday	JJ	O
.	.	O

Fluoxetine	NNP	O
was	VBD	O
prescribed	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
manner	NN	O
,	,	O
and	CC	O
the	DT	O
sample	NN	O
size	NN	O
was	VBD	O
limited	VBN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
observations	NNS	O
support	VBP	O
the	DT	O
findings	NNS	O
of	IN	O
a	DT	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
during	IN	O
SSRI	NNP	O
monotherapy	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
and	CC	O
suggest	VBP	O
that	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
may	MD	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
initial	JJ	O
treatment	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
.	.	O

Seven-star	NNP	O
needle	JJ	O
stimulation	NN	O
improves	VBZ	O
language	NN	ME
and	CC	ME
social	JJ	ME
interaction	NN	ME
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
that	WDT	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
treatment	NN	O
on	IN	O
children	NNS	O
with	IN	O
Autistic	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirty-two	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
into	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	VBD	O
30	CD	O
sessions	NNS	O
of	IN	O
stimulation	NN	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
while	IN	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
on	IN	O
a	DT	O
waiting	VBG	O
list	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
treatment	NN	O
during	IN	O
this	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

Intervention	NNP	O
consisted	VBD	O
of	IN	O
a	DT	O
treatment	NN	O
regime	NN	O
comprising	NN	O
of	IN	O
30	CD	O
sessions	NNS	O
of	IN	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
,	,	O
delivered	VBD	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Each	DT	O
session	NN	O
lasted	VBD	O
5	CD	O
to	TO	O
10	CD	O
min	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
were	VBD	O
stimulated	VBN	O
at	IN	O
the	DT	O
front	NN	O
and	CC	O
back	RB	O
sides	NNS	O
of	IN	O
their	PRP$	O
body	NN	O
and	CC	O
the	DT	O
head	NN	O
by	IN	O
using	VBG	O
Seven-star	JJ	O
Needles	NNP	O
.	.	O

The	DT	O
change	NN	O
in	IN	O
the	DT	O
children	NNS	ME
's	POS	ME
behavior	NN	ME
was	VBD	O
evaluated	VBN	O
using	VBG	O
parents	NNS	O
'	POS	O
report	NN	O
and	CC	O
neurophysiological	JJ	O
changes	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
quantitative	JJ	O
EEG	NNP	O
(	(	O
qEEG	NN	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
language	NN	ME
and	CC	ME
social	JJ	ME
interaction	NN	ME
,	,	O
but	CC	O
not	RB	O
in	IN	O
stereotyped	JJ	ME
behavior	NN	ME
or	CC	ME
motor	NN	ME
function	NN	ME
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

qEEG	JJ	PH
spectral	JJ	PH
amplitudes	NNS	PH
in	IN	O
the	DT	O
treatment	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
were	VBD	O
also	RB	O
reduced	VBN	O
significantly	RB	O
.	.	O

The	DT	O
results	NNS	O
suggested	VBD	O
that	IN	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
might	MD	O
be	VB	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
improve	VB	O
language	NN	ME
and	CC	ME
social	JJ	ME
functioning	NN	ME
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Feedlot	NNP	O
performance	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
Holstein	NNP	O
steers	NNS	O
as	IN	O
affected	VBN	O
by	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
protein	NN	O
and	CC	O
level	NN	O
of	IN	O
ruminally	RB	O
protected	VBN	O
lysine	NN	O
and	CC	O
methionine	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	Ot
of	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
level	NN	O
of	IN	O
ruminally	RB	O
protected	VBN	O
lysine	NN	O
and	CC	O
methionine	NN	O
(	(	O
RPLM	NNP	O
)	)	O
on	IN	O
feedlot	NN	Ot
performance	NN	Ot
and	CC	ME
carcass	NN	Ot
characteristics	NNS	Ot
of	IN	O
Holstein	NNP	O
steers	NNS	O
during	IN	O
a	DT	O
growing-finishing	JJ	O
trial	NN	O
(	(	O
266	CD	O
d	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
168	CD	O
Holstein	NNP	O
steers	NNS	O
(	(	O
182.7	CD	O
+/-	JJ	O
27.5	CD	O
kg	NN	O
)	)	O
were	VBD	O
used	VBN	O
in	IN	O
a	DT	O
completely	RB	O
randomized	JJ	O
design	NN	O
experiment	NN	O
(	(	O
eight	CD	O
treatments	NNS	O
;	:	O
three	CD	O
pens	NNS	O
of	IN	O
seven	CD	O
steers/treatment	NN	O
)	)	O
.	.	O

Steers	NNPS	O
were	VBD	O
given	VBN	O
ad	NN	O
libitum	NN	O
access	NN	O
to	TO	O
high-concentrate	JJ	O
diets	NNS	O
(	(	O
13	CD	O
%	NN	O
CP	NNP	O
)	)	O
containing	VBG	O
71	CD	O
%	NN	O
whole	JJ	O
shelled	VBN	O
corn	NN	O
,	,	O
10	CD	O
%	NN	O
corn	NN	O
silage	NN	O
,	,	O
4	CD	O
%	NN	O
condensed	JJ	O
distillers	NNS	O
solubles	NNS	O
,	,	O
and	CC	O
15	CD	O
%	NN	O
protein	NN	O
supplements	NNS	O
(	(	O
DM	NNP	O
basis	NN	O
)	)	O
.	.	O

Treatments	NNS	O
were	VBD	O
arranged	VBN	O
as	IN	O
a	DT	O
2	CD	O
x	NN	O
4	CD	O
factorial	JJ	O
.	.	O

The	DT	O
main	JJ	O
factors	NNS	O
were	VBD	O
two	CD	O
sources	NNS	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
four	CD	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
.	.	O

The	DT	O
sources	NNS	O
of	IN	O
dietary	JJ	Ot
CP	NNP	Ot
were	VBD	O
soybean	JJ	O
meal	NN	O
(	(	O
SBM	NNP	O
)	)	O
or	CC	O
SBM	NNP	O
and	CC	O
urea	JJ	O
(	(	O
SBM-U	NNP	O
)	)	O
.	.	O

Urea-N	NNP	Ot
replaced	VBD	O
50	CD	O
%	NN	O
of	IN	O
SBM-N	NNP	O
in	IN	O
the	DT	O
SBM-U	NNP	O
diet	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
were	VBD	O
0	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
15	CD	O
g	NN	O
per	IN	O
steer	NN	O
daily	RB	O
.	.	O

No	UH	O
interactions	NNS	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
between	IN	O
source	NN	O
of	IN	O
dietary	JJ	PH
CP	NNP	PH
and	CC	PH
level	NN	PH
of	IN	PH
RPLM	NNP	PH
were	VBD	O
observed	VBN	O
for	IN	O
feedlot	NN	O
performance	NN	O
or	CC	O
carcass	NN	Ot
characteristics	NNS	Ot
.	.	ME

Feedlot	NNP	Ot
performance	NN	Ot
showed	VBD	O
an	DT	O
advantage	NN	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
to	TO	O
feeding	VBG	O
SMB	NNP	O
during	IN	O
the	DT	O
first	JJ	O
84	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
and	CC	O
an	DT	O
advantage	NN	O
to	TO	O
feeding	VBG	O
SBM-U	NNP	O
during	IN	O
the	DT	O
last	JJ	O
98	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

However	RB	O
,	,	O
feedlot	JJ	Ot
performance	NN	Ot
for	IN	O
the	DT	O
whole	JJ	O
trial	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
(	(	O
except	IN	O
for	IN	O
fat	JJ	PH
thickness	NN	PH
)	)	PH
were	VBD	O
not	RB	O
affected	VBN	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
by	IN	O
the	DT	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
.	.	O

Steers	NNP	O
fed	VBD	O
diets	NNS	O
containing	VBG	O
SBM-U	NNP	O
had	VBD	O
12	CD	O
%	NN	O
less	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
fat	VBZ	PH
thickness	JJ	PH
than	IN	O
those	DT	O
fed	JJ	O
diets	NNS	O
containing	VBG	O
SBM	NNP	O
.	.	O

Supplementation	NN	O
of	IN	O
diets	NNS	O
with	IN	O
increasing	VBG	O
levels	NNS	O
of	IN	O
RPLM	NNP	PH
did	VBD	O
not	RB	O
affect	VB	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
ADG	NNP	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
.	.	O

However	RB	O
,	,	O
DMI	NNP	O
and	CC	O
gain	NN	O
:	:	O
feed	NN	O
showed	VBD	O
cubic	JJ	Ot
(	(	Ot
P	NNP	Ot
<	NNP	Ot
.10	NNP	Ot
)	)	Ot
responses	VBZ	Ot
to	TO	O
increasing	VBG	O
dietary	JJ	O
level	NN	O
of	IN	O
RPLM	NNP	O
.	.	O

Supplementation	NN	O
of	IN	O
RPLM	NNP	O
at	IN	O
the	DT	O
10	CD	O
g/d	NNS	O
level	NN	O
improved	VBD	O
gain	NN	PH
:	:	PH
feed	VBN	PH
by	IN	O
12	CD	O
%	NN	O
during	IN	O
the	DT	O
last	JJ	O
98	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
and	CC	O
this	DT	O
was	VBD	O
a	DT	O
direct	JJ	O
response	NN	O
to	TO	O
the	DT	O
cubic	JJ	O
effects	NNS	O
of	IN	O
RPLM	NNP	O
on	IN	O
DMI	NNP	O
.	.	O

Results	NNP	O
suggest	VBP	O
a	DT	O
cost	NN	O
advantage	NN	O
for	IN	O
replacing	VBG	O
50	CD	O
%	NN	O
of	IN	O
SBM-N	NNP	O
with	IN	O
that	DT	O
from	IN	O
urea	JJ	O
in	IN	O
high-corn	JJ	O
diets	NNS	O
without	IN	O
negative	JJ	O
effects	NNS	O
on	IN	O
feedlot	NN	O
performance	NN	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
growing-finishing	JJ	O
Holstein	NNP	O
steers	NNS	O
with	IN	O
extended	JJ	O
feeding	NN	O
periods	NNS	O
(	(	O
266	CD	O
d	NN	O
)	)	O
.	.	O

These	DT	O
types	NNS	O
of	IN	O
diets	NNS	O
seem	VBP	O
to	TO	O
meet	VB	O
the	DT	O
amino	NN	O
acid	NN	O
requirements	NNS	O
and	CC	O
are	VBP	O
not	RB	O
limiting	VBG	O
in	IN	O
lysine	NN	O
and	CC	O
methionine	NN	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
the	DT	O
influence	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
diclofenac	NN	O
,	,	O
or	CC	O
naproxen	RB	O
on	IN	O
aspirin-induced	JJ	O
inhibition	NN	O
of	IN	O
platelet	NN	PH
aggregation	NN	PH
.	.	O

Nonsteroidal	NNP	O
anti-inflammatory	JJ	O
drugs	NNS	O
(	(	O
NSAID	NNP	O
)	)	O
may	MD	O
interfere	VB	O
with	IN	O
aspirin	NN	O
(	(	O
acetylsalicylic	JJ	O
acid	NN	O
)	)	O
and	CC	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
cardiovascular	JJ	PH
events	NNS	PH
.	.	O

The	DT	O
clinical	JJ	O
relevance	NN	O
is	VBZ	O
uncertain	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
aspirin	NN	O
and	CC	O
NSAID	NNP	O
on	IN	O
platelet	NN	PH
aggregation	NN	PH
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
,	,	O
eleven	RB	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
studied	VBN	O
during	IN	O
4	CD	O
separate	JJ	O
study	NN	O
periods	NNS	O
of	IN	O
4	CD	O
days	NNS	O
each	DT	O
.	.	O

Individuals	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
each	DT	O
occasion	NN	O
with	IN	O
100	CD	O
mg	NNS	O
aspirin	JJ	O
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
either	DT	O
3	CD	O
x	VBD	O
1	CD	O
g	NN	O
acetaminophen	NN	O
,	,	O
3	CD	O
x	NN	O
50	CD	O
mg	NN	O
diclofenac	NN	O
,	,	O
3	CD	O
x	NN	O
250	CD	O
mg	NN	O
naproxen	NN	O
,	,	O
or	CC	O
3	CD	O
x	JJ	O
1	CD	O
placebo	NN	O
.	.	O

Primary	JJ	PH
hemostasis	NN	PH
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
platelet	NN	O
function	NN	O
analyser	NN	O
(	(	O
PFA-100	NNP	O
)	)	O
,	,	O
which	WDT	O
measures	VBZ	O
the	DT	Ot
closure	NN	PH
time	NN	PH
(	(	PH
CT	NNP	PH
)	)	PH
of	IN	Ot
a	DT	Ot
collagen-	JJ	Ot
and	CC	Ot
epinephrine-coated	JJ	Ot
pore	NN	Ot
by	IN	Ot
aggregating	VBG	Ot
platelets	NNS	Ot
in	IN	Ot
flowing	VBG	Ot
blood	NN	Ot
.	.	O

Naproxen	NNP	O
enhanced	VBD	O
the	DT	O
anti-aggregatory	JJ	PH
action	NN	PH
of	IN	O
aspirin	NN	O
after	IN	O
24	CD	O
h	NN	O
(	(	O
CT	NNP	PH
rising	VBG	O
from	IN	O
104+/-16	JJ	O
s	NN	O
at	IN	O
baseline	NN	O
to	TO	O
212+/-69	JJ	O
s	NN	O
at	IN	O
24	CD	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
any	DT	O
other	JJ	O
drug	NN	O
combination	NN	O
.	.	O

Diclofenac	NNP	O
reduced	VBD	O
the	DT	O
anti-aggregatory	JJ	PH
action	NN	PH
of	IN	O
aspirin	NN	O
in	IN	O
the	DT	O
first	JJ	O
two	CD	O
days	NNS	O
,	,	O
since	IN	O
the	DT	O
CT	NNP	PH
did	VBD	O
not	RB	O
rise	VB	O
significantly	RB	O
(	(	O
109+/-19	JJ	O
s	NN	O
,	,	O
148+/-56	JJ	O
s	NN	O
,	,	O
and	CC	O
168+/-66	JJ	O
s	NN	O
at	IN	O
0	CD	O
h	NN	O
,	,	O
24	CD	O
h	NN	O
,	,	O
48	CD	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Acetaminophen	NNP	O
had	VBD	O
no	DT	O
effect	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

After	IN	O
4	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
platelet	NN	PH
aggregation	NN	PH
was	VBD	O
similarly	RB	O
inhibited	VBN	O
by	IN	O
all	DT	O
combinations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
NSAID	NNP	O
and	CC	O
aspirin	NN	O
may	MD	O
interfere	VB	O
with	IN	O
platelet	NN	PH
inhibition	NN	PH
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
a	DT	O
treatment	NN	O
with	IN	O
an	DT	O
increase	NN	O
of	IN	O
naproxen	JJ	O
and	CC	O
a	DT	O
decrease	NN	O
of	IN	O
diclofenac	NN	O
.	.	O

This	DT	O
effect	NN	O
is	VBZ	O
lost	VBN	O
after	IN	O
4	CD	O
days	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
regular	JJ	O
daily	JJ	O
co-administration	NN	O
of	IN	O
NSAID	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
an	DT	O
influence	NN	O
on	IN	O
platelet	NN	PH
inhibition	NN	PH
by	IN	O
aspirin	NN	O
.	.	O

Effect	NN	O
of	IN	O
adhesive	JJ	O
system	NN	O
type	NN	O
and	CC	O
tooth	DT	O
region	NN	O
on	IN	O
the	DT	O
bond	NN	O
strength	NN	O
to	TO	O
dentin	VB	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
bond	NN	O
strength	NN	O
of	IN	O
two	CD	O
etch-and-rinse	JJ	O
adhesive	JJ	O
systems	NNS	O
(	(	O
two-	JJ	O
and	CC	O
three-step	NN	O
)	)	O
and	CC	O
a	DT	O
self-etching	JJ	O
system	NN	O
to	TO	O
coronal	VB	PH
and	CC	PH
root	VB	PH
canal	JJ	PH
dentin	NN	PH
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
root	NN	O
canals	NNS	O
of	IN	O
30	CD	O
human	JJ	O
incisors	NNS	O
and	CC	O
canines	NNS	O
were	VBD	O
instrumented	VBN	O
and	CC	O
prepared	VBN	O
with	IN	O
burs	NNS	O
.	.	O

The	DT	O
posts	NNS	O
used	VBD	O
for	IN	O
luting	VBG	O
were	VBD	O
duplicated	VBN	O
with	IN	O
dual	JJ	O
resin	NN	O
cement	NN	O
(	(	O
Duo-link	NNP	O
)	)	O
inside	IN	O
Aestheti	NNP	O
Plus	NNP	O
#	#	O
2	CD	O
molds	NNS	O
.	.	O

Thus	RB	O
,	,	O
three	CD	O
groups	NNS	O
were	VBD	O
formed	VBN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
adhesive	JJ	O
system	NN	O
employed	VBN	O
:	:	O
All-Bond	JJ	O
2	CD	O
(	(	O
TE3	NNP	O
)	)	O
+	VBP	O
resin	JJ	O
cement	NN	O
post	NN	O
(	(	O
rcp	NN	O
)	)	O
+	VBZ	O
Duo-link	NNP	O
(	(	O
Dl	NNP	O
)	)	O
;	:	O
One-Step	JJ	O
Plus	NNP	O
(	(	O
TE2	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
;	:	O
Tyrian/One-Step	JJ	O
Plus	NNP	O
(	(	O
SE	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
.	.	O

Afterwards	NNP	O
,	,	O
8	CD	O
transverse	NN	O
sections	NNS	O
(	(	O
1.5	CD	O
mm	NN	O
)	)	O
were	VBD	O
cut	VBN	O
from	IN	O
4	CD	O
mm	NNS	O
above	IN	O
the	DT	O
CEJ	NNP	O
up	RB	O
to	TO	O
4	CD	O
mm	NNS	O
short	JJ	O
of	IN	O
the	DT	O
root	NN	O
canal	JJ	O
apex	NN	O
,	,	O
comprising	VBG	O
coronal	JJ	O
and	CC	O
root	JJ	O
canal	JJ	O
dentin	NN	O
.	.	O

The	DT	O
sections	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
push-out	JJ	O
testing	NN	O
in	IN	O
a	DT	O
universal	JJ	O
testing	VBG	O
machine	NN	O
EMIC	NNP	O
(	(	O
1	CD	O
mm/min	NN	O
)	)	O
.	.	O

Bond	NNP	Ot
strength	NN	Ot
data	NNS	Ot
were	VBD	O
analyzed	VBN	O
with	IN	O
two-way	JJ	Ot
repeated	JJ	Ot
measures	NNS	Ot
ANOVA	NNP	Ot
and	CC	Ot
Tukey	NNP	Ot
's	POS	Ot
test	NN	Ot
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
relationship	NN	Ot
between	IN	Ot
the	DT	Ot
adhesives	NNS	Ot
was	VBD	O
not	RB	O
the	DT	O
same	JJ	O
in	IN	O
the	DT	O
different	JJ	O
regions	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
means	NNS	O
achieved	VBN	O
with	IN	O
the	DT	O
adhesives	NNS	O
in	IN	O
each	DT	O
region	NN	O
(	(	O
Tukey	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.05	CD	O
)	)	O
revealed	VBD	O
that	IN	O
TE3	NNP	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
:	:	O
5.22	CD	O
+/-	JJ	O
1.70	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
TE2	NNP	O
(	(	O
2.60	CD	O
+/-	JJ	O
1.74	CD	O
)	)	O
and	CC	O
SE	NNP	O
(	(	O
1.68	CD	O
+/-	JJ	O
1.85	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Under	IN	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
,	,	O
better	JJR	O
bonding	VBG	O
to	TO	O
dentin	VB	O
was	VBD	O
achieved	VBN	O
using	VBG	O
the	DT	O
three-step	JJ	O
etch-and-rinse	JJ	O
system	NN	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
coronal	JJ	O
region	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
traditional	JJ	O
etch-and-rinse	JJ	O
three-step	NN	O
adhesive	JJ	O
system	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
best	JJS	O
choice	NN	O
for	IN	O
teeth	NN	O
needing	VBG	O
adhesive	JJ	O
endodontic	JJ	O
restorations	NNS	O
.	.	O

Amphotericin	NNP	O
B	NNP	O
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
toxicities	NNS	O
and	CC	O
pharmacokinetics	NNS	O
of	IN	O
amphotericin	NN	O
B	NNP	O
administered	VBN	O
in	IN	O
dextrose	JJ	O
versus	NN	O
lipid	JJ	O
emulsion	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
toxicity	NN	O
of	IN	O
1	CD	O
mg	NN	O
of	IN	O
amphotericin	NN	O
B	NNP	O
(	(	O
AmB	NNP	O
)	)	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
day	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
AmB	NNP	O
infused	VBD	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
.	.	O

In	IN	O
an	DT	O
analysis	NN	O
of	IN	O
82	CD	O
children	NNS	O
who	WP	O
received	VBD	O
a	DT	O
full	JJ	O
course	NN	O
of	IN	O
6	CD	O
days	NNS	O
or	CC	O
more	JJR	O
of	IN	O
AmB	NNP	O
(	(	O
117	CD	O
courses	NNS	O
)	)	O
,	,	O
it	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
there	EX	O
were	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
plasma	JJ	O
urea	JJ	O
and	CC	O
creatinine	JJ	O
concentrations	NNS	O
and	CC	O
in	IN	O
potassium	NN	O
requirement	NN	O
after	IN	O
6	CD	O
days	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
both	DT	O
AmB	NNP	O
infused	VBN	O
in	IN	O
dextrose	NN	O
and	CC	O
AmB	NNP	O
infused	VBD	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
of	IN	O
AmB	NNP	O
administration	NN	O
.	.	O

An	DT	O
intent-to-treat	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
numbers	NNS	O
of	IN	O
courses	NNS	O
affected	VBN	O
by	IN	O
acute	JJ	O
toxicity	NN	O
(	(	O
fever	NN	O
,	,	O
rigors	NNS	O
)	)	O
and	CC	O
chronic	JJ	O
toxicity	NN	O
(	(	O
nephrotoxicity	NN	O
)	)	O
also	RB	O
indicated	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
AmB	NNP	O
infused	VBD	O
in	IN	O
dextrose	NN	O
(	(	O
78	CD	O
courses	NNS	O
)	)	O
and	CC	O
AmB	NNP	O
infused	VBD	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
(	(	O
84	CD	O
courses	NNS	O
)	)	O
.	.	O

The	DT	O
pharmacokinetics	NNS	PH
of	IN	PH
AmB	NNP	PH
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	O
children	NNS	O
who	WP	O
received	VBD	O
AmB	NNP	O
in	IN	O
dextrose	NN	O
and	CC	O
15	CD	O
children	NNS	O
who	WP	O
received	VBD	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
up	RB	O
to	TO	O
24	CD	O
h	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
and	CC	O
the	DT	O
concentration	NN	PH
of	IN	PH
AmB	NNP	PH
in	IN	PH
plasma	NN	PH
was	VBD	O
analyzed	VBN	O
by	IN	O
a	DT	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
assay	NN	O
.	.	O

The	DT	O
clearance	NN	PH
(	(	PH
CL	NNP	PH
)	)	PH
of	IN	PH
AmB	NNP	PH
in	IN	PH
dextrose	NN	PH
(	(	O
0.039	CD	O
+/-	JJ	O
0.016	CD	O
liter	NN	O
.	.	O

h-1	NN	O
.	.	O

kg-1	NN	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
than	IN	O
the	DT	O
CL	NNP	O
of	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
(	(	O
0.062	CD	O
+/-	JJ	O
0	CD	O
.	.	O

024	CD	O
liter	NN	O
.	.	O

h-1	NN	O
.	.	O

kg-1	NN	O
)	)	O
.	.	O

The	DT	O
steady-state	JJ	PH
volume	NN	PH
of	IN	PH
distribution	NN	PH
for	IN	PH
AmB	NNP	PH
in	IN	O
dextrose	NN	O
(	(	O
0.83	CD	O
+/-	JJ	O
0.33	CD	O
liter	NN	O
.	.	O

kg-1	NN	O
)	)	O
was	VBD	O
also	RB	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
than	IN	O
that	DT	O
for	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
(	(	O
1.47	CD	O
+/-	JJ	O
0.77	CD	O
liter	NN	O
.	.	O

kg-1	NN	O
)	)	O
.	.	O

Although	IN	O
AmB	NNP	PH
in	IN	PH
lipid	JJ	PH
emulsion	NN	PH
is	VBZ	O
apparently	RB	O
cleared	VBN	O
faster	RBR	O
and	CC	O
distributes	VBZ	O
more	RBR	O
widely	RB	O
than	IN	O
AmB	NNP	PH
in	IN	PH
dextrose	NN	PH
,	,	O
this	DT	O
study	NN	O
did	VBD	O
not	RB	O
reveal	VB	O
any	DT	O
significant	JJ	O
advantage	NN	O
with	IN	O
respect	NN	O
to	TO	O
safety	NN	Ot
and	CC	Ot
tolerance	NN	Ot
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
compared	VBN	O
to	TO	O
its	PRP$	O
administration	NN	O
in	IN	O
dextrose	NN	O
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
methylphenidate	NN	O
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	Ot
and	CC	O
safety	NN	O
of	IN	O
methylphenidate	NN	O
(	(	O
MPH	NNP	O
)	)	O
to	TO	O
treat	VB	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
in	IN	O
an	DT	O
understudied	JJ	O
population	NN	O
of	IN	O
preschoolers	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
or	CC	O
intellectual	JJ	O
disability	NN	O
(	(	O
ID	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
(	(	O
DD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
14	CD	O
;	:	O
PDD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
12	CD	O
;	:	O
ID	NNP	O
,	,	O
n	JJ	O
=	NNP	O
2	CD	O
)	)	O
underwent	NN	O
MPH	NNP	O
titration	NN	O
in	IN	O
a	DT	O
single-blind	JJ	O
manner	NN	O
followed	VBN	O
by	IN	O
a	DT	O
4-week	JJ	O
double-blind	NN	O
crossover	NN	O
phase	NN	O
.	.	O

Each	DT	O
child	NN	O
was	VBD	O
administered	VBN	O
placebo	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
optimal	JJ	O
dose	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Diagnostic	NNP	ME
and	CC	ME
Statistical	NNP	ME
Manual	NNP	ME
of	IN	ME
Mental	NNP	ME
Disorders	NNP	ME
,	,	ME
4	CD	ME
(	(	ME
th	NN	ME
)	)	ME
edition	NN	ME
(	(	ME
DSM-IV	NNP	ME
)	)	ME
ADHD	NNP	ME
subscale	NN	ME
of	IN	ME
the	DT	ME
Conners	NNP	ME
'	POS	ME
Parent	NN	ME
Rating	VBG	ME
Scale-Revised	JJ	ME
(	(	O
CPRS-R-DSM-IV-ADHD	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
MPH	NNP	O
improved	VBD	O
parent-rated	JJ	ME
ADHD	NNP	ME
symptoms	NNS	ME
of	IN	O
the	DT	O
preschoolers	NNS	O
;	:	O
50	CD	O
%	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
.	.	O

The	DT	O
CPRS-R-DSM-IV-ADHD	JJ	ME
subscale	NN	ME
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
PDD	NNP	O
subgroup	NN	O
(	(	O
p	JJ	O
=	NN	O
0.005	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.97	CD	O
)	)	O
and	CC	O
marginally	RB	O
significant	JJ	O
for	IN	O
the	DT	O
entire	JJ	O
DD	NNP	O
sample	NN	O
(	(	O
p	JJ	O
=	NN	O
0.08	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.50	CD	O
)	)	O
.	.	O

Half	NN	O
of	IN	O
the	DT	O
preschoolers	NNS	O
experienced	VBD	O
side	JJ	A
effects	NNS	A
with	IN	O
MPH	NNP	O
,	,	O
including	VBG	O
reports	NNS	O
of	IN	O
increased	VBN	O
stereotypic	NN	ME
behavior	NN	ME
,	,	ME
upset	JJ	ME
stomach	NN	ME
,	,	ME
sleep-related	JJ	ME
difficulties	NNS	ME
,	,	ME
and	CC	ME
emotional	JJ	ME
lability	NN	ME
.	.	O

One	CD	O
child	NN	O
discontinued	VBN	O
during	IN	O
titration	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
predominant	JJ	O
direction	NN	O
of	IN	O
response	NN	O
in	IN	O
these	DT	O
preschoolers	NNS	O
with	IN	O
both	DT	O
ADHD	NNP	O
and	CC	O
PDD/ID	NNP	O
favored	VBD	O
MPH	NNP	O
,	,	O
even	RB	O
though	IN	O
the	DT	O
response	NN	O
was	VBD	O
more	RBR	O
subtle	JJ	O
and	CC	O
variable	JJ	O
than	IN	O
in	IN	O
older	JJR	O
and	CC	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

Due	NNP	O
to	TO	O
high	JJ	O
rates	NNS	O
of	IN	O
adverse	JJ	O
effects	NNS	O
,	,	O
preschoolers	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	O

Effect	NN	O
of	IN	O
intravenous	JJ	O
fructose-1,6-diphosphate	NN	O
on	IN	O
myocardial	JJ	PH
contractility	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fructose-1,6-diphosphate	NN	O
on	IN	O
myocardial	JJ	PH
performance	NN	PH
using	VBG	O
nuclear	JJ	O
scintigraphy	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Urban	NNP	O
teaching	VBG	O
hospital	JJ	O
clinical	JJ	O
research	NN	O
center	NN	O
.	.	O

PATIENTS	JJ	O
Individuals	NNS	O
with	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
II-III	NNP	O
heart	NN	O
failure	NN	O
(	(	O
mild	JJ	O
to	TO	O
moderate	VB	O
)	)	O
.	.	O

INTERVENTIONS	JJ	O
Subjects	NNPS	O
received	VBD	O
either	DT	O
intravenous	JJ	O
fructose-1,6-diphosphate	JJ	O
125	CD	O
mg/kg	NN	O
or	CC	O
normal	JJ	O
saline	JJ	O
1.3	CD	O
ml/kg	NN	O
every	DT	O
12	CD	O
hours	NNS	O
over	IN	O
10	CD	O
minutes	NNS	O
for	IN	O
four	CD	O
consecutive	JJ	O
doses	NNS	O
.	.	O

Left	NNP	O
ventricular	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
radionuclide	NN	O
ventriculography	NN	O
at	IN	O
baseline	NN	O
and	CC	O
within	IN	O
60	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
fourth	JJ	O
infusion	NN	O
.	.	O

Vital	JJ	O
signs	NNS	O
were	VBD	O
monitored	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Fructose-1,6-diphosphate	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
modest	JJ	O
7	CD	O
%	NN	O
increase	NN	O
in	IN	O
left	JJ	PH
ventricular	JJ	PH
ejection	NN	PH
fraction	NN	PH
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Peak	JJ	PH
ejection	NN	PH
rate	NN	PH
and	CC	PH
peak	VB	PH
diastolic	JJ	PH
filling	VBG	PH
rate	NN	PH
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
changes	NNS	O
in	IN	O
blood	NN	PH
pressure	NN	PH
or	CC	PH
heart	NN	PH
rate	NN	PH
with	IN	O
either	DT	O
fructose-1,6-diphosphate	JJ	O
or	CC	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Fructose-1,6-diphosphate	NNP	O
produces	VBZ	O
a	DT	O
modest	JJ	O
but	CC	O
significant	JJ	O
increase	NN	O
in	IN	O
left	JJ	PH
ventricular	JJ	PH
ejection	NN	PH
fraction	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
heart	NN	O
failure	NN	O
.	.	O

Preschool	NNP	O
based	VBN	O
JASPER	NNP	O
intervention	NN	O
in	IN	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
pilot	NN	O
RCT	NNP	O
.	.	O

In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
we	PRP	O
tested	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
novel	JJ	O
intervention	NN	O
(	(	O
JASPER	NNP	O
,	,	O
Joint	NNP	O
Attention	NNP	O
Symbolic	NNP	O
Play	NNP	O
Engagement	NNP	O
and	CC	O
Regulation	NNP	O
)	)	O
on	IN	O
3	CD	O
to	TO	O
5	CD	O
year	NN	O
old	JJ	O
,	,	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
who	WP	O
were	VBD	O
attending	VBG	O
a	DT	O
non-public	JJ	O
preschool	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
treatment	NN	O
as	IN	O
usual	JJ	O
,	,	O
30	CD	O
h	NN	O
of	IN	O
ABA-based	JJ	O
therapy	NN	O
per	IN	O
week	NN	O
)	)	O
or	CC	O
a	DT	O
treatment	NN	O
group	NN	O
(	(	O
substitution	NN	O
of	IN	O
30	CD	O
min	NN	O
of	IN	O
JASPER	NNP	O
treatment	NN	O
,	,	O
twice	RB	O
weekly	RB	O
during	IN	O
their	PRP$	O
regular	JJ	O
program	NN	O
)	)	O
.	.	O

A	DT	O
baseline	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
in	IN	O
which	WDT	O
no	DT	O
changes	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
core	NN	ME
deficits	NNS	ME
was	VBD	O
followed	VBN	O
by	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
intervention	NN	O
for	IN	O
children	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
JASPER	NNP	O
treatment	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
greater	JJR	O
play	NN	ME
diversity	NN	ME
on	IN	O
a	DT	O
standardized	JJ	O
assessment	NN	O
.	.	O

Effects	NNS	O
also	RB	O
generalized	VBD	O
to	TO	O
the	DT	O
classroom	NN	O
,	,	O
where	WRB	O
participants	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
initiated	VBD	O
more	JJR	O
gestures	NNS	O
and	CC	O
spent	VB	O
less	JJR	O
time	NN	O
unengaged	JJ	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
further	JJ	O
support	NN	O
that	WDT	O
even	RB	O
brief	VBP	O
,	,	O
targeted	JJ	O
interventions	NNS	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
can	MD	O
improve	VB	O
core	NN	O
deficits	NNS	O
in	IN	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Serum	NNP	O
selenium	NN	O
concentration	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

AIM	NNP	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
chemo	NN	O
and	CC	O
radio	NN	O
therapies	NNS	O
on	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
content	NN	O
and	CC	O
antioxidant	JJ	PH
activity	NN	PH
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
was	VBD	O
evaluated	VBN	O
.	.	O

METHODS	NNP	O
Among	IN	O
104	CD	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
selected	VBN	O
for	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
54	CD	O
and	CC	O
50	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
chemo-	JJ	O
and	CC	O
radiotherapy	NN	O
respectively	RB	O
.	.	O

Plasma	NNP	O
Se	NNP	O
,	,	O
Zn	NNP	O
,	,	O
Cu	NNP	O
and	CC	O
some	DT	O
enzymatic	JJ	O
antioxidants	NNS	O
activities	NNS	O
were	VBD	O
estimated	VBN	O
in	IN	O
serum	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
decreased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	PH
trace	NN	PH
elements	NNS	PH
,	,	O
glutathione	NN	PH
peroxidase	NN	PH
activity	NN	PH
and	CC	PH
total	JJ	PH
antioxidant	JJ	PH
capacity	NN	PH
,	,	O
and	CC	O
increased	VBD	O
malondialdehyde	NN	PH
,	,	PH
glutathion	NN	PH
reductase	NN	PH
was	VBD	O
observed	VBN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
healthy	JJ	O
controls	NNS	O
.	.	O

The	DT	O
increased	JJ	O
concentration	NN	PH
of	IN	PH
serum	NN	PH
Se	NNP	PH
,	,	PH
Zn	NNP	PH
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
.	.	O

Simultaneously	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
increase	NN	O
in	IN	O
glutathione	JJ	PH
peroxidase	NN	PH
and	CC	PH
total	JJ	PH
antioxidant	JJ	PH
capacity	NN	PH
,	,	O
and	CC	O
significant	JJ	O
decrease	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
malondialdehyde	NN	PH
and	CC	PH
glutathion	NN	PH
reductase	NN	PH
levels	NNS	PH
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
compared	VBN	O
to	TO	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
chemotherapy	NN	O
but	CC	O
not	RB	O
radiotherapy	JJ	O
results	NNS	O
in	IN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
trace	NN	PH
elements	NNS	PH
levels	NNS	PH
and	CC	PH
antioxidant	JJ	PH
activities	NNS	PH
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

Caudal	NNP	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
surgery	NN	O
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
bupivacaine	NN	O
and	CC	O
diamorphine	NN	O
.	.	O

Seventy-three	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
perianal	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
a	DT	O
caudal	JJ	O
injection	NN	O
of	IN	O
20	CD	O
ml	NNS	O
bupivacaine	VBP	O
0.5	CD	O
%	NN	O
plain	NN	O
and	CC	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
diamorphine	JJ	O
2.5	CD	O
mg	NN	O
in	IN	O
10	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
by	IN	O
caudal	JJ	O
injection	NN	O
;	:	O
a	DT	O
comparison	NN	O
was	VBD	O
then	RB	O
made	VBN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
requirements	NNS	O
.	.	O

The	DT	O
bupivacaine	NN	O
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	PH
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
8	CD	O
hours	NNS	O
,	,	O
after	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
.	.	O

The	DT	O
diamorphine	NN	O
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	PH
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

Side	JJ	A
effects	NNS	A
were	VBD	O
less	RBR	O
in	IN	O
the	DT	O
diamorphine	NN	O
group	NN	O
than	IN	O
the	DT	O
control	NN	O
,	,	O
or	CC	O
the	DT	O
bupivacaine	NN	O
group	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
41	CD	O
%	NN	O
of	IN	O
the	DT	O
bupivacaine	NN	O
group	NN	O
complained	VBD	O
of	IN	O
some	DT	A
degree	NN	A
of	IN	A
urinary	JJ	A
retention	NN	A
and	CC	O
one	CD	O
patient	NN	O
required	VBN	O
temporary	JJ	A
catheterisation	NN	A
.	.	A

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
caudal	JJ	O
diamorphine	NN	O
gives	VBZ	O
good	JJ	O
postoperative	JJ	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
operations	NNS	O
,	,	O
particularly	RB	O
when	WRB	O
motor	NN	O
blockade	NN	O
is	VBZ	O
not	RB	O
wanted	VBN	O
by	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Low	JJ	O
body	NN	O
mass	NN	O
index	NN	O
and	CC	O
dyslipidemia	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
linked	VBN	O
to	TO	O
elevated	VBN	O
plasma	NN	O
fibroblast	NN	O
growth	NN	O
factor	NN	O
23	CD	O
.	.	O

BACKGROUND	NNP	O
Fibroblast	NNP	O
growth	NN	O
factor	NN	O
23	CD	O
(	(	O
FGF23	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
death	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

Since	IN	O
FGF23	NNP	O
shares	NNS	O
structural	JJ	O
features	NNS	O
with	IN	O
FGF19	NNP	O
subfamily	RB	O
members	NNS	O
that	IN	O
exert	JJ	O
hormonal	JJ	O
control	NN	O
of	IN	O
fat	JJ	O
mass	NN	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	DT	O
high	JJ	O
circulating	NN	O
FGF23	NNP	O
concentrations	NNS	O
would	MD	O
be	VB	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
uremic	JJ	O
lipid	NN	O
profile	NN	O
and	CC	O
lower	JJR	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
654	CD	O
patients	NNS	O
receiving	VBG	O
chronic	JJ	O
hemodialysis	NN	O
.	.	O

C-terminal	JJ	PH
FGF23	NNP	PH
concentrations	NNS	PH
were	VBD	O
measured	VBN	O
in	IN	O
stored	JJ	O
plasma	NN	O
samples	NNS	O
.	.	O

Linear	JJ	O
regression	NN	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
cross-sectional	JJ	O
associations	NNS	O
of	IN	O
plasma	NN	PH
FGF23	NNP	PH
concentrations	NNS	PH
with	IN	PH
BMI	NNP	PH
,	,	PH
total	JJ	PH
cholesterol	NN	PH
(	(	PH
TC	NNP	PH
)	)	PH
,	,	PH
low-density	JJ	PH
lipoprotein-cholesterol	NN	PH
(	(	PH
LDL-C	NNP	PH
)	)	PH
,	,	PH
high-density	JJ	PH
lipoprotein-cholesterol	NN	PH
(	(	PH
HDL-C	NNP	PH
)	)	PH
and	CC	PH
triglycerides	NNS	PH
.	.	PH

Cox	NNP	O
proportional	JJ	O
hazard	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
association	NN	O
between	IN	O
FGF23	NNP	O
concentrations	NNS	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
.	.	O

RESULTS	JJ	O
Participants	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60	CD	O
?	.	O
11	CD	O
years	NNS	O
and	CC	O
a	DT	O
median	JJ	O
(	(	O
IQR	NNP	O
)	)	O
FGF23	NNP	O
concentration	NN	O
of	IN	O
4,212	CD	O
(	(	O
1,411-13,816	JJ	O
)	)	O
RU/ml	NNP	O
.	.	O

An	DT	O
increase	NN	O
per	IN	O
SD	NNP	O
in	IN	O
log10	JJ	O
FGF23	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
?	.	O
=	NNP	O
-1.11	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.008	CD	O
)	)	O
,	,	O
TC	NNP	O
(	(	O
?	.	O
=	NNP	O
-6.46	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.02	CD	O
)	)	O
,	,	O
LDL-C	NNP	O
(	(	O
?	.	O
=	NNP	O
-4.73	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.04	CD	O
)	)	O
and	CC	O
HDL-C	NNP	O
(	(	O
?	.	O
=	NNP	O
-2.14	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.03	CD	O
)	)	O
;	:	O
after	IN	O
adjusting	VBG	O
for	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
race	NN	O
,	,	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
serum	NN	O
albumin	NN	O
,	,	O
markers	NNS	O
of	IN	O
mineral	JJ	O
metabolism	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
lipid-lowering	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
association	NN	O
of	IN	O
FGF23	NNP	O
with	IN	O
death	NN	O
was	VBD	O
attenuated	VBN	O
after	IN	O
adjustment	NN	O
for	IN	O
HDL-C	NNP	O
(	(	O
HR	NNP	O
of	IN	O
highest	JJS	O
quartile	NN	O
1.53	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.06-2.20	CD	O
compared	VBN	O
to	TO	O
lowest	VB	O
quartile	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
higher	JJR	O
plasma	NN	O
FGF23	NNP	O
levels	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
and	CC	O
dyslipidemia	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

The	DT	O
association	NN	O
between	IN	O
FGF23	NNP	O
and	CC	O
death	NN	O
may	MD	O
be	VB	O
mediated	VBN	O
through	IN	O
unexplored	JJ	O
metabolic	JJ	O
risk	NN	O
factors	NNS	O
unrelated	VBD	O
to	TO	O
mineral	JJ	O
metabolism	NN	O
.	.	O

Cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
for	IN	O
anxiety	NN	ME
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
often	RB	O
present	JJ	O
with	IN	O
comorbid	NN	O
anxiety	NN	O
disorders	NNS	O
that	WDT	O
cause	VBP	O
significant	JJ	O
functional	JJ	ME
impairment	NN	ME
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
a	DT	O
modular	JJ	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
this	DT	O
profile	NN	O
.	.	O

A	DT	O
standard	JJ	O
CBT	NNP	O
program	NN	O
was	VBD	O
augmented	VBN	O
with	IN	O
multiple	JJ	O
treatment	NN	O
components	NNS	O
designed	VBN	O
to	TO	O
accommodate	VB	O
or	CC	O
remediate	VB	O
the	DT	O
social	JJ	O
and	CC	O
adaptive	JJ	O
skill	NN	O
deficits	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
that	WDT	O
could	MD	O
pose	VB	O
barriers	NNS	O
to	TO	O
anxiety	VB	ME
reduction	NN	ME
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	O
or	CC	O
a	DT	O
3-month	JJ	O
waitlist	NN	O
(	(	O
36	CD	O
completed	VBN	O
treatment	NN	O
or	CC	O
waitlist	NN	O
)	)	O
.	.	O

Therapists	NNS	O
worked	VBD	O
with	IN	O
individual	JJ	O
families	NNS	O
.	.	O

The	DT	O
CBT	NNP	O
model	NN	O
emphasized	VBD	O
behavioral	JJ	O
experimentation	NN	O
,	,	O
parent-training	NN	O
,	,	O
and	CC	O
school	NN	O
consultation	NN	O
.	.	O

Independent	JJ	O
evaluators	NNS	O
blind	VBP	O
to	TO	O
treatment	NN	O
condition	NN	O
conducted	VBN	O
structured	JJ	O
diagnostic	JJ	O
interviews	NNS	O
and	CC	O
parents	NNS	O
and	CC	O
children	NNS	O
completed	VBN	O
anxiety	NN	ME
symptom	NN	ME
checklists	NNS	ME
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
intent-to-treat	JJ	O
analyses	NNS	O
,	,	O
78.5	CD	O
%	NN	O
of	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
met	VBD	O
Clinical	JJ	ME
Global	NNP	ME
Impressions-Improvement	NNP	ME
scale	NN	ME
criteria	NNS	ME
for	IN	O
positive	JJ	O
treatment	NN	O
response	NN	O
at	IN	O
posttreatment	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
only	RB	O
8.7	CD	O
%	NN	O
of	IN	O
the	DT	O
waitlist	NN	O
group	NN	O
.	.	O

CBT	NNP	O
also	RB	O
outperformed	VBD	O
the	DT	O
waitlist	NN	O
on	IN	O
diagnostic	JJ	O
outcomes	NNS	O
and	CC	O
parent	NN	ME
reports	NNS	ME
of	IN	ME
child	NN	ME
anxiety	NN	ME
,	,	O
but	CC	O
not	RB	O
children	NNS	O
's	POS	O
self-reports	NNS	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
CBT	NNP	O
manual	JJ	O
employed	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
adaptations	NNS	O
of	IN	O
an	DT	O
evidence-based	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Remission	NN	O
of	IN	O
anxiety	NN	ME
disorders	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
achievable	JJ	O
goal	NN	O
among	IN	O
high-functioning	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Reversal	NNP	O
of	IN	O
skeletal	JJ	O
effects	NNS	Ot
of	IN	O
endocrine	NN	O
treatments	NNS	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
.	.	O

The	DT	O
adjuvant	JJ	O
use	NN	O
of	IN	O
aromatase	NN	O
inhibitors	NNS	O
in	IN	O
breast	NN	O
cancer	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
adverse	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
health	NN	O
.	.	O

We	PRP	O
previously	RB	O
reported	VBD	O
a	DT	O
decline	NN	O
in	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
following	VBG	O
the	DT	O
switch	NN	O
from	IN	O
tamoxifen	NN	O
to	TO	O
exemestane	VB	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
(	(	O
IES	NNP	O
)	)	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
effects	NNS	O
of	IN	O
endocrine	JJ	O
treatment	NN	O
withdrawal	NN	O
on	IN	O
BMD	NNP	O
,	,	O
bone	NN	O
turnover	NN	O
markers	NNS	O
(	(	O
BTM	NNP	O
)	)	O
and	CC	O
fracture	JJ	O
rates	NNS	O
.	.	O

4,724	CD	O
patients	NNS	O
took	VBD	O
part	NN	O
in	IN	O
IES	NNP	O
,	,	O
and	CC	O
206	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
bone	NN	O
sub-study	NN	O
.	.	O

BMD	NNP	O
and	CC	O
BTM	NNP	O
were	VBD	O
assessed	VBN	O
pre-randomization	NN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
EOT	NNP	O
)	)	O
.	.	O

To	TO	O
evaluate	VB	O
treatment	NN	O
withdrawal	NN	O
effects	NNS	O
,	,	O
12-	JJ	O
and	CC	O
24-month	JJ	O
post	NN	O
EOT	NNP	O
BMD	NNP	O
results	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
122	CD	O
and	CC	O
126	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

Similar	JJ	O
patient	NN	O
numbers	NNS	O
had	VBD	O
BTM	NNP	O
measured	VBD	O
post	NN	O
EOT	NNP	O
.	.	O

Following	VBG	O
treatment	NN	O
withdrawal	NN	O
,	,	O
the	DT	O
differences	NNS	O
in	IN	O
BMD	NNP	O
observed	VBD	O
between	IN	O
the	DT	O
two	CD	O
endocrine	NN	O
strategies	NNS	O
were	VBD	O
partially	RB	O
reversed	VBN	O
.	.	O

At	IN	O
24	CD	O
months	NNS	O
from	IN	O
EOT	NNP	O
,	,	O
spine	JJ	PH
BMD	NNP	PH
increased	VBN	O
by	IN	O
1.53	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.63-2.43	CD	O
;	:	O
p	CC	O
=	VB	O
0.001	CD	O
)	)	O
after	IN	O
stopping	VBG	O
exemestane	NN	O
and	CC	O
fell	VBD	O
by	IN	O
1.93	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-2.91	NNP	O
to	TO	O
0.95	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.0002	CD	O
)	)	O
following	VBG	O
tamoxifen	NN	O
withdrawal	NN	O
.	.	O

A	DT	O
similar	JJ	O
pattern	NN	O
of	IN	O
changes	NNS	O
was	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
hip	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
post	RB	O
EOT	NNP	O
,	,	O
BMD	NNP	PH
changes	NNS	PH
from	IN	O
baseline	NN	O
were	VBD	O
similar	JJ	O
with	IN	O
both	DT	O
treatment	NN	O
strategies	NNS	O
.	.	O

Corresponding	VBG	O
inverse	JJ	PH
changes	NNS	PH
in	IN	PH
BTM	NNP	PH
were	VBD	O
seen	VBN	O
,	,	O
with	IN	O
an	DT	O
increase	NN	O
following	VBG	O
tamoxifen	JJ	O
withdrawal	NN	O
and	CC	O
a	DT	O
reduction	NN	O
after	IN	O
exemestane	NN	O
.	.	O

A	DT	O
higher	JJR	O
number	NN	PH
of	IN	PH
fractures	NNS	PH
occurred	VBD	PH
during	IN	O
exemestane	NN	O
treatment	NN	O
,	,	O
but	CC	O
fracture	NN	PH
rates	NNS	PH
were	VBD	O
similar	JJ	O
after	IN	O
treatment	NN	O
withdrawal	NN	O
.	.	O

With	IN	O
the	DT	O
switch	NN	O
strategy	NN	O
used	VBN	O
in	IN	O
IES	NNP	O
,	,	O
the	DT	O
on	IN	O
treatment	NN	O
adverse	JJ	A
bone	NN	A
effects	NNS	A
of	IN	O
exemestane	NN	O
are	VBP	O
reversed	VBN	O
.	.	O

Ongoing	VBG	O
monitoring	NN	O
of	IN	O
BMD	NNP	O
is	VBZ	O
therefore	RB	O
not	RB	O
routinely	RB	O
required	VBN	O
.	.	O

Osteopontin	NNP	O
is	VBZ	O
a	DT	O
prognostic	JJ	O
factor	NN	O
for	IN	O
survival	NN	MO
of	IN	O
acute	JJ	O
myeloid	JJ	O
leukemia	NN	O
patients	NNS	O
.	.	O

Osteopontin	NNP	PH
(	(	PH
OPN	NNP	PH
)	)	PH
is	VBZ	O
a	DT	O
glycoprotein	NN	O
that	WDT	O
is	VBZ	O
secreted	VBN	O
by	IN	O
osteoblasts	NNS	O
and	CC	O
hematopoietic	JJ	O
cells	NNS	O
.	.	O

OPN	NNP	O
suppresses	VBZ	O
the	DT	O
proliferation	NN	O
of	IN	O
hematopoietic	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
vitro	NN	O
and	CC	O
may	MD	O
regulate	VB	O
the	DT	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
pool	NN	O
.	.	O

Increased	VBN	O
serum	NN	O
OPN	NNP	O
concentrations	NNS	O
occur	VBP	O
in	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
,	,	O
multiple	JJ	O
myeloma	NN	O
,	,	O
and	CC	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
(	(	O
AML	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
we	PRP	O
analyzed	VBD	O
the	DT	O
prognostic	JJ	O
impact	NN	O
of	IN	O
OPN	NNP	O
in	IN	O
AML	NNP	O
by	IN	O
investigating	VBG	O
the	DT	O
expression	NN	PH
and	CC	PH
relevance	NN	PH
of	IN	PH
OPN	NNP	PH
in	IN	O
newly	RB	O
diagnosed	VBN	O
AML	NNP	O
patients	NNS	O
from	IN	O
2	CD	O
large	JJ	O
study	NN	O
groups	NNS	O
(	(	O
the	DT	O
German	JJ	O
AML	NNP	O
Cooperative	NNP	O
Group	NNP	O
and	CC	O
the	DT	O
Dutch-Belgian	JJ	O
Hematology	NNP	O
Oncology	NNP	O
Cooperative	NNP	O
group	NN	O
)	)	O
.	.	O

IHC	NNP	PH
(	(	O
n	JJ	O
=	NNP	O
84	CD	O
)	)	O
,	,	O
ELISAs	NNP	O
of	IN	O
blood/BM	NN	O
sera	NN	O
(	(	O
n	JJ	O
=	NNP	O
41	CD	O
)	)	O
,	,	O
and	CC	O
microarray	NN	O
data	NNS	O
for	IN	O
mRNA	NN	O
levels	NNS	O
(	(	O
n	JJ	O
=	NNP	O
261	CD	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

Expression	NN	PH
of	IN	PH
OPN	NNP	PH
protein	NN	PH
was	VBD	O
increased	VBN	O
in	IN	O
AML	NNP	O
patients	NNS	O
both	DT	O
in	IN	O
BM	NNP	O
blasts	NNS	O
(	(	O
IHC	NNP	O
)	)	O
and	CC	O
in	IN	O
BM	NNP	O
serum	NN	O
(	(	O
ELISA	NNP	O
)	)	O
compared	VBN	O
with	IN	O
healthy	JJ	O
controls	NNS	O
.	.	O

Patients	NNS	O
expressing	VBG	O
high	JJ	O
levels	NNS	PH
of	IN	PH
OPN	NNP	PH
within	IN	PH
the	DT	PH
BM	NNP	PH
(	(	O
IHC	NNP	O
)	)	O
experienced	VBD	O
shortened	VBN	O
overall	JJ	MO
survival	NN	MO
(	(	O
OS	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.025	NNP	O
)	)	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
identified	VBD	O
karyotype	NN	Ot
,	,	O
blast	JJ	Ot
clearance	NN	Ot
(	(	O
day	NN	O
16	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
level	NN	PH
of	IN	PH
OPN	NNP	PH
expression	NN	PH
as	IN	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
for	IN	O
OS	NNP	MO
.	.	O

This	DT	O
prompted	VBD	O
us	PRP	O
to	TO	O
analyze	VB	O
microarray	NN	O
data	NNS	O
from	IN	O
261	CD	O
patients	NNS	O
from	IN	O
a	DT	O
third	JJ	O
cohort	NN	O
.	.	O

The	DT	O
analysis	NN	O
confirmed	VBD	O
OPN	NNP	O
as	IN	O
a	DT	O
prognostic	JJ	O
marker	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
high	JJ	O
OPN	NNP	PH
mRNA	NN	PH
expression	NN	PH
indicated	VBD	O
decreased	JJ	O
event-free	JJ	MO
survival	NN	MO
(	(	O
P	NNP	O
=	NNP	O
.0002	NNP	O
)	)	O
and	CC	O
OS	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
prognostic	JJ	O
role	NN	O
of	IN	O
OPN	NNP	O
was	VBD	O
most	RBS	O
prominent	JJ	O
in	IN	O
intermediate-risk	JJ	O
AML	NNP	O
.	.	O

These	DT	O
data	NNS	O
provide	VBP	O
evidence	NN	O
that	IN	O
OPN	NNP	PH
expression	NN	PH
is	VBZ	O
an	DT	O
independent	JJ	O
prognostic	JJ	O
factor	NN	O
in	IN	O
AML	NNP	O
.	.	O

Pazopanib	NNP	O
in	IN	O
locally	RB	O
advanced	JJ	O
or	CC	O
metastatic	JJ	O
renal	NN	O
cell	NN	O
carcinoma	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Pazopanib	NNP	O
is	VBZ	O
an	DT	O
oral	JJ	O
angiogenesis	NN	O
inhibitor	NN	O
targeting	VBG	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
and	CC	O
c-Kit	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
pazopanib	JJ	O
monotherapy	NN	O
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
RCC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Adult	NNP	O
patients	NNS	O
with	IN	O
measurable	JJ	O
,	,	O
locally	RB	O
advanced	JJ	O
,	,	O
and/or	JJ	O
metastatic	JJ	O
RCC	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
2:1	CD	O
to	TO	O
receive	VB	O
oral	JJ	O
pazopanib	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
progression-free	JJ	MO
survival	NN	MO
(	(	MO
PFS	NNP	MO
)	)	MO
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
overall	JJ	MO
survival	NN	MO
,	,	O
tumor	NN	PH
response	NN	PH
rate	NN	PH
(	(	O
Response	NNP	PH
Evaluation	NNP	PH
Criteria	NNP	PH
in	IN	PH
Solid	NNP	PH
Tumors	NNP	PH
)	)	O
,	,	O
and	CC	O
safety	NN	Ot
.	.	O

Radiographic	JJ	O
assessments	NNS	O
of	IN	O
tumors	NNS	O
were	VBD	O
independently	RB	O
reviewed	VBN	O
.	.	O

Results	NNS	O
Of	IN	O
435	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
233	CD	O
were	VBD	O
treatment	NN	O
naive	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
and	CC	O
202	CD	O
were	VBD	O
cytokine	NN	O
pretreated	VBN	O
(	(	O
46	CD	O
%	NN	O
)	)	O
.	.	O

PFS	NNP	MO
was	VBD	O
significantly	RB	O
prolonged	VBN	O
with	IN	O
pazopanib	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
overall	JJ	O
study	NN	O
population	NN	O
(	(	O
median	JJ	O
,	,	O
PFS	NNP	O
9.2	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
hazard	PRP$	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.34	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
the	DT	O
treatment-naive	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
11.1	CD	O
v	NN	O
2.8	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.27	CD	O
to	TO	O
0.60	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
cytokine-pretreated	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
,	,	O
7.4	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.54	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.35	CD	O
to	TO	O
0.84	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
objective	JJ	PH
response	NN	PH
rate	NN	PH
was	VBD	O
30	CD	O
%	NN	O
with	IN	O
pazopanib	NN	O
compared	VBN	O
with	IN	O
3	CD	O
%	NN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	PH
duration	NN	PH
of	IN	PH
response	NN	PH
was	VBD	O
longer	JJR	O
than	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
diarrhea	RB	A
,	,	O
hypertension	NN	A
,	,	O
hair	NN	A
color	NN	A
changes	NNS	A
,	,	O
nausea	NN	PH
,	,	O
anorexia	NN	A
,	,	O
and	CC	O
vomiting	VBG	A
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
differences	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
for	IN	O
pazopanib	JJ	O
versus	NN	O
placebo	NN	O
.	.	O

CONCLUSION	NNP	O
Pazopanib	NNP	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
PFS	NNP	O
and	CC	O
tumor	NN	O
response	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
and/or	NNS	O
metastatic	JJ	O
RCC	NNP	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trial	NN	O
:	:	O
Multimodal	NNP	O
Anxiety	NNP	O
and	CC	O
Social	NNP	O
Skill	NNP	O
Intervention	NNP	O
for	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Anxiety	NN	O
is	VBZ	O
common	JJ	O
among	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
may	MD	O
amplify	VB	O
the	DT	O
core	NN	O
social	JJ	O
disability	NN	O
,	,	O
thus	RB	O
necessitating	VBG	O
combined	VBN	O
treatment	NN	O
approaches	NNS	O
.	.	O

This	DT	O
pilot	NN	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
evaluated	VBD	O
the	DT	O
feasibility	NN	Ot
and	CC	O
preliminary	JJ	Ot
outcomes	NNS	Ot
of	IN	O
the	DT	O
Multimodal	NNP	O
Anxiety	NNP	O
and	CC	O
Social	NNP	O
Skills	NNP	O
Intervention	NNP	O
(	(	O
MASSI	NNP	O
)	)	O
program	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
30	CD	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
anxiety	NN	O
symptoms	NNS	O
of	IN	O
moderate	JJ	O
or	CC	O
greater	JJR	O
severity	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
acceptable	JJ	O
to	TO	O
families	NNS	O
,	,	O
subject	JJ	Ot
adherence	NN	Ot
was	VBD	O
high	JJ	O
,	,	O
and	CC	O
therapist	JJ	Ot
fidelity	NN	Ot
was	VBD	O
high	JJ	O
.	.	O

A	DT	O
16	CD	O
%	NN	O
improvement	NN	O
in	IN	O
ASD	NNP	ME
social	JJ	ME
impairment	NN	ME
(	(	O
within-group	JJ	O
effect	NN	O
size	NN	O
=	NNP	O
1.18	CD	O
)	)	O
was	VBD	O
observed	VBN	O
on	IN	O
a	DT	O
parent-reported	JJ	O
scale	NN	O
.	.	O

Although	IN	O
anxiety	NN	ME
symptoms	NNS	ME
declined	VBD	O
by	IN	O
26	CD	O
%	NN	O
,	,	O
the	DT	O
change	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
MASSI	NNP	O
is	VBZ	O
a	DT	O
feasible	JJ	Ot
treatment	NN	O
program	NN	O
and	CC	O
further	JJ	O
evaluation	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Evaluation	NN	O
of	IN	O
an	DT	O
intervention	NN	O
to	TO	O
change	VB	O
benzodiazepine-prescribing	JJ	O
behavior	NN	O
in	IN	O
a	DT	O
prepaid	NN	O
group	NN	O
practice	NN	O
setting	VBG	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
levels	NNS	O
of	IN	O
educational	JJ	O
intervention	NN	O
on	IN	O
benzodiazepine-prescribing	JJ	O
behavior	NN	O
in	IN	O
an	DT	O
elderly	JJ	O
population	NN	O
in	IN	O
a	DT	O
controlled	JJ	O
prepaid	NN	O
group	NN	O
practice	NN	O
(	(	O
PPGP	NNP	O
)	)	O
setting	NN	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
prospective	JJ	O
controlled	VBN	O
trial	NN	O
,	,	O
with	IN	O
six-month	JJ	O
follow-up	NN	O
.	.	O

Our	PRP$	O
setting	NN	O
was	VBD	O
a	DT	O
270,000	CD	O
member	NN	O
group-model	JJ	O
PPGP	NNP	O
in	IN	O
Colorado	NNP	O
,	,	O
from	IN	O
1990	CD	O
to	TO	O
1991	CD	O
.	.	O

Participants	NNS	O
included	VBD	O
91	CD	O
physicians	NNS	O
,	,	O
62	CD	O
men	NNS	O
and	CC	O
29	CD	O
women	NNS	O
;	:	O
median	JJ	O
age	NN	O
was	VBD	O
38.7	CD	O
years	NNS	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
a	DT	O
one-on-one	JJ	O
educational	JJ	O
presentation	NN	O
by	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
,	,	O
written	VBN	O
educational	JJ	O
materials	NNS	O
,	,	O
a	DT	O
brief	JJ	O
follow-up	JJ	O
visit	NN	O
,	,	O
and	CC	O
feedback	NN	O
with	IN	O
recommendations	NNS	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
only	RB	O
a	DT	O
face-to-face	JJ	O
presentation	NN	O
,	,	O
given	VBN	O
to	TO	O
departmental	VB	O
groups	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
same	JJ	O
written	VBN	O
educational	JJ	O
materials	NNS	O
used	VBN	O
in	IN	O
group	NN	O
1	CD	O
.	.	O

Controls	NNP	O
received	VBD	O
no	DT	O
intervention	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
was	VBD	O
the	DT	O
benzodiazepine	NN	Ot
on/off	NN	Ot
status	NN	Ot
of	IN	Ot
the	DT	Ot
elderly	JJ	Ot
PPGP	NNP	Ot
members	NNS	Ot
.	.	O

The	DT	O
secondary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
median	JJ	Ot
change	NN	Ot
(	(	Ot
preintervention	NN	Ot
minus	IN	Ot
postintervention	NN	Ot
)	)	Ot
in	IN	Ot
a	DT	Ot
standardized	JJ	Ot
amount	NN	Ot
of	IN	Ot
benzodiazepines	NNS	Ot
prescribed	VBN	Ot
per	IN	Ot
physician	NN	Ot
.	.	O

Logistic	JJ	O
regression	NN	O
analysis	NN	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
postintervention	NN	O
benzodiazepine	NN	Ot
on/off	NN	Ot
status	NN	Ot
between	IN	O
study	NN	O
groups	NNS	O
,	,	O
when	WRB	O
controlling	VBG	O
for	IN	O
preintervention	NN	O
on/off	NN	O
status	NN	O
,	,	O
PPGP-member	NNP	O
age	NN	O
,	,	O
PPGP-member	NNP	O
gender	NN	O
,	,	O
and	CC	O
all	DT	O
possible	JJ	O
interactions	NNS	O
.	.	O

Analysis	NN	O
of	IN	O
variance	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
an	DT	O
effect	NN	O
of	IN	O
either	DT	O
intervention	NN	O
on	IN	O
the	DT	O
median	JJ	Ot
change	NN	Ot
in	IN	Ot
standardized	JJ	Ot
amount	NN	Ot
of	IN	Ot
benzodiazepines	NNS	Ot
prescribed	VBN	O
per	IN	O
physician	NN	O
,	,	O
with	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
controls	NNS	O
yielding	VBG	O
values	NNS	O
of	IN	O
-278	NN	O
(	(	O
range	NN	O
:	:	O
-4,137	NN	O
,	,	O
2,844	CD	O
)	)	O
,	,	O
-330	NNP	O
(	(	O
-1,531	NNP	O
,	,	O
1,358	CD	O
)	)	O
,	,	O
and	CC	O
-541	NNP	O
(	(	O
range	NN	O
:	:	O
-3,716	NN	O
,	,	O
2,185	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
strategies	NNS	O
effective	JJ	O
in	IN	O
changing	VBG	O
physician	JJ	O
prescribing	VBG	O
behavior	NN	O
in	IN	O
other	JJ	O
settings	NNS	O
may	MD	O
not	RB	O
be	VB	O
effective	JJ	O
in	IN	O
a	DT	O
PPGP	NNP	O
setting	VBG	O
with	IN	O
benzodiazepines	NNS	O
in	IN	O
the	DT	O
elderly	JJ	O
as	IN	O
the	DT	O
target	NN	O
for	IN	O
change	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
bepotastine	NN	O
besilate	NN	O
ophthalmic	JJ	O
solution	NN	O
1.5	CD	O
%	NN	O
for	IN	O
seasonal	JJ	PH
allergic	JJ	PH
conjunctivitis	NN	PH
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
natural	JJ	O
exposure	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

Allergic	NNP	O
conjunctivitis	NN	O
(	(	O
AC	NNP	O
)	)	O
affects	VBZ	O
an	DT	O
estimated	JJ	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
population	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
with	IN	O
a	DT	O
large	JJ	O
fraction	NN	O
suffering	VBG	O
due	JJ	O
to	TO	O
seasonal	JJ	O
or	CC	O
perennial	JJ	O
allergen	NN	O
exposures	NNS	O
.	.	O

Bepotastine	NNP	O
besilate	NN	O
ophthalmic	JJ	O
solution	NN	O
(	(	O
BBOS	NNP	O
)	)	O
1.5	CD	O
%	NN	O
,	,	O
a	DT	O
dual-acting	JJ	O
histamine	NN	O
(	(	O
H	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
receptor	NN	O
antagonist	NN	O
and	CC	O
mast	NN	O
cell	NN	O
stabilizer	NN	O
,	,	O
is	VBZ	O
indicated	VBN	O
for	IN	O
itching	VBG	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
for	IN	O
reducing	VBG	O
ocular	JJ	O
itching	NN	O
associated	VBN	O
with	IN	O
AC	NNP	O
in	IN	O
subjects	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
trial	NN	O
.	.	O

Eligible	JJ	O
subjects	NNS	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-masked	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
natural	JJ	O
exposure	NN	O
clinical	JJ	O
trial	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
or	CC	O
placebo	NN	O
eyedrops	NNS	O
on	IN	O
a	DT	O
1:1	CD	O
basis	NN	O
and	CC	O
instilled	VBD	O
1	CD	O
drop	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
into	IN	O
both	DT	O
eyes	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	PH
ocular	JJ	PH
itching	NN	PH
scores	NNS	PH
at	IN	O
the	DT	O
end	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
were	VBD	O
evaluated	VBN	O
based	VBN	O
on	IN	O
subject-assessed	JJ	O
severity	NN	O
of	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
itching	NN	O
.	.	O

Subject-reported	JJ	A
adverse	JJ	A
events	NNS	A
(	(	A
AEs	NNP	A
)	)	A
were	VBD	O
also	RB	O
recorded	VBN	O
for	IN	O
safety	NN	O
.	.	O

Treatment	NN	O
with	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
significantly	RB	O
reduced	VBN	O
instantaneous	JJ	Ot
and	CC	Ot
reflective	JJ	Ot
ocular	JJ	Ot
itching	NN	Ot
scores	NNS	Ot
from	IN	O
baseline	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
over	IN	O
the	DT	O
2-week	JJ	O
study	NN	O
period	NN	O
(	(	O
p	JJ	O
=	NN	O
0.007	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.005	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

BBOS	$	O
1.5	CD	O
%	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Ot
,	,	O
and	CC	O
AEs	NNP	A
were	VBD	O
generally	RB	O
transient	JJ	O
and	CC	O
mild	JJ	O
.	.	O

This	DT	O
clinical	JJ	O
study	NN	O
indicates	VBZ	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
effectively	RB	Ot
and	CC	O
safely	RB	Ot
treated	VBD	O
ocular	JJ	PH
itching	NN	PH
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
allergy	NN	O
study	NN	O
and	CC	O
is	VBZ	O
a	DT	O
useful	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
ocular	JJ	O
itching	NN	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
identifier	VBZ	O
number	NN	O
:	:	O
NCT01174823	NNP	O
.	.	O

)	)	O
Poylmerized	VBN	O
whole	JJ	O
ragweed	NN	O
:	:	O
an	DT	O
improved	JJ	O
method	NN	O
of	IN	O
immunotherapy	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
study	NN	O
compared	VBN	O
the	DT	O
effectiveness	NN	O
of	IN	O
glutaraldehyde-treated	JJ	O
polymerized	NNS	O
ragweed	VBP	O
with	IN	O
nonpolymerized	JJ	O
monomeric	JJ	O
ragweed	NN	O
.	.	O

These	DT	O
studies	NNS	O
are	VBP	O
an	DT	O
extension	NN	O
of	IN	O
those	DT	O
previously	RB	O
reported	VBN	O
for	IN	O
polymerized	JJ	O
AgE	NNP	O
using	VBG	O
a	DT	O
readily	RB	O
available	JJ	O
ragweed	NN	O
preparation	NN	O
containing	VBG	O
all	DT	O
ragweed	NN	O
antigens	NNS	O
.	.	O

Nineteen	JJ	O
ragweed-sensitive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
;	:	O
10	CD	O
received	VBD	O
the	DT	O
polymerized	JJ	O
form	NN	O
and	CC	O
9	CD	O
received	VBD	O
the	DT	O
monomeric	JJ	O
form	NN	O
.	.	O

Four	CD	O
parameters	NNS	O
were	VBD	O
followed	VBN	O
:	:	O
serum-specific	JJ	O
IgE	NNP	O
against	IN	O
antigen	NN	O
E	NNP	O
,	,	O
total	JJ	O
blocking	VBG	O
antibody	NN	O
against	IN	O
antigen	NN	O
E	NNP	O
,	,	O
local	JJ	O
and	CC	O
systemic	JJ	O
reactions	NNS	O
to	TO	O
injection	NN	O
therapy	NN	O
,	,	O
and	CC	O
symptom	NN	O
score	NN	O
indices	NNS	O
.	.	O

Pretreatment	NNP	O
levels	NNS	O
of	IN	O
antigen	NN	O
E	NNP	O
--	:	O
specific	JJ	O
IgE	NNP	O
and	CC	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

After	IN	O
a	DT	O
total	NN	O
of	IN	O
15,000	CD	O
protein	NNS	O
nitrogen	JJ	O
units	NNS	O
(	(	O
PNU	NNP	O
)	)	O
had	VBD	O
been	VBN	O
given	VBN	O
,	,	O
blocking	VBG	PH
antibody	NN	PH
activity	NN	PH
in	IN	O
the	DT	O
monomer	NN	O
group	NN	O
rose	VBD	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
170	CD	O
ng	JJ	O
AgE	NNP	O
bound	NN	O
per	IN	O
ml	NN	O
to	TO	O
a	DT	O
mean	NN	O
of	IN	O
2,813	CD	O
.	.	O

The	DT	O
rise	NN	PH
in	IN	PH
blocking	VBG	PH
antibody	NN	PH
activity	NN	PH
in	IN	O
the	DT	O
polymer	NN	O
group	NN	O
was	VBD	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
181	CD	O
ng	JJ	O
AgE	NNP	O
bound	NN	O
per	IN	O
ml	NN	O
to	TO	O
1,574	CD	O
.	.	O

At	IN	O
15,000	CD	O
PNU	NNP	O
,	,	O
blocking	VBG	PH
antibody	NN	PH
activity	NN	PH
levels	NNS	PH
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

After	IN	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
,	,	O
no	DT	O
consistent	JJ	O
decrease	NN	O
in	IN	O
postseasonal	JJ	PH
specific	JJ	PH
IgE	NNP	PH
rise	NN	PH
could	MD	O
be	VB	O
shown	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Forty	NNP	O
times	NNS	O
less	RBR	O
erythema	JJ	PH
and	CC	O
15	CD	O
times	NNS	O
less	JJR	O
induration	NN	PH
were	VBD	O
found	VBN	O
with	IN	O
polymerized	JJ	O
ragweed	NN	O
.	.	O

There	EX	O
were	VBD	O
7	CD	O
systemic	JJ	A
reactions	NNS	A
with	IN	O
the	DT	O
monomer	NN	O
and	CC	O
none	NN	O
with	IN	O
the	DT	O
polymer	NN	O
.	.	O

Both	DT	O
groups	NNS	O
experienced	VBD	O
symptomatic	JJ	Ot
improvement	NN	Ot
with	IN	O
treatment	NN	O
.	.	O

Treatment	NN	O
with	IN	O
buspirone	NN	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
buspirone	NN	O
hydrochloride	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
autism	NN	O
and	CC	O
hyperactivity	NN	O
disorder	NN	O
and	CC	O
determines	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
buspirone	NN	O
on	IN	O
the	DT	O
number	NN	O
of	IN	O
performance	NN	O
tasks	NNS	O
completed	VBN	O
by	IN	O
the	DT	O
patient	NN	O
at	IN	O
school	NN	O
.	.	O

A	DT	O
3-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
private	JJ	O
physician	NN	O
,	,	O
office-based	JJ	O
practice	NN	O
.	.	O

A	DT	O
child	NN	O
with	IN	O
autism	NN	O
,	,	O
which	WDT	O
was	VBD	O
diagnosed	VBN	O
by	IN	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
,	,	O
Revised	VBN	O
,	,	O
criteria	NNS	O
,	,	O
was	VBD	O
studied	VBN	O
.	.	O

The	DT	O
child	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
and	CC	O
buspirone	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
;	:	O
there	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
interval	NN	O
between	IN	O
the	DT	O
2	CD	O
treatments	NNS	O
.	.	O

The	DT	O
outcome	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
using	VBG	O
Conners	NNS	Ot
abbreviated	VBD	Ot
parent	NN	Ot
and	CC	Ot
teacher	NN	Ot
questionnaires	NNS	Ot
and	CC	O
by	IN	O
determining	VBG	O
the	DT	O
number	NN	O
of	IN	O
daily	JJ	O
performance	NN	O
tasks	NNS	O
completed	VBN	O
by	IN	O
the	DT	O
child	NN	O
at	IN	O
school	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
linear	JJ	O
models	NNS	O
and	CC	O
standard	JJ	O
F	NNP	O
tests	NNS	O
.	.	O

Buspirone	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	Ot
and	CC	Ot
efficacious	JJ	Ot
,	,	O
without	IN	A
side	JJ	A
effects	NNS	A
,	,	O
for	IN	O
decreasing	VBG	O
hyperactivity	NN	ME
and	CC	O
increasing	VBG	O
completed	VBN	ME
performance	NN	ME
tasks	NNS	ME
.	.	O

The	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
buspirone	NN	O
in	IN	O
helping	VBG	O
this	DT	O
patient	NN	O
with	IN	O
autism	NN	O
in	IN	O
his	PRP$	O
natural	JJ	O
daily	JJ	O
settings	NNS	O
suggest	VBP	O
that	IN	O
buspirone	NN	O
may	MD	O
be	VB	O
an	DT	O
alternative	JJ	O
to	TO	O
neuroleptic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
medical	JJ	O
therapy	NN	O
of	IN	O
autism	NN	O
;	:	O
further	JJ	O
study	NN	O
in	IN	O
other	JJ	O
patients	NNS	O
is	VBZ	O
needed	VBN	O
.	.	O

Most	RBS	O
effective	JJ	O
regimen	NNS	O
of	IN	O
tranexamic	JJ	O
acid	NN	O
in	IN	O
knee	NN	O
arthroplasty	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
in	IN	O
240	CD	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
antifibrinolytic	JJ	O
tranexamic	JJ	O
acid	NN	O
reduces	NNS	O
surgical	JJ	O
blood	NN	O
loss	NN	O
,	,	O
but	CC	O
studies	NNS	O
have	VBP	O
not	RB	O
identified	VBN	O
an	DT	O
optimal	JJ	O
regimen	NNS	O
.	.	O

QUESTIONS/PURPOSES	NNP	O
We	PRP	O
studied	VBD	O
different	JJ	O
dosages	NNS	O
,	,	O
timings	NNS	O
,	,	O
and	CC	O
modes	NNS	O
of	IN	O
administration	NN	O
to	TO	O
identify	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
regimen	NNS	O
of	IN	O
tranexamic	JJ	O
acid	NN	O
in	IN	O
achieving	VBG	O
maximum	JJ	O
reduction	NN	O
of	IN	O
blood	NN	O
loss	NN	O
in	IN	O
TKA	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
studied	VBD	O
five	CD	O
regimens	NNS	O
(	(	O
four	CD	O
intravenous	NN	O
,	,	O
one	CD	O
local	JJ	O
;	:	O
40	CD	O
patients	NNS	O
each	DT	O
)	)	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
no	DT	O
tranexamic	JJ	O
acid	NN	O
)	)	O
.	.	O

The	DT	O
four	CD	O
intravenous	JJ	O
(	(	O
10-mg/kg	JJ	O
dose	NN	O
)	)	O
regimens	VBZ	O
included	VBN	O
(	(	O
1	CD	O
)	)	O
intraoperative	NN	O
dose	NN	O
(	(	O
IO	NNP	O
)	)	O
given	VBN	O
before	IN	O
tourniquet	JJ	O
deflation	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
additional	JJ	O
preoperative	NN	O
dose	NN	O
(	(	O
POIO	NNP	O
)	)	O
,	,	O
(	(	O
3	CD	O
)	)	O
additional	JJ	O
postoperative	NN	O
dose	NN	O
(	(	O
IOPO	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
all	DT	O
three	CD	O
doses	NNS	O
(	(	O
POIOPO	NNP	O
)	)	O
.	.	O

The	DT	O
fifth	JJ	O
regimen	NN	O
was	VBD	O
a	DT	O
single	JJ	O
local	JJ	O
application	NN	O
(	(	O
LA	NNP	O
)	)	O
.	.	O

Two	CD	O
independent	JJ	O
parameters	NNS	O
of	IN	O
drain	NN	PH
loss	NN	PH
and	CC	O
total	JJ	PH
blood	NN	PH
loss	NN	PH
,	,	O
calculated	VBN	O
by	IN	O
the	DT	O
hemoglobin	NN	O
balance	NN	O
method	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
statistically	RB	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
parameters	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
all	DT	O
five	CD	O
regimens	NNS	O
as	IN	O
against	IN	O
the	DT	O
control	NN	O
.	.	O

A	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
drain	NN	PH
loss	NN	PH
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
POIO	NNP	O
,	,	O
IOPO	NNP	O
,	,	O
and	CC	O
POIOPO	NNP	O
groups	NNS	O
whereas	VBP	O
total	JJ	O
blood	NN	PH
loss	NN	PH
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
POIO	NNP	O
,	,	O
POIOPO	NNP	O
,	,	O
and	CC	O
LA	NNP	O
groups	NNS	O
.	.	O

The	DT	O
POIOPO	NNP	O
group	NN	O
had	VBD	O
the	DT	O
least	JJS	O
drain	JJ	PH
loss	NN	PH
(	(	O
303	CD	O
mL	NN	O
)	)	O
and	CC	O
least	JJS	O
total	JJ	O
blood	NN	PH
loss	NN	PH
(	(	O
688	CD	O
mL	NN	O
)	)	O
.	.	O

The	DT	O
IO	NNP	O
group	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
drain	NN	PH
loss	NN	PH
and	CC	O
the	DT	O
IOPO	NNP	O
group	NN	O
the	DT	O
greatest	JJS	O
total	JJ	PH
blood	NN	PH
loss	NN	PH
.	.	O

CONCLUSIONS	NNP	O
Single-dose	JJ	O
tranexamic	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
give	VB	O
effective	JJ	O
results	NNS	O
.	.	O

The	DT	O
two-dose	JJ	O
regimen	NNS	O
of	IN	O
POIO	NNP	O
was	VBD	O
the	DT	O
least	JJS	O
amount	NN	O
necessary	JJ	O
for	IN	O
effective	JJ	O
results	NNS	O
.	.	O

When	WRB	O
compared	VBN	O
against	IN	O
the	DT	O
control	NN	O
,	,	O
this	DT	O
regimen	NNS	O
produced	VBD	O
reduction	NN	O
of	IN	O
drain	NN	PH
loss	NN	PH
and	CC	O
total	JJ	PH
blood	NN	PH
loss	NN	PH
,	,	O
whereas	IN	O
the	DT	O
IOPO	NNP	O
regimen	NNS	O
did	VBD	O
not	RB	O
.	.	O

The	DT	O
three-dose	JJ	O
regimen	NNS	O
of	IN	O
POIOPO	NNP	O
produced	VBD	O
maximum	JJ	O
effective	JJ	O
reduction	NN	O
of	IN	O
drain	NN	PH
loss	NN	PH
and	CC	O
total	JJ	PH
blood	NN	PH
loss	NN	PH
.	.	O

Osteoporosis	NN	O
and	CC	O
gait	NN	O
and	CC	O
balance	NN	O
disturbances	NNS	O
in	IN	O
older	JJR	O
sarcopenic	JJ	O
obese	JJ	O
New	NNP	O
Zealanders	NNP	O
.	.	O

UNLABELLED	NNP	O
Bone	NNP	O
,	,	O
muscle	NN	O
,	,	O
and	CC	O
fat	NN	O
may	MD	O
affect	VB	O
gait	NN	O
and	CC	O
balance	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
.	.	O

Osteoporosis	NN	O
was	VBD	O
prevalent	JJ	O
in	IN	O
low	JJ	O
muscle	NN	O
mass	NN	O
participants	NNS	O
and	CC	O
related	VBN	O
to	TO	O
gait	VB	O
and	CC	O
balance	VB	O
deficits	NNS	O
.	.	O

Low	JJ	O
muscle	NN	O
combined	VBN	O
with	IN	O
high	JJ	O
fat	JJ	O
mass	NN	O
had	VBD	O
more	RBR	O
functional	JJ	O
deficits	NNS	O
and	CC	O
poorer	JJR	O
bone	NN	O
health	NN	O
,	,	O
which	WDT	O
has	VBZ	O
implications	NNS	O
for	IN	O
falls	NNS	O
risk	NN	O
and	CC	O
fractures	NNS	O
.	.	O

INTRODUCTION	NNP	O
Decreasing	VBG	O
bone	NN	O
density	NN	O
and	CC	O
muscle	NN	O
mass	NN	O
and	CC	O
increasing	VBG	O
fat	JJ	O
mass	NN	O
may	MD	O
act	VB	O
synergistically	RB	O
to	TO	O
affect	VB	O
gait	NN	O
and	CC	O
balance	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
eighty-three	JJ	O
older	NN	O
adults	NNS	O
(	(	O
age	NN	O
72.7	CD	O
+/-	JJ	O
6	CD	O
years	NNS	O
,	,	O
range	VBP	O
56-93	JJ	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
28.2	CD	O
+/-	JJ	O
4.9	CD	O
,	,	O
range	VBP	O
16.6-46.0	JJ	O
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
a	DT	O
New	NNP	O
Zealand	NNP	O
falls	VBZ	O
prevention	NN	O
intervention	NN	O
trial	NN	O
.	.	O

Total	JJ	PH
and	CC	PH
appendicular	JJ	PH
skeletal	JJ	PH
muscle	NN	PH
mass	NN	PH
(	(	PH
ASM	NNP	PH
)	)	PH
,	,	O
percent	JJ	PH
fat	NN	PH
,	,	O
and	CC	O
bone	NN	PH
mineralization	NN	PH
were	VBD	O
assessed	VBN	O
by	IN	O
dual	JJ	O
energy	NN	O
X-ray	JJ	O
absorptiometry	NN	O
and	CC	O
used	VBD	O
to	TO	O
characterize	VB	O
normal	JJ	O
lean	JJ	O
(	(	O
NL	NNP	O
,	,	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
,	,	O
sarcopenic	JJ	O
(	(	O
SS	NNP	O
,	,	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
,	,	O
sarcopenic	JJ	O
obese	NN	O
(	(	O
SO	NNP	O
,	,	O
n	JJ	O
=	NNP	O
29	CD	O
)	)	O
,	,	O
and	CC	O
obese	JJ	O
(	(	O
OO	NNP	O
,	,	O
n	JJ	O
=	NNP	O
85	CD	O
)	)	O
phenotypes	NNS	O
.	.	O

Functional	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
,	,	O
chair	NN	O
stand	NN	O
,	,	O
single	JJ	O
leg	NN	O
stand	NN	O
,	,	O
and	CC	O
step	VB	O
test	NN	O
.	.	O

Regression	NN	O
models	NNS	O
were	VBD	O
adjusted	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
medications	NNS	O
,	,	O
and	CC	O
physical	JJ	O
activity	NN	O
.	.	O

RESULTS	NNP	O
Femoral	NNP	PH
neck	NN	PH
osteoporosis	NN	PH
was	VBD	O
present	JJ	O
in	IN	O
22	CD	O
%	NN	O
SS	NNP	O
,	,	O
17	CD	O
%	NN	O
SO	NNP	O
,	,	O
12	CD	O
%	NN	O
NL	NNP	O
,	,	O
and	CC	O
7	CD	O
%	NN	O
OO	NNP	O
.	.	O

Femoral	NNP	O
neck	NN	O
osteoporosis	NN	O
with	IN	O
low	JJ	O
ASM	NNP	PH
predicted	VBD	O
poor	JJ	O
chair	NN	PH
stand	VBP	PH
performance	NN	PH
(	(	O
beta	JJ	O
-3.3	NNP	O
,	,	O
standard	JJ	O
error	NN	O
1.6	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

SO	RB	O
scored	JJ	O
lowest	NN	O
on	IN	O
the	DT	O
chair	NN	O
stand	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
step	JJ	O
test	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Higher	JJR	PH
ASM	NNP	PH
predicted	VBD	O
faster	RBR	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
performance	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Osteoporosis	NNP	O
was	VBD	O
prevalent	VBN	O
in	IN	O
low	JJ	O
ASM	NNP	O
groups	NNS	O
(	(	O
SS	NNP	O
and	CC	O
SO	NNP	O
)	)	O
and	CC	O
related	VBN	O
to	TO	O
gait	VB	O
and	CC	O
balance	VB	O
deficits	NNS	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
SO	NNP	O
.	.	O

This	DT	O
has	VBZ	O
implications	NNS	O
for	IN	O
falls	NNS	O
risk	NN	O
,	,	O
fractures	NNS	O
,	,	O
and	CC	O
interventions	NNS	O
.	.	O

[	NN	O
Encephalopathy	NNP	O
therapeutic	JJ	O
tongue	NN	O
acupoint	NN	O
apparatus	NN	O
(	(	O
ETTAA	NNP	O
)	)	O
for	IN	O
42	CD	O
cases	NNS	O
of	IN	O
autism	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
encephalopathy	JJ	O
therapeutic	JJ	O
tongue	NN	O
acupoint	NN	O
apparatus	NN	O
(	(	O
ETTAA	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
Eighty-four	JJ	O
children	NNS	O
of	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
tongue	JJ	O
acupuncture	NN	O
group	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
a	DT	O
conventional	JJ	O
training	NN	O
group	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
,	,	O
42	CD	O
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
behavior	JJ	O
training	NN	O
and	CC	O
sensory	JJ	O
integration	NN	O
training	NN	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
the	DT	O
ETTAA	NNP	O
was	VBD	O
added	VBN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

The	DT	O
apparatus	NN	O
was	VBD	O
switched	VBN	O
on	IN	O
for	IN	O
20	CD	O
min	NN	O
every	DT	O
time	NN	O
and	CC	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

Treatment	NN	O
of	IN	O
two	CD	O
months	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
score	NN	ME
of	IN	ME
childhood	NN	ME
autism	NN	ME
rating	NN	ME
scale	NN	ME
(	(	ME
CARS	NNP	ME
)	)	ME
and	CC	O
clinical	JJ	Ot
efficacy	NN	Ot
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
observed	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
CARS	NNPS	ME
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
42.39	CD	O
+/-	JJ	O
6.86	CD	O
vs	JJ	O
32.15	CD	O
+/-	JJ	O
5.12	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
44.58	CD	O
+/-	JJ	O
6.76	CD	O
vs	JJ	O
39.72	CD	O
+/-	JJ	O
7.11	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
more	RBR	O
significant	JJ	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
totally	RB	Ot
effective	JJ	Ot
rate	NN	Ot
in	IN	O
group	NN	O
A	NNP	O
[	RB	O
90.5	CD	O
%	NN	O
(	(	O
38/42	CD	O
)	)	O
]	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
that	DT	O
in	IN	O
group	NN	O
B	NNP	O
[	VBZ	O
66.7	CD	O
%	NN	O
(	(	O
28/42	CD	O
)	)	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
clinical	JJ	Ot
efficacy	NN	Ot
in	IN	O
tongue	JJ	O
acupuncture	NN	O
group	NN	O
is	VBZ	O
apparently	RB	O
superior	JJ	O
to	TO	O
that	DT	O
in	IN	O
conventional	JJ	O
training	NN	O
group	NN	O
,	,	O
ETTAA	NNP	O
combined	VBD	O
with	IN	O
conventional	JJ	O
training	NN	O
have	VBP	O
a	DT	O
better	JJR	O
curative	JJ	Ot
effect	NN	Ot
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

Sialyl	NNP	O
Lewisa	NNP	O
expression	NN	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
colon	NN	O
carcinoma	NN	O
patients	NNS	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
metastatic	JJ	O
potential	NN	O
of	IN	O
tumors	NNS	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
cell	NN	O
to	TO	O
cell	VB	O
adhesion	NN	O
by	IN	O
cell	NN	O
surface	NN	O
carbohydrate	NN	O
antigens	NNS	O
.	.	O

Thus	RB	O
,	,	O
expression	NN	O
of	IN	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
important	JJ	O
molecules	NNS	O
of	IN	O
cell	NN	O
surface	NN	O
carbohydrates	NNS	O
,	,	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
prognostic	JJ	O
marker	NN	O
of	IN	O
aggressive	JJ	O
and	CC	O
metastasizing	VBG	O
tumor	NN	O
growth	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
sialyl	JJ	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
in	IN	O
colon	NN	O
cancer	NN	O
is	VBZ	O
still	RB	O
controversial	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
expression	NN	O
of	IN	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
antigen	NN	O
in	IN	O
233	CD	O
colon	NN	O
cancer	NN	O
specimens	NNS	O
from	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
registered	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
adjuvant	NN	O
immunochemotherapy	NN	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
clinical	JJ	O
course	NN	O
and	CC	O
the	DT	O
prognosis	NN	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
after	IN	O
all	PDT	O
the	DT	O
immunohistochemical	JJ	O
analyses	NNS	O
had	VBD	O
been	VBN	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Sialyl	NNP	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
levels	NNS	O
were	VBD	O
correlated	VBN	O
with	IN	O
both	DT	O
overall	JJ	MO
survival	NN	MO
(	(	O
P	NNP	O
=	NNP	O
0.0006	CD	O
)	)	O
and	CC	O
disease-free	JJ	MO
survival	NN	MO
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
.	.	O

This	DT	O
result	NN	O
could	MD	O
be	VB	O
assumed	VBN	O
to	TO	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
metastatic	JJ	O
preponderance	NN	O
in	IN	O
a	DT	O
high	JJ	O
versus	NN	O
low	JJ	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
in	IN	O
the	DT	O
tumor	NN	O
cells	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
prospective	JJ	O
study	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
suggests	VBZ	O
that	IN	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
levels	NNS	O
may	MD	O
serve	VB	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
the	DT	O
metastatic	JJ	O
potential	NN	O
of	IN	O
colon	NN	O
cancer	NN	O
cells	NNS	O
,	,	O
which	WDT	O
would	MD	O
strongly	RB	O
predict	VB	O
the	DT	O
prognosis	NN	O
.	.	O

Effects	NNS	O
of	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
on	IN	O
cutaneous	JJ	PH
vasodilation	NN	PH
in	IN	O
response	NN	O
to	TO	O
acupuncture	VB	O
stimulation	NN	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
mechanism	NN	O
of	IN	O
cutaneous	JJ	O
vasodilation	NN	O
following	VBG	O
acupuncture	NN	O
stimulation	NN	O
by	IN	O
investigating	VBG	O
the	DT	O
roles	NNS	O
of	IN	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
and	CC	O
axon	$	O
reflex	JJ	O
vasodilation	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
subjects	NNS	O
were	VBD	O
17	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
NO	NNP	O
was	VBD	O
investigated	VBN	O
by	IN	O
administering	VBG	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-nitro-l-arginine	VBP	O
methyl	JJ	O
ester	NN	O
hydrochloride	NN	O
(	(	O
L-NAME	NNP	O
,	,	O
20	CD	O
mM	NN	O
)	)	O
,	,	O
an	DT	O
NO	NNP	O
synthase	NN	O
inhibitor	NN	O
or	CC	O
Ringer	NNP	O
's	POS	O
solution	NN	O
(	(	O
control	VB	O
site	NN	O
)	)	O
,	,	O
via	IN	O
intradermal	JJ	O
microdialysis	NN	O
(	(	O
protocol	JJ	O
1	CD	O
;	:	O
n=7	NN	O
)	)	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
axon	JJ	O
reflex	JJ	O
vasodilation	NN	O
by	IN	O
local	JJ	O
sensory	NN	O
neurones	NNS	O
was	VBD	O
investigated	VBN	O
by	IN	O
comparing	VBG	O
vasodilation	NN	O
at	IN	O
sites	NNS	O
treated	VBN	O
with	IN	O
'eutectic	JJ	O
mixture	NN	O
of	IN	O
local	JJ	O
anaesthetics	NNS	O
'	POS	O
(	(	O
EMLA	NNP	O
)	)	O
cream	NN	O
(	(	O
2.5	CD	O
%	NN	O
lidocaine	NN	O
and	CC	O
2.5	CD	O
%	NN	O
prilocaine	NN	O
)	)	O
with	IN	O
untreated	JJ	O
sites	NNS	O
(	(	O
control	VB	O
site	NN	O
)	)	O
(	(	O
protocol	JJ	O
2	CD	O
;	:	O
n=10	NN	O
)	)	O
.	.	O

After	IN	O
5	CD	O
min	NN	O
of	IN	O
baseline	NN	O
recording	NN	O
,	,	O
acupuncture	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
PC4	NNP	O
and	CC	O
a	DT	O
control	NN	O
site	NN	O
in	IN	O
proximity	NN	O
to	TO	O
PC4	NNP	O
for	IN	O
10	CD	O
min	NNS	O
and	CC	O
scanning	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
60	CD	O
min	NN	O
after	IN	O
acupuncture	JJ	O
stimulation	NN	O
.	.	O

Skin	NNP	PH
blood	NN	PH
flow	NN	PH
(	(	PH
SkBF	NNP	PH
)	)	PH
was	VBD	O
evaluated	VBN	O
by	IN	O
laser	NN	O
Doppler	NNP	Ot
perfusion	NN	Ot
imaging	VBG	Ot
.	.	O

Cutaneous	JJ	PH
vascular	JJ	PH
conductance	NN	PH
(	(	PH
CVC	NNP	PH
)	)	PH
was	VBD	O
calculated	VBN	O
from	IN	O
the	DT	O
ratio	NN	O
of	IN	O
SkBF	NNP	O
to	TO	O
mean	VB	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
first	JJ	O
protocol	NN	O
,	,	O
sites	NNS	O
administered	VBD	O
L-NAME	NNP	O
showed	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
CVC	NNP	PH
responses	NNS	PH
following	VBG	O
acupuncture	NN	O
stimulation	NN	O
compared	VBN	O
to	TO	O
control	VB	O
sites	NNS	O
(	(	O
administered	VBN	O
Ringer	NNP	O
's	POS	O
solution	NN	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
protocol	NN	O
,	,	O
changes	NNS	PH
in	IN	PH
CVC	NNP	PH
responses	NNS	PH
after	IN	O
acupuncture	JJ	O
stimulation	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
treated	VBN	O
sites	NNS	O
with	IN	O
EMLA	NNP	O
cream	NN	O
and	CC	O
untreated	JJ	O
sites	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
cutaneous	JJ	O
vasodilation	NN	O
in	IN	O
response	NN	O
to	TO	O
acupuncture	VB	O
stimulation	NN	O
may	MD	O
not	RB	O
occur	VB	O
through	IN	O
an	DT	O
axon	JJ	O
reflex	NN	O
as	IN	O
previously	RB	O
reported	VBN	O
.	.	O

Rather	NNP	O
,	,	O
NO	NNP	O
mechanisms	NN	O
appear	VBP	O
to	TO	O
contribute	VB	O
to	TO	O
the	DT	O
vasodilator	NN	O
response	NN	O
.	.	O

Effects	NNS	O
of	IN	O
fenoterol	NN	O
on	IN	O
inspiratory	JJ	O
effort	NN	O
sensation	NN	O
and	CC	O
fatigue	NN	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
fenoterol	NN	O
on	IN	O
the	DT	O
relationship	NN	O
between	IN	O
inspiratory	NN	O
effort	NN	O
sensation	NN	O
(	(	O
IES	NNP	O
)	)	O
and	CC	O
inspiratory	JJ	O
muscle	NN	O
fatigue	NN	O
induced	VBN	O
by	IN	O
inspiratory	NN	O
threshold	NN	O
loading	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
threshold	NN	O
was	VBD	O
60	CD	O
%	NN	O
of	IN	O
maximal	JJ	O
static	JJ	O
inspiratory	NN	O
mouth	NN	O
pressure	NN	O
(	(	O
PI	NNP	O
,	,	O
mmax	NN	O
)	)	O
at	IN	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
,	,	O
and	CC	O
the	DT	O
duty	NN	O
cycle	NN	O
was	VBD	O
0.5	CD	O
.	.	O

Subjects	NNS	O
continued	VBD	O
the	DT	O
threshold	NN	O
loaded	VBD	O
breathing	NN	O
until	IN	O
the	DT	O
target	NN	O
mouth	NN	O
pressure	NN	O
could	MD	O
no	RB	O
longer	RB	O
be	VB	O
maintained	VBN	O
(	(	O
endurance	JJ	O
time	NN	O
)	)	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
was	VBD	O
scored	VBN	O
with	IN	O
a	DT	O
modified	JJ	O
Borg	NNP	O
scale	NN	O
.	.	O

Either	CC	O
fenoterol	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
was	VBD	O
given	VBN	O
orally	RB	O
2	CD	O
h	NN	O
before	IN	O
loading	VBG	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
protocol	NN	O
.	.	O

The	DT	O
endurance	NN	PH
time	NN	PH
with	IN	O
fenoterol	NN	O
(	(	O
34.4	CD	O
+/-	JJ	O
8.6	CD	O
min	NN	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
22.2	CD	O
+/-	JJ	O
7.1	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	PH
of	IN	PH
high-	JJ	PH
to	TO	PH
low-frequency	JJ	PH
power	NN	PH
of	IN	PH
the	DT	PH
diaphragmatic	JJ	PH
electromyogram	NN	PH
(	(	PH
EMGdi	NNP	PH
)	)	PH
decreased	VBD	O
during	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
less	RBR	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
EMGdi	NNP	PH
also	RB	O
decreased	VBD	O
with	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
greater	JJR	O
on	IN	O
fenoterol	NN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
PI	NNP	PH
,	,	PH
mmax	NN	PH
and	CC	PH
maximal	JJ	PH
transdiaphragmatic	JJ	PH
pressure	NN	PH
(	(	PH
Pdi	NNP	PH
)	)	PH
were	VBD	O
similarly	RB	O
decreased	VBN	O
after	IN	O
loading	VBG	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
intensity	NN	PH
of	IN	PH
the	DT	PH
IES	NNP	PH
rose	VBD	PH
with	IN	PH
time	NN	PH
during	IN	O
loading	VBG	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
lower	JJR	O
with	IN	O
fenoterol	NN	O
than	IN	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	PH
of	IN	PH
Pdi	NNP	PH
to	TO	O
integrated	JJ	O
activity	NN	O
of	IN	O
the	DT	O
EMGdi	NNP	O
increased	VBD	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Fenoterol	NNP	O
treatment	NN	O
increased	VBD	O
both	DT	O
superimposed	VBN	PH
Pdi	NNP	PH
twitch	NN	PH
and	CC	PH
Pdi	NNP	PH
twitch	NN	PH
of	IN	PH
relaxed	JJ	PH
diaphragm	NN	PH
and	CC	O
decreased	VBD	O
the	DT	O
value	NN	PH
of	IN	PH
(	(	PH
1-superimposed	JJ	PH
Pdi	NNP	PH
twitch/Pdi	NN	PH
twitch	NN	PH
of	IN	PH
relaxed	JJ	PH
diaphragm	NN	PH
)	)	PH
.	.	PH

Thus	IN	O
we	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
fenoterol	JJ	O
reduces	NNS	O
diaphragmatic	JJ	O
fatigue	NN	O
and	CC	O
decreases	VBZ	O
the	DT	O
motor	NN	O
command	NN	O
to	TO	O
the	DT	O
diaphragm	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
IES	NNP	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
endurance	NN	O
.	.	O

A	DT	O
search	NN	O
for	IN	O
serologic	JJ	O
correlates	NNS	O
of	IN	O
immunity	NN	O
to	TO	O
Bordetella	NNP	O
pertussis	NN	O
cough	NN	O
illnesses	NNS	O
.	.	O

In	IN	O
a	DT	O
pertussis	NN	O
vaccine	NN	O
efficacy	NN	O
trial	NN	O
in	IN	O
Germany	NNP	O
we	PRP	O
collected	VBD	O
sera	NN	O
from	IN	O
vaccinees	NNS	O
(	(	O
DTaP	NNP	O
or	CC	O
DTP	NNP	O
)	)	O
after	IN	O
the	DT	O
third	JJ	O
and	CC	O
fourth	JJ	O
doses	NNS	O
of	IN	O
vaccine	NN	O
or	CC	O
at	IN	O
comparable	JJ	O
time	NN	O
periods	NNS	O
in	IN	O
DT	NNP	O
vaccine	NN	O
recipients	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
sera	NN	O
were	VBD	O
collected	VBN	O
from	IN	O
a	DT	O
randomized	JJ	O
sample	NN	O
of	IN	O
subjects	NNS	O
in	IN	O
each	DT	O
vaccine	NN	O
group	NN	O
at	IN	O
approximately	RB	O
3-month	JJ	O
intervals	NNS	O
from	IN	O
which	WDT	O
antibody	NN	O
kinetic	JJ	O
curves	NNS	O
were	VBD	O
constructed	VBN	O
,	,	O
which	WDT	O
allowed	VBD	O
us	PRP	O
to	TO	O
estimate	VB	O
specific	JJ	O
antibody	NN	O
values	NNS	O
to	TO	O
pertussis	VB	O
toxin	NN	O
(	(	O
PT	NNP	O
)	)	O
,	,	O
filamentous	JJ	O
hemagglutinin	NN	O
(	(	O
FHA	NNP	O
)	)	O
,	,	O
pertactin	JJ	O
and	CC	O
fimbriae-2	JJ	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
exposure	NN	O
in	IN	O
the	DT	O
household	NN	O
setting	NN	O
.	.	O

The	DT	O
imputed	JJ	O
geometric	JJ	O
mean	NN	O
antibody	NN	O
values	NNS	O
to	TO	O
PT	NNP	O
,	,	O
pertactin	NN	O
and	CC	O
fimbriae-2	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
household	NN	O
exposure	NN	O
to	TO	O
Bordetella	NNP	O
pertussis	NN	O
infection	NN	O
were	VBD	O
higher	JJR	O
(	(	O
p	JJ	O
<	VBP	O
0.07	CD	O
or	CC	O
lower	JJR	O
)	)	O
in	IN	O
non-cases	NNS	O
compared	VBN	O
with	IN	O
cases	NNS	O
.	.	O

A	DT	O
multivariate	NN	O
(	(	O
classification	NN	O
tree	NN	O
)	)	O
analysis	NN	O
found	VBD	O
that	IN	O
only	RB	O
pertactin	NN	O
and	CC	O
PT	NNP	O
were	VBD	O
significant	JJ	O
in	IN	O
protection	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
an	DT	O
imputed	JJ	O
pertactin	NN	O
value	NN	O
of	IN	O
<	$	O
7	CD	O
EU	NNP	O
ml-1	NN	O
had	VBD	O
a	DT	O
67	CD	O
%	NN	O
(	(	O
18/27	CD	O
)	)	O
chance	NN	O
of	IN	O
infection	NN	O
regardless	NN	O
of	IN	O
the	DT	O
PT	NNP	O
value	NN	O
.	.	O

If	IN	O
the	DT	O
pertactin	NN	O
value	NN	O
was	VBD	O
>	JJ	O
or	CC	O
=	JJ	O
7	CD	O
EU	NNP	O
ml-1	NN	O
and	CC	O
the	DT	O
PT	NNP	O
value	NN	O
>	NN	O
or	CC	O
=	$	O
66	CD	O
EU	NNP	O
ml-1	CD	O
all	DT	O
subjects	NNS	O
were	VBD	O
non-cases	NNS	O
.	.	O

If	IN	O
the	DT	O
pertactin	NN	O
value	NN	O
was	VBD	O
>	JJ	O
or	CC	O
=	JJ	O
7	CD	O
and	CC	O
the	DT	O
PT	NNP	O
value	NN	O
was	VBD	O
<	JJ	O
66	CD	O
EU	NNP	O
ml-1	CD	O
the	DT	O
predicted	JJ	O
probability	NN	O
of	IN	O
being	VBG	O
a	DT	O
case	NN	O
was	VBD	O
31	CD	O
%	NN	O
(	(	O
15/49	CD	O
)	)	O
.	.	O

Logistic	JJ	Ot
regression	NN	Ot
analysis	NN	Ot
also	RB	O
found	VBD	O
that	IN	O
high	JJ	O
versus	NN	O
low	JJ	O
pertactin	NN	O
values	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
illness	JJ	O
prevention	NN	O
following	VBG	O
household	NN	O
exposure	NN	O
.	.	O

In	IN	O
the	DT	O
presence	NN	O
of	IN	O
antibody	NN	O
to	TO	O
pertactin	VB	O
,	,	O
PT	NNP	O
and	CC	O
fimbriae-2	JJ	O
,	,	O
the	DT	O
additional	JJ	O
presence	NN	O
of	IN	O
antibody	NN	O
to	TO	O
FHA	NNP	O
did	VBD	O
not	RB	O
contribute	VB	O
to	TO	O
protection	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
support	NN	O
historical	JJ	O
data	NNS	O
indicating	VBG	O
that	IN	O
agglutinating	VBG	O
antibodies	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
protection	NN	O
and	CC	O
also	RB	O
recent	JJ	O
serologic	JJ	O
correlates	NNS	O
data	NNS	O
and	CC	O
clinical	JJ	O
efficacy	NN	O
data	NNS	O
which	WDT	O
indicate	VBP	O
that	IN	O
multicomponent	NN	O
vaccines	NNS	O
containing	VBG	O
pertactin	NN	O
and	CC	O
fimbriae	NN	O
have	VBP	O
better	JJR	O
efficacy	NN	O
than	IN	O
PT	NNP	O
or	CC	O
PT/FHA	NNP	O
vaccines	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
intranasal	NN	O
beclomethasone	NN	O
dipropionate	NN	O
after	IN	O
polypectomy	NN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
intranasal	NN	O
beclomethasone	NN	O
dipropionate	NN	O
(	(	O
Bdp	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
earlier	RBR	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
investigate	VB	O
whether	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
Bdp	NNP	O
after	IN	O
polypectomy	NN	O
could	MD	O
prevent	VB	O
formation	NN	O
of	IN	O
new	JJ	O
polyps	NNS	O
and	CC	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
surgical	JJ	O
removals	NNS	O
.	.	O

Forty	NNP	O
consecutive	JJ	O
patients	NNS	O
without	IN	O
laboratory	NN	O
or	CC	O
other	JJ	O
clinical	JJ	O
signs	NNS	O
of	IN	O
allergy	NN	O
but	CC	O
with	IN	O
severe	JJ	O
nasal	JJ	O
polyposis	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Twenty	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
intranasal	JJ	O
Bdp	NNP	O
and	CC	O
twenty	JJ	O
patients	NNS	O
received	VBD	O
no	DT	O
treatment	NN	O
after	IN	O
polypectomy	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
at	IN	O
least	JJS	O
2.5	CD	O
years	NNS	O
.	.	O

The	DT	O
size	NN	PH
of	IN	PH
the	DT	PH
polyps	NNS	PH
that	WDT	PH
recurred	VBD	PH
was	VBD	O
estimated	VBN	O
at	IN	O
different	JJ	O
time-intervals	NNS	O
by	IN	O
the	DT	O
examining	VBG	O
doctor	NN	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
there	RB	O
was	VBD	O
already	RB	O
a	DT	O
significant	JJ	O
difference	NN	Ot
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
intranasal	JJ	O
Bdp	NNP	O
.	.	O

Further	NNP	O
results	NNS	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
the	DT	O
clinical	JJ	O
implications	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Intervention	NN	O
for	IN	O
ineffective	JJ	PH
airway	JJ	PH
clearance	NN	PH
in	IN	O
asthmatic	JJ	O
children	NNS	O
:	:	O
a	DT	O
controlled	VBN	O
and	CC	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
intervention	NN	O
for	IN	O
the	DT	O
nursing	NN	O
diagnosis	NN	O
of	IN	O
ineffective	JJ	PH
airway	JJ	PH
clearance	NN	PH
in	IN	O
asthmatic	JJ	O
children	NNS	O
.	.	O

A	DT	O
blinded	JJ	O
,	,	O
randomized	VBN	O
and	CC	O
controlled	VBN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
developed	VBN	O
in	IN	O
a	DT	O
paediatric	JJ	O
hospital	NN	O
located	VBN	O
on	IN	O
northeast	NN	O
of	IN	O
Brazil	NNP	O
with	IN	O
42	CD	O
asthmatic	JJ	O
children	NNS	O
aged	VBN	O
?	.	O
36	CD	O
months	NNS	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
intervention	NN	O
and	CC	O
control	NN	O
)	)	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
simple	JJ	O
drawing	NN	O
.	.	O

The	DT	O
applied	JJ	O
intervention	NN	O
included	VBD	O
actions	NNS	O
related	VBN	O
to	TO	O
change	VB	O
of	IN	O
positioning	NN	O
and	CC	O
stimulation	NN	O
of	IN	O
cough	NN	O
.	.	O

The	DT	O
main	JJ	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	VBP	O
that	IN	O
before	IN	O
the	DT	O
intervention	NN	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
health	NN	O
status	NN	O
of	IN	O
the	DT	O
children	NNS	O
.	.	O

After	IN	O
the	DT	O
intervention	NN	O
,	,	O
the	DT	O
indicators	NNS	O
of	IN	O
choking	VBG	O
(	(	O
16.83	CD	O
vs.	FW	O
26.17	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
and	CC	O
adventitious	JJ	O
breath	NN	O
sounds	NNS	O
(	(	O
16.4	CD	O
vs.	FW	O
26.6	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
were	VBD	O
higher	JJR	O
,	,	O
on	IN	O
average	NN	O
,	,	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

It	PRP	O
was	VBD	O
observed	VBN	O
an	DT	O
improvement	NN	O
in	IN	O
obstructive	JJ	O
symptoms	NNS	O
in	IN	O
children	NNS	O
who	WP	O
received	VBD	O
the	DT	O
intervention	NN	O
proposed	VBN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
plus	CC	O
amantadine	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
10-week	JJ	O
randomized	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
amantadine	NN	O
to	TO	O
risperidone	VB	O
for	IN	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
outpatients	NNS	O
aged	VBD	O
4	CD	O
to12	NN	O
years	NNS	O
,	,	O
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
based	VBN	O
on	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
Text	NNP	O
Revision	NNP	O
criteria	NNS	O
,	,	O
were	VBD	O
assigned	VBN	O
to	TO	O
this	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
risperidone	JJ	O
plus	CC	O
amantadine	JJ	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
received	VBD	O
risperidone	JJ	O
plus	CC	O
placebo	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
between	IN	O
1	CD	O
and	CC	O
2.0	CD	O
mg/d	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
amantadine	NN	O
was	VBD	O
100	CD	O
or	CC	O
150	CD	O
mg/d	NNS	O
for	IN	O
patients	NNS	O
less	JJR	O
than	IN	O
30	CD	O
kg	NN	O
or	CC	O
more	JJR	O
than	IN	O
30	CD	O
kg	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Aberrant	NNP	ME
Behavioral	NNP	ME
Checklist-Community	NNP	ME
(	(	ME
ABC-C	NNP	ME
)	)	ME
and	CC	ME
adverse	JJ	A
effects	NNS	A
checklist	NN	A
as	RB	O
well	RB	O
as	IN	O
clinical	JJ	ME
global	JJ	ME
impression-improvement	NN	ME
(	(	ME
CGI-I	NNP	ME
)	)	ME
at2	VBZ	O
checkpoints	NNS	O
of	IN	O
5-week	JJ	O
intervals	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
.	.	O

Informed	NNP	O
consentwas	NN	O
obtained	VBN	O
from	IN	O
the	DT	O
parents	NNS	O
of	IN	O
each	DT	O
participant	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
ABC-C	NNP	ME
subscales	NNS	ME
,	,	ME
Hyperactivity	NNP	ME
and	CC	ME
Irritability	NNP	ME
showed	VBD	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
adverse	JJ	A
effects	NNS	A
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
CGI-I	JJ	ME
scores	NNS	ME
show	VBP	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
amantadine	NN	O
may	MD	O
be	VB	O
a	DT	O
potential	JJ	O
adjunctive	JJ	O
treatment	NN	O
strategy	NN	O
for	IN	O
autism	NN	O
and	CC	O
it	PRP	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

[	JJ	O
Efficacy	NNP	Ot
and	CC	O
immune	JJ	PH
memory	NN	PH
of	IN	O
plasma-derived	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
11	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	Ot
efficacy	NN	Ot
of	IN	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
10	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
to	TO	O
provide	VB	O
scientific	JJ	O
basis	NN	O
for	IN	O
the	DT	O
time	NN	O
of	IN	O
revaccination	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
strictly	RB	O
designed	VBN	O
with	IN	O
randomization	NN	O
,	,	O
double-blinding	NN	O
,	,	O
and	CC	O
placebo-controlled	JJ	O
method	NN	O
to	TO	O
observe	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	O
immune	JJ	PH
memory	NN	PH
11	CD	O
years	NNS	O
following	VBG	O
hepatitis	NN	O
B	NNP	O
vaccination	NN	O
.	.	O

RESULTS	NNP	O
Immunogenicity	NNP	PH
and	CC	PH
protective	JJ	PH
rate	NN	PH
of	IN	PH
vaccine	NN	PH
were	VBD	O
still	RB	O
kept	VBN	O
well	RB	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
with	IN	O
a	DT	O
protective	JJ	PH
rate	NN	PH
against	IN	O
HBV	NNP	O
infection	NN	O
of	IN	O
73.5	CD	O
%	NN	O
.	.	O

But	CC	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
HBV	NNP	PH
infection	NN	PH
rates	NNS	PH
between	IN	O
vaccine	NN	O
group	NN	O
and	CC	O
placebo-controlled	JJ	O
group	NN	O
(	(	O
7.89	CD	O
%	NN	O
vs.	FW	O
13.25	CD	O
%	NN	O
,	,	O
P	NNP	O
>	NNP	O
0.1	CD	O
)	)	O
nine	CD	O
to	TO	O
11	CD	O
years	NNS	O
following	VBG	O
immunization	NN	O
.	.	O

There	EX	O
still	RB	O
existed	VBD	O
immune	JJ	PH
memory	NN	PH
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
significantly	RB	O
weaker	JJR	O
than	IN	O
that	DT	O
within	IN	O
the	DT	O
first	JJ	O
10	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
efficacy	NN	Ot
of	IN	O
the	DT	O
vaccine	NN	O
had	VBD	O
begun	VBN	O
to	TO	O
drop	VB	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
,	,	O
which	WDT	O
should	MD	O
be	VB	O
followed	VBN	O
up	RP	O
further	RBR	O
to	TO	O
reach	VB	O
a	DT	O
clear	JJ	O
conclusion	NN	O
.	.	O

Body	NN	O
size	NN	O
indexes	NNS	O
for	IN	O
optimizing	VBG	O
iodine	NN	O
dose	NN	O
for	IN	O
aortic	JJ	O
and	CC	O
hepatic	JJ	O
enhancement	NN	O
at	IN	O
multidetector	NN	O
CT	NNP	O
:	:	O
comparison	NN	O
of	IN	O
total	JJ	O
body	NN	O
weight	NN	O
,	,	O
lean	JJ	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
blood	NN	O
volume	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
total	JJ	PH
body	NN	PH
weight	NN	PH
(	(	PH
TBW	NNP	PH
)	)	PH
,	,	O
lean	JJ	PH
body	NN	PH
weight	NN	PH
(	(	PH
LBW	NNP	PH
)	)	PH
,	,	O
and	CC	O
estimated	VBD	PH
blood	NN	PH
volume	NN	PH
(	(	PH
BV	NNP	PH
)	)	PH
for	IN	O
the	DT	O
adjustment	NN	O
of	IN	O
the	DT	O
iodine	NN	O
dose	NN	O
required	VBN	O
for	IN	O
contrast	NN	O
material-enhanced	JJ	O
multidetector	NN	O
computed	VBD	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
of	IN	O
the	DT	O
aorta	NN	O
and	CC	O
liver	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Institutional	NNP	O
review	NN	O
committee	NN	O
approval	NN	O
and	CC	O
written	VBN	O
informed	JJ	O
consent	NN	O
were	VBD	O
obtained	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
twenty	NN	O
patients	NNS	O
(	(	O
54	CD	O
men	NNS	O
,	,	O
66	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
64.1	CD	O
years	NNS	O
;	:	O
range	NN	O
,	,	O
19-88	CD	O
years	NNS	O
)	)	O
who	WP	O
underwent	JJ	O
multidetector	NN	O
CT	NNP	O
of	IN	O
the	DT	O
upper	JJ	O
abdomen	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
of	IN	O
40	CD	O
patients	NNS	O
each	DT	O
:	:	O
(	(	O
a	DT	O
)	)	O
TBW	NNP	O
group	NN	O
(	(	O
0.6	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
TBW	NNP	O
)	)	O
,	,	O
(	(	O
b	NN	O
)	)	O
LBW	NNP	O
group	NN	O
(	(	O
0.821	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
LBW	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
BV	NNP	O
group	NN	O
(	(	O
men	NNS	O
,	,	O
8.6	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
liter	NN	O
of	IN	O
BV	NNP	O
;	:	O
women	NNS	O
,	,	O
9.9	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
liter	NN	O
of	IN	O
BV	NNP	O
)	)	O
.	.	O

Change	NN	O
in	IN	O
CT	NNP	O
number	NN	O
between	IN	O
unenhanced	JJ	O
and	CC	O
contrast-enhanced	JJ	O
images	NNS	O
per	IN	O
gram	NN	O
of	IN	O
iodine	NN	O
and	CC	O
maximum	JJ	O
hepatic	JJ	O
enhancement	NN	O
(	(	O
MHE	NNP	O
)	)	O
adjusted	VBD	O
for	IN	O
iodine	NN	O
dose	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
correlation	NN	O
with	IN	O
TBW	NNP	O
,	,	O
LBW	NNP	O
,	,	O
and	CC	O
BV	NNP	O
by	IN	O
using	VBG	O
linear	JJ	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
portal	JJ	O
venous	JJ	O
phase	NN	O
,	,	O
correlation	NN	PH
coefficients	NNS	PH
for	IN	O
the	DT	O
correlation	NN	PH
of	IN	PH
change	NN	PH
in	IN	PH
CT	NNP	PH
number	NN	PH
per	IN	PH
gram	NN	PH
of	IN	O
iodine	NN	O
with	IN	O
TBW	NNP	PH
for	IN	O
the	DT	O
aorta	NN	O
and	CC	O
liver	NN	O
were	VBD	O
-0.71	NNP	O
and	CC	O
-0.79	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
TBW	NNP	O
group	NN	O
;	:	O
-0.80	CC	O
and	CC	O
-0.86	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
;	:	O
and	CC	O
-0.68	VB	O
and	CC	O
-0.66	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
BV	NNP	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
liver	NN	O
,	,	O
they	PRP	O
were	VBD	O
marginally	RB	O
higher	JJR	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BV	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

Adjusted	VBN	PH
MHE	NNP	PH
remained	VBD	O
constant	JJ	O
at	IN	O
77.9	CD	O
HU	NNP	O
+/-	JJ	O
10.2	CD	O
(	(	O
standard	JJ	O
deviation	NN	O
)	)	O
in	IN	O
the	DT	O
LBW	NNP	PH
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
TBW	NNP	PH
,	,	O
but	CC	O
it	PRP	O
increased	VBD	O
in	IN	O
the	DT	O
TBW	NNP	PH
(	(	O
r	VB	O
=	RB	O
0.80	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
BV	NNP	PH
(	(	O
r	VB	O
=	RB	O
0.70	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
groups	NNS	O
as	IN	O
TBW	NNP	PH
increased	VBD	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
LBW	NNP	PH
,	,	O
rather	RB	O
than	IN	O
TBW	NNP	PH
or	CC	O
BV	NNP	PH
,	,	O
is	VBZ	O
used	VBN	O
,	,	O
the	DT	O
iodine	NN	O
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
consistent	JJ	O
hepatic	JJ	O
enhancement	NN	O
may	MD	O
be	VB	O
estimated	VBN	O
more	RBR	O
precisely	RB	O
and	CC	O
with	IN	O
reduced	JJ	O
patient-to-patient	JJ	O
variability	NN	O
.	.	O

[	JJ	O
Supplementary	NNP	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
of	IN	O
female	JJ	O
patients	NNS	O
undergoing	VBG	O
curative	JJ	O
adjuvant	JJ	O
irradiation	NN	O
following	VBG	O
breast	NN	O
cancer	NN	O
]	NNP	O
.	.	O

1	CD	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
supposed	VBN	O
to	TO	O
investigate	VB	O
a	DT	O
possible	JJ	O
prevention	NN	PH
or	CC	PH
reduction	NN	PH
of	IN	PH
the	DT	PH
toxicity	NN	PH
of	IN	O
radiotherapy	NN	O
by	IN	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
.	.	O

This	DT	O
question	NN	O
arose	VBD	O
when	WRB	O
performing	VBG	O
an	DT	O
investigation	NN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
in	IN	O
a	DT	O
combined	JJ	O
chemo-radiotherapy	NN	O
.	.	O

Whereas	IN	O
the	DT	O
latter	JJ	O
induces	NNS	O
above	IN	O
all	PDT	O
a	DT	O
systemic	JJ	O
damage	NN	O
to	TO	O
the	DT	O
hemopoietic	JJ	O
system	NN	O
,	,	O
radiotherapy	NN	O
is	VBZ	O
a	DT	O
regional	JJ	O
noxa	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
present	JJ	O
prospective	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
50	CD	O
patients	NNS	O
submitted	VBN	O
to	TO	O
curative	VB	O
adjuvant	JJ	O
irradiation	NN	O
following	VBG	O
surgery	NN	O
for	IN	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

The	DT	O
radiotherapy	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
way	NN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
irradiations	NNS	O
of	IN	O
the	DT	O
thoracic	NN	O
wall	NN	O
and	CC	O
the	DT	O
regional	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
were	VBD	O
built	VBN	O
by	IN	O
randomization	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
received	VBD	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
receive	VB	O
an	DT	O
additional	JJ	O
treatment	NN	O
.	.	O

3	CD	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
no	DT	O
protective	JJ	O
influence	NN	O
of	IN	O
Esberitox	NNP	O
could	MD	O
be	VB	O
demonstrated	VBN	O
.	.	O

The	DT	O
parameters	NNS	O
investigated	VBN	O
were	VBD	O
the	DT	O
peripheral	JJ	PH
blood	NN	PH
count	NN	PH
(	(	PH
leucocytes	NNS	PH
,	,	PH
granulocytes	NNS	PH
,	,	PH
lymphocytes	NNS	PH
,	,	PH
monocytes	NNS	PH
,	,	PH
thrombocytes	NNS	PH
,	,	PH
hemoglobin	NN	PH
,	,	PH
hematocrit	NN	PH
)	)	PH
and	CC	PH
the	DT	PH
incidence	NN	PH
of	IN	PH
infections	NNS	PH
.	.	O

4	CD	O
.	.	O

This	DT	O
result	NN	O
diverging	VBG	O
from	IN	O
literature	NN	O
is	VBZ	O
discussed	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
probably	RB	O
affected	VBN	O
by	IN	O
volume	NN	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
injury	NN	O
induced	VBN	O
by	IN	O
a	DT	O
hematotoxic	NN	O
noxa	NN	O
and	CC	O
furthermore	NN	O
by	IN	O
the	DT	O
ability	NN	O
of	IN	O
regeneration	NN	O
.	.	O

If	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
exhausted	VBN	O
,	,	O
the	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
can	MD	O
act	VB	O
no	DT	O
longer	JJR	O
.	.	O

Therefore	VB	O
the	DT	O
essential	JJ	O
factor	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
duration	NN	O
of	IN	O
exposure	NN	O
to	TO	O
the	DT	O
noxa	NN	O
.	.	O

Esberitox	NNP	O
was	VBD	O
effective	JJ	O
in	IN	O
case	NN	O
of	IN	O
a	DT	O
short	JJ	O
toxicity	NN	O
,	,	O
it	PRP	O
was	VBD	O
ineffective	JJ	O
in	IN	O
case	NN	O
of	IN	O
prolonged	JJ	O
toxicity	NN	O
,	,	O
if	IN	O
the	DT	O
treatment	NN	O
continuity	NN	O
(	(	O
noxa	JJ	O
)	)	O
was	VBD	O
not	RB	O
broken	VBN	O
up	RP	O
by	IN	O
some	DT	O
regeneration	NN	O
intervals	NNS	O
.	.	O

The	DT	O
radiotherapy	NN	O
studied	VBN	O
in	IN	O
this	DT	O
trial	NN	O
had	VBD	O
a	DT	O
duration	NN	O
of	IN	O
50	CD	O
days	NNS	O
,	,	O
and	CC	O
its	PRP$	O
effect	NN	O
was	VBD	O
that	IN	O
of	IN	O
a	DT	O
longterm	JJ	O
injury	NN	O
.	.	O

Visit-to-visit	NNP	O
blood	NN	PH
pressure	NN	PH
variability	NN	PH
in	IN	O
the	DT	O
European	NNP	O
Lacidipine	NNP	O
Study	NNP	O
on	IN	O
Atherosclerosis	NNP	O
:	:	O
methodological	JJ	O
aspects	NNS	O
and	CC	O
effects	NNS	O
of	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

BACKGROUND	NNP	O
Recent	NNP	O
studies	NNS	O
have	VBP	O
reported	VBN	O
that	IN	O
in	IN	O
patients	NNS	O
under	IN	O
antihypertensive	JJ	O
treatment	NN	O
visit-to-visit	NN	O
(	(	O
or	CC	O
long-term	JJ	O
)	)	O
variability	NN	PH
of	IN	PH
clinic	JJ	PH
BP	NNP	PH
within	IN	O
a	DT	O
given	VBN	O
patient	NN	O
has	VBZ	O
an	DT	O
independent	JJ	O
prognostic	JJ	O
significance	NN	O
.	.	O

Partly	RB	O
based	VBN	O
on	IN	O
between-patient	JJ	O
dispersion	NN	O
of	IN	O
BP	NNP	O
values	NNS	O
during	IN	O
treatment	NN	O
(	(	O
interindividual	JJ	O
variability	NN	O
)	)	O
it	PRP	O
has	VBZ	O
also	RB	O
been	VBN	O
reported	VBN	O
that	IN	O
long-term	JJ	PH
clinic	JJ	PH
BP	NNP	PH
variability	NN	PH
is	VBZ	O
greater	JJR	O
for	IN	O
?-blocker	JJR	O
than	IN	O
for	IN	O
calcium	NN	O
antagonist	NN	O
and	CC	O
other	JJ	O
types	NNS	O
of	IN	O
treatment	NN	O
.	.	O

GOALS	NNP	O
To	TO	O
measure	VB	O
visit-to-visit	JJ	O
intraindividual	JJ	O
variations	NNS	O
of	IN	O
both	DT	O
clinic	JJ	O
and	CC	O
24-h	JJ	O
mean	NN	O
BP	NNP	O
in	IN	O
the	DT	O
hypertensive	JJ	O
patients	NNS	O
of	IN	O
the	DT	O
European	NNP	O
Lacidipine	NNP	O
Study	NNP	O
on	IN	O
Atherosclerosis	NNP	O
(	(	O
ELSA	NNP	O
)	)	O
trial	NN	O
treated	VBD	O
for	IN	O
4	CD	O
years	NNS	O
with	IN	O
either	DT	O
atenolol	NN	O
or	CC	O
lacidipine	NN	O
,	,	O
and	CC	O
to	TO	O
check	VB	O
whether	IN	O
interindividual	JJ	O
clinic	NN	O
and	CC	O
24-h	JJ	O
BP	NNP	O
variabilities	NNS	O
during	IN	O
treatment	NN	O
can	MD	O
really	RB	O
be	VB	O
considered	VBN	O
a	DT	O
surrogate	NN	O
of	IN	O
intraindividual	JJ	O
variabilities	NNS	O
in	IN	O
exploring	VBG	O
differences	NNS	O
between	IN	O
?-blocker	NN	O
and	CC	O
calcium	NN	O
antagonist	NN	O
treatments	NNS	O
.	.	O

METHODS	NNP	O
Long-term	JJ	O
intraindividual	JJ	O
BP	NNP	O
variability	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
coefficient	NN	O
of	IN	O
variation	NN	O
of	IN	O
the	DT	O
average	JJ	O
systolic	JJ	O
or	CC	O
diastolic	JJ	O
values	NNS	O
of	IN	O
clinic	JJ	O
and	CC	O
24-h	JJ	O
BP	NNP	O
measured	VBD	O
at	IN	O
each	DT	O
visit	NN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

Patients	NNS	O
in	IN	O
whom	WP	O
at	IN	O
least	JJS	O
seven	CD	O
clinic	JJ	O
(	(	O
6-month	JJ	O
intervals	NNS	O
)	)	O
or	CC	O
at	IN	O
least	JJS	O
three	CD	O
(	(	O
yearly	JJ	O
intervals	NNS	O
)	)	O
24-h	JJ	O
values	NNS	O
were	VBD	O
available	JJ	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
drug	NN	O
titration	NN	O
phase	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
were	VBD	O
considered	VBN	O
.	.	O

RESULTS	JJ	O
Visit-to-visit	JJ	O
24-h	JJ	O
SBP/DBP	NNP	O
variabilities	NNS	O
were	VBD	O
20-25	CD	O
%	NN	O
smaller	JJR	O
than	IN	O
,	,	O
and	CC	O
loosely	RB	O
correlated	VBN	O
with	IN	O
clinic	JJ	O
BP	NNP	O
variability	NN	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
<	FW	O
0.022	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
very	RB	O
limited	JJ	O
relationship	NN	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
<	FW	O
0.026	CD	O
)	)	O
between	IN	O
visit-to-visit	NN	O
and	CC	O
within	IN	O
24-h	JJ	O
ambulatory	NN	O
BP	NNP	O
variabilities	NNS	O
,	,	O
the	DT	O
latter	JJ	O
being	VBG	O
two	CD	O
to	TO	O
three	CD	O
times	NNS	O
greater	JJR	O
than	IN	O
the	DT	O
former	JJ	O
.	.	O

Visit-to-visit	JJ	O
intraindividual	JJ	O
clinic	NN	O
SBP	NNP	O
variability	NN	O
was	VBD	O
only	RB	O
slightly	RB	O
lower	JJR	O
on	IN	O
calcium	NN	O
antagonist	NN	O
than	IN	O
on	IN	O
?-blocker	JJ	O
treatment	NN	O
but	CC	O
little	JJ	O
or	CC	O
no	DT	O
between-treatment	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
for	IN	O
visit-to-visit	NN	O
clinic	NN	O
DBP	NNP	O
and	CC	O
ambulatory	JJ	O
SBP/DBP	NNP	O
particularly	RB	O
in	IN	O
patients	NNS	O
under	IN	O
monotherapy	NN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Interindividual	NNP	O
BP	NNP	O
variability	NN	O
was	VBD	O
markedly	RB	O
greater	JJR	O
than	IN	O
the	DT	O
intra-individiual	JJ	O
one	CD	O
of	IN	O
which	WDT	O
it	PRP	O
did	VBD	O
not	RB	O
precisely	RB	O
reflect	VB	O
the	DT	O
treatment-induced	JJ	O
changes	NNS	O
.	.	O

CONCLUSION	NN	O
In	IN	O
mild-to-moderate	JJ	O
hypertensive	JJ	O
patients	NNS	O
,	,	O
visit-to-visit	JJ	O
BP	NNP	O
variability	NN	O
does	VBZ	O
not	RB	O
differ	VB	O
substantially	RB	O
between	IN	O
?-blocker	NN	O
and	CC	O
calcium	NN	O
antagonist	NN	O
treatment	NN	O
.	.	O

Major	JJ	O
discrepancies	NNS	O
exist	VBP	O
between	IN	O
visit-to-visit	NN	O
BP	NNP	O
variability	NN	O
as	IN	O
quantified	VBN	O
by	IN	O
24-h	JJ	O
vs.	FW	O
clinic	JJ	O
BP	NNP	O
,	,	O
making	VBG	O
investigation	NN	O
of	IN	O
which	WDT	O
of	IN	O
these	DT	O
indices	NNS	O
is	VBZ	O
clinically	RB	O
more	RBR	O
relevant	JJ	O
important	JJ	O
.	.	O

Interindividual	JJ	O
BP	NNP	O
variability	NN	O
during	IN	O
treatment	NN	O
shows	NNS	O
marked	VBD	O
quantitative	JJ	O
differences	NNS	O
with	IN	O
intraindividual	JJ	O
BP	NNP	O
variability	NN	O
questioning	VBG	O
whether	IN	O
its	PRP$	O
use	NN	O
can	MD	O
accurately	RB	O
reflect	VB	O
individual	JJ	O
BP	NNP	O
variations	NNS	O
from	IN	O
one	CD	O
visit	NN	O
to	TO	O
another	DT	O
.	.	O

Azelnidipine	NNP	O
and	CC	O
amlodipine	VB	O
anti-coronary	JJ	O
atherosclerosis	NN	O
trial	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
intervention	NN	O
by	IN	O
serial	JJ	O
volumetric	JJ	O
intravascular	NN	O
ultrasound	NN	O
analysis	NN	O
in	IN	O
Juntendo	NNP	O
university	NN	O
(	(	O
ALPS-J	NNP	O
)	)	O
.	.	O

PURPOSE	NNP	O
Many	JJ	O
trials	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
(	(	O
CCBs	NNP	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
cardiovascular	NN	PH
(	(	PH
CV	NNP	PH
)	)	PH
events	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
mechanisms	NN	O
of	IN	O
this	DT	O
effect	NN	O
could	MD	O
be	VB	O
associated	VBN	O
with	IN	O
plaque	JJ	O
regression	NN	O
due	JJ	O
to	TO	O
the	DT	O
anti-atherosclerotic	JJ	O
properties	NNS	O
of	IN	O
CCBs	NNP	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
CCB	NNP	O
on	IN	O
volumetric	JJ	O
quantitative	JJ	O
changes	NNS	O
of	IN	O
coronary	JJ	O
plaques	NNS	O
accessed	VBN	O
by	IN	O
intravascular	JJ	O
ultrasound	NN	O
(	(	O
IVUS	NNP	O
)	)	O
.	.	O

To	TO	O
confirm	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
trial	NN	O
of	IN	O
CCBs	NNP	O
treatment	NN	O
with	IN	O
azelnidipine	NN	O
or	CC	O
amlodipine	NN	O
will	MD	O
be	VB	O
conducted	VBN	O
in	IN	O
hypertensive	JJ	O
CAD	NNP	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Patients	NNPS	O
who	WP	O
have	VBP	O
hypertension	NN	O
and	CC	O
are	VBP	O
scheduled	VBN	O
for	IN	O
PCI	NNP	O
will	MD	O
be	VB	O
enrolled	VBN	O
.	.	O

Subjects	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
azelnidipine	VB	O
or	CC	O
amlodipine	VB	O
and	CC	O
observed	VB	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
will	MD	O
be	VB	O
the	DT	O
percent	NN	PH
change	NN	PH
of	IN	PH
coronary	JJ	PH
plaque	NN	PH
volume	NN	PH
.	.	O

The	DT	O
secondary	JJ	O
endpoint	NN	O
will	MD	O
include	VB	O
inflammatory	JJ	PH
markers	NNS	PH
,	,	PH
antioxidant	JJ	PH
activity	NN	PH
,	,	PH
and	CC	PH
incidence	NN	PH
of	IN	PH
composite	JJ	PH
cardiovascular	JJ	PH
events	NNS	PH
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
will	MD	O
investigate	VB	O
the	DT	O
improvement	NN	O
of	IN	O
coronary	JJ	PH
plaque	NN	PH
with	IN	O
IVUS	NNP	O
by	IN	O
treatment	NN	O
with	IN	O
two	CD	O
dihydropyridine	NN	O
CCBs	NNP	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

This	DT	O
result	NN	O
will	MD	O
lead	VB	O
to	TO	O
the	DT	O
discovery	NN	O
of	IN	O
more	RBR	O
effective	JJ	O
drug	NN	O
therapy	NN	O
for	IN	O
inhibition	NN	O
of	IN	O
coronary	JJ	PH
events	NNS	PH
.	.	O

[	NNP	O
Medical	NNP	O
safety	NN	O
and	CC	O
staff	NN	O
mental	JJ	O
health	NN	O
]	NNP	O
.	.	O

Improvement	NNP	O
in	IN	O
patient	JJ	O
safety	NN	O
is	VBZ	O
a	DT	O
high-priority	JJ	O
issue	NN	O
of	IN	O
great	JJ	O
social	JJ	O
import	NN	O
.	.	O

Several	JJ	O
studies	NNS	O
have	VBP	O
reported	VBN	O
that	IN	O
most	JJS	O
adverse	JJ	O
events	NNS	O
are	VBP	O
due	JJ	O
to	TO	O
errors	NNS	O
of	IN	O
hospital	JJ	O
staff	NN	O
,	,	O
and	CC	O
emphasized	VBD	O
the	DT	O
necessity	NN	O
of	IN	O
promoting	VBG	O
countermeasures	NNS	O
against	IN	O
medical	JJ	O
errors	NNS	O
.	.	O

Root	NNP	O
cause	NN	O
analysis	NN	O
(	(	O
RCA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
implemented	VBN	O
to	TO	O
prevent	VB	O
such	JJ	O
errors	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
retrospective	NN	O
and	CC	O
qualitative	JJ	O
nature	NN	O
of	IN	O
RCA	NNP	O
is	VBZ	O
a	DT	O
limitation	NN	O
in	IN	O
scientific	JJ	O
analyses	NNS	O
examining	VBG	O
causal	JJ	O
relationships	NNS	O
.	.	O

We	PRP	O
showed	VBD	O
that	IN	O
prospective	JJ	O
design	NN	O
path	NN	O
analysis	NN	O
using	VBG	O
structural	JJ	O
equation	NN	O
modeling	NN	O
(	(	O
SEM	NNP	O
)	)	O
model	NN	O
for	IN	O
both	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
effects	NNS	O
enabled	VBD	O
statistical	JJ	O
exploration	NN	O
of	IN	O
root	NN	O
causes	NNS	O
and	CC	O
estimation	NN	O
of	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
the	DT	O
outcome	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggested	VBD	O
such	JJ	O
analysis	NN	O
to	TO	O
be	VB	O
useful	JJ	O
in	IN	O
devising	VBG	O
countermeasures	NNS	O
against	IN	O
medical	JJ	O
errors	NNS	O
.	.	O

The	DT	O
SEM	NNP	O
model	NN	O
constructed	VBN	O
in	IN	O
this	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
one	CD	O
of	IN	O
the	DT	O
potential	JJ	O
root	NN	O
causes	NNS	O
was	VBD	O
sleep	JJ	ME
disturbance	NN	ME
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
whether	IN	O
or	CC	O
not	RB	O
brief	JJ	O
bright	JJ	O
light	NN	O
(	(	O
BL	NNP	O
)	)	O
exposure	NN	O
on	IN	O
workday	JJ	O
mornings	NNS	O
can	MD	O
improve	VB	O
health	NN	O
,	,	O
performance	NN	O
and	CC	O
safety	NN	O
in	IN	O
nurses	NNS	O
with	IN	O
rapidly	RB	O
rotating	VBG	O
shifts	NNS	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
BL	NNP	O
periods	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
for	IN	O
self-assessed	JJ	ME
sleepiness	NN	ME
at	IN	O
10	CD	O
:	:	O
00	CD	O
on	IN	O
day-shift	JJ	O
days	NNS	O
,	,	O
self-assessment	NN	ME
of	IN	ME
night	NN	ME
sleep	NN	ME
for	IN	ME
day-shift	JJ	ME
days	NNS	ME
and	CC	ME
for	IN	ME
fatigue	NN	ME
.	.	O

Mean	NNP	PH
response	NN	PH
time	NN	PH
evaluated	VBN	O
using	VBG	O
the	DT	O
psychomotor	NN	O
vigilance	NN	O
task	NN	O
test	NN	O
(	(	O
PVT	NNP	O
)	)	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
BL	NNP	O
periods	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
.	.	O

The	DT	O
frequency	NN	A
of	IN	A
perceived	JJ	A
adverse	JJ	A
events	NNS	A
and	CC	A
near	JJ	A
misses	NNS	A
was	VBD	O
also	RB	O
lower	JJR	O
in	IN	O
the	DT	O
BL	NNP	O
than	IN	O
in	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
,	,	O
possibly	RB	O
indicating	VBG	O
that	IN	O
the	DT	O
one-month	JJ	O
observation	NN	O
period	NN	O
was	VBD	O
too	RB	O
short	JJ	O
to	TO	O
achieve	VB	O
any	DT	O
significant	JJ	O
success	NN	O
.	.	O

Despite	IN	O
our	PRP$	O
study	NN	O
's	POS	O
limitations	NNS	O
,	,	O
we	PRP	O
have	VBP	O
effectively	RB	O
demonstrated	VBN	O
the	DT	O
potential	NN	O
for	IN	O
preventing	VBG	O
medical	JJ	O
error	NN	O
risk	NN	O
among	IN	O
night-shift	JJ	O
workers	NNS	O
.	.	O

Factors	NNS	O
that	WDT	O
influence	NN	O
cancer	NN	O
patients	NNS	O
'	POS	O
anxiety	NN	PH
following	VBG	O
a	DT	O
medical	JJ	O
consultation	NN	O
:	:	O
impact	NN	O
of	IN	O
a	DT	O
communication	NN	O
skills	VBZ	O
training	VBG	O
programme	NN	O
for	IN	O
physicians	NNS	O
.	.	O

BACKGROUND	NNP	O
No	NNP	O
study	NN	O
has	VBZ	O
yet	RB	O
assessed	VBN	O
the	DT	O
impact	NN	O
of	IN	O
physicians	NNS	O
'	POS	O
skills	NNS	O
acquisition	NN	O
after	IN	O
a	DT	O
communication	NN	O
skills	VBZ	O
training	VBG	O
programme	NN	O
on	IN	O
the	DT	O
evolution	NN	O
of	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
following	VBG	O
a	DT	O
medical	JJ	O
consultation	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
impact	NN	O
,	,	O
on	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
,	,	O
of	IN	O
a	DT	O
basic	JJ	O
communication	NN	O
skills	NNS	O
training	VBG	O
programme	NN	O
(	(	O
BT	NNP	O
)	)	O
and	CC	O
the	DT	O
same	JJ	O
programme	NN	O
consolidated	VBN	O
by	IN	O
consolidation	NN	O
workshops	NNS	O
(	(	O
CW	NNP	O
)	)	O
,	,	O
and	CC	O
to	TO	O
investigate	VB	O
physicians	NNS	O
'	POS	O
communication	NN	O
variables	NNS	O
associated	VBN	O
with	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Physicians	NNP	O
,	,	O
after	IN	O
attending	VBG	O
the	DT	O
BT	NNP	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
CW	NNP	O
or	CC	O
to	TO	O
a	DT	O
waiting	VBG	O
list	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
was	VBD	O
not	RB	O
a	DT	O
non-intervention	JJ	O
group	NN	O
.	.	O

Consultations	NNS	O
with	IN	O
a	DT	O
cancer	NN	O
patient	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

Patients	NNS	O
'	POS	O
anxiety	NN	PH
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
State	NNP	ME
Trait	NNP	ME
Anxiety	NNP	ME
Inventory	NNP	ME
before	IN	O
and	CC	O
after	IN	O
a	DT	O
consultation	NN	O
.	.	O

Communication	NNP	ME
skills	NNS	ME
were	VBD	O
analysed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Cancer	NNP	O
Research	NNP	O
Campaign	NNP	O
Workshop	NNP	O
Evaluation	NNP	O
Manual	NNP	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
change	NN	O
over	IN	O
time	NN	Ot
and	CC	O
between	IN	O
groups	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Mixed-effects	NNS	O
modelling	VBG	O
showed	VBD	O
that	IN	O
a	DT	O
decrease	NN	O
in	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
was	VBD	O
linked	VBN	O
with	IN	O
screening	JJ	O
questions	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.045	CD	O
)	)	O
,	,	O
physicians	NNS	Ot
'	POS	Ot
satisfaction	NN	Ot
about	IN	O
support	NN	O
given	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
with	IN	O
patients	NNS	O
'	POS	O
distress	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
anxiety	NN	O
was	VBD	O
linked	VBN	O
with	IN	O
breaking	VBG	O
bad	JJ	O
news	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.050	CD	O
)	)	O
and	CC	O
with	IN	O
supportive	JJ	O
skills	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

No	DT	O
impact	NN	O
of	IN	O
the	DT	O
training	NN	O
programme	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
the	DT	O
influence	NN	O
of	IN	O
some	DT	O
communication	NN	O
skills	NNS	O
on	IN	O
the	DT	O
evolution	NN	O
of	IN	O
patients	NNS	ME
'	POS	ME
anxiety	NN	ME
.	.	O

Physicians	NNS	O
should	MD	O
be	VB	O
aware	JJ	O
of	IN	O
these	DT	O
influences	NNS	O
.	.	O

Heart	NNP	PH
rate	NN	PH
variability	NN	PH
and	CC	O
QT	NNP	PH
dispersion	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
subclinical	JJ	O
hypothyroidism	NN	O
.	.	O

UNLABELLED	IN	O
The	DT	O
effect	NN	O
of	IN	O
subclinical	JJ	O
hypothyroidism	NN	O
(	(	O
SH	NNP	O
)	)	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
yet	RB	O
elucidated	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
dispersion	NN	O
of	IN	O
QT	NNP	O
interval	NN	O
,	,	O
i.e	NN	O
.	.	O

an	DT	O
index	NN	O
of	IN	O
inhomogeneity	NN	O
of	IN	O
repolarization	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
,	,	O
i.e	RB	O
.	.	O

a	DT	O
measure	NN	O
of	IN	O
cardiac	JJ	O
autonomic	JJ	O
modulation	NN	O
,	,	O
in	IN	O
SH	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
42	CD	O
patients	NNS	O
(	(	O
29	CD	O
women	NNS	O
and	CC	O
13	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
53.2+/-14.2	JJ	O
years	NNS	O
;	:	O
body	NN	O
surface	JJ	O
area	NN	O
1.76+/-0.14	JJ	O
m2	NN	O
)	)	O
with	IN	O
SH	NNP	O
,	,	O
as	IN	O
judged	VBN	O
by	IN	O
elevated	JJ	O
serum	NN	O
TSH	NNP	O
levels	NNS	O
(	(	O
>	$	O
3.6	CD	O
mIU/l	NN	O
;	:	O
range	NN	O
,	,	O
3.8-12.0	JJ	O
)	)	O
and	CC	O
normal	JJ	O
free	JJ	O
thyroid	NN	O
hormones	NNS	O
(	(	O
FT4	NNP	O
and	CC	O
FT3	NNP	O
)	)	O
and	CC	O
30	CD	O
euthyroid	JJ	O
volunteer	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
cardiac	JJ	O
,	,	O
metabolic	JJ	O
,	,	O
neurological	JJ	O
disease	NN	O
or	CC	O
any	DT	O
other	JJ	O
systemic	JJ	O
disease	NN	O
that	WDT	O
could	MD	O
affect	VB	O
autonomic	JJ	O
activity	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
SH	NNP	O
and	CC	O
control	VB	O
subjects	NNS	O
underwent	VB	O
a	DT	O
full	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
standard	JJ	O
12-lead	JJ	O
ECG	NNP	O
,	,	O
and	CC	O
24-h	JJ	O
ambulatory	NN	O
ECG	NNP	O
monitoring	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
L-thyroxine	NNP	O
on	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
HRV	NNP	O
,	,	O
15	CD	O
patients	NNS	O
with	IN	O
SH	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
therapy	NN	O
with	IN	O
L-thyroxine	NNP	O
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
enrolment	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patients	NNPS	O
with	IN	O
SH	NNP	O
showed	VBD	O
higher	JJR	O
QT	NNP	PH
dispersion	NN	PH
and	CC	O
lower	JJR	PH
HRV	NNP	PH
measures	NNS	PH
than	IN	O
healthy	JJ	O
controls	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.01	CD	O
for	IN	O
all	DT	O
)	)	O
.	.	O

In	IN	O
SH	NNP	O
patients	NNS	O
,	,	O
the	DT	O
standard	JJ	PH
deviation	NN	PH
of	IN	PH
N-Ns	NNP	PH
(	(	PH
SDNN	NNP	PH
)	)	PH
was	VBD	O
negatively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=-0.42	JJ	O
,	,	O
P=0.006	NNP	O
)	)	O
,	,	O
while	IN	O
low	JJ	PH
frequency	NN	PH
(	(	PH
LF	NNP	PH
)	)	PH
/high	VBP	PH
frequency	NN	PH
(	(	PH
HF	NNP	PH
)	)	PH
ratio	NN	PH
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.42	NN	O
,	,	O
P=0.006	NNP	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
in	IN	O
SH	NNP	O
patients	NNS	O
both	DT	O
QT	NNP	PH
dispersion	NN	PH
and	CC	O
QTc	NNP	PH
dispersion	NN	PH
were	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.64	NN	O
and	CC	O
r=0.63	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
L-tiroxine	NNP	O
exhibited	VBD	O
a	DT	O
reduction	NN	O
of	IN	O
QT	NNP	PH
dispersion	NN	PH
and	CC	O
an	DT	O
increase	NN	O
of	IN	O
HRV	NNP	PH
parameters	NNS	PH
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
SH	NNP	O
can	MD	O
alter	VB	O
autonomic	JJ	O
modulation	NN	O
of	IN	O
heart	NN	PH
rate	NN	PH
and	CC	O
cause	NN	O
increased	VBD	O
inhomogeneity	NN	O
of	IN	O
ventricular	JJ	O
recovery	NN	O
times	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
early	JJ	O
L-thyroxine	JJ	O
treatment	NN	O
may	MD	O
be	VB	O
advised	VBN	O
not	RB	O
only	RB	O
to	TO	O
prevent	VB	O
progression	NN	O
to	TO	O
overt	VB	O
hypothyroidism	NN	O
but	CC	O
also	RB	O
to	TO	O
improve	VB	O
abnormal	JJ	O
cardiac	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
inhomogeneity	NN	O
.	.	O

Effect	NN	O
of	IN	O
intravenous	JJ	O
dezocine	NN	O
on	IN	O
fentanyl-induced	JJ	O
cough	NN	PH
during	IN	O
general	JJ	O
anesthesia	JJ	O
induction	NN	O
:	:	O
a	DT	O
double-blinded	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
suppressive	JJ	O
effect	NN	O
of	IN	O
intravenous	JJ	O
dezocine	NN	O
on	IN	O
fentanyl-induced	JJ	O
cough	NN	PH
during	IN	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
120	CD	O
patients	NNS	O
,	,	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
(	(	O
ASA	NNP	O
)	)	O
physical	JJ	O
status	NN	O
I-II	NNP	O
,	,	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
equally	RB	O
sized	JJ	O
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
.	.	O

These	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
given	VBN	O
either	RB	O
intravenous	JJ	O
dezocine	NN	O
0.1	CD	O
mg/kg	NN	O
or	CC	O
a	DT	O
matching	JJ	O
placebo	NN	O
(	(	O
equal	JJ	O
volume	NN	O
of	IN	O
0.9	CD	O
%	NN	O
saline	NN	O
)	)	O
10	CD	O
min	NN	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
induced	VBN	O
with	IN	O
midazolam	JJ	O
0.1	CD	O
mg/kg	NN	O
,	,	O
fentanyl	VBP	O
5	CD	O
?g/kg	NN	O
,	,	O
propofol	JJ	O
1-1.5	JJ	O
mg/kg	NN	O
,	,	O
and	CC	O
suxamethonium	NN	O
1.5	CD	O
mg/kg	NN	O
.	.	O

The	DT	O
injection	NN	O
time	NN	O
of	IN	O
fentanyl	NN	O
was	VBD	O
less	JJR	O
than	IN	O
2	CD	O
s	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
cough	NN	O
was	VBD	O
recorded	VBN	O
2	CD	O
min	NN	O
after	IN	O
fentanyl	JJ	O
bolus	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
patient	NN	O
in	IN	O
the	DT	O
dezocine	NN	O
group	NN	O
had	VBD	O
cough	VBN	PH
,	,	O
and	CC	O
42	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
had	VBD	O
cough	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
statistically	RB	O
different	JJ	O
between	IN	O
these	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.000	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
intravenous	JJ	O
dezocine	NN	O
0.1	CD	O
mg/kg	NN	O
10	CD	O
min	NN	O
prior	RB	O
to	TO	O
induction	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
suppressing	VBG	O
fentanyl-induced	JJ	O
cough	NN	O
in	IN	O
our	PRP$	O
patients	NNS	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
dose	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
Adjuvant	NNP	O
locoregional	JJ	O
chemotherapy	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
to	TO	O
prevent	VB	O
recurrence	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
(	(	O
HCC	NNP	O
)	)	O
in	IN	O
some	DT	O
retrospective	JJ	O
studies	NNS	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
dose	JJ	O
effect	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tumor	NN	O
recurrence	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
HCC	NNP	O
;	:	O
they	PRP	O
were	VBD	O
given	VBN	O
either	DT	O
one	CD	O
intra-arterial	JJ	O
dose	NN	O
of	IN	O
cisplatin/lipiodol	NN	O
,	,	O
or	CC	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
once	RB	O
every	DT	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
rates	NNS	PH
of	IN	PH
recurrence	NN	PH
,	,	O
disease-free	JJ	MO
and	CC	O
overall	JJ	MO
survival	NN	MO
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
During	IN	O
a	DT	O
median	JJ	O
follow	NN	O
up	IN	O
of	IN	O
818	CD	O
days	NNS	O
,	,	O
21	CD	O
patients	NNS	O
received	VBD	O
one	CD	O
dose	NN	O
and	CC	O
19	CD	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
with	IN	O
10	CD	O
(	(	O
47.6	CD	O
%	NN	O
)	)	O
and	CC	O
eight	CD	O
(	(	O
42.1	CD	O
%	NN	O
)	)	O
recurrences	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
1-year	JJ	MO
,	,	MO
2-year	JJ	MO
and	CC	MO
3-year	JJ	MO
disease-free	JJ	MO
survival	NN	MO
rates	NNS	MO
were	VBD	O
71	CD	O
%	NN	O
,	,	O
54	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
for	IN	O
the	DT	O
one-dose	JJ	O
group	NN	O
and	CC	O
74	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
for	IN	O
the	DT	O
four-dose	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.78	CD	O
)	)	O
.	.	O

The	DT	O
respective	JJ	O
overall	JJ	MO
survival	NN	MO
rates	NNS	MO
were	VBD	O
85	CD	O
%	NN	O
,	,	O
74	CD	O
%	NN	O
,	,	O
55	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
,	,	O
71	CD	O
%	NN	O
,	,	O
40	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.64	CD	O
)	)	O
.	.	O

The	DT	O
only	JJ	O
prognostic	JJ	O
factor	NN	O
was	VBD	O
presence	NN	PH
of	IN	PH
vascular	JJ	PH
permeation	NN	PH
.	.	O

The	DT	O
side-effects	NNS	A
were	VBD	O
mild	JJ	O
and	CC	O
tolerable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
survival	NN	MO
rates	NNS	MO
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Adjuvant	NNP	O
chemotherapy	NN	O
may	MD	O
not	RB	O
be	VB	O
useful	JJ	O
.	.	O

Effect	NN	O
of	IN	O
inhaled	JJ	O
heparin	NN	O
on	IN	O
adenosine-induced	JJ	O
bronchial	JJ	O
hyperreactivity	NN	O
.	.	O

Glycosaminoglycan	JJ	O
heparin	NN	O
possesses	VBZ	O
multiple	JJ	O
noncoagulant	JJ	O
properties	NNS	O
including	VBG	O
antiinflammatory	JJ	O
actions	NNS	O
.	.	O

We	PRP	O
have	VBP	O
previously	RB	O
shown	VBN	O
that	IN	O
heparin	NN	O
attenuates	VBZ	O
the	DT	O
methacholine-induced	JJ	O
bronchoconstriction	NN	O
in	IN	O
humans	NNS	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
methacholine	VB	O
,	,	O
a	DT	O
stimulus	NN	O
that	WDT	O
induces	VBZ	O
airway	RP	O
constriction	NN	O
mainly	RB	O
by	IN	O
direct	JJ	O
stimulation	NN	O
of	IN	O
airway	JJ	O
smooth	JJ	O
muscle	NN	O
cells	NNS	O
,	,	O
adenosine	JJ	O
airway	RB	O
responsiveness	JJ	O
reflects	VBZ	O
indirectly	RB	O
induced	VBN	O
airway	RP	O
narrowing	VBG	O
via	IN	O
inflammatory	JJ	O
mediators	NNS	O
or	CC	O
neural	JJ	O
reflex	JJ	O
mechanisms	NNS	O
.	.	O

Whether	NNP	O
heparin	NN	O
modulates	VBZ	O
bronchial	JJ	O
hyperreactivity	NN	O
induced	VBN	O
by	IN	O
adenosine	NN	O
,	,	O
is	VBZ	O
not	RB	O
well	RB	O
known	VBN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
inhaled	JJ	O
heparin	NN	O
on	IN	O
adenosine-induced	JJ	O
bronchoconstriction	NN	O
and	CC	O
compared	VBN	O
the	DT	O
inhibitory	JJ	O
role	NN	O
of	IN	O
heparin	NN	O
on	IN	O
the	DT	O
adenosine	NN	O
challenge	NN	O
test	NN	O
with	IN	O
that	DT	O
on	IN	O
the	DT	O
methacholine	NN	O
challenge	NN	O
test	NN	O
.	.	O

Fifteen	JJ	O
subjects	NNS	O
(	(	O
7	CD	O
males	NNS	O
,	,	O
8	CD	O
females	NNS	O
)	)	O
with	IN	O
mild	JJ	O
asthma	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Bronchial	JJ	O
provocation	NN	O
tests	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
single-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
randomized	VBN	O
order	NN	O
,	,	O
and	CC	O
repeated	VBD	O
45	CD	O
minutes	NNS	O
after	IN	O
placebo	NN	O
or	CC	O
aerosolized	VBN	O
heparin	JJ	O
inhalation	NN	O
(	(	O
1,000	CD	O
U/kg	NNP	O
)	)	O
.	.	O

The	DT	O
heparin	NN	O
increased	VBD	O
the	DT	O
geometric	JJ	Ot
mean	NN	Ot
log	NN	Ot
methacholine	NN	Ot
PD20	NNP	Ot
value	NN	Ot
from	IN	O
0.47	CD	O
+/-	JJ	O
0.16	CD	O
(	(	O
2.95	CD	O
mg/ml	NN	O
)	)	O
to	TO	O
0.96	CD	O
+/-	JJ	O
0.10	CD	O
(	(	O
8.91	CD	O
mg/ml	NN	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.0009	CD	O
)	)	O
in	IN	O
15	CD	O
patients	NNS	O
and	CC	O
the	DT	O
geometric	JJ	Ot
mean	NN	Ot
log	NN	Ot
adenosine	NN	Ot
PD20	NNP	Ot
values	VBZ	Ot
from	IN	O
1.59	CD	O
+/-	JJ	O
0.23	CD	O
(	(	O
38.9	CD	O
mg/ml	NN	O
)	)	O
to	TO	O
1.98	CD	O
+/-	JJ	O
0.14	CD	O
(	(	O
97.7	CD	O
mg/ml	NN	O
)	)	O
(	(	O
NS	NNP	O
)	)	O
in	IN	O
7	CD	O
patients	NNS	O
whose	WP$	O
baseline	JJ	O
adenosine	NN	O
PD20	NNP	O
levels	NNS	O
were	VBD	O
less	JJR	O
than	IN	O
200	CD	O
mg/ml	NN	O
.	.	O

The	DT	O
degree	NN	Ot
of	IN	Ot
protection	NN	Ot
by	IN	O
heparin	NN	O
against	IN	O
adenosine-induced	JJ	O
bronchoconstriction	NN	O
was	VBD	O
not	RB	O
correlated	VBN	O
with	IN	O
that	DT	O
against	IN	O
methacholine-induced	JJ	O
bronchoconstriction	NN	O
(	(	O
r	JJ	O
=	NN	O
0.60	CD	O
,	,	O
NS	NNP	O
)	)	O
.	.	O

The	DT	O
data	NN	O
suggest	NN	O
that	WDT	O
inhaled	VBD	O
heparin	NN	O
may	MD	O
have	VB	O
an	DT	O
inhibitory	JJ	O
effect	NN	O
on	IN	O
the	DT	O
methacholine	NN	O
bronchial	JJ	O
challenge	NN	O
,	,	O
and	CC	O
thus	RB	O
,	,	O
most	JJS	O
likely	JJ	O
directs	VBZ	O
its	PRP$	O
effect	NN	O
against	IN	O
smooth	JJ	O
muscle	NN	O
.	.	O

Heparin	NNP	O
caused	VBD	O
less	JJR	O
attenuation	NN	O
of	IN	O
a	DT	O
challenge	NN	O
with	IN	O
adenosine	NN	O
and	CC	O
probably	RB	O
does	VBZ	O
not	RB	O
affect	VB	O
mast	NN	O
cell	NN	O
degranulation	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
six	CD	O
epoetin	JJ	O
alfa	NN	O
dosing	VBG	O
regimens	NNS	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
without	IN	O
acute	JJ	O
blood	NN	O
loss	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
the	DT	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
six	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
for	IN	O
epoetin	NN	O
alfa	NN	O
,	,	O
and	CC	O
whether	IN	O
more	JJR	O
rapid	JJ	O
and	CC	O
robust	JJ	O
reticulocytosis	NN	O
can	MD	O
be	VB	O
elicited	VBN	O
with	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
epoetin	JJ	O
alfa	NN	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
open-label	NN	O
,	,	O
multicenter	NN	O
,	,	O
28-day	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Ten	CD	O
centers	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PATIENTS	VB	O
Adult	NNP	O
(	(	O
age	NN	O
>	VBN	O
or=18	CD	O
years	NNS	O
)	)	O
critically	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
hemoglobin	JJ	O
<	NNP	O
or=12	NN	O
g/dL	NN	O
,	,	O
expected	VBN	O
hospitalization	NN	O
of	IN	O
>	NNP	O
or=7	NNP	O
days	NNS	O
,	,	O
with	IN	O
no	DT	O
ongoing	VBG	O
acute	RB	O
blood	NN	O
loss	NN	O
.	.	O

INTERVENTIONS	NNP	O
One	CD	O
of	IN	O
six	CD	O
dosing	VBG	O
epoetin	NN	O
alfa	NN	O
regimens	VBZ	O
for	IN	O
15	CD	O
days	NNS	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
40,000	CD	O
IU	NNP	O
once	RB	O
weekly	RB	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
;	:	O
15,000	CD	O
IU	NNP	O
every	DT	O
other	JJ	O
day	NN	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
D	NNP	O
)	)	O
;	:	O
or	CC	O
40,000	CD	O
IU	NNP	O
day	NN	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
F	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
15,000	CD	O
IU	NNP	O
once	RB	O
every	DT	O
other	JJ	O
day	NN	O
on	IN	O
[	NN	O
corrected	VBN	O
]	JJ	O
days	NNS	O
5-15	JJ	O
[	NNP	O
corrected	VBD	O
]	NN	O
MEASUREMENTS	NNP	O
Serum	NNP	PH
erythropoietin	NN	PH
concentration	NN	PH
,	,	O
absolute	JJ	PH
reticulocyte	NN	PH
count	NN	PH
,	,	O
and	CC	O
adverse	JJ	A
events	NNS	A
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Of	IN	O
the	DT	O
60	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
(	(	O
60	CD	O
%	NN	O
men	NNS	O
,	,	O
mean	JJ	O
age	NN	O
53	CD	O
years	NNS	O
,	,	O
mean	VBP	O
Acute	NNP	O
Physiology	NNP	O
and	CC	O
Chronic	NNP	O
Health	NNP	O
Evaluation	NNP	O
II	NNP	O
score	NN	O
,	,	O
19.5	CD	O
)	)	O
,	,	O
30	CD	O
were	VBD	O
evaluable	JJ	O
for	IN	O
both	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
.	.	O

Erythropoietin	NNP	PH
exposure	NN	PH
was	VBD	O
approximately	RB	O
ten	JJ	O
times	NNS	O
greater	JJR	O
for	IN	O
IV	NNP	O
dosing	VBG	O
than	IN	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	O
.	.	O

Mean	NNP	PH
absolute	JJ	PH
reticulocyte	NN	PH
count	NN	PH
peaked	VBD	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
appeared	VBD	O
to	TO	O
be	VB	O
greater	JJR	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
149-169	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
compared	VBN	O
with	IN	O
IV	NNP	O
dosing	VBG	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
138-147	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
at	IN	O
most	JJS	O
visits	NNS	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
adverse	JJ	A
events	NNS	A
were	VBD	O
pyrexia	NNS	A
(	(	O
18	CD	O
%	NN	O
)	)	O
,	,	O
hypokalemia	NN	A
(	(	O
15	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
hypophosphatemia	NN	A
(	(	O
15	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
of	IN	O
anemic	JJ	O
critically	NN	O
ill	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
epoetin	JJ	O
alfa	NN	O
,	,	O
all	DT	O
dosing	VBG	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	Ot
and	CC	O
appeared	VBN	O
to	TO	O
effect	NN	O
reticulocytosis	NN	PH
,	,	O
with	IN	O
a	DT	O
peak	NN	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
epoetin	JJ	O
alfa	NN	O
did	VBD	O
not	RB	O
predict	VB	O
pharmacodynamic	JJ	PH
response	NN	PH
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
web-based	JJ	O
tailored	JJ	O
smoking	NN	O
cessation	NN	O
advice	NN	O
reports	NNS	O
(	(	O
iQuit	NN	O
)	)	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
web-based	JJ	O
tailored	JJ	O
cessation	NN	O
advice	NN	O
,	,	O
based	VBN	O
on	IN	O
social	JJ	O
cognitive	JJ	O
theory	NN	O
and	CC	O
the	DT	O
perspectives	NNS	O
on	IN	O
change	NN	O
model	NN	O
,	,	O
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
aiding	VBG	O
a	DT	O
quit	NN	O
attempt	NN	O
than	IN	O
broadly	RB	O
similar	JJ	O
web-based	JJ	O
advice	NN	O
that	WDT	O
was	VBD	O
not	RB	O
tailored	VBN	O
.	.	O

DESIGN	JJ	O
Participants	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
,	,	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
cessation	NN	O
advice	NN	O
report	NN	O
and	CC	O
progress	JJ	O
report	NN	O
that	WDT	O
were	VBD	O
tailored	VBN	O
to	TO	O
individual-level	JJ	O
characteristics	NNS	O
or	CC	O
a	DT	O
cessation	NN	O
advice	NN	O
report	NN	O
that	WDT	O
presented	VBD	O
standardized	JJ	O
(	(	O
non-tailored	JJ	O
)	)	O
content	NN	O
.	.	O

Tailoring	NNP	O
was	VBD	O
based	VBN	O
on	IN	O
smoking-related	JJ	O
beliefs	NN	O
,	,	O
personal	JJ	O
characteristics	NNS	O
and	CC	O
smoking	NN	O
patterns	NNS	O
,	,	O
self-efficacy	NN	O
and	CC	O
outcome	JJ	O
expectations	NNS	O
.	.	O

SETTING	NN	O
Participant	JJ	O
enrolment	NN	O
and	CC	O
baseline	NN	O
assessments	NNS	O
were	VBD	O
conducted	VBN	O
remotely	RB	O
online	JJ	O
via	IN	O
the	DT	O
study	NN	O
website	NN	O
,	,	O
with	IN	O
the	DT	O
advice	NN	O
reports	NNS	O
presented	VBN	O
by	IN	O
the	DT	O
same	JJ	O
website	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
n	IN	O
=	NNP	O
1758	CD	O
)	)	O
were	VBD	O
visitors	NNS	O
to	TO	O
the	DT	O
QUIT	NNP	O
website	NN	O
who	WP	O
were	VBD	O
based	VBN	O
in	IN	O
the	DT	O
United	NNP	O
Kingdom	NNP	O
,	,	O
aged	VBD	O
18	CD	O
years	NNS	O
or	CC	O
over	RB	O
and	CC	O
who	WP	O
smoked	VBD	O
cigarettes	NNS	O
or	CC	O
hand-rolled	JJ	O
tobacco	NN	O
.	.	O

MEASUREMENTS	NNP	O
Follow-up	JJ	O
assessments	NNS	O
were	VBD	O
made	VBN	O
at	IN	O
6	CD	O
months	NNS	O
by	IN	O
telephone	NN	O
interview	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
self-reported	JJ	O
3	CD	O
months	NNS	O
prolonged	VBN	ME
abstinence	NN	ME
,	,	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
were	VBD	O
1	CD	O
month	NN	O
prolonged	VBD	O
abstinence	NN	O
,	,	O
7-day	JJ	O
and	CC	O
24-hour	JJ	O
point	NN	O
prevalence	NN	O
abstinence	NN	O
.	.	O

FINDINGS	IN	O
The	DT	O
intervention	NN	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
(	(	O
9.1	CD	O
%	NN	O
versus	IN	O
9.3	CD	O
%	NN	O
;	:	O
odds	NNS	O
ratio	VBP	O
=	$	O
1.02	CD	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.73-1.42	NN	O
)	)	O
or	CC	O
on	IN	O
any	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Intervention	NN	O
participants	NNS	O
gave	VBD	O
more	RBR	O
positive	JJ	O
evaluations	NNS	O
of	IN	O
the	DT	O
materials	NNS	O
than	IN	O
control	NN	O
participants	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
web-based	JJ	O
intervention	NN	O
that	WDT	O
tailored	VBD	O
content	JJ	O
according	VBG	O
to	TO	O
smoking-related	JJ	O
beliefs	NN	O
,	,	O
personal	JJ	O
characteristics	NNS	O
and	CC	O
smoking	NN	O
patterns	NNS	O
,	,	O
self-efficacy	NN	O
and	CC	O
outcome	NN	O
expectations	NNS	O
,	,	O
was	VBD	O
not	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
web-based	JJ	O
materials	NNS	O
presenting	VBG	O
broadly	RB	O
similar	JJ	O
non-tailored	JJ	O
information	NN	O
.	.	O

Why	WRB	O
are	VBP	O
there	RB	O
sometimes	RB	O
concreteness	JJ	ME
effects	NNS	ME
in	IN	ME
memory	NN	ME
for	IN	O
prose	NN	O
?	.	O
Four	CD	O
experiments	NNS	O
explored	VBD	O
on-line	JJ	O
encoding	NN	O
strategies	NNS	O
and	CC	O
memory	NN	O
for	IN	O
high	JJ	O
imagery	NN	O
and	CC	O
low	JJ	O
imagery	NN	O
texts	NN	O
.	.	O

Results	NNP	O
consistently	RB	O
indicated	VBD	O
that	IN	O
concreteness	NN	ME
effects	NNS	ME
in	IN	ME
memory	NN	ME
for	IN	ME
text	JJ	ME
depend	NN	O
on	IN	O
how	WRB	O
materials	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
several	JJ	O
different	JJ	O
respects	NNS	O
.	.	O

Most	JJS	O
importantly	RB	O
,	,	O
the	DT	O
experiments	NNS	O
clarified	VBD	O
apparently	RB	O
contradictory	JJ	O
results	NNS	O
of	IN	O
previous	JJ	O
studies	NNS	O
by	IN	O
indicating	VBG	O
that	IN	O
concreteness	NN	ME
effects	NNS	ME
generally	RB	O
do	VBP	O
not	RB	O
occur	VB	O
in	IN	O
memory	NN	O
for	IN	O
prose	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
between-subjects	NNS	O
,	,	O
and	CC	O
that	IN	O
their	PRP$	O
occurrence	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
within-subjects	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
order	NN	O
occurrence	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
within-subjects	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
order	NN	O
of	IN	O
presentation	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
moving	VBG	O
window	JJ	O
analyses	NNS	O
of	IN	O
text	JJ	O
processing	NN	O
strategies	NNS	O
indicated	VBD	O
that	IN	O
differential	JJ	O
strategies	NNS	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
when	WRB	O
subjects	NNS	O
listened	VBD	O
to	TO	O
high	JJ	O
vs	NN	O
low	JJ	O
imagery	NN	O
text	NN	O
do	VBP	O
not	RB	O
generalize	VB	O
to	TO	O
reading	NN	O
of	IN	O
the	DT	O
same	JJ	O
materials	NNS	O
.	.	O

Potential	JJ	O
explanations	NNS	O
for	IN	O
the	DT	O
pattern	NN	O
of	IN	O
results	NNS	O
are	VBP	O
evaluated	VBN	O
,	,	O
and	CC	O
implications	NNS	O
for	IN	O
theories	NNS	O
of	IN	O
mental	JJ	O
imagery	NN	O
and	CC	O
memory	NN	O
are	VBP	O
considered	VBN	O
.	.	O

Determinants	NNS	O
of	IN	O
exclusive	JJ	O
breastfeeding	NN	O
in	IN	O
an	DT	O
urban	JJ	O
population	NN	O
of	IN	O
primiparas	NNS	O
in	IN	O
Lebanon	NNP	O
:	:	O
a	DT	O
cross-sectional	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
proportion	NN	O
of	IN	O
mothers	NNS	O
who	WP	O
exclusively	RB	O
breastfeed	VBP	O
their	PRP$	O
babies	NNS	O
up	IN	O
to	TO	O
6	CD	O
months	NNS	O
remains	VBZ	O
low	JJ	O
.	.	O

Determinants	NNS	O
of	IN	O
breastfeeding	VBG	O
practices	NNS	O
have	VBP	O
been	VBN	O
largely	RB	O
documented	VBN	O
in	IN	O
high-income	JJ	O
countries	NNS	O
.	.	O

Little	JJ	O
evidence	NN	O
exists	NNS	O
on	IN	O
possible	JJ	O
predictors	NNS	O
of	IN	O
breastfeeding	VBG	O
behaviors	NNS	O
in	IN	O
the	DT	O
Middle	NNP	O
East	NNP	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
breastfeeding	VBG	O
in	IN	O
Beirut	NNP	O
and	CC	O
determine	VB	O
the	DT	O
factors	NNS	O
that	WDT	O
impact	VBP	O
breastfeeding	VBG	O
behavior	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
for	IN	O
this	DT	O
longitudinal	JJ	O
study	NN	O
is	VBZ	O
nested	VBN	O
within	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
assessing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
24-hour	JJ	O
hotline	NN	O
and	CC	O
postpartum	NN	O
support	NN	O
film	NN	O
on	IN	O
postpartum	NN	O
stress	NN	O
.	.	O

Healthy	JJ	O
first-time	JJ	O
mothers	NNS	O
delivering	VBG	O
in	IN	O
the	DT	O
capital	NN	O
Beirut	NNP	O
between	IN	O
March	NNP	O
and	CC	O
July	NNP	O
2009	CD	O
,	,	O
were	VBD	O
interviewed	VBN	O
at	IN	O
1-3	JJ	O
days	NNS	O
and	CC	O
8-12	JJ	O
weeks	NNS	O
post	NN	O
delivery	NN	O
.	.	O

A	DT	O
multiple	JJ	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
factors	NNS	O
associated	VBN	O
with	IN	O
exclusive	JJ	O
breastfeeding	NN	O
at	IN	O
8-12	JJ	O
weeks	NNS	O
postpartum	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
overall	JJ	PH
breastfeeding	NN	PH
rate	NN	PH
at	IN	O
8-12	JJ	O
weeks	NNS	O
postpartum	NN	O
was	VBD	O
67	CD	O
%	NN	O
.	.	O

The	DT	O
exclusive	JJ	PH
breastfeeding	NN	PH
rate	NN	PH
was	VBD	O
27.4	CD	O
%	NN	O
.	.	O

Factors	NNS	O
associated	VBD	O
with	IN	O
exclusive	JJ	O
breastfeeding	NN	O
included	VBD	O
maternal	JJ	Ot
work	NN	Ot
(	(	O
OR=3.92	NNP	O
;	:	O
p-value	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
planned	VBN	Ot
pregnancy	NN	Ot
(	(	O
OR=2.42	NNP	O
,	,	O
p-value=0.010	NN	O
)	)	O
,	,	O
intention	NN	Ot
to	TO	Ot
breastfeed	VB	Ot
(	(	O
OR=3.28	NNP	O
;	:	O
p-value=0.043	NN	O
)	)	O
,	,	O
source	NN	Ot
of	IN	Ot
maternal	JJ	Ot
emotional	JJ	Ot
support	NN	Ot
(	(	O
OR=1.87	NNP	O
,	,	O
p-value=0.039	NN	O
)	)	O
and	CC	O
the	DT	O
use	NN	Ot
the	DT	Ot
postpartum	NN	Ot
support	NN	Ot
video	NN	Ot
,	,	Ot
the	DT	Ot
hotline	NN	Ot
service	NN	Ot
or	CC	Ot
both	DT	Ot
(	(	O
OR=2.55	NNP	O
,	,	O
p-value=0.044	NN	O
;	:	O
OR=3.87	NNP	O
,	,	O
p-value=0.004	NN	O
and	CC	O
OR=4.13	NNP	O
,	,	O
p-value=0.003	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
proportion	NN	O
of	IN	O
healthy	JJ	O
first-time	JJ	O
mothers	NNS	O
who	WP	O
exclusively	RB	O
breastfeed	VBP	O
in	IN	O
Beirut	NNP	O
is	VBZ	O
extremely	RB	O
low	JJ	O
.	.	O

Factors	NNS	O
associated	VBD	O
with	IN	O
breastfeeding	NN	O
behavior	NN	O
are	VBP	O
diverse	JJ	O
.	.	O

Future	JJ	O
research	NN	O
and	CC	O
interventions	NNS	O
should	MD	O
target	VB	O
different	JJ	O
levels	NNS	O
of	IN	O
the	DT	O
maternal-child	JJ	O
pair	NN	O
's	POS	O
ecosystem	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00857051	NNP	O
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
hepatic	JJ	O
artery	NN	O
infusion	NN	O
with	IN	O
5-fluorouracil	JJ	O
versus	NN	O
intravenous	JJ	O
5-fluorouracil	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
hepatic	JJ	O
metastases	NNS	O
from	IN	O
colorectal	JJ	O
cancer	NN	O
:	:	O
A	DT	O
Central	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

In	IN	O
a	DT	O
controlled	VBN	O
,	,	O
prospectively	RB	O
randomized	VBN	O
trial	NN	O
,	,	O
74	CD	O
patients	NNS	O
with	IN	O
hepatic	JJ	O
metastases	NNS	O
from	IN	O
colorectal	JJ	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
intra-arterial	JJ	O
hepatic	JJ	O
artery	NN	O
infusion	NN	O
with	IN	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
or	CC	O
systemic	JJ	O
chemotherapy	NN	O
with	IN	O
5-FU	JJ	O
.	.	O

In	IN	O
61	CD	O
acceptable	JJ	O
patients	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
response	NN	Ot
rate	NN	Ot
,	,	O
time	NN	Ot
to	TO	Ot
progression	NN	Ot
,	,	O
duration	NN	Ot
of	IN	Ot
the	DT	Ot
response	NN	Ot
,	,	O
and	CC	O
survival	JJ	MO
rate	NN	MO
.	.	O

Though	IN	O
the	DT	O
response	NN	Ot
rate	NN	Ot
for	IN	O
the	DT	O
intra-arterial	JJ	O
infusion	NN	O
arm	NN	O
was	VBD	O
slightly	RB	O
higher	JJR	O
than	IN	O
for	IN	O
the	DT	O
systemic	JJ	O
arm	NN	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
,	,	O
and	CC	O
the	DT	O
intra-arterial	JJ	O
infusion	NN	O
arm	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
greater	JJR	O
incidence	NN	O
of	IN	O
nausea	NN	A
,	,	O
vomiting	VBG	A
,	,	O
diarrhea	NN	A
,	,	O
in	IN	O
addition	NN	O
to	TO	O
complications	NNS	O
of	IN	O
femoral-arterial	JJ	PH
thrombosis	NN	PH
,	,	O
bleeding	NN	A
,	,	O
and	CC	O
infection	NN	A
at	IN	A
the	DT	A
catheter	NN	A
site	NN	A
not	RB	O
seen	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
by	IN	O
systemic	JJ	O
chemotherapy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
an	DT	O
objective	JJ	O
response	NN	O
to	TO	O
chemotherapy	VB	O
on	IN	O
either	DT	O
treatment	NN	O
arm	NN	O
survived	VBD	MO
twice	RB	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
nonresponders	NNS	O
.	.	O

Long-term	JJ	MO
survival	NN	MO
in	IN	O
one	CD	O
patient	NN	O
,	,	O
77	CD	O
months	NNS	O
,	,	O
can	MD	O
occasionally	RB	O
be	VB	O
achieved	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
hepatic	JJ	O
metastases	NNS	O
.	.	O

Immunologic	NNP	O
profiles	NNS	O
of	IN	O
persons	NNS	O
recruited	VBN	O
for	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
hookworm	NN	O
infection	NN	O
.	.	O

Data	NNS	O
from	IN	O
epidemiologic	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
hookworm	NN	O
infections	NNS	O
,	,	O
in	IN	O
establishing	VBG	O
an	DT	O
immunologic	JJ	O
phenotype	NN	O
conducive	NN	O
to	TO	O
parasite	VB	O
survival	NN	O
,	,	O
may	MD	O
protect	VB	O
against	IN	O
the	DT	O
development	NN	O
of	IN	O
allergic	JJ	O
disease	NN	O
.	.	O

We	PRP	O
describe	VBP	O
immunologic	JJ	O
findings	NNS	O
from	IN	O
a	DT	O
clinical	JJ	O
study	NN	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
of	IN	O
iatrogenic	JJ	O
hookworm	NN	O
infection	NN	O
in	IN	O
participants	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

The	DT	O
low	JJ	O
,	,	O
relatively	RB	O
safe	JJ	O
level	NN	O
of	IN	O
hookworm	NN	O
infection	NN	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
was	VBD	O
immunogenic	JJ	O
,	,	O
inducing	VBG	O
eosinophilia	NNS	PH
and	CC	O
a	DT	O
significant	JJ	O
specific	JJ	PH
IgG	NNP	PH
response	NN	PH
.	.	PH

Importantly	RB	O
,	,	O
no	DT	O
potentiation	NN	O
of	IN	O
IgE	NNP	PH
responses	NNS	PH
to	TO	PH
the	DT	PH
environmental	JJ	PH
allergens	NNS	PH
to	TO	PH
which	WDT	PH
the	DT	PH
participants	NNS	PH
were	VBD	PH
sensitized	VBN	PH
was	VBD	O
seen	VBN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
evidence	NN	O
of	IN	O
systemic	JJ	PH
immune	JJ	PH
regulation	NN	PH
was	VBD	O
seen	VBN	O
in	IN	O
infected	JJ	O
participants	NNS	O
.	.	O

This	DT	O
finding	NN	O
may	MD	O
indicate	VB	O
that	IN	O
the	DT	O
level	NN	PH
of	IN	PH
infection	NN	PH
or	CC	O
the	DT	O
frequency	NN	PH
of	IN	PH
infection	NN	PH
may	MD	O
have	VB	O
to	TO	O
be	VB	O
altered	VBN	O
in	IN	O
future	JJ	O
trials	NNS	O
to	TO	O
induce	VB	O
a	DT	O
therapeutically	RB	O
conducive	JJ	O
immunologic	NN	O
phenotype	NN	O
.	.	O

Combining	VBG	O
weight-loss	JJ	O
counseling	NN	O
with	IN	O
the	DT	O
weight	NN	O
watchers	NNS	O
plan	VBP	O
for	IN	O
obese	JJ	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
develop	VB	O
effective	JJ	O
weight-loss	JJ	O
methods	NNS	O
for	IN	O
women	NNS	O
who	WP	O
have	VBP	O
had	VBN	O
breast	VBN	O
cancer	NN	O
,	,	O
because	IN	O
obesity	NN	O
may	MD	O
result	VB	O
in	IN	O
an	DT	O
adverse	JJ	O
prognosis	NN	O
.	.	O

RESEARCH	NNP	O
METHODS	NNP	O
AND	NNP	O
PROCEDURES	NNP	O
This	DT	O
randomized	VBN	O
pilot	NN	O
study	NN	O
tested	VBD	O
an	DT	O
individualized	JJ	O
approach	NN	O
toward	IN	O
weight	JJ	PH
loss	NN	PH
in	IN	O
obese	JJ	O
women	NNS	O
who	WP	O
have	VBP	O
had	VBD	O
a	DT	O
diagnosis	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
.	.	O

An	DT	O
individualized	JJ	O
approach	NN	O
was	VBD	O
applied	VBN	O
either	CC	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
the	DT	O
commercial	JJ	O
Weight	NNP	O
Watchers	NNP	O
program	NN	O
.	.	O

Forty-eight	JJ	O
women	NNS	O
(	(	O
body	NN	O
mass	NN	O
index	NN	O
of	IN	O
30	CD	O
to	TO	O
44	CD	O
kg/m	NNS	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
enrolled	VBN	O
.	.	O

RESULTS	NNP	O
Weight	NNP	PH
change	NN	PH
after	IN	O
12	CD	O
months	NNS	O
of	IN	O
intervention	NN	O
was	VBD	O
as	IN	O
follows	VBZ	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
:	:	O
0.85	CD	O
+/-	JJ	O
6.0	CD	O
kg	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
-2.6	VBZ	O
+/-	JJ	O
5.9	CD	O
kg	NN	O
in	IN	O
the	DT	O
Weight	NNP	O
Watchers	NNP	O
group	NN	O
,	,	O
-8.0	VBZ	O
+/-	JJ	O
5.5	CD	O
kg	NN	O
in	IN	O
the	DT	O
individualized	JJ	O
group	NN	O
,	,	O
and	CC	O
-9.4	VBD	O
+/-	JJ	O
8.6	CD	O
kg	NN	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
that	WDT	O
used	VBD	O
both	DT	O
individualized	JJ	O
counseling	NN	O
and	CC	O
Weight	NNP	O
Watchers	NNP	O
.	.	O

Weight	NNP	PH
loss	NN	PH
relative	NN	O
to	TO	O
control	VB	O
was	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
randomization	NN	O
,	,	O
whereas	JJ	O
weight	NN	PH
loss	NN	PH
in	IN	O
the	DT	O
individualized	JJ	O
group	NN	O
was	VBD	O
significant	JJ	O
only	RB	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

Weight	NNP	PH
loss	NN	PH
of	IN	O
10	CD	O
%	NN	O
or	CC	O
more	JJR	O
of	IN	O
initial	JJ	O
body	NN	O
weight	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
6	CD	O
of	IN	O
10	CD	O
women	NNS	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
comprehensive	JJ	O
and	CC	O
Weight	NNP	O
Watchers-only	NNP	O
groups	NNS	O
,	,	O
weight	JJ	PH
loss	NN	PH
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
frequency	NN	O
of	IN	O
attendance	NN	O
at	IN	O
Weight	NNP	O
Watchers	NNP	O
meetings	NNS	O
,	,	O
and	CC	O
attendance	NN	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
.	.	O

DISCUSSION	NNP	O
These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
most	RBS	O
weight	JJ	PH
loss	NN	PH
was	VBD	O
achieved	VBN	O
when	WRB	O
the	DT	O
counseling	NN	O
approach	NN	O
combined	VBD	O
both	DT	O
Weight	NNP	O
Watchers	NNPS	O
and	CC	O
individualized	JJ	O
contacts	NNS	O
.	.	O

This	DT	O
was	VBD	O
effective	JJ	O
even	RB	O
though	IN	O
most	JJS	O
of	IN	O
the	DT	O
individualized	JJ	O
contacts	NNS	O
were	VBD	O
by	IN	O
telephone	NN	O
.	.	O

Zinc	NNP	PH
and	CC	PH
copper	NN	PH
balances	NNS	PH
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

Preterm	NNP	O
infants	NNS	O
are	VBP	O
at	IN	O
risk	NN	O
for	IN	O
copper	NN	O
and	CC	O
zinc	NN	O
depletion	NN	O
if	IN	O
sufficient	JJ	O
quantities	NNS	O
of	IN	O
these	DT	O
nutrients	NNS	O
are	VBP	O
not	RB	O
provided	VBN	O
in	IN	O
a	DT	O
bioavailable	JJ	O
form	NN	O
in	IN	O
postnatal	JJ	O
life	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
whey-predominant	JJ	O
,	,	O
50	CD	O
%	NN	O
medium	NN	O
chain	NN	O
triglyceride	IN	O
formula	NN	O
with	IN	O
relatively	RB	O
high	JJ	O
concentrations	NNS	O
of	IN	O
zinc	NN	O
and	CC	O
copper	NN	O
would	MD	O
promote	VB	O
the	DT	O
achievement	NN	O
of	IN	O
the	DT	O
in	IN	PH
utero	JJ	PH
accretion	NN	PH
rate	NN	PH
for	IN	PH
zinc	NN	PH
and	CC	PH
copper	NN	PH
in	IN	O
the	DT	O
preterm	NN	O
infant	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
five	CD	O
preterm	JJ	O
infants	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
diet	JJ	O
containing	VBG	O
12.5	CD	O
mg/L	NN	O
of	IN	O
zinc	NN	O
and	CC	O
either	DT	O
0.9	CD	O
mg/L	NN	O
or	CC	O
2.1	CD	O
mg/L	NN	O
of	IN	O
copper	NN	O
.	.	O

Seventy-two-hour	JJ	O
metabolic	JJ	O
balance	NN	O
studies	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
an	DT	O
average	JJ	O
postconceptual	JJ	O
age	NN	O
of	IN	O
34	CD	O
weeks	NNS	O
and	CC	O
an	DT	O
average	JJ	O
weight	NN	O
of	IN	O
1,549	CD	O
g.	NN	O
All	DT	O
infants	NNS	O
were	VBD	O
in	IN	O
positive	JJ	PH
zinc	NN	PH
balance	NN	PH
and	CC	O
nine	CD	O
of	IN	O
ten	NNS	O
achieved	VBN	O
the	DT	O
in	IN	PH
utero	JJ	PH
accretion	NN	PH
rate	NN	PH
for	IN	PH
zinc	NN	PH
for	IN	O
a	DT	O
34-week	JJ	O
gestation	NN	O
fetus	NN	O
(	(	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.432	CD	O
mg/d	NN	O
)	)	O
.	.	O

Three	CD	O
infants	NNS	O
receiving	VBG	O
the	DT	O
high	JJ	O
copper	NN	O
formula	NN	O
and	CC	O
two	CD	O
receiving	VBG	O
the	DT	O
lower	JJR	O
copper	NN	O
formula	NN	O
were	VBD	O
in	IN	O
positive	JJ	PH
copper	NN	PH
balance	NN	PH
.	.	PH

Two	CD	O
infants	NNS	O
from	IN	O
each	DT	O
group	NN	O
achieved	VBD	O
the	DT	O
in	IN	PH
utero	JJ	PH
accretion	NN	PH
rate	NN	PH
for	IN	PH
copper	NN	PH
for	IN	O
a	DT	O
34-week	JJ	O
gestation	NN	O
fetus	NN	O
(	(	O
0.088	CD	O
mg/d	NN	O
)	)	O
.	.	O

A	DT	O
formula	NN	O
that	WDT	O
provides	VBZ	O
12.5	CD	O
mg/L	NN	O
of	IN	O
zinc	NN	O
permits	NNS	O
positive	JJ	PH
zinc	NN	PH
balance	NN	PH
and	CC	PH
zinc	NN	PH
retention	NN	PH
similar	JJ	O
to	TO	O
in	IN	O
utero	JJ	O
rates	NNS	O
.	.	O

A	DT	O
formula	NN	O
that	WDT	O
provides	VBZ	O
as	RB	O
much	JJ	O
as	IN	O
2.1	CD	O
mg/L	NN	O
of	IN	O
copper	NN	O
,	,	O
however	RB	O
,	,	O
may	MD	O
not	RB	O
always	RB	O
permit	VBP	O
positive	JJ	O
copper	NN	PH
balance	NN	PH
.	.	O

Association	NNP	O
of	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
disease	NN	O
with	IN	O
increased	JJ	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
knee	JJ	O
osteoarthritis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
(	(	O
PF	NNP	O
)	)	O
disease	NN	O
with	IN	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
tibiofemoral	JJ	O
(	(	O
TF	NNP	O
)	)	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Radiographic	NNP	O
views	NNS	O
of	IN	O
the	DT	O
TF	NNP	O
and	CC	O
PF	NNP	O
compartments	NNS	O
,	,	O
knee	VB	O
extension	NN	O
strength	NN	O
,	,	O
and	CC	O
knee	VB	O
range	NN	O
of	IN	O
motion	NN	O
were	VBD	O
obtained	VBN	O
for	IN	O
167	CD	O
patients	NNS	O
with	IN	O
knee	JJ	O
OA	NNP	O
.	.	O

Additionally	RB	O
,	,	O
knee-specific	JJ	PH
symptoms	NNS	PH
and	CC	O
functional	JJ	PH
limitations	NNS	PH
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Western	NNP	PH
Ontario	NNP	PH
and	CC	PH
McMaster	NNP	PH
Universities	NNP	PH
Osteoarthritis	NNP	PH
Index	NNP	PH
(	(	PH
WOMAC	NNP	PH
)	)	PH
and	CC	Ot
the	DT	Ot
Activities	NNS	PH
of	IN	PH
Daily	NNP	PH
Living	NNP	PH
Scale	NNP	PH
(	(	PH
ADLS	NNP	PH
)	)	PH
.	.	O

RESULTS	NNP	O
Moderate/severe	NNP	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
knee	NN	PH
extension	NN	PH
strength	NN	PH
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.4	CD	O
?	.	O
0.5	CD	O
Nm/body	NN	O
weight	VBD	O
[	NNP	O
BW	NNP	O
]	NNP	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.8	CD	O
?	.	O
0.5	CD	O
Nm/BW	NNP	O
)	)	O
.	.	O

Additionally	RB	O
,	,	O
total	JJ	O
knee	NN	O
range	NN	O
of	IN	O
motion	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
moderate/severe	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
120.8?	CD	O
?	.	O
14.4?	CD	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
133.5?	CD	O
?	.	O
10.7?	CD	O
)	)	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
125.8?	CD	O
?	.	O
13.0?	CD	O
)	)	O
.	.	O

Moderate/severe	NNP	O
PFOA	NNP	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
less	JJR	O
pain	NN	O
while	IN	O
standing	VBG	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	$	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
0.1-0.7	JJ	O
and	CC	O
OR	NNP	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.1-0.6	CD	O
,	,	O
respectively	RB	O
)	)	O
on	IN	O
the	DT	O
WOMAC	NNP	O
,	,	O
and	CC	O
moderate/severe	RB	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
difficulty	NN	O
with	IN	O
going	VBG	O
downstairs	NNS	O
(	(	O
OR	NNP	O
2.9	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.0-8.1	CD	O
)	)	O
on	IN	O
the	DT	O
ADLS	NNP	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
appears	VBZ	O
that	IN	O
knees	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
coexisting	VBG	O
PF	NNP	O
disease	NN	O
demonstrate	NN	O
features	NNS	O
distinct	VBP	O
from	IN	O
those	DT	O
observed	VBN	O
in	IN	O
TFOA	NNP	O
in	IN	O
isolation	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
mild	JJ	O
PF	NNP	O
disease	NN	O
.	.	O

Treatment	NNP	O
strategies	VBZ	O
targeting	VBG	O
the	DT	O
PF	NNP	O
joint	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
to	TO	O
mitigate	VB	O
the	DT	O
specific	JJ	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
problems	NNS	O
present	JJ	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

Treatment	NN	O
with	IN	O
the	DT	O
dipeptidyl	JJ	O
peptidase-4	JJ	O
inhibitor	NN	O
vildagliptin	NN	O
improves	VBZ	O
fasting	VBG	O
islet-cell	JJ	O
function	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

CONTEXT	NNP	O
Dipeptidyl	NNP	O
peptidase	NN	O
4	CD	O
(	(	O
DPP-4	NNP	O
)	)	O
inhibitors	NNS	O
are	VBP	O
proposed	VBN	O
to	TO	O
lower	VB	O
blood	NN	O
glucose	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
mellitus	FW	O
(	(	O
T2DM	NNP	O
)	)	O
by	IN	O
prolonging	VBG	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
circulating	NN	O
incretins	NNS	O
,	,	O
glucose-dependent	JJ	O
insulinotropic	NN	O
polypeptide	NN	O
(	(	O
GIP	NNP	O
)	)	O
and	CC	O
glucagon-like	JJ	O
peptide	NN	O
1	CD	O
(	(	O
GLP-1	NNP	O
)	)	O
.	.	O

Consistent	JJ	O
with	IN	O
this	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
,	,	O
DPP-4	NNP	O
inhibitors	NNS	O
improve	VBP	O
glucose	JJ	O
tolerance	NN	O
after	IN	O
meals	NNS	O
by	IN	O
increasing	VBG	O
insulin	NN	O
and	CC	O
reducing	VBG	O
glucagon	NN	O
levels	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
.	.	O

However	RB	O
,	,	O
DPP-4	NNP	O
inhibitors	NNS	O
also	RB	O
reduce	VB	O
fasting	VBG	O
blood	NN	O
glucose	NN	O
,	,	O
an	DT	O
unexpected	JJ	O
effect	NN	O
because	IN	O
circulating	VBG	O
levels	NNS	O
of	IN	O
active	JJ	O
GIP	NNP	O
and	CC	O
GLP-1	NNP	O
are	VBP	O
low	JJ	O
in	IN	O
the	DT	O
postabsorptive	JJ	O
state	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	PH
of	IN	PH
DPP-4	NNP	PH
inhibition	NN	PH
on	IN	PH
fasting	VBG	PH
islet	NN	PH
function	NN	PH
.	.	O

DESIGN	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

SETTING	VB	O
The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
General	NNP	O
Clinical	NNP	O
Research	NNP	O
Centers	NNPS	O
at	IN	O
two	CD	O
University	NNP	O
Hospitals	NNP	O
.	.	O

SUBJECTS	NNP	O
Forty-one	JJ	O
subjects	NNS	O
with	IN	O
T2DM	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
metformin	NN	O
or	CC	O
diet	NN	O
,	,	O
having	VBG	O
good	JJ	O
glycemic	NNS	O
control	NN	O
with	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
values	NNS	O
of	IN	O
6.2-7.5	JJ	O
%	NN	O
.	.	O

INTERVENTION	JJ	O
Subjects	NNPS	O
were	VBD	O
treated	VBN	O
with	IN	O
vildagliptin	NN	O
(	(	O
50	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	O
for	IN	O
3	CD	O
months	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
2-wk	JJ	O
washout	NN	O
.	.	O

Major	JJ	O
Outcome	JJ	O
Measure	NN	O
:	:	O
We	PRP	O
measured	VBD	O
insulin	JJ	PH
secretion	NN	PH
in	IN	PH
response	NN	PH
to	TO	PH
iv	VB	PH
glucose	JJ	PH
and	CC	PH
arginine	JJ	PH
before	NN	O
and	CC	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
drug	NN	O
washout	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
small	JJ	O
and	CC	O
comparable	JJ	O
reductions	NNS	O
in	IN	O
glycosylated	JJ	PH
hemoglobin	NN	PH
in	IN	O
both	DT	O
groups	NNS	O
over	IN	O
3	CD	O
months	NNS	O
.	.	O

Vildagliptin	NNP	O
increased	VBD	O
fasting	VBG	O
GLP-1	NNP	PH
levels	NNS	O
in	IN	O
subjects	NNS	O
taking	VBG	O
metformin	NN	O
,	,	O
but	CC	O
not	RB	O
those	DT	O
managed	VBN	O
with	IN	O
diet	JJ	O
,	,	O
and	CC	O
raised	VBD	O
active	JJ	O
GIP	NNP	O
levels	NNS	O
slightly	RB	O
.	.	O

DPP-4	JJ	O
inhibitor	NN	O
treatment	NN	O
improved	VBD	O
the	DT	O
acute	JJ	PH
insulin	NN	PH
and	CC	PH
C-peptide	JJ	PH
responses	NNS	PH
to	TO	O
glucose	VB	O
(	(	O
50	CD	O
and	CC	O
100	CD	O
%	NN	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
increased	VBD	O
the	DT	O
slope	NN	O
of	IN	O
the	DT	O
C-peptide	NNP	PH
response	NN	PH
to	TO	O
glucose	VB	O
(	(	O
33	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Vildagliptin	NNP	O
improves	VBZ	O
islet	JJ	O
function	NN	O
in	IN	O
T2DM	NNP	O
under	IN	O
fasting	VBG	O
conditions	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
DPP-4	NNP	O
inhibition	NN	O
has	VBZ	O
metabolic	JJ	O
benefits	NNS	O
in	IN	O
addition	NN	O
to	TO	O
enhancing	VBG	O
meal-induced	JJ	O
GLP-1	NNP	O
and	CC	O
GIP	NNP	O
activity	NN	O
.	.	O

Safety	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
cellulose	JJ	O
sulfate	NN	O
as	IN	O
a	DT	O
vaginal	JJ	O
microbicide	NN	O
in	IN	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
Few	JJ	O
studies	NNS	O
of	IN	O
topical	JJ	O
microbicides	NNS	O
have	VBP	O
assessed	VBN	O
their	PRP$	O
safety	NN	Ot
in	IN	Ot
HIV-infected	JJ	Ot
women	NNS	Ot
.	.	O

We	PRP	O
conducted	VBD	O
this	DT	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
acceptability	NN	Ot
of	IN	O
6	CD	O
%	NN	O
cellulose	JJ	O
sulfate	NN	O
(	(	O
CS	NNP	O
)	)	O
gel	NN	O
as	IN	O
a	DT	O
vaginal	JJ	O
microbicide	NN	O
in	IN	O
sexually	RB	O
abstinent	JJ	O
and	CC	O
active	JJ	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

METHODS	NNP	O
Fifty-nine	JJ	O
HIV-infected	JJ	O
women	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
comparing	VBG	O
6	CD	O
%	NN	O
CS	NNP	O
to	TO	O
placebo	VB	O
gel	NNS	O
used	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Sexually	NNP	O
abstinent	JJ	O
women	NNS	O
applied	VBD	O
gel	JJ	O
once	RB	O
or	CC	O
twice	JJ	O
daily	JJ	O
and	CC	O
sexually	RB	O
active	JJ	O
women	NNS	O
used	VBN	O
gel	JJ	O
once	RB	O
daily	JJ	O
.	.	O

RESULTS	NNP	O
CS	NNP	O
gel	NN	O
was	VBD	O
safe	JJ	O
with	IN	O
no	DT	O
reported	VBN	O
severe	RB	A
or	CC	A
life-threatening	JJ	A
adverse	JJ	A
events	NNS	A
(	(	A
AE	NNP	A
)	)	A
.	.	O

Thirty-nine	NNP	O
(	(	O
66	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
urogenital	JJ	A
AE	NNP	A
judged	VBD	O
as	IN	O
probably	RB	O
or	CC	O
possibly	RB	O
related	VBN	O
to	TO	O
gel	VB	O
.	.	O

The	DT	O
majority	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
participants	NNS	O
reported	VBD	O
only	RB	O
mild	JJ	A
events	NNS	A
.	.	O

Fewer	JJR	O
women	NNS	O
(	(	O
62	CD	O
%	NN	O
)	)	O
who	WP	O
used	VBD	O
CS	NNP	O
experienced	VBD	O
urogenital	JJ	A
AE	NNP	A
than	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
placebo	VB	O
gel	NN	O
(	(	O
70	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.59	CD	O
)	)	O
.	.	O

Eleven	NNP	O
(	(	O
19	CD	O
%	NN	O
)	)	O
women	NNS	O
experienced	VBD	O
intermenstrual	JJ	A
bleeding	NN	A
judged	VBD	O
to	TO	O
be	VB	O
probably	RB	O
or	CC	O
possibly	RB	O
related	VBN	O
to	TO	O
gel	VB	O
use	NN	O
(	(	O
four	CD	O
in	IN	O
the	DT	O
CS	NNP	O
and	CC	O
seven	CD	O
in	IN	O
the	DT	O
placebo	NN	O
gel	NN	O
group	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
AE	NNP	A
by	IN	O
frequency	NN	O
of	IN	O
gel	NN	O
use	NN	O
or	CC	O
sexual	JJ	O
activity	NN	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
abdominal/pelvic	NN	A
pain	NN	A
which	WDT	O
was	VBD	O
noted	VBN	O
more	RBR	O
frequently	RB	O
with	IN	O
twice	RB	O
daily	JJ	O
use	NN	O
among	IN	O
sexually	RB	O
abstinent	JJ	O
women	NNS	O
.	.	O

Women	NNS	O
and	CC	O
men	NNS	O
found	VBD	O
the	DT	O
gel	NN	O
highly	RB	O
acceptable	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
Phase	NNP	O
I	PRP	O
study	VBP	O
demonstrated	VBD	O
that	IN	O
CS	NNP	O
vaginal	JJ	O
gel	NN	O
was	VBD	O
safe	JJ	Ot
,	,	Ot
well	RB	Ot
tolerated	VBN	Ot
and	CC	Ot
acceptable	JJ	Ot
by	IN	O
HIV-infected	JJ	O
women	NNS	O
and	CC	O
their	PRP$	O
male	JJ	O
partners	NNS	O
.	.	O

Thus	RB	O
,	,	O
further	JJ	O
development	NN	O
of	IN	O
CS	NNP	O
is	VBZ	O
warranted	VBN	O
as	IN	O
a	DT	O
potential	JJ	O
method	NN	O
to	TO	O
prevent	VB	O
HIV	NNP	PH
transmission	NN	PH
and	CC	PH
acquisition	NN	PH
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
cutting	VBG	O
balloon	NN	O
angioplasty	JJ	O
versus	NN	O
high-pressure	NN	O
balloon	NN	O
angioplasty	NN	O
in	IN	O
hemodialysis	NN	O
arteriovenous	JJ	O
fistula	NN	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
cutting	VBG	O
balloon	NN	O
angioplasty	NN	O
(	(	O
CBA	NNP	O
)	)	O
versus	IN	O
high-pressure	NN	O
balloon	NN	O
angioplasty	NN	O
(	(	O
HPBA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hemodialysis	NN	O
autogenous	JJ	O
fistula	NN	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
percutaneous	JJ	O
transluminal	JJ	O
angioplasty	NN	O
(	(	O
PTA	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
patients	NNS	O
with	IN	O
dysfunctional	JJ	O
,	,	O
stenotic	JJ	O
hemodialysis	NN	O
arteriovenous	JJ	O
fistulas	NNS	O
(	(	O
AVFs	NNP	O
)	)	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
CBA	NNP	O
or	CC	O
HPBA	NNP	O
if	IN	O
conventional	JJ	O
PTA	NNP	O
had	VBD	O
suboptimal	JJ	O
results	NNS	O
(	(	O
ie	JJ	O
,	,	O
residual	JJ	O
stenosis	NN	O
>	VBD	O
30	CD	O
%	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
516	CD	O
patients	NNS	O
consented	VBN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
from	IN	O
October	NNP	O
2008	CD	O
to	TO	O
September	NNP	O
2011	CD	O
,	,	O
85	CD	O
%	NN	O
of	IN	O
whom	WP	O
(	(	O
n	JJ	O
=	NNP	O
439	CD	O
)	)	O
had	VBD	O
technically	RB	O
successful	JJ	O
conventional	JJ	O
PTA	NNP	O
.	.	O

The	DT	O
remaining	VBG	O
71	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
60	CD	O
y	NN	O
;	:	O
49	CD	O
men	NNS	O
)	)	O
with	IN	O
suboptimal	JJ	O
PTA	NNP	O
results	NNS	O
were	VBD	O
eventually	RB	O
randomized	VBN	O
:	:	O
36	CD	O
to	TO	O
the	DT	O
CBA	NNP	O
arm	NN	O
and	CC	O
35	CD	O
to	TO	O
the	DT	O
HPBA	NNP	O
arm	NN	O
.	.	O

Primary	JJ	O
and	CC	O
secondary	JJ	O
target	NN	O
lesion	NN	O
patencies	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
Kaplan-Meier	NNP	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Clinical	JJ	Ot
success	NN	Ot
rates	NNS	Ot
were	VBD	O
100	CD	O
%	NN	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

Primary	JJ	PH
target	NN	PH
lesion	NN	PH
patency	NN	PH
rates	NNS	PH
at	IN	O
6	CD	O
months	NNS	O
were	VBD	O
66.4	CD	O
%	NN	O
and	CC	O
39.9	CD	O
%	NN	O
for	IN	O
CBA	NNP	O
and	CC	O
HPBA	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Secondary	JJ	PH
target	NN	PH
lesion	NN	PH
patency	NN	PH
rates	NNS	PH
at	IN	O
6	CD	O
months	NNS	O
were	VBD	O
96.5	CD	O
%	NN	O
for	IN	O
CBA	NNP	O
and	CC	O
80.0	CD	O
%	NN	O
for	IN	O
HPBA	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
single	JJ	O
major	JJ	A
complication	NN	A
of	IN	O
venous	JJ	A
perforation	NN	A
following	VBG	O
CBA	NNP	O
.	.	O

The	DT	O
30-day	JJ	MO
mortality	NN	MO
rate	NN	MO
was	VBD	O
1.4	CD	O
%	NN	O
,	,	O
with	IN	O
one	CD	O
non-procedure-related	JJ	O
death	NN	O
in	IN	O
the	DT	O
HPBA	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Primary	NNP	O
and	CC	O
secondary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
of	IN	O
CBA	NNP	O
were	VBD	O
statistically	RB	O
superior	JJ	O
to	TO	O
those	DT	O
of	IN	O
HPBA	NNP	O
following	VBG	O
suboptimal	JJ	O
conventional	JJ	O
PTA	NNP	O
.	.	O

For	IN	O
AVF	NNP	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
PTA	NNP	O
,	,	O
CBA	NNP	O
may	MD	O
be	VB	O
a	DT	O
better	JJR	O
second-line	JJ	O
treatment	NN	O
given	VBN	O
its	PRP$	O
superior	JJ	O
patency	NN	O
rates	NNS	O
.	.	O

Dexamethasone	NNP	O
therapy	NN	O
and	CC	O
cortisol	JJ	O
excretion	NN	O
in	IN	O
severe	JJ	O
pediatric	JJ	O
head	NN	O
injury	NN	O
.	.	O

Glucocorticoids	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reduce	VB	O
brain	NN	O
edema	NN	O
secondary	JJ	O
to	TO	O
head	VB	O
injury	NN	O
.	.	O

Nevertheless	RB	O
,	,	O
their	PRP$	O
usefulness	JJ	O
remains	NNS	O
uncertain	JJ	O
and	CC	O
contradictory	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
24	CD	O
children	NNS	O
with	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
,	,	O
urinary	JJ	O
free	JJ	O
cortisol	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
(	(	O
group	NN	O
1	CD	O
)	)	O
received	VBD	O
dexamethasone	NN	O
and	CC	O
12	CD	O
(	(	O
group	NN	O
2	CD	O
)	)	O
did	VBD	O
not	RB	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
standardized	JJ	O
regimen	NN	O
.	.	O

In	IN	O
group	NN	O
1	CD	O
there	EX	O
was	VBD	O
complete	JJ	O
suppression	NN	Ot
of	IN	Ot
endogenous	JJ	Ot
cortisol	NN	Ot
production	NN	Ot
.	.	O

In	IN	O
group	NN	O
2	CD	O
free	JJ	O
cortisol	NN	O
was	VBD	O
up	RB	O
to	TO	O
20-fold	CD	O
higher	JJR	O
than	IN	O
under	IN	O
basal	JJ	O
conditions	NNS	O
and	CC	O
reached	VBN	O
maximum	JJ	O
values	NNS	O
on	IN	O
days	NNS	O
1-3	RB	O
.	.	O

Since	IN	O
the	DT	O
excretion	NN	PH
of	IN	PH
cortisol	NN	PH
in	IN	PH
urine	JJ	PH
reflects	VBZ	O
the	DT	O
production	NN	O
rate	NN	O
closely	RB	O
and	CC	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
liver	NN	O
function	NN	O
and	CC	O
barbiturates	NNS	O
,	,	O
the	DT	O
results	NNS	O
in	IN	O
group	NN	O
2	CD	O
show	NN	O
that	IN	O
the	DT	O
endogenous	JJ	O
production	NN	O
of	IN	O
steroids	NNS	O
is	VBZ	O
an	DT	O
adequate	JJ	O
reaction	NN	O
to	TO	O
severe	VB	O
head	JJ	O
injury	NN	O
.	.	O

Exogenous	JJ	O
glucocorticoids	NNS	O
are	VBP	O
thus	RB	O
unlikely	JJ	O
to	TO	O
have	VB	O
any	DT	O
more	JJR	O
beneficial	JJ	O
effects	NNS	O
than	IN	O
endogenous	JJ	O
cortisol	NN	O
.	.	O

Feasibility	NN	O
of	IN	O
two	CD	O
dose-dense	JJ	O
FEC	NNP	O
regimens	VBZ	O
with	IN	O
growth	NN	O
factor	NN	O
support	NN	O
for	IN	O
adjuvant	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	JJ	O
study	NN	O
of	IN	O
the	DT	O
Central	NNP	O
European	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
CECOG	NNP	O
)	)	O
.	.	O

Addition	NN	O
of	IN	O
epirubicin	NN	O
to	TO	O
adjuvant	VB	O
chemotherapy	NN	O
can	MD	O
provide	VB	O
important	JJ	O
benefits	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
but	CC	O
the	DT	O
optimal	JJ	O
dose	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

Further	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
dose-dense	JJ	O
regimens	NNS	O
,	,	O
but	CC	O
densification	NN	O
of	IN	O
fluorouracil/epirubicin/cyclophosphamide	NN	O
(	(	O
FEC	NNP	O
)	)	O
has	VBZ	O
proved	VBN	O
difficult	JJ	O
,	,	O
with	IN	O
FEC	NNP	O
(	(	O
60	CD	O
)	)	O
providing	VBG	O
little	JJ	O
benefit	NN	O
over	IN	O
standard	JJ	O
chemotherapy	NN	O
and	CC	O
FEC	NNP	O
(	(	O
100	CD	O
)	)	O
associated	VBN	O
with	IN	O
toxicity	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
two	CD	O
intermediate	JJ	O
dose-dense	JJ	O
FEC	NNP	O
regimens	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
six	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
or	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
,	,	O
with	IN	O
all	DT	O
three	CD	O
drugs	NNS	O
given	VBN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
14-day	JJ	O
cycle	NN	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
pegfilgrastim	JJ	O
6	CD	O
mg	NN	O
as	IN	O
a	DT	O
single	JJ	O
subcutaneous	JJ	O
injection	NN	O
on	IN	O
day	NN	O
2	CD	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
proportion	NN	PH
of	IN	PH
subjects	NNS	PH
receiving	VBG	PH
>	NN	PH
or	CC	PH
=85	CD	PH
%	NN	PH
relative	JJ	PH
dose	JJ	PH
intensity	NN	PH
and	CC	O
was	VBD	O
achieved	VBN	O
by	IN	O
96	CD	O
%	NN	O
and	CC	O
88	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
and	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Of	IN	O
147	CD	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
infusions	NNS	O
,	,	O
4.1	CD	O
%	NN	O
were	VBD	O
delayed	VBN	O
,	,	O
while	IN	O
9.8	CD	O
%	NN	O
of	IN	O
143	CD	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
infusions	NNS	O
were	VBD	O
delayed	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
reasons	NNS	O
for	IN	O
delay	NN	O
were	VBD	O
adverse	JJ	A
events	NNS	A
and	CC	O
personal/logistical	JJ	O
reasons	NNS	O
.	.	O

One	CD	O
dose	JJ	O
reduction	NN	O
occurred	VBD	O
during	IN	O
the	DT	O
study	NN	O
(	(	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
)	)	O
,	,	O
related	VBN	O
to	TO	O
diarrhoea	VB	PH
.	.	O

Grade	VB	A
3-4	JJ	A
haematological	JJ	A
toxicities	NNS	A
were	VBD	O
reported	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
arm	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
febrile	JJ	A
neutropenia	NN	A
during	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
increases	NNS	O
in	IN	O
liver	NN	PH
enzymes	NNS	PH
and	CC	PH
gastrointestinal	JJ	PH
events	NNS	PH
;	:	O
no	DT	O
event	NN	O
resulted	VBD	O
in	IN	O
discontinuation	NN	O
.	.	O

Only	RB	O
one	CD	O
patient	NN	O
(	(	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
)	)	O
experienced	VBD	O
serious	JJ	A
adverse	JJ	A
events	NNS	A
(	(	A
vomiting	VBG	A
and	CC	A
throat	VB	A
oedema	NN	A
)	)	A
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
dose-dense	JJ	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
and	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
are	VBP	O
feasible	JJ	O
with	IN	O
pegfilgrastim	JJ	O
support	NN	O
.	.	O

These	DT	O
regimens	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
risk	NN	O
of	IN	O
Grade	NNP	A
3-4	JJ	A
toxicity	NN	A
.	.	O

The	DT	O
accuracy	NN	Ot
of	IN	O
clinical	JJ	PH
neurosensory	NN	PH
testing	VBG	PH
for	IN	O
nerve	JJ	O
injury	NN	O
diagnosis	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
accuracy	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
neurosensory	JJ	O
test	NN	O
to	TO	O
diagnose	VB	O
trigeminal	JJ	O
nerve	NN	O
injuries	NNS	O
has	VBZ	O
never	RB	O
been	VBN	O
statistically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
statistical	JJ	Ot
efficacy	NN	Ot
of	IN	Ot
the	DT	Ot
clinical	JJ	Ot
neurosensory	JJ	Ot
test	NN	Ot
using	VBG	O
surgical	JJ	O
findings	NNS	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
whether	IN	O
a	DT	O
correlation	NN	O
existed	VBN	O
between	IN	O
the	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
obtained	VBN	O
by	IN	O
preoperative	JJ	O
testing	NN	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
nerve	NN	O
injury	NN	O
found	VBD	O
at	IN	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
blinded	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
130	CD	O
patients	NNS	O
with	IN	O
inferior	JJ	O
alveolar	JJ	O
nerve	NN	O
(	(	O
IAN	NNP	O
)	)	O
and	CC	O
lingual	JJ	O
nerve	NN	O
(	(	O
LN	NNP	O
)	)	O
injuries	NNS	O
.	.	O

Preoperatively	RB	O
,	,	O
patients	NNS	O
were	VBD	O
provided	VBN	O
a	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
using	VBG	O
a	DT	O
three-level	JJ	O
drop-out	JJ	O
clinical	JJ	O
neurosensory	NN	O
test	NN	O
(	(	O
NST	NNP	O
)	)	O
,	,	O
and	CC	O
blind	IN	O
comparisons	NNS	O
were	VBD	O
made	VBN	O
with	IN	O
the	DT	O
surgical	JJ	O
findings	NNS	O
postoperatively	RB	O
.	.	O

RESULTS	VB	O
The	DT	O
positive	JJ	ME
predictive	NN	ME
and	CC	ME
negative	JJ	ME
predictive	NN	ME
values	NNS	ME
for	IN	O
LN-injured	JJ	O
patients	NNS	O
were	VBD	O
95	CD	O
%	NN	O
and	CC	O
100	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
positive	JJ	O
predictive	NN	O
and	CC	O
negative	JJ	O
predictive	NN	O
values	NNS	O
for	IN	O
IAN	NNP	O
patients	NNS	O
were	VBD	O
77	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
distribution	NN	O
of	IN	O
age	NN	O
,	,	O
duration	NN	O
of	IN	O
injury	NN	O
,	,	O
cause	NN	O
of	IN	O
injury	NN	O
,	,	O
presence	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
,	,	O
presence	NN	O
of	IN	O
trigger	NN	O
pain	NN	O
,	,	O
and	CC	O
degree	NN	O
of	IN	O
injury	NN	O
between	IN	O
the	DT	O
IAN	NNP	O
and	CC	O
LN	NNP	O
patient	JJ	O
populations	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	PH
significant	JJ	PH
positive	JJ	PH
relationship	NN	PH
found	VBD	PH
between	IN	PH
the	DT	PH
sensory	JJ	PH
impairment	NN	PH
score	NN	PH
and	CC	PH
the	DT	PH
degree	NN	PH
of	IN	PH
nerve	NN	PH
injury	NN	PH
.	.	O

CONCLUSIONS	VB	O
The	DT	O
NST	NNP	O
is	VBZ	O
a	DT	O
clinically	RB	O
useful	JJ	O
method	NN	O
to	TO	O
diagnose	VB	O
IAN	NNP	O
and	CC	O
LN	NNP	O
injuries	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
NST	NNP	O
results	NNS	O
are	VBP	O
less	RBR	Ot
efficient	JJ	Ot
for	IN	O
IAN	NNP	O
injuries	NNS	O
than	IN	O
LN	NNP	O
injuries	NNS	O
,	,	O
and	CC	O
have	VBP	O
a	DT	O
high	JJ	PH
incidence	NN	PH
of	IN	PH
false-positive	JJ	PH
(	(	O
23	CD	O
%	NN	O
)	)	O
and	CC	O
false-negative	JJ	Ot
(	(	O
40	CD	O
%	NN	O
)	)	O
results	NNS	O
when	WRB	O
testing	VBG	O
patients	NNS	O
with	IN	O
IAN	NNP	O
injuries	NNS	O
.	.	O

The	DT	O
different	JJ	O
rates	NNS	O
of	IN	O
statistical	JJ	Ot
efficiency	NN	Ot
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
may	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
prevalence	NN	O
and	CC	O
biologic	NN	O
covariates	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
individualized	JJ	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Studies	NNPS	O
have	VBP	O
shown	VBN	O
that	IN	O
a	DT	O
majority	NN	O
of	IN	O
women	NNS	O
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
have	VBP	O
exaggerated	VBN	O
perceptions	NNS	O
of	IN	O
their	PRP$	O
own	JJ	O
risk	NN	O
of	IN	O
this	DT	O
disease	NN	O
and	CC	O
experience	NN	O
excessive	JJ	O
anxiety	NN	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
the	DT	O
need	NN	O
to	TO	O
communicate	VB	O
more	JJR	O
accurate	JJ	O
risk	NN	O
information	NN	O
to	TO	O
these	DT	O
women	NNS	O
,	,	O
specialized	JJ	O
programs	NNS	O
for	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	VBG	O
have	VBP	O
been	VBN	O
initiated	VBN	O
in	IN	O
medical	JJ	O
centers	NNS	O
across	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PURPOSE	VB	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
1	CD	O
)	)	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
standardized	JJ	O
protocol	NN	O
for	IN	O
individualized	JJ	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	VBG	O
on	IN	O
comprehension	NN	ME
of	IN	ME
personal	JJ	ME
risk	NN	ME
among	IN	O
first-degree	JJ	O
relatives	NNS	O
of	IN	O
index	NN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
and	CC	O
2	CD	O
)	)	O
to	TO	O
identify	VB	O
women	NNS	O
most	RBS	O
and	CC	O
least	JJS	O
likely	JJ	O
to	TO	O
benefit	VB	O
from	IN	O
such	JJ	O
counseling	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
individualized	VBN	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	VBG	O
to	TO	O
general	JJ	O
health	NN	O
counseling	NN	O
(	(	O
control	NN	O
)	)	O
.	.	O

We	PRP	O
studied	VBD	O
200	CD	O
women	NNS	O
aged	VBN	O
35	CD	O
years	NNS	O
and	CC	O
older	JJR	O
who	WP	O
had	VBD	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
in	IN	O
a	DT	O
first-degree	JJ	O
relative	NN	O
.	.	O

Women	NNS	O
with	IN	O
a	DT	O
personal	JJ	O
history	NN	O
of	IN	O
cancer	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Risk	NNP	ME
comprehension	NN	ME
was	VBD	O
assessed	VBN	O
as	IN	O
the	DT	O
concordance	NN	O
between	IN	O
perceived	VBN	O
subjective	JJ	O
lifetime	NN	O
breast	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
estimated	VBN	O
objective	JJ	O
lifetime	NN	O
risk	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
of	IN	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
women	NNS	O
who	WP	O
received	VBD	O
risk	NN	O
counseling	NN	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
improve	VB	O
their	PRP$	O
risk	NN	ME
comprehension	NN	ME
,	,	O
compared	VBN	O
with	IN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
=	VBZ	O
3.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	NNP	O
1.3-9.5	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
about	RB	O
two	CD	O
thirds	NNS	O
of	IN	O
women	NNS	O
continued	VBN	O
to	TO	O
overestimate	VB	ME
their	PRP$	ME
lifetime	NN	ME
risks	NNS	ME
substantially	RB	O
following	VBG	O
counseling	VBG	O
.	.	O

Examination	NN	O
of	IN	O
subjects	NNS	O
by	IN	O
treatment	NN	O
interaction	NN	O
effects	NNS	O
indicated	VBD	O
that	IN	O
risk	NN	O
counseling	VBG	O
did	VBD	O
not	RB	O
produce	VB	O
improved	JJ	O
comprehension	NN	ME
among	IN	O
the	DT	O
large	JJ	O
proportion	NN	O
of	IN	O
women	NNS	O
who	WP	O
had	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
anxious	JJ	O
preoccupation	NN	O
with	IN	O
breast	NN	O
cancer	NN	O
at	IN	O
base	NN	O
line	NN	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
white	JJ	O
women	NNS	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
benefit	VB	O
than	IN	O
African-American	JJ	O
women	NNS	O
(	(	O
OR	NNP	O
=	VBZ	O
0.34	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.11-0.99	NN	O
;	:	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Efforts	NNPS	O
to	TO	O
counsel	NN	O
women	NNS	O
about	IN	O
their	PRP$	O
breast	NN	O
cancer	NN	O
risks	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
effective	JJ	O
unless	IN	O
their	PRP$	O
breast	NN	O
cancer	NN	O
anxieties	NNS	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

IMPLICATIONS	NNP	O
Attention	NNP	O
to	TO	O
the	DT	O
psychological	JJ	O
aspects	NNS	O
of	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
will	MD	O
be	VB	O
critical	JJ	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
risk-counseling	JJ	O
programs	NNS	O
that	WDT	O
incorporate	VBP	O
testing	VBG	O
for	IN	O
the	DT	O
recently	RB	O
cloned	VBN	O
breast	NN	O
cancer	NN	O
susceptibility	NN	O
gene	NN	O
,	,	O
BRCA1	NNP	O
(	(	O
and	CC	O
BRCA2	NNP	O
when	WRB	O
that	DT	O
gene	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
cloned	VBN	O
)	)	O
.	.	O

Prevention	NN	O
of	IN	O
coronary	JJ	O
spasm	NN	O
by	IN	O
nicorandil	NNS	O
:	:	O
comparison	NN	O
with	IN	O
nifedipine	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
nicorandil	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
nifedipine	NN	O
in	IN	O
13	CD	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
coronary	JJ	O
spasm	NN	O
during	IN	O
coronary	JJ	O
arteriography	NN	O
,	,	O
either	CC	O
spontaneously	RB	O
or	CC	O
ergometrine-induced	JJ	O
.	.	O

During	IN	O
two	CD	O
consecutive	JJ	O
periods	NNS	O
of	IN	O
2	CD	O
days	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
active	JJ	O
drugs	NNS	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
30	CD	O
mg	NN	O
nicorandil	NN	O
,	,	O
10	CD	O
mg	NN	O
nifedipine	NN	O
,	,	O
and	CC	O
,	,	O
on	IN	O
2	CD	O
days	NNS	O
,	,	O
a	DT	O
placebo	NN	O
.	.	O

One	CD	O
hour	NN	O
after	IN	O
drug	NN	O
intake	NN	O
,	,	O
patients	NNS	O
underwent	VBD	O
an	DT	O
ergometrine	JJ	O
test	NN	O
with	IN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
Methergin	NNP	O
(	(	O
ergometrine	NN	O
)	)	O
(	(	O
0.05	CD	O
,	,	O
0.10	CD	O
,	,	O
0.20	CD	O
,	,	O
and	CC	O
0.40	CD	O
mg	NN	O
every	DT	O
5	CD	O
min	NN	O
)	)	O
.	.	O

After	IN	O
placebo	NN	O
,	,	O
the	DT	O
tests	NNS	O
always	RB	O
were	VBD	O
positive	JJ	O
,	,	O
and	CC	O
the	DT	O
ECG	NNP	Ot
changes	NNS	Ot
occurred	VBD	O
at	IN	O
the	DT	O
same	JJ	O
+/-	JJ	O
1	CD	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
10	CD	O
cases	NNS	O
,	,	O
showing	VBG	O
good	JJ	Ot
reproducibility	NN	Ot
.	.	O

After	IN	O
nicorandil	NN	O
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
nine	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
lower	JJR	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
three	CD	O
and	CC	O
one	CD	O
patient	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0034	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

After	IN	O
nifedipine	NN	O
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
five	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
four	CD	O
and	CC	O
four	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0039	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Nifedipine	NNP	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
and	CC	O
nicorandil	$	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
eight	CD	O
patients	NNS	O
;	:	O
in	IN	O
the	DT	O
remaining	VBG	O
five	CD	O
patients	NNS	O
,	,	O
nicorandil	NNS	O
had	VBD	O
better	JJR	O
results	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

Nicorandil	NNP	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
prevents	VBZ	O
ergometrine-induced	JJ	PH
coronary	JJ	PH
spasm	NN	PH
.	.	O

This	DT	O
compound	NN	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
vasospastic	JJ	PH
angina	NN	PH
.	.	O

Financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
of	IN	O
dysfunctional	JJ	O
uterine	JJ	O
bleeding	NN	O
among	IN	O
women	NNS	O
agreeing	VBG	O
to	TO	O
obtain	VB	O
surgical	JJ	O
treatment	NN	O
.	.	O

PURPOSE	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
1	CD	O
)	)	O
describe	NN	O
elements	NNS	O
of	IN	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
of	IN	O
dysfunctional	JJ	O
uterine	JJ	O
bleeding	NN	O
(	(	O
DUB	NNP	O
)	)	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
women	NNS	O
who	WP	O
agreed	VBD	O
to	TO	O
obtain	VB	O
surgical	JJ	O
treatment	NN	O
;	:	O
2	CD	O
)	)	O
explore	NN	O
associations	NNS	O
between	IN	O
DUB	NNP	O
symptom	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
;	:	O
3	CD	O
)	)	O
estimate	VBP	O
the	DT	O
annual	JJ	O
dollar	NN	O
value	NN	O
of	IN	O
the	DT	O
financial	JJ	O
burden	NN	O
;	:	O
and	CC	O
4	CD	O
)	)	O
estimate	VBP	O
the	DT	O
most	RBS	O
that	DT	O
could	MD	O
be	VB	O
spent	VBN	O
on	IN	O
surgery	NN	O
to	TO	O
eliminate	VB	O
DUB	NNP	O
symptoms	NNS	O
for	IN	O
which	WDT	O
medical	JJ	O
treatment	NN	O
has	VBZ	O
been	VBN	O
unsuccessful	JJ	O
that	WDT	O
would	MD	O
result	VB	O
in	IN	O
a	DT	O
$	$	O
50,000/quality-adjusted	JJ	O
life-year	JJ	O
incremental	JJ	O
cost-effectiveness	NN	O
ratio	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
collected	VBD	O
baseline	NN	O
data	NNS	O
on	IN	O
DUB	NNP	O
symptoms	NNS	O
and	CC	O
aspects	NNS	O
of	IN	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
for	IN	O
237	CD	O
women	NNS	O
agreeing	VBG	O
to	TO	O
surgery	VB	O
for	IN	O
DUB	NNP	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
hysterectomy	NN	O
with	IN	O
endometrial	JJ	O
ablation	NN	O
.	.	O

Measures	NNS	O
included	VBD	O
out-of-pocket	JJ	Ot
pharmaceutical	JJ	Ot
expenditures	NNS	Ot
,	,	O
excess	JJ	Ot
expenditures	NNS	Ot
on	IN	Ot
pads	NNS	Ot
or	CC	Ot
tampons	NNS	Ot
,	,	O
the	DT	Ot
value	NN	Ot
of	IN	Ot
time	NN	Ot
missed	VBN	Ot
from	IN	Ot
paid	VBN	Ot
work	NN	Ot
and	CC	Ot
home	NN	Ot
management	NN	Ot
activities	NNS	Ot
,	,	O
and	CC	O
health	NN	Ot
utility	NN	Ot
.	.	O

We	PRP	O
used	VBD	O
chi2	NN	O
and	CC	O
t	NN	O
tests	NNS	O
to	TO	O
assess	VB	O
the	DT	O
statistical	JJ	O
significance	NN	O
of	IN	O
associations	NNS	O
between	IN	O
DUB	NNP	O
characteristics	NNS	O
and	CC	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
.	.	O

The	DT	O
annual	JJ	O
financial	JJ	O
burden	NN	O
was	VBD	O
estimated	VBN	O
.	.	O

RESULTS	NNP	O
Pelvic	NNP	PA
pain	NN	PA
and	CC	PA
cramps	NNS	PA
were	VBD	O
associated	VBN	O
with	IN	O
activity	NN	PA
limitations	NNS	PA
and	CC	O
tiredness	NN	PH
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	Ot
health	NN	Ot
utility	NN	Ot
.	.	O

Excess	NNP	Ot
pharmaceutical	JJ	Ot
and	CC	Ot
pad	NN	Ot
and	CC	Ot
tampon	NN	Ot
costs	NNS	Ot
were	VBD	O
$	$	O
333	CD	O
per	IN	O
patient	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
$	$	O
263-	JJ	O
$	$	O
403	CD	O
)	)	O
.	.	O

Excess	NNP	O
paid	VBD	Ot
work	NN	Ot
and	CC	Ot
home	NN	Ot
management	NN	Ot
loss	NN	Ot
costs	NNS	Ot
were	VBD	O
$	$	O
2,291	CD	O
per	IN	O
patient	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
$	$	O
1847-	JJ	O
$	$	O
2752	CD	O
)	)	O
.	.	O

Effective	JJ	Ot
surgical	JJ	Ot
treatment	NN	Ot
costing	VBG	O
$	$	O
40,000	CD	O
would	MD	O
be	VB	O
cost-effective	JJ	Ot
compared	VBN	O
with	IN	O
unsuccessful	JJ	O
medical	JJ	O
treatment	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
effects	NNS	O
of	IN	O
DUB	NNP	O
represent	VBP	O
a	DT	O
substantial	JJ	O
burden	NN	O
.	.	O

A	DT	O
short-term	JJ	O
cognitive	JJ	O
group	NN	O
treatment	NN	O
program	NN	O
gives	VBZ	O
substantial	JJ	O
weight	NN	PH
reduction	NN	PH
up	RB	O
to	TO	O
18	CD	O
months	NNS	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
and	CC	O
evaluate	VB	O
long-term	JJ	O
efficacy	NN	O
(	(	O
18	CD	O
months	NNS	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
)	)	O
of	IN	O
a	DT	O
new	JJ	O
cognitive	JJ	O
short-term	JJ	O
weight	NN	O
reducing	VBG	O
treatment	NN	O
program	NN	O
for	IN	O
obese	JJ	O
patients	NNS	O
.	.	O

SUBJECTS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
five	CD	O
obese	JJ	O
[	NN	O
Body	NNP	O
Mass	NNP	O
Index	NNP	O
(	(	O
BMI	NNP	O
)	)	O
>	VBD	O
or	CC	O
=	$	O
30	CD	O
]	JJ	O
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
62	CD	O
took	VBD	O
part	NN	O
in	IN	O
the	DT	O
treatment	NN	O
program	NN	O
and	CC	O
43	CD	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O

METHOD	NNP	O
From	IN	O
an	DT	O
obesity	NN	O
unit	NN	O
's	POS	O
waiting	VBG	O
list	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
treatment	NN	O
group	NN	O
or	CC	O
remained	VBN	O
in	IN	O
the	DT	O
waiting	VBG	O
list	NN	O
to	TO	O
serve	VB	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
participated	VBD	O
in	IN	O
a	DT	O
10-week	JJ	O
(	(	O
30	CD	O
hours	NNS	O
)	)	O
cognitive	VBP	O
group	NN	O
treatment	NN	O
program	NN	O
.	.	O

All	DT	O
participants	NNS	O
were	VBD	O
weighed	VBN	O
at	IN	O
the	DT	O
outset	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
directly	RB	O
after	IN	O
treatment	NN	O
and	CC	O
at	IN	O
a	DT	O
6-	JJ	O
,	,	O
12-	JJ	O
and	CC	O
18-month	JJ	O
post-treatment	JJ	O
follow-up	NN	O
without	IN	O
any	DT	O
booster	NN	O
treatment	NN	O
after	IN	O
the	DT	O
10-week	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Fifty-seven	NNP	O
(	(	O
92	CD	O
%	NN	O
)	)	O
patients	NNS	O
completed	VBN	O
treatment	NN	O
.	.	O

For	IN	O
the	DT	O
34	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
18	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
was	VBD	O
terminated	VBN	O
,	,	O
the	DT	O
mean	JJ	PH
weight	NN	PH
loss	NN	PH
at	IN	O
treatment	NN	O
's	POS	O
end	NN	O
was	VBD	O
8.5	CD	O
kg	NN	O
(	(	O
SD=16.1	NNP	O
)	)	O
.	.	O

Eighteen	JJ	O
months	NNS	O
later	RB	O
their	PRP$	O
mean	JJ	PH
weight	NN	PH
loss	NN	PH
was	VBD	O
10.4	CD	O
kg	NN	O
(	(	O
SD=10.8	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
patients	NNS	O
(	(	O
n=31.72	JJ	O
%	NN	O
)	)	O
that	WDT	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
increased	VBD	O
in	IN	O
weight	NN	PH
by	IN	O
2.3	CD	O
kg	NNS	O
(	(	O
SD=7.0	NNP	O
)	)	O
.	.	O

The	DT	O
weight	NN	PH
difference	NN	PH
between	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
group	NN	O
at	IN	O
the	DT	O
18-month	JJ	O
follow-up	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
cognitive	JJ	O
group	NN	O
treatment	NN	O
program	NN	O
was	VBD	O
highly	RB	O
acceptable	JJ	O
among	IN	O
the	DT	O
participants	NNS	O
and	CC	O
was	VBD	O
completed	VBN	O
by	IN	O
nearly	RB	O
all	PDT	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
10-week	JJ	O
treatment	NN	O
program	NN	O
resulted	VBD	O
in	IN	O
satisfactory	JJ	O
weight	JJ	PH
loss	NN	PH
.	.	PH

The	DT	O
weight	NN	O
difference	NN	O
between	IN	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
controls	NNS	O
was	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
at	IN	O
18	CD	O
months	NNS	O
after	IN	O
end	NN	O
of	IN	O
treatment	NN	O
as	IN	O
at	IN	O
six	CD	O
months	NNS	O
.	.	O

The	DT	O
study	NN	O
,	,	O
therefore	RB	O
,	,	O
does	VBZ	O
not	RB	O
provide	VB	O
support	NN	O
for	IN	O
the	DT	O
contention	NN	O
that	IN	O
a	DT	O
lengthy	JJ	O
therapy	NN	O
for	IN	O
obesity	NN	O
is	VBZ	O
necessary	JJ	O
if	IN	O
treatment	NN	O
results	NNS	O
are	VBP	O
lasting	VBG	O
.	.	O

Dose-response	JJ	Ot
effect	NN	Ot
of	IN	O
flecainide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
paroxysmal	JJ	O
atrial	JJ	O
fibrillation	NN	O
and/or	NN	O
flutter	NN	O
monitored	VBD	O
with	IN	O
trans-telephonic	JJ	O
electrocardiography	NN	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
paroxysmal	JJ	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
flutter	NN	O
(	(	O
PAF/PAFL	NNP	O
)	)	O
experiencing	VBG	O
2	CD	O
or	CC	O
more	JJR	O
episodes	NNS	O
of	IN	O
symptomatic	JJ	O
PAF/PAFL	NNP	O
during	IN	O
a	DT	O
28-day	JJ	O
observation	NN	O
period	NN	O
to	TO	O
determine	VB	O
the	DT	O
dose-response	JJ	O
effect	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
flecainide	NN	O
.	.	O

METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
143	CD	O
patients	NNS	O
at	IN	O
30	CD	O
centers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
25	CD	O
,	,	O
50	CD	O
,	,	O
or	CC	O
100	CD	O
mg	NN	O
of	IN	O
flecainide	NN	O
or	CC	O
placebo	VB	O
twice	JJ	O
daily	JJ	O
(	(	O
BID	NNP	O
)	)	O
.	.	O

In	IN	O
123	CD	O
patients	NNS	O
(	(	O
per	IN	O
protocol	NN	O
set	NN	O
)	)	O
,	,	O
those	DT	O
remaining	VBG	O
free	JJ	O
from	IN	O
PAF/PAFL	NNP	PH
after	IN	O
the	DT	O
treatment	NN	O
were	VBD	O
3.1	CD	O
%	NN	O
on	IN	O
placebo	NN	O
,	,	O
7.7	CD	O
%	NN	O
on	IN	O
25	CD	O
mg/BID	NN	O
,	,	O
9.4	CD	O
%	NN	O
on	IN	O
50	CD	O
mg/BID	NN	O
,	,	O
and	CC	O
39.4	CD	O
%	NN	O
on	IN	O
100	CD	O
mg/BID	NN	O
of	IN	O
flecainide	NN	O
.	.	O

As	IN	O
a	DT	O
whole	JJ	O
group	NN	O
,	,	O
a	DT	O
significant	JJ	Ot
linear	JJ	Ot
dose-response	NN	Ot
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
was	VBD	O
observed	VBN	O
and	CC	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
placebo	NN	O
and	CC	O
100	CD	O
mg/BID	NN	O
was	VBD	O
observed	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
similar	JJ	O
dose-response	NN	Ot
between	IN	O
the	DT	O
present	JJ	O
study	NN	O
and	CC	O
Caucasian	NNP	O
study	NN	O
was	VBD	O
demonstrated	VBN	O
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
5	CD	O
patients	NNS	O
who	WP	O
needed	VBD	O
cardioversion	NN	PH
or	CC	O
ablation	NN	PH
because	IN	O
of	IN	O
frequent	JJ	O
episodes	NNS	O
of	IN	O
PAF/PAFL	NNP	O
(	(	O
2	CD	O
in	IN	O
25	CD	O
mg/BID	NN	O
,	,	O
1	CD	O
in	IN	O
50	CD	O
mg/BID	NN	O
,	,	O
and	CC	O
2	CD	O
in	IN	O
100	CD	O
mg/BID	NN	O
of	IN	O
flecainide	NN	O
)	)	O
,	,	O
neither	CC	O
death	NN	MO
nor	CC	O
ventricular	JJ	MO
proarrhythmic	JJ	MO
event	NN	MO
was	VBD	O
reported	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
indicated	VBD	O
that	IN	O
flecainide	NN	O
exerted	VBD	O
a	DT	O
significant	JJ	O
dose-dependent	JJ	O
effect	NN	O
on	IN	O
the	DT	O
prevention	NN	O
of	IN	O
symptomatic	JJ	O
PAF/PAFL	NNP	O
recurrence	NN	O
and	CC	O
showed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
inter-ethnic	JJ	O
difference	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
effect	NN	O
of	IN	O
flecainide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
PAF/PAFL	NNP	O
.	.	O

Human	NNP	O
papillomavirus	NN	O
and	CC	O
Papanicolaou	NNP	O
tests	NNS	O
to	TO	O
screen	VB	O
for	IN	O
cervical	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Screening	NNP	O
for	IN	O
cervical	JJ	O
cancer	NN	O
based	VBN	O
on	IN	O
testing	VBG	O
for	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
increases	VBZ	O
the	DT	O
sensitivity	NN	O
of	IN	O
detection	NN	O
of	IN	O
high-grade	NN	O
(	(	O
grade	JJ	O
2	CD	O
or	CC	O
3	CD	O
)	)	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
,	,	O
but	CC	O
whether	IN	O
this	DT	O
gain	NN	O
represents	VBZ	O
overdiagnosis	NN	O
or	CC	O
protection	NN	O
against	IN	O
future	JJ	O
high-grade	JJ	O
cervical	JJ	O
epithelial	JJ	O
neoplasia	NN	O
or	CC	O
cervical	JJ	O
cancer	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
population-based	JJ	O
screening	NN	O
program	NN	O
in	IN	O
Sweden	NNP	O
,	,	O
12,527	CD	O
women	NNS	O
32	CD	O
to	TO	O
38	CD	O
years	NNS	O
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
at	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
to	TO	O
have	VB	O
an	DT	O
HPV	NNP	O
test	NN	O
plus	CC	O
a	DT	O
Papanicolaou	NNP	O
(	(	O
Pap	NNP	O
)	)	O
test	NN	O
(	(	O
intervention	NN	O
group	NN	O
)	)	O
or	CC	O
a	DT	O
Pap	JJ	O
test	NN	O
alone	RB	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

Women	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
HPV	NNP	O
test	NN	O
and	CC	O
a	DT	O
normal	JJ	O
Pap	NNP	O
test	NN	O
result	NN	O
were	VBD	O
offered	VBN	O
a	DT	O
second	JJ	O
HPV	NNP	O
test	NN	O
at	IN	O
least	JJS	O
1	CD	O
year	NN	O
later	RB	O
,	,	O
and	CC	O
those	DT	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
persistently	RB	O
infected	VBN	O
with	IN	O
the	DT	O
same	JJ	O
high-risk	JJ	O
type	NN	O
of	IN	O
HPV	NNP	O
were	VBD	O
then	RB	O
offered	VBN	O
colposcopy	NN	O
with	IN	O
cervical	JJ	O
biopsy	NN	O
.	.	O

A	DT	O
similar	JJ	O
number	NN	O
of	IN	O
double-blinded	JJ	PH
Pap	NNP	PH
smears	NNS	PH
and	CC	Ot
colposcopies	NNS	Ot
with	IN	Ot
biopsy	NN	Ot
were	VBD	O
performed	VBN	O
in	IN	O
randomly	RB	O
selected	VBN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Comprehensive	JJ	O
registry	NN	O
data	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
follow	VB	O
the	DT	O
women	NNS	O
for	IN	O
a	DT	O
mean	NN	O
of	IN	O
4.1	CD	O
years	NNS	O
.	.	O

The	DT	O
relative	JJ	O
rates	NNS	PH
of	IN	PH
grade	JJ	PH
2	CD	PH
or	CC	PH
3	CD	PH
cervical	JJ	PH
intraepithelial	JJ	PH
neoplasia	NN	PH
or	CC	Ot
cancer	NN	Ot
detected	VBN	Ot
at	IN	O
enrollment	NN	O
and	CC	O
at	IN	O
subsequent	JJ	O
screening	VBG	O
examinations	NNS	O
were	VBD	O
calculated	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
enrollment	NN	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
lesions	NNS	PH
of	IN	PH
grade	NN	PH
2	CD	PH
or	CC	PH
3	CD	PH
cervical	JJ	PH
intraepithelial	JJ	PH
neoplasia	NN	PH
or	CC	Ot
cancer	NN	PH
was	VBD	O
51	CD	O
%	NN	O
greater	JJR	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
13	CD	O
to	TO	O
102	CD	O
)	)	O
than	IN	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
such	JJ	O
lesions	NNS	O
.	.	O

At	IN	O
subsequent	JJ	O
screening	VBG	O
examinations	NNS	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
grade	VBN	O
2	CD	PH
or	CC	PH
3	CD	PH
lesions	NNS	PH
or	CC	PH
cancer	NN	PH
was	VBD	O
42	CD	O
%	NN	O
less	JJR	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
4	CD	O
to	TO	O
64	CD	O
)	)	O
and	CC	O
the	DT	O
proportion	NN	O
with	IN	O
grade	JJ	O
3	CD	O
lesions	NNS	O
or	CC	O
cancer	NN	O
was	VBD	O
47	CD	O
%	NN	O
less	JJR	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
2	CD	O
to	TO	O
71	CD	O
)	)	O
than	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
control	NN	O
women	NNS	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
such	JJ	O
lesions	NNS	O
.	.	O

Women	NNS	O
with	IN	O
persistent	JJ	O
HPV	NNP	O
infection	NN	O
remained	VBD	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
grade	JJ	O
2	CD	O
or	CC	O
3	CD	O
lesions	NNS	O
or	CC	O
cancer	NN	O
after	IN	O
referral	JJ	O
for	IN	O
colposcopy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
an	DT	O
HPV	NNP	O
test	NN	O
to	TO	O
the	DT	O
Pap	NNP	O
test	NN	O
to	TO	O
screen	JJ	O
women	NNS	O
in	IN	O
their	PRP$	O
mid-30s	NN	O
for	IN	O
cervical	JJ	O
cancer	NN	O
reduces	VBZ	O
the	DT	O
incidence	NN	O
of	IN	O
grade	NN	O
2	CD	O
or	CC	O
3	CD	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
or	CC	O
cancer	NN	O
detected	VBN	O
by	IN	O
subsequent	JJ	O
screening	NN	O
examinations	NNS	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00479375	NNP	O
[	NNP	O
ClinicalTrials.gov	NNP	O
]	NNP	O
.	.	O

)	)	O
.	.	O

Midazolam	NNP	O
vs	NN	O
ondansetron	NN	O
for	IN	O
preventing	VBG	O
postoperative	JJ	A
nausea	NN	A
and	CC	A
vomiting	NN	A
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
prophylactic	JJ	O
anti-emetic	JJ	O
efficacy	NN	O
of	IN	O
midazolam	NN	O
and	CC	O
ondansetron	NN	O
in	IN	O
90	CD	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
minor	JJ	O
gynaecological	JJ	O
(	(	O
hysteroscopy	NN	O
)	)	O
or	CC	O
urological	JJ	O
(	(	O
ureteroscopy	JJ	O
)	)	O
procedures	NNS	O
planned	VBN	O
to	TO	O
last	JJ	O
1-2	JJ	O
h	NN	O
under	IN	O
sevoflurane	NN	O
anaesthesia	NN	O
with	IN	O
spontaneous	JJ	O
ventilation	NN	O
of	IN	O
the	DT	O
lungs	NNS	O
via	IN	O
a	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
.	.	O

Midazolam	NNP	O
2	CD	O
mg	NN	O
or	CC	O
ondansetron	$	O
4	CD	O
mg	NN	O
were	VBD	O
administered	VBN	O
intravenously	RB	O
30	CD	O
min	NN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

The	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
experienced	VBD	O
postoperative	JJ	A
nausea	NN	A
and	CC	A
vomiting	NN	A
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
h	NN	O
(	(	O
30	CD	O
%	NN	O
and	CC	O
27	CD	O
%	NN	O
for	IN	O
the	DT	O
midazolam	NN	O
and	CC	O
ondansetron	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	A
nausea	NN	A
and	CC	A
vomiting	NN	A
was	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
both	DT	O
groups	NNS	O
than	IN	O
predicted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
underlying	JJ	O
risks	NNS	O
(	(	O
midazolam	JJ	O
group	NN	O
:	:	O
p	NN	O
=	VBZ	O
0.018	CD	O
;	:	O
ondansetron	VBN	O
group	NN	O
:	:	O
p	NN	O
=	VBZ	O
0.017	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	Ot
significant	JJ	Ot
differences	NNS	Ot
in	IN	O
average	JJ	PH
sedation	NN	PH
scores	NNS	PH
or	CC	O
pain	NN	PH
scores	NNS	PH
.	.	O

Treatment	NNP	O
using	VBG	O
ondansetron	NN	O
for	IN	O
anti-emetic	JJ	O
prophylaxis	NN	O
did	VBD	O
not	RB	O
provide	VB	O
a	DT	O
superior	JJ	O
benefit	NN	O
compared	VBN	O
to	TO	O
midazolam	VB	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

Resistance	NNP	O
training	NN	O
increases	NNS	O
basal	VBP	O
limb	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
in	IN	O
aging	VBG	O
humans	NNS	O
.	.	O

Age-related	JJ	O
reductions	NNS	O
in	IN	O
basal	NN	O
limb	NN	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
,	,	O
functional	JJ	O
impairments	NNS	O
,	,	O
and	CC	O
osteoporosis	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
a	DT	O
strength	NN	O
training	NN	O
program	NN	O
would	MD	O
increase	VB	O
basal	JJ	PH
femoral	JJ	PH
blood	NN	PH
flow	NN	PH
in	IN	O
aging	VBG	O
adults	NNS	O
.	.	O

Twenty-six	JJ	O
sedentary	JJ	O
but	CC	O
healthy	JJ	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
a	DT	O
whole	JJ	O
body	NN	O
strength	NN	O
training	VBG	O
intervention	NN	O
group	NN	O
(	(	O
52	CD	O
+/-	JJ	O
2	CD	O
yr	NN	O
,	,	O
3	CD	O
men	NNS	O
,	,	O
10	CD	O
women	NNS	O
)	)	O
who	WP	O
underwent	VBD	O
three	CD	O
supervised	VBN	O
resistance	NN	O
training	NN	O
sessions	NNS	O
per	IN	O
week	NN	O
for	IN	O
13	CD	O
wk	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
53	CD	O
+/-	JJ	O
2	CD	O
yr	NN	O
,	,	O
4	CD	O
men	NNS	O
,	,	O
9	CD	O
women	NNS	O
)	)	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
supervised	JJ	O
stretching	NN	O
program	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
blood	NN	PH
pressure	NN	PH
,	,	O
cardiac	JJ	PH
output	NN	PH
,	,	O
basal	JJ	PH
femoral	JJ	PH
blood	NN	PH
flow	NN	PH
(	(	PH
via	IN	PH
Doppler	NNP	PH
ultrasound	NN	PH
)	)	PH
,	,	O
vascular	JJ	PH
conductance	NN	PH
,	,	O
and	CC	O
vascular	JJ	PH
resistance	NN	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
strength	NN	O
training	VBG	O
group	NN	O
increased	VBD	O
maximal	JJ	PH
strength	NN	PH
in	IN	O
all	PDT	O
the	DT	O
major	JJ	O
muscle	NN	O
groups	NNS	O
tested	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Whole	JJ	PH
body	NN	PH
lean	JJ	PH
body	NN	PH
mass	NN	PH
increased	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
strength	NN	O
training	NN	O
,	,	O
but	CC	O
leg	VBZ	PH
fat-free	JJ	PH
mass	NN	PH
did	VBD	O
not	RB	O
.	.	O

Basal	NNP	PH
femoral	JJ	PH
blood	NN	PH
flow	NN	PH
and	CC	PH
vascular	JJ	PH
conductance	NN	PH
increased	VBN	O
by	IN	O
55-60	CD	O
%	NN	O
after	IN	O
strength	NN	O
training	NN	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
such	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
brachial	JJ	PH
blood	NN	PH
pressure	NN	PH
,	,	O
plasma	JJ	PH
endothelin-1	NN	PH
and	CC	PH
angiotensin	NN	PH
II	NNP	PH
concentrations	NNS	PH
,	,	O
femoral	JJ	PH
artery	NN	PH
wall	NN	PH
thickness	NN	PH
,	,	O
cardiac	JJ	PH
output	NN	PH
,	,	O
and	CC	O
systemic	JJ	PH
vascular	JJ	PH
resistance	NN	PH
.	.	O

Our	PRP$	O
results	NNS	O
indicate	VBP	O
that	IN	O
short-term	JJ	O
strength	NN	O
training	NN	O
increases	NNS	O
basal	VBP	O
femoral	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
in	IN	O
healthy	JJ	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
adults	NNS	O
.	.	O

Determinants	NNS	O
of	IN	O
serum	JJ	O
creatinine	NN	O
trajectory	NN	O
in	IN	O
acute	JJ	O
contrast	NN	O
nephropathy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
describe	VB	O
the	DT	O
trajectory	NN	O
of	IN	O
creatinine	NN	PH
(	(	PH
Cr	NNP	PH
)	)	PH
rise	NN	O
and	CC	O
its	PRP$	O
determinants	NNS	O
after	IN	O
exposure	NN	O
to	TO	O
radiocontrast	VB	O
media	NNS	O
.	.	O

Included	VBN	O
were	VBD	O
98	CD	O
subjects	NNS	O
who	WP	O
underwent	VBP	O
cardiac	JJ	O
catheterization	NN	O
and	CC	O
were	VBD	O
randomized	VBN	O
to	TO	O
forced	VBN	O
diuresis	NN	O
with	IN	O
i.v	NN	O
.	.	O

crystalloid	NN	O
,	,	O
furosemide	RB	O
,	,	O
mannitol	NN	O
(	(	O
if	IN	O
pulmonary	JJ	O
capillary	JJ	O
wedge	NN	O
pressure	NN	O
was	VBD	O
<	JJ	O
20	CD	O
mmHg	NN	O
)	)	O
,	,	O
and	CC	O
low	JJ	O
dose	JJ	O
dopamine	NN	O
versus	NN	O
intravenous	JJ	O
crystalloid	NN	O
and	CC	O
matching	VBG	O
placebos	NNS	O
.	.	O

Baseline	NNP	O
and	CC	O
postcatheterization	NN	O
serum	NN	PH
Cr	NNP	PH
levels	NNS	PH
were	VBD	O
analyzed	VBN	O
in	IN	O
a	DT	O
longitudinal	JJ	O
fashion	NN	O
,	,	O
allowing	VBG	O
for	IN	O
differences	NNS	O
in	IN	O
the	DT	O
time	NN	O
between	IN	O
blood	NN	O
draws	NNS	O
,	,	O
to	TO	O
determine	VB	O
the	DT	O
different	JJ	O
critical	JJ	O
trajectories	NNS	O
of	IN	O
serum	NN	O
Cr	NNP	O
.	.	O

The	DT	O
mean	JJ	PH
age	NN	PH
,	,	O
baseline	NN	PH
serum	NN	PH
Cr	NNP	PH
,	,	O
and	CC	O
Cr	NNP	PH
clearance	NN	PH
(	(	PH
CrCl	NNP	PH
)	)	PH
were	VBD	O
69.3	CD	O
+/-	JJ	O
10.8	CD	O
years	NNS	O
,	,	O
2.5	CD	O
+/-	JJ	O
0.9	CD	O
mg/dL	NN	O
,	,	O
and	CC	O
31.4	CD	O
+/-	JJ	O
12.1	CD	O
mL/min	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
clinically	RB	Ot
driven	JJ	Ot
postprocedural	JJ	Ot
observation	NN	Ot
time	NN	Ot
was	VBD	O
5.5	CD	O
+/-	JJ	O
5.1	CD	O
days	NNS	O
(	(	O
range	VB	O
19	CD	O
hours	NNS	O
and	CC	O
one	CD	O
Cr	NNP	O
value	NN	O
to	TO	O
25.7	CD	O
days	NNS	O
and	CC	O
18	CD	O
values	NNS	O
)	)	O
.	.	O

The	DT	O
mean	JJ	PH
maximum	NN	PH
Cr	NNP	PH
was	VBD	O
3.3	CD	O
+/-	JJ	O
1.4	CD	O
,	,	O
range	NN	O
1.7-8.7	JJ	O
mg/dL	NN	O
)	)	O
.	.	O

Longitudinal	JJ	O
models	NNS	O
support	VBP	O
baseline	JJ	O
Cr	NNP	PH
clearance	NN	PH
predictions	NNS	O
for	IN	O
the	DT	O
change	NN	O
in	IN	O
Cr	NNP	O
at	IN	O
24	CD	O
hours	NNS	O
,	,	O
time	NN	O
as	IN	O
the	DT	O
determinant	NN	O
of	IN	O
Cr	NNP	O
trajectory	NN	O
,	,	O
and	CC	O
requisite	JJ	O
monitoring	NN	O
.	.	O

For	IN	O
any	DT	O
given	VBN	O
individual	NN	O
,	,	O
a	DT	O
rise	NN	O
in	IN	O
Cr	NNP	PH
of	IN	O
<	NNP	O
or	CC	O
=	$	O
0.5	CD	O
mg/dL	NN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
after	IN	O
contrast	NN	O
exposure	NN	O
predicted	VBD	O
a	DT	O
favorable	JJ	O
outcome	NN	O
.	.	O

Baseline	NNP	PH
renal	JJ	PH
function	NN	PH
is	VBZ	O
the	DT	O
major	JJ	O
determinant	NN	O
of	IN	O
the	DT	O
rate	NN	O
of	IN	O
rise	NN	O
,	,	O
height	NN	O
,	,	O
and	CC	O
duration	NN	O
of	IN	O
Cr	NNP	O
trajectory	NN	O
after	IN	O
contrast	NN	O
exposure	NN	O
.	.	O

Length	NNP	O
of	IN	O
observation	NN	O
and	CC	O
frequency	NN	O
of	IN	O
laboratory	NN	O
measures	NNS	O
can	MD	O
be	VB	O
anticipated	VBN	O
from	IN	O
these	DT	O
models	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
dopexamine	NN	O
in	IN	O
splanchnic	JJ	O
perfusion	NN	O
during	IN	O
surgery	NN	O
of	IN	O
the	DT	O
abdominal	JJ	O
aorta	NN	O
]	NNP	O
.	.	O

Abdominal	NNP	O
aortic	JJ	O
surgery	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
cardiac	NN	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
dopexamine	NN	O
,	,	O
an	DT	O
inodilator	JJ	O
drug	NN	O
,	,	O
on	IN	O
hemodynamic	JJ	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
with	IN	O
measurement	NN	O
of	IN	O
gastric	JJ	O
intramucosal	NN	O
pH	NN	O
,	,	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
gastric	JJ	O
tonometry	NN	O
,	,	O
during	IN	O
abdominal	JJ	O
aneurysm	JJ	O
resection	NN	O
.	.	O

Twenty-five	JJ	O
patients	NNS	O
undergoing	VBG	O
excision	NN	O
of	IN	O
an	DT	O
aortic	JJ	O
abdominal	JJ	O
aneurysm	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
Group	NNP	O
II	NNP	O
patients	NNS	O
received	VBD	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
microgram/kg/m	NN	O
,	,	O
and	CC	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	O
micrograms/kg/m	NN	O
from	IN	O
declamping	VBG	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
surgery	NN	O
.	.	O

Whereas	NNP	O
Group	NNP	O
I	PRP	O
patients	NNS	O
did	VBD	O
not	RB	O
receive	VB	O
a	DT	O
dopexamine	JJ	O
infusion	NN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	VBG	O
the	DT	O
intramucosal	NN	PH
pH	VBZ	PH
value	NN	PH
decreased	VBN	O
in	IN	O
Group	NNP	O
I	PRP	O
patients	NNS	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
Group	NNP	O
II	NNP	O
patients	NNS	O
.	.	O

Heart	NNP	PH
rate	NN	PH
,	,	PH
cardiac	JJ	PH
index	NN	PH
,	,	PH
and	CC	PH
mixed	JJ	PH
venous	JJ	PH
oxygen	NN	PH
saturation	NN	PH
increased	VBD	O
significantly	RB	O
during	IN	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
whereas	JJ	O
systemic	JJ	PH
vascular	NN	PH
resistance	NN	PH
was	VBD	O
reduced	VBN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
dopexamine	NN	O
was	VBD	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
improving	VBG	O
splanchnic	JJ	PH
blood	NN	PH
flow	NN	PH
,	,	PH
cardiac	JJ	PH
index	NN	PH
venous	JJ	PH
saturation	NN	PH
.	.	O

Also	RB	O
,	,	O
since	IN	O
the	DT	O
drug	NN	O
produces	VBZ	O
dose	RB	O
related	JJ	O
hemodynamic	JJ	O
changes	NNS	O
of	IN	O
rapid	JJ	O
onset	NN	O
and	CC	O
reversibility	NN	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
interrupt	VB	O
the	DT	O
infusion	NN	O
before	IN	O
aortic	JJ	O
declamping	NN	O
to	TO	O
avoid	VB	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
.	.	O

Effect	NN	O
of	IN	O
resistance	NN	O
exercise	NN	O
contraction	NN	O
mode	NN	O
and	CC	O
protein	JJ	O
supplementation	NN	O
on	IN	O
members	NNS	O
of	IN	O
the	DT	O
STARS	NNP	O
signalling	VBG	O
pathway	RB	O
.	.	O

The	DT	O
striated	JJ	O
muscle	NN	O
activator	NN	O
of	IN	O
Rho	NNP	O
signalling	VBG	O
(	(	O
STARS	NNP	O
)	)	O
pathway	NN	O
is	VBZ	O
suggested	VBN	O
to	TO	O
provide	VB	O
a	DT	O
link	NN	O
between	IN	O
external	JJ	O
stress	NN	O
responses	NNS	O
and	CC	O
transcriptional	JJ	O
regulation	NN	O
in	IN	O
muscle	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
STARS	NNP	O
signalling	VBG	O
to	TO	O
different	JJ	O
mechanical	JJ	O
stresses	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

In	IN	O
a	DT	O
comparative	JJ	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
regulation	NN	O
of	IN	O
the	DT	O
STARS	NNP	O
signalling	VBG	O
pathway	RB	O
in	IN	O
response	NN	O
to	TO	O
unilateral	JJ	O
resistance	NN	O
exercise	NN	O
performed	VBN	O
as	IN	O
either	DT	O
eccentric	JJ	O
(	(	O
ECC	NNP	O
)	)	O
or	CC	O
concentric	JJ	O
(	(	O
CONC	NNP	O
)	)	O
contractions	NNS	O
as	RB	O
well	RB	O
as	IN	O
prolonged	JJ	O
training	NN	O
;	:	O
with	IN	O
and	CC	O
without	IN	O
whey	JJ	O
protein	NN	O
supplementation	NN	O
.	.	O

Skeletal	JJ	O
muscle	NN	O
STARS	NNP	O
,	,	O
myocardian-related	JJ	O
transcription	NN	O
factor-A	NN	O
(	(	O
MRTF-A	NNP	O
)	)	O
and	CC	O
serum	JJ	O
response	NN	O
factor	NN	O
(	(	O
SRF	NNP	O
)	)	O
mRNA	NN	O
and	CC	O
protein	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
muscle	NN	O
cross-sectional	JJ	O
area	NN	O
and	CC	O
maximal	JJ	O
voluntary	JJ	O
contraction	NN	O
,	,	O
were	VBD	O
measured	VBN	O
.	.	O

A	DT	O
single-bout	NN	O
of	IN	O
exercise	NN	O
produced	VBN	O
increases	NNS	O
in	IN	O
STARS	NNP	PH
and	CC	PH
SRF	NNP	PH
mRNA	NN	PH
and	CC	PH
decreases	NNS	PH
in	IN	PH
MRTF-A	NNP	PH
mRNA	NN	PH
with	IN	PH
both	DT	PH
ECC	NNP	PH
and	CC	PH
CONC	NNP	PH
exercise	NN	PH
,	,	O
but	CC	O
with	IN	O
an	DT	O
enhanced	JJ	O
response	NN	O
occurring	VBG	O
following	VBG	O
ECC	NNP	O
exercise	NN	O
.	.	O

A	DT	O
31	CD	O
%	NN	O
increase	NN	O
in	IN	O
STARS	NNP	PH
protein	NN	PH
was	VBD	O
observed	VBN	O
exclusively	RB	O
after	IN	O
CONC	NNP	O
exercise	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
while	IN	O
pSRF	JJ	PH
protein	NN	O
levels	NNS	O
increased	VBD	O
similarly	RB	O
by	IN	O
48	CD	O
%	NN	O
with	IN	O
both	DT	O
CONC	NNP	O
and	CC	O
ECC	NNP	O
exercise	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Prolonged	VBN	O
ECC	NNP	O
and	CC	O
CONC	NNP	O
training	VBG	O
equally	RB	O
stimulated	VBN	O
muscle	NN	O
hypertrophy	NN	O
and	CC	O
produced	VBD	O
increases	NNS	O
in	IN	O
MRTF-A	NNP	PH
protein	NN	PH
of	IN	O
125	CD	O
%	NN	O
and	CC	O
99	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	UH	O
changes	NNS	O
occurred	VBD	O
for	IN	O
total	JJ	PH
SRF	NNP	PH
protein	NN	PH
.	.	O

There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
of	IN	O
whey	NN	PH
protein	NN	PH
supplementation	NN	PH
.	.	PH

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
resistance	NN	O
exercise	NN	O
provides	VBZ	O
an	DT	O
acute	JJ	PH
stimulation	NN	PH
of	IN	PH
the	DT	PH
STARS	NNP	PH
pathway	NN	PH
that	WDT	O
is	VBZ	O
contraction	JJ	O
mode	NN	O
dependent	NN	O
.	.	O

The	DT	O
responses	NNS	O
to	TO	O
acute	VB	O
exercise	NN	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
than	IN	O
responses	NNS	O
to	TO	O
accumulated	JJ	O
training	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
STARS	NNP	O
signalling	VBG	O
is	VBZ	O
primarily	RB	O
involved	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
phase	NN	O
of	IN	O
exercise-induced	JJ	O
muscle	NN	O
adaptations	NNS	O
.	.	O

A	DT	O
phase	NN	O
III	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
antithrombin	NN	O
in	IN	O
heparin-resistant	JJ	O
patients	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
cardiac	JJ	O
surgery	NN	O
necessitating	VBG	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
antithrombin	NN	O
(	(	O
rhAT	NN	O
)	)	O
for	IN	O
restoring	VBG	O
heparin	NN	PH
responsiveness	NN	PH
in	IN	O
heparin	NN	O
resistant	JJ	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
heparin-resistant	JJ	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
with	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

Heparin	NNP	O
resistance	NN	O
was	VBD	O
diagnosed	VBN	O
when	WRB	O
the	DT	O
activated	VBN	O
clotting	NN	O
time	NN	O
was	VBD	O
less	JJR	O
than	IN	O
480	CD	O
s	NNS	O
after	IN	O
400	CD	O
U/kg	NNP	O
heparin	NN	O
.	.	O

Fifty-four	JJ	O
heparin-resistant	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

One	CD	O
cohort	NN	O
received	VBD	O
75	CD	O
U/kg	NNP	O
rhAT	NN	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
received	VBD	O
normal	JJ	O
saline	NN	O
.	.	O

If	IN	O
the	DT	O
activated	JJ	O
clotting	NN	O
time	NN	O
remained	VBD	O
less	JJR	O
than	IN	O
480	CD	O
s	NN	O
,	,	O
this	DT	O
was	VBD	O
considered	VBN	O
treatment	NN	O
failure	NN	O
,	,	O
and	CC	O
2	CD	O
units	NNS	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
was	VBD	O
transfused	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
Only	RB	O
19	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
rhAT	NN	O
group	NN	O
received	VBD	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
,	,	O
compared	VBN	O
with	IN	O
81	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

During	IN	O
their	PRP$	O
hospitalization	NN	O
,	,	O
48	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
rhAT	NN	O
group	NN	O
received	VBD	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
,	,	O
compared	VBN	O
with	IN	O
85	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.009	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
required	VBD	O
higher	JJR	O
heparin	NN	O
doses	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
for	IN	O
anticoagulation	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
rhAT	NN	O
.	.	O

There	EX	O
was	VBD	O
increased	VBN	PH
blood	NN	PH
loss	NN	PH
12	CD	O
h	NN	O
postoperatively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
with	IN	O
a	DT	O
trend	NN	O
toward	IN	O
increased	VBN	O
24-h	JJ	PH
bleeding	NN	PH
in	IN	O
the	DT	O
rhAT	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
blood	NN	O
and	CC	O
platelet	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
75	CD	O
U/kg	NNP	O
rhAT	NN	O
is	VBZ	O
effective	JJ	PH
in	IN	PH
restoring	VBG	PH
heparin	NN	PH
responsiveness	NN	PH
and	CC	O
promoting	VBG	O
therapeutic	JJ	PH
anticoagulation	NN	PH
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
heparin-resistant	JJ	O
patients	NNS	O
.	.	O

Treating	VBG	O
heparin-resistant	JJ	O
patients	NNS	O
with	IN	O
rhAT	NN	O
may	MD	O
decrease	VB	PH
the	DT	PH
requirement	NN	PH
for	IN	PH
heparin	NN	PH
and	CC	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
.	.	O

Remote	NNP	O
ischaemic	JJ	O
conditioning	NN	O
before	IN	O
hospital	JJ	O
admission	NN	O
,	,	O
as	IN	O
a	DT	O
complement	NN	O
to	TO	O
angioplasty	VB	O
,	,	O
and	CC	O
effect	NN	O
on	IN	O
myocardial	JJ	PH
salvage	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
:	:	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Remote	NNP	O
ischaemic	JJ	O
preconditioning	NN	O
attenuates	NNS	O
cardiac	JJ	O
injury	NN	O
at	IN	O
elective	JJ	O
surgery	NN	O
and	CC	O
angioplasty	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
remote	VBP	O
ischaemic	JJ	O
conditioning	NN	O
during	IN	O
evolving	VBG	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
done	VBN	O
before	IN	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
,	,	O
increases	VBZ	O
myocardial	JJ	PH
salvage	NN	PH
.	.	O

METHODS	NNP	O
333	CD	O
consecutive	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
a	DT	O
suspected	VBN	O
first	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
by	IN	O
computerised	JJ	O
block	NN	O
randomisation	NN	O
to	TO	O
receive	VB	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
with	IN	O
(	(	O
n=166	JJ	O
patients	NNS	O
)	)	O
versus	NN	O
without	IN	O
(	(	O
n=167	NN	O
)	)	O
remote	VBP	O
conditioning	VBG	O
(	(	O
intermittent	JJ	O
arm	NN	O
ischaemia	NN	O
through	IN	O
four	CD	O
cycles	NNS	O
of	IN	O
5-min	JJ	O
inflation	NN	O
and	CC	O
5-min	JJ	O
deflation	NN	O
of	IN	O
a	DT	O
blood-pressure	JJ	O
cuff	NN	O
)	)	O
.	.	O

Allocation	NN	O
was	VBD	O
concealed	VBN	O
with	IN	O
opaque	NN	O
sealed	VBN	O
envelopes	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
remote	JJ	O
conditioning	NN	O
during	IN	O
transport	NN	O
to	TO	O
hospital	NN	O
,	,	O
and	CC	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
hospital	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
myocardial	JJ	PH
salvage	NN	PH
index	NN	PH
at	IN	PH
30	CD	PH
days	NNS	PH
after	IN	PH
primary	JJ	PH
percutaneous	JJ	PH
coronary	JJ	PH
intervention	NN	PH
,	,	O
measured	VBN	O
by	IN	O
myocardial	JJ	PH
perfusion	NN	PH
imaging	NN	PH
as	IN	O
the	DT	O
proportion	NN	O
of	IN	O
the	DT	O
area	NN	O
at	IN	O
risk	NN	O
salvaged	VBN	O
by	IN	O
treatment	NN	O
;	:	O
analysis	NN	O
was	VBD	O
per	IN	O
protocol	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00435266	NNP	O
.	.	O

FINDINGS	NNP	O
82	CD	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
on	IN	O
arrival	NN	O
at	IN	O
hospital	NN	O
because	IN	O
they	PRP	O
did	VBD	O
not	RB	O
meet	VB	O
inclusion	NN	O
criteria	NNS	O
,	,	O
32	CD	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NN	O
,	,	O
and	CC	O
77	CD	O
did	VBD	O
not	RB	O
complete	VB	O
the	DT	O
follow-up	JJ	O
with	IN	O
data	NNS	O
for	IN	O
salvage	NN	O
index	NN	O
.	.	O

Median	JJ	PH
salvage	NN	PH
index	NN	PH
was	VBD	O
0.75	CD	O
(	(	O
IQR	NNP	O
0.50-0.93	CD	O
,	,	O
n=73	NN	O
)	)	O
in	IN	O
the	DT	O
remote	JJ	O
conditioning	NN	O
group	NN	O
versus	VBD	O
0.55	CD	O
(	(	O
0.35-0.88	CD	O
,	,	O
n=69	NN	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
median	JJ	O
difference	NN	O
of	IN	O
0.10	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.22	CD	O
;	:	O
p=0.0333	NN	O
)	)	O
;	:	O
mean	JJ	O
salvage	NN	O
index	NN	O
was	VBD	O
0.69	CD	O
(	(	O
SD	NNP	O
0.27	CD	O
)	)	O
versus	NN	O
0.57	CD	O
(	(	O
0.26	CD	O
)	)	O
,	,	O
with	IN	O
mean	JJ	O
difference	NN	O
of	IN	O
0.12	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.21	CD	O
;	:	O
p=0.0333	NN	O
)	)	O
.	.	O

Major	JJ	A
adverse	JJ	A
coronary	JJ	A
events	NNS	A
were	VBD	O
death	NN	MO
(	(	O
n=3	JJ	O
per	IN	O
group	NN	O
)	)	O
,	,	O
reinfarction	NN	A
(	(	O
n=1	JJ	O
per	IN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
heart	NN	A
failure	NN	A
(	(	O
n=3	JJ	O
per	IN	O
group	NN	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Remote	NNP	O
ischaemic	JJ	O
conditioning	NN	O
before	IN	O
hospital	JJ	O
admission	NN	O
increases	VBZ	O
myocardial	JJ	PH
salvage	NN	PH
,	,	O
and	CC	O
has	VBZ	O
a	DT	O
favourable	JJ	O
safety	NN	Ot
profile	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
merit	VBP	O
a	DT	O
larger	JJR	O
trial	NN	O
to	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
remote	JJ	O
conditioning	NN	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
.	.	O

FUNDING	NN	O
Fondation	NNP	O
Leducq	NNP	O
.	.	O

Effect	NN	O
of	IN	O
entacapone	NN	O
,	,	O
a	DT	O
peripherally	RB	O
acting	VBG	O
catechol-O-methyltransferase	NN	O
inhibitor	NN	O
,	,	O
on	IN	O
the	DT	O
motor	NN	PH
response	NN	PH
to	TO	PH
acute	VB	PH
treatment	NN	PH
with	IN	PH
levodopa	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Catechol-O-methyltransferase	NNP	O
(	(	O
COMT	NNP	O
)	)	O
inhibitors	NNS	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
by	IN	O
improving	VBG	O
the	DT	O
bioavailability	NN	Ot
of	IN	O
levodopa	NN	O
and	CC	O
by	IN	O
prolonging	VBG	O
its	PRP$	O
effects	NNS	O
.	.	O

Entacapone	NNP	O
(	(	O
OR-611	NNP	O
)	)	O
,	,	O
a	DT	O
novel	JJ	O
COMT	NNP	O
inhibitor	NN	O
,	,	O
which	WDT	O
does	VBZ	O
not	RB	O
cross	VB	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
and	CC	O
motor	NN	O
fluctuations	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
,	,	O
single	JJ	O
dose	NN	O
study	NN	O
.	.	O

The	DT	O
magnitude	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
response	NN	O
to	TO	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
levodopa/50	JJ	O
mg	FW	O
carbidopa	NN	O
was	VBD	O
evaluated	VBN	O
after	IN	O
concomitant	JJ	O
placebo	NN	O
,	,	O
or	CC	O
200	CD	O
or	CC	O
800	CD	O
mg	NN	O
entacapone	NN	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
duration	NN	PH
of	IN	PH
the	DT	PH
motor	NN	PH
response	NN	PH
to	TO	PH
levodopa	NN	PH
was	VBD	O
seen	VBN	O
when	WRB	O
200	CD	O
mg	NN	O
entacapone	NN	O
was	VBD	O
given	VBN	O
with	IN	O
levodopa/carbidopa	NN	O
.	.	O

Plasma	NNP	Ot
levodopa	JJ	Ot
concentrations	NNS	Ot
were	VBD	O
increased	VBN	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
the	DT	O
COMT	NNP	O
inhibitor	NN	O
.	.	O

The	DT	O
latency	NN	PH
to	TO	PH
onset	VB	PH
of	IN	PH
motor	NN	PH
response	NN	PH
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
active	JJ	O
drug	NN	O
and	CC	O
placebo	NN	O
.	.	O

Entacapone	NN	O
may	MD	O
prove	VB	O
useful	JJ	O
in	IN	O
prolonging	VBG	Ot
the	DT	Ot
duration	NN	Ot
of	IN	Ot
the	DT	Ot
benefit	NN	Ot
obtained	VBN	O
from	IN	O
individual	JJ	O
doses	NNS	O
of	IN	O
levodopa	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
24-h	JJ	O
psychological	JJ	O
training	NN	O
program	NN	O
on	IN	O
attitudes	NNS	ME
,	,	ME
communication	NN	ME
skills	NNS	ME
and	CC	ME
occupational	JJ	ME
stress	NN	ME
in	IN	O
oncology	NN	O
:	:	O
a	DT	O
randomised	JJ	O
study	NN	O
.	.	O

The	DT	O
usefulness	NN	O
of	IN	O
psychological	JJ	O
training	NN	O
programs	NNS	O
(	(	O
P.T.P	NNP	O
.	.	O

)	)	O
in	IN	O
health	NN	O
care	NN	O
settings	NNS	O
devoted	VBN	O
to	TO	O
cancer	NN	O
care	NN	O
is	VBZ	O
beginning	VBG	O
to	TO	O
be	VB	O
recognised	VBN	O
but	CC	O
their	PRP$	O
content	NN	O
,	,	O
form	NN	O
and	CC	O
effectiveness	VB	O
need	NN	O
further	JJ	O
investigation	NN	O
.	.	O

Seventy-two	JJ	O
oncology	NN	O
nurses	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
24-h	JJ	O
P.T.P	NNP	O
.	.	O

or	CC	O
to	TO	O
a	DT	O
waiting	VBG	O
list	NN	O
period	NN	O
.	.	O

Attitudes	NNS	ME
were	VBD	O
assessed	VBN	O
by	IN	O
a	DT	O
semantic	JJ	ME
differential	NN	ME
questionnaire	NN	ME
,	,	O
occupational	JJ	ME
stress	NN	ME
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	ME
Nursing	NNP	ME
Stress	NNP	ME
Scale	NNP	ME
and	CC	O
communication	NN	ME
skills	NNS	ME
were	VBD	O
assessed	VBN	O
by	IN	O
standardised	JJ	ME
videotaped	VBD	ME
role-playing	NN	ME
exercises	NNS	ME
.	.	ME

These	DT	O
were	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
trained	JJ	O
(	(	O
T.S	NNP	O
.	.	O

)	)	O
and	CC	O
control	NN	O
subjects	NNS	O
(	(	O
C.S.	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
a	DT	O
significant	JJ	O
training	NN	O
effect	NN	O
on	IN	O
attitudes	NNS	ME
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
especially	RB	O
on	IN	O
those	DT	O
related	VBN	O
to	TO	O
self	VB	ME
concept	NN	ME
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
level	NN	ME
of	IN	ME
occupational	JJ	ME
stress	NN	ME
related	VBN	O
to	TO	O
inadequate	VB	O
preparation	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Limited	VBN	O
changes	NNS	O
were	VBD	O
found	VBN	O
regarding	VBG	O
post-training	JJ	O
communication	NN	O
skills	NNS	O
.	.	O

T.S	NNP	O
.	.	O

were	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
control	NN	O
of	IN	O
the	DT	O
interview	NN	O
than	IN	O
C.S	NNP	O
.	.	O

(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
24-h	JJ	O
P.T.P	NNP	O
.	.	O

assessed	VBN	O
here	RB	O
are	VBP	O
effective	JJ	O
.	.	O

The	DT	O
data	NN	O
also	RB	O
demonstrate	VBP	O
the	DT	O
need	NN	O
to	TO	O
consolidate	VB	O
the	DT	O
skills	NNS	O
acquired	VBN	O
by	IN	O
regular	JJ	O
post-training	JJ	O
sessions	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
weight	JJ	O
loss	NN	O
and	CC	O
exercise	NN	O
on	IN	O
insulin	NN	O
resistance	NN	O
,	,	O
and	CC	O
intramyocellular	JJ	O
triacylglycerol	NN	O
,	,	O
diacylglycerol	NN	O
and	CC	O
ceramide	NN	O
.	.	O

AIMS/HYPOTHESIS	NNP	O
Intramyocellular	NNP	O
lipids	NNS	O
,	,	O
including	VBG	O
diacylglycerol	NN	O
(	(	O
DAG	NNP	O
)	)	O
and	CC	O
ceramides	NNS	O
,	,	O
have	VBP	O
been	VBN	O
linked	VBN	O
to	TO	O
insulin	VB	O
resistance	NN	O
.	.	O

This	DT	O
randomised	VBD	O
repeated-measures	NNS	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
diet-induced	JJ	O
weight	JJ	O
loss	NN	O
(	(	O
DIWL	NNP	O
)	)	O
and	CC	O
aerobic	JJ	O
exercise	NN	O
(	(	O
EX	NNP	O
)	)	O
on	IN	O
insulin	NN	O
sensitivity	NN	O
and	CC	O
intramyocellular	JJ	O
triacylglycerol	NN	O
(	(	O
IMTG	NNP	O
)	)	O
,	,	O
DAG	NNP	O
and	CC	O
ceramide	NN	O
.	.	O

METHODS	NNP	O
Sixteen	NNP	O
overweight	MD	O
to	TO	O
obese	VB	O
adults	NNS	O
(	(	O
BMI	NNP	O
30.6	CD	O
?	.	O
0.8	CD	O
;	:	O
67.2	CD	O
?	.	O
4.0	CD	O
years	NNS	O
of	IN	O
age	NN	O
)	)	O
with	IN	O
either	DT	O
impaired	JJ	O
fasting	NN	O
glucose	NN	O
,	,	O
or	CC	O
impaired	VBD	O
glucose	JJ	O
tolerance	NN	O
completed	VBD	O
one	CD	O
of	IN	O
two	CD	O
lifestyle	JJ	O
interventions	NNS	O
:	:	O
DIWL	NNP	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
or	CC	O
EX	NNP	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
.	.	O

Insulin	NNP	O
sensitivity	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
hyperinsulinaemic-euglycaemic	JJ	O
clamps	NNS	O
.	.	O

Intramyocellular	JJ	O
lipids	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
muscle	NN	O
biopsies	NNS	O
using	VBG	O
histochemistry	NN	O
and	CC	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
.	.	O

RESULTS	NNP	O
Insulin	NNP	O
sensitivity	NN	O
was	VBD	O
improved	VBN	O
with	IN	O
DIWL	NNP	O
(	(	O
20.6	CD	O
?	.	O
4.7	CD	O
%	NN	O
)	)	O
and	CC	O
EX	NNP	O
(	(	O
19.2	CD	O
?	.	O
12.9	CD	O
%	NN	O
)	)	O
.	.	O

Body	NNP	O
weight	VBD	O
and	CC	O
body	NN	O
fat	NNS	O
were	VBD	O
decreased	VBN	O
by	IN	O
both	DT	O
interventions	NNS	O
,	,	O
with	IN	O
greater	JJR	O
decreases	NNS	O
in	IN	O
DIWL	NNP	O
compared	VBN	O
with	IN	O
EX	NNP	O
.	.	O

Muscle	NNP	O
glycogen	NN	O
,	,	O
IMTG	NNP	O
content	NN	O
and	CC	O
oxidative	JJ	O
capacity	NN	O
were	VBD	O
all	DT	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
decreased	VBN	O
with	IN	O
DIWL	NNP	O
and	CC	O
increased	VBD	O
with	IN	O
EX	NNP	O
.	.	O

There	EX	O
were	VBD	O
decreases	NNS	O
in	IN	O
DAG	NNP	O
with	IN	O
DIWL	NNP	O
(	(	O
-12.4	NNP	O
?	.	O
14.6	CD	O
%	NN	O
)	)	O
and	CC	O
EX	NNP	O
(	(	O
-40.9	NNP	O
?	.	O
12.0	CD	O
%	NN	O
)	)	O
.	.	O

Ceramide	NNP	O
decreased	VBD	O
with	IN	O
EX	NNP	O
(	(	O
-33.7	NNP	O
?	.	O
11.2	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
DIWL	NNP	O
.	.	O

Dihydroceramide	NNP	O
was	VBD	O
decreased	VBN	O
with	IN	O
both	DT	O
interventions	NNS	O
.	.	O

Sphingosine	NNP	O
was	VBD	O
decreased	VBN	O
only	RB	O
with	IN	O
EX	NNP	O
.	.	O

Changes	NNS	O
in	IN	O
total	JJ	O
DAG	NNP	O
,	,	O
total	JJ	O
ceramides	NNS	O
and	CC	O
other	JJ	O
sphingolipids	NNS	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
changes	NNS	O
in	IN	O
glucose	NN	O
disposal	NN	O
.	.	O

Stearoyl-coenzyme	VB	O
A	DT	O
desaturase	NN	O
1	CD	O
(	(	O
SCD1	NNP	O
)	)	O
content	NN	O
was	VBD	O
decreased	VBN	O
with	IN	O
DIWL	NNP	O
(	(	O
-19.5	NNP	O
?	.	O
8.5	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
increased	VBD	O
with	IN	O
EX	NNP	O
(	(	O
19.6	CD	O
?	.	O
7.4	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Diacylglycerol	NNP	O
acyltransferase	VBD	O
1	CD	O
(	(	O
DGAT1	NNP	O
)	)	O
was	VBD	O
unchanged	JJ	O
with	IN	O
the	DT	O
interventions	NNS	O
.	.	O

CONCLUSIONS/INTERPRETATION	NNP	O
Diet-induced	NNP	O
weight	NN	O
loss	NN	O
and	CC	O
exercise	NN	O
training	NN	O
both	DT	O
improved	JJ	O
insulin	NN	O
resistance	NN	O
and	CC	O
decreased	VBD	O
DAG	NNP	O
,	,	O
while	IN	O
only	RB	O
exercise	NN	O
decreased	VBD	O
ceramides	NNS	O
,	,	O
despite	IN	O
the	DT	O
interventions	NNS	O
having	VBG	O
different	JJ	O
effects	NNS	O
on	IN	O
IMTG	NNP	O
.	.	O

These	DT	O
alterations	NNS	O
may	MD	O
be	VB	O
mediated	VBN	O
through	IN	O
differential	JJ	O
changes	NNS	O
in	IN	O
skeletal	JJ	O
muscle	NN	O
capacity	NN	O
for	IN	O
oxidation	NN	O
and	CC	O
triacylglycerol	NN	O
synthesis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
NCT00766298	NNP	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
.	.	O

Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
relative	JJ	O
efficacies	NNS	O
of	IN	O
various	JJ	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
are	VBP	O
not	RB	O
well	RB	O
known	VBN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
imipramine	NN	O
,	,	O
mexiletine	NN	O
,	,	O
pirmenol	NN	O
,	,	O
procainamide	NN	O
,	,	O
propafenone	NN	O
,	,	O
quinidine	NN	O
,	,	O
and	CC	O
sotalol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
trial	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
serial	JJ	O
testing	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
by	IN	O
one	CD	O
of	IN	O
two	CD	O
strategies	NNS	O
:	:	O
electrophysiologic	NN	O
study	NN	O
or	CC	O
Holter	NNP	O
monitoring	VBG	O
together	RB	O
with	IN	O
exercise	NN	O
testing	NN	O
.	.	O

The	DT	O
seven	CD	O
drugs	NNS	O
were	VBD	O
then	RB	O
tested	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
random	JJ	O
order	NN	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
eligible	JJ	O
to	TO	O
receive	VB	O
them	PRP	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
predictions	NNS	O
of	IN	O
drug	NN	O
efficacy	NN	O
and	CC	O
of	IN	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
the	DT	O
initial	JJ	O
drug	NN	O
titration	NN	O
were	VBD	O
tabulated	VBN	O
for	IN	O
all	DT	O
486	CD	O
randomized	VBN	O
subjects	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
long-term	JJ	O
treatment	NN	O
with	IN	O
the	DT	O
first	JJ	O
antiarrhythmic	JJ	O
drug	NN	O
that	WDT	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
drug	NN	O
testing	NN	O
.	.	O

Recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
,	,	O
deaths	NNS	O
,	,	O
and	CC	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
long-term	JJ	O
follow-up	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
296	CD	O
patients	NNS	O
in	IN	O
whom	WP	O
an	DT	O
antiarrhythmic	JJ	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
electrophysiologic-study	JJ	O
group	NN	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
predictions	NNS	O
of	IN	O
drug	NN	ME
efficacy	NN	ME
was	VBD	O
higher	JJR	ME
with	IN	O
sotalol	NN	O
(	(	O
35	CD	O
percent	NN	O
)	)	O
than	IN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
16	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	ME
significant	JJ	ME
difference	NN	ME
among	IN	O
the	DT	O
drugs	NNS	O
in	IN	O
the	DT	O
Holter-monitoring	NNP	O
group	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	ME
with	IN	ME
adverse	JJ	ME
drug	NN	ME
effects	NNS	ME
was	VBD	O
lowest	JJS	ME
among	IN	O
those	DT	O
receiving	VBG	O
sotalol	NN	O
.	.	O

The	DT	O
actuarial	JJ	ME
probability	NN	ME
of	IN	ME
a	DT	ME
recurrence	NN	ME
of	IN	ME
arrhythmia	NN	ME
after	IN	O
a	DT	O
prediction	NN	O
of	IN	O
drug	NN	O
efficacy	NN	O
by	IN	O
either	DT	O
strategy	NN	O
was	VBD	O
significantly	RB	Ot
lower	JJR	Ot
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
sotalol	NN	O
than	IN	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.43	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.29	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

With	IN	O
sotalol	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
combined	VBN	O
,	,	O
there	EX	O
were	VBD	O
lower	JJR	Ot
risks	NNS	Ot
of	IN	Ot
death	NN	Ot
from	IN	O
any	DT	O
cause	NN	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.50	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.30	CD	O
to	TO	O
0.80	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
death	NN	O
from	IN	O
cardiac	JJ	O
causes	NNS	O
,	,	O
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
death	NN	Ot
from	IN	Ot
arrhythmia	NN	Ot
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
a	DT	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
in	IN	O
whom	WP	O
it	PRP	O
remained	VBD	O
effective	JJ	O
and	CC	O
tolerated	VBD	O
was	VBD	O
higher	JJR	O
for	IN	O
sotalol	JJR	O
than	IN	O
for	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Sotalol	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
other	JJ	O
six	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
preventing	VBG	O
death	NN	O
and	CC	O
recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
.	.	O

In	IN	O
patients	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
if	IN	O
antiarrhythmic-drug	JJ	O
therapy	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
to	TO	O
prevent	VB	O
recurrences	NNS	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
,	,	O
treatment	NN	O
with	IN	O
sotalol	NN	O
and	CC	O
assessment	NN	O
of	IN	O
its	PRP$	O
potential	JJ	O
efficacy	NN	O
by	IN	O
Holter	NNP	O
monitoring	NN	O
are	VBP	O
a	DT	O
reasonable	JJ	O
initial	JJ	O
strategy	NN	O
.	.	O

Baseline	NNP	O
factors	NNS	O
predicting	VBG	O
placebo	NN	O
response	NN	O
to	TO	O
treatment	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	VBZ	O
The	DT	O
finding	NN	O
of	IN	O
factors	NNS	O
that	WDT	O
differentially	RB	O
predict	VBP	O
the	DT	O
likelihood	NN	O
of	IN	O
response	NN	O
to	TO	O
placebo	VB	O
over	IN	O
that	DT	O
of	IN	O
an	DT	O
active	JJ	O
drug	NN	O
could	MD	O
have	VB	O
a	DT	O
significant	JJ	O
impact	NN	O
on	IN	O
study	NN	O
design	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
identify	VB	O
possible	JJ	O
nonspecific	NN	O
,	,	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
response	NN	Ot
to	TO	Ot
intervention	NN	Ot
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
citalopram	NN	O
hydrobromide	NN	O
for	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
prominent	JJ	O
repetitive	JJ	O
behavior	NN	O
.	.	O

Baseline	NNP	O
data	NN	O
at	IN	O
study	NN	O
entry	NN	O
were	VBD	O
examined	VBN	O
with	IN	O
respect	NN	O
to	TO	O
final	JJ	O
outcome	NN	O
to	TO	O
determine	VB	O
if	IN	O
response	NN	O
predictors	NNS	O
could	MD	O
be	VB	O
identified	VBN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
149	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
of	IN	O
age	NN	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
9.4	CD	O
[	NN	O
3.1	CD	O
]	CD	O
years	NNS	O
)	)	O
from	IN	O
6	CD	O
academic	JJ	O
centers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
citalopram	VB	O
(	(	O
n	JJ	O
=	NNP	O
73	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
76	CD	O
)	)	O
.	.	O

Participants	NNS	O
had	VBD	O
autistic	JJ	O
disorder	NN	O
,	,	O
Asperger	NNP	O
syndrome	NN	O
,	,	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
;	:	O
had	VBD	O
illness	JJ	O
severity	NN	O
ratings	NNS	O
that	WDT	O
were	VBD	O
moderate	JJ	O
or	CC	O
more	JJR	O
than	IN	O
moderate	VB	O
on	IN	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impression-Severity	NNP	O
scale	NN	O
;	:	O
and	CC	O
scored	VBD	O
moderate	JJ	O
or	CC	O
more	JJR	O
than	IN	O
moderate	VB	O
on	IN	O
compulsive	JJ	O
behaviors	NNS	O
measured	VBN	O
with	IN	O
the	DT	O
modified	JJ	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive-Compulsive	JJ	O
Scale	NNP	O
.	.	O

INTERVENTIONS	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
citalopram	NN	O
(	(	O
10	CD	O
mg/5	RB	O
mL	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
maximum	VBD	O
dose	NN	O
of	IN	O
citalopram	NN	O
was	VBD	O
16.5	CD	O
(	(	O
6.5	CD	O
)	)	O
mg	NN	O
by	IN	O
mouth	JJ	O
daily	JJ	O
(	(	O
maximum	JJ	O
dose	NN	O
,	,	O
20	CD	O
mg/d	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
AND	NNP	O
MEASURES	NNP	O
A	NNP	O
positive	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
having	VBG	O
a	DT	O
score	NN	O
of	IN	O
at	IN	O
least	JJS	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
Clinical	JJ	Ot
Global	NNP	Ot
Impression-Improvement	NNP	Ot
scale	NN	Ot
at	IN	O
week	NN	O
12	CD	O
.	.	O

Baseline	NNP	O
measures	VBZ	O
included	VBN	O
demographic	JJ	O
(	(	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
pubertal	JJ	O
status	NN	O
)	)	O
,	,	O
clinical	JJ	O
,	,	O
and	CC	O
family	NN	O
measures	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
included	VBD	O
baseline	NN	O
illness	NN	O
severity	NN	O
ratings	NNS	O
(	(	PH
the	DT	PH
Aberrant	NNP	PH
Behavior	NNP	PH
Checklist	NNP	PH
,	,	PH
the	DT	PH
Child	NNP	PH
and	CC	PH
Adolescent	NNP	PH
Symptom	NNP	PH
Inventory	NNP	PH
,	,	PH
the	DT	PH
Vineland	NNP	PH
Adaptive	NNP	PH
Behavior	NNP	PH
Scales	NNP	PH
,	,	PH
the	DT	PH
Repetitive	JJ	PH
Behavior	NNP	PH
Scale-Revised	JJ	PH
,	,	PH
and	CC	PH
the	DT	PH
Children	NNP	PH
's	POS	PH
Yale-Brown	JJ	PH
Obsessive-Compulsive	JJ	PH
Scale	NNP	PH
)	)	PH
.	.	O

Family	JJ	O
measures	NNS	O
included	VBD	O
the	DT	O
Caregiver	NNP	Ot
Strain	NNP	Ot
Questionnaire	NNP	Ot
.	.	PH

RESULTS	NNP	O
Several	JJ	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
response	NN	O
were	VBD	O
identified	VBN	O
,	,	O
and	CC	O
a	DT	O
principal	JJ	O
component	NN	O
analysis	NN	O
yielded	VBD	O
3	CD	O
composite	JJ	O
measures	NNS	O
(	(	ME
disruptive	JJ	ME
behavior	NN	ME
,	,	ME
autism/mood	NN	ME
,	,	ME
and	CC	ME
caregiver	RB	ME
strain	NN	ME
)	)	ME
that	WDT	O
significantly	RB	O
predicted	VBD	O
response	NN	O
at	IN	O
week	NN	O
12	CD	O
.	.	O

Specifically	RB	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
than	IN	O
participants	NNS	O
in	IN	O
the	DT	O
citalopram	NN	O
group	NN	O
to	TO	O
respond	VB	O
at	IN	O
week	NN	O
12	CD	O
if	IN	O
they	PRP	O
entered	VBD	O
the	DT	O
study	NN	O
more	RBR	O
symptomatic	JJ	O
on	IN	O
each	DT	O
of	IN	O
the	DT	O
3	CD	O
composite	JJ	O
measures	NNS	O
,	,	O
and	CC	O
they	PRP	O
were	VBD	O
at	IN	O
least	JJS	O
2	CD	O
times	NNS	O
less	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
responders	NNS	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
RELEVANCE	NNP	O
This	DT	O
analysis	NN	O
suggests	VBZ	O
strategies	NNS	O
that	WDT	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
anticipating	VBG	O
and	CC	O
potentially	RB	O
mitigating	VBG	O
the	DT	O
nonspecific	JJ	O
response	NN	O
in	IN	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00086645	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
sequential	JJ	O
annual	JJ	O
vaccination	NN	O
and	CC	O
of	IN	O
DHEA	NNP	O
administration	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
repeated	VBN	O
vaccination	NN	O
and	CC	O
of	IN	O
dehydroepiandrosterone	NN	O
(	(	O
DHEA	NNP	O
)	)	O
treatment	NN	O
on	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Seventy-one	CD	O
elderly	JJ	O
volunteers	NNS	O
,	,	O
aged	VBN	O
61-89	CD	O
years	NNS	O
,	,	O
enrolled	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
DHEA	NNP	O
(	(	O
50	CD	O
mg	NN	O
qd	NN	O
p.o	NN	O
.	.	O

for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
starting	VBG	O
2	CD	O
days	NNS	O
before	IN	O
immunization	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Antibody	NNP	O
response	NN	O
against	IN	O
the	DT	O
three	CD	O
strains	NNS	O
of	IN	O
vaccine	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
vaccination	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
previously	RB	O
vaccinated	VBN	O
and	CC	O
non-vaccinated	JJ	O
subjects	NNS	O
.	.	O

DHEA	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
enhance	VB	O
established	VBN	PH
immunity	NN	PH
.	.	PH

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
attainment	NN	O
of	IN	O
protective	JJ	Ot
antibody	NN	Ot
titer	NN	Ot
(	(	O
titer	NN	O
of	IN	O
1:40	CD	O
or	CC	O
greater	JJR	O
)	)	O
against	IN	O
A/Texas	NNP	O
in	IN	O
subjects	NNS	O
with	IN	O
non-protective	JJ	O
baseline	NN	O
antibody	NN	O
titer	NN	O
was	VBD	O
recorded	VBN	O
following	VBG	O
DHEA	NNP	O
treatment	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
52	CD	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Post-immunization	NN	Ot
titers	NNS	Ot
against	IN	O
influenza	VBP	O
A	DT	O
strains	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
immunized	VBN	O
before	RB	O
.	.	O

Additionally	RB	O
,	,	O
post-vaccination	JJ	Ot
protective	JJ	Ot
titers	NNS	Ot
against	IN	O
the	DT	O
A/Johannesburg	NNP	O
strain	NN	O
were	VBD	O
more	RBR	O
prevalent	JJ	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
vaccinated	VBN	O
before	RB	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
not	RB	O
the	DT	O
same	JJ	O
for	IN	O
anti-B/Harbin	JJ	O
antibodies-repeated	JJ	O
vaccination	NN	O
caused	VBD	O
a	DT	O
non-significant	JJ	O
increase	NN	O
in	IN	O
HI	NNP	O
titer	NN	O
in	IN	O
previously	RB	O
vaccinated	VBN	O
subjects	NNS	O
.	.	O

[	JJ	O
Metastatic	NNP	PH
breast	NN	PH
cancer	NN	PH
:	:	O
a	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
tamoxifen	NN	O
and	CC	O
the	DT	O
sequential	JJ	O
administration	NN	O
of	IN	O
tamoxifen	NN	O
and	CC	O
medroxyprogesterone	NN	O
acetate	NN	O
]	NNP	O
.	.	O

Seventy-nine	JJ	O
patients	NNS	O
with	IN	O
an	DT	O
histologically	RB	O
proven	RB	O
disseminated	VBN	O
breast	NN	O
cancer	NN	O
,	,	O
never	RB	O
treated	VBN	O
before	IN	O
with	IN	O
additive	JJ	O
hormonal	JJ	O
therapy	NN	O
,	,	O
entered	VBD	O
into	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
between	IN	O
june	NN	O
1981	CD	O
and	CC	O
december	VB	O
1982	CD	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
group	NN	O
44	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
continually	RB	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
tamoxifen	NN	O
(	(	O
TAM	NNP	O
)	)	O
of	IN	O
20	CD	O
mg/m2	NN	O
.	.	O

In	IN	O
the	DT	O
2nd	CD	O
group	NN	O
35	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
TAM	NNP	O
of	IN	O
20	CD	O
mg/m2	NN	O
for	IN	O
15	CD	O
days	NNS	O
and	CC	O
then	RB	O
an	DT	O
oral	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
medroxyprogesterone	NN	O
acetate	NN	O
of	IN	O
350	CD	O
mg/m2	NN	O
for	IN	O
the	DT	O
next	JJ	O
15	CD	O
days	NNS	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
stopped	VBN	O
at	IN	O
the	DT	O
first	JJ	O
manifestation	NN	O
of	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
hormonal	JJ	O
receptor	NN	O
status	NN	O
was	VBD	O
determined	VBN	O
in	IN	O
30	CD	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
I	PRP	O
and	CC	O
23	CD	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
II	NNP	O
.	.	O

An	DT	O
objective	JJ	O
response	NN	O
to	TO	O
treatment	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
48	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
I	PRP	O
and	CC	O
60	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
group	NN	O
II	NNP	O
.	.	O

This	DT	O
difference	NN	O
is	VBZ	O
not	RB	O
significant	JJ	O
(	(	O
X2	NNP	O
=	NNP	O
1,05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mean	JJ	PH
duration	NN	Ot
of	IN	Ot
therapeutic	JJ	Ot
response	NN	Ot
is	VBZ	O
significantly	RB	O
higher	RBR	O
in	IN	O
the	DT	O
group	NN	O
II	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0,01	CD	O
)	)	O
.	.	O

[	RB	O
Comparative	NNP	O
study	NN	O
between	IN	O
5	CD	O
%	NN	O
prilocaine	NN	O
and	CC	O
2	CD	O
%	NN	O
mepivacaine	NN	O
by	IN	O
the	DT	O
subarachnoid	JJ	O
route	NN	O
in	IN	O
transurethral	JJ	O
resections	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
duration	NN	Ot
of	IN	O
spinal	JJ	O
block	NN	O
with	IN	O
5	CD	O
%	NN	O
prilocaine	NN	O
and	CC	O
2	CD	O
%	NN	O
mepivacaine	NN	O
in	IN	O
short	JJ	O
procedures	NNS	O
for	IN	O
transurethral	JJ	O
resection	NN	O
and	CC	O
to	TO	O
assess	VB	A
possible	JJ	A
complications	NNS	A
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Fifty-seven	NNP	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
or	CC	O
a	DT	O
vesical	JJ	O
tumor	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
ASA	NNP	O
I-III	NNP	O
,	,	O
over	IN	O
55	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
5	CD	O
%	NN	O
prilocaine	NN	O
(	(	O
1	CD	O
mg/kg	NN	O
,	,	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
or	CC	O
2	CD	O
%	NN	O
mepivacaine	NN	O
(	(	O
0.8	CD	O
mg/kg	NN	O
,	,	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
.	.	O

We	PRP	O
collected	VBD	O
data	NNS	O
on	IN	O
anesthetic	JJ	Ot
technique	NN	Ot
,	,	PH
levels	NNS	Ot
of	IN	Ot
extension	NN	Ot
of	IN	Ot
motor	NN	Ot
and	CC	Ot
sensory	JJ	Ot
blockades	NNS	Ot
,	,	PH
duration	NN	Ot
of	IN	Ot
blockades	NNS	Ot
and	CC	PH
complications	NNS	PH
within	IN	PH
the	DT	PH
first	JJ	PH
24	CD	PH
hours	NNS	PH
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
Demographic	NNP	O
data	NNS	O
,	,	O
ASA	NNP	O
classification	NN	O
and	CC	O
duration	NN	O
of	IN	O
surgery	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

We	PRP	O
found	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
duration	NN	Ot
of	IN	Ot
sensory	JJ	Ot
blockade	NN	Ot
(	(	O
120.92	CD	O
+/-	JJ	O
36.21	CD	O
min	NN	O
with	IN	O
prilocaine	NN	O
and	CC	O
145.83	CD	O
+/-	JJ	O
35.81	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	O
)	)	O
and	CC	O
in	IN	O
motor	NN	Ot
blockade	NN	Ot
(	(	O
106.29	CD	O
+/-	JJ	O
38.16	CD	O
min	NN	O
with	IN	O
prilocaine	NN	O
and	CC	O
133.16	CD	O
+/-	JJ	O
42.21	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	O
)	)	O
.	.	O

Five	JJ	O
cases	NNS	O
of	IN	O
hypotension	NN	A
and	CC	O
4	CD	O
of	IN	O
bradycardia	NN	A
occurred	VBN	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
one	CD	O
patient	NN	O
in	IN	O
the	DT	O
mepivacaine	NN	O
group	NN	O
suffered	VBD	O
slight	JJ	O
postoperative	JJ	O
cephalea	NN	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
local	JJ	O
anesthetics	NNS	O
offer	VBP	O
good	JJ	O
surgical	JJ	Ot
conditions	NNS	Ot
with	IN	O
hemodynamic	JJ	O
stability	NN	O
and	CC	O
few	JJ	O
complications	NNS	A
.	.	O

The	DT	O
duration	NN	O
of	IN	O
sensory	NN	Ot
and	CC	PH
motor	NN	Ot
blockade	NN	Ot
is	VBZ	O
shorter	JJR	O
with	IN	O
prilocaine	NN	O
than	IN	O
with	IN	O
mepivacaine	NN	O
,	,	O
making	VBG	O
prilocaine	NN	O
more	JJR	O
appropriate	JJ	O
for	IN	O
short	JJ	O
interventions	NNS	O
.	.	O

Granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
as	IN	O
immunomodulating	VBG	O
factor	NN	O
together	RB	O
with	IN	O
influenza	JJ	O
vaccination	NN	O
in	IN	O
stem	NN	O
cell	NN	O
transplant	NN	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
on	IN	O
the	DT	O
serological	JJ	PH
response	NN	PH
at	IN	O
influenza	JJ	O
vaccination	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
117	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
undergone	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
SCT	NNP	O
)	)	O
.	.	O

The	DT	O
vaccine	NN	PH
response	NN	PH
was	VBD	O
evaluated	VBN	O
as	IN	O
significant	JJ	O
increases	NNS	O
in	IN	O
levels	NNS	PH
of	IN	PH
influenza	JJ	PH
hemagglutination-inhibition	NN	PH
(	(	PH
HAI	NNP	PH
)	)	PH
antibodies	NNS	PH
and	CC	O
of	IN	O
IgG	NNP	PH
antibodies	NNS	PH
measured	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
antibody	NN	PH
response	NN	PH
to	TO	O
either	DT	O
influenza	VB	O
A	NNP	O
or	CC	O
B	NNP	O
in	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
GM-CSF	NNP	O
at	IN	O
vaccination	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
53	NNS	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

In	IN	O
the	DT	O
subgroup	NN	O
of	IN	O
allogeneic	JJ	O
SCT	NNP	O
patients	NNS	O
,	,	O
HAI	NNP	O
showed	VBD	O
that	IN	O
the	DT	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
influenza	NN	Ot
B	NNP	Ot
vaccine	NN	Ot
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

ELISA	NN	PH
showed	VBD	O
that	IN	O
autologous	JJ	O
SCT	NNP	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
who	WP	O
received	VBD	O
GM-CSF	NNP	O
had	VBD	O
a	DT	O
better	JJR	O
response	NN	O
to	TO	O
influenza	VB	PH
A	NNP	PH
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

At	IN	O
early	JJ	O
vaccination	NN	O
,	,	O
4-12	JJ	O
months	NNS	O
after	IN	O
stem	NN	O
cell	NN	O
transplantation	NN	O
,	,	O
these	DT	O
responses	NNS	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
.	.	O

GM-CSF	JJ	O
appears	VBZ	O
to	TO	O
improve	VB	O
the	DT	O
response	NN	PH
to	TO	PH
influenza	VB	Ot
vaccination	NN	Ot
in	IN	O
some	DT	O
groups	NNS	O
of	IN	O
SCT	NNP	O
patients	NNS	O
,	,	O
but	CC	O
only	RB	O
to	TO	O
a	DT	O
limited	JJ	O
extent	NN	O
.	.	O

Engagement	NN	O
with	IN	O
electronic	JJ	O
screen	JJ	O
media	NNS	O
among	IN	O
students	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
relative	JJ	O
engagement	JJ	O
potential	NN	O
of	IN	O
four	CD	O
types	NNS	O
of	IN	O
electronic	JJ	O
screen	JJ	O
media	NNS	O
(	(	O
ESM	NNP	O
)	)	O
:	:	O
animated	VBN	O
video	NN	O
,	,	O
video	NN	O
of	IN	O
self	NN	O
,	,	O
video	NN	O
of	IN	O
a	DT	O
familiar	JJ	O
person	NN	O
engaged	VBD	O
with	IN	O
an	DT	O
immersive	JJ	O
virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
game	NN	O
,	,	O
and	CC	O
immersion	NN	O
of	IN	O
self	NN	O
in	IN	O
the	DT	O
VR	NNP	O
game	NN	O
.	.	O

Forty-two	JJ	O
students	NNS	O
with	IN	O
autism	NN	O
,	,	O
varying	VBG	O
in	IN	O
age	NN	O
and	CC	O
expressive	JJ	O
communication	NN	O
ability	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
.	.	O

Gaze	NNP	ME
duration	NN	ME
and	CC	O
vocalization	NN	ME
served	VBD	O
as	IN	O
dependent	JJ	O
measures	NNS	O
of	IN	O
engagement	NN	O
.	.	O

The	DT	O
results	NNS	O
reveal	VBP	O
differential	JJ	O
responding	NN	O
across	IN	O
ESM	NNP	PH
,	,	O
with	IN	O
some	DT	O
variation	NN	O
related	VBN	O
to	TO	O
the	DT	O
engagement	NN	O
metric	JJ	O
employed	VBN	O
.	.	O

Preferences	NNS	O
for	IN	O
seeing	VBG	ME
themselves	PRP	ME
on	IN	ME
the	DT	ME
screen	NN	ME
,	,	ME
as	RB	ME
well	RB	ME
as	IN	ME
for	IN	ME
viewing	VBG	ME
the	DT	ME
VR	NNP	ME
scenarios	NNS	ME
,	,	O
emerged	VBD	O
from	IN	O
the	DT	O
data	NNS	O
.	.	O

While	IN	O
the	DT	O
study	NN	O
did	VBD	O
not	RB	O
yield	VB	O
definitive	JJ	O
data	NNS	O
about	IN	O
the	DT	O
relative	JJ	O
engagement	JJ	O
potential	NN	O
of	IN	O
ESM	NNP	O
alternatives	NNS	O
,	,	O
it	PRP	O
does	VBZ	O
provide	VB	O
a	DT	O
foundation	NN	O
for	IN	O
future	JJ	O
research	NN	O
,	,	O
including	VBG	O
guidance	NN	O
related	VBN	O
to	TO	O
participant	JJ	O
profiles	NNS	O
,	,	O
stimulus	NN	O
characteristics	NNS	O
,	,	O
and	CC	O
data	NNS	O
coding	NN	O
challenges	NNS	O
.	.	O

Long-stay	JJ	O
versus	NN	O
short-stay	JJ	O
hospital	NN	O
treatment	NN	O
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
contrast	VB	O
early	JJ	O
discharge	NN	O
versus	NN	O
attempted	VBD	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
in	IN	O
hospital	NN	O
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
(	(	O
PEM	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Field	NNP	O
experiment	NN	O
,	,	O
two-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
with	IN	O
one	CD	O
between	IN	O
group	NN	O
(	(	O
short-	JJ	O
versus	IN	O
long-stay	NN	O
)	)	O
and	CC	O
one	CD	O
repeated	VBN	O
measures	NNS	O
factor	NN	O
(	(	O
admission	NN	O
,	,	O
then	RB	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
,	,	O
30	CD	O
and	CC	O
36	CD	O
months	NNS	O
post-admission	NN	O
)	)	O
.	.	O

Covariates	NNPS	O
introduced	VBD	O
.	.	O

SETTING	NNP	O
Primary	NNP	O
health	NN	O
care	NN	O
,	,	O
Kingston	NNP	O
,	,	O
Jamaica	NNP	O
.	.	O

SUBJECTS	NNP	O
n	JJ	O
=	NNP	O
81	CD	O
;	:	O
mean	JJ	O
age	NN	O
11	CD	O
months	NNS	O
;	:	O
79	CD	O
contribute	VBP	O
longitudinal	JJ	O
data	NNS	O
;	:	O
44	CD	O
every	DT	O
measurement	NN	O
.	.	O

INTERVENTIONS	NNP	O
When	WRB	O
concurrent	NN	O
illnesses	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
and	CC	O
normal	JJ	O
feeding	VBG	O
re-established	JJ	O
(	(	O
weight	JJ	O
gain	NN	O
5	CD	O
g/kg.day-1	NN	O
)	)	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
short-stay	NN	O
(	(	O
SS	NNP	O
)	)	O
or	CC	O
long-stay	JJ	O
(	(	O
LS	NNP	O
)	)	O
group	NN	O
.	.	O

LS	NNP	O
retained	VBD	O
in	IN	O
hospital	NN	O
for	IN	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
mean	VB	O
40	CD	O
days	NNS	O
)	)	O
.	.	O

SS	NNP	O
discharged	VBD	O
immediately	RB	O
(	(	O
mean	JJ	O
18	CD	O
days	NNS	O
)	)	O
for	IN	O
standard	JJ	O
Health	NNP	O
Service	NNP	O
care	NN	O
at	IN	O
home	NN	O
for	IN	O
6	CD	O
months	NNS	O
plus	CC	O
high-energy	JJ	O
supplement	NN	O
(	(	O
3.31	CD	O
MJ	NNP	O
with	IN	O
20.6	CD	O
g	NNS	O
protein	JJ	O
daily	JJ	O
)	)	O
for	IN	O
first	JJ	O
3	CD	O
months	NNS	O
.	.	O

After	IN	O
discharge	NN	O
LS	NNP	O
received	VBD	O
6	CD	O
months	NNS	O
home	NN	O
care	NN	O
,	,	O
but	CC	O
without	IN	O
supplementation	NN	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
advantages	VBZ	O
for	IN	O
LS	NNP	O
group	NN	O
on	IN	O
NCHS	NNP	PH
weight	NN	PH
&	CC	PH
length	NN	PH
for	IN	PH
age	NN	PH
at	IN	PH
discharge	NN	PH
,	,	O
and	CC	O
at	IN	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
and	CC	O
for	IN	O
length	NN	O
also	RB	O
30	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
to	TO	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Weight	NNP	PH
advantage	NN	PH
peaked	VBD	O
at	IN	O
12	CD	O
and	CC	O
18	CD	O
months	NNS	O
,	,	O
length	NN	O
later	RB	O
at	IN	O
18	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Contrary	NNP	O
to	TO	O
earlier	VB	O
reports	NNS	O
,	,	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
hospital	NN	O
for	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
PEM	NNP	O
.	.	O

Although	IN	O
in	IN	O
the	DT	O
long-term	JJ	O
both	DT	O
groups	NNS	O
move	VBP	O
towards	NNS	O
expected	VBN	O
levels	NNS	O
in	IN	O
their	PRP$	O
home	NN	O
community	NN	O
,	,	O
a	DT	O
significant	JJ	O
advantage	NN	O
maintained	VBD	O
for	IN	O
approximately	RB	O
2	CD	O
years	NNS	O
is	VBZ	O
developmentally	RB	O
advantageous	JJ	O
during	IN	O
the	DT	O
critical	JJ	O
time	NN	O
after	IN	O
weaning	VBG	O
.	.	O

Prevention	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
with	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplements	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
undergoing	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
central	JJ	O
neck	NN	O
dissection	NN	O
.	.	O

BACKGROUND	NNP	O
Routine	NNP	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
may	MD	O
prevent	VB	O
hypocalcemic	JJ	O
crisis	NN	O
,	,	O
but	CC	O
its	PRP$	O
efficacy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
thyroidectomy	JJ	O
plus	JJ	O
central	JJ	O
neck	NN	O
dissection	NN	O
(	(	O
CND	NNP	O
)	)	O
.	.	O

The	DT	O
authors	NNS	O
therefore	VBP	O
prospectively	RB	O
evaluated	VBN	O
the	DT	O
clinical	JJ	O
usefulness	NN	O
of	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
hypocalcemia	NN	O
after	IN	O
total	JJ	O
thyroidectomy	NN	O
and	CC	O
CND	NNP	O
.	.	O

METHODS	NNP	O
Of	IN	O
197	CD	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
,	,	O
49	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
and	CC	O
148	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
CND	NNP	O
.	.	O

The	DT	O
latter	JJ	O
were	VBD	O
randomized	VBN	O
to	TO	O
oral	JJ	O
calcium	NN	O
(	(	O
3	CD	O
g/day	NN	O
)	)	O
plus	CC	O
vitamin	JJ	O
D	NNP	O
(	(	O
1	CD	O
mg/day	NN	O
)	)	O
(	(	O
Group	NNP	O
A	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
calcium	NN	O
alone	RB	O
(	(	O
Group	NNP	O
B	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
or	CC	O
no	DT	O
supplements	NNS	O
(	(	O
Group	NNP	O
C	NNP	O
,	,	O
n=50	RB	O
)	)	O
.	.	O

Hypocalcemic	NNP	PH
symptoms	NNS	PH
,	,	PH
serum	JJ	PH
calcium	NN	PH
,	,	PH
and	CC	PH
parathyroid	VB	PH
hormone	NN	PH
(	(	PH
PTH	NNP	PH
)	)	PH
levels	NNS	PH
were	VBD	O
compared	VBN	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Group	NNP	O
C	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
(	(	O
26.0	CD	O
%	NN	O
vs	JJ	O
6.1	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
and	CC	O
laboratory	NN	O
(	(	O
44.0	CD	O
%	NN	O
vs	JJ	O
14.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
hypocalcemia	NN	PH
than	IN	O
the	DT	O
group	NN	O
without	IN	O
CND	NNP	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	PH
and	CC	PH
laboratory	JJ	PH
hypocalcemia	NN	PH
were	VBD	O
significantly	RB	O
decreased	VBN	O
in	IN	O
Groups	NNP	O
A	NNP	O
(	(	O
2.0	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
12.2	CD	O
%	NN	O
and	CC	O
24.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Serum	NNP	PH
calcium	NN	PH
levels	NNS	PH
decreased	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
after	IN	O
surgery	NN	O
,	,	O
but	CC	O
recovered	VBD	O
earliest	JJS	O
in	IN	O
Group	NNP	O
A.	NNP	O
Hypercalcemia	NNP	O
and	CC	O
PTH	NNP	O
inhibition	NN	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
gs	NN	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
CND	NNP	O
significantly	RB	O
increases	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
postoperative	JJ	PH
hypocalcemia	NN	PH
,	,	O
which	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
routine	JJ	O
postoperative	JJ	O
supplementation	NN	O
with	IN	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
remifentanil	NN	O
with	IN	O
fentanyl	NN	O
for	IN	O
deep	JJ	PH
sedation	NN	PH
in	IN	O
oral	JJ	O
surgery	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
recovery	NN	O
for	IN	O
oral	JJ	O
surgery	NN	O
patients	NNS	O
given	VBN	O
a	DT	O
deep	JJ	O
sedation	NN	O
regimen	NNS	O
of	IN	O
midazolam	NN	O
,	,	O
propofol	NN	O
,	,	O
and	CC	O
remifentanil	NN	O
with	IN	O
a	DT	O
standard	JJ	O
control	NN	O
of	IN	O
fentanyl	NN	O
in	IN	O
place	NN	O
of	IN	O
remifentanil	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
investigation	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
randomized	NN	O
,	,	O
prospective	JJ	O
,	,	O
single-blinded	JJ	O
controlled	VBD	O
study	NN	O
.	.	O

Group	NNP	O
1	CD	O
,	,	O
the	DT	O
control	NN	O
,	,	O
received	VBD	O
midazolam	JJ	O
0.03	CD	O
mg/kg	NN	O
,	,	O
fentanyl	VBP	O
1	CD	O
microg/kg	NN	O
,	,	O
and	CC	O
propofol	VB	O
initially	RB	O
at	IN	O
140	CD	O
microg/kg/min	NN	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
midazolam	RB	O
0.03	CD	O
mg/kg	NN	O
,	,	O
remifentanil	NN	O
:	:	O
propofol	NN	O
(	(	O
1:500	CD	O
)	)	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
propofol	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
40	CD	O
microg/kg/min	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
time	NN	Ot
to	TO	Ot
response	NN	Ot
to	TO	Ot
verbal	JJ	Ot
command	NN	Ot
,	,	O
Aldrete	NNP	PH
score	VBD	PH
=	JJ	PH
9	CD	PH
,	,	O
Postanesthesia	NNP	Ot
Discharge	NNP	Ot
Scoring	NNP	Ot
System	NNP	Ot
=	VBD	PH
7	CD	PH
,	,	O
and	CC	O
assessment	NN	PH
by	IN	PH
the	DT	PH
Digit	NNP	PH
Symbol	NNP	PH
Substitution	NNP	PH
Test	NNP	PH
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
subjects	NNS	O
were	VBD	O
entered	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Baseline	NNP	O
findings	NNS	O
were	VBD	O
homogenous	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
2	CD	O
recovered	VBN	O
earlier	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
and	CC	O
required	VBN	O
less	JJR	O
propofol	NN	O
for	IN	O
both	DT	O
the	DT	O
induction	NN	PH
(	(	O
0.8	CD	O
+/-	JJ	O
0.4	CD	O
versus	NN	O
1.2	CD	O
+/-	JJ	O
0.6	CD	O
mg/kg	NN	O
;	:	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
maintenance	NN	Ot
of	IN	Ot
deep	JJ	Ot
sedation	NN	Ot
(	(	O
46	CD	O
+/-	JJ	O
9	CD	O
versus	NN	O
131	CD	O
+/-	JJ	O
17	CD	O
microg/kg/min	NN	O
;	:	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
minor	JJ	O
differences	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
this	DT	O
remifentanil	JJ	O
regimen	NNS	O
provided	VBD	O
significantly	RB	O
more	RBR	O
rapid	JJ	Ot
recovery	NN	Ot
and	CC	O
used	VBD	O
significantly	RB	O
less	JJR	O
propofol	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
fentanyl	JJ	O
regimen	NNS	O
.	.	O

Group	NNP	O
cognitive	JJ	O
behavior	NN	O
therapy	NN	O
for	IN	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
anxiety	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
are	VBP	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
developing	VBG	O
significant	JJ	O
anxiety	NN	PH
.	.	O

Anxiety	NN	O
can	MD	O
adversely	RB	O
impact	VB	O
functioning	VBG	O
across	IN	O
school	NN	O
,	,	O
home	NN	O
and	CC	O
community	NN	O
environments	NNS	O
.	.	O

Cognitive	JJ	O
behavioral	JJ	O
therapies	NNS	O
(	(	O
CBT	NNP	O
)	)	O
are	VBP	O
frequently	RB	O
used	VBN	O
with	IN	O
success	NN	O
for	IN	O
children	NNS	O
with	IN	O
anxiety	NN	ME
symptoms	NNS	ME
.	.	ME

Modified	NNP	O
CBT	NNP	O
interventions	NNS	O
for	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
have	VBP	O
also	RB	O
yielded	VBN	O
promising	JJ	O
results	NNS	O
.	.	O

METHODS	NNP	O
Fifty	NNP	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
ASD	NNP	O
and	CC	O
anxiety	NN	O
were	VBD	O
randomizedto	JJ	O
group	NN	O
CBT	NNP	O
or	CC	O
treatment-as-usual	JJ	O
(	(	O
TAU	NNP	O
)	)	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Independent	NNP	O
clinical	JJ	O
evaluators	NNS	O
,	,	O
blind	NN	O
to	TO	O
condition	NN	O
,	,	O
completed	VBN	O
structured	JJ	O
interviews	NNS	O
(	(	O
Anxiety	NNP	O
Disorders	NNP	O
Interview	NNP	O
Schedule	NNP	O
?	.	O
Parent	NNP	O
Version	NNP	O
;	:	O
ADIS-P	NNP	O
)	)	O
pre-	NN	O
and	CC	O
post-intervention	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
children	NNS	O
completed	VBN	O
either	CC	O
the	DT	O
CBT	NNP	O
or	CC	O
TAU	NNP	O
condition	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
markedly	RB	O
better	RBR	O
outcomes	NNS	O
for	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
.	.	O

Significant	JJ	O
differences	NNS	O
by	IN	O
group	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
Clinician	JJ	O
Severity	NNP	O
Ratings	NNP	O
,	,	O
diagnostic	JJ	ME
status	NN	ME
,	,	O
and	CC	O
clinician	JJ	O
ratings	NNS	O
of	IN	O
global	JJ	O
improvement	NN	O
.	.	O

In	IN	O
the	DT	O
intent-to-treat	JJ	O
sample	NN	O
,	,	O
10	CD	O
of	IN	O
20	CD	O
children	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
had	VBD	O
a	DT	O
clinically	RB	O
meaningful	JJ	O
positive	JJ	O
treatment	NN	O
response	NN	O
,	,	O
compared	VBN	O
to	TO	O
2	CD	O
of	IN	O
23	CD	O
children	NNS	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TAU	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Initial	JJ	O
results	NNS	O
from	IN	O
this	DT	O
randomized	VBN	O
,	,	O
designed	VBN	O
treatment	NN	O
study	NN	O
suggest	VBP	O
that	IN	O
agroup	NN	O
CBT	NNP	O
intervention	NN	O
specifically	RB	O
developed	VBD	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
anxiety	NN	O
.	.	O

Limitations	NNS	O
of	IN	O
this	DT	O
study	NN	O
include	VBP	O
small	JJ	O
sample	JJ	O
size	NN	O
,	,	O
lack	NN	O
of	IN	O
an	DT	O
attention	NN	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
outcome	NN	O
measures	NNS	O
normed	VBN	O
with	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
[	JJ	O
Treatment	NNP	O
of	IN	O
autism	NN	O
children	NNS	O
:	:	O
observation	NN	O
on	IN	O
efficacy	NN	O
of	IN	O
behavior	JJ	O
training	NN	O
with	IN	O
retention	NN	O
of	IN	O
needles	NNS	O
on	IN	O
head	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effect	NN	O
difference	NN	O
of	IN	O
behavior	JJ	O
training	NN	O
with	IN	O
head	NN	O
needling	VBG	O
retention	NN	O
and	CC	O
behavior	NN	O
training	NN	O
after	IN	O
acupuncture	NN	O
for	IN	O
autism	NN	O
children	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
qualified	VBD	O
autism	NN	O
children	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
simultaneous	JJ	O
head	NN	O
needling	VBG	O
retention	NN	O
and	CC	O
behavior	JJ	O
training	NN	O
group	NN	O
(	(	O
trial	NN	O
group	NN	O
)	)	O
and	CC	O
behavior	JJ	O
training	NN	O
after	IN	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
with	IN	O
30	CD	O
case	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Retention	NNP	O
needles	NNS	O
on	IN	O
the	DT	O
head	NN	O
with	IN	O
simultaneous	JJ	O
behavior	NN	O
training	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
the	DT	O
trial	NN	O
group	NN	O
.	.	O

The	DT	O
main	JJ	O
acupoints	NNS	O
included	VBD	O
Sishen	NNP	O
Xue	NNP	O
,	,	O
Dingshen	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
tranquilization	NN	O
)	)	O
,	,	O
Nao	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
the	DT	O
function	NN	O
of	IN	O
brain	NN	O
)	)	O
,	,	O
Shou	NNP	O
Zhisanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
hand	NN	O
)	)	O
and	CC	O
Zozhi	NNP	O
Sonxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
foot	NN	O
)	)	O
.	.	O

Other	JJ	O
points	NNS	O
were	VBD	O
combined	VBN	O
according	VBG	O
to	TO	O
conditions	NNS	O
of	IN	O
patients	NNS	O
.	.	O

Needles	NNS	O
on	IN	O
the	DT	O
4	CD	O
extremities	NNS	O
were	VBD	O
withdrawn	VBN	O
first	RB	O
after	IN	O
30	CD	O
minutes	NNS	O
,	,	O
needles	NNS	O
on	IN	O
head	NN	O
were	VBD	O
remained	VBN	O
during	IN	O
behavior	JJ	O
training	NN	O
.	.	O

While	IN	O
behavior	JJ	O
training	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
when	WRB	O
acupuncture	NN	O
treatment	NN	O
was	VBD	O
completely	RB	O
accomplished	VBN	O
.	.	O

Treatments	NNS	O
were	VBD	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
to	TO	O
both	DT	O
groups	NNS	O
.	.	O

And	CC	O
3	CD	O
months	NNS	O
was	VBD	O
taken	VBN	O
as	IN	O
one	CD	O
observation	NN	O
cycle	NN	O
.	.	O

Estimation	NN	O
was	VBD	O
made	VBN	O
on	IN	O
therapeutic	JJ	ME
effect	NN	ME
and	CC	O
developing	VBG	ME
level	NN	ME
of	IN	ME
autism	NN	ME
children	NNS	ME
with	IN	ME
CARS	NNP	ME
and	CC	ME
PEP	NNP	ME
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	Ot
effective	JJ	Ot
rate	NN	Ot
of	IN	O
the	DT	O
trial	NN	O
group	NN	O
was	VBD	O
83.3	CD	O
%	NN	O
(	(	O
25/30	CD	O
)	)	O
,	,	O
better	JJR	O
than	IN	O
66.7	CD	O
%	NN	O
(	(	O
20/30	CD	O
)	)	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
CARS	NNPS	ME
scores	NNS	ME
of	IN	O
both	DT	O
groups	NNS	O
declined	VBD	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

And	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

While	IN	O
the	DT	O
PEP	NNP	ME
scores	NNS	ME
of	IN	O
both	DT	O
groups	NNS	O
increased	VBD	O
,	,	O
and	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increasing	VBG	O
level	NN	O
of	IN	O
scores	NNS	ME
of	IN	ME
cognitive	JJ	ME
understanding	NN	ME
and	CC	ME
cognitive	JJ	ME
expression	NN	ME
were	VBD	O
all	DT	O
better	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
effect	NN	O
of	IN	O
behavior	JJ	O
training	NN	O
with	IN	O
head	NN	O
needle	JJ	O
retention	NN	O
on	IN	O
autism	NN	O
children	NNS	O
is	VBZ	O
better	JJR	O
than	IN	O
behavior	JJ	O
training	NN	O
after	IN	O
acupuncture	NN	O
treatment	NN	O
,	,	O
especially	RB	O
in	IN	O
enhancing	VBG	ME
cognition	NN	ME
understanding	NN	ME
and	CC	ME
cognition	NN	ME
expression	NN	ME
.	.	ME

Noradrenergic	NNP	O
moderation	NN	Ot
of	IN	O
working	VBG	O
memory	NN	O
impairments	NNS	O
in	IN	O
adults	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
having	VBG	O
difficulties	NNS	O
with	IN	O
social	JJ	O
communications	NNS	O
,	,	O
individuals	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
often	RB	O
also	RB	O
experience	JJ	O
impairment	NN	ME
in	IN	ME
higher-order	NN	ME
,	,	ME
executive	NN	ME
skills	NNS	ME
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
pharmacological	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
norepinephrine	NN	O
system	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
such	JJ	O
impairments	NNS	O
.	.	O

A	DT	O
sample	NN	O
of	IN	O
14	CD	O
high-functioning	JJ	O
adults	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
a	DT	O
demographically-matched	JJ	O
comparison	NN	O
group	NN	O
of	IN	O
13	CD	O
typically	RB	O
developing	VBG	O
individuals	NNS	O
participated	VBN	O
.	.	O

An	DT	O
AX	NNP	ME
continuous	JJ	ME
performance	NN	ME
test	NN	ME
(	(	ME
AX-CPT	NNP	ME
)	)	ME
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
working	VBG	O
memory	NN	O
and	CC	O
inhibitory	NN	O
control	NN	O
.	.	O

AX-CPT	JJ	ME
performance	NN	ME
was	VBD	O
assessed	VBN	O
following	VBG	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
propranolol	NN	O
(	(	O
a	DT	O
beta	NN	O
adrenergic	JJ	O
antagonist	NN	O
)	)	O
and	CC	O
following	VBG	O
placebo	NN	O
(	(	O
sugar	NN	O
pill	NN	O
)	)	O
administration	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
ASD	NNP	O
performed	VBD	ME
more	RBR	O
poorly	RB	O
than	IN	O
non-ASD	JJ	O
individuals	NNS	O
in	IN	O
the	DT	O
working	JJ	O
memory	NN	O
condition	NN	O
(	(	O
BX	NNP	O
trials	NNS	O
)	)	O
.	.	O

Importantly	RB	O
,	,	O
administration	NN	O
of	IN	O
propranolol	NN	O
attenuated	VBN	ME
this	DT	ME
impairment	NN	ME
,	,	O
with	IN	O
the	DT	O
ASD	NNP	O
group	NN	O
performing	VBG	ME
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
condition	NN	O
than	IN	O
the	DT	O
placebo	JJ	O
condition	NN	O
.	.	O

Working	VBG	ME
memory	NN	ME
performance	NN	ME
of	IN	O
the	DT	O
non-ASD	JJ	O
group	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
propranolol/placebo	JJ	O
administration	NN	O
.	.	O

No	DT	O
group	NN	O
or	CC	O
medication	NN	O
effects	NNS	Ot
were	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
inhibition	NN	ME
condition	NN	ME
(	(	O
AY	NNP	O
trials	NNS	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
norepinephrine	NN	O
may	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
necessarily	RB	O
all	RB	O
,	,	O
cognitive	JJ	ME
impairments	NNS	ME
associated	VBN	O
with	IN	O
ASD	NNP	O
.	.	O

Additional	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
whether	IN	O
this	DT	O
role	NN	O
is	VBZ	O
primarily	RB	O
causal	JJ	O
or	CC	O
compensatory	NN	O
in	IN	O
nature	NN	O
.	.	O

BNP-guided	JJ	O
vs	NN	O
symptom-guided	JJ	O
heart	NN	O
failure	NN	O
therapy	NN	O
:	:	O
the	DT	O
Trial	NNP	O
of	IN	O
Intensified	NNP	O
vs	FW	O
Standard	NNP	O
Medical	NNP	O
Therapy	NNP	O
in	IN	O
Elderly	JJ	O
Patients	NNS	O
With	IN	O
Congestive	NNP	O
Heart	NNP	O
Failure	NNP	O
(	(	O
TIME-CHF	NNP	O
)	)	O
randomized	VBD	O
trial	NN	O
.	.	O

CONTEXT	VB	O
It	PRP	O
is	VBZ	O
uncertain	JJ	O
whether	IN	O
intensified	JJ	O
heart	NN	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	JJ	O
brain	NN	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
is	VBZ	O
superior	JJ	O
to	TO	O
symptom-guided	JJ	O
therapy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
18-month	JJ	O
outcomes	NNS	O
of	IN	O
N-terminal	JJ	O
BNP-guided	JJ	O
vs	NN	O
symptom-guided	JJ	O
heart	NN	O
failure	NN	O
therapy	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
Randomized	NNP	O
controlled	VBD	O
multicenter	RBR	O
Trial	NNP	O
of	IN	O
Intensified	NNP	O
vs	FW	O
Standard	NNP	O
Medical	NNP	O
Therapy	NNP	O
in	IN	O
Elderly	JJ	O
Patients	NNS	O
With	IN	O
Congestive	NNP	O
Heart	NNP	O
Failure	NNP	O
(	(	O
TIME-CHF	NNP	O
)	)	O
of	IN	O
499	CD	O
patients	NNS	O
aged	VBN	O
60	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
(	(	O
ejection	NN	O
fraction	NN	O
<	NN	O
or	CC	O
=	VB	O
45	CD	O
%	NN	O
)	)	O
,	,	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
(	(	O
NYHA	NNP	O
)	)	O
class	NN	O
of	IN	O
II	NNP	O
or	CC	O
greater	JJR	O
,	,	O
prior	JJ	O
hospitalization	NN	O
for	IN	O
heart	NN	O
failure	NN	O
within	IN	O
1	CD	O
year	NN	O
,	,	O
and	CC	O
N-terminal	JJ	O
BNP	NNP	O
level	NN	O
of	IN	O
2	CD	O
or	CC	O
more	JJR	O
times	NNS	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
.	.	O

The	DT	O
study	NN	O
had	VBD	O
an	DT	O
18-month	JJ	O
follow-up	NN	O
and	CC	O
it	PRP	O
was	VBD	O
conducted	VBN	O
at	IN	O
15	CD	O
outpatient	NN	O
centers	NNS	O
in	IN	O
Switzerland	NNP	O
and	CC	O
Germany	NNP	O
between	IN	O
January	NNP	O
2003	CD	O
and	CC	O
June	NNP	O
2008	CD	O
.	.	O

INTERVENTION	NNP	O
Uptitration	NNP	O
of	IN	O
guideline-based	JJ	O
treatments	NNS	O
to	TO	O
reduce	VB	O
symptoms	NNS	O
to	TO	O
NYHA	NNP	O
class	NN	O
of	IN	O
II	NNP	O
or	CC	O
less	JJR	O
(	(	O
symptom-guided	JJ	O
therapy	NN	O
)	)	O
and	CC	O
BNP	NNP	O
level	NN	O
of	IN	O
2	CD	O
times	NNS	O
or	CC	O
less	JJR	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
and	CC	O
symptoms	NNS	O
to	TO	O
NYHA	NNP	O
class	NN	O
of	IN	O
II	NNP	O
or	CC	O
less	JJR	O
(	(	O
BNP-guided	JJ	O
therapy	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Primary	NNP	O
outcomes	NNS	O
were	VBD	O
18-month	JJ	MO
survival	JJ	MO
free	JJ	MO
of	IN	MO
all-cause	JJ	MO
hospitalizations	NNS	MO
and	CC	MO
quality	NN	MO
of	IN	MO
life	NN	MO
as	IN	MO
assessed	VBN	MO
by	IN	MO
structured	JJ	MO
validated	JJ	MO
questionnaires	NNS	MO
.	.	MO

RESULTS	NNP	O
Heart	NNP	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	JJ	O
BNP	NNP	O
and	CC	O
symptom-guided	JJ	O
therapy	NN	O
resulted	VBD	O
in	IN	O
similar	JJ	O
rates	NNS	O
of	IN	O
survival	JJ	MO
free	JJ	MO
of	IN	MO
all-cause	JJ	MO
hospitalizations	NNS	MO
(	(	O
41	CD	O
%	NN	O
vs	JJ	O
40	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	PRP	O
ratio	VBP	O
[	JJ	O
HR	NNP	O
]	NNP	O
,	,	O
0.91	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.72-1.14	JJ	O
]	NN	O
;	:	O
P	NNP	O
=	NNP	O
.39	NNP	O
)	)	O
.	.	O

Patients	NNS	Ot
'	POS	Ot
quality-of-life	JJ	Ot
metrics	NNS	Ot
improved	VBN	O
over	IN	O
18	CD	O
months	NNS	O
of	IN	O
follow-up	JJ	O
but	CC	O
these	DT	O
improvements	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
the	DT	O
N-terminal	JJ	O
BNP-guided	JJ	O
and	CC	O
symptom-guided	JJ	O
strategies	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
symptom-guided	JJ	O
group	NN	O
,	,	O
survival	JJ	MO
free	JJ	MO
of	IN	MO
hospitalization	NN	MO
for	IN	MO
heart	NN	MO
failure	NN	MO
,	,	O
a	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
,	,	O
was	VBD	O
higher	JJR	O
among	IN	O
those	DT	O
in	IN	O
the	DT	O
N-terminal	JJ	O
BNP-guided	NNP	O
group	NN	O
(	(	O
72	CD	O
%	NN	O
vs	JJ	O
62	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
HR	NNP	O
,	,	O
0.68	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.50-0.92	JJ	O
]	NN	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Heart	NNP	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	NNP	O
BNP	NNP	O
improved	VBD	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
aged	VBD	O
60	CD	O
to	TO	O
75	CD	O
years	NNS	O
but	CC	O
not	RB	O
in	IN	O
those	DT	O
aged	VBN	O
75	CD	O
years	NNS	O
or	CC	O
older	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
for	IN	O
interaction	NN	O
)	)	O
CONCLUSION	NNP	O
Heart	NNP	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	JJ	O
BNP	NNP	O
did	VBD	O
not	RB	O
improve	VB	O
overall	JJ	O
clinical	JJ	O
outcomes	NNS	O
or	CC	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
compared	VBN	O
with	IN	O
symptom-guided	JJ	O
treatment	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
isrctn.org	NN	O
Identifier	NNP	O
:	:	O
ISRCTN43596477	NNP	O
.	.	O

Skin	NNP	PH
manifestations	NNS	PH
of	IN	PH
inhaled	JJ	PH
corticosteroids	NNS	PH
in	IN	O
COPD	NNP	O
patients	NNS	O
:	:	O
results	NNS	O
from	IN	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
define	VB	O
the	DT	O
relationship	NN	O
between	IN	O
skin	NN	A
bruising	NN	A
(	(	PH
as	RB	PH
well	RB	PH
as	IN	PH
other	JJ	PH
cutaneous	JJ	A
manifestations	NNS	A
)	)	PH
and	CC	O
inhaled	VBN	O
corticosteroid	NN	O
(	(	O
ICS	NNP	O
)	)	O
therapy	NN	O
vs	NN	O
placebo	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
who	WP	O
were	VBD	O
participating	VBG	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

To	TO	O
explore	VB	O
the	DT	O
relationship	NN	O
between	IN	O
easy	JJ	PH
skin	NN	PH
bruising	NN	PH
and	CC	O
other	JJ	O
systemic	JJ	PH
effects	NNS	PH
of	IN	PH
ICS	NNP	PH
therapy	NN	PH
,	,	O
including	VBG	O
adrenal	JJ	A
suppression	NN	A
and	CC	PH
loss	NN	A
of	IN	A
bone	JJ	A
mineral	JJ	A
density	NN	A
(	(	A
BMD	NNP	A
)	)	PH
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	NN	O
(	(	O
1200	CD	O
microg	FW	O
daily	RB	O
)	)	O
vs	NN	O
placebo	NN	O
in	IN	O
participants	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
.	.	O

SETTING	NNP	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
,	,	O
a	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ICS	NNP	O
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
1,116	CD	O
participants	NNS	O
in	IN	O
10	CD	O
centers	NNS	O
over	IN	O
>	$	O
3.5	CD	O
to	TO	O
4.5	CD	O
years	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1,116	CD	O
smokers	NNS	O
or	CC	O
recent	JJ	O
ex-smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
(	(	O
age	NN	O
range	NN	O
,	,	O
40	CD	O
to	TO	O
69	CD	O
years	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
56.3	CD	O
years	NNS	O
;	:	O
37.2	CD	O
%	NN	O
female	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
RESULTS	NNP	O
Every	NNP	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
structured	JJ	O
questionnaire	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
elicit	VB	O
reports	NNS	O
of	IN	O
any	DT	O
bruising	NN	A
and/or	NN	A
skin	NN	A
rashes	NNS	A
,	,	A
slow	JJ	A
healing	NN	A
of	IN	A
cuts	NNS	A
or	CC	A
sores	NNS	A
,	,	PH
or	CC	PH
other	JJ	PH
skin	JJ	A
changes	NNS	A
.	.	PH

Compliance	NN	O
with	IN	O
inhaler	NN	O
use	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
canister	NN	O
weighing	VBG	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
ICS	NNP	O
than	IN	O
placebo	NN	O
participants	NNS	O
who	WP	O
complied	VBD	O
with	IN	O
using	VBG	O
their	PRP$	O
inhaler	NN	O
reported	VBD	O
easy	JJ	A
bruising	NN	A
(	(	O
11.2	CD	O
%	NN	O
vs	JJ	O
3.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
slow	JJ	A
healing	NN	A
of	IN	A
skin	NN	A
cuts	NNS	A
or	CC	A
sores	NNS	A
(	(	O
2.4	CD	O
%	NN	O
vs	JJ	O
0.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Older	JJR	O
men	NNS	O
in	IN	O
the	DT	O
ICS	NNP	O
group	NN	O
with	IN	O
good	JJ	O
inhaler	NN	O
compliance	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
at	IN	O
the	DT	O
greatest	JJS	O
risk	NN	A
of	IN	A
bruising	VBG	A
.	.	PH

In	IN	O
those	DT	O
participants	NNS	O
undergoing	VBG	O
serial	JJ	O
measurements	NNS	O
of	IN	O
adrenal	JJ	O
function	NN	O
and	CC	O
BMD	NNP	O
,	,	O
no	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	A
bruising	NN	A
and	CC	O
either	CC	O
the	DT	O
suppression	NN	A
of	IN	A
adrenal	JJ	A
function	NN	A
or	CC	O
the	DT	O
loss	NN	A
of	IN	A
BMD	NNP	A
as	IN	O
systemic	JJ	O
complications	NNS	O
of	IN	O
ICS	NNP	O
use	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
moderate-to-high	JJ	O
doses	NNS	O
of	IN	O
ICSs	NNP	O
result	NN	O
in	IN	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
easy	JJ	A
bruising	NN	A
and	CC	O
impairment	NN	A
in	IN	A
skin	NN	A
healing	NN	A
in	IN	O
middle-aged	JJ	O
to	TO	O
elderly	JJ	O
persons	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	A
bruising	NN	A
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	A
toxicity	NN	A
from	IN	O
the	DT	O
use	NN	O
of	IN	O
ICSs	NNP	O
.	.	O

Plasmakinetic	JJ	O
prostate	NN	O
resection	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
benign	JJ	O
prostate	JJ	O
hyperplasia	NN	O
:	:	O
results	NNS	O
of	IN	O
1-year	JJ	O
follow	VBP	O
up	RP	O
.	.	O

AIM	NNP	O
In	IN	O
our	PRP$	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
,	,	O
we	PRP	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
plasmakinetic	JJ	O
resection	NN	O
of	IN	O
prostate	NN	O
(	(	O
PKRP	NNP	O
)	)	O
by	IN	O
comparing	VBG	O
the	DT	O
preoperative	NN	O
and	CC	O
postoperative	JJ	O
results	NNS	O
of	IN	O
the	DT	O
transurethral	JJ	O
resection	NN	O
of	IN	O
prostate	NN	O
(	(	O
TURP	NNP	O
)	)	O
and	CC	O
PKRP	NNP	O
techniques	NNS	O
which	WDT	O
we	PRP	O
administered	VBD	O
in	IN	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostate	NN	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
in	IN	O
our	PRP$	O
clinic	NN	O
.	.	O

METHODS	NNP	O
Of	IN	O
57	CD	O
patients	NNS	O
for	IN	O
whom	WP	O
we	PRP	O
thought	VBD	O
an	DT	O
operative	JJ	O
intervention	NN	O
was	VBD	O
necessary	JJ	O
,	,	O
30	CD	O
cases	NNS	O
in	IN	O
the	DT	O
first	JJ	O
group	NN	O
had	VBD	O
a	DT	O
TURP	NNP	O
and	CC	O
24	CD	O
cases	NNS	O
in	IN	O
the	DT	O
second	JJ	O
group	NN	O
had	VBD	O
a	DT	O
PKRP	NNP	O
.	.	O

International	NNP	PH
prostate	JJ	PH
symptom	NN	PH
scores	NNS	PH
(	(	PH
I-PSS	NNP	PH
)	)	PH
,	,	O
uroflowmetry	UH	PH
,	,	O
measurement	NN	Ot
of	IN	Ot
residual	JJ	PH
urine	JJ	PH
amount	NN	PH
and	CC	Ot
ultrasonography	NN	Ot
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
patient	NN	O
both	DT	O
preoperatively	RB	O
and	CC	O
postoperatively	RB	O
(	(	O
first	JJ	O
month	NN	O
and	CC	O
first	JJ	O
year	NN	O
)	)	O
.	.	O

Operation	NNP	Ot
times	NNS	Ot
,	,	O
urethral	JJ	Ot
catheterization	NN	Ot
times	NNS	Ot
,	,	O
preoperative	JJ	PH
and	CC	PH
postoperative	JJ	PH
Hb	NNP	PH
,	,	Ot
Htc	NNP	PH
and	CC	PH
serum	VB	PH
Na	NNP	PH
values	NNS	PH
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
complications	NNS	O
of	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
also	RB	O
compared	VBN	O
.	.	O

RESULTS	VB	O
On	IN	O
first	JJ	O
month	NN	O
and	CC	O
first	JJ	O
year	NN	O
follow	VBP	O
up	RP	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
in	IN	O
I-PSS	NNP	PH
,	,	O
maximum	JJ	PH
flow	NN	PH
rate	NN	PH
,	,	O
average	NN	PH
flow	NN	PH
,	,	O
residual	JJ	PH
urine	NN	PH
and	CC	PH
size	NN	PH
of	IN	PH
the	DT	PH
prostate	NN	PH
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
serum	NN	PH
Na	NNP	PH
level	NN	PH
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
TURP	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
operation	NN	Ot
times	NNS	Ot
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

While	IN	O
the	DT	O
postoperative	JJ	Ot
catheterization	NN	Ot
time	NN	Ot
was	VBD	O
75.7	CD	O
h	NN	O
in	IN	O
TURP	NNP	O
group	NN	O
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
42	CD	O
h	NN	O
in	IN	O
PKRP	NNP	O
group	NN	O
and	CC	O
it	PRP	O
was	VBD	O
clear	JJ	O
that	IN	O
catheterization	NN	Ot
time	NN	Ot
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
obvious	JJ	O
that	IN	O
PKRP	NNP	O
is	VBZ	O
as	RB	O
efficient	JJ	O
as	IN	O
TURP	NNP	O
and	CC	O
it	PRP	O
has	VBZ	O
a	DT	O
similar	JJ	O
morbidity	NN	O
.	.	O

In	IN	O
our	PRP$	O
opinion	NN	O
,	,	O
PKRP	NNP	O
makes	VBZ	O
a	DT	O
promising	JJ	O
treatment	NN	O
for	IN	O
BPH	NNP	O
with	IN	O
its	PRP$	O
advantages	NNS	O
,	,	O
such	JJ	O
as	IN	O
early	JJ	O
removal	NN	O
of	IN	O
postoperative	JJ	O
urethral	JJ	O
catheter	NN	O
,	,	O
a	DT	O
shorter	JJR	O
hospital	NN	O
stay	NN	O
and	CC	O
the	DT	O
absence	NN	O
of	IN	O
TUR	NNP	O
syndrome	NN	O
risk	NN	O
.	.	O

Vaginal	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
:	:	O
a	DT	O
randomized	JJ	O
feasibility	NN	O
study	NN	O
in	IN	O
urinary	JJ	O
incontinent	NN	O
elderly	JJ	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
intravaginal	JJ	O
electrical	JJ	O
stimulation	NN	O
(	(	O
ES	NNP	O
)	)	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
for	IN	O
urinary	JJ	O
incontinence	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
whether	IN	O
ES	NNP	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
is	VBZ	O
a	DT	O
preferable	JJ	O
treatment	NN	O
for	IN	O
urinary	JJ	O
incontinence	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
.	.	O

METHODS	NNP	O
Postmenopausal	NNP	O
women	NNS	O
(	(	O
age	NN	O
65	CD	O
years	NNS	O
or	CC	O
older	JJR	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
and	CC	O
underwent	JJ	O
every-other-day	JJ	O
ES	NNP	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
,	,	O
or	CC	O
a	DT	O
daily	JJ	O
Kegel	NNP	O
exercise	NN	O
(	(	O
KE	NNP	O
)	)	O
program	NN	O
.	.	O

Objective	NNP	O
outcome	NN	O
variables	NNS	O
were	VBD	O
:	:	O
(	(	O
1	CD	O
)	)	O
Urinary	JJ	PH
leakage	NN	PH
(	(	O
during	IN	O
a	DT	O
standardized	JJ	O
PAD	NNP	O
test	NN	O
)	)	O
,	,	O
(	(	O
2	CD	O
)	)	O
pelvic	NN	PH
muscle	NN	PH
strength	NN	PH
(	(	O
measured	VBN	O
by	IN	O
a	DT	O
perineometer	NN	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
detrusor	NN	PH
instability	NN	PH
(	(	O
on	IN	O
ambulant	NN	PH
urodynamic	JJ	PH
registration	NN	PH
)	)	O
.	.	O

Subjective	JJ	O
outcome	NN	O
variables	NNS	O
were	VBD	O
women	NNS	ME
's	POS	ME
subjective	JJ	ME
assessment	NN	ME
of	IN	ME
change	NN	ME
in	IN	ME
urinary	JJ	ME
symptoms	NNS	ME
based	VBN	ME
on	IN	ME
the	DT	ME
PRAFAB	NNP	ME
score	NN	ME
.	.	O

Twenty-four	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
ES	NNP	O
and	CC	O
11	CD	O
women	NNS	O
treated	VBN	O
with	IN	O
Kegel	NNP	O
exercises	NNS	O
completed	VBD	O
the	DT	O
8-week	JJ	O
study	NN	O
program	NN	O
.	.	O

The	DT	O
Chi-square	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
for	IN	O
statistical	JJ	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
improvement	NN	O
in	IN	O
objective	JJ	O
outcome	NN	O
variables	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
population	NN	O
treated	VBD	O
with	IN	O
ES	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
population	NN	O
treated	VBD	O
with	IN	O
KE	NNP	O
(	(	O
with	IN	O
29.2	CD	O
%	NN	O
vs.	FW	O
36.4	CD	O
%	NN	O
of	IN	O
the	DT	O
women	NNS	O
showing	VBG	O
objective	JJ	O
improvement	NN	O
in	IN	O
measured	JJ	PH
urinary	JJ	PH
leakage	NN	PH
)	)	O
.	.	O

Neither	CC	O
was	VBD	O
subjective	JJ	O
improvement	NN	O
significant	JJ	O
,	,	O
with	IN	O
29.2	CD	O
%	NN	O
vs.	FW	O
27.3	CD	O
%	NN	O
of	IN	O
the	DT	O
women	NNS	O
reporting	VBG	O
improvement	NN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
urinary	JJ	PH
leakage	NN	PH
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
number	NN	O
of	IN	O
enrolled	JJ	O
women	NNS	O
was	VBD	O
very	RB	O
small	JJ	O
this	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
:	:	O
1	CD	O
.	.	O

Treating	VBG	O
elderly	JJ	O
women	NNS	O
with	IN	O
vaginal	JJ	O
ES	NNP	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
has	VBZ	O
a	DT	O
high	JJ	O
physical	JJ	O
and	CC	O
emotional	JJ	O
cost	NN	O
for	IN	O
the	DT	O
individual	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
effectiveness	NN	Ot
of	IN	O
ES	NNP	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
in	IN	O
urinary	JJ	O
incontinent	NN	O
elderly	JJ	O
women	NNS	O
is	VBZ	O
low	JJ	O
.	.	O

3	CD	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
great	JJ	O
discrepancy	NN	O
between	IN	O
objective	JJ	O
amelioration	NN	O
(	(	O
PAD	NNP	O
test	NN	O
)	)	O
and	CC	O
subjective	JJ	O
amelioration	NN	O
(	(	O
PRAFAB	NNP	O
score/quantity	NN	O
of	IN	O
urinary	JJ	O
leakage	NN	O
)	)	O
,	,	O
if	IN	O
the	DT	O
objective	JJ	O
improvement	NN	O
is	VBZ	O
adequately	RB	O
defined	VBN	O
.	.	O

4	CD	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
reasonable	JJ	O
to	TO	O
advise	VB	O
elderly	JJ	O
women	NNS	O
with	IN	O
urinary	JJ	O
incontinence	NN	O
to	TO	O
undertake	VB	O
this	DT	O
treatment	NN	O
procedure	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
treatment	NN	O
does	VBZ	O
not	RB	O
compensate	VB	O
for	IN	O
the	DT	O
long-lasting	JJ	O
and	CC	O
intense	JJ	O
treatment	NN	O
protocol	NN	O
.	.	O

5	CD	O
.	.	O

We	PRP	O
terminated	VBD	O
this	DT	O
study	NN	O
because	IN	O
of	IN	O
the	DT	O
negative	JJ	O
outcome	NN	O
with	IN	O
ES	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
supervised	JJ	O
exercise	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
Postoperative	NNP	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
has	VBZ	O
a	DT	O
number	NN	O
of	IN	O
associated	JJ	O
complications	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
could	MD	O
mitigate	VB	O
the	DT	O
complications	NNS	O
that	WDT	O
occur	VBP	O
during	IN	O
radiotherapy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty	NNP	O
women	NNS	O
were	VBD	O
randomized	VBN	O
before	IN	O
radiotherapy	NN	O
after	IN	O
various	JJ	O
operations	NNS	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
exercise	NN	O
group	NN	O
performed	VBD	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
for	IN	O
50	CD	O
min	NN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

Twenty-three	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
perform	VB	O
self-shoulder	JJ	O
stretching	VBG	O
exercise	NN	O
.	.	O

The	DT	O
World	NNP	Ot
Health	NNP	Ot
Organization	NNP	Ot
Quality	NNP	Ot
of	IN	Ot
Life-BREF	NNP	Ot
(	(	Ot
WHOQOL-BREF	NNP	Ot
)	)	Ot
,	,	O
brief	JJ	Ot
fatigue	JJ	Ot
inventory	NN	Ot
(	(	Ot
BFI	NNP	Ot
)	)	Ot
,	,	O
range	NN	PH
of	IN	PH
motion	NN	PH
(	(	PH
ROM	NNP	PH
)	)	PH
of	IN	PH
the	DT	PH
shoulder	NN	PH
,	,	O
and	CC	O
pain	NN	PA
score	NN	PA
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
noted	VBD	O
at	IN	O
baseline	NN	O
between	IN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
exercise	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	Ot
and	CC	Ot
shoulder	NN	Ot
ROM	NNP	Ot
and	CC	O
decrease	NN	PA
in	IN	PA
BFI	NNP	PA
and	CC	PA
pain	NN	PA
score	NN	PA
after	IN	O
radiotherapy	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
showed	VBD	O
decrease	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	PH
and	CC	O
shoulder	NN	PH
ROM	NNP	PH
and	CC	O
increase	VB	PA
in	IN	PA
BFI	NNP	PA
and	CC	PA
pain	NN	PA
score	NN	PA
after	IN	O
radiotherapy	NN	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
WHOQOL	NNP	PH
,	,	O
BFI	NNP	PH
,	,	O
shoulder	NN	PH
ROM	NNP	PH
,	,	O
and	CC	O
pain	VB	PA
score	NN	PA
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Patients	NNPS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
may	MD	O
benefit	VB	O
in	IN	O
physical	JJ	O
and	CC	O
psychological	JJ	O
aspects	NNS	O
from	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
.	.	O

Effect	NN	O
of	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
on	IN	O
postexercise	NN	O
hypotension	NN	O
in	IN	O
humans	NNS	O
.	.	O

An	DT	O
acute	JJ	O
bout	NN	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
blood	NN	PH
pressure	NN	PH
that	WDT	O
lasts	VBZ	O
several	JJ	O
hours	NNS	O
.	.	O

Animal	NNP	O
studies	NNS	O
suggest	VBP	O
this	DT	O
response	NN	O
is	VBZ	O
mediated	VBN	O
by	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
[	NNP	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-monomethyl-L-arginine	NN	O
(	(	O
L-NMMA	NNP	O
)	)	O
]	NN	O
can	MD	O
reverse	VB	O
the	DT	O
drop	NN	O
in	IN	O
blood	NN	PH
pressure	NN	PH
that	WDT	O
occurs	VBZ	O
after	IN	O
exercise	NN	O
in	IN	O
humans	NNS	O
.	.	O

Eight	NNP	O
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
parallel	JJ	O
experiments	NNS	O
on	IN	O
2	CD	O
separate	JJ	O
days	NNS	O
.	.	O

The	DT	O
order	NN	O
of	IN	O
the	DT	O
experiments	NNS	O
was	VBD	O
randomized	VBN	O
between	IN	O
sham	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
seated	JJ	O
upright	JJ	O
rest	NN	O
)	)	O
and	CC	O
exercise	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
upright	JJ	O
cycling	NN	O
at	IN	O
60	CD	O
%	NN	O
peak	NN	O
aerobic	JJ	O
capacity	NN	O
)	)	O
.	.	O

After	IN	O
both	DT	O
sham	NN	O
and	CC	O
exercise	NN	O
,	,	O
subjects	VBZ	O
received	VBN	O
,	,	O
in	IN	O
sequence	NN	O
,	,	O
systemic	JJ	O
alpha-adrenergic	JJ	O
blockade	NN	O
(	(	O
phentolamine	NN	O
)	)	O
and	CC	O
L-NMMA	NNP	O
.	.	O

Phentolamine	NNP	O
was	VBD	O
given	VBN	O
first	RB	O
to	TO	O
isolate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
to	TO	O
postexercise	VB	O
hypotension	NN	O
by	IN	O
preventing	VBG	O
reflex	JJ	O
changes	NNS	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
that	WDT	O
result	NN	O
from	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
and	CC	O
to	TO	O
control	VB	O
for	IN	O
alterations	NNS	O
in	IN	O
resting	VBG	O
sympathetic	JJ	O
activity	NN	O
after	IN	O
exercise	NN	O
.	.	O

During	IN	O
each	DT	O
condition	NN	O
,	,	O
systemic	JJ	PH
and	CC	PH
regional	JJ	PH
hemodynamics	NNS	PH
were	VBD	O
measured	VBN	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
,	,	O
arterial	JJ	PH
pressure	NN	PH
and	CC	PH
vascular	JJ	PH
resistances	NNS	PH
remained	VBD	O
lower	JJR	O
postexercise	NN	O
vs.	FW	O
postsham	NN	O
despite	IN	O
nitric	JJ	ME
oxide	JJ	ME
synthase	NN	ME
inhibition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mean	JJ	Ot
arterial	JJ	Ot
pressure	NN	Ot
after	IN	Ot
L-NMMA	NNP	Ot
was	VBD	O
108.0+/-2.4	JJ	O
mmHg	NN	O
postsham	NN	O
vs.	FW	O
102.1+/-3.3	JJ	O
mmHg	NN	O
postexercise	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Thus	VB	O
it	PRP	O
does	VBZ	O
not	RB	O
appear	VB	O
that	IN	O
postexercise	NN	PH
hypotension	NN	PH
is	VBZ	O
dependent	JJ	O
on	IN	O
increased	JJ	O
production	NN	ME
of	IN	ME
nitric	JJ	ME
oxide	NN	ME
in	IN	O
humans	NNS	O
.	.	O

[	JJ	O
Effectiveness	NNP	O
of	IN	O
adjuvant	JJ	O
hormone	NN	O
therapy	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
]	NNP	O
.	.	O

A	NNP	O
third	JJ	O
series	NN	O
of	IN	O
randomized	JJ	O
tests	NNS	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	Ot
the	DT	O
efficacy	NN	PH
of	IN	O
postoperative	JJ	O
adjuvant	JJ	O
hormone	NN	O
therapy	NN	O
(	(	O
tamoxifen	NN	O
,	,	O
diethylstilbestrol	NN	O
,	,	O
orimethen	VBP	O
amino	JJ	O
glutethymide	NN	O
)	)	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

Tamoxifen	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
176	CD	O
patients	NNS	O
with	IN	O
T1-2N0M0	NNP	O
tumors	NNS	O
.	.	O

Five-year	JJ	MO
recurrence-free	JJ	MO
survival	NN	MO
was	VBD	O
registered	VBN	O
in	IN	O
85.2	CD	O
%	NN	O
of	IN	O
menopausal	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tamoxifen	JJ	O
versus	NN	O
71.1	CD	O
%	NN	O
in	IN	O
control	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Five-year	JJ	MO
recurrence-free	JJ	MO
survival	NN	MO
in	IN	O
menopausal	NN	O
females	NNS	O
with	IN	O
breast	NN	O
tumors	NNS	O
,	,	O
stage	NN	O
IIb	NNP	O
,	,	O
was	VBD	O
71.1	CD	O
%	NN	O
among	IN	O
those	DT	O
treated	VBN	O
with	IN	O
diethylstilbestrol	NN	O
and	CC	O
as	RB	O
low	JJ	O
as	IN	O
57.4	CD	O
%	NN	O
in	IN	O
the	DT	O
tamoxifen	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Untoward	NNP	A
side-effect	JJ	A
incidence	NN	A
was	VBD	O
much	JJ	PH
higher	JJR	PH
in	IN	O
the	DT	O
diethylstilbestrol	NN	O
group	NN	O
(	(	O
30.4	CD	O
%	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
tamoxifen	NN	O
(	(	O
3.5	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
for	IN	O
the	DT	O
relationship	NN	O
between	IN	O
orimethen	NN	O
and	CC	O
tamoxifen	JJ	O
treatment	NN	O
with	IN	O
respect	NN	O
to	TO	O
5-year	JJ	MO
survival	NN	MO
and	CC	MO
recurrence-free	JJ	MO
survival	NN	MO
.	.	MO

A	DT	O
comparative	JJ	Ot
study	NN	Ot
of	IN	Ot
the	DT	Ot
pharmacokinetics	NNS	Ot
of	IN	O
ibuprofen	JJ	O
arginate	NN	O
versus	NN	O
dexibuprofen	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

OBJECTIVE	NNP	O
Ibuprofen	NNP	O
arginate	NN	O
is	VBZ	O
a	DT	O
salt	JJ	O
formulation	NN	O
of	IN	O
ibuprofen	NN	O
designed	VBN	O
to	TO	O
reach	VB	O
target	NN	O
concentrations	NNS	O
rapidly	RB	O
.	.	O

The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
12-h	JJ	O
pharmacokinetic	JJ	Ot
profile	NN	Ot
of	IN	O
S	NNP	O
(	(	O
+	NNP	O
)	)	O
-ibuprofen	VBD	O
following	VBG	O
administration	NN	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
ibuprofen	JJ	O
arginate	NN	O
(	(	O
600	CD	O
mg	NN	O
)	)	O
and	CC	O
dexibuprofen	NN	O
(	(	O
400	CD	O
mg	NN	O
)	)	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
Twenty-four	JJ	O
volunteers	NNS	O
were	VBD	O
recruited	VBN	O
into	IN	O
an	DT	O
open-label	JJ	O
,	,	O
randomised	JJ	O
,	,	O
two-period	JJ	O
,	,	O
single-centre	JJ	O
study	NN	O
with	IN	O
crossover	NN	O
design	NN	O
.	.	O

RESULTS	NNP	O
Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Ibuprofen	NNP	O
arginate	NN	O
and	CC	O
dexibuprofen	NN	O
showed	VBD	O
similar	JJ	O
bioavailability	NN	Ot
for	IN	Ot
S	NNP	Ot
(	(	Ot
+	NNP	Ot
)	)	Ot
-ibuprofen	NN	Ot
.	.	O

Compared	VBN	O
with	IN	O
dexibuprofen	NN	O
,	,	O
ibuprofen	JJ	O
arginate	NN	O
demonstrated	VBD	O
a	DT	O
45	CD	O
%	NN	O
higher	JJR	O
maximum	JJ	Ot
concentration	NN	Ot
(	(	Ot
C	NNP	Ot
(	(	Ot
max	NN	Ot
)	)	Ot
)	)	Ot
,	,	O
and	CC	O
a	DT	O
time	NN	Ot
to	TO	Ot
peak	VB	Ot
concentration	NN	Ot
(	(	Ot
T	NNP	Ot
(	(	Ot
max	NN	Ot
)	)	Ot
)	)	Ot
2	CD	O
h	NN	O
sooner	NN	O
.	.	O

CONCLUSION	NNP	O
Ibuprofen	NNP	O
arginate	NN	O
approaches	NNS	O
maximum	JJ	O
concentrations	NNS	O
of	IN	O
S	NNP	O
(	(	O
+	NNP	O
)	)	O
-ibuprofen	VBP	O
faster	RBR	O
and	CC	O
higher	JJR	O
than	IN	O
dexibuprofen	NN	O
.	.	O

Tomato	NNP	O
paste	NN	O
rich	JJ	O
in	IN	O
lycopene	JJ	O
protects	NNS	O
against	IN	O
cutaneous	JJ	PH
photodamage	NN	PH
in	IN	O
humans	NNS	O
in	IN	O
vivo	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
epidemiological	JJ	O
,	,	O
animal	JJ	O
and	CC	O
human	JJ	O
data	NNS	O
report	NN	O
that	IN	O
lycopene	NN	O
has	VBZ	O
a	DT	O
protective	JJ	O
effect	NN	O
against	IN	O
ultraviolet	NN	PH
radiation	NN	PH
(	(	PH
UVR	NNP	PH
)	)	PH
-induced	VBD	PH
erythema	NN	PH
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
whether	IN	O
tomato	NN	O
paste	NN	O
--	:	O
rich	JJ	O
in	IN	O
lycopene	NN	O
,	,	O
a	DT	O
powerful	JJ	O
antioxidant	NN	O
--	:	O
can	MD	O
protect	VB	O
human	JJ	O
skin	NN	O
against	IN	O
UVR-induced	JJ	O
effects	NNS	O
partially	RB	O
mediated	VBN	O
by	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
i.e	NN	O
.	.	O

erythema	NN	O
,	,	O
matrix	NN	O
changes	NNS	O
and	CC	O
mitochondrial	JJ	O
DNA	NNP	O
(	(	O
mtDNA	NN	O
)	)	O
damage	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
,	,	O
20	CD	O
healthy	JJ	O
women	NNS	O
(	(	O
median	JJ	O
age	NN	O
33	CD	O
years	NNS	O
,	,	O
range	VBP	O
21-47	JJ	O
;	:	O
phototype	JJ	O
I/II	NNP	O
)	)	O
ingested	VBD	O
55	CD	O
g	NN	O
tomato	NN	O
paste	NN	O
(	(	O
16	CD	O
mg	RB	O
lycopene	NN	O
)	)	O
in	IN	O
olive	JJ	O
oil	NN	O
,	,	O
or	CC	O
olive	JJ	O
oil	NN	O
alone	RB	O
,	,	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Pre-	NNP	O
and	CC	O
postsupplementation	NN	O
,	,	O
UVR	NNP	O
erythemal	JJ	PH
sensitivity	NN	PH
was	VBD	O
assessed	VBN	O
visually	RB	O
as	IN	O
the	DT	O
minimal	JJ	O
erythema	NN	O
dose	NN	O
(	(	O
MED	NNP	O
)	)	O
and	CC	O
quantified	VBN	O
with	IN	O
a	DT	O
reflectance	NN	O
instrument	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
unexposed	JJ	O
and	CC	O
UVR-exposed	JJ	O
(	(	O
3	CD	O
?	.	O
MED	NNP	O
24	CD	O
h	NN	O
earlier	RBR	O
)	)	O
buttock	NN	O
skin	JJ	O
pre-	NN	O
and	CC	O
postsupplementation	NN	O
,	,	O
and	CC	O
analysed	VBD	O
immunohistochemically	RB	O
for	IN	O
procollagen	NN	O
(	(	O
pC	NN	O
)	)	O
I	PRP	O
,	,	O
fibrillin-1	JJ	O
and	CC	O
matrix	JJ	O
metalloproteinase	NN	O
(	(	O
MMP	NNP	O
)	)	O
-1	NN	O
,	,	O
and	CC	O
by	IN	O
quantitative	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
for	IN	O
mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
.	.	O

RESULTS	VB	O
Mean	NNP	O
?	.	O
SD	NNP	O
erythemal	JJ	O
D	NNP	O
(	(	O
30	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
following	VBG	O
tomato	JJ	O
paste	NN	O
vs.	FW	O
control	NN	O
(	(	O
baseline	NN	O
,	,	O
26?5	CD	O
?	.	O
7?5	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
23	CD	O
?	.	O
6?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
36?6	CD	O
?	.	O
14?7	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MED	NNP	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
(	(	O
baseline	NN	O
,	,	O
35?1	CD	O
?	.	O
9?9	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
32?6	CD	O
?	.	O
9?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
42?2	CD	O
?	.	O
11?3	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
.	.	O

Presupplementation	NN	O
,	,	O
UVR	NNP	O
induced	VBD	O
an	DT	O
increase	NN	O
in	IN	O
MMP-1	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
.	.	O

Postsupplementation	NN	O
,	,	O
UVR-induced	JJ	O
MMP-1	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
tomato	NN	O
paste	NN	O
vs.	FW	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?04	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
UVR-induced	JJ	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
was	VBD	O
similarly	RB	O
abrogated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
pCI	JJ	O
deposition	NN	O
was	VBD	O
seen	VBN	O
following	VBG	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?05	CD	O
)	)	O
.	.	O

mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
following	VBG	O
3	CD	O
?	.	O
MED	NNP	O
UVR	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
postsupplementation	NN	O
with	IN	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Tomato	NNP	O
paste	NN	O
containing	VBG	O
lycopene	NNP	O
provides	VBZ	O
protection	NN	O
against	IN	O
acute	NN	O
and	CC	O
potentially	RB	O
longer-term	JJ	O
aspects	NNS	O
of	IN	O
photodamage	NN	O
.	.	O

Aerobic	NNP	O
exercise	NN	O
improves	VBZ	O
self-reported	JJ	ME
sleep	NN	ME
and	CC	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
insomnia	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
moderate	JJ	O
aerobic	JJ	O
physical	JJ	O
activity	NN	O
with	IN	O
sleep	JJ	O
hygiene	NN	O
education	NN	O
to	TO	O
improve	VB	ME
sleep	NN	ME
,	,	ME
mood	NN	ME
and	CC	O
quality	NN	PH
of	IN	PH
life	NN	PH
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
chronic	JJ	O
insomnia	NN	O
.	.	O

METHODS	NNP	O
Seventeen	NNP	O
sedentary	JJ	O
adults	NNS	O
aged	VBN	O
>	JJ	O
or=55	CD	O
years	NNS	O
with	IN	O
insomnia	NN	O
(	(	O
mean	JJ	O
age	NN	O
61.6	CD	O
[	NN	O
SD?4.3	NNP	O
]	NNP	O
years	NNS	O
;	:	O
16	CD	O
female	NN	O
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
comparing	VBG	O
16	CD	O
weeks	NNS	O
of	IN	O
aerobic	JJ	O
physical	JJ	O
activity	NN	O
plus	CC	O
sleep	JJ	O
hygiene	NN	O
to	TO	O
non-physical	JJ	O
activity	NN	O
plus	CC	O
sleep	JJ	O
hygiene	NN	O
.	.	O

Eligibility	NNP	O
included	VBD	O
primary	JJ	O
insomnia	NN	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
,	,	O
habitual	JJ	O
sleep	NN	O
duration	NN	O
<	POS	O
6.5h	CD	O
and	CC	O
a	DT	O
Pittsburgh	NNP	O
Sleep	NNP	O
Quality	NNP	O
Index	NNP	O
(	(	O
PSQI	NNP	O
)	)	O
score	VBD	O
>	JJ	O
5	CD	O
.	.	O

Outcomes	NNS	O
included	VBD	O
sleep	JJ	O
quality	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
(	(	O
PSQI	NNP	O
,	,	O
Epworth	NNP	O
Sleepiness	NNP	O
Scale	NNP	O
[	NNP	O
ESS	NNP	O
]	NNP	O
,	,	O
Short-form	NNP	O
36	CD	O
[	NNP	O
SF-36	NNP	O
]	NNP	O
,	,	O
Center	NNP	O
for	IN	O
Epidemiological	NNP	O
Studies	NNPS	O
Depression	NNP	O
Scale	NNP	O
[	NNP	O
CES-D	NNP	O
]	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
physical	JJ	O
activity	NN	O
group	NN	O
improved	VBD	O
in	IN	O
sleep	JJ	O
quality	NN	O
on	IN	O
the	DT	O
global	JJ	O
PSQI	NNP	O
(	(	O
p	JJ	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
sleep	JJ	O
latency	NN	O
(	(	O
p=.049	NN	O
)	)	O
,	,	O
sleep	JJ	O
duration	NN	O
(	(	O
p=.04	NN	O
)	)	O
,	,	O
daytime	JJ	O
dysfunction	NN	O
(	(	O
p=.027	NN	O
)	)	O
,	,	O
and	CC	O
sleep	JJ	O
efficiency	NN	O
(	(	O
p=.036	NN	O
)	)	O
PSQI	NNP	O
sub-scores	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
physical	JJ	O
activity	NN	O
group	NN	O
also	RB	O
had	VBD	O
reductions	NNS	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
(	(	O
p=.044	NN	O
)	)	O
,	,	O
daytime	JJ	O
sleepiness	NN	O
(	(	O
p=.02	NN	O
)	)	O
and	CC	O
improvements	NNS	O
in	IN	O
vitality	NN	O
(	(	O
p=.017	NN	O
)	)	O
compared	VBN	O
to	TO	O
baseline	VB	O
scores	NNS	O
.	.	O

CONCLUSION	NNP	O
Aerobic	NNP	O
physical	JJ	O
activity	NN	O
with	IN	O
sleep	JJ	O
hygiene	NN	O
education	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
approach	NN	O
to	TO	O
improve	VB	O
sleep	JJ	O
quality	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
chronic	JJ	O
insomnia	NN	O
.	.	O

Trace	NNP	O
element	NN	O
supplementation	NN	O
after	IN	O
major	JJ	O
burns	NNS	O
modulates	VBZ	O
antioxidant	JJ	O
status	NN	O
and	CC	O
clinical	JJ	O
course	NN	O
by	IN	O
way	NN	O
of	IN	O
increased	JJ	O
tissue	NN	PH
trace	NN	PH
element	NN	PH
concentrations	NNS	PH
.	.	PH

BACKGROUND	NNP	O
After	IN	O
major	JJ	O
burns	NNS	O
,	,	O
patients	NNS	O
can	MD	O
develop	VB	O
nutritional	JJ	O
deficiencies	NNS	O
including	VBG	O
trace	NN	PH
element	NN	PH
(	(	PH
TE	NNP	PH
)	)	PH
deficiencies	NNS	O
.	.	O

Various	JJ	O
complications	NNS	O
,	,	O
such	JJ	O
as	IN	O
infections	NNS	O
and	CC	O
delayed	VBN	O
wound	NN	O
healing	NN	O
,	,	O
influence	VB	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
such	JJ	O
patients	NNS	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
large	JJ	O
,	,	O
intravenous	JJ	O
doses	NNS	O
of	IN	O
TE	NNP	O
supplements	NNS	O
on	IN	O
circulating	NN	O
and	CC	O
cutaneous	JJ	O
TE	NNP	O
tissue	NN	O
concentrations	NNS	O
,	,	O
on	IN	O
antioxidant	JJ	O
status	NN	O
,	,	O
and	CC	O
on	IN	O
clinical	JJ	PH
outcome	NN	PH
after	IN	O
major	JJ	O
burns	NNS	O
.	.	O

DESIGN	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
21	CD	O
patients	NNS	O
aged	VBD	O
35	CD	O
+/-	JJ	O
11	CD	O
y	NN	O
(	(	O
x	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
with	IN	O
burns	NNS	O
on	IN	O
45	CD	O
+/-	JJ	O
21	CD	O
%	NN	O
of	IN	O
their	PRP$	O
body	NN	O
surface	NN	O
area	NN	O
.	.	O

Intravenous	JJ	O
copper	NN	O
,	,	O
selenium	NN	O
,	,	O
and	CC	O
zinc	NN	O
(	(	O
TE	NNP	O
group	NN	O
)	)	O
or	CC	O
vehicle	NN	O
(	(	O
V	NNP	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
with	IN	O
a	DT	O
saline	JJ	O
solution	NN	O
for	IN	O
14-21	JJ	O
d.	NN	O
Blood	NNP	O
and	CC	O
urine	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
until	IN	O
day	NN	O
20	CD	O
,	,	O
and	CC	O
skin	FW	O
biopsy	NN	O
specimens	NNS	O
were	VBD	O
collected	VBN	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
20	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
and	CC	O
the	DT	O
severity	NN	O
of	IN	O
their	PRP$	O
burns	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Plasma	NNP	PH
TE	NNP	PH
concentrations	NNS	PH
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
.	.	O

In	IN	O
burned	JJ	O
areas	NNS	O
,	,	O
skin	JJ	PH
contents	NNS	PH
of	IN	PH
both	DT	PH
selenium	NN	PH
(	(	O
P=0.05	NNP	O
)	)	O
and	CC	O
zinc	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
increased	VBD	O
significantly	RB	O
by	IN	O
day	NN	O
20	CD	O
.	.	O

Plasma	NNP	O
and	CC	O
tissue	NN	O
antioxidant	NN	O
status	NN	O
was	VBD	O
improved	VBN	O
by	IN	O
supplementation	NN	O
.	.	O

The	DT	O
number	NN	PH
of	IN	PH
infections	NNS	PH
in	IN	O
the	DT	O
first	JJ	O
30	CD	O
d	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
(	(	O
P=0.015	NNP	O
)	)	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
number	NN	O
of	IN	O
2	CD	O
versus	NN	O
4	CD	O
infections	NNS	O
per	IN	O
patient	NN	O
in	IN	O
the	DT	O
TE	NNP	O
and	CC	O
V	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
a	DT	O
reduction	NN	O
in	IN	O
pulmonary	JJ	O
infections	NNS	O
(	(	O
P=0.03	NNP	O
)	)	O
.	.	O

Wound	IN	O
healing	NN	O
was	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
,	,	O
with	IN	O
lower	JJR	O
requirements	NNS	O
for	IN	O
regrafting	VBG	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
TE	NNP	O
supplementation	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
circulating	NN	O
plasma	NN	O
and	CC	O
skin	JJ	O
tissue	NN	O
contents	NNS	O
of	IN	O
selenium	NN	O
and	CC	O
zinc	NN	O
and	CC	O
improved	VBN	O
antioxidant	JJ	O
status	NN	O
.	.	O

These	DT	O
changes	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
clinical	JJ	O
outcome	NN	O
,	,	O
including	VBG	O
fewer	JJR	O
pulmonary	JJ	O
infections	NNS	O
and	CC	O
better	JJR	O
wound	NN	O
healing	NN	O
.	.	O

A	DT	O
double	JJ	O
blind	NN	O
randomized	VBD	O
study	NN	O
of	IN	O
oral	JJ	O
clodronate	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
tumors	NNS	O
poorly	RB	O
responsive	VBP	O
to	TO	O
chemotherapy	VB	O
.	.	O

Bisphosphonates	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
oncology	NN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
decreasing	VBG	O
complications	NNS	O
due	JJ	O
to	TO	O
bone	VB	O
metastases	NNS	O
,	,	O
in	IN	O
association	NN	O
with	IN	O
anticancer	NN	O
treatment	NN	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
with	IN	O
breast	NN	O
cancer	NN	O
,	,	O
prostate	NN	O
cancer	NN	O
and	CC	O
myeloma	NN	O
.	.	O

Little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
bisphosphonates	NNS	O
on	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
other	JJ	O
tumors	NNS	O
and	CC	O
in	IN	O
particular	JJ	O
from	IN	O
tumors	NNS	O
for	IN	O
which	WDT	O
no	DT	O
effective	JJ	O
treatment	NN	O
is	VBZ	O
available	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
clodronate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
tumors	NNS	O
poorly	RB	O
responsive	VBP	O
to	TO	O
chemotherapy	VB	O
,	,	O
with	IN	O
the	DT	O
aims	NNS	O
of	IN	O
evaluating	VBG	O
the	DT	O
effects	NNS	PH
of	IN	PH
this	DT	PH
drug	NN	PH
on	IN	PH
symptoms	NNS	PH
control	NN	PH
and	CC	PH
bone	NN	PH
metastases	NNS	PH
evolution	NN	PH
.	.	O

Sixty-six	JJ	O
patients	NNS	O
with	IN	O
poorly	JJ	O
responsive	JJ	O
tumors	NNS	O
such	JJ	O
as	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
,	,	O
bladder	NN	O
cancer	NN	O
,	,	O
gastrointestinal	JJ	O
cancers	NNS	O
,	,	O
kidney	NN	O
cancer	NN	O
,	,	O
melanoma	NN	O
and	CC	O
metastatic	JJ	O
carcinoma	NN	O
of	IN	O
unknown	JJ	O
origin	NN	O
entered	VBD	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
clodronate	NN	O
1,600	CD	O
mg/day	NN	O
for	IN	O
one	CD	O
year	NN	O
or	CC	O
identical	JJ	O
placebo-containing	JJ	O
tablets	NNS	O
.	.	O

Various	JJ	O
parameters	NNS	O
such	JJ	O
as	IN	O
Karnofsky	NNP	PH
performance	NN	PH
status	NN	PH
,	,	O
pain	NN	PA
score	NN	PA
(	(	PA
measured	VBN	PA
by	IN	PA
a	DT	PA
visual-analogue	JJ	PA
scale	NN	PA
)	)	PA
and	CC	O
analgesic	JJ	PA
requirement	NN	PH
were	VBD	O
recorded	VBN	O
at	IN	O
monthly	JJ	O
intervals	NNS	O
.	.	O

Of	IN	O
the	DT	O
66	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
9	CD	O
were	VBD	O
observed	VBN	O
for	IN	O
one	CD	O
month	NN	O
or	CC	O
less	JJR	O
;	:	O
7	CD	O
were	VBD	O
followed	VBN	O
for	IN	O
two	CD	O
months	NNS	O
;	:	O
only	RB	O
50	CD	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	O
months	NNS	O
and	CC	O
could	MD	O
be	VB	O
adequately	RB	O
evaluated	VBN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
both	DT	O
clodronate	NN	O
and	CC	O
placebo-treated	JJ	O
patients	NNS	O
had	VBD	O
a	DT	O
decrease	NN	PH
in	IN	PH
Karnofsky	NNP	PH
performance	NN	PH
status	NN	PH
,	,	O
with	IN	O
the	DT	O
decrease	NN	O
being	VBG	O
more	RBR	O
evident	JJ	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Mean	NNP	PA
pain	NN	PA
scores	NNS	PA
showed	VBD	O
an	DT	O
increase	NN	PA
of	IN	PA
pain	NN	PA
in	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
and	CC	O
a	DT	O
decrease	NN	O
of	IN	O
pain	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
clodronate	NN	O
,	,	O
although	IN	O
the	DT	O
difference	NN	O
failed	VBD	O
to	TO	O
be	VB	O
statistically	RB	O
significant	JJ	O
.	.	O

Analgesics	NNPS	PA
requirement	NN	PA
increased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
but	CC	O
significantly	RB	O
more	RBR	O
in	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.042	CD	O
)	)	O
,	,	O
in	IN	O
whom	WP	O
increase	NN	O
in	IN	O
opioid	JJ	O
requirements	NNS	O
was	VBD	O
particularly	RB	O
evident	JJ	O
.	.	O

Toxicity	NNP	A
was	VBD	A
low	JJ	A
,	,	O
with	IN	O
occasional	JJ	A
gastroenteric	JJ	A
discomfort	NN	A
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
main	JJ	O
problem	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
the	DT	O
difficulty	NN	O
in	IN	O
recruiting	VBG	O
an	DT	O
adequate	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
and	CC	O
following	VBG	O
them	PRP	O
for	IN	O
a	DT	O
sufficient	JJ	O
period	NN	O
of	IN	O
time	NN	O
:	:	O
general	JJ	O
conditions	NNS	O
rapidly	RB	O
deteriorated	VBD	O
in	IN	O
many	JJ	O
patients	NNS	O
,	,	O
and	CC	O
approximately	RB	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
66	CD	O
enrolled	NNS	O
were	VBD	O
not	RB	O
considered	VBN	O
evaluable	JJ	O
;	:	O
few	JJ	O
patients	NNS	O
survived	VBD	O
for	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
one	CD	O
year	NN	O
.	.	O

This	DT	O
might	MD	O
partly	RB	O
account	VB	O
for	IN	O
the	DT	O
lack	NN	O
of	IN	O
significance	NN	O
of	IN	O
some	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
under	IN	O
study	NN	O
.	.	O

With	IN	O
these	DT	O
limits	NNS	O
,	,	O
oral	JJ	O
clodronate	NN	O
demonstrated	VBD	O
some	DT	O
efficacy	NN	O
in	IN	O
symptom	NN	O
control	NN	O
and	CC	O
in	IN	O
reducing	VBG	O
the	DT	O
need	NN	O
for	IN	O
analgesics	NNS	O
.	.	O

Effect	NN	O
of	IN	O
diltiazem	NN	O
on	IN	O
symptomatic	JJ	O
and	CC	O
asymptomatic	JJ	O
episodes	NNS	O
of	IN	O
ST	NNP	ME
segment	NN	ME
depression	NN	ME
occurring	VBG	O
during	IN	O
daily	JJ	O
life	NN	O
and	CC	O
during	IN	O
exercise	NN	O
.	.	O

BACKGROUND	NNP	O
Silent	NNP	O
myocardial	JJ	O
ischemia	NN	O
is	VBZ	O
an	DT	O
adverse	JJ	O
prognostic	JJ	O
marker	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
disease	NN	O
;	:	O
however	RB	O
,	,	O
controlled	VBN	O
data	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
are	VBP	O
sparse	JJ	O
and	CC	O
contradictory	NN	O
,	,	O
and	CC	O
the	DT	O
relations	NNS	O
among	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
ST	NNP	ME
segment	NN	ME
depression	NN	ME
,	,	O
drug	NN	O
efficacy	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
are	VBP	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Sixty	NNP	O
patients	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
a	DT	O
positive	JJ	O
treadmill	NN	O
exercise	NN	O
test	NN	O
and	CC	O
asymptomatic	JJ	O
ST	NNP	O
segment	NN	O
depression	NN	O
on	IN	O
ambulatory	JJ	O
electrocardiographic	JJ	O
recording	VBG	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
.	.	O

Treadmill	NNP	Ot
exercise	NN	Ot
tests	NNS	Ot
and	CC	O
72-hour	JJ	Ot
electrocardiographic	JJ	Ot
recordings	NNS	Ot
were	VBD	O
obtained	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
two	CD	O
2-week	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
sustained-release	JJ	O
diltiazem	NN	O
180	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

or	CC	O
equivalent	JJ	O
placebo	NN	O
.	.	O

Episodes	NNS	ME
of	IN	ME
asymptomatic	JJ	ME
ST	NNP	ME
depression	NN	ME
decreased	VBN	O
by	IN	O
50	CD	O
%	NN	O
or	CC	O
more	JJR	O
in	IN	O
70	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
from	IN	O
a	DT	O
median	JJ	O
number	NN	O
of	IN	O
4.5	CD	O
(	(	O
range	NN	O
,	,	O
0-19	NN	O
)	)	O
to	TO	O
1.5	CD	O
(	(	O
range	NN	O
,	,	O
0-13	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
;	:	O
their	PRP$	O
cumulative	JJ	PH
duration	NN	PH
also	RB	O
decreased	VBD	O
from	IN	O
78.5	CD	O
(	(	O
range	NN	O
,	,	O
0-60	NN	O
)	)	O
to	TO	O
24.5	CD	O
(	(	O
range	NN	O
,	,	O
0-411	NN	O
)	)	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
circadian	JJ	PH
variation	NN	PH
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
diltiazem	NN	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
ischemic	JJ	PH
type	NN	PH
ST	NNP	PH
segment	NN	PH
depression	NN	PH
was	VBD	O
modulated	VBN	O
by	IN	O
changes	NNS	PH
in	IN	PH
heart	NN	PH
rate	NN	PH
rather	RB	O
than	IN	O
by	IN	O
absolute	JJ	O
heart	NN	O
rate	NN	O
.	.	O

Diltiazem	NNP	O
also	RB	O
improved	VBD	O
exercise	NN	PH
test	NN	PH
end	NN	PH
points	NNS	PH
but	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
.	.	O

Time	NN	PH
to	TO	PH
ST	NNP	PH
segment	NN	PH
depression	NN	PH
increased	VBD	O
to	TO	O
341	CD	O
+/-	JJ	O
148	CD	O
from	IN	O
296	CD	O
+/-	JJ	O
154	CD	O
seconds	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Although	IN	O
less	JJR	O
frequent	JJ	O
with	IN	O
diltiazem	JJ	O
administration	NN	O
(	(	O
45	CD	O
versus	NN	O
54	CD	O
patients	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.03	CD	O
)	)	O
,	,	O
exercise-induced	JJ	PH
ST	NNP	PH
depression	NN	PH
was	VBD	O
more	RBR	O
often	RB	O
asymptomatic	JJ	O
(	(	O
98	CD	O
%	NN	O
versus	IN	O
72	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Diltiazem	NNP	O
reduces	VBZ	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
ischemic	JJ	ME
type	NN	ME
ST	NNP	ME
depression	NN	ME
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Transthoracic	NNP	O
versus	NN	O
transesophageal	NN	O
cardioversion	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
under	IN	O
light	JJ	O
sedation	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Electrical	JJ	O
cardioversion	NN	O
(	(	O
ECV	NNP	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
a	DT	O
5-10	JJ	O
%	NN	O
failure	NN	O
rate	NN	O
and	CC	O
by	IN	O
the	DT	O
expense	NN	O
arising	VBG	O
from	IN	O
a	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

A	DT	O
transesophageal	JJ	O
approach	NN	O
using	VBG	O
light	JJ	O
sedation	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
augmenting	VBG	O
the	DT	O
success	NN	O
rate	NN	O
and	CC	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
success	NN	O
and	CC	O
the	DT	O
lower	JJR	O
energy	NN	O
requirement	NN	O
associated	VBN	O
with	IN	O
biphasic	JJ	O
cardioversion	NN	O
might	MD	O
eliminate	VB	O
any	DT	O
advantage	NN	O
of	IN	O
the	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
60	CD	O
patients	NNS	O
attending	VBG	O
for	IN	O
ECV	NNP	O
of	IN	O
persistent	JJ	O
AF	NNP	O
to	TO	O
a	DT	O
transesophageal	NN	O
or	CC	O
a	DT	O
transthoracic	JJ	O
approach	NN	O
.	.	O

Sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
midazolam	NN	O
was	VBD	O
titrated	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Sinus	NNP	PH
rhythm	NN	PH
was	VBD	O
restored	VBN	O
in	IN	O
29/30	CD	O
patients	NNS	O
(	(	O
97	CD	O
%	NN	O
)	)	O
in	IN	O
each	DT	O
group	NN	O
using	VBG	O
a	DT	O
similar	JJ	O
number	NN	O
of	IN	O
shocks	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
1.3	CD	O
+/-	JJ	O
0.6	CD	O
transesophageal	NN	O
vs	NN	O
1.4	CD	O
+/-	JJ	O
0.7	CD	O
transthoracic	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
with	IN	O
a	DT	O
similar	JJ	O
procedure	NN	O
duration	NN	O
(	(	O
14.1	CD	O
+/-	JJ	O
8.2	CD	O
minutes	NNS	O
vs	JJ	O
13.8	CD	O
+/-	JJ	O
7.5	CD	O
minutes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
similar	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.7	CD	O
mg	NN	O
vs	NN	O
4.4	CD	O
+/-	JJ	O
2.8	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
and	CC	O
both	DT	O
reported	VBD	O
a	DT	O
similar	JJ	O
discomfort	NN	PA
score	NN	PA
in	IN	O
(	(	O
0.9	CD	O
+/-	JJ	O
1.3	CD	O
vs	JJ	O
1.1	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
complication	NN	A
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
AF	NNP	O
may	MD	O
be	VB	O
cardioverted	VBN	O
safely	RB	Ot
and	CC	Ot
effectively	RB	Ot
by	IN	O
either	CC	O
a	DT	O
transthoracic	NN	O
or	CC	O
a	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
renders	NNS	O
cardioversion	NN	O
by	IN	O
either	DT	O
approach	NN	O
acceptable	JJ	O
.	.	O

As	IN	O
transesophageal	NN	O
ECV	NNP	O
shows	VBZ	O
no	DT	O
clear	JJ	O
advantage	NN	O
,	,	O
transthoracic	JJ	O
cardioversion	NN	O
should	MD	O
remain	VB	O
the	DT	O
approach	NN	O
of	IN	O
first	JJ	O
choice	NN	O
.	.	O

Five-year	JJ	O
outcome	NN	O
of	IN	O
surgical	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	PA
headaches	NNS	PA
.	.	PH

BACKGROUND	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
surgical	JJ	O
deactivation	NN	O
of	IN	O
migraine	NN	PH
headache	NN	PH
trigger	NN	O
sites	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
twenty-five	JJ	O
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
(	(	O
n	JJ	O
=	NNP	O
100	CD	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
after	IN	O
examination	NN	O
by	IN	O
the	DT	O
team	NN	O
neurologist	NN	O
to	TO	O
ensure	VB	O
a	DT	O
diagnosis	NN	O
of	IN	O
migraine	NN	PA
headache	NN	PA
.	.	O

Patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
complete	VB	O
the	DT	O
Medical	NNP	PH
Outcomes	NNP	PH
Study	NNP	PH
36-Item	JJ	PH
Short	NNP	PH
Form	NNP	PH
Health	NNP	PH
Survey	NNP	PH
,	,	O
Migraine-Specific	NNP	Ot
Quality	NNP	Ot
of	IN	Ot
Life	NNP	Ot
,	,	O
and	CC	O
Migraine	NNP	PH
Disability	NNP	PH
Assessment	NNP	PH
questionnaires	VBZ	PH
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
12-	JJ	O
and	CC	O
60-month	JJ	O
postoperative	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
botulinum	RB	O
toxin	NN	O
to	TO	O
confirm	VB	O
the	DT	O
trigger	NN	O
sites	VBZ	O
;	:	O
controls	NNS	O
received	VBD	O
saline	JJ	O
injections	NNS	O
.	.	O

Treated	VBN	O
patients	NNS	O
underwent	JJ	O
surgical	JJ	O
deactivation	NN	O
of	IN	O
trigger	NN	O
site	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
previously	RB	O
published	VBN	O
)	)	O
and	CC	O
5	CD	O
years	NNS	O
postoperatively	RB	O
(	(	O
the	DT	O
subject	NN	O
of	IN	O
this	DT	O
report	NN	O
)	)	O
.	.	O

RESULTS	JJ	O
Eighty-nine	NNP	O
of	IN	O
100	CD	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	JJ	O
surgery	NN	O
,	,	O
and	CC	O
79	CD	O
were	VBD	O
followed	VBN	O
for	IN	O
5	CD	O
years	NNS	O
.	.	O

Ten	CD	O
patients	NNS	O
underwent	JJ	O
deactivation	NN	O
of	IN	O
additional	JJ	O
(	(	O
different	JJ	O
)	)	O
trigger	NN	O
sites	NNS	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
and	CC	O
were	VBD	O
not	RB	O
included	VBN	O
in	IN	O
the	DT	O
data	NN	O
analysis	NN	O
.	.	O

The	DT	O
final	JJ	O
outcome	NN	O
with	IN	O
or	CC	O
without	IN	O
inclusion	NN	O
of	IN	O
these	DT	O
10	CD	O
patients	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

Sixty-one	NN	O
(	(	O
88	CD	O
percent	NN	O
)	)	O
of	IN	O
69	CD	O
patients	NNS	O
have	VBP	O
experienced	VBN	O
a	DT	O
positive	JJ	PH
response	NN	PH
to	TO	O
the	DT	O
surgery	NN	O
after	IN	O
5	CD	O
years	NNS	O
.	.	O

Twenty	NNP	O
(	(	O
29	CD	O
percent	NN	O
)	)	O
reported	VBD	O
complete	JJ	Ot
elimination	NN	Ot
of	IN	Ot
migraine	NN	Ot
headache	NN	Ot
,	,	O
41	CD	O
(	(	O
59	CD	O
percent	NN	O
)	)	O
noticed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
,	,	O
and	CC	O
eight	CD	O
(	(	O
12	CD	O
percent	NN	O
)	)	O
experienced	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
values	NNS	O
,	,	O
all	DT	O
measured	VBD	O
variables	NNS	O
at	IN	O
60	CD	O
months	NNS	O
improved	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
the	DT	O
5-year	JJ	O
follow-up	JJ	O
data	NNS	O
,	,	O
there	EX	O
is	VBZ	O
strong	JJ	O
evidence	NN	O
that	IN	O
surgical	JJ	O
manipulation	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
migraine	JJ	O
trigger	NN	O
sites	NNS	O
can	MD	O
successfully	RB	O
eliminate	VB	Ot
or	CC	Ot
reduce	VB	Ot
the	DT	Ot
frequency	NN	Ot
,	,	Ot
duration	NN	Ot
,	,	Ot
and	CC	Ot
intensity	NN	Ot
of	IN	Ot
migraine	NN	Ot
headache	NN	Ot
in	IN	O
a	DT	O
lasting	JJ	O
manner	NN	O
.	.	O

Teaching	VBG	O
picture-to-object	JJ	O
relations	NNS	O
in	IN	O
picture-based	JJ	O
requesting	NN	O
by	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
comparison	NN	O
between	IN	O
error	NN	O
prevention	NN	O
and	CC	O
error	NN	O
correction	NN	O
teaching	NN	O
procedures	NNS	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
who	WP	O
have	VBP	O
a	DT	O
combination	NN	O
of	IN	O
language	NN	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
with	IN	O
autism	NN	O
often	RB	O
experience	JJ	O
major	JJ	O
difficulties	NNS	O
in	IN	O
learning	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
their	PRP$	O
graphic	JJ	O
representations	NNS	O
.	.	O

Therefore	RB	O
,	,	O
they	PRP	O
would	MD	O
benefit	VB	O
from	IN	O
teaching	VBG	O
procedures	NNS	O
that	WDT	O
minimize	VBP	O
their	PRP$	O
difficulties	NNS	O
in	IN	O
acquiring	VBG	O
these	DT	O
relations	NNS	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
teaching	NN	O
procedures	NNS	O
,	,	O
an	DT	O
error	NN	O
prevention	NN	O
procedure	NN	O
and	CC	O
an	DT	O
error	NN	O
correction	NN	O
procedure	NN	O
,	,	O
for	IN	O
teaching	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
pictures	NNS	O
.	.	O

METHOD	JJ	O
Participants	NNS	O
were	VBD	O
two	CD	O
groups	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
aged	VBD	O
between	IN	O
3	CD	O
and	CC	O
7	CD	O
years	NNS	O
.	.	O

In	IN	O
the	DT	O
context	NN	O
of	IN	O
picture-to-object	JJ	O
requesting	NN	O
,	,	O
one	CD	O
group	NN	O
was	VBD	O
taught	VBN	O
using	VBG	O
an	DT	O
error	NN	O
correction	NN	O
method	NN	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
with	IN	O
an	DT	O
error	NN	O
prevention	NN	O
method	NN	O
.	.	O

The	DT	O
measures	NNS	O
for	IN	O
each	DT	O
child	NN	O
were	VBD	O
accuracy	NN	Ot
of	IN	Ot
correspondences	NNS	Ot
between	IN	Ot
taught	JJ	Ot
picture	NN	Ot
and	CC	Ot
object	JJ	Ot
pairs	NNS	Ot
and	CC	Ot
accuracy	NN	Ot
of	IN	Ot
delayed	JJ	Ot
correspondences	NNS	Ot
in	IN	Ot
learning	VBG	Ot
outcome	JJ	Ot
tests	NNS	Ot
with	IN	O
all	DT	O
combinations	NNS	O
of	IN	O
object	NN	O
and	CC	O
picture	NN	O
pairs	NNS	O
presented	VBN	O
to	TO	O
them	PRP	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
The	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
error	NN	O
prevention-based	JJ	O
teaching	NN	O
made	VBN	O
significantly	RB	O
fewer	JJR	O
errors	NNS	Ot
during	IN	O
the	DT	O
teaching	NN	O
phases	NNS	O
and	CC	O
in	IN	O
their	PRP$	O
learning	NN	O
outcome	NN	O
test	NN	O
for	IN	O
correspondences	NNS	O
between	IN	O
all	DT	O
combinations	NNS	O
of	IN	O
pictures	NNS	O
and	CC	O
objects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
error	NN	O
prevention	NN	O
teaching	NN	O
procedure	NN	O
would	MD	O
seem	VB	O
to	TO	O
provide	VB	O
a	DT	O
more	RBR	O
efficient	JJ	O
and	CC	O
ecologically	RB	O
valid	JJ	O
method	NN	O
than	IN	O
the	DT	O
error	NN	O
correction	NN	O
procedure	NN	O
for	IN	O
teaching	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
their	PRP$	O
graphic-based	JJ	O
referents	NNS	O
.	.	O

Improvements	NNS	O
in	IN	O
the	DT	O
methodology	NN	O
were	VBD	O
suggested	VBN	O
for	IN	O
providing	VBG	O
a	DT	O
stronger	JJR	O
basis	NN	O
for	IN	O
comparison	NN	O
between	IN	O
error	NN	O
correction	NN	O
and	CC	O
error	NN	O
prevention	NN	O
teaching	VBG	O
methods	NNS	O
.	.	O

Laparoscopic	NNP	O
vs	NN	O
open	JJ	O
appendectomy	NN	O
in	IN	O
overweight	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Laparoscopic	NNP	O
appendectomy	NN	O
(	(	O
LA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
faster	JJ	O
recovery	NN	O
and	CC	O
less	RBR	O
postoperative	JJ	O
pain	NN	O
than	IN	O
the	DT	O
open	JJ	O
technique	NN	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
the	DT	O
clinical	JJ	O
outcome	NN	O
of	IN	O
LA	NNP	O
in	IN	O
overweight	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
group	NN	O
of	IN	O
106	CD	O
patients	NNS	O
with	IN	O
a	DT	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
>	VBD	O
26.4	CD	O
,	,	O
representing	VBG	O
the	DT	O
upper	JJ	O
quintile	NN	O
of	IN	O
500	CD	O
prospectively	RB	O
randomized	JJ	O
patients	NNS	O
,	,	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
either	DT	O
laparoscopic	NN	O
or	CC	O
open	JJ	O
appendectomy	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

Operating	NN	Ot
and	CC	Ot
anesthesia	NN	Ot
times	NNS	Ot
,	,	O
postoperative	JJ	PA
pain	NN	PA
,	,	O
complications	NNS	A
,	,	O
hospital	NN	Ot
stay	NN	Ot
,	,	O
functional	JJ	PH
index	NN	PH
(	(	O
1	CD	O
week	NN	O
postoperatively	RB	O
)	)	O
,	,	O
sick	JJ	Ot
leave	VBP	Ot
,	,	O
and	CC	O
time	NN	Ot
to	TO	Ot
full	JJ	Ot
recovery	NN	Ot
were	VBD	O
documented	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
OA	NNP	O
,	,	O
the	DT	O
operating	NN	Ot
time	NN	Ot
for	IN	O
overweight	JJ	O
patients	NNS	O
was	VBD	O
significantly	RB	O
longer	JJR	O
than	IN	O
that	DT	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
normal	JJ	O
weight	NN	O
range	NN	O
(	(	O
40	CD	O
vs	RB	O
35	CD	O
min	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
LA	NNP	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
operating	NN	Ot
time	NN	Ot
between	IN	O
the	DT	O
normal	JJ	O
and	CC	O
overweight	JJ	O
patients	NNS	O
.	.	O

Overweight	JJ	O
patients	NNS	O
who	WP	O
underwent	JJ	O
LA	NNP	O
had	VBD	O
longer	RBR	O
operating	NN	Ot
and	CC	Ot
anesthesia	NN	Ot
times	NNS	Ot
than	IN	O
their	PRP$	O
OA	NNP	O
counterparts	NNS	O
(	(	O
55	CD	O
vs	RB	O
40	CD	O
min	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
;	:	O
and	CC	O
125	CD	O
vs	NN	O
100	CD	O
min	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Postoperative	JJ	PA
pain	NN	PA
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
overweight	JJ	O
patients	NNS	O
who	WP	O
underwent	VBP	O
OA	NNP	O
than	IN	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
the	DT	O
laparoscopic	NN	O
technique	NN	O
.	.	O

Postoperative	JJ	PA
pain	NN	PA
was	VBD	O
also	RB	O
significantly	RB	O
greater	JJR	O
in	IN	O
overweight	JJ	O
patients	NNS	O
subjected	VBN	O
to	TO	O
OA	NNP	O
than	IN	O
in	IN	O
patients	NNS	O
of	IN	O
normal	JJ	O
weight	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
;	:	O
the	DT	O
clinical	JJ	O
significance	NN	O
may	MD	O
,	,	O
however	RB	O
,	,	O
be	VB	O
of	IN	O
less	JJR	O
importance	NN	O
since	IN	O
the	DT	O
values	NNS	O
are	VBP	O
low	JJ	O
(	(	O
0.26	CD	O
vs	NN	O
0.09	CD	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
operating	VBG	O
techniques	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
complications	NNS	O
.	.	O

Hospital	NNP	Ot
stay	NN	Ot
was	VBD	O
longer	JJR	O
for	IN	O
overweight	NN	O
patients	NNS	O
than	IN	O
for	IN	O
normal-weight	JJ	O
patients	NNS	O
undergoing	VBG	O
OA	NNP	O
(	(	O
3.0	CD	O
vs	NN	O
2.0	CD	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
functional	JJ	O
index	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
any	DT	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

Sick	NNP	Ot
leave	NN	Ot
was	VBD	O
longer	JJR	O
for	IN	O
overweight	JJ	O
patients	NNS	O
who	WP	O
underwent	VBP	O
OA	NNP	O
than	IN	O
for	IN	O
normal-weight	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
same	JJ	O
technique	NN	O
(	(	O
17	CD	O
vs	RB	O
13	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
laparoscopic	NN	O
group	NN	O
,	,	O
however	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
overweight	NN	O
and	CC	O
normal-weight	JJ	O
patients	NNS	O
.	.	O

Time	NN	Ot
to	TO	Ot
full	JJ	Ot
recovery	NN	Ot
was	VBD	O
greater	JJR	O
in	IN	O
overweight	JJ	O
patients	NNS	O
subjected	VBN	O
to	TO	O
OA	NNP	O
than	IN	O
in	IN	O
the	DT	O
overweight	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
LA	NNP	O
group	NN	O
(	(	O
22	CD	O
vs	RB	O
15	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
overweight	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
submitted	VBN	O
to	TO	O
LA	NNP	O
had	VBD	O
less	RBR	O
postoperative	JJ	PA
pain	NN	PA
and	CC	O
a	DT	O
faster	RBR	O
postoperative	JJ	Ot
recovery	NN	Ot
than	IN	O
overweight	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
OA	NNP	O
.	.	O

LA	NNP	O
also	RB	O
abolished	VBD	O
some	DT	O
of	IN	O
the	DT	O
negative	JJ	O
effects	NNS	O
that	WDT	O
overweight	VBD	O
had	VBD	O
on	IN	O
operating	NN	Ot
time	NN	Ot
,	,	O
hospital	NN	Ot
stay	NN	Ot
,	,	O
and	CC	O
sick	JJ	Ot
leave	NN	Ot
with	IN	O
the	DT	O
open	JJ	O
technique	NN	O
.	.	O

However	RB	O
,	,	O
anesthesia	NN	O
and	CC	O
operating	NN	O
times	NNS	O
were	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
LA	NNP	O
for	IN	O
both	DT	O
overweight	JJ	O
patients	NNS	O
and	CC	O
those	DT	O
with	IN	O
a	DT	O
normal	JJ	O
BMI	NNP	O
.	.	O

Two	CD	O
large	JJ	O
preoperative	JJ	O
doses	NNS	O
of	IN	O
erythropoietin	NN	O
do	VBP	O
not	RB	O
reduce	VB	O
the	DT	O
systemic	JJ	O
inflammatory	NN	O
response	NN	O
to	TO	O
cardiac	VB	O
surgery	NN	O
.	.	O

OBJECTIVES	NNP	O
Cardiac	NNP	O
surgery	NN	O
and	CC	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
induce	VBP	O
an	DT	O
inflammatory	JJ	O
reaction	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
tissue	VB	O
injury	NN	O
.	.	O

Experimental	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
recombinant	JJ	O
human	JJ	O
erythropoietin	NN	O
(	(	O
EPO	NNP	O
)	)	O
independent	JJ	O
of	IN	O
its	PRP$	O
erythropoietic	JJ	O
effect	NN	O
may	MD	O
be	VB	O
used	VBN	O
clinically	RB	O
as	IN	O
an	DT	O
anti-inflammatory	JJ	O
drug	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
2	CD	O
large	JJ	O
doses	NNS	O
of	IN	O
EPO	NNP	O
administered	VBD	O
shortly	RB	O
before	IN	O
CPB	NNP	O
ameliorate	VBP	O
the	DT	O
systemic	JJ	O
inflammatory	NN	O
response	NN	O
to	TO	O
CPB	NNP	O
.	.	O

DESIGN	NNP	O
AND	NNP	O
SETTING	NNP	O
A	NNP	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
and	CC	O
randomized	JJ	O
study	NN	O
at	IN	O
a	DT	O
single	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	CC	O
Patients	NNS	O
scheduled	VBN	O
for	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
with	IN	O
CPB	NNP	O
.	.	O

INTERVENTIONS	NNP	O
EPO	NNP	O
(	(	O
epoetin	JJ	O
alfa	NN	O
,	,	O
500	CD	O
IU/kg	NNP	O
intravenously	RB	O
,	,	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
was	VBD	O
administered	VBN	O
12	CD	O
to	TO	O
18	CD	O
hours	NNS	O
preoperatively	RB	O
and	CC	O
again	RB	O
at	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
CPB	NNP	O
in	IN	O
both	DT	O
groups	NNS	O
greatly	RB	O
increased	VBD	O
plasma	JJ	PH
concentrations	NNS	PH
of	IN	PH
tumor	NN	PH
necrosis	NN	PH
factor	NN	PH
alpha	NN	PH
(	(	PH
TNF-alpha	NNP	PH
)	)	PH
,	,	O
interleukin	FW	PH
(	(	PH
IL	NNP	PH
)	)	PH
-1beta	NN	PH
,	,	O
IL-1beta	NNP	PH
receptor	NN	PH
antagonist	NN	PH
,	,	PH
IL-6	NNP	PH
,	,	O
IL-10	NNP	PH
,	,	O
and	CC	O
N-terminal	JJ	PH
probrain	NN	PH
natriuretic	JJ	PH
peptide	NN	PH
(	(	PH
NT-proBNP	NNP	PH
)	)	PH
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
EPO	NNP	O
at	IN	O
day	NN	O
3	CD	O
after	IN	O
CPB	NNP	O
augmented	VBD	O
the	DT	O
TNF-alpha	JJ	ME
response	NN	ME
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
at	IN	O
2	CD	O
hours	NNS	O
after	IN	O
CPB	NNP	O
increased	VBD	O
NT-proBNP	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
EPO	NNP	O
tended	VBD	O
to	TO	O
enhance	VB	O
the	DT	O
CPB-induced	JJ	O
increase	NN	O
in	IN	O
IL-1beta	NNP	PH
receptor	NN	PH
antagonist	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.057	CD	O
)	)	O
.	.	O

Otherwise	UH	O
,	,	O
EPO	NNP	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
pro-	NN	PH
and	CC	PH
antiinflammatory	NN	PH
mediators	NNS	PH
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Two	CD	O
large	JJ	O
doses	NNS	O
of	IN	O
EPO	NNP	O
given	VBN	O
shortly	RB	O
before	IN	O
CPB	NNP	O
do	VBP	O
not	RB	O
reduce	VB	O
perioperative	JJ	PH
release	NN	PH
of	IN	PH
inflammatory	JJ	PH
cytokines	NNS	PH
.	.	O

In	IN	O
contrast	NN	O
,	,	O
EPO	NNP	O
may	MD	O
augment	VB	O
the	DT	O
TNF-alpha	NNP	O
and	CC	O
NT-proBNP	NNP	O
response	NN	O
.	.	O

Although	IN	O
the	DT	O
long-term	JJ	O
clinical	JJ	O
impact	NN	O
remains	VBZ	O
unknown	JJ	O
,	,	O
the	DT	O
findings	NNS	O
do	VBP	O
not	RB	O
support	VB	O
use	NN	O
of	IN	O
EPO	NNP	O
as	IN	O
an	DT	O
anti-inflammatory	JJ	O
drug	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
cardiac	JJ	O
surgery	NN	O
.	.	O

Music	NNP	O
or	CC	O
guided	VBN	O
imagery	NN	O
for	IN	O
women	NNS	O
undergoing	VBG	O
colposcopy	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
of	IN	O
effects	NNS	O
on	IN	O
anxiety	NN	PA
,	,	O
perceived	VBD	PA
pain	NN	PA
,	,	O
and	CC	O
patient	JJ	Ot
satisfaction	NN	Ot
.	.	O

OBJECTIVE	IN	O
It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
music	NN	O
or	CC	O
guided	VBN	O
imagery	NN	O
versus	NN	O
usual	JJ	O
care	NN	O
would	MD	O
result	VB	O
in	IN	O
less	JJR	O
anxiety	NN	ME
and	CC	O
perceived	VBD	PA
pain	NN	PA
for	IN	O
colposcopy	NN	O
patients	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
music	NN	O
,	,	O
guided	VBD	O
imagery	NN	O
,	,	O
or	CC	O
usual	JJ	O
care	NN	O
after	IN	O
completing	VBG	O
a	DT	O
baseline	NN	O
questionnaire	NN	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBD	O
a	DT	O
postprocedure	NN	O
questionnaire	NN	O
.	.	O

RESULTS	NNP	O
Study	NNP	O
participants	NNS	O
(	(	O
N=170	NNP	O
)	)	O
had	VBD	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
28.4	CD	O
years	NNS	O
(	(	O
SD=9.6	NNP	O
;	:	O
range	VB	O
18-60	JJ	O
)	)	O
and	CC	O
formed	VBD	O
a	DT	O
racially	RB	O
diverse	JJ	O
group	NN	O
.	.	O

Education/income	NNP	O
levels	NNS	O
were	VBD	O
low	JJ	O
.	.	O

No	DT	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
postprocedure	NN	PA
anxiety	NN	PA
or	CC	O
pain	NN	PA
rating	NN	PA
.	.	O

CONCLUSIONS	NNP	O
Mind-body	JJ	O
interventions	NNS	O
had	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
impact	NN	O
on	IN	O
reported	VBN	O
anxiety	NN	ME
,	,	O
perceived	VBD	PA
pain	NN	PA
,	,	O
or	CC	ME
satisfaction	NN	Ot
with	IN	Ot
care	NN	Ot
,	,	O
even	RB	O
for	IN	O
those	DT	O
who	WP	O
anticipated	VBD	O
the	DT	O
most	RBS	O
pain	NN	O
or	CC	O
started	VBN	O
with	IN	O
high	JJ	O
anxiety	NN	O
.	.	O

Capsular	JJ	O
contracture	NN	O
around	IN	O
saline-filled	JJ	O
fine	NN	O
textured	VBN	O
and	CC	O
smooth	JJ	O
mammary	JJ	O
implants	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
7.5-year	JJ	O
follow-up	NN	O
.	.	O

In	IN	O
a	DT	O
previous	JJ	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
study	NN	O
comparing	VBG	O
in	IN	O
the	DT	O
same	JJ	O
patient	NN	O
textured	VBD	O
and	CC	O
smooth	JJ	O
saline-filled	JJ	O
mammary	JJ	O
implants	NNS	O
(	(	O
Biocell	NNP	O
)	)	O
with	IN	O
large	JJ	O
pore	NN	O
size	NN	O
(	(	O
300	CD	O
to	TO	O
600	CD	O
microm	NN	O
)	)	O
,	,	O
we	PRP	O
saw	VBD	O
no	DT	O
difference	NN	O
in	IN	O
capsular	JJ	O
contracture	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
to	TO	O
compare	VB	O
capsular	JJ	O
contracture	NN	O
around	IN	O
smooth	JJ	O
and	CC	O
textured	VBD	O
saline-filled	JJ	O
prostheses	NNS	O
with	IN	O
pores	NNS	O
of	IN	O
small	JJ	O
size	NN	O
.	.	O

During	IN	O
a	DT	O
period	NN	O
of	IN	O
7.5	CD	O
years	NNS	O
,	,	O
the	DT	O
breast	NN	O
hardness	NN	O
was	VBD	O
followed	VBN	O
up	RP	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
patient	JJ	O
satisfaction	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

Twenty	NNP	O
healthy	JJ	O
women	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
30	CD	O
years	NNS	O
were	VBD	O
operated	VBN	O
on	IN	O
for	IN	O
breast	NN	O
augmentation	NN	O
.	.	O

Two	CD	O
surgeons	NNS	O
performed	VBD	O
all	DT	O
operations	NNS	O
in	IN	O
a	DT	O
standardized	JJ	O
way	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
subglandularly	RB	O
a	DT	O
Siltex	NNP	O
textured	VBD	O
saline-filled	JJ	O
prosthesis	NN	O
with	IN	O
a	DT	O
pore	NN	O
size	NN	O
of	IN	O
30	CD	O
to	TO	O
70	CD	O
microm	NN	O
in	IN	O
one	CD	O
breast	NN	O
,	,	O
and	CC	O
a	DT	O
smooth	JJ	O
saline-filled	JJ	O
prosthesis	NN	O
in	IN	O
the	DT	O
other	JJ	O
.	.	O

The	DT	PH
hardness	NN	PH
of	IN	PH
the	DT	PH
breasts	NNS	PH
was	VBD	O
evaluated	VBN	O
after	IN	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
and	CC	O
7.5	CD	O
years	NNS	O
using	VBG	O
Baker	NNP	Ot
grading	NN	Ot
and	CC	Ot
applanation	NN	Ot
tonometry	NN	Ot
.	.	O

Eighteen	JJ	O
patients	NNS	O
completed	VBN	O
1-year	JJ	O
and	CC	O
7.5-year	JJ	O
follow-up	NN	O
.	.	O

Two	CD	O
breasts	NNS	O
with	IN	O
smooth	JJ	O
prostheses	NNS	O
were	VBD	O
contracted	VBN	O
after	IN	O
6	CD	O
months	NNS	O
(	(	O
Baker	NNP	O
III	NNP	O
or	CC	O
IV	NNP	O
)	)	O
.	.	O

After	IN	O
1	CD	O
year	NN	O
,	,	O
four	CD	O
patients	NNS	O
with	IN	O
smooth	JJ	O
prostheses	NNS	O
and	CC	O
one	CD	O
with	IN	O
a	DT	O
textured	JJ	O
prosthesis	NN	O
had	VBD	O
capsular	JJ	PH
contracture	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.34	CD	O
)	)	O
.	.	O

Seven	CD	O
and	CC	O
one-half	JJ	O
years	NNS	O
after	IN	O
surgery	NN	O
,	,	O
six	CD	O
patents	NNS	O
with	IN	O
smooth	DT	O
and	CC	O
four	CD	O
with	IN	O
textured	JJ	O
implants	NNS	O
had	VBD	O
contracture	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.66	CD	O
)	)	O
.	.	O

On	IN	O
two	CD	O
patients	NNS	O
with	IN	O
smooth	JJ	O
prostheses	NNS	O
and	CC	O
one	CD	O
patient	NN	O
with	IN	O
a	DT	O
textured	JJ	O
prosthesis	NN	O
,	,	O
the	DT	O
capsule	NN	PH
around	IN	PH
the	DT	PH
implant	NN	PH
hardened	VBD	PH
between	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Between	NNP	O
1	CD	O
year	NN	O
and	CC	O
7.5	CD	O
years	NNS	O
,	,	O
three	CD	O
breasts	NNS	O
with	IN	O
smooth	JJ	Ot
and	CC	Ot
textured	JJ	Ot
implants	NNS	Ot
contracted	VBD	Ot
and	CC	O
one	CD	Ot
with	IN	Ot
a	DT	Ot
textured	JJ	Ot
implant	NN	Ot
softened.The	NN	Ot
patients	NNS	O
reported	VBN	O
on	IN	O
a	DT	O
Visual	NNP	O
Analogue	NNP	O
Scale	NNP	O
(	(	O
1	CD	O
to	TO	O
10	CD	O
)	)	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
augmentation	NN	O
on	IN	O
their	PRP$	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
to	TO	O
be	VB	O
9	CD	O
+/-	JJ	O
1	CD	O
.	.	O

Four	CD	O
patients	NNS	O
preferred	VBD	O
the	DT	O
breast	NN	O
with	IN	O
the	DT	O
smooth	JJ	O
prosthesis	NN	O
,	,	O
three	CD	O
preferred	VBD	O
the	DT	O
breast	NN	O
with	IN	O
the	DT	O
textured	JJ	O
prosthesis	NN	O
,	,	O
and	CC	O
the	DT	O
others	NNS	O
found	VBD	O
both	DT	O
breasts	NNS	O
equal	VBP	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	Ot
difference	NN	Ot
of	IN	O
contracture	NN	PH
with	IN	O
smooth	JJ	O
versus	FW	O
fine	JJ	O
textured	VBN	O
implants	NNS	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
the	DT	O
patients	NNS	O
preferred	VBD	Ot
the	DT	Ot
smooth	JJ	Ot
implants	NNS	Ot
.	.	O

The	DT	O
patients	NNS	O
reported	VBD	O
that	IN	O
the	DT	O
breast	NN	O
augmentation	NN	O
had	VBD	O
had	VBN	O
an	DT	O
extremely	RB	O
high	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Interventions	NNS	O
in	IN	O
the	DT	O
initial	JJ	O
prodromal	JJ	O
states	NNS	O
of	IN	O
psychosis	NN	O
in	IN	O
Germany	NNP	O
:	:	O
concept	NN	O
and	CC	O
recruitment	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
Early	JJ	O
Detection	NN	O
and	CC	O
Intervention	NNP	O
Programme	NNP	O
of	IN	O
the	DT	O
German	JJ	O
Research	NNP	O
Network	NNP	O
on	IN	O
Schizophrenia	NNP	O
(	(	O
GRNS	NNP	O
)	)	O
investigates	VBZ	O
the	DT	O
initial	JJ	O
prodromal	JJ	O
phase	NN	O
of	IN	O
psychosis	NN	O
in	IN	O
a	DT	O
multidimensional	JJ	O
approach	NN	O
.	.	O

Two	CD	O
intervention	NN	O
strategies	NNS	O
are	VBP	O
being	VBG	O
studied	VBN	O
by	IN	O
two	CD	O
large-scale	JJ	O
multicentre	JJ	O
projects	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
present	VB	O
the	DT	O
concept	NN	O
of	IN	O
the	DT	O
intervention	NN	O
studies	NNS	O
,	,	O
and	CC	O
to	TO	O
provide	VB	O
an	DT	O
interim	JJ	O
report	NN	O
of	IN	O
the	DT	O
recruitment	JJ	O
procedure	NN	O
.	.	O

METHOD	NNP	O
Comprehensive	NNP	O
cognitive-behavioural	JJ	O
therapy	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
early	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
.	.	O

For	IN	O
patients	NNS	O
in	IN	O
the	DT	O
late	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
amisulpride	NN	O
is	VBZ	O
explored	VBN	O
.	.	O

Both	DT	O
interventions	NNS	O
are	VBP	O
evaluated	VBN	O
in	IN	O
randomised	JJ	O
controlled	VBN	O
trials	NNS	O
using	VBG	O
clinical	JJ	O
management	NN	O
as	IN	O
the	DT	O
control	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
January	NNP	O
2001	CD	O
and	CC	O
March	NNP	O
2003	CD	O
,	,	O
1212	CD	O
individuals	NNS	O
seeking	VBG	O
help	NN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
putative	JJ	O
prodromal	NN	O
symptoms	NNS	O
at	IN	O
four	CD	O
university	NN	O
centres	NNS	O
.	.	O

More	JJR	O
than	IN	O
388	CD	O
individuals	NNS	O
fulfilled	VBD	O
criteria	NNS	O
for	IN	O
both	DT	O
interventions	NNS	O
and	CC	O
188	CD	O
(	(	O
48.5	CD	O
%	NN	O
)	)	O
gave	VBD	O
informed	VBN	ME
consent	NN	ME
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
trials	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
screening	NN	O
procedure	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
feasible	JJ	Ot
and	CC	O
trial	NN	ME
participation	NN	ME
seems	VBZ	O
to	TO	O
be	VB	O
acceptable	JJ	O
to	TO	O
a	DT	O
relevant	JJ	O
proportion	NN	O
of	IN	O
people	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
developing	VBG	O
psychosis	NN	O
.	.	O

Blood	NNP	PH
pressure	NN	PH
biofeedback	NN	O
treatment	NN	O
of	IN	O
white-coat	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
blood	NN	PH
pressure	NN	PH
(	(	PH
BP	NNP	PH
)	)	PH
biofeedback	NN	O
treatment	NN	O
(	(	O
BF	NNP	O
)	)	O
effects	NNS	O
between	IN	O
white-coat	JJ	O
hypertension	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	O
white-coat	JJ	O
hypertensive	JJ	O
out-patients	NNS	O
and	CC	O
23	CD	O
essential	JJ	O
hypertensive	JJ	O
out-patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
groups	NNS	O
A	NNP	O
or	CC	O
B	NNP	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
A	NNP	O
underwent	NN	O
BF	NNP	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
sessions	NNS	O
.	.	O

Those	DT	O
in	IN	O
group	NN	O
B	NNP	O
visited	VBD	O
the	DT	O
clinic	NN	O
only	RB	O
to	TO	O
measure	VB	O
BP	NNP	PH
and	CC	O
later	RB	O
underwent	VBD	O
the	DT	O
same	JJ	O
BF	NNP	O
.	.	O

RESULTS	NNP	O
In	IN	O
group	NN	O
A	NNP	O
,	,	O
BPs	NNP	PH
of	IN	PH
white-coat	JJ	PH
hypertensives	NNS	PH
and	CC	PH
essential	JJ	PH
hypertensives	NNS	PH
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
22/11	CD	O
and	CC	O
14/8	CD	O
mmHg	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
group	NN	O
B	NNP	O
,	,	O
they	PRP	O
were	VBD	O
unchanged	JJ	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
but	CC	O
later	RB	O
suppressed	VBN	O
by	IN	O
BF	NNP	O
.	.	O

Under	IN	O
BF	NNP	O
,	,	O
pulse	NN	PH
and	CC	O
respiratory	NN	PH
rates	NNS	PH
were	VBD	O
significantly	RB	O
higher	JJR	O
,	,	O
and	CC	O
elevation	NN	PH
of	IN	PH
diastolic	JJ	PH
BP	NNP	PH
due	JJ	PH
to	TO	PH
mental	JJ	PH
stress	NN	PH
testing	NN	PH
was	VBD	O
better	RBR	O
suppressed	VBN	O
in	IN	O
white-coat	NN	O
hypertensives	NNS	O
than	IN	O
in	IN	O
essential	JJ	O
hypertensives	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
treatment	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
both	DT	O
types	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
and	CC	O
pressor	NN	O
response	NN	O
to	TO	O
stress	VB	PH
seems	VBZ	O
to	TO	O
be	VB	O
important	JJ	O
in	IN	O
the	DT	O
differentiated	JJ	O
BF	NNP	O
effect	NN	O
.	.	O

Measurement	NN	O
of	IN	O
health-related	JJ	PH
quality	NN	PH
of	IN	PH
life	NN	PH
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Nordic	NNP	O
Myeloma	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

When	WRB	O
a	DT	O
randomized	VBN	O
trial	NN	O
(	(	O
NMSG	NNP	O
4/90	CD	O
)	)	O
comparing	VBG	O
treatment	NN	O
with	IN	O
melphalan/prednisone	NN	O
to	TO	O
melphalan/	VB	O
prednisone	NN	O
+	NNP	O
interferon	VBZ	O
alpha-2b	NN	O
in	IN	O
newly	RB	O
diagnosed	VBN	O
multiple	JJ	O
myeloma	NN	O
was	VBD	O
initiated	VBN	O
in	IN	O
1990	CD	O
,	,	O
a	DT	O
quality-of-life	JJ	Ot
assessment	NN	PH
was	VBD	O
integrated	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
questionnaire	NN	O
(	(	O
QLQ-C30	NNP	O
)	)	O
developed	VBN	O
by	IN	O
the	DT	O
European	JJ	O
Organization	NNP	O
of	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
(	(	O
EORTC	NNP	O
)	)	O
Study	NNP	O
Group	NNP	O
on	IN	O
Quality	NNP	PH
of	IN	PH
Life	NNP	PH
.	.	O

The	DT	O
QLQ-C30	JJ	O
incorporates	NNS	O
five	CD	O
functional	JJ	O
scales	NNS	O
,	,	O
three	CD	O
symptom	NN	O
scales	NNS	O
,	,	O
a	DT	O
global	JJ	O
health	NN	O
and	CC	O
quality-of	JJ	Ot
life	NN	Ot
scale	NN	Ot
and	CC	O
some	DT	O
single	JJ	O
symptom	NN	O
measures	NNS	O
.	.	O

The	DT	O
questionnaire	NN	O
was	VBD	O
completed	VBN	O
prior	JJ	O
to	TO	O
treatment	NN	O
and	CC	O
after	IN	O
1	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
24	CD	O
,	,	O
36	CD	O
and	CC	O
48	CD	O
months	NNS	O
.	.	O

524	CD	O
(	(	O
90.2	CD	O
%	NN	O
)	)	O
of	IN	O
581	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
NMSG	NNP	O
4/90	CD	O
completed	VBD	O
the	DT	O
first	JJ	O
questionnaire	NN	O
,	,	O
and	CC	O
484	CD	O
(	(	O
83.3	CD	O
%	NN	O
)	)	O
completed	VBD	O
all	DT	O
questionnaires	NNS	O
given	VBN	O
to	TO	O
them	PRP	O
.	.	O

All	DT	O
but	CC	O
one	CD	O
of	IN	O
the	DT	O
scales	NNS	O
met	VBD	O
the	DT	O
minimum	JJ	O
criteria	NNS	O
of	IN	O
reliability	NN	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
>	NNP	O
/	NNP	O
0.70	CD	O
)	)	O
.	.	O

Validity	NNP	O
was	VBD	O
shown	VBN	O
by	IN	O
(	(	O
1	CD	O
)	)	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
scales	NNS	O
to	TO	O
discriminate	VB	O
clearly	RB	O
between	IN	O
patients	NNS	O
differing	VBG	O
in	IN	O
clinical	JJ	O
status	NN	O
as	IN	O
defined	VBN	O
by	IN	O
pretreatment	NN	O
W.H.O	NNP	O
.	.	O

performance	NN	O
index	NN	O
and	CC	O
Durie	NNP	O
&	CC	O
Salmon	NNP	O
stage	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
the	DT	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
in	IN	O
objective	JJ	O
disease	NN	O
status	NN	O
(	(	O
response	NN	O
and	CC	O
relapse	NN	O
)	)	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
the	DT	O
measurement	NN	O
of	IN	O
health-related	JJ	Ot
quality	NN	Ot
of	IN	Ot
life	NN	Ot
in	IN	O
a	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
the	DT	O
QLQ-C30	NNP	Ot
is	VBZ	O
a	DT	O
reliable	JJ	O
and	CC	O
valid	JJ	O
instrument	NN	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

The	DT	O
data	NN	O
will	MD	O
be	VB	O
used	VBN	O
for	IN	O
a	DT	O
cost-utility	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
NMSG	NNP	O
4/90	CD	O
trial	NN	O
.	.	O

Local	JJ	O
delivery	NN	O
of	IN	O
a	DT	O
recombinant	NN	O
adenoassociated	VBN	O
vector	NN	O
containing	VBG	O
a	DT	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	IN	O
antagonist	JJ	O
gene	NN	O
in	IN	O
inflammatory	JJ	O
arthritis	NN	O
:	:	O
a	DT	O
phase	NN	O
1	CD	O
dose-escalation	NN	O
safety	NN	Ot
and	CC	Ot
tolerability	NN	Ot
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
tolerability	NN	Ot
of	IN	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
,	,	O
an	DT	O
adenoassociated	JJ	O
virus	NN	O
serotype	NN	O
2	CD	O
vector	NN	O
containing	VBG	O
the	DT	O
cDNA	NN	O
for	IN	O
the	DT	O
human	JJ	O
tumour	JJ	O
necrosis	NN	O
factor-immunoglobulin	JJ	O
Fc	NNP	O
fusion	NN	O
gene	NN	O
(	(	O
tgAAC94	NN	O
)	)	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	JJ	O
1	CD	O
,	,	O
dose-escalation	NN	O
study	NN	O
,	,	O
15	CD	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
(	(	O
14	CD	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
and	CC	O
1	CD	O
with	IN	O
ankylosing	VBG	O
spondylitis	NN	O
)	)	O
not	RB	O
receiving	VBG	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	NN	O
(	(	O
TNFalpha	NNP	O
)	)	O
inhibitors	NNS	O
with	IN	O
persistent	JJ	O
moderate	NN	O
(	(	O
grade	JJ	O
2	CD	O
)	)	O
or	CC	O
severe	JJ	O
(	(	O
grade	JJ	O
3	CD	O
)	)	O
swelling	NN	O
in	IN	O
a	DT	O
target	NN	O
joint	NN	O
due	JJ	O
to	TO	O
inflammatory	JJ	O
arthritis	NN	O
received	VBD	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
at	IN	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
11	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
DNase	NNP	O
resistant	JJ	O
particles	NNS	O
per	IN	O
ml	NN	O
joint	NN	O
volume	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
into	IN	O
a	DT	O
knee	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	O
ankle	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Safety	NN	Ot
was	VBD	O
assessed	VBN	O
through	IN	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
.	.	O

As	IN	O
a	DT	O
secondary	JJ	O
objective	NN	O
,	,	O
changes	NNS	PH
in	IN	PH
injected	JJ	PH
joint	NN	PH
tenderness	NN	PH
and	CC	PH
swelling	VBG	PH
scores	NNS	PH
,	,	O
each	DT	O
measured	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Intra-articular	JJ	O
injections	NNS	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
no	DT	O
major	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

One	CD	O
event	NN	O
,	,	O
mild	JJ	O
knee	NN	O
pruritus	NN	O
,	,	O
was	VBD	O
considered	VBN	O
probably	RB	O
related	VBN	O
.	.	O

Synovial	JJ	PH
fluid	NN	PH
TNFR	NNP	PH
:	:	PH
Fc	NNP	PH
protein	NN	PH
was	VBD	O
not	RB	O
detected	VBN	O
(	(	O
nor	CC	O
expected	VBN	O
)	)	O
at	IN	O
the	DT	O
doses	NNS	O
used	VBN	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
,	,	O
a	DT	O
two-point	JJ	O
decrease	NN	PH
in	IN	PH
swelling	VBG	PH
was	VBD	O
noted	VBN	O
in	IN	O
2/11	CD	O
and	CC	O
2/4	CD	O
subjects	NNS	O
injected	VBN	O
with	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intra-articular	JJ	O
rAAV2-TNFR	NN	O
:	:	O
Fc	CD	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
subjects	NNS	O
without	IN	O
concurrent	JJ	O
systemic	JJ	O
TNFalpha	NNP	O
antagonist	NN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
thus	RB	O
feasible	JJ	O
to	TO	O
proceed	VB	O
with	IN	O
larger	JJR	O
trials	NNS	O
to	TO	O
further	JJ	O
test	NN	O
the	DT	O
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
local	JJ	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
gene	NN	O
transfer	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

Prevalence	NN	O
and	CC	O
treatment	NN	O
outcome	NN	O
of	IN	O
cervicitis	NN	PH
of	IN	O
unknown	JJ	O
etiology	NN	O
.	.	O

BACKGROUND	NNP	O
Mucopurulent	NNP	O
cervicitis	NN	O
(	(	O
MPC	NNP	O
)	)	O
is	VBZ	O
a	DT	O
clinical	JJ	O
syndrome	NN	O
characterized	VBN	O
by	IN	O
mucopurulent	JJ	O
discharge	NN	O
from	IN	O
the	DT	O
cervix	NN	O
and	CC	O
other	JJ	O
signs	NNS	O
of	IN	O
inflammation	NN	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
phase	NN	O
III	NNP	O
,	,	O
multicenter	NN	O
study	NN	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
placebo	NN	O
versus	NN	O
empiric	JJ	O
antibiotic	JJ	O
treatment	NN	O
for	IN	O
clinical	JJ	O
cure	NN	O
of	IN	O
MPC	NNP	PH
of	IN	O
unknown	JJ	O
etiology	NN	O
at	IN	O
2-month	JJ	O
follow-up	NN	O
.	.	O

Unfortunately	RB	O
,	,	O
enrollment	NN	O
was	VBD	O
terminated	VBN	O
because	IN	O
of	IN	O
low	JJ	O
accrual	NNS	O
of	IN	O
women	NNS	O
with	IN	O
cervicitis	NN	O
of	IN	O
unknown	JJ	O
etiology	NN	O
,	,	O
but	CC	O
important	JJ	O
prevalence	NN	O
and	CC	O
outcome	NN	O
data	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

METHODS	NNP	O
Five	CD	O
hundred	VBD	O
seventy-seven	JJ	O
women	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
MPC	NNP	O
.	.	O

Women	NNP	O
with	IN	O
MPC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
or	CC	O
placebo	NN	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
2	CD	O
arms	NNS	O
were	VBD	O
evaluated	VBN	O
based	VBN	O
on	IN	O
the	DT	O
etiology	NN	O
,	,	O
clinical	JJ	Ot
cure	NN	Ot
rates	NNS	Ot
,	,	O
adverse	JJ	PH
events	NNS	PH
(	(	PH
AEs	NNP	PH
)	)	PH
,	,	O
and	CC	O
rates	NNS	PH
of	IN	PH
pelvic	JJ	PH
inflammatory	JJ	PH
disease	NN	PH
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
thirty-one	NN	O
(	(	O
23	CD	O
%	NN	O
[	CC	O
131/577	CD	O
]	NN	O
)	)	O
screened	VBD	O
women	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
MPC	NNP	O
.	.	O

Eighty-seven	NNP	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomized	VBN	O
.	.	O

After	IN	O
excluding	VBG	O
women	NNS	O
with	IN	O
sexually	RB	O
transmitted	VBN	O
infections	NNS	O
and	CC	O
other	JJ	O
exclusions	NNS	O
,	,	O
61	CD	O
%	NN	O
(	(	O
53/87	CD	O
)	)	O
had	VBD	O
cervicitis	NN	PH
of	IN	O
unknown	JJ	O
etiology	NN	O
.	.	O

The	DT	O
overall	JJ	Ot
clinical	JJ	Ot
failure	NN	Ot
rate	NN	Ot
was	VBD	O
30	CD	O
%	NN	O
(	(	O
10/33	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
clinical	JJ	Ot
cure	NN	Ot
rate	NN	Ot
was	VBD	O
only	RB	O
24	CD	O
%	NN	O
(	(	O
8/33	CD	O
)	)	O
.	.	O

Rates	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
arms	NNS	O
.	.	O

There	EX	O
were	VBD	O
24	CD	O
gastrointestinal	JJ	PH
AEs	NNP	PH
in	IN	O
the	DT	O
treatment	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
1	CD	O
AE	NNP	O
in	IN	O
the	DT	O
placebo	NN	O
arm	NN	O
.	.	O

CONCLUSIONS	NNP	O
More	JJR	O
than	IN	O
half	NN	O
of	IN	O
the	DT	O
cases	NNS	O
of	IN	O
MPC	NNP	O
were	VBD	O
of	IN	O
unknown	JJ	O
etiology	NN	O
.	.	O

Clinical	JJ	Ot
cure	NN	Ot
rates	NNS	Ot
for	IN	O
the	DT	O
placebo	NN	O
and	CC	O
treatment	NN	O
arms	NNS	O
were	VBD	O
extremely	RB	O
low	JJ	O
,	,	O
with	IN	O
most	JJS	O
women	NNS	O
concluding	VBG	O
the	DT	O
study	NN	O
with	IN	O
a	DT	O
partial	JJ	O
response	NN	O
.	.	O

Gastrointestinal	JJ	PH
AEs	NNP	PH
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
treatment	NN	O
arm	NN	O
.	.	O

Oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	O
after	IN	O
Roux-en-Y	NNP	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

OBJECTIVES	CC	O
Roux-en-Y	JJ	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
commonly	RB	O
performed	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
morbid	NN	O
obesity	NN	O
.	.	O

This	DT	O
anatomical	JJ	O
alteration	NN	O
may	MD	O
affect	VB	O
the	DT	O
absorption	NN	O
and	CC	O
consequently	RB	O
the	DT	O
bioavailability	NN	O
of	IN	O
oral	JJ	O
drugs	NNS	O
.	.	O

This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	O
in	IN	O
12	CD	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
each	DT	O
subject	NN	O
received	VBD	O
two	CD	O
single	JJ	O
standard	NN	O
doses	NNS	O
of	IN	O
400	CD	O
mg	NN	O
of	IN	O
moxifloxacin	NN	O
orally	RB	O
or	CC	O
intravenously	RB	O
administered	VBN	O
on	IN	O
two	CD	O
occasions	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
.	.	O

Serial	JJ	O
venous	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
up	RB	O
to	TO	O
72	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
and	CC	O
moxifloxacin	JJ	PH
plasma	NN	PH
levels	NNS	PH
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
validated	JJ	O
HPLC	NNP	O
method	NN	O
with	IN	O
fluorescence	NN	O
detection	NN	O
.	.	O

[	CC	O
clinicaltrials.gov	JJ	O
database	NN	O
(	(	O
identifier	NN	O
:	:	O
NCT01130922	NNP	O
)	)	O
.	.	O

]	JJ	O
RESULTS	NNP	O
After	IN	O
oral	JJ	O
dosing	NN	O
,	,	O
moxifloxacin	FW	PH
plasma	NN	PH
concentrations	NNS	PH
reached	VBD	O
a	DT	O
maximum	JJ	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
of	IN	O
3.38	CD	O
?	.	O
1.41	CD	O
mg/L	NN	O
after	IN	O
1.75	CD	O
h	NN	O
(	(	O
0.75-4.00	JJ	O
)	)	O
.	.	O

After	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
max	NN	O
)	)	O
were	VBD	O
4.53	CD	O
?	.	O
1.43	CD	O
mg/L	NN	O
and	CC	O
1.03	CD	O
h	NN	O
(	(	O
0.75-2.50	JJ	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	Ot
areas	NNS	Ot
under	IN	Ot
the	DT	Ot
plasma	JJ	Ot
concentration	NN	Ot
time	NN	Ot
curve	NN	Ot
extrapolated	VBD	O
to	TO	O
infinity	NN	O
(	(	O
AUC	NNP	O
(	(	O
?	.	O
)	)	O
)	)	O
were	VBD	O
46.2	CD	O
?	.	O
1.4	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
oral	JJ	O
dosing	NN	O
and	CC	O
52.3	CD	O
?	.	O
1.3	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
mean	JJ	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
88.32	CD	O
%	NN	O
[	JJ	O
90	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
85.64	CD	O
%	NN	O
-91.08	CD	O
%	NN	O
]	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
exposure	NN	O
to	TO	O
moxifloxacin	VB	O
is	VBZ	O
equivalent	JJ	O
for	IN	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
administration	NN	O
of	IN	O
400	CD	O
mg	NN	O
dosages	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

But	CC	O
these	DT	O
exposures	NNS	O
were	VBD	O
more	JJR	O
than	IN	O
50	CD	O
%	NN	O
higher	JJR	O
than	IN	O
those	DT	O
described	VBN	O
for	IN	O
subjects	NNS	O
without	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

This	DT	O
may	MD	O
suggest	VB	O
a	DT	O
higher	JJR	O
enterohepatic	JJ	O
recirculation	NN	O
of	IN	O
moxifloxacin	NN	O
after	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

Effect	NN	O
of	IN	O
home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
on	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
:	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Fatigue	NNP	O
is	VBZ	O
a	DT	O
common	JJ	O
symptom	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
,	,	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
reduction	NN	O
of	IN	O
daily	JJ	O
activity	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
authors	NNS	O
aimed	VBN	O
to	TO	O
identify	VB	O
the	DT	O
effect	NN	O
of	IN	O
home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
on	IN	O
fatigue	NN	O
,	,	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
(	(	O
ADL	NNP	O
)	)	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

A	NNP	O
block	NN	O
randomisation	NN	O
method	NN	O
was	VBD	O
used	VBN	O
to	TO	O
randomise	VB	O
participants	NNS	O
into	IN	O
case	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Fatigue	NNP	PH
,	,	O
ADL	NNP	ME
and	CC	O
QOL	NNP	ME
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Independent	NNP	O
and	CC	O
paired	VBD	O
t-tests	NNS	O
,	,	O
chi-squared	JJ	O
tests	NNS	O
and	CC	O
covariance	NN	O
analysis	NN	O
were	VBD	O
used	VBN	O
to	TO	O
analysing	VBG	O
data	NNS	O
.	.	O

Findings	NNS	O
showed	VBD	O
the	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
mean	JJ	PH
scores	NNS	PH
of	IN	PH
fatigue	NN	PH
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
significant	JJ	O
improvement	NN	O
in	IN	O
mean	JJ	PH
scores	NNS	PH
of	IN	PH
ADL	NNP	ME
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
QOL	NNP	ME
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
after	IN	O
home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
.	.	O

Home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
can	MD	O
be	VB	O
an	DT	O
effective	JJ	Ot
,	,	O
inexpensive	JJ	Ot
and	CC	O
accessible	JJ	Ot
programme	NN	O
for	IN	O
decreasing	VBG	PH
fatigue	NN	PH
and	CC	O
improving	VBG	PH
ADL	NNP	ME
and	CC	PH
QOL	NNP	ME
for	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
comparing	VBG	O
radiotherapy	NN	O
with	IN	O
concurrent	JJ	O
weekly	JJ	O
cisplatin	NN	O
or	CC	O
weekly	JJ	O
paclitaxel	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
cervical	JJ	O
cancer	NN	O
.	.	O

PURPOSE/OBJECTIVE	VB	O
This	DT	O
is	VBZ	O
a	DT	O
prospective	JJ	O
comparison	NN	O
of	IN	O
weekly	JJ	O
cisplatin	NN	O
to	TO	O
weekly	VB	O
paclitaxel	NN	O
as	IN	O
concurrent	JJ	O
chemotherapy	NN	O
with	IN	O
standard	JJ	O
radiotherapy	NN	O
for	IN	O
locally	RB	O
advanced	JJ	O
cervical	JJ	O
carcinoma	NN	O
.	.	O

MATERIALS/METHODS	NNP	O
Between	NNP	O
May	NNP	O
2000	CD	O
and	CC	O
May	NNP	O
2004	CD	O
,	,	O
31	CD	O
women	NNS	O
with	IN	O
FIGO	NNP	O
stage	NN	O
IB2-IVA	NNP	O
cervical	JJ	O
cancer	NN	O
or	CC	O
with	IN	O
postsurgical	JJ	O
pelvic	JJ	O
recurrence	NN	O
were	VBD	O
enrolled	VBN	O
into	IN	O
this	DT	O
phase	NN	O
II	NNP	O
study	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
on	IN	O
a	DT	O
weekly	JJ	O
basis	NN	O
either	CC	O
40	CD	O
mg/m?	NN	O
Cisplatin	NNP	O
(	(	O
group	NN	O
I	PRP	O
;	:	O
16	CD	O
patients	NNS	O
)	)	O
or	CC	O
50	CD	O
mg/m?	NNS	O
paclitaxel	NN	O
(	(	O
group	NN	O
II	NNP	O
;	:	O
15	CD	O
patients	NNS	O
)	)	O
concurrently	RB	O
with	IN	O
radiotherapy	NN	O
.	.	O

Median	JJ	O
total	NN	O
dose	NN	O
to	TO	O
point	VB	O
A	NNP	O
was	VBD	O
74	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
66-92	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
66	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
40-98	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

Median	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
46	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
chemotherapy	NN	O
cycles	NNS	O
was	VBD	O
also	RB	O
comparable	JJ	O
with	IN	O
87	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
at	IN	O
least	JJS	O
4	CD	O
doses	NNS	O
in	IN	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
respectively	RB	O
.	.	O

Seven	JJ	O
patients	NNS	O
(	(	O
44	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
I	PRP	O
and	CC	O
8	CD	O
patients	NNS	O
(	(	O
53	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
II	NNP	O
developed	VBD	O
tumor	NN	O
recurrence	NN	O
.	.	O

The	DT	O
Median	JJ	O
Survival	NNP	O
time	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
for	IN	O
Group	NNP	O
I	PRP	O
and	CC	O
53	CD	O
months	NNS	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
surviving	VBG	O
at	IN	O
2	CD	O
and	CC	O
5	CD	O
years	NNS	O
was	VBD	O
78	CD	O
%	NN	O
and	CC	O
54	CD	O
%	NN	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
73	CD	O
%	NN	O
and	CC	O
43	CD	O
%	NN	O
for	IN	O
group	NN	O
II	NNP	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
small	JJ	O
prospective	JJ	O
study	NN	O
shows	NNS	O
that	WDT	O
weekly	VBP	O
paclitaxel	NN	O
does	VBZ	O
not	RB	O
provide	VB	O
any	DT	O
clinical	JJ	O
advantage	NN	O
over	IN	O
weekly	JJ	O
cisplatin	NN	O
for	IN	O
concurrent	JJ	O
chemoradiation	NN	O
for	IN	O
advanced	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
cervix	NN	O
.	.	O

Hysteroscopic	NNP	O
transcervical	JJ	O
endometrial	JJ	O
resection	NN	O
versus	IN	O
thermal	JJ	O
destruction	NN	O
for	IN	O
menorrhagia	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
on	IN	O
satisfaction	NN	O
rate	NN	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
satisfaction	NN	Ot
rate	NN	Ot
and	CC	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
transcervical	JJ	O
hysteroscopic	NN	O
endometrial	JJ	O
resection	NN	O
and	CC	O
thermal	JJ	O
destruction	NN	O
of	IN	O
the	DT	O
endometrium	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
2	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Gynecology	NNP	O
of	IN	O
the	DT	O
University	NNP	O
of	IN	O
Naples	NNP	O
.	.	O

Eighty-two	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
affected	VBN	O
by	IN	O
menorrhagia	NN	O
that	WDT	O
was	VBD	O
unresponsive	JJ	O
to	TO	O
medical	JJ	O
treatment	NN	O
were	VBD	O
respectively	RB	O
randomized	VBN	O
to	TO	O
transcervical	JJ	O
hysteroscopic	NN	O
endometrial	JJ	O
resection	NN	O
or	CC	O
to	TO	O
thermal	JJ	O
destruction	NN	O
of	IN	O
the	DT	O
endometrium	NN	O
.	.	O

Satisfaction	NN	Ot
rate	NN	Ot
,	,	O
operative	JJ	Ot
time	NN	Ot
,	,	O
discharge	NN	Ot
time	NN	Ot
,	,	O
complication	NN	A
rate	NN	A
,	,	O
reintervention	NN	Ot
rate	NN	Ot
,	,	O
and	CC	O
resumption	NN	Ot
of	IN	Ot
normal	JJ	Ot
activity	NN	Ot
were	VBD	O
evaluated	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
satisfaction	NN	Ot
rate	NN	Ot
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
.	.	O

Operative	JJ	Ot
time	NN	Ot
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
24	CD	O
+/-	JJ	O
4	CD	O
minutes	NNS	O
vs	JJ	O
37	CD	O
+/-	JJ	O
6	CD	O
minutes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	A
blood	NN	A
loss	NN	A
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
7.2	CD	O
+/-	JJ	O
2.8	CD	O
mL	NN	O
vs	NN	O
89	CD	O
+/-	JJ	O
38	CD	O
mL	NN	O
)	)	O
.	.	O

Reintervention	NN	Ot
rates	NNS	Ot
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
transcervical	JJ	O
hysteroscopic	NN	O
endometrial	JJ	O
resection	NN	O
group	NN	O
,	,	O
although	IN	O
postoperative	JJ	O
pain	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Discharge	NNP	Ot
time	NN	Ot
,	,	O
complication	NN	A
rate	NN	A
,	,	O
and	CC	O
resumption	NN	Ot
of	IN	Ot
normal	JJ	Ot
activity	NN	Ot
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Thermal	NNP	O
destruction	NN	O
of	IN	O
the	DT	O
endometrium	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
should	MD	O
be	VB	O
considered	VBN	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
because	IN	O
of	IN	O
its	PRP$	O
acceptability	NN	Ot
among	IN	O
patients	NNS	O
,	,	O
shorter	RB	Ot
operative	JJ	Ot
time	NN	Ot
,	,	O
and	CC	O
lower	JJR	Ot
blood	NN	Ot
loss	NN	Ot
.	.	O

Validation	NN	O
of	IN	O
a	DT	O
novel	JJ	O
satisfaction	NN	O
questionnaire	NN	O
for	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
receiving	VBG	O
outpatient	JJ	O
clinical	JJ	O
nurse	NN	O
specialist	NN	O
care	NN	O
,	,	O
inpatient	NN	O
care	NN	O
,	,	O
or	CC	O
day	NN	O
patient	JJ	O
team	NN	O
care	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
develop	VB	O
and	CC	O
validate	VB	O
a	DT	O
questionnaire	NN	O
for	IN	O
measuring	VBG	O
satisfaction	NN	Ot
with	IN	O
different	JJ	O
forms	NNS	O
of	IN	O
complex	JJ	O
multidisciplinary	JJ	O
care	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
satisfaction	NN	Ot
questionnaire	NN	Ot
(	(	O
score	JJ	O
range	NN	O
0-100	NN	O
)	)	O
comprised	VBD	O
28	CD	O
items	NNS	O
covering	VBG	O
11	CD	O
domains	NNS	O
.	.	O

Together	RB	O
with	IN	O
a	DT	O
visual	JJ	Ot
analog	NN	Ot
scale	NN	Ot
(	(	Ot
VAS	NNP	Ot
,	,	Ot
range	VB	Ot
0-100	NNP	Ot
)	)	Ot
on	IN	O
overall	JJ	Ot
satisfaction	NN	Ot
,	,	O
the	DT	O
questionnaire	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
210	CD	O
RA	NNP	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
3	CD	O
types	NNS	O
of	IN	O
multidisciplinary	JJ	O
care	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
questionnaire	NN	O
was	VBD	O
returned	VBN	O
by	IN	O
174	CD	O
patients	NNS	O
(	(	O
83	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
questionnaire	NN	Ot
and	CC	Ot
VAS	NNP	Ot
scores	NNS	Ot
in	IN	O
the	DT	O
total	JJ	O
group	NN	O
were	VBD	O
75	CD	O
(	(	O
SD	NNP	O
12	CD	O
)	)	O
and	CC	O
83	CD	O
(	(	O
SD	NNP	O
20	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Reliability	NNP	O
analysis	NN	O
showed	VBD	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
of	IN	O
the	DT	Ot
questionnaire	NN	Ot
was	VBD	O
0.91	CD	O
.	.	O

Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficient	NN	O
between	IN	O
the	DT	O
satisfaction	NN	Ot
questionnaire	NN	Ot
score	NN	Ot
and	CC	Ot
VAS	NNP	Ot
score	NN	Ot
was	VBD	O
0.58	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Mean	JJ	Ot
total	JJ	Ot
satisfaction	NN	Ot
questionnaire	NN	Ot
scores	NNS	Ot
were	VBD	O
72	CD	O
(	(	O
SD	NNP	O
9	CD	O
)	)	O
,	,	O
76	CD	O
(	(	O
SD	NNP	O
14	CD	O
)	)	O
,	,	O
and	CC	O
78	CD	O
(	(	O
SD	NNP	O
11	CD	O
)	)	O
,	,	O
in	IN	O
the	DT	O
nurse	JJ	O
specialist	NN	O
,	,	O
inpatient	JJ	O
and	CC	O
day	NN	O
patient	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
nurse	JJ	O
specialist	NN	O
versus	IN	O
day	NN	O
patient	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

Significant	JJ	O
differences	NNS	O
between	IN	O
nurse	JJ	O
specialist	NN	O
and	CC	O
day	NN	O
patients	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
following	JJ	O
domains	NNS	O
:	:	O
waiting	VBG	Ot
time	NN	Ot
during	IN	Ot
the	DT	Ot
treatment	NN	Ot
,	,	Ot
autonomy	NN	Ot
,	,	Ot
coordination	NN	Ot
,	,	Ot
non-financial	JJ	Ot
access	NN	Ot
,	,	Ot
and	CC	Ot
quality	NN	Ot
of	IN	Ot
general	JJ	Ot
information	NN	Ot
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
highly	RB	O
satisfied	VBN	O
with	IN	O
the	DT	O
multidisciplinary	JJ	O
care	NN	O
they	PRP	O
received	VBD	O
.	.	O

Major	JJ	O
differences	NNS	O
regarding	VBG	O
the	DT	O
organization	NN	O
of	IN	O
care	NN	O
were	VBD	O
reflected	VBN	O
in	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
questionnaire	NN	O
scores	NNS	O
.	.	O

The	DT	O
satisfaction	NN	Ot
questionnaire	NN	Ot
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
useful	JJ	O
instrument	NN	O
for	IN	O
measuring	VBG	O
satisfaction	NN	Ot
with	IN	O
complex	JJ	O
multidisciplinary	NN	O
care	NN	O
in	IN	O
RA	NNP	O
patients	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
intensive	JJ	O
early	JJ	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

Young	NNP	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
intensive	VB	O
treatment	NN	O
or	CC	O
parent	NN	O
training	NN	O
.	.	O

The	DT	O
intensive	JJ	O
treatment	NN	O
group	NN	O
(	(	O
7	CD	O
with	IN	O
autism	NN	O
,	,	O
8	CD	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
--	:	O
NOS	NNP	O
)	)	O
averaged	VBD	O
24.52	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
individual	JJ	O
treatment	NN	O
for	IN	O
one	CD	O
year	NN	O
,	,	O
gradually	RB	O
reducing	VBG	O
hours	NNS	O
over	IN	O
the	DT	O
next	JJ	O
1	CD	O
to	TO	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
parent	NN	O
training	NN	O
group	NN	O
(	(	O
7	CD	O
with	IN	O
autism	NN	O
,	,	O
6	CD	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
NOS	NNP	O
)	)	O
received	VBD	O
3	CD	O
to	TO	O
9	CD	O
months	NNS	O
of	IN	O
parent	NN	O
training	NN	O
.	.	O

The	DT	O
groups	NNS	O
appeared	VBD	O
similar	JJ	O
at	IN	O
intake	NN	O
on	IN	O
all	DT	O
measures	NNS	O
;	:	O
however	RB	O
,	,	O
at	IN	O
follow-up	JJ	O
the	DT	O
intensive	JJ	O
treatment	NN	O
group	NN	O
outperformed	VBD	O
the	DT	O
parent	NN	O
training	VBG	O
group	NN	O
on	IN	O
measures	NNS	O
of	IN	O
intelligence	NN	ME
,	,	ME
visual-spatial	JJ	ME
skills	NNS	ME
,	,	ME
language	NN	ME
,	,	ME
and	CC	ME
academics	NNS	ME
,	,	O
though	IN	O
not	RB	O
adaptive	JJ	ME
functioning	NN	ME
or	CC	ME
behavior	NN	ME
problems	NNS	ME
.	.	O

Children	NNP	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
NOS	NNP	O
may	MD	O
have	VB	O
gained	VBN	O
more	JJR	O
than	IN	O
those	DT	O
with	IN	O
autism	NN	O
.	.	O

Mediterranean	NNP	O
diet	NN	O
and	CC	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
associated	VBN	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
:	:	O
effect	NN	PH
on	IN	O
bone	NN	PH
metabolism	NN	PH
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
analyze	VB	O
the	DT	O
effect	NN	O
of	IN	O
differing	VBG	O
diet	NN	O
on	IN	O
the	DT	O
acid	JJ	O
load	NN	O
content	NN	O
on	IN	O
bone	NN	PH
metabolism	NN	PH
.	.	O

DESIGN	NNP	O
Multicentric	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel-group	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	JJ	O
clinics	NNS	O
.	.	O

PARTICIPANTS	VB	O
Two	CD	O
hundred	CD	O
thirty-eight	JJ	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
aged	VBD	O
60	CD	O
to	TO	O
80	CD	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
interventional	JJ	O
groups	NNS	O
:	:	O
a	DT	O
recommended	JJ	O
low-fat	JJ	O
diet	NN	O
(	(	O
control	VB	O
diet	JJ	O
group	NN	O
)	)	O
,	,	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
,	,	O
or	CC	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Main	NNP	O
outcomes	NNS	O
were	VBD	O
12-month	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
bone	NN	PH
formation	NN	PH
and	CC	PH
resorption	NN	PH
markers	NNS	PH
and	CC	PH
bone	NN	PH
mass	NN	PH
measured	VBD	PH
according	VBG	O
to	TO	O
quantitative	JJ	O
ultrasound	JJ	O
scanning	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
data	NNS	O
on	IN	O
the	DT	O
anthropometric	NN	PH
,	,	PH
bone	NN	PH
densitometry	NN	PH
,	,	PH
and	CC	PH
biochemical	JJ	PH
variables	NNS	PH
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Dietary	NNP	PH
potential	JJ	PH
renal	JJ	PH
acid	NN	PH
load	NN	PH
(	(	PH
PRAL	NNP	PH
)	)	PH
and	CC	O
daily	JJ	PH
net	NN	PH
endogenous	JJ	PH
acid	NN	PH
production	NN	PH
(	(	PH
NEAP	NNP	PH
)	)	PH
at	IN	O
baseline	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
groups	NNS	O
.	.	O

After	IN	O
intervention	NN	O
,	,	O
subjects	NNS	O
allocated	VBD	O
to	TO	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
had	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
PRAL	NNP	PH
and	CC	O
NEAP	NNP	PH
.	.	O

In	IN	O
comparison	NN	O
,	,	O
subjects	NNS	O
in	IN	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
nuts	NNS	O
group	NN	O
had	VBD	O
higher	JJR	O
parathyroid	NN	PH
hormone	NN	PH
(	(	PH
PTH	NNP	PH
)	)	PH
levels	NNS	PH
(	(	O
2.63	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
=-1.01-6.35	NN	O
,	,	O
P=.02	NNP	O
)	)	O
and	CC	O
a	DT	O
nonsignificantly	RB	O
higher	JJR	O
(	(	O
0.31	CD	O
,	,	O
95	CD	O
%	NN	O
CI=-0.13-0.74	NNP	O
,	,	O
P=.14	NNP	O
)	)	O
urine	VBP	PH
free	JJ	PH
deoxypyridoxine	NN	PH
:	:	PH
creatinine	NN	PH
ratio	NN	PH
,	,	O
a	DT	O
marker	NN	O
of	IN	O
bone	NN	O
resorption	NN	O
,	,	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
group	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
Mediterranean	NNP	O
dietary	JJ	O
pattern	NN	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
derived	VBN	O
from	IN	O
consumption	NN	O
of	IN	O
mixed	JJ	O
nuts	NNS	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
have	VB	O
a	DT	O
much	RB	O
greater	JJR	O
effect	NN	O
on	IN	O
bone	NN	PH
metabolism	NN	PH
biomarkers	NNS	PH
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
PTH	NNP	PH
levels	NNS	PH
,	,	O
than	IN	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
without	IN	O
mixed	JJ	O
nuts	NNS	O
or	CC	O
a	DT	O
control	NN	O
diet	NN	O
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Pentoxifylline	NNP	O
therapy	NN	O
in	IN	O
HIV	NNP	O
seropositive	JJ	O
subjects	NNS	O
with	IN	O
elevated	JJ	O
TNF	NNP	O
.	.	O

Tumor	NNP	O
necrosis	IN	O
factor-alpha	JJ	O
(	(	O
TNF-alpha	NNP	O
)	)	O
is	VBZ	O
thought	VBN	O
to	TO	O
induce	VB	O
cachexia	NN	O
in	IN	O
subjects	NNS	O
infected	VBN	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
,	,	O
and	CC	O
it	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
HIV-seropositive	JJ	O
patients	NNS	O
would	MD	O
benefit	VB	O
from	IN	O
treatment	NN	O
with	IN	O
pentoxifylline	NN	O
,	,	O
a	DT	O
known	VBN	O
suppressor	NN	O
of	IN	O
TNF-alpha	NNP	O
production	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
how	WRB	O
pentoxifylline	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
800	CD	O
mg	JJ	O
thrice	JJ	O
daily	RB	O
would	MD	O
influence	VB	O
the	DT	O
cellular	JJ	PH
immune	NN	PH
system	NN	PH
in	IN	O
HIV-seropositive	JJ	O
persons	NNS	O
with	IN	O
elevated	JJ	O
TNF-alpha	NNP	O
.	.	O

Six	NNP	O
HIV-seropositive	JJ	O
subjects	NNS	O
with	IN	O
elevated	JJ	O
amounts	NNS	O
of	IN	O
TNF-alpha	NNP	O
in	IN	O
plasma	NN	O
at	IN	O
least	JJS	O
at	IN	O
two	CD	O
occasions	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
an	DT	O
open	JJ	O
,	,	O
controlled	VBN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
study	NN	O
consisting	VBG	O
of	IN	O
a	DT	O
6	CD	O
week	NN	O
treatment	NN	O
period	NN	O
and	CC	O
a	DT	O
6	CD	O
week	NN	O
control	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
period	NN	O
.	.	O

Pentoxifylline	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
concentration	NN	PH
of	IN	PH
plasma-TNF-alpha	NN	PH
,	,	PH
subpopulations	NNS	PH
of	IN	PH
blood	NN	PH
mononuclear	NN	PH
cells	NNS	PH
,	,	PH
the	DT	PH
proliferative	JJ	PH
responses	NNS	PH
nor	CC	PH
the	DT	PH
natural	JJ	PH
killer	NN	PH
(	(	PH
NK	NNP	PH
)	)	PH
,	,	PH
and	CC	PH
lymphokine	NN	PH
activated	VBN	PH
killer	NN	PH
(	(	PH
LAK	NNP	PH
)	)	PH
cell	NN	PH
activities	NNS	PH
.	.	PH

Furthermore	RB	O
,	,	O
pentoxifylline	JJ	O
treatment	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
weight	NN	PH
,	,	PH
temperature	NN	PH
,	,	PH
well	RB	PH
being	VBG	PH
,	,	PH
or	CC	PH
tiredness	NN	PH
of	IN	PH
the	DT	PH
subjects	NNS	PH
.	.	PH

However	RB	O
,	,	O
the	DT	O
patients	NNS	O
frequently	RB	O
reported	VBD	O
gastrointestinal	JJ	A
side	NN	A
effects	NNS	A
.	.	A

In	IN	O
vitro	NN	O
,	,	O
however	RB	O
,	,	O
pentoxifylline	NN	O
at	IN	O
suprapharmacological	JJ	O
concentrations	NNS	O
inhibited	VBD	O
the	DT	O
blood	NN	Ot
mononuclear	NN	Ot
cell	NN	Ot
(	(	Ot
BMNC	NNP	Ot
)	)	Ot
proliferative	NN	Ot
responses	NNS	Ot
,	,	O
NK	NNP	PH
,	,	O
and	CC	O
LAK	NNP	PH
cell	NN	PH
activities	NNS	PH
.	.	O

Sleep	NNP	PH
patterns	NNS	PH
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

Sleep	JJ	PH
disturbances	NNS	PH
are	VBP	O
regarded	VBN	O
as	IN	O
a	DT	O
common	JJ	O
clinical	JJ	O
feature	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
concept	NN	O
is	VBZ	O
based	VBN	O
primarily	RB	O
on	IN	O
informal	JJ	O
observations	NNS	O
or	CC	O
studies	NNS	O
conducted	VBN	O
with	IN	O
questionnaires	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
compared	VBN	O
data	NNS	O
obtained	VBN	O
by	IN	O
questionnaires	NNS	O
to	TO	O
that	DT	O
obtained	VBN	O
with	IN	O
actigraphy	NN	O
.	.	O

Among	IN	O
22	CD	O
autistic	JJ	O
children	NNS	O
,	,	O
12	CD	O
were	VBD	O
reported	VBN	O
as	IN	O
having	VBG	O
sleep	JJ	O
problems	NNS	O
and	CC	O
8	CD	O
patients	NNS	O
completed	VBD	O
72	CD	O
hours	NNS	O
actigraphy	RB	O
.	.	O

While	IN	O
the	DT	O
employment	NN	O
of	IN	O
questionnaires	NNS	O
disclosed	VBN	O
that	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
an	DT	O
earlier	JJR	PH
morning	NN	PH
awakening	NN	PH
time	NN	PH
and	CC	O
multiple	NN	PH
and	CC	PH
early	JJ	PH
night	NN	PH
arousals	NNS	PH
,	,	O
actigraphic	JJ	O
monitoring	NN	O
showed	VBD	O
that	IN	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
an	DT	O
earlier	JJR	PH
morning	NN	PH
arousal	NN	PH
time	NN	PH
(	(	O
p	JJ	O
=	NNP	O
.045	NNP	O
)	)	O
,	,	O
sleep	JJ	PH
patterns	NNS	PH
of	IN	O
autistic	JJ	O
children	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
normal	JJ	O
children	NNS	O
.	.	O

Parental	JJ	O
oversensitivity	NN	O
to	TO	O
sleep	VB	PH
disturbances	NNS	PH
of	IN	O
the	DT	O
autistic	JJ	O
children	NNS	O
may	MD	O
explain	VB	O
this	DT	O
phenomenon	NN	O
.	.	O

The	DT	O
injured	JJ	O
colon	NN	O
:	:	O
therapeutic	JJ	O
considerations	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
the	DT	O
Detroit	NNP	O
General	NNP	O
Hospital	NNP	O
over	IN	O
a	DT	O
two	CD	O
year	NN	O
period	NN	O
to	TO	O
evaluate	VB	O
methods	NNS	O
of	IN	O
management	NN	O
in	IN	O
165	CD	O
patients	NNS	O
with	IN	O
colonic	JJ	O
injuries	NNS	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
show	NN	O
that	IN	O
primary	JJ	O
closure	NN	O
is	VBZ	O
a	DT	O
safe	JJ	Ot
and	CC	O
reiable	JJ	Ot
method	NN	O
of	IN	O
management	NN	O
when	WRB	O
rigid	JJ	O
criteria	NNS	O
are	VBP	O
incorporated	VBN	O
in	IN	O
an	DT	O
ongoing	JJ	O
protocol	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
technic	NN	O
of	IN	O
exteriorization	NN	O
is	VBZ	O
a	DT	O
safe	JJ	Ot
adjunct	NN	O
to	TO	O
management	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
any	DT	O
patient	NN	O
with	IN	O
a	DT	O
colonic	JJ	O
injury	NN	O
above	IN	O
18	CD	O
cm	NN	O
in	IN	O
which	WDT	O
one	CD	O
suture	NN	O
line	NN	O
is	VBZ	O
required	VBN	O
and	CC	O
in	IN	O
which	WDT	O
the	DT	O
additional	JJ	O
operating	NN	O
time	NN	O
of	IN	O
twenty	NN	O
minutes	NNS	O
will	MD	O
not	RB	O
compromise	VB	O
the	DT	O
management	NN	O
of	IN	O
secondary	JJ	O
injuries	NNS	O
.	.	O

Patients	NNS	O
not	RB	O
fulfilling	VBG	O
these	DT	O
criteria	NNS	O
should	MD	O
have	VB	O
primary	JJ	PH
colostomy	NN	PH
.	.	PH

These	DT	O
principles	NNS	O
make	VBP	O
it	PRP	O
possible	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
need	NN	O
for	IN	O
primary	JJ	PH
colostomy	NN	PH
to	TO	O
approximately	RB	O
50	CD	O
per	IN	O
cent	NN	O
in	IN	O
a	DT	O
large	JJ	O
ongoing	VBG	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
colonic	JJ	O
injury	NN	O
.	.	O

A	DT	O
randomized	JJ	O
prospective	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
versus	IN	O
oral	JJ	O
valacyclovir	NN	O
for	IN	O
prophylaxis	NN	O
of	IN	O
cytomegalovirus	NN	PH
disease	NN	PH
after	IN	O
renal	JJ	O
transplantation	NN	O
.	.	O

Oral	NNP	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
cytomegalovirus	NN	PH
(	(	PH
CMV	NNP	PH
)	)	PH
disease	NN	PH
after	IN	O
renal	JJ	O
transplantation	NN	O
(	(	O
RTx	NNP	O
)	)	O
.	.	O

Our	PRP$	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Ot
,	,	O
costs	NNS	Ot
,	,	O
and	CC	O
safety	NN	Ot
of	IN	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
over	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
RTx	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
38	CD	O
patients	NNS	O
was	VBD	O
randomized	VBN	O
to	TO	O
3-month	JJ	O
treatment	NN	O
with	IN	O
either	DT	O
oral	JJ	O
ganciclovir	NN	O
(	(	O
1	CD	O
g	NN	O
t.i.d.	NN	O
,	,	O
n=14	RB	O
,	,	O
GAN	NNP	O
group	NN	O
)	)	O
or	CC	O
oral	JJ	O
valacyclovir	NN	O
(	(	O
2	CD	O
g	NN	O
q.i.d.	NN	O
,	,	O
n=12	RB	O
,	,	O
VAL	NNP	O
group	NN	O
)	)	O
.	.	O

A	DT	O
third	JJ	O
group	NN	O
(	(	O
C	NNP	O
,	,	O
n=12	NN	O
)	)	O
received	VBD	O
no	DT	O
prophylaxis	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
CMV-nested	JJ	O
PCR	NNP	O
in	IN	O
whole	JJ	O
blood	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
their	PRP$	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
immunosuppressive	JJ	O
protocols	NNS	O
,	,	O
or	CC	O
donor	NN	O
and	CC	O
recipient	NN	O
CMV	NNP	O
serology	NN	O
.	.	O

Thirty-six	CD	O
out	IN	O
of	IN	O
38	CD	O
(	(	O
94.7	CD	O
%	NN	O
)	)	O
recipients	NNS	O
were	VBD	O
CMV-seropositive	JJ	PH
.	.	PH

Over	IN	O
the	DT	O
6-month	JJ	O
post-RTx	JJ	O
period	NN	O
,	,	O
there	EX	O
were	VBD	O
13	CD	O
episodes	NNS	O
of	IN	O
CMV	NNP	PH
disease	NN	O
in	IN	O
eight	CD	O
(	(	O
66.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
C	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
and	CC	O
VAL	NNP	O
groups	NNS	O
(	(	O
P=0.0005	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	PH
of	IN	PH
CMV	NNP	PH
viremia	NN	PH
was	VBD	O
30.8	CD	O
%	NN	O
,	,	O
50.0	CD	O
%	NN	O
,	,	O
and	CC	O
91.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.004	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.07	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

Treatment	JJ	Ot
failure	NN	Ot
(	(	O
death	NN	MO
,	,	O
graft	NN	A
loss	NN	A
,	,	O
CMV	NNP	PH
disease	NN	PH
,	,	O
or	CC	O
withdrawal	NN	Ot
from	IN	Ot
study	NN	Ot
)	)	O
occurred	VBD	O
in	IN	O
14.3	CD	O
%	NN	O
,	,	O
0	CD	O
%	NN	O
and	CC	O
66.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.014	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

The	DT	O
average	JJ	Ot
CMV-associated	JJ	Ot
costs	NNS	Ot
per	IN	Ot
patient	NN	Ot
(	(	O
in	IN	O
2001	CD	O
euros	NN	O
)	)	O
were	VBD	O
2,449+/-1,178	JJ	O
,	,	O
2,485+/-581	JJ	O
,	,	O
and	CC	O
4,259+/-4,616	JJ	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Ganciclovir	NNP	O
and	CC	O
valacyclovir	NN	O
were	VBD	O
well	RB	Ot
tolerated	VBN	Ot
,	,	O
with	IN	O
ganciclovir	JJ	O
having	VBG	O
had	VBD	O
to	TO	O
be	VB	O
withdrawn	VBN	O
shortly	RB	O
in	IN	O
one	CD	O
patient	NN	O
only	RB	O
because	IN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
are	VBP	O
equally	RB	Ot
safe	JJ	Ot
and	CC	Ot
effective	JJ	Ot
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
RTx	NNP	O
.	.	O

Both	DT	O
are	VBP	O
cost-effective	JJ	Ot
and	CC	O
help	VB	O
reduce	VB	O
CMV-associated	JJ	Ot
costs	NNS	Ot
by	IN	O
some	DT	O
40	CD	O
%	NN	O
compared	VBN	O
with	IN	O
patients	NNS	O
without	IN	O
prophylaxis	NN	O
.	.	O

Report	NN	O
on	IN	O
the	DT	O
second	JJ	O
myelomatosis	NN	O
trial	NN	O
after	IN	O
five	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Medical	NNP	O
Research	NNP	O
Council	NNP	O
's	POS	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	O
in	IN	O
Adults	NNP	O
.	.	O

Three	CD	O
hundred	VBD	O
and	CC	O
seventy-two	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
between	IN	O
3	CD	O
regimens	NNS	O
of	IN	O
chemotherapy	NN	O
:	:	O
cyclophosphamide	NN	O
,	,	O
intermittent	NN	O
melphalan	NN	O
,	,	O
and	CC	O
melphalan	NN	O
with	IN	O
prednisone	NN	O
,	,	O
and	CC	O
were	VBD	O
followed	VBN	O
up	RP	O
to	TO	O
death	NN	O
or	CC	O
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
years	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	MO
between	IN	O
the	DT	O
treatments	NNS	O
,	,	O
either	RB	O
overall	JJ	O
or	CC	O
in	IN	O
any	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
choice	NN	O
among	IN	O
these	DT	O
3	CD	O
treatments	NNS	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
comfort	NN	O
and	CC	O
convenience	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
prognostic	JJ	O
feature	NN	O
at	IN	O
presentation	NN	O
was	VBD	O
the	DT	O
quality	NN	O
of	IN	O
renal	JJ	PH
function	NN	PH
.	.	O

It	PRP	O
was	VBD	O
possible	JJ	O
to	TO	O
define	VB	O
good	JJ	O
,	,	O
intermediate	JJ	O
and	CC	O
poor	JJ	O
renal-function	NN	O
groups	NNS	O
which	WDT	O
were	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
(	(	O
X2	NNP	O
for	IN	O
trend	NN	O
=	NNP	O
62.6	CD	O
)	)	O
.	.	O

The	DT	O
haemoglobin	JJ	PH
level	NN	PH
at	IN	O
presentation	NN	O
was	VBD	O
strongly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
good	JJ	O
renal-function	NN	O
group	NN	O
.	.	O

Among	IN	O
107	CD	O
patients	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
good	JJ	O
renal	JJ	O
function	NN	O
and	CC	O
with	IN	O
haemoglobin	NNS	O
above	IN	O
100	CD	O
g/l	NN	O
,	,	O
the	DT	O
5-year	JJ	O
survival	NN	MO
was	VBD	O
43	CD	O
%	NN	O
.	.	O

Other	JJ	O
prognostic	JJ	O
features	NNS	O
were	VBD	O
much	RB	O
less	RBR	O
important	JJ	O
when	WRB	O
account	NN	O
was	VBD	O
taken	VBN	O
of	IN	O
renal	JJ	O
function	NN	O
and	CC	O
haemoglobin	JJ	O
level	NN	O
.	.	O

A	DT	O
controlled	VBN	O
comparison	NN	O
between	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
intravenous	JJ	O
and	CC	O
intramuscular	JJ	O
morphine	NN	O
with	IN	O
respect	NN	O
to	TO	O
analgesic	JJ	Ot
effects	NNS	Ot
and	CC	Ot
patient	JJ	Ot
safety	NN	Ot
.	.	Ot

UNLABELLED	VBN	O
BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
OF	NNP	O
INVESTIGATION	NNP	O
:	:	O
Intramuscular	NNP	O
(	(	O
IM	NNP	O
)	)	O
administration	NN	O
has	VBZ	O
been	VBN	O
considered	VBN	O
to	TO	O
be	VB	O
safer	JJR	O
than	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
for	IN	O
opioids	NNS	O
on	IN	O
wards	NNS	O
,	,	O
but	CC	O
a	DT	O
comparative	JJ	O
knowledge	NN	O
of	IN	O
patient	JJ	Ot
safety	NN	Ot
and	CC	Ot
analgesic	JJ	Ot
potency	NN	Ot
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
IV	NNP	O
and	CC	O
IM	NNP	O
administration	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
compare	VB	O
patient	JJ	Ot
safety	NN	Ot
and	CC	Ot
analgesic	JJ	Ot
efficacy	NN	Ot
of	IN	O
a	DT	O
single	JJ	O
and	CC	O
high	JJ	O
dose	NN	O
of	IN	O
morphine	NN	O
given	VBN	O
IM	NNP	O
or	CC	O
IV	NNP	O
for	IN	O
post-operative	JJ	O
pain	NN	O
management	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty-eight	NNP	O
patients	NNS	O
with	IN	O
post-operative	JJ	O
pain	NN	O
following	VBG	O
hip	NN	O
replacement	NN	O
surgery	NN	O
were	VBD	O
given	VBN	O
IM	NNP	O
or	CC	O
IV	NNP	O
morphine	VBP	O
10	CD	O
mg	NN	O
at	IN	O
a	DT	O
specified	JJ	O
pain	NN	O
level	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
randomized	VBN	O
and	CC	O
double	JJ	O
blinded	VBN	O
.	.	O

Time	NN	PH
to	TO	PH
onset	VB	PH
of	IN	PH
analgesic	JJ	PH
effect	NN	PH
(	(	PH
11-point	JJ	PH
numeric	NN	PH
rating	NN	PH
scale	NN	PH
)	)	PH
,	,	PH
respiratory	JJ	PH
function	NN	PH
(	(	PH
p	NN	PH
(	(	PH
a	DT	PH
)	)	PH
CO2	NNP	PH
,	,	PH
p	NN	PH
(	(	PH
a	DT	PH
)	)	PH
O2	NNP	PH
,	,	PH
and	CC	PH
respiratory	JJ	PH
rate	NN	PH
)	)	PH
,	,	PH
level	NN	PH
of	IN	PH
sedation	NN	PH
(	(	PH
5-point	JJ	PH
verbal	NN	PH
rating	NN	PH
scale	NN	PH
)	)	PH
,	,	PH
and	CC	PH
hemodynamic	JJ	PH
function	NN	PH
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
IV	NNP	O
group	NN	O
there	EX	O
was	VBD	O
a	DT	O
slight	JJ	O
but	CC	O
significant	JJ	O
increase	NN	O
in	IN	O
p	NN	O
(	(	O
a	DT	O
)	)	O
CO2	NNP	O
after	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
15	CD	O
min	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
IM	NNP	O
group	NN	O
(	(	O
5.2	CD	O
vs.	FW	O
4.8	CD	O
,	,	O
5.4	CD	O
,	,	O
vs.	FW	O
5.0	CD	O
and	CC	O
5.5	CD	O
vs.	FW	O
5.1	CD	O
kPa	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
IV	NNP	O
group	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
faster	RBR	O
onset	NN	PH
of	IN	PH
analgesic	JJ	PH
effect	NN	PH
than	IN	O
the	DT	O
IM	NNP	O
group	NN	O
(	(	O
5	CD	O
vs.	FW	O
20	CD	O
min	NN	O
)	)	O
.	.	O

Between	$	O
5	CD	O
and	CC	O
25	CD	O
min	NN	O
after	IN	O
morphine	JJ	O
administration	NN	O
,	,	O
pain	NN	PA
status	NN	PA
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
compared	VBN	O
with	IN	O
the	DT	O
IM	NNP	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
were	VBD	O
slightly	RB	O
more	RBR	O
sedated	JJ	PH
than	IN	O
the	DT	O
IM	NNP	O
group	NN	O
5	CD	O
and	CC	O
10	CD	O
min	NN	O
after	IN	O
morphine	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
10	CD	O
mg	NN	O
bolus	NN	O
dose	NN	O
of	IN	O
IV	NNP	O
morphine	NN	O
given	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
moderate	JJ	O
pain	NN	O
after	IN	O
surgery	NN	O
does	VBZ	O
not	RB	O
cause	VB	O
severe	JJ	PH
respiratory	NN	PH
depression	NN	PH
,	,	O
but	CC	O
provides	VBZ	O
more	RBR	O
rapid	JJ	O
and	CC	O
better	RBR	O
initial	JJ	PH
analgesia	NN	PH
than	IN	O
10	CD	O
mg	NNS	O
given	VBN	O
IM	NNP	O
.	.	O

IV	NNP	O
morphine	VBD	O
even	RB	O
at	IN	O
a	DT	O
dose	NN	O
as	RB	O
high	JJ	O
as	IN	O
10	CD	O
mg	NN	O
IV	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	Ot
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
certain	JJ	O
level	NN	O
of	IN	O
pain	NN	O
at	IN	O
its	PRP$	O
administration	NN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
IV	NNP	O
morphine	NN	O
on	IN	O
the	DT	O
general	JJ	O
ward	NN	O
needs	VBZ	O
to	TO	O
be	VB	O
further	RB	O
explored	VBN	O
in	IN	O
adequately	RB	O
controlled	JJ	O
studies	NNS	O
.	.	O

Postoperative	JJ	PA
pain	NN	PA
control	NN	PA
for	IN	O
outpatient	JJ	O
oral	JJ	O
surgery	NN	O
.	.	O

16	CD	O
healthy	JJ	O
patients	NNS	O
requiring	VBG	O
removal	NN	O
of	IN	O
bilateral	JJ	O
symmetrically-impacted	JJ	O
mandibular	JJ	O
third	JJ	O
molars	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
double-blind	NN	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	PA
of	IN	PA
postoperative	JJ	PA
pain	NN	PA
control	NN	PA
using	VBG	O
a	DT	O
long-acting	JJ	O
anti-inflammatory	JJ	O
agent	NN	O
(	(	O
diflunisal	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
long-acting	JJ	O
local	JJ	O
anaesthetic	JJ	O
agent	NN	O
(	(	O
bupivacaine	NN	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
more	RBR	O
traditional	JJ	O
method	NN	O
of	IN	O
using	VBG	O
an	DT	O
oral	JJ	O
analgesic	NN	O
with	IN	O
shorter	JJR	O
duration	NN	O
of	IN	O
action	NN	O
(	(	O
paracetamol	NN	O
with	IN	O
codeine	NN	O
)	)	O
with	IN	O
lignocaine	NN	O
as	IN	O
the	DT	O
local	JJ	O
anaesthetic	NN	O
.	.	O

Using	VBG	O
a	DT	O
visual	JJ	PA
analogue	NN	PA
pain	NN	PA
scale	NN	PA
,	,	O
patients	NNS	O
reported	VBD	O
that	IN	O
significantly	RB	O
reduced	VBN	O
pain	NN	PA
was	VBD	O
experienced	VBN	O
over	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
postoperatively	RB	O
with	IN	O
the	DT	O
diflunisal/bupivacaine	NN	O
treatment	NN	O
and	CC	O
patient	JJ	PA
preference	NN	PA
for	IN	O
this	DT	O
treatment	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
.	.	O

This	DT	O
report	NN	O
represents	VBZ	O
the	DT	O
first	JJ	O
such	JJ	O
study	NN	O
of	IN	O
diflunisal	NN	O
used	VBN	O
for	IN	O
an	DT	O
extended	JJ	O
course	NN	O
in	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
pain	NN	PA
assessment	NN	O
over	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
side-effects	NNS	A
or	CC	A
adverse	JJ	A
reactions	NNS	A
were	VBD	O
encountered	VBN	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
calcium	NN	O
carbasalate	NN	O
plus	CC	O
metoclopramide	JJ	O
versus	NN	O
ergotamine	NN	O
tartrate	NN	O
plus	CC	O
caffeine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
migraine	NN	O
attacks	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
,	,	O
multicenter	NN	O
,	,	O
parallel-group	JJ	O
study	NN	O
aimed	VBN	O
at	IN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
calcium	NN	O
carbasalate	NN	O
(	(	O
equivalent	JJ	O
to	TO	O
900	CD	O
mg	NNS	O
aspirin	RB	O
)	)	O
plus	CC	O
metoclopramide	$	O
10	CD	O
mg	NN	O
(	(	O
CM	NNP	O
)	)	O
with	IN	O
ergotamine	JJ	O
tartrate	NN	O
1	CD	O
mg	NN	O
plus	CC	O
caffeine	JJ	O
100	CD	O
mg	NN	O
(	(	O
EC	NNP	O
)	)	O
administered	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
2	CD	O
acute	JJ	O
migraine	NN	O
attacks	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
296	CD	O
patients	NNS	O
fulfilling	VBG	O
the	DT	O
International	NNP	O
Headache	NNP	O
Society	NNP	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
migraine	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
one	CD	O
or	CC	O
two	CD	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
268	CD	O
and	CC	O
235	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
for	IN	O
the	DT	O
first	JJ	O
treated	VBD	O
attack	NN	O
was	VBD	O
headache	NN	O
relief	NN	O
,	,	O
with	IN	O
intensity	NN	O
decreasing	VBG	O
from	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
to	TO	O
mild	VB	O
or	CC	O
absent	VB	O
2	CD	O
h	NN	O
after	IN	O
drug	NN	O
intake	NN	O
.	.	O

Usual	JJ	O
secondary	JJ	O
efficacy	NN	O
endpoints	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

A	DT	O
superiority	NN	O
of	IN	O
CM	NNP	O
over	IN	O
EC	NNP	O
was	VBD	O
observed	VBN	O
for	IN	O
both	DT	O
treated	JJ	O
attacks	NNS	O
for	IN	O
the	DT	O
main	JJ	O
endpoint	NN	O
:	:	O
success	NN	O
in	IN	O
54	CD	O
versus	NN	O
36	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0.003	CD	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
and	CC	O
60	CD	O
versus	NN	O
44	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0.02	CD	O
for	IN	O
the	DT	O
second	JJ	O
attack	NN	O
.	.	O

CM	NNP	O
was	VBD	O
also	RB	O
significantly	RB	O
superior	JJ	O
to	TO	O
EC	NNP	O
during	IN	O
the	DT	O
first	JJ	O
attack	NN	O
for	IN	O
complete	JJ	PH
headache	NN	PH
relief	NN	PH
(	(	O
20	CD	O
vs.	FW	O
8	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
nausea	NN	A
(	(	O
42	CD	O
vs.	FW	O
63	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0	CD	O
.	.	O

007	CD	O
)	)	O
and	CC	O
willingness	NN	ME
to	TO	ME
take	VB	ME
the	DT	ME
drug	NN	ME
again	RB	ME
(	(	O
90	CD	O
vs.	FW	O
80	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

The	DT	O
global	JJ	Ot
efficacy	NN	Ot
evaluation	NN	Ot
,	,	Ot
rated	VBN	Ot
by	IN	Ot
the	DT	Ot
investigators	NNS	Ot
,	,	O
was	VBD	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
to	TO	O
CM	NNP	O
for	IN	O
both	DT	O
attacks	NNS	O
(	(	O
p	VB	O
=	$	O
0.001	CD	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
and	CC	O
p	NN	O
=	VBP	O
0.02	CD	O
for	IN	O
the	DT	O
second	JJ	O
)	)	O
.	.	O

The	DT	Ot
patients	NNS	Ot
'	POS	Ot
evaluation	NN	Ot
was	VBD	Ot
significant	JJ	Ot
for	IN	Ot
the	DT	Ot
first	JJ	Ot
attack	NN	Ot
(	(	Ot
p	JJ	Ot
=	NNP	Ot
0.002	CD	Ot
)	)	Ot
.	.	O

The	DT	O
global	JJ	A
incidence	NN	A
of	IN	A
adverse	JJ	A
events	NNS	A
was	VBD	O
45	CD	O
%	NN	O
higher	JJR	O
with	IN	O
EC	NNP	O
,	,	O
though	IN	O
not	RB	O
significant	JJ	O
(	(	O
32	CD	O
vs.	FW	O
22	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.075	CD	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
most	RBS	O
often	RB	O
unspecific	JJ	O
and	CC	O
mild	JJ	O
to	TO	O
moderate	VB	O
in	IN	O
intensity	NN	O
.	.	O

Gastrointestinal	JJ	A
side	NN	A
effects	NNS	A
were	VBD	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
with	IN	O
CM	NNP	O
than	IN	O
EC	NNP	O
(	(	O
7	CD	O
vs.	FW	O
21	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

Thus	RB	Ot
,	,	Ot
CM	NNP	Ot
is	VBZ	Ot
more	RBR	Ot
effective	JJ	Ot
and	CC	Ot
has	VBZ	Ot
a	DT	Ot
better	JJR	Ot
gastrointestinal	JJ	Ot
safety	NN	Ot
than	IN	Ot
EC	NNP	Ot
in	IN	Ot
the	DT	Ot
acute	JJ	Ot
treatment	NN	Ot
of	IN	Ot
migraine	NN	Ot
attacks	NNS	Ot
.	.	O

Ropivacaine-clonidine	JJ	O
combination	NN	O
for	IN	O
caudal	NN	O
blockade	NN	O
in	IN	O
children	NNS	O
.	.	O

BACKGROUND	NNP	O
Adding	NNP	O
clonidine	NN	O
to	TO	O
weak	JJ	O
ropivacaine	JJ	O
solutions	NNS	O
(	(	O
<	VB	O
0.2	CD	O
%	NN	O
)	)	O
could	MD	O
potentially	RB	O
enhance	VB	Ot
analgesia	NN	Ot
as	RB	O
well	RB	O
as	IN	O
further	JJ	O
reduce	VB	PH
the	DT	PH
risk	NN	PH
for	IN	PH
unwanted	JJ	PH
motor	NN	PH
blockade	NN	PH
.	.	PH

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
postoperative	JJ	O
pain-relieving	JJ	PA
quality	NN	PA
of	IN	O
a	DT	O
ropivacaine	JJ	O
0.1	CD	O
%	NN	O
-clonidine	JJ	O
mixture	NN	O
to	TO	O
that	DT	O
of	IN	O
plain	NN	O
ropivacaine	VBP	O
0.2	CD	O
%	NN	O
following	VBG	O
caudal	JJ	O
administration	NN	O
in	IN	O
children	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
observer-blinded	JJ	O
fashion	NN	O
,	,	O
40	CD	O
ASA	NNP	O
1	CD	O
paediatric	JJ	O
patients	NNS	O
undergoing	VBG	O
subumbilical	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
a	DT	O
caudal	JJ	O
injection	NN	O
of	IN	O
either	DT	O
plain	NN	O
ropivacaine	VBP	O
0.2	CD	O
%	NN	O
(	(	O
1	CD	O
ml/kg	NN	O
)	)	O
(	(	O
R0.2	NNP	O
)	)	O
or	CC	O
a	DT	O
mixture	NN	O
of	IN	O
ropivacaine	JJ	O
0.1	CD	O
%	NN	O
with	IN	O
clonidine	JJ	O
2	CD	O
microg/kg	NN	O
(	(	O
1	CD	O
ml/kg	NN	O
)	)	O
(	(	O
R0.1C	NNP	O
)	)	O
.	.	O

Objective	JJ	PA
pain	NN	PA
scale	NN	PA
score	NN	PA
and	CC	PA
need	NN	PA
for	IN	PA
supplemental	JJ	PA
analgesia	NN	PA
were	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
analgesia	NN	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

Residual	JJ	PH
postoperative	JJ	PH
sedation	NN	PH
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
A	DT	O
significantly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
R0.1C	NNP	O
group	NN	O
(	(	O
18/20	CD	O
)	)	O
could	MD	O
be	VB	O
managed	VBN	O
without	IN	O
supplemental	JJ	PH
analgesia	NN	PH
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
h	NN	O
postoperatively	RB	O
compared	VBN	O
to	TO	O
the	DT	O
R0.2	NNP	O
group	NN	O
(	(	O
11/20	CD	O
)	)	O
(	(	O
P=0.034	NNP	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
degree	NN	PH
and	CC	PH
the	DT	PH
duration	NN	PH
of	IN	PH
postoperative	JJ	PH
sedation	NN	PH
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
signs	NNS	O
of	IN	O
postoperative	JJ	PH
motor	NN	PH
blockade	NN	PH
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
combination	NN	O
of	IN	O
clonidine	NN	O
(	(	O
2	CD	O
microg/kg	NN	O
)	)	O
and	CC	O
ropivacaine	VB	O
0.1	CD	O
%	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
improved	JJ	Ot
quality	NN	Ot
of	IN	Ot
postoperative	JJ	Ot
analgesia	NN	Ot
compared	VBN	O
to	TO	O
plain	VB	O
0.2	CD	O
%	NN	O
ropivacaine	NN	O
.	.	O

The	DT	O
improved	JJ	Ot
analgesic	JJ	Ot
quality	NN	Ot
of	IN	O
the	DT	O
clonidine-ropivacaine	JJ	O
mixture	NN	O
is	VBZ	O
achieved	VBN	O
without	IN	O
causing	VBG	O
any	DT	O
significant	JJ	O
degree	NN	O
of	IN	O
postoperative	JJ	O
sedation	NN	O
.	.	O

Peripheral	JJ	O
arterial	JJ	O
disease	NN	O
:	:	O
therapeutic	JJ	O
confidence	NN	O
of	IN	O
CT	NNP	O
versus	NNP	O
digital	JJ	O
subtraction	NN	O
angiography	NN	O
and	CC	O
effects	NNS	O
on	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
multi-detector	JJ	O
row	NN	O
computed	VBN	O
tomographic	JJ	O
(	(	O
CT	NNP	O
)	)	O
angiography	NN	O
and	CC	O
digital	JJ	O
subtraction	NN	O
angiography	NN	O
(	(	O
DSA	NNP	O
)	)	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
assessing	VBG	O
recommendations	NNS	O
for	IN	O
additional	JJ	O
imaging	NN	O
and	CC	O
physician	JJ	O
confidence	NN	O
ratings	NNS	O
for	IN	O
chosen	NN	O
therapy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
73	CD	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
CT	NNP	O
angiography	NN	O
,	,	O
and	CC	O
72	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
DSA	NNP	O
.	.	O

Physician	JJ	ME
confidence	NN	ME
in	IN	ME
the	DT	ME
treatment	NN	ME
decision	NN	ME
was	VBD	O
measured	VBN	O
as	IN	O
a	DT	O
continuous	JJ	O
outcome	NN	O
on	IN	O
a	DT	O
scale	NN	O
of	IN	O
0-10	NNP	O
(	(	O
uncertain	JJ	O
to	TO	O
certain	JJ	O
)	)	O
and	CC	O
as	IN	O
a	DT	O
dichotomous	JJ	O
outcome	NN	O
(	(	O
further	JJ	O
imaging	NN	O
recommended	VBD	O
,	,	O
yes	UH	O
or	CC	O
no	DT	O
)	)	O
.	.	O

Mean	JJ	ME
confidence	NN	ME
scores	NNS	ME
and	CC	O
additional	JJ	Ot
imaging	NN	Ot
recommendations	NNS	Ot
were	VBD	O
compared	VBN	O
between	IN	O
CT	NNP	O
and	CC	O
DSA	NNP	O
groups	NNS	O
in	IN	O
an	DT	O
intention-to-diagnose-and-treat	JJ	O
analysis	NN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
confidence	NN	O
,	,	O
confidence	NN	O
scores	NNS	O
were	VBD	O
plotted	VBN	O
over	IN	O
time	NN	O
,	,	O
and	CC	O
multiple	JJ	O
linear	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
additional	JJ	Ot
imaging	NN	Ot
recommendations	NNS	Ot
,	,	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
.	.	O

Data	NNS	O
from	IN	O
eligible	JJ	O
nonrandomized	JJ	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
groups	NNS	O
was	VBD	O
found	VBN	O
.	.	O

CT	NNP	O
had	VBD	O
a	DT	O
lower	JJR	ME
confidence	NN	ME
score	JJR	ME
than	IN	O
did	VBD	O
DSA	NNP	O
(	(	O
7.2	CD	O
vs	NN	O
8.2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Further	JJ	O
imaging	NN	O
was	VBD	O
recommended	VBN	O
more	RBR	O
often	RB	O
after	IN	O
CT	NNP	O
(	(	O
25	CD	O
of	IN	O
71	CD	O
patients	NNS	O
,	,	O
35	CD	O
%	NN	O
)	)	O
than	IN	O
after	IN	O
DSA	NNP	O
(	(	O
nine	CD	O
of	IN	O
66	CD	O
patients	NNS	O
,	,	O
14	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Analysis	NN	O
of	IN	O
trends	NNS	O
demonstrated	VBN	O
increasing	VBG	O
(	(	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
)	)	O
confidence	NN	ME
in	IN	O
CT	NNP	O
and	CC	O
stable	JJ	O
confidence	NN	ME
in	IN	O
DSA	NNP	O
.	.	O

No	NNP	Ot
significant	JJ	Ot
difference	NN	Ot
was	VBD	O
found	VBN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
and	CC	O
nonrandomized	JJ	O
patients	NNS	O
.	.	O

Among	IN	O
nonrandomized	JJ	O
patients	NNS	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
mean	JJ	ME
confidence	NN	ME
score	NN	ME
(	(	O
8.2	CD	O
vs	NN	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
.26	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
CT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
and	CC	O
DSA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
With	IN	O
CT	NNP	O
angiography	NN	O
,	,	O
physician	JJ	O
confidence	NN	O
decreases	NNS	O
with	IN	O
an	DT	O
associated	JJ	O
increase	NN	O
in	IN	O
additional	JJ	O
imaging	NN	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

Given	VBN	O
that	IN	O
CT	NNP	O
is	VBZ	O
less	RBR	O
invasive	JJ	O
than	IN	O
DSA	NNP	O
,	,	O
results	NNS	O
suggest	VBP	O
that	IN	O
CT	NNP	O
may	MD	O
replace	VB	O
DSA	NNP	O
in	IN	O
selected	VBN	O
cases	NNS	O
.	.	O

Chronology	NN	O
of	IN	O
panic	NN	O
and	CC	O
avoidance	NN	O
,	,	O
age	NN	O
of	IN	O
onset	NN	O
in	IN	O
panic	JJ	O
disorder	NN	O
,	,	O
and	CC	O
prediction	NN	O
of	IN	O
treatment	NN	O
response	NN	O
.	.	O

A	DT	O
report	NN	O
from	IN	O
the	DT	O
Cross-National	JJ	O
Collaborative	NNP	O
Panic	NNP	O
Study	NNP	O
.	.	O

The	DT	O
relevance	NN	O
of	IN	O
the	DT	O
chronology	NN	O
between	IN	O
panic	JJ	O
disorder	NN	O
and	CC	O
avoidance	NN	O
behavior	NN	O
and	CC	O
of	IN	O
an	DT	O
early	JJ	O
,	,	O
medium	NN	O
or	CC	O
late	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
was	VBD	O
tested	VBN	O
.	.	O

Groups	NNP	O
from	IN	O
the	DT	O
sample	NN	O
of	IN	O
the	DT	O
cross-national	JJ	O
collaborative	NN	O
panic	NN	O
study	NN	O
(	(	O
CNCPS	NNP	O
)	)	O
were	VBD	O
compared	VBN	O
for	IN	O
differences	NNS	O
in	IN	O
basic	JJ	O
characteristics	NNS	O
and	CC	O
for	IN	O
the	DT	O
ability	NN	O
to	TO	O
predict	VB	O
treatment	NN	O
response	NN	O
.	.	O

Patients	NNS	O
who	WP	O
developed	VBD	O
avoidance	NN	ME
behavior	NN	ME
before	IN	O
the	DT	O
full	JJ	O
syndrome	NN	O
of	IN	O
panic	JJ	ME
disorder	NN	ME
had	VBD	O
less	RBR	O
often	RB	O
a	DT	O
full	JJ	O
agoraphobia	NN	ME
but	CC	O
were	VBD	O
not	RB	O
different	JJ	O
in	IN	O
their	PRP$	O
response	NN	O
to	TO	O
treatment	NN	O
.	.	O

Patients	NNS	O
with	IN	O
an	DT	O
early	JJ	ME
onset	NN	ME
of	IN	ME
panic	JJ	ME
disorder	NN	ME
suffered	VBD	O
more	RBR	O
often	RB	O
from	IN	O
agoraphobia	NNS	ME
.	.	O

The	DT	O
treatment	NN	Ot
response	NN	Ot
was	VBD	O
similar	JJ	Ot
in	IN	O
the	DT	O
groups	NNS	O
with	IN	O
early	JJ	ME
,	,	ME
medium	NN	ME
or	CC	ME
late	JJ	ME
onset	NN	ME
of	IN	ME
panic	JJ	ME
disorder	NN	ME
.	.	O

Neither	CC	O
the	DT	O
chronology	NN	O
between	IN	O
panic	JJ	ME
disorder	NN	ME
and	CC	ME
avoidance	NN	ME
behavior	NN	ME
nor	CC	O
the	DT	O
age	NN	ME
of	IN	ME
onset	NN	ME
of	IN	ME
panic	JJ	ME
disorder	NN	ME
predicted	VBD	O
outcome	NN	O
in	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
alprazolam	NN	O
or	CC	O
imipramine	NN	O
.	.	O

Adult	NNP	O
height	NN	O
in	IN	O
short	JJ	O
children	NNS	O
born	VBN	O
SGA	NNP	O
treated	VBD	O
with	IN	O
growth	NN	O
hormone	NN	O
and	CC	O
gonadotropin	NN	O
releasing	VBG	O
hormone	NN	O
analog	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
dose-response	JJ	O
GH	NNP	O
trial	NN	O
.	.	O

CONTEXT	NNP	O
GH	NNP	O
treatment	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
improving	VBG	O
height	NN	O
in	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
(	(	O
SGA	NNP	O
)	)	O
.	.	O

GH	NNP	O
is	VBZ	O
thought	VBN	O
to	TO	O
have	VB	O
limited	VBN	O
effect	NN	O
when	WRB	O
started	VBD	O
during	IN	O
adolescence	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
GH	NNP	O
treatment	NN	O
efficacy	NN	Ot
in	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
when	WRB	O
treatment	NN	O
was	VBD	O
started	VBN	O
during	IN	O
adolescence	NN	O
;	:	O
to	TO	O
assess	VB	O
whether	IN	O
GH	NNP	O
2	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	JJ	O
improves	NNS	O
adult	VBP	O
height	NN	O
(	(	O
AH	NNP	O
)	)	O
compared	VBN	O
with	IN	O
1	CD	O
mg/m	NNS	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
;	:	O
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
an	DT	O
additional	JJ	O
2-yr	JJ	O
postponement	NN	O
of	IN	O
puberty	NN	O
by	IN	O
GnRH	NNP	O
analog	NN	O
(	(	O
GnRHa	NNP	O
)	)	O
improves	VBZ	O
AH	NNP	O
in	IN	O
children	NNS	O
who	WP	O
are	VBP	O
short	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
puberty	NN	O
(	(	O
<	JJ	O
140	CD	O
cm	NN	O
)	)	O
,	,	O
with	IN	O
a	DT	O
poor	JJ	O
AH	NNP	O
expectation	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
DESIGN	NNP	O
In	IN	O
this	DT	O
longitudinal	JJ	O
,	,	O
randomized	VBN	O
,	,	O
dose-response	JJ	O
GH	NNP	O
trial	NN	O
,	,	O
we	PRP	O
included	VBD	O
121	CD	O
short	JJ	O
SGA	NNP	O
children	NNS	O
(	(	O
60	CD	O
boys	NNS	O
)	)	O
at	IN	O
least	JJS	O
8	CD	O
yr	NN	O
of	IN	O
age	NN	O
.	.	O

We	PRP	O
performed	VBD	O
intention-to-treat	JJ	O
analyses	NNS	O
on	IN	O
all	DT	O
children	NNS	O
and	CC	O
uncensored	JJ	O
case	NN	O
analyses	VBZ	O
on	IN	O
84	CD	O
children	NNS	O
who	WP	O
reached	VBD	O
AH	NNP	O
.	.	O

Besides	NNP	O
,	,	O
we	PRP	O
evaluated	VBD	O
growth	NN	O
during	IN	O
2	CD	O
yr	NNS	O
of	IN	O
combined	JJ	O
GH/GnRHa	NNP	O
and	CC	O
subsequent	JJ	O
GH	NNP	O
treatment	NN	O
until	IN	O
AH	NNP	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
40	CD	O
pubertal	JJ	O
children	NNS	O
with	IN	O
a	DT	O
height	NN	O
of	IN	O
less	JJR	O
than	IN	O
140	CD	O
cm	NN	O
at	IN	O
the	DT	O
start	NN	O
.	.	O

RESULTS	NNP	O
Short	NNP	O
SGA	NNP	O
children	NNS	O
started	VBD	O
treatment	NN	O
at	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
11.2	CD	O
yr	NNS	O
,	,	O
when	WRB	O
46	CD	O
%	NN	O
had	VBD	O
already	RB	O
started	VBN	O
puberty	NN	O
.	.	O

Median	JJ	O
height	NN	O
increased	VBD	O
from	IN	O
-2.9	NN	O
at	IN	O
start	NN	O
to	TO	O
-1.7	VB	O
sd	NN	O
score	NN	O
(	(	O
SDS	NNP	O
)	)	O
at	IN	O
AH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
GH	NNP	O
2	CD	O
vs.	FW	O
1	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	NN	O
resulted	VBD	O
in	IN	O
significantly	RB	O
better	JJR	O
AH	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
also	RB	O
after	IN	O
correction	NN	O
for	IN	O
gender	NN	O
,	,	O
age	NN	O
at	IN	O
start	NN	O
,	,	O
height	VBD	O
SDS	NNP	O
at	IN	O
start	NN	O
,	,	O
treatment	NN	O
years	NNS	O
before	IN	O
puberty	NN	O
,	,	O
and	CC	O
target	VB	O
height	JJ	O
SDS	NNP	O
.	.	O

AH	NNP	O
was	VBD	O
similar	JJ	O
in	IN	O
children	NNS	O
who	WP	O
started	VBD	O
puberty	NN	O
at	IN	O
less	JJR	O
than	IN	O
140	CD	O
cm	NN	O
and	CC	O
received	VBD	O
GH/GnRHa	NNP	O
,	,	O
compared	VBN	O
with	IN	O
children	NNS	O
who	WP	O
started	VBD	O
puberty	NN	O
greater	JJR	O
than	IN	O
140	CD	O
cm	NN	O
and	CC	O
received	VBD	O
GH	NNP	O
only	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.795	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
started	VBN	O
in	IN	O
adolescence	NN	O
,	,	O
GH	NNP	O
treatment	NN	O
significantly	RB	O
improves	VBZ	O
AH	NNP	O
in	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
,	,	O
particularly	RB	O
with	IN	O
GH	NNP	O
2	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	NN	O
.	.	O

When	WRB	O
SGA	NNP	O
children	NNS	O
are	VBP	O
short	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
puberty	NN	O
,	,	O
they	PRP	O
can	MD	O
benefit	VB	O
from	IN	O
combined	JJ	O
GH/GnRHa	NNP	O
treatment	NN	O
.	.	O

The	DT	O
11-beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
1	CD	O
inhibitor	NN	O
INCB13739	NNP	O
improves	VBZ	O
hyperglycemia	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

OBJECTIVE	CC	O
11-Beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
1	CD	O
(	(	O
11betaHSD1	CD	O
)	)	O
converts	NNS	O
inactive	JJ	O
cortisone	NN	O
into	IN	O
active	JJ	O
cortisol	NN	O
,	,	O
thereby	RB	O
amplifying	VBG	O
intracellular	JJ	O
glucocorticoid	JJ	O
action	NN	O
.	.	O

The	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
the	DT	O
11betaHSD1	CD	O
inhibitor	NN	O
INCB13739	NNP	O
were	VBD	O
assessed	VBN	O
when	WRB	O
added	VBN	O
to	TO	O
ongoing	VBG	O
metformin	NN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
exhibiting	VBG	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
(	(	O
A1C	NNP	O
7-11	CD	O
%	NN	O
)	)	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
This	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
paralleled	VBN	O
study	NN	O
randomized	VBD	O
302	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
(	(	O
mean	JJ	O
A1C	NNP	O
8.3	CD	O
%	NN	O
)	)	O
on	IN	O
metformin	NN	O
monotherapy	NN	O
(	(	O
mean	JJ	O
1.5	CD	O
g/day	NN	O
)	)	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
five	CD	O
INCB13739	NNP	O
doses	NNS	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
change	NN	PH
in	IN	PH
A1C	NNP	PH
at	IN	PH
study	JJ	PH
end	NN	PH
.	.	O

Other	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
changes	NNS	PH
in	IN	PH
fasting	VBG	PH
glucose	NN	PH
,	,	O
lipids	NNS	PH
,	,	O
weight	NN	PH
,	,	O
adverse	JJ	A
events	NNS	A
,	,	O
and	CC	O
safety	NN	Ot
.	.	O

RESULTS	NNP	O
After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
200	CD	O
mg	NN	O
of	IN	O
INCB13739	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
A1C	NNP	O
(	(	O
-0.6	NNP	O
%	NN	O
)	)	O
,	,	O
fasting	VBG	PH
plasma	NN	PH
glucose	NN	PH
(	(	O
-24	NNP	O
mg/dl	NN	O
)	)	O
,	,	O
and	CC	O
homeostasis	NN	PH
model	NN	PH
assessment-insulin	JJ	PH
resistance	NN	PH
(	(	O
HOMA-IR	NNP	O
)	)	O
(	(	O
-24	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Total	JJ	PH
cholesterol	NN	PH
,	,	O
LDL	NNP	PH
cholesterol	NN	PH
,	,	O
and	CC	O
triglycerides	NNS	PH
were	VBD	O
all	DT	O
significantly	RB	O
decreased	VBN	O
in	IN	O
hyperlipidemic	JJ	O
patients	NNS	O
.	.	O

Body	NNP	PH
weight	VBD	PH
decreased	JJ	O
relative	NN	O
to	TO	O
placebo	VB	O
after	IN	O
INCB13739	NNP	O
therapy	NN	O
.	.	O

A	DT	O
reversible	JJ	O
dose-dependent	JJ	O
elevation	NN	O
in	IN	O
adrenocorticotrophic	JJ	PH
hormone	NN	PH
,	,	O
generally	RB	O
within	IN	O
the	DT	O
normal	JJ	O
reference	NN	O
range	NN	O
,	,	O
was	VBD	O
observed	VBN	O
.	.	O

Basal	NNP	PH
cortisol	JJ	PH
homeostasis	NN	PH
,	,	O
testosterone	NN	PH
in	IN	PH
men	NNS	PH
,	,	O
and	CC	O
free	JJ	PH
androgen	NN	PH
index	NN	PH
in	IN	PH
women	NNS	PH
were	VBD	O
unchanged	JJ	O
by	IN	O
INCB13739	NNP	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
similar	JJ	O
across	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
INCB13739	NNP	O
added	VBD	O
to	TO	O
ongoing	VBG	O
metformin	NN	O
therapy	NN	O
was	VBD	O
efficacious	JJ	Ot
and	CC	O
well	RB	O
tolerated	VBN	Ot
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
who	WP	O
had	VBD	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
with	IN	O
metformin	NN	O
alone	RB	O
.	.	O

11BetaHSD1	CD	O
inhibition	NN	O
offers	NNS	O
a	DT	O
new	JJ	O
potential	JJ	O
approach	NN	O
to	TO	O
control	VB	O
glucose	JJ	PH
and	CC	PH
cardiovascular	JJ	PH
risk	NN	PH
factors	NNS	PH
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

Long-term	JJ	O
follow-up	NN	O
of	IN	O
a	DT	O
phase	NN	O
I/II	NNP	O
randomized	VBD	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
palifermin	NN	O
to	TO	O
prevent	VB	O
graft-versus-host	JJ	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
after	IN	O
related	VBN	O
donor	NN	O
allogeneic	NN	O
hematopoietic	JJ	O
cell	NN	O
transplantation	NN	O
(	(	O
HCT	NNP	O
)	)	O
.	.	O

We	PRP	O
previously	RB	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
conducted	VBN	O
from	IN	O
2000	CD	O
to	TO	O
2003	CD	O
of	IN	O
palifermin	NN	O
,	,	O
a	DT	O
recombinant	JJ	O
human	JJ	O
keratinocyte	NN	O
growth	NN	O
factor	NN	O
,	,	O
dosed	VBN	O
from	IN	O
240	CD	O
microg/kg	NNS	O
to	TO	O
720	CD	O
microg/kg	NN	O
,	,	O
in	IN	O
100	CD	O
allogeneic	JJ	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
HCT	NNP	O
)	)	O
recipients	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
palifermin	NN	O
showed	VBD	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
mucositis	NN	PH
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
engraftment	NN	PH
,	,	PH
acute	JJ	PH
graft-versus-host	JJ	PH
disease	NN	PH
(	(	PH
GVHD	NNP	PH
)	)	PH
,	,	O
or	CC	O
early	JJ	MO
survival	NN	MO
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
effect	NN	O
of	IN	O
palifermin	NN	O
on	IN	O
mucosa	NN	PH
,	,	PH
other	JJ	PH
pleotrophic	JJ	PH
effects	NNS	PH
,	,	PH
including	VBG	PH
more	RBR	PH
rapid	JJ	PH
immune	JJ	PH
reconstitution	NN	PH
,	,	O
have	VBP	O
been	VBN	O
seen	VBN	O
in	IN	O
experimental	JJ	O
transplant	NN	O
models	NNS	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
with	IN	O
longer	JJR	O
follow-up	NN	O
we	PRP	O
could	MD	O
detect	VB	O
additional	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
palifermin-treated	JJ	O
and	CC	O
placebo	JJ	O
cohorts	NNS	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
CMV	NNP	PH
or	CC	PH
invasive	JJ	PH
fungal	JJ	PH
infections	NNS	PH
,	,	O
chronic	JJ	PH
GVHD	NNP	PH
,	,	O
or	CC	O
long-term	JJ	MO
survival	NN	MO
between	IN	O
cohorts	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
palifermin	NN	O
appear	VBP	O
primarily	RB	O
to	TO	O
be	VB	O
limited	VBN	O
to	TO	O
ameliorating	VBG	O
mucotoxicity	NN	PH
when	WRB	O
given	VBN	O
to	TO	O
allogeneic	VB	O
HCT	NNP	O
recipients	NNS	O
.	.	O

Early	RB	O
versus	NN	O
late	JJ	O
hCG	NN	O
administration	NN	O
to	TO	O
trigger	VB	O
ovulation	NN	O
in	IN	O
mild	NN	O
stimulated	VBN	O
IUI	NNP	O
cycles	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
verify	VB	O
non-inferiority	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
of	IN	O
Early	NNP	O
hCG	NN	O
administration	NN	O
(	(	O
leading	VBG	O
follicle	NN	O
sizes	NNS	O
within	IN	O
16.0-16.9	JJ	O
mm	NN	O
in	IN	O
diameter	NN	O
)	)	O
compared	VBN	O
to	TO	O
Late	NNP	O
hCG	NN	O
administration	NN	O
(	(	O
leading	VBG	O
follicle	NN	O
sizes	NNS	O
within	IN	O
18.0-18.9	JJ	O
mm	NN	O
in	IN	O
diameter	NN	O
)	)	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
trial	NN	O
.	.	O

Six	CD	O
hundred	CD	O
and	CC	O
twelve	VB	O
infertile	JJ	O
women	NNS	O
candidates	NNS	O
for	IN	O
intrauterine	JJ	O
insemination	NN	O
(	(	O
IUI	NNP	O
)	)	O
received	VBD	O
HP-hMG	JJ	O
75	CD	O
IU/day	NNP	O
SC	NNP	O
from	IN	O
cycle	NN	O
days	NNS	O
4	CD	O
to	TO	O
8	CD	O
and	CC	O
then	RB	O
as	IN	O
per	IN	O
ovarian	JJ	O
response	NN	O
.	.	O

Ovulation	NN	O
was	VBD	O
randomly	RB	O
triggered	VBN	O
(	(	O
hCG	JJ	O
5000	CD	O
IU	NNP	O
,	,	O
IM	NNP	O
)	)	O
when	WRB	O
the	DT	O
leading	VBG	O
follicle	NN	O
diameter	NN	O
ranged	VBD	O
between	IN	O
either	CC	O
16.0	CD	O
and	CC	O
16.9	CD	O
mm	NN	O
(	(	O
Early	JJ	O
hCG	NN	O
group	NN	O
,	,	O
n=227	RB	O
)	)	O
or	CC	O
18.0	CD	O
and	CC	O
18.9	CD	O
mm	NNS	O
(	(	O
Late	JJ	O
hCG	NN	O
group	NN	O
,	,	O
n=207	NN	O
)	)	O
and	CC	O
IUI	NNP	O
was	VBD	O
performed	VBN	O
approximately	RB	O
36	CD	O
h	NN	O
later	RB	O
.	.	O

RESULTS	NNP	O
Whereas	NNP	O
population	NN	PH
and	CC	PH
sperm	JJ	PH
characteristics	NNS	PH
were	VBD	O
comparable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
number	NN	PH
of	IN	PH
follicles	NNS	PH
?	.	O
14	CD	O
mm	NN	O
in	IN	O
diameter	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.007	CD	O
)	)	O
and	CC	O
serum	JJ	PH
estradiol	NN	PH
levels	NNS	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
hCG	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
Early	JJ	O
versus	NN	O
the	DT	O
Late	NNP	O
hCG	NN	O
groups	NNS	O
.	.	O

Clinical	NNP	O
(	(	O
11.9	CD	O
%	NN	O
versus	IN	O
12.1	CD	O
%	NN	O
)	)	O
and	CC	O
ongoing	VBG	O
(	(	O
11.0	CD	O
%	NN	O
versus	IN	O
8.6	CD	O
%	NN	O
)	)	O
pregnancy	NN	PH
rates	NNS	PH
per	IN	O
randomized	VBN	O
women	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
and	CC	O
statistical	JJ	O
non-inferiority	NN	O
of	IN	O
clinical	JJ	O
and	CC	O
ongoing	JJ	O
pregnancy	NN	O
rates	NNS	O
was	VBD	O
demonstrated	VBN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
hCG	NN	O
administered	VBD	O
when	WRB	O
the	DT	O
largest	JJS	O
follicle	NN	O
size	NN	O
reaches	VBZ	O
16.0-16.9	JJ	O
mm	NN	O
leads	VBZ	O
to	TO	O
similar	JJ	O
clinical	JJ	O
and	CC	O
ongoing	JJ	O
pregnancy	NN	O
rates	NNS	O
as	IN	O
when	WRB	O
it	PRP	O
reaches	VBZ	O
18.0-18.9	JJ	O
mm	NN	O
in	IN	O
IUI	NNP	O
cycles	NNS	O
.	.	O

Avatar	NNP	O
assistant	NN	O
:	:	O
improving	VBG	O
social	JJ	ME
skills	NNS	ME
in	IN	O
students	NNS	O
with	IN	O
an	DT	O
ASD	NNP	O
through	IN	O
a	DT	O
computer-based	JJ	O
intervention	NN	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
efficacy	NN	Ot
of	IN	O
FaceSay	NNP	O
,	,	O
a	DT	O
computer-based	JJ	O
social	JJ	ME
skills	NNS	ME
training	VBG	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	VBN	O
study	NN	O
(	(	O
N	NNP	O
=	NNP	O
49	CD	O
)	)	O
indicates	VBZ	O
that	IN	O
providing	VBG	O
children	NNS	O
with	IN	O
low-functioning	JJ	O
autism	NN	O
(	(	O
LFA	NNP	O
)	)	O
and	CC	O
high	JJ	O
functioning	NN	O
autism	NN	O
(	(	O
HFA	NNP	O
)	)	O
opportunities	VBZ	O
to	TO	O
practice	NN	O
attending	VBG	O
to	TO	O
eye	NN	O
gaze	NN	O
,	,	O
discriminating	VBG	O
facial	JJ	O
expressions	NNS	O
and	CC	O
recognizing	VBG	O
faces	VBZ	O
and	CC	O
emotions	NNS	O
in	IN	O
FaceSay	NNP	O
's	POS	O
structured	JJ	O
environment	NN	O
with	IN	O
interactive	JJ	O
,	,	O
realistic	JJ	O
avatar	NN	O
assistants	NNS	O
improved	VBD	O
their	PRP$	O
social	JJ	O
skills	NNS	O
abilities	NNS	O
.	.	O

The	DT	O
children	NNS	O
with	IN	O
LFA	NNP	O
demonstrated	VBD	O
improvements	NNS	O
in	IN	O
two	CD	O
areas	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
:	:	O
emotion	NN	O
recognition	NN	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

The	DT	O
children	NNS	O
with	IN	O
HFA	NNP	O
demonstrated	VBD	O
improvements	NNS	O
in	IN	O
all	DT	O
three	CD	O
areas	NNS	O
:	:	O
facial	JJ	O
recognition	NN	O
,	,	O
emotion	NN	O
recognition	NN	O
,	,	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

These	DT	O
findings	NNS	O
,	,	O
particularly	RB	O
the	DT	O
measured	JJ	O
improvements	NNS	O
to	TO	O
social	JJ	O
interactions	NNS	O
in	IN	O
a	DT	O
natural	JJ	O
environment	NN	O
,	,	O
are	VBP	O
encouraging	VBG	O
.	.	O

Effects	NNS	O
of	IN	O
creatine	JJ	O
supplementation	NN	O
on	IN	O
repetitive	JJ	O
sprint	NN	O
performance	NN	O
and	CC	O
body	NN	O
composition	NN	O
in	IN	O
competitive	JJ	O
swimmers	NNS	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
and	CC	O
randomized	JJ	O
manner	NN	O
,	,	O
18	CD	O
male	NN	O
and	CC	O
female	JJ	O
junior	JJ	O
competitive	JJ	O
swimmers	NNS	O
supplemented	VBD	O
their	PRP$	O
diets	NNS	O
with	IN	O
21	CD	O
g.day-1	NN	O
of	IN	O
creatine	NN	O
monohydrate	NN	O
(	(	O
Cr	NNP	O
)	)	O
or	CC	O
a	DT	O
maltodextrin	JJ	O
placebo	NN	O
(	(	O
P	NNP	O
)	)	O
for	IN	O
9	CD	O
days	NNS	O
during	IN	O
training	NN	O
.	.	O

Prior	NNP	O
to	TO	O
and	CC	O
following	VBG	O
supplementation	NN	O
,	,	O
subjects	NNS	O
performed	VBD	O
three	CD	O
100-m	JJ	O
freestyle	JJ	O
sprint	NN	O
swims	NNS	O
(	(	O
long	JJ	O
course	NN	O
)	)	O
with	IN	O
60	CD	O
s	JJ	O
rest/recovery	NN	O
between	IN	O
heats	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
subjects	NNS	O
performed	VBD	O
three	CD	O
20-s	JJ	O
arm	NN	O
ergometer	NN	O
maximal-effort	JJ	O
sprint	NN	O
tests	NNS	O
in	IN	O
the	DT	O
prone	NN	O
position	NN	O
with	IN	O
60	CD	O
s	JJ	O
rest/recovery	NN	O
between	IN	O
sprint	NN	O
tests	NNS	O
.	.	O

Significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
among	IN	O
swim	JJ	Ot
times	NNS	Ot
,	,	O
with	IN	O
Cr	NNP	O
subjects	NNS	O
swimming	VBG	O
significantly	RB	O
faster	RBR	O
than	IN	O
P	NNP	O
subjects	NNS	O
following	VBG	O
supplementation	NN	O
in	IN	O
Heat	NNP	O
1	CD	O
and	CC	O
significantly	RB	O
decreasing	VBG	O
swim	JJ	Ot
time	NN	Ot
in	IN	O
the	DT	O
second	JJ	O
100-m	JJ	O
sprint	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
some	DT	O
evidence	NN	O
that	IN	O
cumulative	JJ	Ot
time	NN	Ot
to	TO	Ot
perform	VB	Ot
the	DT	Ot
three	CD	Ot
100-m	JJ	Ot
swims	NNS	Ot
was	VBD	O
decreased	VBN	O
in	IN	O
the	DT	O
Cr	NNP	O
group	NN	O
.	.	O

Results	NNP	O
indicate	VBP	O
that	IN	O
9	CD	O
days	NNS	O
of	IN	O
Cr	NNP	O
supplementation	NN	O
during	IN	O
swim	JJ	O
training	NN	O
may	MD	O
provide	VB	O
some	DT	O
ergogenic	JJ	O
value	NN	O
to	TO	O
competitive	JJ	O
junior	JJ	O
swimmers	NNS	O
during	IN	O
repetitive	JJ	O
sprint	NN	O
performance	NN	O
.	.	O

[	JJ	O
Myocardial	NNP	O
ischemia	NN	O
with	IN	O
stable	JJ	O
angina	JJ	O
pectoris	NN	O
:	:	O
clinico-ergometric	JJ	O
evaluation	NN	O
after	IN	O
the	DT	O
use	NN	O
of	IN	O
diltiazem	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
diltiazem	JJ	O
versus	NN	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

METHODS	NNP	O
Eight-seven	JJ	O
angina	NNS	O
pectoris	JJ	O
patients	NNS	O
,	,	O
mean	JJ	O
age	NN	O
of	IN	O
57	CD	O
+/-	JJ	O
9	CD	O
,	,	O
82	CD	O
white	JJ	O
and	CC	O
79	CD	O
male	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
of	IN	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
diltiazem	JJ	O
and	CC	O
placebo	NN	O
,	,	O
3	CD	O
to	TO	O
4	CD	O
tablets	NNS	O
a	DT	O
day	NN	O
(	(	O
diltiazem	JJ	O
180	CD	O
to	TO	O
240	CD	O
mg	NNS	O
daily	RB	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
after	IN	O
laboratory	NN	O
tests	NNS	O
and	CC	O
clinical-ergometric	JJ	O
examinations	NNS	O
.	.	O

A	DT	O
coronary	JJ	O
arteriography	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
study	NN	O
entry	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	NN	PH
of	IN	PH
anginal	JJ	PH
attacks	NNS	PH
,	,	Ot
number	NN	Ot
of	IN	Ot
weekly	JJ	Ot
sublingual	JJ	Ot
nitrate	NN	Ot
,	,	Ot
heart	NN	PH
rate	NN	PH
,	,	Ot
systolic	JJ	PH
and	CC	PH
diastolic	JJ	PH
pressure	NN	PH
at	IN	PH
rest	NN	PH
and	CC	PH
at	IN	PH
the	DT	PH
end	NN	PH
of	IN	PH
diltiazem	JJ	PH
period	NN	PH
were	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
regarding	VBG	O
same	JJ	O
periods	NNS	O
on	IN	O
placebo	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
depression	NN	PH
for	IN	PH
ST-segment	NNP	PH
was	VBD	O
lower	JJR	O
for	IN	O
diltiazem	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
that	WDT	O
reach	VBP	O
higher	JJR	O
stages	NNS	O
in	IN	O
the	DT	O
ergometric	JJ	O
test	NN	O
was	VBD	O
significantly	RB	O
better	JJR	O
for	IN	O
diltiazem	NN	O
.	.	O

Heart	NNP	PH
rate	NN	PH
and	CC	Ot
systolic	JJ	PH
plus	CC	PH
diastolic	JJ	PH
pressures	NNS	PH
after	IN	O
exercise	NN	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Diltiazem	NNP	O
reduced	VBD	O
the	DT	O
clinical	JJ	O
and	CC	O
electrocardiographical	JJ	O
aspects	NNS	O
and	CC	O
raises	VBZ	O
the	DT	O
effort	NN	O
tolerance	NN	O
during	IN	O
the	DT	O
ergometric	JJ	O
test	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

Application	NN	O
of	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
to	TO	O
clinical	JJ	O
therapeutic	JJ	O
decisions	NNS	O
in	IN	O
hypertension	NN	O
.	.	O

The	DT	O
antihypertensive	JJ	PH
efficacies	NNS	O
of	IN	O
lisinopril	NN	O
and	CC	O
captopril	NN	O
were	VBD	O
compared	VBN	O
using	VBG	O
office	NN	O
sphygmomanometry	NN	O
and	CC	O
24-h	JJ	O
ambulatory	NN	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
prospective	JJ	O
,	,	O
randomly	RB	O
allocated	VBN	O
trial	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
captopril	NN	O
at	IN	O
25-100	JJ	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
or	CC	O
lisinopril	NN	O
at	IN	O
10-40	JJ	O
mg	NN	O
once	IN	O
a	DT	O
day	NN	O
until	IN	O
a	DT	O
clinical	JJ	PH
response	NN	PH
was	VBD	O
achieved	VBN	O
or	CC	O
the	DT	O
highest	JJS	O
dose	NN	O
was	VBD	O
reached	VBN	O
.	.	O

A	DT	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reduction	NN	PH
in	IN	PH
diastolic	JJ	PH
pressure	NN	PH
below	IN	PH
90	CD	PH
mmHg	NN	PH
or	CC	PH
a	DT	PH
fall	NN	PH
of	IN	PH
at	IN	PH
least	JJS	PH
10	CD	PH
mmHg	NN	PH
from	IN	PH
baseline	NN	PH
.	.	PH

The	DT	O
ambulatory	NN	O
monitoring	NN	O
showed	VBD	O
that	IN	O
lisinopril	NN	O
reduced	VBD	O
blood	NN	PH
pressure	NN	PH
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
final	JJ	O
value	NN	O
and	CC	O
maintained	VBD	PH
the	DT	PH
reduction	NN	PH
to	TO	O
a	DT	O
greater	JJR	O
degree	NN	O
than	IN	O
captopril	NN	O
throughout	IN	O
24-h	JJ	O
periods	NNS	O
of	IN	O
observation	NN	O
.	.	O

The	DT	O
office	NN	PH
measurements	NNS	PH
showed	VBD	O
a	DT	O
similar	JJ	O
trend	NN	O
,	,	O
but	CC	O
the	DT	O
intertreatment	JJ	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
first-dose	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
either	DT	O
drug	NN	O
.	.	O

Once	IN	O
a	DT	O
day	NN	O
lisinopril	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
a	DT	O
more	RBR	O
effective	JJ	O
antihypertensive	JJ	O
regimen	NNS	O
than	IN	O
twice	RB	O
a	DT	O
day	NN	O
captopril	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
nitinol	JJ	O
tipless	NN	O
stone	NN	O
baskets	NNS	O
in	IN	O
an	DT	O
in	IN	O
vitro	JJ	PH
caliceal	NN	O
model	NN	O
.	.	O

PURPOSE	NNP	O
Tipless	NNP	O
stone	NN	O
baskets	NNS	O
facilitate	VBP	O
caliceal	JJ	O
calculi	JJ	O
extraction	NN	O
during	IN	O
flexible	JJ	O
ureteroscopy	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
stone	NN	O
capture	NN	O
rate	NN	O
of	IN	O
9	CD	O
commercially	RB	O
available	JJ	O
tipless	NN	O
stone	NN	O
baskets	NNS	O
in	IN	O
an	DT	O
in	IN	O
vitro	NN	O
model	NN	O
using	VBG	O
novice	NN	O
and	CC	O
expert	NN	O
operators	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
Microvasive	NNP	O
Zerotip	NNP	O
(	(	O
2.4Fr	CD	O
,	,	O
3.0Fr	CD	O
)	)	O
,	,	O
Cook	NNP	O
N-Circle	NNP	O
(	(	O
2.2Fr	CD	O
,	,	O
3.0Fr	CD	O
,	,	O
3.2Fr	CD	O
)	)	O
,	,	O
Bard	NNP	O
Dimension	NNP	O
(	(	O
3.0Fr	CD	O
,	,	O
Sacred	NNP	O
Heart	NNP	O
Medical	NNP	O
Halo	NNP	O
(	(	O
1.9Fr	CD	O
)	)	O
,	,	O
Vantage	NNP	O
(	(	O
1.9Fr	CD	O
)	)	O
and	CC	O
Circon-ACMI	JJ	O
Sur-Catch-NT	NNP	O
(	(	O
3.0Fr	CD	O
)	)	O
were	VBD	O
tested	VBN	O
by	IN	O
3	CD	O
novice	NNS	O
and	CC	O
3	CD	O
experienced	VBD	O
basket	NN	O
operators	NNS	O
.	.	O

Each	DT	O
operator	NN	O
performed	VBD	O
stone	JJ	O
extraction	NN	O
of	IN	O
2	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
mm	NN	O
calculi	NN	O
(	(	O
size	NN	O
determined	VBN	O
by	IN	O
digital	JJ	O
caliper	NN	O
with	IN	O
3	CD	O
repetitions	NNS	O
of	IN	O
each	DT	O
basket	NN	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
extraction	NN	O
of	IN	O
the	DT	O
calculus	NN	O
from	IN	O
a	DT	O
convex	NN	O
based	VBN	O
test	NN	O
tube	NN	O
caliceal	NN	O
model	NN	O
was	VBD	O
recorded	VBN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
and	CC	O
Fisher	NNP	O
's	POS	O
pairwise	NN	O
comparisons	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
a	DT	O
learning	JJ	O
curve	NN	O
of	IN	O
27	CD	O
basket	NN	O
retrievals	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
stone	NN	Ot
capture	NN	Ot
times	NNS	Ot
between	IN	O
novice	NN	O
(	(	O
38	CD	O
+/-	JJ	O
54	CD	O
seconds	NNS	O
)	)	O
and	CC	O
expert	JJ	O
operators	NNS	O
(	(	O
32	CD	O
+/-	JJ	O
49	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.174	CD	O
)	)	O
.	.	O

For	IN	O
total	JJ	O
stone	NN	O
capture	NN	O
(	(	O
all	DT	O
sizes	NNS	O
)	)	O
the	DT	O
Sacred	NNP	O
Heart	NNP	O
Halo	NNP	O
resulted	VBD	O
in	IN	O
the	DT	O
most	RBS	O
rapid	JJ	Ot
stone	NN	Ot
extraction	NN	Ot
(	(	O
17	CD	O
+/-	JJ	O
14	CD	O
seconds	NNS	O
)	)	O
by	IN	O
novices	NNS	O
and	CC	O
experts	NNS	O
,	,	O
while	IN	O
the	DT	O
Sur-Catch	NNP	O
NT	NNP	O
resulted	VBD	O
in	IN	O
the	DT	O
slowest	JJS	O
stone	NN	O
extraction	NN	O
(	(	O
78	CD	O
+/-	JJ	O
90	CD	O
,	,	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
Halo	NNP	O
(	(	O
14	CD	O
+/-	JJ	O
9	CD	O
seconds	NNS	O
)	)	O
and	CC	O
Vantage	NNP	O
(	(	O
19	CD	O
+/-	JJ	O
12	CD	O
seconds	NNS	O
)	)	O
baskets	NNS	O
were	VBD	O
significantly	RB	O
faster	JJR	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
than	IN	O
the	DT	O
N-Circle	NNP	O
(	(	O
73	CD	O
+/-	JJ	O
60	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
Sur-Catch	NNP	O
(	(	O
169	CD	O
+/-	JJ	O
85	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.0005	CD	O
)	)	O
and	CC	O
Dimension	NNP	O
(	(	O
73	CD	O
+/-	JJ	O
70	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

The	DT	O
Zerotip	NNP	O
functioned	VBD	O
well	RB	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
expert	NN	O
operators	NNS	O
(	(	O
15	CD	O
+/-	JJ	O
9	CD	O
seconds	NNS	O
)	)	O
but	CC	O
not	RB	O
novice	JJ	O
operators	NNS	O
(	(	O
94	CD	O
+/-	JJ	O
95	CD	O
seconds	NNS	O
)	)	O
.	.	O

The	DT	O
Sur-Catch	JJ	O
NT	NNP	O
was	VBD	O
significantly	RB	O
slower	JJR	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
than	IN	O
the	DT	O
N-Circle	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
Dimension	NNP	O
(	(	O
p	JJ	O
=.03	NN	O
)	)	O
,	,	O
Halo	NNP	O
(	(	O
p	JJ	O
=.0005	NN	O
)	)	O
,	,	O
Vantage	NNP	O
(	(	O
p	JJ	O
=.001	NN	O
)	)	O
and	CC	O
Zerotip	NNP	O
(	(	O
p	JJ	O
=.002	NN	O
)	)	O
.	.	O

For	IN	O
5	CD	O
mm	NNS	O
calculi	VBP	O
the	DT	O
Halo	NNP	O
was	VBD	O
superior	JJ	O
(	(	O
12	CD	O
+/-	JJ	O
8	CD	O
seconds	NNS	O
)	)	O
,	,	O
while	IN	O
the	DT	O
Zerotip	NNP	O
were	VBD	O
superior	JJ	O
for	IN	O
8	CD	O
mm	NNS	O
calculi	NN	O
(	(	O
8	CD	O
+/-	JJ	O
3	CD	O
seconds	NNS	O
)	)	O
compared	VBN	O
to	TO	O
the	DT	O
N-Circle	NNP	O
(	(	O
23	CD	O
+/-	JJ	O
28	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.026	CD	O
)	)	O
,	,	O
Halo	NNP	O
(	(	O
26	CD	O
+/-	JJ	O
18	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.021	CD	O
)	)	O
and	CC	O
Vantage	NNP	O
(	(	O
23	CD	O
+/-	JJ	O
15	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Sacred	NNP	O
Heart	NNP	O
Halo	NNP	O
and	CC	O
Vantage	NNP	O
baskets	NNS	O
resulted	VBD	O
in	IN	O
the	DT	O
most	RBS	Ot
expeditious	JJ	Ot
stone	NN	Ot
extraction	NN	Ot
,	,	O
especially	RB	O
for	IN	O
2	CD	O
to	TO	O
5	CD	O
mm	NNS	O
calculi	VBP	O
while	IN	O
the	DT	O
Microvasive	NNP	O
Zerotip	NNP	O
was	VBD	O
optimal	JJ	O
for	IN	O
8	CD	O
mm	NN	O
calculi	NN	O
.	.	O

The	DT	O
Sur-Catch	JJ	O
NT	NNP	O
had	VBD	O
the	DT	O
slowest	JJS	Ot
stone	JJ	Ot
capture	NN	Ot
rate	NN	Ot
for	IN	O
all	DT	O
stone	NN	O
sizes	VBZ	O
.	.	O

Caliceal	NNP	O
models	NNS	O
of	IN	O
stone	NN	O
basketing	NN	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
train	VB	O
novice	JJ	O
urology	NN	O
residents	NNS	O
and	CC	O
nursing	NN	O
assistants	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
liberal	JJ	O
versus	NN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
transfusion	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

OBJECTIVE	NNP	O
Although	IN	O
many	JJ	O
centers	NNS	O
have	VBP	O
introduced	VBN	O
more	RBR	O
restrictive	JJ	O
transfusion	NN	O
policies	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
in	IN	O
recent	JJ	O
years	NNS	O
,	,	O
the	DT	O
benefits	NNS	O
and	CC	O
adverse	JJ	O
consequences	NNS	O
of	IN	O
allowing	VBG	O
lower	JJR	O
hematocrit	NN	O
levels	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
transfusions	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
can	MD	O
reduce	VB	O
the	DT	O
number	NN	Ot
of	IN	Ot
transfusions	NNS	Ot
without	IN	O
adverse	JJ	O
consequences	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
enrolled	VBD	O
100	CD	O
hospitalized	JJ	O
preterm	NN	O
infants	NNS	O
with	IN	O
birth	JJ	O
weights	NNS	O
of	IN	O
500	CD	O
to	TO	O
1300	CD	O
g	NN	O
into	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
2	CD	O
levels	NNS	O
of	IN	O
hematocrit	NN	O
threshold	NN	O
for	IN	O
RBC	NNP	O
transfusion	NN	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
infants	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
either	VB	O
the	DT	O
liberal-	NN	O
or	CC	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
.	.	O

For	IN	O
each	DT	O
group	NN	O
,	,	O
transfusions	NNS	O
were	VBD	O
given	VBN	O
only	RB	O
when	WRB	O
the	DT	O
hematocrit	NN	O
level	NN	O
fell	VBD	O
below	IN	O
the	DT	O
assigned	JJ	O
value	NN	O
.	.	O

In	IN	O
each	DT	O
group	NN	O
,	,	O
the	DT	O
transfusion	NN	O
threshold	NN	O
levels	NNS	O
decreased	VBN	O
with	IN	O
improving	VBG	O
clinical	JJ	O
status	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
We	PRP	O
recorded	VBD	O
the	DT	O
number	NN	Ot
of	IN	Ot
transfusions	NNS	Ot
,	,	O
the	DT	O
number	NN	Ot
of	IN	Ot
donor	JJ	Ot
exposures	NNS	Ot
,	,	O
and	CC	O
various	JJ	Ot
clinical	JJ	Ot
and	CC	Ot
physiologic	JJ	Ot
outcomes	NNS	Ot
.	.	O

RESULTS	JJ	O
Infants	NNS	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
received	VBD	O
more	JJR	O
RBC	JJ	PH
transfusions	NNS	PH
(	(	O
5.2	CD	O
+/-	JJ	O
4.5	CD	O
[	JJ	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
]	NNP	O
vs	VBD	O
3.3	CD	O
+/-	JJ	O
2.9	CD	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
number	NN	PH
of	IN	PH
donors	NNS	PH
to	TO	O
whom	WP	O
the	DT	O
infants	NNS	O
were	VBD	O
exposed	VBN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
2.8	CD	O
+/-	JJ	O
2.5	CD	O
vs	JJ	O
2.2	CD	O
+/-	JJ	O
2.0	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
percentage	NN	PH
of	IN	PH
infants	NNS	PH
who	WP	PH
avoided	VBD	PH
transfusions	NNS	PH
altogether	RB	PH
(	(	O
12	CD	O
%	NN	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
versus	VBD	O
10	CD	O
%	NN	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

Infants	NNS	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
intraparenchymal	JJ	PH
brain	NN	PH
hemorrhage	NN	PH
or	CC	PH
periventricular	JJ	PH
leukomalacia	NN	PH
,	,	O
and	CC	O
they	PRP	O
had	VBD	O
more	RBR	PH
frequent	JJ	PH
episodes	NNS	PH
of	IN	PH
apnea	NN	PH
,	,	O
including	VBG	O
both	DT	O
mild	JJ	PH
and	CC	PH
severe	JJ	PH
episodes	NNS	PH
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
both	DT	O
transfusion	NN	O
programs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
our	PRP$	O
finding	NN	O
of	IN	O
more	RBR	O
frequent	JJ	O
major	JJ	A
adverse	JJ	A
neurologic	NN	A
events	NNS	A
in	IN	O
the	DT	O
restrictive	JJ	O
RBC-transfusion	NNP	O
group	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
practice	NN	O
of	IN	O
restrictive	JJ	O
transfusions	NNS	O
may	MD	O
be	VB	O
harmful	JJ	O
to	TO	O
preterm	VB	O
infants	NNS	O
.	.	O

Heparin-coated	JJ	O
cardiopulmonary	JJ	O
bypass	NN	O
circuits	NNS	O
reduce	VB	O
circulating	VBG	O
complement	JJ	O
factors	NNS	O
and	CC	O
interleukin-6	NN	O
in	IN	O
paediatric	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

Children	NNP	O
are	VBP	O
sensitive	JJ	O
to	TO	O
the	DT	O
inflammatory	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
.	.	O

Our	PRP$	O
intention	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
if	IN	O
the	DT	O
biocompatibility	NN	O
benefits	NNS	O
of	IN	O
heparin-coated	JJ	O
CPB	NNP	O
circuits	NNS	O
apply	VBP	O
to	TO	O
children	NNS	O
.	.	O

In	IN	O
20	CD	O
operations	NNS	O
,	,	O
19	CD	O
children	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
heparin-coated	JJ	O
(	(	O
group	NN	O
HC	NNP	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
standard	JJ	O
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
bypass	NN	O
circuits	NNS	O
.	.	O

Plasma	NNP	PH
levels	NNS	PH
of	IN	PH
acute	JJ	PH
phase	NN	PH
reactants	NNS	PH
,	,	O
interleukins	NNS	PH
,	,	O
granulocytic	JJ	PH
proteins	NNS	PH
and	CC	O
complement	JJ	PH
factors	NNS	PH
were	VBD	O
measured	VBN	O
.	.	O

All	DT	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
after	IN	O
CPB	NNP	O
.	.	O

Levels	NNP	PH
of	IN	PH
complement	NN	PH
factor	NN	PH
C3a	NNP	PH
(	(	O
851	CD	O
(	(	O
791-959	CD	O
)	)	O
ng/ml	FW	O
[	JJ	O
median	NN	O
with	IN	O
quartiles	NNS	O
]	VBP	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
497	CD	O
(	(	O
476-573	JJ	O
)	)	O
ng/ml	NN	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
Terminal	NNP	PH
Complement	NNP	PH
Complex	NNP	PH
(	(	O
114	CD	O
(	(	O
71-130	CD	O
)	)	O
AU/ml	NNP	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
35.5	CD	O
(	(	O
28.9-51.4	JJ	O
)	)	O
AU/ml	NNP	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
interleukin-6	NN	PH
(	(	O
570	CD	O
(	(	O
203-743	JJ	O
)	)	O
pg/ml	NN	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
168	CD	O
(	(	O
111-206	CD	O
)	)	O
pg/ml	NN	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
group	NN	O
HC	NNP	O
.	.	O

Heparin-coated	JJ	O
CPB	NNP	O
circuits	NNS	O
improve	VBP	O
the	DT	O
biocompatibility	NN	O
of	IN	O
CPB	NNP	O
during	IN	O
heart	NN	O
surgery	NN	O
in	IN	O
the	DT	O
paediatric	JJ	O
patient	NN	O
population	NN	O
,	,	O
as	IN	O
reflected	VBN	O
by	IN	O
significantly	RB	O
reduced	VBN	O
levels	NNS	O
of	IN	O
circulating	VBG	O
complement	JJ	O
factors	NNS	O
and	CC	O
interleukin-6	NN	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
5-fluorouracil	JJ	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
human	JJ	O
interferon-beta	NN	O
,	,	O
for	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
monotherapy	NN	O
to	TO	O
that	DT	O
of	IN	O
5-FU	JJ	O
combined	VBN	O
with	IN	O
natural	JJ	O
human	JJ	O
interferon-beta	NN	O
(	(	O
IFN-beta	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
,	,	O
advanced	JJ	O
colorectal	JJ	O
carcinoma	NN	O
.	.	O

Forty-nine	JJ	O
chemotherapy-naive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
or	CC	O
to	TO	O
the	DT	O
combination	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	JJ	O
)	)	O
day	NN	O
(	(	O
-1	JJ	O
)	)	O
5-FU	NN	O
for	IN	O
5	CD	O
days	NNS	O
by	IN	O
continuous	JJ	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
infusion	NN	O
,	,	O
followed	VBD	O
after	IN	O
day	NN	O
15	CD	O
by	IN	O
a	DT	O
weekly	JJ	O
i.v	NN	O
.	.	O

bolus	NN	O
of	IN	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
.	.	O

IFN-beta	NNP	O
was	VBD	O
injected	VBN	O
intramuscularly	RB	O
three	CD	O
times	NNS	O
weekly	RB	O
at	IN	O
9	CD	O
M	NNP	O
IU	NNP	O
.	.	O

Treatment	NNP	O
continued	VBD	O
for	IN	O
52	CD	O
weeks	NNS	O
,	,	O
or	CC	O
until	IN	O
disease	JJ	PH
progression	NN	PH
or	CC	O
intolerable	JJ	A
toxicity	NN	A
.	.	O

Clinical	JJ	O
endpoints	NNS	O
were	VBD	O
tumor	JJ	PH
response	NN	PH
,	,	O
time	NN	PH
to	TO	PH
progression	NN	PH
,	,	O
survival	NN	PH
and	CC	PH
toxicity	NN	PH
.	.	O

The	DT	O
addition	NN	O
of	IN	O
IFN-3	NNP	O
to	TO	O
5-FU	CD	O
significantly	RB	O
improved	VBN	PH
response	NN	PH
rate	NN	PH
(	(	O
33.3	CD	O
%	NN	O
vs	JJ	O
4.5	CD	O
%	NN	O
for	IN	O
evaluable	JJ	O
patients	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
,	,	O
time	NN	PH
to	TO	PH
progression	NN	PH
(	(	O
median	JJ	O
7.2	CD	O
vs	JJ	O
4.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.0435	CD	O
)	)	O
,	,	O
and	CC	O
survival	JJ	MO
time	NN	MO
(	(	O
median	JJ	O
15.9	CD	O
vs	JJ	O
7.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
without	IN	O
significantly	RB	O
increasing	VBG	O
toxicity	NN	PH
compared	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
.	.	O

Cumulative	JJ	PH
5-FU	JJ	PH
dose	NN	PH
was	VBD	O
higher	JJR	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
:	:	O
more	JJR	O
patients	NNS	O
receiving	VBG	O
monotherapy	JJ	O
discontinued	VBN	O
treatment	NN	O
because	IN	O
of	IN	O
disease	NN	PH
progression	NN	PH
.	.	O

Fever	NNP	PH
was	VBD	O
more	RBR	O
frequent	JJ	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
other	JJ	O
differences	NNS	O
in	IN	O
toxicity	NN	A
.	.	O

The	DT	O
only	JJ	O
grade	NN	A
IV	NNP	A
toxicity	NN	A
observed	VBD	O
was	VBD	O
neutropenia	JJ	O
(	(	O
two	CD	O
patients	NNS	O
per	IN	O
group	NN	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
has	VBZ	O
been	VBN	O
initiated	VBN	O
to	TO	O
confirm	VB	O
the	DT	O
synergy	NN	O
between	IN	O
5-FU	JJ	O
and	CC	O
IFN-beta	NNP	O
.	.	O

Cryotherapy	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
peroneal	JJ	O
reaction	NN	O
following	VBG	O
sudden	JJ	O
inversion	NN	O
.	.	O

CONTEXT	NNP	O
If	IN	O
ankle	JJ	O
joint	NN	O
cryotherapy	NN	O
impairs	VBZ	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
ankle	JJ	O
musculature	NN	O
to	TO	O
counteract	VB	O
potentially	RB	O
injurious	JJ	O
forces	NNS	O
,	,	O
the	DT	O
ankle	NN	O
is	VBZ	O
left	VBN	O
vulnerable	JJ	O
to	TO	O
injury	VB	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
peroneal	JJ	O
reaction	NN	O
to	TO	O
sudden	JJ	O
inversion	NN	O
following	VBG	O
ankle	JJ	O
joint	JJ	O
cryotherapy	NN	O
.	.	O

DESIGN	NNP	O
Repeated	VBD	O
measures	NNS	O
design	NN	O
with	IN	O
independent	JJ	O
variables	NNS	O
,	,	O
treatment	NN	O
(	(	O
cryotherapy	NN	O
and	CC	O
control	NN	O
)	)	O
,	,	O
and	CC	O
time	NN	O
(	(	O
baseline	NN	O
,	,	O
immediately	RB	O
post	NN	O
treatment	NN	O
,	,	O
15	CD	O
minutes	NNS	O
post	RB	O
treatment	NN	O
,	,	O
and	CC	O
30	CD	O
minutes	NNS	O
post	RB	O
treatment	NN	O
)	)	O
.	.	O

SETTING	NNP	O
University	NNP	O
research	NN	O
laboratory	NN	O
.	.	O

PATIENTS	CC	O
OR	CC	O
OTHER	NNP	O
PARTICIPANTS	NNP	O
Twenty-seven	NNP	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
An	DT	O
ice	NN	O
bag	NN	O
was	VBD	O
secured	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
ankle	NN	O
joint	NN	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
onset	NN	PH
and	CC	PH
average	JJ	PH
root	NN	PH
mean	JJ	PH
square	JJ	PH
amplitude	NN	PH
of	IN	PH
EMG	NNP	PH
activity	NN	PH
in	IN	PH
the	DT	PH
peroneal	NN	PH
muscles	NNS	PH
was	VBD	PH
calculated	VBN	O
following	VBG	O
the	DT	O
release	NN	Ot
of	IN	Ot
a	DT	Ot
trap	NN	Ot
door	NN	Ot
mechanism	NN	Ot
causing	VBG	Ot
inversion	NN	Ot
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
for	IN	O
peroneal	JJ	PH
reaction	NN	PH
time	NN	PH
or	CC	PH
average	JJ	PH
peroneal	JJ	PH
muscle	NN	PH
activity	NN	PH
at	IN	O
any	DT	O
post	NN	O
treatment	NN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cryotherapy	NNP	O
does	VBZ	O
not	RB	O
affect	VB	O
peroneal	JJ	O
muscle	NN	O
reaction	NN	O
following	VBG	O
sudden	JJ	O
inversion	NN	O
perturbation	NN	O
.	.	O

RESPECT-PTSD	JJ	O
:	:	O
re-engineering	JJ	O
systems	NNS	O
for	IN	O
the	DT	O
primary	JJ	O
care	NN	O
treatment	NN	O
of	IN	O
PTSD	NNP	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
collaborative	JJ	O
care	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
depression	NN	O
and	CC	O
other	JJ	O
mental	JJ	O
disorders	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
,	,	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
randomized	JJ	O
trials	NNS	O
of	IN	O
collaborative	JJ	O
care	NN	O
specifically	RB	O
for	IN	O
patients	NNS	O
with	IN	O
Posttraumatic	NNP	O
stress	NN	O
disorder	NN	O
(	(	O
PTSD	NNP	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
a	DT	O
collaborative	JJ	O
approach	NN	O
,	,	O
the	DT	O
Three	NNP	O
Component	NNP	O
Model	NNP	O
(	(	O
3CM	CD	O
)	)	O
,	,	O
with	IN	O
usual	JJ	O
care	NN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
two-arm	JJ	O
,	,	O
parallel	JJ	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

PTSD	JJ	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
five	CD	O
primary	JJ	O
care	NN	O
clinics	NNS	O
at	IN	O
four	CD	O
Veterans	NNS	O
Affairs	NNP	O
healthcare	NN	O
facilities	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
usual	JJ	O
care	NN	O
or	CC	O
usual	JJ	O
care	NN	O
plus	CC	O
3CM	CD	O
.	.	O

Blinded	VBN	O
assessors	NNS	O
collected	VBD	O
data	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
3-month	JJ	O
and	CC	O
6-month	JJ	O
follow-up	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
were	VBD	O
195	CD	O
Veterans	NNPS	O
.	.	O

Their	PRP$	O
average	JJ	O
age	NN	O
was	VBD	O
45	CD	O
years	NNS	O
,	,	O
91	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
58	CD	O
%	NN	O
were	VBD	O
white	JJ	O
,	,	O
40	CD	O
%	NN	O
served	VBN	O
in	IN	O
Iraq	NNP	O
or	CC	O
Afghanistan	NNP	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
served	VBD	O
in	IN	O
Vietnam	NNP	O
.	.	O

INTERVENTION	NNP	O
All	NNP	O
participants	NNS	O
received	VBD	O
usual	JJ	O
care	NN	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	O
also	RB	O
received	VBD	O
telephone	NN	O
care	NN	O
management	NN	O
.	.	O

Care	NN	O
managers	NNS	O
received	VBD	O
supervision	NN	O
from	IN	O
a	DT	O
psychiatrist	NN	O
.	.	O

MAIN	NNP	O
MEASURES	NNP	O
PTSD	NNP	PH
symptom	NN	PH
severity	NN	PH
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

Depression	NNP	PH
,	,	ME
functioning	NN	PH
,	,	O
perceived	VBD	PH
quality	NN	PH
of	IN	PH
care	NN	PH
,	,	Ot
utilization	NN	Ot
,	,	O
and	CC	O
costs	NNS	Ot
were	VBD	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

KEY	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
3CM	CD	O
and	CC	O
usual	JJ	O
care	NN	O
in	IN	O
symptoms	NNS	O
or	CC	O
functioning	VBG	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
mental	JJ	ME
health	NN	ME
visit	NN	ME
,	,	O
fill	VB	Ot
an	DT	Ot
antidepressant	JJ	Ot
prescription	NN	Ot
,	,	O
and	CC	O
have	VBP	Ot
adequate	VBN	Ot
antidepressant	JJ	Ot
refills	NNS	Ot
.	.	Ot

3CM	CD	O
participants	NNS	O
also	RB	O
had	VBD	O
more	RBR	O
mental	JJ	ME
health	NN	ME
visits	NNS	ME
and	CC	O
higher	JJR	O
outpatient	NN	Ot
pharmacy	NN	Ot
costs	NNS	Ot
.	.	Ot

CONCLUSIONS	NNP	O
Results	NNP	O
suggest	VBP	O
the	DT	O
need	NN	O
for	IN	O
careful	JJ	O
examination	NN	O
of	IN	O
the	DT	O
way	NN	O
that	IN	O
collaborative	JJ	O
care	NN	O
models	NNS	O
are	VBP	O
implemented	VBN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
,	,	O
and	CC	O
for	IN	O
additional	JJ	O
supports	NNS	O
to	TO	O
encourage	VB	O
primary	JJ	O
care	NN	O
providers	NNS	O
to	TO	O
manage	VB	O
PTSD	NNP	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
extended	JJ	O
radical	JJ	O
versus	NN	O
radical	JJ	O
mastectomy	NN	O
.	.	O

Ten-year	JJ	O
results	NNS	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
increasing	VBG	O
debate	NN	O
over	IN	O
possible	JJ	O
benefit	NN	O
of	IN	O
more	JJR	O
complete	JJ	O
surgery	NN	O
compared	VBN	O
to	TO	O
conservative	JJ	O
procedures	NNS	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
contrasting	VBG	O
the	DT	O
then	RB	O
standard	NN	O
Halsted	NNP	O
radical	NN	O
(	(	O
RDL	NNP	O
)	)	O
operation	NN	O
with	IN	O
the	DT	O
more	RBR	O
complete	JJ	O
extended	JJ	O
radical	NN	O
(	(	O
EXT	NNP	O
)	)	O
mastectomy	NN	O
was	VBD	O
initiated	VBN	O
in	IN	O
1973	CD	O
.	.	O

Between	IN	O
November	NNP	O
1973	CD	O
and	CC	O
July	NNP	O
1982	CD	O
,	,	O
123	CD	O
women	NNS	O
younger	JJR	O
than	IN	O
70	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
at	IN	O
clinical	JJ	O
Stages	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
were	VBD	O
enrolled	VBN	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
series	NN	O
,	,	O
112	CD	O
were	VBD	O
treated	VBN	O
by	IN	O
the	DT	O
same	JJ	O
surgeon	NN	O
and	CC	O
confirmed	VBD	O
pathologically	RB	O
as	IN	O
having	VBG	O
invasive	JJ	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

In	IN	O
this	DT	O
more	RBR	O
homogeneous	JJ	O
subgroup	NN	O
,	,	O
the	DT	O
10-year	JJ	MO
survival	NN	MO
rates	NNS	MO
(	(	O
and	CC	O
standard	JJ	O
errors	NNS	O
)	)	O
were	VBD	O
for	IN	O
RDL	NNP	O
,	,	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
7	CD	O
%	NN	O
)	)	O
and	CC	O
for	IN	O
EXT	NNP	O
,	,	O
74	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
value	NN	O
for	IN	O
comparison	NN	O
of	IN	O
survival	JJ	O
curves	NNS	O
=	VBP	O
0.13	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
from	IN	O
this	DT	O
subgroup	NN	O
with	IN	O
central-medial	JJ	O
tumors	NNS	O
,	,	O
comprising	VBG	O
62	CD	O
%	NN	O
of	IN	O
the	DT	O
total	NN	O
,	,	O
survival	NN	MO
after	IN	O
RDL	NNP	O
at	IN	O
10	CD	O
years	NNS	O
was	VBD	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
8	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
after	IN	O
EXT	NNP	O
86	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
with	IN	O
lateral	JJ	O
tumors	NNS	O
,	,	O
survival	JJ	MO
rates	NNS	MO
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
:	:	O
58	CD	O
%	NN	O
(	(	O
+/-	JJ	O
13	CD	O
%	NN	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
(	(	O
+/-	JJ	O
11	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.62	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
a	DT	O
nonrandomized	JJ	O
series	NN	O
of	IN	O
266	CD	O
RDL	NNP	O
and	CC	O
124	CD	O
EXT	NNP	O
patients	NNS	O
treated	VBD	O
between	IN	O
1960	CD	O
and	CC	O
1978	CD	O
found	VBD	O
differences	NNS	O
consistent	JJ	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
randomized	VBN	O
study	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
program	NN	O
on	IN	O
sensory	JJ	O
problems	NNS	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
planned	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
program	NN	O
on	IN	O
sensory	JJ	Ot
problems	NNS	Ot
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Trakya	NNP	O
University	NNP	O
Training	NNP	O
and	CC	O
Research	NNP	O
Center	NNP	O
for	IN	O
Mentally	NNP	O
and	CC	O
Physically	NNP	O
Handicapped	NNP	O
Children	NNP	O
in	IN	O
Turkey	NNP	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
separated	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
each	DT	O
comprising	VBG	O
15	CD	O
children	NNS	O
between	IN	O
7	CD	O
and	CC	O
11	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
autism	NN	O
,	,	O
according	VBG	O
to	TO	O
DSM-IV	NNP	O
criteria	NNS	O
.	.	O

The	DT	O
children	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
assessed	VBN	O
initially	RB	O
on	IN	O
a	DT	O
checklist	NN	O
,	,	O
Sensory	NNP	O
Evaluation	NNP	O
Form	NNP	O
for	IN	O
Children	NNP	O
with	IN	O
Autism	NNP	O
,	,	O
developed	VBD	O
to	TO	O
evaluate	VB	O
sensory	JJ	ME
characteristics	NNS	ME
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
participants	NNS	O
were	VBD	O
assessed	VBN	O
again	RB	O
on	IN	O
the	DT	O
checklist	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
program	NN	O
positively	RB	O
affected	VBD	O
treated	JJ	O
children	NNS	O
.	.	O

The	DT	O
therapeutic	JJ	Ot
efficacy	NN	Ot
and	CC	O
cost-effectiveness	NN	Ot
of	IN	O
aggressive	JJ	O
tocolysis	NN	O
for	IN	O
premature	JJ	O
labor	NN	O
associated	VBN	O
with	IN	O
premature	JJ	O
rupture	NN	O
of	IN	O
the	DT	O
membranes	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
bed	VBD	O
rest	NN	O
with	IN	O
tocolysis	NN	O
to	TO	O
determine	VB	O
the	DT	O
therapeutic	JJ	Ot
efficacy	NN	Ot
,	,	O
safety	NN	Ot
,	,	O
and	CC	O
cost-effectiveness	NN	Ot
of	IN	O
tocolysis	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
preterm	JJ	O
labor	NN	O
after	IN	O
membrane	JJ	O
rupture	NN	O
.	.	O

One	CD	O
hundred	VBD	O
nine	CD	O
women	NNS	O
participated	VBD	O
over	IN	O
a	DT	O
26-month	JJ	O
interval	NN	O
.	.	O

Treatment	NNP	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
terms	NNS	O
of	IN	O
gestational	JJ	PH
age	NN	PH
at	IN	PH
membrane	NN	PH
rupture	NN	PH
,	,	O
gestational	JJ	PH
age	NN	PH
at	IN	PH
delivery	NN	PH
,	,	O
birth	NN	PH
weight	NN	PH
,	,	O
maternal	JJ	A
or	CC	A
fetal	JJ	A
infectious	JJ	A
morbidity	NN	A
,	,	O
respiratory	JJ	A
distress	NN	A
syndrome	NN	A
,	,	O
necrotizing	VBG	A
enterocolitis	NN	A
,	,	O
or	CC	O
perinatal	JJ	MO
mortality	NN	MO
.	.	O

Prolongation	NN	O
of	IN	O
intrauterine	JJ	O
time	NN	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
uterine	JJ	O
contractions	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
women	NNS	O
receiving	VBG	O
tocolysis	NN	O
(	(	O
105.2	CD	O
+/-	JJ	O
157	CD	O
hours	NNS	O
versus	JJ	O
62.1	CD	O
+/-	JJ	O
77	CD	O
hours	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.06	CD	O
)	)	O
.	.	O

This	DT	O
prolongation	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
total	JJ	Ot
cost	NN	Ot
per	IN	O
surviving	VBG	O
infant	NN	O
(	(	O
tocolysis	NN	O
,	,	O
$	$	O
38,593	CD	O
+/-	JJ	O
$	$	O
40,887	CD	O
versus	NN	O
bed	NN	O
rest	NN	O
,	,	O
$	$	O
43,158	CD	O
+/-	JJ	O
$	$	O
37,116	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.445	CD	O
)	)	O
.	.	O

The	DT	O
cost	NN	Ot
difference	NN	Ot
was	VBD	O
artifactual	JJ	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
very	RB	PH
premature	JJ	PH
infants	NNS	PH
born	VBN	PH
(	(	O
less	JJR	O
than	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
)	)	O
was	VBD	O
unequal	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
12	CD	O
in	IN	O
the	DT	O
bed	NN	O
rest	NN	O
group	NN	O
and	CC	O
5	CD	O
in	IN	O
the	DT	O
tocolysis	NN	O
group	NN	O
)	)	O
and	CC	O
skewed	VBD	O
the	DT	O
results	NNS	O
.	.	O

Before	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
tocolysis	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	PH
in	IN	PH
intrauterine	JJ	PH
time	NN	PH
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
regular	JJ	PH
contractions	NNS	PH
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
identifiable	JJ	O
perinatal	JJ	O
benefit	NN	O
garnered	VBD	O
from	IN	O
the	DT	O
additional	JJ	O
5	CD	O
days	NNS	O
.	.	O

After	IN	O
28	CD	O
weeks	NNS	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
intrauterine	NN	PH
time	NN	PH
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
regular	JJ	PH
contractions	NNS	PH
and	CC	O
total	JJ	O
cost	NN	O
per	IN	O
surviving	VBG	O
infant	NN	O
.	.	O

Because	IN	O
tocolysis	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
perinatal	JJ	O
outcome	NN	O
and	CC	O
can	MD	O
itself	PRP	O
be	VB	O
associated	VBN	O
with	IN	O
major	JJ	O
maternal	JJ	O
morbidity	NN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
avoided	VBN	O
after	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
.	.	O

Before	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
tocolysis	NN	O
may	MD	O
greatly	RB	O
increase	VB	O
intrauterine	JJ	O
time	NN	O
,	,	O
but	CC	O
the	DT	O
benefit	NN	O
of	IN	O
this	DT	O
prolongation	NN	O
is	VBZ	O
not	RB	O
clear	JJ	O
.	.	O

Comparison	NNP	O
between	IN	O
intermittent	JJ	O
mandatory	JJ	O
ventilation	NN	O
and	CC	O
synchronized	JJ	O
intermittent	NN	O
mandatory	JJ	O
ventilation	NN	O
with	IN	O
pressure	NN	O
support	NN	O
in	IN	O
children	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
compare	VB	O
intermittent	JJ	O
mandatory	JJ	O
ventilation	NN	O
(	(	O
IMV	NNP	O
)	)	O
with	IN	O
synchronized	JJ	O
intermittent	JJ	O
mandatory	NN	O
ventilation	NN	O
plus	CC	O
pressure	NN	O
support	NN	O
(	(	O
SIMV+PS	NNP	O
)	)	O
in	IN	O
terms	NNS	O
of	IN	O
time	NN	PH
on	IN	PH
mechanical	JJ	PH
ventilation	NN	PH
,	,	Ot
duration	NN	Ot
of	IN	Ot
weaning	VBG	Ot
and	CC	Ot
length	NN	Ot
of	IN	Ot
stay	NN	Ot
in	IN	Ot
a	DT	Ot
pediatric	JJ	Ot
intensive	JJ	Ot
care	NN	Ot
unit	NN	Ot
(	(	O
PICU	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
enrolled	VBD	O
children	NNS	O
aged	VBN	O
28	CD	O
days	NNS	O
to	TO	O
4	CD	O
years	NNS	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
a	DT	O
PICU	NNP	O
between	IN	O
October	NNP	O
of	IN	O
2005	CD	O
and	CC	O
June	NNP	O
of	IN	O
2007	CD	O
and	CC	O
put	VB	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
(	(	O
MV	NNP	O
)	)	O
for	IN	O
more	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
by	IN	O
drawing	VBG	O
lots	NNS	O
:	:	O
IMV	NNP	O
group	NN	O
(	(	O
IMVG	NNP	O
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
and	CC	O
SIMV+PS	NNP	O
group	NN	O
(	(	O
SIMVG	NNP	O
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
undergone	JJ	O
tracheotomy	NN	O
or	CC	O
had	VBD	O
chronic	JJ	O
respiratory	NN	O
diseases	NNS	O
.	.	O

Data	NNS	O
on	IN	O
oxygenation	NN	PH
and	CC	Ot
ventilation	NN	PH
were	VBD	O
recorded	VBN	O
at	IN	O
admission	NN	O
and	CC	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
weaning	VBG	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	Ot
,	,	Ot
sex	NN	Ot
,	,	Ot
indication	NN	Ot
for	IN	Ot
MV	NNP	Ot
,	,	Ot
PRISM	NNP	Ot
score	NN	Ot
,	,	Ot
Comfort	NNP	Ot
scale	NN	Ot
,	,	Ot
use	NN	Ot
of	IN	Ot
sedatives	NNS	Ot
or	CC	Ot
ventilation	NN	Ot
and	CC	Ot
oxygenation	NN	Ot
parameters	NNS	Ot
.	.	Ot

The	DT	O
median	JJ	Ot
time	NN	Ot
on	IN	Ot
MV	NNP	Ot
was	VBD	O
5	CD	O
days	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
duration	NN	Ot
of	IN	Ot
weaning	VBG	Ot
[	JJ	O
IMVG	NNP	O
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	O
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.262	CD	O
]	NN	O
or	CC	O
length	NN	Ot
of	IN	Ot
hospital	NN	Ot
stay	NN	Ot
[	JJ	O
IMVG	NNP	O
:	:	O
8	CD	O
days	NNS	O
(	(	O
2-22	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	O
:	:	O
6	CD	O
days	NNS	O
(	(	O
3-20	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.113	CD	O
]	NNP	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
the	DT	O
children	NNS	O
studied	VBN	O
here	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
IMV	NNP	O
and	CC	O
SIMV+PS	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
MV	NNP	Ot
,	,	Ot
duration	NN	Ot
of	IN	Ot
weaning	VBG	Ot
or	CC	Ot
time	NN	Ot
spent	VBN	Ot
in	IN	Ot
the	DT	Ot
PICU	NNP	Ot
.	.	Ot

ClinicalTrials.govID	NN	O
:	:	O
NCT00549809	NNP	O
.	.	O

Predictive	JJ	O
validity	NN	O
of	IN	O
a	DT	O
medication	NN	O
adherence	NN	O
measure	NN	O
in	IN	O
an	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

This	DT	O
study	NN	O
examines	VBZ	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
and	CC	O
tests	VBZ	O
the	DT	O
concurrent	NN	O
and	CC	O
predictive	JJ	O
validity	NN	O
of	IN	O
a	DT	O
structured	JJ	O
,	,	O
self-reported	JJ	O
medication	NN	O
adherence	NN	O
measure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
.	.	O

The	DT	O
authors	NNS	O
also	RB	O
assessed	VBD	O
various	JJ	O
psychosocial	JJ	ME
determinants	NNS	ME
of	IN	ME
adherence	NN	ME
,	,	O
such	JJ	O
as	IN	O
knowledge	NN	ME
,	,	O
social	JJ	ME
support	NN	ME
,	,	O
satisfaction	NN	Ot
with	IN	Ot
care	NN	Ot
,	,	O
and	CC	O
complexity	NN	Ot
of	IN	Ot
the	DT	Ot
medical	JJ	Ot
regimen	NNS	Ot
.	.	O

A	DT	O
total	NN	O
of	IN	O
1367	CD	O
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
;	:	O
mean	JJ	O
age	NN	O
was	VBD	O
52.5	CD	O
years	NNS	O
,	,	O
40.8	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
76.5	CD	O
%	NN	O
were	VBD	O
black	JJ	O
,	,	O
50.8	CD	O
%	NN	O
graduated	VBN	O
from	IN	O
high	JJ	O
school	NN	O
,	,	O
26	CD	O
%	NN	O
were	VBD	O
married	VBN	O
,	,	O
and	CC	O
54.1	CD	O
%	NN	O
had	VBD	O
income	NN	O
<	NNP	O
$	$	O
5,000	CD	O
.	.	O

The	DT	O
8-item	JJ	O
medication	NN	O
adherence	NN	O
scale	NN	O
was	VBD	O
reliable	JJ	O
(	(	O
alpha=.83	NN	O
)	)	O
and	CC	O
significantly	RB	O
associated	VBN	O
with	IN	O
blood	NN	PH
pressure	NN	PH
control	NN	PH
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
cutpoint	NN	O
of	IN	O
<	$	O
6	CD	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
measure	NN	O
to	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
poor	JJ	O
blood	NN	PH
pressure	NN	PH
control	NN	PH
was	VBD	O
estimated	VBN	O
to	TO	O
be	VB	O
93	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
specificity	NN	O
was	VBD	O
53	CD	O
%	NN	O
.	.	O

The	DT	O
medication	NN	O
adherence	NN	O
measure	NN	O
proved	VBD	O
to	TO	O
be	VB	O
reliable	JJ	O
,	,	O
with	IN	O
good	JJ	O
concurrent	NN	O
and	CC	O
predictive	JJ	O
validity	NN	O
in	IN	O
primarily	RB	O
low-income	JJ	O
,	,	O
minority	NN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
might	MD	O
function	VB	O
as	IN	O
a	DT	O
screening	VBG	O
tool	NN	O
in	IN	O
outpatient	JJ	O
settings	NNS	O
with	IN	O
other	JJ	O
patient	NN	O
groups	NNS	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
plus	CC	O
topiramate	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
Autism	NNP	O
is	VBZ	O
a	DT	O
complex	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
that	WDT	O
forms	VBZ	O
part	NN	O
of	IN	O
a	DT	O
spectrum	NN	O
of	IN	O
related	JJ	O
disorders	NNS	O
referred	VBD	O
to	TO	O
as	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
topiramate	NN	O
plus	CC	O
risperidone	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
4	CD	O
and	CC	O
12	CD	O
years	NNS	O
with	IN	O
a	DT	O
DSM	NNP	O
IV	NNP	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	O
who	WP	O
were	VBD	O
outpatients	NNS	O
from	IN	O
a	DT	O
specialty	NN	O
clinic	NN	O
for	IN	O
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
children	NNS	O
presented	VBN	O
with	IN	O
a	DT	O
chief	JJ	O
complaint	NN	O
of	IN	O
severely	RB	O
disruptive	JJ	O
symptoms	NNS	O
related	VBN	O
to	TO	O
autistic	JJ	O
disorder	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
topiramate+risperidone	VB	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
or	CC	O
placebo+risperidone	NN	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
for	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
between	IN	O
10	CD	O
and	CC	O
40	CD	O
kg	NN	O
and	CC	O
3	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
weighting	VBG	O
above	IN	O
40	CD	O
kg	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
topiramate	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
200	CD	O
mg/day	NN	O
depending	VBG	O
on	IN	O
weight	NN	O
(	(	O
100	CD	O
mg/day	NN	O
for	IN	O
<	$	O
30	CD	O
kg	NN	O
and	CC	O
200	CD	O
mg/day	NN	O
for	IN	O
>	$	O
30	CD	O
kg	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
after	IN	O
starting	VBG	O
medication	NN	O
.	.	O

Measure	NN	O
of	IN	O
outcome	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	Ot
Behavior	NNP	Ot
Checklist-Community	NNP	Ot
(	(	Ot
ABC-C	NNP	Ot
)	)	Ot
Rating	VBG	Ot
Scale	NNP	Ot
.	.	O

RESULTS	NNP	O
Difference	NNP	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
topiramate	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
reduction	NN	Ot
in	IN	Ot
ABC-C	NNP	Ot
subscale	NN	Ot
scores	NNS	Ot
for	IN	Ot
irritability	NN	Ot
,	,	O
stereotypic	JJ	PH
behavior	NN	PH
and	CC	O
hyperactivity/noncompliance	NN	ME
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
topiramate	NN	O
with	IN	O
risperidone	NN	O
may	MD	O
be	VB	O
superior	JJ	O
to	TO	O
risperidone	VB	O
monotherapy	NN	O
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

However	RB	O
the	DT	O
results	NNS	O
need	VBP	O
to	TO	O
be	VB	O
further	RB	O
confirmed	VBN	O
by	IN	O
a	DT	O
larger	JJR	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In-season	JJ	O
effect	NN	O
of	IN	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
programs	NNS	O
on	IN	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
2	CD	O
in-season	JJ	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
protocols	NNS	O
on	IN	O
vertical	JJ	O
countermovement	NN	O
jump	NN	O
height	NN	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
arms	NNS	O
)	)	O
,	,	O
sprint	NN	O
(	(	O
Sprint-15m	NNP	O
)	)	O
speed	NN	O
,	,	O
and	CC	O
agility	NN	O
(	(	O
Agility-15m	NNP	O
)	)	O
speed	NN	O
in	IN	O
male	JJ	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

Twenty	NNP	O
highly	RB	O
trained	VBD	O
soccer	NN	O
players	NNS	O
(	(	O
age	NN	O
18.3	CD	O
+/-	JJ	O
0.6	CD	O
years	NNS	O
,	,	O
height	VBD	O
177	CD	O
+/-	JJ	O
4	CD	O
cm	NN	O
,	,	O
body	NN	O
mass	VBD	O
71.4	CD	O
+/-	JJ	O
6.9	CD	O
kg	NN	O
,	,	O
sum	NN	O
skinfolds	NNS	O
48.1	CD	O
+/-	JJ	O
11.4	CD	O
mm	NN	O
)	)	O
,	,	O
members	NNS	O
of	IN	O
a	DT	O
professional	JJ	O
soccer	NN	O
academy	NN	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
CONTRAST	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
SPRINT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
group	NN	O
.	.	O

The	DT	O
training	NN	O
intervention	NN	O
consisted	VBD	O
of	IN	O
6	CD	O
supervised	JJ	O
training	NN	O
sessions	NNS	O
over	IN	O
7	CD	O
weeks	NNS	O
,	,	O
targeting	VBG	O
the	DT	O
improvement	NN	O
of	IN	O
the	DT	O
players	NNS	O
'	POS	O
speed	NN	ME
and	CC	ME
power	NN	ME
.	.	PH

CONTRAST	NNP	O
protocol	NN	O
consisted	VBD	O
of	IN	O
alternating	VBG	O
heavy-light	JJ	O
resistance	NN	O
(	(	O
15-50	CD	O
%	NN	O
body	NN	O
mass	NN	O
)	)	O
with	IN	O
soccer-specific	JJ	O
drills	NNS	O
(	(	O
small-sided	JJ	O
games	NNS	O
or	CC	O
technical	JJ	O
skills	NNS	O
)	)	O
.	.	O

SPRINT	NNP	O
training	NN	O
protocol	NN	O
used	VBN	O
line	NN	O
30-m	JJ	O
sprints	NNS	O
(	(	O
2-4	JJ	O
sets	NNS	O
of	IN	O
4	CD	O
x	JJ	O
30	CD	O
m	NN	O
with	IN	O
180	CD	O
and	CC	O
90	CD	O
seconds	NNS	O
of	IN	O
recovery	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

At	IN	O
baseline	JJ	O
no	DT	O
difference	NN	O
between	IN	O
physical	JJ	PH
test	NN	PH
performance	NN	PH
was	VBD	O
evident	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
time	NN	O
x	VBZ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
vertical	JJ	Ot
jump	NN	Ot
and	CC	Ot
Agility-15m	JJ	Ot
variables	NNS	Ot
(	(	PH
p	JJ	PH
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
time	NN	O
x	JJ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
Sprint-15m	JJ	O
performance	NN	O
with	IN	O
the	DT	O
CONTRAST	NNP	O
group	NN	O
showing	VBG	O
significantly	RB	O
better	JJR	O
scores	NNS	O
than	IN	O
the	DT	O
SPRINT	NNP	O
group	NN	O
(	(	O
7.23	CD	O
+/-	JJ	O
0.18	CD	O
vs.	FW	O
7.09	CD	O
+/-	JJ	O
0.20	CD	O
m.s	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
these	DT	O
findings	NNS	O
CONTRAST	NNP	O
training	NN	O
should	MD	O
be	VB	O
preferred	VBN	O
to	TO	O
line	NN	O
sprint	NN	O
training	NN	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
in	IN	O
young	JJ	O
elite	JJ	O
soccer	NN	O
players	NNS	O
when	WRB	O
the	DT	O
aim	NN	O
is	VBZ	O
to	TO	O
improve	VB	O
soccer-specific	JJ	ME
sprint	NN	ME
performance	NN	ME
(	(	PH
15	CD	PH
m	NN	PH
)	)	PH
during	IN	O
the	DT	O
competitive	JJ	O
season	NN	O
.	.	O

A	DT	O
program	NN	O
of	IN	O
screening	VBG	O
and	CC	O
prompting	VBG	O
improves	NNS	O
short-term	JJ	O
physician	JJ	O
counseling	NN	O
of	IN	O
dependent	NN	O
and	CC	O
nondependent	JJ	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

BACKGROUND	NNP	O
Physicians	NNPS	O
in	IN	O
the	DT	O
general	JJ	O
medical	JJ	O
setting	VBG	O
commonly	RB	O
encounter	RB	O
but	CC	O
rarely	RB	O
counsel	NN	O
patients	NNS	O
with	IN	O
dependent	JJ	O
or	CC	O
harmful	JJ	O
drinking	NN	O
behaviors	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
whether	IN	O
providing	VBG	O
physicians	NNS	O
with	IN	O
their	PRP$	O
patients	NNS	O
'	POS	O
results	NNS	O
on	IN	O
the	DT	O
alcohol	NN	O
module	NN	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
would	MD	O
prompt	VB	O
them	PRP	O
to	TO	O
counsel	NN	O
these	DT	O
patients	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
83	CD	O
first-	JJ	O
,	,	O
second-	JJ	O
,	,	O
and	CC	O
third-year	JJ	O
medical	JJ	O
residents	NNS	O
to	TO	O
receive	VB	O
or	CC	O
not	RB	O
to	TO	O
receive	VB	O
diagnostic	JJ	O
information	NN	O
and	CC	O
counseling	VBG	O
directives	NNS	O
on	IN	O
214	CD	O
patients	NNS	O
who	WP	O
reported	VBD	O
at	IN	O
least	JJS	O
one	CD	O
symptom	NN	O
of	IN	O
alcohol	NN	O
impairment	NN	O
as	IN	O
defined	VBN	O
in	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
.	.	O

Using	VBG	O
binary	JJ	O
logistic	JJ	O
regression	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
specific	JJ	O
covariables	NNS	O
on	IN	O
rates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
.	.	O

These	DT	O
variables	NNS	O
included	VBD	O
physician	JJ	O
information	NN	O
status	NN	O
,	,	O
patient	JJ	O
gender	NN	O
,	,	O
and	CC	O
drinking	VBG	O
disorder	NN	O
severity	NN	O
and	CC	O
recency	NN	O
.	.	O

We	PRP	O
also	RB	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
physician	JJ	O
prompting	VBG	O
on	IN	O
counseling	NN	O
of	IN	O
female	JJ	O
patients	NNS	O
,	,	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

We	PRP	O
determined	VBD	O
counseling	VBG	O
by	IN	O
post-visit	JJ	O
patient	JJ	O
interviews	NNS	O
.	.	O

RESULTS	NNP	O
Physician	JJ	ME
prompting	NN	ME
,	,	O
dependent	JJ	ME
drinking	NN	ME
,	,	O
and	CC	O
recent	JJ	ME
disorder	NN	ME
activity	NN	ME
were	VBD	O
significant	JJ	O
correlates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
,	,	O
while	IN	O
male	JJ	O
gender	NN	O
was	VBD	O
a	DT	O
marginally	RB	O
significant	JJ	O
correlate	NN	O
(	(	O
P	NNP	O
=	NNP	O
.08	NNP	O
)	)	O
.	.	O

Informed	VBN	O
physicians	NNS	O
counseled	VBD	O
female	JJ	O
patients	NNS	O
,	,	O
harmful	JJ	O
but	CC	O
nondependent	JJ	O
drinkers	NNS	O
,	,	O
and	CC	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
more	RBR	O
often	RB	O
than	IN	O
their	PRP$	O
uninformed	JJ	O
colleagues	NNS	O
,	,	O
although	IN	O
only	RB	O
the	DT	O
last	JJ	O
variable	JJ	O
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Providing	VBG	O
physicians	NNS	O
with	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
resulted	VBD	O
in	IN	O
short-term	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
rates	NNS	O
of	IN	O
counseling	VBG	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
dependent	NN	O
or	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinking	NN	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
determine	VB	O
long-term	JJ	O
gains	NNS	O
in	IN	O
rates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
and	CC	O
improvements	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

Antihistamines	NNS	O
do	VBP	O
not	RB	O
inhibit	VB	O
the	DT	O
wheal	NN	O
induced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
autologous	JJ	O
serum	NN	O
in	IN	O
resistant	JJ	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
.	.	O

Some	DT	O
patients	NNS	O
with	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
(	(	O
CIU	NNP	O
)	)	O
are	VBP	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
doses	NNS	O
of	IN	O
antihistamines	NNS	O
(	(	O
AHs	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
check	VB	O
whether	IN	O
the	DT	O
skin	JJ	PH
wheal	NN	PH
and	CC	A
flare	JJ	PH
reaction	NN	PH
produced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
autologous	JJ	O
serum	NN	O
(	(	O
AS	IN	O
)	)	O
and	CC	O
by	IN	O
histamine	NN	O
differs	NNS	O
in	IN	O
AH-resistant	NNP	O
and	CC	O
AH	NNP	O
responder	VBP	O
CIU	NNP	O
patients	NNS	O
.	.	O

CIU	NNP	O
patients	NNS	O
with	IN	O
treatment	NN	O
failure	NN	O
under	IN	O
fexofenadine	NN	O
at	IN	O
180	CD	O
mg	NN	O
q.d	NN	O
.	.	O

increased	VBD	O
their	PRP$	O
daily	JJ	O
dose	NN	O
of	IN	O
AH	NNP	O
to	TO	O
4	CD	O
tablets	NNS	O
daily	RB	O
.	.	O

Those	DT	O
with	IN	O
significant	JJ	O
improvement	NN	O
of	IN	O
urticaria	JJ	O
activity	NN	O
score	NN	O
under	IN	O
fexofenadine	NN	O
at	IN	O
180	CD	O
mg	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
CIU	NNP	O
group	NN	O
.	.	O

Subjects	VBZ	O
with	IN	O
treatment	NN	O
failure	NN	O
despite	IN	O
a	DT	O
full	JJ	O
8-week	JJ	O
fourfold	JJ	O
fexofenadine	NN	O
treatment	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
resistant	JJ	O
CIU	NNP	O
(	(	O
R-CIU	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
sex-	JJ	O
and	CC	O
age-matched	JJ	O
patents	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

The	DT	O
AS	NNP	O
skin	JJ	O
test	NN	O
and	CC	O
intradermal	JJ	O
histamine-induced	JJ	O
wheal	NN	O
and	CC	O
flare	JJ	O
reaction	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
(	(	O
without	IN	O
AH	NNP	O
)	)	O
,	,	O
after	IN	O
8	CD	O
and	CC	O
16	CD	O
weeks	NNS	O
(	(	O
under	IN	O
AH	NNP	O
treatment	NN	O
)	)	O
.	.	O

Forty-six	JJ	O
subjects	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
CIU	NNP	O
group	NN	O
,	,	O
21	CD	O
were	VBD	O
in	IN	O
the	DT	O
R-CIU	NNP	O
group	NN	O
,	,	O
and	CC	O
44	CD	O
were	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Under	IN	O
AH	NNP	O
therapy	NN	O
,	,	O
the	DT	O
skin	JJ	A
reaction	NN	A
to	TO	A
intradermal	VB	A
histamine	JJ	A
injection	NN	A
was	VBD	O
significantly	RB	O
diminished	VBN	O
in	IN	O
all	DT	O
study	NN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
R-CIU	NNP	O
group	NN	O
,	,	O
fexofenadine	NN	O
at	IN	O
180	CD	O
mg	NNS	O
did	VBD	O
not	RB	O
suppress	VB	O
AS-induced	NNP	PH
wheal	JJ	PH
reaction	NN	PH
(	(	O
5.96	CD	O
?	.	O
2.25	CD	O
mm	NN	O
;	:	O
p	CC	O
=	VB	O
0.85	CD	O
)	)	O
,	,	O
and	CC	O
with	IN	O
a	DT	O
fourfold	JJ	O
AH	NNP	O
dose	VB	O
some	DT	O
reduction	NN	O
of	IN	O
AS-induced	NNP	O
wheal	NN	O
(	(	O
3.79	CD	O
?	.	O
1.74	CD	O
mm	NN	O
;	:	O
p	CC	O
=	VB	O
0.008	CD	O
)	)	O
was	VBD	O
observed	VBN	O
but	CC	O
remained	VBD	O
larger	JJR	O
than	IN	O
in	IN	O
the	DT	O
CIU	NNP	O
(	(	O
2.31	CD	O
?	.	O
1.12	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.006	CD	O
)	)	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
2.52	CD	O
?	.	O
1.36	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.037	CD	O
)	)	O
.	.	O

AHs	NNP	O
do	VBP	O
not	RB	O
inhibit	VB	O
the	DT	O
wheal	NN	O
induced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
AS	NNP	O
in	IN	O
R-CIU	NNP	O
.	.	O

Plasma	NNP	O
pH	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
maximal	JJ	O
whole	JJ	O
body	NN	O
exercise	NN	O
.	.	O

Exercise	NN	O
lowers	VBZ	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
of	IN	O
O2	NNP	O
to	TO	O
carbohydrate	VB	O
(	(	O
glucose+1/2	JJ	O
lactate	NN	O
)	)	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
appears	VBZ	O
to	TO	O
promote	VB	Ot
cerebral	JJ	Ot
lactate	JJ	Ot
uptake	NN	Ot
.	.	O

However	RB	O
,	,	O
the	DT	O
influence	NN	O
of	IN	O
pH	NN	O
on	IN	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
and	CC	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
on	IN	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
exercise	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Sodium	NN	O
bicarbonate	NN	O
(	(	O
Bicarb	NNP	O
,	,	O
1	CD	O
M	NNP	O
;	:	O
350-500	CD	O
ml	NN	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
(	(	O
Sal	NNP	O
)	)	O
was	VBD	O
infused	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
constant	JJ	O
rate	NN	O
during	IN	O
a	DT	O
'2000	CD	O
m	NN	O
'	''	O
maximal	JJ	O
ergometer	NN	O
row	NN	O
in	IN	O
six	CD	O
male	JJ	O
oarsmen	NNS	O
(	(	O
23?2	CD	O
years	NNS	O
;	:	O
mean?S.D.	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
Sal	NNP	O
trial	NN	O
,	,	O
pH	NN	O
decreased	VBD	O
from	IN	O
7.41?0.01	CD	O
at	IN	O
rest	NN	O
to	TO	O
7.02?0.02	CD	O
but	CC	O
only	RB	O
to	TO	O
7.36?0.02	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
during	IN	O
the	DT	O
Bicarb	NNP	O
trial	NN	O
.	.	O

Arterial	JJ	O
lactate	NN	O
increased	VBD	O
to	TO	O
21.4?0.8	CD	O
and	CC	O
32.7?2.3	CD	O
mM	NN	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
arterial-jugular	JJ	O
venous	JJ	O
lactate	NN	O
difference	NN	O
increased	VBD	O
from-0.03?0.01	JJ	O
mM	NN	O
at	IN	O
rest	NN	O
to	TO	O
3.2?0.9	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
3.4?1.4	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
following	VBG	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
cerebral	JJ	PH
metabolic	NN	PH
ratio	NN	PH
decreased	VBD	O
equally	RB	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
:	:	O
from	IN	O
5.8?0.6	CD	O
at	IN	O
rest	NN	O
to	TO	O
1.7?0.1	CD	O
and	CC	O
1.8?0.2	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
enlarged	JJ	O
blood-buffering	NN	O
capacity	NN	O
after	IN	O
infusion	NN	O
of	IN	O
Bicarb	NNP	O
eliminated	VBD	O
metabolic	JJ	O
acidosis	NN	O
during	IN	O
maximal	JJ	O
exercise	NN	O
but	CC	O
that	DT	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	O
lactate	NN	O
uptake	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
.	.	O

Incidence	NN	O
and	CC	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
.	.	O

PURPOSE	NNP	O
Since	IN	O
most	JJS	O
patients	NNS	O
do	VBP	O
not	RB	O
undergo	VB	O
repeat	NN	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
after	IN	O
a	DT	O
biopsy	NN	O
is	VBZ	O
positive	JJ	O
for	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
the	DT	O
true	JJ	O
incidence	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
is	VBZ	O
not	RB	O
well	RB	O
defined	VBN	O
.	.	O

We	PRP	O
assess	VBP	O
the	DT	O
incidence	NN	O
and	CC	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
radical	JJ	O
prostatectomy	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
118	CD	O
patients	NNS	O
with	IN	O
biopsy	NN	O
proved	VBN	O
prostate	JJ	O
cancer	NN	O
underwent	JJ	O
repeat	NN	O
sextant	JJ	O
prostate	NN	O
biopsy	NN	O
before	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
radical	JJ	O
prostatectomy	NN	O
with	IN	O
or	CC	O
without	IN	O
neoadjuvant	JJ	O
hormonal	JJ	O
therapy	NN	O
.	.	O

Clinical	JJ	O
parameters	NNS	O
were	VBD	O
assessed	VBN	O
to	TO	O
determine	VB	O
potential	JJ	O
sources	NNS	O
of	IN	O
bias	NN	O
.	.	O

Pathological	JJ	O
parameters	NNS	O
and	CC	O
prostate	NN	A
specific	JJ	A
antigen	NN	A
relapse-free	JJ	A
survival	NN	A
rates	NNS	A
were	VBD	O
compared	VBN	O
to	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
118	CD	O
patients	NNS	O
27	CD	O
(	(	O
23	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
negative	JJ	O
repeat	NN	O
sextant	JJ	O
biopsy	NN	O
.	.	O

Except	IN	O
for	IN	O
initial	JJ	O
clinical	JJ	O
stage	NN	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
clinical	JJ	PH
or	CC	PH
pathological	JJ	PH
parameters	NNS	PH
,	,	O
or	CC	O
prostate	VB	PH
specific	JJ	PH
antigen	NN	PH
relapse	NN	PH
rates	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
negative	JJ	O
versus	NN	O
positive	JJ	O
repeat	NN	O
biopsies	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
this	DT	O
23	CD	O
%	NN	O
incidence	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
represents	VBZ	O
significant	JJ	O
cancer	NN	O
.	.	O

This	DT	O
relatively	RB	O
high	JJ	O
incidence	NN	O
is	VBZ	O
important	JJ	O
to	TO	O
consider	VB	O
in	IN	O
treatment	NN	O
modalities	NNS	O
in	IN	O
which	WDT	O
prostate	VBP	O
biopsy	NN	O
may	MD	O
be	VB	O
performed	VBN	O
to	TO	O
determine	VB	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
an	DT	O
allograft	NN	O
in	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
and	CC	O
a	DT	O
bovine-derived	JJ	O
xenograft	NN	O
used	VBN	O
in	IN	O
ridge	JJ	O
preservation	NN	O
:	:	O
a	DT	O
clinical	JJ	O
and	CC	O
histologic	JJ	O
study	NN	O
in	IN	O
humans	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
blinded	VBD	O
clinical	JJ	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
ridge	JJ	PH
dimensions	NNS	PH
and	CC	PH
histologic	JJ	PH
characteristics	NNS	PH
of	IN	PH
ridges	NNS	PH
preserved	VBN	O
with	IN	O
2	CD	O
different	JJ	O
graft	NN	O
materials	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Twenty-four	NNP	O
subjects	NNS	O
,	,	O
each	DT	O
requiring	VBG	O
a	DT	O
nonmolar	JJ	O
extraction	NN	O
and	CC	O
delayed	JJ	O
implant	NN	O
placement	NN	O
,	,	O
were	VBD	O
randomly	RB	O
selected	VBN	O
to	TO	O
receive	VB	O
ridge	NN	O
preservation	NN	O
treatment	NN	O
with	IN	O
either	DT	O
an	DT	O
allograft	NN	O
in	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
plus	CC	O
a	DT	O
calcium	NN	O
sulfate	NN	O
barrier	NN	O
(	(	O
PUT	NNP	O
)	)	O
or	CC	O
a	DT	O
bovine-derived	JJ	O
xenograft	NN	O
(	(	O
BDX	NNP	O
)	)	O
plus	CC	O
a	DT	O
collagen	NN	O
membrane	NN	O
.	.	O

Horizontal	NNP	PH
and	CC	PH
vertical	JJ	PH
ridge	NN	PH
dimensions	NNS	PH
were	VBD	O
determined	VBN	O
using	VBG	O
a	DT	O
digital	JJ	O
caliper	NN	O
and	CC	O
a	DT	O
template	NN	O
.	.	O

At	IN	O
4	CD	O
months	NNS	O
postextraction	NN	O
,	,	O
a	DT	O
trephine	NN	O
core	NN	O
was	VBD	O
obtained	VBN	O
for	IN	O
histologic	JJ	PH
analysis	NN	PH
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	O
ridge	NN	PH
width	NN	PH
decreased	VBN	O
by	IN	O
0.50	CD	O
mm	NN	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

The	DT	O
midbuccal	JJ	PH
vertical	JJ	PH
change	NN	PH
for	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
was	VBD	O
a	DT	O
loss	NN	O
of	IN	O
0.3+/-0.7	JJ	O
mm	NN	O
versus	IN	O
a	DT	O
gain	NN	O
of	IN	O
0.7+/-1.2	JJ	O
mm	NN	O
for	IN	O
the	DT	O
BDX	NNP	O
group	NN	O
,	,	O
a	DT	O
difference	NN	O
of	IN	O
1.0	CD	O
mm	NN	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
.	.	O

Histologic	NNP	O
analysis	NN	O
revealed	VBD	O
vital	JJ	PH
bone	NN	PH
in	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
of	IN	O
about	RB	O
61	CD	O
%	NN	O
+/-9	JJ	O
%	NN	O
versus	IN	O
26	CD	O
%	NN	O
+/-20	JJ	O
%	NN	O
for	IN	O
the	DT	O
BDX	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

DISCUSSION	NNP	O
Greater	NNP	O
vital	JJ	PH
bone	NN	PH
fill	NN	PH
in	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
may	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
earlier	RBR	O
and	CC	O
greater	JJR	O
vascular	JJ	O
invasion	NN	O
of	IN	O
the	DT	O
carrier	NN	O
material	NN	O
.	.	O

The	DT	O
putty	JJ	O
material	NN	O
was	VBD	O
characterized	VBN	O
by	IN	O
ease	NN	O
of	IN	O
handling	VBG	O
,	,	O
simple	JJ	O
placement	NN	O
,	,	O
and	CC	O
enhanced	VBD	O
graft	NN	O
particle	NN	O
containment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Allograft	NNP	O
mixed	VBD	O
with	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
produced	VBD	O
significantly	RB	O
more	RBR	O
vital	JJ	O
bone	NN	O
fill	NN	O
than	IN	O
did	VBD	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
xenograft	NN	O
with	IN	O
no	DT	O
carrier	NN	O
material	NN	O
.	.	O

Ridge	NNP	PH
width	NN	PH
and	CC	PH
height	JJ	PH
dimensions	NNS	PH
were	VBD	O
similarly	RB	O
preserved	VBN	O
with	IN	O
both	DT	O
graft	NN	O
materials	NNS	O
.	.	O

Lamivudine	NNP	O
300	CD	O
mg	NN	O
QD	NNP	O
versus	NN	O
continued	VBD	O
lamivudine	JJ	O
150	CD	O
mg	NNS	O
BID	NNP	O
with	IN	O
stavudine	NN	O
and	CC	O
a	DT	O
protease	NN	O
inhibitor	NN	O
in	IN	O
suppressed	JJ	O
patients	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
(	(	O
sustained	VBN	O
virologic	IN	O
suppression	NN	O
)	)	O
and	CC	O
safety/tolerability	NN	O
of	IN	O
a	DT	O
switch	NN	O
to	TO	O
lamivudine	VB	O
300	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
(	(	O
QD	NNP	O
)	)	O
versus	NN	O
continued	VBD	O
lamivudine	JJ	O
150	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
(	(	O
BID	NNP	O
)	)	O
in	IN	O
virologically	RB	O
suppressed	VBN	O
patients	NNS	O
(	(	O
HIV-1	NNP	O
RNA	NNP	O
<	NNP	O
400	CD	O
copies/mL	NN	O
for	IN	O
>	NN	O
or	CC	O
=3	JJ	O
months	NNS	O
)	)	O
on	IN	O
stable	JJ	O
(	(	O
>	JJ	O
or	CC	O
=6	JJ	O
months	NNS	O
)	)	O
therapy	NN	O
with	IN	O
lamivudine	JJ	O
150	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
stavudine	NN	O
and	CC	O
either	DT	O
indinavir	NN	O
or	CC	O
nelfinavir	NN	O
.	.	O

METHOD	NNP	O
Eighty-nine	NNP	O
suppressed	VBD	O
patients	NNS	O
>	CD	O
or	CC	O
=18	CD	O
years	NNS	O
old	JJ	O
with	IN	O
CD4	NNP	O
counts	VBZ	O
>	JJ	O
50	CD	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
phase	NN	O
II	NNP	O
,	,	O
open-label	NN	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
stratified	VBN	O
(	(	O
by	IN	O
pretrial	JJ	O
protease	NN	O
inhibitor	NN	O
[	NNP	O
PI	NNP	O
]	NNP	O
)	)	O
,	,	O
parallel-group	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Eighty-one	JJ	O
patients	NNS	O
received	VBD	O
either	RB	O
lamivudine	JJ	O
300	CD	O
mg	NN	O
QD	NNP	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
or	CC	O
150	CD	O
mg	NNS	O
BID	NNP	O
(	(	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
with	IN	O
their	PRP$	O
pretrial	JJ	O
stavudine/PI	NN	O
regimens	NNS	O
for	IN	O
24	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
high	JJ	O
rate	NN	PH
of	IN	PH
virologic	JJ	PH
suppression	NN	PH
was	VBD	O
sustained	VBN	O
with	IN	O
both	DT	O
regimens	NNS	O
throughout	IN	O
the	DT	O
trial	NN	O
.	.	O

At	IN	O
week	NN	O
24	CD	O
,	,	O
intent-to-treat	NN	O
:	:	O
exposed	VBN	O
(	(	O
missing	VBG	O
=	NNP	O
failure	NN	O
)	)	O
analyses	VBZ	O
showed	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
percentage	NN	PH
of	IN	PH
patients	NNS	PH
with	IN	PH
HIV-1	NNP	PH
RNA	NNP	PH
<	NNP	O
400	CD	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
[	JJ	O
QD	NNP	O
]	NNP	O
vs.	IN	O
90	CD	O
%	NN	O
[	JJ	O
BID	NNP	O
]	NNP	O
)	)	O
or	CC	O
<	$	O
50	CD	O
copies/mL	NN	O
(	(	O
82	CD	O
%	NN	O
[	JJ	O
QD	NNP	O
]	NNP	O
vs.	IN	O
81	CD	O
%	NN	O
[	JJ	O
BID	NNP	O
]	NNP	O
)	)	O
or	CC	O
in	IN	O
the	DT	O
median	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
CD4	NNP	PH
counts	NNS	PH
(	(	O
+42	JJ	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
[	NN	O
QD	NNP	O
]	NNP	O
vs.	FW	O
+22	NNP	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
[	FW	O
BID	NNP	O
]	NNP	O
)	)	O
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

No	DT	O
patient	NN	O
experienced	VBD	O
virologic	JJ	PH
failure	NN	PH
,	,	PH
clinical	JJ	PH
disease	NN	PH
progression	NN	PH
,	,	O
or	CC	O
a	DT	O
drug-related	JJ	A
serious	JJ	A
adverse	JJ	A
event	NN	A
during	IN	O
the	DT	O
trial	NN	O
.	.	O

Self-reported	JJ	ME
medication	NN	ME
adherence	NN	ME
was	VBD	O
high	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Patients	NNPS	O
who	WP	O
experience	VBP	O
virologic	JJ	PH
suppression	NN	PH
with	IN	O
a	DT	O
regimen	NNS	O
of	IN	O
lamivudine	JJ	O
150	CD	O
mg	NN	O
BID	NNP	O
in	IN	O
combination	NN	O
with	IN	O
stavudine/PI	NN	O
can	MD	O
maintain	VB	O
that	DT	O
suppression	NN	PH
by	IN	O
continuing	VBG	O
their	PRP$	O
regimen	NNS	O
or	CC	O
switching	VBG	O
to	TO	O
lamivudine	VB	O
300	CD	O
mg	NN	O
QD	NNP	O
and	CC	O
continuing	VBG	O
the	DT	O
other	JJ	O
components	NNS	O
.	.	O

Adverse	JJ	O
event	NN	O
profiles	NNS	O
were	VBD	O
comparable	JJ	O
among	IN	O
treatment	NN	O
regimens	NNS	O
,	,	O
and	CC	O
no	DT	O
new	JJ	O
safety	NN	O
concerns	NNS	O
were	VBD	O
raised	VBN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
chlorhexidine	NN	O
gluconate	NN	O
use	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
perirectal	JJ	O
infections	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
rectal	JJ	PH
infections	NNS	PH
is	VBZ	O
increased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

Complications	NNS	O
associated	VBN	O
with	IN	O
rectal	JJ	O
lesions	NNS	O
may	MD	O
be	VB	O
severe	JJ	O
enough	RB	O
to	TO	O
cause	VB	O
life-threatening	JJ	O
septicemia	NN	O
.	.	O

Clinical	JJ	O
research	NN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
preventive	JJ	O
perirectal	NN	O
skin	NN	O
care	NN	O
is	VBZ	O
scarce	JJ	O
.	.	O

This	DT	O
study	NN	O
's	POS	O
purpose	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
using	VBG	O
chlorhexidine	JJ	O
gluconate	NN	O
(	(	O
CHG	NNP	O
)	)	O
in	IN	O
a	DT	O
prophylactic	JJ	O
perirectal	JJ	O
skin-care	JJ	O
regimen	NNS	O
decreases	VBZ	O
perirectal	JJ	O
infections	NNS	O
and	CC	O
whether	IN	O
it	PRP	O
produces	VBZ	O
more	JJR	O
skin	JJ	O
irritation	NN	O
than	IN	O
a	DT	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

The	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
40	CD	O
patients	NNS	O
,	,	O
16	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
chlorhexidine	NN	O
and	CC	O
24	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

Chi-square	JJ	O
and	CC	O
t-tests	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
incidence	NN	O
of	IN	O
skin	JJ	PH
breakdown	NN	PH
and	CC	O
rectal	JJ	PH
infections	NNS	PH
;	:	PH
the	DT	O
correlation	NN	O
between	IN	O
the	DT	O
two	CD	O
factors	NNS	O
;	:	O
a	DT	O
positive	JJ	O
history	NN	O
of	IN	O
rectal	JJ	O
infections	NNS	O
,	,	O
fissures	NNS	O
,	,	O
or	CC	O
hemorrhoids	NNS	O
;	:	O
presence	NN	O
of	IN	O
hemorrhoids	NNS	O
;	:	O
severity	NN	O
of	IN	O
diarrhea	NN	O
;	:	O
and	CC	O
duration	NN	O
and	CC	O
severity	NN	O
of	IN	O
granulocytopenia	NN	O
.	.	O

A	DT	O
positive	JJ	O
relationship	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
severity	NN	PH
of	IN	PH
granulocytopenia	NN	PH
and	CC	O
the	DT	O
incidence	NN	PH
of	IN	PH
rectal	JJ	PH
infections	NNS	PH
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
occurrence	NN	PH
of	IN	PH
perirectal	JJ	PH
infections	NNS	PH
(	(	O
p	JJ	O
=	NNP	O
0.35	CD	O
)	)	O
or	CC	O
skin	JJ	PH
breakdown	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.18	CD	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
data	NN	O
suggest	NN	O
that	IN	O
CHG	NNP	O
does	VBZ	O
not	RB	O
offer	VB	O
increased	JJ	O
protection	NN	O
against	IN	O
perirectal	JJ	O
infections	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
intensive	JJ	O
chemotherapy	NN	O
,	,	O
nor	CC	O
is	VBZ	O
it	PRP	O
more	RBR	O
irritating	JJ	O
than	IN	O
a	DT	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hygienic	JJ	O
measures	NNS	O
such	JJ	O
as	IN	O
using	VBG	O
skin	JJ	O
disinfectants	NNS	O
to	TO	O
prevent	VB	O
infections	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
immunocompromised	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
intravesical	JJ	O
instillations	NNS	O
of	IN	O
mitoxantrone	NN	O
and	CC	O
doxorubicin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
randomized	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	O
side	JJ	A
effects	NNS	A
of	IN	O
intravesical	JJ	O
mitoxantrone	NN	O
instillation	NN	O
with	IN	O
those	DT	O
of	IN	O
doxorubicin	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
following	VBG	O
transurethral	JJ	O
resection	NN	O
.	.	O

METHODS	NNP	O
Sixty-three	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
mitoxantrone	NN	O
and	CC	O
doxorubicin	NN	O
groups	NNS	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
enrolled	VBN	O
were	VBD	O
elderly	JJ	O
people	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
71	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
instilled	JJ	O
doses	NNS	O
of	IN	O
doxorubicin	NN	O
and	CC	O
mitoxantrone	NN	O
were	VBD	O
30	CD	O
and	CC	O
14	CD	O
mg	NN	O
,	,	O
respectively	RB	O
.	.	O

Disease	NNP	PH
recurrence	NN	PH
and	CC	O
side	NN	A
effects	NNS	A
were	VBD	O
compared	VBN	O
using	VBG	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
.	.	O

The	DT	O
interval	NN	Ot
to	TO	Ot
recurrence	NN	Ot
was	VBD	O
shown	VBN	O
by	IN	O
Kaplan-Meier	NNP	O
survivorship	NN	O
curves	NNS	O
,	,	O
and	CC	O
the	DT	O
log-rank	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
the	DT	O
time	NN	Ot
to	TO	Ot
recurrence	VB	Ot
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
36	CD	O
months	NNS	O
.	.	O

Thirty-three	JJ	O
patients	NNS	O
received	VBD	O
mitoxantrone	NN	O
,	,	O
whereas	JJ	O
30	CD	O
patients	NNS	O
used	VBN	O
doxorubicin	NN	O
.	.	O

The	DT	O
recurrence	NN	Ot
rate	NN	Ot
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
was	VBD	O
30	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
19.8	CD	O
%	NN	O
-38.8	NNP	O
%	NN	O
)	)	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
27.3	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
17.5	CD	O
%	NN	O
-36.8	NNP	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
.	.	O

The	DT	O
median	JJ	MO
recurrence-free	JJ	MO
survival	NN	MO
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
and	CC	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
was	VBD	O
22	CD	O
and	CC	O
20	CD	O
months	NNS	O
,	,	O
respectively	RB	O
(	(	O
p=0.580	NN	O
)	)	O
.	.	O

Higher	JJR	O
recurrence	NN	Ot
rates	NNS	Ot
were	VBD	O
found	VBN	O
for	IN	O
Grade	NNP	O
III	NNP	O
and	CC	O
multiple	JJ	O
primary	JJ	O
tumors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	Ot
rates	NNS	Ot
(	(	O
p=0.784	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
side	NN	A
effects	NNS	A
was	VBD	O
20	CD	O
%	NN	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
and	CC	O
21.2	CD	O
%	NN	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
(	(	O
p	JJ	O
>	NNP	O
0.99	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
efficacy	NN	Ot
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
mitoxantrone	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
of	IN	O
doxorubicin	NN	O
.	.	O

Especially	RB	O
for	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
tuberculosis	NN	O
or	CC	O
aged	VBN	O
patients	NNS	O
with	IN	O
primary	JJ	O
bladder	NN	O
tumors	NNS	O
,	,	O
mitoxantrone	NN	O
and	CC	O
doxorubicin	NN	O
may	MD	O
be	VB	O
the	DT	O
tolerable	JJ	O
and	CC	O
effective	JJ	O
intravesical	JJ	O
agents	NNS	O
.	.	O

Different	NNP	O
therapeutic	JJ	O
modalities	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
melasma	NN	O
.	.	O

BACKGROUND	NNP	O
Chemical	NNP	O
peels	NNS	O
and	CC	O
topical	JJ	O
depigmenting	NN	O
agents	NNS	O
have	VBP	O
become	VBN	O
a	DT	O
popular	JJ	O
modality	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
melasma	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	Ot
efficacy	NN	Ot
of	IN	O
trichloroacetic	JJ	O
acid	NN	O
peel	VB	O
20	CD	O
%	NN	O
vs	NN	O
.	.	O

Jessner	NNP	O
's	POS	O
solution	NN	O
peel	NN	O
vs.	IN	O
the	DT	O
topical	JJ	O
mixture	NN	O
of	IN	O
hydroquinone	NN	O
2	CD	O
%	NN	O
and	CC	O
kojic	NN	O
acid	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty	NNP	O
five	CD	O
patients	NNS	O
with	IN	O
melasma	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
of	IN	O
fifteen	JJ	O
patients	NNS	O
each	DT	O
.	.	O

Group	NNP	O
A	NNP	O
received	VBD	O
Jessner	NNP	O
's	POS	O
solution	NN	O
peel	NN	O
,	,	O
group	NN	O
B	NNP	O
received	VBD	O
trichloroacetic	JJ	O
acid	NN	O
peel	VB	O
20	CD	O
%	NN	O
,	,	O
and	CC	O
group	NN	O
C	NNP	O
received	VBD	O
topical	JJ	O
hydroquinone	NN	O
2	CD	O
%	NN	O
and	CC	O
kojic	NN	O
acid	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
follow-up	JJ	O
period	NN	O
after	IN	O
16	CD	O
weeks	NNS	O
;	:	O
clinical	JJ	O
evaluation	NN	O
using	VBG	O
Melasma	NNP	PH
Area	NNP	PH
and	CC	PH
Severity	NNP	PH
Index	NNP	PH
(	(	PH
MASI	NNP	PH
)	)	PH
score	NN	PH
and	CC	PH
photography	NN	PH
were	VBD	O
recorded	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
16	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
MASI	NNP	PH
score	NN	PH
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
follow-up	JJ	O
period	NN	O
but	CC	O
after	IN	O
treatment	NN	O
MASI	NNP	PH
score	NN	PH
was	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
A	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
also	RB	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

After	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
MASI	NNP	PH
score	NN	PH
was	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
A	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

The	DT	O
statistical	JJ	O
analysis	NN	O
was	VBD	O
done	VBN	O
through	IN	O
one-way	JJ	O
anova	NN	O
followed	VBN	O
by	IN	O
least	JJS	O
significant	JJ	O
difference	NN	O
(	(	O
LSD	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Trichloroacetic	NNP	O
acid	VBD	O
20	CD	O
%	NN	O
showed	VBD	O
better	JJR	O
results	NNS	O
than	IN	O
Jessner	NNP	O
's	POS	O
solution	NN	O
as	IN	O
peeling	NN	O
agent	NN	O
and	CC	O
hydroquinone	VB	O
2	CD	O
%	NN	O
with	IN	O
kojic	JJ	O
acid	NN	O
as	IN	O
a	DT	O
topical	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
melasma	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
follicular	JJ	O
dynamics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
versus	NN	O
recombinant	JJ	O
FSH	NNP	O
during	IN	O
ovarian	JJ	O
stimulation	NN	O
for	IN	O
IVF	NNP	O
.	.	O

A	NNP	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	O
FSH	NNP	O
(	(	O
rFSH	NN	O
)	)	O
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

This	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
assessed	VBD	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
versus	IN	O
daily	JJ	O
200IU	CD	O
rFSH	NN	O
in	IN	O
1509	CD	O
patients	NNS	O
.	.	O

Comparative	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
(	(	O
pharmacokinetics	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
,	,	O
and	CC	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamics	NNS	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
follicular	JJ	O
development	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

By	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
,	,	O
33	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
corifollitropin	NN	O
alfa	NN	O
reached	VBD	O
the	DT	O
criterion	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
(	(	O
HCG	NNP	O
)	)	O
injection	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
follicles	NNS	O
?11mm	NNP	O
was	VBD	O
slightly	RB	O
higher	JJR	O
after	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
at	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
(	(	O
difference	NN	O
,	,	O
1.2	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.5-1.8	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
HCG	NNP	O
injection	NN	O
(	(	O
difference	NN	O
,	,	O
2.1	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.4-2.8	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
rise	NN	O
of	IN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Although	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
and	CC	O
rFSH	NN	O
are	VBP	O
quite	RB	O
different	JJ	O
their	PRP$	O
pharmacodynamic	JJ	O
profiles	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

A	DT	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	O
FSH	NNP	O
(	(	O
rFSH	NN	O
)	)	O
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	JJ	O
versus	JJ	O
daily	JJ	O
rFSH	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1509	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
either	VB	O
a	DT	O
single	JJ	O
injection	NN	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
or	CC	O
to	TO	O
daily	JJ	O
injections	NNS	O
of	IN	O
200IU	CD	O
rFSH	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
ovarian	JJ	O
stimulation	NN	O
.	.	O

Serum	NNP	O
levels	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
were	VBD	O
analysed	VBN	O
(	(	O
pharmacokinetic	JJ	O
analysis	NN	O
)	)	O
,	,	O
together	RB	O
with	IN	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
and	CC	O
serum	NN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
the	DT	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamic	JJ	O
analysis	NN	O
)	)	O
.	.	O

Serum	NNP	O
FSH	NNP	O
immunoreactivity	NN	O
levels	NNS	O
were	VBD	O
higher	JJR	O
up	RB	O
to	TO	O
stimulation	VB	O
day	NN	O
5	CD	O
for	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
the	DT	O
daily	JJ	O
rFSH	NN	O
regimen	NNS	O
but	CC	O
were	VBD	O
similar	JJ	O
from	IN	O
day	NN	O
8	CD	O
onwards	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
started	VBD	O
rFSH	RB	O
if	IN	O
the	DT	O
criteria	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
were	VBD	O
not	RB	O
yet	RB	O
reached	VBN	O
.	.	O

Corifollitropin	NNP	O
alfa	JJ	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
similar	JJ	O
growth	NN	O
rate	NN	O
of	IN	O
follicles	NNS	O
though	IN	O
a	DT	O
slightly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
follicles	NNS	O
were	VBD	O
recruited	VBN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
and	CC	O
rFSH	NN	O
are	VBP	O
quite	RB	O
different	JJ	O
but	CC	O
their	PRP$	O
induced	JJ	O
pharmacodynamic	JJ	O
effects	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

14	CD	O
day	NN	O
endoscopy	NN	O
study	NN	O
comparing	VBG	O
risedronate	NN	O
and	CC	O
alendronate	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
stratified	VBN	O
by	IN	O
Helicobacter	NNP	O
pylori	NN	O
status	NN	O
.	.	O

OBJECTIVE	NNP	O
Bisphosphonates	NNPS	O
are	VBP	O
effective	JJ	O
treatment	NN	O
for	IN	O
osteoporosis	NN	O
but	CC	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
mucosal	NN	O
injury	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
after	IN	O
treatment	NN	O
with	IN	O
risedronate	NN	O
,	,	O
a	DT	O
pyridinyl	NN	O
bisphosphonate	NN	O
,	,	O
or	CC	O
alendronate	NN	O
,	,	O
a	DT	O
primary	JJ	O
amino	NN	O
bisphosphonate	NN	O
,	,	O
in	IN	O
healthy	JJ	O
postmenopausal	NN	O
women	NNS	O
stratified	VBN	O
by	IN	O
Helicobacter	NNP	O
pylori	NN	O
status	NN	O
.	.	O

METHODS	NNP	O
Subjects	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
risedronate	NN	O
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
318	CD	O
)	)	O
or	CC	O
alendronate	$	O
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
317	CD	O
)	)	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Endoscopy	NNP	O
and	CC	O
evaluator-blind	JJ	O
assessments	NNS	O
of	IN	O
the	DT	O
esophageal	NN	O
,	,	O
gastric	NN	O
,	,	O
and	CC	O
duodenal	JJ	O
mucosa	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
on	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
gastric	JJ	PH
ulcers	NNS	PH
>	VBP	O
or	CC	O
=	VBP	O
3	CD	O
mm	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
18	CD	O
(	(	O
6.0	CD	O
%	NN	O
)	)	O
of	IN	O
300	CD	O
evaluable	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
risedronate	NN	O
group	NN	O
and	CC	O
36	CD	O
(	(	O
12.1	CD	O
%	NN	O
)	)	O
of	IN	O
297	CD	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
during	IN	O
treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

On	IN	O
Day	NNP	O
8	CD	O
,	,	O
the	DT	O
incidences	NNS	PH
of	IN	PH
gastric	JJ	PH
ulcers	NNS	PH
in	IN	O
the	DT	O
risedronate	NN	O
and	CC	O
alendronate	NN	O
groups	NNS	O
were	VBD	O
3.6	CD	O
%	NN	O
and	CC	O
6.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.133	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
Day	NNP	O
15	CD	O
,	,	O
they	PRP	O
were	VBD	O
3.3	CD	O
%	NN	O
and	CC	O
8.7	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	PH
of	IN	PH
gastric	JJ	PH
ulcers	NNS	PH
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
H.	NNP	O
pylori	NN	O
status	NN	O
.	.	O

Mean	NNP	Ot
gastric	JJ	Ot
endoscopy	NN	Ot
scores	NNS	Ot
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
risedronate	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Mean	JJ	Ot
esophageal	NN	Ot
and	CC	Ot
duodenal	JJ	Ot
endoscopy	NN	Ot
scores	NNS	Ot
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
.	.	O

When	WRB	O
the	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
combined	VBN	O
,	,	O
gastric	JJ	Ot
endoscopy	NN	Ot
scores	NNS	Ot
were	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
H.	NNP	O
pylori	FW	O
negative	JJ	O
than	IN	O
H.	NNP	O
pylori	FW	O
positive	JJ	O
subjects	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
(	(	O
p	NN	O
<	RB	O
0.05	CD	O
)	)	O
.	.	O

Upper	NNP	A
GI	NNP	A
adverse	JJ	A
events	NNS	A
were	VBD	O
reported	VBN	O
by	IN	O
18	CD	O
(	(	O
5.7	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
in	IN	O
the	DT	O
risedronate	NN	O
group	NN	O
(	(	O
19	CD	O
events	NNS	O
)	)	O
and	CC	O
28	CD	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
(	(	O
32	CD	O
events	NNS	O
)	)	O
.	.	O

Symptoms	NNS	O
did	VBD	O
not	RB	O
predict	VB	O
the	DT	O
presence	NN	O
of	IN	O
mucosal	JJ	O
damage	NN	O
.	.	O

CONCLUSION	NNP	O
Risedronate	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
than	IN	O
alendronate	NN	O
.	.	O

H.	NNP	O
pylori	JJ	O
infection	NN	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
incidence	NN	O
of	IN	O
bisphosphonate	NN	O
related	VBN	O
gastric	JJ	O
ulcers	NNS	O
.	.	O

The	DT	O
findings	NNS	O
from	IN	O
this	DT	O
14	CD	O
day	NN	O
study	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	WDT	O
bisphosphonates	VBZ	O
may	MD	O
differ	VB	O
from	IN	O
one	CD	O
another	DT	O
in	IN	O
their	PRP$	O
potential	JJ	O
to	TO	O
produce	VB	O
upper	JJ	O
GI	NNP	O
mucosal	NN	O
damage	NN	O
.	.	O

Prophylactic	JJ	O
lidocaine	NN	O
in	IN	O
the	DT	O
early	JJ	O
phase	NN	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Four	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
seen	VBN	O
within	IN	O
6	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
lidocaine	NN	O
vs	NN	O
placebo	NN	O
.	.	O

During	IN	O
the	DT	O
1	CD	O
hour	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
the	DT	O
incidence	NN	PH
of	IN	PH
ventricular	JJ	PH
fibrillation	NN	PH
or	CC	O
sustained	VBN	PH
ventricular	JJ	PH
tachycardia	NN	PH
among	IN	O
the	DT	O
204	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
low	JJ	O
,	,	O
1.5	CD	O
%	NN	O
.	.	O

Lidocaine	NNP	O
,	,	O
given	VBN	O
in	IN	O
a	DT	O
300	CD	O
mg	NN	O
dose	VBD	O
intramuscularly	RB	O
followed	VBN	O
by	IN	O
100	CD	O
mg	NN	O
intravenously	RB	O
,	,	O
did	VBD	O
not	RB	O
prevent	VB	O
sustained	JJ	PH
ventricular	JJ	PH
tachycardia	NN	PH
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	PH
of	IN	PH
patients	NNS	PH
with	IN	PH
warning	VBG	PH
arrhythmias	NNS	PH
between	IN	O
15	CD	O
and	CC	O
45	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
average	JJ	PH
plasma	JJ	PH
lidocaine	JJ	PH
level	NN	PH
10	CD	O
minutes	NNS	Ot
after	IN	Ot
administration	NN	O
for	IN	O
patients	NNS	O
without	IN	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
patients	NNS	O
with	IN	O
an	DT	O
acute	JJ	O
infarction	NN	O
.	.	O

The	DT	O
mean	JJ	PH
plasma	NN	PH
lidocaine	JJ	PH
level	NN	PH
of	IN	O
patients	NNS	O
on	IN	O
beta-blocking	JJ	O
agents	NNS	O
was	VBD	O
no	DT	O
different	JJ	O
from	IN	O
that	DT	O
in	IN	O
patients	NNS	O
not	RB	O
on	IN	O
beta	NN	O
blocking	VBG	O
agents	NNS	O
.	.	O

During	IN	O
the	DT	O
1-hour	JJ	O
study	NN	O
period	NN	O
,	,	O
the	DT	O
incidence	NN	A
of	IN	A
central	JJ	A
nervous	JJ	A
system	NN	A
side	NN	A
effects	NNS	A
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
lidocaine	NN	O
group	NN	O
,	,	O
hypotension	NN	PH
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
,	,	O
nine	CD	O
of	IN	O
whom	WP	O
had	VBD	O
received	VBN	O
lidocaine	NN	O
,	,	O
and	CC	O
four	CD	O
patients	NNS	O
died	VBD	MO
from	IN	O
asystole	NN	O
,	,	O
three	CD	O
of	IN	O
whom	WP	O
had	VBD	O
had	VBN	O
lidocaine	NN	O
.	.	O

We	PRP	O
can	MD	O
not	RB	O
advocate	VB	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	JJ	O
prophylactically	RB	O
in	IN	O
the	DT	O
early	JJ	O
hours	NNS	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Intravenous	JJ	O
platelet	NN	O
blockade	NN	O
with	IN	O
cangrelor	NN	O
during	IN	O
PCI	NNP	O
.	.	O

BACKGROUND	NNP	O
Intravenous	NNP	O
cangrelor	NN	O
,	,	O
a	DT	O
rapid-acting	NN	O
,	,	O
reversible	JJ	O
adenosine	NN	O
diphosphate	NN	O
(	(	O
ADP	NNP	O
)	)	O
receptor	NN	O
antagonist	NN	O
,	,	O
might	MD	O
reduce	VB	O
ischemic	JJ	O
events	NNS	O
during	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	JJ	O
5362	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
clopidogrel	NN	O
to	TO	O
receive	VB	O
either	DT	O
cangrelor	NN	O
or	CC	O
placebo	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
PCI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
600	CD	O
mg	NNS	O
of	IN	O
clopidogrel	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
composite	JJ	MO
of	IN	MO
death	NN	MO
,	,	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	PH
or	CC	PH
ischemia-driven	JJ	PH
revascularization	NN	PH
at	IN	PH
48	CD	PH
hours	NNS	PH
.	.	PH

Enrollment	NN	O
was	VBD	O
stopped	VBN	O
when	WRB	O
an	DT	O
interim	JJ	O
analysis	NN	O
concluded	VBD	O
that	IN	O
the	DT	O
trial	NN	O
would	MD	O
be	VB	O
unlikely	JJ	O
to	TO	O
show	VB	O
superiority	NN	O
for	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
primary	JJ	PH
end	NN	PH
point	NN	PH
occurred	VBD	O
in	IN	O
185	CD	O
of	IN	O
2654	CD	O
patients	NNS	O
receiving	VBG	O
cangrelor	NN	O
(	(	O
7.0	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
210	CD	O
of	IN	O
2641	CD	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
8.0	CD	O
%	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	NN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
0.87	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.71	CD	O
to	TO	O
1.07	CD	O
;	:	O
P=0.17	NNP	O
)	)	O
(	(	O
modified	VBN	O
intention-to-treat	NN	O
population	NN	O
adjusted	VBN	O
for	IN	O
missing	VBG	O
data	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
two	CD	O
prespecified	VBD	O
secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
48	CD	O
hours	NNS	O
:	:	O
the	DT	O
rate	NN	PH
of	IN	PH
stent	JJ	PH
thrombosis	NN	PH
,	,	O
from	IN	O
0.6	CD	O
%	NN	O
to	TO	O
0.2	CD	O
%	NN	O
(	(	O
odds	JJ	O
ratio	NN	O
,	,	O
0.31	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.11	CD	O
to	TO	O
0.85	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
rate	NN	MO
of	IN	MO
death	NN	MO
from	IN	MO
any	DT	MO
cause	NN	MO
,	,	O
from	IN	O
0.7	CD	O
%	NN	O
to	TO	O
0.2	CD	O
%	NN	O
(	(	O
odds	JJ	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.13	CD	O
to	TO	O
0.83	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	PH
of	IN	PH
blood	NN	PH
transfusion	NN	PH
(	(	O
1.0	CD	O
%	NN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
and	CC	O
0.6	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
P=0.13	NNP	O
)	)	O
,	,	O
though	IN	O
major	JJ	PH
bleeding	VBG	PH
on	IN	O
one	CD	O
scale	NN	O
was	VBD	O
increased	VBN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
from	IN	O
3.5	CD	O
%	NN	O
to	TO	O
5.5	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
because	IN	O
of	IN	O
more	JJR	O
groin	JJ	PH
hematomas	NN	PH
.	.	PH

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
periprocedural	JJ	O
cangrelor	NN	O
during	IN	O
PCI	NNP	O
was	VBD	O
not	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
reducing	VBG	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
.	.	O

The	DT	O
prespecified	JJ	O
secondary	JJ	O
end	NN	O
points	NNS	O
of	IN	O
stent	JJ	O
thrombosis	NN	O
and	CC	O
death	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
transfusion	NN	O
.	.	O

Further	NNP	O
study	NN	O
of	IN	O
intravenous	JJ	O
ADP	NNP	O
blockade	NN	O
with	IN	O
cangrelor	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00385138	NNP	O
.	.	O

)	)	O
Comparative	JJ	O
efficacy	NN	O
of	IN	O
oral	JJ	O
erythromycin	FW	O
versus	FW	O
oral	JJ	O
tetracycline	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acne	JJ	PH
vulgaris	NN	PH
.	.	PH

A	DT	O
double-blind	JJ	O
study	NN	O
.	.	O

The	DT	O
efficacy	NN	Ot
of	IN	O
erythromycin	JJ	PH
base	NN	PH
(	(	PH
E-Mycin	JJ	PH
tablets	NNS	PH
,	,	PH
333	CD	PH
mg	NN	PH
)	)	PH
and	CC	O
the	DT	O
efficacy	NN	PH
of	IN	O
tetracycline	JJ	PH
hydrochloride	NN	PH
(	(	O
Panmycin	NNP	O
tablets	NNS	O
)	)	O
were	VBD	O
compared	VBN	O
in	IN	O
this	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

Two	CD	O
hundred	VBD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
moderately	RB	O
severe	JJ	O
acne	NNS	O
vulgaris	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
study	NN	O
.	.	O

One	CD	O
hundred	VBD	O
patients	NNS	O
received	VBD	O
1	CD	O
gm	NN	O
of	IN	O
erythromycin	JJ	O
base	NN	O
by	IN	O
mouth	JJ	O
per	IN	O
day	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
333	CD	O
mg/day	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
,	,	O
plus	CC	O
placebo	NN	O
for	IN	O
tetracycline	NN	O
.	.	O

The	DT	O
second	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
received	VBD	O
1	CD	O
gm	NN	O
of	IN	O
tetracycline	NN	O
by	IN	O
mouth	JJ	O
per	IN	O
day	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
500	CD	O
mg/day	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
,	,	O
plus	CC	O
placebo	NN	O
for	IN	O
erythromycin	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
reduced	VBD	O
acne	JJ	PH
severity	NN	PH
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
.	.	O

Pustules	NNP	PH
,	,	PH
papules	NNS	PH
,	,	PH
and	CC	PH
open	JJ	PH
comedo	NN	PH
counts	NNS	PH
decreased	VBN	O
significantly	RB	O
over	IN	O
the	DT	O
12-week	JJ	O
period	NN	O
.	.	O

Seventy-seven	JJ	O
percent	NN	O
of	IN	O
the	DT	O
erythromycin-treated	JJ	O
patients	NNS	O
and	CC	O
89	CD	O
%	NN	O
of	IN	O
the	DT	O
tetracycline-treated	JJ	O
patients	NNS	O
stated	VBD	O
that	IN	O
their	PRP$	O
acne	NN	PH
was	VBD	O
markedly	RB	O
improved	VBN	O
or	CC	O
improved	VBN	O
by	IN	O
week	NN	O
12	CD	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
side	NN	O
effects	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
erythromycin	NNS	O
were	VBD	O
gastrointestinal	JJ	A
symptoms	NNS	A
.	.	A

Among	IN	O
the	DT	O
side	NN	O
effects	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tetracycline	NN	O
were	VBD	O
Candida	NNP	PH
vaginitis	NN	PH
in	IN	O
one	CD	O
patient	NN	O
and	CC	O
pseudotumor	NN	PH
cerebri	NN	PH
in	IN	O
one	CD	O
patient	NN	O
.	.	O

Randomized	NNP	O
comparison	NN	O
of	IN	O
two	CD	O
communication	NN	O
interventions	NNS	O
for	IN	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
group	NN	O
experiment	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
2	CD	O
communication	NN	O
interventions	NNS	O
(	(	O
Responsive	JJ	O
Education	NN	O
and	CC	O
Prelinguistic	NNP	O
Milieu	NNP	O
Teaching	NNP	O
[	NNP	O
RPMT	NNP	O
]	NNP	O
and	CC	O
the	DT	O
Picture	NNP	O
Exchange	NNP	O
Communication	NNP	O
System	NNP	O
[	NNP	O
PECS	NNP	O
]	NNP	O
)	)	O
in	IN	O
36	CD	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Each	DT	O
treatment	NN	O
was	VBD	O
delivered	VBN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
in	IN	O
20-min	JJ	O
sessions	NNS	O
,	,	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
RPMT	NNP	O
facilitated	VBD	O
the	DT	O
frequency	NN	ME
of	IN	ME
generalized	JJ	ME
turn	NN	ME
taking	VBG	ME
and	CC	O
generalized	VBN	ME
initiating	NN	ME
joint	JJ	ME
attention	NN	ME
more	RBR	O
than	IN	O
did	VBD	O
the	DT	O
PECS	NNP	O
.	.	O

The	DT	O
latter	JJ	O
effect	NN	O
occurred	VBD	O
only	RB	O
for	IN	O
children	NNS	O
who	WP	O
began	VBD	O
treatment	NN	O
with	IN	O
at	IN	O
least	JJS	O
some	DT	O
initiating	VBG	ME
joint	JJ	ME
attention	NN	ME
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
PECS	NNP	O
facilitated	VBD	O
generalized	JJ	ME
requests	NNS	ME
more	RBR	O
than	IN	O
the	DT	O
RPMT	NNP	O
in	IN	O
children	NNS	O
with	IN	O
very	RB	O
little	JJ	O
initiating	VBG	ME
joint	JJ	ME
attention	NN	ME
prior	RB	O
to	TO	O
treatment	NN	O
.	.	O

These	DT	O
effect	NN	Ot
sizes	NNS	Ot
were	VBD	O
large	JJ	Ot
.	.	O

Remifentanil	NNP	O
with	IN	O
morphine	JJ	O
transitional	JJ	O
analgesia	NN	O
shortens	VBZ	O
neurological	JJ	PH
recovery	NN	PH
compared	VBN	O
to	TO	O
fentanyl	VB	O
for	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
recovery	NN	PH
profiles	NNS	PH
,	,	O
efficacy	NN	Ot
and	CC	O
safety	NN	Ot
of	IN	O
remifentanil	NN	O
and	CC	O
morphine	NN	O
for	IN	O
transitional	JJ	O
analgesia	NN	O
with	IN	O
fentanyl	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
craniotomy	NN	O
for	IN	O
supratentorial	JJ	O
mass	NN	O
lesions	NNS	O
.	.	O

METHODS	NNP	O
Ninety-one	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicentre	FW	O
study	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	O
and	CC	O
remifentanil	NN	O
(	(	O
1.0	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
bolus	NN	O
and	CC	O
a	DT	O
1	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
infusion	NN	O
)	)	O
or	CC	O
fentanyl	NN	O
(	(	O
1	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
bolus	NN	O
and	CC	O
a	DT	O
1.0	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
infusion	NN	O
)	)	O
.	.	O

The	DT	O
opioid	JJ	O
infusion	NN	O
continued	VBD	O
until	IN	O
the	DT	O
level	NN	O
of	IN	O
anesthesia	NN	O
was	VBD	O
deemed	VBN	O
appropriate	JJ	O
for	IN	O
intubation	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
N	NNP	O
(	(	O
2	CD	O
)	)	O
O/O	NNP	O
(	(	O
2	CD	O
)	)	O
,	,	O
isoflurane	$	O
0.5	CD	O
MAC	NNP	O
and	CC	O
remifentanil	VB	O
0.2	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	JJ	O
)	)	O
or	CC	O
fentanyl	$	O
0.04	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

At	IN	O
bone	NN	O
flap	NN	O
replacement	NN	O
,	,	O
either	DT	O
morphine	NN	O
0.08	CD	O
mg	NN	O
x	NN	O
kg	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
remifentanil	JJ	O
group	NN	O
)	)	O
or	CC	O
saline	NN	O
(	(	O
fentanyl	JJ	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
.	.	O

RESULTS	NNP	O
Systolic	NNP	PH
blood	NN	PH
pressure	NN	PH
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
receiving	VBG	O
fentanyl	NN	O
during	IN	O
induction	NN	O
(	(	O
145.6	CD	O
+/-17.5	JJ	O
mmHg	NN	O
vs	NN	O
128.8	CD	O
+/-18.3	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
intubation	NN	O
(	(	O
126.9	CD	O
+/-17.1	JJ	O
vs	NN	O
110.9	CD	O
+/-16.5	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Median	JJ	PH
time	NN	PH
to	TO	PH
tracheal	VB	PH
extubation	NN	PH
was	VBD	O
similar	JJ	O
but	CC	O
less	RBR	O
variable	JJ	O
in	IN	O
the	DT	O
remifentanil	NN	O
group	NN	O
(	(	O
remifentanil	JJ	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
2-44	JJ	O
min	NN	O
;	:	O
fentanyl	CC	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
1-732	JJ	O
min	NN	O
)	)	O
.	.	O

The	DT	O
fentanyl	JJ	O
patients	NNS	O
required	VBD	O
a	DT	O
longer	JJR	O
time	NN	PH
to	TO	PH
achieve	VB	PH
the	DT	PH
first	JJ	PH
normal	JJ	PH
neurological	JJ	PH
score	NN	PH
(	(	O
fentanyl	JJ	O
=	$	O
38.0	CD	O
min	NN	O
;	:	O
remifentanil	CC	O
=	$	O
26.0	CD	O
min	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
anesthesiologists	NNS	O
and	CC	O
the	DT	O
recovery	NN	O
room	NN	O
nurses	NNS	O
rated	VBD	O
remifentanil	JJ	O
better	RBR	O
with	IN	O
respect	NN	O
to	TO	O
level	NN	ME
of	IN	ME
consciousness	NN	ME
.	.	O

Analgesics	NNS	PA
were	VBD	O
required	VBN	O
earlier	RBR	O
in	IN	O
patients	NNS	O
receiving	VBG	O
remifentanil	NN	O
;	:	O
median	JJ	O
time	NN	O
0.5	CD	O
vs	NN	O
1.08	CD	O
hr	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
.	.	O

CONCLUSIONS	NNP	O
Remifentanil	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
in	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

Time	NN	PH
to	TO	PH
preoperative	VB	PH
neurological	JJ	PH
recovery	NN	PH
is	VBZ	O
faster	RBR	O
and	CC	O
morphine	VB	O
provides	VBZ	O
some	DT	O
transitional	JJ	PA
analgesia	NN	PA
without	IN	O
compromising	VBG	O
the	DT	O
quality	NN	Ot
of	IN	Ot
recovery	NN	Ot
.	.	O

Effect	NN	O
of	IN	O
delayed	JJ	O
cord	NN	O
clamping	VBG	O
on	IN	O
iron	NN	PH
stores	NNS	PH
in	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
anemic	JJ	O
mothers	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
cord	NN	O
clamping	VBG	O
on	IN	O
iron	NN	O
stores	NNS	O
of	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
anemic	VB	O
mothers	NNS	O
at	IN	O
3	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
Teaching	NNP	O
hospital	NN	O
.	.	O

METHODS	NNP	O
Infants	NNPS	O
born	VBN	O
to	TO	O
mothers	NNS	O
with	IN	O
hemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
<	VBD	O
100	CD	O
g/L	NNS	O
were	VBD	O
randomized	VBN	O
at	IN	O
delivery	NN	O
to	TO	O
either	DT	O
immediate	JJ	O
cord	NN	O
clamping	NN	O
(	(	O
early	JJ	O
group	NN	O
)	)	O
or	CC	O
cord	NN	O
clamping	VBG	O
delayed	VBN	O
till	JJ	O
descent	NN	O
of	IN	O
placenta	NN	O
into	IN	O
vagina	NN	O
(	(	O
delayed	VBN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
infant	NN	PH
's	POS	PH
hemoglobin	NN	PH
and	CC	PH
serum	NN	PH
ferritin	VBP	PH
3	CD	PH
months	NNS	PH
after	IN	PH
delivery	NN	PH
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
102	CD	O
neonates	NNS	O
randomized	VBN	O
to	TO	O
early	JJ	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
or	CC	O
delayed	VBN	O
cord	NN	O
clamping	NN	O
(	(	O
n	JJ	O
=	NNP	O
59	CD	O
)	)	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
maternal	JJ	O
age	NN	O
,	,	O
parity	NN	O
,	,	O
weight	NN	O
and	CC	O
supplemental	JJ	O
iron	NN	O
intake	NN	O
,	,	O
infant	JJ	O
s	NN	O
birth	NN	O
weight	NN	O
,	,	O
gestation	NN	O
and	CC	O
sex	NN	O
.	.	O

The	DT	O
mean	JJ	PH
infant	NN	PH
ferritin	NN	PH
and	CC	PH
Hb	NNP	PH
at	IN	PH
3	CD	PH
months	NNS	PH
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
delayed	JJ	O
clamping	NN	O
group	NN	O
(	(	O
118.4	CD	O
microg/L	NN	O
and	CC	O
99	CD	O
g/L	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
early	JJ	O
clamping	NN	O
group	NN	O
(	(	O
73	CD	O
microg/L	NN	O
and	CC	O
88	CD	O
g/L	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
Hb	NNP	PH
(	(	O
g/L	NN	O
)	)	O
at	IN	O
3	CD	O
months	NNS	O
adjusted	VBN	O
for	IN	O
co-variates	NNS	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
delayed	JJ	O
clamping	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
early	JJ	O
clamping	NN	O
group	NN	O
(	(	O
-1.09	NNP	O
,	,	O
95	CD	O
%	NN	O
CI-1.58	NNP	O
to	TO	O
-0.62	VB	O
,	,	O
p	VB	O
>	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
odds	NNS	O
for	IN	O
anemia	NN	PH
(	(	O
<	JJ	O
100	CD	O
g/L	NN	O
)	)	O
at	IN	O
3	CD	O
months	NNS	O
was	VBD	O
7.7	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.84-34.9	CD	O
)	)	O
times	NNS	O
higher	RBR	O
in	IN	O
the	DT	O
early	JJ	O
compared	VBN	O
to	TO	O
the	DT	O
delayed	JJ	O
clamping	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Iron	NNP	PH
stores	NNS	PH
and	CC	O
Hb	NNP	PH
in	IN	O
infancy	NN	O
can	MD	O
be	VB	O
improved	VBN	O
in	IN	O
neonates	NNS	O
born	VBN	O
to	TO	O
anemic	VB	O
mothers	NNS	O
by	IN	O
delaying	VBG	O
cord	NN	O
clamping	NN	O
at	IN	O
birth	NN	O
.	.	O

Teaching	VBG	O
emotion	NN	ME
recognition	NN	ME
skills	NNS	ME
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
emotion	NN	O
training	NN	O
programme	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
have	VBP	O
difficulties	NNS	O
in	IN	O
emotion	NN	O
recognition	NN	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
to	TO	O
target	VB	O
these	DT	O
problems	NNS	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
emotion	NN	O
training	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
trialled	VBN	O
with	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
co-morbid	JJ	O
ID	NNP	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
an	DT	O
emotion	NN	O
training	NN	O
programme	NN	O
for	IN	O
a	DT	O
group	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
intellectual	JJ	O
ability	NN	O
.	.	O

METHODS	NNP	O
Participants	NNPS	O
were	VBD	O
55	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBN	O
4-7	CD	O
years	NNS	O
(	(	O
FSIQ	NNP	O
42-107	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	O
designed	VBN	O
to	TO	O
teach	VB	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
the	DT	O
Transporters	NNPS	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	O
of	IN	O
Thomas	NNP	O
the	DT	O
Tank	NNP	O
Engine	NNP	O
.	.	O

Participants	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
complete	VB	O
basic	JJ	ME
emotion	NN	ME
recognition	NN	ME
tasks	NNS	ME
,	,	O
mindreading	VBG	ME
and	CC	O
theory	NN	ME
of	IN	ME
mind	NN	ME
(	(	ME
TOM	NNP	ME
)	)	ME
tasks	NNS	ME
before	IN	O
and	CC	O
after	IN	O
the	DT	O
4-week	JJ	O
intervention	NN	O
period	NN	O
,	,	O
and	CC	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Analyses	NNP	O
controlled	VBD	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
chronological	JJ	O
age	NN	O
,	,	O
verbal	JJ	O
intelligence	NN	O
,	,	O
gender	NN	O
and	CC	O
DVD	NNP	O
viewing	VBG	O
time	NN	O
on	IN	O
outcomes	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
improved	JJ	O
performance	NN	O
in	IN	O
the	DT	O
recognition	NN	ME
of	IN	ME
anger	NN	ME
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
few	JJ	O
improvements	NNS	O
maintained	VBD	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
generalisation	NN	O
of	IN	O
skills	NNS	O
to	TO	O
TOM	NNP	ME
or	CC	O
social	JJ	ME
skills	NNS	ME
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Transporters	NNP	O
programme	NN	O
showed	VBD	O
limited	JJ	O
efficacy	NN	Ot
in	IN	O
teaching	VBG	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
lower	JJR	O
range	NN	O
of	IN	O
cognitive	JJ	O
ability	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
recognition	NN	O
of	IN	O
expressions	NNS	O
of	IN	O
anger	NN	O
,	,	O
with	IN	O
poor	JJ	O
maintenance	NN	O
of	IN	O
these	DT	O
skills	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

These	DT	O
findings	NNS	O
provide	VBP	O
limited	JJ	O
support	NN	O
for	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
Transporters	NNP	O
programme	NN	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
of	IN	O
a	DT	O
lower	JJR	O
cognitive	JJ	O
range	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
yoga	NNP	O
versus	NN	O
stretching	VBG	O
for	IN	O
chronic	JJ	PA
low	JJ	PA
back	RB	PA
pain	NN	PA
:	:	O
protocol	NN	O
for	IN	O
the	DT	O
Yoga	NNP	O
Exercise	NNP	O
Self-care	NNP	O
(	(	O
YES	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Back	NNP	PA
pain	NN	PA
,	,	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
prevalent	JJ	O
conditions	NNS	O
afflicting	VBG	O
American	JJ	O
adults	NNS	O
,	,	O
is	VBZ	O
the	DT	O
leading	VBG	O
reason	NN	O
for	IN	O
using	VBG	O
complementary	JJ	O
and	CC	O
alternative	JJ	O
medicine	NN	O
(	(	O
CAM	NNP	O
)	)	O
therapies	NNS	O
.	.	O

Yoga	NNP	O
is	VBZ	O
an	DT	O
increasingly	RB	O
popular	JJ	O
mind-body	NN	O
CAM	NNP	O
therapy	NN	O
often	RB	O
used	VBN	O
for	IN	O
relieving	VBG	PA
back	RB	PA
pain	NN	PA
and	CC	O
several	JJ	O
small	JJ	O
studies	NNS	O
have	VBP	O
found	VBN	O
yoga	RB	O
effective	JJ	O
for	IN	O
this	DT	O
condition	NN	O
.	.	O

This	DT	O
study	NN	O
will	MD	O
assess	VB	O
whether	IN	O
yoga	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
chronic	JJ	PA
low	JJ	PA
back	RB	PA
pain	NN	PA
compared	VBN	O
with	IN	O
self	PRP	O
care	NN	O
and	CC	O
exercise	NN	O
and	CC	O
will	MD	O
explore	VB	O
the	DT	O
mechanisms	NNS	O
responsible	JJ	O
for	IN	O
any	DT	O
observed	JJ	O
benefits	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	O
participants	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
lasting	NN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
will	MD	O
be	VB	O
recruited	VBN	O
from	IN	O
primary	JJ	O
care	NN	O
clinics	NNS	O
of	IN	O
a	DT	O
large	JJ	O
healthcare	NN	O
system	NN	O
based	VBN	O
in	IN	O
Seattle	NNP	O
.	.	O

They	PRP	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
a	DT	O
2:2:1	CD	O
ratio	NN	O
to	TO	O
receive	VB	O
12	CD	O
weekly	JJ	O
yoga	NN	O
classes	NNS	O
,	,	O
12	CD	O
weekly	JJ	O
conventional	JJ	O
therapeutic	JJ	O
exercise	NN	O
classes	NNS	O
of	IN	O
comparable	JJ	O
physical	JJ	O
exertion	NN	O
,	,	O
or	CC	O
a	DT	O
self-care	JJ	O
book	NN	O
.	.	O

Interviewers	NNS	O
masked	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
treatment	NN	O
group	NN	O
will	MD	O
assess	VB	O
outcomes	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
26	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
will	MD	O
be	VB	O
back-related	JJ	PH
dysfunction	NN	PH
and	CC	PH
symptom	NN	PH
bothersomeness	NN	PH
.	.	PH

In	IN	O
addition	NN	O
,	,	O
data	NNS	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
physical	JJ	PH
measurements	NNS	PH
(	(	O
e.g.	NN	O
,	,	O
flexion	NN	PH
)	)	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
and	CC	O
saliva	NN	O
samples	NNS	O
will	MD	O
be	VB	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

Information	NN	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
specific	JJ	O
physical	JJ	O
,	,	O
psychological	JJ	O
,	,	O
and	CC	O
physiological	JJ	O
factors	NNS	O
to	TO	O
allow	VB	O
exploration	NN	O
of	IN	O
possible	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
through	IN	O
which	WDT	O
yoga	NN	O
could	MD	O
relieve	VB	PA
back	RB	PA
pain	NN	PA
and	CC	PA
dysfunction	NN	PA
.	.	PA

The	DT	O
effectiveness	NN	O
of	IN	O
yoga	NN	O
will	MD	O
be	VB	O
assessed	VBN	O
using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
(	(	O
using	VBG	O
general	JJ	O
estimating	VBG	O
equations	NNS	O
-	:	O
GEE	NNP	O
)	)	O
within	IN	O
an	DT	O
intention-to-treat	JJ	O
context	NN	O
.	.	O

If	IN	O
yoga	NN	O
is	VBZ	O
found	VBN	O
effective	JJ	O
,	,	O
further	JJ	O
analyses	NNS	O
will	MD	O
explore	VB	O
whether	IN	O
yoga	NN	O
's	POS	O
benefits	NNS	O
are	VBP	O
attributable	JJ	O
to	TO	O
physical	JJ	O
,	,	O
psychological	JJ	O
and/or	NN	O
physiological	JJ	O
factors	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
will	MD	O
provide	VB	O
the	DT	O
clearest	JJS	O
evidence	NN	O
to	TO	O
date	NN	O
about	IN	O
the	DT	O
value	NN	O
of	IN	O
yoga	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
option	NN	O
for	IN	O
treating	VBG	O
chronic	JJ	PA
back	RB	PA
pain	NN	PA
,	,	O
and	CC	O
if	IN	O
the	DT	O
results	NNS	O
are	VBP	O
positive	JJ	O
,	,	O
will	MD	O
help	VB	O
focus	VB	O
future	JJ	O
,	,	O
more	RBR	O
in-depth	JJ	O
,	,	O
research	NN	O
on	IN	O
the	DT	O
most	RBS	O
promising	JJ	O
potential	JJ	O
mechanisms	NN	O
of	IN	O
action	NN	O
identified	VBN	O
by	IN	O
this	DT	O
study	NN	O
.	.	O

Clinical	JJ	O
pathway	NN	O
for	IN	O
fractured	JJ	O
neck	NN	O
of	IN	O
femur	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
outcomes	NNS	O
of	IN	O
using	VBG	O
a	DT	O
clinical	JJ	O
pathway	NN	O
for	IN	O
managing	VBG	O
patients	NNS	O
with	IN	O
fractured	JJ	O
neck	NN	O
of	IN	O
femur	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
pseudorandomised	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
St	NNP	O
Vincent	NNP	O
's	POS	O
Hospital	NNP	O
,	,	O
Melbourne	NNP	O
,	,	O
Victoria	NNP	O
(	(	O
a	DT	O
tertiary	JJ	O
referral	NN	O
,	,	O
university	NN	O
teaching	VBG	O
hospital	NN	O
)	)	O
,	,	O
1	CD	O
October	NNP	O
1997	CD	O
to	TO	O
30	CD	O
November	NNP	O
1998	CD	O
.	.	O

PARTICIPANTS	VB	O
111	CD	O
patients	NNS	O
(	(	O
80	CD	O
women	NNS	O
and	CC	O
31	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
81	CD	O
years	NNS	O
)	)	O
admitted	VBD	O
via	IN	O
the	DT	O
emergency	NN	O
department	NN	O
with	IN	O
a	DT	O
primary	JJ	O
diagnosis	NN	O
of	IN	O
fractured	JJ	O
neck	NN	O
of	IN	O
femur	NN	O
.	.	O

INTERVENTIONS	NNP	O
Management	NNP	O
guided	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
pathway	NN	O
(	(	O
55	CD	O
patients	NNS	O
)	)	O
or	CC	O
established	VBN	O
standard	NN	O
of	IN	O
care	NN	O
(	(	O
control	NN	O
group	NN	O
,	,	O
56	CD	O
patients	NNS	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Timing	NNP	Ot
of	IN	Ot
referrals	NNS	Ot
and	CC	Ot
discharge	NN	Ot
planning	NN	Ot
;	:	Ot
total	JJ	Ot
length	NN	Ot
of	IN	Ot
stay	NN	Ot
;	:	O
and	CC	O
complication	NN	A
and	CC	O
readmission	NN	Ot
rates	NNS	Ot
within	IN	Ot
28	CD	Ot
days	NNS	Ot
of	IN	Ot
discharge	NN	Ot
.	.	O

RESULTS	JJ	O
Patients	NNS	O
managed	VBD	O
according	VBG	O
to	TO	O
the	DT	O
clinical	JJ	O
pathway	NN	O
had	VBD	O
a	DT	O
shorter	NN	O
total	JJ	O
stay	NN	O
(	(	O
6.6	CD	O
versus	NN	O
8.0	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
even	RB	O
if	IN	O
assessment	NN	O
for	IN	O
placement	NN	O
by	IN	O
the	DT	O
Aged	NNP	O
Care	NNP	O
Assessment	NNP	O
Service	NNP	O
was	VBD	O
required	VBN	O
(	(	O
9.5	CD	O
versus	NN	O
13.6	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
complication	NN	O
and	CC	O
readmission	NN	O
rates	NNS	O
between	IN	O
pathway	NN	O
and	CC	O
control	NN	O
patients	NNS	O
(	(	O
complication	NN	O
rates	NNS	O
,	,	O
24	CD	O
%	NN	O
versus	IN	O
36	CD	O
%	NN	O
;	:	O
P	NNP	O
=	VBZ	O
0.40	CD	O
;	:	O
readmission	NN	O
rates	NNS	O
,	,	O
4	CD	O
%	NN	O
versus	IN	O
11	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.28	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Coordinated	VBD	O
multidisciplinary	JJ	O
care	NN	O
of	IN	O
patients	NNS	O
with	IN	O
fractured	JJ	O
neck	NN	O
of	IN	O
femur	NN	O
reduces	NNS	O
length	NN	O
of	IN	O
stay	NN	O
without	IN	O
increasing	VBG	O
complications	NNS	O
.	.	O

Effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
paromomycin	NN	O
on	IN	O
endotoxemia	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
--	:	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
experimental	JJ	O
and	CC	O
clinical	JJ	O
studies	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	IN	O
gut-derived	JJ	O
endotoxins	NNS	O
might	MD	O
be	VB	O
of	IN	O
relevance	NN	O
for	IN	O
the	DT	O
development	NN	O
and	CC	O
course	NN	O
of	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
nonabsorbable	JJ	O
,	,	O
broad-spectrum	JJ	O
antibiotic	NN	O
on	IN	O
endotoxemia	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
(	(	O
27	CD	O
with	IN	O
cirrhosis	NN	O
,	,	O
23	CD	O
without	IN	O
cirrhosis	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
paromomycin	NN	O
sulfate	NN	O
(	(	O
3	CD	O
x	RB	O
1	CD	O
g/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
weeks	NNS	O
,	,	O
and	CC	O
if	IN	O
possible	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

Endotoxin	NNP	PH
concentration	NN	PH
,	,	O
liver	JJ	PH
function	NN	PH
tests	NNS	PH
,	,	O
and	CC	O
other	JJ	O
laboratory	NN	O
parameters	NNS	O
were	VBD	O
determined	VBN	O
in	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

Endotoxin	NNP	PH
concentration	NN	PH
was	VBD	O
also	RB	O
determined	VBN	O
in	IN	O
15	CD	O
healthy	JJ	O
controls	NNS	O
.	.	O

Groups	NNP	O
receiving	VBG	O
paromomycin	NN	O
or	CC	O
placebo	NN	O
were	VBD	O
similar	JJ	O
for	IN	O
clinical	JJ	O
and	CC	O
biological	JJ	O
items	NNS	O
collected	VBN	O
initially	RB	O
.	.	O

Mean	JJ	PH
initial	JJ	PH
endotoxin	NN	PH
concentrations	NNS	PH
were	VBD	O
significantly	RB	O
elevated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
;	:	O
paromomycin	NN	O
,	,	O
16.7	CD	O
+/-	JJ	O
5.3	CD	O
pg/ml	NN	O
;	:	O
placebo	NN	O
,	,	O
17.5	CD	O
+/-	JJ	O
6.9	CD	O
pg/ml	NN	O
;	:	O
healthy	JJ	O
controls	NNS	O
,	,	O
2.3	CD	O
+/-	JJ	O
0.4	CD	O
pg/ml	NN	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
mean	JJ	PH
endotoxin	NN	PH
concentration	NN	PH
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
verum	NN	O
group	NN	O
after	IN	O
1	CD	O
week	NN	O
(	(	O
paromomycin	NN	O
,	,	O
8.0	CD	O
+/-	JJ	O
1.9	CD	O
pg/ml	NN	O
;	:	O
placebo	NN	O
,	,	O
14.6	CD	O
+/-	JJ	O
3.5	CD	O
pg/ml	NN	O
;	:	O
p	CC	O
>	VB	O
0.05	CD	O
)	)	O
,	,	O
paromomycin	JJ	O
treatment	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
endotoxin	NN	PH
concentration	NN	PH
or	CC	O
liver	JJ	PH
function	NN	PH
tests	NNS	PH
during	IN	O
the	DT	O
4-week	JJ	O
period	NN	O
.	.	O

The	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
paromomycin	NN	O
treatment	NN	O
on	IN	O
endotoxemia	NN	PH
in	IN	O
cirrhotics	NNS	O
reported	VBN	O
in	IN	O
earlier	JJR	O
studies	NNS	O
could	MD	O
not	RB	O
be	VB	O
reproduced	VBN	O
under	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
this	DT	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
dose-intensified	JJ	O
MEC	NNP	O
(	(	O
methotrexate	NN	O
,	,	O
epirubicin	NN	O
and	CC	O
cisplatin	NN	O
)	)	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	O
urothelial	JJ	O
carcinoma	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
MEC	NNP	O
and	CC	O
M-VAC	NNP	O
(	(	O
methotrexate	NN	O
,	,	O
vinblastine	NN	O
,	,	O
doxorubicin	NN	O
and	CC	O
cisplatin	NN	O
)	)	O
.	.	O

Japanese	JJ	O
Urothelial	JJ	O
Cancer	NNP	O
Research	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
antitumor	NN	Ot
activity	NN	Ot
in	IN	O
patients	NNS	O
with	IN	O
T3b	NNP	O
,	,	O
T4	NNP	O
or	CC	O
metastatic	JJ	O
urothelial	JJ	O
carcinoma	NN	O
treated	VBN	O
with	IN	O
MEC	NNP	O
or	CC	O
M-VAC	NNP	O
chemotherapy	NN	O
,	,	O
by	IN	O
performing	VBG	O
a	DT	O
multi-center	JJ	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
1991	CD	O
to	TO	O
1995	CD	O
,	,	O
89	CD	O
patients	NNS	O
with	IN	O
T3b	NNP	O
,	,	O
T4	NNP	O
or	CC	O
metastatic	JJ	O
urothelial	JJ	O
carcinoma	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
a	DT	O
methotrexate	NN	O
,	,	O
epirubicin	NN	O
and	CC	O
cisplatin	NN	O
chemotherapy	NN	O
group	NN	O
(	(	O
arm	JJ	O
1	CD	O
:	:	O
S-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
29	CD	O
)	)	O
,	,	O
a	DT	O
dose-intensified	JJ	O
MEC	NNP	O
therapy	NN	O
combined	VBN	O
with	IN	O
G-CSF	NNP	O
group	NN	O
(	(	O
arm	JJ	O
2	CD	O
:	:	O
I-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
methotrexate	NN	O
,	,	O
vinblastine	NN	O
,	,	O
doxorubicin	NN	O
and	CC	O
cisplatin	NN	O
chemotherapy	NN	O
(	(	O
arm	JJ	O
3	CD	O
:	:	O
M-VAC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
.	.	O

At	IN	O
the	DT	O
registration	NN	O
center	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
into	IN	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
recurrence	NN	O
after	IN	O
radical	JJ	O
operation	NN	O
and	CC	O
then	RB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
each	DT	O
arm	NN	O
,	,	O
two	CD	O
or	CC	O
more	JJR	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
(	(	O
4-week	JJ	O
cycles	NNS	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
88	CD	O
eligible	JJ	O
patients	NNS	O
,	,	O
four	CD	O
treated	VBN	O
with	IN	O
S-MEC	NNP	O
therapy	NN	O
and	CC	O
two	CD	O
treated	VBN	O
with	IN	O
I-MEC	NNP	O
therapy	NN	O
showed	VBD	O
CR	NNP	O
.	.	O

The	DT	O
response	NN	Ot
rates	NNS	Ot
(	(	O
CR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
were	VBD	O
52	CD	O
%	NN	O
(	(	O
15/29	CD	O
)	)	O
with	IN	O
S-MEC	NNP	O
therapy	NN	O
,	,	O
76	CD	O
%	NN	O
(	(	O
22/29	CD	O
)	)	O
with	IN	O
I-MEC	NNP	O
therapy	NN	O
and	CC	O
47	CD	O
%	NN	O
(	(	O
14/30	CD	O
)	)	O
with	IN	O
M-VAC	NNP	O
therapy	NN	O
.	.	O

The	DT	O
response	NN	Ot
rate	NN	Ot
with	IN	Ot
I-MEC	NNP	Ot
therapy	NN	Ot
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
with	IN	O
M-VAC	NNP	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
leukopenia	NN	O
was	VBD	O
low	JJ	O
with	IN	O
I-MEC	NNP	Ot
therapy	NN	Ot
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
thrombocytopenia	NN	PH
was	VBD	O
high	JJ	O
with	IN	O
this	DT	O
therapy	NN	O
.	.	O

CONCLUSION	NNP	O
MEC	NNP	O
therapy	NN	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
promising	VBG	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
antitumor	NN	Ot
effects	NNS	Ot
.	.	Ot

Milk	NNP	O
protein	NN	O
quantity	NN	O
and	CC	O
quality	NN	O
in	IN	O
low-birth-weight	JJ	O
infants	NNS	O
.	.	O

IV	NNP	O
.	.	O

Effects	NNS	O
on	IN	O
tyrosine	NN	PH
and	CC	O
phenylalanine	NN	PH
in	IN	O
plasma	NN	O
and	CC	O
urine	NN	O
.	.	O

Well	UH	O
,	,	O
appropriate-for-gestational	JJ	O
age	NN	O
,	,	O
low-birth-weight	JJ	O
infants	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
gestational	JJ	O
age	NN	O
groups	NNS	O
and	CC	O
assigned	VBD	O
randomly	RB	O
within	IN	O
each	DT	O
age	NN	O
group	NN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
feeding	VBG	O
regimens	NNS	O
:	:	O
pooled	VBN	O
human	JJ	O
milk	NN	O
(	(	O
BM	NNP	O
)	)	O
;	:	O
formula	$	O
1	CD	O
(	(	O
F1	NNP	O
)	)	O
=	VBD	O
1.5	CD	O
gm/dl	NN	O
protein	NN	O
,	,	O
60	CD	O
parts	NNS	O
bovine	NN	O
whey	NN	O
proteins	NNS	O
:	:	O
40	CD	O
parts	NNS	O
bovine	NN	O
caseins	NNS	O
;	:	O
F2	NNP	O
=	VBD	O
3.0	CD	O
gm/dl	NN	O
,	,	O
60:40	CD	O
;	:	O
F3	NNP	O
=	VBD	O
1.5	CD	O
gm/dl	NN	O
,	,	O
18:82	CD	O
;	:	O
F4	NNP	O
=	VBD	O
3.0	CD	O
gm/dl	NN	O
,	,	O
18:82	CD	O
.	.	O

Plasma	NNP	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
tyrosine	NN	PH
and	CC	O
phenylalanine	NN	PH
were	VBD	O
far	RB	O
higher	JJR	O
in	IN	O
the	DT	O
infants	NNS	O
fed	VBP	O
F1	NNP	O
to	TO	O
F4	NNP	O
,	,	O
especially	RB	O
F2	NNP	O
and	CC	O
F4	NNP	O
,	,	O
than	IN	O
in	IN	O
the	DT	O
infants	NNS	O
fed	VBN	O
BM	NNP	O
.	.	O

These	DT	O
findings	NNS	O
offer	VBP	O
further	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
limited	JJ	O
capacity	NN	O
of	IN	O
the	DT	O
low-birth-weight	JJ	O
infant	NN	O
to	TO	O
catabolize	VB	PH
tyrosine	NN	PH
.	.	O

Infants	NNS	O
fed	VBD	O
F3	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
plasma	JJ	PH
tyrosine	NN	PH
concentrations	NNS	PH
than	IN	O
infants	NNS	O
fed	VBN	O
F1	NNP	O
,	,	O
and	CC	O
those	DT	O
fed	VBN	O
F4	NNP	O
had	VBD	O
higher	JJR	O
concentrations	NNS	O
than	IN	O
those	DT	O
fed	JJ	O
F2	NNP	O
.	.	O

Thus	NNP	O
,	,	O
increased	VBD	O
plasma	JJ	PH
tyrosine	NN	PH
concentrations	NNS	PH
in	IN	O
low-birth-weight	JJ	O
infants	NNS	O
are	VBP	O
related	VBN	O
directly	RB	O
both	DT	O
to	TO	O
the	DT	O
quantity	NN	O
and	CC	O
to	TO	O
the	DT	O
quality	NN	O
of	IN	O
the	DT	O
protein	NN	O
in	IN	O
their	PRP$	O
diets	NNS	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
improves	VBZ	O
venous	JJ	O
hemodynamics	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
are	VBP	O
post-thrombotic	JJ	O
.	.	O

PURPOSE	NNP	O
Deep	NNP	O
vein	NN	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
preventable	JJ	O
cause	NN	O
of	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
hospitalized	VBN	O
.	.	O

An	DT	O
important	JJ	O
part	NN	O
of	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
DVT	NNP	O
prophylaxis	NN	O
with	IN	O
intermittent	JJ	O
pneumatic	JJ	O
compression	NN	O
(	(	O
IPC	NNP	O
)	)	O
is	VBZ	O
reduced	VBN	O
venous	JJ	O
stasis	NN	O
with	IN	O
increased	JJ	O
velocity	NN	O
of	IN	O
venous	JJ	O
return	NN	O
.	.	O

The	DT	O
conventional	JJ	O
methods	NNS	O
of	IN	O
IPC	NNP	O
use	NN	O
low	JJ	O
pressure	NN	O
and	CC	O
slow	JJ	O
inflation	NN	O
of	IN	O
the	DT	O
air	NN	O
bladder	NN	O
on	IN	O
the	DT	O
leg	NN	O
to	TO	O
augment	VB	O
venous	JJ	O
return	NN	O
.	.	O

Recently	RB	O
,	,	O
compression	NN	O
devices	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
that	IN	O
produce	VBP	O
high	JJ	O
pressure	NN	O
and	CC	O
rapid	JJ	O
inflation	NN	O
of	IN	O
air	NN	O
cuffs	NNS	O
on	IN	O
the	DT	O
plantar	NN	O
plexus	NN	O
of	IN	O
the	DT	O
foot	NN	O
and	CC	O
the	DT	O
calf	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
venous	JJ	O
velocity	NN	O
response	NN	O
to	TO	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
devices	NNS	O
versus	VBP	O
standard	JJ	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
compression	NN	O
devices	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
severe	JJ	O
post-thrombotic	JJ	O
venous	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Twenty-two	NNP	O
lower	JJR	O
extremities	NNS	O
from	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
11	CD	O
lower	JJR	O
extremities	NNS	O
from	IN	O
patients	NNS	O
with	IN	O
class	NN	O
4	CD	O
to	TO	O
class	NN	O
6	CD	O
post-thrombotic	JJ	O
chronic	JJ	O
venous	JJ	O
insufficiency	NN	O
were	VBD	O
studied	VBN	O
.	.	O

With	IN	O
duplex	JJ	O
ultrasound	NN	O
scanning	NN	O
(	(	O
ATL-Ultramark	NNP	O
9	CD	O
,	,	O
Advanced	NNP	O
Tech	NNP	O
Laboratory	NNP	O
,	,	O
Bothell	NNP	O
,	,	O
Wash	NNP	O
)	)	O
,	,	O
acute	JJ	O
DVT	NNP	O
was	VBD	O
excluded	VBN	O
before	IN	O
subject	JJ	O
evaluation	NN	O
.	.	O

Venous	JJ	O
velocities	NNS	O
were	VBD	O
monitored	VBN	O
after	IN	O
the	DT	O
application	NN	O
of	IN	O
each	DT	O
of	IN	O
five	CD	O
IPC	NNP	O
devices	NNS	O
,	,	O
with	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

Three	CD	O
high-pressure	NN	O
,	,	O
rapid-compression	NN	O
devices	NNS	O
and	CC	O
two	CD	O
standard	NN	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
compression	NN	O
devices	NNS	O
were	VBD	O
applied	VBN	O
in	IN	O
a	DT	O
random	JJ	O
sequence	NN	O
.	.	O

Maximal	NNP	O
venous	JJ	O
velocities	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
the	DT	O
common	JJ	O
femoral	JJ	O
vein	NN	O
and	CC	O
the	DT	O
popliteal	NN	O
vein	NN	O
for	IN	O
all	PDT	O
the	DT	O
devices	NNS	O
and	CC	O
were	VBD	O
recorded	VBN	O
as	IN	O
the	DT	O
mean	JJ	O
peak	JJ	O
velocity	NN	O
of	IN	O
three	CD	O
compression	NN	O
cycles	NNS	O
and	CC	O
compared	VBN	O
with	IN	O
baseline	NN	O
velocities	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
venous	JJ	O
velocities	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
femoral	JJ	O
veins	NNS	O
than	IN	O
in	IN	O
the	DT	O
popliteal	NN	O
veins	NNS	O
in	IN	O
both	DT	O
the	DT	O
volunteers	NNS	O
and	CC	O
the	DT	O
post-thrombotic	JJ	O
subjects	NNS	O
.	.	O

Standard	NNP	PH
and	CC	PH
high-pressure	NN	PH
,	,	O
rapid-inflation	NN	PH
compression	NN	PH
significantly	RB	O
increased	VBD	O
the	DT	O
popliteal	NN	PH
and	CC	PH
femoral	JJ	PH
vein	NN	PH
velocities	NNS	PH
in	IN	O
healthy	JJ	O
and	CC	O
post-thrombotic	JJ	O
subjects	NNS	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
produced	VBD	O
significantly	RB	O
higher	JJR	O
maximal	JJ	PH
venous	JJ	PH
velocities	NNS	PH
in	IN	O
the	DT	O
popliteal	NN	PH
and	CC	PH
femoral	JJ	PH
veins	NNS	PH
in	IN	O
both	DT	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
compression	NN	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
healthy	JJ	O
volunteers	NNS	O
,	,	O
the	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
had	VBD	O
a	DT	O
significantly	RB	O
attenuated	VBN	O
velocity	NN	PH
response	NN	PH
at	IN	O
both	DT	O
the	DT	O
popliteal	NN	O
and	CC	O
the	DT	O
femoral	JJ	O
vein	NN	O
levels	NNS	O
.	.	O

CONCLUSION	NNP	O
High-pressure	NNP	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
increases	NNS	O
popliteal	NN	PH
and	CC	PH
femoral	JJ	PH
vein	NN	PH
velocity	NN	PH
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
pneumatic	JJ	O
compression	NN	O
.	.	O

Patients	NNS	O
with	IN	O
post-thrombotic	JJ	O
venous	JJ	O
disease	NN	O
have	VBP	O
a	DT	O
compromised	JJ	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
all	DT	O
IPC	NNP	O
devices	NNS	O
.	.	O

However	RB	O
,	,	O
an	DT	O
increased	VBN	O
velocity	NN	O
response	NN	O
to	TO	O
the	DT	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
device	NN	O
is	VBZ	O
preserved	VBN	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
may	MD	O
offer	VB	O
additional	JJ	O
protection	NN	O
from	IN	O
thrombotic	JJ	O
complications	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
an	DT	O
improved	JJ	O
hemodynamic	JJ	PH
response	NN	PH
,	,	O
both	DT	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
.	.	O

Acute	JJ	O
effects	NNS	O
of	IN	O
caffeine	JJ	O
ingestion	NN	O
on	IN	O
signal-averaged	JJ	PH
electrocardiograms	NNS	PH
.	.	PH

BACKGROUND	NNP	O
Although	IN	O
moderate	JJ	O
caffeine	NN	O
ingestion	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
arrhythmogenic	JJ	O
,	,	O
caffeine	JJ	O
toxicity	NN	O
can	MD	O
cause	VB	O
severe	JJ	O
cardiac	JJ	O
arrhythmias	NN	O
,	,	O
including	VBG	O
atrial	JJ	O
fibrillation	NN	O
and	CC	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

Atrial	JJ	O
fibrillation	NN	O
and	CC	O
ventricular	JJ	O
tachycardia	NN	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
prolongation	NN	PH
of	IN	PH
P-wave	NNP	PH
and	CC	PH
QRS	NNP	PH
complex	JJ	PH
durations	NNS	PH
on	IN	PH
signal-averaged	JJ	PH
electrocardiograms	NNS	PH
.	.	PH

This	DT	O
study	NN	O
investigated	VBD	O
acute	JJ	O
effects	NNS	O
of	IN	O
caffeine	JJ	O
ingestion	NN	O
on	IN	O
signal-averaged	JJ	PH
P-wave	NNP	PH
and	CC	PH
QRS	NNP	PH
complexes	NNS	PH
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Signal-averaged	JJ	O
electrocardiograms	NNS	O
were	VBD	O
obtained	VBN	O
from	IN	O
12	CD	O
normal	JJ	O
subjects	NNS	O
(	(	O
6	CD	O
men	NNS	O
,	,	O
6	CD	O
women	NNS	O
;	:	O
ages	VBZ	O
21	CD	O
to	TO	O
26	CD	O
years	NNS	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
ingestion	NN	O
of	IN	O
caffeine	NN	O
(	(	O
5	CD	O
mg/kg	NN	O
body	NN	O
weight	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
fashion	NN	O
.	.	O

Electrocardiograms	NNP	O
for	IN	O
signal	JJ	O
averaging	NN	O
were	VBD	O
recorded	VBN	O
from	IN	O
electrodes	NNS	O
left	VBN	O
in	IN	O
a	DT	O
constant	JJ	O
location	NN	O
.	.	O

After	IN	O
bandpass	NN	O
filtering	NN	O
(	(	O
30	CD	O
to	TO	O
300	CD	O
Hz	NNP	O
)	)	O
and	CC	O
amplification	NN	O
,	,	O
signals	NNS	O
were	VBD	O
sampled	VBN	O
over	IN	O
7.2	CD	O
minutes	NNS	O
at	IN	O
2000	CD	O
Hz	NNP	O
.	.	O

Signal-averaged	JJ	PH
P-wave	NNP	PH
and	CC	PH
QRS	NNP	PH
complex	JJ	PH
durations	NNS	PH
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
after	IN	O
placebo	NN	O
ingestion	NN	O
.	.	O

After	IN	O
caffeine	JJ	O
ingestion	NN	O
QRS	NNP	PH
duration	NN	PH
prolonged	VBD	O
in	IN	O
9	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
at	IN	O
90	CD	O
minutes	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
=	NNP	O
0.8+/-0.3	JJ	O
ms	NN	O
,	,	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
and	CC	O
in	IN	O
8	CD	O
of	IN	O
9	CD	O
after	IN	O
3	CD	O
hours	NNS	O
(	(	O
1.1+/-0.2	JJ	O
ms	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
in	IN	O
P-wave	NNP	PH
duration	NN	PH
or	CC	PH
heart	NN	PH
rate	NN	PH
was	VBD	O
found	VBN	O
after	IN	O
caffeine	JJ	O
ingestion	NN	O
at	IN	O
any	DT	O
test	NN	O
interval	NN	O
.	.	O

Average	JJ	PH
caffeine	JJ	PH
level	NN	PH
in	IN	PH
saliva	JJ	PH
90	CD	O
minutes	NNS	O
after	IN	O
ingestion	NN	O
was	VBD	O
6.6+/-1.6	JJ	O
(	(	O
SD	NNP	O
)	)	O
microg/dL	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
probably	RB	O
not	RB	O
arrhythmogenic	JJ	O
in	IN	O
normal	JJ	O
subjects	NNS	O
,	,	O
moderate	JJ	O
caffeine	NN	O
ingestion	NN	O
does	VBZ	O
produce	VB	O
a	DT	O
small	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
prolongation	NN	O
of	IN	O
signal-averaged	JJ	PH
QRS	NNP	PH
complexes	NNS	PH
.	.	O

Further	JJ	O
prolongation	NN	O
caused	VBN	O
by	IN	O
excessive	JJ	O
caffeine	NNS	O
intake	VBP	O
may	MD	O
be	VB	O
a	DT	O
factor	NN	O
in	IN	O
the	DT	O
genesis	NN	O
of	IN	O
arrhythmias	NNS	O
associated	VBN	O
with	IN	O
caffeine	JJ	O
toxicity	NN	O
.	.	O

Working	VBG	O
well	RB	O
with	IN	O
a	DT	O
disability	NN	O
:	:	O
health	NN	O
promotion	NN	O
as	IN	O
a	DT	O
means	NN	O
to	TO	O
employment	NN	O
.	.	O

PURPOSE/OBJECTIVE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
utility	NN	O
of	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
with	IN	O
a	DT	O
Disability	NNP	O
health-promotion	NN	O
program	NN	O
with	IN	O
vocational	JJ	O
rehabilitation	NN	O
(	(	O
VR	NNP	O
)	)	O
clients	NNS	O
.	.	O

Health-promotion	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
limitation	NN	O
from	IN	O
secondary	JJ	O
conditions	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
a	DT	O
significant	JJ	O
barrier	NN	O
to	TO	O
labor	NN	O
force	NN	O
participation	NN	O
among	IN	O
people	NNS	O
with	IN	O
disabilities	NNS	O
.	.	O

The	DT	O
state	NN	O
and	CC	O
federal	JJ	O
VR	NNP	O
system	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
access	NN	O
point	NN	O
for	IN	O
delivery	NN	O
of	IN	O
health-promotion	NN	O
activities	NNS	O
.	.	O

RESEARCH	NNP	O
METHOD/DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
297	CD	O
VR	NNP	O
clients	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
health	NN	O
promotion	NN	O
program	NN	O
.	.	O

Control	NNP	O
and	CC	O
intervention	NN	O
participants	NNS	O
provided	VBD	O
baseline	NN	O
and	CC	O
four	CD	O
waves	NNS	O
of	IN	O
quarterly	JJ	O
follow-up	JJ	O
data	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
with	IN	O
repeated-measures	NNS	O
ANOVA	NNP	O
.	.	O

RESULTS	NNP	O
Intervention-group	JJ	O
participants	NNS	O
who	WP	O
attended	VBD	O
over	IN	O
half	NN	O
of	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
sessions	NNS	O
reported	VBD	O
significantly	RB	O
lower	JJR	O
rates	NNS	ME
of	IN	ME
limitation	NN	ME
from	IN	ME
secondary	JJ	ME
conditions	NNS	ME
over	IN	O
the	DT	O
1-year	JJ	O
study	NN	O
span	NN	O
,	,	O
F	NNP	O
(	(	O
1	CD	O
,	,	O
124	CD	O
)	)	O
=	NN	O
4.11	CD	O
,	,	O
p	NN	O
=	NNP	O
.004	NNP	O
.	.	O

Control-group	NN	O
participants	NNS	O
also	RB	O
experienced	VBD	O
significantly	RB	O
lower	JJR	ME
rates	NNS	ME
of	IN	ME
limitation	NN	ME
,	,	O
but	CC	O
pre-	JJ	O
to	TO	O
postdifferences	NNS	O
were	VBD	O
less	RBR	O
dramatic	JJ	O
,	,	O
F	NNP	O
(	(	O
1	CD	O
,	,	O
308	CD	O
)	)	O
=	NN	O
4.19	CD	O
,	,	O
p	NN	O
=	NNP	O
.006	NNP	O
.	.	O

CONCLUSIONS/IMPLICATIONS	NNP	O
Overall	NNP	O
,	,	O
health	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
program	NN	O
may	MD	O
be	VB	O
particularly	RB	O
helpful	JJ	O
to	TO	O
VR	NNP	O
clients	NNS	O
with	IN	O
higher	JJR	O
rates	NNS	O
of	IN	O
secondary	JJ	O
health	NN	O
conditions	NNS	O
and	CC	O
may	MD	O
represent	VB	O
one	CD	O
strategy	NN	O
for	IN	O
overcoming	VBG	Ot
barriers	NNS	Ot
to	TO	Ot
employment	NN	Ot
.	.	O

The	DT	O
effect	NN	O
of	IN	O
metronidazole	NN	O
on	IN	O
the	DT	O
incidence	NN	PH
of	IN	PH
postoperative	JJ	PH
wound	NN	PH
infection	NN	PH
in	IN	O
elective	JJ	O
colon	NN	O
surgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
assessing	VBG	O
the	DT	O
relative	JJ	O
effectiveness	NN	O
of	IN	O
erythromycin-neomycin	JJ	O
and	CC	O
metronidazole-neomycin	JJ	O
as	IN	O
a	DT	O
preoperative	JJ	O
bowel	NN	O
preparation	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

Bacteriologic	NNP	O
studies	NNS	O
of	IN	O
feces	NNS	O
and	CC	O
colon	NN	O
content	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
reduction	NN	PH
of	IN	PH
aerobic	JJ	PH
bacteria	NNS	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
anaerobic	JJ	O
bacteria	NNS	O
in	IN	O
the	DT	O
feces	NNS	O
and	CC	O
colon	NN	O
contents	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
metronidazole	NN	O
.	.	O

Wound	IN	PH
infection	NN	PH
rate	NN	PH
was	VBD	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
erythromycin	NN	O
group	NN	O
,	,	O
and	CC	O
organisms	NNS	O
recovered	VBN	O
from	IN	O
the	DT	O
wound	NN	O
in	IN	O
all	DT	O
cases	NNS	O
were	VBD	O
fecal	JJ	O
in	IN	O
nature	NN	O
.	.	O

Two	CD	O
wound	IN	O
infections	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
metronidazole	NN	O
group	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
both	DT	O
cases	NNS	O
the	DT	O
organisms	NNS	O
recovered	VBN	O
were	VBD	O
staphylococci	NNS	PH
of	IN	PH
presumed	JJ	PH
skin	JJ	PH
origin	NN	PH
.	.	PH

These	DT	O
studies	NNS	O
suggest	VBP	O
that	IN	O
anaerobic	JJ	O
bacteria	NNS	O
are	VBP	O
the	DT	O
major	JJ	O
contributors	NNS	O
to	TO	O
wound	VB	O
infection	NN	O
after	IN	O
colon	NN	O
surgery	NN	O
and	CC	O
that	IN	O
their	PRP$	O
specific	JJ	O
reduction	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
wound	JJ	O
infection	NN	O
.	.	O

Effect	NN	O
of	IN	O
chelation	NN	O
therapy	NN	O
on	IN	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
and	CC	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

BACKGROUND	VB	O
A	DT	O
previous	JJ	O
study	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	NN	O
burdens	VBZ	O
showed	VBD	O
that	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
slows	VBZ	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
during	IN	O
a	DT	O
12-month	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
longer	JJR	O
course	NN	O
of	IN	O
therapy	NN	O
on	IN	O
kidney	NN	O
function	NN	O
decrease	NN	O
over	IN	O
a	DT	O
longer	JJR	O
follow-up	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
12-month	JJ	O
run-in	JJ	O
phase	NN	O
,	,	O
then	RB	O
a	DT	O
randomized	VBN	O
single-blind	NN	O
study	NN	O
with	IN	O
a	DT	O
27-month	JJ	O
intervention	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
University	NNP	O
medical	JJ	O
center	NN	O
;	:	O
50	CD	O
patients	NNS	O
(	(	O
serum	JJ	O
creatinine	NN	O
,	,	O
1.5-3.9	JJ	O
mg/dL	NN	O
)	)	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burden	NN	O
(	(	O
?80-	JJ	O
<	NN	O
600	CD	O
?g	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
weekly	JJ	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
to	TO	O
reduce	VB	O
their	PRP$	O
body	NN	O
lead	JJ	O
burden	NN	O
to	TO	O
<	VB	O
60	CD	O
?g	NNS	O
and	CC	O
then	RB	O
as	IN	O
needed	VBN	O
for	IN	O
24	CD	O
months	NNS	O
to	TO	O
maintain	VB	O
this	DT	O
level	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
months	NNS	O
and	CC	O
then	RB	O
weekly	VB	O
for	IN	O
5	CD	O
weeks	NNS	O
at	IN	O
6-month	JJ	O
intervals	NNS	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

OUTCOMES	IN	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
change	NN	O
in	IN	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
eGFR	NN	O
)	)	O
over	IN	O
time	NN	O
.	.	O

A	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
2-fold	JJ	O
increase	NN	O
in	IN	O
baseline	JJ	O
serum	NN	O
creatinine	NN	O
level	NN	O
or	CC	O
the	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
.	.	O

MEASUREMENTS	NNP	O
Body	NNP	O
lead	JJ	O
burdens	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
EDTA	NNP	O
mobilization	NN	O
tests	NNS	O
and	CC	O
eGFR	NN	O
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	O
equation	NN	O
for	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
baseline	NN	O
eGFRs	NN	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
of	IN	O
chelation	NN	O
therapy	NN	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
eGFR	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
+1.0	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
differed	VBN	O
significantly	RB	O
from	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
-1.5	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
subsequent	JJ	O
24-month	JJ	O
intervention	NN	O
,	,	O
the	DT	O
yearly	JJ	O
rate	NN	O
of	IN	O
decrease	NN	O
in	IN	O
eGFR	NN	O
(	(	O
5.6	CD	O
?	.	O
5.0	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
slower	JJR	O
than	IN	O
that	DT	O
(	(	O
9.2	CD	O
?	.	O
3.6	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

17	CD	O
(	(	O
68	CD	O
%	NN	O
)	)	O
control-group	NN	O
patients	NNS	O
and	CC	O
9	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
treatment-group	NN	O
patients	NNS	O
achieved	VBD	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
.	.	O

LIMITATIONS	NNP	O
Small	NNP	O
sample	NN	O
size	NN	O
,	,	O
not	RB	O
double	JJ	O
blind	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
27-month	JJ	O
course	NN	O
of	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
retards	VBZ	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
health	NN	O
care	NN	O
program	NN	O
for	IN	O
first-time	JJ	O
adolescent	NN	O
mothers	NNS	O
and	CC	O
their	PRP$	O
infants	NNS	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
special	JJ	O
health	NN	O
care	NN	O
program	NN	O
for	IN	O
adolescent	JJ	O
mothers	NNS	O
(	(	O
17	CD	O
years	NNS	O
old	JJ	O
or	CC	O
younger	JJR	O
)	)	O
and	CC	O
their	PRP$	O
infants	NNS	O
,	,	O
243	CD	O
mother-infant	JJ	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
unwed	JJ	O
,	,	O
on	IN	O
Medicaid	NNP	O
,	,	O
and	CC	O
black	JJ	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
routine	JJ	O
well-baby	NN	O
care	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
received	VBD	O
routine	JJ	O
care	NN	O
and	CC	O
services	NNS	O
that	WDT	O
included	VBD	O
rigorous	JJ	O
follow-up	NN	O
,	,	O
discussions	NNS	O
with	IN	O
the	DT	O
mother	NN	O
about	IN	O
her	PRP$	O
plans	NNS	O
for	IN	O
return	NN	O
to	TO	O
school	NN	O
and	CC	O
use	NN	O
of	IN	O
family	NN	O
planning	NN	O
methods	NNS	O
,	,	O
and	CC	O
extra	JJ	O
health	NN	O
teaching	NN	O
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
60	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
less	JJR	O
after	IN	O
18	CD	O
months	NNS	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
high	JJ	O
dropout	NN	O
rate	NN	O
,	,	O
91	CD	O
%	NN	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
located	VBN	O
for	IN	O
the	DT	O
18	CD	O
month	NN	O
follow-up	JJ	O
interview	NN	O
.	.	O

The	DT	O
repeat	JJ	PH
pregnancy	NN	PH
rate	NN	PH
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
12	CD	O
%	NN	O
after	IN	O
18	CD	O
months	NNS	O
,	,	O
and	CC	O
28	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
percentage	NN	ME
returning	VBG	ME
to	TO	ME
school	NN	ME
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
fully	RB	PH
immunized	VBN	PH
(	(	O
33	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mothers	NNS	O
in	IN	O
the	DT	O
special	JJ	O
care	NN	O
program	NN	O
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
clinic	NN	O
used	VBN	Ot
the	DT	Ot
emergency	NN	Ot
room	NN	Ot
less	JJR	Ot
than	IN	O
the	DT	O
mothers	NNS	O
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
comprehensive	JJ	O
health	NN	O
care	NN	O
program	NN	O
is	VBZ	O
one	CD	O
way	NN	O
to	TO	O
bring	VB	O
about	RP	O
better	JJR	O
outcomes	NNS	O
for	IN	O
both	DT	O
adolescent	JJ	O
mothers	NNS	O
and	CC	O
their	PRP$	O
infants	NNS	O
.	.	O

Prognostic	JJ	O
factor	NN	O
analysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
treated	VBN	O
by	IN	O
castration	NN	O
plus	CC	O
anandron	NN	O
or	CC	O
placebo	NN	O
:	:	O
a	DT	O
final	JJ	O
update	NN	O
.	.	O

PURPOSE	NNP	O
Different	NNP	O
outcome	NN	O
results	NNS	O
have	VBP	O
been	VBN	O
published	VBN	O
in	IN	O
trials	NNS	O
comparing	VBG	O
maximal	JJ	O
androgen	NN	O
blockade	NN	O
(	(	O
MAB	NNP	O
)	)	O
with	IN	O
chemical	NN	O
or	CC	O
surgical	JJ	O
castration	NN	O
alone	RB	O
.	.	O

The	DT	O
conflicting	NN	O
results	NNS	O
could	MD	O
be	VB	O
explained	VBN	O
by	IN	O
the	DT	O
fact	NN	O
that	IN	O
patients	NNS	O
were	VBD	O
included	VBN	O
with	IN	O
different	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

In	IN	O
this	DT	O
new	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Anandron	NNP	O
European	NNP	O
Study	NNP	O
,	,	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
have	VBP	O
been	VBN	O
evaluated	VBN	O
in	IN	O
order	NN	O
to	TO	O
identify	VB	O
those	DT	O
which	WDT	O
could	MD	O
influence	VB	O
the	DT	O
study	NN	O
outcome	NN	O
and	CC	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
399	CD	O
out	IN	O
of	IN	O
457	CD	O
patients	NNS	O
recruited	VBN	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
divided	VBN	O
in	IN	O
a	DT	O
good	JJ	O
or	CC	O
poor	JJ	O
prognostic	JJ	O
group	NN	O
depending	VBG	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
poor	JJ	O
prognostic	JJ	O
factors	NNS	O
,	,	O
these	DT	O
were	VBD	O
pain	NN	O
requiring	VBG	O
treatment	NN	O
,	,	O
>	VBZ	O
5	CD	O
bone	NN	O
metastases	NNS	O
,	,	O
hydronephrosis	NN	O
,	,	O
and	CC	O
alkaline	JJ	O
phosphatase	NN	O
>	VBD	O
2	CD	O
ULN	NNP	O
.	.	O

RESULTS	NNP	O
When	WRB	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
,	,	O
the	DT	O
improvement	NN	PH
in	IN	PH
time	NN	PH
to	TO	PH
progression	NN	PH
,	,	PH
overall	JJ	MO
and	CC	MO
cancer	NN	MO
specific	JJ	MO
survival	NN	MO
in	IN	O
the	DT	O
Anandron	NNP	O
treated	VBD	O
patients	NNS	O
was	VBD	O
identical	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
absolute	JJ	O
terms	NNS	O
this	DT	O
improvement	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
good	JJ	O
prognostic	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
comparison	NN	O
with	IN	O
surgical	JJ	O
castration	NN	O
MAB	NNP	O
using	VBG	O
Anandron	NNP	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
prostate	NN	O
cancer	NN	O
improves	VBZ	O
the	DT	O
time	NN	O
to	TO	O
objective	VB	PH
progression	NN	PH
,	,	PH
overall	JJ	MO
and	CC	MO
cancer	NN	MO
specific	JJ	MO
survival	NN	MO
,	,	O
irrespective	NN	O
of	IN	O
certain	JJ	O
poor	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Tetrahydrobiopterin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

Twelve	NNP	O
children	NNS	O
,	,	O
all	DT	O
boys	NNS	O
,	,	O
aged	VBD	O
4	CD	O
to	TO	O
7	CD	O
years	NNS	O
,	,	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
and	CC	O
low	JJ	O
concentrations	NNS	O
of	IN	O
spinal	JJ	O
6R-l-erythro-5,6,7,8-tetrahydrobiopterin	JJ	O
(	(	O
tetrahydrobiopterin	NN	O
)	)	O
were	VBD	O
selected	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

The	DT	O
children	NNS	O
received	VBD	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
3	CD	O
mg	NNS	O
tetrahydrobiopterin	JJ	O
per	IN	O
kilogram	NN	O
during	IN	O
6	CD	O
months	NNS	O
alternating	VBG	O
with	IN	O
placebo	NN	O
.	.	O

Treatment-induced	JJ	PH
effects	NNS	PH
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
Childhood	NNP	ME
Autism	NNP	ME
Rating	NNP	ME
Scale	NNP	ME
every	DT	O
third	JJ	O
month	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
small	JJ	O
nonsignificant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
total	JJ	ME
scores	NNS	ME
of	IN	ME
Childhood	NNP	ME
Autism	NNP	ME
Rating	NNP	ME
Scale	NNP	ME
after	IN	O
3-	JJ	O
and	CC	O
6-month	JJ	O
treatment	NN	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
looking	VBG	O
at	IN	O
the	DT	O
3	CD	O
core	NN	O
symptoms	NNS	O
of	IN	O
autism	NN	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
social	JJ	ME
interaction	NN	ME
,	,	ME
communication	NN	ME
,	,	ME
and	CC	ME
stereotyped	VBD	ME
behaviors	NNS	ME
,	,	O
revealed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
of	IN	O
the	DT	O
social	JJ	ME
interaction	NN	ME
score	NN	ME
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
active	JJ	O
treatment	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
high	JJ	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
response	NN	ME
of	IN	ME
the	DT	ME
social	JJ	ME
interaction	NN	ME
score	NN	ME
and	CC	ME
IQ	NNP	ME
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
a	DT	O
possible	JJ	O
effect	NN	O
of	IN	O
tetrahydrobiopterin	NN	O
treatment	NN	O
.	.	O

Tramadol	NNP	O
suppository	NN	O
versus	NN	O
placebo	NN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
perineal	NN	PA
pain	NN	PA
after	IN	O
perineorrhaphy	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
in	IN	O
Thailand	NNP	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
randomized	JJ	O
double-blinded	JJ	O
control	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
tramodol	NN	O
and	CC	O
placebo	NN	O
rectal	JJ	O
suppository	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postpartum	NN	PA
perineal	NN	PA
pain	NN	PA
after	IN	O
perineorrhaphy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHOD	NNP	O
One	NNP	O
hundred	VBD	O
women	NNS	O
who	WP	O
gave	VBD	O
birth	NN	O
vaginally	RB	O
with	IN	O
episiotomy	NN	O
and	CC	O
a	DT	O
second-	JJ	O
or	CC	O
third-degree	JJ	O
tear	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assign	VBN	O
to	TO	O
receive	VB	O
two	CD	O
tablets	NNS	O
oftramadol	VBP	O
50	CD	O
mg	NNS	O
or	CC	O
two	CD	O
tablets	NNS	O
ofplacebo	RB	O
,	,	O
the	DT	O
pill	NN	O
were	VBD	O
physically	RB	O
similar	JJ	O
to	TO	O
the	DT	O
real	JJ	O
drug	NN	O
.	.	O

Pain	VB	PA
ratings	NNS	PA
were	VBD	O
recorded	VBN	O
immediately	RB	O
after	IN	O
perineorrhaphy	NN	O
,	,	O
30	CD	O
minutes	NNS	O
,	,	O
and	CC	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
first	JJ	O
dose	NN	O
on	IN	O
a	DT	O
10-cm	JJ	O
visual	JJ	PH
analogue	NN	PH
scale	NN	PH
.	.	PH

Side	JJ	A
effects	NNS	A
and	CC	A
overall	JJ	A
opinion	NN	A
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
had	VBD	O
no	DT	O
statistical	JJ	O
significances	NNS	O
in	IN	O
analgesic	JJ	PA
properties	NNS	PA
,	,	O
assessed	VBN	O
by	IN	O
the	DT	O
means	NNS	O
of	IN	O
pain	NN	PA
rating	NN	PA
at	IN	O
the	DT	O
different	JJ	O
time	NN	O
intervals	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	A
serious	JJ	A
adverse	JJ	A
events	NNS	A
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
between	IN	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
in	IN	O
relief	NN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
Instant	JJ	O
Recess?	NNP	O
:	:	O
a	DT	O
practical	JJ	O
tool	NN	O
for	IN	O
increasing	VBG	O
physical	JJ	O
activity	NN	O
during	IN	O
the	DT	O
school	NN	O
day	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
increased	JJ	O
prevalence	NN	O
of	IN	O
overweight/obesity	NN	O
among	IN	O
children	NNS	O
has	VBZ	O
led	VBN	O
to	TO	O
school	NN	O
district	NN	O
level	NN	O
policies	NNS	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
(	(	O
PA	NNP	O
)	)	O
among	IN	O
elementary	JJ	O
school	NN	O
students	NNS	O
.	.	O

Interventions	NNS	O
are	VBP	O
needed	VBN	O
that	IN	O
increase	NN	O
activity	NN	O
levels	NNS	O
without	IN	O
sacrificing	VBG	O
time	NN	O
spent	VBN	O
in	IN	O
academics	NNS	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
evaluated	VBD	O
a	DT	O
policy	NN	O
implementation	NN	O
intervention	NN	O
for	IN	O
to	TO	O
increase	VB	O
in-school	JJ	O
PA	NNP	O
in	IN	O
elementary	JJ	O
schools	NNS	O
in	IN	O
Forsyth	NNP	O
County	NNP	O
,	,	O
North	NNP	O
Carolina	NNP	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
with	IN	O
a	DT	O
delayed	JJ	O
intervention	NN	O
control	NN	O
group	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
third-	JJ	O
through	IN	O
fifth-grade	JJ	O
classrooms	NNS	O
in	IN	O
eight	CD	O
elementary	JJ	O
schools	NNS	O
.	.	O

Instant	NNP	O
Recess?	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
introduce	VB	O
10-minute	JJ	O
PA	NNP	O
breaks	NNS	O
in	IN	O
classrooms	NNS	O
on	IN	O
schedules	NNS	O
determined	VBN	O
by	IN	O
teachers	NNS	O
.	.	O

Direct	JJ	O
observation	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
activity	NN	O
levels	NNS	O
,	,	O
other	JJ	O
student	NN	O
behaviors	NNS	O
,	,	O
and	CC	O
teacher	NN	O
behaviors	NNS	O
related	VBN	O
to	TO	O
PA	NNP	O
in	IN	O
the	DT	O
classrooms	NNS	O
.	.	O

RESULTS	NNP	O
Twenty-eight	JJ	O
visits	NNS	O
to	TO	O
schools	NNS	O
were	VBD	O
made	VBN	O
during	IN	O
the	DT	O
spring	NN	O
and	CC	O
fall	NN	O
semesters	NNS	O
of	IN	O
2009	CD	O
.	.	O

At	IN	O
baseline	JJ	O
11	CD	O
%	NN	O
to	TO	O
44	CD	O
%	NN	O
of	IN	O
intervention	NN	O
and	CC	O
control	NN	O
schools	NNS	O
were	VBD	O
engaged	VBN	O
in	IN	O
classroom-based	JJ	O
PA.	NNP	O
PA	NNP	O
increased	VBD	O
from	IN	O
baseline	NN	O
to	TO	O
spring	VB	O
follow-up	NN	O
in	IN	O
intervention	NN	O
schools	NNS	O
and	CC	O
was	VBD	O
maintained	VBN	O
the	DT	O
following	VBG	O
fall	NN	O
.	.	O

Control	NNP	O
schools	NNS	O
decreased	VBD	O
PA	NNP	O
from	IN	O
baseline	NN	O
to	TO	O
spring	NN	O
and	CC	O
increased	VBD	O
PA	NNP	O
once	RB	O
they	PRP	O
began	VBD	O
the	DT	O
intervention	NN	O
.	.	O

Students	NNS	O
in	IN	O
classrooms	NNS	O
engaged	VBN	O
in	IN	O
Instant	NNP	O
Recess	NNP	O
exhibited	VBD	O
statistically	RB	O
significant	JJ	O
increases	NNS	O
in	IN	O
light	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
and	CC	O
moderate-intensity	NN	O
(	(	O
16	CD	O
%	NN	O
)	)	O
PA	NNP	O
and	CC	O
increases	NNS	O
in	IN	O
time	NN	O
spent	VBN	O
in	IN	O
on-task	JJ	O
behavior	NN	O
(	(	O
11	CD	O
%	NN	O
)	)	O
.	.	O

Control	NNP	O
schools	NNS	O
experienced	VBD	O
similar	JJ	O
benefits	NNS	O
after	IN	O
they	PRP	O
began	VBD	O
implementing	VBG	O
Instant	NNP	O
Recess	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Instant	NNP	O
Recess	NNP	O
is	VBZ	O
useful	JJ	O
for	IN	O
increasing	VBG	O
PA	NNP	O
and	CC	O
improving	VBG	O
behavior	NN	O
among	IN	O
elementary	JJ	O
school	NN	O
children	NNS	O
.	.	O

Additional	NNP	O
research	NN	O
may	MD	O
be	VB	O
needed	VBN	O
to	TO	O
understand	VB	O
how	WRB	O
to	TO	O
create	VB	O
policies	NNS	O
supporting	VBG	O
classroom	NN	O
activity	NN	O
breaks	NNS	O
and	CC	O
how	WRB	O
to	TO	O
assess	VB	O
policy	NN	O
adherence	NN	O
.	.	O

Beta	NNP	O
radiation	NN	O
as	IN	O
an	DT	O
adjunct	JJ	O
to	TO	O
low-risk	JJ	O
trabeculectomy	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intraoperative	JJ	O
beta	NN	O
radiation	NN	O
used	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
success	NN	O
rate	NN	O
of	IN	O
trabeculectomy	NN	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
low-risk	JJ	O
glaucoma	NN	O
patients	NNS	O
in	IN	O
whom	WP	O
antimetabolites	NNS	O
might	MD	O
not	RB	O
be	VB	O
indicated	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
65	CD	O
eyes	NNS	O
was	VBD	O
designed	VBN	O
,	,	O
with	IN	O
31	CD	O
eyes	NNS	O
receiving	VBG	O
750	CD	O
rads	NNS	O
of	IN	O
intraoperative	JJ	O
beta	NN	O
radiation	NN	O
(	(	O
group	NN	O
1	CD	O
)	)	O
,	,	O
and	CC	O
34	CD	O
eyes	NNS	O
receiving	VBG	O
no	DT	O
supplementation	NN	O
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
24	CD	O
months	NNS	O
.	.	O

Mean	NNP	PH
postoperative	JJ	PH
intraocular	JJ	PH
pressure	NN	PH
was	VBD	O
12.2	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
13.7	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.16	CD	O
)	)	O
.	.	O

Mean	JJ	O
decrease	NN	O
in	IN	O
intraocular	JJ	PH
pressure	NN	PH
was	VBD	O
10.3	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
9.3	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.49	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
surgical	JJ	PH
complications	NNS	PH
.	.	O

CONCLUSION	NN	O
For	IN	O
this	DT	O
population	NN	O
of	IN	O
low-risk	JJ	O
patients	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
outcome	NN	O
after	IN	O
applications	NNS	O
of	IN	O
a	DT	O
single	JJ	O
intraoperative	JJ	O
dose	NN	O
of	IN	O
beta	NN	O
radiation	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
haloperidol	NN	O
on	IN	O
discrimination	NN	ME
learning	NN	ME
and	CC	ME
behavioral	JJ	ME
symptoms	NNS	ME
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
three	CD	O
objectives	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
to	TO	O
replicate	VB	O
earlier	JJR	O
findings	NNS	O
that	IN	O
haloperidol	JJ	O
administration	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
behavioral	JJ	ME
symptoms	NNS	ME
;	:	O
(	(	O
b	NN	O
)	)	O
to	TO	O
further	JJ	O
assess	NN	O
its	PRP$	O
safety	NN	Ot
when	WRB	O
given	VBN	O
on	IN	O
a	DT	O
short-term	JJ	O
basis	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
to	TO	O
assess	VB	O
whether	IN	O
it	PRP	O
has	VBZ	O
an	DT	O
effect	NN	ME
on	IN	ME
discrimination	NN	ME
learning	NN	ME
.	.	O

Forty-five	JJ	O
children	NNS	O
,	,	O
2.02	CD	O
to	TO	O
7.58	CD	O
years	NNS	O
old	JJ	O
(	(	O
M	NNP	O
=	NNP	O
4.49	CD	O
)	)	O
,	,	O
completed	VBD	O
this	DT	O
crossover	NN	O
design	NN	O
,	,	O
with	IN	O
random	JJ	O
assignment	NN	O
to	TO	O
treatment	NN	O
sequences	NNS	O
.	.	O

Haloperidol	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
powerful	JJ	O
therapeutic	JJ	O
agent	NN	O
when	WRB	O
administered	VBN	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
free	JJ	O
of	IN	O
side	JJ	A
effects	NNS	A
;	:	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.25	CD	O
to	TO	O
4.0	CD	O
mg/day	NN	O
(	(	O
M	NNP	O
=	NNP	O
0.844	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
variety	NN	ME
of	IN	ME
symptoms	NNS	ME
.	.	O

Under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
,	,	O
the	DT	O
children	NNS	O
failed	VBD	O
to	TO	O
learn	VB	O
on	IN	O
either	DT	O
haloperidol	NN	O
or	CC	O
placebo	NN	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	O
or	CC	O
aerosolized	JJ	O
pentamidine	NN	O
for	IN	O
secondary	JJ	O
prophylaxis	NN	O
of	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
.	.	O

AIDS	NNP	O
Clinical	JJ	O
Trials	NNP	O
Group	NNP	O
Protocol	NNP	O
021	CD	O
.	.	O

BACKGROUND	NNP	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
(	(	O
PCP	NNP	O
)	)	O
continues	VBZ	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
common	JJ	O
index	NN	O
diagnosis	NN	O
in	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
which	WDT	O
of	IN	O
several	JJ	O
available	JJ	O
agents	NNS	O
is	VBZ	O
the	DT	O
most	RBS	O
effective	JJ	O
in	IN	O
preventing	VBG	PH
a	DT	PH
recurrence	NN	PH
of	IN	PH
PCP	NNP	PH
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
comparative	JJ	O
,	,	O
open-label	JJ	O
trial	NN	O
in	IN	O
310	CD	O
adults	NNS	O
with	IN	O
AIDS	NNP	O
who	WP	O
had	VBD	O
recently	RB	O
recovered	VBN	O
from	IN	O
an	DT	O
initial	JJ	O
episode	NN	O
of	IN	O
PCP	NNP	O
and	CC	O
had	VBD	O
no	DT	O
treatment-limiting	JJ	O
toxic	NN	O
effects	NNS	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	O
or	CC	O
pentamidine	NN	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
zidovudine	NN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
800	CD	O
mg	NN	O
of	IN	O
sulfamethoxazole	NN	O
and	CC	O
160	CD	O
mg	NN	O
of	IN	O
trimethoprim	JJ	O
once	JJ	O
daily	JJ	O
or	CC	O
300	CD	O
mg	NN	O
of	IN	O
aerosolized	JJ	O
pentamidine	NN	O
administered	VBN	O
every	DT	O
four	CD	O
weeks	NNS	O
by	IN	O
jet	NN	O
nebulizer	NN	O
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
a	DT	O
median	NN	O
of	IN	O
17.4	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
154	CD	O
)	)	O
there	EX	O
were	VBD	O
14	CD	O
recurrences	NNS	PH
of	IN	PH
PCP	NNP	PH
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
36	CD	O
recurrences	NNS	O
(	(	O
including	VBG	O
1	CD	O
extrapulmonary	JJ	O
recurrence	NN	O
)	)	O
in	IN	O
the	DT	O
aerosolized-pentamidine	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
156	CD	O
)	)	O
.	.	O

The	DT	O
estimated	JJ	O
recurrence	NN	PH
rates	NNS	PH
at	IN	O
18	CD	O
months	NNS	O
were	VBD	O
11.4	CD	O
percent	NN	O
with	IN	O
trimethoprim-sulfamethoxazole	JJ	O
and	CC	O
27.6	CD	O
percent	NN	O
with	IN	O
pentamidine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
a	DT	O
recurrence	NN	PH
(	(	O
adjusted	VBN	O
for	IN	O
initial	JJ	O
CD4	NNP	O
cell	NN	O
count	NN	O
)	)	O
was	VBD	O
3.25	CD	O
times	NNS	O
higher	RBR	O
in	IN	O
the	DT	O
pentamidine	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
,	,	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.72	CD	O
to	TO	O
6.16	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
survival	NN	MO
or	CC	O
in	IN	O
hematologic	JJ	A
or	CC	A
hepatic	JJ	A
toxicity	NN	A
.	.	A

Crossovers	NNS	O
from	IN	O
trimethoprim-sulfamethoxazole	JJ	O
to	TO	O
aerosolized	JJ	O
pentamidine	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
than	IN	O
the	DT	O
reverse	NN	O
(	(	O
27	CD	O
vs.	FW	O
4	CD	O
percent	NN	O
)	)	O
,	,	O
partly	RB	O
because	IN	O
of	IN	O
the	DT	O
study	NN	O
protocols	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
leukopenia	NN	O
.	.	O

There	EX	O
were	VBD	O
19	CD	O
serious	JJ	O
bacterial	JJ	PH
infections	NNS	PH
in	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
and	CC	O
38	CD	O
in	IN	O
the	DT	O
pentamidine	NN	O
group	NN	O
.	.	O

The	DT	O
time	NN	PH
to	TO	PH
a	DT	PH
first	JJ	PH
bacterial	JJ	PH
infection	NN	PH
was	VBD	O
significantly	RB	O
greater	JJR	O
for	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
trimethoprim-sulfamethoxazole	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
who	WP	O
are	VBP	O
receiving	VBG	O
zidovudine	NN	O
,	,	O
trimethoprim-sulfamethoxazole	JJ	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
aerosolized	JJ	O
pentamidine	NN	O
in	IN	O
conventional	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
prevention	NN	PH
of	IN	PH
recurrent	NN	PH
pneumocystis	NN	PH
infection	NN	PH
.	.	O

Effects	NNS	O
of	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
added	VBD	O
to	TO	O
docosahexaenoic	VB	O
acid	NN	O
on	IN	O
social	JJ	O
impairment	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

Autism	NNP	O
spectrum	NN	O
disorders	NNS	O
are	VBP	O
a	DT	O
neurodevelopmental	JJ	O
disorders	NNS	O
with	IN	O
reduced	JJ	O
cortical	JJ	O
functional	JJ	O
connectivity	NN	O
relating	VBG	O
to	TO	O
social	JJ	O
cognition	NN	O
.	.	O

Polyunsaturated	VBN	O
fatty	JJ	O
acids	NNS	O
arachidonic	JJ	O
acid	NN	O
(	(	O
ARA	NNP	O
)	)	O
and	CC	O
docosahexaenoic	JJ	O
acid	NN	O
(	(	O
DHA	NNP	O
)	)	O
may	MD	O
have	VB	O
key	JJ	O
role	NN	O
in	IN	O
brain	NN	O
network	NN	O
maturation	NN	O
.	.	O

In	IN	O
particularly	RB	O
,	,	O
ARA	NNP	O
is	VBZ	O
important	JJ	O
in	IN	O
signal	JJ	O
transduction	NN	O
related	VBN	O
to	TO	O
neuronal	JJ	O
maturation	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
larger	JJR	O
ARA	NNP	O
doses	VBZ	O
added	VBN	O
to	TO	O
DHA	NNP	O
may	MD	O
therefore	VB	O
mitigate	VB	O
social	JJ	O
impairment	NN	O
.	.	O

In	IN	O
a	DT	O
16-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
supplementation	NN	O
with	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
ARA	NNP	O
added	VBD	O
to	TO	O
DHA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
in	IN	O
13	CD	O
participants	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
14.6	CD	O
[	NN	O
SD	NNP	O
,	,	O
5.9	CD	O
]	CD	O
years	NNS	O
)	)	O
.	.	O

To	TO	O
examine	VB	O
underlying	JJ	O
mechanisms	NNS	O
underlying	VBG	O
the	DT	O
effect	NN	O
of	IN	O
our	PRP$	O
supplementation	NN	O
regimen	NNS	O
,	,	O
we	PRP	O
examined	VBD	O
plasma	JJ	PH
levels	NNS	PH
of	IN	PH
antioxidants	NNS	PH
transferrin	JJ	PH
and	CC	PH
superoxide	JJ	PH
dismutase	NN	PH
,	,	O
which	WDT	O
are	VBP	O
useful	JJ	O
markers	NNS	O
of	IN	O
signal	JJ	O
transduction	NN	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
Social	NNP	ME
Responsiveness	NNP	ME
Scale	NNP	ME
and	CC	ME
the	DT	ME
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist-Community	NNP	ME
.	.	O

Repeated-measures	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
our	PRP$	O
supplementation	NN	O
regimen	NNS	O
significantly	RB	O
improved	VBN	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist-Community-measured	NNP	ME
social	JJ	ME
withdrawal	NN	ME
and	CC	O
Social	NNP	ME
Responsiveness	NNP	ME
Scale-measured	JJ	ME
communication	NN	ME
.	.	O

Treatment	NNP	O
effect	NN	O
sizes	NNS	O
were	VBD	O
more	RBR	O
favorable	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
communication	NN	O
:	:	O
treatment	NN	O
groups	NNS	O
,	,	O
0.87	CD	O
vs	NN	O
,	,	O
placebo	NN	O
,	,	O
0.44	CD	O
;	:	O
social	JJ	O
withdrawal	NN	O
:	:	O
treatment	NN	O
groups	NNS	O
,	,	O
0.88	CD	O
,	,	O
vs	NN	O
placebo	NN	O
,	,	O
0.54	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	PH
in	IN	PH
plasma	NN	PH
transferrin	NN	PH
levels	NNS	PH
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasma	JJ	PH
superoxide	JJ	PH
dismutase	NN	PH
levels	NNS	PH
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

This	DT	O
preliminary	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
supplementation	NN	O
with	IN	O
larger	JJR	O
ARA	NNP	O
doses	VBZ	O
added	VBN	O
to	TO	O
DHA	NNP	O
improves	NNS	O
impaired	VBD	O
social	JJ	PH
interaction	NN	PH
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
by	IN	O
up-regulating	JJ	O
signal	JJ	O
transduction	NN	O
.	.	O

Effect	NN	O
of	IN	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
on	IN	O
the	DT	O
blood	NN	PH
pressure	NN	PH
of	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
who	WP	O
received	VBD	O
direct	JJ	O
patient	NN	O
care	NN	O
from	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
had	VBD	O
better	RBR	O
blood	NN	PH
pressure	NN	PH
control	NN	PH
compared	VBN	O
to	TO	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
.	.	O

METHODS	NNP	O
Renal	NNP	O
transplant	NN	O
patients	NNS	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
into	IN	O
an	DT	O
intervention	NN	O
group	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
that	WDT	O
included	VBD	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
performing	VBG	O
patient	JJ	O
medication	NN	O
reviews	NNS	O
,	,	O
with	IN	O
emphasis	NN	O
on	IN	O
preventing	VBG	O
or	CC	O
resolving	VBG	O
medication-related	JJ	O
problems	NNS	O
and	CC	O
providing	VBG	O
medication	NN	O
recommendations	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
routine	JJ	O
clinic	NN	O
services	NNS	O
,	,	O
but	CC	O
had	VBD	O
no	DT	O
clinical	JJ	O
pharmacist	NN	O
interaction	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
detect	VB	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
in	IN	O
baseline	NN	PH
and	CC	PH
quarterly	JJ	PH
systolic	JJ	PH
blood	NN	PH
pressure	NN	PH
(	(	PH
SBP	NNP	PH
)	)	PH
and	CC	O
diastolic	JJ	PH
blood	NN	PH
pressure	NN	PH
(	(	PH
DBP	NNP	PH
)	)	PH
for	IN	O
one	CD	O
year	NN	O
post-study	NN	O
enrollment	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
(	(	O
N	NNP	O
=	NNP	O
13	CD	O
)	)	O
and	CC	O
control	NN	O
(	(	O
N	NNP	O
=	NNP	O
10	CD	O
)	)	O
groups	NNS	O
in	IN	O
baseline	NN	O
blood	NN	PH
pressures	NNS	PH
or	CC	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
SBP	NNP	PH
and	CC	O
DBP	NNP	PH
from	IN	O
baseline	NN	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
second	JJ	O
,	,	O
third	JJ	O
,	,	O
and	CC	O
fourth	JJ	O
quarters	NNS	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
favoring	VBG	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Mean	NNP	PH
SBP	NNP	PH
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
the	DT	O
second	JJ	O
(	(	O
137.8	CD	O
+/-	JJ	O
15.0	CD	O
vs	JJ	O
168.9	CD	O
+/-	JJ	O
15.3	CD	O
)	)	O
,	,	O
third	JJ	O
(	(	O
135.9	CD	O
+/-	JJ	O
11.7	CD	O
vs	JJ	O
164.6	CD	O
+/-	JJ	O
20.1	CD	O
)	)	O
,	,	O
and	CC	O
fourth	JJ	O
(	(	O
145.3	CD	O
+/-	JJ	O
16.8	CD	O
vs	JJ	O
175.8	CD	O
+/-	JJ	O
33.9	CD	O
)	)	O
quarters	NNS	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Mean	NNP	PH
DBP	NNP	PH
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
the	DT	O
second	JJ	O
(	(	O
76.0	CD	O
+/-	JJ	O
11.8	CD	O
vs	JJ	O
84.9	CD	O
+/-	JJ	O
6.1	CD	O
)	)	O
and	CC	O
fourth	JJ	O
(	(	O
77.0	CD	O
+/-	JJ	O
10.2	CD	O
vs	JJ	O
91.8	CD	O
+/-	JJ	O
12.0	CD	O
)	)	O
quarters	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Direct	NNP	O
patient	NN	O
care	NN	O
services	NNS	O
provided	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
routine	VB	O
clinical	JJ	O
services	NNS	O
,	,	O
have	VBP	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
the	DT	O
blood	NN	PH
pressure	NN	PH
of	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
.	.	O

A	DT	O
multidisciplinary	JJ	O
team	NN	O
that	WDT	O
includes	VBZ	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
is	VBZ	O
beneficial	JJ	O
to	TO	O
patient	VB	O
care	NN	O
.	.	O

Granulocyte-colony	JJ	O
stimulating	NN	O
factor	NN	O
for	IN	O
mobilizing	VBG	O
bone	NN	O
marrow	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
subacute	JJ	O
stroke	NN	O
:	:	O
the	DT	O
stem	NN	O
cell	VBP	O
trial	NN	O
of	IN	O
recovery	NN	O
enhancement	NN	O
after	IN	O
stroke	VBD	O
2	CD	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Granulocyte-colony	NNP	O
stimulating	VBG	O
factor	NN	O
(	(	O
G-CSF	NNP	O
)	)	O
is	VBZ	O
neuroprotective	JJ	O
in	IN	O
experimental	JJ	O
stroke	NN	O
and	CC	O
mobilizes	VBZ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
into	IN	O
the	DT	O
circulation	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
safety	NN	O
of	IN	O
G-CSF	NNP	O
in	IN	O
recent	JJ	O
stroke	NN	O
in	IN	O
a	DT	O
phase	NN	O
IIb	NNP	O
single-center	NN	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

METHODS	NNP	O
G-CSF	NNP	O
(	(	O
10	CD	O
?g/kg	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
ratio	VB	O
2:1	CD	O
)	)	O
was	VBD	O
given	VBN	O
SC	NNP	O
for	IN	O
5	CD	O
days	NNS	O
to	TO	O
60	CD	O
patients	NNS	O
3	CD	O
to	TO	O
30	CD	O
days	NNS	O
after	IN	O
ischemic	JJ	O
or	CC	O
hemorrhagic	JJ	O
stroke	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Peripheral	NNP	O
blood	NN	O
counts	NNS	O
,	,	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
count	NN	O
,	,	O
and	CC	O
functional	JJ	O
outcome	NN	O
were	VBD	O
measured	VBN	O
.	.	O

MRI	NNP	O
assessed	VBD	O
lesion	NN	O
volume	NN	O
,	,	O
atrophy	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
reinjected	VBN	O
on	IN	O
day	NN	O
6	CD	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
at	IN	O
mean	NN	O
of	IN	O
8	CD	O
days	NNS	O
(	(	O
SD	NNP	O
?	.	O
5	CD	O
)	)	O
post	NN	O
ictus	NN	O
,	,	O
with	IN	O
mean	JJ	O
age	NN	O
71	CD	O
years	NNS	O
(	(	O
?	.	O
12	CD	O
years	NNS	O
)	)	O
and	CC	O
53	CD	O
%	NN	O
men	NNS	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
baseline	JJ	O
minimization/prognostic	JJ	O
factors	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
participants	NNS	O
with	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
:	:	O
G-CSF	JJ	O
15	CD	O
(	(	O
37.5	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
versus	NN	O
placebo	NN	O
7	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
of	IN	O
20	CD	O
,	,	O
death	NN	O
or	CC	O
dependency	NN	O
(	(	O
modified	JJ	O
Rankin	NNP	O
Score	NN	O
:	:	O
G-CSF	JJ	O
3.3	CD	O
?	.	O
1.3	CD	O
,	,	O
placebo	NN	O
3.0	CD	O
?	.	O
1.3	CD	O
)	)	O
at	IN	O
90	CD	O
days	NNS	O
,	,	O
or	CC	O
the	DT	O
number	NN	O
of	IN	O
injections	NNS	O
received	VBN	O
.	.	O

G-CSF	NNP	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
total	JJ	O
white	JJ	O
cell	NN	O
counts	NNS	O
of	IN	O
9.5-	CD	O
and	CC	O
4.2-fold	JJ	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
reduction	NN	O
in	IN	O
MRI	NNP	O
ischemic	JJ	O
lesion	NN	O
volume	NN	O
with	IN	O
respect	NN	O
to	TO	O
change	VB	O
from	IN	O
baseline	NN	O
in	IN	O
G-CSF-treated	JJ	O
patients	NNS	O
(	(	O
P=0.06	NNP	O
)	)	O
.	.	O

In	IN	O
1	CD	O
participant	NN	O
,	,	O
there	EX	O
was	VBD	O
suggestion	NN	O
that	IN	O
labeled	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
had	VBD	O
migrated	VBN	O
to	TO	O
the	DT	O
ischemic	JJ	O
lesion	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
suggests	VBZ	O
that	IN	O
G-CSF	NNP	O
is	VBZ	O
safe	JJ	O
when	WRB	O
administered	VBN	O
subacutely	RB	O
.	.	O

It	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
label	VB	O
and	CC	O
readminister	VB	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
www.controlled-trials.com	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
ISRCTN63336619	NNP	O
.	.	O

Polymorphisms	NNP	O
of	IN	O
ADORA2A	NNP	O
modulate	NNP	O
psychomotor	NN	O
vigilance	NN	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
caffeine	NN	O
on	IN	O
neurobehavioural	JJ	ME
performance	NN	ME
and	CC	ME
sleep	JJ	ME
EEG	NNP	ME
after	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Prolonged	NNP	O
wakefulness	NN	O
impairs	NNS	O
sustained	VBD	O
vigilant	JJ	ME
attention	NN	ME
,	,	O
measured	VBN	O
with	IN	O
the	DT	O
psychomotor	NN	Ot
vigilance	NN	Ot
task	NN	Ot
(	(	Ot
PVT	NNP	Ot
)	)	Ot
,	,	O
and	CC	O
induces	VBZ	O
a	DT	O
compensatory	JJ	O
increase	NN	O
in	IN	O
sleep	JJ	O
intensity	NN	O
in	IN	O
recovery	NN	O
sleep	NN	O
,	,	O
quantified	VBN	O
by	IN	O
slow-wave	JJ	PH
activity	NN	PH
(	(	PH
SWA	NNP	PH
)	)	PH
in	IN	O
the	DT	O
sleep	JJ	PH
electroencephalogram	NN	PH
(	(	PH
EEG	NNP	PH
)	)	PH
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
sleep	JJ	O
deprivation	NN	O
are	VBP	O
counteracted	VBN	O
by	IN	O
the	DT	O
adenosine	NN	O
receptor	NN	O
antagonist	JJ	O
caffeine	NN	O
,	,	O
implying	VBG	O
involvement	NN	O
of	IN	O
the	DT	O
adenosine	NN	O
neuromodulator/receptor	NN	O
system	NN	O
.	.	O

To	TO	O
examine	VB	O
a	DT	O
role	NN	O
for	IN	O
adenosine	NN	O
A	NNP	O
(	(	O
2A	CD	O
)	)	O
receptors	NNS	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
variation	NN	O
of	IN	O
the	DT	O
A	NNP	O
(	(	O
2A	CD	O
)	)	O
receptor	NN	O
gene	NN	O
(	(	O
ADORA2A	NNP	O
)	)	O
modified	VBD	O
effects	NNS	O
of	IN	O
caffeine	NN	O
on	IN	O
PVT	NNP	Ot
and	CC	O
SWA	NNP	PH
after	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

EXPERIMENTAL	NNP	O
APPROACH	NNP	O
A	NNP	O
haplotype	JJ	O
analysis	NN	O
of	IN	O
eight	CD	O
single-nucleotide	JJ	O
polymorphisms	NNS	O
of	IN	O
ADORA2A	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
82	CD	O
volunteers	NNS	O
.	.	O

In	IN	O
45	CD	O
young	JJ	O
men	NNS	O
carrying	VBG	O
five	CD	O
different	JJ	O
allele	NN	O
combinations	NNS	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
prolonged	JJ	O
waking	NN	O
and	CC	O
2	CD	O
?	.	O
200	CD	O
mg	JJ	O
caffeine	NN	O
or	CC	O
2	CD	O
?	.	O
100	CD	O
mg	NN	O
modafinil	NN	O
on	IN	O
psychomotor	NN	O
vigilance	NN	O
,	,	O
sleepiness	NN	O
,	,	O
and	CC	O
the	DT	O
waking	NN	O
and	CC	O
sleep	JJ	O
EEG	NNP	O
.	.	O

KEY	NNP	O
RESULTS	NNP	O
Throughout	NNP	O
extended	VBD	O
wakefulness	NN	O
,	,	O
the	DT	O
carriers	NNS	O
of	IN	O
haplotype	NN	O
HT4	NNP	O
performed	VBD	O
faster	RBR	O
on	IN	O
the	DT	O
PVT	NNP	O
than	IN	O
carriers	NNS	O
of	IN	O
non-HT4	JJ	O
haplotype	NN	O
alleles	NNS	O
.	.	O

In	IN	O
haplotype	JJ	O
HT4	NNP	O
,	,	O
caffeine	NN	O
failed	VBD	O
to	TO	O
counteract	VB	O
the	DT	O
waking-induced	JJ	O
impairment	NN	O
of	IN	O
PVT	NNP	O
performance	NN	O
and	CC	O
the	DT	O
rebound	NN	O
of	IN	O
SWA	NNP	O
in	IN	O
recovery	NN	O
sleep	NN	O
.	.	O

However	RB	O
,	,	O
caffeine	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
non-HT4	JJ	O
allele	NN	O
carriers	NNS	O
,	,	O
and	CC	O
modafinil	NN	O
reduced	VBD	O
the	DT	O
consequences	NNS	O
of	IN	O
prolonged	JJ	O
waking	NN	O
,	,	O
independently	RB	O
of	IN	O
ADORA2A	NNP	O
haplotype	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
IMPLICATIONS	NNP	O
Common	NNP	O
genetic	JJ	O
variation	NN	O
of	IN	O
ADORA2A	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
determinant	NN	O
of	IN	O
psychomotor	NN	O
vigilance	NN	O
in	IN	O
rested	JJ	O
and	CC	O
sleep-deprived	JJ	O
state	NN	O
.	.	O

It	PRP	O
also	RB	O
modulates	VBZ	O
individual	JJ	O
responses	NNS	O
to	TO	O
caffeine	VB	O
after	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

These	DT	O
findings	NNS	O
demonstrate	VBP	O
a	DT	O
role	NN	O
for	IN	O
adenosine	NN	O
A	NNP	O
(	(	O
2A	CD	O
)	)	O
receptors	NNS	O
in	IN	O
the	DT	O
effects	NNS	O
of	IN	O
prolonged	JJ	O
wakefulness	NN	O
on	IN	O
vigilant	JJ	O
attention	NN	O
and	CC	O
the	DT	O
sleep	JJ	O
EEG	NNP	O
.	.	O

Effect	NN	O
of	IN	O
device-guided	JJ	O
breathing	NN	O
exercises	NNS	O
on	IN	O
blood	NN	PH
pressure	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Hypertension	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
disorder	NN	O
with	IN	O
a	DT	O
high	JJ	O
prevalence	NN	O
worldwide	NN	O
.	.	O

Despite	IN	O
considerable	JJ	O
efforts	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
sometimes	RB	O
hard	JJ	O
to	TO	O
reach	VB	O
treatment	NN	O
goals	NNS	O
for	IN	O
blood	NN	PH
pressure	NN	PH
(	(	PH
BP	NNP	PH
)	)	PH
with	IN	O
classical	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

Reducing	VBG	O
breathing	VBG	O
frequency	NN	O
has	VBZ	O
been	VBN	O
advocated	VBN	O
as	IN	O
a	DT	O
method	NN	O
to	TO	O
reduce	VB	O
BP	NNP	PH
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
30	CD	O
non-diabetic	JJ	O
patients	NNS	O
with	IN	O
hypertension	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
device	NN	O
that	WDT	O
helps	VBZ	O
to	TO	O
slow	VB	PH
breathing	NN	PH
(	(	O
Resperate	NNP	O
)	)	O
on	IN	O
BP	NNP	PH
and	CC	O
quality	NN	PH
of	IN	PH
life	NN	PH
(	(	PH
QoL	NNP	PH
)	)	PH
.	.	O

The	DT	O
control	NN	O
group	NN	O
listened	VBD	O
to	TO	O
music	NN	O
and	CC	O
used	VBN	O
no	DT	O
other	JJ	O
therapeutic	JJ	O
device	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
change	NN	O
in	IN	O
BP	NNP	PH
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
;	:	O
BP	NNP	PH
-4.2	NNP	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-12.4	NNP	O
to	TO	O
3.9	CD	O
)	)	O
/-2.6	NN	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-8.4	NNP	O
to	TO	O
3.3	CD	O
)	)	O
.	.	O

This	DT	O
result	NN	O
did	VBD	O
not	RB	O
alter	VB	O
in	IN	O
post	NN	O
hoc	NN	O
analyses	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
not	RB	O
achieving	VBG	O
target	NN	PH
breathing	NN	PH
frequency	NN	PH
(	(	O
<	JJ	O
10	CD	O
breaths/min	NN	O
)	)	O
or	CC	O
non-compliant	JJ	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

QoL	NNP	PH
did	VBD	O
not	RB	O
change	VB	O
over	IN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
found	VBD	O
no	DT	O
effect	NN	O
of	IN	O
the	DT	O
Resperate	NNP	O
on	IN	O
BP	NNP	PH
or	CC	O
QoL	NNP	PH
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
at	IN	O
this	DT	O
moment	NN	O
,	,	O
this	DT	O
device	NN	O
has	VBZ	O
no	DT	O
added	VBN	O
value	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
.	.	O

Sivelestat	NNP	O
sodium	NN	O
hydrate	NN	O
improves	VBZ	O
septic	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
by	IN	O
reducing	VBG	O
alveolar	JJ	O
dysfunction	NN	O
.	.	O

Sivelestat	NNP	O
sodium	NN	O
hydrate	NN	O
(	(	O
sivelestat	NN	O
)	)	O
is	VBZ	O
a	DT	O
selective	JJ	O
inhibitor	NN	O
of	IN	O
polymorphonuclear	JJ	O
leukocyte	JJ	O
elastase	NN	O
(	(	O
PMN-E	NNP	O
)	)	O
.	.	O

We	PRP	O
administered	VBD	O
sivelestat	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
septic	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
(	(	O
ALI	NNP	O
)	)	O
to	TO	O
examine	VB	O
its	PRP$	O
usefulness	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
duration	NN	Ot
of	IN	Ot
artificial	JJ	Ot
ventilation	NN	Ot
and	CC	PH
pulmonary	JJ	PH
oxygenation	NN	PH
ability	NN	PH
,	,	O
and	CC	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mortality	NN	MO
and	CC	O
the	DT	O
concentrations	NNS	MO
of	IN	MO
PMN-E	NNP	MO
,	,	MO
SP-D	NNP	MO
,	,	MO
TNF-alpha	NNP	MO
and	CC	MO
IL-8	NNP	MO
in	IN	MO
blood	NN	MO
.	.	O

In	IN	O
the	DT	O
sivelestat	NN	O
group	NN	O
,	,	O
the	DT	O
duration	NN	Ot
of	IN	Ot
artificial	JJ	Ot
ventilation	NN	Ot
,	,	O
pulmonary	JJ	PH
oxygenation	NN	PH
ability	NN	PH
,	,	PH
and	CC	O
the	DT	O
blood	NN	PH
PMN-E	NNP	PH
,	,	PH
SP-D	NNP	PH
,	,	PH
TNF-alpha	NNP	PH
and	CC	PH
IL-8	NNP	PH
concentrations	NNS	PH
decreased	VBD	O
significantly	RB	O
.	.	O

Administration	NNP	O
of	IN	O
sivelestat	NN	O
was	VBD	O
found	VBN	O
to	TO	O
reduce	VB	O
alveolar	JJ	PH
dysfunction	NN	PH
and	CC	O
improve	VB	O
respiratory	NN	PH
function	NN	PH
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
suggested	VBN	O
that	IN	O
early	JJ	O
administration	NN	O
might	MD	O
be	VB	O
useful	JJ	O
.	.	O

Rate-modulated	JJ	O
cardiac	NN	O
pacing	NN	O
based	VBN	O
on	IN	O
transthoracic	JJ	O
impedance	NN	O
measurements	NNS	O
of	IN	O
minute	JJ	O
ventilation	NN	O
:	:	O
correlation	NN	O
with	IN	O
exercise	NN	O
gas	NN	O
exchange	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
pacing	VBG	O
rate	NN	O
to	TO	O
physiologic	VB	O
variables	NNS	O
of	IN	O
metabolic	JJ	O
demand	NN	O
was	VBD	O
examined	VBN	O
in	IN	O
10	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
minute	NN	O
ventilation-sensing	NN	O
,	,	O
rate-modulating	JJ	O
ventricular	JJ	O
pacemaker	NN	O
implanted	VBN	O
for	IN	O
complete	JJ	O
heart	NN	O
block	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
paroxysmal	JJ	O
(	(	O
seven	CD	O
patients	NNS	O
)	)	O
or	CC	O
chronic	JJ	O
(	(	O
three	CD	O
patients	NNS	O
)	)	O
atrial	JJ	O
fibrillation	NN	O
and	CC	O
were	VBD	O
referred	VBN	O
for	IN	O
catheter	JJR	O
ablation	NN	O
of	IN	O
the	DT	O
atrioventricular	JJ	O
junction	NN	O
.	.	O

Treadmill	NNP	O
exercise	NN	O
testing	VBG	O
with	IN	O
measurement	NN	O
of	IN	O
expired	NNP	PH
gas	NN	PH
exchange	NN	PH
and	CC	PH
respiratory	NN	PH
flow	NN	PH
was	VBD	O
performed	VBN	O
before	IN	O
ablation	NN	O
and	CC	O
4	CD	O
weeks	NNS	O
after	IN	O
pacemaker	NN	O
implantation	NN	O
,	,	O
with	IN	O
the	DT	O
pacemaker	NN	O
programmed	VBD	O
to	TO	O
both	DT	O
the	DT	O
fixed-rate	JJ	O
VVI	NNP	O
and	CC	O
rate-modulating	JJ	O
minute	NN	O
ventilation	NN	O
VVIR	NNP	O
pacing	VBG	O
modes	NNS	O
in	IN	O
random	JJ	O
sequence	NN	O
.	.	O

The	DT	O
relation	NN	PH
of	IN	PH
pacing	VBG	PH
rate	NN	PH
to	TO	PH
oxygen	VB	PH
consumption	NN	PH
(	(	PH
VO2	NNP	PH
)	)	PH
,	,	O
expired	VBD	PH
carbon	NN	PH
dioxide	NN	PH
concentration	NN	PH
(	(	PH
VCO2	NNP	PH
)	)	PH
,	,	O
respiratory	JJ	PH
quotient	NN	PH
,	,	O
tidal	JJ	PH
volume	NN	PH
,	,	O
respiratory	NN	PH
rate	NN	PH
and	CC	PH
minute	NN	PH
ventilation	NN	PH
was	VBD	O
determined	VBN	O
during	IN	O
exercise	NN	O
in	IN	O
the	DT	O
rate-modulating	JJ	O
minute	NN	O
ventilation	NN	O
pacing	VBG	O
mode	NN	O
.	.	O

Pacing	VBG	PH
rate	NN	PH
was	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
minute	JJ	Ot
ventilation	NN	Ot
(	(	O
r	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
,	,	O
respiratory	JJ	PH
quotient	NN	PH
(	(	O
r	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
,	,	O
VCO2	NNP	PH
(	(	O
r	VB	O
=	RB	O
0.87	CD	O
)	)	O
,	,	O
tidal	JJ	PH
volume	NN	PH
(	(	O
r	JJ	O
=	NNP	O
0.87	CD	O
)	)	O
,	,	O
VO2	NNP	PH
(	(	O
r	VB	O
=	RB	O
0.84	CD	O
)	)	O
and	CC	O
respiratory	JJ	PH
rate	NN	PH
(	(	O
r	NN	O
=	RB	O
0.84	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	PH
exercise	NN	PH
duration	NN	PH
increased	VBD	O
from	IN	O
8.3	CD	O
+/-	JJ	O
2.8	CD	O
min	NN	O
in	IN	O
the	DT	O
fixed	JJ	O
rate	NN	O
pacing	VBG	O
mode	NN	O
to	TO	O
10.2	CD	O
+/-	JJ	O
3.4	CD	O
min	NN	O
in	IN	O
the	DT	O
rate-modulating	NN	O
,	,	O
minute	NN	O
ventilation	NN	O
mode	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	PH
VO2	NNP	PH
increased	VBD	O
from	IN	O
13.4	CD	O
+/-	JJ	O
3.4	CD	O
to	TO	O
16.3	CD	O
+/-	JJ	O
4.1	CD	O
cc/kg	NN	O
per	IN	O
min	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0004	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
heart	NN	O
rate	NN	O
achieved	VBN	O
in	IN	O
the	DT	O
minute	NN	O
ventilation	NN	O
pacing	VBG	O
mode	NN	O
was	VBD	O
136	CD	O
+/-	JJ	O
9.7	CD	O
beats/min	NN	O
,	,	O
similar	JJ	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
intrinsic	JJ	O
cardiac	JJ	O
rhythm	NN	O
before	IN	O
ablation	NN	O
(	(	O
134.9	CD	O
+/-	JJ	O
30.1	CD	O
beats/min	NN	O
,	,	O
p	NN	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Lack	NN	O
of	IN	O
a	DT	O
pharmacokinetic	JJ	PH
interaction	NN	PH
between	IN	O
steady-state	JJ	O
roflumilast	NN	O
and	CC	O
single-dose	JJ	O
midazolam	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

AIMS	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
roflumilast	NN	O
,	,	O
an	DT	O
investigational	JJ	O
PDE4	NNP	O
inhibitor	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
COPD	NNP	O
and	CC	O
asthma	RB	O
,	,	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	PH
of	IN	PH
the	DT	PH
CYP3A	NNP	PH
probe	NN	PH
drug	NN	O
midazolam	NN	O
and	CC	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
(	(	O
for	IN	O
midazolam	NN	O
treatment	NN	O
sequence	NN	O
)	)	O
study	NN	O
,	,	O
18	CD	O
healthy	JJ	O
male	NN	O
subjects	NNS	O
received	VBD	O
single	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
2	CD	O
mg	RB	O
oral	JJ	O
and	CC	O
1	CD	O
mg	NN	O
i.v.	NN	O
,	,	O
1	CD	O
day	NN	O
apart	RB	O
)	)	O
alone	RB	O
,	,	O
repeated	VBD	O
doses	NNS	O
of	IN	O
roflumilast	NN	O
(	(	O
500	CD	O
microg	NN	O
once	RB	O
daily	JJ	O
for	IN	O
14	CD	O
days	NNS	O
)	)	O
alone	RB	O
,	,	O
and	CC	O
repeated	VBD	O
doses	NNS	O
of	IN	O
roflumilast	NN	O
together	RB	O
with	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
2	CD	O
mg	RB	O
oral	JJ	O
and	CC	O
1	CD	O
mg	NN	O
i.v.	NN	O
,	,	O
1	CD	O
day	NN	O
apart	RB	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
comparison	NN	O
of	IN	O
clearance	NN	PH
and	CC	PH
peak	NN	PH
and	CC	PH
systemic	JJ	PH
exposure	NN	PH
to	TO	O
midazolam	VB	O
following	VBG	O
administration	NN	O
of	IN	O
roflumilast	NN	O
indicated	JJ	O
no	DT	O
effect	NN	O
of	IN	O
roflumilast	NN	O
dosed	VBN	O
to	TO	O
steady	JJ	O
state	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	PH
of	IN	PH
midazolam	NN	PH
.	.	PH

Point	NN	O
estimates	NNS	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
)	)	O
were	VBD	O
0.97	CD	O
(	(	O
0.84	CD	O
,	,	O
1.13	CD	O
)	)	O
for	IN	O
the	DT	O
AUC	NNP	O
of	IN	O
i.v	NN	O
.	.	O

midazolam	NN	O
and	CC	O
0.98	CD	O
(	(	O
0.82	CD	O
,	,	O
1.17	CD	O
)	)	O
for	IN	O
that	DT	O
of	IN	O
oral	JJ	O
midazolam	NN	O
with	IN	O
and	CC	O
without	IN	O
roflumilast	NN	O
.	.	O

CONCLUSIONS	NNP	O
Therapeutic	NNP	O
steady	JJ	O
state	NN	O
concentrations	NNS	O
of	IN	O
roflumilast	NN	O
and	CC	O
its	PRP$	O
N-oxide	NNP	O
do	NN	O
not	RB	O
alter	VB	O
the	DT	O
disposition	NN	PH
of	IN	PH
the	DT	PH
CYP3A	NNP	PH
substrate	NN	PH
midazolam	NN	PH
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

This	DT	O
finding	NN	O
suggests	VBZ	O
that	IN	O
roflumilast	NN	O
is	VBZ	O
unlikely	JJ	O
to	TO	O
alter	VB	O
the	DT	O
clearance	NN	O
of	IN	O
drugs	NNS	O
that	WDT	O
are	VBP	O
metabolized	VBN	O
by	IN	O
CYP3A4	NNP	O
.	.	O

Supporting	VBG	O
families	NNS	O
in	IN	O
challenging	VBG	O
contexts	NN	O
:	:	O
the	DT	O
CAPEDP	NNP	O
project	NN	O
.	.	O

Although	IN	O
France	NNP	O
has	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
generous	JJ	O
health	NN	O
and	CC	O
social	JJ	O
care	NN	O
systems	NNS	O
for	IN	O
infant	NN	O
and	CC	O
maternal	JJ	O
well-being	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
professionals	NNS	O
have	VBP	O
been	VBN	O
increasingly	RB	O
concerned	VBN	O
by	IN	O
the	DT	O
rising	VBG	O
number	NN	O
of	IN	O
children	NNS	O
being	VBG	O
referred	VBN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
.	.	O

The	DT	O
present	JJ	O
article	NN	O
describes	VBZ	O
the	DT	O
first	JJ	O
home-visiting	JJ	O
program	NN	O
in	IN	O
France	NNP	O
to	TO	O
specifically	RB	O
target	VB	O
mental	JJ	O
health	NN	O
questions	NNS	O
in	IN	O
families	NNS	O
living	VBG	O
in	IN	O
vulnerable	JJ	O
contexts	NN	O
.	.	O

The	DT	O
CAPEDP	NNP	O
project	NN	O
,	,	O
involving	VBG	O
440	CD	O
women	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
,	,	O
took	VBD	O
place	NN	O
in	IN	O
Paris	NNP	O
and	CC	O
its	PRP$	O
inner	JJ	O
suburbs	NNS	O
from	IN	O
2006	CD	O
to	TO	O
2011	CD	O
.	.	O

To	TO	O
be	VB	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
,	,	O
women	NNS	O
had	VBD	O
to	TO	O
be	VB	O
(	(	O
i	NN	O
)	)	O
under	IN	O
26	CD	O
years	NNS	O
old	JJ	O
,	,	O
(	(	O
ii	NN	O
)	)	O
less	JJR	O
that	IN	O
27	CD	O
weeks	NNS	O
pregnant	JJ	O
,	,	O
(	(	O
iii	NN	O
)	)	O
sufficiently	RB	O
fluent	VBN	O
in	IN	O
French	JJ	O
to	TO	O
give	VB	O
truly	NN	O
informed	JJ	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
benefit	NN	O
from	IN	O
the	DT	O
intervention	NN	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
presenting	VBG	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
social	JJ	O
vulnerability	NN	O
factors	NNS	O
:	:	O
low	JJ	O
income	NN	O
,	,	O
low	JJ	O
educational	JJ	O
level	NN	O
,	,	O
and/or	RB	O
intending	VBG	O
to	TO	O
bring	VB	O
up	RP	O
the	DT	O
child	NN	O
without	IN	O
the	DT	O
child	NN	O
's	POS	O
father	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
44	CD	O
home	NN	O
visits	NNS	O
from	IN	O
the	DT	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
through	IN	O
to	TO	O
the	DT	O
child	NN	O
's	POS	O
second	JJ	O
birthday	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
promote	VB	O
infant	JJ	ME
mental	JJ	ME
health	NN	ME
and	CC	O
reduce	VB	O
the	DT	O
incidence	NN	ME
of	IN	ME
infant	JJ	ME
mental	JJ	ME
health	NN	ME
problems	NNS	ME
at	IN	O
the	DT	O
age	NN	O
of	IN	O
two	CD	O
years	NNS	O
.	.	O

The	DT	O
intervention	NN	O
paid	VBD	O
particular	JJ	O
attention	NN	O
to	TO	O
postnatal	JJ	O
maternal	JJ	O
depression	NN	O
and	CC	O
promoting	VBG	O
parenting	VBG	O
skills	NNS	O
and	CC	O
attachment	JJ	O
security	NN	O
,	,	O
particularly	RB	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
video	NN	O
during	IN	O
home-visits	NNS	O
.	.	O

A	DT	O
major	JJ	O
issue	NN	O
was	VBD	O
that	IN	O
of	IN	O
adapting	VBG	O
international	JJ	O
best	JJS	O
practice	NN	O
recommendations	NNS	O
with	IN	O
regard	NN	O
to	TO	O
home-visiting	JJ	O
programs	NNS	O
to	TO	O
the	DT	O
particularities	NNS	O
of	IN	O
the	DT	O
existing	VBG	O
French	JJ	O
social	JJ	O
and	CC	O
health	NN	O
care	NN	O
system	NN	O
.	.	O

An	DT	O
original	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
use	VB	O
trained	JJ	O
clinical	JJ	O
psychologists	NNS	O
to	TO	O
conduct	VB	O
all	DT	O
home	NN	O
visits	NNS	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Assessment	NNP	O
for	IN	O
Toddlers	NNP	O
with	IN	O
Autism	NNP	O
(	(	O
SCATA	NNP	O
)	)	O
:	:	O
an	DT	O
instrument	NN	O
to	TO	O
measure	VB	O
the	DT	O
frequency	NN	Ot
,	,	O
form	NN	O
and	CC	O
function	NN	ME
of	IN	ME
communication	NN	ME
in	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Assessment	NNP	O
for	IN	O
Toddlers	NNP	O
with	IN	O
Autism	NNP	O
(	(	O
SCATA	NNP	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
measure	VB	O
non-verbal	JJ	ME
communication	NN	ME
,	,	ME
including	VBG	ME
early	JJ	ME
and	CC	ME
atypical	JJ	ME
communication	NN	ME
,	,	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Each	DT	O
communicative	JJ	O
act	NN	O
is	VBZ	O
scored	VBN	O
according	VBG	O
to	TO	O
its	PRP$	O
form	NN	O
,	,	O
function	NN	O
,	,	O
role	NN	O
and	CC	O
complexity	NN	O
.	.	O

The	DT	O
SCATA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
communicative	JJ	O
ability	NN	O
longitudinally	RB	O
in	IN	O
two	CD	O
samples	NNS	O
of	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Overall	JJ	ME
frequency	NN	ME
of	IN	ME
non-verbal	JJ	ME
communicative	JJ	ME
acts	NNS	ME
did	VBD	O
not	RB	O
change	NN	O
between	IN	O
the	DT	O
two	CD	O
assessments	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
form	NN	ME
and	CC	ME
complexity	NN	ME
,	,	ME
the	DT	ME
function	NN	ME
and	CC	ME
the	DT	ME
role	NN	ME
the	DT	O
child	NN	O
took	VBD	O
in	IN	O
the	DT	O
interaction	NN	O
did	VBD	O
change	VB	O
with	IN	O
time	NN	O
.	.	O

Both	DT	O
frequency	NN	ME
and	CC	ME
function	NN	ME
of	IN	ME
communicative	JJ	ME
acts	NNS	ME
in	IN	O
toddlerhood	NN	O
were	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
later	JJ	ME
language	NN	ME
ability	NN	ME
:	:	ME
social	JJ	ME
acts	NNS	ME
,	,	ME
comments	NNS	ME
and	CC	ME
initiations	NNS	ME
showed	VBD	O
greater	JJR	O
predictive	JJ	O
association	NN	O
than	IN	O
requests	NNS	O
and	CC	O
responses	NNS	O
.	.	O

[	JJ	O
Comparative	NNP	O
effects	NNS	O
of	IN	O
nebivolol	NN	O
and	CC	O
valsartan	NN	O
on	IN	O
atrial	JJ	PH
electromechanical	JJ	PH
coupling	NN	PH
in	IN	O
newly	RB	O
diagnosed	VBN	O
stage	NN	O
1	CD	O
hypertensive	JJ	O
patients	NNS	O
]	VBP	O
.	.	O

OBJECTIVES	NNP	O
Hypertension	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
cardiovascular	NN	O
risk	NN	O
factor	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
atrial	JJ	PH
fibrillation	NN	PH
(	(	PH
AF	NNP	PH
)	)	PH
.	.	PH

Increased	VBN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
time	NN	O
interval	NN	O
measured	VBN	O
by	IN	O
tissue	NN	O
Doppler	NNP	O
is	VBZ	O
accepted	VBN	O
as	IN	O
an	DT	O
important	JJ	O
factor	NN	O
for	IN	O
prediction	NN	O
of	IN	O
AF	NNP	PH
development	NN	PH
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
valsartan	NN	O
,	,	O
an	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
,	,	O
and	CC	O
nebivolol	RB	O
,	,	O
a	DT	O
beta-blocker	NN	O
,	,	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
in	IN	O
newly	RB	O
diagnosed	VBN	O
stage	NN	O
1	CD	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
The	DT	O
study	NN	O
included	VBD	O
60	CD	O
newly	RB	O
diagnosed	VBN	O
stage	NN	O
1	CD	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
no	DT	O
other	JJ	O
systemic	JJ	O
disease	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
nebivolol	JJ	O
5	CD	O
mg	NN	O
(	(	O
30	CD	O
patients	NNS	O
;	:	O
21	CD	O
women	NNS	O
,	,	O
9	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
48.4	CD	O
?	.	O
11.4	CD	O
years	NNS	O
)	)	O
and	CC	O
valsartan	$	O
160	CD	O
mg	NN	O
(	(	O
30	CD	O
patients	NNS	O
;	:	O
21	CD	O
women	NNS	O
,	,	O
9	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
49.8	CD	O
?	.	O
11.3	CD	O
years	NNS	O
)	)	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
underwent	JJ	O
tissue	NN	O
Doppler	NNP	O
echocardiographic	JJ	O
examination	NN	O
before	IN	O
and	CC	O
three	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
blood	NN	O
pressures	NNS	O
,	,	O
electrocardiographic	JJ	O
and	CC	O
echocardiographic	JJ	O
findings	NNS	O
,	,	O
and	CC	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
significantly	RB	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
after	IN	O
treatment	NN	O
,	,	O
with	IN	O
similar	JJ	O
efficacy	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
time	NN	O
intervals	NNS	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Prolonged	VBD	O
interatrial	JJ	O
electromechanical	JJ	O
time	NN	O
intervals	NNS	O
in	IN	O
hypertensives	NNS	O
are	VBP	O
improved	VBN	O
with	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

Beta-carotene	NNP	O
in	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

beta-Carotene	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
beta-carotene	JJ	O
supplementation	NN	O
can	MD	O
increase	VB	O
CD4	NNP	PH
counts	NNS	PH
in	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Our	PRP$	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
beta-carotene	NN	O
in	IN	O
raising	VBG	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Twenty-one	CD	O
HIV-seropositive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
beta-carotene	NN	O
,	,	O
180	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
receive	VB	O
the	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
following	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

beta-Carotene	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
total	JJ	PH
WBC	NNP	PH
count	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
%	NN	O
change	NN	O
in	IN	O
CD4	NNP	PH
count	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
%	NN	O
change	NN	O
in	IN	O
CD4/CD8	NNP	PH
ratios	NNS	PH
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
absolute	JJ	O
CD4	NNP	PH
count	NN	PH
,	,	O
absolute	JJ	O
CD4/CD8	NNP	PH
ratio	NN	PH
,	,	O
and	CC	O
total	JJ	O
and	CC	O
B-lymphocytes	NNP	O
all	DT	O
increased	VBN	O
on	IN	O
carotene	NN	O
and	CC	O
fell	VBD	O
during	IN	O
placebo	NN	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
toxicity	NN	PH
was	VBD	O
observed	VBN	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

beta-Carotene	JJ	O
appears	VBZ	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	Ot
effect	NN	Ot
in	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
demonstrate	VB	O
whether	IN	O
beta-carotene	NN	O
has	VBZ	O
a	DT	O
role	NN	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
treatment	NN	O
of	IN	O
HIV-infected	JJ	PH
patients	NNS	PH
.	.	O

Abstinence	NN	O
or	CC	O
controlled	VBN	O
drinking	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
:	:	O
indications	NNS	O
at	IN	O
initial	JJ	O
assessment	NN	O
.	.	O

Previous	JJ	O
research	NN	O
has	VBZ	O
suggested	VBN	O
two	CD	O
leading	JJ	O
hypotheses	NNS	O
concerning	VBG	O
which	WDT	O
excessive	JJ	O
drinkers	NNS	O
can	MD	O
re-establish	VB	O
control	NN	O
:	:	O
one	CD	O
based	VBN	O
upon	IN	O
level	NN	O
of	IN	O
dependence	NN	O
,	,	O
the	DT	O
other	JJ	O
upon	IN	O
the	DT	O
client	NN	O
's	POS	O
personal	JJ	O
persuasion	NN	O
.	.	O

Using	VBG	O
initial	JJ	O
assessment	NN	O
data	NNS	O
from	IN	O
46	CD	O
clients	NNS	O
of	IN	O
a	DT	O
clinical	JJ	O
psychology	NN	O
alcohol	NN	O
problems	NNS	O
service	NN	O
(	(	O
30	CD	O
men	NNS	O
,	,	O
16	CD	O
women	NNS	O
)	)	O
,	,	O
an	DT	O
attempt	NN	O
was	VBD	O
made	VBN	O
to	TO	O
operationalize	VB	O
the	DT	O
concepts	NNS	O
of	IN	O
dependence	NN	O
and	CC	O
personal	JJ	O
persuasion	NN	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
indicators	NNS	O
of	IN	O
each	DT	O
.	.	O

Although	IN	O
SADQ	NNP	ME
scores	NNS	ME
and	CC	O
Rand	NNP	ME
definite	VBP	ME
alcoholism	NN	ME
were	VBD	O
in	IN	O
general	JJ	O
agreement	NN	O
,	,	O
there	EX	O
were	VBD	O
a	DT	O
number	NN	O
of	IN	O
borderline	JJ	O
instances	NNS	O
and	CC	O
cases	NNS	O
of	IN	O
disagreement	NN	O
,	,	O
and	CC	O
neither	DT	O
was	VBD	O
in	IN	O
good	JJ	O
agreement	NN	O
with	IN	O
estimates	NNS	O
of	IN	O
problem	NN	O
duration	NN	O
,	,	O
nor	CC	O
with	IN	O
reports	NNS	O
of	IN	O
recent	JJ	O
or	CC	O
earlier	RBR	O
attainment	NN	O
of	IN	O
abstinence	NN	O
or	CC	O
control	NN	O
.	.	O

Indicators	NNS	O
of	IN	O
personal	JJ	ME
persuasion	NN	ME
were	VBD	O
more	RBR	O
consistent	JJ	O
.	.	O

Those	DT	O
with	IN	O
dependence	NN	O
indicators	NNS	ME
for	IN	ME
abstinence	NN	ME
tended	VBD	O
to	TO	O
prefer	VB	O
abstinence	NN	O
as	IN	O
a	DT	O
goal	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
many	JJ	O
departures	NNS	O
from	IN	O
this	DT	O
pattern	NN	O
particularly	RB	O
for	IN	O
women	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
in	IN	O
clinical	JJ	O
practice	NN	O
it	PRP	O
will	MD	O
be	VB	O
very	RB	O
difficult	JJ	O
to	TO	O
make	VB	O
a	DT	O
clear	JJ	O
cut	NN	O
recommendation	NN	O
about	IN	O
treatment	NN	O
goal	NN	O
at	IN	O
initial	JJ	O
assessment	NN	O
except	IN	O
in	IN	O
a	DT	O
few	JJ	O
cases	NNS	O
.	.	O

Predictors	NNS	O
of	IN	O
recruited	JJ	O
melanoma	NN	O
families	NNS	O
into	IN	O
a	DT	O
behavioral	JJ	O
intervention	NN	O
project	NN	O
.	.	O

BACKGROUND	NNP	O
Examination	NNP	O
of	IN	O
families	NNS	O
represents	VBZ	O
an	DT	O
important	JJ	O
priority	NN	O
in	IN	O
health	NN	O
research	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
we	PRP	O
report	VBP	Ot
on	IN	O
individual	JJ	ME
and	CC	ME
family-level	JJ	ME
factors	NNS	ME
associated	VBN	O
with	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
cancer	NN	O
prevention	NN	O
research	NN	O
project	NN	O
.	.	O

We	PRP	O
approached	VBD	O
families	NNS	O
affected	VBN	O
by	IN	O
melanoma	NN	O
for	IN	O
possible	JJ	O
participation	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
a	DT	O
web-based	JJ	O
communication	NN	O
and	CC	O
support	NN	O
intervention	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
recruited	VBD	O
three	CD	O
family	NN	O
members	NNS	O
per	IN	O
family	NN	O
for	IN	O
assessment	NN	O
-	:	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
a	DT	O
first-degree	JJ	O
relative	NN	O
(	(	O
FDR	NNP	O
)	)	O
,	,	O
and	CC	O
a	DT	O
relative	NN	O
who	WP	O
is	VBZ	O
a	DT	O
parent	NN	O
of	IN	O
a	DT	O
child	JJ	O
age	NN	O
18	CD	O
or	CC	O
younger	JJR	O
.	.	O

Recruitment	NNP	O
involved	VBD	O
three	CD	O
steps	NNS	O
:	:	O
requesting	VBG	O
the	DT	O
physician	NN	O
's	POS	O
consent	NN	O
to	TO	O
approach	VB	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
approaching	VBG	O
the	DT	O
case	NN	O
to	TO	O
request	VB	O
their	PRP$	O
participation	NN	O
and	CC	O
family	NN	O
contact	NN	O
information	NN	O
,	,	O
and	CC	O
they	PRP	O
approaching	VBG	O
the	DT	O
FDRs	NNP	O
and	CC	O
parents	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
1380	CD	O
families	NNS	O
approached	VBD	O
,	,	O
313	CD	O
were	VBD	O
enrolled	VBN	O
,	,	O
263	CD	O
were	VBD	O
excluded	VBN	O
because	IN	O
we	PRP	O
could	MD	O
not	RB	O
find	VB	O
or	CC	O
contact	VB	O
a	DT	O
family	NN	O
member	NN	O
(	(	O
FDR	CD	O
or	CC	O
parent	NN	O
)	)	O
,	,	O
331	CD	O
did	VBD	O
not	RB	O
have	VB	O
eligible	JJ	O
family	NN	O
members	NNS	O
,	,	O
and	CC	O
473	CD	O
refused	VBD	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
noted	VBD	O
reason	NN	O
for	IN	O
refusal	NN	Ot
was	VBD	O
being	VBG	O
too	RB	O
busy	JJ	O
or	CC	O
having	VBG	O
no	DT	O
time	NN	O
.	.	O

The	DT	O
primary	JJ	O
predictors	NNS	O
of	IN	O
participation	NN	O
for	IN	O
cases	NNS	O
(	(	O
OR=1.6	NNP	O
;	:	O
CI=1.01-2.51	NNP	O
)	)	O
and	CC	O
FDRs	NNP	O
(	(	O
OR=2.15	NNP	O
;	:	O
CI=1.11-4.13	NNP	O
)	)	O
included	VBD	O
higher	JJR	ME
educational	JJ	ME
attainment	NN	ME
.	.	ME

FDRs	NNP	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
they	PRP	O
were	VBD	O
female	JJ	O
(	(	O
OR=1.77	NNP	O
;	:	O
CI=1.1-.85	NNP	O
)	)	O
and	CC	O
parents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
the	DT	O
case	NN	O
had	VBD	O
been	VBN	O
diagnosed	VBN	PH
more	RBR	PH
recently	RB	PH
(	(	O
OR=3.3	NNP	O
;	:	O
CI=1.9-5.93	NNP	O
)	)	O
,	,	O
if	IN	O
the	DT	O
parent	NN	Ot
was	VBD	Ot
partnered	VBN	Ot
(	(	O
OR=4.37	NNP	O
;	:	O
CI=1.86-10.26	NNP	O
)	)	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
parent	NN	ME
lived	VBD	ME
in	IN	ME
the	DT	ME
same	JJ	ME
city	NN	ME
as	IN	ME
the	DT	ME
case	NN	ME
(	(	O
OR=2.88	NNP	O
;	:	O
CI=1.08-7.68	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
can	MD	O
provide	VB	O
information	NN	O
on	IN	O
potential	JJ	O
directions	NNS	O
for	IN	O
future	JJ	O
family	NN	O
recruitment	NN	O
.	.	O

Suppression	NN	O
of	IN	O
immediate	JJ	O
and	CC	O
late	JJ	O
anti-IgE-induced	JJ	PH
skin	NN	PH
reactions	NNS	PH
by	IN	O
topically	RB	O
applied	VBN	O
alcohol/onion	NN	O
extract	NN	O
.	.	O

In	IN	O
a	DT	O
double	JJ	O
blind	NN	O
study	NN	O
,	,	O
alcohol/onion	NN	O
extract	NN	O
(	(	O
5	CD	O
%	NN	O
ethanol	NN	O
)	)	O
was	VBD	O
injected	VBN	O
simultaneously	RB	O
with	IN	O
20	CD	O
IU	NNP	O
and	CC	O
200	CD	O
IU	NNP	O
rabbit	NN	O
anti-human-IgE	JJ	O
intradermally	RB	O
in	IN	O
12	CD	O
adult	NN	O
volunteers	NNS	O
(	(	O
6	CD	O
atopics	NNS	O
,	,	O
6	CD	O
non-atopics	NNS	O
)	)	O
.	.	O

Diameters	NNS	O
of	IN	O
wheals	NNS	O
and	CC	O
flares	NNS	O
were	VBD	O
measured	VBN	O
10	CD	O
min	NN	O
after	IN	O
and	CC	O
compared	VBN	O
with	IN	O
control	NN	O
sites	NNS	O
challenged	VBD	O
with	IN	O
20	CD	O
IU	NNP	O
and	CC	O
200	CD	O
IU	NNP	O
anti-IgE	NN	O
in	IN	O
a	DT	O
5	CD	O
%	NN	O
ethanol	JJ	O
solution	NN	O
.	.	O

The	DT	O
skin	NN	O
sites	NNS	O
were	VBD	O
then	RB	O
treated	VBN	O
epidermally	RB	O
with	IN	O
45	CD	O
%	NN	O
alcohol/onion	NN	O
extract	NN	O
and	CC	O
45	CD	O
%	NN	O
ethanol	NN	O
under	IN	O
occlusion	NN	O
.	.	O

Diameters	NNS	O
of	IN	O
late	JJ	O
cutaneous	JJ	O
reactions	NNS	O
were	VBD	O
measured	VBN	O
hourly	RB	O
.	.	O

Oedema	NNP	O
formation	NN	O
was	VBD	O
clinically	RB	O
estimated	VBN	O
according	VBG	O
to	TO	O
an	DT	O
arbitrary	JJ	O
scale	NN	O
and	CC	O
skin	NN	O
thickness	NN	O
measured	VBN	O
with	IN	O
a	DT	O
calliper	NN	O
.	.	O

In	IN	O
the	DT	O
onion-treated	JJ	O
skin	NN	O
sites	VBZ	O
the	DT	O
wheal	JJ	PH
areas	NNS	PH
were	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
20	CD	O
IU	NNP	O
:	:	O
control	NN	O
:	:	O
108	CD	O
+/-	JJ	O
53	CD	O
mm2	NN	O
;	:	O
onion	NN	O
69	CD	O
+/-	JJ	O
42	CD	O
mm2	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
;	:	O
200	CD	O
IU	NNP	O
anti-IgE	JJ	O
:	:	O
control	NN	O
:	:	O
152	CD	O
+/-	JJ	O
25	CD	O
mm2	NN	O
,	,	O
onion	NN	O
:	:	O
138	CD	O
+/-	JJ	O
26	CD	O
mm2	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
oedema	JJ	PH
formation	NN	PH
during	IN	O
the	DT	O
late	JJ	O
phase	NN	O
skin	JJ	O
reaction	NN	O
was	VBD	O
markedly	RB	O
depressed	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.005	CD	O
at	IN	O
2	CD	O
h	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
at	IN	O
4	CD	O
and	CC	O
6	CD	O
h	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
at	IN	O
8	CD	O
h	NN	O
)	)	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
late	JJ	O
skin	NN	PH
reactions	NNS	PH
was	VBD	O
slightly	RB	O
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
reduced	VBN	O
.	.	O

Obviously	RB	O
,	,	O
onions	NNS	O
contain	VBP	O
pharmacologically	RB	O
active	JJ	O
substances	NNS	O
with	IN	O
anti-inflammatory	JJ	O
and/or	NN	O
allergic	NN	O
properties	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
multi-component	JJ	O
higher-functioning	JJ	O
autism	NN	O
anti-stigma	JJ	O
program	NN	O
on	IN	O
adolescent	JJ	O
boys	NNS	O
.	.	O

A	DT	O
six-session	JJ	O
higher-functioning	JJ	O
autism	NN	O
anti-stigma	JJ	O
program	NN	O
incorporating	NN	O
descriptive	NN	O
,	,	O
explanatory	NN	O
and	CC	O
directive	JJ	O
information	NN	O
was	VBD	O
delivered	VBN	O
to	TO	O
adolescent	VB	O
boys	NNS	O
and	CC	O
the	DT	O
impact	NN	O
upon	IN	O
knowledge	NN	ME
,	,	ME
attitudes	NNS	ME
and	CC	ME
behavioural	JJ	ME
intentions	NNS	ME
towards	NNS	O
peers	NNS	O
with	IN	O
autism	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
seventh-	JJ	O
,	,	O
eighth-	JJ	O
and	CC	O
ninth-grade	JJ	O
students	NNS	O
(	(	O
N	NNP	O
=	NNP	O
395	CD	O
)	)	O
from	IN	O
regular	JJ	O
classes	NNS	O
in	IN	O
a	DT	O
mainstream	JJ	O
school	NN	O
.	.	O

Two-eighth-grade	JJ	O
classes	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
condition	NN	O
and	CC	O
all	DT	O
remaining	VBG	O
students	NNS	O
were	VBD	O
either	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
no-intervention	JJ	O
peer	NN	O
or	CC	O
no-intervention	JJ	O
non-peer	JJ	O
condition	NN	O
.	.	O

The	DT	O
anti-stigma	JJ	O
program	NN	O
improved	VBD	O
the	DT	O
knowledge	NN	O
and	CC	O
attitudes	NNS	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
behavioural	JJ	O
intentions	NNS	O
of	IN	O
participants	NNS	O
towards	VBP	O
their	PRP$	O
peers	NNS	O
with	IN	O
autism	NN	O
.	.	O

Knowledge	NNP	O
and	CC	O
attitudinal	JJ	O
changes	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
follow-up	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
spill-over	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
program	NN	O
to	TO	O
non-targeted	JJ	O
students	NNS	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
some	DT	O
preliminary	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
multi-session	NN	O
anti-stigma	JJ	O
programs	NNS	O
incorporating	VBG	O
combined	VBN	O
information	NN	O
for	IN	O
adolescent	NN	O
students	NNS	O
in	IN	O
inclusive	JJ	O
educational	JJ	O
environments	NNS	O
.	.	O

Take	VB	O
a	DT	O
walk	NN	O
in	IN	O
the	DT	O
park	NN	O
?	.	O
A	DT	O
cross-over	NN	O
pilot	NN	O
trial	NN	O
comparing	VBG	O
brisk	JJ	O
walking	VBG	O
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
:	:	O
park	NN	O
and	CC	O
urban	JJ	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
whether	IN	O
differences	NNS	O
exist	VBP	O
between	IN	O
a	DT	O
30	CD	O
minute	NN	O
brisk	NN	O
walk	VBP	O
taken	VBN	O
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
which	WDT	O
environment	NN	O
best	JJS	O
facilitates	NNS	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
:	:	O
park	NN	O
or	CC	O
urban	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomised	JJ	O
cross-over	NN	O
pilot	NN	O
study	NN	O
,	,	O
participants	NNS	O
performed	VBD	O
a	DT	O
self-timed	JJ	O
30	CD	O
minute	NN	O
brisk	NN	O
walk	VBP	O
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
,	,	O
park	NN	O
and	CC	O
urban	JJ	O
,	,	O
in	IN	O
Glasgow	NNP	O
,	,	O
Scotland	NNP	O
(	(	O
October	NNP	O
2009	CD	O
to	TO	O
January	NNP	O
2010	CD	O
)	)	O
.	.	O

Cadence	NN	PH
,	,	O
recorded	VBD	O
using	VBG	O
the	DT	O
activPAL?	NN	O
activity	NN	O
monitor	NN	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
intensity	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
:	:	O
mean	JJ	O
cadence	NN	O
;	:	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
time	NN	O
accumulated	VBN	O
in	IN	O
bouts	NNS	O
lasting	VBG	O
?	.	O
10	CD	O
min	NN	O
;	:	O
number	NN	O
of	IN	O
walking	VBG	O
breaks	NNS	O
;	:	O
and	CC	O
duration	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
convenience	NN	O
sample	NN	O
of	IN	O
40	CD	O
healthy	JJ	O
adults	NNS	O
was	VBD	O
recruited	VBN	O
:	:	O
16	CD	O
males	NNS	O
,	,	O
24	CD	O
females	NNS	O
,	,	O
mean	JJ	O
age	NN	O
22.9	CD	O
(	(	O
5.5	CD	O
)	)	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
cadence	NN	O
for	IN	O
the	DT	O
whole	JJ	O
walk	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
park	NN	O
:	:	O
119.3	CD	O
(	(	O
8.3	CD	O
)	)	O
vs.	FW	O
110.9	CD	O
(	(	O
8.9	CD	O
)	)	O
steps/min	NN	O
.	.	O

Participants	NNS	O
accumulated	VBD	O
more	RBR	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
in	IN	O
?	.	O
10	CD	O
minute	NN	O
bouts	NNS	O
during	IN	O
park	JJ	O
walks	NNS	O
:	:	O
25.5	CD	O
(	(	O
9.6	CD	O
)	)	O
[	NN	O
median	JJ	O
(	(	O
interquartile	JJ	O
range	NN	O
)	)	O
]	VBZ	O
vs.	FW	O
14.0	CD	O
(	(	O
20.3	CD	O
)	)	O
min	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
self-timed	JJ	O
duration	NN	O
between	IN	O
locations	NNS	O
.	.	O

CONCLUSION	NNP	O
Participants	NNPS	O
accumulated	VBD	O
more	RBR	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
in	IN	O
bouts	NNS	O
?	.	O
10	CD	O
min	NN	O
in	IN	O
duration	NN	O
on	IN	O
park	NN	O
walks	NNS	O
due	JJ	O
to	TO	O
the	DT	O
lack	NN	O
of	IN	O
interruptions	NNS	O
in	IN	O
walking	VBG	O
.	.	O

Hence	NNP	O
the	DT	O
park	NN	O
environment	NN	O
better	RBR	O
facilitated	VBD	O
the	DT	O
achievement	NN	O
of	IN	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
.	.	O

Further	JJ	O
research	NN	O
involving	VBG	O
a	DT	O
larger	JJR	O
,	,	O
more	RBR	O
heterogeneous	JJ	O
sample	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Predicting	VBG	O
completion	NN	O
of	IN	O
treatment	NN	O
among	IN	O
foreign-born	JJ	O
adolescents	NNS	O
treated	VBN	O
for	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
.	.	O

SETTING	NNP	O
Two	CD	O
health	NN	O
clinics	NNS	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
County	NNP	O
,	,	O
California	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
among	IN	O
foreign-born	JJ	O
adolescents	NNS	O
treated	VBN	O
for	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
(	(	O
LTBI	NNP	O
)	)	O
.	.	O

DESIGN	VB	O
A	DT	O
total	NN	O
of	IN	O
766	CD	O
low-income	JJ	O
adolescents	NNS	O
(	(	O
79	CD	O
%	NN	O
participation	NN	O
rate	NN	O
)	)	O
,	,	O
including	VBG	O
610	CD	O
foreign-born	JJ	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

In	IN	O
prospective	JJ	O
face-to-face	NN	O
interviews	NNS	O
,	,	O
data	NNS	O
were	VBD	O
obtained	VBN	O
on	IN	O
socio-demographic	JJ	O
and	CC	O
lifestyle	JJ	O
characteristics	NNS	O
,	,	O
psychosocial	JJ	O
factors	NNS	O
and	CC	O
clinic-related	JJ	O
variables	NNS	O
.	.	O

Medical	JJ	O
chart	NN	O
data	NNS	O
were	VBD	O
abstracted	VBN	O
regarding	VBG	O
clinic	JJ	O
appointment	NN	O
keeping	VBG	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
.	.	O

Univariate	NNP	O
and	CC	O
multivariate	VB	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

RESULTS	NNP	O
Foreign-born	JJ	O
adolescents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
complete	VB	PH
care	NN	PH
than	IN	O
US-born	JJ	O
adolescents	NNS	O
,	,	O
with	IN	O
82	CD	O
%	NN	O
completion	NN	O
of	IN	O
care	NN	O
rate	NN	O
.	.	O

In	IN	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
after	IN	O
controlling	VBG	O
for	IN	O
age	NN	O
,	,	O
medication	NN	ME
taking	VBG	ME
behavior	NN	ME
(	(	O
OR	CC	O
1.26	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.15-1.39	CD	O
)	)	O
,	,	O
living	VBG	ME
with	IN	ME
both	DT	ME
parents	NNS	ME
(	(	O
OR	NNP	O
1.74	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.02-2.97	CD	O
)	)	O
,	,	O
sexual	JJ	ME
intercourse	NN	ME
(	(	O
OR	CC	O
0.66	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.36-1.19	NN	O
)	)	O
and	CC	O
speaking	VBG	ME
mostly	RB	ME
or	CC	ME
only	RB	ME
English	JJ	ME
with	IN	ME
parents	NNS	ME
(	(	O
OR	NNP	O
0.39	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.15-1.03	NN	O
)	)	O
were	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
contribute	VBP	O
to	TO	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
factors	NNS	O
that	WDT	O
may	MD	O
explain	VB	O
why	WRB	O
some	DT	O
adolescents	NNS	O
complete	JJ	O
care	NN	O
whereas	IN	O
others	NNS	O
do	VBP	O
not	RB	O
.	.	O

They	PRP	O
provide	VBP	O
supportive	JJ	O
evidence	NN	O
that	WDT	O
tailored	VBD	O
intervention	NN	O
programs	NNS	O
should	MD	O
be	VB	O
developed	VBN	O
to	TO	O
support	VB	O
the	DT	O
screening	NN	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
of	IN	O
foreign-born	JJ	O
adolescents	NNS	O
.	.	O

Accumulated	VBN	O
brisk	JJ	O
walking	NN	O
reduces	NNS	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
overweight	JJ	O
adults	NNS	O
:	:	O
evidence	NN	O
from	IN	O
a	DT	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

Arterial	JJ	O
stiffness	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
contributor	NN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
atherosclerosis	NN	O
and	CC	O
consequently	RB	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
examine	VB	O
whether	IN	O
6	CD	O
months	NNS	O
of	IN	O
accumulated	VBN	O
(	(	O
3	CD	O
?	.	O
10	CD	O
minutes	NNS	O
,	,	O
5	CD	O
days/week	NN	O
)	)	O
brisk	NN	O
walking	NN	O
was	VBD	O
sufficient	JJ	O
to	TO	O
reduce	VB	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
sedentary	JJ	O
,	,	O
overweight	JJ	O
individuals	NNS	O
.	.	O

Seventy-seven	JJ	O
individuals	NNS	O
(	(	O
19	CD	O
men	NNS	O
,	,	O
58	CD	O
women	NNS	O
;	:	O
age	NN	O
,	,	O
30-55	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
;	:	O
two	CD	O
groups	NNS	O
completed	VBD	O
30	CD	O
minutes	NNS	O
of	IN	O
accumulated	JJ	O
walking	VBG	O
with	IN	O
either	DT	O
monthly	JJ	O
or	CC	O
weekly	JJ	O
telephone	NN	O
support	NN	O
;	:	O
the	DT	O
third	JJ	O
group	NN	O
(	(	O
control	NN	O
)	)	O
performed	VBD	O
stretching	VBG	O
exercises	NNS	O
.	.	O

The	DT	O
walking	VBG	O
groups	NNS	O
were	VBD	O
combined	VBN	O
and	CC	O
telephone	NN	O
support	NN	O
included	VBD	O
as	IN	O
a	DT	O
covariate	NN	O
.	.	O

Anthropometry	NNP	O
,	,	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
blood	NN	O
lipids	NNS	O
,	,	O
pulse	RB	O
wave	VBP	O
velocity	NN	O
(	(	O
PWV	NNP	O
)	)	O
,	,	O
and	CC	O
NOx	NNP	O
(	(	O
surrogate	JJ	O
marker	NN	O
for	IN	O
nitric	JJ	O
oxide	NN	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
post-intervention	NN	O
and	CC	O
4	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

No	CC	O
changes	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
anthropometry	NN	O
,	,	O
BP	NNP	O
,	,	O
or	CC	O
lipids	NNS	O
.	.	O

However	RB	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
PWV	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
accompanied	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
NOx	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
with	IN	O
changes	NNS	O
maintained	VBD	O
4	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

A	NNP	O
strong	JJ	O
negative	JJ	O
correlation	NN	O
between	IN	O
PWV	NNP	O
and	CC	O
NOx	NNP	O
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
;	:	O
r	NN	O
=	NNP	O
-0.65	NNP	O
)	)	O
.	.	O

A	DT	O
lifestyle	JJ	O
approach	NN	O
to	TO	O
meeting	VBG	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
results	NNS	O
in	IN	O
favorable	JJ	O
alterations	NNS	O
in	IN	O
arterial	JJ	O
function	NN	O
in	IN	O
overweight	JJ	O
individuals	NNS	O
.	.	O

Households	NNS	O
with	IN	O
young	JJ	O
children	NNS	O
and	CC	O
use	NN	O
of	IN	O
freely	RB	O
distributed	VBN	O
bednets	NNS	O
in	IN	O
rural	JJ	O
Madagascar	NNP	O
.	.	O

BACKGROUND	NNP	O
Malaria	NNP	O
infections	NNS	O
are	VBP	O
the	DT	O
leading	VBG	O
cause	NN	O
of	IN	O
death	NN	O
for	IN	O
children	NNS	O
in	IN	O
Madagascar	NNP	O
.	.	O

Insecticide-treated	JJ	O
bednets	NNS	O
offer	VBP	O
effective	JJ	O
prevention	NN	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
unclear	JJ	O
how	WRB	O
well	RB	O
free	JJ	O
bednet	NN	O
distribution	NN	O
programs	NNS	O
reach	VBP	O
young	JJ	O
children	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
secondary	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
free	JJ	O
bednet	NN	O
distribution	NN	O
program	NN	O
in	IN	O
Madagascar	NNP	O
from	IN	O
2007-2008	JJ	O
.	.	O

Interviews	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
construct	VB	O
a	DT	O
wealth	NN	O
and	CC	O
malaria	NNS	O
knowledge	VBP	O
index	NN	O
.	.	O

Coverage	NNP	O
efficiency	NN	O
was	VBD	O
calculated	VBN	O
as	IN	O
coverage	NN	O
of	IN	O
children	NNS	O
per	IN	O
bednet	NN	O
owned	VBN	O
.	.	O

Univariable	JJ	O
and	CC	O
multivariable	JJ	O
regressions	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
predictors	NNS	O
of	IN	O
bednet	NN	O
use	NN	O
.	.	O

RESULTS	NNP	O
Bednet	NNP	Ot
use	NN	Ot
,	,	O
among	IN	O
the	DT	O
560	CD	O
households	NNS	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
increased	VBD	O
from	IN	O
6	CD	O
to	TO	O
91	CD	O
%	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Coverage	NNP	Ot
efficiency	NN	Ot
increased	VBD	O
from	IN	O
1.29	CD	O
to	TO	O
1.56	CD	O
children	NNS	O
covered	VBN	O
per	IN	O
bednet	NN	O
owned	VBN	O
.	.	O

In	IN	O
multivariable	JJ	O
analysis	NN	O
,	,	O
having	VBG	O
a	DT	O
child	NN	O
under	IN	O
5	CD	O
years	NNS	O
of	IN	O
age	NN	O
was	VBD	O
the	DT	O
only	JJ	O
variable	NN	O
associated	VBN	O
with	IN	O
bednet	NN	O
use	NN	O
(	(	O
OR	CC	O
9.10	CD	O
;	:	O
p=0.001	NN	O
)	)	O
,	,	O
yielding	VBG	O
a	DT	O
99	CD	O
%	NN	O
likelihood	NN	O
of	IN	O
using	VBG	O
a	DT	O
bednet	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
96.4	CD	O
to	TO	O
99.9	CD	O
%	NN	O
)	)	O
versus	VBZ	O
82	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
72.2	CD	O
to	TO	O
88.4	CD	O
%	NN	O
)	)	O
in	IN	O
households	NNS	O
without	IN	O
young	JJ	O
children	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
free	JJ	O
bednet	NN	O
distribution	NN	O
program	NN	O
achieved	VBN	O
high	JJ	O
levels	NNS	O
of	IN	O
adherence	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Household	NNP	O
presence	NN	O
of	IN	O
children	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
bednet	NN	O
use	NN	O
,	,	O
but	CC	O
not	RB	O
household	JJ	O
income	NN	O
or	CC	O
education	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
distribution	NN	O
to	TO	O
priority	NN	O
groups	NNS	O
may	MD	O
help	VB	O
overcome	VB	O
traditional	JJ	O
barriers	NNS	O
to	TO	O
adoption	NN	O
in	IN	O
some	DT	O
settings	NNS	O
.	.	O

Safety	NN	Ot
and	CC	O
efficacy	NN	Ot
of	IN	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
Logiparin	NNP	O
)	)	O
versus	NN	O
dextran	NN	O
as	IN	O
prophylaxis	NN	O
against	IN	O
thrombosis	NN	O
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
study	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
factor	NN	O
XaI	NNP	O
and	CC	O
IIaI	NNP	O
activity	NN	O
an	DT	O
enzymatically	RB	O
depolymerized	VBN	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMW-heparin	NNP	O
;	:	O
Logiparin	NNP	O
)	)	O
was	VBD	O
given	VBN	O
s.c.	NN	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
for	IN	O
7	CD	O
days	NNS	O
to	TO	O
10	CD	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
(	(	O
THR	NNP	O
)	)	O
in	IN	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
XaI	NN	O
activity	NN	O
was	VBD	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.24	CD	O
XaI	NNP	O
units/ml	NN	O
and	CC	O
the	DT	O
IIaI	NNP	O
activity	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.043	CD	O
IIaI	NNP	O
mu/ml	NN	O
.	.	O

No	DT	O
accumulation	NN	O
of	IN	O
the	DT	O
activities	NNS	O
were	VBD	O
seen	VBN	O
.	.	O

No	DT	O
phlebographically	RB	PH
verified	VBN	PH
thrombi	NN	PH
or	CC	O
any	DT	O
bleeding	JJ	PH
complications	NNS	PH
were	VBD	O
registered	VBN	O
.	.	O

From	IN	O
this	DT	O
study	NN	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
given	VBN	O
dose	NN	O
of	IN	O
Logiparin	NNP	O
was	VBD	O
safe	JJ	O
with	IN	O
regard	NN	O
to	TO	O
bleeding	VBG	O
complications	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
data	NNS	O
,	,	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
was	VBD	O
started	VBN	O
.	.	O

In	IN	O
this	DT	O
main	JJ	O
study	NN	O
the	DT	O
thromboprophylactic	JJ	PH
effect	NN	PH
of	IN	O
the	DT	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
dextran	NN	O
70	CD	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
THR	NNP	O
.	.	O

100	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

The	DT	O
over-all	JJ	Ot
thrombosis	NN	Ot
rate	NN	Ot
was	VBD	O
28	CD	O
%	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
LMW-heparin	NNP	O
and	CC	O
39	CD	O
%	NN	O
in	IN	O
those	DT	O
given	VBN	O
dextran	NN	O
,	,	O
a	DT	O
non-significant	JJ	O
difference	NN	O
.	.	O

No	UH	O
bleeding	VBG	A
complications	NNS	A
,	,	O
deaths	NNS	MO
or	CC	O
pulmonary	JJ	PH
embolism	NN	PH
were	VBD	O
recorded	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Peroperative	JJ	PH
blood	NN	PH
loss	NN	PH
and	CC	PH
transfusion	NN	PH
requirements	NNS	PH
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
investigated	JJ	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
thromboembolism	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
,	,	O
but	CC	O
the	DT	O
dosage	NN	O
can	MD	O
probably	RB	O
be	VB	O
optimized	VBN	O
.	.	O

Efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
sildenafil	NN	O
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

OBJECTIVE	NNP	O
Assess	NNP	O
the	DT	O
effectiveness	NN	O
of	IN	O
sildenafil	NN	O
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
co-morbidities	NNS	O
,	,	O
mild-to-moderate	JJ	O
hypertension	NN	O
,	,	O
dyslipidemia	NN	O
,	,	O
and	CC	O
diabetes	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHOD	NNP	O
A	NNP	O
six-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
Thailand	NNP	O
,	,	O
Malaysia	NNP	O
and	CC	O
Singapore	NNP	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
fifty	VB	O
five	CD	O
male	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
2:1	CD	O
)	)	O
to	TO	O
sildenafil	VB	O
(	(	O
n	JJ	O
=	NNP	O
104	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Sildenafil	NNP	O
was	VBD	O
started	VBN	O
at	IN	O
50	CD	O
mg	NN	O
and	CC	O
increased	VBD	O
(	(	O
100	CD	O
mg	NN	O
)	)	O
or	CC	O
decreased	VBN	O
(	(	O
25	CD	O
mg	NN	O
)	)	O
at	IN	O
week	NN	O
2	CD	O
if	IN	O
necessary	JJ	O
.	.	O

RESULTS	VB	O
On	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
,	,	O
sildenafil-treated	JJ	O
subjects	NNS	O
had	VBD	O
significantly	RB	O
better	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
International	NNP	PH
Index	NNP	PH
of	IN	PH
Erectile	NNP	PH
Function	NNP	PH
(	(	PH
IIEF	NNP	PH
)	)	PH
questions	NNS	PH
3	CD	PH
and	CC	PH
4	CD	PH
than	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NN	O
0.001	CD	O
,	,	O
both	DT	O
questions	NNS	O
)	)	O
.	.	O

When	WRB	O
accumulated	VBN	O
into	IN	O
IIEF	NNP	O
domains	NNS	O
,	,	O
all	DT	O
five	CD	O
domains	NNS	O
were	VBD	O
significant	JJ	O
in	IN	O
favor	NN	O
of	IN	O
sildenafil	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
sildenafil-treated	JJ	O
subjects	NNS	O
were	VBD	O
more	RBR	O
satisfied	JJ	O
with	IN	O
treatment	NN	O
and	CC	O
had	VBD	O
a	DT	O
higher	JJR	O
intercourse	JJ	PH
success	NN	PH
rate	NN	PH
.	.	O

The	DT	O
majority	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
mild	VBN	O
in	IN	O
severity	NN	O
;	:	O
the	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
treatment-related	JJ	O
events	NNS	O
were	VBD	O
dizziness	NN	A
(	(	O
7.7	CD	O
%	NN	O
)	)	O
and	CC	O
tinnitus	NN	A
(	(	O
2.9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Sildenafil	NNP	O
(	(	O
25	CD	O
,	,	O
50	CD	O
,	,	O
and	CC	O
100	CD	O
mg	NN	O
)	)	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
,	,	O
safe	JJ	O
,	,	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
ED	NNP	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
population	NN	O
of	IN	O
Thai	NNP	O
,	,	O
Malaysian	NNP	O
,	,	O
and	CC	O
Singaporean	NNP	O
males	NNS	O
who	WP	O
also	RB	O
had	VBD	O
increased	VBN	O
cardiovascular	JJ	O
risk	NN	O
T	NNP	O
lymphocyte	JJ	O
subsets	NNS	O
and	CC	O
NK	NNP	O
cell	VBP	O
cytotoxicity	NN	O
in	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
erythropoietin	NN	O
(	(	O
rHu-EPO	JJ	O
)	)	O
treatment	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
subpopulations	NNS	O
of	IN	O
T	NNP	PH
lymphocytes	NNS	PH
,	,	O
NK	NNP	PH
cell	NN	PH
number	NN	PH
and	CC	O
cytotoxic	JJ	Ot
activity	NN	Ot
in	IN	O
14	CD	O
chronic	JJ	O
uremic	JJ	O
patients	NNS	O
on	IN	O
regular	JJ	O
hemodialysis	NN	O
treatment	NN	O
.	.	O

We	PRP	O
observed	VBD	O
a	DT	O
significantly	RB	O
decreased	VBN	O
absolute	NN	PH
lymphocyte	NN	PH
number	NN	PH
and	CC	O
percentage	NN	PH
of	IN	PH
CD3	NNP	PH
cells	NNS	PH
.	.	O

Relative	JJ	O
numbers	NNS	O
of	IN	O
CD16	NNP	PH
cells	NNS	PH
were	VBD	O
significantly	RB	O
elevated	VBN	O
,	,	O
but	CC	O
NK	NNP	PH
cell	VBP	PH
cytotoxic	JJ	PH
activity	NN	PH
was	VBD	O
within	IN	O
a	DT	O
normal	JJ	O
range	NN	O
.	.	O

Nine	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
renal	JJ	O
anemia	NN	O
on	IN	O
maintenance	NN	O
hemodialysis	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
rHu-EPO	JJ	O
treatment	NN	O
trial	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
continued	VBN	O
till	IN	O
the	DT	O
hematocrit	NN	PH
level	NN	PH
reached	VBD	O
30	CD	O
%	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
corrected	VBN	O
anemia	NN	PH
and	CC	O
well-being	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
we	PRP	O
observed	VBD	O
in	IN	O
these	DT	O
patients	NNS	O
decreases	NNS	O
in	IN	O
CD3	NNP	PH
,	,	PH
CD4	NNP	PH
,	,	PH
CD8	NNP	PH
and	CC	PH
CD16	NNP	PH
cell	NN	PH
numbers	NNS	PH
and	CC	O
elevation	NN	O
of	IN	O
CD4/CD8	NNP	PH
ratio	NN	PH
.	.	O

Cytotoxic	NNP	PH
activity	NN	PH
of	IN	PH
NK	NNP	PH
cells	NNS	PH
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

Presented	VBN	O
results	NNS	O
indicate	VBP	O
that	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
have	VBP	O
significantly	RB	O
diminished	VBN	O
lymphocyte	JJ	PH
number	NN	PH
.	.	O

rHu	JJ	O
EPO	NNP	O
treatment	NN	O
affects	VBZ	O
the	DT	O
T	NNP	O
lymphocyte	NN	O
subsets	NNS	O
inducing	VBG	O
a	DT	O
deep	JJ	O
decrease	NN	O
of	IN	O
CD8	NNP	PH
and	CC	PH
CD16	NNP	PH
cell	NN	PH
percentage	NN	PH
leading	VBG	O
to	TO	O
normalisation	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	PH
ratio	NN	PH
.	.	O

Superior	JJ	O
fixation	NN	O
of	IN	O
pegged	JJ	O
trabecular	JJ	O
metal	NN	O
over	IN	O
screw-fixed	JJ	O
pegged	JJ	O
porous	JJ	O
titanium	NN	O
fiber	NN	O
mesh	NN	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
RSA	NNP	O
study	NN	O
on	IN	O
cementless	JJ	O
tibial	JJ	O
components	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Lasting	NNP	O
stability	NN	Ot
of	IN	O
cementless	NN	O
implants	NNS	O
depends	VBZ	O
on	IN	O
osseointegration	NN	O
into	IN	O
the	DT	O
implant	JJ	O
surface	NN	O
,	,	O
and	CC	O
long-term	JJ	O
implant	JJ	O
fixation	NN	O
can	MD	O
be	VB	O
predicted	VBN	O
using	VBG	O
radiostereometric	JJ	O
analysis	NN	O
(	(	O
RSA	NNP	O
)	)	O
with	IN	O
short-term	JJ	O
follow-up	JJ	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
there	EX	O
would	MD	O
be	VB	O
improved	VBN	O
fixation	NN	PH
of	IN	O
high-porosity	NN	O
trabecular	JJ	O
metal	NN	O
(	(	O
TM	NNP	O
)	)	O
tibial	JJ	O
components	NNS	O
compared	VBN	O
to	TO	O
low-porosity	JJ	O
titanium	NN	O
pegged	VBD	O
porous	JJ	O
fiber-metal	JJ	O
(	(	O
Ti	NNP	O
)	)	O
polyethylene	NN	O
metal	JJ	O
backings	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
randomized	VBN	O
unblinded	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
cementless	JJ	O
tibial	JJ	O
components	NNS	O
in	IN	O
patients	NNS	O
aged	VBN	O
70	CD	O
years	NNS	O
and	CC	O
younger	JJR	O
with	IN	O
osteoarthritis	NN	O
.	.	O

The	DT	O
pre-study	JJ	O
sample	NN	O
size	NN	O
calculation	NN	O
was	VBD	O
22	CD	O
patients	NNS	O
per	IN	O
group	NN	O
.	.	O

25	CD	O
TM	NNP	O
tibial	JJ	O
components	NNS	O
were	VBD	O
fixed	VBN	O
press-fit	JJ	O
by	IN	O
2	CD	O
hexagonal	JJ	O
pegs	NN	O
(	(	O
TM	NNP	O
group	NN	O
)	)	O
and	CC	O
25	CD	O
Ti	NNP	O
tibial	JJ	O
components	NNS	O
were	VBD	O
fixed	VBN	O
press-fit	JJ	O
and	CC	O
by	IN	O
4	CD	O
supplemental	JJ	O
screws	NNS	O
(	(	O
Ti	NNP	O
group	NN	O
)	)	O
.	.	O

Stereo	NNP	O
radiographs	NN	O
for	IN	O
evaluation	NN	O
of	IN	O
absolute	JJ	O
component	NN	O
migration	NN	O
(	(	O
primary	JJ	O
effect	NN	O
size	NN	O
)	)	O
and	CC	O
single-direction	JJ	O
absolute	NN	O
component	NN	O
migration	NN	O
(	(	O
secondary	JJ	O
effect	NN	O
size	NN	O
)	)	O
were	VBD	O
obtained	VBN	O
within	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
week	NN	O
and	CC	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
6	CD	O
months	NNS	O
,	,	O
1	CD	O
year	NN	O
,	,	O
and	CC	O
2	CD	O
years	NNS	O
.	.	O

American	JJ	PH
Knee	NNP	PH
Society	NNP	PH
score	NN	PH
was	VBD	O
used	VBN	O
for	IN	O
clinical	JJ	O
assessment	NN	O
preoperatively	RB	O
,	,	O
and	CC	O
at	IN	O
1	CD	O
and	CC	O
2	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
intraoperative	JJ	A
complications	NNS	A
,	,	O
and	CC	O
no	DT	A
postoperative	JJ	A
infections	NNS	A
or	CC	O
revisions	NNS	A
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
improved	VBN	PH
function	NN	PH
and	CC	PH
regained	VBD	PH
full	JJ	PH
extension	NN	PH
.	.	PH

All	DT	O
tibial	JJ	O
components	NNS	O
migrated	VBN	ME
initially	RB	O
.	.	O

Most	JJS	O
migration	NN	PH
of	IN	PH
the	DT	PH
TM	NNP	PH
components	NNS	PH
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
occurred	VBD	O
within	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
whereas	JJ	O
migration	NN	O
of	IN	O
the	DT	O
Ti	NNP	O
components	NNS	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
appeared	VBD	O
to	TO	O
stabilize	VB	O
first	RB	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
TM	NNP	O
components	NNS	O
migrated	VBD	O
less	JJR	O
than	IN	O
the	DT	O
Ti	NNP	O
components	NNS	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
2	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
mechanical	JJ	O
fixation	NN	O
of	IN	O
TM	NNP	O
tibial	JJ	O
components	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
that	DT	O
of	IN	O
screw-fixed	JJ	O
Ti	NNP	O
tibial	JJ	O
components	NNS	O
.	.	O

We	PRP	O
expect	VBP	O
long-term	JJ	MO
implant	JJ	MO
survival	NN	MO
to	TO	O
be	VB	O
better	RB	O
with	IN	O
the	DT	O
TM	NNP	O
tibial	JJ	O
component	NN	O
.	.	O

Immunologic	NNP	O
and	CC	O
hemodynamic	JJ	O
effects	NNS	O
of	IN	O
low-dose	JJ	O
hydrocortisone	NN	O
in	IN	O
septic	JJ	O
shock	NN	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Within	IN	O
the	DT	O
last	JJ	O
few	JJ	O
years	NNS	O
,	,	O
increasing	VBG	O
evidence	NN	O
of	IN	O
relative	JJ	O
adrenal	JJ	O
insufficiency	NN	O
in	IN	O
septic	JJ	O
shock	NN	O
evoked	VBD	O
a	DT	O
reassessment	NN	O
of	IN	O
hydrocortisone	NN	O
therapy	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
hydrocortisone	NN	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
proinflammatory	NN	O
and	CC	O
antiinflammation	NN	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
septic	JJ	O
shock	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
first	JJ	O
100	CD	O
mg	NN	O
of	IN	O
hydrocortisone	NN	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
and	CC	O
10	CD	O
mg	NNS	O
per	IN	O
hour	NN	O
until	IN	O
Day	NNP	O
3	CD	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
the	DT	O
opposite	JJ	O
medication	NN	O
until	IN	O
Day	NNP	O
6	CD	O
.	.	O

Hydrocortisone	CD	O
infusion	NN	O
induced	VBD	O
an	DT	O
increase	NN	O
of	IN	O
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
,	,	PH
systemic	JJ	PH
vascular	NN	PH
resistance	NN	PH
,	,	O
and	CC	O
a	DT	O
decline	NN	O
of	IN	O
heart	NN	PH
rate	NN	PH
,	,	O
cardiac	JJ	PH
index	NN	PH
,	,	O
and	CC	O
norepinephrine	JJ	Ot
requirement	NN	Ot
.	.	O

A	DT	O
reduction	NN	O
of	IN	O
plasma	NN	PH
nitrite/nitrate	NN	PH
indicated	VBD	O
inhibition	NN	O
of	IN	O
nitric	JJ	PH
oxide	JJ	PH
formation	NN	PH
and	CC	O
correlated	VBN	O
with	IN	O
a	DT	O
reduction	NN	PH
of	IN	PH
vasopressor	NN	PH
support	NN	PH
.	.	PH

The	DT	O
inflammatory	JJ	PH
response	NN	PH
(	(	PH
interleukin-6	JJ	PH
and	CC	PH
interleukin-8	JJ	PH
)	)	PH
,	,	PH
endothelial	JJ	PH
(	(	PH
soluble	JJ	PH
E-selectin	NN	PH
)	)	PH
and	CC	PH
neutrophil	JJ	PH
activation	NN	PH
(	(	PH
expression	NN	PH
of	IN	PH
CD11b	NNP	PH
,	,	PH
CD64	NNP	PH
)	)	PH
,	,	PH
and	CC	PH
antiinflammatory	JJ	PH
response	NN	PH
(	(	PH
soluble	JJ	PH
tumor	NN	PH
necrosis	NN	PH
factor	NN	PH
receptors	NNS	PH
I	PRP	PH
and	CC	PH
II	NNP	PH
and	CC	PH
interleukin-10	JJ	PH
)	)	PH
were	VBD	O
attenuated	VBN	O
.	.	O

In	IN	O
peripheral	JJ	O
blood	NN	O
monocytes	NNS	O
,	,	O
human	JJ	PH
leukocyte	VBD	PH
antigen-DR	JJ	PH
expression	NN	PH
was	VBD	O
only	RB	O
slightly	RB	O
depressed	VBN	O
,	,	O
whereas	NNS	O
in	IN	PH
vitro	JJ	PH
phagocytosis	NN	PH
and	CC	PH
the	DT	PH
monocyte-activating	JJ	PH
cytokine	JJ	PH
interleukin-12	NN	PH
increased	VBD	O
.	.	O

Hydrocortisone	NNP	O
withdrawal	NN	O
induced	VBD	O
hemodynamic	JJ	A
and	CC	A
immunologic	JJ	A
rebound	NN	A
effects	NNS	A
.	.	A

In	IN	O
conclusion	NN	O
,	,	O
hydrocortisone	NN	O
therapy	NN	O
restored	VBD	O
hemodynamic	JJ	PH
stability	NN	PH
and	CC	O
differentially	RB	O
modulated	VBD	O
the	DT	O
immunologic	JJ	PH
response	NN	PH
to	TO	PH
stress	VB	PH
in	IN	O
a	DT	O
way	NN	O
of	IN	O
antiinflammation	NN	O
rather	RB	O
than	IN	O
immunosuppression	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
Dader	NNP	O
Method	NNP	O
for	IN	O
pharmaceutical	JJ	O
care	NN	O
on	IN	O
control	NN	PH
of	IN	PH
blood	NN	PH
pressure	NN	PH
and	CC	O
total	JJ	PH
cholesterol	NN	PH
in	IN	O
outpatients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
or	CC	O
cardiovascular	JJ	O
risk	NN	O
:	:	O
EMDADER-CV	JJ	O
randomized	NNS	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
some	DT	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
pharmacist	JJ	O
intervention	NN	O
can	MD	O
improve	VB	O
drug	NN	O
therapy	NN	O
among	IN	O
patients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
,	,	O
more	JJR	O
evidence	NN	O
derived	VBN	O
from	IN	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
is	VBZ	O
needed	VBN	O
,	,	O
including	VBG	O
assessment	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
community	NN	O
pharmacist	NN	O
interventions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
Dader	NNP	O
Method	NNP	O
for	IN	O
pharmaceutical	JJ	O
care	NN	O
on	IN	O
achieving	VBG	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
blood	NN	PH
pressure	NN	PH
(	(	PH
BP	NNP	PH
)	)	PH
,	,	O
total	JJ	PH
cholesterol	NN	PH
(	(	PH
TC	NNP	PH
)	)	PH
,	,	O
and	CC	O
both	DT	PH
BP	NNP	PH
and	CC	O
TC	NNP	PH
(	(	PH
BP/TC	NNP	PH
)	)	PH
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
aged	VBD	O
25	CD	O
to	TO	O
74	CD	O
years	NNS	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
with	IN	O
a	DT	O
prescription	NN	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
drug	NN	O
indicated	VBN	O
for	IN	O
CVD	NNP	O
or	CC	O
CV	NNP	O
risk	NN	O
factors	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
an	DT	O
intervention	NN	O
group	NN	O
that	WDT	O
received	VBD	O
pharmaceutical	JJ	O
care	NN	O
,	,	O
which	WDT	O
was	VBD	O
provided	VBN	O
by	IN	O
specially	RB	O
trained	JJ	O
pharmacists	NNS	O
working	VBG	O
in	IN	O
collaboration	NN	O
with	IN	O
physicians	NNS	O
,	,	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
that	WDT	O
received	VBD	O
usual	JJ	O
care	NN	O
(	(	O
routine	JJ	O
dispensing	VBG	O
counseling	NN	O
)	)	O
and	CC	O
verbal	JJ	O
and	CC	O
written	VBN	O
counseling	VBG	O
regarding	VBG	O
CVD	NNP	O
prevention	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
December	NNP	O
2005	CD	O
to	TO	O
September	NNP	O
2006	CD	O
,	,	O
and	CC	O
both	DT	O
groups	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
8	CD	O
months	NNS	O
.	.	O

Study	NNP	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
16	CD	O
and	CC	O
32	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
proportions	NNS	PH
of	IN	PH
patients	NNS	PH
achieving	VBG	PH
BP	NNP	PH
,	,	O
TC	NNP	PH
,	,	O
and	CC	O
BP/TC	NNP	PH
therapeutic	JJ	PH
goals	NNS	PH
(	(	O
BP	NNP	O
lower	JJR	O
than	IN	O
140/90	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
uncomplicated	JJ	O
hypertension	NN	O
and	CC	O
lower	JJR	O
than	IN	O
130/80	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
,	,	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
,	,	O
or	CC	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
stroke	NN	O
;	:	O
TC	NNP	O
lower	JJR	O
than	IN	O
200	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
without	IN	O
CVD	NNP	O
and	CC	O
lower	JJR	O
than	IN	O
175	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
mean	JJ	PH
BP	NNP	PH
and	CC	O
TC	NNP	PH
values	NNS	PH
.	.	O

BP	NNP	PH
was	VBD	O
assessed	VBN	O
manually	RB	O
by	IN	O
the	DT	O
pharmacist	NN	O
after	IN	O
a	DT	O
10-minute	JJ	O
rest	NN	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

This	DT	O
measurement	NN	O
was	VBD	O
performed	VBN	O
twice	RB	O
for	IN	O
every	DT	O
participant	NN	O
,	,	O
and	CC	O
the	DT	O
average	NN	O
of	IN	O
the	DT	O
2	CD	O
measurements	NNS	O
was	VBD	O
calculated	VBN	O
.	.	O

TC	NNP	PH
was	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
pharmacist	NN	O
during	IN	O
the	DT	O
study	NN	O
visit	NN	O
using	VBG	O
the	DT	O
enzymatic	JJ	O
dry	JJ	O
method	NN	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
2-tailed	JJ	O
McNemar	NNP	O
tests	NNS	O
,	,	O
Pearson	NNP	O
chi-square	NN	O
tests	NNS	O
,	,	O
and	CC	O
Student	NNP	O
's	POS	O
t-tests	NNS	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
.	.	O

RESULTS	VB	O
714	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
(	(	O
356	CD	O
intervention	NN	O
,	,	O
358	CD	O
control	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
was	VBD	O
62.8	CD	O
[	JJ	O
8.1	CD	O
]	JJ	O
years	NNS	O
.	.	O

The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
clinical	JJ	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
including	VBG	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
at	IN	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	PH
,	,	O
TC	NNP	PH
,	,	O
and	CC	O
BP/TC	NNP	PH
.	.	O

After	IN	O
8	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
there	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
favor	NN	O
of	IN	O
pharmaceutical	JJ	O
care	NN	O
in	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	PH
(	(	O
52.5	CD	O
%	NN	O
vs.	FW	O
43.0	CD	O
%	NN	O
,	,	O
P=0.017	NNP	O
)	)	O
,	,	O
TC	NNP	PH
(	(	O
56.5	CD	O
%	NN	O
vs.	FW	O
44.1	CD	O
%	NN	O
,	,	O
P=0.001	NNP	O
)	)	O
,	,	O
and	CC	O
BP/TC	NNP	PH
(	(	O
37.1	CD	O
%	NN	O
vs.	FW	O
21.8	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Compared	NNP	O
with	IN	O
usual	JJ	O
care	NN	O
plus	CC	O
written	VBN	O
education	NN	O
,	,	O
pharmaceutical	JJ	O
care	NN	O
focused	VBN	O
on	IN	O
patient	JJ	O
evaluation	NN	O
and	CC	O
follow-up	NN	O
in	IN	O
collaboration	NN	O
with	IN	O
physicians	NNS	O
improved	VBN	O
the	DT	O
achievement	NN	O
of	IN	O
BP	NNP	PH
,	,	O
TC	NNP	PH
,	,	O
and	CC	O
BP/TC	NNP	PH
treatment	NN	O
goals	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
CV	NNP	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

Argatroban	NNP	O
for	IN	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
:	:	O
the	DT	O
ARG-E04	NNP	O
multi-center	NN	O
study	NN	O
.	.	O

UNLABELLED	IN	O
The	DT	O
synthetic	JJ	O
arginine-derived	JJ	O
direct	JJ	O
thrombin	NN	O
inhibitor	NN	O
argatroban	NN	O
is	VBZ	O
an	DT	O
attractive	JJ	O
anticoagulant	NN	O
for	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
,	,	O
because	IN	O
of	IN	O
its	PRP$	O
rapid	JJ	O
onset	NN	O
and	CC	O
offset	NN	O
,	,	O
and	CC	O
its	PRP$	O
hepatic	JJ	O
elimination	NN	O
.	.	O

Argatroban	NNP	O
was	VBD	O
approved	VBN	O
for	IN	O
PCI	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
heparin-induced	JJ	O
thrombocytopenia	NN	O
(	(	O
HIT	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
limited	VBN	O
data	NNS	O
about	IN	O
argatroban	NN	O
in	IN	O
non-HIT	JJ	O
patients	NNS	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
open-label	JJ	O
,	,	O
multiple-dose	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
argatroban	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Of	IN	O
140	CD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
three	CD	O
argatroban	NNS	O
dose	JJ	O
groups	NNS	O
(	(	O
ARG250	NNP	O
,	,	O
ARG300	NNP	O
,	,	O
and	CC	O
ARG350	NNP	O
with	IN	O
250	CD	O
,	,	O
300	CD	O
,	,	O
or	CC	O
350	CD	O
?g/kg	JJ	O
bolus	NN	O
,	,	O
followed	VBN	O
by	IN	O
15	CD	O
,	,	O
20	CD	O
,	,	O
or	CC	O
25	CD	O
?g/kg/min	JJ	O
infusion	NN	O
)	)	O
and	CC	O
one	CD	O
unfractionated	JJ	O
heparin	NN	O
(	(	O
UFH	NNP	O
)	)	O
group	NN	O
(	(	O
70-100	JJ	O
IU/kg	NNP	O
bolus	NN	O
)	)	O
,	,	O
138	CD	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Argatroban	NNP	O
dose-dependently	RB	O
prolonged	VBD	O
activated	VBN	PH
clotting	NN	PH
time	NN	PH
(	(	PH
ACT	NNP	PH
)	)	PH
with	IN	O
more	JJR	O
patients	NNS	O
reaching	VBG	O
the	DT	O
minimum	NN	O
target	NN	O
ACT	NNP	O
after	IN	O
the	DT	O
initial	JJ	O
bolus	NN	O
injection	NN	O
(	(	O
ARG250	NNP	O
:	:	O
86.1	CD	O
%	NN	O
,	,	O
ARG300	NNP	O
:	:	O
89.5	CD	O
%	NN	O
,	,	O
and	CC	O
ARG350	NNP	O
:	:	O
96.8	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
45.5	CD	O
%	NN	O
in	IN	O
UFH	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
patient	JJ	O
proportion	NN	O
who	WP	O
did	VBD	O
not	RB	O
require	VB	O
additional	JJ	O
bolus	NN	O
injections	NNS	O
to	TO	O
start	VB	O
PCI	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
argatroban	NN	O
than	IN	O
in	IN	O
UFH	NNP	O
(	(	O
p	VB	O
?	.	O
0.002	CD	O
)	)	O
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
time	NN	PH
to	TO	PH
start	VB	PH
of	IN	PH
PCI	NNP	PH
was	VBD	O
shortened	VBN	O
in	IN	O
argatroban	JJ	O
groups	NNS	O
.	.	O

Composite	NNP	O
incidences	NNS	O
of	IN	O
death	NN	MO
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
urgent	JJ	O
revascularization	NN	O
until	IN	O
day	NN	O
30	CD	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
ARG250	NNP	O
:	:	O
2.8	CD	O
%	NN	O
,	,	O
ARG300	NNP	O
:	:	O
0.0	CD	O
%	NN	O
,	,	O
ARG350	NNP	O
:	:	O
3.2	CD	O
%	NN	O
vs.	FW	O
UFH	NNP	O
:	:	O
3.0	CD	O
%	NN	O
)	)	O
.	.	O

Major	JJ	O
bleeding	NN	O
was	VBD	O
observed	VBN	O
only	RB	O
in	IN	O
UFH	NNP	O
(	(	O
3.0	CD	O
%	NN	O
)	)	O
,	,	O
while	IN	O
minor	JJ	A
bleeding	NN	A
occurred	VBD	O
in	IN	O
ARG350	NNP	O
(	(	O
3.2	CD	O
%	NN	O
)	)	O
and	CC	O
UFH	NNP	O
(	(	O
6.1	CD	O
%	NN	O
,	,	O
n.s.	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Argatroban	NNP	O
dose-dependently	JJ	O
increases	NNS	O
coagulation	NN	O
parameters	NNS	O
and	CC	O
,	,	O
compared	VBN	O
to	TO	O
UFH	NNP	O
,	,	O
demonstrates	VBZ	O
a	DT	O
superior	JJ	O
predictable	JJ	O
anticoagulant	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

The	DT	O
lunar	JJ	O
stent	NN	O
characteristics	NNS	O
and	CC	O
clinical	JJ	O
results	NNS	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
frequent	JJ	O
long-term	JJ	O
complications	NNS	O
after	IN	O
stent	JJ	O
implantation	NN	O
is	VBZ	O
restenosis	JJ	O
due	JJ	O
to	TO	O
the	DT	O
building	NN	O
up	IN	O
of	IN	O
a	DT	O
neointima	NN	O
within	IN	O
the	DT	O
artery	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
endovascular	JJ	O
hyperplasia	NN	O
(	(	O
tissue	VB	O
growth	NN	O
)	)	O
.	.	O

The	DT	O
interesting	JJ	O
feature	NN	O
of	IN	O
the	DT	O
Lunar	NNP	O
stent	NN	O
from	IN	O
Inflow	NNP	O
Dynamics	NNP	O
is	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
coated	VBN	O
with	IN	O
a	DT	O
layer	NN	O
of	IN	O
iridium	NN	O
oxide	NN	O
.	.	O

The	DT	O
iridium	NN	O
oxide	IN	O
coating	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
reduce	VB	O
restenosis	NN	PH
by	IN	O
decreasing	VBG	O
the	DT	O
inflammatory	JJ	PH
response	NN	PH
to	TO	O
the	DT	O
stent	NN	O
via	IN	O
its	PRP$	O
antioxidant	JJ	O
action	NN	O
.	.	O

The	DT	O
MOONLIGHT	NNP	O
(	(	O
Multicenter	NNP	O
Objective	NNP	O
ObservatioNal	NNP	O
Lunar	NNP	O
Iridiumoxide	NNP	O
intimal	JJ	O
GrowtH	NNP	O
Trial	NNP	O
)	)	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
immediate	JJ	O
outcome	NN	O
and	CC	O
long-term	JJ	O
angiographic	JJ	O
success	NN	O
after	IN	O
implantation	NN	O
of	IN	O
Lunar	NNP	O
stents	NNS	O
.	.	O

Between	IN	O
March	NNP	O
2001	CD	O
and	CC	O
November	NNP	O
2001	CD	O
,	,	O
87	CD	O
patients	NNS	O
with	IN	O
99	CD	O
lesions	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
and	CC	O
were	VBD	O
treated	VBN	O
with	IN	O
12	CD	O
and	CC	O
16	CD	O
mm	NNS	O
long	JJ	O
iridium-oxide	JJ	O
coated	VBN	O
Lunar	NNP	O
stents	NNS	O
.	.	O

Delivery	NN	O
of	IN	O
the	DT	O
Lunar	NNP	O
stent	NN	O
was	VBD	O
successful	JJ	O
in	IN	O
most	JJS	O
lesions	NNS	O
and	CC	O
the	DT	O
optimal	JJ	O
radiopacity	NN	O
facilitated	VBN	O
optimal	JJ	O
stent	NN	PH
positioning	VBG	PH
with	IN	O
optimal	JJ	O
immediate	JJ	O
clinical	JJ	O
and	CC	O
angiographic	JJ	O
results	NNS	O
is	VBZ	O
an	DT	O
unselected	JJ	O
patient	NN	O
and	CC	O
lesion	NN	O
population	NN	O
.	.	O

Preliminary	JJ	O
clinical	JJ	O
and	CC	O
angiographic	JJ	O
follow-up	JJ	O
show	NN	O
a	DT	O
low	JJ	O
rate	NN	PH
of	IN	PH
cardiac	JJ	PH
events	NNS	PH
at	IN	O
6	CD	O
months	NNS	O
(	(	O
16.1	CD	O
%	NN	O
MACE	NNP	O
)	)	O
and	CC	O
a	DT	O
moderate	JJ	O
hyperplastic	JJ	PH
response	NN	PH
.	.	PH

Probiotics	NNS	O
prevent	VBP	O
IgE-associated	JJ	O
allergy	NN	O
until	IN	O
age	NN	O
5	CD	O
years	NNS	O
in	IN	O
cesarean-delivered	JJ	O
children	NNS	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
total	JJ	O
cohort	NN	O
.	.	O

BACKGROUND	NNP	O
Less	NNP	O
microbial	JJ	O
exposure	NN	O
in	IN	O
early	JJ	O
childhood	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
more	RBR	O
allergic	JJ	O
disease	NN	O
later	RB	O
.	.	O

Allergic	NNP	O
children	NNS	O
have	VBP	O
a	DT	O
different	JJ	O
fecal	JJ	O
microflora	NN	O
,	,	O
with	IN	O
less	JJR	O
lactobacilli	NN	O
and	CC	O
bifidobacteria	NN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
regarding	VBG	O
the	DT	O
development	NN	O
of	IN	O
allergy	NNS	O
have	VBP	O
been	VBN	O
suggested	VBN	O
to	TO	O
come	VB	O
through	IN	O
probiotic	JJ	O
supplementation	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
probiotic	JJ	O
and	CC	O
prebiotic	JJ	O
supplementation	NN	O
in	IN	O
preventing	VBG	O
allergies	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
we	PRP	O
randomized	VBD	O
1223	CD	O
mothers	NNS	O
with	IN	O
infants	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
allergy	NN	O
to	TO	O
receive	VB	O
a	DT	O
probiotic	JJ	O
mixture	NN	O
(	(	O
2	CD	O
lactobacilli	NN	O
,	,	O
bifidobacteria	NN	O
,	,	O
and	CC	O
propionibacteria	NN	O
)	)	O
or	CC	O
placebo	NN	O
during	IN	O
the	DT	O
last	JJ	O
month	NN	O
of	IN	O
pregnancy	NN	O
and	CC	O
their	PRP$	O
infants	NNS	O
to	TO	O
receive	VB	O
it	PRP	O
from	IN	O
birth	NN	O
until	IN	O
age	NN	O
6	CD	O
months	NNS	O
.	.	O

Infants	NNS	O
also	RB	O
received	VBD	O
a	DT	O
prebiotic	JJ	O
galacto-oligosaccharide	NN	O
or	CC	O
placebo	NN	O
.	.	O

At	IN	O
5	CD	O
years	NNS	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
cumulative	JJ	O
incidence	NN	O
of	IN	O
allergic	JJ	PH
diseases	NNS	PH
(	(	PH
eczema	NN	PH
,	,	PH
food	NN	PH
allergy	NN	PH
,	,	PH
allergic	JJ	PH
rhinitis	NN	PH
,	,	PH
and	CC	PH
asthma	NN	PH
)	)	PH
and	CC	O
IgE	NNP	PH
sensitization	NN	PH
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
1018	CD	O
intent-to-treat	NN	O
infants	NNS	O
,	,	O
891	CD	O
(	(	O
88	CD	O
%	NN	O
)	)	O
attended	VBD	O
the	DT	O
5-year	JJ	O
visit	NN	O
.	.	O

Frequencies	NNS	PH
of	IN	PH
allergic	JJ	PH
and	CC	PH
IgE-associated	JJ	PH
allergic	JJ	PH
disease	NN	PH
and	CC	O
sensitization	NN	PH
in	IN	O
the	DT	O
probiotic	JJ	O
and	CC	O
placebo	JJ	O
groups	NNS	O
were	VBD	O
similar	JJ	O
:	:	O
52.6	CD	O
%	NN	O
versus	IN	O
54.9	CD	O
%	NN	O
and	CC	O
29.5	CD	O
%	NN	O
versus	IN	O
26.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
41.3	CD	O
%	NN	O
in	IN	O
both	DT	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
appeared	VBD	O
in	IN	O
frequencies	NNS	PH
of	IN	PH
eczema	NN	PH
(	(	O
39.3	CD	O
%	NN	O
vs	JJ	O
43.3	CD	O
%	NN	O
)	)	O
,	,	O
atopic	JJ	PH
eczema	NN	PH
(	(	O
24.0	CD	O
%	NN	O
vs	JJ	O
25.1	CD	O
%	NN	O
)	)	O
,	,	O
allergic	JJ	PH
rhinitis	NN	PH
(	(	O
20.7	CD	O
%	NN	O
vs	JJ	O
19.1	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
asthma	NN	PH
(	(	O
13.0	CD	O
%	NN	O
vs	JJ	O
14.1	CD	O
%	NN	O
)	)	O
between	IN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
less	JJR	O
IgE-associated	JJ	PH
allergic	JJ	PH
disease	NN	PH
occurred	VBD	O
in	IN	O
cesarean-delivered	JJ	O
children	NNS	O
receiving	VBG	O
probiotics	NNS	O
(	(	O
24.3	CD	O
%	NN	O
vs	JJ	O
40.5	CD	O
%	NN	O
;	:	O
odds	NNS	O
ratio	VBP	O
,	,	O
0.47	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.23	CD	O
%	NN	O
to	TO	O
0.96	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.035	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
allergy-preventive	JJ	O
effect	NN	O
that	WDT	O
extended	VBD	O
to	TO	O
age	NN	O
5	CD	O
years	NNS	O
was	VBD	O
achieved	VBN	O
with	IN	O
perinatal	JJ	O
supplementation	NN	O
of	IN	O
probiotic	JJ	O
bacteria	NNS	O
to	TO	O
high-risk	JJ	O
mothers	NNS	O
and	CC	O
children	NNS	O
.	.	O

It	PRP	O
conferred	VBD	O
protection	NN	O
only	RB	O
to	TO	O
cesarean-delivered	JJ	O
children	NNS	O
.	.	O

Prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
diclofenac	NN	O
and	CC	O
ketorolac	NN	O
after	IN	O
refractive	JJ	O
surgery	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
diclofenac	NN	O
and	CC	O
ketorolac	NN	O
in	IN	O
relieving	VBG	PA
corneal	NN	PA
pain	NN	PA
after	IN	O
refractive	JJ	O
surgery	NN	O
,	,	O
and	CC	O
determine	VB	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
difference	NN	O
in	IN	O
stinging	VBG	O
on	IN	O
instillation	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
prospectively	RB	O
to	TO	O
postoperative	VB	O
diclofenac	NN	O
in	IN	O
one	CD	O
eye	NN	O
and	CC	O
ketorolac	NN	O
in	IN	O
the	DT	O
other	JJ	O
.	.	O

Patients	NNS	O
and	CC	O
surgeon	NN	O
did	VBD	O
not	RB	O
know	VB	O
which	WDT	O
medications	NNS	O
were	VBD	O
used	VBN	O
.	.	O

Ocular	JJ	PA
postoperative	JJ	PA
pain	NN	PA
and	CC	O
discomfort	NN	PA
on	IN	PA
instillation	NN	PA
of	IN	PA
medication	NN	PA
were	VBD	O
measured	VBN	O
after	IN	O
radial	JJ	O
keratotomy	NN	O
with	IN	O
a	DT	O
visual	JJ	PA
analog	NN	PA
scale	NN	PA
and	CC	O
a	DT	O
questionnaire	NN	PA
.	.	O

RESULTS	NNP	O
Both	NNP	O
medications	NNS	O
were	VBD	O
highly	RB	O
effective	JJ	Ot
in	IN	Ot
relieving	VBG	Ot
pain	NN	Ot
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	PA
relief	NN	PA
,	,	O
or	CC	O
stinging	VBG	PA
on	IN	PA
instillation	NN	PA
(	(	O
P	NNP	O
=	NNP	O
.29	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
in	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
medications	NNS	O
on	IN	O
pain	NN	PA
relief	NN	PA
,	,	O
or	CC	O
in	IN	O
stinging	VBG	PA
on	IN	PA
instillation	NN	PA
.	.	O

Is	VBZ	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	O
for	IN	O
transrectal	JJ	O
ultrasound	NN	O
guided	VBD	O
prostate	NN	O
biopsy	NN	O
associated	VBN	O
with	IN	O
increased	JJ	O
infectious	JJ	A
or	CC	A
hemorrhagic	JJ	A
complications	NNS	A
?	.	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Periprostatic	NNP	O
local	JJ	O
anesthesia	NN	O
for	IN	O
prostate	NN	O
biopsy	NN	O
requires	VBZ	O
2	CD	O
or	CC	O
more	JJR	O
extra	JJ	O
needle	JJ	O
punctures	NNS	O
and	CC	O
injection	NN	O
of	IN	O
the	DT	O
local	JJ	O
anesthetic	NN	O
through	IN	O
the	DT	O
highly	RB	O
colonized	JJ	O
rectum	NN	O
.	.	O

To	TO	O
our	PRP$	O
knowledge	NN	O
we	PRP	O
report	VBP	O
the	DT	O
first	JJ	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
infectious	JJ	A
or	CC	A
hemorrhagic	JJ	A
complications	NNS	A
associated	VBN	O
with	IN	O
this	DT	O
method	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
100	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
sterile	JJ	O
urine	JJ	O
cultures	NNS	O
underwent	JJ	O
transrectal	JJ	O
ultrasound	NN	O
guided	VBD	O
prostate	NN	O
biopsy	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
periprostatic	JJ	O
nerve	NN	O
block	NN	O
or	CC	O
no	DT	O
anesthesia	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
the	DT	O
amount	NN	PH
of	IN	PH
rectal	NN	PH
and	CC	PH
urethral	JJ	PH
bleeding	NN	PH
,	,	O
and	CC	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
of	IN	O
infection	NN	A
after	IN	A
biopsy	NN	A
.	.	PH

RESULTS	VB	O
The	DT	O
amount	NN	PH
of	IN	PH
urethral	JJ	PH
bleeding	NN	PH
was	VBD	O
slight	JJ	O
and	CC	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Rectal	JJ	PH
bleeding	NN	PH
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
anesthesia	NN	O
.	.	O

High	JJ	PH
fever	NN	PH
(	(	O
greater	JJR	O
than	IN	O
37.8C	CD	O
)	)	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
nerve	NN	O
block	NN	O
group	NN	O
and	CC	O
2	CD	O
patients	NNS	O
in	IN	O
this	DT	O
group	NN	O
required	VBD	O
rehospitalization	NN	O
.	.	O

Bacteriuria	NNP	PH
in	IN	PH
post-biopsy	JJ	PH
urine	JJ	PH
cultures	NNS	PH
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	O
for	IN	O
prostate	JJ	O
biopsy	NN	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
urethral	JJ	PH
bleeding	NN	PH
.	.	O

It	PRP	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decreased	JJ	O
incidence	NN	O
of	IN	O
rectal	JJ	PH
bleeding	NN	PH
,	,	O
presumably	RB	O
due	JJ	O
to	TO	O
decreased	JJ	O
patient	NN	O
discomfort	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
bacteriuria	NN	PH
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

High	NNP	A
fever	NN	A
and	CC	A
hospitalization	NN	A
due	JJ	O
to	TO	O
infectious	JJ	O
complications	NNS	O
were	VBD	O
also	RB	O
more	RBR	O
common	JJ	O
in	IN	O
the	DT	O
local	JJ	O
anesthesia	NN	O
group	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Prospective	JJ	O
randomized	JJ	O
trials	NNS	O
seem	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimum	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
regimen	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
biopsy	NN	O
with	IN	O
a	DT	O
periprostatic	JJ	O
nerve	NN	O
block	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	O
cefixime	NN	O
with	IN	O
ceftriaxone	NN	O
as	IN	O
treatment	NN	O
for	IN	O
uncomplicated	JJ	PH
gonorrhea	NN	PH
.	.	O

The	DT	O
Gonorrhea	NNP	O
Treatment	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
of	IN	O
the	DT	O
widespread	JJ	O
existence	NN	O
of	IN	O
Neisseria	NNP	O
gonorrhoeae	NN	O
resistant	NN	O
to	TO	O
penicillin	VB	O
or	CC	O
tetracycline	VB	O
,	,	O
ceftriaxone	NN	O
is	VBZ	O
now	RB	O
recommended	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gonorrhea	NN	PH
.	.	O

There	EX	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
a	DT	O
need	NN	O
for	IN	O
effective	JJ	O
antibiotics	NNS	O
that	WDT	O
can	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
ceftriaxone	NN	O
,	,	O
which	WDT	O
requires	VBZ	O
intramuscular	JJ	O
administration	NN	O
.	.	O

Cefixime	NNP	O
is	VBZ	O
an	DT	O
orally	RB	O
absorbed	JJ	O
cephalosporin	NN	O
that	WDT	O
is	VBZ	O
active	JJ	O
against	IN	O
resistant	JJ	O
gonococci	NN	O
and	CC	O
has	VBZ	O
pharmacokinetic	JJ	O
activity	NN	O
suitable	JJ	O
for	IN	O
single-dose	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
unblinded	JJ	O
multicenter	NN	O
study	NN	O
of	IN	O
209	CD	O
men	NNS	O
and	CC	O
124	CD	O
women	NNS	O
with	IN	O
uncomplicated	JJ	O
gonorrhea	NN	O
,	,	O
we	PRP	O
compared	VBN	O
three	CD	O
single-dose	JJ	O
treatment	NN	O
regimens	NNS	O
:	:	O
400	CD	O
mg	NN	O
or	CC	O
800	CD	O
mg	NN	O
of	IN	O
cefixime	NN	O
,	,	O
administered	VBN	O
orally	RB	O
,	,	O
and	CC	O
250	CD	O
mg	NN	O
of	IN	O
ceftriaxone	NN	O
administered	VBN	O
intramuscularly	RB	O
.	.	O

The	DT	O
overall	JJ	Ot
cure	NN	Ot
rates	NNS	Ot
were	VBD	O
96	CD	O
percent	NN	O
for	IN	O
the	DT	O
400-mg	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	O
(	(	O
89	CD	O
of	IN	O
93	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
93.5	CD	O
percent	NN	O
to	TO	O
97.8	CD	O
percent	NN	O
)	)	O
;	:	O
98	CD	O
percent	NN	O
for	IN	O
the	DT	O
800-mg	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	O
(	(	O
86	CD	O
of	IN	O
88	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
94.6	CD	O
percent	NN	O
to	TO	O
100	CD	O
percent	NN	O
)	)	O
;	:	O
and	CC	O
98	CD	O
percent	NN	O
for	IN	O
ceftriaxone	NN	O
(	(	O
92	CD	O
of	IN	O
94	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
94.9	CD	O
to	TO	O
100	CD	O
percent	NN	O
)	)	O
.	.	O

The	DT	O
cure	NN	Ot
rates	NNS	Ot
were	VBD	O
similar	JJ	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
and	CC	O
pharyngeal	JJ	PH
infection	NN	PH
was	VBD	O
eradicated	VBN	O
in	IN	O
20	CD	O
of	IN	O
22	CD	O
patients	NNS	O
(	(	O
91	CD	O
percent	NN	O
)	)	O
.	.	O

Thirty-nine	JJ	O
percent	NN	O
of	IN	O
303	CD	O
pretreatment	JJ	O
gonococcal	JJ	O
isolates	NNS	O
had	VBD	O
one	CD	O
or	CC	O
more	JJR	O
types	NNS	O
of	IN	O
antimicrobial	JJ	O
resistance	NN	O
;	:	O
the	DT	O
efficacy	NN	Ot
of	IN	O
all	DT	O
three	CD	O
regimens	NNS	O
was	VBD	O
independent	JJ	O
of	IN	O
the	DT	O
resistance	NN	O
pattern	NN	O
.	.	O

Chlamydia	NNP	PH
trachomatis	NN	PH
infection	NN	PH
persisted	VBN	O
in	IN	O
at	IN	O
least	JJS	O
half	PDT	O
the	DT	O
patients	NNS	O
infected	VBN	O
in	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	Ot
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	PH
gonorrhea	NN	PH
,	,	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	O
(	(	O
400	CD	O
or	CC	O
800	CD	O
mg	NN	O
)	)	O
given	VBN	O
orally	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	Ot
as	IN	O
the	DT	O
currently	RB	O
recommended	VBN	O
regimen	NNS	O
of	IN	O
ceftriaxone	NN	O
(	(	O
250	CD	O
mg	NN	O
given	VBN	O
intramuscularly	RB	O
)	)	O
.	.	O

Neurophysiological	JJ	ME
responses	NNS	ME
to	TO	ME
faces	VBZ	ME
and	CC	ME
gaze	JJ	ME
direction	NN	ME
differentiate	NN	O
children	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
ADHD	NNP	O
and	CC	O
ASD+ADHD	NNP	O
.	.	O

Children	NNP	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
demonstrate	VBP	O
face	NN	ME
processing	NN	ME
abnormalities	NNS	ME
that	WDT	O
may	MD	O
underlie	VB	O
social	JJ	O
impairment	NN	O
.	.	O

Despite	IN	O
substantial	JJ	O
overlap	NN	O
between	IN	O
ASD	NNP	O
and	CC	O
ADHD	NNP	O
,	,	O
ERP	NNP	ME
markers	NNS	ME
of	IN	ME
face	NN	ME
and	CC	ME
gaze	NN	ME
processing	NN	ME
have	VBP	O
not	RB	O
been	VBN	O
directly	RB	O
compared	VBN	O
across	IN	O
pure	NN	O
and	CC	O
comorbid	NN	O
cases	NNS	O
.	.	O

Children	NNP	O
with	IN	O
ASD	NNP	O
(	(	O
n=19	NN	O
)	)	O
,	,	O
ADHD	NNP	O
(	(	O
n=18	NN	O
)	)	O
,	,	O
comorbid	JJ	O
ASD+ADHD	NNP	O
(	(	O
n=29	NN	O
)	)	O
and	CC	O
typically	RB	O
developing	VBG	O
(	(	O
TD	NNP	O
)	)	O
controls	NNS	O
(	(	O
n=26	NN	O
)	)	O
were	VBD	O
presented	VBN	O
with	IN	O
upright/inverted	JJ	O
faces	VBZ	O
with	IN	O
direct/averted	VBN	O
gaze	NN	O
,	,	O
with	IN	O
concurrent	JJ	O
recording	NN	O
of	IN	O
the	DT	O
P1	NNP	O
and	CC	O
N170	NNP	O
components	NNS	O
.	.	O

While	IN	O
the	DT	O
N170	NNP	O
was	VBD	O
predominant	VBN	O
in	IN	O
the	DT	O
right	NN	O
hemisphere	NN	O
in	IN	O
TD	NNP	O
and	CC	O
ADHD	NNP	O
,	,	O
children	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
ASD/ASD+ADHD	NNP	O
)	)	O
showed	VBD	O
a	DT	O
bilateral	JJ	O
distribution	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
children	NNS	O
with	IN	O
ASD	NNP	O
demonstrated	VBD	O
altered	JJ	O
response	NN	ME
to	TO	ME
gaze	VB	ME
direction	NN	ME
on	IN	O
P1	NNP	O
latency	NN	O
and	CC	O
no	DT	O
sensitivity	NN	ME
to	TO	ME
gaze	VB	ME
direction	NN	ME
on	IN	O
midline-N170	JJ	O
amplitude	NN	O
compared	VBN	O
to	TO	O
TD	NNP	O
and	CC	O
ADHD	NNP	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
children	NNS	O
with	IN	O
ADHD	NNP	O
(	(	O
ADHD/ASD+ADHD	NNP	O
)	)	O
exhibited	VBD	O
a	DT	O
reduced	JJ	O
face	NN	ME
inversion	NN	ME
effect	NN	ME
on	IN	O
P1	NNP	O
latency	NN	O
compared	VBN	O
to	TO	O
TD	NNP	O
and	CC	O
ASD	NNP	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
children	NNS	O
with	IN	O
ASD	NNP	O
have	VBP	O
specific	JJ	O
abnormalities	NNS	ME
in	IN	ME
gaze	NN	ME
processing	NN	ME
and	CC	ME
altered	JJ	ME
neural	JJ	ME
specialisation	NN	ME
,	,	O
whereas	JJ	O
children	NNS	O
with	IN	O
ADHD	NNP	O
show	NN	O
abnormalities	NNS	ME
at	IN	O
early	JJ	O
visual	JJ	O
attention	NN	O
stages	NNS	O
.	.	O

Children	NNP	O
with	IN	O
ASD+ADHD	NNP	O
are	VBP	O
an	DT	O
additive	JJ	O
co-occurrence	NN	O
with	IN	O
deficits	NNS	O
of	IN	O
both	DT	O
disorders	NNS	O
.	.	O

Elucidating	VBG	O
the	DT	O
neural	JJ	O
basis	NN	O
of	IN	O
the	DT	O
overlap	NN	O
between	IN	O
ASD	NNP	O
and	CC	O
ADHD	NNP	O
is	VBZ	O
likely	JJ	O
to	TO	O
inform	VB	O
aetiological	JJ	O
investigation	NN	O
and	CC	O
clinical	JJ	O
assessment	NN	O
.	.	O

Long-term	JJ	O
survival	NN	O
in	IN	O
a	DT	O
phase	NN	O
III	NNP	O
,	,	O
randomised	VBD	O
study	NN	O
of	IN	O
topotecan	JJ	O
versus	NN	O
paclitaxel	NN	O
in	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
carcinoma	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
have	VBP	O
continued	VBN	O
to	TO	O
monitor	VB	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
randomised	VBN	O
in	IN	O
a	DT	O
previously	RB	O
reported	VBN	O
multicentre	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
of	IN	O
topotecan	JJ	O
versus	NN	O
paclitaxel	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
cancer	NN	O
who	WP	O
had	VBD	O
failed	VBN	O
one	CD	O
prior	JJ	O
platinum-based	JJ	O
regimen	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
with	IN	O
bidimensionally	RB	O
measurable	JJ	O
disease	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
topotecan	VB	O
(	(	O
1.5	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
or	CC	O
paclitaxel	NN	O
(	(	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
as	IN	O
a	DT	O
3-h	JJ	O
infusion	NN	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
treatment	NN	O
with	IN	O
the	DT	O
alternate	NN	O
therapy	NN	O
at	IN	O
third	JJ	O
line	NN	O
.	.	O

The	DT	O
European	JJ	Ot
Organisation	NNP	Ot
for	IN	Ot
Research	NNP	Ot
and	CC	Ot
Treatment	NNP	Ot
of	IN	Ot
Cancer	NNP	Ot
Quality	NNP	Ot
of	IN	Ot
Life	NNP	Ot
(	(	Ot
EORTC	NNP	Ot
QOL	NNP	Ot
)	)	Ot
-C30	VBP	Ot
questionnaire	NN	Ot
was	VBD	O
also	RB	O
used	VBN	O
to	TO	O
measure	VB	O
eight	CD	O
symptoms	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
during	IN	O
each	DT	O
course	NN	O
(	(	O
pain	NN	PA
,	,	O
anorexia	NN	PH
,	,	O
diarrhoea	NN	PH
,	,	O
fatigue	NN	PH
,	,	O
nausea	NN	PH
and	CC	O
vomiting	NN	PH
,	,	O
dyspnea	NN	PH
,	,	O
constipation	NN	PH
and	CC	O
insomnia	NN	PH
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
226	CD	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
response	NN	O
.	.	O

Demographic	JJ	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
as	IN	O
were	VBD	O
results	NNS	O
of	IN	O
the	DT	O
EORTC	NNP	O
QOL-30	NNP	O
questionnaire	NN	O
.	.	O

For	IN	O
the	DT	O
topotecan	JJ	O
group	NN	O
,	,	O
median	JJ	PH
time	NN	PH
to	TO	PH
progression	NN	PH
was	VBD	O
18.9	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
92.6+	CD	O
weeks	NNS	O
;	:	O
25	CD	O
%	NN	O
censored	VBN	O
)	)	O
,	,	O
and	CC	O
,	,	O
for	IN	O
paclitaxel	NN	O
,	,	O
14.7	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
137.3+	CD	O
weeks	NNS	O
;	:	O
12.3	CD	O
%	NN	O
censored	VBN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.076	CD	O
.	.	O

At	IN	O
4	CD	O
years	NNS	O
post-randomisation	NN	O
,	,	O
median	JJ	MO
survival	NN	MO
in	IN	O
the	DT	O
topotecan	JJ	O
group	NN	O
was	VBD	O
63.0	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
238.4+	CD	O
weeks	NNS	O
;	:	O
20.5	CD	O
%	NN	O
censored	VBN	O
)	)	O
and	CC	O
,	,	O
for	IN	O
paclitaxel	NN	O
,	,	O
53.0	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
226.3+	CD	O
weeks	NNS	O
;	:	O
12.3	CD	O
%	NN	O
censored	VBN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.44	CD	O
.	.	O

CONCLUSION	NNP	O
Topotecan	NNP	O
continues	VBZ	O
to	TO	O
demonstrate	VB	O
comparable	JJ	O
efficacy	NN	Ot
and	CC	O
survival	NN	MO
to	TO	O
paclitaxel	VB	O
with	IN	O
manageable	JJ	O
and	CC	O
non-cumulative	JJ	O
haematological	JJ	PH
toxicity	NN	PH
.	.	A

Non-haematological	JJ	PH
toxicity	NN	PH
was	VBD	O
generally	RB	O
mild	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
long-term	JJ	O
survival	NN	O
rate	NN	O
indicates	VBZ	O
substantial	JJ	O
therapeutic	JJ	O
benefit	NN	O
for	IN	O
this	DT	O
group	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
topotecan	JJ	O
at	IN	O
relapse	NN	O
of	IN	O
ovarian	JJ	O
cancer	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
audiotapes	NNS	O
in	IN	O
promoting	VBG	ME
psychological	JJ	ME
well-being	NN	ME
in	IN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

Open	VB	O
or	CC	O
uncontrolled	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
providing	VBG	O
cancer	NN	O
patients	NNS	O
with	IN	O
audiotapes	NNS	O
of	IN	O
their	PRP$	O
clinical	JJ	O
interviews	NNS	O
can	MD	O
improve	VB	O
information	NN	ME
recall	NN	ME
and	CC	O
reduce	VB	O
psychological	JJ	ME
distress	NN	ME
.	.	O

We	PRP	O
tested	VBD	O
these	DT	O
hypotheses	NNS	O
in	IN	O
a	DT	O
'clinician-blind	JJ	O
'	''	O
,	,	O
prospective	JJ	O
,	,	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
117	CD	O
patients	NNS	O
newly	RB	O
referred	VBN	O
to	TO	O
a	DT	O
medical	JJ	O
oncology	NN	O
clinic	NN	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
given	VBN	O
'bad	CD	O
news	NN	O
'	POS	O
had	VBD	O
their	PRP$	O
consultations	NNS	O
audiotaped	VBN	O
.	.	O

Blind	NNP	O
to	TO	O
the	DT	O
clinician	JJ	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
a	DT	O
copy	NN	O
of	IN	O
the	DT	O
tape	NN	O
to	TO	O
play	VB	O
at	IN	O
home	NN	O
or	CC	O
not	RB	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
,	,	O
tape	NN	O
group	NN	O
patients	NNS	O
reported	VBD	O
positive	JJ	ME
attitudes	NNS	ME
to	TO	O
the	DT	O
audiotape	NN	O
and	CC	O
were	VBD	O
shown	VBN	O
to	TO	O
recall	VB	ME
significantly	RB	ME
more	JJR	ME
information	NN	ME
about	IN	ME
their	PRP$	ME
illness	NN	ME
than	IN	O
did	VBD	O
controls	NNS	O
.	.	O

Overall	JJ	O
improvement	NN	O
in	IN	O
psychological	JJ	ME
distress	NN	ME
at	IN	O
1	CD	O
and	CC	O
6	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
30-item	JJ	ME
General	NNP	ME
Health	NNP	ME
Questionnaire	NNP	ME
and	CC	ME
the	DT	ME
Hospital	NNP	ME
Anxiety	NNP	ME
and	CC	ME
Depression	NNP	ME
Scale	NNP	ME
was	VBD	O
no	DT	O
different	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
a	DT	O
second-order	JJ	O
interaction	NN	O
suggested	VBD	O
that	IN	O
poor-prognosis	NN	O
patients	NNS	O
were	VBD	O
disadvantaged	VBN	O
specifically	RB	O
by	IN	O
access	NN	O
to	TO	O
the	DT	O
audiotape	NN	O
,	,	O
with	IN	O
less	JJR	O
improvement	NN	O
in	IN	O
psychological	JJ	ME
distress	NN	ME
at	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
than	IN	O
non-tape	JJ	O
controls	NNS	O
.	.	O

Patient	JJ	O
access	NN	O
to	TO	O
audiotapes	NNS	O
of	IN	O
clinical	JJ	O
interviews	NNS	O
promotes	VBZ	O
factual	JJ	ME
retention	NN	ME
but	CC	O
does	VBZ	O
not	RB	O
reliably	RB	O
reduce	VB	O
psychological	JJ	ME
distress	NN	ME
and	CC	O
may	MD	O
be	VB	O
actively	RB	O
unhelpful	JJ	O
in	IN	O
some	DT	O
subgroups	NNS	O
of	IN	O
patients	NNS	O
.	.	O

A	DT	O
randomised	JJ	O
comparison	NN	O
of	IN	O
three	CD	O
drainage	NN	O
systems	NNS	O
following	VBG	O
cholecystectomy	NN	O
.	.	O

The	DT	O
efficacy	NN	Ot
of	IN	O
low	JJ	O
pressure	NN	O
,	,	O
high	JJ	O
pressure	NN	O
and	CC	O
passive	JJ	O
drainage	NN	O
systems	NNS	O
have	VBP	O
been	VBN	O
compared	VBN	O
after	IN	O
cholecystectomy	NN	O
.	.	O

Symptoms	NNS	PA
of	IN	PA
pain	NN	PA
,	,	PH
discomfort	NN	A
and	CC	A
nausea	NN	A
were	VBD	O
compared	VBN	O
using	VBG	O
linear	JJ	O
analogue	NN	O
scales	NNS	O
and	CC	O
spirometry	NN	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
pre-operative	JJ	O
and	CC	O
postoperative	JJ	O
respiratory	NN	PH
function	NN	PH
.	.	PH

The	DT	O
low	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
removed	VBD	O
an	DT	O
intraperitoneal	NN	PH
marker	NN	PH
,	,	PH
gentamicin	NN	PH
,	,	O
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
high	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
,	,	O
but	CC	O
not	RB	O
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
passive	JJ	O
drain	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
postoperative	JJ	PH
respiratory	NN	PH
function	NN	PH
nor	CC	O
in	IN	O
the	DT	O
amount	NN	PA
of	IN	PA
pain	NN	PA
or	CC	PA
discomfort	NN	PA
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
passive	JJ	O
drain	NN	O
group	NN	O
reported	VBD	O
less	JJR	O
nausea	NN	PH
than	IN	O
the	DT	O
suction	NN	O
drain	NN	O
groups	NNS	O
.	.	O

If	IN	O
a	DT	O
negative	JJ	O
pressure	NN	O
drainage	NN	O
system	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
a	DT	O
low	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
a	DT	O
high	JJ	O
pressure	NN	O
system	NN	O
.	.	O

The	DT	O
cost-effectiveness	NN	Ot
of	IN	O
parasitologic	JJ	O
diagnosis	NN	O
for	IN	O
malaria-suspected	JJ	O
patients	NNS	O
in	IN	O
an	DT	O
era	NN	O
of	IN	O
combination	NN	O
therapy	NN	O
.	.	O

The	DT	O
introduction	NN	O
of	IN	O
artemisinin-based	JJ	O
combination	NN	O
therapy	NN	O
in	IN	O
sub-Saharan	NN	O
Africa	NNP	O
has	VBZ	O
prompted	VBN	O
calls	NNS	O
for	IN	O
increased	VBN	O
use	NN	O
of	IN	O
parasitologic	JJ	O
diagnosis	NN	O
for	IN	O
malaria	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
cost-effectiveness	NN	Ot
of	IN	O
rapid	JJ	O
diagnostic	JJ	O
tests	NNS	O
(	(	O
RDTs	NNP	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
microscopy	VB	O
in	IN	O
guiding	VBG	O
treatment	NN	O
of	IN	O
non-severe	JJ	O
febrile	JJ	O
illness	NN	O
at	IN	O
varying	VBG	O
levels	NNS	O
of	IN	O
malaria	NN	O
endemicity	NN	O
using	VBG	O
data	NNS	O
on	IN	O
test	NN	O
accuracy	NN	O
and	CC	O
costs	NNS	Ot
collected	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
Tanzanian	JJ	O
trial	NN	O
.	.	O

If	IN	O
prescribers	NNS	O
complied	VBD	O
with	IN	O
current	JJ	O
guidelines	NNS	O
,	,	O
microscopy	NN	O
would	MD	O
give	VB	O
rise	NN	O
to	TO	O
lower	JJR	O
average	NN	O
costs	NNS	Ot
per	IN	O
patient	NN	O
correctly	RB	O
treated	VBD	O
than	IN	O
RDTs	NNP	O
in	IN	O
areas	NNS	O
of	IN	O
both	DT	O
high	JJ	O
and	CC	O
low	JJ	O
transmission	NN	O
.	.	O

RDT	NNP	O
introduction	NN	O
would	MD	O
result	VB	O
in	IN	O
an	DT	O
additional	JJ	O
2.3	CD	O
%	NN	O
and	CC	O
9.4	CD	O
%	NN	O
of	IN	O
patients	NNS	Ot
correctly	RB	Ot
treated	VBN	Ot
,	,	O
at	IN	O
an	DT	O
incremental	JJ	Ot
cost	NN	Ot
of	IN	O
$	$	O
25	CD	O
and	CC	O
$	$	O
7	CD	O
in	IN	O
the	DT	O
low	JJ	O
and	CC	O
high	JJ	O
transmission	NN	O
settings	NNS	O
,	,	O
respectively	RB	O
.	.	O

Cost-effectiveness	NNP	Ot
would	MD	O
be	VB	O
worse	JJR	O
if	IN	O
prescribers	NNS	O
do	VBP	O
not	RB	O
comply	VB	O
with	IN	O
test	NN	O
results	NNS	O
.	.	O

The	DT	O
cost	NN	O
of	IN	O
this	DT	O
additional	JJ	O
benefit	NN	O
may	MD	O
be	VB	O
higher	JJR	O
than	IN	O
many	JJ	O
countries	NNS	O
can	MD	O
afford	VB	O
without	IN	O
external	JJ	O
assistance	NN	O
or	CC	O
lower	JJR	O
RDT	NNP	O
prices	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
hydraulic	JJ	O
circuit	NN	O
training	NN	O
on	IN	O
cardiovascular	JJ	O
function	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hydraulic	JJ	O
circuit	NN	O
training	NN	O
(	(	O
HCT	NNP	O
)	)	O
on	IN	O
cardiovascular	NN	PH
(	(	PH
CV	NNP	PH
)	)	PH
function	NN	PH
was	VBD	O
assessed	VBN	O
in	IN	O
32	CD	O
healthy	JJ	O
middle-aged	JJ	O
males	NNS	O
(	(	O
X	JJ	O
age	NN	O
=	VBD	O
42.2	CD	O
+/-	JJ	O
2.1	CD	O
yr	NN	O
)	)	O
.	.	O

Maximal	NNP	PH
aerobic	JJ	PH
power	NN	PH
(	(	PH
VO2max	NNP	PH
)	)	PH
,	,	O
with	IN	O
simultaneous	JJ	PH
measurement	NN	PH
of	IN	PH
stroke	NN	PH
volume	NN	PH
(	(	PH
SV	NNP	PH
)	)	PH
and	CC	O
cardiac	JJ	PH
output	NN	PH
(	(	PH
CO	NNP	PH
)	)	PH
,	,	O
by	IN	O
impedance	NN	Ot
cardiography	NN	Ot
,	,	O
was	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-training	JJ	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
nonexercising	JJ	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
cycle	NN	O
training	NN	O
group	NN	O
(	(	O
cycle	NN	O
)	)	O
,	,	O
or	CC	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
HCT	NNP	O
groups	NNS	O
.	.	O

Training	VBG	O
groups	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
9	CD	O
wk	NN	O
program	NN	O
,	,	O
3	CD	O
d.wk-1	NN	O
.	.	O

Subjects	NNS	O
assigned	VBD	O
to	TO	O
HCT	NNP	O
exercised	VBN	O
on	IN	O
a	DT	O
9	CD	O
station	NN	O
circuit	NN	O
,	,	O
completing	VBG	O
3	CD	O
circuits.d-1	JJ	O
.	.	O

Each	DT	O
circuit	NN	O
consisted	VBD	O
of	IN	O
three	CD	O
20	CD	O
s	JJ	O
work	NN	O
intervals	NNS	O
at	IN	O
each	DT	O
station	NN	O
with	IN	O
a	DT	O
1:1	CD	O
work	NN	O
:	:	O
rest	NN	O
ratio	NN	O
.	.	O

One	CD	O
HCT	NNP	O
group	NN	O
(	(	O
HCTmax	NNP	O
)	)	O
completed	VBD	O
the	DT	O
maximal	JJ	O
repetitions	NNS	O
possible	JJ	O
(	(	O
RM	NNP	O
)	)	O
during	IN	O
each	DT	O
work	NN	O
interval	NN	O
.	.	O

The	DT	O
other	JJ	O
HCT	NNP	O
group	NN	O
(	(	O
HCTsub	NNP	O
)	)	O
exercised	VBD	O
at	IN	O
70-85	CD	O
%	NN	O
of	IN	O
RM	NNP	O
.	.	O

Following	VBG	O
training	NN	O
VO2max	NNP	PH
(	(	PH
ml.kg-1	JJ	PH
min-1	NN	PH
)	)	PH
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
all	DT	O
training	NN	O
groups	NNS	O
(	(	O
18.0	CD	O
,	,	O
12.5	CD	O
,	,	O
and	CC	O
11.3	CD	O
%	NN	O
for	IN	O
cycle	NN	O
,	,	O
HCTsub	NNP	O
,	,	O
and	CC	O
HCTmax	NNP	PH
groups	NNS	PH
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
VO2max	NNP	PH
observed	VBD	O
in	IN	O
the	DT	O
cycle	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
recorded	VBN	O
by	IN	O
the	DT	O
two	CD	O
HCT	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

For	IN	O
all	DT	O
three	CD	O
training	VBG	O
groups	NNS	O
,	,	O
the	DT	O
increase	NN	O
in	IN	O
VO2max	NNP	PH
was	VBD	O
associated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
SVmax	NNP	PH
and	CC	O
COmax	NNP	PH
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
both	DT	O
maximal	JJ	O
and	CC	O
submaximal	JJ	O
HCT	NNP	O
programs	NNS	O
can	MD	O
elicit	VB	O
improvements	NNS	O
in	IN	O
cardiovascular	JJ	PH
fitness	NN	PH
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
various	JJ	O
agents	NNS	O
for	IN	O
endoscopic	NN	O
injection	NN	O
sclerotherapy	NN	O
of	IN	O
bleeding	VBG	O
canine	NN	O
gastric	JJ	O
varices	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
relative	JJ	Ot
efficacy	NN	Ot
and	CC	Ot
technical	JJ	Ot
ease	NN	Ot
of	IN	Ot
use	NN	Ot
of	IN	O
eight	CD	O
different	JJ	O
agents	NNS	O
for	IN	O
endoscopic	JJ	O
hemostasis	NN	O
and	CC	O
obliteration	NN	O
of	IN	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
a	DT	O
canine	NN	O
model	NN	O
,	,	O
as	IN	O
no	DT	O
comparative	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
gastric	JJ	O
variceal	NN	O
sclerotherapy	NN	O
.	.	O

Large	JJ	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
20	CD	O
heparinized	JJ	O
dogs	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
endoscopic	VB	O
injection	NN	O
treatment	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
cyanoacrylate	NN	O
;	:	O
a	DT	O
1:1:1	CD	O
mixture	NN	O
of	IN	O
sodium	NN	O
tetradecyl	NN	O
sulfate	VBP	O
3	CD	O
%	NN	O
,	,	O
ethanol	RB	O
98	CD	O
%	NN	O
,	,	O
and	CC	O
normal	JJ	O
saline	JJ	O
solution	NN	O
;	:	O
ethanolamine	VB	O
oleate	VBP	O
5	CD	O
%	NN	O
;	:	O
sodium	NN	O
morrhuate	VBP	O
5	CD	O
%	NN	O
;	:	O
sodium	NN	O
tetradecyl	NN	O
sulfate	VBP	O
1.5	CD	O
%	NN	O
;	:	O
polidocanol	CC	O
1	CD	O
%	NN	O
;	:	O
normal	JJ	O
saline	JJ	O
solution	NN	O
with	IN	O
epinephrine	JJ	O
1:10,000	CD	O
;	:	O
or	CC	O
normal	JJ	O
saline	JJ	O
solution	NN	O
(	(	O
control	NN	O
)	)	O
.	.	O

The	DT	O
number	NN	O
and	CC	O
volume	NN	O
of	IN	O
injections	NNS	O
and	CC	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
complete	JJ	O
hemostasis	NN	O
were	VBD	O
evaluated	VBN	O
;	:	O
follow-up	JJ	O
endoscopy	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
1	CD	O
month	NN	O
to	TO	O
assess	VB	O
gastric	JJ	O
variceal	NN	O
obliteration	NN	O
.	.	O

Cyanoacrylate	NNP	O
was	VBD	O
the	DT	O
best	JJS	O
agent	NN	O
overall	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
immediate	JJ	Ot
efficacy	NN	Ot
,	,	O
low	JJ	PH
volume	NN	PH
requirement	NN	PH
,	,	O
time	NN	Ot
required	VBN	Ot
for	IN	Ot
initial	JJ	Ot
hemostasis	NN	Ot
,	,	O
and	CC	O
reduction	NN	PH
of	IN	PH
gastric	JJ	PH
variceal	NN	PH
size	NN	PH
.	.	O

Cyanoacrylate	NNP	Ot
,	,	O
tetradecyl	NN	Ot
sulfate	NN	Ot
,	,	O
and	CC	O
polidocanol	NN	Ot
were	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
agents	NNS	O
for	IN	O
reducing	VBG	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Epinephrine	NNP	O
was	VBD	O
effective	JJ	O
for	IN	O
controlling	VBG	O
induced	JJ	PH
or	CC	PH
secondary	JJ	PH
bleeding	NN	PH
caused	VBN	O
by	IN	O
puncture	NN	O
of	IN	O
the	DT	O
gastric	JJ	O
varices	NNS	O
with	IN	O
the	DT	O
sclerotherapy	NN	O
needle	NN	O
during	IN	O
intravariceal	JJ	O
injections	NNS	O
.	.	O

Ongoing	VBG	O
studies	NNS	O
are	VBP	O
evaluating	VBG	O
combinations	NNS	O
of	IN	O
agents	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
,	,	O
such	JJ	O
as	IN	O
epinephrine	NN	O
(	(	O
for	IN	O
vasoconstriction	NN	O
to	TO	O
minimize	VB	O
secondary	JJ	O
bleeding	NN	O
)	)	O
plus	CC	O
alcohol	NN	O
,	,	O
and/or	JJ	O
tetradecyl	NN	O
sulfate	NN	O
(	(	O
for	IN	O
variceal	NN	O
thrombosis	NN	O
and	CC	O
sclerosis	NN	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Midazolam	NNP	O
as	IN	O
a	DT	O
main	JJ	O
anesthesia	NN	O
induction	NN	O
agent	NN	O
--	:	O
a	DT	O
comparison	NN	O
with	IN	O
thiopental	JJ	O
and	CC	O
diazepam	NN	O
.	.	O

A	DT	O
clinical	JJ	O
randomized	JJ	O
investigation	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	Ot
of	IN	O
midazolam	NN	O
as	IN	O
a	DT	O
narcotic	JJ	O
adjuvant	NN	O
for	IN	O
anesthetic	JJ	O
induction	NN	O
.	.	O

Thirty	NNP	O
ASA	NNP	O
I-II	NNP	O
adult	NN	O
patients	NNS	O
undergoing	VBG	O
selective	JJ	O
surgery	NN	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
into	IN	O
two	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
midazolam	NN	O
0.3	CD	O
mg/kg	NN	O
,	,	O
thiopental	JJ	O
5	CD	O
mg/kg	NN	O
,	,	O
or	CC	O
diazepam	VB	O
0.4	CD	O
mg/kg	NN	O
.	.	O

The	DT	O
induction	NN	Ot
time	NN	Ot
as	IN	Ot
measured	VBN	Ot
from	IN	Ot
the	DT	Ot
onset	NN	Ot
of	IN	Ot
injection	NN	Ot
to	TO	Ot
loss	NN	Ot
of	IN	Ot
the	DT	Ot
eyelash	NN	Ot
reflex	NN	Ot
was	VBD	O
shortest	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
thiopental	NN	O
;	:	O
while	IN	O
a	DT	O
lower	JJR	PH
frequency	NN	PH
of	IN	PH
apnea	NN	PH
,	,	PH
lesser	JJR	PH
suppression	NN	PH
of	IN	PH
circulation	NN	PH
,	,	O
and	CC	O
lack	NN	PH
of	IN	PH
venous	JJ	PH
irritation	NN	PH
were	VBD	O
points	NNS	O
favoring	VBG	O
midazolam	NN	O
.	.	O

However	RB	O
,	,	O
further	JJ	O
study	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
clarify	VB	O
the	DT	O
moderate	JJ	PH
cardiovascular	JJ	PH
response	NN	PH
seen	VBN	O
during	IN	O
intubation	NN	O
in	IN	O
some	DT	O
cases	NNS	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
elucidate	VB	O
any	DT	O
patient	JJ	O
population	NN	O
differences	NNS	O
.	.	O

Histamine	NNP	O
intolerance-like	NN	O
symptoms	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
after	IN	O
oral	JJ	O
provocation	NN	O
with	IN	O
liquid	JJ	O
histamine	NN	O
.	.	O

Histamine	NNP	O
in	IN	O
food	NN	O
at	IN	O
non-toxic	JJ	O
doses	NNS	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
causing	NN	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
,	,	O
hypotension	NN	O
,	,	O
headache	NN	O
,	,	O
pruritus	NN	O
and	CC	O
flush	NN	O
(	(	O
histamine	JJ	O
intolerance	NN	O
)	)	O
.	.	O

Histamine-rich	JJ	O
foods	NNS	O
such	JJ	O
as	IN	O
cheese	NN	O
,	,	O
sausages	NNS	O
,	,	O
sauerkraut	NN	O
,	,	O
tuna	NN	O
,	,	O
tomatoes	NNS	O
,	,	O
and	CC	O
alcoholic	JJ	O
beverages	NNS	O
may	MD	O
contain	VB	O
histamine	VB	O
up	IN	O
to	TO	O
500	CD	O
mg/kg	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
10	CD	O
healthy	JJ	O
females	NNS	O
(	(	O
age	NN	O
range	NN	O
22-36	CD	O
years	NNS	O
,	,	O
mean	JJ	O
29.1	CD	O
+/-	JJ	O
5.4	CD	O
)	)	O
who	WP	O
were	VBD	O
hospitalized	VBN	O
and	CC	O
challenged	VBN	O
on	IN	O
two	CD	O
consecutive	JJ	O
days	NNS	O
with	IN	O
placebo	NN	O
(	(	O
peppermint	JJ	O
tea	NN	O
)	)	O
or	CC	O
75	CD	O
mg	NN	O
of	IN	O
pure	JJ	O
histamine	NN	O
(	(	O
equaling	VBG	O
124	CD	O
mg	JJ	O
histamine	NN	O
dihydrochloride	NN	O
,	,	O
dissolved	VBN	O
in	IN	O
peppermint	NN	O
tea	NN	O
)	)	O
.	.	O

Objective	JJ	O
parameters	NNS	O
(	(	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
temperature	NN	O
,	,	O
peak	VB	O
flow	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
total	JJ	O
clinical	JJ	O
symptom	NN	O
score	NN	O
using	VBG	O
a	DT	O
standardized	VBN	O
protocol	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
received	VBD	O
a	DT	O
histamine-free	JJ	O
diet	NN	O
also	RB	O
low	JJ	O
in	IN	O
allergen	NN	O
24	CD	O
hours	NNS	O
before	IN	O
hospitalization	NN	O
and	CC	O
over	IN	O
the	DT	O
whole	JJ	O
observation	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
histamine	NN	O
and	CC	O
the	DT	O
histamine-degrading	JJ	O
enzyme	NN	O
diamine	NN	O
oxidase	NN	O
(	(	O
DAO	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

After	IN	O
histamine	JJ	O
challenge	NN	O
,	,	O
5	CD	O
of	IN	O
10	CD	O
subjects	NNS	O
showed	VBD	O
no	DT	PH
reaction	NN	PH
.	.	O

One	CD	O
individual	NN	O
experienced	VBD	O
tachycardia	NN	PH
,	,	O
mild	JJ	PH
hypotension	NN	PH
after	IN	PH
20	CD	PH
minutes	NNS	PH
,	,	O
sneezing	VBG	PH
,	,	O
itching	NN	PH
of	IN	PH
the	DT	PH
nose	NN	PH
,	,	O
and	CC	O
rhinorrhea	NN	PH
after	IN	PH
60	CD	PH
minutes	NNS	PH
.	.	O

Four	CD	O
subjects	NNS	O
experienced	VBD	O
delayed	JJ	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	PH
(	(	PH
4x	CD	PH
)	)	PH
,	,	O
flatulence	NN	PH
(	(	PH
3x	CD	PH
)	)	PH
,	,	O
headache	NN	PH
(	(	PH
3x	CD	PH
)	)	PH
,	,	O
pruritus	NN	PH
(	(	PH
2x	CD	PH
)	)	PH
and	CC	O
ocular	JJ	PH
symptoms	NNS	PH
(	(	O
1x	CD	O
)	)	O
starting	VBG	O
3	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
provocation	NN	O
.	.	O

No	DT	O
subject	NN	O
reacted	VBD	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
histamine	NN	PH
and	CC	PH
DAO	NNP	PH
levels	NNS	PH
within	IN	O
the	DT	O
first	JJ	O
80	CD	O
minutes	NNS	O
in	IN	O
non-reactors	NNS	O
as	RB	O
well	RB	O
as	IN	O
reactors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
challenge	NN	O
with	IN	O
histamine	JJ	O
versus	NN	O
challenge	NN	O
with	IN	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
75	CD	O
mg	NN	O
of	IN	O
pure	NN	O
liquid	JJ	O
oral	JJ	O
histamine	NN	O
--	:	O
a	DT	O
dose	JJ	O
found	VBN	O
in	IN	O
normal	JJ	O
meals	NNS	O
--	:	O
can	MD	O
provoke	VB	O
immediate	JJ	O
as	RB	O
well	RB	O
as	IN	O
delayed	VBN	O
symptoms	NNS	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
healthy	JJ	O
females	NNS	O
without	IN	O
a	DT	O
history	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
.	.	O

The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
.	.	O

OBJECTIVES	NNP	O
Thrombolysis	NNP	O
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
patients	NNS	O
with	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
STEMI	NNP	O
)	)	O
living	NN	O
in	IN	O
rural	JJ	O
areas	NNS	O
with	IN	O
long	JJ	O
transfer	NN	O
delays	NNS	O
to	TO	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
trial	NN	O
compares	VBZ	O
two	CD	O
different	JJ	O
strategies	NNS	O
following	VBG	O
thrombolysis	NN	O
:	:	O
to	TO	O
transfer	VB	O
all	DT	O
patients	NNS	O
for	IN	O
immediate	JJ	O
coronary	JJ	O
angiography	NN	O
and	CC	O
intervention	NN	O
,	,	O
or	CC	O
to	TO	O
manage	VB	O
the	DT	O
patients	NNS	O
more	RBR	O
conservatively	RB	O
.	.	O

DESIGN	VB	O
The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
STEMI	NNP	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
is	VBZ	O
an	DT	O
open	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
STEMI	NNP	O
of	IN	O
less	JJR	O
than	IN	O
6	CD	O
hours	NNS	O
of	IN	O
duration	NN	O
and	CC	O
more	JJR	O
than	IN	O
90	CD	O
minutes	NNS	O
expected	VBD	O
time	NN	O
delay	NN	O
to	TO	O
PCI	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
266	CD	O
patients	NNS	O
will	MD	O
receive	VB	O
full-dose	JJ	O
thrombolysis	NN	O
,	,	O
preferably	RB	O
pre-hospital	JJ	O
,	,	O
and	CC	O
then	RB	O
be	VB	O
randomized	VBN	O
to	TO	O
either	DT	O
strategy	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
one	CD	O
year	NN	O
combined	VBN	MO
incidence	NN	MO
of	IN	MO
death	NN	MO
,	,	O
reinfarction	NN	PH
,	,	O
stroke	VBD	PH
or	CC	O
new	JJ	PH
myocardial	JJ	PH
ischaemia	NN	PH
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00161005	NNP	O
.	.	O

RESULTS	VBN	O
By	IN	O
April	NNP	O
2006	CD	O
,	,	O
109	CD	O
patients	NNS	O
have	VBP	O
been	VBN	O
randomized	VBN	O
.	.	O

Thrombolysis	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
pre-hospital	JJ	O
to	TO	O
52	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
median	JJ	O
transport	NN	O
distance	NN	O
from	IN	O
first	JJ	O
medical	JJ	O
contact	NN	O
to	TO	O
catheterization	NN	O
laboratory	NN	O
was	VBD	O
155	CD	O
km	NN	O
(	(	O
range	JJ	O
90-396	CD	O
km	NN	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
expected	VBN	O
in	IN	O
2008	CD	O
.	.	O

Bradykinin-induced	JJ	O
cough	NN	O
reflex	NN	O
markedly	RB	O
increases	VBZ	O
in	IN	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
captopril	NN	O
and	CC	O
enalapril	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
angiotensin	NN	O
converting	VBG	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibitors	NNS	O
on	IN	O
cough	NN	A
responses	NNS	A
to	TO	O
bradykinin	VB	O
(	(	O
BK	NNP	O
)	)	O
,	,	O
substance	NN	O
P	NNP	O
(	(	O
SP	NNP	O
)	)	O
and	CC	O
citric	JJ	O
acid	NN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
random	NN	O
study	NN	O
on	IN	O
10	CD	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Of	IN	O
these	DT	O
patients	NNS	O
,	,	O
five	CD	O
had	VBD	O
reported	VBN	O
cough	NN	O
with	IN	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Cough	NNP	O
responses	VBZ	O
to	TO	O
citric	VB	O
acid	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
cough	NN	O
,	,	O
and	CC	O
SP	NNP	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

BK	NNP	O
caused	VBD	O
cough	NN	A
at	IN	O
13.4	CD	O
+/-	JJ	O
1.2	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
5	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	O
inhibitors	NNS	O
,	,	O
but	CC	O
it	PRP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	A
at	IN	O
concentrations	NNS	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
other	JJ	O
5	CD	O
patients	NNS	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
the	DT	O
withdrawal	NN	O
of	IN	O
ACE	NNP	O
inhibitors	NNS	O
,	,	O
5	CD	O
patients	NNS	O
were	VBD	O
free	JJ	O
from	IN	O
cough	NN	PH
symptoms	NNS	PH
,	,	O
and	CC	O
BK	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	PH
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
these	DT	O
patients	NNS	O
,	,	O
except	IN	O
for	IN	O
one	CD	O
who	WP	O
coughed	VBD	O
at	IN	O
10	CD	O
(	(	O
-9	NN	O
)	)	O
M	NNP	O
,	,	O
without	IN	O
changes	NNS	O
in	IN	O
responses	NNS	O
to	TO	O
citric	VB	O
acid	NN	O
.	.	O

BK	NNP	O
caused	VBD	O
cough	NN	PH
at	IN	O
14.3	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
although	IN	O
BK1-7	NNP	O
,	,	O
a	DT	O
major	JJ	O
metabolite	NN	O
of	IN	O
BK	NNP	O
by	IN	O
ACE	NNP	O
,	,	O
caused	VBD	O
cough	NN	PH
at	IN	O
5.7	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
another	DT	O
3	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	O
inhibitor	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
impaired	JJ	O
metabolism	NN	O
of	IN	O
BK	NNP	O
induced	VBN	O
by	IN	O
ACE	NNP	O
inhibitors	NNS	O
may	MD	O
relate	VB	O
to	TO	O
the	DT	O
manifestation	NN	O
of	IN	O
cough	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Psychological	JJ	O
well-being	NN	O
correlates	NNS	O
with	IN	O
free	JJ	O
thyroxine	NN	O
but	CC	O
not	RB	O
free	JJ	O
3,5,3'-triiodothyronine	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
on	IN	O
thyroid	JJ	O
hormone	NN	O
replacement	NN	O
.	.	O

CONTEXT	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
An	DT	O
association	NN	O
between	IN	O
mood	NN	O
disorders	NNS	O
and	CC	O
overt	JJ	O
thyroid	JJ	O
dysfunction	NN	O
is	VBZ	O
well	RB	O
established	VBN	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
on	IN	O
the	DT	O
potential	NN	O
for	IN	O
thyroid	JJ	O
hormone	NN	O
levels	NNS	O
closer	RBR	O
to	TO	O
the	DT	O
reference	NN	O
range	NN	O
to	TO	O
correlate	VB	O
with	IN	O
psychological	JJ	O
well-being	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
analyzed	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
psychological	JJ	O
well-being	NN	O
and	CC	O
free	JJ	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
(	(	O
fT4	NN	O
)	)	O
,	,	O
free	JJ	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
(	(	O
fT3	NN	O
)	)	O
,	,	O
TSH	NNP	O
,	,	O
and	CC	O
total	JJ	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
in	IN	O
697	CD	O
patients	NNS	O
on	IN	O
thyroid	JJ	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
at	IN	O
entry	NN	O
to	TO	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
combined	JJ	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
replacement	NN	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
on	IN	O
100	CD	O
mug	NN	O
or	CC	O
more	JJR	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
AND	CC	O
MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Psychological	NNP	ME
well-being	NN	ME
was	VBD	O
assessed	VBN	O
with	IN	O
General	NNP	ME
Health	NNP	ME
Questionnaire-12	NNP	ME
(	(	ME
GHQ-12	NNP	ME
)	)	ME
,	,	O
Thyroid	NNP	ME
Symptom	NNP	ME
Questionnaire	NNP	ME
,	,	O
and	CC	O
Hospital	NNP	ME
Anxiety	NNP	ME
and	CC	ME
Depression	NNP	ME
Scale	NNP	ME
.	.	O

RESULTS	NNP	O
fT	NN	O
(	(	O
4	CD	O
)	)	O
and	CC	O
TSH	NNP	O
showed	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
with	IN	O
GHQ-12	NNP	O
scores	NNS	O
(	(	O
fT4	SYM	O
-	:	O
b	NN	O
:	:	O
-0.16	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
;	:	O
TSH	NNP	O
-	:	O
b	NN	O
:	:	O
0.663	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

No	UH	O
correlations	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
GHQ	NNP	O
scores	NNS	O
and	CC	O
fT3	NN	O
(	(	O
b	NN	O
:	:	O
0.318	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.275	CD	O
)	)	O
,	,	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
(	(	O
b	NN	O
:	:	O
0.095	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.95	CD	O
)	)	O
,	,	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
to	TO	O
fT4	VB	O
ratio	NN	O
(	(	O
b	NN	O
:	:	O
71.83	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.09	CD	O
)	)	O
or	CC	O
fT3	VBN	O
to	TO	O
rT	VB	O
(	(	O
3	CD	O
)	)	O
ratio	NN	O
(	(	O
b	NN	O
:	:	O
0.05	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.32	CD	O
)	)	O
.	.	O

The	DT	O
correlations	NNS	O
remained	VBD	O
when	WRB	O
the	DT	O
data	NN	O
set	NN	O
was	VBD	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
TSH	NNP	O
in	IN	O
the	DT	O
range	NN	O
0.3-4.0	JJ	O
mIU/liter	NN	O
.	.	O

Similar	JJ	O
correlations	NNS	O
were	VBD	O
seen	VBN	O
with	IN	O
the	DT	O
Thyroid	NNP	PH
Symptom	NNP	PH
Questionnaire	NNP	PH
,	,	O
although	IN	O
not	RB	O
with	IN	O
the	DT	O
Hospital	NNP	PH
Anxiety	NNP	PH
and	CC	PH
Depression	NNP	PH
Scale	NNP	PH
scores	NNS	PH
.	.	O

CONCLUSIONS	NNP	O
Differences	NNPS	O
in	IN	O
fT4	NN	O
and	CC	O
TSH	NNP	O
concentration	NN	O
,	,	O
even	RB	O
within	IN	O
the	DT	O
reference	NN	O
range	NN	O
,	,	O
may	MD	O
be	VB	O
a	DT	O
determinant	NN	O
of	IN	O
psychological	JJ	O
well-being	NN	O
in	IN	O
treated	JJ	O
hypothyroid	NN	O
patients	NNS	O
although	IN	O
not	RB	O
necessarily	RB	O
with	IN	O
symptoms	NNS	O
typical	JJ	O
of	IN	O
anxiety	NN	O
or	CC	O
depression	NN	O
.	.	O

Impacts	NNS	O
of	IN	O
a	DT	O
disease	JJ	O
management	NN	O
program	NN	O
for	IN	O
dually	RB	O
eligible	JJ	O
beneficiaries	NNS	O
.	.	O

The	DT	O
LifeMasters	NNPS	O
Supported	NNP	O
SelfCare	NNP	O
demonstration	NN	O
program	NN	O
provides	VBZ	O
disease	JJ	O
management	NN	O
(	(	O
DM	NNP	O
)	)	O
services	NNS	O
to	TO	O
Florida	NNP	O
Medicare	NNP	O
beneficiaries	NNS	O
who	WP	O
are	VBP	O
also	RB	O
enrolled	VBN	O
in	IN	O
Medicaid	NNP	O
and	CC	O
have	VBP	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
,	,	O
diabetes	VBZ	O
,	,	O
or	CC	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
population-based	JJ	O
program	NN	O
provides	VBZ	O
primarily	RB	O
telephonic	JJ	O
patient	JJ	O
education	NN	O
and	CC	O
monitoring	NN	O
services	NNS	O
.	.	O

Findings	NNS	O
from	IN	O
the	DT	O
randomized	VBN	O
,	,	O
intent-to-treat	JJ	O
design	NN	O
over	IN	O
the	DT	O
first	JJ	O
18	CD	O
months	NNS	O
of	IN	O
operations	NNS	O
show	VBP	O
virtually	RB	O
no	DT	O
overall	JJ	O
impacts	NNS	Ot
on	IN	Ot
hospital	NN	Ot
or	CC	Ot
emergency	NN	Ot
room	NN	Ot
(	(	Ot
ER	NNP	Ot
)	)	Ot
use	NN	Ot
,	,	O
Medicare	NNP	Ot
expenditures	VBZ	Ot
,	,	O
quality	NN	Ot
of	IN	Ot
care	NN	Ot
,	,	O
or	CC	O
prescription	NN	Ot
drug	NN	Ot
use	NN	Ot
for	IN	O
the	DT	O
33,000	CD	O
enrollees	NNS	O
.	.	O

However	RB	O
,	,	O
for	IN	O
beneficiaries	NNS	O
with	IN	O
CHF	NNP	O
who	WP	O
resided	VBD	O
in	IN	O
high-cost	NN	O
South	NNP	O
Florida	NNP	O
counties	NNS	O
,	,	O
the	DT	O
program	NN	O
reduced	VBN	O
Medicare	NNP	Ot
expenditures	NNS	Ot
by	IN	O
9.6	CD	O
percent	NN	O
.	.	O

Improved	VBN	Ot
intraoperative	JJ	Ot
management	NN	Ot
of	IN	O
anastomotic	JJ	PH
bleeding	NN	PH
during	IN	O
aortic	JJ	O
reconstruction	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
a	DT	O
polymeric	JJ	O
surgical	JJ	O
sealant	NN	O
(	(	O
CoSeal	NNP	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
Gelfoam/thrombin	NNP	O
for	IN	O
managing	VBG	O
anastomotic	JJ	PH
bleeding	NN	PH
after	IN	O
implantation	NN	O
of	IN	O
Dacron	NNP	O
grafts	NNS	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
for	IN	O
nonruptured	JJ	O
aneurysms	NNS	O
.	.	O

Each	DT	O
treatment	NN	O
was	VBD	O
directly	RB	O
applied	VBN	O
to	TO	O
the	DT	O
suture	NN	O
line	NN	O
after	IN	O
confirmation	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
suture	NN	O
line	NN	O
sites	VBZ	O
that	IN	O
achieved	VBD	O
immediate	JJ	Ot
sealing	NN	Ot
and	CC	O
the	DT	O
proportion	NN	O
sealed	VBD	O
within	IN	O
5	CD	O
minutes	NNS	O
were	VBD	O
determined	VBN	O
among	IN	O
37	CD	O
experimental	JJ	O
(	(	O
59	CD	O
sites	NNS	O
)	)	O
and	CC	O
17	CD	O
control	NN	O
subjects	NNS	O
(	(	O
27	CD	O
sites	NNS	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
greater	JJR	O
proportion	NN	O
of	IN	O
bleeding	VBG	O
suture	NN	O
line	NN	O
sites	NNS	O
treated	VBD	O
with	IN	O
the	DT	O
polymeric	JJ	O
sealant	NN	O
achieved	VBN	O
immediate	JJ	Ot
sealing	NN	Ot
following	VBG	O
reestablishment	NN	O
of	IN	O
blood	NN	O
flow	NN	O
compared	VBN	O
with	IN	O
control-treated	JJ	O
sites	NNS	O
[	VBP	O
48	CD	O
of	IN	O
59	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
vs	VBZ	O
10	CD	O
of	IN	O
27	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.002	CD	O
]	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
was	VBD	O
maintained	VBN	O
after	IN	O
5	CD	O
minutes	NNS	O
with	IN	O
approximately	RB	O
85	CD	O
per	IN	O
cent	NN	O
(	(	O
50	CD	O
of	IN	O
59	CD	O
)	)	O
of	IN	O
CoSeal	NNP	O
sites	NNS	O
compared	VBN	O
to	TO	O
just	RB	O
over	IN	O
one-half	JJ	O
(	(	O
14	CD	O
of	IN	O
27	CD	O
)	)	O
of	IN	O
control	NN	O
sites	VBZ	O
demonstrating	VBG	O
ultimate	JJ	PH
sealing	NN	PH
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polymeric	JJ	O
sealant	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
novel	JJ	O
sealant	NN	O
for	IN	O
the	DT	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
procedures	NNS	O
.	.	O

Exposure	NN	O
to	TO	O
the	DT	O
self-face	NN	O
facilitates	VBZ	O
identification	NN	ME
of	IN	ME
dynamic	JJ	ME
facial	JJ	ME
expressions	NNS	ME
:	:	Ot
influences	NNS	O
on	IN	O
individual	JJ	O
differences	NNS	O
.	.	O

A	DT	O
growing	VBG	O
literature	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
self-face	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
processing	VBG	ME
the	DT	ME
facial	JJ	ME
expressions	NNS	ME
of	IN	O
others	NNS	O
.	.	O

The	DT	O
authors	NNS	O
experimentally	RB	O
activated	VBD	O
self-face	JJ	O
representations	NNS	O
to	TO	O
assess	VB	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
recognition	NN	ME
of	IN	ME
dynamically	RB	ME
emerging	VBG	ME
facial	JJ	ME
expressions	NNS	ME
of	IN	ME
others	NNS	ME
.	.	O

They	PRP	O
exposed	VBD	O
participants	NNS	O
to	TO	O
videos	NNS	O
of	IN	O
either	DT	O
their	PRP$	O
own	JJ	O
faces	VBZ	O
(	(	O
self-face	JJ	O
prime	NN	O
)	)	O
or	CC	O
faces	VBZ	O
of	IN	O
others	NNS	O
(	(	O
nonself-face	JJ	O
prime	NN	O
)	)	O
prior	RB	O
to	TO	O
a	DT	O
facial	JJ	O
expression	NN	O
judgment	NN	O
task	NN	O
.	.	O

Their	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
experimentally	RB	O
activating	VBG	O
self-face	JJ	O
representations	NNS	O
results	NNS	O
in	IN	O
earlier	JJR	O
recognition	NN	ME
of	IN	ME
dynamically	RB	ME
emerging	VBG	ME
facial	JJ	ME
expression	NN	ME
.	.	O

As	IN	O
a	DT	O
group	NN	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
recognized	VBD	ME
expressions	NNS	ME
earlier	RBR	O
(	(	O
when	WRB	O
less	RBR	O
affective	JJ	O
perceptual	JJ	O
information	NN	O
was	VBD	O
available	JJ	O
)	)	O
compared	VBN	O
to	TO	O
participants	NNS	O
in	IN	O
the	DT	O
nonself-face	JJ	O
prime	JJ	O
condition	NN	O
.	.	O

There	EX	O
were	VBD	O
individual	JJ	O
differences	NNS	O
in	IN	O
performance	NN	O
,	,	O
such	JJ	O
that	IN	O
poorer	JJR	O
expression	NN	ME
identification	NN	ME
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
autism	NN	O
traits	NNS	O
(	(	O
in	IN	O
this	DT	O
neurocognitively	RB	O
healthy	JJ	O
sample	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
randomized	VBN	O
into	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
,	,	O
participants	NNS	O
with	IN	O
high	JJ	O
autism	NN	O
traits	NNS	O
performed	VBN	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
with	IN	O
low	JJ	O
autism	NN	O
traits	NNS	O
.	.	O

Taken	VB	O
together	RB	O
,	,	O
these	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
ability	NN	ME
to	TO	ME
recognize	VB	ME
facial	JJ	ME
expressions	NNS	ME
in	IN	O
others	NNS	O
is	VBZ	O
linked	VBN	O
with	IN	O
the	DT	O
internal	JJ	O
representations	NNS	O
of	IN	O
our	PRP$	O
own	JJ	O
faces	VBZ	O
.	.	O

Successful	JJ	O
treatment	NN	O
of	IN	O
blepharitis	NN	O
with	IN	O
bibrocathol	NN	O
(	(	O
Posiformin?	NNP	O
2	CD	O
%	NN	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Bibrocathol	NNP	O
is	VBZ	O
a	DT	O
well-established	JJ	O
antiseptic	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	NN	O
eyelid	JJ	O
diseases	NNS	O
like	IN	O
blepharitis	NN	O
.	.	O

Despite	IN	O
its	PRP$	O
frequent	JJ	O
use	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
,	,	O
no	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
bibrocathol	$	O
2	CD	O
%	NN	O
eye	NN	O
ointment	NN	O
has	VBZ	O
been	VBN	O
performed	VBN	O
until	IN	O
now	RB	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
efficacy	NN	O
,	,	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
bibrocathol	NN	O
(	(	O
Posiformin?	NNP	O
2	CD	O
%	NN	O
)	)	O
eye	NN	O
ointment	NN	O
in	IN	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
blepharitis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
multi-center	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
parallel-group	NN	O
comparison	NN	O
,	,	O
the	DT	O
change	NN	O
of	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
(	(	O
sum	VB	O
score	NN	O
)	)	O
of	IN	O
blepharitis	NN	O
in	IN	O
197	CD	O
patients	NNS	O
(	(	O
ITT	NNP	O
(	(	O
intention-to-treat-group	JJ	O
)	)	O
;	:	O
mean	JJ	O
age	NN	O
56	CD	O
?	.	O
18	CD	O
years	NNS	O
,	,	O
56	CD	O
%	NN	O
female	NN	O
,	,	O
active	JJ	O
drug	NN	O
:	:	O
vehicle	NN	O
=	IN	O
97:100	CD	O
)	)	O
over	IN	O
2	CD	O
weeks	NNS	O
treatment	NN	O
with	IN	O
bibrocathol	JJ	O
2	CD	O
%	NN	O
eye	NN	O
ointment	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
receiving	VBG	O
bibrocathol	RB	O
2	CD	O
%	NN	O
showed	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
the	DT	O
sum	NN	O
score	NN	O
than	IN	O
the	DT	O
placebo	NN	O
patients	NNS	O
(	(	O
p	JJ	O
<	NN	O
0.0001	CD	O
,	,	O
Cohen	NNP	O
's	POS	O
effect	NN	O
size	NN	O
d	NN	O
=	NNP	O
0.73	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
results	NNS	O
from	IN	O
further	JJ	O
efficacy	NN	O
assessments	NNS	O
improvement	NN	O
of	IN	O
single	JJ	O
symptoms	NNS	O
and	CC	O
ocular	JJ	O
discomfort	NN	O
measured	VBN	O
by	IN	O
a	DT	O
VAS	NNP	O
(	(	O
visual	JJ	O
analogue	NN	O
scale	NN	O
)	)	O
supported	VBD	O
treatment	NN	O
with	IN	O
bibrocathol	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
provided	VBD	O
favorable	JJ	O
tolerability	NN	Ot
ratings	NNS	O
preferring	VBG	O
bibrocathol	NN	O
over	IN	O
placebo	NN	O
.	.	O

No	DT	O
safety	NN	O
issues	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
regard	NN	O
to	TO	O
intraocular	JJ	O
pressure	NN	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
or	CC	O
occurrence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Blepharitis	NNP	O
therapy	NN	O
with	IN	O
the	DT	O
antiseptic	JJ	O
bibrocathol	NN	O
2	CD	O
%	NN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
highly	RB	O
efficacious	JJ	O
and	CC	O
safe	JJ	O
.	.	O

Long-term	JJ	O
anticoagulant	NN	O
treatment	NN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

The	DT	O
Warfarin	NNP	O
Re-Infarction	NNP	O
Study	NNP	O
.	.	O

High	NNP	O
levels	NNS	O
of	IN	O
fibrinogen	NN	O
and	CC	O
clotting	VBG	O
factor	NN	O
VII	NNP	O
are	VBP	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	PH
risk	NN	PH
for	IN	O
subsequent	JJ	MO
death	NN	MO
and	CC	O
cardiovascular	JJ	PH
disease	NN	PH
in	IN	O
apparently	RB	O
healthy	JJ	O
individuals	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
pathoanatomic	JJ	O
studies	NNS	O
and	CC	O
coronary	JJ	O
angiography	NN	O
have	VBP	O
confirmed	VBN	O
a	DT	O
relationship	NN	Ot
between	IN	Ot
coronary	JJ	Ot
thrombus	NN	Ot
formation	NN	Ot
and	CC	Ot
acute	JJ	Ot
Q-wave	NNP	Ot
infarction	NN	Ot
.	.	O

Effective	JJ	O
antithrombotic	JJ	O
agents	NNS	O
may	MD	O
prevent	VB	O
or	CC	O
limit	VB	O
thrombus	JJ	PH
formation	NN	PH
and	CC	O
events	NNS	A
related	VBN	A
to	TO	A
thrombosis	NN	A
.	.	A

The	DT	O
Warfarin	NNP	O
Re-Infarction	NNP	O
Study	NNP	O
(	(	O
WARIS	NNP	O
)	)	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
warfarin	NN	O
in	IN	O
survivors	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
75	CD	O
years	NNS	O
or	CC	O
less	JJR	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
test	VB	O
whether	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
warfarin	JJ	O
reduces	NNS	O
the	DT	O
risk	NN	PH
of	IN	O
death	NN	MO
,	,	MO
reinfarction	NN	MO
,	,	O
and	CC	O
thromboembolic	JJ	PH
morbidity	NN	PH
.	.	PH

A	DT	O
total	NN	O
of	IN	O
1918	CD	O
patients	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
participation	NN	O
;	:	O
1214	CD	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
mean	JJ	O
follow-up	NN	O
was	VBD	O
37	CD	O
months	NNS	O
.	.	O

Analyzed	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
,	,	O
123	CD	O
(	(	O
20	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	MO
,	,	O
versus	FW	O
94	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
,	,	O
a	DT	O
risk	NN	PH
reduction	NN	PH
of	IN	O
24	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.026	CD	O
)	)	O
.	.	O

Considering	VBG	O
patients	NNS	O
on	IN	O
treatment	NN	O
or	CC	O
within	IN	O
28	CD	O
days	NNS	O
after	IN	O
discontinuing	VBG	O
the	DT	O
test	NN	O
medication	NN	O
,	,	O
92	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	MO
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
60	CD	O
of	IN	O
the	DT	O
warfarin-treated	JJ	O
patients	NNS	O
,	,	O
a	DT	O
risk	NN	Ot
reduction	NN	Ot
of	IN	O
35	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Relapsing	VBG	PH
myocardial	JJ	PH
infarction	NN	PH
(	(	PH
fatal	JJ	PH
and	CC	PH
nonfatal	JJ	PH
)	)	PH
was	VBD	O
reduced	VBN	O
by	IN	O
43	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	PH
of	IN	PH
cerebrovascular	JJ	PH
attacks	NNS	PH
was	VBD	O
lower	RBR	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
(	(	O
16	CD	O
patients	NNS	O
)	)	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
41	CD	O
patients	NNS	O
)	)	O
,	,	O
a	DT	O
highly	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
61	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

Serious	JJ	A
bleeding	NN	A
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
taking	VBG	O
warfarin	NN	O
,	,	O
an	DT	O
incidence	NN	O
of	IN	O
0.6	CD	O
%	NN	O
per	IN	O
year	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
long-term	JJ	O
anticoagulant	JJ	O
therapy	NN	O
may	MD	O
be	VB	O
recommended	VBN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Conjugated	VBN	O
equine	JJ	O
estrogen	NN	O
influence	NN	O
on	IN	O
mammographic	JJ	PH
density	NN	PH
in	IN	O
postmenopausal	JJ	O
women	NNS	O
in	IN	O
a	DT	O
substudy	NN	O
of	IN	O
the	DT	O
women	NNS	O
's	POS	O
health	NN	O
initiative	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Increased	VBD	O
mammographic	JJ	PH
density	NN	PH
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
breast	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
reduced	JJ	O
sensitivity	NN	O
of	IN	O
screening	VBG	O
mammography	NN	O
and	CC	O
is	VBZ	O
related	VBN	O
to	TO	O
hormone	VB	O
exposure	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
conjugated	JJ	O
equine	NN	O
estrogens	NNS	O
(	(	O
CEEs	NNP	O
)	)	O
alone	RB	O
on	IN	O
mammographic	JJ	PH
density	NN	PH
in	IN	O
diverse	JJ	O
racial/ethnic	JJ	O
populations	NNS	O
are	VBP	O
not	RB	O
established	VBN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
CEE	NNP	O
alone	RB	O
on	IN	O
mammographic	JJ	PH
density	NN	PH
in	IN	O
a	DT	O
subsample	NN	O
of	IN	O
the	DT	O
Women	NNP	O
's	POS	O
Health	NNP	O
Initiative	NNP	O
(	(	O
WHI	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
participants	NNS	O
.	.	O

PATIENTS	NNS	O
AND	CC	O
METHODS	NNP	O
In	IN	O
the	DT	O
WHI	NNP	O
trial	NN	O
,	,	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
daily	VB	O
CEE	NNP	O
0.625	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
CEE	NNP	O
on	IN	O
mammographic	JJ	PH
percent	NN	PH
density	NN	PH
was	VBD	O
determined	VBN	O
over	IN	O
1	CD	O
and	CC	O
2	CD	O
years	NNS	O
in	IN	O
a	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
435	CD	O
racially	RB	O
and	CC	O
ethnically	RB	O
diverse	JJ	O
participants	NNS	O
from	IN	O
15	CD	O
of	IN	O
40	CD	O
WHI	NNP	O
clinics	NNS	O
.	.	O

RESULTS	NNP	O
Use	NNP	O
of	IN	O
CEE	NNP	O
resulted	VBD	O
in	IN	O
mean	JJ	O
increase	NN	O
in	IN	O
mammographic	JJ	PH
percent	NN	PH
density	NN	PH
of	IN	O
1.6	CD	O
percentage	NN	O
points	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.8	CD	O
to	TO	O
2.4	CD	O
)	)	O
at	IN	O
year	NN	O
1	CD	O
compared	VBN	O
with	IN	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
1.0	CD	O
percentage	NN	O
point	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-1.7	NNP	O
to	TO	O
-0.4	VB	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
persisted	VBD	O
for	IN	O
2	CD	O
years	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
increase	NN	O
of	IN	O
1.7	CD	O
percentage	NN	O
points	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.7	CD	O
to	TO	O
2.7	CD	O
)	)	O
versus	NN	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
1.2	CD	O
percentage	NN	O
points	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-1.8	NNP	O
to	TO	O
-0.5	VB	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
in	IN	O
the	DT	O
hormone	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

These	DT	O
effects	NNS	O
were	VBD	O
greater	JJR	O
in	IN	O
women	NNS	O
age	NN	O
60	CD	O
to	TO	O
79	CD	O
years	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
for	IN	O
interaction	NN	O
across	IN	O
age	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
CEE	NNP	O
results	NNS	O
in	IN	O
a	DT	O
modest	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
mammographic	JJ	PH
density	NN	PH
that	WDT	O
is	VBZ	O
sustained	VBN	O
over	IN	O
at	IN	O
least	JJS	O
a	DT	O
2-year	JJ	O
period	NN	O
.	.	O

The	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
the	DT	O
CEE	NNP	O
effect	NN	O
on	IN	O
mammographic	JJ	PH
density	NN	PH
remains	VBZ	O
to	TO	O
be	VB	O
determined	VBN	O
.	.	O

Combined	VBN	O
use	NN	O
of	IN	O
vasopressin	NN	O
and	CC	O
synthetic	JJ	O
hypothalamic	JJ	O
releasing	NN	O
factors	NNS	O
as	IN	O
a	DT	O
new	JJ	O
test	NN	O
of	IN	O
anterior	JJ	O
pituitary	JJ	O
function	NN	O
.	.	O

Nine	NNP	O
normal	JJ	O
volunteers	NNS	O
and	CC	O
15	CD	O
patients	NNS	O
with	IN	O
pituitary	JJ	O
disorders	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
combined	JJ	O
test	NN	O
of	IN	O
anterior	JJ	O
pituitary	JJ	O
function	NN	O
using	VBG	O
four	CD	O
hypothalamic	JJ	O
releasing	VBG	O
factors	NNS	O
and	CC	O
arginine	JJ	O
vasopressin	NN	O
.	.	O

Rapid	JJ	O
sequential	JJ	O
intravenous	JJ	O
infusions	NNS	O
of	IN	O
human	JJ	O
corticotrophin	NN	O
releasing	VBG	O
factor	NN	O
100	CD	O
micrograms	NNS	O
,	,	O
growth	NN	O
hormone	NN	O
releasing	VBG	O
factor	NN	O
100	CD	O
micrograms	NNS	O
,	,	O
luteinising	VBG	O
hormone	NN	O
releasing	VBG	O
hormone	NN	O
100	CD	O
micrograms	NNS	O
,	,	O
and	CC	O
thyrotrophin	IN	O
releasing	VBG	O
hormone	NN	O
200	CD	O
micrograms	NNS	O
were	VBD	O
administered	VBN	O
.	.	O

Arginine	NNP	O
vasopressin	NN	O
(	(	O
10	CD	O
pressor	NN	O
units	NNS	O
)	)	O
was	VBD	O
given	VBN	O
intramuscularly	RB	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
.	.	O

Plasma	NNP	O
or	CC	O
serum	NN	O
samples	NNS	O
were	VBD	O
assayed	VBN	O
for	IN	O
concentrations	NNS	O
of	IN	O
cortisol	NN	O
,	,	O
growth	NN	O
hormone	NN	O
,	,	O
luteinising	VBG	O
hormone	NN	O
,	,	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
,	,	O
prolactin	NN	O
,	,	O
and	CC	O
thyroid	JJ	O
stimulating	VBG	O
hormone	NN	O
at	IN	O
multiple	JJ	O
times	NNS	O
for	IN	O
120	CD	O
minutes	NNS	O
.	.	O

No	DT	O
troublesome	JJ	O
side	NN	ME
effects	NNS	ME
occurred	VBD	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
releasing	VBG	O
factor	NN	O
combined	VBD	O
test	NN	O
with	IN	O
arginine	JJ	O
vasopressin	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
the	DT	O
same	JJ	O
subjects	NNS	O
with	IN	O
a	DT	O
conventional	JJ	O
combined	JJ	O
test	NN	O
using	VBG	O
insulin	NN	O
together	RB	O
with	IN	O
thyrotrophin	JJ	O
releasing	VBG	O
hormone	NN	O
and	CC	O
luteinising	VBG	O
hormone	NN	O
releasing	VBG	O
hormone	NN	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
basal	NN	PH
and	CC	PH
peak	JJ	PH
concentrations	NNS	PH
of	IN	PH
luteinising	VBG	PH
hormone	NN	PH
,	,	PH
follicle	NN	PH
stimulating	VBG	PH
hormone	NN	PH
,	,	PH
thyroid	JJ	PH
stimulating	VBG	PH
hormone	NN	PH
,	,	PH
and	CC	PH
prolactin	NN	PH
.	.	PH

Both	DT	O
cortisol	NN	PH
and	CC	PH
growth	NN	PH
hormone	NN	PH
responses	VBZ	PH
to	TO	O
the	DT	O
releasing	VBG	O
factors	NNS	O
with	IN	O
arginine	JJ	O
vasopressin	NN	O
were	VBD	O
much	RB	O
greater	JJR	O
than	IN	O
those	DT	O
seen	VBN	O
with	IN	O
insulin	NN	O
induced	VBN	O
hypoglycaemia	NN	O
or	CC	O
the	DT	O
combined	JJ	O
releasing	NN	O
factors	NNS	O
without	IN	O
arginine	JJ	O
vasopressin	NN	O
.	.	O

Patients	NNS	O
with	IN	O
pituitary	JJ	PH
hypo-function	NN	PH
were	VBD	O
similarly	RB	O
recognised	VBN	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
rapid	JJ	O
increase	NN	O
in	IN	O
all	DT	O
hormone	NN	ME
values	NNS	ME
with	IN	O
a	DT	O
peak	NN	O
usually	RB	O
by	IN	O
60	CD	O
minutes	NNS	O
.	.	O

In	IN	O
most	JJS	O
people	NNS	O
adequate	VBP	O
assessment	NN	O
of	IN	O
individual	JJ	O
hormone	NN	O
reserves	NNS	O
may	MD	O
be	VB	O
achieved	VBN	O
using	VBG	O
basal	NN	O
,	,	O
30	CD	O
minute	NN	O
,	,	O
and	CC	O
60	CD	O
minute	NN	O
samples	NNS	O
.	.	O

This	DT	O
new	JJ	O
combined	JJ	O
releasing	NN	O
factor	NN	O
test	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
,	,	O
rapid	JJ	O
,	,	O
and	CC	O
useful	JJ	O
test	NN	O
of	IN	O
anterior	JJ	O
pituitary	JJ	O
function	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
to	TO	O
assess	VB	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
multiple	JJ	PH
actinic	JJ	PH
keratoses	NNS	PH
.	.	O

BACKGROUND	NNP	O
Actinic	NNP	PH
keratoses	NNS	PH
(	(	PH
AKs	NNP	PH
)	)	PH
are	VBP	O
precancerous	JJ	O
epidermal	JJ	O
lesions	NNS	O
found	VBD	O
most	JJS	O
frequently	RB	O
on	IN	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
exposed	VBD	O
to	TO	O
the	DT	O
sun	NN	O
.	.	O

Several	JJ	O
case	NN	O
studies	NNS	O
published	VBN	O
recently	RB	O
have	VBP	O
indicated	VBN	O
that	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
,	,	O
currently	RB	O
licensed	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
,	,	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
imiquimod	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
AK	NNP	PH
.	.	O

DESIGN	NNP	O
Patients	NNPS	O
in	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
applied	VBD	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
or	CC	O
vehicle	NN	O
to	TO	O
AK	NNP	PH
lesions	NNS	PH
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
or	CC	O
until	IN	O
lesions	NNS	O
had	VBD	O
resolved	VBN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
an	DT	O
adverse	JJ	O
reaction	NN	O
,	,	O
application	NN	O
of	IN	O
imiquimod	NN	O
was	VBD	O
reduced	VBN	O
to	TO	O
1	CD	O
or	CC	O
2	CD	O
times	NNS	O
per	IN	O
week	NN	O
.	.	O

Rest	JJS	O
periods	NNS	O
were	VBD	O
also	RB	O
allowed	VBN	O
if	IN	O
necessary	JJ	O
.	.	O

SETTING	VB	O
A	DT	O
specialized	JJ	O
outpatient	NN	O
dermatology	NN	O
clinic	NN	O
within	IN	O
a	DT	O
state-funded	JJ	O
hospital	NN	O
in	IN	O
Germany	NNP	O
.	.	O

PATIENTS	VB	O
The	DT	O
study	NN	O
population	NN	O
was	VBD	O
aged	VBN	O
45	CD	O
to	TO	O
85	CD	O
years	NNS	O
.	.	O

Of	IN	O
52	CD	O
patients	NNS	O
screened	VBD	O
,	,	O
36	CD	O
men	NNS	O
and	CC	O
women	NNS	O
with	IN	O
AK	NNP	O
confirmed	VBN	O
by	IN	O
histological	JJ	O
diagnosis	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
histological	JJ	O
diagnosis	NN	O
for	IN	O
AK	NNP	O
,	,	O
if	IN	O
they	PRP	O
were	VBD	O
older	JJR	O
than	IN	O
85	CD	O
years	NNS	O
,	,	O
or	CC	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
comply	VB	O
with	IN	O
the	DT	O
protocol	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
responded	VBN	O
to	TO	O
a	DT	O
notice	NN	O
asking	VBG	O
for	IN	O
volunteers	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
number	NN	PH
and	CC	PH
appearance	NN	PH
of	IN	PH
lesions	NNS	PH
were	VBD	O
evaluated	VBN	O
before	RB	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

All	DT	O
adverse	JJ	A
effects	NNS	A
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Lesions	NNP	O
treated	VBD	O
with	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
were	VBD	O
clinically	RB	PH
cleared	VBN	PH
in	IN	O
21	CD	O
(	(	O
84	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
patients	NNS	O
and	CC	O
partially	RB	PH
cleared	VBN	PH
in	IN	O
2	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
.	.	O

Clearance	NN	PH
was	VBD	O
histologically	RB	O
confirmed	VBN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
last	JJ	O
application	NN	O
of	IN	O
imiquimod	NN	O
in	IN	O
all	DT	O
patients	NNS	O
clinically	RB	O
diagnosed	VBN	O
as	IN	O
lesion	NN	O
free	NN	O
.	.	O

Only	RB	O
10	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
were	VBD	O
clinically	RB	O
diagnosed	VBN	O
with	IN	O
recurrence	NN	O
1	CD	O
year	NN	O
after	IN	O
treatment	NN	O
.	.	O

No	DT	O
reduction	NN	PH
in	IN	PH
the	DT	PH
size	NN	PH
or	CC	PH
number	NN	PH
of	IN	PH
AK	NNP	PH
lesions	NNS	PH
was	VBD	O
observed	VBN	O
in	IN	O
vehicle-treated	JJ	O
patients	NNS	O
.	.	O

Adverse	JJ	O
effects	NNS	O
reported	VBN	O
by	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
included	VBD	O
erythema	NN	A
,	,	O
edema	NN	A
,	,	O
induration	NN	A
,	,	O
vesicles	NNS	A
,	,	O
erosion	NN	A
,	,	O
ulceration	NN	A
,	,	O
excoriation	NN	A
,	,	O
and	CC	O
scabbing	VBG	A
.	.	O

However	RB	O
,	,	O
imiquimod	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Ot
since	IN	O
all	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
12-week	JJ	O
treatment	NN	O
.	.	O

Only	RB	O
a	DT	O
few	JJ	O
,	,	O
mild	JJ	O
adverse	JJ	O
reactions	NNS	O
to	TO	O
the	DT	O
vehicle	NN	O
cream	NN	O
were	VBD	O
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
Application	NNP	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	PH
.	.	O

Analysis	NN	O
of	IN	O
face	NN	O
gaze	NN	O
in	IN	O
autism	NN	O
using	VBG	O
Bubbles	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
abnormal	JJ	O
social	JJ	O
functioning	NN	O
in	IN	O
autism	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
ability	NN	O
to	TO	O
direct	VB	O
eye	NN	O
gaze	NN	O
onto	IN	O
other	JJ	O
people	NNS	O
's	POS	O
faces	VBZ	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
gaze	NN	ME
onto	IN	ME
the	DT	ME
eye	NN	ME
and	CC	ME
mouth	JJ	ME
regions	NNS	ME
of	IN	ME
faces	VBZ	ME
,	,	O
and	CC	O
the	DT	O
visual	JJ	O
information	NN	O
that	WDT	O
was	VBD	O
present	JJ	O
within	IN	O
those	DT	O
regions	NNS	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
Bubbles	NNP	O
method	NN	O
to	TO	O
vary	VB	O
the	DT	O
facial	JJ	O
information	NN	O
available	JJ	O
on	IN	O
any	DT	O
given	VBN	O
trial	NN	O
by	IN	O
revealing	VBG	O
only	RB	O
small	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
measured	VBD	O
the	DT	O
eye	NN	ME
movements	NNS	ME
made	VBN	O
as	IN	O
participants	NNS	O
viewed	IN	O
these	DT	O
stimuli	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
ten	VB	O
IQ-	NNP	O
and	CC	O
age-matched	JJ	O
healthy	JJ	O
controls	NNS	O
,	,	O
eight	CD	O
participants	NNS	O
with	IN	O
autism	NN	O
showed	VBD	O
less	JJR	O
fixation	JJ	ME
specificity	NN	ME
to	TO	O
the	DT	O
eyes	NNS	O
and	CC	O
mouth	NN	O
,	,	O
a	DT	O
greater	JJR	O
tendency	NN	O
to	TO	O
saccade	VB	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
when	WRB	O
information	NN	O
was	VBD	O
present	JJ	O
in	IN	O
those	DT	O
regions	NNS	O
,	,	O
and	CC	O
abnormal	JJ	O
directionality	NN	O
of	IN	O
saccades	NNS	O
.	.	O

The	DT	O
findings	NNS	O
provide	VBP	O
novel	JJ	O
detail	NN	O
to	TO	O
the	DT	O
abnormal	JJ	O
way	NN	O
in	IN	O
which	WDT	O
people	NNS	O
with	IN	O
autism	NN	O
look	NN	O
at	IN	O
faces	VBZ	O
,	,	O
an	DT	O
impairment	NN	O
that	WDT	O
likely	JJ	O
influences	VBZ	O
all	DT	O
subsequent	JJ	O
face	NN	O
processing	NN	O
.	.	O

Action	NNP	O
observation	NN	O
treatment	NN	O
improves	VBZ	O
recovery	NN	O
of	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
:	:	O
evidence	NN	O
for	IN	O
a	DT	O
top-down	JJ	O
effect	NN	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
assess	VB	O
whether	IN	O
action	NN	O
observation	NN	O
treatment	NN	O
(	(	O
AOT	NNP	O
)	)	O
may	MD	O
also	RB	O
improve	VB	O
motor	NN	O
recovery	NN	O
in	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
physiotherapy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Department	NNP	O
of	IN	O
rehabilitation	NN	O
.	.	O

PARTICIPANTS	JJ	O
Patients	NNPS	O
(	(	O
N=60	NNP	O
)	)	O
admitted	VBD	O
to	TO	O
our	PRP$	O
department	NN	O
postorthopedic	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
case	NN	O
(	(	O
n=30	NN	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n=30	JJ	O
)	)	O
group	NN	O
.	.	O

Exclusion	NN	O
criteria	NNS	O
were	VBD	O
age	NN	O
18	CD	O
years	NNS	O
or	CC	O
younger	JJR	O
and	CC	O
90	CD	O
years	NNS	O
or	CC	O
older	JJR	O
,	,	O
Mini-Mental	JJ	O
State	NNP	O
Examination	NNP	O
score	NN	O
of	IN	O
21	CD	O
of	IN	O
30	CD	O
or	CC	O
lower	JJR	O
,	,	O
no	DT	O
ambulating	VBG	O
order	NN	O
,	,	O
advanced	JJ	O
vision	NN	O
impairment	NN	O
,	,	O
malignancy	NN	O
,	,	O
pneumonia	NN	O
,	,	O
or	CC	O
heart	NN	O
failure	NN	O
.	.	O

INTERVENTIONS	NNP	O
All	NNP	O
participants	NNS	O
underwent	JJ	O
conventional	JJ	O
physiotherapy	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
observe	VB	O
video	JJ	O
clips	NNS	O
showing	VBG	O
daily	JJ	O
actions	NNS	O
and	CC	O
to	TO	O
imitate	VB	O
them	PRP	O
afterward	RB	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
observe	VB	O
video	JJ	O
clips	NNS	O
with	IN	O
no	DT	O
motor	NN	O
content	NN	O
and	CC	O
to	TO	O
execute	VB	O
the	DT	O
same	JJ	O
actions	NNS	O
as	IN	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
afterward	RB	O
.	.	O

Participants	NNS	O
were	VBD	O
scored	VBN	O
on	IN	O
functional	JJ	O
scales	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
by	IN	O
a	DT	O
physician	NN	O
blinded	VBD	O
to	TO	O
group	NN	O
assignment	NN	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
MEASURES	NNP	O
Changes	NNP	PH
in	IN	PH
FIM	NNP	PH
and	CC	PH
Tinetti	NNP	PH
scale	NN	PH
scores	NNS	PH
,	,	PH
and	CC	PH
dependence	NN	PH
on	IN	PH
walking	VBG	PH
aids	NNS	PH
.	.	PH

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
clinical	JJ	Ot
and	CC	Ot
functional	JJ	Ot
scale	NN	Ot
scores	NNS	Ot
.	.	Ot

After	IN	O
treatment	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
scored	VBD	O
better	JJR	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	Ot
FIM	NNP	PH
total	NN	PH
score	NN	PH
,	,	O
P=.02	NNP	O
;	:	O
FIM	NNP	PH
motor	NN	PH
subscore	NN	PH
,	,	O
P=.001	NNP	O
;	:	O
Tinetti	NNP	PH
scale	NN	PH
score	NN	PH
,	,	O
P=.04	NNP	O
)	)	O
;	:	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
were	VBD	O
assigned	VBN	O
more	RBR	O
frequently	RB	Ot
to	TO	Ot
1	CD	Ot
crutch	NN	Ot
(	(	O
P=.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
physiotherapy	NN	O
,	,	O
AOT	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
present	JJ	O
results	NNS	O
strongly	RB	O
support	VB	O
top-down	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
treatment	NN	O
in	IN	O
motor	NN	O
recovery	NN	O
,	,	O
even	RB	O
in	IN	O
nonneurologic	JJ	O
patients	NNS	O
.	.	O

Capsaicin	NNP	O
jelly	RB	O
against	IN	O
migraine	NN	PA
pain	NN	PA
.	.	O

OBJECTIVE	NNP	O
Recent	NNP	O
studies	NNS	O
support	VBP	O
the	DT	O
role	NN	O
of	IN	O
extracranial	JJ	O
perivascular	JJ	O
afferents	NNS	O
in	IN	O
a	DT	O
substantial	JJ	O
percentage	NN	O
of	IN	O
migraineurs	NNS	O
.	.	O

Perivascular	JJ	O
afferent	JJ	O
fibres	NNS	O
of	IN	O
the	DT	O
superficial	JJ	O
temporal	JJ	O
artery	NN	O
contain	NN	O
peptides	NNS	O
,	,	O
like	IN	O
calcitonin	JJ	O
gene-related	JJ	O
peptide	NN	O
(	(	O
CGRP	NNP	O
)	)	O
and	CC	O
substance	NN	O
P	NNP	O
(	(	O
SP	NNP	O
)	)	O
.	.	O

CGRP	NNP	O
and	CC	O
SP	NNP	O
are	VBP	O
considered	VBN	O
relevant	JJ	O
in	IN	O
the	DT	O
genesis	NN	O
of	IN	O
migraine	NN	O
pain	NN	O
.	.	O

Capsaicin	NNP	O
is	VBZ	O
an	DT	O
agonist	NN	O
of	IN	O
the	DT	O
transient	NN	O
receptor	NN	O
potential	JJ	O
vanilloid	NN	O
type	NN	O
1	CD	O
.	.	O

It	PRP	O
causes	VBZ	O
membrane	JJ	O
depolarisation	NN	O
of	IN	O
sensory	JJ	O
neurons	NNS	O
,	,	O
which	WDT	O
release	VBP	O
CGRP	NNP	O
,	,	O
SP	NNP	O
and	CC	O
other	JJ	O
pain	NN	O
peptides	NNS	O
;	:	O
excitation	NN	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
refractory	NN	O
state	NN	O
,	,	O
causing	VBG	O
inactivation	NN	O
.	.	O

Topical	JJ	O
capsaicin	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
efficacious	JJ	O
in	IN	O
several	JJ	O
types	NNS	O
of	IN	O
neuropathic	JJ	PA
pain	NN	PA
.	.	O

We	PRP	O
attempted	VBD	O
to	TO	O
verify	VB	O
whether	IN	O
topical	JJ	O
periarterial	JJ	O
capsaicin	NN	O
could	MD	O
ameliorate	VB	O
pain	NN	PA
in	IN	PA
absence	NN	PA
of	IN	PA
and	CC	PA
during	IN	PA
a	DT	PA
migraine	JJ	PA
attack	NN	PA
.	.	O

METHODS	NNP	O
On	IN	O
23	CD	O
migraineurs	NNS	O
showing	VBG	O
pain	NN	O
at	IN	O
pressure	NN	O
on	IN	O
scalp	NN	O
arteries	NNS	O
,	,	O
we	PRP	O
administered	VBD	O
topical	JJ	O
capsaicin	NN	O
0.1	CD	O
%	NN	O
or	CC	O
vaseline	NN	O
jelly	RB	O
on	IN	O
painful	JJ	O
arteries	NNS	O
in	IN	O
absence	NN	O
of	IN	O
migraine	JJ	O
attack	NN	O
.	.	O

In	IN	O
those	DT	O
having	VBG	O
pain	NN	O
reduction	NN	O
>	VBD	O
50	CD	O
%	NN	O
,	,	O
we	PRP	O
made	VBD	O
the	DT	O
same	JJ	O
comparison	NN	O
during	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
.	.	O

RESULTS	NNP	O
Topical	NNP	O
capsaicin	NN	O
caused	VBD	O
>	JJ	O
50	CD	O
%	NN	O
reduction	NN	O
of	IN	O
arterial	JJ	PA
pain	NN	PA
in	IN	O
absence	NN	O
of	IN	O
attack	NN	O
in	IN	O
17/23	CD	O
patients	NNS	O
,	,	O
as	IN	O
opposed	VBN	O
to	TO	O
two	CD	O
with	IN	O
vaseline	NN	O
.	.	O

During	IN	O
attacks	NNS	O
of	IN	O
mild-	NN	O
to	TO	O
moderate-intensity	NN	O
,	,	O
>	VB	O
50	CD	O
%	NN	O
improvement	NN	O
was	VBD	O
obtained	VBN	O
in	IN	O
11/17	CD	O
with	IN	O
capsaicin	NN	O
and	CC	O
in	IN	O
one	CD	O
with	IN	O
vaseline	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
referring	VBG	O
to	TO	O
a	DT	O
small	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
,	,	O
our	PRP$	O
data	NNS	O
show	VBP	O
that	IN	O
topical	JJ	O
capsaicin	NN	O
may	MD	O
relieve	VB	O
arterial	JJ	PA
pain	NN	PA
in	IN	O
absence	NN	O
of	IN	O
and	CC	O
during	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
in	IN	O
a	DT	O
substantial	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
scalp	JJ	O
arterial	JJ	O
tenderness	NN	O
.	.	O

More	RBR	O
active	JJ	O
capsacinoids	NNS	O
might	MD	O
be	VB	O
tried	VBN	O
in	IN	O
the	DT	O
future	NN	O
and	CC	O
could	MD	O
provide	VB	O
a	DT	O
new	JJ	O
method	NN	O
for	IN	O
treating	VBG	O
migraine	NN	O
attacks	NNS	O
.	.	O

Bioequivalence	NNP	O
evaluation	NN	O
of	IN	O
a	DT	O
fixed	VBN	O
dose	JJ	O
combination	NN	O
lamivudine	NN	O
+	NNP	O
stavudine	NN	O
tablet	NN	O
with	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
lamivudine	JJ	O
tablet	NN	O
and	CC	O
stavudine	NN	O
capsule	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
rate	NN	PH
and	CC	PH
extent	NN	PH
of	IN	PH
absorption	NN	PH
of	IN	O
a	DT	O
fixed	VBN	O
dose	JJ	O
combination	NN	O
tablet	NN	O
of	IN	O
lamivudine	NN	O
(	(	O
CAS	NNP	O
134678-17-4	CD	O
)	)	O
and	CC	O
stavudine	NN	O
(	(	O
CAS	NNP	O
3056-17-5	CD	O
)	)	O
with	IN	O
the	DT	O
concurrent	JJ	O
administration	NN	O
of	IN	O
lamivudine	JJ	O
tablet	NN	O
and	CC	O
stavudine	NN	O
capsule	NN	O
in	IN	O
24	CD	O
healthy	JJ	O
volunteers	NNS	O
under	IN	O
fasting	VBG	O
conditions	NNS	O
.	.	O

The	DT	O
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
test	NN	O
or	CC	O
reference	NN	O
treatment	NN	O
,	,	O
with	IN	O
the	DT	O
two	CD	O
treatment	NN	O
periods	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
7	CD	O
days	NNS	O
.	.	O

Plasma	NNP	PH
samples	NNS	PH
were	VBD	O
analyzed	VBN	O
for	IN	O
both	DT	O
analytes	NNS	O
lamivudine	VBP	O
and	CC	O
stavudine	VBP	O
by	IN	O
a	DT	O
validated	JJ	O
analytical	JJ	O
method	NN	O
.	.	O

Since	IN	O
the	DT	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
test/reference	NN	PH
mean	JJ	O
ratio	NN	O
of	IN	O
the	DT	O
In-transformed	NNP	O
pharmacokinetic	JJ	O
variables	NNS	O
C	NNP	PH
(	(	PH
max	NN	PH
)	)	PH
AUC	NNP	PH
(	(	PH
0-t	JJ	PH
)	)	PH
and	CC	PH
AUC	NNP	PH
(	(	PH
0-infinity	NN	PH
)	)	PH
were	VBD	O
clearly	RB	O
within	IN	O
the	DT	O
conventional	JJ	O
bioequivalence	NN	O
range	NN	O
of	IN	O
80	CD	O
%	NN	O
to	TO	O
125	CD	O
%	NN	O
,	,	O
the	DT	O
two	CD	O
treatments	NNS	O
were	VBD	O
considered	VBN	O
bioequivalent	NN	O
.	.	O

The	DT	O
safety	NN	Ot
profiles	NNS	Ot
of	IN	O
both	DT	O
the	DT	O
test	NN	O
and	CC	O
reference	NN	O
formulations	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

Multimodal	NNP	O
therapy	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
primary	JJ	O
,	,	O
nonmetastatic	JJ	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
of	IN	O
bone	NN	O
:	:	O
an	DT	O
Intergroup	NNP	O
Study	NNP	O
.	.	O

A	NNP	O
randomized	JJ	O
study	NN	O
of	IN	O
264	CD	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
localized	JJ	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
of	IN	O
bone	NN	O
was	VBD	O
undertaken	VBN	O
between	IN	O
1973	CD	O
and	CC	O
1978	CD	O
by	IN	O
83	CD	O
institutions	NNS	O
of	IN	O
three	CD	O
national	JJ	O
study	NN	O
groups	NNS	O
:	:	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
,	,	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
,	,	O
and	CC	O
Cancer	NNP	O
and	CC	O
Leukemia	NNP	O
Group	NNP	O
B	NNP	O
.	.	O

The	DT	O
Intergroup	NNP	O
Study	NNP	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
addition	NN	O
of	IN	O
adriamycin	NN	O
(	(	O
ADR	NNP	O
)	)	O
or	CC	O
bilateral	JJ	O
pulmonary	JJ	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
to	TO	O
vincristine	VB	O
,	,	O
dactinomycin	NN	O
,	,	O
and	CC	O
cyclophosphamide	NN	O
(	(	O
VAC	NNP	O
therapy	NN	O
)	)	O
would	MD	O
improve	VB	MO
survival	NN	MO
and	CC	PH
reduce	VB	PH
local	JJ	PH
recurrences	NNS	PH
and	CC	PH
metastases	NNS	PH
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
RT	NNP	O
to	TO	O
the	DT	O
primary	JJ	O
lesion	NN	O
,	,	O
and	CC	O
the	DT	O
survival	NN	MO
rate	NN	MO
after	IN	O
3	CD	O
years	NNS	O
was	VBD	O
65	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
effective	JJ	O
treatment	NN	O
regimen	NNS	O
was	VBD	O
VAC	NNP	O
plus	CC	O
ADR	NNP	O
;	:	O
74	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
free	JJ	O
of	IN	O
disease	NN	O
at	IN	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
lengths	NNS	PH
of	IN	PH
disease-free	JJ	PH
status	NN	PH
and	CC	PH
survival	NN	PH
of	IN	PH
patients	NNS	PH
treated	VBN	O
with	IN	O
VAC	NNP	O
plus	CC	O
ADR	NNP	O
or	CC	O
VAC	NNP	O
plus	CC	O
RT	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

However	RB	O
,	,	O
both	DT	O
regimens	NNS	O
were	VBD	O
significantly	RB	O
superior	JJ	O
to	TO	O
treatment	NN	O
with	IN	O
VAC	NNP	O
alone	RB	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
ADR	NNP	O
or	CC	O
bilateral	JJ	O
pulmonary	JJ	O
RT	NNP	O
to	TO	O
VAC	NNP	O
was	VBD	O
highly	RB	Ot
advantageous	JJ	Ot
to	TO	O
patients	NNS	O
with	IN	O
nonpelvic	JJ	O
primaries	NNS	O
.	.	O

Bone	NN	O
and	CC	O
lung	NN	O
were	VBD	O
the	DT	O
major	JJ	O
sites	NNS	O
of	IN	O
distant	JJ	O
relapse	NN	O
,	,	O
but	CC	O
the	DT	O
addition	NN	O
of	IN	O
bilateral	JJ	O
pulmonary	JJ	O
RT	NNP	O
showed	VBD	O
no	DT	Ot
advantage	NN	Ot
over	IN	O
that	DT	O
of	IN	O
ADR	NNP	O
in	IN	O
reducing	VBG	O
the	DT	O
occurrence	NN	PH
of	IN	PH
lung	NN	PH
metastases	NNS	PH
.	.	PH

These	DT	O
recent	JJ	O
results	NNS	O
should	MD	O
eliminate	VB	O
some	DT	O
of	IN	O
the	DT	O
pessimism	NN	O
that	WDT	O
has	VBZ	O
accompanied	VBN	O
a	DT	O
diagnosis	NN	O
of	IN	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
although	IN	O
distant	JJ	O
metastases	NNS	O
continued	VBD	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
reason	NN	O
for	IN	O
failure	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
this	DT	O
tumor	NN	O
.	.	O

Survival	NN	O
of	IN	O
these	DT	O
patients	NNS	O
can	MD	O
be	VB	O
improved	VBN	O
through	IN	O
well-controlled	JJ	O
clinical	JJ	O
trials	NNS	O
designed	VBN	O
to	TO	O
determine	VB	O
optimal	JJ	O
adjuvant	JJ	O
chemotherapy	NN	O
and	CC	O
treatment	NN	O
of	IN	O
the	DT	O
primary	JJ	O
lesion	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
valsartan/hydrochlorothiazide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
or	CC	O
stage-2	JJ	O
hypertension	NN	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
6-week	JJ	O
,	,	O
multicenter	NN	O
,	,	O
double-blind	NN	O
study	NN	O
examined	VBD	O
the	DT	O
benefits	NNS	O
of	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
combination	NN	O
valsartan/hydrochlorothiazide	NN	O
(	(	O
HCTZ	NNP	O
)	)	O
compared	VBN	O
with	IN	O
initial	JJ	O
valsartan	NNS	O
monotherapy	NN	O
for	IN	O
648	CD	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
or	CC	O
stage-2	JJ	O
hypertension	NN	O
(	(	O
age=52.6+/-10	JJ	O
years	NNS	O
;	:	O
54	CD	O
%	NN	O
male	NN	O
;	:	O
baseline	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
=161/98	VBP	O
mm	JJ	O
Hg	NNP	O
,	,	O
32	CD	O
%	NN	O
stage	NN	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
valsartan	VB	O
80	CD	O
mg	NN	O
(	(	O
V-low	NNP	O
)	)	O
,	,	O
valsartan	$	O
160	CD	O
mg	NN	O
(	(	O
V-high	NNP	O
)	)	O
or	CC	O
valsartan/HCTZ	$	O
160/12.5	CD	O
mg	NN	O
(	(	O
V/HCTZ	NNP	O
)	)	O
,	,	O
and	CC	O
electively	RB	O
titrated	VBN	O
after	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
4	CD	O
to	TO	O
the	DT	O
next	JJ	O
dosage	NN	O
level	NN	O
(	(	O
maximum	JJ	O
dose	NN	O
valsartan/HCTZ	NN	O
160/25	CD	O
mg	NN	O
)	)	O
if	IN	O
BP	NNP	O
remained	VBD	O
>	JJ	O
140/90	CD	O
mm	NN	O
Hg	NNP	O
.	.	O

At	IN	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
initiated	VBN	O
with	IN	O
V/HCTZ	NNP	O
required	VBD	O
less	JJR	Ot
titration	JJ	Ot
steps	NNS	Ot
compared	VBN	O
with	IN	O
the	DT	O
initial	JJ	O
valsartan	NN	O
monotherapy	NN	O
groups	NNS	O
(	(	O
63	CD	O
vs	RB	O
86	CD	O
%	NN	O
required	VBN	O
titration	NN	O
by	IN	O
study	JJ	O
end	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
reached	VBD	O
the	DT	O
target	NN	O
BP	NNP	PH
goal	NN	PH
of	IN	O
<	$	O
140/90	CD	O
mm	NN	O
Hg	NNP	O
in	IN	O
a	DT	O
shorter	JJ	O
period	NN	O
of	IN	O
time	NN	O
(	(	O
2.8	CD	O
weeks	NNS	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
vs	NN	O
V-low	NNP	O
(	(	O
4.3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
V-high	NNP	O
(	(	O
3.9	CD	O
weeks	NNS	O
)	)	O
.	.	O

Initial	JJ	O
combination	NN	O
therapy	NN	O
was	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
BP	NNP	PH
control	NN	PH
rates	NNS	PH
and	CC	O
greater	JJR	O
reductions	NNS	Ot
in	IN	Ot
both	DT	Ot
systolic	JJ	Ot
and	CC	Ot
diastolic	JJ	Ot
BP	NNP	Ot
from	IN	O
baseline	NN	O
(	(	O
63	CD	O
%	NN	O
,	,	O
-27.7+/-13/-15.1+/-8	NNP	O
mm	NNP	O
Hg	NNP	O
)	)	O
compared	VBN	O
with	IN	O
V-low	NNP	O
(	(	O
46	CD	O
%	NN	O
,	,	O
-21.2+/-13/-11.4+/-8	NNP	O
mm	NNP	O
Hg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
or	CC	O
V-high	NNP	O
(	(	O
51	CD	O
%	NN	O
,	,	O
-24.0+/-13/-12.0+/-10	NNP	O
mm	NNP	O
Hg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Overall	JJ	O
and	CC	O
drug-related	JJ	A
AEs	NNP	A
were	VBD	O
mild	JJ	O
to	TO	O
moderate	VB	O
and	CC	O
were	VBD	O
similar	JJ	O
between	IN	O
V/HCTZ	NNP	O
(	(	O
53.1	CD	O
and	CC	O
14.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
two	CD	O
monotherapy	NN	O
groups	NNS	O
,	,	O
V-low	NNP	O
(	(	O
50.5	CD	O
and	CC	O
13.8	CD	O
%	NN	O
)	)	O
and	CC	O
V-high	NNP	O
(	(	O
50.7	CD	O
and	CC	O
11.8	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
initiating	VBG	O
therapy	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
valsartan	NN	O
and	CC	O
low-dose	JJ	O
HCTZ	NNP	O
results	NNS	O
in	IN	O
early	JJ	Ot
,	,	Ot
improved	JJ	Ot
BP	NNP	PH
efficacy	NN	PH
with	IN	O
similar	JJ	O
tolerability	NN	Ot
as	IN	O
compared	VBN	O
with	IN	O
starting	VBG	O
treatment	NN	O
with	IN	O
a	DT	O
low	JJ	O
or	CC	O
higher	JJR	O
dose	NN	O
of	IN	O
valsartan	NN	O
for	IN	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
and	CC	O
stage-2	JJ	O
hypertension	NN	O
.	.	O

Impact	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
on	IN	O
inflammatory	JJ	PH
markers	NNS	PH
in	IN	O
African	JJ	O
Americans	NNPS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
four-arm	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

African	JJ	O
Americans	NNPS	O
have	VBP	O
a	DT	O
disproportionate	JJ	O
burden	NN	O
of	IN	O
inflammation-associated	JJ	O
chronic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
and	CC	O
lower	JJR	O
circulating	NN	O
levels	NNS	O
of	IN	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
(	(	O
cholecalciferol	NN	O
)	)	O
supplementation	NN	O
on	IN	O
inflammatory	JJ	PH
markers	NNS	PH
is	VBZ	O
uncertain	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
supplemental	JJ	O
oral	JJ	O
vitamin	NN	O
D	NNP	O
(	(	O
placebo	NN	O
,	,	O
1,000	CD	O
,	,	O
2,000	CD	O
,	,	O
or	CC	O
4,000	CD	O
IU/day	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
orally	RB	O
for	IN	O
3	CD	O
months	NNS	O
)	)	O
in	IN	O
328	CD	O
African	JJ	O
Americans	NNPS	O
(	(	O
median	JJ	O
age	NN	O
,	,	O
51	CD	O
years	NNS	O
)	)	O
of	IN	O
public	JJ	O
housing	NN	O
communities	NNS	O
in	IN	O
Boston	NNP	O
,	,	O
MA	NNP	O
,	,	O
who	WP	O
were	VBD	O
enrolled	VBN	O
over	RP	O
three	CD	O
consecutive	JJ	O
winter	NN	O
periods	NNS	O
(	(	O
2007-2010	JJ	O
)	)	O
.	.	O

Change	NN	O
from	IN	O
0	CD	O
to	TO	O
3	CD	O
months	NNS	O
of	IN	O
plasma	NN	PH
levels	NNS	PH
of	IN	PH
25	CD	PH
(	(	PH
OH	NNP	PH
)	)	PH
D	NNP	PH
,	,	O
high-sensitivity	JJ	PH
C-reactive	JJ	PH
protein	NN	PH
(	(	PH
CRP	NNP	PH
)	)	PH
,	,	PH
interleukin	FW	PH
(	(	PH
IL	NNP	PH
)	)	PH
-6	NN	PH
,	,	O
IL-10	NNP	PH
,	,	O
and	CC	O
soluble	JJ	O
TNF-?	NNP	O
receptor	NN	O
type	NN	O
2	CD	O
(	(	O
sTNF-R2	NN	O
)	)	O
in	IN	O
292	CD	O
(	(	O
89	CD	O
%	NN	O
)	)	O
participants	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Overall	NNP	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
CRP	NNP	PH
,	,	O
IL-6	NNP	PH
,	,	PH
IL-10	NNP	PH
,	,	O
and	CC	O
sTNF-R2	NNS	PH
were	VBD	O
observed	VBN	O
after	IN	O
the	DT	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
period	NN	O
.	.	O

Baseline	NNP	O
CRP	NNP	O
was	VBD	O
significantly	RB	O
inversely	RB	O
associated	VBN	O
with	IN	O
the	DT	O
baseline	NN	PH
25	CD	PH
(	(	PH
OH	NNP	PH
)	)	PH
D	NNP	PH
level	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
unadjusted	JJ	O
and	CC	O
adjusted	JJ	O
models	NNS	O
.	.	O

An	DT	O
interaction	NN	O
between	IN	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
outcome	JJ	O
change	NN	O
in	IN	O
log	NN	O
CRP	NNP	O
(	(	O
month	NN	O
3-month	RB	O
0	CD	O
;	:	O
P	NNP	O
for	IN	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Within	IN	O
an	DT	O
unselected	JJ	O
population	NN	O
of	IN	O
African	JJ	O
Americans	NNPS	O
,	,	O
short-term	JJ	O
exposure	NN	O
to	TO	O
vitamin	VB	O
D	NNP	O
supplementation	NN	O
produced	VBD	O
no	DT	O
change	NN	O
in	IN	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
strong	JJ	O
independent	JJ	O
association	NN	O
of	IN	O
CRP	NNP	O
with	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
status	NN	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
of	IN	O
longer	JJR	O
supplemental	JJ	O
vitamin	NN	O
D3	NNP	O
duration	NN	O
are	VBP	O
necessary	JJ	O
to	TO	O
examine	VB	O
the	DT	O
complex	JJ	O
influence	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
on	IN	O
CRP	NNP	O
and	CC	O
other	JJ	O
chronic	JJ	O
inflammatory	NN	O
cytokines	NNS	O
for	IN	O
possible	JJ	O
reduction	NN	O
of	IN	O
cancer	NN	O
health	NN	O
disparities	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
.	.	O

[	JJ	O
Local	NNP	O
therapy	NN	O
of	IN	O
grade	NN	O
1	CD	O
and	CC	O
2	CD	O
hemorrhoids	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
a	DT	O
combination	NN	O
preparation	NN	O
with	IN	O
standardized	JJ	O
blood	NN	O
leech	NN	O
extract	NN	O
]	NNP	O
.	.	O

AIMS	NNP	O
Testing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
topical	JJ	O
combination	NN	O
preparation	NN	O
containing	VBG	O
standardized	VBN	O
leech	JJ	O
extract	NN	O
,	,	O
polidocanol	NN	O
and	CC	O
allantoin	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Placebo-controlled	NNP	O
,	,	O
double-blind	NN	O
study	NN	O
in	IN	O
80	CD	O
patients	NNS	O
with	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
;	:	O
duration	NN	O
of	IN	O
treatment	NN	O
one	CD	O
week	NN	O
;	:	O
examinations	NNS	O
performed	VBD	O
on	IN	O
admission	NN	O
and	CC	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
.	.	O

RESULTS	VB	O
Both	DT	O
the	DT	O
subjective	NN	PH
and	CC	PH
objective	JJ	PH
symptoms	NNS	PH
and	CC	PH
signs	NNS	PH
improved	VBN	O
during	IN	O
the	DT	O
one	CD	O
week	NN	O
of	IN	O
treatment	NN	O
statistically	RB	O
significantly	RB	O
more	RBR	O
rapidly	RB	O
under	IN	O
the	DT	O
test	NN	O
preparation	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Histologically	NNP	O
demonstrable	JJ	O
signs	NNS	O
of	IN	O
inflammation	NN	PH
were	VBD	O
more	JJR	O
clearly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

No	DT	O
side	NN	A
effects	NNS	A
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
good	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
topical	JJ	O
therapeutic	JJ	O
preparation	NN	O
in	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
have	VBP	O
been	VBN	O
convincingly	RB	O
demonstrated	VBN	O
.	.	O

Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
:	:	O
an	DT	O
RCT	NNP	O
of	IN	O
a	DT	O
parenting	VBG	O
program	NN	O
with	IN	O
parents	NNS	O
of	IN	O
a	DT	O
child	NN	O
diagnosed	VBN	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Whilst	IN	O
the	DT	O
Triple	NNP	O
P	NNP	O
Positive	NNP	O
Parenting	NNP	O
Program	NNP	O
has	VBZ	O
a	DT	O
large	JJ	O
evidence	NN	O
base	NN	O
(	(	O
Sanders	NNP	O
,	,	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Family	NNP	O
Psychology	NNP	O
Review	NNP	O
2:71-90	CD	O
,	,	O
1999	CD	O
;	:	O
Sanders	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Consulting	NNP	O
and	CC	O
Clinical	NNP	O
Psychology	NNP	O
68:624-640	CD	O
,	,	O
2000	CD	O
)	)	O
and	CC	O
preliminary	JJ	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
also	RB	O
efficacious	JJ	O
(	(	O
Roberts	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Adolescent	NNP	O
Psychology	NNP	O
,	,	O
35	CD	O
(	(	O
2	CD	O
)	)	O
:180-193	NN	O
,	,	O
2006	CD	O
)	)	O
,	,	O
to	TO	O
date	NN	O
Stepping	NNP	O
Stones	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
with	IN	O
the	DT	O
ASD	NNP	O
population	NN	O
.	.	O

Fifty-nine	JJ	O
families	NNS	O
with	IN	O
a	DT	O
child	NN	O
with	IN	O
ASD	NNP	O
aged	VBD	O
between	IN	O
2	CD	O
and	CC	O
9	CD	O
participated	VBN	O
in	IN	O
this	DT	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	ME
reports	NNS	ME
of	IN	ME
child	JJ	ME
behaviour	NN	ME
and	CC	ME
parenting	NN	ME
styles	NNS	ME
with	IN	ME
the	DT	ME
treatment	NN	ME
effects	NNS	ME
for	IN	ME
child	NN	ME
behaviour	NN	ME
,	,	ME
parental	NN	ME
over	IN	ME
reactivity	NN	ME
and	CC	ME
parental	JJ	ME
verbosity	NN	ME
being	VBG	O
maintained	VBN	O
at	IN	O
follow-up	JJ	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Further	RBR	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	ME
satisfaction	NN	ME
and	CC	ME
conflict	NN	ME
about	RB	ME
parenting	VBG	ME
as	RB	O
well	RB	O
as	IN	O
a	DT	O
sleeper	JJ	ME
effect	NN	ME
for	IN	ME
parental	JJ	ME
efficacy	NN	ME
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
a	DT	O
promising	JJ	O
intervention	NN	O
for	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Limitations	NNS	O
and	CC	O
future	JJ	O
research	NN	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

Different	NNP	O
aprotinin	NN	O
applications	NNS	O
influencing	VBG	O
hemostatic	JJ	O
changes	NNS	O
in	IN	O
orthotopic	NN	O
liver	NN	O
transplantation	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
different	JJ	O
aprotinin	NN	O
applications	NNS	O
on	IN	O
hemostatic	JJ	O
changes	NNS	O
and	CC	O
blood	NN	O
product	NN	O
requirements	NNS	O
in	IN	O
orthotopic	JJ	O
liver	NN	O
transplantation	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
open	JJ	O
,	,	O
and	CC	O
randomized	VBD	O
study	NN	O
.	.	O

From	IN	O
November	NNP	O
1989	CD	O
to	TO	O
June	NNP	O
1990	CD	O
,	,	O
13	CD	O
patients	NNS	O
received	VBD	O
aprotinin	RB	O
as	IN	O
a	DT	O
bolus	NN	O
of	IN	O
0.5	CD	O
Mill	NNP	O
.	.	O

Kallikrein	NNP	O
inactivator	JJ	O
units	NNS	O
(	(	O
KIU	NNP	O
)	)	O
on	IN	O
three	CD	O
occasions	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
an	DT	O
OLT	NNP	O
,	,	O
whereas	RB	O
10	CD	O
other	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
continuous	JJ	O
aprotinin	JJ	O
infusion	NN	O
of	IN	O
0.1-0.4	JJ	O
Mill	NNP	O
.	.	O

KIU/hr	NNP	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
reperfusion	NN	O
of	IN	O
the	DT	O
graft	NN	PH
liver	NN	PH
,	,	PH
signs	NNS	PH
of	IN	PH
hyperfibrinolysis	NN	PH
,	,	O
measured	VBN	O
by	IN	O
thrombelastography	NN	O
,	,	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Tissue-type	JJ	PH
plasminogen	NN	PH
activator	NN	PH
(	(	PH
t-PA	JJ	PH
)	)	PH
activity	NN	PH
increased	VBD	O
during	IN	O
the	DT	O
anhepatic	JJ	O
phase	NN	O
but	CC	O
to	TO	O
a	DT	O
significantly	RB	O
lesser	JJR	O
extent	NN	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Blood	NNP	PH
product	NN	PH
requirements	NNS	PH
during	IN	O
OLT	NNP	O
were	VBD	O
tendentiously	RB	O
higher	JJR	O
in	IN	O
the	DT	O
bolus	NN	O
group	NN	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
packed	JJ	PH
red	JJ	PH
blood	NN	PH
cells	NNS	PH
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
fresh	JJ	O
frozen	NN	O
plasma	NN	Ot
requirements	NNS	Ot
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
23	CD	O
patients	NNS	O
have	VBP	O
survived	VBN	MO
,	,	O
and	CC	O
only	RB	O
one	CD	O
woman	NN	O
of	IN	O
each	DT	O
group	NN	O
required	VBN	O
retransplantation	NN	PH
due	JJ	O
to	TO	O
severe	VB	O
host-versus-graft	JJ	PH
reactions	NNS	PH
.	.	PH

Furthermore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
perfusate	NN	O
of	IN	O
the	DT	O
graft	NN	O
liver	NN	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
detected	JJ	O
signs	NNS	O
of	IN	O
a	DT	O
decreased	JJ	O
t-PA	JJ	PH
release	NN	PH
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
demonstrate	VBP	O
an	DT	O
advantage	NN	O
of	IN	O
aprotinin	NN	O
given	VBN	O
as	IN	O
continuous	JJ	O
infusion	NN	O
over	IN	O
bolus	JJ	O
application	NN	O
in	IN	O
OLT	NNP	O
.	.	O

Making	VBG	O
the	DT	O
connection	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
at	IN	O
school	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
interventions	NNS	O
for	IN	O
improving	VBG	O
the	DT	O
social	JJ	ME
skills	NNS	ME
of	IN	O
high	JJ	O
functioning	VBG	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
general	JJ	O
education	NN	O
classrooms	NNS	O
.	.	O

One	CD	O
intervention	NN	O
involved	VBN	O
a	DT	O
peer-mediated	JJ	O
approach	NN	O
(	(	O
PEER	NNP	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
involved	VBD	O
a	DT	O
child-assisted	JJ	O
approach	NN	O
(	(	O
CHILD	NNP	O
)	)	O
.	.	O

METHOD	PDT	O
The	DT	O
two	CD	O
interventions	NNS	O
were	VBD	O
crossed	VBN	O
in	IN	O
a	DT	O
2	CD	O
?	.	O
2	CD	O
factorial	JJ	O
design	NN	O
yielding	VBG	O
control	NN	O
,	,	O
PEER	NNP	O
,	,	O
CHILD	NNP	O
,	,	O
and	CC	O
both	DT	O
PEER	NNP	O
and	CC	O
CHILD	NNP	O
conditions	NNS	O
.	.	O

Sixty	NNP	O
children	NNS	O
participated	VBD	O
from	IN	O
56	CD	O
classrooms	NNS	O
in	IN	O
30	CD	O
schools	NNS	O
.	.	O

Interventions	NNS	O
involved	VBD	O
12	CD	O
sessions	NNS	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
self	NN	O
,	,	O
peer	NN	O
and	CC	O
teacher	JJR	O
reports	NNS	O
of	IN	O
social	JJ	O
skills	NNS	O
and	CC	O
independent	JJ	O
weekly	JJ	O
observations	NNS	O
of	IN	O
children	NNS	O
on	IN	O
their	PRP$	O
school	NN	O
playground	NN	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
social	JJ	O
network	NN	O
salience	NN	O
,	,	O
number	NN	O
of	IN	O
friendship	JJ	O
nominations	NNS	O
,	,	O
teacher	JJ	O
report	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
in	IN	O
the	DT	O
classroom	NN	O
,	,	O
and	CC	O
decreased	JJ	O
isolation	NN	O
on	IN	O
the	DT	O
playground	NN	O
for	IN	O
children	NNS	O
who	WP	O
received	VBD	O
PEER	NNP	O
interventions	NNS	O
.	.	O

Changes	NNS	O
obtained	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
persisted	VBD	O
to	TO	O
the	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
significant	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
peer	JJ	O
social	JJ	O
connections	NNS	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
general	JJ	O
education	NN	O
classrooms	NNS	O
with	IN	O
a	DT	O
brief	JJ	O
intervention	NN	O
,	,	O
and	CC	O
that	IN	O
these	DT	O
gains	NNS	O
persist	VBP	O
over	IN	O
time	NN	O
.	.	O

Why	WRB	O
were	VBD	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
Heart	NNP	O
Outcomes	NNP	O
Prevention	NNP	O
Evaluation	NNP	O
(	(	O
HOPE	NNP	O
)	)	O
trial	NN	O
so	IN	O
astounding	VBG	O
?	.	O
The	DT	O
Heart	NNP	O
Outcomes	NNP	O
Prevention	NNP	O
Evaluation	NNP	O
(	(	O
HOPE	NNP	O
)	)	O
study	NN	O
was	VBD	O
important	JJ	O
because	IN	O
it	PRP	O
showed	VBD	O
the	DT	O
benefits	NNS	O
of	IN	O
ramipril	NN	O
-	:	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibitor	NN	O
-	:	O
in	IN	O
patients	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
ramipril	NN	O
significantly	RB	O
reduced	VBD	MO
the	DT	MO
rates	NNS	MO
of	IN	MO
death	NN	MO
,	,	O
myocardial	JJ	PH
infarction	NN	PH
,	,	O
stroke	NN	PH
,	,	O
coronary	JJ	PH
revascularization	NN	PH
,	,	O
cardiac	JJ	PH
arrest	NN	PH
and	CC	PH
heart	NN	PH
failure	NN	PH
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
risk	NN	O
of	IN	O
diabetes-related	JJ	PH
complications	NNS	PH
and	CC	O
of	IN	O
diabetes	NNS	PH
itself	PRP	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
vitamin	JJ	O
E	NN	O
were	VBD	O
also	RB	O
evaluated	VBN	O
,	,	O
but	CC	O
no	DT	PH
statistical	JJ	PH
benefits	NNS	PH
were	VBD	O
shown	VBN	O
.	.	O

The	DT	O
benefits	NNS	O
of	IN	O
ACE	NNP	O
inhibitor	NN	O
therapy	NN	O
that	WDT	O
were	VBD	O
observed	VBN	O
were	VBD	O
likely	JJ	O
due	JJ	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
mechanisms	NNS	O
,	,	O
not	RB	O
just	RB	O
a	DT	O
reduction	NN	PH
in	IN	PH
blood	NN	PH
pressure	NN	PH
.	.	O

The	DT	O
peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	JJ	O
agonist	NN	O
pioglitazone	NN	O
increases	VBZ	O
number	NN	PH
and	CC	PH
function	NN	PH
of	IN	PH
endothelial	JJ	PH
progenitor	NN	PH
cells	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVE	CC	O
Peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	NN	O
(	(	O
PPAR	NNP	O
gamma	NN	O
)	)	O
agonists	VBZ	O
(	(	O
thiazolidinediones	NNS	O
[	NNP	O
TZDs	NNP	O
]	NNP	O
)	)	O
are	VBP	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Bone	CD	O
marrow-derived	JJ	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
(	(	O
EPCs	NNP	O
)	)	O
improve	VB	O
vascular	JJ	PH
function	NN	PH
and	CC	O
predict	NN	O
cardiovascular	NN	PH
risk	NN	PH
.	.	PH

The	DT	O
effect	NN	O
of	IN	O
pioglitazone	NN	O
therapy	NN	O
on	IN	O
EPCs	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
patients	NNS	O
with	IN	O
documented	JJ	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

Of	IN	O
54	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
fasting	VBG	O
glucose	JJ	O
levels	NNS	O
,	,	O
18	CD	O
showed	VBD	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
and	CC	O
36	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
30-day	JJ	O
treatment	NN	O
with	IN	O
pioglitazone	NN	O
(	(	O
45	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
optimal	VB	O
medical	JJ	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
the	DT	O
TZD	NNP	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
adiponectin	JJ	PH
levels	NNS	PH
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
compliance	NN	O
(	(	O
11.4	CD	O
+/-	JJ	O
1.1	CD	O
to	TO	O
36.8	CD	O
+/-	JJ	O
2.1	CD	O
microg/ml	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

TZD	NNP	O
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
decreased	VBN	O
mean	JJ	PH
high-sensitivity	NN	PH
C-reactive	JJ	PH
protein	NN	PH
to	TO	O
43	CD	O
+/-	JJ	O
19	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Pioglitazone	NN	O
increased	VBD	O
CD34	NNP	PH
(	(	PH
+	NNP	PH
)	)	PH
/kinase	NN	PH
insert	JJ	PH
domain	NN	PH
receptor	NN	PH
(	(	PH
+	NNP	PH
)	)	PH
EPCs	NNP	PH
to	TO	O
142	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
and	CC	O
cultured	VBD	PH
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	JJ	PH
acetylated	JJ	PH
LDL	NNP	PH
(	(	PH
+	NNP	PH
)	)	PH
/lectin	NN	PH
(	(	PH
+	NNP	PH
)	)	PH
EPCs	NNP	PH
to	TO	O
180	CD	O
+/-	JJ	O
3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

EPC	JJ	PH
numbers	NNS	PH
were	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

TZD	NNP	O
increased	VBD	O
the	DT	O
SDF-1-induced	NNP	PH
migratory	NN	PH
capacity	NN	PH
to	TO	O
146	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
per	IN	O
EPC	NNP	O
number	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
upregulated	VBD	O
the	DT	O
clonogenic	JJ	PH
potential	NN	PH
of	IN	PH
EPCs	NNP	PH
,	,	O
increasing	VBG	O
the	DT	PH
colony-forming	JJ	PH
units	NNS	PH
to	TO	O
172	CD	O
+/-	JJ	O
12	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
cultured	JJ	O
human	JJ	O
EPCs	NNP	O
,	,	O
TZD	NNP	O
increased	VBD	O
EPC	NNP	PH
numbers	NNS	PH
and	CC	PH
migration	NN	PH
and	CC	PH
reduced	JJ	PH
NADPH-oxidase	NNP	PH
activity	NN	PH
.	.	PH

The	DT	O
TZD	NNP	O
effect	NN	O
was	VBD	O
reversed	VBN	O
by	IN	O
the	DT	O
PPAR	NNP	O
gamma	NN	O
antagonist	NN	O
GW9662	NNP	O
and	CC	O
mimicked	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
adiponectin	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
PPAR	NNP	O
gamma	NN	O
agonist	NN	O
pioglitazone	NN	O
increases	VBZ	O
the	DT	O
number	NN	PH
and	CC	PH
function	NN	PH
of	IN	PH
EPCs	NNP	PH
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
regenerative	NN	O
mechanism	NN	O
in	IN	O
atherosclerosis	NN	O
and	CC	O
is	VBZ	O
observed	VBN	O
in	IN	O
normoglycemic	JJ	O
individuals	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
Naftidrofuryl	NNP	O
on	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
in	IN	O
chronic	JJ	O
alcoholic	JJ	O
patients	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
intramuscular	JJ	O
Naftidrofuryl	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
32	CD	O
randomly	RB	O
selected	VBN	O
hospitalized	VBN	O
male	JJ	O
alcoholic	JJ	O
patients	NNS	O
with	IN	O
clinical	JJ	O
,	,	O
biochemical	JJ	O
and	CC	O
histological	JJ	O
evidence	NN	O
of	IN	O
hepatic	JJ	O
damage	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
received	VBD	O
the	DT	O
drug	NN	O
(	(	O
40	CD	O
mg	NN	O
in	IN	O
5	CD	O
ml	NN	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
and	CC	O
15	CD	O
patients	NNS	O
received	VBD	O
a	DT	O
placebo	NN	O
(	(	O
5	CD	O
ml	NN	O
in	IN	O
normal	JJ	O
saline	JJ	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
drug	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
adverse	JJ	A
side-effects	NNS	A
.	.	A

Naftidrofuryl	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
physiological	JJ	PH
function	NN	PH
of	IN	PH
the	DT	PH
liver	NN	PH
cells	NNS	PH
as	IN	PH
reflected	VBN	PH
by	IN	PH
indocyanine	NN	PH
green	NN	PH
(	(	PH
ICG	NNP	PH
)	)	PH
clearance	NN	PH
by	IN	O
the	DT	O
liver	NN	O
(	(	O
t	JJ	O
=	VBZ	O
2.61	CD	O
;	:	O
p	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.02	CD	O
)	)	O
and	CC	O
also	RB	O
caused	VBD	O
a	DT	O
larger	JJR	O
fall	NN	O
in	IN	O
raised	VBN	O
serum	NN	PH
levels	NNS	PH
of	IN	PH
gamma	NN	PH
glutamyl	NN	PH
transpeptidase	NN	PH
(	(	PH
GGT	NNP	PH
)	)	PH
than	IN	O
did	VBD	O
the	DT	O
placebo	NN	O
injections	NNS	O
.	.	O

Overall	JJ	O
clinical	JJ	PH
improvement	NN	PH
(	(	PH
e.g	NN	PH
.	.	PH

appetite	NN	PH
,	,	PH
body	NN	PH
weight	NN	PH
,	,	PH
reduced	VBD	PH
liver	JJ	PH
size	NN	PH
,	,	PH
general	JJ	PH
sense	NN	PH
of	IN	PH
well-being	NN	PH
)	)	PH
was	VBD	O
more	RBR	O
clearly	RB	O
evident	JJ	O
in	IN	O
patients	NNS	O
of	IN	O
the	DT	O
treated	VBN	O
group	NN	O
than	IN	O
in	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Naftidrofuryl	NNP	O
,	,	O
therefore	RB	O
,	,	O
appears	VBZ	O
to	TO	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
and	CC	O
more	RBR	O
extensive	JJ	O
long-term	JJ	O
trials	NNS	O
are	VBP	O
suggested	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
(	(	O
ALD	NNP	O
)	)	O
.	.	O

?-Blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
in	IN	O
arterial	JJ	O
occlusive	JJ	O
disease	NN	O
trial	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
?-receptor	NN	O
blockers	NNS	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
is	VBZ	O
controversial	JJ	O
for	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
vasomotor	NN	O
tone	NN	O
.	.	O

The	DT	O
?-blocker	NN	O
nebivolol	NN	O
possesses	VBZ	O
vasodilating	VBG	O
,	,	O
endothelium-dependent	JJ	O
,	,	O
NO-releasing	JJ	O
properties	NNS	O
that	WDT	O
might	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	Ot
and	CC	Ot
tolerability	NN	Ot
of	IN	O
nebivolol	NN	O
in	IN	O
comparison	NN	O
with	IN	O
metoprolol	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
128	CD	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
included	VBN	O
and	CC	O
double-blind	JJ	O
randomized	VBN	O
to	TO	O
receive	VB	O
5	CD	O
mg	NN	O
of	IN	O
nebivolol	NN	O
(	(	O
N=65	NNP	O
)	)	O
or	CC	O
95	CD	O
mg	NN	O
of	IN	O
metoprolol	NN	O
(	(	O
N=63	NNP	O
)	)	O
once	RB	O
daily	JJ	O
.	.	O

End	NN	O
points	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
ankle-brachial	JJ	O
index	NN	O
,	,	O
initial	JJ	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
,	,	O
endothelial	JJ	O
function	NN	O
assessed	VBN	O
by	IN	O
flow-mediated	JJ	O
dilatation	NN	O
of	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
,	,	O
blood	NN	PH
pressure	NN	PH
,	,	O
and	CC	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
using	VBG	Ot
the	DT	Ot
claudication	NN	Ot
scale	NN	Ot
questionnaire	NN	Ot
.	.	O

End	NN	O
point	NN	O
analysis	NN	O
was	VBD	O
possible	JJ	O
in	IN	O
109	CD	O
patients	NNS	O
(	(	O
85.2	CD	O
%	NN	O
)	)	O
.	.	O

After	IN	O
the	DT	O
48-week	JJ	O
treatment	NN	O
period	NN	O
,	,	O
ankle-brachial	JJ	O
index	NN	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
improved	VBD	O
significantly	RB	O
in	IN	O
both	DT	O
patient	JJ	O
groups	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
across	IN	O
treatments	NNS	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
nebivolol	JJ	O
group	NN	O
.	.	O

Adjusted	VBN	O
mean	JJ	O
change	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
33.9	CD	O
%	NN	O
after	IN	O
nebivolol	NN	O
(	(	O
P=0.003	NNP	O
)	)	O
and	CC	O
16.6	CD	O
%	NN	O
after	IN	O
metoprolol	NN	O
(	(	O
P=0.12	NNP	O
)	)	O
treatment	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
relevant	JJ	O
change	NN	O
in	IN	O
flow-mediated	JJ	O
dilatation	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
(	(	O
P=0.16	NNP	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
lowering	VBG	O
blood	NN	O
pressure	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
?-blocker	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
during	IN	O
a	DT	O
treatment	NN	O
period	NN	O
of	IN	O
?1	JJ	O
year	NN	O
.	.	O

In	IN	O
the	DT	O
direct	JJ	O
comparison	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
nebivolol	NNS	O
and	CC	O
metoprolol	NN	O
.	.	O

Rationale	NNP	O
and	CC	O
study	VB	O
design	NN	O
of	IN	O
the	DT	O
increase	NN	O
of	IN	O
vagal	JJ	O
tone	NN	O
in	IN	O
heart	NN	O
failure	NN	O
study	NN	O
:	:	O
INOVATE-HF	NNP	O
.	.	O

BACKGROUND	NNP	O
Imbalance	NNP	O
between	IN	O
the	DT	O
parasympathetic	JJ	O
and	CC	O
sympathetic	JJ	O
nervous	JJ	O
systems	NNS	O
is	VBZ	O
a	DT	O
recognized	VBN	O
contributor	NN	O
to	TO	O
progression	NN	O
of	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Current	JJ	O
therapy	NN	O
with	IN	O
beta	NN	O
adrenergic	JJ	O
antagonists	NNS	O
is	VBZ	O
designed	VBN	O
to	TO	O
moderate	VB	O
the	DT	O
up-regulation	NN	O
of	IN	O
norepinephrine	NN	O
and	CC	O
sympathetic	JJ	O
effects	NNS	O
;	:	O
however	RB	O
,	,	O
to	TO	O
date	NN	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
therapies	NNS	O
that	WDT	O
specifically	RB	O
address	VBP	O
the	DT	O
withdrawal	NN	O
of	IN	O
parasympathetic	JJ	O
influences	NNS	O
on	IN	O
cardiac	JJ	O
function	NN	O
and	CC	O
structure	NN	O
.	.	O

METHODS/RESULTS	NNP	O
In	IN	O
order	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
vagus	NN	O
nerve	NN	O
stimulation	NN	O
,	,	O
an	DT	O
international	JJ	O
multi-center	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
INOVATE-HF	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
designed	VBN	O
to	TO	O
assess	VB	O
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
vagus	NN	O
nerve	NN	O
stimulation	NN	O
in	IN	O
symptomatic	JJ	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
on	IN	O
optimal	JJ	O
medical	JJ	O
therapy	NN	O
using	VBG	O
the	DT	O
CardioFit	NNP	O
System	NNP	O
(	(	O
BioControl	NNP	O
Medical	NNP	O
,	,	O
Yehud	NNP	O
,	,	O
Israel	NNP	O
)	)	O
.	.	O

Up	UH	O
to	TO	O
650	CD	O
patients	NNS	O
from	IN	O
80	CD	O
sites	NNS	O
will	MD	O
be	VB	O
recruited	VBN	O
and	CC	O
randomized	VBN	O
in	IN	O
a	DT	O
3:2	CD	O
ratio	NN	O
to	TO	O
receive	VB	O
active	JJ	O
treatment	NN	O
or	CC	O
standard	NN	O
optimal	JJ	O
medical	JJ	O
therapy	NN	O
.	.	O

Inclusion	NNP	O
criteria	NNS	O
include	VBP	O
left	JJ	O
ventricular	JJ	O
systolic	JJ	O
dysfunction	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
Class	NNP	O
III	NNP	O
symptoms	NNS	O
,	,	O
sinus	NN	O
rhythm	NN	O
,	,	O
and	CC	O
QRS	NNP	O
width	VBD	O
less	JJR	O
than	IN	O
120	CD	O
milliseconds	NNS	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
powered	VBN	O
to	TO	O
detect	VB	O
differences	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	JJ	O
end	NN	O
point	NN	O
of	IN	O
all-cause	JJ	MO
mortality	NN	MO
and	CC	O
heart	NN	PH
failure	NN	PH
hospitalization	NN	PH
and	CC	O
2	CD	Ot
safety	NN	Ot
end	NN	Ot
points	NNS	Ot
.	.	O

CONCLUSION	NNP	O
Vagal	NNP	O
nerve	NN	O
stimulation	NN	O
with	IN	O
CardioFit	NNP	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
symptomatic	JJ	O
heart	NN	O
failure	NN	O
is	VBZ	O
under	IN	O
active	JJ	O
investigation	NN	O
as	IN	O
a	DT	O
novel	JJ	O
approach	NN	O
to	TO	O
restore	VB	O
balance	NN	O
between	IN	O
the	DT	O
sympathetic	JJ	O
and	CC	O
parasympathetic	JJ	O
nervous	JJ	O
systems	NNS	O
.	.	O

If	IN	O
shown	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
heart	NN	PH
failure	NN	PH
events	NNS	PH
and	CC	O
mortality	NN	MO
,	,	O
this	DT	O
novel	JJ	O
approach	NN	O
will	MD	O
impact	VB	O
the	DT	O
treatment	NN	O
paradigm	NN	O
for	IN	O
heart	NN	O
failure	NN	O
.	.	O

Preliminary	JJ	O
findings	NNS	O
of	IN	O
the	DT	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
rtPA	NN	O
for	IN	O
intracerebral	JJ	PH
hemorrhage	NN	PH
evacuation	NN	PH
(	(	O
MISTIE	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Compared	VBD	O
to	TO	O
ischemic	VB	O
stroke	NN	O
,	,	O
intracerebral	JJ	O
hemorrhage	NN	O
(	(	O
ICH	NNP	O
)	)	O
is	VBZ	O
easily	RB	O
and	CC	O
rapidly	RB	O
identified	VBN	O
,	,	O
occurs	VBZ	O
in	IN	O
younger	JJR	O
patients	NNS	O
,	,	O
and	CC	O
produces	VBZ	O
relatively	RB	O
small	JJ	O
initial	JJ	O
injury	NN	O
to	TO	O
cerebral	JJ	O
tissues	NNS	O
--	:	O
all	DT	O
factors	NNS	O
suggesting	VBG	O
that	IN	O
interventional	JJ	O
amelioration	NN	O
is	VBZ	O
possible	JJ	O
.	.	O

Investigations	NNS	O
from	IN	O
the	DT	O
last	JJ	O
decade	NN	O
established	VBD	O
that	IN	O
extent	NN	O
of	IN	O
ICH-mediated	NNP	O
brain	NN	O
injury	NN	O
relates	VBZ	O
directly	RB	O
to	TO	O
blood	VB	O
clot	NN	O
volume	NN	O
and	CC	O
duration	NN	O
of	IN	O
blood	NN	O
exposure	NN	O
to	TO	O
brain	NN	O
tissue	NN	O
.	.	O

Using	VBG	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
recombinant	JJ	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
rtPA	NN	O
)	)	O
,	,	O
MISTIE	NNP	O
investigators	NNS	O
explored	VBD	O
aggressive	JJ	O
avenues	NNS	O
to	TO	O
treat	VB	O
ICH	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
difference	NN	O
between	IN	O
surgical	JJ	O
intervention	NN	O
plus	CC	O
rtPA	NN	O
and	CC	O
standard	JJ	O
medical	JJ	O
management	NN	O
for	IN	O
ICH	NNP	O
.	.	O

Subjects	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
medically	RB	O
managed	VBN	O
according	VBG	O
to	TO	O
standard	JJ	O
ICU	NNP	O
protocols	NNS	O
.	.	O

Subjects	NNS	O
randomized	VBD	O
to	TO	O
surgery	VB	O
underwent	JJ	O
stereotactic	JJ	O
catheter	NN	O
placement	NN	O
and	CC	O
clot	NN	O
aspiration	NN	O
.	.	O

Injections	NNS	O
of	IN	O
rtPA	NN	O
were	VBD	O
then	RB	O
given	VBN	O
through	IN	O
hematoma	NN	O
catheter	NN	O
every	DT	O
8	CD	O
h	NN	O
,	,	O
up	RB	O
to	TO	O
9	CD	O
doses	NNS	O
,	,	O
or	CC	O
until	IN	O
a	DT	O
clot-reduction	JJ	O
endpoint	NN	O
.	.	O

After	IN	O
each	DT	O
injection	NN	O
the	DT	O
system	NN	O
was	VBD	O
flushed	VBN	O
with	IN	O
sterile	JJ	O
saline	NN	O
and	CC	O
closed	VBD	O
for	IN	O
60	CD	O
min	NN	O
before	IN	O
opening	VBG	O
to	TO	O
spontaneous	JJ	O
drainage	NN	O
.	.	O

RESULTS	JJ	O
Average	JJ	PH
aspiration	NN	PH
of	IN	PH
clots	NNS	PH
for	IN	O
all	DT	O
patients	NNS	O
randomized	VBN	O
to	TO	O
surgery	VB	O
plus	CC	O
rtPA	VB	O
was	VBD	O
20	CD	O
%	NN	O
of	IN	O
mean	JJ	O
initial	JJ	O
clot	NN	O
size	NN	O
.	.	O

After	IN	O
acute	JJ	O
treatment	NN	O
phase	NN	O
(	(	O
aspiration	NN	O
plus	CC	O
rtPA	NN	O
)	)	O
,	,	O
clot	NN	PH
was	VBD	O
reduced	VBN	O
an	DT	O
average	NN	O
of	IN	O
46	CD	O
%	NN	O
.	.	O

Recorded	VBN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
within	IN	O
safety	NN	O
limits	NNS	O
,	,	O
including	VBG	O
30-day	JJ	MO
mortality	NN	MO
,	,	O
8	CD	O
%	NN	O
;	:	O
symptomatic	JJ	PH
re-bleeding	NN	PH
,	,	O
8	CD	O
%	NN	O
;	:	O
and	CC	O
bacterial	JJ	PH
ventriculitis	NN	PH
,	,	O
0	CD	O
%	NN	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
medical	JJ	O
management	NN	O
showed	VBD	O
4	CD	O
%	NN	O
clot	NN	PH
resolution	NN	PH
in	IN	O
a	DT	O
similar	JJ	O
time	NN	O
window	NN	O
.	.	O

Preliminary	JJ	O
analysis	NN	O
indicates	VBZ	O
that	IN	O
clot	NN	PH
resolution	NN	PH
rates	NNS	PH
are	VBP	O
greatly	RB	O
dependent	JJ	O
on	IN	O
catheter	NN	O
placement	NN	O
.	.	O

Location	NN	O
of	IN	O
ICH	NNP	O
also	RB	O
affects	VBZ	O
efficacy	NN	O
of	IN	O
aggressive	JJ	O
treatment	NN	O
of	IN	O
ICH	NNP	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
is	VBZ	O
tentative	JJ	O
indication	NN	O
that	IN	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
rtPA	NN	O
shows	NNS	O
greater	JJR	PH
clot	NN	PH
resolution	NN	PH
than	IN	O
traditional	JJ	O
medical	JJ	O
management	NN	O
.	.	O

Efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
bexarotene	NN	O
combined	VBN	O
with	IN	O
psoralen-ultraviolet	NN	O
A	NNP	O
(	(	O
PUVA	NNP	O
)	)	O
compared	VBN	O
with	IN	O
PUVA	NNP	O
treatment	NN	O
alone	RB	O
in	IN	O
stage	JJ	O
IB-IIA	JJ	O
mycosis	NN	O
fungoides	NNS	O
:	:	O
final	JJ	O
results	NNS	O
from	IN	O
the	DT	O
EORTC	NNP	O
Cutaneous	NNP	O
Lymphoma	NNP	O
Task	NNP	O
Force	NNP	O
phase	NN	O
III	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
NCT00056056	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Psoralen	NNP	O
plus	CC	O
ultraviolet	VB	O
A	NNP	O
(	(	O
PUVA	NNP	O
)	)	O
is	VBZ	O
the	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
early	JJ	O
stages	NNS	O
of	IN	O
mycosis	NN	O
fungoides	NNS	O
.	.	O

There	EX	O
have	VBP	O
been	VBN	O
no	DT	O
adequate	JJ	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
with	IN	O
sufficient	JJ	O
power	NN	O
comparing	VBG	O
this	DT	O
modality	NN	O
with	IN	O
other	JJ	O
therapies	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
disease	NN	PH
response	NN	PH
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
response	NN	PH
rates	NNS	PH
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
PUVA	NNP	O
alone	RB	O
or	CC	O
PUVA	NNP	O
and	CC	O
bexarotene	NN	O
.	.	O

METHODS	NNP	O
EORTC	NNP	O
21011	CD	O
(	(	O
NCT	NNP	O
00056056	CD	O
)	)	O
was	VBD	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
comparing	VBG	O
combined	VBN	O
bexarotene	NN	O
(	(	O
Targretin	NNP	O
(	(	O
?	.	O
)	)	O
)	)	O
and	CC	O
PUVA	NNP	O
vs.	FW	O
PUVA	NNP	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
IB	NNP	O
and	CC	O
IIA	NNP	O
mycosis	NN	O
fungoides	NNS	O
(	(	O
MF	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
[	NNP	O
complete	JJ	O
clinical	JJ	O
response	NN	O
(	(	O
CCR	NNP	O
)	)	O
plus	CC	O
partial	JJ	O
response	NN	O
(	(	O
PR	NNP	O
)	)	O
]	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
study	NN	O
was	VBD	O
prematurely	RB	O
closed	VBN	O
due	JJ	O
to	TO	O
low	JJ	O
accrual	JJ	O
after	IN	O
93	CD	O
of	IN	O
145	CD	O
required	JJ	O
patients	NNS	O
(	(	O
65	CD	O
%	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
.	.	O

Of	IN	O
the	DT	O
93	CD	O
randomized	JJ	O
patients	NNS	O
,	,	O
87	CD	O
started	VBD	O
treatment	NN	O
,	,	O
41	CD	O
received	VBD	O
PUVA	NNP	O
and	CC	O
46	CD	O
received	VBD	O
PUVA	NNP	O
+	NNP	O
bexarotene	NN	O
.	.	O

Total	JJ	O
UVA	NNP	O
doses	NNS	O
received	VBD	O
were	VBD	O
107	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NN	O
)	)	O
(	(	O
range	VB	O
1?4-489?9	CD	O
)	)	O
in	IN	O
the	DT	O
PUVA	NNP	O
arm	NN	O
vs.	FW	O
101?7	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NN	O
)	)	O
(	(	O
0?2-529?9	JJ	O
)	)	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
.	.	O

The	DT	O
safety	NN	O
profile	NN	O
was	VBD	O
acceptable	JJ	O
with	IN	O
few	JJ	O
grade	JJ	O
3-4	JJ	O
toxicities	NNS	O
observed	VBN	O
in	IN	O
either	DT	O
arm	NN	O
.	.	O

More	JJR	O
drop-outs	NNS	O
due	JJ	O
to	TO	O
toxicity	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
the	DT	O
PUVA-alone	JJ	O
arm	NN	O
.	.	O

The	DT	O
best	JJS	O
overall	JJ	O
response	NN	O
(	(	O
CCR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
rate	NN	O
was	VBD	O
71	CD	O
%	NN	O
for	IN	O
PUVA	NNP	O
alone	RB	O
and	CC	O
77	CD	O
%	NN	O
for	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?57	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
was	VBD	O
9?7	CD	O
months	NNS	O
for	IN	O
PUVA	NNP	O
vs.	FW	O
5?8	CD	O
months	NNS	O
for	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?33	CD	O
)	)	O
.	.	O

CCR	NNP	O
was	VBD	O
seen	VBN	O
in	IN	O
25	CD	O
patients	NNS	O
of	IN	O
whom	WP	O
10	CD	O
received	VBD	O
PUVA	NNP	O
alone	RB	O
(	(	O
CCR	NNP	O
22	CD	O
%	NN	O
)	)	O
and	CC	O
15	CD	O
received	VBN	O
combination	NN	O
therapy	NN	O
(	(	O
CCR	NNP	O
31	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0?45	CD	O
)	)	O
.	.	O

CCR	NNP	O
was	VBD	O
sustained	VBN	O
in	IN	O
25	CD	O
%	NN	O
of	IN	O
patients	NNS	O
regardless	RB	O
of	IN	O
therapy	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	VBZ	O
fewer	JJR	O
PUVA	NNP	O
sessions	NNS	O
needed	VBD	O
to	TO	O
achieve	VB	O
CCR	NNP	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
median	JJ	O
22	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
PUVA	NNP	O
arm	NN	O
(	(	O
median	JJ	O
27?5	CD	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0?11	CD	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
UVA	NNP	O
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
CCR	NNP	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
median	JJ	O
55?8	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
PUVA	NNP	O
arm	NN	O
alone	RB	O
(	(	O
median	JJ	O
117?5	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0?5	CD	O
)	)	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rate	NN	O
or	CC	O
response	NN	O
duration	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	VBZ	O
fewer	JJR	O
PUVA	NNP	O
sessions	NNS	O
and	CC	O
lower	JJR	O
UVA	NNP	O
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
CCR	NNP	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
PUVA	NNP	O
+	NNP	O
bexarotene	NN	O
)	)	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
achieve	VB	O
statistical	JJ	O
significance	NN	O
due	JJ	O
to	TO	O
insufficient	JJ	O
power	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
random	JJ	O
modulation	NN	O
of	IN	O
functional	JJ	O
electrical	JJ	O
stimulation	NN	O
parameters	NNS	O
on	IN	O
muscle	NN	O
fatigue	NN	O
.	.	O

Muscle	NNP	O
contractions	NNS	O
induced	VBN	O
by	IN	O
functional	JJ	O
electrical	JJ	O
stimulation	NN	O
(	(	O
FES	NNP	O
)	)	O
tend	VBP	O
to	TO	O
result	VB	O
in	IN	O
rapid	JJ	PH
muscle	NN	PH
fatigue	NN	PH
,	,	O
which	WDT	O
greatly	RB	O
limits	VBZ	O
activities	NNS	O
such	JJ	O
as	IN	O
FES-assisted	JJ	O
standing	NN	O
and	CC	O
walking	NN	O
.	.	O

It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
muscle	NN	PH
fatigue	NN	PH
caused	VBN	O
by	IN	O
FES	NNP	O
could	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
randomly	RB	O
modulating	VBG	O
parameters	NNS	O
of	IN	O
the	DT	O
electrical	JJ	O
stimulus	NN	O
.	.	O

Seven	NNP	O
paraplegic	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

While	IN	O
subjects	NNS	O
were	VBD	O
seated	VBN	O
,	,	O
FES	NNP	O
was	VBD	O
applied	VBN	O
to	TO	O
quadriceps	NNS	O
and	CC	O
tibialis	JJ	O
anterior	JJ	O
muscles	NNS	O
bilaterally	RB	O
using	VBG	O
surface	NN	O
electrodes	NNS	O
.	.	O

The	DT	O
isometric	JJ	PH
force	NN	PH
was	VBD	O
measured	VBN	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
for	IN	O
the	DT	O
force	NN	O
to	TO	O
drop	VB	O
by	IN	O
3	CD	O
dB	NN	O
(	(	O
fatigue	JJ	O
time	NN	O
)	)	O
and	CC	O
the	DT	O
normalized	JJ	O
force-time	JJ	PH
integral	JJ	PH
(	(	PH
FTI	NNP	PH
)	)	PH
were	VBD	O
determined	VBN	O
.	.	O

Four	CD	O
different	JJ	O
modes	NNS	O
of	IN	O
FES	NNP	O
were	VBD	O
applied	VBN	O
in	IN	O
random	JJ	O
order	NN	O
:	:	O
constant	JJ	O
stimulation	NN	O
,	,	O
randomized	VBN	O
frequency	NN	O
(	(	O
mean	JJ	O
40	CD	O
Hz	NNP	O
)	)	O
,	,	O
randomized	VBN	O
current	JJ	O
amplitude	NN	O
,	,	O
and	CC	O
randomized	VBD	O
pulsewidth	NN	O
(	(	O
mean	JJ	O
250	CD	O
micros	NN	O
)	)	O
.	.	O

In	IN	O
randomized	JJ	O
trials	NNS	O
,	,	O
stimulation	NN	O
parameters	NNS	O
were	VBD	O
stochastically	RB	O
modulated	VBN	O
every	DT	O
100	CD	O
ms	NN	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
+/-15	NNP	O
%	NN	O
using	VBG	O
a	DT	O
uniform	JJ	O
probability	NN	O
distribution	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
fatigue	NN	PH
time	NN	PH
measurements	NNS	PH
for	IN	O
the	DT	O
four	CD	O
modes	NNS	O
of	IN	O
stimulation	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
FTI	NNP	PH
measurements	NNS	PH
.	.	O

Therefore	RB	O
,	,	O
our	PRP$	O
particular	JJ	O
method	NN	O
of	IN	O
stochastic	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
stimulation	NN	O
parameters	NNS	O
,	,	O
which	WDT	O
involved	VBD	O
moderate	JJ	O
(	(	O
15	CD	O
%	NN	O
)	)	O
variations	NNS	O
updated	VBN	O
every	DT	O
100	CD	O
ms	NN	O
and	CC	O
centered	VBD	O
around	IN	O
40	CD	O
Hz	NNP	O
,	,	O
appeared	VBD	O
to	TO	O
have	VB	O
no	DT	O
effect	NN	O
on	IN	O
muscle	NN	PH
fatigue	NN	PH
.	.	O

There	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
maximum	JJ	O
force	NN	O
measurements	NNS	O
and	CC	O
stimulation	NN	O
order	NN	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
apparent	JJ	O
in	IN	O
the	DT	O
fatigue	JJ	PH
time	NN	PH
or	CC	O
FTI	NNP	PH
measurements	NNS	PH
.	.	O

It	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
10-min	JJ	O
rest	NN	O
period	NN	O
between	IN	O
stimulation	NN	O
trials	NNS	O
was	VBD	O
insufficient	JJ	O
to	TO	O
allow	VB	O
full	JJ	O
recovery	NN	PH
of	IN	PH
muscle	NN	PH
strength	NN	PH
.	.	O

Covariation	NN	O
of	IN	O
adolescent	JJ	PH
physical	JJ	PH
activity	NN	PH
and	CC	O
dietary	JJ	ME
behaviors	NNS	ME
over	IN	O
12	CD	O
months	NNS	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
examined	VBD	O
covariation	NN	O
among	IN	O
changes	NNS	O
in	IN	O
dietary	JJ	O
,	,	O
physical	JJ	O
activity	NN	O
,	,	O
and	CC	O
sedentary	JJ	O
behaviors	NNS	O
over	IN	O
12	CD	O
months	NNS	O
among	IN	O
adolescents	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
health	NN	O
behavior	NN	O
intervention	NN	O
.	.	O

Evidence	NN	O
of	IN	O
covariation	NN	O
among	IN	O
behaviors	NNS	O
would	MD	O
suggest	VB	O
multi-behavior	JJ	O
interventions	NNS	O
could	MD	O
have	VB	O
synergistic	JJ	O
effects	NNS	O
.	.	O

METHODS	NNP	O
Prospective	JJ	O
analyses	NNS	O
were	VBD	O
conducted	VBN	O
with	IN	O
baseline	NN	O
and	CC	O
12-month	JJ	O
assessments	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
to	TO	O
promote	VB	O
improved	JJ	O
diet	JJ	ME
,	,	O
physical	JJ	ME
activity	NN	ME
,	,	O
and	CC	O
sedentary	JJ	ME
behaviors	NNS	ME
(	(	O
experimental	JJ	O
condition	NN	O
)	)	O
or	CC	O
SUN	NNP	ME
protection	NN	ME
behaviors	NNS	ME
(	(	O
comparison	JJ	O
condition	NN	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
adolescent	JJ	O
girls	NNS	O
and	CC	O
boys	NNS	O
(	(	O
N	NNP	O
=	NNP	O
878	CD	O
)	)	O
aged	VBN	O
11-15	CD	O
years	NNS	O
on	IN	O
entry	NN	O
.	.	O

The	DT	O
main	JJ	O
outcomes	NNS	O
were	VBD	O
:	:	O
diet	NN	ME
,	,	O
based	VBN	O
on	IN	O
multiple	JJ	O
24-hour	JJ	O
recalls	NNS	O
(	(	O
total	JJ	O
fat	NN	O
,	,	O
grams	NNS	O
of	IN	O
fiber	NN	O
,	,	O
servings	NNS	O
of	IN	O
fruit	NN	O
and	CC	O
vegetables	NNS	O
,	,	O
total	JJ	O
calories	NNS	O
)	)	O
;	:	O
average	JJ	ME
daily	JJ	ME
energy	NN	ME
expenditure	NN	ME
(	(	O
kcals/kg	NN	O
)	)	O
based	VBN	O
on	IN	O
7-day	JJ	O
physical	JJ	O
activity	NN	O
recall	VBP	O
interviews	NNS	O
;	:	O
daily	JJ	ME
minutes	NNS	ME
of	IN	ME
moderate-vigorous	JJ	ME
physical	JJ	ME
activity	NN	ME
minutes	NNS	O
from	IN	O
accelerometery	NN	O
;	:	O
and	CC	O
self-reported	JJ	ME
daily	JJ	ME
hours	NNS	ME
of	IN	ME
sedentary	JJ	ME
behavior	NN	ME
.	.	O

RESULTS	NNP	O
Covariation	NNP	O
was	VBD	O
found	VBN	O
between	IN	O
fat	NN	O
and	CC	O
calories	NNS	O
(	(	O
r	NN	O
=	NNP	O
.16	NNP	O
)	)	O
,	,	O
fiber	NN	O
and	CC	O
calories	NNS	O
(	(	O
r	NN	O
=	NNP	O
.53	NNP	O
)	)	O
,	,	O
fiber	NN	PH
and	CC	PH
fruit/vegetables	NNS	PH
(	(	O
r	NN	O
=	NNP	O
.53	NNP	O
)	)	O
,	,	O
calories	NNS	PH
and	CC	PH
fruit/vegetables	NNS	PH
(	(	O
r	NN	O
=	NNP	O
.34	NNP	O
)	)	O
,	,	O
and	CC	O
fruit	NN	PH
and	CC	PH
vegetables	NNS	PH
and	CC	O
sedentary	JJ	ME
behavior	NN	ME
(	(	O
r	JJ	O
=	NNP	O
-.12	NNP	O
)	)	O
for	IN	O
the	DT	O
total	JJ	O
sample	NN	O
(	(	O
all	DT	O
p	NN	O
values	NNS	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

The	DT	O
pattern	NN	O
of	IN	O
findings	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
most	JJS	O
subgroups	NNS	O
defined	VBN	O
by	IN	O
gender	NN	O
and	CC	O
study	NN	O
condition	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
strongest	JJS	O
covariation	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
diet	JJ	ME
variables	NNS	ME
that	WDT	O
are	VBP	O
inherently	RB	O
related	VBN	O
(	(	O
calories	NNS	O
and	CC	O
fat	NN	O
,	,	O
fiber	NN	O
,	,	O
and	CC	O
fruit/vegetables	NNS	O
)	)	O
.	.	O

Little	JJ	O
covariation	NN	O
was	VBD	O
detected	VBN	O
within	IN	O
or	CC	O
between	IN	O
other	JJ	O
diet	JJ	ME
,	,	O
physical	JJ	ME
activity	NN	ME
and	CC	O
sedentary	JJ	ME
behavior	NN	ME
domains	NNS	O
suggesting	VBG	O
that	IN	O
interventions	NNS	O
to	TO	O
improve	VB	O
these	DT	O
behaviors	NNS	O
in	IN	O
adolescents	NNS	O
need	VBP	O
to	TO	O
include	VB	O
specific	JJ	O
program	NN	O
components	NNS	O
for	IN	O
each	DT	O
target	NN	O
behavior	NN	O
of	IN	O
interest	NN	O
.	.	O

The	DT	O
evaluation	NN	O
of	IN	O
pulmonary	JJ	O
hypertension	NN	O
using	VBG	O
right	JJ	O
ventricular	JJ	O
myocardial	JJ	O
isovolumic	JJ	O
relaxation	NN	O
time	NN	O
.	.	O

Right	JJ	O
ventricular	NN	O
(	(	O
RV	NNP	O
)	)	O
blood	VBD	O
pool-derived	JJ	O
isovolumic	JJ	O
relaxation	NN	O
time	NN	O
(	(	O
IVRT	NNP	O
)	)	O
correlates	VBZ	O
well	RB	O
with	IN	O
systolic	JJ	O
pulmonary	JJ	O
arterial	JJ	O
pressure	NN	O
(	(	O
PAP	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
because	IN	O
of	IN	O
complex	JJ	O
parameter	NN	O
derivation	NN	O
,	,	O
the	DT	O
method	NN	O
is	VBZ	O
rarely	RB	O
used	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
validate	VB	O
the	DT	O
measurement	NN	O
of	IN	O
myocardial	JJ	O
velocity	NN	O
imaging-derived	JJ	O
RV	NNP	O
IVRT	NNP	O
(	(	O
IVRT	NNP	O
'	POS	O
)	)	O
against	IN	O
invasively	RB	O
measured	VBN	O
PAP	NNP	O
.	.	O

Transthoracic	NNP	O
echocardiography	NN	O
with	IN	O
myocardial	JJ	O
velocity	NN	O
imaging	NN	O
and	CC	O
right	JJ	O
heart	NN	O
catheterization	NN	O
were	VBD	O
performed	VBN	O
in	IN	O
33	CD	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
.	.	O

Blood	NNP	PH
pool	NN	PH
IVRT	NNP	PH
and	CC	PH
myocardial	JJ	PH
IVRTs	NNP	PH
for	IN	PH
the	DT	PH
tricuspid	JJ	PH
valve	NN	PH
annulus	NN	PH
ring	NN	PH
,	,	PH
basal	NN	PH
and	CC	PH
apical	JJ	PH
RV	NNP	PH
free	JJ	PH
wall	NN	PH
segments	NNS	PH
were	VBD	O
measured	VBN	O
and	CC	O
compared	VBN	O
with	IN	O
data	NNS	O
from	IN	O
33	CD	O
age-	JJ	O
and	CC	O
sex-matched	JJ	O
control	NN	O
subjects	NNS	O
.	.	O

Measured	VBN	PH
IVRTs	NNP	PH
were	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
than	IN	O
in	IN	O
control	NN	O
subjects	NNS	O
.	.	O

The	DT	O
strongest	JJS	O
correlation	NN	O
(	(	O
R	NNP	O
=	NNP	O
0.74	CD	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
systolic	JJ	PH
PAP	NNP	PH
and	CC	PH
the	DT	PH
heart	NN	PH
rate-corrected	JJ	PH
IVRT	NNP	PH
'	POS	PH
derived	VBN	O
from	IN	O
the	DT	O
basal	NN	O
RV	NNP	O
free	JJ	O
wall	NN	O
segment	NN	O
.	.	O

The	DT	O
basal	NN	PH
segment	NN	PH
IVRT	NNP	PH
'	POS	PH
corrected	VBN	O
for	IN	O
heart	NN	PH
rate	NN	PH
correlates	NNS	O
well	RB	O
with	IN	O
the	DT	O
invasive	JJ	O
PAP	NNP	O
measurement	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
predict	VB	O
systolic	JJ	PH
PAP	NNP	PH
.	.	O

It	PRP	O
can	MD	O
even	RB	O
be	VB	O
considered	VBN	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
tricuspid	VB	O
regurgitation-derived	JJ	O
PAP	NNP	O
systolic	NN	O
when	WRB	O
tricuspid	JJ	O
regurgitation	NN	O
is	VBZ	O
nonrecordable	JJ	O
.	.	O

A	DT	O
proposed	VBN	O
method	NN	O
to	TO	O
derive	VB	O
systolic	JJ	O
PAP	NNP	O
should	MD	O
be	VB	O
used	VBN	O
while	IN	O
screening	VBG	O
the	DT	O
patients	NNS	O
at	IN	O
risk	NN	O
for	IN	O
pulmonary	JJ	O
hypertension	NN	O
,	,	O
monitoring	VBG	O
the	DT	O
disease	NN	O
progression	NN	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
.	.	O

Prospective	JJ	O
study	NN	O
of	IN	O
Clostridium	NNP	PH
difficile	JJ	PH
intestinal	JJ	O
colonization	NN	O
and	CC	O
disease	NN	O
following	VBG	O
single-dose	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
in	IN	O
surgery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
108	CD	O
volunteers	NNS	O
undergoing	VBG	O
an	DT	O
elective	JJ	O
surgical	JJ	O
procedure	NN	O
were	VBD	O
randomly	RB	O
given	VBN	O
a	DT	O
single	JJ	O
2-g	JJ	O
intravenous	JJ	O
prophylactic	JJ	O
dose	NN	O
of	IN	O
either	CC	O
a	DT	O
cephalosporin	NN	O
or	CC	O
mezlocillin	NN	O
.	.	O

Stool	NNP	O
samples	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
Clostridium	NNP	O
difficile	VBP	O
the	DT	O
day	NN	O
before	IN	O
the	DT	O
operation	NN	O
and	CC	O
later	RB	O
on	IN	O
postoperative	JJ	O
days	NNS	O
4	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
.	.	O

C.	NNP	PH
difficile	NN	PH
was	VBD	O
detected	VBN	O
in	IN	O
23.0	CD	O
%	NN	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
a	DT	O
cephalosporin	NN	O
(	(	O
cefoxitin	NN	O
,	,	O
8.3	CD	O
%	NN	O
;	:	O
cefazolin	NN	O
,	,	O
14.3	CD	O
%	NN	O
;	:	O
cefotetan	NN	O
,	,	O
20.0	CD	O
%	NN	O
;	:	O
ceftriaxone	NN	O
,	,	O
25.0	CD	O
%	NN	O
;	:	O
cefoperazone	NN	O
,	,	O
43.7	CD	O
%	NN	O
)	)	O
,	,	O
in	IN	O
3.3	CD	O
%	NN	O
of	IN	O
patients	NNS	O
given	VBN	O
mezlocillin	NNS	O
,	,	O
and	CC	O
in	IN	O
none	NN	O
of	IN	O
15	CD	O
control	NN	O
volunteers	NNS	O
given	VBN	O
no	DT	O
antimicrobial	JJ	O
agent	NN	O
.	.	O

No	DT	O
patient	NN	O
experienced	VBD	O
diarrhea	NN	A
.	.	A

Treatment	NN	O
of	IN	O
vasculogenic	JJ	O
sexual	JJ	O
dysfunction	NN	O
with	IN	O
pentoxifylline	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
pentoxifylline	NN	O
to	TO	O
treat	VB	O
impotence	NN	O
in	IN	O
men	NNS	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
penile	IN	O
vascular	JJ	O
insufficiency	NN	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Sexual	JJ	O
Dysfunction	NNP	O
Clinic	NNP	O
at	IN	O
VA	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
Sepulveda	NNP	O
,	,	O
CA	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Convenience	NNP	O
sample	NN	O
of	IN	O
couples	NNS	O
.	.	O

INTERVENTION	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
placebo	NN	O
or	CC	O
400	CD	O
mg	JJ	O
tid	NN	O
of	IN	O
pentoxifylline	NN	O
.	.	O

MEASUREMENTS	NNP	O
(	(	O
1	CD	O
)	)	O
Report	NN	ME
of	IN	ME
patient	JJ	ME
verified	VBN	ME
by	IN	ME
partner	NN	ME
as	IN	ME
to	TO	ME
number	NN	ME
of	IN	ME
coital	JJ	ME
episodes	NNS	ME
per	IN	ME
month	NN	ME
;	:	O
(	(	O
2	CD	O
)	)	O
penile-brachial	JJ	PH
pressure	NN	PH
index	NN	PH
determinations	NNS	PH
.	.	O

RESULTS	NNP	O
Pentoxifylline	NNP	O
therapy	VBZ	O
regularly	RB	O
increased	VBN	O
the	DT	O
PBPI	NNP	ME
in	IN	O
impotent	JJ	O
men	NNS	O
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
placebo	NN	O
,	,	O
frequently	RB	O
into	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

Pentoxifylline	NNP	O
therapy	NN	O
was	VBD	O
particularly	RB	O
useful	JJ	O
in	IN	O
restoring	VBG	ME
the	DT	ME
PBPI	NNP	ME
in	IN	O
men	NNS	O
with	IN	O
the	DT	O
pelvic	JJ	O
steal	JJ	O
syndrome	NN	O
;	:	O
six	CD	O
of	IN	O
seven	CD	O
such	JJ	O
subjects	NNS	O
improved	VBN	O
into	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

During	IN	O
the	DT	O
pentoxifylline	JJ	O
treatment	NN	O
period	NN	O
,	,	O
in	IN	O
contrast	NN	O
with	IN	O
the	DT	O
control	NN	O
period	NN	O
,	,	O
nine	CD	O
men	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
reestablish	VB	ME
coital	JJ	ME
function	NN	ME
and	CC	O
three	CD	O
had	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Six	NNP	O
couples	NNS	O
did	VBD	O
not	RB	O
attempt	VB	ME
intercourse	JJ	ME
despite	IN	O
a	DT	O
professed	JJ	O
interest	NN	O
in	IN	O
sexual	JJ	ME
activity	NN	ME
;	:	O
however	RB	O
five	CD	O
out	IN	O
of	IN	O
the	DT	O
six	CD	O
men	NNS	O
experienced	VBD	O
erections	NNS	ME
during	IN	ME
episodes	NNS	ME
of	IN	ME
fantasy	NN	ME
or	CC	ME
attempts	NNS	ME
at	IN	ME
masturbation	NN	ME
during	IN	O
treatment	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
complications	NNS	A
of	IN	O
therapy	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
promising	VBG	O
preliminary	JJ	O
results	NNS	O
suggest	VBP	O
a	DT	O
well	RB	O
tolerated	JJ	O
alternative	JJ	O
therapy	NN	O
for	IN	O
erectile	JJ	O
dysfunction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
penile	IN	O
vascular	JJ	O
disease	NN	O
.	.	O

Removal	NN	O
of	IN	O
inflammatory	JJ	O
cytokines	NNS	O
and	CC	O
endotoxin	NN	O
by	IN	O
veno-venous	JJ	O
continuous	JJ	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
for	IN	O
burned	JJ	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
veno-venous	JJ	O
continuous	JJ	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
(	(	O
CRRT	NNP	O
)	)	O
on	IN	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
endotoxin	NN	O
and	CC	O
cytokines	NNS	O
in	IN	O
severely	RB	O
burned	VBN	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

METHODS	NNP	O
Twenty	NNP	O
adult	NN	O
severely	RB	O
burned	VBD	O
patients	NNS	O
with	IN	O
sepsis	NN	O
were	VBD	O
studied	VBN	O
.	.	O

For	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
sepsis	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
CRRT	NNP	O
(	(	O
n=10	NN	O
)	)	O
and	CC	O
Control	NNP	O
(	(	O
n=10	RB	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
conventional	JJ	O
therapy	NN	O
after	IN	O
admission	NN	O
.	.	O

Veno-venous	JJ	O
CRRT	NNP	O
was	VBD	O
administered	VBN	O
to	TO	O
10	CD	O
patients	NNS	O
in	IN	O
the	DT	O
CRRT	NNP	O
group	NN	O
whenever	WDT	O
patients	NNS	O
were	VBD	O
determined	VBN	O
to	TO	O
be	VB	O
septic	JJ	O
.	.	O

The	DT	O
plasma	JJ	O
level	NN	O
of	IN	O
endotoxin	NN	O
,	,	O
TNF-alpha	NNP	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
were	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
CRRT	NNP	O
initiation	NN	O
,	,	O
and	CC	O
at	IN	O
0	CD	O
,	,	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
diagnosed	VBN	O
as	IN	O
having	VBG	O
sepsis	NN	O
in	IN	O
the	DT	O
Control	NNP	O
group	NN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Plasma	NNP	PH
level	NN	PH
of	IN	PH
endotoxin	NN	PH
and	CC	O
all	PDT	PH
the	DT	PH
cytokines	NNS	PH
after	IN	PH
CRRT	NNP	PH
initiation	NN	PH
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
before	IN	O
the	DT	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
serial	JJ	PH
change	NN	PH
of	IN	PH
endotoxin	NN	PH
,	,	PH
IL-1	NNP	PH
beta	NN	PH
,	,	PH
IL-6	NNP	PH
and	CC	PH
IL-8	NNP	PH
was	VBD	O
significantly	RB	O
lower	JJR	O
at	IN	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
treatment	NN	O
compared	VBN	O
with	IN	O
Control	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
plasma	JJ	PH
TNF-alpha	JJ	PH
levels	NNS	PH
was	VBD	O
seen	VBN	O
at	IN	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
treatment	NN	O
compared	VBN	O
with	IN	O
Control	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Plasma	NNP	O
endotoxin	NN	O
and	CC	O
cytokines	NNS	O
(	(	O
TNF-alpha	NNP	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
)	)	O
can	MD	O
be	VB	O
removed	VBN	O
effectively	RB	O
with	IN	O
CRRT	NNP	O
in	IN	O
severely	RB	O
burned	VBN	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

Predictors	NNS	O
of	IN	O
survival	NN	O
and	CC	O
eradication	NN	O
of	IN	O
Mycobacterium	NNP	O
avium	NN	O
complex	NN	O
bacteremia	NN	O
(	(	O
MAC	NNP	O
)	)	O
in	IN	O
AIDS	NNP	O
patients	NNS	O
in	IN	O
the	DT	O
Canadian	NNP	O
randomized	VBD	O
MAC	NNP	O
treatment	NN	O
trial	NN	O
.	.	O

Canadian	JJ	O
HIV	NNP	O
Trials	NNP	O
Network	NNP	O
Protocol	NNP	O
010	CD	O
Study	NNP	O
Group	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
importance	NN	O
of	IN	O
baseline	NN	O
characteristics	NNS	O
including	VBG	O
medical	JJ	PH
history	NN	PH
,	,	O
indicators	NNS	PH
of	IN	PH
current	JJ	PH
disease	NN	PH
status	NN	PH
,	,	O
therapeutic	JJ	PH
drug	NN	PH
use	NN	PH
,	,	O
in	IN	PH
vitro	JJ	PH
drug	NN	PH
susceptibility	NN	PH
,	,	O
immune	JJ	PH
status	NN	PH
and	CC	O
mycobacterial	JJ	PH
load	NN	PH
on	IN	O
bacteriologic	JJ	PH
response	NN	PH
and	CC	O
survival	NN	MO
in	IN	O
HIV-positive	JJ	O
patients	NNS	O
with	IN	O
Mycobacterium	NNP	O
avium	NN	O
complex	NN	O
(	(	O
MAC	NNP	O
)	)	O
bacteremia	NN	O
.	.	O

DESIGN	NNP	O
An	DT	O
observational	JJ	O
substudy	NN	O
of	IN	O
an	DT	O
open-label	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
two	CD	O
alternative	JJ	O
therapeutic	JJ	O
regimens	NNS	O
for	IN	O
MAC	NNP	O
.	.	O

SETTING	NNP	O
Twenty-four	JJ	O
hospital-based	JJ	O
HIV	NNP	O
clinics	NNS	O
in	IN	O
16	CD	O
Canadian	JJ	O
cities	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
survival	JJ	MO
and	CC	PH
bacteriologic	JJ	PH
response	NN	PH
,	,	O
defined	VBN	PH
by	IN	PH
consecutive	JJ	PH
negative	JJ	PH
blood	NN	PH
cultures	NNS	PH
for	IN	PH
MAC	NNP	PH
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
apart	RB	O
within	IN	O
16	CD	O
weeks	NNS	O
of	IN	O
study	NN	O
entry	NN	O
.	.	O

RESULTS	NNP	O
Prior	NNP	O
AIDS	NNP	O
diagnosis	NN	O
,	,	O
low	JJ	O
Karnofsky	NNP	O
score	NN	O
,	,	O
active	JJ	O
unstable	JJ	O
AIDS-related	JJ	O
conditions	NNS	O
,	,	O
absence	NN	O
of	IN	O
antiretroviral	JJ	O
therapy	NN	O
and	CC	O
absence	NN	O
of	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
prophylaxis	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
shorter	JJR	O
survival	NN	MO
by	IN	O
univariate	JJ	O
regression	NN	O
using	VBG	O
the	DT	O
proportional	JJ	O
hazards	NNS	O
model	NN	O
.	.	O

On	IN	O
multivariate	NN	O
analysis	NN	O
,	,	O
antiretroviral	JJ	O
therapy	NN	O
was	VBD	O
not	RB	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
mortality	NN	MO
,	,	O
and	CC	O
previous	JJ	O
rifabutin	NN	O
prophylaxis	NN	O
was	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
poor	JJ	O
survival	NN	O
outcomes	NNS	O
,	,	O
a	DT	O
result	NN	O
consistent	JJ	O
across	IN	O
study	NN	O
treatment	NN	O
.	.	O

Using	VBG	O
a	DT	O
logistic	JJ	O
regression	NN	O
model	NN	O
,	,	O
baseline	JJ	PH
quantitative	JJ	PH
mycobacterial	JJ	PH
load	NN	PH
[	NNP	O
relative	JJ	O
odds	NNS	O
of	IN	O
clearing	NN	O
,	,	O
1.97	CD	O
for	IN	O
a	DT	O
decrease	NN	O
of	IN	O
1	CD	O
log10	JJ	O
colony	NN	O
forming	VBG	O
count	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
1.36-2.87	JJ	O
;	:	O
P	NNP	O
<	VBD	O
0.001	CD	O
]	NN	O
and	CC	O
Karnofsky	NNP	PH
score	NN	PH
were	VBD	O
the	DT	O
only	JJ	O
statistically	RB	O
significant	JJ	O
univariate	JJ	O
predictors	NNS	O
of	IN	O
clearance	NN	O
,	,	O
although	IN	O
previous	JJ	O
prophylaxis	NN	O
with	IN	O
rifabutin	NN	O
was	VBD	O
also	RB	O
a	DT	O
significant	JJ	O
predictor	NN	O
in	IN	O
a	DT	O
multivariate	NN	O
model	NN	O
(	(	O
relative	JJ	O
odds	NNS	O
of	IN	O
clearing	NN	O
,	,	O
0.39	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.17-0.88	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
although	IN	O
the	DT	O
level	NN	O
of	IN	O
MAC	NNP	O
bacteremia	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
predictor	NN	O
of	IN	O
clearance	NN	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
survival	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	O
on	IN	O
deep	JJ	PH
cervical	JJ	PH
flexor	NN	PH
endurance	NN	PH
:	:	PH
implications	NNS	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	PH
headache	NN	PH
and	CC	O
mechanical	JJ	PH
neck	NN	PH
pain	NN	PH
.	.	O

The	DT	O
convergence	NN	O
of	IN	O
cervical	JJ	O
and	CC	O
trigeminal	JJ	O
afferents	NNS	O
on	IN	O
second-order	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
trigeminocervical	JJ	O
nucleus	NN	O
may	MD	O
refer	VB	O
pain	NN	O
from	IN	O
the	DT	O
upper	JJ	O
cervical	JJ	O
spine	NN	O
into	IN	O
the	DT	O
head	NN	O
and	CC	O
face	NN	O
.	.	O

Furthermore	RB	O
,	,	O
bi-directional	JJ	O
interactions	NNS	O
between	IN	O
trigeminal	JJ	O
and	CC	O
upper	JJ	O
cervical	JJ	O
afferents	NNS	O
may	MD	O
also	RB	O
explain	VB	O
neck	NN	O
symptoms	NNS	O
of	IN	O
trigeminal	JJ	O
origin	NN	O
(	(	O
e.g.	JJ	O
,	,	O
migraine	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
cervicogenic	JJ	O
headache	NN	O
sufferers	NNS	O
present	JJ	O
with	IN	O
several	JJ	O
musculoskeletal	JJ	O
changes	NNS	O
including	VBG	O
poor	JJ	O
endurance	NN	O
of	IN	O
the	DT	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
muscles	NNS	O
.	.	O

These	DT	O
intrinsic	JJ	O
muscles	NNS	O
of	IN	O
the	DT	O
neck	NN	O
contribute	NN	O
to	TO	O
stabilization	NN	O
and	CC	O
protection	NN	O
of	IN	O
the	DT	O
cervical	JJ	O
spine	NN	O
and	CC	O
are	VBP	O
critical	JJ	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
intervertebral	JJ	O
motion	NN	O
and	CC	O
the	DT	O
cervical	JJ	O
lordosis	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	O
(	(	O
SomatoCentric	NNP	O
Systems	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Toronto	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
)	)	O
,	,	O
a	DT	O
posture	NN	O
support	NN	O
and	CC	O
exercise	NN	O
jacket	NN	O
,	,	O
was	VBD	O
effective	JJ	O
in	IN	O
enhancing	VBG	O
deep	JJ	PH
cervical	JJ	PH
muscle	NN	PH
endurance	NN	PH
.	.	O

Forty-five	JJ	O
(	(	O
45	CD	O
)	)	O
female	NN	O
subjects	NNS	O
,	,	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
18	CD	O
and	CC	O
40	CD	O
years	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
consisting	VBG	O
of	IN	O
the	DT	O
no-treatment	JJ	O
control	NN	O
,	,	O
the	DT	O
treatment-control	NN	O
(	(	O
table	JJ	O
stabilization	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
experimental	JJ	O
(	(	O
PostureJac	NNP	O
)	)	O
group	NN	O
.	.	O

The	DT	O
outcome	JJ	O
measure	NN	O
of	IN	O
deep	JJ	PH
cervical	JJ	PH
flexor	NN	PH
muscle	NN	PH
endurance	NN	PH
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
Flexor	NNP	PH
Endurance	NNP	PH
Test	NNP	PH
and	CC	O
was	VBD	O
recorded	VBN	O
in	IN	O
seconds	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
PostureJac	NNP	O
group	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
no-treatment	JJ	O
control	NN	O
(	(	O
p=.001	NN	O
)	)	O
and	CC	O
the	DT	O
treatment-control	NN	O
(	(	O
p=.004	NN	O
)	)	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
increasing	VBG	O
endurance	NN	PH
of	IN	PH
the	DT	PH
deep	JJ	PH
cervical	JJ	PH
flexors	NNS	PH
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
PostureJac	NNP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
therapeutic	JJ	O
tool	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	PH
headache	NN	PH
and	CC	O
mechanical	JJ	PH
neck	NN	PH
pain	NN	PH
.	.	O

The	DT	O
effect	NN	Ot
of	IN	O
quality	NN	O
and	CC	O
amount	NN	O
of	IN	O
dietary	JJ	O
fat	NN	O
on	IN	O
the	DT	O
susceptibility	NN	PH
of	IN	PH
low	JJ	PH
density	NN	PH
lipoprotein	NN	PH
to	TO	PH
oxidation	NN	PH
in	IN	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high	JJ	O
fat	NN	O
diet	JJ	O
rich	JJ	O
in	IN	O
monounsaturated	JJ	O
fat	NN	O
(	(	O
MUFA-diet	NNP	O
)	)	O
and	CC	O
a	DT	O
moderate	JJ	O
fat	NN	O
diet	JJ	O
rich	JJ	O
in	IN	O
polyunsaturated	JJ	O
fat	NN	O
(	(	O
PUFA-diet	NNP	O
)	)	O
on	IN	O
the	DT	O
susceptibility	NN	PH
of	IN	PH
LDL	NNP	PH
to	TO	PH
oxidation	NN	PH
.	.	O

SUBJECTS	NNP	O
29	CD	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
consuming	VBG	O
a	DT	O
run-in	JJ	O
diet	JJ	O
[	FW	O
37	CD	O
%	NN	O
of	IN	O
energy	NN	O
(	(	O
E	NNP	O
%	NN	O
)	)	O
fat	NN	O
,	,	O
18	CD	O
E	NNP	O
%	NN	O
saturated	VBD	O
fat	JJ	O
]	NN	O
for	IN	O
three	CD	O
weeks	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
either	RB	O
to	TO	O
a	DT	O
MUFA-diet	JJ	O
(	(	O
40	CD	O
E	NNP	O
%	NN	O
fat	NN	O
,	,	O
19	CD	O
E	NNP	O
%	NN	O
monounsaturated	VBD	O
fatty	JJ	O
acids	NNS	O
)	)	O
or	CC	O
a	DT	O
PUFA-diet	JJ	O
(	(	O
34	CD	O
E	NNP	O
%	NN	O
fat	NN	O
,	,	O
10	CD	O
E	NNP	O
%	NN	O
polyunsaturated	VBD	O
fat	NN	O
)	)	O
for	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

The	DT	O
susceptibility	NN	PH
of	IN	PH
LDL	NNP	PH
to	TO	PH
oxidation	NN	PH
was	VBD	O
measured	VBN	O
by	IN	O
challenging	VBG	O
LDL	NNP	O
with	IN	O
hemin	NN	O
and	CC	O
H2O2	NNP	O
and	CC	O
measuring	VBG	O
the	DT	O
time	NN	Ot
for	IN	Ot
the	DT	Ot
reaction	NN	Ot
to	TO	Ot
reach	VB	Ot
maximum	JJ	Ot
velocity	NN	Ot
.	.	O

Results	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
lag	NN	Ot
time	NN	Ot
to	TO	Ot
oxidation	NN	Ot
in	IN	O
minutes	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
lag	NN	Ot
time	NN	Ot
tended	VBD	O
to	TO	O
decrease	VB	O
during	IN	O
the	DT	O
experimental	JJ	O
diet	NN	O
(	(	O
97	CD	O
+/-	JJ	O
28	CD	O
vs	JJ	O
90	CD	O
+/-	JJ	O
25	CD	O
min	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
s.d.	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.073	CD	O
)	)	O
,	,	O
whereas	RB	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
(	(	O
lag	JJ	O
time	NN	O
96	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
100	CD	O
+/-	JJ	O
16	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.408	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	Ot
change	NN	Ot
in	IN	Ot
lag	NN	Ot
time	NN	Ot
was	VBD	O
-7	JJ	O
+/-	JJ	O
14	CD	O
min	NN	O
(	(	O
-7.2	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
and	CC	O
+4	VBZ	O
+/-	JJ	O
16	CD	O
min	NN	O
(	(	O
+4.0	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.029	CD	O
,	,	O
PUFA-diet	JJ	O
group	NN	O
vs	VBD	O
MUFA-diet	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
alpha-tocopherol	JJ	PH
concentration	NN	PH
in	IN	PH
LDL	NNP	PH
increased	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
both	DT	O
diet	JJ	O
groups	NNS	O
relative	VBP	O
to	TO	O
the	DT	O
run-in	JJ	O
diet	JJ	O
period	NN	O
,	,	O
but	CC	O
LDL	NNP	PH
particle	VBD	PH
score	RB	PH
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
either	DT	O
of	IN	O
the	DT	O
diet	JJ	O
groups	NNS	O
during	IN	O
the	DT	O
dietary	JJ	O
intervention	NN	O
.	.	O

In	IN	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
a	DT	O
PUFA-rich	JJ	O
diet	NN	O
with	IN	O
a	DT	O
moderate	JJ	O
amount	NN	O
of	IN	O
fat	NN	O
tended	VBN	O
to	TO	O
increase	VB	O
the	DT	O
susceptibility	NN	PH
of	IN	PH
LDL	NNP	PH
to	TO	PH
oxidation	NN	PH
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
higher	JJR	O
fat	JJ	O
diet	JJ	O
rich	NN	O
in	IN	O
MUFA	NNP	O
.	.	O

Furthermore	NNP	O
,	,	O
the	DT	O
negative	JJ	O
mean	NN	O
change	NN	O
in	IN	O
lag	NN	Ot
time	NN	Ot
to	TO	Ot
oxidation	NN	Ot
found	VBN	O
in	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
differed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
slightly	RB	O
positive	JJ	O
mean	NN	O
change	NN	O
found	VBD	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
.	.	O

Nordic	NNP	O
walking	NN	O
and	CC	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
design	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Low	NNP	O
Back	NNP	O
Pain	NNP	O
is	VBZ	O
a	DT	O
major	JJ	O
public	JJ	O
health	NN	O
problem	NN	O
all	DT	O
over	IN	O
the	DT	O
western	JJ	O
world	NN	O
.	.	O

Active	JJ	O
approaches	NNS	O
including	VBG	O
exercise	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
low	JJ	O
back	RB	O
pain	NN	O
results	NNS	O
in	IN	O
better	JJR	O
outcomes	NNS	O
for	IN	O
patients	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
exactly	RB	O
which	WDT	O
types	NNS	O
of	IN	O
back	NN	O
exercises	NNS	O
are	VBP	O
most	RBS	O
beneficial	JJ	O
or	CC	O
whether	IN	O
general	JJ	O
physical	JJ	O
activity	NN	O
provide	VBP	O
similar	JJ	O
benefits	NNS	O
.	.	O

Nordic	NNP	O
Walking	NNP	O
is	VBZ	O
a	DT	O
popular	JJ	O
and	CC	O
fast	JJ	O
growing	VBG	O
type	NN	O
of	IN	O
exercise	NN	O
in	IN	O
Northern	NNP	O
Europe	NNP	O
.	.	O

Initial	NNP	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
persons	NNS	O
performing	VBG	O
Nordic	NNP	O
Walking	NNP	O
are	VBP	O
able	JJ	O
to	TO	O
exercise	VB	O
longer	JJR	O
and	CC	O
harder	RBR	O
compared	VBN	O
to	TO	O
normal	JJ	O
walking	VBG	O
thereby	RB	O
increasing	VBG	O
their	PRP$	O
cardiovascular	JJ	O
metabolism	NN	O
.	.	O

Until	IN	O
now	RB	O
no	DT	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
to	TO	O
investigate	VB	O
whether	IN	O
Nordic	NNP	O
Walking	NNP	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	Ot
in	IN	O
relation	NN	O
to	TO	O
low	VB	O
back	RB	O
pain	NN	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
whether	IN	O
supervised	JJ	O
Nordic	NNP	O
Walking	NNP	O
can	MD	O
reduce	VB	PA
pain	NN	PA
and	CC	O
improve	VB	Ot
function	NN	Ot
in	IN	O
a	DT	O
population	NN	O
of	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
patients	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
unsupervised	JJ	O
Nordic	NNP	O
Walking	NNP	O
and	CC	O
advice	NN	O
to	TO	O
stay	VB	O
active	JJ	O
.	.	O

In	IN	O
addition	NN	O
we	PRP	O
investigate	VBP	O
whether	IN	O
there	EX	O
is	VBZ	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
cardiovascular	JJ	O
metabolism	NN	O
in	IN	O
persons	NNS	O
performing	VBG	O
supervised	VBD	O
Nordic	NNP	O
Walking	NNP	O
compared	VBN	O
to	TO	O
persons	NNS	O
who	WP	O
are	VBP	O
advised	VBN	O
to	TO	O
stay	VB	O
active	JJ	O
.	.	O

Finally	RB	O
,	,	O
we	PRP	O
investigate	VBP	O
whether	IN	O
there	EX	O
is	VBZ	O
a	DT	O
difference	NN	O
in	IN	O
compliance	NN	Ot
between	IN	O
persons	NNS	O
receiving	VBG	O
supervised	VBD	O
Nordic	NNP	O
Walking	NNP	O
and	CC	O
persons	NNS	O
doing	VBG	O
unsupervised	JJ	O
Nordic	NNP	O
Walking	NNP	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
fifty	JJ	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
for	IN	O
at	IN	O
least	JJS	O
eight	CD	O
weeks	NNS	O
and	CC	O
referred	VBD	O
to	TO	O
a	DT	O
specialized	JJ	O
secondary	JJ	O
sector	NN	O
outpatient	NN	O
back	RB	O
pain	NN	O
clinic	NN	O
are	VBP	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
completion	NN	O
of	IN	O
the	DT	O
standard	NN	O
back	RB	O
centre	JJ	O
treatment	NN	O
patients	NNS	O
are	VBP	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
A	DT	O
)	)	O
Nordic	NNP	O
Walking	NNP	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
eight	CD	O
weeks	NNS	O
under	IN	O
supervision	NN	O
of	IN	O
a	DT	O
specially	RB	O
trained	JJ	O
instructor	NN	O
;	:	O
B	NNP	O
)	)	O
Unsupervised	VBD	O
Nordic	NNP	O
Walking	NNP	O
for	IN	O
eight	CD	O
weeks	NNS	O
after	IN	O
one	CD	O
training	NN	O
session	NN	O
with	IN	O
an	DT	O
instructor	NN	O
;	:	O
C	NNP	O
)	)	O
A	DT	O
one	CD	O
hour	NN	O
motivational	JJ	O
talk	NN	O
including	VBG	O
advice	NN	O
to	TO	O
stay	VB	O
active	JJ	O
.	.	O

Outcome	NN	O
measures	NNS	O
are	VBP	O
pain	NN	PA
,	,	O
function	NN	PA
,	,	O
overall	JJ	Ot
health	NN	Ot
,	,	O
cardiovascular	JJ	PH
ability	NN	PH
and	CC	O
activity	NN	PA
level	NN	PA
.	.	O

RESULTS	NNP	O
No	NNP	O
results	NNS	O
available	JJ	O
at	IN	O
this	DT	O
point	NN	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
study	NN	O
will	MD	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
Nordic	NNP	O
Walking	VBG	O
on	IN	O
pain	NN	O
and	CC	O
function	NN	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
people	NNS	O
with	IN	O
chronic	JJ	O
LBP	NNP	O
.	.	O

Calcium	NNP	O
channel	NN	O
blocker	NN	O
inhibition	NN	O
of	IN	O
AGE	NNP	O
and	CC	O
RAGE	NNP	O
axis	VBP	O
limits	NNS	O
renal	JJ	PH
injury	NN	PH
in	IN	O
nondiabetic	JJ	O
patients	NNS	O
with	IN	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
a	DT	O
growing	VBG	O
body	NN	O
of	IN	O
evidence	NN	O
that	IN	O
advanced	VBD	O
glycation	JJ	O
end	NN	O
products	NNS	O
(	(	O
AGE	NNP	O
)	)	O
and	CC	O
their	PRP$	O
receptor	NN	O
(	(	O
RAGE	NNP	O
)	)	O
system	NN	O
are	VBP	O
implicated	VBN	O
in	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
previously	RB	O
found	VBN	O
that	IN	O
a	DT	O
long-acting	JJ	O
calcium	NN	O
channel	NN	O
blocker	NN	O
,	,	O
azelnidipine	NN	O
,	,	O
but	CC	O
not	RB	O
amlodipine	VB	O
,	,	O
improves	VBZ	O
renal	JJ	PH
injury	NN	PH
in	IN	O
CKD	NNP	O
patients	NNS	O
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
azelnidipine	NN	O
on	IN	O
the	DT	O
AGE-RAGE	NNP	PH
axis	NN	PH
in	IN	O
humans	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
whether	IN	O
azelnidipine	JJ	O
addition	NN	O
could	MD	O
have	VB	O
renoprotective	JJ	O
properties	NNS	O
in	IN	O
hypertensive	JJ	O
CKD	NNP	O
patients	NNS	O
by	IN	O
reducing	VBG	O
serum	NN	PH
levels	NNS	PH
of	IN	PH
AGE	NNP	PH
and	CC	PH
soluble	JJ	PH
form	NN	PH
of	IN	PH
RAGE	NNP	PH
(	(	PH
sRAGE	NN	PH
)	)	PH
.	.	O

Thirty	NNP	O
nondiabetic	JJ	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
CKD	NNP	O
patients	NNS	O
who	WP	O
had	VBD	O
already	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

HYPOTHESIS	NNP	O
We	PRP	O
hypothesized	VBD	O
that	IN	O
azelnidipine	NN	O
treatment	NN	O
could	MD	O
limit	VB	O
renal	JJ	O
injury	NN	O
partly	RB	O
by	IN	O
blocking	VBG	O
the	DT	O
AGE-RAGE	NNP	PH
axis	NN	PH
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
;	:	O
one	CD	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
16	CD	O
mg	NNS	O
azelnidipine	NN	O
and	CC	O
the	DT	O
other	JJ	O
with	IN	O
5	CD	O
mg	NNS	O
amlodipine	JJ	O
once	RB	O
daily	JJ	O
.	.	O

They	PRP	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Proteinuria	NNP	PH
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
circulating	VBG	PH
AGE	NNP	PH
and	CC	PH
sRAGE	NN	PH
levels	NNS	PH
in	IN	O
our	PRP$	O
subjects	NNS	O
.	.	O

Both	DT	O
drugs	NNS	O
exhibited	VBN	O
comparable	JJ	O
and	CC	O
significant	JJ	O
blood	NN	PH
pressure	NN	PH
(	(	PH
BP	NNP	PH
)	)	PH
-lowering	VBG	PH
effects	NNS	PH
.	.	O

Although	IN	O
neither	DT	O
of	IN	O
them	PRP	O
affected	VBD	O
glucose	NN	PH
,	,	PH
glycated	VBD	PH
hemoglobin	NN	PH
,	,	PH
lipid	JJ	PH
levels	NNS	PH
,	,	PH
and	CC	PH
estimated	VBD	PH
glomerular	JJ	PH
filtration	NN	PH
rate	NN	PH
,	,	PH
treatment	NN	PH
with	IN	PH
azelnidipine	NN	PH
,	,	O
but	CC	O
not	RB	O
amlodipine	VB	O
,	,	O
decreased	VBN	O
circulating	NN	PH
AGE	NNP	PH
,	,	PH
sRAGE	NN	PH
,	,	PH
proteinuria	NN	PH
,	,	PH
and	CC	PH
urinary	JJ	PH
levels	NNS	PH
of	IN	PH
liver-type	JJ	PH
fatty	JJ	PH
acid	NN	PH
binding	VBG	PH
protein	NN	PH
,	,	O
a	DT	O
marker	NN	O
of	IN	O
tubular	JJ	O
injury	NN	O
,	,	O
in	IN	O
a	DT	O
BP-lowering-independent	JJ	O
manner	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
present	JJ	O
results	NNS	O
suggest	VBP	O
that	IN	O
azelnidipine	NN	O
may	MD	O
exert	VB	O
renoprotective	JJ	PH
properties	NNS	PH
in	IN	O
nondiabetic	JJ	O
hypertensive	JJ	O
CKD	NNP	O
patients	NNS	O
via	IN	O
its	PRP$	O
unique	JJ	O
inhibitory	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
AGE-RAGE	NNP	O
axis	NN	O
.	.	O

Quantification	NN	O
of	IN	O
cyproheptadine	NN	O
in	IN	O
human	JJ	O
plasma	NN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
coupled	VBD	O
to	TO	O
electrospray	VB	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
in	IN	O
a	DT	O
bioequivalence	NN	O
study	NN	O
.	.	O

A	DT	O
rapid	JJ	O
,	,	O
sensitive	JJ	O
and	CC	O
specific	JJ	O
method	NN	O
to	TO	O
quantify	VB	O
cyproheptadine	NN	O
in	IN	O
human	JJ	O
plasma	NN	O
using	VBG	O
amitriptyline	NN	O
as	IN	O
the	DT	O
internal	JJ	O
standard	NN	O
(	(	O
IS	NNP	O
)	)	O
is	VBZ	O
described	VBN	O
.	.	O

The	DT	O
analyte	NN	O
and	CC	O
the	DT	O
IS	NNP	O
were	VBD	O
extracted	VBN	O
from	IN	O
plasma	NN	O
by	IN	O
liquid-liquid	JJ	O
extraction	NN	O
using	VBG	O
a	DT	O
diethyl-ether/dichloromethane	NN	O
(	(	O
70/30	CD	O
;	:	O
v/v	NN	O
)	)	O
solvent	NN	O
.	.	O

After	IN	O
removing	VBG	O
and	CC	O
drying	VBG	O
the	DT	O
organic	JJ	O
phase	NN	O
,	,	O
the	DT	O
extracts	NNS	O
were	VBD	O
reconstituted	VBN	O
with	IN	O
a	DT	O
fixed	JJ	O
volume	NN	O
of	IN	O
acetonitrile/water	NN	O
(	(	O
50/50	CD	O
v/v	NN	O
)	)	O
+0.1	CD	O
%	NN	O
of	IN	O
acetic	JJ	O
acid	NN	O
.	.	O

The	DT	O
extracts	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
high	JJ	O
performance	NN	O
liquid	NN	O
chromatography	NN	O
coupled	VBD	O
to	TO	O
electrospray	VB	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
(	(	O
LC-MS/MS	NNP	O
)	)	O
.	.	O

Chromatography	NNP	O
was	VBD	O
performed	VBN	O
isocratically	RB	O
using	VBG	O
an	DT	O
Alltech	NNP	O
Prevail	NNP	O
C18	NNP	O
5	CD	O
?m	NNP	O
analytical	JJ	O
column	NN	O
,	,	O
(	(	O
150	CD	O
mm	NN	O
x	VBD	O
4.6	CD	O
mm	NNS	O
I.D.	NNP	O
)	)	O
.	.	O

The	DT	O
method	NN	O
had	VBD	O
a	DT	O
chromatographic	JJ	O
run	NN	O
time	NN	O
of	IN	O
4	CD	O
min	NNS	O
and	CC	O
a	DT	O
linear	JJ	O
calibration	NN	O
curve	NN	O
ranging	VBG	O
from	IN	O
0.05	CD	O
to	TO	O
10	CD	O
ng/mL	NNS	O
(	(	O
r2	VB	O
>	RB	O
0.99	CD	O
)	)	O
.	.	O

The	DT	O
limit	NN	O
of	IN	O
quantification	NN	O
was	VBD	O
0.05	CD	O
ng/mL	RB	O
.	.	O

This	DT	O
HPLC/MS/MS	NNP	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
bioequivalence	NN	O
of	IN	O
cyproheptadine	NN	O
in	IN	O
two	CD	O
cyproheptadine	NN	O
+	NNS	O
cobamamide	VBP	O
(	(	O
4	CD	O
mg	NN	O
+	VBD	O
1	CD	O
mg	NN	O
)	)	O
tablet	NN	O
formulations	NNS	O
(	(	O
Cobactin?	NNP	O
[	NNP	O
cyproheptadine	NN	O
+	NNP	O
cobamamide	NN	O
]	NNP	O
test	NN	O
formulation	NN	O
supplied	VBN	O
from	IN	O
Zambon	NNP	O
Laborat?rios	NNP	O
Farmac?uticos	NNP	O
Ltda	NNP	O
.	.	O

and	CC	O
Cobavital?	NNP	O
from	IN	O
Solvay	NNP	O
Farma	NNP	O
(	(	O
standard	JJ	O
reference	NN	O
formulation	NN	O
)	)	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
4	CD	O
mg	NN	O
+	VBD	O
1	CD	O
mg	NN	O
[	NNP	O
cyproheptadine	NN	O
+	NNP	O
cobamamide	NN	O
]	NNP	O
dose	NN	O
of	IN	O
each	DT	O
formulation	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
using	VBG	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
,	,	O
two-period	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
interval	NN	O
.	.	O

Since	IN	O
the	DT	O
90	CD	O
%	NN	O
CI	NNP	O
for	IN	O
Cmax	NNP	O
and	CC	O
AUCs	NNP	O
ratios	NNS	O
were	VBD	O
all	DT	O
within	IN	O
the	DT	O
80-125	JJ	O
%	NN	O
bioequivalence	NN	O
limit	NN	O
proposed	VBN	O
by	IN	O
the	DT	O
US	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
,	,	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
cyproheptadine	JJ	O
test	NN	O
formulation	NN	O
(	(	O
Cobactin?	NNP	O
)	)	O
is	VBZ	O
bioequivalent	JJ	O
to	TO	O
the	DT	O
Cobavital?	NNP	O
formulation	NN	O
for	IN	O
both	DT	O
the	DT	O
rate	NN	O
and	CC	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
of	IN	O
cyproheptadine	NN	O
.	.	O

A	DT	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
in	IN	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
patients	NNS	O
.	.	O

OBJECTIVES	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
a	DT	O
)	)	O
document	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
device	NN	O
intended	VBN	O
to	TO	O
conserve	VB	O
blood	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
;	:	O
b	NN	O
)	)	O
determine	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
this	DT	O
blood	NN	O
conservation	NN	O
on	IN	O
hemoglobin	JJ	PH
concentration	NN	PH
and	CC	O
the	DT	O
need	NN	PH
for	IN	PH
blood	NN	PH
transfusions	NNS	PH
;	:	O
c	NNS	O
)	)	O
determine	VBP	O
if	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
resulted	VBD	O
in	IN	O
interference	NN	O
with	IN	O
arterial	JJ	O
pressure	NN	O
waveforms	NNS	O
;	:	O
d	NN	O
)	)	O
determine	NN	O
if	IN	O
use	NN	O
of	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
difference	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
accidental	JJ	O
needle	JJ	O
punctures	NNS	O
suffered	VBN	O
by	IN	O
healthcare	JJ	O
workers	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
.	.	O

A	DT	O
clinical	JJ	O
trial	NN	O
using	VBG	O
prospective	JJ	O
,	,	O
random	JJ	O
allocation	NN	O
of	IN	O
consecutive	JJ	O
eligible	JJ	O
patients	NNS	O
.	.	O

SETTING	VBG	O
The	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
located	VBN	O
in	IN	O
a	DT	O
large	JJ	O
metropolitan	JJ	O
area	NN	O
.	.	O

PATIENTS	VB	O
A	DT	O
total	NN	O
of	IN	O
100	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
the	DT	O
medical	JJ	O
ICU	NNP	O
,	,	O
required	VBD	O
arterial	JJ	O
line	NN	O
monitoring	NN	O
for	IN	O
clinical	JJ	O
purposes	NNS	O
,	,	O
and	CC	O
were	VBD	O
managed	VBN	O
by	IN	O
the	DT	O
ICU	NNP	O
medical	JJ	O
service	NN	O
.	.	O

Exclusion	NNP	O
criteria	NNS	O
included	VBD	O
active	JJ	O
bleeding	NN	O
or	CC	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
ICU	NNP	O
admission	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
had	VBD	O
a	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
incorporated	VBN	O
into	IN	O
the	DT	O
arterial	JJ	O
pressure	NN	O
monitoring	NN	O
system	NN	O
,	,	O
while	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
conventional	JJ	O
arterial	JJ	O
pressure	NN	O
monitoring	NN	O
system	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Data	NNP	O
gathered	VBD	O
included	VBN	O
:	:	O
age	NN	O
;	:	O
gender	NN	O
;	:	O
ICU	NNP	O
discharge	NN	O
status	NN	O
;	:	O
the	DT	O
duration	NN	Ot
of	IN	Ot
ICU	NNP	Ot
stay	NN	Ot
;	:	Ot
time	NN	Ot
in	IN	Ot
the	DT	Ot
study	NN	Ot
;	:	Ot
volume	NN	Ot
of	IN	Ot
all	DT	Ot
blood	NN	Ot
drawn	NN	Ot
,	,	Ot
discarded	VBD	Ot
,	,	Ot
or	CC	Ot
lost	VBN	Ot
due	JJ	Ot
to	TO	Ot
leakage	VB	Ot
;	:	Ot
hemoglobin	JJ	PH
concentrations	NNS	PH
;	:	O
blood	NN	PH
transfusions	NNS	PH
;	:	O
and	CC	O
accidental	JJ	ME
needle	JJ	ME
injuries	NNS	ME
.	.	O

Arterial	JJ	PH
pressure	NN	PH
waveforms	NNS	PH
were	VBD	O
recorded	VBN	O
and	CC	O
inspected	VBN	O
for	IN	O
dampening	VBG	O
or	CC	O
other	JJ	O
deformation	NN	O
.	.	O

Mean	NNP	PH
hemoglobin	JJ	PH
concentrations	NNS	PH
were	VBD	O
compared	VBN	O
on	IN	O
ICU	NNP	O
admission	NN	O
and	CC	O
at	IN	O
12-hr	JJ	O
intervals	NNS	O
.	.	O

Demographic	NNP	O
and	CC	O
clinical	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

The	DT	O
volume	NN	Ot
of	IN	Ot
blood	NN	Ot
drawn	NN	Ot
and	CC	Ot
discarded	VBD	Ot
from	IN	Ot
arterial	JJ	Ot
catheters	NNS	Ot
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
:	:	O
5.7	CD	O
+/-	JJ	O
7.5	CD	O
mL	NN	O
;	:	O
control	NN	O
:	:	O
96.4	CD	O
+/-	JJ	O
88.5	CD	O
mL	NN	O
;	:	O
p	CC	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
total	JJ	Ot
volume	NN	Ot
of	IN	Ot
blood	NN	Ot
discarded	VBN	Ot
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
:	:	O
19.4	CD	O
+/-	JJ	O
47.4	CD	O
mL	NN	O
;	:	O
control	NN	O
:	:	O
103.5	CD	O
+/-	JJ	O
99.9	CD	O
mL	NN	O
;	:	O
p	CC	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Mean	NNP	PH
hemoglobin	JJ	PH
concentration	NN	PH
on	IN	O
admission	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
group	NN	O
:	:	O
11.8	CD	O
+/-	JJ	O
2.5	CD	O
g/dL	NN	O
;	:	O
control	NN	O
group	NN	O
:	:	O
12.6	CD	O
+/-	JJ	O
2.3	CD	O
g/dL	NN	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
mean	JJ	PH
hemoglobin	NN	PH
concentration	NN	PH
declined	VBD	O
most	JJS	O
rapidly	RB	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
of	IN	O
ICU	NNP	O
care	NN	O
and	CC	O
,	,	O
thereafter	RB	O
,	,	O
declined	VBD	O
more	RBR	O
slowly	RB	O
.	.	O

Although	IN	O
the	DT	O
mean	JJ	PH
hemoglobin	NN	PH
concentration	NN	PH
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
after	IN	O
6	CD	O
days	NNS	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
until	IN	O
9.5	CD	O
days	NNS	O
of	IN	O
ICU	NNP	O
care	NN	O
.	.	O

The	DT	O
mean	JJ	PH
change	NN	PH
in	IN	PH
hemoglobin	JJ	PH
concentration	NN	PH
(	(	O
overall	JJ	O
:	:	O
1.2	CD	O
+/-	JJ	O
2.2	CD	O
g/dL	NN	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
represents	VBZ	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
.0001	NNP	O
)	)	O
decrease	NN	O
of	IN	O
9.7	CD	O
%	NN	O
.	.	O

Hemoglobin	NNP	PH
concentration	NN	PH
during	IN	O
the	DT	O
study	NN	O
decreased	VBN	O
by	IN	O
1.4	CD	O
+/-	JJ	O
2.2	CD	O
g/dL	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
1.0	CD	O
+/-	JJ	O
2.3	CD	O
g/dL	NN	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
nonsignificant	NN	O
)	)	O
.	.	O

Univariate	NNP	PH
and	CC	PH
multiple	JJ	PH
regression	NN	PH
analysis	NN	PH
demonstrated	VBD	O
discarded	JJ	O
blood	NN	PH
volume	NN	PH
to	TO	O
be	VB	O
a	DT	O
significant	JJ	O
and	CC	O
independent	JJ	O
predictor	NN	O
of	IN	O
the	DT	O
decline	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
.	.	O

Transfusion	NN	PH
requirements	NNS	PH
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
blood	NN	O
conservation	NN	O
system	NN	O
did	VBD	O
not	RB	O
alter	VB	O
or	CC	O
interfere	VB	O
with	IN	O
pressure	NN	PH
waveforms	NNS	PH
.	.	O

There	EX	O
were	VBD	O
no	DT	O
accidental	JJ	ME
needle	JJ	ME
injuries	NNS	ME
noted	VBD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
conservation	NN	O
of	IN	O
blood	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
must	MD	O
be	VB	O
a	DT	O
high-priority	JJ	O
concern	NN	O
of	IN	O
all	DT	O
healthcare	JJ	O
workers	NNS	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
system	NN	O
eliminates	VBZ	O
a	DT	O
significant	JJ	O
factor	NN	O
in	IN	O
the	DT	O
decline	NN	O
in	IN	O
hemoglobin	JJ	PH
concentration	NN	PH
.	.	O

With	IN	O
devices	NNS	O
as	IN	O
described	NN	O
here	RB	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
reason	NN	O
to	TO	O
continue	VB	O
the	DT	O
practice	NN	O
of	IN	O
wasting	VBG	O
the	DT	O
blood	NN	O
of	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
preanalytic	JJ	O
error	NN	O
.	.	O

Omega-3/omega-6	NNP	O
fatty	JJ	O
acids	NNS	O
for	IN	O
attention	NN	ME
deficit	NN	ME
hyperactivity	NN	ME
disorder	NN	ME
:	:	ME
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
omega	JJ	O
3/6	CD	O
fatty	JJ	O
acids	NNS	O
(	(	O
eye	NN	O
q	NN	O
)	)	O
in	IN	O
attention	NN	ME
deficit	NN	ME
hyperactivity	NN	ME
disorder	NN	ME
(	(	ME
ADHD	NNP	ME
)	)	ME
.	.	ME

METHOD	PDT	O
The	DT	O
study	NN	O
included	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
3-month	JJ	O
,	,	O
omega	JJ	O
3/6	CD	O
placebo-controlled	JJ	O
,	,	O
one-way	JJ	O
crossover	NN	O
trial	NN	O
with	IN	O
75	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
8-18	CD	O
years	NNS	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	O
months	NNS	O
with	IN	O
omega	JJ	O
3/6	CD	O
for	IN	O
all	DT	O
.	.	O

Investigator-rated	JJ	ME
ADHD	NNP	ME
Rating	NNP	ME
Scale-IV	NNP	ME
and	CC	ME
Clinical	NNP	ME
Global	NNP	ME
Impression	NNP	ME
(	(	ME
CGI	NNP	ME
)	)	ME
scale	NN	ME
were	VBD	O
outcome	JJ	O
measures	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
majority	NN	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
omega	VB	O
3/6	CD	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subgroup	NN	O
of	IN	O
26	CD	O
%	NN	O
responded	VBD	O
with	IN	O
more	JJR	O
than	IN	O
25	CD	O
%	NN	O
reduction	NN	ME
of	IN	ME
ADHD	NNP	ME
symptoms	NNS	ME
and	CC	O
a	DT	O
drop	NN	ME
of	IN	ME
CGI	NNP	ME
scores	NNS	ME
to	TO	O
the	DT	O
near-normal	JJ	O
range	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
47	CD	O
%	NN	O
of	IN	O
all	DT	O
showed	VBD	O
such	JJ	O
improvement	NN	O
.	.	O

Responders	NNS	O
tended	VBD	O
to	TO	O
have	VB	O
ADHD	NNP	ME
inattentive	JJ	O
subtype	NN	O
and	CC	O
comorbid	NN	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

CONCLUSION	VB	O
A	DT	O
subgroup	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ADHD	NNP	ME
,	,	O
characterized	VBN	O
by	IN	O
inattention	NN	O
and	CC	O
associated	VBN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
treated	VBN	O
with	IN	O
omega	JJ	O
3/6	CD	O
fatty	JJ	O
acids	NNS	O
for	IN	O
6	CD	O
months	NNS	O
responded	VBN	O
with	IN	O
meaningful	JJ	O
reduction	NN	ME
of	IN	ME
ADHD	NNP	ME
symptoms	NNS	ME
.	.	ME

Mandibular	JJ	O
advancement	NN	O
splint	NN	O
improves	VBZ	O
indices	NNS	O
of	IN	O
obstructive	JJ	O
sleep	NN	O
apnoea	NN	O
and	CC	O
snoring	VBG	O
but	CC	O
side	JJ	O
effects	NNS	O
are	VBP	O
common	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
mandibular	JJ	O
advancement	NN	O
splint	NN	O
(	(	O
MAS	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obstructive	JJ	PH
sleep	JJ	PH
apnoea	NN	PH
syndrome	NN	PH
(	(	PH
OSAS	NNP	PH
)	)	PH
.	.	PH

METHODS	NNP	O
Nineteen	NNP	O
patients	NNS	O
using	VBG	O
a	DT	O
MAS	NNP	O
for	IN	O
symptomatic	JJ	O
OSAS	NNP	O
underwent	NN	O
polysomnography	NN	O
,	,	O
with	IN	O
MAS	NNP	O
use	NN	O
randomised	VBD	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
night	NN	O
.	.	O

Indices	NNS	PH
of	IN	PH
snoring	VBG	PH
and	CC	O
OSAS	NNP	PH
were	VBD	O
compared	VBN	O
.	.	O

Side	NNP	A
effects	NNS	A
,	,	O
compliance	NN	Ot
and	CC	O
treatment	NN	PH
response	NN	PH
were	VBD	O
evaluated	VBN	O
by	IN	O
questionnaire	NN	O
.	.	O

RESULTS	NNP	O
Use	NNP	O
of	IN	O
the	DT	O
MAS	NNP	O
improved	VBD	O
total	JJ	PH
respiratory	NN	PH
disturbance	NN	PH
index	NN	PH
(	(	PH
RDI	NNP	PH
)	)	PH
from	IN	O
22.2	CD	O
+/-	JJ	O
19.8	CD	O
(	(	O
SD	NNP	O
)	)	O
events	NNS	PH
per	IN	PH
hour	NN	PH
to	TO	O
16.5	CD	O
+/-	JJ	O
21.4/hr	CD	O
(	(	O
p	NN	O
=	RB	O
0.03	CD	O
)	)	O
,	,	O
supine	JJ	PH
RDI	NNP	PH
(	(	O
30.8	CD	O
+/-	JJ	O
23.8/hr	CD	O
to	TO	O
18.8	CD	O
+/-	JJ	O
22.1/hr	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
arousal	JJ	PH
index	NN	PH
(	(	O
25.2	CD	O
+/-	JJ	O
18.9/hr	CD	O
to	TO	O
19.3	CD	O
+/-	JJ	O
14.2/hr	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
snoring	VBG	PH
intensity	NN	PH
(	(	O
52.7	CD	O
+/-	JJ	O
4.1	CD	O
to	TO	O
50.7	CD	O
+/-	JJ	O
2.7	CD	O
dB	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
but	CC	O
not	RB	O
total	JJ	PH
snore	NN	PH
frequency	NN	PH
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Using	VBG	O
polysomnographic	JJ	O
criteria	NNS	O
,	,	O
MAS	NNP	O
treatment	NN	O
was	VBD	O
completely	RB	Ot
successful	JJ	Ot
in	IN	O
four	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
partially	RB	Ot
successful	JJ	Ot
in	IN	O
ten	NN	O
(	(	O
52.6	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
failure	NN	Ot
in	IN	O
five	CD	O
(	(	O
26.3	CD	O
%	NN	O
)	)	O
.	.	O

Treatment	NN	O
over	IN	O
a	DT	O
median	NN	O
of	IN	O
6.5	CD	O
weeks	NNS	O
(	(	O
range	VB	O
2-48	CD	O
)	)	O
was	VBD	O
perceived	VBN	O
as	IN	O
beneficial	JJ	O
by	IN	O
ten	NN	O
of	IN	O
eleven	JJ	O
partners	NNS	O
.	.	O

Fifteen	JJ	O
patients	NNS	O
(	(	O
79	CD	O
%	NN	O
)	)	O
reported	VBD	O
side	JJ	A
effects	NNS	A
,	,	O
9	CD	O
(	(	O
46	CD	O
%	NN	O
)	)	O
did	VBD	O
not	RB	O
use	VB	O
the	DT	O
device	NN	O
every	DT	O
night	NN	O
and	CC	O
four	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
used	VBD	O
the	DT	O
device	NN	O
less	JJR	O
than	IN	O
three	CD	O
nights	NNS	O
per	IN	O
week	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
use	NN	O
of	IN	O
the	DT	O
MAS	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
indices	NNS	O
of	IN	O
OSAS	NNP	PH
and	CC	O
snoring	VBG	PH
.	.	O

However	RB	O
,	,	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
had	VBD	O
difficulty	NN	O
tolerating	NN	O
and	CC	O
regularly	RB	O
using	VBG	O
the	DT	O
device	NN	O
.	.	O

Metabolic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
surgery	NN	O
under	IN	O
local	JJ	O
anesthesia	NN	O
and	CC	O
sedation	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
:	:	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
local	JJ	O
anesthetics	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
epinephrine-free	JJ	O
and	CC	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetic	JJ	O
solutions	NNS	O
on	IN	O
plasma	NN	PH
potassium	NN	PH
and	CC	PH
blood	NN	PH
glucose	JJ	PH
concentrations	NNS	PH
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	O
patients	NNS	O
undergoing	JJ	O
oral	JJ	O
surgery	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
sedation	NN	O
.	.	O

Ten	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
4.4	CD	O
mL	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	O
with	IN	O
1:80,000	CD	O
epinephrine	NN	O
as	IN	O
a	DT	O
local	JJ	O
anesthetic	NN	O
and	CC	O
10	CD	O
were	VBD	O
given	VBN	O
4.4	CD	O
mL	NN	O
of	IN	O
3	CD	O
%	NN	O
prilocaine	NN	O
with	IN	O
0.03	CD	O
IU/mL	NNP	O
felypressin	NN	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
potassium	NN	PH
and	CC	PH
glucose	JJ	PH
concentrations	NNS	PH
both	DT	O
within	IN	O
and	CC	O
between	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
early	JJ	O
postinjection	NN	O
period	NN	O
.	.	O

The	DT	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetic	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
plasma	NN	PH
potassium	NN	PH
concentration	NN	PH
10	CD	PH
min	NN	PH
after	IN	PH
injection	NN	PH
,	,	O
by	IN	O
0.16	CD	O
+/-	JJ	O
0.20	CD	O
mmol/L	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
,	,	O
and	CC	O
increased	VBD	O
the	DT	O
blood	NN	PH
glucose	JJ	PH
concentration	NN	PH
at	IN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
(	(	O
by	IN	O
0.46	CD	O
+/-	JJ	O
0.37	CD	O
,	,	O
0.63	CD	O
+/-	JJ	O
0.45	CD	O
,	,	O
and	CC	O
0.56	CD	O
+/-	JJ	O
0.28	CD	O
mmol/L	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Conversely	RB	O
,	,	O
plasma	JJ	PH
potassium	NN	PH
increased	VBD	O
and	CC	O
blood	NN	PH
glucose	NN	PH
decreased	VBD	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
epinephrine-free	JJ	O
solution	NN	O
.	.	O

At	IN	O
30	CD	PH
min	NN	PH
potassium	NN	PH
was	VBD	O
increased	VBN	O
by	IN	O
0.24	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
,	,	O
and	CC	O
glucose	NN	PH
was	VBD	O
decreased	VBN	O
by	IN	O
0.23	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
epinephrine-free	JJ	O
and	CC	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetics	NNS	O
differ	VBP	O
in	IN	O
their	PRP$	O
metabolic	JJ	O
effects	NNS	O
during	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
midazolam	JJ	O
sedation	NN	O
.	.	O

Active	JJ	O
warming	NN	O
,	,	O
not	RB	O
passive	JJ	O
heat	NN	O
retention	NN	O
,	,	O
maintains	VBZ	O
normothermia	JJ	PH
during	IN	O
combined	JJ	O
epidural-general	JJ	O
anesthesia	NN	O
for	IN	O
hip	NN	O
and	CC	O
knee	NN	O
arthroplasty	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
to	TO	O
compare	VB	O
passive	JJ	O
heat	NN	O
retention	NN	O
by	IN	O
low-flow	JJ	O
anesthesia	NN	O
,	,	O
alone	RB	O
and	CC	O
with	IN	O
additional	JJ	O
thermal	JJ	O
insulation	NN	O
by	IN	O
reflective	JJ	O
blankets	NNS	O
,	,	O
with	IN	O
forced-air	JJ	O
warming	VBG	O
preventing	VBG	O
intraoperative	JJ	O
hypothermia	NN	O
during	IN	O
combined	JJ	O
epidural-general	JJ	O
anesthesia	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Inpatient	NNP	O
anesthesia	NN	O
at	IN	O
a	DT	O
university	NN	O
department	NN	O
of	IN	O
orthopedic	JJ	O
surgery	NN	O
.	.	O

PATIENTS	CC	O
30	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
,	,	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
elective	JJ	O
hip	NN	O
or	CC	O
knee	VB	O
arthroplasty	JJ	O
and	CC	O
were	VBD	O
free	JJ	O
from	IN	O
systemic	JJ	O
disease	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
received	VBD	O
epidural	JJ	O
block	NN	O
up	RB	O
to	TO	O
T10	NNP	O
by	IN	O
alkalinized	JJ	O
lidocaine	JJ	O
2	CD	O
%	NN	O
,	,	O
and	CC	O
then	RB	O
were	VBD	O
administered	VBN	O
standard	JJ	O
general	JJ	O
anesthesia	NN	O
by	IN	O
means	NNS	O
of	IN	O
low-flow	JJ	O
rebreathing	NN	O
system	NN	O
(	(	O
fresh	JJ	O
gas	NN	O
flow	NN	O
=	VBD	O
1	CD	O
L/min	NNP	O
)	)	O
.	.	O

All	DT	O
procedures	NNS	O
started	VBD	O
between	IN	O
8	CD	O
and	CC	O
10	CD	O
AM	NNP	O
,	,	O
and	CC	O
operating	NN	O
room	NN	O
(	(	O
OR	NNP	O
)	)	O
temperature	NN	O
was	VBD	O
maintained	VBN	O
between	IN	O
21	CD	O
degrees	NNS	O
and	CC	O
23	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
with	IN	O
relative	JJ	O
humidity	NN	O
ranging	VBG	O
between	IN	O
40	CD	O
%	NN	O
and	CC	O
45	CD	O
%	NN	O
.	.	O

For	IN	O
heat	NN	O
retention	NN	O
or	CC	O
warming	VBG	O
therapy	NN	O
,	,	O
patients	NNS	O
received	VBD	O
either	RB	O
low-flow	JJ	O
anesthesia	NN	O
only	RB	O
(	(	O
control	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
low-flow	JJ	O
anesthesia	NN	O
with	IN	O
additional	JJ	O
reflective	JJ	O
blankets	NNS	O
(	(	O
blanket	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
or	CC	O
low-flow	JJ	O
anesthesia	NN	O
with	IN	O
active	JJ	O
forced-air	JJ	O
warming	NN	O
(	(	O
forced-air	JJ	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

Tympanic	JJ	PH
temperature	NN	PH
was	VBD	O
measured	VBN	O
at	IN	O
OR	NNP	O
arrival	NN	O
(	(	O
baseline	NN	O
)	)	O
;	:	O
immediately	RB	O
following	VBG	O
general	JJ	O
anesthesia	JJ	O
induction	NN	O
;	:	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
,	,	O
and	CC	O
120	CD	O
minutes	NNS	O
from	IN	O
general	JJ	O
anesthesia	NN	O
induction	NN	O
;	:	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Duration	NNP	PH
of	IN	PH
anesthesia	NN	PH
,	,	PH
invasiveness	NN	PH
of	IN	PH
surgery	NN	PH
,	,	PH
and	CC	PH
baseline	NN	PH
core	NN	PH
temperature	NN	PH
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Core	NNP	PH
temperature	NN	PH
decreased	VBN	O
in	IN	O
all	PDT	O
the	DT	O
three	CD	O
groups	NNS	O
30	CD	O
minutes	NNS	O
after	IN	O
general	JJ	O
anesthesia	NN	O
induction	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
afterwards	NNS	O
,	,	O
it	PRP	O
progressively	RB	O
decreased	VBD	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
blankets	NNS	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
with	IN	O
a	DT	O
reduction	NN	PH
from	IN	PH
baseline	NN	PH
values	NNS	PH
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
of	IN	O
2.0	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
1.6	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
forced-air	JJ	O
group	NN	O
,	,	O
after	IN	O
the	DT	O
initial	JJ	O
significant	JJ	O
decrease	NN	O
(	(	O
p	JJ	O
=	$	O
0.01	CD	O
vs.	FW	O
baseline	NN	O
)	)	O
,	,	O
core	JJ	PH
temperature	NN	PH
progressively	RB	O
increased	VBD	O
to	TO	O
35.8	CD	O
+/-	JJ	O
0.6	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
which	WDT	O
was	VBD	O
similar	JJ	O
to	TO	O
preoperative	VB	O
values	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
either	CC	O
the	DT	O
control	NN	O
or	CC	O
blankets	NNS	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
During	IN	O
combined	VBN	O
epidural-general	JJ	O
anesthesia	NN	O
for	IN	O
elective	JJ	O
hip	NN	O
and	CC	O
knee	NN	O
arthroplasty	NN	O
,	,	O
passive	JJ	O
heat	NN	O
retention	NN	O
by	IN	O
means	NNS	O
of	IN	O
low-flow	JJ	O
anesthesia	NN	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
reflective	JJ	O
blankets	NNS	O
is	VBZ	O
ineffective	JJ	O
in	IN	O
maintaining	VBG	PH
intraoperative	JJ	PH
normothermia	NN	PH
and	CC	O
definitely	RB	O
inferior	JJ	O
to	TO	O
active	JJ	O
forced-air	JJ	O
warning	NN	O
.	.	O

[	JJ	PH
Acute	NNP	PH
cardiovascular	NN	PH
and	CC	PH
metabolic	JJ	PH
changes	NNS	PH
in	IN	O
interval	NN	O
and	CC	O
endurance	NN	O
training	NN	O
in	IN	O
selected	VBN	O
patients	NNS	O
following	VBG	O
aortocoronary	JJ	O
bypass	NN	O
operation	NN	O
]	NNP	O
.	.	O

UNLABELLED	VB	O
This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
acute	NN	PH
changes	NNS	PH
of	IN	PH
cardiovascular	NN	PH
and	CC	PH
metabolic	JJ	PH
reactions	NNS	PH
during	IN	O
interval	NN	O
and	CC	O
continuous	JJ	O
training	NN	O
after	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
9	CD	O
male	JJ	O
patients	NNS	O
(	(	O
age	NN	O
:	:	O
59	CD	O
+/-	JJ	O
4	CD	O
and	CC	O
56	CD	O
+/-	JJ	O
6	CD	O
years	NNS	O
,	,	O
resp	NN	O
.	.	O

)	)	O
each	DT	O
trained	VBN	O
on	IN	O
bicycle	NN	O
ergometer	JJ	O
start	NN	O
on	IN	O
post-operative	JJ	O
days	NNS	O
24	CD	O
and	CC	O
26	CD	O
,	,	O
resp	NN	O
.	.	O

In	IN	O
both	DT	O
training	NN	O
groups	NNS	O
training	VBG	PH
heart	NN	PH
rate	NN	PH
was	VBD	O
set	VBN	O
at	IN	O
86	CD	O
%	NN	O
of	IN	O
individual	JJ	O
maximum	JJ	O
heart	NN	O
rate	NN	O
.	.	O

In	IN	O
the	DT	O
last	JJ	O
week	NN	O
of	IN	O
training	VBG	O
the	DT	O
exercise	NN	O
intensity	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
trained	VBN	O
by	IN	O
the	DT	O
continuous	JJ	O
method	NN	O
was	VBD	O
at	IN	O
83	CD	O
watts	NN	O
,	,	O
and	CC	O
at	IN	O
20:121	CD	O
watts	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
trained	VBN	O
by	IN	O
interval	JJ	O
method	NN	O
(	(	O
rest	NN	O
:	:	O
work	NN	O
each	DT	O
1:1	CD	O
min	NN	O
)	)	O
.	.	O

At	IN	O
this	DT	O
exercise	NN	O
training	NN	O
that	WDT	O
lasted	VBD	O
for	IN	O
20	CD	O
min	PDT	O
the	DT	O
acute	JJ	PH
response	NN	PH
of	IN	PH
heart	NN	PH
rate	NN	PH
,	,	O
blood	NN	PH
pressure	NN	PH
,	,	O
rate-pressure	JJ	PH
product	NN	PH
,	,	O
glucose	JJ	PH
,	,	O
lactate	JJ	PH
and	CC	O
catecholamines	NNS	PH
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
both	DT	O
methods	NNS	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
systolic	JJ	Ot
and	CC	Ot
diastolic	JJ	Ot
pressure	NN	Ot
,	,	O
rate-pressure	JJ	Ot
product	NN	Ot
,	,	O
in	IN	O
glucose	NN	Ot
or	CC	O
catecholamine	NN	Ot
levels	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
rate	NN	PH
of	IN	PH
lactate	NN	PH
in	IN	O
the	DT	O
second	JJ	O
10	CD	O
min	NN	O
of	IN	O
the	DT	O
interval	JJ	O
training	NN	O
.	.	O

And	CC	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
higher	JJR	O
peripheral	JJ	O
exercise	NN	O
intensity	NN	O
by	IN	O
interval	JJ	O
training	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
higher	JJR	O
cardiac	NN	PH
work	NN	PH
than	IN	O
by	IN	O
the	DT	O
continuous	JJ	O
training	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
interval	JJ	O
training	NN	O
strains	VBZ	O
the	DT	O
oxidative	JJ	O
capacity	NN	O
of	IN	O
the	DT	O
trained	JJ	O
muscles	NNS	O
in	IN	O
a	DT	O
more	RBR	O
intensive	JJ	O
and	CC	O
direct	JJ	O
way	NN	O
than	IN	O
does	VBZ	O
continuous	JJ	O
training	NN	O
.	.	O

Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
(	(	O
CYBOCS	NNP	O
)	)	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDDs	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
Raters	NNPS	O
from	IN	O
five	CD	O
Research	NNP	O
Units	NNS	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
were	VBD	O
trained	VBN	O
to	TO	O
reliability	NN	O
.	.	O

The	DT	O
modified	JJ	O
scale	NN	O
(	(	O
CYBOCS-PDD	NNP	O
)	)	O
,	,	O
which	WDT	O
contains	VBZ	O
only	RB	O
the	DT	O
five	CD	O
Compulsion	NNP	O
severity	NN	O
items	NNS	O
(	(	O
range	VB	O
0-20	NN	O
)	)	O
,	,	O
was	VBD	O
administered	VBN	O
to	TO	O
172	CD	O
medication-free	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
8.2	CD	O
+/-	JJ	O
2.6	CD	O
years	NNS	O
)	)	O
with	IN	O
PDD	NNP	O
(	(	O
autistic	JJ	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
152	CD	O
;	:	O
Asperger	NNP	O
's	POS	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
6	CD	O
;	:	O
PDD	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
participating	NN	O
in	IN	O
RUPP	NNP	O
clinical	JJ	O
trials	NNS	O
.	.	O

Reliability	NNP	ME
was	VBD	O
assessed	VBN	O
by	IN	O
intraclass	NN	O
correlation	NN	O
coefficient	NN	O
(	(	O
ICC	NNP	O
)	)	O
and	CC	O
internal	JJ	O
consistency	NN	O
by	IN	O
Cronbach	NNP	O
's	POS	O
alpha	JJ	O
coefficient	NN	O
.	.	O

Correlations	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
and	CC	O
disruptive	JJ	O
behavior	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
validity	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
raters	NNS	O
showed	VBD	O
excellent	JJ	O
reliability	NN	ME
(	(	O
ICC	NNP	O
=	NNP	O
0.97	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	ME
CYBOCS	NNP	ME
score	NN	ME
was	VBD	O
14.4	CD	O
(	(	O
+/-	JJ	O
3.86	CD	O
)	)	O
with	IN	O
excellent	JJ	O
internal	JJ	Ot
consistency	NN	Ot
(	(	O
alpha	JJ	O
=	NNP	O
.85	NNP	O
)	)	O
.	.	O

Correlations	NNS	O
with	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
ranged	VBD	O
from	IN	O
r	NN	O
=	$	O
0.11	CD	O
to	TO	O
r	VB	O
=	JJ	O
0.28	CD	O
and	CC	O
were	VBD	O
similar	JJ	O
to	TO	O
correlations	NNS	O
with	IN	O
measures	NNS	ME
of	IN	ME
irritability	NN	ME
(	(	O
r	JJ	O
=	NNP	O
0.24	CD	O
)	)	O
and	CC	O
hyperactivity	NN	ME
(	(	O
r	JJ	O
=	NNP	O
0.25	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
CYBOCS-PDD	NNP	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
maladaptive	JJ	ME
behaviors	NNS	ME
and	CC	O
lower	JJR	ME
adaptive	JJ	ME
functioning	NN	ME
.	.	O

CONCLUSIONS	VB	O
The	DT	O
five-item	JJ	O
CYBOCS-PDD	NNP	O
is	VBZ	O
reliable	JJ	O
,	,	O
distinct	JJ	O
from	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
,	,	O
and	CC	O
sensitive	JJ	O
to	TO	O
change	VB	O
.	.	O

Response	NN	O
of	IN	O
pre-core	NN	O
mutant	NN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
to	TO	O
lamivudine	VB	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
chronic	JJ	O
liver	NN	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
pre-core	JJ	O
mutant	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
(	(	O
HBV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
increasing	VBG	O
,	,	O
particularly	RB	O
in	IN	O
Mediterranean	NNP	O
Europe	NNP	O
and	CC	O
in	IN	O
Asia	NNP	O
.	.	O

The	DT	O
pre-core	JJ	O
mutant	NN	O
HBV	NNP	O
is	VBZ	O
unable	JJ	O
to	TO	O
produce	VB	O
hepatitis	NN	O
B	NNP	O
e	NN	O
antigen	NN	O
(	(	O
HBeAg	NNP	O
)	)	O
,	,	O
so	RB	O
that	IN	O
patients	NNS	O
with	IN	O
this	DT	O
variant	NN	O
do	VBP	O
not	RB	O
present	VB	O
with	IN	O
HBV	NNP	O
characterised	VBN	O
by	IN	O
HBeAg	NNP	PH
in	IN	PH
the	DT	PH
serum	NN	PH
.	.	PH

Pre-core	NN	O
mutant	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
usually	RB	O
proceeds	VBZ	O
to	TO	O
serious	JJ	O
liver	JJ	O
disease	NN	O
.	.	O

Wild-type	JJ	O
HBV	NNP	O
infection	NN	O
may	MD	O
be	VB	O
mild	JJ	O
and	CC	O
respond	NN	O
relatively	RB	O
well	RB	O
to	TO	O
interferon	VB	O
(	(	O
IFN	NNP	O
)	)	O
alpha	NN	O
therapy	NN	O
,	,	O
but	CC	O
IFN	NNP	O
alpha	NN	O
is	VBZ	O
not	RB	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
in	IN	O
pre-core	NN	O
mutant	NN	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
and	CC	O
new	JJ	O
therapeutic	JJ	O
options	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Clinical	JJ	O
data	NNS	O
show	VBP	O
that	IN	O
lamivudine	NN	O
is	VBZ	O
an	DT	O
effective	JJ	Ot
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
pre-core	JJ	O
mutant	NN	O
hepatitis	NN	O
B	NNP	O
.	.	O

There	EX	O
is	VBZ	O
profound	JJ	O
suppression	NN	O
of	IN	O
HBV	NNP	PH
replication	NN	PH
and	CC	O
improvement	NN	O
in	IN	O
indicators	NNS	PH
of	IN	PH
liver	JJ	PH
disease	NN	PH
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
lamivudine	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
,	,	O
including	VBG	O
those	DT	O
with	IN	O
pre-core	JJ	O
mutant	JJ	O
HBV	NNP	O
infection	NN	O
.	.	O

Evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
is	VBZ	O
related	VBN	O
to	TO	O
baseline	VB	O
severity	NN	O
--	:	O
a	DT	O
prospective	JJ	O
quantitative	JJ	O
angiographic	JJ	O
analysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
coronary	JJ	O
disease	NN	O
.	.	O

INTACT	JJ	O
Investigators	NNPS	O
.	.	O

International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
.	.	O

A	DT	O
correlation	NN	O
of	IN	O
the	DT	O
angiographic	JJ	O
evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
(	(	O
stenosis	NN	O
diameter	NN	O
>	NN	O
or	CC	O
=	VB	O
20	CD	O
%	NN	O
)	)	O
with	IN	O
morphological	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
could	MD	O
help	VB	O
to	TO	O
identify	VB	PH
the	DT	PH
risk	NN	PH
of	IN	PH
progressive	JJ	PH
stenoses	NNS	PH
.	.	PH

Therefore	RB	O
,	,	O
the	DT	O
data	NN	O
of	IN	O
the	DT	O
prospective	JJ	O
INTACT	NNP	O
study	NN	O
(	(	O
International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

In	IN	O
348	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
standardized	VBD	O
coronary	JJ	O
angiograms	NNS	O
were	VBD	O
taken	VBN	O
3	CD	O
years	NNS	O
apart	RB	O
and	CC	O
were	VBD	O
quantitatively	RB	O
analysed	VBN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
minimal	JJ	PH
diameter	NN	PH
of	IN	O
the	DT	O
1063	CD	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
compared	VBN	O
between	IN	O
both	DT	O
angiograms	NNS	O
were	VBD	O
set	VBN	O
in	IN	O
relation	NN	O
to	TO	O
a	DT	O
number	NN	PH
of	IN	PH
conventional	JJ	PH
stenosis	NN	PH
parameters	NNS	PH
at	IN	O
baseline	NN	O
.	.	O

Regression	NNP	O
analysis	NN	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	Ot
of	IN	O
the	DT	O
changes	NNS	PH
in	IN	PH
minimal	JJ	PH
diameter	NN	PH
with	IN	O
baseline	NN	PH
%	NN	PH
diameter	NN	PH
stenosis	NN	PH
(	(	O
r	JJ	O
=	VBZ	O
0.30	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
minimal	JJ	PH
diameter	NN	PH
(	(	O
r	JJ	O
=	NNP	O
-0.28	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
reference	NN	PH
diameter	NN	PH
of	IN	PH
stenoses	NNS	PH
(	(	O
r	NN	O
=	NNP	O
-0.14	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	Ot
were	VBD	Ot
not	RB	Ot
correlated	VBN	Ot
with	IN	O
stenosis	NN	PH
length	NN	PH
and	CC	PH
plaque	JJ	PH
area	NN	PH
.	.	PH

The	DT	O
baseline	NN	O
parameters	NNS	O
of	IN	O
22	CD	O
preexisting	VBG	O
stenoses	NNS	O
progressing	VBG	PH
to	TO	PH
occlusions	NNS	PH
differed	VBN	O
from	IN	O
those	DT	O
remaining	VBG	PH
patent	NN	PH
only	RB	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
%	NN	PH
diameter	NN	PH
stenosis	NN	PH
(	(	O
43	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
vs	JJ	O
39	CD	O
+/-	JJ	O
11	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Additional	JJ	O
progression	NN	PH
of	IN	PH
coronary	JJ	PH
disease	NN	PH
became	VBD	O
manifest	JJS	O
through	IN	O
development	NN	O
of	IN	O
228	CD	O
stenoses	NNS	PH
and	CC	O
19	CD	O
occlusions	NNS	PH
at	IN	O
arterial	JJ	O
sites	NNS	O
free	VBP	O
from	IN	O
definitive	JJ	O
stenoses	NNS	O
in	IN	O
the	DT	O
baseline	NN	O
angiograms	NN	O
.	.	O

Thus	RB	O
,	,	O
progression	NN	PH
of	IN	PH
atherosclerosis	NN	PH
predominantly	RB	PH
occurred	VBD	PH
in	IN	O
mild	NN	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
and	CC	O
developed	VBN	O
at	IN	O
previously	RB	O
angiographically	RB	O
normal	JJ	O
sites	NNS	O
.	.	O

Since	IN	O
the	DT	O
conventional	JJ	O
angiographic	JJ	O
parameters	NNS	O
analysed	VBN	O
in	IN	O
this	DT	O
study	NN	O
failed	VBD	O
to	TO	O
identify	VB	O
individual	JJ	O
arterial	JJ	O
sites	NNS	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
progression	NN	O
,	,	O
definition	NN	O
of	IN	O
new	JJ	O
angiographic	JJ	O
parameters	NNS	O
or	CC	O
application	NN	O
of	IN	O
new	JJ	O
techniques	NNS	O
seem	VBP	O
mandatory	JJ	O
to	TO	O
this	DT	O
end	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
to	TO	O
improve	VB	O
venipuncture	NN	ME
compliance	NN	ME
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
Medical	NNP	O
procedures	NNS	O
,	,	O
particularly	RB	O
venipuncture	NN	O
(	(	O
the	DT	O
puncture	NN	O
of	IN	O
a	DT	O
vein	NN	O
especially	RB	O
for	IN	O
the	DT	O
withdrawal	NN	O
of	IN	O
blood	NN	O
)	)	O
,	,	O
can	MD	O
cause	VB	O
serious	JJ	ME
distress	NN	ME
and	CC	O
behavior	JJ	ME
disturbance	NN	ME
for	IN	O
many	JJ	O
children	NNS	O
.	.	O

Noncompliance	NN	O
to	TO	O
blood	VB	O
draws	NNS	O
can	MD	O
have	VB	O
significant	JJ	O
ramifications	NNS	O
in	IN	O
both	DT	O
research	NN	O
and	CC	O
clinical	JJ	O
settings	NNS	O
.	.	O

The	DT	O
negative	JJ	O
reactions	NNS	O
may	MD	O
be	VB	O
exacerbated	VBN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Even	RB	O
so	RB	O
,	,	O
there	EX	O
has	VBZ	O
been	VBN	O
little	JJ	O
research	NN	O
into	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
the	DT	O
problem	NN	O
or	CC	O
effective	JJ	O
intervention	NN	O
procedures	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
these	DT	O
concerns	NNS	O
,	,	O
we	PRP	O
developed	VBD	O
and	CC	O
evaluated	VBD	O
the	DT	O
Blood	NNP	O
Draw	NNP	O
Intervention	NNP	O
Program	NNP	O
.	.	O

The	DT	O
program	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
be	VB	O
easy	JJ	O
to	TO	O
use	VB	O
,	,	O
require	VB	O
little	JJ	O
provider	NN	O
or	CC	O
family	NN	O
time	NN	O
,	,	O
effectively	RB	O
reduce	VB	O
negative	JJ	ME
behaviors	NNS	ME
,	,	O
and	CC	O
increase	VB	ME
blood	NN	ME
draw	JJ	ME
compliance	NN	ME
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
quasi-randomized	JJ	O
trial	NN	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
?	.	O
18	CD	O
months	NNS	O
,	,	O
58	CD	O
of	IN	O
210	CD	O
families	NNS	O
with	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
larger	JJR	O
study	NN	O
of	IN	O
phenotypic	NN	O
and	CC	O
genotypic	NN	O
factors	NNS	O
reported	VBD	O
significant	JJ	O
concerns	NNS	O
about	IN	O
blood	NN	O
draws	NNS	O
and	CC	O
elected	VBN	O
to	TO	O
use	VB	O
the	DT	O
Blood	NNP	O
Draw	NNP	O
Intervention	NNP	O
Program	NNP	O
.	.	O

RESULTS	NNP	O
Completion	NNP	O
of	IN	O
the	DT	O
program	NN	O
increased	VBD	O
blood	NN	ME
draw	NN	ME
compliance	NN	ME
rates	NNS	ME
from	IN	O
85.4	CD	O
%	NN	O
to	TO	O
96.6	CD	O
%	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
4.80	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
=	VBD	O
1.12	CD	O
,	,	O
20.59	CD	O
;	:	O
p	NN	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Results	NNP	O
indicate	VBP	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
program	NN	O
in	IN	O
a	DT	O
research	NN	O
setting	NN	O
and	CC	O
suggest	VB	O
a	DT	O
potential	JJ	O
clinical	JJ	O
application	NN	O
.	.	O

The	DT	O
current	JJ	O
intervention	NN	O
,	,	O
unlike	IN	O
many	JJ	O
others	NNS	O
for	IN	O
the	DT	O
same	JJ	O
or	CC	O
similar	JJ	O
difficulties	NNS	O
proposed	VBN	O
in	IN	O
the	DT	O
past	NN	O
,	,	O
was	VBD	O
successful	JJ	O
without	IN	O
requiring	VBG	O
extensive	JJ	O
time	NN	O
,	,	O
training	NN	O
,	,	O
or	CC	O
effort	NN	O
on	IN	O
the	DT	O
part	NN	O
of	IN	O
providers	NNS	O
and	CC	O
parents	NNS	O
or	CC	O
their	PRP$	O
children	NNS	O
,	,	O
nor	CC	O
did	VBD	O
it	PRP	O
require	VB	O
large-scale	JJ	O
institutional	JJ	O
changes	NNS	O
.	.	O

Twice-a-day	JJ	O
versus	NN	O
four-times-a-day	JJ	O
ofloxacin	JJ	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
infection	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	Ot
of	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
when	WRB	O
given	VBN	O
twice-a-day	JJ	O
(	(	O
BID	NNP	O
)	)	O
versus	IN	O
four-times-a-day	JJ	O
(	(	O
QID	NNP	O
)	)	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Fifty	NNP	O
patients	NNS	O
with	IN	O
blepharitis	NN	O
,	,	O
conjuctivitis	NN	O
,	,	O
or	CC	O
blepharoconjunctivitis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
BID	NNP	O
or	CC	O
QID	NNP	O
,	,	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

Signs	NNP	O
,	,	O
symptoms	NNS	O
,	,	O
and	CC	O
cultures	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
clinical	JJ	O
outcome	NN	O
was	VBD	O
virtually	RB	O
identical	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
clinical	JJ	Ot
scores	NNS	Ot
in	IN	O
the	DT	O
BID	NNP	O
and	CC	O
QID	NNP	O
groups	NNS	O
by	IN	O
days	NNS	O
3	CD	O
to	TO	O
5	CD	O
(	(	O
2.6-3.0	JJ	O
points	NNS	O
)	)	O
and	CC	O
a	DT	O
further	JJ	O
decrease	NN	O
by	IN	O
day	NN	O
11	CD	O
(	(	O
4.3-5.0	JJ	O
points	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
at	IN	O
any	DT	O
time	NN	O
interval	NN	O
.	.	O

Microbiologic	NNP	O
studies	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
colony-forming	JJ	PH
units	NNS	PH
in	IN	O
87	CD	O
%	NN	O
of	IN	O
the	DT	O
BID	NNP	O
group	NN	O
and	CC	O
in	IN	O
80	CD	O
%	NN	O
of	IN	O
the	DT	O
QID	NNP	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
treatment	NN	O
of	IN	O
external	JJ	PH
ocular	JJ	PH
disease	NN	PH
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	Ot
eyedrops	NN	Ot
was	VBD	Ot
equally	RB	Ot
effective	JJ	Ot
when	WRB	Ot
given	VBN	Ot
BID	NNP	Ot
or	CC	Ot
QID	NNP	Ot
.	.	O

An	DT	O
open	JJ	O
multicenter	NN	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
evaluation	NN	Ot
of	IN	O
amlodipine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
symptomatic	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
amlodipine	NN	O
(	(	O
5-10	JJ	O
mg	NN	O
)	)	O
once	RB	O
daily	JJ	O
were	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
ongoing	VBG	O
and	CC	O
this	DT	O
report	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
an	DT	O
interim	JJ	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
78	CD	O
patients	NNS	O
.	.	O

A	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
maintained	VBD	O
their	PRP$	O
current	JJ	O
antianginal	JJ	O
therapy	NN	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
treatment	NN	O
period	NN	O
with	IN	O
5-10	JJ	O
mg	NN	O
of	IN	O
amlodipine/day	NN	O
.	.	O

Both	CC	O
the	DT	O
median	JJ	PH
number	NN	PH
of	IN	PH
angina	JJ	PH
attacks	NNS	PH
per	IN	PH
week	NN	PH
and	CC	PH
the	DT	PH
median	JJ	PH
number	NN	PH
of	IN	PH
nitroglycerin	NN	PH
(	(	PH
NTG	NNP	PH
)	)	PH
tablets	NNS	PH
consumed/week	VBP	PH
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
amlodipine	NN	O
(	(	O
mean	JJ	O
daily	RB	O
dose	NN	O
of	IN	O
8.6	CD	O
mg	NNS	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
98.4	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
63/64	CD	O
)	)	O
experienced	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
frequency	NN	PH
of	IN	PH
angina	JJ	PH
attacks/week	NN	PH
and	CC	O
91	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
58/64	CD	O
)	)	O
had	VBD	O
angina	VBN	PH
attacks	NNS	PH
reduced	VBD	O
to	TO	O
<	VB	O
or	CC	O
=	VB	O
2/week	CD	O
.	.	O

In	IN	O
self-assessments	NNS	O
,	,	O
95	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
55/58	CD	O
)	)	O
reported	VBD	O
improved	JJ	O
angina	NNS	PH
control	NN	PH
and	CC	O
91	CD	O
%	NN	O
(	(	O
53/58	CD	O
)	)	O
felt	VBD	O
their	PRP$	O
ability	NN	PH
to	TO	PH
perform	VB	PH
usual	JJ	PH
activities	NNS	PH
had	VBD	O
improved	VBN	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
experienced	JJ	O
adverse	JJ	A
events	NNS	A
reported	VBN	O
as	IN	O
drug	NN	O
related	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	A
event	NN	A
noted	VBD	O
was	VBD	O
edema	RB	A
.	.	O

Amlodipine	NNP	O
once	RB	O
daily	RB	O
significantly	RB	O
reduced	VBN	O
the	DT	O
incidence	NN	PH
of	IN	PH
angina	NN	PH
attacks	NNS	PH
and	CC	O
the	DT	O
concomitant	JJ	O
need	NN	PH
of	IN	PH
nitroglycerin	NN	PH
for	IN	O
relief	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
thus	RB	O
improved	VBN	O
the	DT	O
patients	NNS	O
'	POS	O
ability	NN	O
to	TO	O
perform	VB	O
daily	JJ	O
activities	NNS	O
.	.	O

Most	JJS	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
were	VBD	O
mild	JJ	O
or	CC	O
moderate	JJ	O
and	CC	O
the	DT	O
incidence	NN	O
is	VBZ	O
as	RB	O
would	MD	O
be	VB	O
expected	VBN	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
imidapril	NN	O
on	IN	O
plasma	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
early	JJ	O
treatment	NN	O
with	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibitors	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
is	VBZ	O
useful	JJ	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
fibrinolytic	JJ	PH
function	NN	PH
,	,	O
as	RB	O
well	RB	O
as	IN	O
left	VBN	PH
ventricular	JJ	PH
function	NN	PH
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
levels	NNS	O
of	IN	O
plasma	NN	PH
plasminogen	NN	PH
activator	NN	PH
inhibitor	NN	PH
(	(	PH
PAI	NNP	PH
)	)	PH
activity	NN	PH
and	CC	O
serum	JJ	PH
ACE	NNP	PH
activity	NN	PH
during	IN	O
the	DT	O
course	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
in	IN	O
40	CD	O
patients	NNS	O
with	IN	O
AMI	NNP	O
within	IN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
symptom	NN	O
and	CC	O
who	WP	O
randomly	VBP	O
received	VBN	O
early	JJ	O
treatment	NN	O
with	IN	O
either	CC	O
the	DT	O
ACE	NNP	O
inhibitor	NN	O
imidapril	NN	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
20	CD	O
patients	NNS	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
and	CC	O
20	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
levels	NNS	PH
of	IN	PH
serum	JJ	PH
ACE	NNP	PH
activity	NN	PH
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
decreased	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
8	CD	O
hours	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
imidapril	NN	O
,	,	O
and	CC	O
the	DT	O
levels	NNS	O
24	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
3.6	CD	O
+/-	JJ	O
0.6	CD	O
IU/L	NNP	O
vs	VBD	O
7.4	CD	O
+/-	JJ	O
0.8	CD	O
IU/L	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
plasma	JJ	PH
PAI	NNP	PH
activity	NN	PH
increased	VBD	O
gradually	RB	O
to	TO	O
peak	VB	O
levels	NNS	O
16	CD	O
hours	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
imidapril	NN	O
and	CC	O
placebo	NN	O
.	.	O

The	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
decreased	VBD	O
gradually	RB	O
but	CC	O
remained	VBD	O
high	JJ	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
the	DT	O
levels	NNS	PH
of	IN	PH
PAI	NNP	PH
activity	NN	PH
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
decreased	VBD	O
rapidly	RB	O
and	CC	O
those	DT	O
48	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
7.9	CD	O
+/-	JJ	O
1.9	CD	O
IU/ml	NNP	O
vs	VBD	O
18.4	CD	O
+/-	JJ	O
3.5	CD	O
IU/ml	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
levels	NNS	PH
of	IN	PH
left	JJ	PH
ventricular	JJ	PH
ejection	NN	PH
fraction	NN	PH
about	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
admission	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
65.9	CD	O
%	NN	O
+/-	JJ	O
2.5	CD	O
%	NN	O
vs	JJ	O
49.1	CD	O
%	NN	O
+/-	JJ	O
4.4	CD	O
%	NN	O
;	:	O
p	CC	O
<	VB	O
0.01	CD	O
)	)	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
imidapril	NN	O
,	,	O
an	DT	O
ACE	NNP	O
inhibitor	NN	O
,	,	O
might	MD	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
fibrinolytic	JJ	PH
function	NN	PH
and	CC	O
left	VBD	PH
ventricular	JJ	PH
function	NN	PH
in	IN	O
the	DT	O
acute	JJ	O
phase	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Gonadotropin-releasing	VBG	O
hormone	NN	O
agonist	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premenstrual	JJ	O
symptoms	NNS	O
with	IN	O
and	CC	O
without	IN	O
ongoing	VBG	O
dysphoria	NN	O
:	:	O
a	DT	O
controlled	VBN	O
study	NN	O
.	.	O

Gonadotropin-releasing	VBG	O
hormone	NN	O
(	(	O
GnRH	NNP	O
)	)	O
agonists	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
symptoms	NNS	PH
of	IN	PH
premenstrual	JJ	PH
syndrome	NN	PH
(	(	PH
PMS	NNP	PH
)	)	PH
.	.	PH

This	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
GnRH	NNP	O
agonist	NN	O
,	,	O
leuprolide	JJ	O
acetate	NN	O
depot	NN	O
,	,	O
in	IN	O
a	DT	O
clearly	RB	O
defined	VBN	O
PMS	NNP	O
sample	JJ	O
versus	NNS	O
women	NNS	O
with	IN	O
premenstrual	JJ	O
symptoms	NNS	O
in	IN	O
combination	NN	O
with	IN	O
dysphoric	NN	O
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
termed	VBD	O
the	DT	O
premenstrual	JJ	O
exacerbation	NN	O
(	(	O
PME	NNP	O
)	)	O
group	NN	O
.	.	O

Evaluation	NN	O
included	VBD	O
the	DT	O
Structured	NNP	Ot
Clinical	NNP	Ot
Interview	NNP	Ot
for	IN	Ot
DSM-III-R	NNP	Ot
,	,	O
administered	VBN	O
in	IN	O
the	DT	O
follicular	JJ	O
phase	NN	O
,	,	O
and	CC	O
the	DT	O
subject	NN	Ot
Penn	NNP	Ot
Dally	NNP	Ot
Symptoms	NNP	Ot
Report	NNP	Ot
(	(	Ot
DSR	NNP	Ot
)	)	Ot
maintained	VBD	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Thirty-three	NNP	O
eligible	JJ	O
women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
and	CC	O
administered	VBD	O
3.75	CD	O
mg	NN	O
of	IN	O
depot	NN	O
leuprolide	NN	O
or	CC	O
a	DT	O
placebo	NN	O
once	RB	O
a	DT	O
month	NN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
efficacy	NN	Ot
evaluations	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
DSRs	NNP	Ot
and	CC	PH
the	DT	PH
17-item	JJ	Ot
Hamilton	NNP	Ot
Depression	NNP	Ot
Rating	NNP	Ot
Scale	NNP	Ot
(	(	Ot
HAM-D17	NNP	Ot
)	)	Ot
.	.	PH

The	DT	O
PMS	NNP	O
leuprolide	JJ	O
subjects	NNS	O
improved	VBN	O
significantly	RB	O
compared	VBN	O
with	IN	O
the	DT	O
PMS	NNP	O
placebo	NN	O
and	CC	O
PME	NNP	O
leuprolide	RB	O
groups	NNS	O
.	.	O

The	DT	O
PME	NNP	O
leuprolide	NN	O
group	NN	O
,	,	O
who	WP	O
had	VBD	O
dysphoric	NN	ME
symptoms	NNS	ME
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Depression	NNP	ME
symptoms	NNS	ME
were	VBD	O
at	IN	O
clinical	JJ	O
levels	NNS	O
premenstrually	RB	O
in	IN	O
the	DT	O
PMS	NNP	O
and	CC	O
PME	NNP	O
groups	NNS	O
;	:	O
following	VBG	O
treatment	NN	O
they	PRP	O
remitted	VBD	O
in	IN	O
the	DT	O
PMS	NNP	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
PME	NNP	O
leuprolide	JJ	O
subjects	NNS	O
.	.	O

Efficacy	NN	O
did	VBD	O
not	RB	O
occur	VB	O
until	IN	O
after	IN	O
several	JJ	O
months	NNS	O
of	IN	O
leuprolide	JJ	O
treatment	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
PMS	NNP	PH
symptoms	NNS	PH
worsened	VBD	O
with	IN	O
the	DT	O
onset	NN	O
of	IN	O
treatment	NN	O
.	.	O

These	DT	O
results	NNS	O
replicate	VBP	O
the	DT	O
findings	NNS	O
in	IN	O
our	PRP$	O
preliminary	JJ	O
open-label	NN	O
study	NN	O
.	.	O

Leuprolide	NNP	O
reduced	VBD	O
PMS	NNP	PH
symptoms	NNS	PH
to	TO	O
minimal	JJ	O
levels	NNS	O
where	WRB	O
symptoms	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
luteal	JJ	O
phase	NN	O
.	.	O

Leuprolide	NNP	O
was	VBD	O
not	RB	O
effective	JJ	O
for	IN	O
women	NNS	O
with	IN	O
ongoing	VBG	O
dysphoric	NN	O
symptoms	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
premenstrual	JJ	O
depression	NN	O
may	MD	O
have	VB	O
mechanisms	NNS	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
other	JJ	O
dysphoric	JJ	O
mood	NN	O
disorders	NNS	O
.	.	O

Influence	NN	O
of	IN	O
special-effect	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
Crazy	NNP	O
Lenses	NNP	O
)	)	O
on	IN	O
visual	JJ	PH
function	NN	PH
.	.	O

PURPOSE	NNP	O
Special-effect	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
opaque	NN	O
,	,	O
tinted	VBD	O
soft	JJ	O
contact	NN	O
lenses	VBZ	O
that	IN	O
incorporate	JJ	O
decorative	JJ	O
images	NNS	O
such	JJ	O
as	IN	O
cateyes	NNS	O
,	,	O
stars	NNS	O
,	,	O
or	CC	O
hearts	NNS	O
to	TO	O
alter	VB	O
eye	NN	O
color	NN	O
and	CC	O
structure	NN	O
)	)	O
have	VBP	O
become	VBN	O
increasingly	RB	O
popular	JJ	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
such	JJ	O
lenses	NNS	O
impair	VBP	O
visual	JJ	PH
function	NN	PH
.	.	O

METHODS	NNP	O
A	DT	O
clear	JJ	O
soft	JJ	O
contact	NN	O
lens	NNS	O
and	CC	O
a	DT	O
special-effect	JJ	O
soft	JJ	O
contact	NN	O
lens	NNS	O
(	(	O
Crazy	NNP	O
lens	VBZ	O
,	,	O
)	)	O
were	VBD	O
fit	JJ	O
in	IN	O
changing	VBG	O
sequence	NN	O
in	IN	O
nine	CD	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
parameters	NNS	O
studied	VBD	O
included	VBN	O
:	:	O
visual	JJ	PH
acuity	NN	PH
,	,	O
contrast	NN	PH
sensitivity	NN	PH
(	(	PH
with	IN	PH
and	CC	PH
without	IN	PH
glare	NN	PH
)	)	PH
,	,	O
visual	JJ	PH
field	NN	PH
,	,	O
and	CC	O
mesopic	NN	PH
vision	NN	PH
(	(	PH
with	IN	PH
and	CC	PH
without	IN	PH
glare	NN	PH
)	)	PH
.	.	O

RESULTS	VB	O
The	DT	O
following	JJ	O
parameters	NNS	O
displayed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Visual	JJ	PH
acuity	NN	PH
was	VBD	O
decreased	VBN	O
to	TO	O
0.9	CD	O
+/-	JJ	O
0.23	CD	O
in	IN	O
the	DT	O
Crazy	NNP	O
lens	VBZ	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
1.2	CD	O
+/-	JJ	O
0.13	CD	O
in	IN	O
the	DT	O
clear	JJ	O
lens	NNS	O
group	NN	O
.	.	O

Goldmann	NNP	PH
visual	JJ	PH
field	NN	PH
displayed	VBD	O
a	DT	O
significant	JJ	O
constriction	NN	PH
of	IN	PH
the	DT	PH
isopters	NNS	PH
:	:	O
III/4	NNP	O
,	,	O
I/4	NNP	O
,	,	O
and	CC	O
I/3	NNP	O
.	.	O

Mesopic	NNP	PH
vision	NN	PH
without	IN	PH
glare	NN	PH
was	VBD	O
reduced	VBN	O
from	IN	O
1:2.5	CD	O
to	TO	O
1:7.4	CD	O
.	.	O

Contrast	NNP	PH
sensitivity	NN	PH
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
a	DT	O
photopic	JJ	O
condition	NN	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
and	CC	O
in	IN	O
a	DT	O
scotopic	JJ	O
condition	NN	O
without	IN	O
glare	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
special-effect	JJ	O
lenses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
lens	NNS	PH
wearing	VBG	PH
comfort	NN	PH
.	.	O

CONCLUSIONS	NNP	O
Special-effect	JJ	O
contact	NN	O
lenses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
many	JJ	O
visual	JJ	PH
functions	NNS	PH
,	,	O
including	VBG	O
visual	JJ	PH
acuity	NN	PH
and	CC	O
contrast	NN	PH
sensitivity	NN	PH
.	.	O

For	IN	O
some	DT	O
wearers	NNS	O
this	DT	O
may	MD	O
interfere	VB	O
with	IN	O
activities	NNS	O
where	WRB	O
excellent	JJ	O
vision	NN	O
is	VBZ	O
crucial	JJ	O
,	,	O
such	JJ	O
as	IN	O
driving	VBG	O
a	DT	O
car	NN	O
.	.	O

Response	NNP	O
prediction	NN	O
in	IN	O
metastasised	JJ	O
colorectal	NN	O
cancer	NN	O
using	VBG	O
intratumoural	JJ	O
thymidylate	JJ	O
synthase	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
multicentre	NN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Molecular	NNP	O
markers	NNS	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
5-fluorouracil	JJ	O
(	(	O
FU	NNP	O
)	)	O
-based	VBD	O
treatment	NN	O
of	IN	O
recurrent	NN	O
or	CC	O
metastasised	VBN	O
colorectal	JJ	O
cancer	NN	O
(	(	O
mCRC	NN	O
)	)	O
are	VBP	O
not	RB	O
established	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
thymidylate	JJ	O
synthase	NN	O
(	(	O
TS	NNP	O
)	)	O
,	,	O
a	DT	O
key	JJ	O
enzyme	NN	O
of	IN	O
DNA	NNP	O
synthesis	NN	O
and	CC	O
target	NN	O
of	IN	O
5-FU	JJ	O
,	,	O
to	TO	O
predict	VB	PH
response	NN	PH
to	TO	O
chemotherapy	NN	O
of	IN	O
mCRC	NN	O
.	.	O

METHODS	NNP	O
Tumour	NNP	O
tissue	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
168	CD	O
patients	NNS	O
with	IN	O
mCRC	NN	O
for	IN	O
relative	JJ	O
thymidylate	NN	PH
synthase	NN	PH
(	(	PH
TS	NNP	PH
)	)	PH
mRNA	NN	O
quantitation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
5-FU/folinic	JJ	O
acid	NN	O
(	(	O
FA	NNP	O
,	,	O
FUFA	NNP	O
)	)	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
irinotecan	JJ	O
5-fluorouracil/folinic	JJ	O
acid	NN	O
and	CC	O
irinotecan	JJ	O
(	(	O
FOLFIRI	NNP	O
)	)	O
stratified	VBN	O
by	IN	O
TS	NNP	O
(	(	O
low	JJ	O
versus	RB	O
high	JJ	O
)	)	O
.	.	O

Primary	JJ	O
end-point	NN	O
was	VBD	O
overall	JJ	PH
response	NN	PH
to	TO	PH
first-line	JJ	PH
treatment	NN	PH
among	IN	O
TS	NNP	O
high	JJ	O
patients	NNS	O
.	.	O

All	DT	O
parties	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
randomisation	NN	O
centre	NN	O
,	,	O
were	VBD	O
blinded	VBN	O
for	IN	O
TS	NNP	O
status	NN	O
.	.	O

RESULTS	NNP	O
Biopsies	NNP	O
(	(	O
n=168	RB	O
)	)	O
were	VBD	O
taken	VBN	O
without	IN	O
complications	NNS	O
.	.	O

TS	NN	PH
levels	NNS	PH
were	VBD	O
available	JJ	O
for	IN	O
147	CD	O
patients	NNS	O
(	(	O
87.5	CD	O
%	NN	O
)	)	O
.	.	O

Analysing	VBG	O
response	NN	PH
to	TO	PH
FUFA	NNP	PH
and	CC	PH
FOLFIRI	NNP	PH
in	IN	O
the	DT	O
per	NN	O
protocol	NN	O
set	VBN	O
(	(	O
n=119	NN	O
)	)	O
after	IN	O
un-blinding	JJ	O
TS	NNP	O
in	IN	O
the	DT	O
data	NN	O
base	NN	O
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
better	JJR	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
(	(	O
9/19	CD	O
,	,	O
47	CD	O
%	NN	O
)	)	O
in	IN	O
TS	NNP	O
high	JJ	O
compared	VBN	O
to	TO	O
FUFA	NNP	O
(	(	O
5/23	CD	O
,	,	O
22	CD	O
%	NN	O
,	,	O
p=0.077	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
biopsies	NNS	O
taken	VBN	O
from	IN	O
liver	JJ	O
lesions	NNS	O
(	(	O
n=91	NN	O
)	)	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
in	IN	O
TS	NNP	O
high	NN	O
was	VBD	O
53	CD	O
%	NN	O
(	(	O
9/17	CD	O
)	)	O
and	CC	O
18	CD	O
%	NN	O
(	(	O
3/17	CD	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p=0.035	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
TS	NNP	O
,	,	O
no	DT	O
remarkable	JJ	O
difference	NN	O
in	IN	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Taking	VBG	O
a	DT	O
pre-treatment	JJ	O
biopsy	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
feasible	JJ	O
procedure	NN	O
in	IN	O
mCRC	NN	O
.	.	O

After	IN	O
validation	NN	O
of	IN	O
our	PRP$	O
data	NNS	O
in	IN	O
a	DT	O
larger	JJR	O
group	NN	O
TS	NNP	O
determination	NN	O
may	MD	O
have	VB	O
the	DT	O
potential	NN	O
to	TO	O
better	JJR	O
help	NN	O
direct	VB	O
systemic	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primarily	RB	O
non-resectable	JJ	O
mCRC	NN	O
.	.	O

[	JJ	O
Intra-arterial	JJ	O
(	(	O
5-FU/FA	JJ	O
and	CC	O
FUDR	NNP	O
)	)	O
versus	VBP	O
systemic	JJ	O
chemotherapy	NN	O
(	(	O
5-FU/FA	JJ	O
)	)	O
of	IN	O
non-resectable	JJ	PH
colorectal	JJ	PH
liver	NN	PH
metastases	NNS	PH
]	VBP	O
.	.	O

The	DT	O
relative	JJ	Ot
efficacy	NN	Ot
of	IN	O
HAI	NNP	O
FUDR	NNP	O
,	,	O
HAI	NNP	O
5-FU/FA	CD	O
,	,	O
and	CC	O
i.v	NN	O
.	.	O

5-FU/FA	JJ	O
chemotherapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
unresectable	JJ	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
was	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
response	NN	Ot
rate	NN	Ot
after	IN	O
HAI	NNP	O
treatment	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
as	IN	O
compared	VBN	O
to	TO	O
i.v	VB	O
.	.	O

treatment	NN	O
with	IN	O
no	DT	O
statistical	JJ	O
benefit	NN	O
regarding	VBG	O
survival	NN	MO
and	CC	PH
time	NN	PH
to	TO	PH
progression	NN	PH
.	.	O

HAI	NNP	O
FUDR	NNP	O
treatment	NN	O
was	VBD	O
inferior	JJ	Ot
as	IN	O
compared	VBN	O
to	TO	O
HAI	NNP	O
or	CC	O
i.v	NN	O
.	.	O

5-FU/FA	JJ	O
.	.	O

i.v	NN	O
.	.	O

5-FU/FA-therapy	NN	O
is	VBZ	O
therefore	IN	O
the	DT	O
method	NN	O
of	IN	O
choice	NN	O
outside	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

Eberconazole	JJ	O
1	CD	O
%	NN	O
cream	NN	O
is	VBZ	O
an	DT	O
effective	JJ	Ot
and	CC	Ot
safe	JJ	Ot
alternative	NN	O
for	IN	O
dermatophytosis	NN	O
treatment	NN	O
:	:	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
comparative	JJ	O
trial	NN	O
with	IN	O
miconazole	JJ	O
2	CD	O
%	NN	O
cream	NN	O
.	.	O

BACKGROUND	NNP	O
Eberconazole	NNP	O
is	VBZ	O
a	DT	O
topical	JJ	O
,	,	O
broad-spectrum	JJ	O
imidazole	NN	O
derivative	NN	O
,	,	O
effective	JJ	O
in	IN	O
dermatophytoses	NNS	O
,	,	O
candidiasis	NN	O
,	,	O
and	CC	O
pityriasis	NN	O
treatment	NN	O
.	.	O

In	IN	O
previous	JJ	O
trials	NNS	O
,	,	O
it	PRP	O
showed	VBD	O
a	DT	O
higher	JJR	O
efficacy	NN	O
than	IN	O
clotrimazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
eberconazole	JJ	O
1	CD	O
%	NN	O
cream	NN	O
compared	VBN	O
with	IN	O
miconazole	JJ	O
2	CD	O
%	NN	O
cream	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
653	CD	O
patients	NNS	O
with	IN	O
dermatophytoses	NNS	O
,	,	O
randomized	VBN	O
to	TO	O
eberconazole	VB	O
1	CD	O
%	NN	O
cream	NN	O
every	DT	O
12	CD	O
h	NN	O
or	CC	O
miconazole	VB	O
2	CD	O
%	NN	O
cream	NN	O
every	DT	O
12	CD	O
h	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Treatment	NNP	Ot
efficacy	NN	Ot
was	VBD	O
assessed	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
percentage	NN	O
of	IN	O
effective	JJ	O
response	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
through	IN	O
mycologic	NN	O
and	CC	O
clinical	JJ	O
assessment	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
653	CD	O
patients	NNS	O
included	VBN	O
in	IN	O
the	DT	O
trial	NN	O
,	,	O
360	CD	O
produced	VBD	O
positive	JJ	O
baseline	NN	O
mycologic	NN	O
cultures	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
assessment	NN	O
.	.	O

Clinical	JJ	O
efficacy	NN	O
was	VBD	O
shown	VBN	O
in	IN	O
76.1	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
eberconazole	JJ	O
and	CC	O
in	IN	O
75.0	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
miconazole	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	A
events	NNS	A
related	VBN	O
to	TO	O
treatment	NN	O
was	VBD	O
0.91	CD	O
%	NN	O
for	IN	O
eberconazole	NN	O
and	CC	O
0.92	CD	O
%	NN	O
for	IN	O
miconazole	NN	O
,	,	O
none	NN	O
being	VBG	O
serious	JJ	O
,	,	O
and	CC	O
all	DT	O
being	VBG	O
local	JJ	O
and	CC	O
transient	NN	O
.	.	O

CONCLUSIONS	NNP	O
Eberconazole	NNP	O
1	CD	O
%	NN	O
cream	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
fungal	JJ	O
infections	NNS	O
produced	VBN	O
by	IN	O
dermatophytes	NNS	O
,	,	O
with	IN	O
a	DT	O
good	JJ	O
safety	NN	Ot
and	CC	Ot
tolerability	NN	Ot
profile	NN	O
,	,	O
and	CC	O
can	MD	O
be	VB	O
considered	VBN	O
a	DT	O
good	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
Thai	NNP	O
traditional	JJ	O
massage	NN	O
on	IN	O
autistic	JJ	O
children	NNS	O
's	POS	O
behavior	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
access	NN	O
whether	IN	O
there	EX	O
were	VBD	O
any	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
Thai	NNP	O
Traditional	NNP	O
Massage	NNP	O
(	(	O
TTM	NNP	O
)	)	O
on	IN	O
major	JJ	O
behavioral	JJ	O
and	CC	O
emotional	JJ	O
disturbances	NNS	O
in	IN	O
Thai	NNP	O
autistic	JJ	O
children	NNS	O
.	.	O

DESIGN	NN	O
This	DT	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
study	NN	O
.	.	O

SETTINGS/LOCATION	NNP	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Rehabilitation	NNP	O
Centre	NNP	O
of	IN	O
the	DT	O
Thai	NNP	O
Red	NNP	O
Cross	NNP	O
Society	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
60	CD	O
autistic	JJ	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
3	CD	O
and	CC	O
10	CD	O
completed	VBD	O
this	DT	O
study	NN	O
.	.	O

INTERVENTIONS	NNP	O
Standard	NNP	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
(	(	O
SI	NNP	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
SI	NNP	O
with	IN	O
TTM	NNP	O
treatments	NNS	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Parents	NNP	O
and	CC	O
teachers	NNS	O
assessed	VBD	O
major	JJ	ME
behavior	NN	ME
disturbances	NNS	ME
using	VBG	O
the	DT	O
Conners	NNPS	ME
'	POS	ME
Rating	VBG	ME
Scales	NNS	ME
at	IN	O
0	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	ME
Diary	NNP	ME
(	(	ME
SD	NNP	ME
)	)	ME
,	,	O
recorded	VBN	O
by	IN	O
the	DT	O
parents	NNS	O
,	,	O
assessed	VBD	O
the	DT	O
patient	NN	O
's	POS	O
sleeping	NN	O
patterns	NNS	O
every	DT	O
week	NN	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
(	(	O
60	CD	O
)	)	O
autistic	JJ	O
children	NNS	O
,	,	O
mean	JJ	O
age	NN	O
4.67	CD	O
+/-	JJ	O
1.82	CD	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

No	DT	O
statistical	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
demographic	JJ	O
and	CC	O
baseline	JJ	O
data	NN	O
among	IN	O
both	DT	O
groups	NNS	O
.	.	O

From	IN	O
both	CC	O
the	DT	O
Conners	NNPS	ME
'	POS	ME
Teacher	NNP	ME
Questionnaire	NNP	ME
and	CC	O
SD	NNP	ME
,	,	O
statistical	JJ	O
improvement	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
conduct	NN	ME
problem	NN	ME
,	,	ME
hyperactivity	NN	ME
,	,	ME
inattention-passivity	NN	ME
,	,	ME
hyperactivity	NN	ME
index	NN	ME
,	,	ME
and	CC	ME
sleeping	VBG	ME
behavior	NN	ME
.	.	O

However	RB	O
,	,	O
results	NNS	O
from	IN	O
the	DT	O
Conners	NNP	ME
'	POS	ME
Parent	NNP	ME
Questionnaire	NNP	ME
revealed	VBD	O
an	DT	O
improvement	NN	O
only	RB	O
for	IN	O
anxiety	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
massage	NN	O
group	NN	O
,	,	O
whereas	IN	O
when	WRB	O
both	DT	O
groups	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
conduct	NN	ME
problem	NN	ME
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
anxiety	NN	PH
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
was	VBD	O
found	VBN	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
TTM	NNP	O
may	MD	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
in	IN	O
improving	VBG	O
stereotypical	JJ	ME
behaviors	NNS	ME
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Over	IN	O
a	DT	O
period	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
,	,	O
our	PRP$	O
findings	NNS	O
suggested	VBD	O
that	IN	O
TTM	NNP	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
complementary	JJ	O
therapy	NN	O
for	IN	O
autistic	JJ	O
children	NNS	O
in	IN	O
Thailand	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
thin-ideal	JJ	O
media	NNS	O
images	NNS	O
on	IN	O
body	NN	ME
dissatisfaction	NN	ME
:	:	O
testing	VBG	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	O
versus	NN	O
warning	VBG	O
label	NN	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	O
(	(	O
i.e.	FW	O
,	,	O
Retouched	NNP	O
photograph	NN	O
aimed	VBN	O
at	IN	O
changing	VBG	O
a	DT	O
person	NN	O
's	POS	O
physical	JJ	O
appearance	NN	O
.	.	O

)	)	O
or	CC	O
warning	VBG	O
(	(	O
i.e.	FW	O
,	,	O
Warning	VBG	O
:	:	O
Trying	NN	O
to	TO	O
look	VB	O
as	RB	O
thin	JJ	O
as	IN	O
this	DT	O
model	NN	O
may	MD	O
be	VB	O
dangerous	JJ	O
to	TO	O
your	PRP$	O
health	NN	O
.	.	O

)	)	O
added	VBD	O
to	TO	O
images	NNS	O
of	IN	O
thin/attractive	JJ	O
models	NNS	O
would	MD	O
affect	VB	O
body	NN	ME
dissatisfaction	NN	ME
and	CC	O
intent	NN	O
to	TO	O
diet	VB	O
in	IN	O
female	JJ	O
undergraduate	JJ	O
students	NNS	O
(	(	O
n=342	NN	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
disclaimer	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
warning	NN	O
,	,	O
(	(	O
c	NN	O
)	)	O
model	NN	O
control	NN	O
,	,	O
or	CC	O
(	(	O
d	NN	O
)	)	O
car	NN	O
control	NN	O
.	.	O

Results	NNP	O
revealed	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
group	NN	O
and	CC	O
time	NN	O
,	,	O
whereby	WRB	O
only	RB	O
the	DT	O
car	NN	O
control	NN	O
group	NN	O
reported	VBD	O
a	DT	O
significant	JJ	O
change	NN	O
(	(	O
i.e.	FW	O
,	,	O
decrease	NN	O
)	)	O
in	IN	O
body	NN	ME
dissatisfaction	NN	ME
over	IN	O
time	NN	O
.	.	O

Groups	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
intent	NN	O
to	TO	O
diet	VB	ME
measured	VBN	O
at	IN	O
post-exposure	NN	O
.	.	O

The	DT	O
results	NNS	O
largely	RB	O
replicate	VBP	O
other	JJ	O
findings	NNS	O
in	IN	O
this	DT	O
area	NN	O
and	CC	O
call	VB	O
into	IN	O
question	NN	O
advocacy	NN	O
efforts	NNS	O
to	TO	O
label	VB	O
media	NNS	O
images	NNS	O
as	IN	O
a	DT	O
strategy	NN	O
to	TO	O
decrease	VB	O
women	NNS	O
's	POS	O
identification	NN	O
with	IN	O
the	DT	O
stimuli	NNS	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
for	IN	O
behaviorally	RB	O
disordered	VBN	O
mentally	RB	O
handicapped	JJ	O
patients	NNS	O
on	IN	O
staff	NN	O
personnel	NNS	O
in	IN	O
residential	JJ	O
care	NN	O
]	NNP	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
designed	VBN	O
for	IN	O
mentally	RB	O
handicapped	JJ	O
persons	NNS	O
with	IN	O
severely	RB	O
disturbed	VBN	O
or	CC	O
autistic	JJ	O
behavior	NN	O
on	IN	O
their	PRP$	O
staff	NN	O
personal	JJ	O
which	WDT	O
had	VBD	O
an	DT	O
active	JJ	O
role	NN	O
in	IN	O
the	DT	O
program	NN	O
.	.	O

The	DT	O
staff	NN	O
members	NNS	O
rated	VBD	O
their	PRP$	O
professional	JJ	O
competence	NN	O
,	,	O
quality	NN	O
of	IN	O
interaction	NN	O
with	IN	O
the	DT	O
client	NN	O
,	,	O
team	JJ	O
culture	NN	O
and	CC	O
work	NN	O
satisfaction	NN	O
before	IN	O
and	CC	O
after	IN	O
being	VBG	O
engaged	VBN	O
in	IN	O
the	DT	O
program	NN	O
,	,	O
with	IN	O
additional	JJ	O
ratings	NNS	O
of	IN	O
their	PRP$	O
personal	JJ	O
aims	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
program	NN	O
.	.	O

Three	NNP	O
sets	NNS	O
of	IN	O
data	NNS	O
were	VBD	O
obtained	VBN	O
with	IN	O
the	DT	O
program	NN	O
being	VBG	O
conducted	VBN	O
three	CD	O
times	NNS	O
in	IN	O
a	DT	O
row	NN	O
.	.	O

The	DT	O
testings	NNS	O
of	IN	O
the	DT	O
related	VBN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
independent	JJ	O
samples	NNS	O
show	VBP	O
differentiated	JJ	O
program	NN	O
effects	NNS	O
.	.	O

The	DT	O
main	JJ	O
effect	NN	O
is	VBZ	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
professional	JJ	Ot
competence	NN	Ot
and	CC	Ot
quality	NN	Ot
of	IN	Ot
interaction	NN	Ot
,	,	O
especially	RB	O
by	IN	O
the	DT	O
qualified	JJ	O
staff	NN	O
members	NNS	O
.	.	O

Trainees	NNP	O
put	VBD	O
emphasis	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
their	PRP$	O
personal	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
client	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
impact	NN	O
of	IN	O
learning	VBG	O
processes	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
roles	NNS	O
of	IN	O
the	DT	O
staff	NN	O
members	NNS	O
and	CC	O
motivational	JJ	O
factors	NNS	O
on	IN	O
learning	NN	O
and	CC	O
therapy	NN	O
outcome	NN	O
,	,	O
along	IN	O
with	IN	O
institutional	JJ	O
conditions	NNS	O
influencing	VBG	O
successful	JJ	O
learning	NN	O
.	.	O

Thus	VB	O
the	DT	O
program	NN	O
facilitates	VBZ	O
the	DT	O
professional	JJ	O
and	CC	O
interpersonal	JJ	O
learning	NN	O
process	NN	O
of	IN	O
staff	NN	O
members	NNS	O
in	IN	O
a	DT	O
specific	JJ	O
way	NN	O
with	IN	O
success	NN	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
limitations	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
a	DT	O
brief	JJ	O
cognitive-behavioural	JJ	O
therapy	NN	O
intervention	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	PH
.	.	O

BACKGROUND	NNP	O
Little	NNP	O
evidence	NN	O
exists	VBZ	O
to	TO	O
indicate	VB	O
whether	IN	O
community	NN	O
psychiatric	JJ	O
nurses	NNS	O
can	MD	O
achieve	VB	O
the	DT	O
results	NNS	O
reported	VBN	O
by	IN	O
expert	JJ	O
cognitive-behavioural	JJ	O
therapists	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
a	DT	O
brief	JJ	O
cognitive-behavioural	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
intervention	NN	O
in	IN	O
a	DT	O
representative	JJ	O
community	NN	O
sample	NN	O
of	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
in	IN	O
secondary	JJ	O
care	NN	O
settings	NNS	O
.	.	O

METHOD	NNP	O
A	NNP	O
pragmatic	JJ	O
randomised	VBD	O
trial	NN	O
was	VBD	O
performed	VBN	O
involving	VBG	O
422	CD	O
patients	NNS	O
and	CC	O
carers	NNS	O
to	TO	O
compare	VB	O
a	DT	O
brief	JJ	O
CBT	NNP	O
intervention	NN	O
against	IN	O
treatment	NN	O
as	IN	O
usual	JJ	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
who	WP	O
received	VBD	O
CBT	NNP	O
(	(	O
n=257	NN	O
)	)	O
improved	VBN	O
in	IN	O
overall	JJ	ME
symptomatology	NN	ME
(	(	O
P=0.015	NNP	O
;	:	O
number	NN	Ot
needed	VBN	Ot
to	TO	Ot
treat	VB	Ot
[	JJ	O
NNT	NNP	O
]	NNP	O
=13	NNP	O
)	)	O
,	,	O
insight	JJ	ME
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
NNT=10	NNP	O
)	)	O
and	CC	O
depression	NN	ME
(	(	O
P=0.003	NNP	O
;	:	O
NNT=9	NNP	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n=165	RB	O
)	)	O
.	.	O

Insight	NNP	PH
was	VBD	O
clinically	RB	O
significantly	RB	O
improved	VBN	O
(	(	O
risk	NN	O
ratio=1.15	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.01-1.31	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
suicidal	JJ	ME
ideation	NN	ME
.	.	O

CONCLUSIONS	NNP	O
Community	NNP	O
psychiatric	JJ	O
nurses	NNS	O
can	MD	O
safely	RB	Ot
and	CC	Ot
effectively	RB	Ot
deliver	VB	O
a	DT	O
brief	JJ	O
CBT	NNP	O
intervention	NN	O
to	TO	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
and	CC	O
their	PRP$	O
carers	NNS	O
.	.	O

Cost-effectiveness	NN	O
of	IN	O
combined	JJ	O
manipulation	NN	O
,	,	O
stabilizing	VBG	O
exercises	NNS	O
,	,	O
and	CC	O
physician	JJ	O
consultation	NN	O
compared	VBN	O
to	TO	O
physician	JJ	O
consultation	NN	O
alone	RB	O
for	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
2-year	JJ	O
follow-up	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
examine	VB	O
long-term	JJ	O
effects	NNS	O
and	CC	O
costs	NNS	O
of	IN	O
combined	JJ	O
manipulative	JJ	O
treatment	NN	O
,	,	O
stabilizing	VBG	O
exercises	NNS	O
,	,	O
and	CC	O
physician	JJ	O
consultation	NN	O
compared	VBN	O
with	IN	O
physician	JJ	O
consultation	NN	O
alone	RB	O
for	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
cLBP	NN	O
)	)	O
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
An	DT	O
obvious	JJ	O
gap	NN	O
exists	NNS	O
in	IN	O
knowledge	NN	O
concerning	VBG	O
long-term	JJ	O
efficacy	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
manipulative	JJ	O
treatment	NN	O
methods	NNS	O
.	.	O

METHODS	NNP	O
Of	IN	O
204	CD	O
patients	NNS	O
with	IN	O
cLBP	NNS	O
whose	WP$	O
Oswestry	NNP	O
Disability	NNP	O
Index	NNP	O
(	(	O
ODI	NNP	O
)	)	O
was	VBD	O
at	IN	O
least	JJS	O
16	CD	O
%	NN	O
,	,	O
102	CD	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
combined	JJ	O
manipulative	JJ	O
treatment	NN	O
,	,	O
exercise	NN	O
,	,	O
and	CC	O
physician	JJ	O
consultation	NN	O
group	NN	O
(	(	O
i.e.	FW	O
,	,	O
a	DT	O
combination	NN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
102	CD	O
to	TO	O
a	DT	O
consultation	NN	O
alone	RB	O
group	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
clinically	RB	O
examined	VBN	O
,	,	O
informed	VBN	O
about	IN	O
their	PRP$	O
back	NN	O
pain	NN	O
,	,	O
and	CC	O
encouraged	VBD	O
to	TO	O
stay	VB	O
active	JJ	O
and	CC	O
exercise	NN	O
according	VBG	O
to	TO	O
specific	JJ	O
instructions	NNS	O
based	VBN	O
on	IN	O
clinical	JJ	O
evaluation	NN	O
.	.	O

Treatment	NNP	O
included	VBD	O
4	CD	O
sessions	NNS	O
of	IN	O
manual	JJ	O
therapy	NN	O
and	CC	O
stabilizing	NN	O
exercises	NNS	O
aimed	VBN	O
at	IN	O
correcting	VBG	O
the	DT	O
lumbopelvic	JJ	O
rhythm	NN	O
.	.	O

Questionnaires	VBZ	O
inquired	VBN	O
about	IN	O
pain	NN	PA
(	(	PA
visual	JJ	PA
analog	NN	PA
scale	NN	PA
(	(	PA
VAS	NNP	PA
)	)	PA
)	)	PA
,	,	PA
disability	NN	PH
(	(	PH
ODI	NNP	PH
)	)	PH
,	,	O
health-related	JJ	PH
quality	NN	PH
of	IN	PH
life	NN	PH
(	(	O
15D	CD	PH
Quality	NN	PH
of	IN	PH
Life	NNP	PH
Instrument	NNP	PH
)	)	O
,	,	O
satisfaction	NN	Ot
with	IN	Ot
care	NN	Ot
,	,	O
and	CC	O
costs	NNS	Ot
.	.	O

RESULTS	NNP	O
Significant	NNP	O
improvement	NN	O
occurred	VBD	O
in	IN	O
both	DT	O
groups	NNS	O
on	IN	O
every	DT	O
self-rated	JJ	PH
outcome	NN	PH
measurement	NN	O
.	.	O

Within	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
combination	NN	O
group	NN	O
showed	VBD	O
only	RB	O
a	DT	O
slightly	RB	O
more	RBR	O
significant	JJ	O
reduction	NN	O
in	IN	O
VAS	NNP	PA
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
,	,	O
analysis	NN	O
of	IN	O
variance	NN	O
)	)	O
but	CC	O
clearly	RB	O
higher	JJR	O
patient	JJ	Ot
satisfaction	NN	Ot
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
,	,	O
Pearson	NNP	O
chi2	NN	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
consultation	NN	O
group	NN	O
.	.	O

Incremental	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
for	IN	O
combined	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
consultation	NN	O
group	NN	O
,	,	O
a	DT	O
one-point	JJ	O
change	NN	O
in	IN	O
VAS	NNP	O
scale	NN	O
cost	NN	O
$	$	O
512	CD	O
.	.	O

CONCLUSIONS	NNP	O
Physician	JJ	O
consultation	NN	O
alone	RB	O
was	VBD	O
more	RBR	O
cost-effective	JJ	Ot
for	IN	O
both	DT	O
health	NN	O
care	NN	O
use	NN	O
and	CC	O
work	NN	O
absenteeism	NN	O
,	,	O
and	CC	O
led	VBD	O
to	TO	O
equal	JJ	O
improvement	NN	O
in	IN	O
disability	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

It	PRP	O
seems	VBZ	O
obvious	JJ	O
that	IN	O
encouraging	VBG	O
information	NN	O
and	CC	O
advice	NN	O
are	VBP	O
major	JJ	O
elements	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
cLBP	NN	O
.	.	O

The	DT	O
effects	NNS	Ot
of	IN	O
chewing	VBG	O
versus	NN	O
caffeine	NN	O
on	IN	O
alertness	NN	O
,	,	O
cognitive	JJ	O
performance	NN	O
and	CC	O
cardiac	JJ	O
autonomic	JJ	O
activity	NN	O
during	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

Chewing	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
alleviate	VB	O
feelings	NNS	O
of	IN	O
sleepiness	NN	O
and	CC	O
improve	VB	O
cognitive	JJ	O
performance	NN	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	Ot
of	IN	O
chewing	VBG	O
on	IN	O
alertness	NN	O
and	CC	O
cognitive	JJ	O
performance	NN	O
across	IN	O
one	CD	O
night	NN	O
without	IN	O
sleep	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
possible	JJ	O
mediating	JJ	O
role	NN	O
of	IN	O
cardiac	JJ	O
autonomic	JJ	O
activity	NN	O
.	.	O

Fourteen	NNP	O
adults	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
counterbalanced	VBD	O
protocol	NN	O
employing	VBG	O
a	DT	O
chewing	NN	O
,	,	O
placebo	NN	O
and	CC	O
caffeine	JJ	O
condition	NN	O
.	.	O

Participants	NNS	O
completed	VBD	O
tasks	NNS	O
assessing	VBG	O
psychomotor	NN	ME
vigilance	NN	ME
,	,	O
tracking	VBG	ME
,	,	O
grammatical	JJ	ME
reasoning	NN	ME
,	,	O
alertness	NN	ME
and	CC	O
sleepiness	JJ	ME
each	DT	O
hour	NN	O
across	IN	O
the	DT	O
night	NN	O
.	.	O

All	DT	O
participants	NNS	O
received	VBD	O
either	CC	O
placebo	NN	O
or	CC	O
caffeine	NN	O
(	(	O
200	CD	O
mg	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
chewing	VBG	O
condition	NN	O
also	RB	O
chewed	VBD	O
on	IN	O
a	DT	O
tasteless	NN	O
and	CC	O
odorless	JJ	O
substance	NN	O
for	IN	O
15	CD	O
min	NNS	O
each	DT	O
hour	NN	O
.	.	O

Heart	NNP	PH
rate	NN	PH
(	(	PH
HR	NNP	PH
)	)	PH
,	,	O
root	JJ	PH
mean	JJ	PH
square	NN	PH
of	IN	PH
the	DT	PH
successive	JJ	PH
differences	NNS	PH
in	IN	PH
R-R	NNP	PH
intervals	NNS	PH
on	IN	PH
the	DT	PH
ECG	NNP	PH
(	(	PH
RMSSD	NNP	PH
)	)	PH
,	,	O
and	CC	O
preejection	NN	PH
period	NN	PH
(	(	PH
PEP	NNP	PH
)	)	PH
were	VBD	O
simultaneously	RB	O
recorded	VBN	O
.	.	O

Alertness	NNP	ME
and	CC	ME
cognitive	JJ	ME
performance	NN	ME
amongst	VBD	O
the	DT	O
chewing	VBG	O
condition	NN	O
did	VBD	O
not	RB	Ot
differ	VB	Ot
or	CC	Ot
were	VBD	Ot
in	IN	Ot
fact	NN	Ot
worse	NN	Ot
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Similarly	RB	O
,	,	O
measures	NNS	O
of	IN	O
HR	NNP	PH
and	CC	O
RMSSD	NNP	PH
remained	VBD	O
the	DT	O
same	JJ	O
between	IN	O
these	DT	O
two	CD	O
conditions	NNS	O
;	:	O
however	RB	O
,	,	O
PEP	NNP	PH
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
later	JJ	O
part	NN	O
of	IN	O
the	DT	O
night	NN	O
in	IN	O
the	DT	O
chewing	VBG	O
condition	NN	O
compared	VBN	O
with	IN	O
a	DT	O
relative	JJ	O
increase	NN	O
for	IN	O
placebo	NN	O
.	.	O

Caffeine	NNP	O
led	VBD	O
to	TO	O
improved	VBN	Ot
speed	NN	Ot
and	CC	PH
accuracy	NN	Ot
on	IN	Ot
cognitive	JJ	Ot
tasks	NNS	Ot
and	CC	PH
increased	VBD	Ot
alertness	NN	Ot
when	WRB	O
compared	VBN	O
with	IN	O
chewing	VBG	O
.	.	O

Relative	JJ	PH
increases	NNS	PH
in	IN	PH
RMSSD	NNP	PH
and	CC	O
reductions	NNS	PH
in	IN	PH
HR	NNP	PH
were	VBD	O
demonstrated	VBN	O
following	VBG	O
caffeine	NN	O
;	:	O
however	RB	O
,	,	O
no	DT	PH
change	NN	PH
in	IN	PH
PEP	NNP	PH
was	VBD	O
seen	VBN	O
.	.	O

Strong	JJ	O
associations	NNS	O
between	IN	O
cardiac	JJ	O
parasympathetic	JJ	O
activity	NN	O
and	CC	O
complex	JJ	O
cognitive	NN	O
tasks	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
between	IN	O
subjective	JJ	O
alertness	NN	ME
and	CC	O
simpler	NN	ME
cognitive	JJ	ME
tasks	NNS	ME
,	,	O
suggest	VBP	O
a	DT	O
differential	JJ	O
process	NN	O
mediating	VBG	O
complex	JJ	O
versus	NN	O
simple	JJ	O
cognitive	JJ	O
performance	NN	O
during	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

Relaxation	NN	O
and	CC	O
imagery	NN	O
and	CC	O
cognitive-behavioral	JJ	O
training	NN	O
reduce	VB	O
pain	NN	PA
during	IN	O
cancer	NN	O
treatment	NN	O
:	:	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Few	NNP	O
controlled	VBD	O
clinical	JJ	O
trials	NNS	O
of	IN	O
psychological	JJ	O
interventions	NNS	O
for	IN	O
cancer	NN	PA
pain	NN	PA
relief	NN	PA
exist	NN	O
in	IN	O
spite	NN	O
of	IN	O
frequent	JJ	O
support	NN	O
for	IN	O
their	PRP$	O
importance	NN	O
as	IN	O
adjuncts	NNS	O
to	TO	O
medical	JJ	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
oral	JJ	O
mucositis	NN	O
pain	NN	O
levels	NNS	O
in	IN	O
4	CD	O
groups	NNS	O
of	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
bone	NN	O
marrow	NN	O
transplants	NNS	O
(	(	O
BMT	NNP	O
)	)	O
:	:	O
(	(	O
1	CD	O
)	)	O
treatment	NN	O
as	IN	O
usual	JJ	O
control	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
therapist	NN	O
support	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
relaxation	NN	O
and	CC	O
imagery	NN	O
training	NN	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
training	NN	O
in	IN	O
a	DT	O
package	NN	O
of	IN	O
cognitive-behavioral	JJ	O
coping	NN	O
skills	NNS	O
which	WDT	O
included	VBD	O
relaxation	NN	O
and	CC	O
imagery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
94	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
which	WDT	O
involved	VBD	O
two	CD	O
training	NN	O
sessions	NNS	O
prior	RB	O
to	TO	O
treatment	NN	O
and	CC	O
twice	RB	O
a	DT	O
week	NN	O
'booster	POS	O
'	POS	O
sessions	NNS	O
during	IN	O
the	DT	O
first	JJ	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Results	NNS	O
confirmed	VBD	O
our	PRP$	O
hypothesis	NN	O
that	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
either	DT	O
relaxation	NN	O
and	CC	O
imagery	VB	O
alone	RB	O
or	CC	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
package	NN	O
of	IN	O
cognitive-behavioral	JJ	O
coping	NN	O
skills	NNS	O
would	MD	O
report	VB	O
less	JJR	O
pain	NN	PA
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
other	JJ	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
cognitive-behavioral	JJ	O
skills	NNS	O
package	NN	O
would	MD	O
have	VB	O
an	DT	O
additive	JJ	O
effect	NN	O
beyond	IN	O
relaxation	NN	O
and	CC	O
imagery	NN	O
alone	RB	O
was	VBD	O
not	RB	O
confirmed	VBN	O
.	.	O

Average	JJ	PA
visual	JJ	PA
analogue	NN	PA
scale	NN	PA
(	(	PA
VAS	NNP	PA
)	)	PA
report	NN	PA
of	IN	PA
pain	NN	PA
within	IN	O
the	DT	O
therapist	JJ	O
support	NN	O
group	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.103	CD	O
)	)	O
nor	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
training	NN	O
groups	NNS	O
.	.	O

Patient	JJ	O
reports	NNS	O
of	IN	O
relative	JJ	O
helpfulness	NN	O
of	IN	O
the	DT	O
interventions	NNS	O
for	IN	O
managing	VBG	O
pain	NN	PA
and	CC	O
nausea	NN	PA
matched	VBD	O
the	DT	O
results	NNS	O
of	IN	O
VAS	NNP	O
reports	NNS	O
.	.	O

From	IN	O
these	DT	O
results	NNS	O
,	,	O
we	PRP	O
conclude	VBP	O
that	DT	O
relaxation	NN	O
and	CC	O
imagery	NN	O
training	NN	O
reduces	NNS	O
cancer	NN	PA
treatment-related	JJ	PA
pain	NN	PA
;	:	O
adding	VBG	O
cognitive-behavioral	JJ	O
skills	NNS	O
to	TO	O
the	DT	O
relaxation	NN	O
with	IN	O
imagery	NN	O
does	VBZ	O
not	RB	O
,	,	O
on	IN	O
average	NN	O
,	,	O
further	JJ	O
improve	VB	O
pain	NN	PA
relief	NN	PA
.	.	O

Comparison	NNP	O
of	IN	O
inguinal	JJ	O
approach	NN	O
,	,	O
scrotal	JJ	O
sclerotherapy	NN	O
and	CC	O
subinguinal	JJ	O
antegrade	NN	O
sclerotherapy	NN	O
in	IN	O
varicocele	JJ	O
treatment	NN	O
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

We	PRP	O
compared	VBN	O
outcome	NN	O
and	CC	O
complications	NNS	O
of	IN	O
three	CD	O
simple	JJ	O
varicocelectomy	NN	O
techniques	NNS	O
.	.	O

Groups	NNP	O
were	VBD	O
divided	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
they	PRP	O
would	MD	O
receive	VB	O
the	DT	O
Ivanissevich	NNP	O
technique	NN	O
(	(	O
n	JJ	O
=	NNP	O
55	CD	O
)	)	O
,	,	O
Tauber	NNP	O
's	POS	O
technique	NN	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
or	CC	O
subinguinal	JJ	O
sclerotherapy	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

Selection	NN	O
criteria	NNS	O
were	VBD	O
:	:	O
infertility	NN	O
>	VBZ	O
1	CD	O
year	NN	O
,	,	O
subnormal	JJ	O
semen	NNS	O
,	,	O
sonographic	JJ	O
diameter	NN	O
of	IN	O
veins	NNS	O
>	VBP	O
3	CD	O
mm	NN	O
and	CC	O
time	NN	O
of	IN	O
regurge	NN	O
>	$	O
2	CD	O
s.	NN	O
Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
groups	NNS	O
of	IN	O
treatment	NN	O
,	,	O
with	IN	O
follow-up	JJ	O
every	DT	O
3	CD	O
months	NNS	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

Improvement	NNP	O
was	VBD	O
only	RB	O
in	IN	O
sperm	JJ	PH
count	NN	PH
and	CC	O
total	JJ	PH
motility	NN	PH
for	IN	O
all	DT	O
groups	NNS	O
.	.	O

Pregnancy	NN	PH
rates	NNS	PH
were	VBD	O
20	CD	O
,	,	O
13.73	CD	O
and	CC	O
12.24	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
groups	NNS	O
.	.	O

Hydrocele	NNP	A
occurred	VBD	O
only	RB	O
in	IN	O
the	DT	O
group	NN	O
which	WDT	O
received	VBD	O
the	DT	O
Ivanissevich	NNP	O
technique	NN	O
(	(	O
5.5	CD	O
%	NN	O
)	)	O
.	.	O

Tauber	NNP	O
's	POS	O
technique	NN	O
is	VBZ	O
simple	JJ	O
;	:	O
however	RB	O
,	,	O
it	PRP	O
has	VBZ	O
the	DT	O
disadvantage	NN	O
of	IN	O
multiple	JJ	PH
branching	NN	PH
of	IN	PH
small	JJ	PH
veins	NNS	PH
.	.	O

Comparison	NNP	O
of	IN	O
chemotherapy	NN	O
with	IN	O
chemohormonal	JJ	O
therapy	NN	O
as	IN	O
first-line	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	O
,	,	O
hormone-sensitive	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
An	DT	O
Eastern	JJ	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Although	IN	O
hormonal	JJ	O
therapy	NN	O
represents	VBZ	O
standard	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	O
hormone-sensitive	JJ	O
disease	NN	O
,	,	O
many	JJ	O
patients	NNS	O
receive	VBP	O
initial	JJ	O
chemotherapy	NN	O
because	IN	O
of	IN	O
the	DT	O
location	NN	O
,	,	O
bulk	NN	O
,	,	O
or	CC	O
aggressiveness	NN	O
of	IN	O
their	PRP$	O
disease	NN	O
.	.	O

It	PRP	O
is	VBZ	O
uncertain	JJ	O
whether	IN	O
simultaneous	JJ	O
hormonal	JJ	O
therapy	NN	O
provides	VBZ	O
additional	JJ	O
benefit	NN	O
compared	VBN	O
with	IN	O
chemotherapy	NN	O
alone	RB	O
.	.	O

Eastern	JJ	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
trial	NN	O
E3186	NNP	O
was	VBD	O
initiated	VBN	O
to	TO	O
explore	VB	O
this	DT	O
question	NN	O
.	.	O

PATIENTS	NN	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1988	CD	O
and	CC	O
December	NNP	O
1992	CD	O
,	,	O
231	CD	O
patients	NNS	O
with	IN	O
estrogen	JJ	O
receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
-positive	CD	O
or	CC	O
ER-unknown	JJ	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
chemotherapy	NN	O
(	(	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
and	CC	O
fluorouracil	RB	O
?CAF	NNP	O
)	)	O
or	CC	O
chemohormonal	JJ	O
therapy	NN	O
(	(	O
CAF	NNP	O
plus	CC	O
tamoxifen	NN	O
and	CC	O
Halotestin	NNP	O
?fluoxymesterone	NN	O
;	:	O
Pharmacia-Upjohn	NNP	O
,	,	O
Kalamazoo	NNP	O
,	,	O
MI	NNP	O
?CAFTH	NNP	O
)	)	O
as	IN	O
front-line	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

Patients	NNS	O
who	WP	O
experienced	VBD	O
a	DT	O
complete	JJ	O
response	NN	O
to	TO	O
induction	NN	O
therapy	NN	O
either	CC	O
received	VBD	O
or	CC	O
did	VBD	O
not	RB	O
receive	JJ	O
maintenance	NN	O
cyclophosphamide	NN	O
,	,	O
methotrexate	NN	O
,	,	O
fluorouracil	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
TH	NNP	O
as	IN	O
a	DT	O
secondary	JJ	O
randomization	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
response	NN	O
rates	NNS	O
(	(	O
complete	JJ	O
response	NN	O
and	CC	O
partial	JJ	O
response	NN	O
)	)	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
CAF	NNP	O
and	CC	O
CAFTH	NNP	O
were	VBD	O
similar	JJ	O
(	(	O
69.2	CD	O
%	NN	O
v	JJ	O
68.9	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.99	NNP	O
)	)	O
.	.	O

Time	NN	O
to	TO	O
treatment	NN	O
failure	NN	O
(	(	O
TTF	NNP	O
)	)	O
was	VBD	O
slightly	RB	O
longer	JJR	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
chemohormonal	JJ	O
therapy	NN	O
compared	VBN	O
with	IN	O
chemotherapy	NN	O
alone	RB	O
patients	NNS	O
(	(	O
13.4	CD	O
months	NNS	O
v	RB	O
10.3	CD	O
months	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.087	NNP	O
)	)	O
,	,	O
and	CC	O
TTF	NNP	O
was	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
ER-positive	JJ	O
compared	VBN	O
with	IN	O
ER-negative	JJ	O
patients	NNS	O
(	(	O
17.4	CD	O
months	NNS	O
v	RB	O
10.3	CD	O
months	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.048	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
ER	NNP	O
status	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
(	(	O
30.0	CD	O
months	NNS	O
for	IN	O
CAF	NNP	O
v	FW	O
29.3	CD	O
months	NNS	O
for	IN	O
CAFTH	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
potentially	RB	O
hormone-sensitive	JJ	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
chemohormonal	JJ	O
therapy	NN	O
prolongs	NNS	O
TTF	NNP	O
for	IN	O
ER-positive	JJ	O
patients	NNS	O
without	IN	O
improving	VBG	O
overall	JJ	O
survival	NN	O
.	.	O

Digestive	JJ	O
enzyme	NN	O
supplementation	NN	O
for	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
digestive	JJ	O
enzyme	NN	O
supplement	NN	O
in	IN	O
improving	VBG	O
expressive	JJ	ME
language	NN	ME
,	,	O
behaviour	NN	ME
and	CC	O
other	JJ	ME
symptoms	NNS	ME
in	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorder	NNP	O
.	.	O

Randomized	VBN	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
using	VBG	O
crossover	NN	O
design	NN	O
over	IN	O
6	CD	O
months	NNS	O
for	IN	O
43	CD	O
children	NNS	O
,	,	O
aged	VBN	O
3-8	CD	O
years	NNS	O
.	.	O

Outcome	NNP	O
measurement	NN	O
tools	NNS	O
included	VBD	O
monthly	JJ	O
Global	NNP	Ot
Behaviour	NNP	Ot
Rating	NNP	Ot
Scales	NNP	Ot
,	,	O
Additional	NNP	PH
Rating	NNP	PH
Scales	NNP	PH
of	IN	PH
other	JJ	PH
symptoms	NNS	PH
by	IN	PH
parents	NNS	PH
and	CC	PH
therapists	NNS	PH
,	,	O
and	CC	O
monthly	JJ	Ot
completion	NN	Ot
of	IN	Ot
the	DT	Ot
Rescorla	NNP	Ot
Language	NNP	Ot
Development	NNP	Ot
Survey	NNP	Ot
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
treatment	NN	O
with	IN	O
enzyme	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
clinically	RB	O
significant	JJ	PH
improvement	NN	PH
in	IN	PH
behaviour	NN	PH
,	,	O
food	NN	PH
variety	NN	PH
,	,	O
gastrointestinal	JJ	PH
symptoms	NNS	PH
,	,	O
sleep	JJ	PH
quality	NN	PH
,	,	O
engagement	NN	Ot
with	IN	Ot
therapist	NN	Ot
,	,	O
or	CC	O
the	DT	Ot
Language	NNP	Ot
Development	NNP	Ot
Survey	NNP	Ot
Vocabulary	NNP	Ot
or	CC	Ot
Sentence	NNP	Ot
Complexity	NNP	Ot
Scores	NNP	Ot
.	.	O

A	NNP	O
small	JJ	O
statistically	RB	O
significant	JJ	Ot
improvement	NN	Ot
on	IN	O
enzyme	NN	O
therapy	NN	O
was	VBD	O
seen	VBN	O
for	IN	O
the	DT	O
food	NN	O
variety	NN	O
scores	NNS	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
improvement	NN	O
of	IN	O
autism	NN	PH
symptoms	NNS	PH
with	IN	O
enzyme	NN	O
use	NN	O
was	VBD	O
shown	VBN	O
with	IN	O
this	DT	O
trial	NN	O
,	,	O
however	RB	O
,	,	O
possible	JJ	O
effects	NNS	O
on	IN	O
improvement	NN	ME
in	IN	ME
food	NN	ME
variety	NN	ME
warrants	NNS	O
further	RBR	O
detailed	JJ	O
investigation	NN	O
.	.	O

The	DT	O
adrenocorticotrophic	JJ	O
hormone	NN	O
(	(	O
4-9	JJ	O
)	)	O
analog	NN	O
ORG	IN	O
2766	CD	O
benefits	NNS	O
autistic	JJ	O
children	NNS	O
:	:	O
report	NN	O
on	IN	O
a	DT	O
second	JJ	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
controlled	VBN	O
crossover	NN	O
trial	NN	O
,	,	O
20	CD	O
autistic	JJ	O
children	NNS	O
received	VBD	O
40	CD	O
mg/day	NN	O
of	IN	O
the	DT	O
neuropeptide	NN	O
ORG	NNP	O
2766	CD	O
,	,	O
a	DT	O
synthetic	JJ	O
analog	NN	O
of	IN	O
ACTH	NNP	O
(	(	O
4-9	JJ	O
)	)	O
,	,	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Parents	NNS	Ot
'	POS	Ot
checklist	NN	Ot
ratings	NNS	Ot
(	(	Ot
ABC	NNP	Ot
)	)	Ot
as	RB	O
well	RB	O
as	IN	O
clinicians	NNS	Ot
'	POS	Ot
ratings	NNS	Ot
(	(	Ot
CGI	NNP	Ot
)	)	Ot
pointed	VBD	O
to	TO	O
significant	JJ	O
improvements	NNS	O
after	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
;	:	O
improvements	NNS	O
were	VBD	O
clearest	VBN	O
on	IN	O
the	DT	O
ABC	NNP	Ot
social	JJ	Ot
withdrawal	NN	Ot
subscale	NN	Ot
.	.	Ot

The	DT	O
analysis	NN	O
of	IN	O
individual	JJ	O
target	NN	O
symptoms	NNS	O
and	CC	O
the	DT	O
parents	NNS	O
'	POS	O
treatment	NN	O
preferences	NNS	O
substantiated	VBD	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
ORG	NNP	O
2766	CD	O
.	.	O

In	IN	O
an	DT	O
ethologically	RB	O
analyzed	JJ	O
playroom	NN	O
session	NN	O
,	,	O
ORG	NNP	O
2766	CD	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
improvement	NN	O
in	IN	O
the	DT	O
children	NNS	ME
's	POS	ME
play	NN	ME
behavior	NN	ME
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
social	JJ	ME
interaction	NN	ME
between	IN	ME
child	NN	ME
and	CC	ME
experimenter	NN	ME
.	.	ME

Gaze	NNP	ME
coordination	NN	ME
between	IN	O
child	NN	O
and	CC	O
experimenter	NN	O
also	RB	O
was	VBD	O
improved	VBN	O
.	.	O

Disopyramide-pyridostigmine	JJ	O
interaction	NN	O
:	:	O
selective	JJ	O
reversal	NN	O
of	IN	O
anticholinergic	NN	O
symptoms	NNS	O
with	IN	O
preservation	NN	O
of	IN	O
antiarrhythmic	JJ	O
effect	NN	O
.	.	O

This	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo	FW	O
crossover	NN	O
study	NN	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
cholinesterase	NN	O
inhibitor	NN	O
--	:	O
slow-release	JJ	O
pyridostigmine	NN	O
(	(	O
180	CD	O
mg	NNS	O
orally	RB	O
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
--	:	O
on	IN	O
the	DT	O
anticholinergic	NN	PH
and	CC	PH
antiarrhythmic	JJ	PH
properties	NNS	PH
of	IN	O
disopyramide	NN	O
.	.	O

Quantitative	JJ	O
side	NN	O
effects	NNS	O
questionnaire	VBP	O
scores	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
guide	VB	O
disopyramide	JJ	O
administration	NN	O
in	IN	O
20	CD	O
men	NNS	O
with	IN	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

Disopyramide	NNP	O
was	VBD	O
given	VBN	O
to	TO	O
each	DT	O
patient	NN	O
both	DT	O
with	IN	O
placebo	NN	O
and	CC	O
with	IN	O
active	JJ	O
pyridostigmine	NN	O
.	.	O

The	DT	O
maximal	JJ	O
administered	VBD	O
dose	NN	O
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
used	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
corresponding	JJ	O
questionnaire	NN	O
scores	NNS	O
to	TO	O
calculate	VB	O
an	DT	O
index	NN	O
or	CC	O
estimate	NN	O
of	IN	O
the	DT	O
maximal	JJ	Ot
tolerable	JJ	Ot
dose	NN	Ot
of	IN	O
disopyramide	NN	O
.	.	O

Additional	JJ	O
evaluations	NNS	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
each	DT	O
maximal	NN	O
administered	VBD	O
dose	JJ	O
regimen	NNS	O
included	VBD	O
tear	JJ	PH
and	CC	PH
saliva	JJ	PH
quantitation	NN	PH
,	,	PH
24	CD	PH
hour	NN	PH
electrocardiogram	NN	PH
(	(	PH
ECG	NNP	PH
)	)	PH
,	,	PH
exercise	VBP	PH
testing	VBG	PH
and	CC	PH
programmed	VBD	PH
ventricular	JJ	PH
stimulation	NN	PH
.	.	PH

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
maximal	NN	O
administered	VBD	O
dose	NN	O
of	IN	O
disopyramide	NN	O
was	VBD	O
greater	JJR	O
with	IN	O
active	JJ	O
pyridostigmine	NN	O
than	IN	O
with	IN	O
placebo	NN	O
:	:	O
295	CD	O
+/-	JJ	O
75	CD	O
versus	NN	O
245	CD	O
+/-	JJ	O
100	CD	O
mg	NN	O
every	DT	O
6	CD	O
hours	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
calculated	JJ	O
maximal	NN	Ot
tolerable	JJ	Ot
dose	NN	Ot
was	VBD	O
substantially	RB	O
greater	JJR	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pyridostigmine	NN	O
:	:	O
355	CD	O
+/-	JJ	O
90	CD	O
versus	NN	O
260	CD	O
+/-	JJ	O
115	CD	O
mg	NN	O
every	DT	O
6	CD	O
hours	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Maximal	JJ	A
side	NN	A
effects	NNS	A
questionnaire	NN	A
scores	NNS	A
also	RB	O
reflected	VBD	O
decreased	JJ	O
anticholinergic	JJ	PH
activity	NN	PH
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pyridostigmine	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
:	:	O
101.9	CD	O
+/-	JJ	O
2.2	CD	O
versus	NN	O
104.6	CD	O
+/-	JJ	O
2.8	CD	O
,	,	O
respectively	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
.	.	O

Baseline	NNP	O
tear	NN	O
and	CC	O
saliva	JJ	O
production	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
during	IN	O
disopyramide	JJ	O
therapy	NN	O
,	,	O
but	CC	O
was	VBD	O
restored	VBN	O
toward	IN	O
normal	JJ	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
pyridostigmine	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
MF101	NNP	O
,	,	O
a	DT	O
selective	JJ	O
estrogen	NN	O
receptor	NN	O
beta	NN	O
modulator	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menopausal	NN	O
hot	JJ	O
flushes	NNS	O
:	:	O
a	DT	O
phase	NN	O
II	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
dose	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
an	DT	O
estrogen	NN	O
receptor	NN	O
beta	NN	O
selective	JJ	O
Chinese	NNP	O
herbal	NN	O
extract	NN	O
,	,	O
menopausal	JJ	O
formula	NN	O
101	CD	O
(	(	O
MF101	NNP	O
)	)	O
,	,	O
for	IN	O
treating	VBG	O
hot	JJ	O
flushes	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
blinded	VBD	O
trial	NN	O
in	IN	O
217	CD	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
hot	JJ	O
flushes	NNS	O
randomized	VBD	O
to	TO	O
5	CD	O
or	CC	O
10	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
or	CC	O
placebo	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effects	NNS	O
of	IN	O
5	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
those	DT	O
of	IN	O
placebo	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
mean	JJ	Ot
percent	NN	Ot
decrease	NN	Ot
in	IN	Ot
frequency	NN	Ot
of	IN	Ot
hot	JJ	Ot
flushes	NNS	Ot
in	IN	O
the	DT	O
10	CD	O
g/day	NN	O
group	NN	O
was	VBD	O
12.9	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
,	,	O
the	DT	O
median	JJ	O
percent	NN	O
decrease	NN	O
was	VBD	O
11.7	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
proportion	NN	Ot
of	IN	Ot
women	NNS	Ot
with	IN	Ot
at	IN	Ot
least	JJS	Ot
a	DT	Ot
50	CD	Ot
%	NN	Ot
reduction	NN	Ot
in	IN	Ot
hot	JJ	Ot
flushes	NNS	Ot
was	VBD	O
16.2	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Treatment	NNP	O
with	IN	O
10	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
reduces	VBZ	O
the	DT	O
frequency	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
.	.	O

Trials	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
are	VBP	O
planned	VBN	O
.	.	O

Maintenance	NN	O
of	IN	O
response	NN	O
following	VBG	O
stabilization	NN	O
of	IN	O
mixed	JJ	O
index	NN	O
episodes	NNS	O
with	IN	O
olanzapine	JJ	O
monotherapy	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
bipolar	JJ	O
1	CD	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
a	DT	O
population	NN	O
of	IN	O
patients	NNS	O
with	IN	O
manic	JJ	O
and	CC	O
mixed	JJ	O
mood	NN	O
episodes	NNS	O
,	,	O
olanzapine	NN	O
has	VBZ	O
proven	VBN	O
effective	JJ	O
in	IN	O
maintaining	VBG	O
response	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

Whether	IN	O
this	DT	O
is	VBZ	O
true	JJ	O
for	IN	O
the	DT	O
subpopulation	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
mixed	JJ	O
index	NN	O
episode	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

METHODS	NNP	O
Post-hoc	JJ	O
analyses	NNS	O
were	VBD	O
conducted	VBN	O
on	IN	O
data	NNS	O
from	IN	O
patients	NNS	O
presenting	VBG	O
with	IN	O
a	DT	O
mixed	JJ	O
index	NN	O
episode	NN	O
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
larger	JJR	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Patients	NNS	O
who	WP	O
met	VBD	O
remission	NN	O
criteria	NNS	O
at	IN	O
2	CD	O
consecutive	JJ	O
weekly	JJ	O
visits	NNS	O
during	IN	O
6	CD	O
to	TO	O
12	CD	O
weeks	NNS	O
of	IN	O
open-label	JJ	O
olanzapine	JJ	O
treatment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
olanzapine	VB	O
or	CC	O
placebo	VB	O
treatment	NN	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
and	CC	O
time	NN	O
to	TO	O
symptomatic	JJ	PH
relapse	NN	PH
were	VBD	O
calculated	VBN	O
for	IN	O
any	DT	O
mood	NN	O
episode	NN	O
,	,	O
and	CC	O
for	IN	O
depressive	JJ	O
,	,	O
manic	JJ	O
,	,	O
hypo-manic	JJ	O
,	,	O
and	CC	O
mixed	JJ	O
mood	NN	O
episodes	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
121	CD	O
of	IN	O
304	CD	O
patients	NNS	O
(	(	O
39.8	CD	O
%	NN	O
)	)	O
met	VBD	O
criteria	NNS	O
for	IN	O
symptomatic	JJ	PH
remission	NN	PH
in	IN	O
the	DT	O
open-label	JJ	O
treatment	NN	O
phase	NN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
olanzapine	VB	O
(	(	O
n=76	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=45	JJ	O
)	)	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
the	DT	O
olanzapine	NN	O
group	NN	O
had	VBD	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
(	(	O
59.2	CD	O
%	NN	O
versus	IN	O
91.1	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
(	(	O
46	CD	O
versus	NN	O
15	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.001	CD	O
)	)	O
symptomatic	JJ	PH
relapse	NN	PH
of	IN	O
any	DT	O
kind	NN	O
.	.	O

Olanzapine-treated	JJ	O
patients	NNS	O
also	RB	O
experienced	VBD	O
longer	JJR	O
time	NN	PH
to	TO	PH
depressive	VB	PH
symptomatic	JJ	PH
relapse	NN	PH
(	(	O
85	CD	O
versus	NN	O
22	CD	O
days	NNS	O
,	,	O
p=0.001	NN	O
)	)	O
and	CC	O
manic	JJ	PH
symptomatic	JJ	PH
relapse	NN	PH
(	(	O
too	RB	O
few	JJ	O
relapses	NNS	O
to	TO	O
calculate	VB	O
versus	NN	O
42	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.001	CD	O
)	)	O
than	IN	O
did	VBD	O
placebo-treated	JJ	O
patients	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
placebo	NN	O
,	,	O
olanzapine	JJ	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
longer	JJR	O
maintenance	NN	PH
of	IN	PH
response	NN	PH
in	IN	O
patients	NNS	O
presenting	VBG	O
with	IN	O
a	DT	O
mixed	JJ	O
index	NN	O
episode	NN	O
of	IN	O
bipolar	NN	O
I	PRP	O
disorder	VBP	O
.	.	O

Sustained	VBN	O
oral	JJ	PH
health	NN	PH
improvement	NN	PH
and	CC	O
use	NN	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
by	IN	O
previous	JJ	O
users	NNS	O
of	IN	O
traditional	JJ	O
materials	NNS	O
in	IN	O
a	DT	O
rural	JJ	O
population	NN	O
in	IN	O
Andhra	NNP	O
Pradesh	NNP	O
,	,	O
India	NNP	O
.	.	O

AIM	NNP	O
To	TO	O
follow-up	NN	O
,	,	O
one	CD	O
year	NN	O
later	RB	O
,	,	O
a	DT	O
double-blind	NN	O
,	,	O
randomised	VBN	O
study	NN	O
,	,	O
which	WDT	O
investigated	VBD	O
the	DT	O
effect	NN	Ot
of	IN	O
regular	JJ	O
brushing	NN	O
with	IN	O
dentifrices	NNS	O
on	IN	O
the	DT	O
oral	JJ	O
health	NN	O
of	IN	O
an	DT	O
economically	RB	O
disadvantaged	JJ	O
rural	JJ	O
population	NN	O
in	IN	O
Andhra	NNP	O
Pradesh	NNP	O
,	,	O
India	NNP	O
who	WP	O
were	VBD	O
primarily	RB	O
users	NNS	O
of	IN	O
traditional	JJ	O
materials	NNS	O
.	.	O

SUBJECTS	NNP	O
150	CD	O
of	IN	O
the	DT	O
original	JJ	O
study	NN	O
population	NN	O
.	.	O

METHOD	NNP	O
Examination	NNP	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
improvements	NNS	PH
in	IN	PH
oral	JJ	PH
health	NN	PH
status	NN	PH
and	CC	PH
oral	JJ	PH
health	NN	PH
behaviour	NN	PH
(	(	O
use	NN	O
of	IN	O
toothbrush	NN	O
and	CC	O
dentifrice	NN	O
)	)	O
,	,	O
being	VBG	O
unsupported	JJ	O
,	,	O
had	VBD	O
been	VBN	O
sustained	VBN	O
since	IN	O
completion	NN	O
of	IN	O
the	DT	O
original	JJ	O
study	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
analysis	NN	O
showed	VBD	O
sustained	VBN	O
,	,	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
gingival	JJ	PH
health	NN	PH
as	IN	PH
measured	VBN	PH
by	IN	PH
gingival	NN	PH
bleeding	NN	PH
and	CC	PH
plaque	NN	PH
indices	NNS	PH
(	(	PH
GBI	NNP	PH
and	CC	PH
PI	NNP	PH
)	)	PH
comparing	VBG	O
users	NNS	O
and	CC	O
non-users	NNS	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
in	IN	O
the	DT	O
original	JJ	O
study	NN	O
(	(	O
PI	NNP	O
:	:	O
p	NN	O
=	VBZ	O
0.04	CD	O
;	:	O
GBI	NNP	O
:	:	O
p	NN	O
=	VBZ	O
0.03	CD	O
)	)	O
and	CC	O
sustained	VBN	Ot
use	NN	Ot
of	IN	Ot
toothbrushes	NNS	Ot
and	CC	Ot
dentifrice	NN	Ot
by	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
at	IN	O
follow-up	JJ	O
one	CD	O
year	NN	O
later	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
a	DT	O
beneficial	JJ	PH
effect	NN	PH
on	IN	PH
oral	JJ	PH
hygiene	NN	PH
indices	NNS	O
following	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrices	NNS	O
to	TO	O
a	DT	O
community	NN	O
using	VBG	O
traditional	JJ	O
oral	JJ	O
hygiene	NN	O
materials	NNS	O
and	CC	O
sustainability	NN	O
of	IN	O
use	NN	O
of	IN	O
these	DT	O
materials	NNS	O
with	IN	O
motivation	NN	O
and	CC	O
support	NN	O
.	.	O

It	PRP	O
may	MD	O
therefore	RB	O
be	VB	O
concluded	VBN	O
that	IN	O
it	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
achieve	VB	O
significant	JJ	O
use	NN	O
of	IN	O
conventional	JJ	O
toothbrushes	NNS	O
and	CC	O
toothpastes	NNS	O
,	,	O
with	IN	O
consequent	JJ	O
major	JJ	O
and	CC	O
sustained	JJ	O
improvements	NNS	O
in	IN	O
plaque	NN	O
control	NN	O
and	CC	O
gingival	JJ	O
health	NN	O
in	IN	O
a	DT	O
disadvantaged	JJ	O
population	NN	O
hitherto	NN	O
often	RB	O
considered	VBN	O
as	IN	O
not	RB	O
amenable	JJ	O
to	TO	O
conventional	JJ	O
oral	JJ	O
hygiene	NN	O
for	IN	O
cultural	JJ	O
or	CC	O
economic	JJ	O
reasons	NNS	O
.	.	O

Rapid	JJ	O
tightening	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
control	NN	O
leads	VBZ	O
to	TO	O
transient	VB	O
deterioration	NN	O
of	IN	O
retinopathy	NN	PH
in	IN	O
insulin	NN	O
dependent	NN	O
diabetes	VBZ	O
mellitus	NNS	O
:	:	O
the	DT	O
Oslo	NNP	O
study	NN	O
.	.	O

In	IN	O
a	DT	O
study	NN	O
of	IN	O
retinopathy	NN	O
during	IN	O
one	CD	O
year	NN	O
of	IN	O
tight	JJ	O
blood	NN	O
glucose	VB	O
control	NN	O
45	CD	O
type	NN	O
I	PRP	O
(	(	O
insulin	JJ	O
dependent	NN	O
)	)	O
diabetics	NNS	O
without	IN	O
proliferative	JJ	O
retinopathy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	RB	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
infusion	NN	O
,	,	O
multiple	JJ	O
insulin	NN	O
injections	NNS	O
,	,	O
or	CC	O
conventional	JJ	O
insulin	NN	O
treatment	NN	O
(	(	O
controls	NNS	O
)	)	O
.	.	O

Near	IN	O
normoglycaemia	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
continuous	JJ	O
infusion	NN	O
and	CC	O
multiple	JJ	O
injections	NNS	O
but	CC	O
not	RB	O
with	IN	O
conventional	JJ	O
treatment	NN	O
.	.	O

Blind	NNP	O
evaluation	NN	O
of	IN	O
fluorescein	JJ	PH
angiograms	NNS	PH
performed	VBD	O
three	CD	O
monthly	JJ	O
showed	VBD	O
progression	NN	PH
of	IN	PH
retinopathy	NN	PH
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
transient	JJ	O
deterioration	NN	O
in	IN	O
the	DT	O
continuous	JJ	O
infusion	NN	O
group	NN	O
,	,	O
and	CC	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
multiple	JJ	O
injection	NN	O
group	NN	O
.	.	O

Half	PDT	O
the	DT	O
patients	NNS	O
receiving	VBG	O
continuous	JJ	O
infusion	NN	O
and	CC	O
multiple	JJ	O
injections	NNS	O
developed	VBD	O
retinal	JJ	PH
cotton	NN	PH
wool	NN	PH
spots	NNS	PH
after	IN	O
three	CD	O
to	TO	O
six	CD	O
months	NNS	O
.	.	O

These	DT	O
changes	NNS	O
regressed	VBD	O
in	IN	O
all	DT	O
but	CC	O
four	CD	O
patients	NNS	O
after	IN	O
12	CD	O
months	NNS	O
.	.	O

Control	NNP	O
patients	NNS	O
did	VBD	O
not	RB	O
develop	VB	O
cotton	NN	PH
wool	NN	PH
spots	NNS	PH
.	.	O

Patients	NNS	O
who	WP	O
developed	VBD	O
cotton	NN	O
wool	NN	O
spots	NNS	O
are	VBP	O
characterised	VBN	O
by	IN	O
a	DT	O
larger	JJR	O
decrement	NN	O
in	IN	O
glycosylated	JJ	PH
haemoglobin	NN	PH
and	CC	O
blood	NN	PH
glucose	NN	PH
values	NNS	PH
,	,	O
more	RBR	O
frequent	JJ	O
episodes	NNS	PH
of	IN	PH
hypoglycaemia	NN	PH
,	,	O
a	DT	O
longer	JJR	PH
duration	NN	PH
of	IN	PH
diabetes	NNS	PH
,	,	O
and	CC	O
more	RBR	PH
severe	JJ	PH
retinopathy	NN	PH
at	IN	O
onset	NN	O
.	.	O

A	DT	O
large	JJ	O
and	CC	O
rapid	JJ	O
fall	NN	O
in	IN	O
blood	NN	PH
glucose	JJ	PH
concentration	NN	PH
may	MD	O
promote	VB	O
transient	JJ	O
deterioration	NN	O
of	IN	O
diabetic	JJ	O
retinopathy	NN	O
.	.	O

A	DT	O
trial	NN	O
with	IN	O
3'-azido-2',3'-dideoxythymidine	JJ	O
and	CC	O
human	JJ	O
interferon-?	NN	O
in	IN	O
cats	NNS	O
naturally	RB	O
infected	VBN	O
with	IN	O
feline	JJ	O
leukaemia	NN	O
virus	NN	O
.	.	O

Feline	NNP	O
leukaemia	NN	O
virus	NN	O
(	(	O
FeLV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
still	RB	O
one	CD	O
of	IN	O
the	DT	O
leading	JJ	O
causes	NNS	O
of	IN	O
infection-related	JJ	O
deaths	NNS	O
in	IN	O
domestic	JJ	O
cats	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
various	JJ	O
drugs	NNS	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
,	,	O
but	CC	O
none	NN	O
has	VBZ	O
resulted	VBN	O
in	IN	O
cure	NN	O
or	CC	O
complete	JJ	O
virus	NN	O
elimination	NN	O
.	.	O

Human	JJ	O
interferon-?2a	JJ	O
(	(	O
huIFN-?2a	JJ	O
)	)	O
and	CC	O
3'-azido-2',3'-dideoxythymidine	JJ	O
(	(	O
AZT	NNP	O
)	)	O
have	VBP	O
been	VBN	O
proven	VBN	O
to	TO	O
decrease	VB	O
antigenaemia	NN	O
in	IN	O
cats	NNS	O
infected	VBN	O
experimentally	RB	O
with	IN	O
FeLV	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
huIFN-?2a	NN	O
,	,	O
AZT	NNP	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
double-blinded	JJ	O
trial	NN	O
.	.	O

Fourty-four	CD	O
FeLV-infected	JJ	O
cats	NNS	O
in	IN	O
which	WDT	O
free	JJ	O
FeLV	NNP	O
p27	NN	O
antigen	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
serum	NN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	JJ	O
assay	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Cats	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
treatment	NN	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
high	JJ	O
dose	JJ	O
huIFN-?2a	NN	O
(	(	O
10	CD	O
(	(	O
5	CD	O
)	)	O
IU/kg	NNP	O
q24h	NN	O
;	:	O
12	CD	O
cats	NNS	O
)	)	O
,	,	O
AZT	NNP	O
(	(	O
5	CD	O
mg/kg	NN	O
q12h	NN	O
;	:	O
10	CD	O
cats	NNS	O
,	,	O
both	DT	O
of	IN	O
these	DT	O
treatments	NNS	O
(	(	O
12	CD	O
cats	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
10	CD	O
cats	NNS	O
)	)	O
.	.	O

All	DT	O
cats	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
stomatitis	NN	PH
,	,	O
and	CC	O
laboratory	NN	O
parameters	NNS	O
,	,	O
such	JJ	O
as	IN	O
CD4	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
CD8	NNP	PH
(	(	PH
+	NNP	PH
)	)	PH
counts	NNS	PH
and	CC	O
serum	NN	PH
FeLV	NNP	PH
p	VBZ	PH
27	CD	PH
antigen	NN	PH
concentration	NN	PH
,	,	O
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
among	IN	O
the	DT	O
groups	NNS	O
was	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
.	.	O

Aside	RB	O
from	IN	O
anaemia	NN	A
in	IN	O
one	CD	O
cat	NN	O
treated	VBN	O
with	IN	O
AZT	NNP	O
,	,	O
no	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

It	PRP	O
was	VBD	O
not	RB	O
possible	JJ	O
to	TO	O
demonstrate	VB	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
or	CC	O
AZT	NNP	O
alone	RB	O
or	CC	O
together	RB	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
when	WRB	O
given	VBN	O
according	VBG	O
to	TO	O
this	DT	O
regimen	NNS	O
for	IN	O
6	CD	O
weeks	NNS	O
;	:	O
however	RB	O
,	,	O
no	DT	O
notable	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

[	RB	O
Clinical	NNP	O
study	NN	O
on	IN	O
dan	NN	O
shao	NN	O
tang	NN	O
in	IN	O
treating	VBG	O
IgA	NNP	O
nephropathy	NN	O
of	IN	O
deficiency	NN	O
of	IN	O
yin	NN	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
Dan	NNP	O
Shao	NNP	O
Tang	NNP	O
(	(	O
DST	NNP	O
)	)	O
in	IN	O
treating	VBG	O
IgA	NNP	O
nephropathy	NN	O
(	(	O
IgAN	NNP	O
)	)	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
.	.	O

METHODS	NNP	O
90	CD	O
patients	NNS	O
with	IN	O
IgAN	NNP	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

50	CD	O
patients	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
DST	NNP	O
and	CC	O
western	JJ	O
medicine	NN	O
and	CC	O
40	CD	O
patients	NNS	O
in	IN	O
control	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
only	RB	O
with	IN	O
western	JJ	O
medicine	NN	O
.	.	O

The	DT	O
effects	NNS	O
and	CC	O
changes	NNS	O
of	IN	O
the	DT	O
indexes	NNS	O
including	VBG	O
renal	JJ	PH
function	NN	PH
,	,	PH
hematuria	NN	PH
,	,	PH
proteinuria	NN	PH
,	,	PH
blood	NN	PH
IgA	NNP	PH
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
were	VBD	O
observed	VBN	O
.	.	O

RESULTS	NNP	O
After	IN	O
six	CD	O
months	NNS	O
treatment	NN	O
,	,	O
the	DT	O
general	JJ	Ot
effective	JJ	Ot
rate	NN	Ot
in	IN	O
treatment	NN	O
group	NN	O
was	VBD	O
70.00	CD	O
%	NN	O
,	,	O
which	WDT	O
was	VBD	O
markedly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
37.50	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Treatment	NNP	O
group	NN	O
is	VBZ	O
obviously	RB	O
better	JJR	O
than	IN	O
control	NN	O
group	NN	O
on	IN	O
decreasing	VBG	PH
hematuria	NN	PH
,	,	PH
proteinuria	NN	PH
,	,	PH
blood	NN	PH
IgA	NNP	PH
and	CC	PH
improving	VBG	PH
renal	JJ	PH
function	NN	PH
(	(	PH
P	NNP	PH
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
DST	NNP	O
is	VBZ	O
effective	JJ	O
on	IN	O
IgAN	NNP	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
.	.	O

Anti-emetic	JJ	Ot
efficacy	NN	Ot
of	IN	O
prophylactic	JJ	O
granisetron	NNS	O
compared	VBN	O
with	IN	O
perphenazine	NN	O
for	IN	O
the	DT	O
prevention	NN	PH
of	IN	PH
post-operative	JJ	PH
vomiting	NN	PH
in	IN	O
children	NNS	O
.	.	O

We	PRP	O
have	VBP	O
compared	VBN	O
the	DT	O
efficacy	NN	Ot
of	IN	O
granisetron	NN	O
with	IN	O
perphenazine	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
vomiting	VBG	O
after	IN	O
tonsillectomy	NN	O
with	IN	O
or	CC	O
without	IN	O
adenoidectomy	NN	O
in	IN	O
children	NNS	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
,	,	O
90	CD	O
paediatric	JJ	O
patients	NNS	O
,	,	O
ASA	NNP	O
I	PRP	O
,	,	O
aged	VBN	O
4-10	CD	O
years	NNS	O
,	,	O
received	VBD	O
granisetron	NN	O
40	CD	O
mg	JJ	O
kg-1	NN	O
or	CC	O
perphenazine	VB	O
70	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
n	JJ	O
=	RB	O
45	CD	O
each	DT	O
)	)	O
intravenously	RB	O
immediately	RB	O
after	IN	O
an	DT	O
inhalation	NN	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
.	.	O

A	DT	O
standard	JJ	O
general	JJ	O
anaesthetic	JJ	O
technique	NN	O
was	VBD	O
employed	VBN	O
throughout	IN	O
.	.	O

A	DT	O
complete	JJ	PH
response	NN	PH
,	,	PH
defined	VBD	PH
as	IN	PH
no	DT	PH
emesis	NN	PH
with	IN	PH
no	DT	PH
need	NN	PH
for	IN	PH
another	DT	PH
rescue	NN	PH
antiemetic	JJ	PH
,	,	PH
during	IN	PH
the	DT	PH
first	JJ	PH
3	CD	PH
h	NN	PH
(	(	PH
0-3	JJ	PH
h	NN	PH
)	)	PH
after	IN	PH
anesthesia	NN	PH
was	VBD	O
87	CD	O
%	NN	O
with	IN	O
granisetron	NN	O
and	CC	O
78	CD	O
%	NN	O
with	IN	O
perphenazine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.204	CD	O
)	)	O
.	.	O

The	DT	O
corresponding	JJ	PH
incidence	NN	PH
during	IN	O
the	DT	O
next	JJ	O
21	CD	O
h	NN	O
(	(	O
3-24	JJ	O
h	NN	O
)	)	O
after	IN	O
anaesthesia	NN	O
was	VBD	O
87	CD	O
%	NN	O
and	CC	O
62	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
.	.	O

No	UH	O
clinically	RB	A
serious	JJ	A
adverse	JJ	A
events	NNS	A
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
granisetron	NN	O
is	VBZ	O
a	DT	O
better	JJR	PH
anti-emetic	JJ	PH
than	IN	O
perphenazine	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
prevention	NN	O
of	IN	O
post-operative	JJ	PH
vomiting	NN	PH
in	IN	O
children	NNS	O
undergoing	VBG	O
general	JJ	O
anaesthesia	NN	O
for	IN	O
tonsillectomy	NN	O
.	.	O

Fentanyl	NNP	O
supplementation	NN	O
to	TO	O
inhalation	NN	O
anaesthesia	NN	O
.	.	O

In	IN	O
eight	CD	O
out	IN	O
of	IN	O
15	CD	O
healthy	JJ	O
patients	NNS	O
undergoing	VBG	O
body	NN	O
surface	NN	O
surgery	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
fentanyl	JJ	O
infusion	NN	O
on	IN	O
a	DT	O
conventional	JJ	O
thiopentone	NN	O
,	,	O
nitrous	JJ	O
oxide	NN	O
,	,	O
oxygen	NN	O
and	CC	O
halothane	NN	O
anaesthetic	NN	O
was	VBD	O
studied	VBN	O
.	.	O

The	DT	O
fentanyl	JJ	O
infusion	NN	O
(	(	O
2	CD	O
micrograms/kg/hour	NN	O
)	)	O
reduced	VBD	O
the	DT	O
induction	NN	PH
dose	NN	PH
of	IN	PH
thiopentone	NN	PH
and	CC	O
caused	VBD	O
marked	JJ	PH
respiratory	JJ	PH
depression	NN	PH
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
patients	NNS	O
'	POS	O
response	NN	O
to	TO	O
surgery	NN	O
.	.	O

The	DT	O
mean	JJ	PH
arterial	JJ	PH
pressures	NNS	PH
and	CC	O
pulse	JJ	PH
rates	NNS	PH
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
each	DT	O
group	NN	O
throughout	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

The	DT	O
fentanyl	NN	O
made	VBD	O
no	DT	O
difference	NN	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
postoperative	JJ	O
analgesic	JJ	O
requirements	NNS	O
or	CC	O
to	TO	O
their	PRP$	O
recovery	NN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
.	.	O

International	NNP	O
Czech	NNP	O
and	CC	O
Slovak	NNP	O
cooperation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancer	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
paper	NN	O
is	VBZ	O
to	TO	O
present	VB	O
our	PRP$	O
experience	NN	O
concerning	VBG	O
cooperation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Slovak	NNP	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancer	NN	O
in	IN	O
Slovak	NNP	O
and	CC	O
Czech	NNP	O
hospitals	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
demonstrate	VB	O
the	DT	O
means	NNS	ME
of	IN	ME
this	DT	ME
cooperation	NN	ME
and	CC	O
the	DT	O
results	NNS	Ot
of	IN	O
therapy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
September	NNP	O
1991	CD	O
to	TO	O
October	NNP	O
2005	CD	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Ostrava	NNP	O
357	CD	O
patients	NNS	O
from	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
with	IN	O
differentiated	VBN	O
thyroid	NN	O
cancers	NNS	O
(	(	O
follicular	JJ	O
and	CC	O
papillary	JJ	O
)	)	O
underwent	NN	O
complex	JJ	O
therapy	NN	O
.	.	O

They	PRP	O
were	VBD	O
diagnosed	VBN	O
and	CC	O
operated	VBN	O
due	JJ	O
to	TO	O
the	DT	O
cancer	NN	O
(	(	O
near-total	JJ	O
thyroidectomy	NN	O
and	CC	O
removal	NN	O
of	IN	O
lymph	JJ	O
node	JJ	O
metastases	NNS	O
)	)	O
in	IN	O
Slovak	NNP	O
hospitals	NNS	O
.	.	O

Then	RB	O
they	PRP	O
were	VBD	O
sent	VBN	O
to	TO	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Ostrava	NNP	O
in	IN	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
.	.	O

In	IN	O
this	DT	O
department	NN	O
a	DT	O
radioiodine	JJ	O
ablation	NN	O
of	IN	O
thyroid	JJ	O
remnants	NNS	O
,	,	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
amount	NN	O
of	IN	O
radioiodine	NN	O
of	IN	O
a	DT	O
standard	JJ	O
activity	NN	O
of	IN	O
3.7	CD	O
GBq	NNP	O
,	,	O
was	VBD	O
performed	VBN	O
,	,	O
and	CC	O
then	RB	O
a	DT	O
suppression	NN	O
and	CC	O
substitution	NN	O
therapy	NN	O
of	IN	O
thyroid	JJ	O
hormones	NNS	O
was	VBD	O
started	VBN	O
.	.	O

After	IN	O
3-6	JJ	O
months	NNS	O
some	DT	O
patients	NNS	O
were	VBD	O
examined	VBN	O
by	IN	O
means	NNS	O
of	IN	O
diagnostic	JJ	Ot
whole	JJ	Ot
body	NN	Ot
scintigraphy	NN	Ot
after	IN	O
application	NN	O
of	IN	O
300	CD	O
MBq	NNP	O
131I	CD	O
.	.	O

Some	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
standard	JJ	O
activity	NN	O
of	IN	O
7.4	CD	O
GBq	NNP	O
131I	CD	O
and	CC	O
after	IN	O
5	CD	O
days	NNS	O
whole	JJ	O
body	NN	O
scintigraphy	NN	O
(	(	O
WBS	NNP	O
)	)	O
was	VBD	O
performed	VBN	O
.	.	O

In	IN	O
both	DT	O
of	IN	O
these	DT	O
groups	NNS	O
of	IN	O
patients	NNS	O
the	DT	O
diagnostic	JJ	O
or	CC	O
therapeutic	JJ	O
radioiodine	NN	O
application	NN	O
was	VBD	O
done	VBN	O
after	IN	O
withdrawal	NN	O
of	IN	O
thyroid	JJ	O
hormone	NN	O
treatment	NN	O
.	.	O

If	IN	O
thyroglobulin	JJ	PH
levels	NNS	PH
were	VBD	O
low	JJ	O
and	CC	O
WBSs	NNP	PH
were	VBD	O
negative	JJ	O
,	,	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Martin	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
radioiodine	NN	O
accumulated	VBN	O
metastases	NNS	O
were	VBD	O
again	RB	O
treated	VBN	O
with	IN	O
radioiodine	NN	O
in	IN	O
Ostrava	NNP	O
.	.	O

If	IN	O
indicated	VBN	O
,	,	O
external	JJ	O
radiation	NN	O
therapy	NN	O
targeted	VBN	O
on	IN	O
the	DT	O
neck	NN	O
and	CC	O
upper	JJ	O
mediastinum	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
,	,	O
in	IN	O
the	DT	O
University	NNP	O
Hospital	NNP	O
in	IN	O
Martin	NNP	O
.	.	O

Newly	RB	O
formed	VBN	O
lymph	JJ	O
node	NN	O
metastases	NNS	O
were	VBD	O
surgically	RB	O
treated	VBN	O
in	IN	O
Slovakia	NNP	O
,	,	O
too	RB	O
.	.	O

Generally	RB	O
we	PRP	O
have	VBP	O
very	RB	O
good	JJ	Ot
treatment	NN	Ot
results	NNS	Ot
.	.	O

Also	RB	O
,	,	O
economically	RB	O
our	PRP$	O
partnership	NN	O
is	VBZ	O
cost	VBN	Ot
effective	JJ	Ot
.	.	O

Our	PRP$	O
collaboration	NN	O
also	RB	O
successfully	RB	O
continues	VBZ	O
after	IN	O
entrance	NN	O
of	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
and	CC	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
to	TO	O
the	DT	O
European	NNP	O
Union	NNP	O
in	IN	O
2004	CD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
multi-centre	JJ	O
study	NN	O
show	NN	O
that	IN	O
international	JJ	O
Czech	NNP	O
and	CC	O
Slovak	NNP	O
cooperation	NN	O
in	IN	O
the	DT	O
complex	JJ	O
therapy	NN	O
of	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancers	NNS	O
is	VBZ	O
successful	JJ	O
,	,	O
with	IN	O
high	JJ	O
efficacy	NN	O
.	.	O

The	DT	O
treatment	NN	O
results	NNS	O
were	VBD	O
very	RB	O
similar	JJ	O
to	TO	O
therapeutic	JJ	O
results	NNS	O
in	IN	O
our	PRP$	O
patients	NNS	O
from	IN	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
.	.	O

Quantitative	JJ	O
angiographic	JJ	O
methods	NNS	O
for	IN	O
appropriate	JJ	O
end-point	JJ	Ot
analysis	NN	Ot
,	,	O
edge-effect	JJ	Ot
evaluation	NN	Ot
,	,	O
and	CC	O
prediction	NN	PH
of	IN	PH
recurrent	NN	PH
restenosis	NN	PH
after	IN	O
coronary	JJ	O
brachytherapy	NN	O
with	IN	O
gamma	JJ	O
irradiation	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
study	NN	O
was	VBD	O
done	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
relationship	NN	O
between	IN	O
clinical	JJ	O
restenosis	NN	O
and	CC	O
the	DT	O
relative	JJ	O
angiographic	JJ	O
location	NN	O
of	IN	O
the	DT	O
recurrent	NN	O
restenotic	JJ	O
lesion	NN	O
,	,	O
after	IN	O
treatment	NN	O
of	IN	O
in-stent	JJ	O
restenosis	NN	O
with	IN	O
vascular	JJ	O
brachytherapy	NN	O
in	IN	O
the	DT	O
Washington	NNP	O
Radiation	NNP	O
for	IN	O
In-Stent	NNP	O
Restenosis	NNP	O
Trial	NNP	O
(	(	O
WRIST	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Intracoronary	NNP	O
radiation	NN	O
therapy	NN	O
reduces	VBZ	O
recurrence	NN	O
of	IN	O
in-stent	JJ	O
restenosis	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
above	JJ	O
objective	NN	O
in	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
WRIST	NNP	O
.	.	O

METHODS	NNP	O
The	DT	O
WRIST	NNP	O
study	NN	O
randomized	VBD	O
130	CD	O
patients	NNS	O
to	TO	O
double-blinded	JJ	O
therapy	NN	O
with	IN	O
gamma	JJ	O
irradiation	NN	O
(	(	O
iridium-192	JJ	O
[	NNP	O
(	(	O
192	CD	O
)	)	O
Ir	NNP	O
]	NNP	O
)	)	O
versus	NN	O
placebo	NN	O
after	IN	O
interventional	JJ	O
treatment	NN	O
of	IN	O
diffuse	NN	O
in-stent	JJ	O
restenosis	NN	O
.	.	O

After	IN	O
the	DT	O
intervention	NN	O
and	CC	O
at	IN	O
follow-up	NN	O
,	,	O
three	CD	O
vessel	NN	O
segments	NNS	O
were	VBD	O
individually	RB	O
analyzed	VBN	O
with	IN	O
quantitative	JJ	O
coronary	JJ	O
angiography	NN	O
:	:	O
1	CD	O
)	)	O
the	DT	O
stent	NN	O
,	,	O
2	CD	O
)	)	O
the	DT	O
radiation	NN	O
ribbon	NN	O
,	,	O
and	CC	O
3	CD	O
)	)	O
the	DT	O
ribbon+margin	NN	O
segment	NN	O
(	(	O
including	VBG	O
5	CD	O
mm	NN	O
on	IN	O
either	DT	O
end	NN	O
of	IN	O
the	DT	O
injured	JJ	O
or	CC	O
radiation-ribbon	JJ	O
segment	NN	O
)	)	O
.	.	O

Receiver	NNP	O
operator	NN	O
curves	NNS	O
(	(	O
ROC	NNP	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
value	NN	O
of	IN	O
the	DT	O
follow-up	JJ	O
percent	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
DS	NNP	O
)	)	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
analyzed	VBD	O
segments	NNS	O
in	IN	O
predicting	VBG	O
target	NN	O
vessel	NN	O
revascularization	NN	O
(	(	O
TVR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
(	(	O
192	CD	O
)	)	O
Ir	NNP	O
reduced	VBD	O
recurrent	JJ	PH
restenosis	NN	PH
(	(	O
23.7	CD	O
%	NN	O
vs.	FW	O
60.7	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
length	NN	PH
of	IN	PH
recurrent	JJ	PH
restenosis	NN	PH
(	(	O
8.99	CD	O
+/-	JJ	O
4.34	CD	O
mm	NN	O
vs.	FW	O
17.54	CD	O
+/-	JJ	O
10.48	CD	O
mm	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
at	IN	O
follow-up	JJ	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

Isolated	NNP	PH
stent	NN	PH
edge	NN	PH
(	(	O
3.4	CD	O
%	NN	O
)	)	O
and	CC	O
ribbon	NN	PH
edge	NN	PH
(	(	O
1.7	CD	O
%	NN	O
)	)	O
restenoses	VBZ	PH
were	VBD	O
infrequent	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
best	JJS	O
angiographic	JJ	O
surrogate	NN	O
of	IN	O
TVR	NNP	O
was	VBD	O
the	DT	O
50	CD	O
%	NN	O
follow-up	JJ	O
DS	NNP	O
obtained	VBD	O
from	IN	O
the	DT	O
ribbon+margin	NN	O
analysis	NN	O
(	(	O
ROC	NNP	O
area	NN	O
0.806	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
WRIST	NNP	O
,	,	O
not	RB	O
only	RB	O
was	VBD	O
(	(	O
192	CD	O
)	)	O
Ir	NNP	O
therapy	NN	O
effective	JJ	O
in	IN	O
reducing	VBG	O
restenosis	NN	O
,	,	O
but	CC	O
it	PRP	O
also	RB	O
reduced	VBD	O
the	DT	O
lesion	NN	O
length	NN	O
of	IN	O
treatment	NN	O
failures	NNS	O
by	IN	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
edge	NN	O
proliferation	NN	O
.	.	O

The	DT	O
restenosis	NN	O
rate	NN	O
obtained	VBN	O
from	IN	O
the	DT	O
vessel	NN	O
segment	NN	O
inclusive	NN	O
of	IN	O
the	DT	O
dose	JJ	O
fall-off	JJ	O
zones	NNS	O
was	VBD	O
the	DT	O
best	JJS	O
correlate	NN	O
of	IN	O
TVR	NNP	O
and	CC	O
should	MD	O
become	VB	O
a	DT	O
standard	JJ	O
analysis	NN	O
site	NN	O
in	IN	O
all	DT	O
vascular	JJ	O
brachytherapy	NN	O
trials	NNS	O
.	.	O

[	JJ	O
Carbohydrate	NNP	O
substitutes	NNS	O
:	:	O
comparative	JJ	O
study	NN	O
of	IN	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
fructose	NN	O
,	,	O
sorbitol	NN	O
and	CC	O
xylitol	NNP	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
carbohydrate	NN	O
substitutes	NNS	O
fructose	VBP	O
,	,	O
sorbitol	JJ	O
and	CC	O
xylitol	NNS	O
are	VBP	O
gaining	VBG	O
more	JJR	O
and	CC	O
more	JJR	O
importance	NN	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
dietary	JJ	O
food	NN	O
.	.	O

But	CC	O
they	PRP	O
can	MD	O
provoke	VB	O
gastrointestinal	JJ	O
side-effects	NNS	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
study	VBD	O
the	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
of	IN	O
these	DT	O
sugars	NNS	O
was	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
concomitant	NN	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
25	CD	O
healthy	JJ	O
controls	NNS	O
received	VBD	O
25	CD	O
g	NN	O
of	IN	O
each	DT	O
sugar	NN	O
within	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
intestinal	JJ	PH
absorption	NN	PH
was	VBD	PH
determined	VBN	PH
by	IN	PH
H2-exhalation	NNP	PH
tests	NNS	PH
and	CC	O
the	DT	O
clinical	JJ	PH
symptoms	NNS	PH
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
rate	NN	PH
of	IN	PH
malabsorption	NN	PH
was	VBD	O
84	CD	O
%	NN	O
for	IN	O
sorbitol	NN	O
,	,	O
36	CD	O
%	NN	O
for	IN	O
fructose	JJ	O
and	CC	O
12	CD	O
%	NN	O
for	IN	O
xylitol	NNP	O
(	(	O
p	JJ	O
<	VBP	O
0.01	CD	O
for	IN	O
sorbitol	NN	O
versus	NN	O
fructose	NN	O
and	CC	O
xylitol	NN	O
)	)	O
.	.	O

57	CD	O
%	NN	O
of	IN	O
the	DT	O
participants	NNS	O
with	IN	O
pathological	JJ	O
H2-test	NNP	O
after	IN	O
sorbitol	NN	O
and	CC	O
56	CD	O
%	NN	O
after	IN	O
fructose	JJ	O
reported	VBD	O
symptoms	NNS	O
,	,	O
while	IN	O
all	DT	O
of	IN	O
the	DT	O
3	CD	O
malabsorbers	NNS	O
of	IN	O
xylitol	NN	O
were	VBD	O
symptomatic	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
an	DT	O
advantage	NN	O
to	TO	O
administering	VBG	O
xylitol	NN	O
and	CC	O
fructose	JJ	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
intestinal	JJ	PH
absorption	NN	PH
and	CC	O
concomitant	NN	O
symptoms	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
sorbitol	NN	O
.	.	O

H2-exhalation	NN	O
tests	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
a	DT	O
reliable	JJ	O
diagnostic	JJ	O
tool	NN	O
to	TO	O
detect	VB	O
carbohydrate	JJ	PH
malabsorption	NN	PH
and	CC	O
should	MD	O
find	VB	O
broader	JJR	O
application	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
non-specific	JJ	O
abdominal	JJ	O
complaints	NNS	O
.	.	O

Dietary	NNP	O
patterns	NNS	O
differ	VBP	O
between	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
older	JJR	O
,	,	O
long-term	JJ	O
survivors	NNS	O
of	IN	O
breast	NN	O
,	,	O
prostate	NN	O
,	,	O
and	CC	O
colorectal	JJ	O
cancer	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

BACKGROUND	NNP	O
Older	NNP	O
adult	NN	O
cancer	NN	O
survivors	NNS	O
are	VBP	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
cancer	NN	PH
recurrence	NN	PH
and	CC	O
other	JJ	O
comorbidities	NNS	PH
that	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
through	IN	O
improved	VBN	O
diet	JJ	O
and	CC	O
weight	JJ	O
management	NN	O
.	.	O

The	DT	O
tertiary	JJ	O
prevention	NN	O
needs	NNS	O
of	IN	O
rural-dwelling	JJ	O
survivors	NNS	O
can	MD	O
be	VB	O
even	RB	O
greater	JJR	O
,	,	O
yet	RB	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
rural	JJ	O
and	CC	O
urban	JJ	O
differences	NNS	O
in	IN	O
lifestyle	JJ	O
factors	NNS	O
among	IN	O
this	DT	O
high-risk	JJ	O
population	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
dietary	JJ	O
patterns	NNS	O
of	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
cancer	NN	O
survivors	NNS	O
and	CC	O
to	TO	O
examine	VB	O
associations	NNS	O
of	IN	O
dietary	JJ	Ot
patterns	NNS	Ot
with	IN	O
body	NN	PH
mass	NN	PH
index	NN	PH
(	(	PH
BMI	NNP	PH
)	)	PH
.	.	PH

DESIGN	VB	O
A	DT	O
secondary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
of	IN	O
baseline	NN	O
data	NNS	O
from	IN	O
the	DT	O
Reach	NNP	PH
Out	NNP	PH
to	TO	PH
Enhance	VB	PH
Wellness	NNP	PH
(	(	O
RENEW	NNP	O
)	)	O
trial	NN	O
,	,	O
a	DT	O
diet	JJ	O
and	CC	O
exercise	JJ	O
intervention	NN	O
among	IN	O
overweight	JJ	O
,	,	O
long-term	JJ	O
(	(	O
?5	CD	O
years	NNS	O
)	)	O
,	,	O
older	JJR	O
survivors	NNS	O
of	IN	O
colorectal	NN	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
prostate	NN	O
cancer	NN	O
.	.	O

Survivors	NNS	O
in	IN	O
the	DT	O
present	JJ	O
analysis	NN	O
(	(	O
n=729	JJ	O
)	)	O
underwent	JJ	O
two	CD	O
45-	JJ	O
to	TO	O
60-minute	JJ	O
telephone	NN	O
surveys	NNS	O
,	,	O
which	WDT	O
included	VBD	O
two	CD	O
24-hour	JJ	O
dietary	JJ	O
recalls	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
and	CC	O
multivariable	JJ	O
general	JJ	O
linear	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
to	TO	O
evaluate	VB	O
associations	NNS	O
between	IN	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
BMI	NNP	O
,	,	O
respectively	RB	O
.	.	O

RESULTS	VB	O
Principal	JJ	O
components	NNS	O
analysis	NN	O
identified	VBD	O
three	CD	O
primary	JJ	O
dietary	JJ	O
patterns	NNS	O
among	IN	O
rural	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
sweets	NNS	O
and	CC	O
starches	NNS	O
,	,	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
,	,	O
and	CC	O
mixed	JJ	O
)	)	O
and	CC	O
three	CD	O
among	IN	O
urban	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
,	,	O
high	JJ	O
meat	NN	O
and	CC	O
refined	VBD	O
grains	NNS	O
,	,	O
and	CC	O
high	JJ	O
sugar-sweetened	JJ	O
beverages	NNS	O
)	)	O
.	.	O

Among	IN	O
rural	JJ	O
survivors	NNS	O
,	,	O
greater	JJR	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
pattern	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
whereas	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
mixed	JJ	O
pattern	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Greater	NNP	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
pattern	VBP	O
among	IN	O
urban	JJ	O
survivors	NNS	O
was	VBD	O
inversely	RB	O
associated	VBN	O
with	IN	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Urban	NNP	O
and	CC	O
rural	JJ	O
differences	NNS	O
in	IN	O
dietary	JJ	O
intake	NN	O
behavior	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
designing	VBG	O
public	JJ	O
health	NN	O
interventions	NNS	O
among	IN	O
the	DT	O
increasing	VBG	O
population	NN	O
of	IN	O
older	JJR	O
cancer	NN	O
survivors	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
targeting	VBG	O
overall	JJ	O
dietary	JJ	O
patterns	NNS	O
might	MD	O
be	VB	O
one	CD	O
approach	NN	O
to	TO	O
help	VB	O
reduce	VB	O
the	DT	O
burden	NN	O
of	IN	O
obesity	NN	O
among	IN	O
this	DT	O
population	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
heart	NN	O
disease	NN	O
:	:	O
breast	NN	O
cancer	NN	O
prevention	NN	O
trial	NN	O
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
overall	JJ	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
which	WDT	O
include	VBP	O
preventing	VBG	PH
breast	NN	PH
cancer	NN	PH
and	CC	O
altering	VBG	O
cardiovascular	JJ	PH
risk	NN	PH
.	.	O

In	IN	O
a	DT	O
recent	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
postmenopausal	JJ	O
estrogen-progestin	JJ	O
therapy	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
early	JJ	PH
cardiovascular	JJ	PH
events	NNS	PH
among	IN	O
women	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	A
effects	NNS	A
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	O

The	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
(	(	O
BCPT	NNP	O
)	)	O
is	VBZ	O
the	DT	O
only	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
provides	VBZ	O
data	NNS	O
to	TO	O
assess	VB	O
the	DT	O
cardiovascular	JJ	A
effects	NNS	A
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
13	CD	O
388	CD	O
women	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
the	DT	O
BCPT	NNP	O
to	TO	O
receive	VB	O
either	DT	O
tamoxifen	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Cardiovascular	JJ	O
follow-up	NN	O
was	VBD	O
available	JJ	O
for	IN	O
13	CD	O
194	CD	O
women	NNS	O
,	,	O
1048	CD	O
of	IN	O
whom	WP	O
had	VBD	O
prior	RB	O
clinical	JJ	O
CHD	NNP	O
.	.	O

Fatal	NNP	PH
and	CC	PH
nonfatal	JJ	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	O
unstable	JJ	PH
angina	NN	PH
,	,	PH
and	CC	PH
severe	JJ	PH
angina	NN	PH
were	VBD	O
tabulated	VBN	O
(	(	O
mean	JJ	O
follow-up	NN	O
:	:	O
49	CD	O
months	NNS	O
)	)	O
.	.	O

All	DT	O
statistical	JJ	O
tests	NNS	O
were	VBD	O
two-sided	JJ	O
.	.	O

RESULTS	NNP	O
Cardiovascular	JJ	Ot
event	NN	Ot
rates	NNS	Ot
were	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
women	NNS	O
assigned	VBN	O
to	TO	O
receive	VB	O
tamoxifen	NN	O
and	CC	O
those	DT	O
assigned	VBN	O
to	TO	O
receive	VB	O
placebo	NN	O
,	,	O
independent	JJ	O
of	IN	O
pre-existing	JJ	O
CHD	NNP	O
.	.	O

Among	IN	O
women	NNS	O
without	IN	O
CHD	NNP	O
(	(	O
6074	CD	O
on	IN	O
tamoxifen	NN	O
versus	NN	O
6072	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	O
ratios	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
CIs	NNP	O
]	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
1.75	CD	O
(	(	O
0.44	CD	O
to	TO	O
8.13	CD	O
)	)	O
for	IN	O
fatal	JJ	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	O
1.11	CD	O
(	(	O
0.55	CD	O
to	TO	O
2.28	CD	O
)	)	O
for	IN	O
nonfatal	JJ	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	O
0.69	CD	O
(	(	O
0.29	CD	O
to	TO	O
1.57	CD	O
)	)	O
for	IN	O
unstable	JJ	PH
angina	NN	PH
,	,	O
and	CC	O
0.83	CD	O
(	(	O
0.32	CD	O
to	TO	O
2.10	CD	O
)	)	O
for	IN	O
severe	JJ	PH
angina	NN	PH
.	.	O

In	IN	O
women	NNS	O
with	IN	O
CHD	NNP	O
(	(	O
516	CD	O
on	IN	O
tamoxifen	NNS	O
versus	$	O
532	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	Ot
ratios	NNS	Ot
(	(	O
95	CD	O
%	NN	O
CIs	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
0.00	CD	O
(	(	O
0	CD	O
to	TO	O
1.58	CD	O
)	)	O
for	IN	O
fatal	JJ	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	O
1.25	CD	O
(	(	O
0.32	CD	O
to	TO	O
5.18	CD	O
)	)	O
for	IN	O
nonfatal	JJ	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	O
2.26	CD	O
(	(	O
0.87	CD	O
to	TO	O
6.55	CD	O
)	)	O
for	IN	O
unstable	JJ	PH
angina	NN	PH
,	,	O
and	CC	O
1.39	CD	O
(	(	O
0.23	CD	O
to	TO	O
9.47	CD	O
)	)	O
for	IN	O
severe	JJ	PH
angina	NN	PH
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
lack	NN	O
of	IN	O
association	NN	O
between	IN	O
tamoxifen	NN	O
and	CC	O
cardiovascular	JJ	PH
events	NNS	PH
was	VBD	O
related	VBN	O
to	TO	O
an	DT	O
early	JJ	O
increase	NN	PH
in	IN	PH
risk	NN	PH
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
offset	VBN	O
by	IN	O
a	DT	O
late	JJ	O
decrease	NN	O
in	IN	O
risk	NN	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
used	VBN	O
for	IN	O
breast	NN	O
cancer	NN	O
prevention	NN	O
in	IN	O
women	NNS	O
with	IN	O
or	CC	O
without	IN	O
heart	NN	O
disease	NN	O
,	,	O
tamoxifen	NN	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
beneficial	JJ	O
or	CC	O
adverse	JJ	O
cardiovascular	JJ	A
effects	NNS	A
.	.	O

Low-dose	JJ	O
,	,	O
vaginally	RB	O
administered	VBN	O
estrogens	NNS	O
may	MD	O
enhance	VB	O
local	JJ	O
benefits	NNS	O
of	IN	O
systemic	JJ	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
urogenital	JJ	O
atrophy	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
on	IN	O
hormone	NN	O
therapy	NN	O
.	.	O

BACKGROUND	NNP	O
When	WRB	O
genital	JJ	O
atrophy	NN	O
exists	NNS	O
,	,	O
systemic	JJ	O
hormone	NN	O
therapy	NN	O
(	(	O
HT	NNP	O
)	)	O
has	VBZ	O
a	DT	O
timing	NN	O
until	IN	O
to	TO	O
induce	VB	O
vaginal	JJ	O
proliferation	NN	O
and	CC	O
symptomatic	JJ	O
relieve	NN	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
obtain	VB	O
a	DT	O
prompt	JJ	O
improvement	NN	O
,	,	O
the	DT	O
association	NN	O
of	IN	O
local	JJ	O
therapy	NN	O
acting	VBG	O
on	IN	O
the	DT	O
genital	JJ	O
epithelium	NN	O
to	TO	O
the	DT	O
systemic	JJ	O
treatment	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
combined	JJ	O
therapy	NN	O
consisting	NN	O
of	IN	O
vaginal	JJ	O
estriol	NN	O
with	IN	O
transdermal	JJ	O
17-beta-estradiol	JJ	O
(	(	O
50	CD	O
microg/day	NN	O
)	)	O
plus	CC	O
medroxyprogesterone	JJ	O
acetate	NN	O
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
per	IN	O
os	NN	O
in	IN	O
shortening	VBG	O
the	DT	O
period	NN	O
of	IN	O
uro-genital	JJ	O
symptoms	NNS	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
controlled	VBN	O
with	IN	O
placebo	NN	O
study	NN	O
,	,	O
27	CD	O
women	NNS	O
with	IN	O
climacteric	JJ	O
symptoms	NNS	O
and	CC	O
atrophic	JJ	O
vaginitis	NN	O
were	VBD	O
treated	VBN	O
for	IN	O
4	CD	O
months	NNS	O
with	IN	O
HT	NNP	O
plus	CC	O
vaginal	JJ	O
estriol	NN	O
0.5	CD	O
mg/day	NN	O
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
group	NN	O
P	NNP	O
)	)	O
.	.	O

Patients	NNS	O
use	VBP	O
the	DT	O
local	JJ	O
medication	NN	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
weeks	NNS	O
and	CC	O
twice-weekly	JJ	O
thereafter	NN	O
.	.	O

Before	IN	O
entering	VBG	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
were	VBD	O
asked	VBN	O
about	IN	O
HT	NNP	O
and	CC	O
selected	VBN	O
for	IN	O
inclusion	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
visit	NN	O
,	,	O
electible	JJ	O
patients	NNS	O
after	IN	O
written	VBN	O
informed	JJ	O
consent	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
HT	NNP	O
plus	CC	O
local	JJ	O
estriol	NN	O
or	CC	O
placebo	NN	O
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
had	VBD	O
baseline	NN	O
studies	NNS	O
,	,	O
including	VBG	O
medical	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
blood	NN	O
and	CC	O
urine	JJ	O
analysis	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
local	JJ	O
treatment	NN	O
on	IN	O
urinary	JJ	O
and	CC	O
genital	JJ	O
symptoms	NNS	O
,	,	O
a	DT	O
score	NN	O
for	IN	O
genital	NN	O
,	,	O
urinary	JJ	O
and	CC	O
colposcopic	JJ	O
complaints	NNS	O
(	(	O
0	CD	O
minimum-100	JJ	O
maximum	NN	O
)	)	O
was	VBD	O
developed	VBN	O
.	.	O

This	DT	O
score	NN	O
and	CC	O
Blatt-Kuperman	NNP	O
were	VBD	O
recorded	VBN	O
and	CC	O
performed	VBN	O
in	IN	O
every	DT	O
control	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	Ot
differences	NNS	Ot
on	IN	Ot
climacteric	NN	Ot
symptoms	NNS	Ot
relief	NN	Ot
between	IN	Ot
the	DT	Ot
two	CD	Ot
groups	NNS	Ot
.	.	O

Additionally	RB	O
,	,	O
the	DT	O
improvement	NN	Ot
in	IN	Ot
urinary	JJ	Ot
symptoms	NNS	Ot
at	IN	Ot
the	DT	Ot
end	NN	Ot
of	IN	Ot
the	DT	Ot
study	NN	Ot
was	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
from	IN	O
16.5	CD	O
+/-	JJ	O
6.1	CD	O
to	TO	O
8.5	CD	O
+/-	JJ	O
2.4	CD	O
for	IN	O
E	NNP	O
group	NN	O
and	CC	O
from	IN	O
15.8	CD	O
+/-	JJ	O
7.8	CD	O
to	TO	O
8.8	CD	O
+/-	JJ	O
2.7	CD	O
for	IN	O
P	NNP	O
group	NN	O
;	:	O
P	NNP	O
<	VBD	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
those	DT	O
women	NNS	O
in	IN	O
group	NN	O
E	NNP	O
reached	VBD	O
significant	JJ	Ot
improvement	NN	Ot
on	IN	Ot
urinary	JJ	Ot
complaints	NNS	Ot
since	IN	O
the	DT	O
first	JJ	O
month	NN	O
of	IN	O
treatment	NN	O
.	.	O

Additionally	RB	O
,	,	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
E	NNP	O
and	CC	O
P	NNP	O
was	VBD	O
observed	VBN	O
at	IN	O
months	NNS	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
although	IN	O
no	DT	O
differences	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Papanicolaou	NNP	O
smear	JJ	O
showed	VBD	O
reactive	JJ	Ot
or	CC	O
reparative	JJ	Ot
changes	NNS	Ot
and	CC	O
karyopyknotic	JJ	Ot
index	NN	Ot
exhibited	VBD	Ot
a	DT	Ot
significant	JJ	Ot
increase	NN	Ot
in	IN	Ot
superficial	JJ	PH
cells	NNS	PH
in	IN	Ot
both	DT	Ot
groups	NNS	Ot
and	CC	Ot
at	IN	Ot
the	DT	Ot
end	NN	Ot
of	IN	Ot
the	DT	Ot
study	NN	Ot
.	.	O

CONCLUSIONS	NNP	O
Adding	NNP	O
vaginal	JJ	O
estriol	NN	O
to	TO	O
HRT	NNP	O
may	MD	O
shorten	VB	O
the	DT	O
latency	NN	O
period	NN	O
for	IN	O
urinary	JJ	O
symptoms	NNS	O
.	.	O

Timing	NN	MO
of	IN	MO
death	NN	MO
and	CC	O
myocardial	JJ	PH
infarction	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
non-ST	JJ	O
elevation	NN	O
acute	NN	O
coronary	JJ	O
syndromes	NNS	O
:	:	O
insights	NNS	O
from	IN	O
randomized	VBN	O
clinical	JJ	O
trials	NNS	O
.	.	O

BACKGROUND	NNP	O
Adverse	NNP	O
events	NNS	O
occur	VBP	O
following	VBG	O
non-ST	JJ	O
elevation	NN	O
acute	NN	O
coronary	JJ	O
syndromes	NNS	O
(	(	O
NSTE	NNP	O
ACS	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
timing	NN	O
of	IN	O
these	DT	O
events	NNS	O
in	IN	O
relation	NN	O
to	TO	O
index	NN	O
event	NN	O
is	VBZ	O
less	RBR	O
clear	JJ	O
.	.	O

METHODS	NNP	O
Accordingly	RB	O
,	,	O
we	PRP	O
evaluated	VBD	O
26,466	CD	O
NSTE	NNP	O
ACS	NNP	O
patients	NNS	O
from	IN	O
the	DT	O
Global	NNP	O
Use	NNP	O
of	IN	O
Strategies	NNPS	O
to	TO	O
Open	VB	O
Occluded	NNP	O
Arteries	NNPS	O
in	IN	O
Acute	NNP	O
Coronary	NNP	O
Syndromes	NNP	O
(	(	O
GUSTO-IIb	NNP	O
)	)	O
,	,	O
Platelet	NNP	O
Glycoprotein	NNP	O
IIb/IIIa	NNP	O
in	IN	O
Unstable	JJ	O
Angina	NNP	O
:	:	O
Receptor	NNP	O
Suppression	NNP	O
Using	NNP	O
Integrilin	NNP	O
Therapy	NNP	O
(	(	O
PURSUIT	NNP	O
)	)	O
,	,	O
and	CC	O
Platelet	NNP	O
IIb/IIIa	NNP	O
Antagonism	NNP	O
for	IN	O
the	DT	O
Reduction	NNP	O
of	IN	O
Acute	NNP	O
Coronary	NNP	O
Syndrome	NNP	O
Events	NNP	O
in	IN	O
a	DT	O
Global	NNP	O
Organization	NNP	O
Network	NNP	O
(	(	O
PARAGON	NNP	O
)	)	O
A	NNP	O
and	CC	O
B	NNP	O
trials	NNS	O
to	TO	O
ascertain	VB	O
the	DT	O
timing	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

Outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
death	NN	MO
,	,	O
myocardial	JJ	PH
infarction	NN	PH
(	(	PH
MI	NNP	PH
)	)	PH
,	,	O
and	CC	O
death	NN	MO
or	CC	O
MI	NNP	PH
at	IN	PH
180	CD	PH
days	NNS	PH
.	.	O

Logistic	JJ	O
regression	NN	O
modeling	VBG	O
for	IN	O
death	NN	O
was	VBD	O
used	VBN	O
to	TO	O
categorize	VB	O
patients	NNS	O
into	IN	O
low-	JJ	O
,	,	O
medium-	JJ	O
,	,	O
and	CC	O
high-risk	JJ	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
6	CD	O
months	NNS	O
,	,	O
6.2	CD	O
%	NN	O
of	IN	O
patients	NNS	O
died	VBD	MO
,	,	O
12.1	CD	O
%	NN	O
had	VBD	O
MI	NNP	PH
,	,	O
and	CC	O
15.7	CD	O
%	NN	O
suffered	VBD	O
death	NN	MO
or	CC	O
MI	NNP	PH
.	.	O

From	IN	O
15	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
these	DT	O
events	NNS	O
occurred	VBD	O
beyond	IN	O
30	CD	O
days	NNS	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
3	CD	O
%	NN	O
,	,	O
4	CD	O
%	NN	O
,	,	O
and	CC	O
13	CD	O
%	NN	O
of	IN	O
patients	NNS	O
died	VBN	O
in	IN	O
low-	JJ	O
,	,	O
medium-	JJ	O
,	,	O
and	CC	O
high-risk	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
proportion	NN	MO
of	IN	MO
patients	NNS	MO
dying	VBG	MO
beyond	IN	O
30	CD	O
days	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
(	(	O
44	CD	O
%	NN	O
,	,	O
43	CD	O
%	NN	O
,	,	O
and	CC	O
41	CD	O
%	NN	O
of	IN	O
death	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
whereas	JJ	O
death	NN	MO
or	CC	O
MI	NNP	MO
increased	VBD	O
with	IN	O
higher	JJR	O
risk	NN	O
(	(	O
11	CD	O
%	NN	O
,	,	O
14	CD	O
%	NN	O
,	,	O
and	CC	O
23	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
the	DT	O
proportion	NN	PH
of	IN	PH
patients	NNS	PH
with	IN	O
this	DT	O
event	NN	O
beyond	IN	O
30	CD	O
days	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
the	DT	O
three	CD	O
strata	NNS	O
(	(	O
22	CD	O
%	NN	O
,	,	O
20	CD	O
%	NN	O
,	,	O
and	CC	O
25	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
study	NN	O
provides	VBZ	O
important	JJ	O
insights	NNS	O
into	IN	O
the	DT	O
timing	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
suggests	VBZ	O
that	IN	O
the	DT	O
substantial	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
suffer	VBP	O
subsequent	JJ	O
adverse	JJ	O
events	NNS	O
after	IN	O
their	PRP$	O
index	NN	O
NSTE	NNP	O
ACS	NNP	O
.	.	O

Thus	RB	O
,	,	O
these	DT	O
data	NNS	O
call	NN	O
for	IN	O
continuous	JJ	O
surveillance	NN	O
for	IN	O
these	DT	O
events	NNS	O
and	CC	O
efforts	NNS	O
beyond	IN	O
the	DT	O
acute	JJ	O
phase	NN	O
at	IN	O
increasing	VBG	O
adherence	NN	O
to	TO	O
evidence-based	JJ	O
therapies	NNS	O
to	TO	O
improve	VB	O
the	DT	O
outcomes	NNS	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

Blind	NNP	O
versus	NN	O
open	JJ	O
approach	NN	O
to	TO	O
laparoscopic	VB	O
cholecystectomy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

Intraabdominal	NNP	O
structures	NNS	O
may	MD	O
be	VB	O
damaged	VBN	O
during	IN	O
blind	JJ	O
introduction	NN	O
of	IN	O
the	DT	O
first	JJ	O
trocar	NN	O
for	IN	O
laparoscopic	JJ	O
operations	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
150	CD	O
patients	NNS	O
with	IN	O
gallbladder	JJ	O
lithiasis	NN	O
who	WP	O
underwent	JJ	O
laparoscopy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
a	DT	O
blind	NN	O
(	(	O
V	NNP	O
group	NN	O
)	)	O
or	CC	O
an	DT	O
open	JJ	O
(	(	O
H	NNP	O
group	NN	O
)	)	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
compare	VB	O
the	DT	O
results	NNS	O
and	CC	O
the	DT	O
rate	NN	A
of	IN	A
complications	NNS	A
.	.	O

No	DT	O
mortality	NN	MO
was	VBD	O
observed	VBN	O
.	.	O

Major	JJ	A
complications	NNS	A
occurred	VBD	O
in	IN	O
3/75	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
in	IN	O
1/75	CD	O
(	(	O
1.3	CD	O
%	NN	O
)	)	O
patient	NN	O
of	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Minor	JJ	A
complications	NNS	A
occurred	VBD	O
in	IN	O
5/75	CD	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
achievement	NN	PH
of	IN	PH
pneumoperitoneum	NN	PH
required	VBN	O
4.5+/-0.4	JJ	O
min	NN	O
in	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
3.2+/-0.2	JJ	O
min	NN	O
in	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
open	JJ	O
laparoscopic	NN	O
technique	NN	O
is	VBZ	O
safer	JJR	O
and	CC	O
faster	RBR	O
than	IN	O
the	DT	O
blind	JJ	O
approach	NN	O
;	:	O
therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
this	DT	O
approach	NN	O
be	VB	O
routinely	RB	O
used	VBN	O
in	IN	O
all	DT	O
laparoscopic	NN	O
procedures	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
transvaginal	JJ	O
synthetic	JJ	O
mesh	NN	O
for	IN	O
anterior	JJ	O
vaginal	JJ	O
wall	NN	O
prolapse	NN	O
repair	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
AND	CC	O
HYPOTHESIS	NNP	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
transvaginal	JJ	O
trocar-guided	JJ	O
polypropylene	NN	O
mesh	JJ	O
insertion	NN	O
with	IN	O
traditional	JJ	O
colporrhaphy	NN	O
for	IN	O
treatment	NN	O
of	IN	O
anterior	JJ	O
vaginal	JJ	O
wall	NN	O
prolapse	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
women	NNS	O
with	IN	O
advanced	JJ	O
anterior	JJ	O
vaginal	NN	O
wall	NN	O
prolapse	NN	O
,	,	O
at	IN	O
least	JJS	O
stage	NN	O
II	NNP	O
with	IN	O
Ba	NNP	O
?	.	O
+1	NN	O
cm	NN	O
according	VBG	O
to	TO	O
the	DT	O
Pelvic	NNP	O
Organ	NNP	O
Prolapse	NNP	O
Quantification	NNP	O
(	(	O
POP-Q	NNP	O
)	)	O
classification	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
either	DT	O
anterior	JJ	O
colporrhaphy	NN	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
or	CC	O
repair	NN	O
using	VBG	O
trocar-guided	JJ	O
transvaginal	JJ	O
mesh	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
objective	JJ	O
cure	NN	O
rate	NN	O
of	IN	O
the	DT	O
anterior	JJ	O
compartment	NN	O
(	(	O
point	NN	O
Ba	NNP	O
)	)	O
assessed	VBD	O
at	IN	O
the	DT	O
12-month	JJ	O
follow-up	JJ	O
visit	NN	O
,	,	O
with	IN	O
stages	NNS	O
0	CD	O
and	CC	O
I	PRP	O
defined	VBD	O
as	IN	O
anatomical	JJ	O
success	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
quantification	NN	O
of	IN	O
other	JJ	O
vaginal	JJ	O
compartments	NNS	O
(	(	O
POP-Q	NNP	O
points	NNS	O
)	)	O
,	,	O
comparison	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
by	IN	O
the	DT	O
prolapse	NN	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
P-QOL	NNP	O
)	)	O
questionnaire	NN	O
,	,	O
and	CC	O
complication	NN	O
rate	NN	O
between	IN	O
the	DT	O
groups	NNS	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

Study	NNP	O
power	NN	O
was	VBD	O
fixed	VBN	O
as	IN	O
80	CD	O
%	NN	O
with	IN	O
5	CD	O
%	NN	O
cutoff	NN	O
point	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
statistical	JJ	O
significance	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
were	VBD	O
similar	JJ	O
regarding	VBG	O
demographic	JJ	O
and	CC	O
clinical	JJ	O
preoperative	NN	O
parameters	NNS	O
.	.	O

Anatomical	JJ	O
success	NN	O
rates	NNS	O
for	IN	O
colporrhaphy	NN	O
and	CC	O
repair	NN	O
with	IN	O
mesh	JJ	O
placement	NN	O
groups	NNS	O
were	VBD	O
56.4	CD	O
vs	JJ	O
82.5	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.068-0.54	NN	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

Similar	JJ	O
total	JJ	O
complication	NN	O
rates	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
tape	NN	O
exposure	NN	O
observed	VBN	O
in	IN	O
5	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
all	DT	O
P-QOL	NNP	O
domains	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
both	DT	O
procedures	NNS	O
(	(	O
p	VB	O
<	RB	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
they	PRP	O
were	VBD	O
not	RB	O
distinct	JJ	O
between	IN	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Trocar-guided	JJ	O
transvaginal	JJ	O
synthetic	JJ	O
mesh	NN	O
for	IN	O
advanced	JJ	O
anterior	JJ	O
POP	NNP	O
repair	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
anatomical	JJ	O
success	NN	O
rate	NN	O
for	IN	O
the	DT	O
anterior	JJ	O
compartment	NN	O
compared	VBN	O
with	IN	O
traditional	JJ	O
colporrhaphy	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
equally	RB	O
improved	VBN	O
after	IN	O
both	DT	O
techniques	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
trial	NN	O
failed	VBD	O
to	TO	O
detect	VB	O
differences	NNS	O
in	IN	O
P-QOL	NNP	O
scores	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Control	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	PH
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

A	DT	O
randomised	JJ	O
double-blind	NN	O
study	NN	O
comparing	VBG	O
isosorbide	JJ	O
dinitrate	NN	O
and	CC	O
nitroglycerin	NN	O
.	.	O

A	DT	O
reduction	NN	O
in	IN	O
the	DT	O
causes	NNS	O
of	IN	O
myocardial	JJ	PH
ischaemia	NN	PH
remains	VBZ	O
of	IN	O
prime	JJ	O
importance	NN	O
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

Hypertension	NN	PH
with	IN	O
the	DT	O
ensuing	VBG	O
increase	NN	O
in	IN	O
myocardial	JJ	PH
oxygen	NN	PH
demand	NN	PH
is	VBZ	O
a	DT	O
major	JJ	O
factor	NN	O
in	IN	O
the	DT	O
aetiology	NN	O
of	IN	O
perioperative	JJ	O
myocardial	JJ	PH
ischaemia	NN	PH
.	.	O

Nitroglycerin	NNP	O
(	(	O
NTG	NNP	O
)	)	O
has	VBZ	O
long	RB	O
been	VBN	O
used	VBN	O
beneficially	RB	O
to	TO	O
reduce	VB	O
myocardial	JJ	PH
oxygen	NN	PH
demand	NN	PH
by	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
systemic	JJ	O
and	CC	O
peripheral	JJ	O
vascular	JJ	O
resistances	NNS	O
.	.	O

An	DT	O
alternative	JJ	O
nitrate	NN	O
,	,	O
isosorbide	JJ	O
dinitrate	NN	O
(	(	O
ISDN	NNP	O
)	)	O
is	VBZ	O
now	RB	O
available	JJ	O
as	IN	O
an	DT	O
intravenous	JJ	O
preparation	NN	O
,	,	O
and	CC	O
may	MD	O
offer	VB	O
technical	JJ	O
advantages	NNS	O
,	,	O
both	DT	O
due	JJ	O
to	TO	O
its	PRP$	O
stability	NN	O
in	IN	O
solution	NN	O
and	CC	O
also	RB	O
its	PRP$	O
longer	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
.	.	O

We	PRP	O
designed	VBD	O
and	CC	O
carried	VBD	O
out	RP	O
a	DT	O
multi-centre	JJ	O
study	NN	O
to	TO	O
compare	VB	O
and	CC	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	Ot
ISDN	NNP	Ot
and	CC	Ot
NTG	NNP	Ot
in	IN	O
the	DT	O
management	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
in	IN	O
85	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
288	CD	O
events	NNS	O
in	IN	O
which	WDT	O
the	DT	O
systolic	NN	PH
blood	NN	PH
pressure	NN	PH
(	(	PH
SBP	NNP	PH
)	)	PH
exceeded	VBD	O
a	DT	O
predetermined	JJ	O
trigger	NN	O
value	NN	O
were	VBD	O
observed	VBN	O
.	.	O

ISDN	NNP	O
was	VBD	O
successful	JJ	Ot
in	IN	O
treating	VBG	O
hypertension	NN	PH
in	IN	O
63	CD	O
%	NN	O
of	IN	O
the	DT	O
events	NNS	O
,	,	O
whereas	NNS	O
NTG	NNP	O
had	VBD	O
an	DT	O
83	CD	O
%	NN	O
success	NN	O
.	.	O

The	DT	O
SBP	NNP	PH
was	VBD	O
significantly	RB	O
lowered	VBN	O
after	IN	O
treatment	NN	O
with	IN	O
either	DT	O
ISDN	NNP	O
,	,	O
155	CD	O
mmHg	NN	O
to	TO	O
138	CD	O
mmHg	NN	O
,	,	O
or	CC	O
NTG	NNP	O
,	,	O
160	CD	O
mmHg	NN	O
to	TO	O
130	CD	O
mmHg	NN	O
.	.	O

The	DT	O
mean	JJ	Ot
successful	JJ	Ot
dose	NN	Ot
rate	NN	Ot
for	IN	O
ISDN	NNP	O
was	VBD	O
6.5	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
,	,	O
whereas	NNS	O
for	IN	O
NTG	NNP	O
this	DT	O
was	VBD	O
3.8	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
.	.	O

In	IN	O
the	DT	O
ISDN	NNP	O
group	NN	O
less	JJR	O
events	NNS	PH
took	VBD	O
place	NN	O
possibly	RB	O
due	JJ	O
to	TO	O
the	DT	O
longer	JJR	O
duration	NN	O
of	IN	O
this	DT	O
drug	NN	O
.	.	O

In	IN	O
many	JJ	O
previous	JJ	O
studies	NNS	O
NTG	NNP	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
controlling	VBG	O
hypertension	NN	PH
;	:	O
ISDN	NNP	O
offers	NNS	O
and	CC	O
alternative	JJ	O
approach	NN	O
in	IN	O
reducing	VBG	PH
hypertension	NN	PH
.	.	O

Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	O
impedance	NN	O
threshold	JJ	O
device	NN	O
on	IN	O
a	DT	O
facemask	NN	O
and	CC	O
endotracheal	VB	O
tube	NN	O
to	TO	O
reduce	VB	O
intrathoracic	JJ	PH
pressures	NNS	PH
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	PH
cardiopulmonary	JJ	PH
resuscitation	NN	PH
.	.	O

INTRODUCTION	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	O
impedance	NN	O
threshold	NN	O
device	NN	O
(	(	O
ITD	NNP	O
)	)	O
significantly	RB	O
increases	VBZ	O
coronary	JJ	O
perfusion	NN	O
pressures	NNS	O
and	CC	O
survival	NN	O
in	IN	O
patients	NNS	O
ventilated	VBN	O
with	IN	O
an	DT	O
endotracheal	JJ	O
tube	NN	O
(	(	O
ETT	NNP	O
)	)	O
during	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
ITD	NNP	O
could	MD	O
lower	VB	O
intratracheal	NN	O
pressures	NNS	O
when	WRB	O
attached	VBN	O
to	TO	O
either	VB	O
a	DT	O
facemask	NN	O
or	CC	O
ETT	NNP	O
.	.	O

METHODS	NNP	O
An	DT	O
active	JJ	O
and	CC	O
sham	JJ	O
ITD	NNP	O
were	VBD	O
randomly	RB	O
applied	VBN	O
first	RB	O
to	TO	O
a	DT	O
facemask	NN	O
and	CC	O
then	RB	O
to	TO	O
an	DT	O
ETT	NNP	O
during	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
in	IN	O
13	CD	O
out-of-hospital	JJ	O
cardiac	JJ	O
arrest	NN	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
compression-to-bag-valve	JJ	O
ventilation	NN	O
ratio	NN	O
was	VBD	O
15:2	CD	O
.	.	O

Airway	NN	O
pressures	NNS	O
(	(	O
surrogate	NN	O
for	IN	O
intrathoracic	JJ	O
pressure	NN	O
)	)	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
pressure	NN	O
transducer	NN	O
.	.	O

A	DT	O
sham	NN	O
and	CC	O
an	DT	O
active	JJ	O
ITD	NNP	O
were	VBD	O
used	VBN	O
for	IN	O
1	CD	O
min	NNS	O
each	DT	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
first	RB	O
on	IN	O
a	DT	O
facemask	NN	O
and	CC	O
then	RB	O
on	IN	O
an	DT	O
ETT	NNP	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
made	VBN	O
using	VBG	O
Friedman	NNP	O
's	POS	O
and	CC	O
Wilcoxon	NNP	O
's	POS	O
rank-sum	JJ	O
tests	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
,	,	O
mean	JJ	PH
+/-	JJ	PH
sd	NN	PH
maximum	JJ	PH
negative	JJ	PH
intrathoracic	NN	PH
pressures	NNS	PH
(	(	O
mm	VB	O
Hg	NNP	O
)	)	O
during	IN	O
the	DT	O
decompression	NN	PH
phase	NN	PH
of	IN	PH
cardiopulmonary	JJ	PH
resuscitation	NN	PH
were	VBD	O
-1.0	JJ	O
+/-	JJ	O
0.73	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	O
vs.	FW	O
-4.6	NNP	O
+/-	JJ	O
3.7	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	O
ITD	NN	O
on	IN	O
the	DT	O
facemask	NN	O
(	(	O
p	JJ	O
=	NNP	O
.003	NNP	O
)	)	O
and	CC	O
-1.3	JJ	O
+/-	JJ	O
1.3	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	O
ITD	NNP	O
vs.	IN	O
-7.3	NNP	O
+/-	JJ	O
4.5	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	O
ITD	NNP	O
on	IN	O
an	DT	O
ETT	NNP	O
(	(	O
p	JJ	O
=	NNP	O
.0009	NNP	O
)	)	O
.	.	O

Decompression	NNP	PH
phase	NN	PH
airway	NN	PH
pressures	NNS	PH
with	IN	O
the	DT	O
facemask	NN	O
and	CC	O
ETT	NNP	O
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
active	JJ	O
ITD	NNP	O
attached	VBD	O
to	TO	O
a	DT	O
facemask	NN	O
or	CC	O
an	DT	O
ETT	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
negative	JJ	PH
intratracheal	JJ	PH
pressure	NN	PH
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Airway	NNP	O
pressures	VBZ	O
with	IN	O
an	DT	O
ITD	NNP	O
on	IN	O
either	CC	O
a	DT	O
facemask	NN	O
or	CC	O
ETT	NNP	O
were	VBD	O
similar	JJ	O
.	.	O

The	DT	O
ITD-facemask	JJ	O
combination	NN	O
was	VBD	O
practical	JJ	O
and	CC	O
enables	VBZ	O
rapid	JJ	O
deployment	NN	O
of	IN	O
this	DT	O
life-saving	JJ	O
technology	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
dried	JJ	O
purple	JJ	O
carrot	NN	O
on	IN	O
body	NN	O
mass	NN	O
,	,	O
lipids	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
body	NN	O
composition	NN	O
,	,	O
and	CC	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
overweight	NN	O
and	CC	O
obese	JJ	O
adults	NNS	O
:	:	O
the	DT	O
QUENCH	NNP	O
trial	NN	O
.	.	O

Obesity	NNP	O
is	VBZ	O
a	DT	O
significant	JJ	O
health	NN	O
issue	NN	O
worldwide	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
chronic	JJ	O
,	,	O
low-grade	JJ	O
inflammation	NN	O
predisposing	VBG	O
the	DT	O
individual	NN	O
to	TO	O
cardiovascular	VB	O
disease	NN	O
and	CC	O
impaired	JJ	O
blood	NN	O
glucose	JJ	O
homeostasis	NN	O
.	.	O

Anthocyanins	NNS	O
and	CC	O
phenolic	JJ	O
acids	NNS	O
from	IN	O
purple	JJ	O
carrots	NNS	O
are	VBP	O
effective	JJ	O
at	IN	O
reversing	VBG	O
inflammation	NN	O
and	CC	O
metabolic	JJ	O
alterations	NNS	O
in	IN	O
animal	NN	O
models	NNS	O
,	,	O
potentially	RB	O
through	IN	O
inhibition	NN	O
of	IN	O
inflammatory	JJ	O
pathways	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
dried	JJ	O
purple	JJ	O
carrot	NN	O
on	IN	O
body	NN	PH
mass	NN	PH
,	,	O
body	NN	PH
composition	NN	PH
,	,	O
blood	NN	PH
pressure	NN	PH
,	,	O
lipids	NNS	PH
,	,	O
inflammatory	JJ	PH
markers	NNS	PH
,	,	O
liver	JJ	Ot
function	NN	Ot
tests	NNS	Ot
,	,	O
and	CC	O
appetite	RB	PH
were	VBD	O
investigated	VBN	O
in	IN	O
16	CD	O
males	NNS	O
(	(	O
aged	VBN	O
53.1	CD	O
?	.	O
7.6	CD	O
years	NNS	O
and	CC	O
with	IN	O
a	DT	O
mean	JJ	O
BMI	NNP	O
of	IN	O
32.8	CD	O
?	.	O
4.6	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
with	IN	O
normal	JJ	O
lipid	JJ	O
and	CC	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
118.5	CD	O
mg/day	NN	O
of	IN	O
anthocyanins	NNS	O
and	CC	O
259.2	CD	O
mg/day	NN	O
of	IN	O
phenolic	JJ	O
acids	NNS	O
for	IN	O
4	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
body	NN	O
mass	NN	O
,	,	O
body	NN	O
composition	NN	O
,	,	O
appetite	RB	O
,	,	O
dietary	JJ	O
intake	NN	O
,	,	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
,	,	O
total	JJ	O
cholesterol	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
or	CC	O
C-reactive	JJ	O
protein	NN	O
in	IN	O
these	DT	O
obese	JJ	O
participants	NNS	O
at	IN	O
the	DT	O
dose	NN	O
and	CC	O
length	NN	O
of	IN	O
intervention	NN	O
used	VBN	O
in	IN	O
this	DT	O
trial	NN	O
.	.	O

High	JJ	O
density	NN	O
lipoprotein	VBP	O
cholesterol	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Aspartate	NNP	O
amino	NN	O
transferase	NN	O
and	CC	O
alanine	NN	O
amino	NN	O
transferase	NN	O
did	VBD	O
not	RB	O
change	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
safe	JJ	O
.	.	O

More	JJR	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
establish	VB	O
the	DT	O
bioavailability	NN	O
and	CC	O
pharmacokinetic	JJ	O
effects	NNS	O
of	IN	O
purple	JJ	O
carrot	NN	O
anthocyanins	NNS	O
and	CC	O
phenolic	JJ	O
acids	NNS	O
prior	RB	O
to	TO	O
further	JJ	O
trials	NNS	O
of	IN	O
efficacy	NN	O
with	IN	O
respect	NN	O
to	TO	O
treating	VBG	O
inflammation	NN	O
and	CC	O
metabolic	JJ	O
alterations	NNS	O
.	.	O

Effect	NN	O
of	IN	O
m-chlorophenylpiperazine	NN	O
on	IN	O
plasma	NN	O
homovanillic	JJ	O
acid	NN	O
concentrations	NNS	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
abundant	JJ	O
anatomical	JJ	O
and	CC	O
functional	JJ	O
interactions	NNS	O
between	IN	O
serotonin	NN	O
and	CC	O
dopamine	NN	O
systems	NNS	O
,	,	O
this	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
serotonin	JJ	O
agonist	NN	O
,	,	O
m-chlorophenylpiperazine	NN	O
(	(	O
mCPP	NN	O
)	)	O
on	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
the	DT	O
dopamine	NN	O
metabolite	NN	O
,	,	O
homovanillic	JJ	O
acid	NN	O
.	.	O

Plasma	NNP	O
prolactin	NN	O
levels	NNS	O
,	,	O
body	NN	O
temperature	NN	O
,	,	O
and	CC	O
mCPP	RB	A
blood	NN	O
level	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

mCPP	NN	O
(	(	O
0.35	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
placebo	$	O
were	VBD	O
administered	VBN	O
orally	RB	O
to	TO	O
10	CD	O
healthy	JJ	O
men	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
design	NN	O
.	.	O

Variables	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
210	CD	O
min	NNS	O
after	IN	O
administration	NN	O
of	IN	O
capsules	NNS	O
.	.	O

mCPP	NNS	PH
raised	VBD	PH
prolactin	NN	PH
and	CC	PH
temperature	NN	PH
as	IN	PH
compared	VBN	PH
to	TO	PH
placebo	VB	PH
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
plasma	NN	PH
homovanillic	JJ	PH
acid	JJ	PH
concentrations	NNS	PH
.	.	PH

Results	VB	O
suggest	JJS	O
that	IN	O
mCPP	NN	PH
does	VBZ	PH
not	RB	PH
alter	VB	PH
dopamine	NN	PH
function	NN	PH
.	.	PH

A	DT	O
double-blind	JJ	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
piracetam	NN	O
added	VBN	O
to	TO	O
risperidone	VB	O
in	IN	O
patients	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
autism	NN	O
is	VBZ	O
a	DT	O
hypoglutamatergic	JJ	O
disorder	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
was	VBD	O
of	IN	O
interest	NN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
piracetam	NN	O
,	,	O
a	DT	O
positive	JJ	O
modulator	NN	O
of	IN	O
AMPA-sensitive	JJ	O
glutamate	NN	O
receptors	NNS	O
in	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

About	IN	O
40	CD	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
three	CD	O
and	CC	O
11	CD	O
years	NNS	O
(	(	O
inclusive	JJ	O
)	)	O
with	IN	O
a	DT	O
DSM	NNP	O
IV	NNP	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	O
and	CC	O
who	WP	O
were	VBD	O
outpatients	NNS	O
from	IN	O
a	DT	O
specialty	NN	O
clinic	NN	O
for	IN	O
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
children	NNS	O
presented	VBN	O
with	IN	O
a	DT	O
chief	JJ	O
complaint	NN	O
of	IN	O
severely	RB	O
disruptive	JJ	O
symptoms	NNS	O
related	VBN	O
to	TO	O
autistic	JJ	O
disorder	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
piracetam	VB	O
+	NNP	O
risperidone	NN	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
or	CC	O
placebo	JJ	O
+	NN	O
risperidone	NN	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
for	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
between	IN	O
10	CD	O
and	CC	O
40	CD	O
kg	NN	O
and	CC	O
3	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
weighting	VBG	O
above	IN	O
40	CD	O
kg	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
piracetam	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
800	CD	O
mg/day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
and	CC	O
10	CD	O
weeks	NNS	O
of	IN	O
starting	VBG	O
medication	NN	O
.	.	O

The	DT	O
measure	NN	O
of	IN	O
the	DT	O
outcome	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	Ot
Behavior	NNP	Ot
Checklist-Community	NNP	Ot
(	(	Ot
ABC-C	NNP	Ot
)	)	Ot
Rating	VBG	Ot
Scale	NNP	Ot
(	(	PH
total	JJ	PH
score	NN	PH
)	)	PH
.	.	O

The	DT	O
ABC-C	JJ	Ot
Rating	NNP	Ot
Scale	NNP	Ot
scores	VBZ	Ot
improved	VBN	O
with	IN	O
piracetam	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
indicated	VBN	O
by	IN	O
the	DT	O
effect	NN	O
of	IN	O
group	NN	O
,	,	O
the	DT	O
between	IN	O
subjects	NNS	O
factor	NN	O
(	(	O
F	NNP	O
=	NNP	O
5.85	CD	O
,	,	O
d.f	NN	O
.	.	O

=	CC	O
1	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
at	IN	O
the	DT	O
endpoint	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
were	VBD	O
:	:	O
-11.90	JJ	O
+/-	JJ	O
3.79	CD	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
and	CC	O
-5.15	JJ	O
+/-	JJ	O
3.04	CD	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
respectively	RB	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
the	DT	O
change	NN	O
in	IN	O
scores	NNS	Ot
in	IN	Ot
the	DT	Ot
ABC-C	NNP	Ot
Rating	NNP	Ot
Scale	NNP	Ot
in	IN	O
week	NN	O
10	CD	O
compared	VBN	O
with	IN	O
baseline	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
t	JJ	O
=	NN	O
6.017	CD	O
,	,	O
d.f	NN	O
.	.	O

=	CC	O
38	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
combination	NN	O
of	IN	O
atypical	JJ	O
antipsychotic	JJ	O
medications	NNS	O
and	CC	O
a	DT	O
glutamate	JJ	O
agent	NN	O
such	JJ	O
as	IN	O
piracetam	NNS	O
,	,	O
might	MD	O
have	VB	O
increase	VBN	O
synergistic	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

Iobitridol	NNP	O
300	CD	O
compared	VBN	O
to	TO	O
iopromide	VB	O
300	CD	O
--	:	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
phase-III	NN	O
study	NN	O
of	IN	O
clinical	JJ	O
tolerance	NN	O
in	IN	O
total	JJ	O
body	NN	O
CT.	NNP	O
UNLABELLED	NNP	O
PURPOSE	NNP	O
,	,	O
MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
:	:	O
The	DT	O
clinical	JJ	O
safety	NN	O
of	IN	O
iobitriodol	JJ	O
300	CD	O
mg	NN	O
I/ml	NNP	O
and	CC	O
iopromide	RB	O
300	CD	O
mg	NNS	O
I/ml	NNP	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	IN	O
phase-III	JJ	O
study	NN	O
conducted	VBD	O
on	IN	O
60	CD	O
patients	NNS	O
undergoing	JJ	O
abdominal	JJ	O
CT	NNP	O
for	IN	O
a	DT	O
variety	NN	O
of	IN	O
indications	NNS	O
.	.	O

Each	DT	O
examination	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
diagnostic	JJ	O
or	CC	O
nondiagnostic	JJ	O
and	CC	O
the	DT	O
image	NN	O
quality	NN	O
was	VBD	O
noted	VBN	O
.	.	O

Nature	NN	O
,	,	O
onset	NN	Ot
,	,	O
intensity	NN	O
as	RB	O
well	RB	O
as	IN	O
outcome	NN	O
of	IN	O
each	DT	O
adverse	JJ	A
reaction	NN	A
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
imaging	VBG	Ot
quality	NN	Ot
and	CC	O
side	NN	A
effects	NNS	A
between	IN	O
the	DT	O
contrast	NN	O
media	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
both	DT	O
iobitridol	NNS	O
and	CC	O
iopromide	NN	O
provided	VBD	O
excellent	JJ	Ot
image	NN	Ot
quality	NN	Ot
and	CC	O
a	DT	O
low	JJ	A
rate	NN	A
of	IN	A
side	NN	A
effects	NNS	A
.	.	O

CONCLUSION	NNP	O
Iobitridol	NNP	O
is	VBZ	O
a	DT	O
safe	JJ	Ot
and	CC	O
effective	JJ	Ot
nonionic	JJ	Ot
contrast	NN	Ot
agent	NN	Ot
for	IN	O
contrast-enhanced	JJ	O
body	NN	O
CT	NNP	O
.	.	O

The	DT	O
double-blind	JJ	O
sham-controlled	JJ	O
study	NN	O
of	IN	O
high-frequency	NN	O
rTMS	NN	O
(	(	O
20	CD	O
Hz	NNP	O
)	)	O
for	IN	O
negative	JJ	O
symptoms	NNS	O
in	IN	O
schizophrenia	NN	O
:	:	O
negative	JJ	O
results	NNS	O
.	.	O

The	DT	O
high-frequency	NN	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
HF-rTMS	NNP	O
)	)	O
over	IN	O
the	DT	O
prefrontal	JJ	O
cortex	NN	O
is	VBZ	O
a	DT	O
promising	JJ	O
method	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
.	.	O

Using	VBG	O
double-blind	JJ	O
sham-controlled	JJ	O
parallel	NN	O
design	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
HF-rTMS	NNP	O
over	IN	O
the	DT	O
left	JJ	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
(	(	O
DLPFC	NNP	O
)	)	O
on	IN	O
negative	JJ	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

Sixteen	NNP	O
schizophrenia	NN	O
patients	NNS	O
with	IN	O
predominantly	RB	O
negative	JJ	O
symptoms	NNS	O
on	IN	O
stable	JJ	O
antipsychotic	JJ	O
medication	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
20	CD	O
Hz	NNP	O
rTMS	NN	O
(	(	O
90	CD	O
%	NN	O
of	IN	O
motor	NN	O
threshold	NN	O
,	,	O
2000	CD	O
stimuli	NN	O
per	IN	O
session	NN	O
)	)	O
over	IN	O
ten	JJ	O
days	NNS	O
within	IN	O
2	CD	O
weeks	NNS	O
with	IN	O
six	CD	O
weeks	NNS	O
follow-up	RB	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
PANSS	NNP	PH
,	,	PH
CGI	NNP	PH
,	,	PH
MADRS	NNP	PH
and	CC	PH
neuropsychological	JJ	PH
tests	NNS	PH
.	.	PH

We	PRP	O
failed	VBD	O
to	TO	O
find	VB	O
any	DT	O
significant	JJ	O
effect	NN	O
of	IN	O
active	JJ	PH
rTMS	NN	PH
.	.	PH

Sham	NNP	PH
rTMS	NN	PH
showed	VBD	O
a	DT	O
trend	NN	O
for	IN	O
improvement	NN	PH
over	IN	PH
time	NN	PH
on	IN	O
positive	JJ	Ot
and	CC	Ot
negative	JJ	Ot
subscales	NNS	Ot
of	IN	Ot
PANSS	NNP	Ot
and	CC	Ot
MADRS	NNP	Ot
.	.	PH

Between-group	NNP	O
comparisons	NNS	O
failed	VBD	O
to	TO	O
reveal	VB	O
any	DT	O
significant	JJ	O
differences	NNS	O
on	IN	O
any	DT	O
rating	NN	PH
scales	NNS	PH
except	IN	O
a	DT	O
positive	JJ	PH
subscale	NN	PH
of	IN	PH
PANSS	NNP	PH
after	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Results	NNS	O
from	IN	O
our	PRP$	O
study	NN	O
did	VBD	O
not	RB	O
confirm	VB	O
that	IN	O
HF-rTMS	NNP	PH
over	IN	O
the	DT	O
left	JJ	O
DLPCF	NNP	PH
affects	VBZ	PH
the	DT	PH
negative	JJ	PH
symptoms	NNS	PH
of	IN	PH
schizophrenia	NN	PH
and	CC	O
alternative	JJ	O
rTMS	NN	O
approaches	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

The	DT	O
clinical	JJ	O
and	CC	O
biochemical	JJ	O
effects	NNS	O
of	IN	O
propofol	JJ	O
infusion	NN	O
with	IN	O
and	CC	O
without	IN	O
EDTA	NNP	O
for	IN	O
maintenance	NN	O
anesthesia	NN	O
in	IN	O
healthy	JJ	O
children	NNS	O
undergoing	VBG	O
ambulatory	NN	O
surgery	NN	O
.	.	O

UNLABELLED	IN	O
We	PRP	O
conducted	VBD	O
this	DT	O
randomized	VBN	O
,	,	O
double-blinded	JJ	O
,	,	O
comparative	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
to	TO	O
determine	VB	O
whether	IN	O
adding	VBG	O
EDTA	NNP	O
to	TO	O
propofol	VB	O
would	MD	O
affect	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
,	,	O
calcium	NN	O
and	CC	O
magnesium	NN	O
homeostasis	NN	O
,	,	O
or	CC	O
renal	JJ	O
function	NN	O
in	IN	O
healthy	JJ	O
children	NNS	O
.	.	O

After	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
halothane	NN	O
,	,	O
69	CD	O
ambulatory	JJ	O
surgical	JJ	O
patients	NNS	O
(	(	O
1	CD	O
mo	NN	O
to	TO	O
<	VB	O
17	CD	O
yr	NNP	O
old	JJ	O
)	)	O
,	,	O
received	VBD	O
propofol	NN	O
without	IN	O
EDTA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
or	CC	O
propofol	NN	O
with	IN	O
EDTA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
.	.	O

Blood	NN	ME
samples	NNS	ME
were	VBD	O
obtained	VBN	O
for	IN	O
the	DT	O
measurement	NN	ME
of	IN	ME
ionized	JJ	ME
calcium	NN	ME
,	,	ME
ionized	JJ	ME
magnesium	NN	ME
,	,	ME
and	CC	ME
laboratory	JJ	ME
indicators	NNS	ME
of	IN	ME
renal	JJ	ME
function	NN	ME
.	.	ME

Hemodynamic	NNP	PH
measurements	NNS	PH
,	,	PH
recovery	NN	PH
,	,	O
and	CC	O
adverse	JJ	PH
events	NNS	PH
were	VBD	O
recorded	VBN	O
.	.	O

Propofol	NNP	O
with	IN	O
EDTA	NNP	O
produced	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
clinical	JJ	PH
efficacy	NN	PH
or	CC	PH
renal	JJ	PH
function	NN	PH
.	.	PH

Propofol	NNP	O
and	CC	O
propofol	JJ	O
EDTA	NNP	O
produced	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	PH
from	IN	PH
baseline	NN	PH
in	IN	PH
serum	JJ	PH
concentrations	NNS	PH
of	IN	PH
ionized	JJ	PH
calcium	NN	PH
and	CC	PH
magnesium	NN	PH
during	IN	PH
infusion	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Hemodynamic	NNP	PH
measurements	NNS	PH
generally	RB	O
remained	VBD	O
stable	JJ	O
and	CC	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
changes	NNS	O
in	IN	O
systolic	JJ	Ot
blood	NN	Ot
pressure	NN	Ot
,	,	Ot
mean	JJ	Ot
arterial	JJ	Ot
pressure	NN	Ot
,	,	Ot
and	CC	Ot
heart	NN	Ot
rate	NN	Ot
were	VBD	O
not	RB	O
considered	VBN	O
clinically	RB	O
significant	JJ	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
mild	JJ	O
or	CC	O
moderate	JJ	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
EDTA	NNP	O
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
of	IN	O
propofol	NN	O
in	IN	O
pediatric	JJ	O
ambulatory	JJ	O
surgical	JJ	O
patients	NNS	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
EDTA	NNP	O
,	,	O
propofol	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
ionized	JJ	Ot
calcium	NN	Ot
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

IMPLICATIONS	VBZ	O
The	DT	O
addition	NN	O
of	IN	O
EDTA	NNP	O
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
of	IN	O
propofol	NN	O
in	IN	O
pediatric	JJ	O
ambulatory	JJ	O
surgical	JJ	O
patients	NNS	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
EDTA	NNP	O
,	,	O
propofol	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
ionized	JJ	PH
calcium	NN	PH
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Simulating	VBG	O
a	DT	O
memory	NN	O
impairment	NN	O
:	:	O
can	MD	O
amnesics	VB	O
implicitly	RB	O
outperform	JJ	O
simulators	NNS	O
?	.	O
OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
tests	NNS	O
in	IN	O
differentiating	VBG	O
simulating	VBG	ME
test	NN	ME
performances	NNS	ME
from	IN	O
genuine	JJ	O
memory-impaired	JJ	ME
and	CC	O
normal	JJ	O
(	(	O
control	NN	O
)	)	O
test	NN	O
performances	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
simulation	NN	O
design	NN	O
was	VBD	O
implemented	VBN	O
,	,	O
based	VBN	O
on	IN	O
an	DT	O
analogue	NN	O
design	NN	O
in	IN	O
which	WDT	O
normal	JJ	O
participants	NNS	O
were	VBD	O
given	VBN	O
experimental	JJ	O
instructions	NNS	O
to	TO	O
feign	VB	O
a	DT	O
mental	JJ	O
impairment	NN	O
and	CC	O
are	VBP	O
compared	VBN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
other	JJ	O
normal	JJ	O
participants	NNS	O
with	IN	O
instructions	NNS	O
to	TO	O
perform	VB	O
honestly	RB	O
,	,	O
and	CC	O
(	(	O
b	NN	O
)	)	O
a	DT	O
comparison	NN	O
group	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
acquired	VBD	O
brain-injured	JJ	O
persons	NNS	O
,	,	O
with	IN	O
similar	JJ	O
instructions	NNS	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
individuals	NNS	O
comprised	VBD	O
the	DT	O
simulating	NN	O
and	CC	O
control	NN	O
group	NN	O
and	CC	O
all	DT	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
simulating	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Twenty	CD	O
memory-impaired	JJ	O
patients	NNS	O
,	,	O
all	DT	O
of	IN	O
whom	WP	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
as	IN	O
suffering	VBG	O
from	IN	O
a	DT	O
memory	NN	O
impairment	NN	O
following	VBG	O
acquired	VBD	O
brain	NN	O
damage	NN	O
,	,	O
participated	VBD	O
as	IN	O
the	DT	O
memory-impaired	JJ	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
simulation	NN	O
group	NN	O
was	VBD	O
directed	VBN	O
to	TO	O
imitate	VB	O
a	DT	O
person	NN	O
with	IN	O
a	DT	O
memory	NN	O
impairment	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
involved	VBN	O
identifying	VBG	ME
those	DT	ME
tests	NNS	ME
,	,	ME
if	IN	ME
any	DT	ME
,	,	ME
where	WRB	ME
simulators	NNS	ME
were	VBD	ME
significantly	RB	ME
different	JJ	ME
from	IN	ME
normal	JJ	ME
and	CC	ME
memory-impaired	JJ	ME
participants	NNS	ME
.	.	ME

RESULTS	VB	O
On	IN	O
5	CD	O
of	IN	O
the	DT	O
15	CD	O
tasks	NNS	O
administered	VBN	O
,	,	O
simulators	NNS	ME
performed	VBD	ME
significantly	RB	ME
differently	RB	ME
from	IN	ME
normal	JJ	ME
and	CC	ME
memory-impaired	JJ	ME
participants	NNS	ME
.	.	ME

Of	IN	O
these	DT	O
5	CD	O
tasks	NNS	O
,	,	O
the	DT	O
coin-in-the-hand	NN	O
,	,	O
when	WRB	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
autobiographical	JJ	O
interview	NN	O
,	,	O
identified	VBD	O
95	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
simulators	NNS	O
without	IN	O
misclassifying	VBG	O
any	DT	O
of	IN	O
the	DT	O
memory-impaired	JJ	O
or	CC	O
normal	JJ	O
participants	NNS	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
these	DT	O
two	CD	O
tests	NNS	O
,	,	O
when	WRB	O
administered	VBN	O
jointly	RB	O
,	,	O
might	MD	O
be	VB	O
of	IN	O
use	NN	O
in	IN	O
clinical	JJ	O
settings	NNS	O
to	TO	O
assist	VB	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
malingerers	NNS	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
whey	JJ	O
protein	NN	O
concentrate	NN	O
derived	VBN	O
from	IN	O
the	DT	O
milk	NN	O
of	IN	O
cows	NNS	O
immunized	VBN	O
against	IN	O
Clostridium	NNP	O
difficile	NN	O
.	.	O

A	DT	O
whey	JJ	O
protein	NN	O
concentrate	NN	O
prepared	VBN	O
from	IN	O
the	DT	O
milk	NN	O
of	IN	O
cows	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
immunized	VBN	O
against	IN	O
Clostridium	NNP	O
difficile	NN	O
(	(	O
C.	NNP	O
difficile	NN	O
)	)	O
and	CC	O
its	PRP$	O
toxins	NNS	O
,	,	O
toxin	NN	O
A	NNP	O
and	CC	O
toxin	NN	O
B	NNP	O
,	,	O
is	VBZ	O
produced	VBN	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
medical	JJ	O
food	NN	O
for	IN	O
the	DT	O
dietary	JJ	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
C.	NNP	O
difficile-associated	JJ	O
diarrhea	NN	O
(	(	O
CDAD	NNP	O
)	)	O
to	TO	O
prevent	VB	O
a	DT	O
relapse	NN	O
of	IN	O
the	DT	O
infection	NN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
anti-C.	JJ	O
difficile	NN	O
whey	NN	O
protein	VBP	O
concentrate	NN	O
(	(	O
anti-CD	JJ	O
WPC	NNP	O
)	)	O
is	VBZ	O
supported	VBN	O
by	IN	O
analytical	JJ	O
data	NNS	O
comparing	VBG	O
the	DT	O
composition	NN	O
of	IN	O
raw	JJ	O
milk	NN	O
from	IN	O
immunized	JJ	O
cows	NNS	O
versus	VBP	O
that	IN	O
from	IN	O
non-immunized	JJ	O
cows	NNS	O
,	,	O
and	CC	O
the	DT	O
composition	NN	O
of	IN	O
anti-CD	JJ	O
WPC	NNP	O
versus	NN	O
that	IN	O
of	IN	O
regular	JJ	O
whey	NN	O
protein	NN	O
concentrate	NN	O
.	.	O

Additionally	RB	O
,	,	O
a	DT	O
prospective	JJ	O
clinical	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
77	CD	O
patients	NNS	O
with	IN	O
CDAD	NNP	O
to	TO	O
demonstrate	VB	O
the	DT	O
safety	NN	O
of	IN	O
consuming	VBG	O
anti-CD	JJ	O
WPC	NNP	O
to	TO	O
prevent	VB	O
relapse	NN	O
of	IN	O
the	DT	O
infection	NN	O
.	.	O

This	DT	O
study	NN	O
,	,	O
which	WDT	O
included	VBD	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
,	,	O
physical	JJ	O
examinations	NNS	O
,	,	O
and	CC	O
extensive	JJ	O
hematological	NN	O
and	CC	O
biochemical	JJ	O
assessments	NNS	O
,	,	O
showed	VBD	O
that	IN	O
anti-CD	JJ	O
WPC	NNP	O
is	VBZ	O
safe	JJ	Ot
to	TO	O
consume	VB	O
by	IN	O
patients	NNS	O
with	IN	O
CDAD	NNP	O
.	.	O

The	DT	O
available	JJ	O
analytical	JJ	O
and	CC	O
clinical	JJ	O
evidence	NN	O
demonstrate	NN	O
that	IN	O
anti-CD	JJ	O
WPC	NNP	O
is	VBZ	O
safe	JJ	Ot
for	IN	O
use	NN	O
by	IN	O
individuals	NNS	O
with	IN	O
CDAD	NNP	O
,	,	O
under	IN	O
the	DT	O
described	JJ	O
conditions	NNS	O
of	IN	O
use	NN	O
.	.	O

Levamisole	NNP	O
versus	NN	O
placebo	NN	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
primary	JJ	O
therapy	NN	O
of	IN	O
laryngopharyngeal	JJ	O
epidermoid	JJ	O
carcinoma	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
immune	JJ	O
status	NN	O
.	.	O

Twenty-four	CD	O
patients	NNS	O
,	,	O
with	IN	O
a	DT	O
biopsy-proven	JJ	O
laryngeal	NN	O
or	CC	O
hypopharyngeal	NN	O
carcinoma	NN	O
,	,	O
received	VBD	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
their	PRP$	O
primary	JJ	O
treatment	NN	O
(	(	O
surgery	JJ	O
and/or	RB	O
radiotherapy	NN	O
)	)	O
,	,	O
levamisole	JJ	O
(	(	O
150	CD	O
mg	NNS	O
daily	RB	O
during	IN	O
three	CD	O
consecutive	JJ	O
days	NNS	O
,	,	O
every	DT	O
fortnight	NN	O
)	)	O
or	CC	O
placebo	NN	O
,	,	O
following	VBG	O
a	DT	O
single-blind	JJ	O
,	,	O
but	CC	O
randomized	VBD	O
method	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	NN	O
,	,	O
an	DT	O
investigation	NN	O
of	IN	O
the	DT	O
immune	NN	PH
status	NN	O
was	VBD	O
done	VBN	O
,	,	O
and	CC	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
healthy	JJ	O
control-group	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
immunity	NN	PH
is	VBZ	O
disturbed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
laryngo-pharyngeal	JJ	O
cancer	NN	O
,	,	O
but	CC	O
that	IN	O
this	DT	O
disturbance	NN	O
does	VBZ	O
not	RB	O
clearly	RB	O
correlate	NN	O
with	IN	O
the	DT	O
clinical	JJ	O
state	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
immunological	JJ	O
measures	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
relevant	JJ	O
to	TO	O
the	DT	O
significantly	RB	O
favourable	JJ	O
effect	NN	O
of	IN	O
levamisole	NN	O
on	IN	O
the	DT	O
prognosis	NN	O
.	.	O

[	NNS	O
Localised	VBN	O
prostate	JJ	O
cancer	NN	O
:	:	O
the	DT	O
PREFERE	NNP	O
trial	NN	O
]	NNP	O
.	.	O

Prostate	NNP	O
cancer	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
elderly	JJ	O
man	NN	O
and	CC	O
holds	VBZ	O
the	DT	O
third	JJ	O
place	NN	O
in	IN	O
the	DT	O
ranking	NN	O
of	IN	O
cancer-specific	JJ	MO
mortality	NN	MO
.	.	O

However	RB	O
,	,	O
mortality	NN	MO
rates	NNS	MO
of	IN	O
3	CD	O
%	NN	O
are	VBP	O
low	JJ	O
,	,	O
and	CC	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	O
will	MD	O
die	VB	O
from	IN	O
intercurrent	JJ	O
disease	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
significantly	RB	O
improved	VBN	O
diagnostic	JJ	O
methods	NNS	O
and	CC	O
the	DT	O
increasing	VBG	O
use	NN	O
of	IN	O
PSA	NNP	O
screening	NN	O
,	,	O
there	EX	O
has	VBZ	O
been	VBN	O
a	DT	O
stage	NN	O
migration	NN	O
towards	NNS	O
early	RB	O
tumour	VBP	O
stages	NNS	O
that	WDT	O
are	VBP	O
prognostically	RB	O
heterogeneous	JJ	O
and	CC	O
require	NN	O
differentiated	VBN	O
treatment	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
discussions	NNS	O
of	IN	O
the	DT	O
Joint	NNP	O
Federal	NNP	O
Committee	NNP	O
(	(	O
G-BA	NNP	O
)	)	O
and	CC	O
the	DT	O
conceptual	JJ	O
work	NN	O
of	IN	O
the	DT	O
MDS	NNP	O
,	,	O
the	DT	O
Competence	NNP	O
Centre	NNP	O
Oncology	NNP	O
of	IN	O
the	DT	O
MDK	NNP	O
,	,	O
the	DT	O
IQWIG	NNP	O
and	CC	O
the	DT	O
National	NNP	O
Association	NNP	O
of	IN	O
Statutory	NNP	O
Health	NNP	O
Insurance	NNP	O
Funds	NNP	O
(	(	O
GKV-Spitzenverband	NNP	O
)	)	O
,	,	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
multicentre	JJ	O
trial	NN	O
was	VBD	O
developed	VBN	O
comparing	VBG	O
the	DT	O
four	CD	O
treatments	NNS	O
actually	RB	O
recommended	VBN	O
by	IN	O
the	DT	O
German	JJ	O
and	CC	O
European	JJ	O
guidelines	NNS	O
for	IN	O
localised	JJ	O
prostate	NN	O
cancer	NN	O
(	(	O
radical	JJ	Ot
prostatectomy	NN	Ot
,	,	O
percutaneous	JJ	Ot
radiotherapy	NN	Ot
and	CC	O
permanent	JJ	Ot
seed	NN	Ot
implantation	NN	Ot
and	CC	O
active	JJ	Ot
surveillance	NN	Ot
)	)	O
allowing	VBG	O
a	DT	O
rejection	NN	O
of	IN	O
one	CD	O
or	CC	O
two	CD	O
treatment	NN	O
options	NNS	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
expected	VBN	O
to	TO	O
start	VB	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
next	JJ	O
year	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
in	IN	O
hormone-resistant	JJ	O
metastatic	JJ	O
prostate	NN	O
carcinoma	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
51	CD	O
patients	NNS	O
with	IN	O
stage	JJ	O
D	NNP	O
hormone-resistant	JJ	O
prostatic	JJ	O
carcinoma	NN	O
,	,	O
comparing	VBG	O
a	DT	O
combination	NN	O
of	IN	O
doxorubicin	NN	O
and	CC	O
lomustine	NN	O
(	(	O
DC	NNP	O
)	)	O
with	IN	O
cyclophosphamide	NN	O
and	CC	O
5-FU	JJ	O
(	(	O
CF	NNP	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
objectively	RB	O
(	(	O
employing	VBG	O
National	NNP	O
Prostate	NNP	O
Cancer	NNP	O
Project	NNP	O
criteria	NNS	O
)	)	O
and	CC	O
subjectively	RB	O
(	(	O
using	VBG	O
a	DT	O
numerical	JJ	O
scoring	NN	O
scheme	NN	O
)	)	O
.	.	O

Each	DT	O
regimen	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Ot
with	IN	O
acceptable	JJ	O
levels	NNS	PH
of	IN	PH
myelosuppression	NN	PH
.	.	O

The	DT	O
objective	JJ	Ot
partial	JJ	Ot
response	NN	Ot
rate	NN	Ot
was	VBD	O
57	CD	O
%	NN	O
for	IN	O
DC	NNP	O
and	CC	O
8	CD	O
%	NN	O
for	IN	O
CF	NNP	O
.	.	O

Objective	NNP	PH
stabilization	NN	PH
occurred	VBD	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
14	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

Similarly	RB	O
,	,	O
DC	NNP	O
demonstrated	VBD	O
a	DT	O
significantly	RB	O
superior	JJ	O
subjective	JJ	Ot
response	NN	Ot
rate	NN	Ot
(	(	Ot
partial	JJ	Ot
plus	CC	Ot
complete	JJ	Ot
)	)	Ot
of	IN	O
82	CD	O
%	NN	O
,	,	O
compared	VBN	O
to	TO	O
48	CD	O
%	NN	O
for	IN	O
CF	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
poor	JJ	O
initial	JJ	O
performance	NN	O
status	NN	O
or	CC	O
liver	VB	O
involvement	NN	O
had	VBD	O
significantly	RB	O
lower	JJR	O
response	NN	Ot
rates	NNS	Ot
and	CC	O
reduced	JJ	O
survival	NN	MO
.	.	O

Overall	JJ	O
,	,	O
there	EX	O
was	VBD	O
no	DT	Ot
significant	JJ	Ot
difference	NN	Ot
in	IN	Ot
survival	NN	MO
between	IN	Ot
the	DT	Ot
two	CD	Ot
arms	NNS	Ot
,	,	O
reflecting	VBG	O
the	DT	O
similarity	NN	PH
between	IN	PH
DC	NNP	PH
and	CC	PH
CF	NNP	PH
in	IN	PH
total	JJ	PH
objective	JJ	PH
response	NN	PH
rate	NN	PH
(	(	O
partial	JJ	O
response	NN	O
plus	CC	O
stable	JJ	O
disease	NN	O
)	)	O
.	.	O

DC	NNP	O
provided	VBD	O
superior	JJ	O
palliation	NN	PH
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	Ot
by	IN	O
an	DT	O
essentially	RB	O
geriatric	JJ	O
population	NN	O
.	.	O

Improved	VBN	O
frontoparietal	JJ	PH
white	JJ	PH
matter	NN	PH
integrity	NN	PH
in	IN	O
overweight	JJ	O
children	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
attendance	NN	O
at	IN	O
an	DT	O
after-school	JJ	O
exercise	NN	O
program	NN	O
.	.	O

Aerobic	NNP	O
fitness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
white	JJ	PH
matter	NN	PH
integrity	NN	PH
(	(	PH
WMI	NNP	PH
)	)	PH
in	IN	O
adults	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
diffusion	NN	PH
tensor	NN	PH
imaging	NN	PH
(	(	PH
DTI	NNP	PH
)	)	PH
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
8-month	JJ	O
exercise	NN	O
intervention	NN	O
on	IN	O
WMI	NNP	PH
in	IN	O
children	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
18	CD	O
sedentary	JJ	O
,	,	O
overweight	JJ	O
(	(	O
BMI?85th	NNP	O
percentile	NN	O
)	)	O
8-	CD	O
to	TO	O
11-year-old	JJ	O
children	NNS	O
(	(	O
94	CD	O
%	NN	O
Black	NNP	O
)	)	O
,	,	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
aerobic	JJ	O
exercise	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
sedentary	JJ	O
attention	NN	O
control	NN	O
group	NN	O
(	(	O
n=8	RB	O
)	)	O
.	.	O

Each	DT	O
group	NN	O
was	VBD	O
offered	VBN	O
an	DT	O
instructor-led	JJ	O
after-school	JJ	O
program	NN	O
every	DT	O
school	NN	O
day	NN	O
for	IN	O
approximately	RB	O
8	CD	O
months	NNS	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
the	DT	O
program	NN	O
,	,	O
all	DT	O
subjects	NNS	O
participated	VBN	O
in	IN	O
DTI	NNP	O
scans	NNS	O
.	.	O

Tractography	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
superior	JJ	O
longitudinal	JJ	O
fasciculus	NN	O
and	CC	O
investigate	VB	O
whether	IN	O
the	DT	O
exercise	NN	O
intervention	NN	O
affected	VBD	O
WMI	NNP	O
in	IN	O
this	DT	O
region	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
group	NN	O
by	IN	O
time	NN	O
interaction	NN	O
for	IN	O
WMI	NNP	O
in	IN	O
the	DT	O
superior	JJ	O
longitudinal	JJ	O
fasciculus	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
group	NN	O
by	IN	O
time	NN	O
by	IN	O
attendance	NN	O
interaction	NN	O
,	,	O
however	RB	O
,	,	O
such	JJ	O
that	IN	O
higher	JJR	O
attendance	NN	O
at	IN	O
the	DT	O
exercise	NN	O
intervention	NN	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
control	NN	O
intervention	NN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
WMI	NNP	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
exercise	NN	O
correlated	VBN	O
with	IN	O
WMI	NNP	O
changes	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
overall	JJ	O
sample	NN	O
,	,	O
increased	VBD	O
WMI	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
scores	NNS	O
on	IN	O
a	DT	O
measure	NN	O
of	IN	O
attention	NN	O
and	CC	O
improved	VBN	O
teacher	JJ	O
ratings	NNS	O
of	IN	O
executive	NN	O
function	NN	O
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
participating	VBG	O
in	IN	O
an	DT	O
exercise	NN	O
intervention	NN	O
improves	VBZ	O
WMI	NNP	O
in	IN	O
children	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
sedentary	JJ	O
after-school	JJ	O
program	NN	O
.	.	O

Physical	JJ	O
activity	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
an	DT	O
allogeneic	JJ	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
:	:	O
benefits	NNS	O
of	IN	O
a	DT	O
moderate	JJ	O
exercise	NN	O
intervention	NN	O
.	.	O

UNLABELLED	IN	O
An	DT	O
allogeneic	JJ	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
HSCT	NNP	O
)	)	O
can	MD	O
have	VB	O
profound	VBN	O
and	CC	O
lasting	JJ	O
adverse	JJ	O
effects	NNS	O
on	IN	O
a	DT	O
patient	NN	O
's	POS	O
physical	JJ	O
and	CC	O
psychological	JJ	O
well-being	NN	O
.	.	O

So	RB	O
far	RB	O
,	,	O
only	RB	O
few	JJ	O
studies	NNS	O
have	VBP	O
investigated	VBN	O
the	DT	O
effectiveness	NN	Ot
of	IN	O
physical	JJ	O
activity	NN	O
over	IN	O
the	DT	O
entire	JJ	O
inpatient	NN	O
phase	NN	O
of	IN	O
an	DT	O
allogeneic	JJ	O
HSCT	NNP	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
to	TO	O
examine	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
controlled	JJ	O
moderate	JJ	O
exercise	NN	O
program	NN	O
starting	VBG	O
parallel	JJ	O
to	TO	O
chemotherapeutic	JJ	O
conditioning	NN	O
and	CC	O
total	JJ	O
body	NN	O
irradiation	NN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
physical	JJ	O
and	CC	O
psychological	JJ	O
constitution	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty-seven	NNP	O
patients	NNS	O
undergoing	VBG	O
an	DT	O
allogeneic	JJ	O
HSCT	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
exercise	NN	O
group	NN	O
(	(	O
EG	NNP	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
CG	NNP	O
)	)	O
.	.	O

While	IN	O
the	DT	O
EG	NNP	O
took	VBD	O
part	NN	O
in	IN	O
an	DT	O
endurance	NN	O
and	CC	O
activity	NN	O
of	IN	O
daily	JJ	O
living-training	JJ	O
twice	NN	O
a	DT	O
day	NN	O
,	,	O
the	DT	O
CG	NNP	O
received	VBD	O
the	DT	O
clinic	NN	O
's	POS	O
standard	JJ	O
physiotherapy	NN	O
program	NN	O
once	RB	O
a	DT	O
day	NN	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
differences	VBZ	O
and/or	JJ	O
trends	NNS	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
EG	NNP	O
were	VBD	O
observed	VBN	O
regarding	VBG	O
the	DT	O
primary	JJ	O
endpoint	NN	O
endurance	NN	PH
performance	NN	PH
(	(	O
P=0.002	NNP	O
)	)	O
,	,	O
muscular	JJ	PH
strength	NN	PH
(	(	O
P=0.022	NNP	O
)	)	O
,	,	O
fatigue	NN	PH
(	(	O
P=0.046	NNP	O
)	)	O
,	,	O
and	CC	O
emotional	JJ	PH
state	NN	PH
(	(	O
P=0.028	NNP	O
)	)	O
without	IN	O
posing	VBG	O
an	DT	O
additional	JJ	O
risk	NN	O
for	IN	O
the	DT	O
individual	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
training	NN	O
program	NN	O
is	VBZ	O
feasible	JJ	O
and	CC	O
seems	VBZ	O
to	TO	O
have	VB	O
positive	JJ	O
influences	NNS	O
on	IN	O
physical	JJ	PH
performance	NN	PH
and	CC	PH
quality	NN	PH
of	IN	PH
life	NN	PH
in	IN	O
patients	NNS	O
undergoing	VBG	O
an	DT	O
allogeneic	JJ	O
HSCT	NNP	O
.	.	O

However	RB	O
,	,	O
further	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
confirm	VB	O
these	DT	O
results	NNS	O
.	.	O

Assessment	NN	O
of	IN	O
therapeutic	JJ	Ot
response	NN	O
of	IN	O
Plasmodium	NNP	O
falciparum	NN	O
to	TO	O
chloroquine	VB	O
and	CC	O
sulfadoxine-pyrimethamine	VB	O
in	IN	O
an	DT	O
area	NN	O
of	IN	O
low	JJ	O
malaria	NNS	O
transmission	NN	O
in	IN	O
Colombia	NNP	O
.	.	O

Although	IN	O
chloroquine	NN	O
(	(	O
CQ	NNP	O
)	)	O
resistance	NN	O
was	VBD	O
first	RB	O
reported	VBN	O
in	IN	O
Colombia	NNP	O
in	IN	O
1961	CD	O
and	CC	O
sulfadoxine-pyrimethamine	JJ	O
(	(	O
SP	NNP	O
)	)	O
resistance	NN	O
in	IN	O
1981	CD	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
treatment	NN	O
failures	NNS	O
to	TO	O
these	DT	O
drugs	NNS	O
in	IN	O
Colombia	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

A	DT	O
modified	JJ	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
14-day	JJ	O
in	IN	O
vivo	JJ	O
drug	NN	O
efficacy	NN	O
test	NN	O
for	IN	O
uncomplicated	JJ	O
Plasmodium	NNP	O
falciparum	NN	O
malaria	NN	O
in	IN	O
areas	NNS	O
with	IN	O
intense	JJ	O
malaria	NNS	O
transmission	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
epidemiologic	JJ	O
features	NNS	O
of	IN	O
a	DT	O
low-intensity	JJ	O
malaria	NN	O
transmission	NN	O
area	NN	O
in	IN	O
the	DT	O
Pacific	NNP	O
Coast	NNP	O
Region	NNP	O
of	IN	O
Colombia	NNP	O
.	.	O

Patients	NNPS	O
>	JJ	O
or	CC	O
=1	JJ	O
year	NN	O
of	IN	O
age	NN	O
with	IN	O
a	DT	O
parasite	JJ	O
density	NN	O
>	NN	O
or	CC	O
=1,000	CD	O
asexual	JJ	O
parasites	NNS	O
per	IN	O
microliter	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Forty-four	CD	O
percent	NN	O
(	(	O
24	CD	O
of	IN	O
54	CD	O
)	)	O
of	IN	O
the	DT	O
CQ-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	Ot
failures	NNS	Ot
,	,	O
including	VBG	O
7	CD	O
early	JJ	Ot
treatment	NN	Ot
failures	NNS	Ot
(	(	Ot
ETFs	NNP	Ot
)	)	PH
and	CC	O
17	CD	O
late	JJ	Ot
treatment	NN	Ot
failures	NNS	Ot
(	(	PH
LTFs	NNP	PH
)	)	PH
.	.	PH

Four	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
67	CD	O
SP-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	Ot
failures	NNS	Ot
(	(	O
2	CD	O
ETFs	NNP	O
and	CC	O
2	CD	O
LTFs	NNP	O
)	)	O
.	.	O

Therapeutic	JJ	Ot
failure	NN	Ot
in	IN	O
the	DT	O
CQ-treated	JJ	O
group	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
age	NN	O
<	VBD	O
15	CD	O
years	NNS	O
old	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
initial	JJ	O
parasite	JJ	O
density	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
CQ	NNP	O
or	CC	O
sulfa-containing	JJ	O
drugs	NNS	O
in	IN	O
urine	NN	O
,	,	O
or	CC	O
a	DT	O
history	NN	O
of	IN	O
malaria	NN	O
.	.	O

The	DT	O
high	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	Ot
failures	NNS	Ot
to	TO	O
CQ	NNP	O
detected	VBN	O
in	IN	O
this	DT	O
study	NN	O
underscores	VBZ	O
the	DT	O
need	NN	O
and	CC	O
importance	NN	O
of	IN	O
drug	NN	O
efficacy	NN	Ot
evaluation	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
rational	JJ	O
national	JJ	O
antimalarial	JJ	O
drug	NN	O
policy	NN	O
.	.	O

The	DT	O
relatively	RB	O
low	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	Ot
failures	NNS	Ot
to	TO	O
SP	NNP	O
compared	VBN	O
with	IN	O
other	JJ	O
South	JJ	O
American	JJ	O
countries	NNS	O
raises	VBZ	O
further	JJ	O
questions	NNS	O
regarding	VBG	O
factors	NNS	O
that	WDT	O
might	MD	O
have	VB	O
prevented	VBN	O
the	DT	O
rapid	JJ	O
development	NN	O
of	IN	O
in	IN	O
vivo	NN	O
resistance	NN	O
to	TO	O
this	DT	O
drug	NN	O
combination	NN	O
.	.	O

Use	NNP	O
of	IN	O
topical	JJ	O
selamectin	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Syphacia	NNP	O
muris	NNP	O
infection	NN	O
in	IN	O
laboratory	NN	O
rats	NNS	O
.	.	O

Efficacy	NN	Ot
of	IN	O
selamectin	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
naturally	RB	O
acquired	VBN	O
S.	NNP	O
muris	JJ	O
infections	NNS	O
in	IN	O
rats	NNS	O
.	.	O

Fourty-eight	JJ	O
S.	NNP	O
muris-positive	JJ	O
rats	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
six	CD	O
treated	JJ	O
and	CC	O
two	CD	O
control	NN	O
groups	NNS	O
.	.	O

Selamectin	NNP	O
(	(	O
6	CD	O
mg/kg	NN	O
)	)	O
was	VBD	O
applied	VBN	O
topically	RB	O
to	TO	O
the	DT	O
skin	NN	O
in	IN	O
a	DT	O
single	JJ	O
spot	NN	O
at	IN	O
the	DT	O
base	NN	O
of	IN	O
the	DT	O
neck	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
rats	NNS	O
of	IN	O
treated	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
necropsied	VBN	O
on	IN	O
the	DT	O
24th	CD	O
day	NN	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

Topical	NNP	O
selamectin	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
40.7-63.3	JJ	O
%	NN	O
effective	JJ	Ot
(	(	Ot
based	VBN	Ot
on	IN	Ot
egg	NN	Ot
per	IN	Ot
gram	NN	Ot
method	NN	Ot
)	)	Ot
in	IN	Ot
eliminating	VBG	Ot
S.	NNP	Ot
muris	JJ	PH
infection	NN	PH
in	IN	O
rats	NNS	O
.	.	O

The	DT	O
efficacy	NN	Ot
of	IN	Ot
the	DT	Ot
treatment	NN	Ot
against	IN	O
S.	NNP	O
muris	NNP	O
(	(	O
based	VBN	O
on	IN	O
adult	NN	O
worm	NN	O
counts	NNS	O
)	)	O
in	IN	O
male	NN	O
and	CC	O
female	JJ	O
rats	NNS	O
was	VBD	O
35.14-58.88	JJ	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
mean	JJ	O
48.39	CD	O
%	NN	O
)	)	O
.	.	O

Prospective	JJ	O
randomised	VBD	O
trial	NN	O
of	IN	O
amifostine	JJ	O
cytoprotection	NN	O
in	IN	O
myeloma	NN	O
patients	NNS	O
undergoing	VBG	O
high-dose	JJ	O
melphalan	NN	O
conditioned	VBN	O
autologous	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
multicentre	NN	O
trial	NN	O
,	,	O
90	CD	O
patients	NNS	O
undergoing	VBG	O
autologous	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
ASCT	NNP	O
)	)	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
(	(	O
n=43	NN	O
)	)	O
or	CC	O
not	RB	O
receive	JJ	O
(	(	O
n=47	JJ	O
)	)	O
amifostine	VBP	O
910	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
prior	RB	O
to	TO	O
melphalan	VB	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
regimen-related	JJ	PA
toxicity	NN	PA
,	,	PA
engraftment	NN	PA
,	,	PA
supportive	JJ	PA
care	NN	PA
,	,	PA
response	NN	PA
and	CC	PA
survival	NN	PA
.	.	PA

Both	DT	O
groups	NNS	O
underwent	VBD	O
ASCT	NNP	O
at	IN	O
a	DT	O
median	NN	O
of	IN	O
8	CD	O
months	NNS	O
from	IN	O
diagnosis	NN	O
and	CC	O
were	VBD	O
matched	VBN	O
for	IN	O
disease	NN	O
characteristics	NNS	O
,	,	O
prior	JJ	O
therapy	NN	O
and	CC	O
pre-ASCT	JJ	O
disease	NN	O
responsiveness	NN	O
.	.	O

Amifostine	NNP	O
infusional	JJ	O
side-effects	NNS	O
were	VBD	O
frequent	JJ	O
,	,	O
occurring	VBG	O
in	IN	O
65	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
but	CC	O
of	IN	O
mild	JJ	O
severity	NN	O
.	.	O

Amifostine	NNP	O
use	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	PA
in	IN	O
the	DT	O
median	JJ	ME
grade	NN	ME
of	IN	ME
oral	JJ	ME
mucositis	NN	ME
(	(	O
1	CD	O
vs	NN	O
2	CD	O
,	,	O
P=0.01	NNP	O
)	)	O
and	CC	O
the	DT	O
frequency	NN	ME
of	IN	ME
severe	JJ	ME
(	(	ME
WHO	NNP	ME
grades	VBZ	ME
3	CD	ME
or	CC	ME
4	CD	ME
)	)	ME
mucositis	NN	ME
(	(	O
12	CD	O
vs	RB	O
33	CD	O
%	NN	O
,	,	O
P=0.02	NNP	O
)	)	O
,	,	O
but	CC	O
no	DT	O
reduction	NN	O
in	IN	O
the	DT	O
requirement	NN	O
for	IN	O
parenteral	JJ	O
nutrition	NN	O
or	CC	O
analgesic	JJ	O
use	NN	O
.	.	O

Conversion	NN	O
to	TO	O
complete	VB	O
remission	NN	O
post-ASCT	NN	ME
occurred	VBD	O
in	IN	O
30	CD	O
and	CC	O
14	CD	O
%	NN	O
of	IN	O
the	DT	O
amifostine	NN	O
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.09	NNP	O
)	)	O
.	.	O

With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
35	CD	O
months	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
median	JJ	ME
progression-free	NN	ME
or	CC	ME
overall	JJ	ME
survival	NN	ME
times	NNS	ME
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
amifostine	NN	O
can	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
prior	RB	O
to	TO	O
high-dose	JJ	O
melphalan	NN	O
and	CC	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
frequency	NN	ME
and	CC	ME
severity	NN	ME
of	IN	ME
therapy-induced	JJ	ME
oral	JJ	ME
mucositis	NN	ME
.	.	ME

Treatment	NN	O
of	IN	O
acute	JJ	O
asthma	NN	O
.	.	O

Lack	NNP	O
of	IN	O
therapeutic	JJ	PH
benefit	NN	PH
and	CC	O
increase	NN	A
of	IN	A
the	DT	A
toxicity	NN	A
from	IN	O
aminophylline	JJ	O
given	VBN	O
in	IN	O
addition	NN	O
to	TO	O
high	JJ	O
doses	NNS	O
of	IN	O
salbutamol	NN	O
delivered	VBN	O
by	IN	O
metered-dose	JJ	O
inhaler	NN	O
with	IN	O
a	DT	O
spacer	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
intravenous	JJ	O
aminophylline	NN	O
adds	VBZ	O
any	DT	O
benefit	NN	O
to	TO	O
high	JJ	O
doses	NNS	O
of	IN	O
inhaled	JJ	O
salbutamol	NN	O
in	IN	O
patients	NNS	O
who	WP	O
presented	VBD	O
for	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
asthma	NN	O
.	.	O

We	PRP	O
studied	VBD	O
94	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
35.6	CD	O
+/-	JJ	O
11.2	CD	O
years	NNS	O
)	)	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
acute	JJ	O
asthma	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
therapy	NN	O
with	IN	O
salbutamol	NN	O
delivered	VBN	O
with	IN	O
metered-dose	JJ	O
inhaler	NN	O
(	(	O
MDI	NNP	O
)	)	O
into	IN	O
a	DT	O
spacer	NN	O
device	NN	O
(	(	O
Volumatic	NNP	O
)	)	O
in	IN	O
four	CD	O
puffs	NNS	O
(	(	O
400	CD	O
micrograms	NNS	O
)	)	O
at	IN	O
10-min	JJ	O
interval	NN	O
,	,	O
and	CC	O
intravenous	JJ	O
hydrocortisone	NN	O
(	(	O
500	CD	O
mg	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
loading	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
aminophylline	NN	O
followed	VBN	O
by	IN	O
a	DT	O
routine	JJ	O
infusion	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
placebo	NN	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
and	CC	O
infusion	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
showed	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
measurements	NNS	O
of	IN	O
peak	JJ	PH
expiratory	NN	PH
flow	NN	PH
,	,	O
FEV1	NNP	PH
,	,	O
and	CC	O
FVC	NNP	PH
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
aminophylline	NN	O
had	VBD	O
significantly	RB	O
more	RBR	O
adverse	JJ	A
effects	NNS	A
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
final	JJ	O
mean	NN	O
dose	NN	O
of	IN	O
salbutamol	NN	O
(	(	O
6.3	CD	O
+/-	JJ	O
44.5	CD	O
mg	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
5.8	CD	O
+/-	JJ	O
4.2	CD	O
mg	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
,	,	O
hospital	JJ	O
admission	NN	O
rate	NN	O
(	(	O
10.2	CD	O
percent	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
9.0	CD	O
percent	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
mean	JJ	O
duration	NN	O
of	IN	O
Emergency	NNP	O
Department	NNP	O
treatment	NN	O
(	(	O
2.5	CD	O
+/-	JJ	O
1.83	CD	O
h	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
2.37	CD	O
+/-	JJ	O
1.75	CD	O
h	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
similar	JJ	O
when	WRB	O
the	DT	O
patients	NNS	O
were	VBD	O
divided	VBN	O
in	IN	O
accord	NN	O
with	IN	O
the	DT	O
degree	NN	O
of	IN	O
respiratory	NN	PH
obstruction	NN	PH
(	(	O
baseline	JJ	O
FEV1	NNP	O
<	NNP	O
30	CD	O
percent	NN	O
of	IN	O
predicted	VBN	O
)	)	O
and	CC	O
theophylline	JJ	PH
level	NN	PH
at	IN	O
30	CD	O
min	NN	O
of	IN	O
treatment	NN	O
(	(	O
placebo	JJ	O
group	NN	O
patients	NNS	O
with	IN	O
theophylline	JJ	O
level	NN	O
<	VBD	O
10	CD	O
mg/L	NN	O
vs	NN	O
aminophylline	NN	O
group	NN	O
patients	NNS	O
with	IN	O
theophylline	JJ	O
level	NN	O
>	NN	O
or	CC	O
=	$	O
10	CD	O
mg/L	NN	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
intravenous	JJ	O
aminophylline	NN	O
adds	VBZ	O
to	TO	O
the	DT	O
toxicity	NN	A
but	CC	O
not	RB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
inhaled	JJ	O
salbutamol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
asthma	NN	O
.	.	O

Effects	NNS	O
of	IN	O
extended	JJ	O
release	NN	O
methylphenidate	NN	O
treatment	NN	O
on	IN	O
ratings	NNS	ME
of	IN	ME
attention-deficit/hyperactivity	NN	ME
disorder	NN	ME
(	(	ME
ADHD	NNP	ME
)	)	ME
and	CC	O
associated	VBN	ME
behavior	NN	ME
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
ADHD	NNP	O
symptoms	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
behavioral	JJ	ME
effects	NNS	ME
of	IN	O
four	CD	O
doses	NNS	O
of	IN	O
psychostimulant	JJ	O
medication	NN	O
,	,	O
combining	VBG	O
extended-release	JJ	O
methylphenidate	NN	O
(	(	O
MPH	NNP	O
)	)	O
in	IN	O
the	DT	O
morning	NN	O
with	IN	O
immediate-release	JJ	O
MPH	NNP	O
in	IN	O
the	DT	O
afternoon	NN	O
.	.	O

METHOD	NNP	O
The	DT	O
sample	NN	O
comprised	VBD	O
24	CD	O
children	NNS	O
(	(	O
19	CD	O
boys	NNS	O
;	:	O
5	CD	O
girls	NNS	O
)	)	O
who	WP	O
met	VBD	O
American	NNP	O
Psychiatric	NNP	O
Association	NNP	O
,	,	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4th	CD	O
ed	NN	O
.	.	O

(	(	O
DSM-IV-TR	NNP	O
)	)	O
criteria	NN	O
for	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
on	IN	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Interview-Revised	JJ	O
(	(	O
ADI-R	NNP	O
)	)	O
and	CC	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
(	(	O
ADOS	NNP	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
significant	JJ	O
symptoms	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
.	.	O

This	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
elementary	JJ	O
school-age	NN	O
,	,	O
community-based	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
chronological	JJ	O
age=8.8	NN	O
years	NNS	O
,	,	O
SD=1.7	NNP	O
;	:	O
mean	JJ	O
intelligence	NN	O
quotient	NN	O
[	NNP	O
IQ	NNP	O
]	NNP	O
=85	NNP	O
;	:	O
SD=16.8	NNP	O
)	)	O
.	.	O

Effects	NNS	O
of	IN	O
four	CD	O
dose	NN	O
levels	NNS	O
of	IN	O
MPH	NNP	O
on	IN	O
parent	NN	Ot
and	CC	Ot
teacher	RB	Ot
behavioral	JJ	Ot
ratings	NNS	Ot
were	VBD	O
investigated	VBN	O
using	VBG	O
a	DT	O
within-subject	JJ	O
,	,	O
crossover	NN	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
.	.	O

RESULTS	NNP	O
MPH	NNP	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
declines	NNS	O
in	IN	O
hyperactive	JJ	ME
and	CC	ME
impulsive	JJ	ME
behavior	NN	ME
at	IN	ME
both	DT	ME
home	NN	ME
and	CC	ME
school	NN	ME
.	.	O

Parents	NNS	O
noted	VBD	O
significant	JJ	O
declines	NNS	O
in	IN	O
inattentive	JJ	ME
and	CC	ME
oppositional	JJ	ME
behavior	NN	ME
,	,	O
and	CC	O
improvements	NNS	O
in	IN	O
social	JJ	ME
skills	NNS	ME
.	.	O

No	DT	O
exacerbation	NN	ME
of	IN	ME
stereotypies	NNS	ME
was	VBD	O
noted	VBN	O
,	,	O
and	CC	O
side	JJ	A
effects	NNS	A
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
seen	VBN	O
in	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
with	IN	O
ADHD	NNP	O
.	.	O

Dose	NNP	O
response	NN	O
was	VBD	O
primarily	RB	O
linear	JJ	O
in	IN	O
the	DT	O
dose	JJ	O
range	NN	O
studied	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
MPH	NNP	O
formulations	NNS	O
are	VBP	O
efficacious	JJ	Ot
and	CC	Ot
well-tolerated	JJ	Ot
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
significant	JJ	O
ADHD	NNP	O
symptoms	NNS	O
.	.	O

[	JJ	O
Therapeutic	NNP	O
efficacy	NN	O
of	IN	O
compound	NN	O
Xuanju	NNP	O
capsule	NN	O
on	IN	O
type	NN	O
III	NNP	O
prostatitis	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
Compound	NNP	O
Xuanju	NNP	O
Capsule	NNP	O
on	IN	O
type	NN	O
III	NNP	O
prostatitis	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
242	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
III	NNP	O
prostatitis	NN	O
diagnosed	VBN	O
by	IN	O
the	DT	O
NIH	NNP	O
criteria	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
an	DT	O
experimental	JJ	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
equal	JJ	O
number	NN	O
,	,	O
the	DT	O
former	JJ	O
treated	VBN	O
with	IN	O
Compound	NNP	O
Xuanju	NNP	O
Capsule	NNP	O
+	NNP	O
Tamsulosin	NNP	O
Hydrochloride	NNP	O
,	,	O
and	CC	O
the	DT	O
latter	NN	O
with	IN	O
Quinolinone	NNP	O
antibiotics	NNS	O
+	VBP	O
Tamsulosin	NNP	O
and	CC	O
Hydrochloride	NNP	O
,	,	O
both	DT	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
therapeutic	JJ	PH
effects	NNS	PH
based	VBN	PH
on	IN	PH
the	DT	PH
NIH-CPSI	JJ	PH
scores	NNS	PH
and	CC	O
the	DT	O
improvement	NN	A
of	IN	A
relevant	JJ	A
complications	NNS	A
.	.	O

RESULTS	NNP	O
All	PDT	O
the	DT	O
242	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
total	JJ	Ot
effectiveness	NN	Ot
rate	NN	Ot
was	VBD	O
77.69	CD	O
%	NN	O
(	(	O
94/121	CD	O
)	)	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
,	,	O
71.56	CD	O
%	NN	O
(	(	O
78/109	CD	O
)	)	O
in	IN	O
those	DT	O
with	IN	O
complications	NNS	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
it	PRP	O
was	VBD	O
only	RB	O
47.10	CD	O
%	NN	O
(	(	O
57/121	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
31.78	CD	O
%	NN	O
(	(	O
34/107	CD	O
)	)	O
in	IN	O
those	DT	O
with	IN	O
complications	NNS	O
.	.	O

Both	DT	O
the	DT	O
NIH-CPSI	NNP	PH
scores	NNS	PH
and	CC	O
the	DT	O
improvement	NN	A
of	IN	A
complications	NNS	A
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
experimental	JJ	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Compound	NNP	O
Xuanju	NNP	O
Capsule	NNP	O
has	VBZ	O
a	DT	O
good	JJ	O
therapeutic	JJ	O
effect	NN	O
on	IN	O
type	NN	O
III	NNP	O
prostatitis	NN	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
evaluating	VBG	O
the	DT	O
treatment	NN	O
of	IN	O
plantar	NN	O
fasciitis	NN	O
with	IN	O
an	DT	O
extracoporeal	NN	O
shockwave	NN	O
therapy	NN	O
(	(	O
ESWT	NNP	O
)	)	O
device	NN	O
:	:	O
a	DT	O
North	JJ	O
American	JJ	O
confirmatory	NN	O
study	NN	O
.	.	O

Despite	IN	O
numerous	JJ	O
publications	NNS	O
and	CC	O
clinical	JJ	O
trials	NNS	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
treatment	NN	O
of	IN	O
recalcitrant	JJ	O
chronic	JJ	O
plantar	NN	O
fasciitis	NN	O
with	IN	O
extracorporeal	JJ	O
shockwave	JJ	O
therapy	NN	O
(	(	O
ESWT	NNP	O
)	)	O
still	RB	O
remain	VBP	O
equivocal	JJ	O
as	IN	O
to	TO	O
whether	IN	O
or	CC	O
not	RB	O
this	DT	O
treatment	NN	O
provides	VBZ	O
relief	NN	Ot
from	IN	O
the	DT	PA
pain	NN	PA
associated	VBN	O
with	IN	O
this	DT	O
condition	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
extracorporeal	NN	O
shock	NN	O
wave	VBP	O
therapy	NN	O
can	MD	O
safely	RB	Ot
and	CC	O
effectively	RB	Ot
relieve	VB	Ot
the	DT	Ot
pain	NN	Ot
associated	VBN	O
with	IN	O
chronic	JJ	O
plantar	NN	O
fasciitis	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
treatment	NN	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
pain	NN	O
with	IN	O
walking	NN	O
in	IN	O
the	DT	O
morning	NN	O
.	.	O

This	DT	O
was	VBD	O
set	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
confirmatory	JJ	O
clinical	JJ	O
study	NN	O
undertaken	VBN	O
in	IN	O
four	CD	O
outpatient	NN	O
orthopedic	NN	O
clinics	NNS	O
.	.	O

The	DT	O
patients	NNS	O
,	,	O
114	CD	O
adult	NN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
plantar	NN	O
fasciitis	NN	O
,	,	O
recalcitrant	JJ	O
to	TO	O
conservative	JJ	O
therapies	NNS	O
for	IN	O
at	IN	O
least	JJS	O
6	CD	O
months	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
approximately	RB	O
3,800	CD	O
total	JJ	O
shock	NN	O
waves	NNS	O
(	(	O
+/-10	JJ	O
)	)	O
reaching	VBG	O
an	DT	O
approximated	JJ	O
total	NN	O
energy	NN	O
delivery	NN	O
of	IN	O
1,300	CD	O
mJ/mm	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
ED+	NNP	O
)	)	O
in	IN	O
a	DT	O
single	JJ	O
session	NN	O
versus	IN	O
placebo	NN	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
3	CD	O
months	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
outcome	NN	O
of	IN	O
pain	NN	PA
during	IN	O
the	DT	Ot
first	JJ	Ot
few	JJ	Ot
minutes	NNS	Ot
of	IN	O
walking	VBG	O
measured	VBN	O
by	IN	O
a	DT	O
visual	JJ	PA
analog	NN	PA
scale	NN	PA
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
participants	NNS	O
whose	WP$	O
changes	NNS	O
in	IN	O
Visual	NNP	PA
Analog	NNP	PA
Scale	NNP	PA
scores	VBZ	PA
met	VBD	O
the	DT	O
study	NN	O
definition	NN	O
of	IN	O
success	NN	O
at	IN	O
both	DT	O
6	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
posttreatment	NN	O
;	:	O
and	CC	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
3	CD	O
months	NNS	O
posttreatment	NN	O
in	IN	O
the	DT	O
Roles	NNP	PA
and	CC	PA
Maudsley	NNP	PA
Score	NNP	PA
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
confirm	VBP	O
that	IN	O
ESWT	NNP	O
administered	VBD	O
with	IN	O
the	DT	O
Dornier	NNP	O
Epos	NNP	O
Ultra	NNP	O
is	VBZ	O
a	DT	O
safe	JJ	Ot
and	CC	O
effective	JJ	Ot
treatment	NN	O
for	IN	O
recalcitrant	JJ	O
plantar	NN	O
fasciitis	NN	O
.	.	O

Relation	NN	O
of	IN	O
improvement	NN	O
in	IN	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
with	IN	O
atorvastatin	NN	O
to	TO	O
reductions	NNS	O
in	IN	O
hospitalizations	NNS	O
for	IN	O
heart	NN	O
failure	NN	O
(	(	O
from	IN	O
the	DT	O
Treating	NNP	O
to	TO	O
New	NNP	O
Targets	NNP	O
[	NNP	O
TNT	NNP	O
]	NNP	O
study	NN	O
)	)	O
.	.	O

Impaired	NNP	O
kidney	NN	O
function	NN	O
often	RB	O
accompanies	VBZ	O
heart	NN	O
failure	NN	O
(	(	O
HF	NNP	O
)	)	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
worse	JJR	O
prognosis	NN	O
.	.	O

This	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
of	IN	O
the	DT	O
Treating	NNP	O
to	TO	O
New	NNP	O
Targets	NNP	O
(	(	O
TNT	NNP	O
)	)	O
trial	NN	O
examined	VBD	O
whether	IN	O
the	DT	O
observed	JJ	O
decrease	NN	O
in	IN	O
HF	NNP	O
hospitalizations	NNS	O
with	IN	O
high-	JJ	O
compared	VBN	O
to	TO	O
low-dose	JJ	O
atorvastatin	NN	O
could	MD	O
be	VB	O
related	VBN	O
to	TO	O
improvements	NNS	O
in	IN	O
kidney	NN	O
function	NN	O
.	.	O

Of	IN	O
10,001	CD	O
TNT	NNP	O
participants	NNS	O
,	,	O
9,376	CD	O
had	VBD	O
estimated	VBN	O
glomerular	JJ	A
filtration	NN	A
rate	NN	A
(	(	A
eGFR	NN	A
)	)	A
measurements	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
1	CD	O
year	NN	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
analysis	NN	O
.	.	O

The	DT	O
association	NN	O
of	IN	O
change	NN	O
in	IN	O
year-1	JJ	O
eGFR	NN	O
and	CC	O
subsequent	JJ	O
HF	NNP	O
hospitalization	NN	O
was	VBD	O
examined	VBN	O
using	VBG	O
Cox	NNP	O
regression	NN	O
models	NNS	O
.	.	O

In	IN	O
total	JJ	O
218	CD	O
participants	NNS	O
developed	VBD	O
subsequent	JJ	O
HF	NNP	O
hospitalization	NN	O
.	.	O

Little	JJ	O
change	NN	O
in	IN	O
eGFR	NN	PA
occurred	VBD	O
over	IN	O
1	CD	O
year	NN	O
in	IN	O
the	DT	O
atorvastatin	JJ	O
10-mg	JJ	O
group	NN	O
,	,	O
whereas	IN	O
eGFR	NN	O
improved	VBN	O
in	IN	O
the	DT	O
80-mg	JJ	O
group	NN	O
by	IN	O
1.48	CD	O
ml/min/1.73	NNS	O
m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
1.29	CD	O
to	TO	O
1.67	CD	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Subsequent	JJ	O
HF	NNP	O
was	VBD	O
preceded	VBN	O
by	IN	O
a	DT	O
decrease	NN	O
in	IN	O
eGFR	NN	A
over	IN	O
1	CD	O
year	NN	O
compared	VBN	O
to	TO	O
modest	JJ	O
improvement	NN	O
in	IN	O
those	DT	O
without	IN	O
subsequent	JJ	O
HF	NNP	O
(	(	O
-0.09	NNP	O
?	.	O
7.89	CD	O
vs	NN	O
0.81	CD	O
?	.	O
6.90	CD	O
ml/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
p	JJ	O
=	NNP	O
0.0015	CD	O
)	)	O
.	.	O

After	IN	O
adjusting	VBG	O
for	IN	O
baseline	NN	O
eGFR	NN	O
,	,	O
each	DT	O
5-ml/min/1.73	JJ	O
m	NN	O
(	(	O
2	CD	O
)	)	O
increase	NN	O
in	IN	O
eGFR	NN	O
at	IN	O
1	CD	O
year	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
risk	NN	O
of	IN	O
subsequent	JJ	O
HF	NNP	O
hospitalization	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
0.85	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.77	CD	O
to	TO	O
0.94	CD	O
,	,	O
p	NN	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

This	DT	O
relation	NN	O
was	VBD	O
independent	JJ	O
of	IN	O
treatment	NN	O
effect	NN	O
or	CC	O
change	NN	O
in	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
level	NN	O
at	IN	O
1	CD	O
year	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
treatment	NN	O
with	IN	O
high-	JJ	O
compared	VBN	O
to	TO	O
low-dose	JJ	O
atorvastatin	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
improvement	NN	O
in	IN	O
eGFR	NN	O
at	IN	O
1	CD	O
year	NN	O
,	,	O
which	WDT	O
was	VBD	O
related	VBN	O
to	TO	O
a	DT	O
decrease	NN	O
in	IN	O
subsequent	JJ	O
HF	NNP	O
hospitalization	NN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	WDT	O
improvement	NN	O
in	IN	O
kidney	NN	O
function	NN	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
high-dose	JJ	O
atorvastatin	NN	O
on	IN	O
HF	NNP	O
hospitalization	NN	O
.	.	O

Serum	NNP	PH
bactericidal	NN	PH
activities	NNS	PH
and	CC	PH
comparative	JJ	Ot
pharmacokinetics	NNS	Ot
of	IN	O
meropenem	NN	O
and	CC	O
imipenem-cilastatin	NN	O
.	.	O

The	DT	O
pharmacokinetics	NNS	Ot
and	CC	PH
serum	NN	PH
bactericidal	NN	PH
activities	NNS	PH
(	(	PH
SBAs	NNP	PH
)	)	PH
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

Twelve	NNP	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
received	VBD	O
a	DT	O
constant	JJ	O
30-min	JJ	O
infusion	NN	O
of	IN	O
either	CC	O
1	CD	O
g	NN	O
of	IN	O
imipenem	JJ	O
plus	CC	O
1	CD	O
g	NN	O
of	IN	O
cilastatin	NN	O
or	CC	O
1	CD	O
g	NN	O
of	IN	O
meropenem	NN	O
.	.	O

The	DT	O
concentrations	NNS	PH
of	IN	PH
the	DT	PH
drugs	NNS	PH
in	IN	PH
serum	NN	PH
and	CC	PH
urine	NN	PH
were	VBD	O
determined	VBN	O
by	IN	O
bioassay	NN	Ot
and	CC	Ot
high-pressure	NN	Ot
liquid	NN	Ot
chromatography	NN	Ot
.	.	Ot

Pharmacokinetic	JJ	O
parameters	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
an	DT	O
open	JJ	O
two-compartment	JJ	O
model	NN	O
and	CC	O
a	DT	O
noncompartmental	JJ	O
technique	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
infusion	NN	O
,	,	O
the	DT	O
mean	JJ	PH
concentrations	NNS	PH
of	IN	PH
imipenem	NN	PH
and	CC	PH
meropenem	NN	PH
measured	VBN	PH
in	IN	PH
serum	NN	PH
were	VBD	O
61.2	CD	O
+/-	JJ	O
9.8	CD	O
and	CC	O
51.6	CD	O
+/-	JJ	O
6.5	CD	O
mg/liter	NN	O
,	,	O
respectively	RB	O
;	:	O
urinary	JJ	PH
recoveries	NNS	PH
were	VBD	O
48.6	CD	O
%	NN	O
+/-	JJ	O
8.2	CD	O
%	NN	O
and	CC	O
60.0	CD	O
%	NN	O
+/-	JJ	O
6.5	CD	O
%	NN	O
of	IN	O
the	DT	O
dose	NN	O
in	IN	O
12	CD	O
h	NN	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
the	DT	O
areas	NNS	PH
under	IN	PH
the	DT	PH
concentration-time	JJ	PH
curve	NN	PH
from	IN	O
time	NN	O
zero	CD	O
to	TO	O
infinity	NN	O
were	VBD	O
96.1	CD	O
+/-	JJ	O
14.4	CD	O
and	CC	O
70.5	CD	O
+/-	JJ	O
10.3	CD	O
mg.h/liter	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
or	CC	O
=	VB	O
0.02	CD	O
)	)	O
.	.	O

Imipenem	NNP	O
had	VBD	O
a	DT	O
mean	JJ	O
half-life	NN	O
of	IN	O
66.7	CD	O
+/-	JJ	O
10.4	CD	O
min	NN	O
;	:	O
that	IN	O
of	IN	O
meropenem	NN	O
was	VBD	O
64.4	CD	O
+/-	JJ	O
6.9	CD	O
min	NN	O
.	.	O

The	DT	O
volumes	NNS	O
of	IN	O
distribution	NN	O
at	IN	O
steady	JJ	O
state	NN	O
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
were	VBD	O
15.3	CD	O
+/-	JJ	O
3.3	CD	O
and	CC	O
18.6	CD	O
+/-	JJ	O
3.0	CD	O
liters/70	NN	O
kg	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
renal	JJ	O
clearances	NNS	O
per	IN	O
1.73	CD	O
m2	NNS	O
were	VBD	O
85.6	CD	O
+/-	JJ	O
17.6	CD	O
and	CC	O
144.6	CD	O
+/-	JJ	O
26.0	CD	O
ml/min	NN	O
,	,	O
respectively	RB	O
.	.	O

Both	DT	O
antibiotics	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
this	DT	O
single-dose	JJ	O
administration	NN	O
study	NN	O
.	.	O

The	DT	O
SBAs	NNP	PH
were	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
microdilution	NN	Ot
method	NN	Ot
of	IN	Ot
Reller	NNP	Ot
and	CC	Ot
Stratton	NNP	Ot
(	(	O
L.	NNP	O
B.	NNP	O
Reller	NNP	O
and	CC	O
C.	NNP	O
W.	NNP	O
Stratton	NNP	O
,	,	O
J.	NNP	O
Infect	NNP	O
.	.	O

Dis	NNP	O
.	.	O

136:196-204	CD	O
,	,	O
1977	CD	O
)	)	O
against	IN	O
40	CD	O
clinically	RB	O
isolated	JJ	O
strains	NNS	O
.	.	O

Mean	NNP	PH
reciprocal	JJ	PH
bactericidal	NN	PH
titers	NNS	PH
were	VBD	O
measured	VBN	O
1	CD	O
and	CC	O
6	CD	O
h	NN	O
after	IN	O
administration	NN	O
.	.	O

After	IN	O
1	CD	O
and	CC	O
6	CD	O
h	NN	O
the	DT	O
median	JJ	O
SBAs	NNP	PH
for	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
,	,	O
were	VBD	O
409	CD	O
and	CC	O
34.9	CD	O
and	CC	O
97.9	CD	O
and	CC	O
5.8	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Staphylococcus	NNP	O
aureus	NN	O
,	,	O
19.9	CD	O
and	CC	O
4.4	CD	O
and	CC	O
19.4	CD	O
and	CC	O
4.8	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Pseudomonas	NNP	O
aeruginosa	NN	O
,	,	O
34.3	CD	O
and	CC	O
2.2	CD	O
and	CC	O
232	CD	O
and	CC	O
15.5	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Enterobacter	NNP	O
cloacae	NN	O
,	,	O
and	CC	O
13.4	CD	O
and	CC	O
2.25	CD	O
and	CC	O
90.7	CD	O
and	CC	O
7.9	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Proteus	NNP	O
mirabilis	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
had	VBD	O
rather	RB	O
short	JJ	O
biological	JJ	O
elimination	NN	O
half-lives	NNS	Ot
and	CC	O
a	DT	O
predominantly	RB	O
renal	JJ	O
route	NN	O
of	IN	O
elimination	NN	O
.	.	O

Both	DT	O
carbapenems	NNS	O
revealed	VBD	O
high	JJ	O
SBAs	NNP	PH
against	IN	PH
clinically	RB	PH
important	JJ	PH
pathogens	NNS	PH
at	IN	O
1	CD	O
h	NN	O
;	:	O
meropenem	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
SBA	NNP	PH
against	IN	O
E.	NNP	O
cloacae	NN	O
and	CC	O
P.	NNP	O
mirabilis	NN	O
,	,	O
and	CC	O
the	DT	O
SBA	NNP	PH
of	IN	O
imipenem	NN	O
against	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
the	DT	O
SBA	NNP	O
of	IN	O
meropenem	NN	O
.	.	O

Study	NNP	O
protocol	NN	O
:	:	O
Phase	NNP	O
III	NNP	O
single-blinded	JJ	O
fast-track	JJ	O
pragmatic	NN	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
a	DT	O
complex	JJ	O
intervention	NN	O
for	IN	O
breathlessness	NN	PH
in	IN	PH
advanced	JJ	PH
disease	NN	PH
.	.	O

BACKGROUND	NNP	O
Breathlessness	NNP	O
in	IN	O
advanced	JJ	O
disease	NN	O
causes	VBZ	O
significant	JJ	O
distress	NN	PH
to	TO	PH
patients	NNS	PH
and	CC	O
carers	NNS	O
and	CC	O
presents	NNS	O
management	NN	O
challenges	VBZ	O
to	TO	O
health	NN	O
care	NN	O
professionals	NNS	O
.	.	O

The	DT	O
Breathlessness	NNP	O
Intervention	NNP	O
Service	NNP	O
(	(	O
BIS	NNP	O
)	)	O
seeks	VBZ	O
to	TO	O
improve	VB	O
the	DT	O
care	NN	PH
of	IN	PH
breathless	NN	PH
patients	NNS	PH
with	IN	O
advanced	JJ	O
disease	NN	O
(	(	O
regardless	NN	O
of	IN	O
cause	NN	O
)	)	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
evidence-based	JJ	O
practice	NN	O
and	CC	O
working	VBG	O
with	IN	O
other	JJ	O
healthcare	NN	O
providers	NNS	O
.	.	O

BIS	NNP	O
delivers	VBZ	O
a	DT	O
complex	JJ	O
intervention	NN	O
(	(	O
of	IN	O
non-pharmacological	JJ	O
and	CC	O
pharmacological	JJ	O
treatments	NNS	O
)	)	O
via	IN	O
a	DT	O
multi-professional	JJ	O
team	NN	O
.	.	O

BIS	NNP	O
is	VBZ	O
being	VBG	O
continuously	RB	O
developed	VBN	O
and	CC	O
its	PRP$	O
impact	NN	O
evaluated	VBN	O
using	VBG	O
the	DT	O
MRC	NNP	O
's	POS	O
framework	NN	O
for	IN	O
complex	JJ	O
interventions	NNS	O
(	(	O
PreClinical	NNP	O
,	,	O
Phase	NNP	O
I	PRP	O
and	CC	O
Phase	NNP	O
II	NNP	O
completed	VBD	O
)	)	O
.	.	O

This	DT	O
paper	NN	O
presents	VBZ	O
the	DT	O
protocol	NN	O
for	IN	O
Phase	NNP	O
III	NNP	O
.	.	O

METHODS/DESIGN	NNP	O
Phase	NNP	O
III	NNP	O
comprises	VBZ	O
a	DT	O
pragmatic	JJ	O
,	,	O
fast-track	JJ	O
,	,	O
single-blind	JJ	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
BIS	NNP	O
versus	FW	O
standard	NN	O
care	NN	O
.	.	O

Due	NNP	O
to	TO	O
differing	VBG	O
disease	NN	O
trajectories	NNS	O
,	,	O
the	DT	O
service	NN	O
uses	VBZ	O
two	CD	O
broad	JJ	O
service	NN	O
models	NNS	O
:	:	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
(	(	O
intervention	NN	O
delivered	VBN	O
over	IN	O
two	CD	O
weeks	NNS	O
)	)	O
and	CC	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
non-malignant	JJ	O
disease	NN	O
(	(	O
intervention	NN	O
delivered	VBN	O
over	IN	O
four	CD	O
weeks	NNS	O
)	)	O
.	.	O

The	DT	O
Phase	NNP	O
III	NNP	O
trial	NN	O
therefore	NN	O
consists	VBZ	O
of	IN	O
two	CD	O
sub-protocols	NNS	O
:	:	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
conditions	NNS	O
(	(	O
four	CD	O
week	NN	O
protocol	NN	O
)	)	O
and	CC	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
non-malignant	JJ	O
conditions	NNS	O
(	(	O
eight	CD	O
week	NN	O
protocol	NN	O
)	)	O
.	.	O

Mixed	JJ	O
method	NN	O
interviews	NNS	O
are	VBP	O
conducted	VBN	O
with	IN	O
patients	NNS	O
and	CC	O
their	PRP$	O
lay	NN	O
carers	NNS	O
at	IN	O
three	CD	O
to	TO	O
five	CD	O
measurement	NN	O
points	NNS	O
depending	VBG	O
on	IN	O
randomisation	NN	O
and	CC	O
sub-protocol	NN	O
.	.	O

Qualitative	JJ	O
interviews	NNS	O
are	VBP	O
conducted	VBN	O
with	IN	O
referring	VBG	O
and	CC	O
non-referring	JJ	O
health	NN	O
care	NN	O
professionals	NNS	O
(	(	O
malignant	JJ	O
disease	NN	O
protocol	NN	O
only	RB	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
is	VBZ	O
'patient	JJ	PH
distress	NN	PH
due	JJ	PH
to	TO	PH
breathlessness	VB	PH
'	''	PH
measured	VBN	PH
on	IN	PH
a	DT	PH
numerical	JJ	PH
rating	NN	PH
scale	NN	PH
(	(	PH
0-10	JJ	PH
)	)	PH
.	.	O

The	DT	O
trial	NN	O
includes	VBZ	O
economic	JJ	Ot
evaluation	NN	Ot
.	.	O

Analysis	NN	O
will	MD	O
be	VB	O
on	IN	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
basis	NN	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
breathlessness	NN	O
intervention	NN	O
for	IN	O
advanced	JJ	O
disease	NN	O
to	TO	O
have	VB	O
followed	VBN	O
the	DT	O
MRC	NNP	O
framework	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
palliative	JJ	O
care	NN	O
trials	NNS	O
to	TO	O
use	VB	O
fast	JJ	O
track	NN	O
methodology	NN	O
and	CC	O
single-blinding	NN	O
.	.	O

The	DT	O
results	NNS	O
will	MD	O
provide	VB	O
evidence	NN	O
of	IN	O
the	DT	O
clinical	JJ	Ot
and	CC	Ot
cost-effectiveness	NN	Ot
of	IN	Ot
the	DT	Ot
service	NN	Ot
,	,	O
informing	VBG	O
its	PRP$	O
longer	JJR	O
term	NN	O
development	NN	O
and	CC	O
implementation	NN	O
of	IN	O
the	DT	O
model	NN	O
in	IN	O
other	JJ	O
centres	NNS	O
nationally	RB	O
and	CC	O
internationally	RB	O
.	.	O

It	PRP	O
adds	VBZ	O
to	TO	O
methodological	JJ	O
developments	NNS	O
in	IN	O
palliative	JJ	O
care	NN	O
research	NN	O
where	WRB	O
complex	JJ	O
interventions	NNS	O
are	VBP	O
common	JJ	O
but	CC	O
evidence	NN	O
sparse	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
:	:	O
NCT00678405ISRCTN	NN	O
:	:	O
ISRCTN04119516	NNP	O
.	.	O

Carotid	NNP	O
sinus	CC	O
syndrome	NN	O
:	:	O
a	DT	O
modifiable	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
nonaccidental	JJ	PH
falls	NNS	PH
in	IN	O
older	JJR	O
adults	NNS	O
(	(	O
SAFE	NNP	O
PACE	NNP	O
)	)	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
cardiac	JJ	O
pacing	NN	O
reduces	NNS	O
falls	VBZ	PH
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
cardioinhibitory	JJ	O
carotid	NNS	O
sinus	VBP	O
hypersensitivity	NN	O
(	(	O
CSH	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Cardioinhibitory	NNP	O
carotid	NN	O
sinus	NN	O
syndrome	JJ	O
causes	NNS	O
syncope	NN	O
,	,	O
and	CC	O
symptoms	NNS	O
respond	NN	O
to	TO	O
cardiac	VB	O
pacing	NN	O
.	.	O

There	EX	O
is	VBZ	O
circumstantial	JJ	O
evidence	NN	O
for	IN	O
an	DT	O
association	NN	O
between	IN	O
falls	NNS	PH
and	CC	O
the	DT	O
syndrome	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
done	VBN	O
of	IN	O
consecutive	JJ	O
older	JJR	O
patients	NNS	O
(	(	O
>	JJ	O
50	CD	O
years	NNS	O
)	)	O
attending	VBG	O
an	DT	O
accident	NN	O
and	CC	O
emergency	NN	O
facility	NN	O
because	IN	O
of	IN	O
a	DT	O
non-accidental	JJ	PH
fall	NN	PH
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
dual-chamber	VB	O
pacemaker	NN	O
implant	NN	O
(	(	O
paced	JJ	O
patients	NNS	O
)	)	O
or	CC	O
standard	JJ	O
treatment	NN	O
(	(	O
controls	NNS	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
number	NN	PH
of	IN	PH
falls	NNS	PH
during	IN	PH
one	CD	PH
year	NN	PH
of	IN	PH
follow-up	NN	PH
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
seventy-five	JJ	O
eligible	JJ	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
73	CD	O
+/-	JJ	O
10	CD	O
years	NNS	O
;	:	O
60	CD	O
%	NN	O
women	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
trial	NN	O
:	:	O
pacemaker	NN	O
87	CD	O
;	:	O
controls	NNS	O
88	CD	O
.	.	O

Falls	NNP	PH
(	(	PH
without	IN	PH
loss	NN	PH
of	IN	PH
consciousness	NN	PH
)	)	PH
were	VBD	O
reduced	VBN	O
by	IN	O
two-thirds	NNS	O
:	:	O
controls	NNS	O
reported	VBD	O
669	CD	O
falls	NNS	O
(	(	O
mean	JJ	O
9.3	CD	O
;	:	O
range	NN	O
0	CD	O
to	TO	O
89	CD	O
)	)	O
,	,	O
and	CC	O
paced	VBD	O
patients	NNS	O
216	CD	O
falls	NNS	O
(	(	O
mean	JJ	O
4.1	CD	O
;	:	O
range	NN	O
0	CD	O
to	TO	O
29	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
paced	VBD	O
patients	NNS	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
fall	VB	PH
(	(	O
odds	NNS	O
ratio	VBP	O
0.42	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
0.23	CD	O
,	,	O
0.75	CD	O
)	)	O
than	IN	O
were	VBD	O
controls	NNS	O
.	.	O

Syncopal	JJ	PH
events	NNS	PH
were	VBD	O
also	RB	O
reduced	VBN	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
much	RB	O
fewer	JJR	O
syncopal	JJ	PH
events	NNS	PH
than	IN	O
falls-28	JJ	PH
episodes	NNS	O
in	IN	O
paced	JJ	O
patients	NNS	O
and	CC	O
47	CD	O
in	IN	O
controls	NNS	O
.	.	O

Injurious	JJ	PH
events	NNS	PH
were	VBD	O
reduced	VBN	O
by	IN	O
70	CD	O
%	NN	O
(	(	O
202	CD	O
in	IN	O
controls	NNS	O
compared	VBN	O
to	TO	O
61	CD	O
in	IN	O
paced	JJ	O
patients	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
a	DT	O
strong	JJ	O
association	NN	O
between	IN	O
non-accidental	JJ	PH
falls	NNS	O
and	CC	O
cardioinhibitory	NN	O
CSH	NNP	O
.	.	O

These	DT	O
patients	NNS	O
would	MD	O
not	RB	O
usually	RB	O
be	VB	O
referred	VBN	O
for	IN	O
cardiovascular	JJ	O
assessment	NN	O
.	.	O

Carotid	NNP	O
sinus	JJ	O
hypersensitivity	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
all	DT	O
older	JJR	O
adults	NNS	O
who	WP	O
have	VBP	O
non-accidental	JJ	O
falls	NNS	O
.	.	O

Additive	JJ	O
IOP-reducing	JJ	PH
effect	NN	PH
of	IN	O
latanoprost	NN	O
in	IN	O
patients	NNS	O
insufficiently	RB	O
controlled	VBN	O
on	IN	O
timolol	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
on	IN	O
intraocular	JJ	PH
pressure	NN	PH
(	(	PH
IOP	NNP	PH
)	)	PH
of	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
or	CC	O
adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
in	IN	O
patients	NNS	O
with	IN	O
open	JJ	O
angle	NN	O
glaucoma	NN	O
or	CC	O
ocular	JJ	O
hypertension	NN	O
where	WRB	O
IOP	NNP	PH
is	VBZ	O
not	RB	O
adequately	RB	O
controlled	VBN	O
with	IN	O
timolol	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
6-week	JJ	O
,	,	O
double-masked	JJ	O
,	,	O
randomised	VBD	O
multi-centre	NN	O
study	NN	O
.	.	O

53	CD	O
patients	NNS	O
with	IN	O
primary	JJ	O
open	JJ	O
angle	NN	O
glaucoma	NN	O
,	,	O
capsular	JJ	O
glaucoma	NN	O
,	,	O
or	CC	O
ocular	JJ	O
hypertension	NN	O
with	IN	O
an	DT	O
IOP	NNP	O
of	IN	O
at	IN	O
least	JJS	O
21	CD	O
mmHg	NN	O
on	IN	O
current	JJ	O
therapy	NN	O
were	VBD	O
recruited	VBN	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
on	IN	O
timolol	NN	O
,	,	O
5	CD	O
mg/ml	NN	O
twice	RB	O
daily	RB	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
continued	VBD	O
on	IN	O
timolol	NN	O
,	,	O
one	CD	O
switched	VBN	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
50	CD	O
microg/ml	NN	O
once	RB	O
daily	JJ	O
,	,	O
and	CC	O
a	DT	O
third	JJ	O
group	NN	O
received	VBD	O
latanoprost	RB	O
in	IN	O
addition	NN	O
to	TO	O
timolol	VB	O
.	.	O

The	DT	O
efficacy	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
comparing	VBG	O
IOP	NNP	PH
at	IN	O
9	CD	O
AM	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
IOP	NNP	PH
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SEM	NNP	O
)	)	O
were	VBD	O
24.2	CD	O
+/-	JJ	O
0.9	CD	O
and	CC	O
23.8	CD	O
+/-	JJ	O
1.0	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
for	IN	O
patients	NNS	O
continuing	VBG	O
on	IN	O
timolol	NN	O
,	,	O
26.3	CD	O
+/-	JJ	O
1.2	CD	O
and	CC	O
19.6	CD	O
+/-	JJ	O
1.1	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
switching	VBG	O
to	TO	O
latanoprost	VB	O
,	,	O
and	CC	O
23.2	CD	O
+/-	JJ	O
1.0	CD	O
and	CC	O
17.5	CD	O
+/-	JJ	O
0.8	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
combined	JJ	O
treatment	NN	O
.	.	O

Adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
reduced	VBN	O
IOP	NNP	PH
with	IN	O
5.9	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
reduced	VBN	O
IOP	NNP	PH
with	IN	O
5.0	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
caused	VBD	O
in	IN	O
each	DT	O
group	NN	O
a	DT	O
significant	JJ	O
IOP	NNP	PH
reduction	NN	O
of	IN	O
about	RB	O
25	CD	O
%	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
effect	NN	O
of	IN	O
latanoprost	NN	O
was	VBD	O
additive	JJ	O
to	TO	O
that	DT	O
of	IN	O
timolol	NN	O
,	,	O
and	CC	O
a	DT	O
good	JJ	O
effect	NN	O
on	IN	O
IOP	NNP	PH
reduction	NN	O
was	VBD	O
also	RB	O
achieved	VBN	O
by	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
switch	NN	O
in	IN	O
many	JJ	O
patients	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
combination	NN	O
treatment	NN	O
.	.	O

[	NN	O
Study	NNP	O
on	IN	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
oral	JJ	O
poliomyelitis	NN	O
attenuated	VBD	O
live	JJ	O
vaccine	NN	O
(	(	O
human	JJ	O
diploid	NN	O
cell	NN	O
)	)	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Ot
and	CC	O
Immunogenicity	NNP	PH
of	IN	O
the	DT	O
Poliomyelitis	NNP	O
vaccine	NN	O
(	(	O
Human	NNP	O
Diploid	NNP	O
Cell	NNP	O
)	)	O
in	IN	O
>	NN	O
or	CC	O
=2	VB	O
month-old	JJ	O
children	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
random	NN	O
,	,	O
blind	NN	O
and	CC	O
control	NN	O
trial	NN	O
,	,	O
1200	CD	O
healthy	JJ	O
children	NNS	O
of	IN	O
2-5	JJ	O
months	NNS	O
old	JJ	O
in	IN	O
Jiangsu	NNP	O
province	NN	O
were	VBD	O
administered	VBN	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
and	CC	O
control	NN	O
vaccines	NNS	O
.	.	O

The	DT	O
antibody	NN	O
was	VBD	O
tested	VBN	O
by	IN	O
neutralization	NN	O
test	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
3	CD	O
doses	NNS	O
of	IN	O
the	DT	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
,	,	O
the	DT	O
systemic	JJ	PH
reactions	NNS	PH
were	VBD	O
mild	JJ	O
.	.	O

After	IN	O
1	CD	O
month	NN	O
of	IN	O
vaccination	NN	O
with	IN	O
3	CD	O
doses	NNS	O
of	IN	O
the	DT	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
,	,	O
the	DT	O
immune	JJ	PH
success	NN	PH
rates	NNS	PH
of	IN	PH
I	PRP	PH
,	,	PH
II	NNP	PH
,	,	PH
III	NNP	PH
type	NN	PH
were	VBD	O
98.28	CD	O
%	NN	O
,	,	O
99.45	CD	O
%	NN	O
,	,	O
and	CC	O
95.71	CD	O
%	NN	O
respectively	RB	O
,	,	O
the	DT	O
GMTs	NNP	PH
of	IN	PH
I	PRP	PH
,	,	PH
II	NNP	PH
,	,	PH
III	NNP	PH
type	NN	PH
in	IN	O
susceptible	JJ	O
children	NNS	O
were	VBD	O
1:1243.72	CD	O
,	,	O
1:234.38	CD	O
and	CC	O
1:273.10	CD	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
was	VBD	O
safe	JJ	O
and	CC	O
immunogenicity	NN	O
for	IN	O
the	DT	O
children	NNS	O
>	VBP	O
or	CC	O
=2	JJ	O
months	NNS	O
old	JJ	O
.	.	O

Influence	NN	O
of	IN	O
lime	NN	O
juice	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
sickle	NN	O
cell	NN	O
anemia	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
OBJECTIVES	NNP	O
The	DT	O
pain	NN	O
in	IN	O
sickle	NN	O
cell	NN	O
anemia	NN	O
(	(	O
SCA	NNP	O
)	)	O
is	VBZ	O
often	RB	O
triggered	VBN	O
by	IN	O
dehydration	NN	O
,	,	O
acidosis	NN	O
,	,	O
and	CC	O
fever	NN	O
that	WDT	O
are	VBP	O
usually	RB	O
due	JJ	O
to	TO	O
malaria	VB	O
.	.	O

Intake	NNP	O
of	IN	O
lime	JJ	O
juice	NN	O
was	VBD	O
recently	RB	O
demonstrated	VBN	O
to	TO	O
facilitate	VB	O
clearance	NN	O
of	IN	O
the	DT	O
malaria	NN	O
parasite	NN	O
.	.	O

It	PRP	O
was	VBD	O
therefore	RB	O
sought	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
regular	JJ	O
intake	NN	O
of	IN	O
lime	JJ	O
juice	NN	O
will	MD	O
ameliorate	VB	O
crisis	NN	O
,	,	O
especially	RB	O
recurrent	JJ	PA
bone	NN	PA
pain	NN	PA
.	.	PA

DESIGN	NN	O
In	IN	O
this	DT	O
preliminary	JJ	O
,	,	O
open-labeled	JJ	O
,	,	O
randomized	JJ	O
study	NN	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
lime	JJ	O
juice	NN	O
on	IN	O
the	DT	O
clinical	JJ	O
and	CC	O
some	DT	O
laboratory	JJ	O
characteristics	NNS	O
of	IN	O
children	NNS	O
with	IN	O
SCA	NNP	O
were	VBD	O
tested	VBN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
113	CD	O
children	NNS	O
with	IN	O
SCA	NNP	O
studied	VBN	O
in	IN	O
two	CD	O
hospitals	NNS	O
,	,	O
the	DT	O
58	CD	O
receiving	NN	O
lime	NN	O
treatment	NN	O
had	VBD	O
lower	JJR	O
rates	NNS	O
of	IN	O
significant	JJ	PA
painful	JJ	PA
episodes	NNS	PA
than	IN	O
the	DT	O
55	CD	O
without	IN	O
lime	NN	O
(	(	O
37	CD	O
versus	NN	O
83	CD	O
crises	NNS	O
in	IN	O
6	CD	O
months	NNS	O
,	,	O
and	CC	O
0.64?0.11	CD	O
versus	NN	O
1.51?0.34	CD	O
average	JJ	O
rates	NNS	O
per	IN	O
child	NN	O
,	,	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
fewer	JJR	O
subjects	NNS	O
than	IN	O
the	DT	O
controls	NNS	O
had	VBD	O
significant	JJ	O
painful	JJ	O
episodes	NNS	O
(	(	O
50.0	CD	O
%	NN	O
versus	IN	O
92.7	CD	O
%	NN	O
)	)	O
;	:	O
febrile	JJ	O
illness	NN	O
(	(	O
46.6	CD	O
%	NN	O
versus	IN	O
87.3	CD	O
%	NN	O
)	)	O
and	CC	O
admission	NN	O
rate	NN	O
(	(	O
3.4	CD	O
%	NN	O
versus	IN	O
34.5	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
hematocrit	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
(	(	O
26.23?2.03	CD	O
%	NN	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
also	RB	O
higher	JJR	O
,	,	O
p	JJ	O
<	NN	O
0.001	CD	O
.	.	O

However	RB	O
,	,	O
transfusion	NN	O
rate	NN	O
,	,	O
presence	NN	O
of	IN	O
hepatomegaly	NN	O
,	,	O
splenomegaly	NN	O
,	,	O
and	CC	O
jaundice	NN	O
was	VBD	O
similar	JJ	O
.	.	O

Treatment	NN	O
with	IN	O
lime	NN	O
did	VBD	O
not	RB	O
cause	VB	O
any	DT	O
significant	JJ	O
side-effect	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Regular	NNP	O
intake	NN	O
of	IN	O
lime	JJ	O
juice	NN	O
may	MD	O
be	VB	O
of	IN	O
great	JJ	O
therapeutic	JJ	O
and	CC	O
nutritional	JJ	O
relevance	NN	O
in	IN	O
children	NNS	O
with	IN	O
SCA	NNP	O
.	.	O

Inflammatory	JJ	O
response	NN	O
in	IN	O
humans	NNS	O
exposed	VBN	O
to	TO	O
2.0	CD	O
ppm	NNS	O
nitrogen	JJ	O
dioxide	NN	O
.	.	O

Nitrogen	NNP	O
dioxide	NN	O
(	(	O
NO2	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
indoor	NN	O
air	NN	O
pollutant	NN	O
,	,	O
especially	RB	O
in	IN	O
homes	NNS	O
with	IN	O
unvented	JJ	O
combustion	NN	O
appliances	NNS	O
.	.	O

Epidemiological	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
children	NNS	O
living	VBG	O
in	IN	O
homes	NNS	O
with	IN	O
unvented	JJ	O
heating	NN	O
sources	NNS	O
are	VBP	O
more	JJR	O
prone	NN	O
to	TO	O
respiratory	NN	O
infections	NNS	O
than	IN	O
children	NNS	O
living	VBG	O
in	IN	O
homes	NNS	O
with	IN	O
lower	JJR	O
levels	NNS	O
of	IN	O
NO2	NNP	O
.	.	O

However	RB	O
,	,	O
experimental	JJ	O
studies	NNS	O
in	IN	O
which	WDT	O
human	JJ	O
volunteers	NNS	O
were	VBD	O
exposed	VBN	O
acutely	RB	O
to	TO	O
moderate	JJ	O
levels	NNS	O
of	IN	O
NO2	NNP	O
(	(	O
0.5-2.0	JJ	O
ppm	NN	O
)	)	O
have	VBP	O
shown	VBN	O
little	JJ	O
evidence	NN	O
of	IN	O
lung	NN	O
inflammation	NN	O
or	CC	O
decreased	VBN	O
host	NN	O
resistance	NN	O
capacity	NN	O
.	.	O

In	IN	O
the	DT	O
study	NN	O
reported	VBD	O
here	RB	O
,	,	O
8	CD	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
2.0	CD	O
ppm	NN	O
NO2	NNP	O
and	CC	O
to	TO	O
filtered	VB	O
air	NN	O
for	IN	O
4	CD	O
h	NNS	O
while	IN	O
undergoing	VBG	O
intermittent	JJ	O
moderate	JJ	O
exercise	NN	O
.	.	O

Bronchoalveolar	JJ	O
lavage	NN	O
was	VBD	O
performed	VBN	O
the	DT	O
following	JJ	O
morning	NN	O
.	.	O

The	DT	O
lavage	NN	O
was	VBD	O
divided	VBN	O
into	IN	O
a	DT	O
predominantly	RB	O
bronchial	JJ	O
washing	NN	O
(	(	O
first	JJ	O
20	CD	O
ml	NN	O
of	IN	O
lavage	NN	O
;	:	O
BL	NNP	O
)	)	O
and	CC	O
a	DT	O
predominantly	RB	O
alveolar	JJ	O
washing	NN	O
(	(	O
BAL	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
BL	NNP	O
,	,	O
NO2	NNP	PH
exposure	NN	PH
caused	VBD	O
increases	NNS	O
in	IN	O
polymorphonuclear	JJ	PH
neutrophils	NNS	PH
(	(	PH
PMNs	NNP	PH
)	)	PH
,	,	PH
interleukin	JJ	PH
6	CD	PH
(	(	PH
IL-6	NNP	PH
)	)	PH
,	,	PH
IL-8	NNP	PH
,	,	PH
alpha1-antitrypsin	NN	PH
,	,	PH
and	CC	PH
tissue	NN	PH
plasminogen	NN	PH
activator	NN	PH
,	,	O
and	CC	O
decreases	NNS	O
in	IN	O
epithelial	JJ	PH
cells	NNS	PH
.	.	PH

In	IN	O
the	DT	O
BAL	NNP	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
NO2-induced	JJ	O
changes	NNS	O
in	IN	O
either	DT	O
cell	NN	PH
numbers	NNS	PH
or	CC	PH
soluble	JJ	PH
mediators	NNS	PH
.	.	PH

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
alveolar	JJ	O
macrophages	NNS	O
from	IN	O
BAL	NNP	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
ability	NN	O
to	TO	O
phagocytose	VB	PH
unopsonized	JJ	PH
Candida	NNP	PH
albicans	NNS	PH
and	CC	O
a	DT	O
decrease	NN	O
in	IN	O
superoxide	JJ	PH
production	NN	PH
.	.	PH

No	DT	O
difference	NN	O
in	IN	O
susceptibility	NN	PH
to	TO	PH
virus	VB	PH
infection	NN	PH
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
NO2-	NNP	O
and	CC	O
air-exposed	JJ	O
macrophages	NNS	O
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
lung	NN	O
function	NN	O
were	VBD	O
observed	VBN	O
,	,	O
but	CC	O
the	DT	O
aerosol	JJ	O
bolus	JJ	O
recovery	NN	O
technique	NN	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
decrease	NN	O
in	IN	O
the	DT	O
fraction	NN	O
of	IN	O
aerosol	NN	O
recovered	VBD	O
following	VBG	O
nitrogen	NN	O
dioxide	NN	O
exposure	NN	O
,	,	O
which	WDT	O
is	VBZ	O
suggestive	JJ	O
of	IN	O
small	JJ	O
obstructive	JJ	O
changes	NNS	O
induced	VBN	O
by	IN	O
NO2	NNP	O
.	.	O

Lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
warfarin	NN	O
on	IN	O
the	DT	O
restenosis	NN	PH
rate	NN	PH
or	CC	O
on	IN	O
clinical	JJ	O
outcome	NN	O
after	IN	O
balloon	NN	O
coronary	JJ	O
angioplasty	NN	O
.	.	O

Between	NNP	O
September	NNP	O
1985	CD	O
and	CC	O
April	NNP	O
1987	CD	O
,	,	O
110	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
successful	JJ	O
coronary	JJ	O
angioplasty	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
prospective	NN	O
controlled	VBN	O
evaluation	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
warfarin	NN	O
on	IN	O
restenosis	NN	O
.	.	O

The	DT	O
warfarin	NN	O
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
and	CC	O
the	DT	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
groups	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
previous	JJ	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
or	CC	O
coronary	JJ	O
balloon	NN	O
angioplasty	NN	O
,	,	O
severity	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
and	CC	O
frequency	NN	O
of	IN	O
multivessel	JJ	O
disease	NN	O
or	CC	O
of	IN	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
.	.	O

Warfarin	NNP	O
was	VBD	O
started	VBN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
procedure	NN	O
and	CC	O
the	DT	O
dosage	NN	O
was	VBD	O
adjusted	VBN	O
to	TO	O
maintain	VB	O
the	DT	O
thromboplastin	JJ	O
international	JJ	O
normalised	VBN	O
ratio	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
2.5	CD	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
five	CD	O
(	(	O
96	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
verapamil	NNS	O
and	CC	O
other	JJ	O
antianginal	JJ	O
drugs	NNS	O
were	VBD	O
prescribed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Low	JJ	O
molecular	JJ	O
weight	NN	O
dextran	NN	O
and	CC	O
heparin	NN	O
were	VBD	O
given	VBN	O
during	IN	O
the	DT	O
procedure	NN	O
and	CC	O
heparin	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
24	CD	O
hours	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eight	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
clinically	RB	O
after	IN	O
a	DT	O
median	NN	O
of	IN	O
five	CD	O
months	NNS	O
(	(	O
range	VB	O
1-20	CD	O
)	)	O
.	.	O

Eighty	NNP	O
five	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
had	VBD	O
follow	VBN	O
up	RP	O
angiography	NN	O
at	IN	O
five	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
symptoms	NNS	PH
improved	VBN	Ot
in	IN	O
46	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
patients	NNS	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
angina	JJ	O
class	NN	O
and	CC	O
31	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
were	VBD	O
symptom	JJ	Ot
free	JJ	Ot
;	:	O
the	DT	O
exercise	NN	O
test	NN	O
remained	VBD	O
positive	JJ	O
in	IN	O
20	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
the	DT	O
angiographic	JJ	PH
restenosis	NN	PH
rate	NN	PH
was	VBD	O
25	CD	O
%	NN	O
per	IN	O
lesion	NN	O
and	CC	O
29	CD	O
%	NN	O
per	IN	O
patient	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
major	JJ	A
bleeding	NN	A
complications	NNS	A
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
46	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
patients	NNS	O
were	VBD	O
improved	VBN	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
angina	JJ	O
class	NN	O
and	CC	O
31	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
were	VBD	O
symptom	JJ	O
free	JJ	O
;	:	O
the	DT	O
exercise	NN	Ot
test	NN	Ot
was	VBD	O
positive	JJ	O
in	IN	O
11	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
the	DT	O
angiographic	JJ	PH
restenosis	NN	PH
rate	NN	PH
was	VBD	O
33	CD	O
%	NN	O
per	IN	O
lesion	NN	O
and	CC	O
37	CD	O
%	NN	O
per	IN	O
patient	NN	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
angiographic	JJ	O
restenosis	NN	O
tended	VBD	O
to	TO	O
be	VB	O
lower	JJR	O
with	IN	O
warfarin	NN	O
,	,	O
none	NN	O
of	IN	O
these	DT	O
differences	NNS	O
was	VBD	O
significant	JJ	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
verapamil	NN	O
and	CC	O
warfarin	NN	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
aspirin	NN	O
,	,	O
is	VBZ	O
not	RB	O
significantly	RB	O
better	JJR	O
than	IN	O
verapamil	NN	O
alone	RB	O
in	IN	O
preventing	VBG	O
symptom	JJ	O
recurrence	NN	O
or	CC	O
angiographic	JJ	PH
restenosis	NN	PH
after	IN	O
coronary	JJ	O
angioplasty	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	O
computer	NN	O
intervention	NN	O
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
to	TO	O
recognize	VB	O
and	CC	O
predict	VB	O
emotions	NNS	O
in	IN	O
others	NNS	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
looked	VBD	O
at	IN	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
new	JJ	O
computer	NN	O
program	NN	O
designed	VBN	O
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
to	TO	O
better	JJR	O
recognize	VB	O
and	CC	O
predict	VBP	O
emotional	JJ	O
responses	NNS	O
in	IN	O
others	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
11	CD	O
children	NNS	O
(	(	O
age	NN	O
12-18	CD	O
)	)	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
at	IN	O
two	CD	O
special	JJ	O
schools	NNS	O
participated	VBD	O
:	:	O
one	CD	O
group	NN	O
used	VBD	O
the	DT	O
computer	NN	O
program	NN	O
for	IN	O
10	CD	O
half-hour	JJ	O
sessions	NNS	O
over	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Within-program	NNP	O
data	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
errors	NNS	O
made	VBN	O
from	IN	O
first	JJ	O
to	TO	O
last	JJ	O
use	NN	O
.	.	O

Students	NNS	O
were	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
using	VBG	O
facial	JJ	ME
expression	NN	ME
photographs	NN	ME
,	,	Ot
cartoons	NNS	ME
depicting	VBG	ME
emotion-laden	JJ	ME
situations	NNS	ME
,	,	Ot
and	CC	Ot
non-literal	JJ	ME
stories	NNS	ME
.	.	O

Scores	NNS	O
were	VBD	O
not	RB	O
related	VBN	O
to	TO	O
age	NN	O
or	CC	O
verbal	JJ	O
ability	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
made	VBD	O
gains	NNS	O
relative	JJ	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
all	DT	O
three	CD	O
measures	NNS	O
.	.	O

Gains	NNP	O
correlated	VBD	O
significantly	RB	O
with	IN	O
the	DT	O
number	NN	O
of	IN	O
times	NNS	O
the	DT	O
computer	NN	O
program	NN	O
was	VBD	O
used	VBN	O
and	CC	O
results	NNS	O
suggest	VBP	O
positive	JJ	O
effects	NNS	O
.	.	O

Further	NNP	O
research	NN	O
could	MD	O
assess	VB	O
whether	IN	O
these	DT	O
gains	NNS	O
generalized	VBD	O
into	IN	O
real	JJ	O
life	NN	O
or	CC	O
improved	VBN	O
performance	NN	O
on	IN	O
theory	NN	O
of	IN	O
mind	NN	O
measures	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
AMSA	NNP	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

A	DT	O
Pediatric	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

One	CD	O
hundred	VBD	O
four	CD	O
children	NNS	O
with	IN	O
advanced	JJ	O
leukemia	NN	O
in	IN	O
relapse	NN	O
(	(	O
74	CD	O
with	IN	O
acute	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
[	NNP	O
ALL	NNP	O
]	NNP	O
and	CC	O
30	CD	O
with	IN	O
acute	JJ	O
nonlymphocytic	JJ	O
leukemia	NN	O
[	NNP	O
ANLL	NNP	O
]	NNP	O
)	)	O
received	VBD	O
AMSA	NNP	O
(	(	O
4'-	JJ	O
(	(	O
9-Acridinylamino	CD	O
)	)	O
methanesulfon	FW	O
-m-anisidide	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
120	CD	O
mg/m2/day	NN	O
for	IN	O
5	CD	O
days	NNS	O
(	(	O
Regimen	NNP	O
I	PRP	O
)	)	O
or	CC	O
60	CD	O
mg/m2/day	NN	O
for	IN	O
10	CD	O
days	NNS	O
(	(	O
Regimen	NNP	O
II	NNP	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
ALL	NNP	O
were	VBD	O
randomized	VBN	O
between	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
(	(	O
31	CD	O
and	CC	O
36	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

All	DT	O
29	CD	O
evaluable	JJ	O
patients	NNS	O
with	IN	O
ANLL	NNP	O
were	VBD	O
treated	VBN	O
on	IN	O
Regimen	NNP	O
I.	NNP	O
Eighty-eight	NNP	O
percent	NN	O
of	IN	O
evaluable	JJ	O
patients	NNS	O
experienced	VBD	O
severe	JJ	A
or	CC	A
life-threatening	JJ	A
toxicity	NN	A
,	,	O
with	IN	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
.	.	O

Bacterial	NNP	A
or	CC	A
fungal	JJ	A
infections	NNS	A
(	(	O
considered	VBN	O
life-threatening	NN	O
or	CC	O
fatal	NN	O
)	)	O
occurred	VBD	O
in	IN	O
17	CD	O
children	NNS	O
with	IN	O
ALL	DT	O
and	CC	O
in	IN	O
7	CD	O
with	IN	O
ANLL	NNP	O
.	.	O

Fatal	NNP	A
cardiac	JJ	A
toxicity	NN	A
occurred	VBD	O
in	IN	O
one	CD	O
patient	NN	O
.	.	O

Complete	NNP	PH
or	CC	PH
partial	JJ	PH
response	NN	PH
occurred	VBD	O
in	IN	O
25.0	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.8	CD	O
%	NN	O
)	)	O
,	,	O
28.1	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.0	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
25.9	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.4	CD	O
%	NN	O
)	)	O
of	IN	O
evaluable	JJ	O
patients	NNS	O
on	IN	O
ALL	NNP	O
Regimen	NNP	O
I	PRP	O
,	,	O
ALL	DT	O
Regimen	NNP	O
II	NNP	O
,	,	O
and	CC	O
ANLL	NNP	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
responses	NNS	PH
were	VBD	O
of	IN	O
short	JJ	O
duration	NN	O
(	(	O
16-91	JJ	O
days	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
duration	NN	MO
of	IN	MO
survival	NN	MO
from	IN	O
treatment	NN	O
start	NN	O
for	IN	O
the	DT	O
two	CD	O
ALL	DT	O
regimens	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.46	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	MO
duration	NN	MO
of	IN	MO
survival	NN	MO
for	IN	O
ANLL	NNP	O
patients	NNS	O
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
than	IN	O
that	DT	O
of	IN	O
ALL	NNP	O
patients	NNS	O
treated	VBD	O
on	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
combined	VBD	O
.	.	O

Eighty-two	JJ	O
percent	NN	O
of	IN	O
the	DT	O
complete	JJ	O
or	CC	O
partial	JJ	O
responses	NNS	O
(	(	O
18	CD	O
of	IN	O
22	CD	O
)	)	O
occurred	VBD	O
after	IN	O
the	DT	O
first	JJ	O
course	NN	O
of	IN	O
AMSA	NNP	O
.	.	O

At	IN	O
the	DT	O
dose	JJ	O
schedules	NNS	O
investigated	VBN	O
,	,	O
and	CC	O
in	IN	O
a	DT	O
heavily	RB	O
pretreated	VBN	O
patient	JJ	O
population	NN	O
,	,	O
AMSA	NNP	O
had	VBD	O
activity	NN	PH
in	IN	PH
childhood	NN	PH
leukemia	NN	PH
.	.	O

However	RB	O
,	,	O
the	DT	O
high	JJ	O
incidence	NN	PH
of	IN	PH
severe	JJ	PH
,	,	PH
life-threatening	JJ	PH
,	,	PH
or	CC	PH
fatal	JJ	PH
infections	NNS	PH
meant	VBP	O
that	IN	O
the	DT	O
quality	NN	MO
and	CC	MO
quantity	NN	MO
of	IN	MO
responses	NNS	MO
and	CC	MO
survival	NN	MO
was	VBD	O
not	RB	O
commensurate	JJ	O
with	IN	O
the	DT	O
toxicity	NN	PH
,	,	O
and	CC	O
that	IN	O
it	PRP	O
would	MD	O
be	VB	O
difficult	JJ	O
to	TO	O
incorporate	VB	O
this	DT	O
drug	NN	O
into	IN	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
other	JJ	O
myelosuppressive	JJ	O
agents	NNS	O
.	.	O

Perceptual	JJ	Ot
wind-up	NN	Ot
in	IN	O
the	DT	O
human	JJ	O
oesophagus	NN	O
is	VBZ	O
enhanced	VBN	O
by	IN	O
central	JJ	O
sensitisation	NN	O
.	.	O

BACKGROUND	NNP	O
Oesophageal	NNP	O
acid	JJ	O
infusion	NN	O
induces	NNS	O
enhanced	VBD	O
pain	NN	O
hypersensitivity	NN	O
in	IN	O
non-acid	JJ	O
exposed	JJ	O
upper	JJ	O
oesophagus	NN	O
(	(	O
secondary	JJ	O
hyperalgesia	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
non-cardiac	JJ	O
chest	NN	O
pain	NN	O
,	,	O
thus	RB	O
suggesting	VBG	O
central	JJ	O
sensitisation	NN	O
contributes	NNS	O
to	TO	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
in	IN	O
functional	JJ	O
gut	NN	O
disorders	NNS	O
(	(	O
FGD	NNP	O
)	)	O
.	.	O

Perceptual	JJ	O
wind-up	JJ	O
(	(	O
increased	JJ	O
pain	NN	O
perception	NN	O
to	TO	O
constant	JJ	O
intensity	NN	O
sensory	NN	O
stimuli	NN	O
at	IN	O
frequencies	NNS	O
>	VBP	O
or=0.3	JJ	O
Hz	NNP	O
)	)	O
is	VBZ	O
used	VBN	O
as	IN	O
a	DT	O
proxy	NN	O
for	IN	O
central	JJ	O
sensitisation	NN	O
to	TO	O
investigate	VB	O
pain	NN	O
syndromes	NNS	O
where	WRB	O
pain	NN	O
hypersensitivity	NN	O
is	VBZ	O
important	JJ	O
(	(	O
for	IN	O
example	NN	O
,	,	O
fibromyalgia	NN	O
)	)	O
.	.	O

AIMS	$	O
Wind-up	JJ	O
in	IN	O
central	JJ	O
sensitisation	NN	O
induced	VBD	O
human	JJ	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
explored	VBN	O
.	.	O

We	PRP	O
hypothesised	VBD	O
that	IN	O
if	IN	O
wind-up	NN	O
is	VBZ	O
a	DT	O
proxy	NN	O
for	IN	O
central	JJ	O
sensitisation	NN	O
induced	VBD	O
human	JJ	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
,	,	O
then	RB	O
oesophageal	JJ	O
wind-up	NN	O
should	MD	O
be	VB	O
enhanced	VBN	O
by	IN	O
secondary	JJ	O
hyperalgesia	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
eight	CD	O
healthy	JJ	O
volunteers	NNS	O
(	(	O
seven	CD	O
males	NNS	O
;	:	O
mean	JJ	O
age	NN	O
32	CD	O
years	NNS	O
)	)	O
,	,	O
perception	NN	O
at	IN	O
pain	NN	O
threshold	NN	O
to	TO	O
a	DT	O
train	NN	O
of	IN	O
20	CD	O
electrical	JJ	O
stimuli	NNS	O
applied	VBN	O
to	TO	O
the	DT	O
hand	NN	O
and	CC	O
upper	JJ	O
oesophagus	NN	O
(	(	O
UO	NNP	O
)	)	O
at	IN	O
either	DT	O
0.1	CD	O
Hz	NNP	O
(	(	O
control	NN	O
)	)	O
or	CC	O
2	CD	O
Hz	NNP	O
was	VBD	O
determined	VBN	O
before	IN	O
and	CC	O
one	CD	O
hour	NN	O
after	IN	O
a	DT	O
30	CD	O
minute	NN	O
lower	JJR	O
oesophageal	NN	O
acid	JJ	O
infusion	NN	O
.	.	O

RESULTS	NNP	O
Wind-up	JJ	Ot
occurred	VBD	O
only	RB	O
with	IN	O
the	DT	O
2	CD	O
Hz	NNP	O
train	NN	O
in	IN	O
the	DT	O
UO	NNP	O
and	CC	O
hand	NN	O
(	(	O
both	DT	O
p=0.01	NN	O
)	)	O
.	.	O

Following	VBG	O
acid	JJ	O
infusion	NN	O
,	,	O
pain	VBP	PA
threshold	JJ	PA
decreased	VBN	PA
(	(	O
17	CD	O
(	(	O
4	CD	O
)	)	O
%	NN	O
;	:	O
p=0.01	NN	O
)	)	O
in	IN	O
the	DT	O
UO	NNP	O
,	,	O
suggesting	VBG	O
the	DT	O
presence	NN	O
of	IN	O
secondary	JJ	O
hyperalgesia	NN	O
.	.	O

Wind-up	UH	Ot
to	TO	Ot
the	DT	Ot
2	CD	Ot
Hz	NNP	Ot
train	NN	Ot
increased	VBD	O
in	IN	O
the	DT	O
UO	NNP	PH
(	(	O
wind-up	JJ	O
ratio	NN	O
1.4	CD	O
(	(	O
0.1	CD	O
)	)	O
to	TO	O
1.6	CD	O
(	(	O
0.1	CD	O
)	)	O
;	:	O
p=0.03	NN	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
hand	NN	O
(	(	O
wind-up	JJ	O
ratio	NN	O
1.3	CD	O
(	(	O
0.1	CD	O
)	)	O
and	CC	O
1.3	CD	O
(	(	O
0.1	CD	O
)	)	O
;	:	O
p=0.3	NN	O
)	)	O
CONCLUSION	NNP	O
Enhanced	NNP	O
wind-up	NN	O
after	IN	O
secondary	JJ	O
oesophageal	NN	O
hyperalgesia	NN	O
suggests	VBZ	O
that	IN	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
induced	VBN	O
by	IN	O
central	JJ	O
sensitisation	NN	O
results	NNS	O
from	IN	O
increased	JJ	O
central	JJ	O
neuronal	JJ	O
excitability	NN	O
.	.	O

Wind-up	JJ	O
may	MD	O
offer	VB	O
new	JJ	O
opportunities	NNS	O
to	TO	O
investigate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
central	JJ	O
neuronal	JJ	O
changes	NNS	O
to	TO	O
symptoms	NNS	O
in	IN	O
FGD	NNP	O
.	.	O

Humoral	NNP	PH
immune	JJ	PH
response	NN	PH
to	TO	O
tetanus-diphtheria	JJ	O
vaccine	NN	O
given	VBN	O
during	IN	O
extended	VBN	O
use	NN	O
of	IN	O
chloroquine	NN	O
or	CC	O
primaquine	NN	O
malaria	NNS	O
chemoprophylaxis	NN	O
.	.	O

Immune	NNP	PH
suppression	NN	PH
resulting	VBG	O
from	IN	O
prolonged	VBN	O
chemoprophylaxis	NN	O
and	CC	O
potential	JJ	O
drug-vaccine	JJ	O
interaction	NN	O
were	VBD	O
investigated	VBN	O
within	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
daily	RB	O
primaquine	NN	O
or	CC	O
weekly	JJ	O
chloroquine	NN	O
administration	NN	O
for	IN	O
malaria	JJ	O
prevention	NN	O
.	.	O

After	IN	O
11	CD	O
months	NNS	O
of	IN	O
prophylaxis	NN	O
,	,	O
adult	VB	O
male	JJ	O
subjects	NNS	O
received	VBD	O
a	DT	O
tetanus-diphtheria	NN	O
(	(	O
Td	NNP	O
)	)	O
vaccination	NN	O
.	.	O

Prophylaxis	NNP	O
continued	VBD	O
4	CD	O
weeks	NNS	O
longer	RBR	O
.	.	O

Anti-tetanus	JJ	PH
and	CC	PH
anti-diphtheria	JJ	PH
antibody	NN	PH
levels	NNS	PH
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	PH
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
months	NNS	O
after	IN	O
Td	NNP	O
vaccination	NN	O
.	.	O

All	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Immunization	NN	O
triggered	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
anti-tetanus	JJ	PH
and	CC	PH
anti-diphtheria	JJ	PH
IgG	NNP	PH
levels	NNS	PH
over	IN	O
each	DT	O
group	NN	O
's	POS	O
pre-Td	JJ	O
baseline	NN	O
levels	NNS	O
and	CC	O
those	DT	O
of	IN	O
an	DT	O
unvaccinated	JJ	O
control	NN	O
group	NN	O
.	.	O

Geometric	JJ	PH
mean	JJ	PH
anti-tetanus	JJ	PH
titers	NNS	PH
(	(	PH
GMTs	NNP	PH
)	)	PH
in	IN	O
the	DT	O
primaquine	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
14	CD	O
months	NNS	O
.	.	O

Anti-tetanus	NNP	PH
GMTs	NNP	PH
in	IN	O
placebo	NN	O
and	CC	O
chloroquine	NN	O
groups	NNS	O
declined	VBD	O
over	IN	O
14	CD	O
months	NNS	O
to	TO	O
levels	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unvaccinated	JJ	O
controls	NNS	O
,	,	O
but	CC	O
levels	NNS	O
in	IN	O
the	DT	O
primaquine	NN	O
group	NN	O
remained	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

A	DT	O
six-month	JJ	O
crossover	NN	O
chemoprevention	NN	O
clinical	JJ	O
trial	NN	O
of	IN	O
tea	NN	O
in	IN	O
smokers	NNS	O
and	CC	O
non-smokers	NNS	O
:	:	O
methodological	JJ	O
issues	NNS	O
in	IN	O
a	DT	O
feasibility	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Chemoprevention	NNP	O
crossover	NN	O
trials	NNS	O
of	IN	O
tea	NN	O
can	MD	O
be	VB	O
more	RBR	O
efficient	JJ	O
than	IN	O
parallel	JJ	O
designs	NNS	O
but	CC	O
the	DT	O
attrition	NN	O
and	CC	O
compliance	NN	O
rates	NNS	O
with	IN	O
such	JJ	O
trials	NNS	O
are	VBP	O
unknown	JJ	O
.	.	O

METHODS	NNP	O
Attrition	NNP	O
(	(	O
dropouts	NNS	O
)	)	O
and	CC	O
compliance	NN	O
with	IN	O
treatment	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
25-week	JJ	O
randomized	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
,	,	O
crossover	NN	O
,	,	O
feasibility	NN	O
clinical	JJ	O
trial	NN	O
of	IN	O
four	CD	O
tea	NN	O
treatments	NNS	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
tea	NN	O
on	IN	O
oral	JJ	O
cancer	NN	O
biomarkers	NNS	O
.	.	O

Each	DT	O
treatment	NN	O
lasted	VBD	O
4	CD	O
weeks	NNS	O
with	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
washout	NN	O
in	IN	O
between	IN	O
.	.	O

Participants	NNS	O
were	VBD	O
32	CD	O
smokers	NNS	O
and	CC	O
33	CD	O
non-smokers	NNS	O
without	IN	O
any	DT	O
evidence	NN	O
of	IN	O
premalignant	JJ	O
oral	JJ	O
lesions	NNS	O
.	.	O

The	DT	O
interventions	NNS	O
consisted	VBD	O
of	IN	O
packets	NNS	O
of	IN	O
green	JJ	O
tea	NN	O
,	,	O
black	JJ	O
tea	NN	O
,	,	O
caffeinated	JJ	O
water	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
each	DT	O
treatment	NN	O
for	IN	O
four	CD	O
weeks	NNS	O
,	,	O
and	CC	O
were	VBD	O
instructed	VBN	O
to	TO	O
drink	VB	O
five	CD	O
packets	NNS	O
per	IN	O
day	NN	O
while	IN	O
on	IN	O
the	DT	O
treatment	NN	O
.	.	O

Dropout	IN	O
from	IN	O
the	DT	O
trial	NN	O
and	CC	O
compliance	NN	O
(	(	O
consumption	NN	O
of	IN	O
?85	NNP	O
%	NN	O
of	IN	O
the	DT	O
prescribed	JJ	O
treatment	NN	O
packets	NNS	O
)	)	O
are	VBP	O
the	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
reported	VBN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
high	JJ	Ot
rate	NN	Ot
of	IN	Ot
dropout	NN	Ot
(	(	O
51	CD	O
%	NN	O
)	)	O
from	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
rates	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
smokers	NNS	O
(	(	O
64	CD	O
%	NN	O
)	)	O
than	IN	O
non-smokers	NNS	O
(	(	O
36	CD	O
%	NN	O
)	)	O
.	.	O

Among	IN	O
participants	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
the	DT	O
rate	NN	O
of	IN	O
compliance	NN	O
was	VBD	O
72	CD	O
%	NN	O
.	.	O

The	DT	O
highest	JJS	O
rates	NNS	Ot
of	IN	Ot
dropouts	NNS	Ot
occurred	VBD	O
between	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
treatment	NN	O
visits	NNS	O
in	IN	O
both	DT	O
smokers	NNS	O
(	(	O
38	CD	O
%	NN	O
dropout	NN	O
)	)	O
and	CC	O
non-smokers	NNS	O
(	(	O
18	CD	O
%	NN	O
dropout	NN	O
)	)	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
smokers	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
dropout	VB	Ot
than	IN	O
non-smokers	NNS	O
.	.	O

Black	NNP	O
tea	NN	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
highest	JJS	O
rates	NNS	Ot
of	IN	Ot
dropout	NN	Ot
among	IN	O
smokers	NNS	O
(	(	O
37	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
lowest	JJS	O
rate	NN	O
of	IN	O
dropout	NN	O
among	IN	O
non-smokers	NNS	O
(	(	O
4	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
a	DT	O
study	NN	O
conducted	VBN	O
to	TO	O
test	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
a	DT	O
four-treatment	JJ	O
crossover	NN	O
tea	NN	O
trial	NN	O
,	,	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
dropout	NN	O
among	IN	O
smokers	NNS	O
and	CC	O
non-smokers	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Multi-arm	JJ	O
crossover	NN	O
tea	NN	O
trials	NNS	O
might	MD	O
pose	VB	O
a	DT	O
higher	JJR	O
burden	NN	O
on	IN	O
participants	NNS	O
and	CC	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
improve	VB	O
adherence	NN	O
and	CC	O
treatment	NN	O
compliance	NN	O
in	IN	O
such	JJ	O
trials	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NUMBER	NNP	O
ISRCTN70410203	NNP	O
.	.	O

Prospectively	RB	O
randomized	VBN	O
toxicity	NN	A
study	NN	O
of	IN	O
high-dose	JJ	O
versus	NN	O
low-dose	JJ	O
treatment	NN	O
strategies	NNS	O
for	IN	O
lymphoblastoid	JJ	O
interferon	NN	O
.	.	O

It	PRP	O
is	VBZ	O
unclear	JJ	O
from	IN	O
preliminary	JJ	O
laboratory	NN	O
studies	NNS	O
whether	IN	O
a	DT	O
high-	NN	O
or	CC	O
a	DT	O
low-dose	JJ	O
interferon	NN	O
treatment	NN	O
strategy	NN	O
is	VBZ	O
optimal	JJ	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
an	DT	O
ongoing	JJ	O
study	NN	O
of	IN	O
mechanisms	NNS	O
of	IN	O
interferon	NN	O
action	NN	O
,	,	O
we	PRP	O
have	VBP	O
evaluated	VBN	O
toxicity	NN	O
in	IN	O
a	DT	O
two-arm	JJ	O
protocol	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
lymphoblastoid	JJ	O
interferon	NN	O
by	IN	O
either	CC	O
a	DT	O
low-dose	JJ	O
treatment	NN	O
strategy	NN	O
(	(	O
2	CD	O
X	RB	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2	JJ	O
daily	JJ	O
X	$	O
28	CD	O
days	NNS	O
then	RB	O
daily	JJ	O
X	NNP	O
5	CD	O
days	NNS	O
every	DT	O
other	JJ	O
week	NN	O
by	IN	O
im	JJ	O
injection	NN	O
)	)	O
or	CC	O
a	DT	O
high-dose	JJ	O
treatment	NN	O
strategy	NN	O
(	(	O
5	CD	O
X	RB	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2	NN	O
by	IN	O
continuous	JJ	O
iv	JJ	O
infusion	NN	O
over	IN	O
24	CD	O
hours	NNS	O
,	,	O
escalating	VBG	O
by	IN	O
5	CD	O
X	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2/day	NN	O
as	IN	O
tolerated	VBN	O
over	IN	O
10	CD	O
days	NNS	O
,	,	O
repeated	VBD	O
every	DT	O
28	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
main	JJ	A
toxic	NN	A
effects	NNS	A
in	IN	O
both	DT	O
arms	NNS	O
were	VBD	O
fever	RB	A
,	,	A
fatigue	NN	A
,	,	A
and	CC	A
anorexia	RB	A
.	.	A

Marked	JJ	O
interpatient	NN	O
differences	NNS	O
within	IN	O
each	DT	O
dose	JJ	O
arm	NN	O
were	VBD	O
greater	JJR	O
than	IN	O
differences	NNS	O
between	IN	O
arms	NNS	O
.	.	O

Additional	JJ	O
significant	JJ	A
toxic	NN	A
effects	NNS	A
included	VBD	A
nausea	NN	A
and	CC	A
vomiting	NN	A
,	,	A
hypotension	NN	A
,	,	A
leukopenia	NN	A
,	,	A
thrombocytopenia	NN	A
,	,	A
and	CC	A
evidence	NN	A
of	IN	A
hepatic	JJ	A
toxicity	NN	A
.	.	O

Minor	JJ	O
changes	NNS	A
in	IN	A
serum	NN	A
electrolytes	NNS	A
were	VBD	O
noted	VBN	O
.	.	O

Coagulation	NNP	PH
studies	NNS	PH
were	VBD	O
normal	JJ	O
.	.	O

The	DT	O
dose-limiting	JJ	O
toxic	NN	A
effect	NN	A
for	IN	O
the	DT	O
high-dose	JJ	O
arm	NN	O
was	VBD	O
myelosuppression	NN	A
.	.	O

Median	JJ	O
maximum	NN	Ot
tolerated	VBD	Ot
dose	JJ	Ot
among	IN	O
high-dose	JJ	O
strategy	NN	O
patients	NNS	O
was	VBD	O
18	CD	O
X	JJ	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
marked	VBN	O
interpatient	JJ	O
variation	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
both	DT	O
dose	JJ	O
schedules	NNS	O
were	VBD	O
relatively	RB	Ot
well-tolerated	JJ	Ot
.	.	Ot

Because	IN	O
of	IN	O
individual	JJ	O
variation	NN	O
in	IN	O
tolerance	NN	Ot
,	,	O
high-dose	JJ	O
treatment	NN	O
should	MD	O
include	VB	O
a	DT	O
dose	JJ	O
escalation	NN	O
strategy	NN	O
.	.	O

Risperidone	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
negative	JJ	ME
symptoms	NNS	ME
of	IN	O
schizophrenia	NN	O
:	:	O
a	DT	O
meta-analysis	NN	O
.	.	O

Risperidone	NN	O
has	VBZ	O
antiserotonergic	VBN	O
and	CC	O
antidopaminergic	JJ	O
properties	NNS	O
that	WDT	O
may	MD	O
make	VB	O
it	PRP	O
more	RBR	O
effective	JJ	O
than	IN	O
conventional	JJ	O
antipsychotic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
negative	JJ	ME
symptoms	NNS	ME
of	IN	O
schizophrenia	NN	O
.	.	O

Clinical	JJ	O
trials	NNS	O
in	IN	O
chronic	JJ	O
schizophrenic	JJ	O
patients	NNS	O
have	VBP	O
shown	VBN	O
trends	NNS	O
in	IN	O
favor	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
negative	JJ	ME
symptoms	NNS	ME
compared	VBN	O
with	IN	O
haloperidol	NN	O
,	,	O
perphenazine	NN	O
or	CC	O
zuclopenthixol	NN	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
consistently	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
meta-analysis	NN	O
of	IN	O
the	DT	O
pooled	JJ	O
results	NNS	O
from	IN	O
six	CD	O
double-blind	JJ	O
trials	NNS	O
showed	VBD	O
that	IN	O
risperidone	NN	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
4	CD	O
to	TO	O
8	CD	O
mg/day	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.004	CD	O
)	)	O
higher	JJR	O
negative	JJ	ME
symptom	JJ	ME
response	NN	ME
rate	NN	ME
,	,	O
defined	VBN	O
as	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
20	CD	O
%	NN	O
or	CC	O
more	JJR	PA
reduction	NN	PA
in	IN	PA
scores	NNS	PA
on	IN	PA
the	DT	PA
negative	JJ	PA
subscale	NN	PA
of	IN	PA
the	DT	PA
Positive	NNP	Ot
and	CC	Ot
Negative	NNP	Ot
Syndrome	NNP	Ot
Scale	NNP	Ot
,	,	O
than	IN	O
patients	NNS	O
receiving	VBG	O
active	JJ	O
controls	NNS	O
.	.	O

The	DT	O
combined	JJ	O
patient	JJ	O
population	NN	O
treated	VBN	O
with	IN	O
4-8	JJ	O
mg/day	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
1.43	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
had	VBN	O
a	DT	O
clinical	JJ	ME
response	NN	ME
on	IN	ME
the	DT	ME
negative	JJ	ME
symptom	NN	ME
subscale	NN	ME
than	IN	O
the	DT	O
combined	JJ	O
population	NN	O
treated	VBN	O
with	IN	O
haloperidol	NN	O
,	,	O
perphenazine	NN	O
or	CC	O
zuclopenthixol	NN	O
.	.	O

Temozolomide	NNP	O
and	CC	O
cisplatin	VB	O
versus	NN	O
temozolomide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NN	O
:	:	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
the	DT	O
Hellenic	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
Temozolomide	NNP	O
(	(	O
TMZ	NNP	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
alkylating	NN	O
agent	NN	O
that	WDT	O
produces	VBZ	O
methyl	JJ	O
adducts	NNS	O
at	IN	O
the	DT	O
0.6	CD	O
position	NN	O
of	IN	O
guanine	NN	O
.	.	O

The	DT	O
methyl	NN	O
adducts	NNS	O
are	VBP	O
removed	VBN	O
by	IN	O
the	DT	O
DNA	NNP	O
repair	NN	O
enzyme	JJ	O
AGAT	NNP	O
.	.	O

As	IN	O
demonstrated	VBN	O
by	IN	O
in	IN	O
vitro	NN	O
studies	NNS	O
,	,	O
cisplatin	NN	O
(	(	O
CDDP	NNP	O
)	)	O
is	VBZ	O
able	JJ	O
to	TO	O
down-regulate	VB	O
the	DT	O
AGAT	NNP	O
activity	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
CDDP	NNP	O
could	MD	O
enhance	VB	O
the	DT	O
antitumor	NN	PH
activity	NN	PH
of	IN	PH
TMZ	NNP	PH
.	.	O

We	PRP	O
designed	VBD	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
to	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
activity	NN	O
and	CC	O
safety	NN	O
profile	NN	O
of	IN	O
the	DT	O
combination	NN	O
versus	IN	O
single-agent	JJ	O
TMZ	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
January	NNP	O
2000	CD	O
to	TO	O
April	NNP	O
2002	CD	O
,	,	O
132	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
on	IN	O
the	DT	O
study	NN	O
.	.	O

Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
well	RB	O
balanced	VBN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
cerebral	JJ	O
metastases	NNS	O
were	VBD	O
included	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
TMZ	NNP	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
orally	RB	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
or	CC	O
TMZ	NNP	O
+	NNP	O
CDDP	NNP	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
daily	RB	O
on	IN	O
days	NNS	O
1-5	CD	O
and	CC	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
of	IN	O
CDDP	NNP	O
on	IN	O
day	NN	O
1	CD	O
.	.	O

RESULTS	NNP	O
Tumor	NNP	PH
responses	VBZ	PH
(	(	O
complete	JJ	O
and	CC	O
partial	JJ	O
responses	NNS	O
)	)	O
were	VBD	O
seen	VBN	O
in	IN	O
16	CD	O
patients	NNS	O
(	(	O
26	CD	O
%	NN	O
)	)	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
19	CD	O
patients	NNS	O
(	(	O
29	CD	O
%	NN	O
)	)	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
median	JJ	PH
time	NN	PH
to	TO	PH
progression	NN	PH
(	(	PH
TTP	NNP	PH
)	)	PH
was	VBD	O
3.8	CD	O
months	NNS	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
5.8	CD	O
months	NNS	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
median	JJ	MO
overall	JJ	MO
survival	NN	MO
(	(	MO
OS	NNP	MO
)	)	MO
was	VBD	O
11.5	CD	O
months	NNS	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
12	CD	O
months	NNS	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
arms	NNS	O
regarding	VBG	O
objective	JJ	PH
response	NN	PH
rates	NNS	PH
,	,	O
TTP	NNP	O
and	CC	O
OS	NNP	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Toxicity	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
for	IN	O
anemia	NN	A
,	,	A
leukopenia	NN	A
,	,	A
neutropenia	NN	A
,	,	A
thrombocytopenia	NN	A
,	,	A
fatigue	NN	A
,	,	A
constipation	NN	A
and	CC	A
arthralgias/myalgias	NN	A
.	.	O

There	EX	O
was	VBD	O
significantly	RB	O
more	JJR	O
grade	JJ	A
3	CD	A
and	CC	A
4	CD	A
emesis	NN	A
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	Ot
clear	JJ	Ot
benefit	NN	Ot
in	IN	O
terms	NNS	O
of	IN	O
response	NN	PH
rates	NNS	PH
,	,	O
median	JJ	PH
TTP	NNP	PH
or	CC	O
OS	NNP	O
was	VBD	O
shown	VBN	O
with	IN	O
the	DT	O
combination	NN	O
of	IN	O
TMZ	NNP	O
+	NNP	O
CDDP	NNP	O
.	.	O

Additionally	RB	O
,	,	O
the	DT	O
combination	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
incidence	NN	O
of	IN	O
grade	NN	A
3	CD	A
and	CC	A
4	CD	A
emesis	NN	A
.	.	O

Delayed	VBN	O
perceptual	JJ	O
awareness	NN	O
in	IN	O
rapid	JJ	O
perceptual	JJ	O
decisions	NNS	O
.	.	O

The	DT	O
flourishing	NN	O
of	IN	O
studies	NNS	O
on	IN	O
the	DT	O
neural	JJ	O
correlates	NNS	O
of	IN	O
decision-making	JJ	O
calls	NNS	O
for	IN	O
an	DT	O
appraisal	NN	O
of	IN	O
the	DT	O
relation	NN	O
between	IN	O
perceptual	JJ	O
decisions	NNS	O
and	CC	O
conscious	JJ	O
perception	NN	O
.	.	O

By	IN	O
exploiting	VBG	O
the	DT	O
long	JJ	O
integration	NN	O
time	NN	O
of	IN	O
noisy	JJ	O
motion	NN	O
stimuli	NN	O
,	,	O
and	CC	O
by	IN	O
forcing	VBG	O
human	JJ	O
observers	NNS	O
to	TO	O
make	VB	O
difficult	JJ	O
speeded	VBN	O
decisions	NNS	O
--	:	O
sometimes	RB	O
a	DT	O
blind	JJ	O
guess	NN	O
--	:	O
about	IN	O
stimulus	JJ	O
direction	NN	O
,	,	O
we	PRP	O
traced	VBD	O
the	DT	O
temporal	JJ	O
buildup	NN	O
of	IN	O
motion	NN	O
discrimination	NN	O
capability	NN	O
and	CC	O
perceptual	JJ	O
awareness	NN	O
,	,	O
as	IN	O
assessed	VBN	O
trial	NN	O
by	IN	O
trial	NN	O
through	IN	O
direct	JJ	O
rating	NN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
both	DT	O
increased	VBN	O
gradually	RB	O
with	IN	O
motion	NN	ME
coherence	NN	ME
and	CC	ME
viewing	NN	ME
time	NN	ME
,	,	O
but	CC	O
discrimination	NN	ME
was	VBD	ME
systematically	RB	ME
leading	JJ	ME
awareness	NN	ME
,	,	ME
reaching	VBG	ME
a	DT	ME
plateau	NN	ME
much	RB	ME
earlier	RBR	ME
.	.	ME

Sensitivity	NNP	O
and	CC	O
criterion	NN	O
changes	NNS	O
contributed	VBD	O
jointly	RB	O
to	TO	O
the	DT	O
slow	JJ	ME
buildup	NN	ME
of	IN	ME
perceptual	JJ	ME
awareness	NN	ME
.	.	ME

It	PRP	O
made	VBD	O
no	DT	O
difference	NN	O
whether	IN	O
motion	NN	ME
discrimination	NN	ME
was	VBD	O
accomplished	VBN	O
by	IN	O
saccades	NNS	ME
or	CC	ME
verbal	JJ	ME
responses	NNS	ME
.	.	ME

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
perceptual	JJ	ME
awareness	NN	ME
emerges	VBZ	O
on	IN	O
the	DT	O
top	NN	O
of	IN	O
a	DT	O
developing	NN	O
or	CC	O
even	RB	O
mature	VBP	O
perceptual	JJ	O
decision	NN	O
.	.	O

We	PRP	O
argue	VBP	O
that	IN	O
the	DT	O
middle	JJ	O
temporal	JJ	O
(	(	O
MT	NNP	O
)	)	O
cortical	JJ	O
region	NN	O
does	VBZ	O
not	RB	O
confer	VB	O
us	PRP	O
the	DT	O
full	JJ	ME
phenomenic	JJ	ME
depth	NN	ME
of	IN	ME
motion	NN	ME
perception	NN	ME
,	,	O
although	IN	O
it	PRP	O
may	MD	O
represent	VB	O
a	DT	O
precursor	NN	ME
stage	NN	ME
in	IN	ME
building	VBG	ME
our	PRP$	ME
subjective	JJ	ME
sense	NN	ME
of	IN	ME
visual	JJ	ME
motion	NN	ME
.	.	ME

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
brief	JJ	O
alcohol	NN	O
intervention	NN	O
for	IN	O
needle	JJ	O
exchangers	NNS	O
(	(	O
BRAINE	NNP	O
)	)	O
.	.	O

AIMS	UH	O
To	TO	O
test	VB	O
motivational	JJ	O
interviewing	NN	O
(	(	O
MI	NNP	O
)	)	O
as	IN	O
a	DT	O
brief	JJ	O
intervention	NN	O
for	IN	O
reducing	VBG	O
alcohol	NN	PA
use	NN	PA
among	IN	O
needle	JJ	O
exchange	NN	O
clients	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Needle	NNP	O
exchange	NN	O
program-Providence	NN	O
,	,	O
Rhode	NNP	O
Island	NNP	O
,	,	O
USA	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Between	NNP	O
2/98	CD	O
and	CC	O
10/99	CD	O
,	,	O
we	PRP	O
recruited	VBD	O
187	CD	O
AUDIT-positive	JJ	O
(	(	O
>	JJ	O
8	CD	O
)	)	O
active	JJ	O
injection	NN	O
drug	NN	O
users	NNS	O
.	.	O

INTERVENTION	NNP	O
Those	DT	O
assigned	VBN	O
to	TO	O
a	DT	O
brief	JJ	O
motivational	JJ	O
intervention	NN	O
(	(	O
MI	NNP	O
)	)	O
condition	NN	O
received	VBD	O
two	CD	O
1-hour	JJ	O
therapist	JJ	O
sessions	NNS	O
following	VBG	O
assessment	NN	O
visits	NNS	O
,	,	O
1	CD	O
month	NN	O
apart	RB	O
,	,	O
focusing	VBG	O
on	IN	O
alcohol	NN	O
use	NN	O
and	CC	O
HIV	NNP	O
risk-taking	NN	O
.	.	O

MEASUREMENTS	NNP	O
Control	NNP	O
and	CC	O
MI	NNP	O
subjects	NNS	O
received	VBD	O
identical	JJ	O
research	NN	O
assessments	NNS	O
at	IN	O
baseline	NN	O
,	,	O
1	CD	O
and	CC	O
6	CD	O
months	NNS	O
following	VBG	O
study	NN	O
enrollment	NN	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
study	NN	O
outcomes	NNS	O
included	VBD	O
days	NNS	PA
of	IN	PA
alcohol	NN	PA
use	NN	PA
measured	VBD	O
using	VBG	O
the	DT	O
time-line	JJ	O
follow-back	JJ	O
method	NN	O
.	.	O

FINDINGS	NNP	O
Study	NNP	MO
retention	NN	MO
was	VBD	O
96.8	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Participants	NNS	O
reported	VBD	O
an	DT	O
average	NN	O
of	IN	O
12.0	CD	O
drinking	NN	Ot
days	NNS	Ot
at	IN	O
baseline	NN	O
and	CC	O
8.3	CD	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Significant	JJ	O
reductions	NNS	O
in	IN	O
drinking	NN	Ot
days	NNS	Ot
were	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
conditions	NNS	O
.	.	O

We	PRP	O
found	VBD	O
significant	JJ	O
treatment	NN	O
x	NNP	O
baseline	NN	Ot
drinking	VBG	Ot
day	NN	Ot
interaction	NN	Ot
effects	NNS	Ot
.	.	Ot

Tests	NNS	O
for	IN	O
simple	JJ	O
main	JJ	O
effects	NNS	O
were	VBD	O
significant	JJ	O
for	IN	O
subjects	NNS	O
with	IN	O
above	JJ	O
median	NN	Ot
(	(	Ot
>	JJ	Ot
9	CD	Ot
)	)	Ot
baseline	NN	Ot
drinking	VBG	Ot
day	NN	Ot
frequency	NN	Ot
,	,	O
but	CC	O
not	RB	O
for	IN	O
those	DT	O
with	IN	O
below	JJ	O
median	JJ	O
baseline	NN	Ot
drinking	NN	Ot
frequency	NN	Ot
.	.	Ot

Comparisons	NNS	O
on	IN	O
dichotomous	JJ	O
outcomes	NNS	O
provided	VBD	O
supporting	VBG	O
evidence	NN	O
of	IN	O
treatment	NN	Ot
efficacy	NN	Ot
;	:	Ot
those	DT	O
in	IN	O
MI	NNP	O
were	VBD	O
over	RB	O
two	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
than	IN	O
controls	NNS	O
to	TO	O
report	VB	O
reductions	NNS	O
of	IN	O
7	CD	O
days	NNS	O
or	CC	O
more	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
provides	VBZ	O
the	DT	O
first	JJ	O
direct	JJ	O
evidence	NN	O
that	IN	O
brief	JJ	O
MI	NNP	O
can	MD	O
decrease	VB	O
alcohol	NN	O
use	NN	O
among	IN	O
active	JJ	O
injection	NN	O
drug	NN	O
users	NNS	O
with	IN	O
drinking	NN	O
problems	NNS	O
.	.	O

Heavier	JJR	O
drinkers	NNS	O
seem	VBP	O
best	RB	O
suited	VBN	O
for	IN	O
this	DT	O
intervention	NN	O
,	,	O
but	CC	O
the	DT	O
optimal	JJ	O
intensity	NN	O
of	IN	O
treatments	NNS	O
and	CC	O
which	WDT	O
components	NNS	O
of	IN	O
brief	JJ	O
intervention	NN	O
are	VBP	O
most	RBS	O
effective	JJ	O
deserve	NN	O
further	RB	O
study	NN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
a	DT	O
barrier	NN	O
cream	NN	O
and	CC	O
its	PRP$	O
vehicle	NN	O
as	IN	O
protective	JJ	O
measures	NNS	O
against	IN	O
occupational	JJ	PH
irritant	JJ	PH
contact	NN	PH
dermatitis	NN	PH
.	.	O

The	DT	O
actual	JJ	O
advantage	NN	O
of	IN	O
barrier	NN	O
creams	NNS	O
over	IN	O
bland	NN	O
emollients	NNS	O
for	IN	O
skin	NN	O
protection	NN	O
is	VBZ	O
still	RB	O
hotly	RB	O
debated	VBN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
study	NN	O
,	,	O
a	DT	O
newly-introduced	JJ	O
barrier	NN	O
cream	NN	O
and	CC	O
its	PRP$	O
moisturizing	NN	O
vehicle	NN	O
were	VBD	O
compared	VBN	O
regarding	VBG	O
their	PRP$	O
skin	NN	PH
compatibility	NN	PH
,	,	PH
efficacy	NN	PH
and	CC	PH
resulting	VBG	PH
acceptance	NN	PH
.	.	O

Thus	NNP	O
,	,	O
2	CD	O
panels	NNS	O
of	IN	O
25	CD	O
hospital	NN	O
nurses	NNS	O
with	IN	O
mild	JJ	O
signs	NNS	O
of	IN	O
skin	JJ	O
irritation	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
use	VB	O
1	CD	O
of	IN	O
the	DT	O
test	NN	O
products	NNS	O
provided	VBN	O
(	(	O
verum	NN	O
or	CC	O
vehicle	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
both	DT	O
types	NNS	O
of	IN	O
preparations	NNS	O
were	VBD	O
studied	VBN	O
weekly	JJ	O
by	IN	O
clinical	JJ	O
examination	NN	O
and	CC	O
the	DT	O
instrumental	JJ	O
assessment	NN	O
of	IN	O
bioengineering	VBG	O
parameters	NNS	O
.	.	O

Results	NNS	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
barrier	NN	O
cream	NN	O
and	CC	O
vehicle	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
clinical	JJ	PH
skin	NN	PH
status	NN	PH
improved	VBN	O
and	CC	O
stratum	JJ	PH
corneum	NN	PH
hydration	NN	PH
increased	VBD	O
significantly	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Both	DT	O
preparations	NNS	O
were	VBD	O
tolerated	VBN	Ot
and	CC	PH
accepted	VBN	PH
well	RB	PH
,	,	O
thus	RB	O
showing	VBG	O
both	DT	O
skin	JJ	PH
protection	NN	PH
and	CC	PH
skin	NN	PH
care	NN	PH
.	.	PH

These	DT	O
results	NNS	O
contribute	VBP	O
to	TO	O
the	DT	O
debate	NN	O
as	IN	O
to	TO	O
whether	IN	O
a	DT	O
strict	JJ	O
distinction	NN	O
between	IN	O
skin	NN	O
care	NN	O
and	CC	O
skin	NN	O
protection	NN	O
products	NNS	O
is	VBZ	O
justified	JJ	O
.	.	O

The	DT	O
vehicle	NN	O
alone	RB	O
is	VBZ	O
capable	JJ	O
of	IN	O
positively	RB	O
influencing	VBG	O
skin	NN	O
status	NN	O
.	.	O

Emphasis	NN	O
must	MD	O
be	VB	O
laid	VBN	O
on	IN	O
regular	JJ	O
,	,	O
frequent	JJ	O
,	,	O
and	CC	O
correct	JJ	O
application	NN	O
of	IN	O
a	DT	O
product	NN	O
for	IN	O
it	PRP	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

Is	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
mobile	JJ	O
phone	NN	O
radiofrequency	NN	O
waves	NNS	O
on	IN	O
human	JJ	O
skin	JJ	O
perfusion	NN	O
non-thermal	JJ	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
establish	VB	O
whether	IN	O
SkBF	NNP	PH
can	MD	O
be	VB	O
modified	VBN	O
by	IN	O
exposure	NN	O
to	TO	O
the	DT	O
radiofrequency	NN	O
waves	NNS	O
emitted	VBN	O
by	IN	O
a	DT	O
mobile	JJ	O
phone	NN	O
when	WRB	O
the	DT	O
latter	NN	O
is	VBZ	O
held	VBN	O
against	IN	O
the	DT	O
jaw	NN	O
and	CC	O
ear	NN	O
.	.	O

METHODS	NNP	O
Variations	NNP	PH
in	IN	PH
SkBF	NNP	PH
and	CC	O
Tsk	NNP	O
in	IN	O
adult	NN	O
volunteers	NNS	O
were	VBD	O
simultaneously	RB	O
recorded	VBN	O
with	IN	O
a	DT	O
thermostatic	JJ	O
laser	NN	O
Doppler	NNP	O
system	NN	O
during	IN	O
a	DT	O
20-minute	JJ	O
radiofrequency	NN	O
exposure	NN	O
session	NN	O
and	CC	O
a	DT	O
20-minute	JJ	O
sham	NN	O
session	NN	O
.	.	O

The	DT	O
skin	JJ	O
microvessels	NNS	O
'	POS	O
vasodilatory	NN	O
reserve	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
heat	NN	O
challenge	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
the	DT	O
radiofrequency	NN	O
exposure	NN	O
session	NN	O
,	,	O
SkBF	NNP	PH
increased	VBD	O
(	(	O
vs.	FW	O
baseline	NN	O
)	)	O
more	JJR	O
than	IN	O
during	IN	O
the	DT	O
sham	JJ	O
exposure	NN	O
session	NN	O
.	.	O

The	DT	O
sessions	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significant	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
Tsk	NNP	Ot
time-course	JJ	Ot
response	NN	Ot
.	.	O

The	DT	O
skin	JJ	PH
microvessels	NNS	PH
'	POS	PH
vasodilatory	NN	PH
ability	NN	PH
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
greater	JJR	O
during	IN	O
radiofrequency	NN	O
exposure	NN	O
than	IN	O
during	IN	O
sham	JJ	O
exposure	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
reveal	VBP	O
the	DT	O
existence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
vasodilatory	JJ	Ot
effect	NN	O
of	IN	O
mobile	JJ	O
phone	NN	O
radiofrequency	NN	O
emission	NN	O
on	IN	O
skin	JJ	O
perfusion	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
controlled	JJ	O
release	NN	O
melatonin	NN	O
treatment	NN	O
of	IN	O
delayed	JJ	O
sleep	JJ	O
phase	NN	O
syndrome	NN	O
and	CC	O
impaired	JJ	O
sleep	JJ	O
maintenance	NN	O
in	IN	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disabilities	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
controlled-release	NN	O
(	(	O
CR	NNP	O
)	)	O
melatonin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
delayed	JJ	O
sleep	JJ	O
phase	NN	O
syndrome	NN	O
and	CC	O
impaired	JJ	O
sleep	JJ	O
maintenance	NN	O
of	IN	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disabilities	NNS	O
including	VBG	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
CR	NNP	O
melatonin	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
3-month	JJ	O
open-label	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
during	IN	O
which	WDT	O
the	DT	O
dose	NN	O
was	VBD	O
gradually	RB	O
increased	VBN	O
until	IN	O
the	DT	O
therapy	NN	O
showed	VBD	O
optimal	JJ	O
beneficial	JJ	O
effects	NNS	O
.	.	O

Sleep	JJ	PH
characteristics	NNS	PH
were	VBD	O
measured	VBN	O
by	IN	O
caregiver	NN	O
who	WP	O
completed	VBD	O
somnologs	NNS	O
and	CC	O
wrist	JJ	O
actigraphs	NN	O
.	.	O

Clinician	JJ	Ot
rating	NN	Ot
of	IN	O
severity	NN	O
of	IN	O
the	DT	O
sleep	JJ	O
disorder	NN	O
and	CC	O
improvement	NN	O
from	IN	O
baseline	NN	O
,	,	O
along	IN	O
with	IN	O
caregiver	JJ	Ot
ratings	NNS	Ot
of	IN	O
global	JJ	O
functioning	NN	O
and	CC	O
family	NN	O
stress	NN	O
were	VBD	O
also	RB	O
obtained	VBN	O
.	.	O

Fifty-one	CD	O
children	NNS	O
(	(	O
age	NN	O
range	NN	O
2-18	CD	O
years	NNS	O
)	)	O
who	WP	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
sleep	VB	O
hygiene	NN	O
intervention	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
crossover	NN	O
trial	NN	O
and	CC	O
47	CD	O
completed	VBD	O
the	DT	O
open-label	JJ	O
phase	NN	O
.	.	O

Recordings	NNS	O
of	IN	O
total	JJ	PH
night-time	JJ	PH
sleep	NN	PH
and	CC	O
sleep	JJ	PH
latency	NN	PH
showed	VBD	O
significant	JJ	O
improvement	NN	O
of	IN	O
approximately	RB	O
30	CD	O
min	NNS	O
.	.	O

Similarly	RB	O
,	,	O
significant	JJ	Ot
improvement	NN	Ot
was	VBD	O
observed	VBN	O
in	IN	O
clinician	JJ	Ot
and	CC	Ot
parent	JJ	Ot
ratings	NNS	Ot
.	.	Ot

There	EX	O
was	VBD	O
additional	JJ	O
improvement	NN	Ot
in	IN	O
the	DT	O
open-label	JJ	PH
somnolog	NN	PH
measures	NNS	PH
of	IN	O
sleep	JJ	PH
efficiency	NN	PH
and	CC	O
the	DT	PH
longest	JJS	PH
sleep	JJ	PH
episode	NN	PH
in	IN	O
the	DT	O
open-label	JJ	O
phase	NN	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
therapy	NN	O
improved	VBD	PH
the	DT	PH
sleep	NN	PH
of	IN	O
47	CD	O
children	NNS	O
and	CC	O
was	VBD	O
effective	JJ	ME
in	IN	ME
reducing	VBG	ME
family	NN	ME
stress	NN	ME
.	.	O

Children	NNP	O
with	IN	O
neurodevelopmental	JJ	O
disabilities	NNS	O
,	,	O
who	WP	O
had	VBD	O
treatment	NN	PH
resistant	JJ	PH
chronic	JJ	PH
delayed	VBN	PH
sleep	JJ	PH
phase	NN	PH
syndrome	NN	PH
and	CC	O
impaired	JJ	PH
sleep	JJ	PH
maintenance	NN	PH
,	,	O
showed	VBD	O
improvement	NN	O
in	IN	O
melatonin	NN	O
therapy	NN	O
.	.	O

[	JJ	O
Comparison	NNP	O
between	IN	O
anterior	JJ	O
rhinomanometry	NN	O
and	CC	O
impulse-oscillometric	JJ	O
rhinometry	NN	O
found	VBD	O
within	IN	O
nasal	JJ	PH
allergen	JJ	PH
provocation	NN	PH
]	NNP	O
.	.	O

UNLABELLED	NNP	O
Besides	IN	O
the	DT	O
standard	JJ	O
method	NN	O
of	IN	O
anterior	JJ	O
rhinomanometry	NN	O
(	(	O
aR	NN	O
)	)	O
,	,	O
the	DT	O
impulse-oscillometric	JJ	O
rhinometry	NN	O
(	(	O
IOS	NNP	O
)	)	O
is	VBZ	O
available	JJ	O
for	IN	O
measurements	NNS	O
of	IN	O
the	DT	O
nasal	JJ	PH
resistance	NN	PH
.	.	O

The	DT	O
aR	NN	O
is	VBZ	O
a	DT	O
procedure	NN	O
dependent	NN	O
on	IN	O
the	DT	O
cooperation	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
whereas	JJ	O
IOS	NNP	O
is	VBZ	O
measured	VBN	O
regardless	RB	O
from	IN	O
the	DT	O
breathing	NN	O
activities	NNS	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

We	PRP	O
examined	VBD	O
weather	RP	O
the	DT	O
resistance-measurement	NN	O
by	IN	O
means	NNS	O
of	IN	O
IOS	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
aR	NN	O
is	VBZ	O
a	DT	O
more	RBR	O
suitable	JJ	O
method	NN	O
for	IN	O
nasal	JJ	PH
allergic	JJ	PH
provocation	NN	PH
.	.	O

METHOD	NNP	O
17	CD	O
patients	NNS	O
with	IN	O
anamnestic	JJ	O
known	VBN	O
rhinokonjunktivitis	NN	O
(	(	O
6	CD	O
f	NN	O
,	,	O
11	CD	O
m	NN	O
)	)	O
had	VBD	O
a	DT	O
pricktest	NN	O
and	CC	O
then	RB	O
a	DT	O
nasal	JJ	O
provocation	NN	O
testing	VBG	O
with	IN	O
an	DT	O
allergen	NN	O
which	WDT	O
provoked	VBD	O
a	DT	O
reaction	NN	O
on	IN	O
the	DT	O
skin	NN	O
.	.	O

The	DT	O
complete	JJ	O
resistance	NN	PH
of	IN	O
the	DT	O
nose	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
by	IN	O
means	NNS	O
of	IN	O
aR	NN	O
and	CC	O
IOS	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
complete	JJ	PH
resistance	NN	PH
showed	VBD	O
neither	CC	O
in	IN	O
the	DT	O
basic	JJ	O
measurement	NN	O
(	(	O
aR	JJ	O
0,38	CD	O
+/-	JJ	O
0,14	CD	O
kPa/l/s	NN	O
;	:	O
IOS	NNP	O
0,38	CD	O
+/-	JJ	O
0,11	CD	O
kPa/l/s	NN	O
)	)	O
nor	CC	O
in	IN	O
the	DT	O
control	NN	O
solution	NN	O
(	(	O
aR	JJ	O
0,38	CD	O
+/-	JJ	O
0,14	CD	O
;	:	O
IOS	NNP	O
0,39	CD	O
+/-	JJ	O
0,14	CD	O
)	)	O
nor	CC	O
after	IN	O
application	NN	O
of	IN	O
the	DT	O
allergenic	JJ	O
solution	NN	O
(	(	O
15	CD	O
min	NN	O
:	:	O
aR	JJ	O
0,69	CD	O
+/-	JJ	O
0,27	CD	O
;	:	O
IOS	NNP	O
0,77	CD	O
+/-	JJ	O
0,42	CD	O
;	:	O
30	CD	O
min	NN	O
:	:	O
aR	JJ	O
0,65	CD	O
+/-	JJ	O
0,29	CD	O
;	:	O
IOS	NNP	O
0,6	CD	O
+/-	JJ	O
0,38	CD	O
)	)	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
measurement	NN	PH
of	IN	PH
aR	NN	PH
and	CC	PH
IOS	NNP	PH
after	IN	O
the	DT	O
allergenic	JJ	O
solution	NN	O
showed	VBD	O
a	DT	O
positive	JJ	O
correlation	NN	PH
(	(	O
15	CD	O
min	NN	O
:	:	O
r	NN	O
=	VBZ	O
0,63	CD	O
,	,	O
p	NN	O
<	VBD	O
0,01	CD	O
;	:	O
30	CD	O
min	NN	O
:	:	O
r	NN	O
=	VBZ	O
0,67	CD	O
,	,	O
p	NN	O
<	NNP	O
0,01	CD	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
by	IN	O
means	NNS	O
of	IN	O
clinic	NN	O
and	CC	O
measurement	NN	O
methods	NNS	O
in	IN	O
the	DT	O
aR	NN	O
of	IN	O
7	CD	O
patients	NNS	O
a	DT	O
positive	JJ	O
reaction	NN	O
,	,	O
within	IN	O
7	CD	O
patient	NN	O
a	DT	O
negative	JJ	O
reaction	NN	O
,	,	O
3	CD	O
patients	NNS	O
had	VBD	O
a	DT	O
unspecific	JJ	PH
nasal	NN	PH
hyperreactivity	NN	PH
.	.	O

There	EX	O
was	VBD	O
a	DT	O
correspondence	NN	O
in	IN	O
6	CD	O
of	IN	O
the	DT	O
7	CD	O
patients	NNS	O
with	IN	O
positive	JJ	O
reaction	NN	O
in	IN	O
aR	NN	O
between	IN	O
both	DT	O
methods	NNS	O
.	.	O

4	CD	O
of	IN	O
the	DT	O
7	CD	O
results	NNS	O
with	IN	O
negative	JJ	O
reaction	NN	O
in	IN	O
the	DT	O
aR	NN	O
would	MD	O
have	VB	O
been	VBN	O
positive	JJ	O
then	RB	O
underlying	VBG	O
the	DT	O
same	JJ	O
criteria	NNS	O
in	IN	O
the	DT	O
IOS	NNP	O
without	IN	O
announcing	VBG	O
the	DT	O
symptomscore	NN	PH
a	DT	O
relevant	JJ	O
clinical	JJ	O
symptomatic	NN	O
while	IN	O
testing	VBG	O
.	.	O

CONCLUSION	NNP	O
IOS	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
procedure	NN	O
for	IN	O
nasal	JJ	O
provocation	NN	O
testing	VBG	O
and	CC	O
provides	VBZ	O
results	NNS	O
similar	JJ	O
to	TO	O
the	DT	O
aR	NN	O
.	.	O

In	IN	O
comparison	NN	O
to	TO	O
aR	VB	O
IOS	NNP	O
is	VBZ	O
not	RB	O
dependent	JJ	O
on	IN	O
the	DT	O
patients	NNS	O
cooperation	NN	O
.	.	O

Due	NNP	O
to	TO	O
its	PRP$	O
higher	JJR	O
sensitivity	NN	O
the	DT	O
valid	JJ	O
limits	NNS	O
of	IN	O
the	DT	O
aR	NN	O
at	IN	O
provocation	NN	O
testings	NNS	O
can	MD	O
not	RB	O
be	VB	O
transferred	VBN	O
to	TO	O
IOS	NNP	O
to	TO	O
avoid	VB	O
a	DT	O
false	JJ	PH
positive	JJ	PH
reaction	NN	PH
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
phase	NN	O
I/II	NNP	O
trial	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
granulocyte-macrophage	NN	O
colony-stimulating	NN	O
factor	NN	O
in	IN	O
very	RB	O
low	JJ	O
birthweight	NN	O
neonates	NNS	O
:	:	O
significant	JJ	O
induction	NN	O
of	IN	O
circulatory	NN	O
neutrophils	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
platelets	NNS	O
,	,	O
and	CC	O
bone	NN	O
marrow	NN	O
neutrophils	NNS	O
.	.	O

Neonates	NNS	O
,	,	O
especially	RB	O
those	DT	O
of	IN	O
very	RB	O
low	JJ	O
birthweight	NN	O
(	(	O
VLBW	NNP	O
)	)	O
,	,	O
have	VBP	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
nosocomial	JJ	O
infections	NNS	O
secondary	JJ	O
to	TO	O
deficiencies	NNS	O
in	IN	O
development	NN	O
.	.	O

We	PRP	O
previously	RB	O
demonstrated	VBD	O
that	IN	O
granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
production	NN	O
and	CC	O
mRNA	JJ	O
expression	NN	O
from	IN	O
stimulated	VBN	O
neonatal	JJ	O
mononuclear	JJ	O
cells	NNS	O
are	VBP	O
significantly	RB	O
less	JJR	O
than	IN	O
that	DT	O
from	IN	O
adult	NN	O
cells	NNS	O
.	.	O

Recombinant	JJ	O
murine	JJ	O
GM-CSF	NNP	O
administration	NN	O
to	TO	O
neonatal	JJ	O
rats	NNS	O
has	VBZ	O
resulted	VBN	O
in	IN	O
neutrophilia	JJ	O
,	,	O
increased	JJ	O
neutrophil	NN	O
production	NN	O
,	,	O
and	CC	O
increased	VBD	O
survival	NN	O
of	IN	O
pups	NNS	O
during	IN	O
experimental	JJ	O
Staphylococcus	NNP	O
aureus	NN	O
sepsis	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
safety	NN	O
and	CC	O
biologic	JJ	O
response	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
(	(	O
rhu	NN	O
)	)	O
GM-CSF	NNP	O
in	IN	O
VLBW	NNP	O
neonates	NNS	O
.	.	O

Twenty	NNP	O
VLBW	NNP	O
neonates	NNS	O
(	(	O
500	CD	O
to	TO	O
1,500	CD	O
g	NN	O
)	)	O
,	,	O
aged	VBD	O
<	JJ	O
72	CD	O
hours	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
rhuGM-CSF	NN	O
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
,	,	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
,	,	O
or	CC	O
10	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
given	VBN	O
via	IN	O
2-hour	JJ	O
intravenous	JJ	O
infusion	NN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

Complete	JJ	O
blood	NN	O
counts	NNS	O
,	,	O
differential	NN	O
,	,	O
and	CC	O
platelet	NN	O
counts	NNS	O
were	VBD	O
obtained	VBN	O
,	,	O
and	CC	O
tibial	JJ	O
bone	NN	O
marrow	NN	O
aspirate	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
day	NN	O
8	CD	O
.	.	O

Neutrophil	NNP	O
C3bi	NNP	O
receptor	NN	O
expression	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

GM-CSF	JJ	PH
levels	NNS	PH
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
sandwich	JJ	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
rhuGM-CSF	NN	O
.	.	O

At	IN	O
all	DT	O
doses	NNS	O
,	,	O
rhuGM-CSF	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
grade	NN	PH
III	NNP	PH
or	CC	PH
IV	NNP	PH
toxicity	NN	PH
.	.	O

Within	IN	O
48	CD	O
hours	NNS	O
of	IN	O
administration	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
circulating	VBG	PH
absolute	JJ	PH
neutrophil	NN	PH
count	NN	PH
(	(	PH
ANC	NNP	PH
)	)	PH
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
and	CC	O
10.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
,	,	O
which	WDT	O
continued	VBD	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
hours	NNS	O
after	IN	O
discontinuation	NN	O
of	IN	O
rhuGM-CSF	NN	O
.	.	O

When	WRB	O
the	DT	O
ANC	NNP	O
was	VBD	O
normalized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
's	POS	O
first	JJ	O
ANC	NNP	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
ANC	NNP	PH
on	IN	O
days	NNS	O
6	CD	O
and	CC	O
7	CD	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
.	.	O

By	IN	O
day	NN	O
7	CD	O
,	,	O
all	DT	O
tested	JJ	O
doses	NNS	O
of	IN	O
rhuGM-CSF	NN	O
resulted	VBD	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
absolute	NN	PH
monocyte	NN	PH
count	NN	PH
(	(	PH
AMC	NNP	PH
)	)	PH
compared	VBN	O
with	IN	O
placebo-treated	JJ	O
neonates	NNS	O
.	.	O

In	IN	O
those	DT	O
receiving	VBG	O
rhuGM-CSF	JJ	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
,	,	O
there	EX	O
was	VBD	O
additionally	RB	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
day	NN	PH
7	CD	PH
and	CC	PH
8	CD	PH
platelet	NN	PH
count	NN	PH
.	.	O

Tibial	NNP	O
bone	NN	O
marrow	NN	O
aspirates	VBZ	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
bone	NN	PH
marrow	NN	PH
neutrophil	JJ	PH
storage	NN	PH
pool	NN	PH
(	(	PH
BM	NNP	PH
NSP	NNP	PH
)	)	PH
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
and	CC	O
10.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
.	.	O

Neutrophil	NNP	PH
C3bi	NNP	PH
receptor	NN	PH
expression	NN	PH
was	VBD	O
significantly	RB	O
increased	VBN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
rhuGM-CSF	NN	O
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
.	.	O

The	DT	O
elimination	NN	O
half-life	NN	O
(	(	O
T1/2	NNP	O
)	)	O
of	IN	O
rhuGM-CSF	NN	O
was	VBD	O
1.4	CD	O
+/-	JJ	O
0.8	CD	O
to	TO	O
3.9	CD	O
+/-	JJ	O
2.8	CD	O
hours	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
400	CD	O
WORDS	NNP	O
)	)	O
Immunogenicity	NN	PH
and	CC	O
reactogenicity	NN	PH
of	IN	O
a	DT	O
group	NN	O
C	NNP	O
meningococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
A+C	NNP	O
meningococcal	JJ	O
polysaccharide	NN	O
vaccine	NN	O
in	IN	O
adolescents	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
observer-blind	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
immunogenicity	NN	PH
and	CC	O
reactogenicity	NN	PH
of	IN	O
a	DT	O
group	NN	O
C	NNP	O
meningococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
(	(	O
MenC	NNP	O
)	)	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
A+C	NNP	O
meningococcal	JJ	O
polysaccharide	NN	O
vaccine	NN	O
(	(	O
MenPS	NNP	O
)	)	O
in	IN	O
healthy	JJ	O
adolescents	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
one	CD	O
dose	NN	O
of	IN	O
either	DT	O
MenC	NNP	O
(	(	O
n=92	NN	O
)	)	O
or	CC	O
MenPS	NNP	O
(	(	O
n=90	NN	O
)	)	O
.	.	O

Group	NNP	O
C	NNP	O
meningococcal	JJ	PH
IgG	NNP	PH
antibody	NN	PH
concentrations	NNS	PH
and	CC	PH
bactericidal	JJ	PH
titres	NNS	PH
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
MenC	NNP	O
group	NN	O
than	IN	O
the	DT	O
MenPS	NNP	O
group	NN	O
at	IN	O
1	CD	O
month	NN	O
(	(	O
22.8	CD	O
U/ml	NNP	O
vs	NN	O
4.0	CD	O
U/ml	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
and	CC	O
87	CD	O
vs	NN	O
20	CD	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
6.1	CD	O
U/ml	NNP	O
vs	NN	O
3.0	CD	O
U/ml	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
and	CC	O
81.3	CD	O
vs	NN	O
20.2	CD	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
differences	NNS	O
in	IN	O
post	NN	PH
immunisation	NN	PH
reaction	NN	PH
rates	NNS	PH
were	VBD	O
noted	VBN	O
between	IN	O
the	DT	O
two	CD	O
vaccinated	VBD	O
groups	NNS	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
the	DT	O
safety	NN	O
and	CC	O
enhanced	JJ	O
immunogenicity	NN	PH
of	IN	O
the	DT	O
candidate	NN	O
meningococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
licensed	JJ	O
polysaccharide	NN	O
vaccine	NN	O
in	IN	O
adolescents	NNS	O
.	.	O

New	NNP	O
hope	NN	O
for	IN	O
children	NNS	O
with	IN	O
Kawasaki	NNP	O
disease	NN	O
.	.	O

Kawasaki	NNP	O
disease	NN	O
is	VBZ	O
now	RB	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
acquired	VBN	O
heart	NN	O
disease	NN	O
in	IN	O
America	NNP	O
's	POS	O
children	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
an	DT	O
acute	JJ	O
febrile	NN	O
illness	NN	O
that	WDT	O
may	MD	O
cause	VB	O
coronary	JJ	O
artery	NN	O
aneurysm	NN	O
formation	NN	O
in	IN	O
infected	JJ	O
children	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
gamma	JJ	O
globulin	NN	O
(	(	O
IVGG	NNP	O
)	)	O
plus	CC	O
aspirin	JJ	O
versus	NN	O
aspirin	NN	O
alone	RB	O
upon	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
show	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
coronary	JJ	PH
aneurysm	NN	PH
formation	NN	PH
from	IN	O
the	DT	O
usual	JJ	O
20	CD	O
%	NN	O
-30	NN	O
%	NN	O
to	TO	O
3	CD	O
%	NN	O
.	.	O

Administration	NNP	O
of	IN	O
IVGG	NNP	O
presents	VBZ	O
some	DT	O
unique	JJ	O
challenges	NNS	O
for	IN	O
nurses	NNS	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
pediatric	JJ	O
nurse	NN	O
must	MD	O
educate	VB	O
parents	NNS	O
and	CC	O
children	NNS	O
about	IN	O
this	DT	O
disease	NN	O
to	TO	O
prepare	VB	O
them	PRP	O
for	IN	O
discharge	NN	O
and	CC	O
long-term	JJ	O
follow-up	JJ	O
care	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
non-depolarizing	JJ	O
neuromuscular	JJ	O
blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NN	O
disease	NN	O
.	.	O

To	TO	O
compare	VB	O
haemodynamic	JJ	O
responses	NNS	O
associated	VBN	O
with	IN	O
equipotent	JJ	O
doses	NNS	O
of	IN	O
neuromuscular	JJ	O
blockers	NNS	O
and	CC	O
high-dose	JJ	O
fentanyl	NN	O
(	(	O
50	CD	O
micrograms.kg-1	NN	O
)	)	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NNS	O
stenosis	NN	O
(	(	O
AS	IN	O
)	)	O
and	CC	O
20	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
insufficiency	NN	O
(	(	O
AI	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
four	CD	O
study	NN	O
groups	NNS	O
to	TO	O
receive	VB	O
the	DT	O
following	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
pancuronium	NN	O
0.12	CD	O
mg.kg-1	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
vecuronium	NN	O
0.12	CD	O
mg.kg-1	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
atracurium	NN	O
0.4	CD	O
mg.kg-1	NN	O
,	,	O
or	CC	O
(	(	O
4	CD	O
)	)	O
pancuronium-metocurine	NN	O
mixture	NN	O
(	(	O
0.4	CD	O
mg	NN	O
+	VBD	O
1.6	CD	O
mg/ml	NN	O
)	)	O
:	:	O
1	CD	O
ml/10	NNS	O
kg	NN	O
)	)	O
.	.	O

Neuromuscular	JJ	O
blockers	NNS	O
were	VBD	O
injected	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
with	IN	O
the	DT	O
fentanyl	NN	O
;	:	O
haemodynamics	NNS	O
were	VBD	O
recorded	VBN	O
with	IN	O
the	DT	O
patients	NNS	O
awake	VBP	O
(	(	O
baseline	NN	O
)	)	O
,	,	O
at	IN	O
two	CD	O
minutes	NNS	O
post-induction	NN	O
,	,	O
and	CC	O
at	IN	O
two	CD	O
and	CC	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
AS	NNP	O
,	,	O
pancuronium	NN	O
increased	VBD	O
heart	NN	PH
rate	NN	PH
more	JJR	O
than	IN	O
vecuronium	NN	O
or	CC	O
atracurium	NN	O
;	:	O
heart	NN	PH
rates	NNS	PH
were	VBD	O
also	RB	O
higher	JJR	O
with	IN	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
than	IN	O
with	IN	O
vecuronium	NN	O
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
no	DT	O
ECG	NNP	PH
signs	NNS	PH
of	IN	PH
ischaemia	NN	PH
,	,	O
one	CD	O
patient	NN	O
given	VBN	O
pancuronium	NN	O
developed	VBD	O
severe	JJ	PH
hypotension	NN	PH
associated	VBN	PH
with	IN	PH
tachycardia	NN	PH
.	.	O

Reductions	NNS	O
in	IN	O
SVR	NNP	PH
after	IN	O
atracurium	NN	O
allowed	VBD	O
small	JJ	O
but	CC	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
decreases	NNS	O
in	IN	O
MAP	NNP	PH
which	WDT	O
were	VBD	O
well	RB	Ot
tolerated	VBN	Ot
;	:	O
one	CD	O
patient	NN	O
,	,	O
however	RB	O
,	,	O
did	VBD	O
develop	VB	O
severe	JJ	PH
hypotension	NN	PH
.	.	O

Intubation	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
increases	NNS	O
in	IN	O
MAP	NNP	PH
in	IN	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
group	NN	O
.	.	O

Vecuronium	NNP	O
permitted	VBD	O
the	DT	O
most	RBS	O
stable	JJ	O
overall	JJ	PH
haemodynamic	JJ	PH
course	NN	PH
at	IN	O
all	DT	O
measurement	JJ	O
times	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
patients	NNS	O
with	IN	O
AI	NNP	O
showed	VBD	O
stable	JJ	PH
haemodynamics	NNS	PH
after	IN	O
vecuronium	NN	O
,	,	O
pancuronium	NN	O
and	CC	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
;	:	O
one	CD	O
patient	NN	O
became	VBD	O
tachycardic	JJ	PH
following	VBG	O
vecuronium	NN	O
.	.	O

Atracurium	NNP	O
caused	VBD	O
unexplained	JJ	O
elevations	NNS	PH
in	IN	PH
diastolic	JJ	PH
and	CC	PH
mean	JJ	PH
arterial	NN	PH
pressures	NNS	PH
which	WDT	O
were	VBD	O
significant	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
vecuronium	VB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
in	IN	O
increases	NNS	O
in	IN	O
PCWP	NNP	PH
;	:	O
mean	JJ	PH
PA	NNP	PH
pressures	NNS	PH
and	CC	O
CVP	NNP	PH
were	VBD	O
also	RB	O
increased	VBN	Ot
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
atracurium	NN	O
inpatients	NNS	O
with	IN	O
Al	NNP	O
need	VBP	O
further	JJ	O
evaluation	NN	O
.	.	O

Monotherapy	NNP	O
of	IN	O
mild	JJ	O
hypertension	NN	PH
with	IN	O
nifedipine	NN	O
.	.	O

The	DT	O
effectiveness	NN	Ot
of	IN	O
nifedipine	JJ	O
as	IN	O
first-line	JJ	O
monotherapy	NN	O
for	IN	O
mild	JJ	O
diastolic	JJ	PH
hypertension	NN	PH
(	(	O
range	NN	O
:	:	O
95	CD	O
to	TO	O
105	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
was	VBD	O
tested	VBN	O
in	IN	O
this	DT	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
,	,	O
after	IN	O
titration	NN	O
of	IN	O
the	DT	O
placebo	NN	O
or	CC	O
active	JJ	O
drug	NN	O
,	,	O
they	PRP	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Significant	JJ	O
declines	NNS	O
in	IN	O
the	DT	O
sitting	VBG	O
systolic	JJ	PH
and	CC	PH
diastolic	JJ	PH
pressures	NNS	PH
of	IN	O
-19	JJ	O
+/-	JJ	O
4	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
standard	JJ	O
error	NN	O
)	)	O
and	CC	O
-13	$	O
+/-	JJ	O
2	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
observed	VBN	O
during	IN	O
this	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

Overall	JJ	O
,	,	O
75	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
active	JJ	O
drug	NN	O
had	VBD	O
diastolic	JJ	PH
pressures	NNS	PH
less	RBR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
90	CD	O
mm	NNS	O
Hg	NNP	O
at	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
visit	NN	O
.	.	O

Heart	NNP	PH
rate	NN	PH
was	VBD	O
not	RB	O
significantly	RB	O
changed	VBN	O
in	IN	O
the	DT	O
sitting	VBG	O
position	NN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
(	(	O
75	CD	O
percent	NN	O
)	)	O
showed	VBD	O
a	DT	O
response	NN	O
to	TO	O
nifedipine	JJ	O
doses	NNS	O
of	IN	O
10	CD	O
or	CC	O
20	CD	O
mg	NNS	O
orally	RB	O
three	CD	O
times	NNS	O
daily	RB	O
in	IN	O
the	DT	O
capsule	NN	O
form	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
the	DT	O
systolic	NN	PH
and	CC	O
diastolic	JJ	PH
pressures	NNS	PH
at	IN	O
entry	NN	O
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
nifedipine	NN	O
required	VBN	O
for	IN	O
effective	JJ	Ot
blood	NN	Ot
pressure	NN	Ot
control	NN	O
.	.	O

Inhaled	VBN	O
fluticasone	NN	O
reduces	NNS	O
sputum	VBP	PH
inflammatory	JJ	PH
indices	NNS	PH
in	IN	O
severe	JJ	O
bronchiectasis	NN	O
.	.	O

Although	IN	O
corticosteroid	JJ	O
therapy	NN	O
might	MD	O
be	VB	O
clinically	RB	O
beneficial	JJ	O
for	IN	O
bronchiectasis	NN	O
,	,	O
very	RB	O
little	JJ	O
is	VBZ	O
known	VBN	O
of	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
inflammatory	NN	PH
and	CC	PH
infective	JJ	PH
markers	NNS	PH
in	IN	O
bronchiectasis	NN	O
.	.	O

We	PRP	O
have	VBP	O
therefore	RB	O
performed	VBN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
4-wk	JJ	O
administration	NN	O
of	IN	O
inhaled	JJ	O
fluticasone	NN	O
in	IN	O
bronchiectasis	NN	O
.	.	O

Twenty-four	CD	O
patients	NNS	O
(	(	O
12	CD	O
female	NN	O
;	:	O
mean	JJ	O
age	NN	O
51	CD	O
yr	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
into	IN	O
receiving	VBG	O
either	CC	O
inhaled	JJ	O
fluticasone	NN	O
(	(	O
500	CD	O
microgram	NN	O
twice	RB	O
daily	RB	O
)	)	O
via	IN	O
the	DT	O
Accuhaler	NNP	O
device	NN	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

At	IN	O
each	DT	O
visit	NN	O
,	,	O
spirometry	NN	O
,	,	O
24-h	JJ	O
sputum	NN	O
volume	NN	O
,	,	O
sputum	NN	O
leukocyte	NN	O
density	NN	O
,	,	O
bacterial	JJ	O
densities	NNS	O
,	,	O
and	CC	O
concentrations	NNS	PH
of	IN	PH
interleukin	NN	PH
(	(	PH
IL	NNP	PH
)	)	PH
-1beta	NN	PH
,	,	O
IL-8	NNP	PH
,	,	PH
tumor	NN	PH
necrosis	NN	PH
factor-alpha	JJ	PH
(	(	PH
TNF-alpha	NNP	PH
)	)	PH
,	,	O
and	CC	O
leukotriene	JJ	PH
B4	NNP	PH
(	(	PH
LTB4	NNP	PH
)	)	PH
were	VBD	O
determined	VBN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
decrease	NN	O
in	IN	O
sputum	NN	PH
leukocyte	NN	PH
density	NN	PH
and	CC	O
IL-1beta	NNP	PH
,	,	O
IL-8	NNP	PH
,	,	O
and	CC	O
LTB4	NNP	PH
after	IN	O
fluticasone	NN	O
treatment	NN	O
.	.	O

The	DT	O
fluticasone	NN	O
group	NN	O
had	VBD	O
one	CD	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
three	CD	O
episodes	NNS	O
of	IN	O
exacerbation	NN	A
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
spirometry	NN	PH
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
or	CC	O
any	DT	O
reported	JJ	O
adverse	JJ	A
reactions	NNS	A
in	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	VB	O
that	IN	O
high-dose	JJ	O
fluticasone	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
sputum	NN	PH
inflammatory	NN	PH
indices	NNS	PH
in	IN	O
bronchiectasis	NN	O
.	.	O

Large-scale	JJ	O
and	CC	O
long-term	JJ	O
studies	NNS	O
are	VBP	O
indicated	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
inhaled	JJ	O
steroid	JJ	O
therapy	NN	O
on	IN	O
the	DT	O
inflammatory	JJ	O
components	NNS	O
in	IN	O
bronchiectasis	NN	O
.	.	O

Couple-responsible	JJ	O
therapy	NN	O
process	NN	O
:	:	O
positive	JJ	Ot
proximal	JJ	Ot
outcomes	NNS	Ot
.	.	Ot

Therapist-couple	JJ	O
struggle	NN	O
vs.	FW	O
cooperation	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
clinical	JJ	O
outcome	NN	O
.	.	O

This	DT	O
research	NN	O
conceptualizes	NN	O
and	CC	O
investigates	VBZ	O
treatment	NN	O
process	NN	O
as	IN	O
it	PRP	O
relates	VBZ	O
to	TO	O
the	DT	O
occurrence	NN	O
of	IN	O
struggle	NN	O
versus	NN	O
cooperation	NN	O
.	.	O

Models	NNS	O
of	IN	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
process	NN	O
in	IN	O
couple	NN	O
therapy	NN	O
were	VBD	O
developed	VBN	O
.	.	O

Couple-responsible	JJ	O
process	NN	O
consists	VBZ	O
of	IN	O
enactments	NNS	O
,	,	O
accommodation	NN	O
,	,	O
and	CC	O
inductive	JJ	O
process	NN	O
.	.	O

Therapist-responsible	JJ	O
process	NN	O
consists	VBZ	O
of	IN	O
primary	JJ	O
therapist-couple	JJ	O
interaction	NN	O
,	,	O
therapist	JJ	O
interpretation	NN	O
,	,	O
and	CC	O
direct	JJ	O
instruction	NN	O
.	.	O

In	IN	O
counterbalanced	JJ	O
order	NN	O
,	,	O
25	CD	O
couples	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
episodes	NNS	O
during	IN	O
one	CD	O
therapy	NN	O
session	NN	O
.	.	O

Couples	NNP	O
reviewed	VBD	O
videotapes	NNS	O
of	IN	O
the	DT	O
episodes	NNS	O
and	CC	O
completed	VBD	O
measures	NNS	O
of	IN	O
responsibility	NN	O
,	,	O
struggle	NN	O
,	,	O
and	CC	O
cooperation	NN	O
.	.	O

Perceived	NNP	Ot
responsibility	NN	Ot
was	VBD	O
higher	JJR	O
and	CC	O
struggle	NN	Ot
was	VBD	O
lower	JJR	O
during	IN	O
couple-responsible	JJ	O
episodes	NNS	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
cooperation	NN	ME
was	VBD	O
found	VBN	O
.	.	O

Presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
a	DT	O
contrast	NN	O
condition	NN	O
,	,	O
where	WRB	O
couples	NNS	O
reported	VBD	O
on	IN	O
one	CD	O
therapist	NN	O
process	NN	O
after	IN	O
already	RB	O
experiencing	VBG	O
its	PRP$	O
opposite	NN	O
,	,	O
led	VBN	O
to	TO	O
main	JJ	O
effects	NNS	O
for	IN	O
responsibility	NN	O
and	CC	O
struggle	NN	O
,	,	O
and	CC	O
mediated	VBD	O
effects	NNS	O
of	IN	O
struggle	NN	O
and	CC	O
cooperation	NN	O
.	.	O

Generally	NNP	O
speaking	NN	O
,	,	O
responsibility	NN	ME
was	VBD	O
even	RB	O
higher	JJR	O
during	IN	O
couple-responsible	JJ	O
episodes	NNS	O
and	CC	O
even	RB	O
lower	JJR	O
during	IN	O
therapist-responsible	JJ	O
episodes	NNS	O
when	WRB	O
contrast	NN	O
was	VBD	O
present	JJ	O
.	.	O

Similarly	RB	O
,	,	O
struggle	NN	ME
was	VBD	O
even	RB	O
lower	JJR	O
during	IN	O
couple-responsible	JJ	O
episodes	NNS	O
and	CC	O
even	RB	O
higher	JJR	O
during	IN	O
therapist-responsible	JJ	O
episodes	NNS	O
when	WRB	O
contrast	NN	O
was	VBD	O
present	JJ	O
.	.	O

For	IN	O
both	DT	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
episodes	NNS	O
,	,	O
cooperation	NN	ME
was	VBD	O
negatively	RB	O
affected	VBN	O
by	IN	O
a	DT	O
shift	NN	O
from	IN	O
the	DT	O
prior	JJ	O
,	,	O
opposite	JJ	O
therapist	NN	O
process	NN	O
.	.	O

Significant	JJ	O
proportions	NNS	O
of	IN	O
the	DT	O
variance	NN	O
in	IN	O
responsibility	NN	ME
,	,	ME
struggle	NN	ME
,	,	ME
and	CC	ME
cooperation	NN	ME
,	,	O
however	RB	O
,	,	O
were	VBD	O
not	RB	O
accounted	VBN	O
for	IN	O
by	IN	O
therapist	JJ	O
process	NN	O
alone	RB	O
.	.	O

Addition	NN	O
of	IN	O
fexofenadine	NN	O
to	TO	O
inhaled	VB	O
corticosteroid	JJ	O
therapy	NN	O
to	TO	O
reduce	VB	O
inflammatory	JJ	PH
biomarkers	NNS	PH
in	IN	O
atopic	NN	O
asthma	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
previously	RB	O
showed	VBD	O
that	IN	O
H1-antihistamines	NNP	O
may	MD	O
shift	VB	O
the	DT	O
PC20	NNP	O
(	(	O
provocation	NN	O
concentration	NN	O
that	WDT	O
caused	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
1	CD	O
second	NN	O
of	IN	O
20	CD	O
%	NN	O
)	)	O
threshold	NN	O
to	TO	O
adenosine	VB	O
monophosphate	NN	O
(	(	O
AMP	NNP	O
)	)	O
challenge	NN	O
but	CC	O
may	MD	O
paradoxically	RB	O
prolong	VB	O
recovery	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
measure	VB	O
AMP	NNP	O
recovery	NN	O
using	VBG	O
a	DT	O
constant	JJ	O
predetermined	VBN	O
AMP	NNP	O
PC20	NNP	O
and	CC	O
to	TO	O
evaluate	VB	O
whether	IN	O
fexofenadine	NN	O
use	NN	O
confers	NNS	O
add-on	JJ	O
effects	NNS	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
fluticasone	NN	O
propionate	NN	O
alone	RB	O
or	CC	O
combined	VBN	O
fluticasone	CD	O
propionate-salmeterol	NN	O
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
atopic	NN	O
patients	NNS	O
with	IN	O
mild-to-moderate	JJ	O
asthma	NN	O
(	(	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
1	CD	O
second	NN	O
of	IN	O
76	CD	O
%	NN	O
)	)	O
completed	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	NN	O
study	NN	O
consisting	VBG	O
of	IN	O
3-week	JJ	O
treatment	NN	O
blocks	NNS	O
of	IN	O
either	DT	O
fluticasone	JJ	O
propionate-salmeterol	NN	O
,	,	O
250	CD	O
microg	NN	O
twice	RB	O
daily	RB	O
,	,	O
or	CC	O
fluticasone	JJ	O
propionate	NN	O
alone	RB	O
,	,	O
250	CD	O
microg	NN	O
twice	RB	O
daily	RB	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
either	DT	O
fexofenadine	NN	O
,	,	O
180	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
,	,	O
or	CC	O
matched	VBD	O
placebo	NN	O
.	.	O

Recovery	NN	Ot
after	IN	O
a	DT	O
predetermined	JJ	Ot
AMP	NNP	Ot
PC20	NNP	Ot
challenge	NN	Ot
was	VBD	O
measured	VBN	O
(	(	O
primary	JJ	O
outcome	NN	O
)	)	O
,	,	O
along	IN	O
with	IN	O
exhaled	JJ	PH
nitric	JJ	PH
oxide	NN	PH
levels	NNS	PH
,	,	O
plasma	NN	PH
eosinophil	NN	PH
cationic	JJ	PH
protein	NN	PH
levels	NNS	PH
,	,	O
peripheral	JJ	PH
eosinophil	NN	PH
counts	NNS	PH
,	,	O
pulmonary	JJ	PH
function	NN	PH
,	,	O
diary	JJ	Ot
card	NN	Ot
outcomes	NNS	Ot
,	,	O
and	CC	O
quality	NN	ME
of	IN	ME
life	NN	ME
(	(	O
all	DT	O
secondary	JJ	O
outcomes	NNS	O
)	)	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
primary	JJ	O
or	CC	O
secondary	JJ	O
outcomes	NNS	O
when	WRB	O
fexofenadine	NN	O
was	VBD	O
added	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
fluticasone	JJ	O
propionate-salmeterol	NN	O
or	CC	O
fluticasone	NN	O
propionate	NN	O
alone	RB	O
.	.	O

The	DT	O
mean	NN	O
AMP	NNP	O
recovery	NN	O
time	NN	O
was	VBD	O
25.0	CD	O
vs	NN	O
23.4	CD	O
minutes	NNS	O
for	IN	O
fexofenadine	NN	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
,	,	O
as	IN	O
add-on	JJ	O
to	TO	O
fluticasone-salmeterol	NN	O
and	CC	O
22.5	CD	O
vs	NN	O
23.9	CD	O
minutes	NNS	O
,	,	O
respectively	RB	O
,	,	O
as	IN	O
add-on	JJ	O
to	TO	O
fluticasone	VB	O
alone	RB	O
.	.	O

CONCLUSION	NNP	O
Fexofenadine	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
recovery	NN	O
to	TO	O
a	DT	O
fixed	VBN	O
dose	NN	O
of	IN	O
AMP	NNP	O
challenge	NN	O
or	CC	O
any	DT	O
other	JJ	O
surrogate	JJ	O
inflammatory	NN	O
markers	NNS	O
when	WRB	O
given	VBN	O
as	IN	O
add-on	JJ	O
therapy	NN	O
to	TO	O
corticosteroid-treatedatopic	JJ	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

Fusidic	NNP	O
acid	VBZ	O
prophylaxis	NN	O
before	IN	O
cataract	JJ	O
surgery	NN	O
:	:	O
patient	JJ	O
self-administration	NN	O
.	.	O

In	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
authors	NNS	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
patient-administered	JJ	O
1	CD	O
%	NN	O
fusidic	JJ	O
acid	RB	O
viscous	JJ	O
eye	NN	O
drops	NNS	O
in	IN	O
clearing	VBG	O
the	DT	O
commonest	JJS	O
organisms	JJ	O
causing	VBG	O
pseudophakic	NN	O
endophthalmitis	NN	O
(	(	O
Staphylococcus	NNP	O
epidermidis	RB	O
and	CC	O
aureus	RB	O
)	)	O
from	IN	O
the	DT	O
lids	NNS	O
and	CC	O
conjunctivae	NN	O
of	IN	O
79	CD	O
patients	NNS	O
before	IN	O
cataract	JJ	O
surgery	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
self-administered	JJ	O
fusidic	JJ	O
acid	NN	O
viscous	JJ	O
eye	NN	O
drops	VBZ	O
four	CD	O
times	NNS	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
before	IN	O
surgery	NN	O
;	:	O
the	DT	O
placebo	NN	O
group	NN	O
received	VBD	O
inert	JJ	O
ophthalmic	JJ	O
drops	NNS	O
.	.	O

Fellow	NNP	O
eyes	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
remained	VBD	O
untreated	JJ	O
as	IN	O
a	DT	O
natural	JJ	O
control	NN	O
.	.	O

Lower	JJR	O
fornix	NN	O
and	CC	O
lid	JJ	O
margin	NN	O
cultures	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
both	DT	O
eyes	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

Before	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
in	IN	O
organism	NN	PH
counts	NNS	PH
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
eyes	NNS	O
receiving	VBG	O
fusidic	JJ	O
acid	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
free	JJ	O
of	IN	O
clinically	RB	O
relevant	JJ	O
Staphylococcus	NNP	O
spp	NN	O
.	.	O

than	IN	O
all	DT	O
pre-treatment	JJ	O
eyes	NNS	O
(	(	O
for	IN	O
lids	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
conjunctivae	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
number	NN	PH
of	IN	PH
lid	JJ	PH
margins	NNS	PH
were	VBD	O
rendered	VBN	O
'clinically	RB	O
clean	JJ	O
'	''	O
(	(	O
i.e.	FW	O
,	,	O
0-49	JJ	O
organisms/swab	NN	O
)	)	O
by	IN	O
fusidic	JJ	O
acid	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
untreated	JJ	O
eyes	NNS	O
.	.	O

Treatment	NNP	O
also	RB	O
effectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
reduced	VBD	O
the	DT	O
numbers	NNS	PH
of	IN	PH
bacteria	NNS	PH
isolated	VBN	PH
from	IN	PH
conjunctivae	NN	PH
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
a	DT	O
highly	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
Staphylococcus	NNP	O
spp	NN	O
.	.	O

(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
non-Staphylococcus	JJ	O
spp	NN	O
.	.	O

(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
attainment	NN	O
of	IN	O
sterile	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
at	IN	O
operation	NN	O
gained	VBN	O
by	IN	O
patient	JJ	O
self-administration	NN	O
of	IN	O
1	CD	O
%	NN	O
fusidic	JJ	O
acid	RB	O
four	CD	O
times	NNS	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
before	IN	O
surgery	NN	O
.	.	O

Treatment	NN	O
of	IN	O
whiplash	NN	O
associated	VBN	O
neck	RB	O
pain	VBP	O
[	RB	O
corrected	VBN	O
]	NN	O
with	IN	O
botulinum	JJ	O
toxin-A	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Up	NNP	O
to	TO	O
87	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
whiplash	NN	O
associated	VBN	O
disorder	NN	O
(	(	O
WAD	NNP	O
)	)	O
have	VBP	O
some	DT	O
degree	NN	O
of	IN	O
muscle	NN	O
spasm	NN	O
that	WDT	O
is	VBZ	O
contributory	JJ	O
to	TO	O
both	DT	O
pain	NN	O
and	CC	O
dysfunction	NN	O
.	.	O

Botulinum	NNP	O
toxin	NN	O
A	NNP	O
(	(	O
BTX-A	NNP	O
)	)	O
produces	VBZ	O
prolonged	JJ	O
muscle	NN	O
relaxation	NN	O
that	WDT	O
is	VBZ	O
dose-dependent	JJ	O
and	CC	O
can	MD	O
be	VB	O
easily	RB	O
targeted	VBN	O
to	TO	O
affected	JJ	O
muscles	NNS	O
.	.	O

BTX-A	NNP	O
therapy	NN	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
form	NN	O
of	IN	O
therapy	NN	O
offering	VBG	O
an	DT	O
alternative	NN	O
or	CC	O
adjunct	NN	O
to	TO	O
conventional	JJ	O
modalities	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
BTX-A	NNP	O
as	IN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
WAD	NNP	O
.	.	O

METHODS	NNP	O
This	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
compares	VBZ	O
outcome	JJ	O
measures	NNS	O
in	IN	O
26	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
neck	NN	O
pain	NN	O
(	(	O
WAD-II	NNP	O
chronic	NN	O
)	)	O
subsequent	NN	O
to	TO	O
a	DT	O
motor	NN	O
vehicle	NN	O
accident	NN	O
.	.	O

One-half	NN	O
of	IN	O
the	DT	O
patients	NNS	O
received	VBD	O
100	CD	O
units	NNS	O
BTX-A	NNP	O
,	,	O
diluted	VBD	O
in	IN	O
1	CD	O
ml	NNS	O
saline	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
half	NN	O
received	VBD	O
just	RB	O
saline	NN	O
(	(	O
1	CD	O
ml	NN	O
)	)	O
.	.	O

Five	CD	O
trigger	NN	O
points	NNS	O
received	VBD	O
0.2	CD	O
ml	NNS	O
each	DT	O
of	IN	O
injectant	JJ	O
via	IN	O
a	DT	O
30	CD	O
gauge	NN	O
needle	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
total	JJ	PA
subjective	JJ	PA
neck	NN	PA
,	,	PA
shoulder	NN	PA
,	,	PA
and	CC	PA
head	NN	PA
pain	NN	PA
based	VBN	PA
on	IN	PA
visual	JJ	PA
analog	NN	PA
scales	NNS	PA
;	:	O
objective	JJ	PH
total	JJ	PH
range	NN	PH
of	IN	PH
neck	NN	PH
motion	NN	PH
(	(	PH
ROM	NNP	PH
)	)	PH
,	,	PH
and	CC	O
the	DT	O
Vernon-Mior	NNP	PH
subjective	JJ	PH
function	NN	PH
index	NN	PH
.	.	O

Followup	CD	O
assessments	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
post-treatment	JJ	O
.	.	O

RESULTS	NNP	O
Fourteen	NNP	O
subjects	VBZ	O
receiving	VBG	O
BTX-A	NNP	O
and	CC	O
12	CD	O
receiving	NN	O
saline	NN	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
in	IN	O
ROM	NNP	PH
and	CC	O
reduction	NN	O
in	IN	O
pain	NN	PA
at	IN	O
2	CD	O
weeks	NNS	O
post-injection	NN	O
.	.	O

At	IN	O
4	CD	O
weeks	NNS	O
post-injection	NN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
from	IN	O
preinjection	NN	O
levels	NNS	O
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
at	IN	O
any	DT	O
post-treatment	JJ	O
time	NN	O
.	.	O

The	DT	O
Vernon-Mior	JJ	PH
scale	NN	PH
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
improvement	NN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
BTX-A	NNP	O
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
WAD	NNP	O
II	NNP	O
neck	NN	O
pain	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
improvement	NN	O
in	IN	O
ROM	NNP	PH
and	CC	O
subjective	JJ	PA
pain	NN	PA
compared	VBN	O
to	TO	O
a	DT	O
placebo	NN	O
group	NN	O
,	,	O
but	CC	O
only	RB	O
a	DT	O
trend	NN	O
to	TO	O
improvement	NN	O
in	IN	O
subjective	JJ	PH
functioning	NN	PH
.	.	O

Comparison	NNP	O
of	IN	O
0.25	CD	O
%	NN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	VBP	O
with	IN	O
0.25	CD	O
%	NN	O
RS-bupivacaine	NNP	O
for	IN	O
epidural	JJ	O
analgesia	NN	PA
in	IN	O
labour	NN	O
.	.	O

We	PRP	O
have	VBP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
0.25	CD	O
%	NN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	VBP	O
with	IN	O
0.25	CD	O
%	NN	O
RS-bupivacaine	NNP	O
in	IN	O
providing	VBG	O
epidural	JJ	PA
analgesia	NN	PA
for	IN	O
labour	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
multicentre	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
initiated	VBN	O
with	IN	O
10	CD	O
ml	NN	O
of	IN	O
the	DT	O
study	NN	O
solution	NN	O
and	CC	O
maintained	VBN	O
with	IN	O
10-ml	JJ	O
top-ups	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
137	CD	O
women	NNS	O
and	CC	O
treatments	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
equivalent	JJ	O
for	IN	O
onset	NN	O
,	,	O
duration	NN	O
and	CC	O
quality	NN	O
of	IN	O
block	NN	O
.	.	O

Median	JJ	PA
onset	NN	PA
of	IN	PA
pain	NN	PA
relief	NN	PA
was	VBD	O
12	CD	O
min	NN	O
for	IN	O
both	DT	O
drugs	NNS	O
and	CC	O
median	JJ	O
duration	NN	O
was	VBD	O
49	CD	O
(	(	O
range	VB	O
3-129	NNP	O
)	)	O
min	NN	O
and	CC	O
51	CD	O
(	(	O
7-157	CD	O
)	)	O
min	NN	O
for	IN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	NN	O
and	CC	O
RS	NNP	O
bupivacaine	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
estimated	JJ	O
treatment	NN	O
difference	NN	O
for	IN	O
duration	NN	PA
of	IN	PA
pain	NN	PA
relief	NN	PA
was	VBD	O
-4	NNP	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
-13	NNP	O
,	,	O
6	CD	O
)	)	O
min	NN	O
.	.	O

Thirty	NNP	O
patients	NNS	O
failed	VBD	O
to	TO	O
achieve	VB	PA
pain	NN	PA
relief	NN	PA
after	IN	O
the	DT	O
first	JJ	O
injection	NN	O
(	(	O
20	CD	O
patients	NNS	O
after	IN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	NN	O
and	CC	O
10	CD	O
after	IN	O
RS-bupivacaine	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
median	JJ	PA
duration	NN	PA
of	IN	PA
pain	NN	PA
relief	NN	PA
from	IN	O
the	DT	O
first	JJ	O
top-up	NN	O
was	VBD	O
82	CD	O
(	(	O
range	VB	O
3-164	NNP	O
)	)	O
min	NN	O
for	IN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	NN	O
and	CC	O
76	CD	O
(	(	O
22-221	JJ	O
)	)	O
min	NN	O
for	IN	O
RS-bupivacaine	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
quality	NN	PA
of	IN	PA
analgesia	NN	PA
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
the	DT	O
investigators	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
extent	NN	O
of	IN	O
sensory	JJ	PH
block	NN	PH
,	,	PH
percentage	NN	PH
of	IN	PH
patients	NNS	PH
with	IN	PH
motor	NN	PH
block	NN	PH
or	CC	O
incidence	NN	A
of	IN	A
adverse	JJ	A
events	NNS	A
.	.	O

Efficacy	NN	Ot
of	IN	O
latanoprost	NN	O
when	WRB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
ocular	JJ	O
hypotensive	JJ	O
effect	NN	PH
for	IN	O
24	CD	O
hours	NNS	O
and	CC	O
the	DT	O
tolerability	NN	O
of	IN	O
latanoprost	NN	O
stored	VBN	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
30	CD	O
degrees	NNS	O
C.	NNP	O
Seventeen	NNP	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
crossover	NN	O
trial	NN	O
.	.	O

Latanoprost	VB	O
0.005	CD	O
%	NN	O
(	(	O
Xalatan	NNP	O
)	)	O
was	VBD	O
stored	VBN	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
30	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
4	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
dark	NN	O
.	.	O

The	DT	O
subjects	NNS	O
enrolled	VBD	O
to	TO	O
the	DT	O
study	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
latanoprost	NN	O
stored	VBD	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
that	IN	O
stored	VBN	O
at	IN	O
30	CD	O
degrees	NNS	O
C.	NNP	O
The	DT	O
eye	NN	O
drop	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
right	JJ	O
eye	NN	O
of	IN	O
each	DT	O
subject	NN	O
for	IN	O
3	CD	O
days	NNS	O
.	.	O

The	DT	O
left	NN	O
eye	NN	O
served	VBD	O
as	IN	O
a	DT	O
control	NN	O
without	IN	O
administration	NN	O
.	.	O

Slit-lamp	JJ	O
biomicroscopy	NN	O
and	CC	O
circadian	JJ	O
intra	NN	O
ocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
curve	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
Day	NNP	O
3	CD	O
,	,	O
every	DT	O
3	CD	O
hours	NNS	O
from	IN	O
6	CD	O
pm	NN	O
.	.	O

This	DT	O
procedure	NN	O
was	VBD	O
repeated	VBN	O
7	CD	O
days	NNS	O
after	IN	O
changing	VBG	O
the	DT	O
drug	NN	O
from	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
to	TO	O
30	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
vice	NN	O
versa	NN	O
,	,	O
and	CC	O
application	NN	O
to	TO	O
the	DT	O
left	NN	O
eye	NN	O
for	IN	O
3	CD	O
days	NNS	O
.	.	O

Eyes	NNS	O
treated	VBD	O
with	IN	O
latanoprost	NN	O
,	,	O
stored	VBD	O
both	DT	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
30	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
achieved	VBD	O
statistically	RB	PH
significantly	RB	PH
lower	JJR	PH
mean	NN	PH
IOPs	NNP	PH
than	IN	O
untreated	JJ	O
eyes	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
,	,	O
except	IN	O
at	IN	O
21	CD	O
hours	NNS	O
treated	VBN	O
by	IN	O
the	DT	O
drug	NN	O
stored	VBD	O
at	IN	O
30	CD	O
degrees	NNS	O
C.	NNP	O
We	PRP	O
subtracted	VBD	O
the	DT	O
IOP	NNP	O
of	IN	O
eyes	NNS	O
receiving	VBG	O
latanoprost	NN	O
from	IN	O
the	DT	O
IOP	NNP	O
of	IN	O
untreated	JJ	O
eyes	NNS	O
for	IN	O
each	DT	O
time	NN	O
point	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
the	DT	O
eye	NN	O
drops	NNS	O
(	(	O
delta	JJ	O
IOP	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	PH
statistically	RB	PH
significant	JJ	PH
differences	NNS	PH
between	IN	PH
the	DT	PH
delta	NN	PH
IOPs	NNP	PH
with	IN	PH
the	DT	PH
drug	NN	PH
stored	VBD	PH
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
30	CD	O
degrees	NNS	O
C.	NNP	O
During	IN	O
the	DT	O
study	NN	O
,	,	O
no	DT	A
subject	NN	A
developed	VBD	A
a	DT	A
serious	JJ	A
adverse	JJ	A
event	NN	A
.	.	A

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
latanoprost	NN	O
stored	VBN	O
at	IN	O
30	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
4	CD	Ot
weeks	NNS	Ot
after	IN	Ot
opening	VBG	Ot
the	DT	Ot
bottle	NN	Ot
remains	VBZ	Ot
as	IN	Ot
effective	JJ	Ot
and	CC	Ot
safe	JJ	Ot
as	IN	O
latanoprost	NN	O
stored	VBN	O
under	IN	O
cold	JJ	O
conditions	NNS	O
.	.	O

Single	NNP	O
negative	JJ	O
colposcopy	NN	O
:	:	O
is	VBZ	O
it	PRP	O
enough	RB	O
to	TO	O
rule	VB	O
out	IN	O
high-grade	JJ	O
disease	NN	O
?	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
that	IN	O
women	NNS	O
who	WP	O
have	VBP	O
a	DT	O
negative	JJ	O
colposcopic	NN	O
examination	NN	O
or	CC	O
who	WP	O
have	VBP	O
no	DT	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
(	(	O
CIN	NNP	O
)	)	O
on	IN	O
colposcopic	NN	O
biopsy	NN	O
can	MD	O
be	VB	O
safely	RB	O
returned	VBN	O
to	TO	O
routine	VB	O
screening	VBG	O
with	IN	O
the	DT	O
next	JJ	O
visit	NN	O
being	VBG	O
three	CD	O
or	CC	O
five	CD	O
years	NNS	O
later	RB	O
.	.	O

We	PRP	O
present	JJ	O
data	NNS	O
regarding	VBG	O
551	CD	O
women	NNS	O
who	WP	O
had	VBD	O
colposcopy	NN	O
in	IN	O
Wales	NNP	O
for	IN	O
a	DT	O
low-grade	JJ	O
cytological	JJ	O
abnormality	NN	O
and	CC	O
who	WP	O
were	VBD	O
followed	VBN	O
through	IN	O
Cervical	NNP	O
Screening	NNP	O
Wales	NNP	O
for	IN	O
subsequent	JJ	O
CIN	NNP	O
.	.	O

Of	IN	O
436	CD	O
women	NNS	O
declared	VBD	O
CIN	NNP	PH
free	JJ	PH
initially	RB	O
,	,	O
26	CD	O
(	(	O
6.0	CD	O
%	NN	O
)	)	O
had	VBD	O
high-grade	JJ	PH
CIN	NNP	PH
diagnosed	VBD	O
on	IN	O
follow-up	NN	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
additional	JJ	O
screening	NN	O
at	IN	O
an	DT	O
interval	NN	O
of	IN	O
less	JJR	O
than	IN	O
three	CD	O
years	NNS	O
should	MD	O
be	VB	O
offered	VBN	O
to	TO	O
women	NNS	O
with	IN	O
a	DT	O
negative	JJ	O
colposcopy	NN	O
or	CC	O
a	DT	O
biopsy	NN	O
without	IN	O
CIN	NNP	O
.	.	O

Bronchodilator	NNP	O
response	NN	O
to	TO	O
salbutamol	VB	O
after	IN	O
spontaneous	JJ	O
recovery	NN	O
from	IN	O
nonspecific	JJ	O
bronchial	JJ	O
provocation	NN	O
tests	NNS	O
in	IN	O
asthma	NN	O
.	.	O

Assessment	NN	O
of	IN	O
airway	NN	O
responsiveness	NN	O
by	IN	O
bronchoprovocation	NN	O
and	CC	O
bronchodilatation	NN	O
tests	NNS	O
is	VBZ	O
important	JJ	O
in	IN	O
the	DT	O
diagnostic	JJ	O
work-up	JJ	O
protocol	NN	O
of	IN	O
bronchial	JJ	O
asthma	NN	O
and	CC	O
it	PRP	O
would	MD	O
be	VB	O
convenient	JJ	O
to	TO	O
undertake	VB	O
both	DT	O
tests	NNS	O
on	IN	O
the	DT	O
same	JJ	O
occasion	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
can	MD	O
be	VB	O
done	VBN	O
accurately	RB	O
.	.	O

Therefore	RB	O
,	,	O
this	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
prior	JJ	O
bronchial	JJ	O
provocation	NN	O
test	NN	O
on	IN	O
the	DT	O
bronchodilator	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
after	IN	O
spontaneous	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV1	NNP	PH
)	)	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
asthmatic	JJ	O
subjects	NNS	O
.	.	O

On	IN	O
two	CD	O
separate	JJ	O
occasions	NNS	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
of	IN	O
day	NN	O
,	,	O
concentration-response	JJ	O
studies	NNS	O
with	IN	O
inhaled	JJ	O
histamine	NN	O
or	CC	O
methacholine	NN	O
,	,	O
or	CC	O
a	DT	O
sham	JJ	O
challenge	NN	O
with	IN	O
normal	JJ	O
saline	NN	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
a	DT	O
blinded	JJ	O
,	,	O
randomized	JJ	O
manner	NN	O
.	.	O

Changes	NNS	O
in	IN	O
airway	NN	O
calibre	NN	O
were	VBD	O
followed	VBN	O
as	IN	O
FEV1	NNP	PH
and	CC	O
agonist	JJ	O
responsiveness	NN	O
expressed	VBN	O
as	IN	O
the	DT	O
provocative	JJ	O
concentration	NN	O
causing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	PH
(	(	O
PC20	NNP	O
)	)	O
.	.	O

After	IN	O
either	DT	O
spontaneous	JJ	O
recovery	NN	O
or	CC	O
a	DT	O
fixed-duration	JJ	O
wait	NN	O
of	IN	O
45	CD	O
min	NNS	O
(	(	O
when	WRB	O
appropriate	NN	O
)	)	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
2x100	CD	O
microg	NN	O
of	IN	O
salbutamol	NN	O
from	IN	O
a	DT	O
metered	VBN	O
dose	NN	O
inhaler	NN	O
with	IN	O
a	DT	O
spacer	NN	O
.	.	O

The	DT	O
bronchodilator	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
was	VBD	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
initial	JJ	PH
FEV1	NNP	PH
(	(	O
deltaFEV1	CD	O
%	NN	O
init	NN	O
)	)	O
.	.	O

Bronchial	JJ	O
challenge	NN	O
with	IN	O
both	DT	O
agonists	NNS	O
failed	VBD	O
to	TO	O
alter	VB	O
significantly	RB	O
the	DT	O
airway	NN	PH
response	NN	PH
to	TO	O
salbutamol	VB	O
,	,	O
with	IN	O
the	DT	O
deltaFEV1	NN	PH
%	NN	PH
init	JJ	PH
mean	JJ	PH
value	NN	PH
(	(	O
range	NN	O
)	)	O
being	VBG	O
16.9	CD	O
%	NN	O
(	(	O
9.0-31.9	CD	O
)	)	O
and	CC	O
17.5	CD	O
%	NN	O
(	(	O
11.6-31.2	JJ	O
)	)	O
on	IN	O
the	DT	O
sham	NN	O
and	CC	O
histamine/methacholine	JJ	O
challenge	NN	O
day	NN	O
respectively	RB	O
.	.	O

It	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
the	DT	O
degree	NN	O
of	IN	O
bronchodilatation	NN	O
achieved	VBN	O
after	IN	O
salbutamol	JJ	O
200	CD	O
microg	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
prior	JJ	O
bronchoprovocation	NN	O
testing	VBG	O
when	WRB	O
enough	JJ	O
time	NN	O
is	VBZ	O
allowed	VBN	O
for	IN	O
the	DT	O
airways	NNS	O
to	TO	O
recover	VB	O
spontaneously	RB	O
to	TO	O
baseline	VB	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
.	.	O

Thus	NNP	O
evaluation	NN	O
of	IN	O
airway	NN	O
responsiveness	NN	O
by	IN	O
both	DT	O
bronchial	JJ	O
provocation	NN	O
tests	NNS	O
and	CC	O
bronchodilator	NN	O
testing	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
reliably	RB	O
within	IN	O
a	DT	O
few	JJ	O
hours	NNS	O
in	IN	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

Are	NNP	O
oral	JJ	O
cathartics	NNS	O
of	IN	O
value	NN	O
in	IN	O
optimizing	VBG	O
the	DT	O
gallium	NN	O
scan	JJ	O
?	.	O
Concise	NNP	O
communication	NN	O
.	.	O

The	DT	O
normal	JJ	O
intestinal	JJ	O
secretion	NN	O
of	IN	O
9-15	CD	O
%	NN	O
of	IN	O
an	DT	O
administered	VBN	O
dose	NN	O
of	IN	O
gallium-67	NN	O
may	MD	O
prevent	VB	O
early	JJ	O
detection	NN	O
of	IN	O
intra-abdominal	JJ	O
disease	NN	O
.	.	O

We	PRP	O
randomized	VBD	O
50	CD	O
patients	NNS	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	O
bowel	NN	O
preparation	NN	O
or	CC	O
30	CD	O
cc	NN	O
of	IN	O
milk	NN	O
of	IN	O
magnesia	JJ	O
plus	CC	O
5	CD	O
cc	NN	O
of	IN	O
cascara	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
frequency	NN	ME
with	IN	ME
which	WDT	ME
gallium	NN	ME
interfered	VBD	ME
with	IN	ME
readings	NNS	ME
or	CC	ME
time	NN	ME
to	TO	ME
complete	VB	ME
the	DT	ME
study	NN	ME
.	.	ME

Isoflurane	NNP	O
and	CC	O
propofol	NN	O
for	IN	O
long-term	JJ	O
sedation	NN	O
in	IN	O
the	DT	O
intensive	JJ	O
care	NN	O
unit	NN	O
.	.	O

A	DT	O
crossover	NN	O
study	NN	O
.	.	O

Propofol	NNP	O
and	CC	O
isoflurane	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
recently	RB	O
to	TO	O
offer	VB	O
better	JJR	O
sedation	NN	Ot
than	IN	O
alternative	JJ	O
agents	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
require	VBP	O
long-term	JJ	O
ventilation	NN	O
in	IN	O
the	DT	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
a	DT	O
direct	JJ	O
comparison	NN	O
between	IN	O
propofol	NN	O
and	CC	O
isoflurane	NN	O
.	.	O

Twenty-four	CD	O
patients	NNS	O
predicted	VBN	O
to	TO	O
require	VB	O
artificial	JJ	O
ventilation	NN	O
for	IN	O
at	IN	O
least	JJS	O
48	CD	O
h	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
a	DT	O
randomised	VBN	O
crossover	NN	O
study	NN	O
to	TO	O
monitor	VB	O
sedation	NN	Ot
quality	NN	Ot
and	CC	PH
time	NN	Ot
to	TO	Ot
recovery	NN	Ot
from	IN	Ot
sedation	NN	Ot
.	.	PH

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
agents	NNS	O
in	IN	O
either	DT	O
end-point	NN	O
,	,	O
with	IN	O
over	IN	O
95	CD	O
%	NN	O
optimal	JJ	Ot
sedation	NN	Ot
achieved	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
each	DT	O
drug	NN	O
.	.	O

Few	JJ	O
adverse	JJ	A
events	NNS	A
were	VBD	O
noted	VBN	O
.	.	O

Technological	JJ	O
advances	NNS	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
volatile	JJ	O
agents	NNS	O
as	IN	O
long-term	JJ	O
sedatives	NNS	O
in	IN	O
the	DT	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
may	MD	O
facilitate	VB	O
their	PRP$	O
more	JJR	O
widespread	JJ	O
use	NN	O
.	.	O

Expectancies	NNS	O
,	,	O
not	RB	O
aroma	RB	O
,	,	O
explain	JJ	O
impact	NN	O
of	IN	O
lavender	NN	O
aromatherapy	NN	O
on	IN	O
psychophysiological	JJ	O
indices	NNS	O
of	IN	O
relaxation	NN	O
in	IN	O
young	JJ	O
healthy	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
In	IN	O
aromatherapy	NN	O
,	,	O
lavender	JJR	O
aroma	NN	O
is	VBZ	O
reputed	VBN	O
to	TO	O
assist	VB	O
with	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
while	IN	O
there	EX	O
is	VBZ	O
much	JJ	O
anecdotal	JJ	O
evidence	NN	O
to	TO	O
that	DT	O
effect	NN	O
,	,	O
the	DT	O
empirical	JJ	O
literature	NN	O
is	VBZ	O
very	RB	O
inconsistent	JJ	O
.	.	O

Failure	NN	O
to	TO	O
employ	VB	O
adequate	JJ	O
placebos	NNS	O
,	,	O
proper	JJ	O
blinding	NN	O
,	,	O
objective	JJ	O
measures	NNS	O
,	,	O
or	CC	O
screening	NN	O
of	IN	O
prior	JJ	O
beliefs	NNS	O
about	IN	O
aromatherapy	NN	O
means	NNS	O
that	IN	O
many	JJ	O
previous	JJ	O
findings	NNS	O
could	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
sought	VBD	O
to	TO	O
establish	VB	O
whether	IN	O
lavender	NN	O
aroma	NN	O
and/or	JJ	O
expectancies	NNS	O
affect	VBP	O
post-stress	JJ	O
relaxation	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
double-blind	NN	O
,	,	O
3	CD	O
(	(	O
aroma	NN	O
)	)	O
x	VBZ	O
3	CD	O
(	(	O
instruction	NN	O
)	)	O
x	VBZ	O
10	CD	O
(	(	O
time	NN	O
in	IN	O
minutes	NNS	O
)	)	O
mixed-factorial	JJ	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
laboratory	NN	O
,	,	O
96	CD	O
healthy	JJ	O
undergraduate	JJ	O
women	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
lavender	VB	O
,	,	O
placebo	NN	O
,	,	O
or	CC	O
no	DT	O
aroma	NN	O
during	IN	O
physiologically	RB	O
assessed	VBN	O
relaxation	NN	O
after	IN	O
an	DT	O
arousing	VBG	O
cognitive	JJ	O
task	NN	O
.	.	O

Where	WRB	O
an	DT	O
aroma	NN	O
was	VBD	O
presented	VBN	O
,	,	O
an	DT	O
instructional	JJ	O
priming	NN	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
manipulate	VB	O
participants	NNS	O
'	POS	O
expectancies	NNS	O
about	IN	O
the	DT	O
aroma	NN	O
's	POS	O
likely	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
relax	VB	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
showed	VBD	O
no	DT	O
effect	NN	O
of	IN	O
aroma	NN	Ot
on	IN	Ot
galvanic	JJ	Ot
skin	NN	Ot
response	NN	Ot
during	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
nature	NN	O
of	IN	O
instructional	JJ	O
prime	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
relaxation	NN	ME
patterns	NNS	ME
:	:	O
when	WRB	O
expecting	VBG	O
the	DT	O
aroma	NN	O
to	TO	O
inhibit	VB	O
them	PRP	O
,	,	O
participants	NNS	O
relaxed	VBD	ME
more	RBR	O
;	:	O
when	WRB	O
expecting	VBG	O
facilitation	NN	O
,	,	O
participants	NNS	O
relaxed	VBD	ME
less	RBR	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
regard	NN	O
to	TO	O
self-reported	JJ	ME
relaxation	NN	ME
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
state	NN	O
anxiety	NN	O
)	)	O
and	CC	O
was	VBD	O
independent	JJ	O
of	IN	O
ratings	NNS	O
of	IN	O
attitudes	NNS	ME
towards	NNS	O
aromatherapy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
imply	VBP	O
that	IN	O
the	DT	O
previous	JJ	O
associations	NNS	O
of	IN	O
lavender	NN	O
aroma	NN	O
with	IN	O
assisted	JJ	O
relaxation	NN	O
may	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
relevant	JJ	O
expectancies	NNS	O
are	VBP	O
easily	RB	O
manipulable	JJ	O
.	.	O

Primary	JJ	O
stenting	NN	O
of	IN	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
PRISON	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	O
intracoronary	JJ	O
stent	NN	O
placement	NN	O
after	IN	O
successfully	RB	O
crossing	VBG	O
chronic	JJ	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
high	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
long-term	JJ	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
balloon	NN	O
angioplasty	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
stent	JJ	O
implantation	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
months	NNS	O
with	IN	O
angiographic	JJ	O
follow-up	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Quantitative	JJ	O
coronary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
core	NN	O
lab	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Baseline	JJ	O
characteristics	NNS	O
were	VBD	O
evenly	RB	O
distributed	VBN	O
.	.	O

After	IN	O
the	DT	O
procedure	NN	O
the	DT	O
mean	NN	PH
minimal	JJ	PH
luminal	JJ	PH
diameter	NN	PH
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
was	VBD	O
2.34	CD	O
+/-	JJ	O
0.46	CD	O
mm	NN	O
versus	NN	O
2.90	CD	O
+/-	JJ	O
0.41	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
showed	VBD	O
a	DT	O
mean	JJ	PH
minimal	JJ	PH
luminal	JJ	PH
diameter	NN	PH
of	IN	O
1.57	CD	O
+/-	JJ	O
0.74	CD	O
mm	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
1.93	CD	O
+/-	JJ	O
0.85	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.009	NNP	O
)	)	O
and	CC	O
a	DT	O
mean	JJ	PH
diameter	NN	PH
stenosis	NN	PH
of	IN	O
44.7	CD	O
%	NN	O
+/-	JJ	O
25.0	CD	O
%	NN	O
versus	IN	O
35.5	CD	O
%	NN	O
+/-	JJ	O
26.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=.036	NNP	O
)	)	O
.	.	O

Binary	JJ	PH
angiographic	JJ	PH
restenosis	NN	PH
(	(	O
>	JJ	O
50	CD	O
%	NN	O
diameter	JJ	O
stenosis	NN	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
22	CD	O
%	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.137	NNP	O
)	)	O
.	.	O

The	DT	O
reocclusion	NN	Ot
rates	NNS	Ot
were	VBD	O
7.3	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
1.00	CD	O
)	)	O
.	.	O

At	IN	O
12	CD	O
month	NN	O
follow-up	NN	O
,	,	O
the	DT	O
rate	NN	Ot
of	IN	Ot
target	NN	Ot
lesion	NN	Ot
revascularization	NN	Ot
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
(	(	O
29	CD	O
%	NN	O
versus	IN	O
13	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
stenting	VBG	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
balloon	VB	O
angioplasty	JJ	O
alone	RB	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
target	NN	PH
lesion	NN	PH
revascularization	NN	PH
and	CC	O
a	DT	O
lower	JJR	O
,	,	O
but	CC	O
not	RB	O
significant	JJ	O
,	,	O
restenosis	NN	PH
rate	NN	PH
.	.	O

Quick	JJ	O
change	NN	O
versus	NN	O
double	JJ	O
pump	NN	O
while	IN	O
changing	VBG	O
the	DT	O
infusion	NN	O
of	IN	O
inotropes	NNS	O
:	:	O
an	DT	O
experimental	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Quick	NNP	O
change	NN	O
(	(	O
QC	NNP	O
)	)	O
and	CC	O
double	JJ	O
pumping	NN	O
(	(	O
DP	NNP	O
)	)	O
are	VBP	O
common	JJ	O
methods	NNS	O
of	IN	O
substituting	VBG	O
the	DT	O
infusion	NN	O
of	IN	O
inotropes	NNS	O
given	VBN	O
through	IN	O
intravenous	JJ	O
pump	NN	O
.	.	O

AIMS	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
two	CD	O
methods	NNS	O
in	IN	O
respect	NN	O
with	IN	O
the	DT	O
variation	NN	O
in	IN	O
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
(	(	PH
MAP	NNP	PH
)	)	PH
.	.	O

The	DT	O
hypothesis	NN	O
was	VBD	O
that	IN	O
the	DT	O
DP	NNP	O
method	NN	O
could	MD	O
be	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
in	IN	O
achieving	VBG	O
haemodynamic	JJ	PH
stability	NN	PH
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
research	NN	O
in	IN	O
an	DT	O
open	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
took	VBD	O
place	NN	O
at	IN	O
the	DT	O
Paediatric	NNP	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
of	IN	O
Padua	NNP	O
Hospital	NNP	O
.	.	O

It	PRP	O
considered	VBD	O
patients	NNS	O
of	IN	O
0-36	JJ	O
months	NNS	O
,	,	O
not	RB	O
premature	NN	O
,	,	O
treated	VBN	O
with	IN	O
inotropic	JJ	O
infusion	NN	O
with	IN	O
monitoring	NN	O
of	IN	O
blood	NN	PH
pressure	NN	PH
.	.	O

The	DT	O
research	NN	O
obtained	VBD	O
the	DT	O
approval	NN	O
of	IN	O
the	DT	O
Hospital	NNP	O
Research	NNP	O
Ethics	NNP	O
committee	NN	O
and	CC	O
parents	NNS	O
signed	VBD	O
informed	JJ	O
consent	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
made	VBN	O
use	NN	O
of	IN	O
the	DT	O
Wilcoxon	NNP	O
test	NN	O
for	IN	O
the	DT	O
continuous	JJ	O
variables	NNS	O
and	CC	O
the	DT	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
for	IN	O
the	DT	O
comparison	NN	O
of	IN	O
frequencies	NNS	O
,	,	O
at	IN	O
significance	NN	O
value	NN	O
of	IN	O
5	CD	O
%	NN	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
registered	VBN	O
in	IN	O
an	DT	O
Excel	NNP	O
spreadsheet	NN	O
and	CC	O
analysed	VBN	O
with	IN	O
SAS	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
sample	NN	O
comprised	VBD	O
30	CD	O
patients	NNS	O
of	IN	O
age	NN	O
between	IN	O
1	CD	O
and	CC	O
27	CD	O
months	NNS	O
,	,	O
of	IN	O
whom	WP	O
13	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
were	VBD	O
male	JJ	O
.	.	O

They	PRP	O
were	VBD	O
all	DT	O
affected	VBN	O
by	IN	O
cardiac	NN	O
,	,	O
respiratory	NN	O
or	CC	O
infective	JJ	O
pathology	NN	O
,	,	O
all	DT	O
of	IN	O
them	PRP	O
intubated	VBN	O
and	CC	O
on	IN	O
artificial	JJ	O
respiratory	NN	O
support	NN	O
,	,	O
sedated	VBN	O
and	CC	O
infused	VBN	O
with	IN	O
dopamine	NN	O
.	.	O

The	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

The	DT	O
percentage	NN	O
variation	NN	O
of	IN	O
the	DT	O
baseline	NN	O
value	NN	O
of	IN	O
MAP	NNP	PH
after	IN	O
30	CD	O
min	NN	O
from	IN	O
starting	VBG	O
the	DT	O
treatment	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.85	CD	O
)	)	O
.	.	O

The	DT	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
for	IN	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
percentage	NN	O
variation	NN	O
of	IN	O
MAP	NNP	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
(	(	O
-3.1	JJ	O
,	,	O
+3.7	NNP	O
)	)	O
.	.	O

From	IN	O
a	DT	O
clinical	JJ	O
perspective	NN	O
,	,	O
the	DT	O
methods	NNS	O
are	VBP	O
to	TO	O
be	VB	O
considered	VBN	O
equivalent	JJ	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
a	DT	O
limited	JJ	O
sample	NN	O
;	:	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
detected	VBN	O
;	:	O
QC	NNP	O
is	VBZ	O
the	DT	O
quickest	JJS	Ot
and	CC	O
more	JJR	O
cost-effective	JJ	Ot
method	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
the	DT	O
MA-sensitive	JJ	O
leukocyte	NN	O
chemotaxis	NN	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
griseofulvin	NN	O
treatment	NN	O
.	.	O

Polymorphonuclear	JJ	O
leukocyte	NN	O
(	(	O
PMN	NNP	O
)	)	O
chemotaxis	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
play	VB	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

PMN	NNP	O
chemotaxis	NN	O
is	VBZ	O
in	IN	O
part	NN	O
sensitive	NN	O
to	TO	O
microtubule	VB	O
antagonists	NNS	O
(	(	O
MAs	NNP	O
)	)	O
,	,	O
e.g	RB	O
.	.	O

colchicine	NN	O
.	.	O

The	DT	O
antimycotic	JJ	O
antibiotic	JJ	O
griseofulvin	NN	O
inhibits	VBZ	O
the	DT	O
MA-sensitive	JJ	O
PMN	NNP	O
chemotaxis	NN	O
in	IN	O
vitro	NN	O
in	IN	O
concentrations	NNS	O
far	RB	O
below	IN	O
those	DT	O
obtained	VBN	O
in	IN	O
serum	NN	O
during	IN	O
antimycotic	JJ	O
therapy	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
the	DT	O
MA-sensitive	JJ	O
chemotaxis	NN	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
could	MD	O
thus	RB	O
be	VB	O
elucidated	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
griseofulvin	NN	O
treatment	NN	O
.	.	O

Griseofulvin	NNP	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
was	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
study	NN	O
versus	IN	O
placebo	NN	O
(	(	O
m	JJ	O
=	NNP	O
19	CD	O
)	)	O
during	IN	O
one	CD	O
year	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
of	IN	O
mild-moderate	JJ	O
activity	NN	O
.	.	O

No	DT	O
beneficial	JJ	Ot
effect	NN	Ot
of	IN	O
griseofulvin	NN	O
treatment	NN	O
was	VBD	O
noted	VBN	O
on	IN	PH
clinical	JJ	PH
symptoms	NNS	PH
or	CC	PH
laboratory	JJ	PH
parameters	NNS	PH
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
placebo-treated	JJ	O
patients	NNS	O
showed	VBD	O
more	RBR	O
improvement	NN	Ot
than	IN	O
the	DT	O
griseofulvin-treated	JJ	O
patients	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
therefore	RB	O
suggested	VBN	O
that	IN	O
the	DT	O
MA-sensitive	JJ	O
chemotaxis	NN	O
plays	VBZ	O
a	DT	O
reparative	JJ	O
role	NN	O
in	IN	O
the	DT	O
inflammatory	JJ	O
lesions	NNS	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

Antioxidant	JJ	O
supplementation	NN	O
and	CC	O
exercise-induced	JJ	O
oxidative	JJ	O
stress	NN	O
in	IN	O
the	DT	O
60-year-old	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
antipyrine	NN	O
hydroxylates	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
antioxidant	JJ	O
supplementation	NN	O
on	IN	O
exercise-induced	JJ	O
oxidative	JJ	O
stress	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
older	JJR	O
adults	NNS	O
(	(	O
60	CD	O
(	(	O
SE	NNP	O
1	CD	O
)	)	O
years	NNS	O
;	:	O
BMI	NNP	O
26	CD	O
(	(	O
SE	NNP	O
1	CD	O
)	)	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
in	IN	O
two	CD	O
groups	NNS	O
:	:	O
supplementation	NN	O
(	(	O
n	JJ	O
11	CD	O
)	)	O
with	IN	O
100	CD	O
mg	NNS	O
dl-alpha-tocopheryl	JJ	O
acetate	NN	O
,	,	O
200	CD	O
mg	NN	O
ascorbic	JJ	O
acid	NN	O
,	,	O
and	CC	O
2	CD	O
mg	NN	O
beta-carotene	NN	O
,	,	O
and	CC	O
placebo	NN	O
(	(	O
n	JJ	O
9	CD	O
)	)	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
the	DT	O
12	CD	O
week	NN	O
supplementation	NN	O
period	NN	O
,	,	O
subjects	NNS	O
cycled	VBD	O
for	IN	O
45	CD	O
min	NN	O
at	IN	O
submaximal	JJ	O
intensity	NN	O
(	(	O
50	CD	O
%	NN	O
maximal	JJ	O
workload	NN	O
capacity	NN	O
)	)	O
.	.	O

Antipyrine	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
marker	NN	O
for	IN	O
oxidative	JJ	O
stress	NN	O
.	.	O

Antipyrine	NNP	O
reacts	VBZ	O
quickly	RB	O
with	IN	O
hydroxyl	JJ	O
radicals	NNS	O
to	TO	O
form	VB	O
para-	JJ	O
and	CC	O
ortho-hydroxyantipyrine	JJ	O
.	.	O

The	DT	O
latter	JJ	O
metabolite	NN	O
is	VBZ	O
not	RB	O
formed	VBN	O
in	IN	O
man	NN	O
through	IN	O
the	DT	O
mono-oxygenase	JJ	O
pathway	NN	O
of	IN	O
cytochrome	JJ	O
P450	NNP	O
.	.	O

Daily	NNP	O
supplementation	NN	O
significantly	RB	O
increased	VBD	O
plasma	JJ	PH
concentrations	NNS	PH
of	IN	PH
alpha-tocopherol	NN	PH
and	CC	PH
beta-carotene	NN	PH
in	IN	O
the	DT	O
supplemented	VBN	O
group	NN	O
(	(	O
Delta	NNP	O
14.4	CD	O
(	(	O
SE	NNP	O
3.2	CD	O
)	)	O
and	CC	O
0.4	CD	O
(	(	O
se	VB	O
0.1	CD	O
)	)	O
micromol/l	NN	O
;	:	O
P	NNP	O
<	VBZ	O
0.001	CD	O
and	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
,	,	O
within	IN	O
and	CC	O
between	IN	O
groups	NNS	O
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
exercise-induced	JJ	PH
increase	NN	PH
in	IN	PH
the	DT	PH
ratios	NNS	PH
para-	JJ	PH
and	CC	PH
ortho-hydroxyantipyrine	JJ	PH
to	TO	PH
antipyrine	VB	PH
.	.	PH

In	IN	O
addition	NN	O
,	,	O
supplementation	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
exercise-induced	JJ	PH
increase	NN	PH
in	IN	PH
thiobarbituric	JJ	PH
acid	NN	PH
reactive	JJ	PH
substances	NNS	PH
in	IN	PH
plasma	NN	PH
.	.	PH

In	IN	O
conclusion	NN	O
,	,	O
in	IN	O
60-year-old	JJ	O
subjects	NNS	O
antioxidant	JJ	O
supplementation	NN	O
had	VBD	PH
no	DT	PH
effect	NN	PH
on	IN	PH
the	DT	PH
exercise-induced	JJ	PH
increase	NN	PH
in	IN	PH
oxidative	JJ	PH
stress	NN	PH
as	IN	O
measured	VBN	O
by	IN	O
free	JJ	Ot
radical	JJ	Ot
products	NNS	Ot
of	IN	Ot
antipyrine	NN	Ot
.	.	O

An	DT	O
empirical	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Disease	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
setting	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
are	VBP	O
the	DT	O
two	CD	O
most	JJS	O
widely	RB	O
used	VBN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

A	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
directly	RB	O
the	DT	O
self-administered	JJ	O
version	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
with	IN	O
respect	NN	O
to	TO	O
feasibility	NN	O
,	,	O
internal	JJ	O
consistency	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
resulting	VBG	O
from	IN	O
bronchodilator	NN	O
therapy	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
forty	VB	O
four	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
COPD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
three	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
either	DT	O
salmeterol	NN	O
,	,	O
salmeterol	NN	O
+	NNP	O
ipratropium	NN	O
bromide	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Quality	NN	PH
of	IN	PH
life	NN	PH
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
proportions	NNS	PH
of	IN	PH
missing	VBG	PH
values	NNS	PH
per	IN	O
patient	NN	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
0.54	CD	O
%	NN	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
2	CD	O
%	NN	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

The	DT	O
internal	JJ	Ot
consistency	NN	Ot
was	VBD	O
good	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
coefficients	NNS	O
>	VBP	O
/=	$	O
0.84	CD	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
>	NNP	O
/=	NNP	O
0.76	CD	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

Factor	NNP	O
analysis	NN	O
confirmed	VBD	O
the	DT	O
original	JJ	O
domain	NN	O
structure	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
but	CC	O
not	RB	O
of	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

Correlations	NNS	O
with	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	PH
FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	PH
)	)	PH
%	NN	PH
predicted	VBN	O
and	CC	O
peak	JJ	PH
expiratory	NN	PH
flow	NN	PH
rate	NN	PH
(	(	PH
PEFR	NNP	PH
)	)	PH
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
but	CC	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
than	IN	O
for	IN	O
the	DT	O
CRQ	NNP	O
.	.	O

The	DT	O
ability	NN	O
to	TO	O
discriminate	VB	O
between	IN	O
subjects	NNS	O
with	IN	O
different	JJ	O
levels	NNS	O
of	IN	O
FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	PH
was	VBD	O
somewhat	RB	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

The	DT	O
correlations	NNS	O
with	IN	O
symptom	JJ	O
scores	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
.	.	O

Cross	NNP	O
sectionally	RB	O
,	,	O
the	DT	O
scores	NNS	O
of	IN	O
the	DT	O
two	CD	O
questionnaires	NNS	O
were	VBD	O
moderately	RB	O
to	TO	O
highly	RB	O
correlated	VBN	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.35	CD	O
to	TO	O
0.72	CD	O
)	)	O
.	.	O

Longitudinally	RB	O
,	,	O
these	DT	O
correlations	NNS	O
were	VBD	O
lower	JJR	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.17	CD	O
to	TO	O
0.54	CD	O
)	)	O
but	CC	O
were	VBD	O
still	RB	O
significant	JJ	O
.	.	O

The	DT	O
CRQ	NNP	Ot
total	NN	Ot
and	CC	Ot
emotions	NNS	Ot
score	NN	Ot
and	CC	PH
the	DT	PH
SGRQ	NNP	Ot
symptoms	NNS	Ot
score	NN	Ot
were	VBD	O
the	DT	O
most	RBS	O
responsive	JJ	O
to	TO	O
change	VB	O
.	.	O

The	DT	O
SGRQ	NNP	PH
symptoms	NNS	PH
domain	NN	PH
was	VBD	O
the	DT	O
only	JJ	O
domain	NN	O
where	WRB	O
the	DT	O
improvement	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
combination	NN	O
treatment	NN	O
crossed	VBD	O
the	DT	O
threshold	NN	O
for	IN	O
clinical	JJ	O
relevance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Since	IN	O
this	DT	O
analysis	NN	O
of	IN	O
reliability	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
responsiveness	NN	O
to	TO	O
change	VB	O
did	VBD	O
not	RB	O
clearly	RB	O
favour	VBP	O
one	CD	O
instrument	NN	O
above	IN	O
the	DT	O
other	JJ	O
,	,	O
the	DT	O
choice	NN	O
between	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
can	MD	O
be	VB	O
based	VBN	O
on	IN	O
other	JJ	O
considerations	NNS	O
such	JJ	O
as	IN	O
the	DT	O
required	JJ	O
sample	NN	O
size	NN	O
or	CC	O
the	DT	O
availability	NN	O
of	IN	O
reference	NN	O
values	NNS	O
.	.	O

Levels	NNS	O
of	IN	O
recombinant	JJ	PH
human	JJ	PH
granulocyte	NN	PH
colony-stimulating	NN	PH
factor	NN	PH
in	IN	O
serum	NN	O
are	VBP	O
inversely	RB	O
correlated	VBN	O
with	IN	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
.	.	O

Recombinant	NNP	O
human	JJ	O
granulocyte	NN	O
colony-stimulating	NN	O
factor	NN	O
(	(	O
rhG-CSF	NN	O
)	)	O
is	VBZ	O
effective	JJ	O
in	IN	O
countering	VBG	O
chemotherapy-induced	JJ	O
neutropenia	NN	O
.	.	O

However	RB	O
,	,	O
serum	JJ	PH
rhG-CSF	NN	PH
levels	NNS	PH
can	MD	O
not	RB	O
be	VB	O
maintained	VBN	O
throughout	IN	O
the	DT	O
course	NN	O
of	IN	O
rhG-CSF	JJ	O
therapy	NN	O
.	.	O

The	DT	O
drop	NN	O
in	IN	O
serum	JJ	PH
rhG-CSF	JJ	PH
levels	NNS	PH
may	MD	O
vary	VB	O
with	IN	O
the	DT	O
duration	NN	O
of	IN	O
rhG-CSF	JJ	O
administration	NN	O
or	CC	O
with	IN	O
the	DT	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
serum	JJ	PH
G-CSF	NNP	PH
levels	NNS	PH
and	CC	O
circulating	VBG	PH
neutrophil	JJ	PH
counts	NNS	PH
and	CC	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
rhG-CSF	NN	O
for	IN	O
patients	NNS	O
with	IN	O
lung	NN	O
cancer	NN	O
who	WP	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
myelosuppressive	JJ	O
chemotherapy	NN	O
and	CC	O
then	RB	O
with	IN	O
subcutaneous	JJ	O
rhG-CSF	NN	O
(	(	O
lenograstim	NN	O
,	,	O
2	CD	O
micrograms	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
day	NN	O
)	)	O
.	.	O

Twelve	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
with	IN	O
different	JJ	O
rhG-CSF	JJ	O
therapy	NN	O
schedules	NNS	O
.	.	O

Serum	NNP	PH
G-CSF	JJ	PH
levels	NNS	PH
were	VBD	O
measured	VBN	O
by	IN	O
an	DT	O
enzyme	JJ	O
immunoassay	NN	O
method	NN	O
.	.	O

Serum	NNP	PH
G-CSF	NNP	PH
levels	NNS	PH
during	IN	O
the	DT	O
rhG-CSF	JJ	O
therapy	NN	O
greatly	RB	O
exceeded	VBD	O
endogenous	JJ	PH
G-CSF	NNP	PH
levels	NNS	PH
and	CC	O
were	VBD	O
mainly	RB	O
due	JJ	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
exogenous	JJ	O
rhG-CSF	NN	O
rather	RB	O
than	IN	O
increased	VBN	O
levels	NNS	O
of	IN	O
endogenous	JJ	O
G-CSF	NNP	O
.	.	O

Despite	IN	O
the	DT	O
duration	NN	O
of	IN	O
rhG-CSF	JJ	O
administration	NN	O
,	,	O
serum	JJ	PH
G-CSF	NNP	PH
levels	NNS	PH
during	IN	O
rhG-CSF	JJ	O
therapy	NN	O
were	VBD	O
inversely	RB	O
correlated	VBN	O
with	IN	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
(	(	O
r2	VB	O
=	RB	O
0.73	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
value	NN	O
for	IN	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	PH
curve	NN	PH
of	IN	O
rhG-CSF	NN	PH
on	IN	O
the	DT	O
day	NN	O
of	IN	O
neutrophilia	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
neutropenia	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
fall	NN	O
in	IN	O
serum	JJ	PH
G-CSF	NNP	PH
levels	NNS	PH
during	IN	O
rhG-CSF	JJ	O
therapy	NN	O
may	MD	O
result	VB	O
from	IN	O
increased	VBN	O
clearance	NN	O
and/or	NN	O
decreased	VBD	O
absorption	NN	O
of	IN	O
rhG-CSF	NN	O
,	,	O
two	CD	O
processes	NNS	O
related	VBN	O
to	TO	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
.	.	O

Measuring	VBG	O
the	DT	O
impact	NN	O
of	IN	O
patient	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
pharmacy	NN	O
setting	NN	O
:	:	O
the	DT	O
research	NN	O
design	NN	O
of	IN	O
the	DT	O
Kaiser	NNP	O
Permanente/USC	NNP	O
patient	NN	O
consultation	NN	O
study	NN	O
.	.	O

This	DT	O
article	NN	O
describes	VBZ	O
the	DT	O
research	NN	O
method	NN	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
impact	NN	O
of	IN	O
three	CD	O
alternative	JJ	O
models	NNS	O
of	IN	O
patient	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
pharmacy	NN	O
setting	VBG	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
pharmacies	NNS	O
operated	VBN	O
by	IN	O
the	DT	O
Southern	NNP	O
California	NNP	O
region	NN	O
Kaiser	NNP	O
Permanente	NNP	O
Medical	NNP	O
Care	NNP	O
Program	NNP	O
.	.	O

Both	DT	O
random	JJ	O
assignment	NN	O
and	CC	O
large-scale	JJ	O
geographic	JJ	O
area	NN	O
research	NN	O
designs	NNS	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
presentation	NN	O
of	IN	O
the	DT	O
research	NN	O
design	NN	O
includes	VBZ	O
discussions	NNS	O
of	IN	O
data	NNS	O
collection	NN	O
and	CC	O
patient	JJ	O
sampling	VBG	O
methods	NNS	O
;	:	O
the	DT	O
measurement	NN	O
of	IN	O
patient	JJ	ME
outcomes	NNS	ME
,	,	O
including	VBG	O
measures	NNS	Ot
of	IN	Ot
health	NN	Ot
care	NN	Ot
costs	NNS	Ot
and	CC	Ot
utilization	NN	Ot
,	,	O
patient	JJ	PH
functional	JJ	PH
status	NN	PH
,	,	O
and	CC	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
.	.	O

Demographic	NNP	O
data	NNS	O
are	VBP	O
presented	VBN	O
for	IN	O
the	DT	O
study	NN	O
population	NN	O
,	,	O
including	VBG	O
an	DT	O
analysis	NN	O
of	IN	O
potential	JJ	O
biased	JJ	O
selection	NN	O
of	IN	O
patients	NNS	O
electing	VBG	O
to	TO	O
participate	VB	O
in	IN	O
random	JJ	O
assignment	NN	O
.	.	O

Data	NNS	O
are	VBP	O
also	RB	O
presented	VBN	O
documenting	VBG	O
potential	JJ	O
selection	NN	O
bias	NN	O
across	IN	O
geographically	RB	O
determined	VBN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
geographic	JJ	O
area	NN	O
design	NN	O
arm	NN	O
.	.	O

Finally	RB	O
,	,	O
the	DT	O
article	NN	O
presents	VBZ	O
the	DT	O
analysis	NN	O
plan	NN	O
for	IN	O
the	DT	O
study	NN	O
and	CC	O
discusses	NNS	O
study	VBP	O
limitations	NNS	O
.	.	O

Randomised	VBN	O
trial	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
in	IN	O
liver-transplant	JJ	O
recipients	NNS	O
.	.	O

The	DT	O
Oral	NNP	O
Ganciclovir	NNP	O
International	NNP	O
Transplantation	NNP	O
Study	NNP	O
Group	NNP	O
[	NNP	O
corrected	VBD	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
Cytomegalovirus	NNP	O
(	(	O
CMV	NNP	O
)	)	O
disease	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
cause	NN	O
of	IN	O
serious	JJ	O
morbidity	NN	O
after	IN	O
solid-organ	JJ	O
transplantation	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
regimens	NNS	O
used	VBN	O
to	TO	O
prevent	VB	O
CMV	NNP	O
infection	NN	O
and	CC	O
disease	NN	O
have	VBP	O
shown	VBN	O
limited	JJ	O
benefit	NN	O
in	IN	O
seronegative	JJ	O
recipients	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
following	VBG	O
orthotopic	NN	O
liver	JJ	O
transplantation	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
December	NNP	O
,	,	O
1993	CD	O
,	,	O
and	CC	O
April	NNP	O
,	,	O
1995	CD	O
,	,	O
304	CD	O
liver-transplant	JJ	O
recipients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
oral	JJ	O
ganciclovir	NN	O
1000	CD	O
mg	NN	O
or	CC	O
matching	VBG	O
placebo	NN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

Seronegative	JJ	O
recipients	NNS	O
of	IN	O
seronegative	JJ	O
livers	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

Study	NNP	O
drug	NN	O
was	VBD	O
administered	VBN	O
as	RB	O
soon	RB	O
as	IN	O
the	DT	O
patient	NN	O
was	VBD	O
able	JJ	O
to	TO	O
take	VB	O
medication	NN	O
by	IN	O
mouth	NN	O
(	(	O
no	DT	O
later	RB	O
than	IN	O
day	NN	O
10	CD	O
)	)	O
until	IN	O
the	DT	O
98th	CD	O
day	NN	O
after	IN	O
transplantation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
specified	VBN	O
times	NNS	O
throughout	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
for	IN	O
evidence	NN	O
of	IN	O
CMV	NNP	Ot
infection	NN	Ot
,	,	Ot
CMV	NNP	Ot
disease	NN	Ot
,	,	Ot
rejection	NN	Ot
,	,	Ot
opportunistic	JJ	Ot
infections	NNS	Ot
,	,	Ot
and	CC	Ot
possible	JJ	Ot
drug	NN	Ot
toxicity	NN	Ot
.	.	Ot

FINDINGS	IN	O
The	DT	O
Kaplan-Meier	NNP	O
estimate	NN	O
of	IN	O
the	DT	O
6-month	JJ	Ot
incidence	NN	Ot
of	IN	Ot
CMV	NNP	Ot
disease	NN	Ot
was	VBD	O
29	CD	O
(	(	O
18.9	CD	O
%	NN	O
)	)	O
of	IN	O
154	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
seven	CD	O
(	(	O
4.8	CD	O
%	NN	O
)	)	O
of	IN	O
150	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
high-risk	JJ	O
group	NN	O
of	IN	O
seronegative	JJ	O
recipients	NNS	O
(	(	O
R-	NNP	O
)	)	O
of	IN	O
seropositive	JJ	O
livers	NNS	O
(	(	O
D+	NNP	O
)	)	O
,	,	O
incidence	NN	Ot
of	IN	Ot
CMV	NNP	Ot
disease	NN	Ot
was	VBD	O
11	CD	O
(	(	O
44.0	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
three	CD	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
of	IN	O
21	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Significant	JJ	O
benefit	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
those	DT	O
receiving	VBG	O
antibodies	NNS	O
to	TO	O
lymphocytes	NNS	O
,	,	O
where	WRB	O
the	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	Ot
disease	NN	Ot
was	VBD	O
12	CD	O
(	(	O
32.9	CD	O
%	NN	O
)	)	O
of	IN	O
37	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
two	CD	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Oral	JJ	O
ganciclovir	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	Ot
of	IN	Ot
CMV	NNP	Ot
infection	NN	Ot
(	(	O
placebo	JJ	O
79	CD	O
[	JJ	O
51.5	CD	O
%	NN	O
]	NN	O
of	IN	O
154	CD	O
;	:	O
ganciclovir	CC	O
37	CD	O
[	JJ	O
24.5	CD	O
%	NN	O
]	NN	O
of	IN	O
150	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.001	CD	O
)	)	O
and	CC	O
also	RB	O
reduced	VBN	O
symptomatic	JJ	Ot
herpes-simplex	JJ	Ot
infections	NNS	Ot
(	(	O
Kaplan-Meier	NNP	O
estimates	NNS	O
:	:	O
placebo	NN	O
36	CD	O
[	JJ	O
23.5	CD	O
%	NN	O
]	NN	O
of	IN	O
154	CD	O
;	:	O
ganciclovir	JJ	O
five	CD	O
[	JJ	O
3.5	CD	O
%	NN	O
]	NN	O
of	IN	O
150	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.001	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Oral	NNP	O
ganciclovir	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
method	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
orthotopic	NN	O
liver	NN	O
transplantation	NN	O
.	.	O

Naltrexone	NNP	O
plasma	NN	O
levels	NNS	O
,	,	O
clinical	JJ	O
response	NN	O
and	CC	O
effect	NN	O
on	IN	O
weight	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
research	NN	O
measured	VBD	O
naltrexone	NN	O
levels	NNS	O
in	IN	O
plasma	NN	O
,	,	O
to	TO	O
assess	VB	O
the	DT	O
relationship	NN	O
between	IN	O
behavioral	JJ	O
response	NN	O
to	TO	O
naltrexone	CD	O
and	CC	O
plasma	NN	O
levels	NNS	O
,	,	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
naltrexone	NN	O
on	IN	O
weight	NN	O
in	IN	O
hospitalized	VBN	O
autistic	JJ	O
children	NNS	O
(	(	O
n	JJ	O
=	NNP	O
41	CD	O
)	)	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
groups	NNS	O
design	NN	O
with	IN	O
fixed	JJ	O
dose	NN	O
was	VBD	O
used	VBN	O
,	,	O
with	IN	O
random	JJ	O
assignment	NN	O
to	TO	O
naltrexone	CD	O
or	CC	O
placebo	VB	O
.	.	O

Drug	NNP	PH
plasma	NN	PH
levels	NNS	PH
were	VBD	O
analyzed	VBN	O
by	IN	O
gas	NN	O
chromatography/mass	NN	O
spectrometry	NN	O
,	,	O
and	CC	O
weights	NNS	O
were	VBD	O
obtained	VBN	O
weekly	RB	O
.	.	O

Naltrexone	NN	O
levels	NNS	O
measured	VBN	O
in	IN	O
17	CD	O
children	NNS	O
ranged	VBD	O
from	IN	O
0.12	CD	O
to	TO	O
5.60	CD	O
ng/mL	NNS	O
(	(	O
mean	JJ	O
=	NN	O
0.71	CD	O
,	,	O
standard	JJ	O
error	NN	O
of	IN	O
the	DT	O
mean	JJ	O
=	NNP	O
0.32	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
relationship	NN	O
between	IN	O
plasma	NN	O
levels	NNS	O
and	CC	O
age	NN	O
,	,	O
level	NN	O
of	IN	O
intellectual	JJ	O
functioning	NN	O
,	,	O
scores	NNS	O
on	IN	O
the	DT	O
14	CD	O
selected	VBD	O
Children	NNP	ME
's	POS	ME
Psychiatric	NNP	ME
Rating	NNP	ME
Scale	NNP	ME
(	(	ME
CPRS	NNP	ME
)	)	ME
items	NNS	ME
,	,	ME
Clinical	NNP	ME
Global	NNP	ME
Impressions	NNP	ME
,	,	ME
Global	NNP	ME
Clinical	NNP	ME
Consensus	NNP	ME
,	,	ME
and	CC	ME
the	DT	ME
CPRS	NNP	ME
hyperactivity	NN	ME
factor	NN	ME
.	.	ME

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
(	(	O
p	JJ	O
=	NNP	O
.06	NNP	O
)	)	O
for	IN	O
children	NNS	O
receiving	VBG	O
naltrexone	NN	O
in	IN	O
the	DT	O
highest	JJS	O
weight	NN	O
percentile	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
90th	CD	O
)	)	O
to	TO	O
lose	VB	O
weight	NN	O
(	(	O
mean	JJ	O
=	NNP	O
-0.42	NNP	O
kg	NN	O
)	)	O
but	CC	O
this	DT	O
was	VBD	O
not	RB	O
the	DT	O
case	NN	O
for	IN	O
those	DT	O
in	IN	O
the	DT	O
lower	JJR	O
weight	NN	O
percentiles	NNS	O
(	(	O
mean	JJ	O
=	NNP	O
+0.03	NNP	O
kg	NN	O
)	)	O
.	.	O

Scales	NNS	O
for	IN	O
the	DT	O
assessment	NN	O
of	IN	O
neuroleptic	JJ	PH
response	NN	PH
in	IN	O
schizophrenic	JJ	O
children	NNS	O
:	:	O
specific	JJ	O
measures	NNS	O
derived	VBN	O
from	IN	O
the	DT	O
CPRS	NNP	O
.	.	O

This	DT	O
article	NN	O
reports	VBZ	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
of	IN	O
two	CD	O
scales	NNS	O
for	IN	O
rating	NN	O
positive	JJ	O
and	CC	O
negative	JJ	O
schizophrenic	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
.	.	O

These	DT	O
Positive	NNP	PH
and	CC	PH
Negative	NNP	PH
Syndrome	NNP	PH
Scales	NNP	PH
consist	NN	O
of	IN	O
items	NNS	O
selected	VBN	O
from	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Psychiatric	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
CPRS	NNP	O
)	)	O
,	,	O
which	WDT	O
contains	VBZ	O
items	NNS	O
covering	VBG	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
childhood	NN	O
psychopathology	NN	O
.	.	O

CPRS	NNP	O
rating	NN	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
19	CD	O
schizophrenic	JJ	O
children	NNS	O
,	,	O
16	CD	O
males	NNS	O
and	CC	O
3	CD	O
females	NNS	O
,	,	O
mean	JJ	O
age	NN	O
8.9	CD	O
years	NNS	O
(	(	O
range	VB	O
5.5-11.7	NNP	O
)	)	O
,	,	O
evaluated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
of	IN	O
haloperidol	NN	O
.	.	O

We	PRP	O
describe	VBP	O
the	DT	O
item	NN	O
composition	NN	O
and	CC	O
coherence	NN	O
of	IN	O
each	DT	O
scale	NN	O
,	,	O
the	DT	O
interrater	NN	O
reliabilities	NNS	O
of	IN	O
clinicians	NNS	O
using	VBG	O
the	DT	O
scales	NNS	O
,	,	O
and	CC	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
scales	NNS	O
for	IN	O
resolving	VBG	O
treatment	NN	O
response	NN	O
.	.	O

Schizophrenic	JJ	O
children	NNS	O
showed	VBD	O
both	DT	O
positive	JJ	PH
and	CC	PH
negative	JJ	PH
signs	NNS	PH
and	CC	PH
symptoms	NNS	PH
,	,	O
and	CC	O
both	DT	O
improved	VBN	O
with	IN	O
neuroleptic	JJ	PH
treatment	NN	PH
.	.	O

Failure	NN	O
of	IN	O
lithium	NN	O
to	TO	O
reduce	VB	O
period	NN	O
of	IN	O
neutropenia	NN	O
during	IN	O
induction	NN	O
therapy	NN	O
of	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
.	.	O

Fifty-four	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
daunorubicin	NN	O
,	,	O
cytosine	JJ	O
arabinoside	NN	O
and	CC	O
thioquanine	NN	O
for	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
oral	JJ	O
lithium	NN	O
carbonate	NN	O
1200	CD	O
mg	JJ	O
daily	JJ	O
or	CC	O
no	DT	O
lithium	NN	O
.	.	O

The	DT	O
duration	NN	PH
of	IN	PH
neutropenia	NN	PH
(	(	O
less	JJR	O
than	IN	O
0.5	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
was	VBD	O
similar	JJ	O
between	IN	O
controls	NNS	O
(	(	O
median	JJ	O
22.5	CD	O
days	NNS	O
)	)	O
and	CC	O
patients	NNS	O
treated	VBN	O
with	IN	O
lithium	NN	O
(	(	O
median	JJ	O
24	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
number	NN	PH
of	IN	PH
remissions	NNS	PH
,	,	O
relapse-free	JJ	MO
survival	NN	MO
and	CC	O
survival	NN	MO
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
lithium	NN	O
treated	VBD	O
and	CC	O
control	VB	O
groups	NNS	O
of	IN	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
apparent	JJ	O
clinical	JJ	Ot
efficacy	NN	Ot
in	IN	O
the	DT	O
use	NN	O
of	IN	O
lithium	NN	O
to	TO	O
reduce	VB	O
the	DT	O
period	NN	O
of	IN	O
neutropenia	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
remission	NN	O
induction	NN	O
therapy	NN	O
for	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
.	.	O

The	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
anxiety	NN	O
and	CC	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
pilot	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
pilot	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
a	DT	O
modified	JJ	O
version	NN	O
of	IN	O
the	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
could	MD	O
be	VB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
anxiety	NN	ME
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Twenty-two	JJ	O
children	NNS	O
(	(	O
ages	VBZ	O
8-14	NN	O
;	:	O
IQ	NNP	O
?	.	O
70	CD	O
)	)	O
with	IN	O
ASD	NNP	O
and	CC	O
clinically	RB	O
significant	JJ	O
anxiety	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
the	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
(	(	O
cognitive-behavioral	JJ	O
therapy	NN	O
;	:	O
CBT	NNP	O
)	)	O
or	CC	O
a	DT	O
16-week	JJ	O
waitlist	NN	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
CBT	NNP	O
condition	NN	O
evidenced	VBD	O
significantly	RB	O
larger	JJR	O
reductions	NNS	O
in	IN	O
anxiety	NN	ME
than	IN	O
those	DT	O
in	IN	O
the	DT	O
waitlist	NN	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
largely	RB	O
maintained	VBN	O
at	IN	O
two-month	JJ	O
follow-up	NN	O
.	.	O

Results	NNP	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
a	DT	O
modified	JJ	O
version	NN	O
of	IN	O
the	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
may	MD	O
be	VB	O
a	DT	O
feasible	JJ	O
and	CC	O
effective	JJ	O
program	NN	O
for	IN	O
reducing	VBG	O
clinically	RB	O
significant	JJ	O
levels	NNS	O
of	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
ASD	NNP	O
.	.	O

Supplementation	NN	O
with	IN	O
iron	NN	O
and	CC	O
riboflavin	NN	O
enhances	NNS	O
dark	JJ	O
adaptation	NN	O
response	NN	O
to	TO	O
vitamin	VB	O
A-fortified	NNP	O
rice	NN	O
in	IN	O
iron-deficient	JJ	O
,	,	O
pregnant	JJ	O
,	,	O
nightblind	JJ	O
Nepali	NNP	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
Nightblindness	NNP	O
affects	VBZ	O
16-52	CD	O
%	NN	O
of	IN	O
pregnant	JJ	O
women	NNS	O
in	IN	O
areas	NNS	O
of	IN	O
Nepal	NNP	O
and	CC	O
in	IN	O
some	DT	O
cases	NNS	O
persists	NNS	O
after	IN	O
vitamin	VBG	O
A	DT	O
treatment	NN	O
.	.	O

Iron	NNP	O
and	CC	O
riboflavin	VB	O
affect	JJ	O
vitamin	NN	O
A	DT	O
utilization	NN	O
and	CC	O
photoreceptor	NN	O
function	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
pilot	NN	O
data	NNS	O
in	IN	O
the	DT	O
study	NN	O
population	NN	O
showed	VBD	O
a	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
iron	NN	O
and	CC	O
riboflavin	NN	O
deficiencies	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
supplemental	JJ	O
iron	NN	O
and	CC	O
riboflavin	NN	O
on	IN	O
pupillary	JJ	O
threshold	NN	O
(	(	O
PT	NNP	O
)	)	O
and	CC	O
plasma	JJ	O
retinol	NN	O
in	IN	O
nightblind	NN	O
,	,	O
pregnant	JJ	O
Nepali	NNP	O
women	NNS	O
given	VBN	O
vitamin	JJ	O
A-fortified	JJ	O
rice	NN	O
.	.	O

DESIGN	NNP	O
Nightblind	NNP	O
pregnant	JJ	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
,	,	O
6	CD	O
d/wk	NN	O
under	IN	O
supervision	NN	O
for	IN	O
6	CD	O
wk	NN	O
,	,	O
a	DT	O
vitamin	JJ	O
A-fortified	JJ	O
rice	NN	O
curry	NN	O
dish	JJ	O
providing	VBG	O
850	CD	O
microg	JJ	O
retinal	JJ	O
activity	NN	O
equivalents/d	NN	O
with	IN	O
either	DT	O
a	DT	O
30-mg	JJ	O
Fe	NNP	O
and	CC	O
6-mg	JJ	O
riboflavin	NN	O
(	(	O
FeR	NNP	O
+	NNP	O
VA	NNP	O
)	)	O
capsule	NN	O
or	CC	O
a	DT	O
placebo	NN	O
control	NN	O
(	(	O
VA	NNP	O
only	RB	O
)	)	O
capsule	NN	O
.	.	O

Hemoglobin	NNP	PH
,	,	PH
erythrocyte	NN	PH
riboflavin	NN	PH
,	,	PH
and	CC	PH
plasma	NN	PH
ferritin	NN	PH
and	CC	PH
retinol	NN	PH
were	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

Dark	NNP	O
adaptation	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
PT	NNP	O
score	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
who	WP	O
were	VBD	O
iron	JJ	O
deficient	NN	O
at	IN	O
baseline	NN	O
(	(	O
n=38	JJ	O
)	)	O
had	VBD	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
PT	NNP	PH
score	NN	PH
with	IN	PH
iron	NN	PH
and	CC	PH
riboflavin	NN	PH
supplementation	NN	PH
than	IN	O
without	IN	O
(	(	O
P=0.05	NNP	O
)	)	O
.	.	O

Iron	NNP	O
and	CC	O
riboflavin	JJ	O
supplements	NNS	O
significantly	RB	O
reduced	VBD	O
the	DT	O
prevalences	NNS	O
of	IN	O
riboflavin	JJ	PH
deficiency	NN	PH
(	(	O
from	IN	O
60	CD	O
%	NN	O
to	TO	O
6	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
iron	JJ	PH
deficiency	NN	PH
anemia	NN	PH
(	(	O
from	IN	O
35	CD	O
%	NN	O
to	TO	O
15	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.007	CD	O
)	)	O
,	,	O
and	CC	O
abnormal	JJ	PH
PT	NNP	PH
(	(	O
from	IN	O
87	CD	O
%	NN	O
to	TO	O
30	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
baseline	NN	O
.	.	O

Mean	JJ	O
increases	NNS	O
in	IN	O
erythrocyte	JJ	O
riboflavin	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
plasma	JJ	Ot
ferritin	NN	Ot
(	(	O
P=0.01	NNP	O
)	)	O
were	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
FeR	NNP	O
+	NNP	O
VA	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
VA	NNP	O
only	RB	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Iron	NNP	O
deficiency	NN	O
may	MD	O
limit	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
vitamin	NN	O
A	DT	O
to	TO	O
normalize	VB	O
dark	JJ	O
adaptation	NN	O
in	IN	O
pregnant	JJ	O
Nepali	NNP	O
women	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
simultaneous	JJ	O
delivery	NN	O
of	IN	O
iron	NN	O
and	CC	O
vitamin	VB	O
A	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nightblindness	NN	O
.	.	O

Ongoing	VBG	O
Telmisartan	NNP	O
Alone	NNP	O
and	CC	O
in	IN	O
Combination	NNP	O
With	IN	O
Ramipril	NNP	O
Global	NNP	O
Endpoint	NNP	O
Trial	NNP	O
(	(	O
ONTARGET	NNP	O
)	)	O
:	:	O
implications	NNS	O
for	IN	O
reduced	JJ	O
cardiovascular	JJ	PH
risk	NN	PH
.	.	O

The	DT	O
recently	RB	O
published	VBN	O
Ongoing	NNP	O
Telmisartan	NNP	O
Alone	NNP	O
and	CC	O
in	IN	O
Combination	NNP	O
With	IN	O
Ramipril	NNP	O
Global	NNP	O
Endpoint	NNP	O
Trial	NNP	O
(	(	O
ONTARGET	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
disease	NN	O
or	CC	O
high-risk	JJ	O
diabetes	NNS	O
,	,	O
as	IN	O
the	DT	O
largest	JJS	O
published	VBN	O
comparative	JJ	O
trial	NN	O
of	IN	O
these	DT	O
agent	NN	O
classes	NNS	O
,	,	O
provides	VBZ	O
further	JJ	O
evidence	NN	O
concerning	VBG	O
the	DT	O
comparison	NN	O
between	IN	O
the	DT	O
angiotensin-receptor	NN	O
blockers	NNS	O
(	(	O
ARBs	NNP	O
)	)	O
and	CC	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
(	(	O
ACEIs	NNP	O
)	)	O
.	.	O

In	IN	O
this	DT	O
trial	NN	O
,	,	O
telmisartan	NN	O
(	(	O
an	DT	O
ARB	NNP	O
)	)	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
ramipril	VB	O
(	(	O
an	DT	O
ACEI	NNP	O
)	)	O
in	IN	O
reducing	VBG	O
fatal	JJ	PH
and	CC	PH
nonfatal	JJ	PH
cardiovascular	JJ	PH
events	NNS	PH
.	.	O

Moreover	RB	O
,	,	O
ONTARGET	NNP	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
high-quality	JJ	O
noninferiority	NN	O
trial	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
the	DT	O
2	CD	O
agents	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
more	JJR	O
adverse	JJ	A
effects	NNS	A
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
benefit	NN	O
.	.	O

The	DT	O
study	NN	O
differed	VBD	O
from	IN	O
several	JJ	O
other	JJ	O
comparative	JJ	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
dose	NN	O
and	CC	O
choice	NN	O
of	IN	O
ACEI	NNP	O
was	VBD	O
left	VBN	O
to	TO	O
individual	JJ	O
physicians	NNS	O
.	.	O

Further	NNP	O
,	,	O
in	IN	O
ONTARGET	NNP	O
,	,	O
the	DT	O
ACEI	NNP	O
was	VBD	O
not	RB	O
titrated	VBN	O
to	TO	O
the	DT	O
maximum	JJ	O
dose	NN	O
and	CC	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Event-related	JJ	O
potentials	NNS	O
and	CC	O
monoamines	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
on	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
fenfluramine	NN	O
.	.	O

In	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
the	DT	O
response	NN	O
of	IN	O
autistic	JJ	O
subjects	NNS	O
to	TO	O
fenfluramine	VB	O
,	,	O
event-related	JJ	O
potentials	NNS	O
(	(	O
ERPs	NNP	O
)	)	O
were	VBD	O
recorded	VBN	O
from	IN	O
7	CD	O
subjects	NNS	O
on	IN	O
an	DT	O
attention-demanding	JJ	O
auditory	NN	O
choice	NN	O
reaction	NN	O
time	NN	O
task	NN	O
(	(	O
ACRT	NNP	O
)	)	O
.	.	O

ACRT	NNP	O
,	,	O
IQ	NNP	O
and	CC	O
biochemical	JJ	O
measures	NNS	O
were	VBD	O
taken	VBN	O
after	IN	O
5	CD	O
months	NNS	O
placebo	NN	O
and	CC	O
5	CD	O
months	NNS	O
fenfluramine	JJ	O
treatment	NN	O
.	.	O

After	IN	O
fenfluramine	JJ	O
treatment	NN	O
blood	NN	O
serotonin	NN	O
levels	NNS	O
fell	VBD	O
,	,	O
urinary	JJ	O
catecholamine	NN	O
levels	NNS	O
fell	VBD	O
and	CC	O
the	DT	O
HVA/DA	NNP	O
ratio	NN	O
rose	VBD	O
.	.	O

IQ	NNP	ME
and	CC	ME
ACRT	NNP	ME
performance	NN	ME
improved	VBD	O
.	.	O

On	IN	O
the	DT	O
ACRT	NNP	PH
subjects	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
press	VB	O
a	DT	O
button	NN	O
to	TO	O
a	DT	O
rare	JJ	O
target	NN	O
(	(	O
500	CD	O
Hz	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.14	CD	O
)	)	O
and	CC	O
to	TO	O
ignore	VB	O
higher	JJR	O
pitched	VBN	O
rare	JJ	O
(	(	O
2,000	CD	O
Hz	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.14	CD	O
)	)	O
and	CC	O
frequent	JJ	O
non-targets	NNS	O
(	(	O
1,000	CD	O
Hz	NNP	O
)	)	O
.	.	O

After	IN	O
fenfluramine	JJ	O
treatment	NN	O
N1	NNP	ME
latencies	NNS	ME
increased	VBD	O
.	.	O

The	DT	O
scalp	JJ	PH
distribution	NN	PH
of	IN	PH
ERP	NNP	PH
maxima	NNP	O
changes	NNS	O
slightly	RB	O
with	IN	O
treatment	NN	O
.	.	O

P3	NNP	O
maxima	NN	O
elicited	VBN	O
by	IN	O
rare	JJ	O
non-targets	NNS	O
were	VBD	O
recorded	VBN	O
more	RBR	O
rostrally	RB	O
after	IN	O
fenfluramine	JJ	O
treatment	NN	O
.	.	O

After	IN	O
rare	JJ	O
non-targets	NNS	O
N1	NNP	PH
amplitudes	NNS	PH
at	IN	PH
Fz	NNP	PH
decreased	VBD	O
but	CC	O
P3	NNP	PH
amplitudes	NNS	PH
at	IN	PH
Pz	NNP	PH
increased	VBD	O
.	.	O

Early	JJ	O
negativity	NN	O
after	IN	O
the	DT	O
rare	JJ	O
non-target	JJ	O
(	(	O
particularly	RB	O
on	IN	O
the	DT	O
right	JJ	O
side	NN	O
)	)	O
was	VBD	O
negatively	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
HVA/DA	NNP	O
ratio	NN	O
.	.	O

Subtraction	NN	O
of	IN	O
the	DT	O
P3	NNP	O
component	NN	O
elicited	VBN	O
in	IN	O
a	DT	O
passive	JJ	O
condition	NN	O
where	WRB	O
no	DT	O
response	NN	O
was	VBD	O
required	VBN	O
from	IN	O
the	DT	O
active	JJ	O
condition	NN	O
showed	VBD	O
that	IN	O
P3	NNP	PH
positivity	NN	PH
to	TO	O
targets	NNS	O
was	VBD	O
halved	VBN	O
with	IN	O
treatment	NN	O
.	.	O

(	(	O
In	IN	O
contrast	NN	O
Nd	NNP	O
increased	VBD	O
on	IN	O
fenfluramine	JJ	O
treatment	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
N1	NNP	O
and	CC	O
P3	NNP	O
components	NNS	O
showed	VBD	O
greatest	JJS	O
responsiveness	NN	O
to	TO	O
rare	VB	O
non-targets	NNS	O
on	IN	O
fenfluramine	NN	O
.	.	O

N1	NNP	O
but	CC	O
not	RB	O
P3	NNP	O
changes	NNS	O
may	MD	O
represent	VB	O
slight	JJ	O
improvement	NN	O
of	IN	O
attention-related	JJ	O
function	NN	O
with	IN	O
treatment	NN	O
.	.	O

Small	JJ	O
changes	NNS	O
in	IN	O
ERP	NNP	O
latency	NN	O
and	CC	O
distribution	NN	O
,	,	O
associated	VBN	O
with	IN	O
the	DT	O
neuroleptic	JJ	O
action	NN	O
of	IN	O
fenfluramine	NN	O
may	MD	O
be	VB	O
partly	RB	O
responsible	JJ	O
for	IN	O
a	DT	O
mild	JJ	O
improvement	NN	O
of	IN	O
IQ	NNP	O
and	CC	O
ACRT	NNP	O
performance	NN	O
on	IN	O
medication	NN	O
.	.	O

Deliberate	NNP	PH
hypotension	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
intracranial	JJ	O
arteriovenous	JJ	O
malformations	NNS	O
:	:	O
esmolol	NN	O
compared	VBN	O
with	IN	O
isoflurane	NN	O
and	CC	O
sodium	NN	O
nitroprusside	RB	O
.	.	O

Thirty	JJ	O
patients	NNS	O
undergoing	VBG	O
resection	NN	O
of	IN	O
arteriovenous	JJ	O
malformations	NNS	O
with	IN	O
deliberate	JJ	O
hypotension	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
3	CD	O
hypotensive	JJ	O
agents	NNS	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	O
and	CC	O
nitrous	JJ	O
oxide	NN	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
20	CD	O
%	NN	O
to	TO	O
60-65	JJ	O
mm	NN	O
Hg	NNP	O
with	IN	O
use	NN	O
of	IN	O
either	DT	O
isoflurane	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
4	CD	O
%	NN	O
)	)	O
,	,	O
sodium	JJ	O
nitroprusside	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
micrograms.kg-1.min-1	NN	O
)	)	O
,	,	O
or	CC	O
esmolol	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
24	CD	O
mg/min	NN	O
)	)	O
.	.	O

Esmolol	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	PH
output	NN	PH
from	IN	O
6.2	CD	O
+/-	JJ	O
1.3	CD	O
to	TO	O
3.8	CD	O
+/-	JJ	O
0.8	CD	O
L/min	NNP	O
,	,	O
which	WDT	O
,	,	O
because	IN	O
of	IN	O
a	DT	O
22	CD	O
%	NN	O
increase	NN	O
in	IN	O
systemic	JJ	PH
vascular	JJ	PH
resistance	NN	PH
,	,	O
far	RB	O
exceeded	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	PH
pressure	NN	PH
.	.	O

Systemic	NNP	PH
vascular	JJ	PH
resistance	NN	PH
increased	VBD	O
despite	IN	O
a	DT	O
32	CD	O
%	NN	O
decrease	NN	O
in	IN	O
plasma	JJ	PH
renin	NN	PH
activity	NN	PH
.	.	O

In	IN	O
contrast	NN	O
,	,	O
with	IN	O
sodium	JJ	O
nitroprusside	NN	O
or	CC	O
isoflurane	NN	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
was	VBD	O
associated	VBN	O
with	IN	O
decreases	NNS	O
in	IN	O
systemic	JJ	PH
vascular	JJ	PH
resistance	NN	PH
of	IN	O
similar	JJ	O
magnitude	NN	O
,	,	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
cardiac	JJ	PH
output	NN	PH
.	.	O

Plasma	NNP	PH
renin	NN	PH
activity	NN	PH
levels	NNS	PH
increased	VBD	O
48	CD	O
%	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
and	CC	O
126	CD	O
%	NN	O
with	IN	O
isoflurane	NN	O
.	.	O

Heart	NNP	PH
rate	NN	PH
increased	VBD	O
13	CD	O
%	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
,	,	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
isoflurane	NN	O
,	,	O
and	CC	O
decreased	VBD	O
23	CD	O
%	NN	O
with	IN	O
esmolol	NN	O
.	.	O

Although	IN	O
esmolol	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
primary	JJ	O
hypotensive	JJ	O
agent	NN	O
,	,	O
the	DT	O
potential	NN	O
for	IN	O
marked	JJ	PH
myocardial	JJ	PH
depression	NN	PH
must	MD	O
be	VB	O
recognized	VBN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
pharmacologic	NN	O
properties	NNS	O
for	IN	O
the	DT	O
different	JJ	O
hypotensive	JJ	O
agents	NNS	O
suggest	VBP	O
that	IN	O
combinations	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
may	MD	O
provide	VB	O
a	DT	O
pharmacologic	NN	O
profile	NN	O
superior	JJ	O
to	TO	O
either	DT	O
agent	NN	O
alone	RB	O
.	.	O

Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
levocetirizine	NN	O
on	IN	O
adenosine	JJ	O
monophosphate	NN	O
bronchoprovocation	NN	O
in	IN	O
atopic	NN	O
asthma	NN	O
.	.	O

AIMS	NNP	O
Adenosine	NNP	O
monophosphate	NN	O
(	(	O
AMP	NNP	O
)	)	O
acts	VBZ	O
indirectly	RB	O
via	IN	O
primed	VBN	O
airway	RB	O
mast	JJ	O
cells	NNS	O
to	TO	O
induce	VB	O
bronchial	JJ	O
hyper-responsiveness	NN	O
,	,	O
which	WDT	O
in	IN	O
turn	NN	O
correlates	NNS	O
with	IN	O
eosinophilic	JJ	PH
asthmatic	JJ	PH
inflammation	NN	PH
and	CC	PH
atopic	JJ	PH
disease	NN	PH
expression	NN	PH
.	.	PH

We	PRP	O
evaluated	VBD	O
single	JJ	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
a	DT	O
modern	JJ	O
histamine	NN	O
H1-receptor	NNP	O
antagonist	NN	O
,	,	O
levocetirizine	NN	O
,	,	O
given	VBN	O
at	IN	O
the	DT	O
usual	JJ	O
clinically	RB	O
recommended	VBD	O
dose	NN	O
,	,	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
AMP	NNP	O
bronchoprovocation	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	O
atopic	NN	O
asthmatics	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
double-blind	NN	O
,	,	O
cross-over	JJ	O
fashion	NN	O
to	TO	O
receive	VB	O
for	IN	O
1	CD	O
week	NN	O
either	CC	O
levocetirizine	JJ	O
5	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

The	DT	O
provocative	JJ	O
concentration	NN	O
of	IN	O
AMP	NNP	O
producing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
PC20	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
after	IN	O
each	DT	O
washout	NN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
4-6	JJ	O
h	NN	O
following	VBG	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
mean	JJ	PH
+/-	JJ	PH
SEM	NNP	PH
values	NNS	PH
after	IN	O
washout	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
for	IN	O
prechallenge	NN	O
FEV1	NNP	PH
(	(	O
%	NN	O
predicted	VBN	O
)	)	O
83	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
AMP	NNP	PH
PC20	NNP	PH
(	(	O
mg	JJ	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
45	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
45	CD	O
+/-	JJ	O
22	CD	O
,	,	O
respectively	RB	O
.	.	O

Airway	NNP	PH
calibre	NN	PH
as	IN	PH
prechallenge	NN	PH
FEV1	NNP	PH
for	IN	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
86	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
85	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
83	CD	O
+/-	JJ	O
4	CD	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
improvements	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
AMP	NNP	PH
PC20	NNP	PH
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
123	CD	O
+/-	JJ	O
73	CD	O
vs	JJ	O
48	CD	O
+/-	JJ	O
24	CD	O
,	,	O
a	DT	O
1.4	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.8	CD	O
,	,	O
1.9	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
127	CD	O
+/-	JJ	O
74	CD	O
vs	JJ	O
53	CD	O
+/-	JJ	O
29	CD	O
,	,	O
a	DT	O
1.2	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.5	CD	O
,	,	O
2.0	CD	O
)	)	O
.	.	O

AMP	NNP	PH
PC20	NNP	PH
was	VBD	O
also	RB	O
improved	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
by	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
levocetirizine	NN	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
vs	FW	O
respective	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
protection	NN	O
between	IN	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
with	IN	O
levocetirizine	NN	O
conferred	VBN	O
similar	JJ	O
improvements	NNS	O
in	IN	O
bronchial	JJ	PH
hyper-responsiveness	NN	PH
to	TO	PH
AMP	NNP	PH
challenge	NN	O
,	,	O
which	WDT	O
was	VBD	O
unrelated	JJ	O
to	TO	O
prechallenge	VB	O
airway	RB	O
calibre	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
indicated	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
longer-term	JJ	O
effects	NNS	O
of	IN	O
levocetirizine	NN	O
on	IN	O
asthma	JJ	PH
exacerbations	NNS	PH
.	.	PH

Brief	JJ	O
report	NN	O
:	:	O
effects	NNS	O
of	IN	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
on	IN	O
parent-reported	JJ	ME
autism	NN	ME
symptoms	NNS	ME
in	IN	O
school-age	JJ	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
effect	NN	O
of	IN	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
on	IN	O
parent-reported	JJ	O
autism	NN	O
symptoms	NNS	O
.	.	O

Nineteen	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
an	DT	O
anxiety	NN	O
disorder	NN	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	O
or	CC	O
a	DT	O
waitlist	JJ	O
condition	NN	O
.	.	O

The	DT	O
CBT	NNP	O
program	NN	O
emphasized	VBN	O
in	IN	O
vivo	NN	O
exposure	NN	O
supported	VBN	O
by	IN	O
parent	NN	O
training	NN	O
and	CC	O
school	NN	O
consultation	NN	O
to	TO	O
promote	VB	O
social	JJ	O
communication	NN	O
and	CC	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
.	.	O

Parents	NNS	O
completed	VBD	O
a	DT	O
standardized	JJ	Ot
autism	NN	Ot
symptom	JJ	Ot
checklist	NN	Ot
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
and	CC	O
3-month	JJ	O
follow-up	JJ	O
assessments	NNS	O
.	.	O

CBT	NNP	O
outperformed	VBD	O
the	DT	O
waitlist	JJ	O
condition	NN	O
at	IN	O
posttreatment/postwaitlist	NN	O
on	IN	O
total	JJ	ME
parent-reported	JJ	ME
autism	NN	ME
symptoms	NNS	ME
(	(	O
Cohen	NNP	O
's	POS	O
d	JJ	O
effect	NN	O
size	NN	O
=	NNP	O
.77	NNP	O
)	)	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

Further	JJ	O
investigation	NN	O
of	IN	O
this	DT	O
intervention	NN	O
modality	NN	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
broader	JJR	O
outcome	NN	O
measures	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
indicated	VBN	O
.	.	O

Impact	NN	O
of	IN	O
disease	NN	O
severity	NN	O
on	IN	O
outcome	NN	O
of	IN	O
antiviral	JJ	O
therapy	NN	O
for	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
:	:	O
Lessons	NNS	O
from	IN	O
the	DT	O
HALT-C	NNP	O
trial	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
,	,	O
advanced	VBD	O
fibrosis	NN	O
and	CC	O
cirrhosis	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
lower	JJR	O
rates	NNS	O
of	IN	O
sustained	JJ	PH
virologic	JJ	PH
response	NN	PH
(	(	PH
SVR	NNP	PH
)	)	PH
to	TO	O
interferon	VB	O
(	(	O
IFN	NNP	O
)	)	O
-based	VBD	O
therapy	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
virologic	JJ	PH
response	NN	PH
to	TO	O
retreatment	VB	O
with	IN	O
peginterferon	JJ	O
alfa-2a	JJ	O
and	CC	O
ribavirin	NN	O
(	(	O
RBV	NNP	O
)	)	O
,	,	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
baseline	NN	O
fibrosis	NN	O
score	NN	O
(	(	O
Ishak	NNP	O
staging	VBG	O
)	)	O
and	CC	O
platelet	NN	O
count	NN	O
,	,	O
in	IN	O
1,046	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Hepatitis	NNP	O
C	NNP	O
Antiviral	NNP	O
Long-term	NNP	O
Treatment	NNP	O
against	IN	O
Cirrhosis	NNP	O
(	(	O
HALT-C	NNP	O
)	)	O
Trial	NNP	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
failed	VBN	O
prior	RB	O
treatment	NN	O
with	IN	O
IFN	NNP	O
or	CC	O
peginterferon	VB	O
+/-	JJ	O
RBV	NNP	O
and	CC	O
had	VBD	O
Ishak	NNP	O
fibrosis	NN	O
scores	VBZ	O
>	CD	O
or	CC	O
=	VB	O
3	CD	O
.	.	O

Four	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
increasingly	RB	O
severe	JJ	O
liver	NN	O
disease	NN	O
were	VBD	O
compared	VBN	O
:	:	O
(	(	O
A	DT	O
)	)	O
bridging	NN	O
fibrosis	NN	O
(	(	O
Ishak	NNP	O
3	CD	O
and	CC	O
4	CD	O
)	)	O
with	IN	O
platelet	NN	O
counts	NNS	O
>	VBP	O
125,000/mm3	CD	O
(	(	O
n	JJ	O
=	NNP	O
559	CD	O
)	)	O
;	:	O
(	(	O
B	NNP	O
)	)	O
bridging	VBG	O
fibrosis	NN	O
with	IN	O
platelet	NN	O
counts	NNS	O
<	VBP	O
or	CC	O
=125,000/mm3	NNP	O
(	(	O
n	JJ	O
=	NNP	O
96	CD	O
)	)	O
;	:	O
(	(	O
C	NNP	O
)	)	O
cirrhosis	NN	O
(	(	O
Ishak	NNP	O
5	CD	O
and	CC	O
6	CD	O
)	)	O
with	IN	O
platelet	NN	O
counts	NNS	O
>	VBP	O
125,000/mm3	CD	O
(	(	O
n	JJ	O
=	NNP	O
198	CD	O
)	)	O
;	:	O
and	CC	O
(	(	O
D	NNP	O
)	)	O
cirrhosis	NN	O
with	IN	O
platelet	NN	O
counts	NNS	O
<	VBP	O
or	CC	O
=125,000/mm3	NNP	O
(	(	O
n	JJ	O
=	NNP	O
193	CD	O
)	)	O
.	.	O

SVR	JJ	PH
rates	NNS	PH
were	VBD	O
23	CD	O
%	NN	O
,	,	O
17	CD	O
%	NN	O
,	,	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
9	CD	O
%	NN	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
and	CC	O
D	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
for	IN	O
trend	NN	O
)	)	O
.	.	O

Reduction	NN	PH
in	IN	PH
SVR	NNP	PH
as	IN	O
a	DT	O
function	NN	O
of	IN	O
increasingly	RB	O
severe	JJ	O
disease	NN	O
was	VBD	O
independent	JJ	O
of	IN	O
age	NN	O
,	,	O
percent	JJ	O
African	JJ	O
American	NNP	O
,	,	O
HCV	NNP	O
genotype	NN	O
,	,	O
HCV	NNP	O
level	NN	O
,	,	O
and	CC	O
type	NN	O
of	IN	O
prior	JJ	O
therapy	NN	O
.	.	O

Dose	NNP	O
reduction	NN	O
lowered	VBD	O
SVR	NNP	PH
frequencies	NNS	PH
,	,	O
but	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
than	IN	O
disease	NN	O
severity	NN	O
.	.	O

By	IN	O
logistic	JJ	O
regression	NN	O
,	,	O
cirrhosis	NN	PH
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
was	VBD	O
the	DT	O
major	JJ	O
determinant	NN	O
that	WDT	O
impaired	VBD	O
virologic	JJ	PH
response	NN	PH
,	,	O
independent	JJ	O
of	IN	O
dose	JJ	O
reduction	NN	O
or	CC	O
platelet	NN	O
count	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
disease	NN	O
severity	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
independent	JJ	O
determinant	NN	O
of	IN	O
rate	NN	PH
of	IN	PH
SVR	NNP	PH
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
chronic	JJ	O
hepatitis	NN	O
C.	NNP	O
New	NNP	O
strategies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
optimize	VB	O
antiviral	JJ	O
therapy	NN	O
in	IN	O
these	DT	O
difficult-to-cure	JJ	O
patients	NNS	O
.	.	O

Randomised	VBN	O
trial	NN	O
of	IN	O
laparoscopic	NN	O
versus	NN	O
open	JJ	O
cholecystectomy	NN	O
for	IN	O
acute	NN	O
and	CC	O
gangrenous	JJ	O
cholecystitis	NN	O
.	.	O

BACKGROUND	NNP	O
Laparoscopic	NNP	O
cholecystectomy	NN	O
(	(	O
LC	NNP	O
)	)	O
has	VBZ	O
become	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
elective	JJ	O
cholecystectomy	NN	O
,	,	O
but	CC	O
controversy	NN	O
persists	NNS	O
over	IN	O
use	NN	O
of	IN	O
this	DT	O
approach	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
cholecystitis	NN	O
.	.	O

We	PRP	O
undertook	VBD	O
a	DT	O
randomised	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
outcome	NN	O
of	IN	O
LC	NNP	O
and	CC	O
open	JJ	O
cholecystectomy	NN	O
(	(	O
OC	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
cholecystitis	NN	O
.	.	O

METHODS	NNP	O
63	CD	O
of	IN	O
68	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
acute	JJ	O
cholecystitis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
OC	NNP	O
(	(	O
31	CD	O
patients	NNS	O
)	)	O
or	CC	O
LC	NNP	O
(	(	O
32	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
were	VBD	O
hospital	JJ	MO
mortality	NN	MO
and	CC	O
morbidity	NN	MO
,	,	O
length	NN	Ot
of	IN	Ot
hospital	NN	Ot
stay	NN	Ot
,	,	O
and	CC	O
length	NN	Ot
of	IN	Ot
sick	JJ	Ot
leave	VBP	Ot
from	IN	Ot
work	NN	Ot
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

Suspected	VBN	PH
bile-duct	NN	PH
stones	NNS	PH
were	VBD	O
investigated	VBN	O
by	IN	O
preoperative	JJ	O
endoscopic	NN	O
retrograde	NN	O
cholangiography	NN	O
(	(	O
LC	NNP	O
group	NN	O
)	)	O
or	CC	O
intraoperative	JJ	O
cholangiography	NN	O
(	(	O
OC	NNP	O
group	NN	O
)	)	O
.	.	O

FINDINGS	PDT	O
The	DT	O
two	CD	O
randomised	VBD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
demographic	JJ	O
,	,	O
physical	JJ	O
,	,	O
and	CC	O
clinical	JJ	O
characteristics	NNS	O
.	.	O

48	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
OC	NNP	O
group	NN	O
and	CC	O
59	CD	O
%	NN	O
in	IN	O
the	DT	O
LC	NNP	O
group	NN	O
were	VBD	O
older	JJR	O
than	IN	O
60	CD	O
years	NNS	O
.	.	O

13	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
had	VBD	O
gangrene	NN	PH
or	CC	O
empyema	NN	PH
,	,	O
and	CC	O
one	CD	O
in	IN	O
each	DT	O
group	NN	O
had	VBD	O
perforation	NN	PH
of	IN	PH
the	DT	PH
gallbladder	NN	PH
causing	NN	PH
diffuse	NN	PH
peritonitis	NN	PH
.	.	O

Five	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
LC	NNP	O
group	NN	O
required	VBD	O
conversion	NN	O
to	TO	O
OC	NNP	O
,	,	O
in	IN	O
most	JJS	O
because	IN	O
severe	JJ	PH
inflammation	NN	PH
distorted	VBD	O
the	DT	O
anatomy	NN	O
of	IN	O
Calot	NNP	O
's	POS	O
triangle	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
deaths	NNS	MO
or	CC	PH
bile-duct	NN	PH
lesions	NNS	PH
in	IN	O
either	DT	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
postoperative	JJ	A
complication	NN	A
rate	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p=0.0048	NN	O
)	)	O
higher	JJR	O
in	IN	O
the	DT	O
OC	NNP	O
than	IN	O
in	IN	O
the	DT	O
LC	NNP	O
group	NN	O
:	:	O
seven	CD	O
(	(	O
23	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
major	JJ	O
and	CC	O
six	CD	O
(	(	O
19	CD	O
%	NN	O
)	)	O
minor	NN	PH
complications	NNS	PH
after	IN	O
OC	NNP	O
,	,	O
whereas	IN	O
only	RB	O
one	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
minor	JJ	O
complication	NN	O
occurred	VBD	O
after	IN	O
LC	NNP	O
.	.	O

The	DT	O
postoperative	JJ	Ot
hospital	NN	Ot
stay	NN	Ot
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
LC	NNP	O
than	IN	O
the	DT	O
OC	NNP	O
group	NN	O
(	(	O
median	JJ	O
4	CD	O
[	JJ	O
IQR	NNP	O
2-5	JJ	O
]	NNP	O
vs	NN	O
6	CD	O
[	JJ	O
5-8	JJ	O
]	NNP	O
days	NNS	O
;	:	O
p=0.0063	NN	O
)	)	O
.	.	O

Mean	JJ	Ot
length	NN	Ot
of	IN	Ot
sick	JJ	Ot
leave	NN	Ot
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
LC	NNP	O
group	NN	O
(	(	O
13.9	CD	O
vs	RB	O
30.1	CD	O
days	NNS	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
10.9-21.7	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Even	RB	O
though	IN	O
LC	NNP	O
for	IN	O
acute	NN	O
and	CC	O
gangrenous	JJ	O
cholecystitis	NN	O
is	VBZ	O
technically	RB	O
demanding	VBG	O
,	,	O
in	IN	O
experienced	JJ	O
hands	NNS	O
it	PRP	O
is	VBZ	O
safe	JJ	Ot
and	CC	O
effective	JJ	Ot
.	.	O

It	PRP	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
mortality	NN	MO
rate	NN	MO
,	,	O
and	CC	O
the	DT	O
morbidity	NN	MO
rate	NN	MO
seems	VBZ	O
to	TO	O
be	VB	O
even	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
OC	NNP	O
.	.	O

However	RB	O
,	,	O
a	DT	O
moderately	RB	O
high	JJ	O
conversion	NN	O
rate	NN	O
must	MD	O
be	VB	O
accepted	VBN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
nebulized	JJ	O
flunisolide	NN	O
combined	VBN	O
with	IN	O
salbutamol	NN	O
and	CC	O
ipratropium	NN	O
bromide	NN	O
in	IN	O
stable	JJ	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
efficacy	NN	Ot
of	IN	O
nebulized	JJ	O
corticosteroids	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
exacerbation	NN	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
poorly	RB	O
studied	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
and	CC	O
tolerability	NN	Ot
of	IN	O
nebulized	JJ	O
flunisolide	NN	O
(	(	O
1	CD	O
mg	NN	O
)	)	O
+	VBZ	O
salbutamol/ipratropium	JJ	O
bromide	NN	O
(	(	O
1,875/375	CD	O
microg	NN	O
)	)	O
b.i.d	NN	O
.	.	O

in	IN	O
comparison	NN	O
with	IN	O
placebo	NN	O
+	NNP	O
salbutamol/ipratropium	NN	O
bromide	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
114	CD	O
patients	NNS	O
with	IN	O
COPD	NNP	O
of	IN	O
moderate-to-severe	JJ	O
degree	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	PH
of	IN	PH
severe	JJ	PH
exacerbations	NNS	PH
over	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
respiratory	NN	PH
symptoms	NNS	PH
,	,	PH
forced	VBD	PH
expiratory	JJ	PH
volume	NN	PH
in	IN	PH
1	CD	PH
s	NN	PH
(	(	PH
FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	PH
)	)	PH
,	,	PH
shuttle	JJ	PH
walking	VBG	PH
test	NN	PH
distance	NN	PH
and	CC	PH
St.	NNP	PH
George	NNP	PH
's	POS	PH
Respiratory	NNP	PH
Questionnaire	NNP	PH
scores	NNS	PH
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	PH
number	NN	PH
of	IN	PH
exacerbations	NNS	PH
was	VBD	O
slightly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
19	CD	O
vs.	FW	O
34	CD	O
,	,	O
p	NN	O
=	NNP	O
0.054	CD	O
)	)	O
;	:	O
the	DT	O
number	NN	PH
of	IN	PH
patients	NNS	PH
experiencing	VBG	PH
at	IN	PH
least	JJS	PH
one	CD	PH
exacerbation	NN	PH
during	IN	PH
the	DT	PH
study	NN	PH
was	VBD	O
also	RB	O
decreased	VBN	O
(	(	O
16	CD	O
vs.	FW	O
26	CD	O
,	,	O
p	NN	O
=	NNP	O
0.059	CD	O
)	)	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
type	JJ	PH
3	CD	PH
Anthonisens	NNP	PH
's	POS	PH
exacerbations	NNS	PH
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
flunisolide	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.044	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
scores	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
in	IN	O
the	DT	O
flunisolide	JJ	O
group	NN	O
but	CC	O
nonsignificant	NN	O
for	IN	O
dyspnea	NN	A
,	,	A
cough	NN	A
,	,	A
sputum	NN	A
amount	NN	A
and	CC	A
purulence	NN	A
.	.	O

FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	PH
was	VBD	O
significantly	RB	O
increased	VBN	O
compared	VBN	O
to	TO	O
baseline	VB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
the	DT	O
area	NN	PH
under	IN	PH
the	DT	PH
FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	PH
-time	NN	PH
curve	NN	PH
during	IN	PH
the	DT	PH
6-month	JJ	PH
period	NN	PH
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	O
group	NN	O
(	(	O
5.2	CD	O
+/-	JJ	O
10.6	CD	O
vs.	FW	O
2.1	CD	O
+/-	JJ	O
5.0	CD	O
,	,	O
flunisolide	RB	O
vs.	FW	O
placebo	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
=	$	O
0.047	CD	O
)	)	O
.	.	O

For	IN	O
shuttle	JJ	PH
walking	VBG	PH
test	NN	PH
distance	NN	PH
and	CC	PH
scores	NNS	PH
of	IN	PH
the	DT	PH
St.	NNP	PH
George	NNP	PH
's	POS	PH
Respiratory	NNP	PH
Questionnaire	NNP	PH
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
evaluation	NN	O
and	CC	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Nebulized	NNP	O
flunisolide	NN	O
is	VBZ	O
a	DT	O
good	JJ	O
alternative	NN	O
to	TO	O
other	JJ	O
inhaled	JJ	O
corticosteroids	NNS	O
when	WRB	O
added	VBN	O
to	TO	O
nebulized	JJ	O
salbutamol/ipratropium	NN	O
bromide	NN	O
in	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
moderate-to-severe	JJ	O
COPD	NNP	O
patients	NNS	O
.	.	O

Abacavir	NNP	O
once	RB	O
or	CC	O
twice	RB	O
daily	RB	O
combined	VBN	O
with	IN	O
once-daily	JJ	O
lamivudine	NN	O
and	CC	O
efavirenz	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
antiretroviral-naive	JJ	PH
HIV-infected	JJ	O
adults	NNS	O
:	:	O
results	NNS	O
of	IN	O
the	DT	O
Ziagen	NNP	O
Once	NNP	O
Daily	NNP	O
in	IN	O
Antiretroviral	NNP	O
Combination	NNP	O
Study	NNP	O
.	.	O

The	DT	O
long	JJ	O
intracellular	JJ	O
half-life	NN	O
of	IN	O
abacavir	NN	O
(	(	O
ABC	NNP	O
)	)	O
supports	VBZ	O
its	PRP$	O
once-daily	JJ	O
use	NN	O
,	,	O
and	CC	O
this	DT	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
simplify	VB	O
treatment	NN	O
if	IN	O
ABC	NNP	O
could	MD	O
be	VB	O
given	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
complete	JJ	O
once-daily	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	Ot
and	CC	O
safety	NN	Ot
of	IN	O
600	CD	O
mg	NN	O
of	IN	O
ABC	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
384	CD	O
)	)	O
versus	NN	O
300	CD	O
mg	NN	O
of	IN	O
ABC	NNP	O
administered	VBD	O
twice	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
386	CD	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
300	CD	O
mg	NNS	O
of	IN	O
lamivudine	NN	O
(	(	O
3TC	CD	O
)	)	O
and	CC	O
600	CD	O
mg	NN	O
of	IN	O
efavirenz	NN	O
(	(	O
EFV	NNP	O
)	)	O
administered	VBD	O
once	RB	O
daily	JJ	O
in	IN	O
antiretroviral-naive	JJ	O
patients	NNS	O
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
baseline	NN	PH
median	JJ	PH
plasma	NN	PH
HIV-1	NNP	PH
RNA	NNP	PH
level	NN	PH
was	VBD	O
4.89	CD	O
log10	JJ	O
copies/mL	NN	O
(	(	O
44	CD	O
%	NN	O
with	IN	O
viral	JJ	O
load	NN	O
>	VBD	O
100,000	CD	O
copies/mL	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
CD4	NNP	O
cell	NN	O
count	NN	O
was	VBD	O
262	CD	O
cells/mm	NN	O
.	.	O

ABC	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
twice-daily	JJ	O
regimen	NNS	O
,	,	O
with	IN	O
66	CD	O
%	NN	O
and	CC	O
68	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
these	DT	O
respective	JJ	O
treatment	NN	O
arms	NNS	O
achieving	VBG	O
a	DT	O
confirmed	JJ	O
plasma	NN	PH
HIV-1	NNP	PH
RNA	NNP	PH
level	NN	PH
<	VBD	O
50	CD	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
-8.4	CD	O
%	NN	O
,	,	O
4.9	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
ABC	NNP	O
once-daily	JJ	O
and	CC	O
twice-daily	JJ	O
regimens	NNS	O
were	VBD	O
similar	JJ	O
with	IN	O
respect	NN	O
to	TO	O
infrequency	NN	PH
of	IN	PH
virologic	JJ	PH
failure	NN	PH
(	(	O
10	CD	O
%	NN	O
vs.	FW	O
8	CD	O
%	NN	O
)	)	O
,	,	O
emergence	NN	PH
of	IN	PH
resistance	NN	PH
mutations	NNS	PH
,	,	PH
CD4	NNP	PH
cell	NN	PH
increases	NNS	PH
from	IN	PH
baseline	NN	PH
(	(	O
median	JJ	O
,	,	O
188	CD	O
vs.	FW	O
200	CD	O
cells/mm	NN	O
)	)	O
,	,	O
safety	NN	PH
profile	NN	PH
,	,	O
and	CC	O
incidence	NN	PH
of	IN	PH
ABC-related	NNP	PH
hypersensitivity	NN	PH
reactions	NNS	PH
(	(	O
9	CD	O
%	NN	O
vs.	FW	O
7	CD	O
%	NN	O
)	)	O
.	.	O

ABC	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
in	IN	O
combination	NN	O
with	IN	O
3TC	CD	O
and	CC	O
EFV	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
ABC	NNP	O
twice-daily	JJ	O
dosing	NN	O
schedule	NN	O
when	WRB	O
combined	VBN	O
with	IN	O
3TC	CD	O
and	CC	O
EFV	NNP	O
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
levofloxacin	NN	O
,	,	O
omeprazole	NN	O
,	,	O
nitazoxanide	RB	O
,	,	O
and	CC	O
doxycycline	VB	O
versus	NN	O
triple	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	PH
pylori	NN	PH
.	.	O

OBJECTIVES	NNP	O
Resistance	NNP	O
to	TO	O
standard	VB	O
Helicobacter	NNP	O
pylori	NN	O
(	(	O
HP	NNP	O
)	)	O
treatment	NN	O
regimens	VBZ	O
has	VBZ	O
led	VBN	O
to	TO	O
unsatisfactory	JJ	O
cure	NN	O
rates	NNS	O
in	IN	O
HP-infected	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
a	DT	O
novel	JJ	O
four-drug	JJ	O
regimen	NNS	O
(	(	O
three	CD	O
antibiotics	NNS	O
and	CC	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
)	)	O
for	IN	O
eradication	NN	O
of	IN	O
HP	NNP	O
infection	NN	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
HP	NNP	O
gastritis	NN	O
or	CC	O
peptic	JJ	O
ulcer	JJ	O
disease	NN	O
confirmed	VBD	O
using	VBG	O
endoscopy	NN	O
and	CC	O
stool	NN	O
antigen	NN	O
testing	VBG	O
were	VBD	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
underwent	VBD	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
any	DT	O
prior	JJ	O
antibiotic	JJ	O
or	CC	O
PPI	JJ	O
usage	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomized	VBN	O
to	TO	O
either	DT	O
levofloxacin	NN	O
,	,	O
omeprazole	NN	O
,	,	O
nitazoxanide	RB	O
,	,	O
and	CC	O
doxycycline	NN	O
(	(	O
LOAD	NNP	O
)	)	O
therapy	NN	O
for	IN	O
7	CD	O
days	NNS	O
(	(	O
LOAD-7	NNP	O
)	)	O
or	CC	O
10	CD	O
days	NNS	O
(	(	O
LOAD-10	NNP	O
)	)	O
,	,	O
including	VBG	O
levofloxacin	JJ	O
250	CD	O
mg	NN	O
with	IN	O
breakfast	NN	O
,	,	O
omeprazole	JJ	O
40	CD	O
mg	NN	O
before	IN	O
breakfast	NN	O
,	,	O
nitazoxanide	RB	O
(	(	O
Alina	NNP	O
)	)	O
500	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
with	IN	O
meals	NNS	O
and	CC	O
doxycycline	VB	O
100	CD	O
mg	NN	O
at	IN	O
dinner	NN	O
,	,	O
or	CC	O
lansoprozole	NN	O
,	,	O
amoxicillin	NN	O
,	,	O
and	CC	O
clarithromycin	NN	O
(	(	O
LAC	NNP	O
)	)	O
therapy	NN	O
for	IN	O
10	CD	O
days	NNS	O
,	,	O
which	WDT	O
included	VBD	O
lansoprozole	JJ	O
30	CD	O
mg	NN	O
,	,	O
amoxicillin	VBZ	O
1	CD	O
g	NN	O
with	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
,	,	O
and	CC	O
clarithromycin	VBZ	O
500	CD	O
mg	NN	O
with	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
.	.	O

HP	NNP	O
eradication	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
stool	NN	PH
antigen	NN	PH
testing	VBG	PH
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
Intention-to-treat	JJ	Ot
analysis	NN	Ot
revealed	VBD	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
respective	JJ	O
eradication	NN	PH
rates	NNS	PH
of	IN	PH
the	DT	PH
LOAD	NNP	PH
therapies	NNS	PH
(	(	O
88.9	CD	O
%	NN	O
(	(	O
80/90	CD	O
)	)	O
LOAD-10	NNP	O
,	,	O
90	CD	O
%	NN	O
(	(	O
81/90	CD	O
)	)	O
LOAD-7	NNP	O
,	,	O
89.4	CD	O
%	NN	O
(	(	O
161/180	CD	O
)	)	O
for	IN	O
combined	VBN	O
LOAD	NNP	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
receiving	VBG	O
LAC	NNP	PH
,	,	O
73.3	CD	O
%	NN	O
(	(	O
66/90	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
adverse	JJ	A
effects	NNS	A
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
open-label	JJ	O
,	,	O
prospective	JJ	O
trial	NN	O
demonstrates	VBZ	O
that	IN	O
LOAD	NNP	PH
is	VBZ	O
a	DT	O
highly	RB	O
active	JJ	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HP	NNP	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

A	DT	O
large	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
is	VBZ	O
warranted	VBN	O
to	TO	O
further	RBR	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
this	DT	O
regimen	NNS	O
.	.	O

A	DT	O
two-part	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
cediranib	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
solid	JJ	O
tumours	NN	O
:	:	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
single-dose	JJ	O
pharmacokinetics	NNS	O
and	CC	O
an	DT	O
evaluation	NN	O
of	IN	O
safety	NN	Ot
,	,	Ot
efficacy	NN	Ot
and	CC	Ot
imaging	VBG	Ot
pharmacodynamics	NNS	Ot
.	.	Ot

BACKGROUND	NNP	O
Cediranib	NNP	O
(	(	O
RECENTIN?	NNP	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
,	,	O
highly	RB	O
potent	JJ	O
VEGF	NNP	O
inhibitor	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
cediranib	NN	O
and	CC	O
compared	VBN	O
the	DT	O
administration	NN	O
of	IN	O
continual	JJ	O
cediranib	NN	O
via	IN	O
two	CD	O
dosing	VBG	O
strategies	NNS	O
using	VBG	O
this	DT	O
as	IN	O
a	DT	O
platform	NN	O
to	TO	O
investigate	VB	O
pharmacodynamic	JJ	O
imaging	NN	O
biomarkers	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
two	CD	O
single	JJ	O
doses	NNS	O
of	IN	O
cediranib	NN	O
in	IN	O
either	CC	O
fed/fasted	VBD	O
or	CC	O
fasted/fed	JJ	O
state	NN	O
(	(	O
Part	NNP	O
A	NNP	O
)	)	O
.	.	O

In	IN	O
continual	JJ	O
dosage	NN	O
phase	NN	O
(	(	O
Part	NNP	O
B	NNP	O
)	)	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
a	DT	O
fixed-dose	JJ	O
or	CC	O
dose-escalation	JJ	O
arm	NN	O
.	.	O

Exploratory	JJ	O
pharmacodynamic	JJ	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
DCE-MRI	NNP	O
and	CC	O
CT	NNP	O
enhancing	VBG	O
fraction	NN	O
(	(	O
EnF	NNP	O
)	)	O
.	.	O

RESULTS	VBN	O
In	IN	O
part	NN	O
A	NNP	O
,	,	O
plasma	NN	PH
AUC	NNP	PH
and	CC	PH
C	NNP	PH
(	(	PH
max	NN	PH
)	)	PH
of	IN	PH
cediranib	NN	PH
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
food	NN	O
by	IN	O
a	DT	O
mean	NN	O
of	IN	O
24	CD	O
and	CC	O
33	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
94	CD	O
%	NN	O
CI	NNP	O
:	:	O
AUC	NNP	O
,	,	O
12-34	CD	O
%	NN	O
and	CC	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
,	,	O
20-43	JJ	O
%	NN	O
)	)	O
,	,	O
indicating	VBG	O
food	NN	O
reduces	NNS	O
cediranib	VBP	O
plasma	JJ	O
exposure	NN	O
.	.	O

In	IN	O
part	NN	O
B	NNP	O
,	,	O
cediranib	VBZ	O
30	CD	O
mg/day	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
sustainable	JJ	O
for	IN	O
chronic	JJ	O
dosing	NN	O
.	.	O

Continuous	JJ	O
cediranib	NN	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
sustained	JJ	O
antivascular	JJ	O
effects	NNS	O
up	RB	O
to	TO	O
16	CD	O
weeks	NNS	O
,	,	O
with	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
DCE-MRI	NNP	PH
parameters	NNS	PH
and	CC	PH
CT	NNP	PH
EnF	NNP	PH
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
cediranib	NN	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
1	CD	O
h	NN	O
before	IN	O
or	CC	O
2	CD	O
h	NN	O
after	IN	O
food	NN	O
.	.	O

Evidence	NN	O
of	IN	O
antitumour	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
,	,	O
with	IN	O
significant	JJ	O
sustained	JJ	O
effects	NNS	O
upon	IN	O
imaging	VBG	O
vascular	JJ	O
parameters	NNS	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
an	DT	O
intervention	NN	O
for	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
:	:	O
the	DT	O
Early	JJ	O
Start	NNP	O
Denver	NNP	O
Model	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
conduct	VB	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBD	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
the	DT	O
Early	JJ	O
Start	NNP	O
Denver	NNP	O
Model	NNP	O
(	(	O
ESDM	NNP	O
)	)	O
,	,	O
a	DT	O
comprehensive	JJ	O
developmental	JJ	O
behavioral	JJ	O
intervention	NN	O
,	,	O
for	IN	O
improving	VBG	O
outcomes	NNS	O
of	IN	O
toddlers	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Forty-eight	JJ	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
ASD	NNP	O
between	IN	O
18	CD	O
and	CC	O
30	CD	O
months	NNS	O
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
2	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
ESDM	NNP	O
intervention	NN	O
,	,	O
which	WDT	O
is	VBZ	O
based	VBN	O
on	IN	O
developmental	JJ	O
and	CC	O
applied	JJ	O
behavioral	JJ	O
analytic	JJ	O
principles	NNS	O
and	CC	O
delivered	VBN	O
by	IN	O
trained	JJ	O
therapists	NNS	O
and	CC	O
parents	NNS	O
for	IN	O
2	CD	O
years	NNS	O
;	:	O
or	CC	O
(	(	O
2	CD	O
)	)	O
referral	NN	O
to	TO	O
community	NN	O
providers	NNS	O
for	IN	O
intervention	NN	O
commonly	RB	O
available	JJ	O
in	IN	O
the	DT	O
community	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
children	NNS	O
who	WP	O
received	VBD	O
community-intervention	NN	O
,	,	O
children	NNS	O
who	WP	O
received	VBD	O
ESDM	NNP	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
IQ	NNP	PH
,	,	PH
adaptive	JJ	PH
behavior	NN	PH
,	,	PH
and	CC	PH
autism	NN	PH
diagnosis	NN	PH
.	.	PH

Two	CD	O
years	NNS	O
after	IN	O
entering	VBG	O
intervention	NN	O
,	,	O
the	DT	O
ESDM	NNP	O
group	NN	O
on	IN	O
average	NN	O
improved	VBD	O
17.6	CD	O
standard	NN	O
score	NN	O
points	NNS	O
(	(	O
1	CD	O
SD	NNP	O
:	:	O
15	CD	O
points	NNS	O
)	)	O
compared	VBN	O
with	IN	O
7.0	CD	O
points	NNS	O
in	IN	O
the	DT	O
comparison	NN	O
group	NN	O
relative	VBP	O
to	TO	O
baseline	VB	O
scores	NNS	O
.	.	O

The	DT	O
ESDM	NNP	O
group	NN	O
maintained	VBD	O
its	PRP$	O
rate	NN	PH
of	IN	PH
growth	NN	PH
in	IN	PH
adaptive	JJ	PH
behavior	NN	PH
compared	VBN	O
with	IN	O
a	DT	O
normative	JJ	O
sample	NN	O
of	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
over	IN	O
the	DT	O
2-year	JJ	O
span	NN	O
,	,	O
the	DT	O
comparison	NN	O
group	NN	O
showed	VBD	O
greater	JJR	O
delays	NNS	O
in	IN	O
adaptive	JJ	O
behavior	NN	O
.	.	O

Children	NNP	O
who	WP	O
received	VBD	O
ESDM	NNP	O
also	RB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
a	DT	O
change	NN	PH
in	IN	PH
diagnosis	NN	PH
from	IN	O
autism	NN	O
to	TO	O
pervasive	VB	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
than	IN	O
the	DT	O
comparison	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
demonstrate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
comprehensive	JJ	O
developmental	JJ	O
behavioral	JJ	O
intervention	NN	O
for	IN	O
toddlers	NNS	O
with	IN	O
ASD	NNP	O
for	IN	O
improving	VBG	O
cognitive	JJ	O
and	CC	O
adaptive	JJ	O
behavior	NN	O
and	CC	O
reducing	VBG	O
severity	NN	O
of	IN	O
ASD	NNP	O
diagnosis	NN	O
.	.	O

Results	NNS	O
of	IN	O
this	DT	O
study	NN	O
underscore	VBD	O
the	DT	O
importance	NN	O
of	IN	O
early	JJ	O
detection	NN	O
of	IN	O
and	CC	O
intervention	NN	O
in	IN	O
autism	NN	O
.	.	O

Effect	NN	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
myocardial	JJ	O
metabolism	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
balanced	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
open	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
cardiac	JJ	O
performance	NN	O
after	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
balanced	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
in	IN	O
38	CD	O
patients	NNS	O
.	.	O

Preoperative	JJ	O
haemodynamic	JJ	O
status	NN	O
was	VBD	O
good	JJ	O
in	IN	O
all	DT	O
of	IN	O
them	PRP	O
.	.	O

Seventeen	JJ	O
subjects	NNS	O
underwent	JJ	O
mitral	JJ	O
valve	NN	O
replacement	NN	O
and	CC	O
19	CD	O
patients	NNS	O
coronary	JJ	O
artery	JJ	O
bypass	NN	O
grafting	NN	O
.	.	O

Five	CD	O
grams	NNS	O
L-carnitine	JJ	O
were	VBD	O
given	VBN	O
intravenously	RB	O
over	IN	O
2	CD	O
h	NNS	O
,	,	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
consecutive	JJ	O
days	NNS	O
;	:	O
moreover	RB	O
,	,	O
10	CD	O
g	JJ	O
L-carnitine	NNP	O
in	IN	O
1500	CD	O
ml	NN	O
cardioplegia	NN	O
were	VBD	O
administered	VBN	O
through	IN	O
the	DT	O
aortic	JJ	O
root	NN	O
after	IN	O
aortic	JJ	O
cross-clamping	NN	O
.	.	O

Surgery	NN	O
was	VBD	O
always	RB	O
planned	VBN	O
on	IN	O
treatment	NN	O
day	NN	O
3	CD	O
.	.	O

The	DT	O
post-ischaemic	JJ	O
functional	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
heart	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
clinical	JJ	O
parameters	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
biochemical	JJ	O
and	CC	O
ultrastructure	JJ	O
evaluations	NNS	O
on	IN	O
biopsy	NN	O
specimens	NNS	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
treatment	NN	O
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
all	DT	O
clinical	JJ	O
parameters	NNS	O
of	IN	O
cardiac	JJ	O
performance	NN	O
after	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

At	IN	O
anaesthesia	JJ	O
induction	NN	O
,	,	O
serum	JJ	PH
carnitine	NN	PH
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
treated	JJ	O
patients	NNS	O
,	,	O
but	CC	O
carnitine	JJ	PH
concentrations	NNS	PH
in	IN	O
the	DT	O
right	JJ	O
atrial	JJ	O
biopsy	NN	O
obtained	VBN	O
just	RB	O
before	RB	O
aortic	JJ	O
declamping	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
mitral	JJ	O
valve	FW	O
replacement	NN	O
,	,	O
L-carnitine	JJ	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
pyruvate	NN	PH
,	,	O
ATP	NNP	PH
and	CC	O
creatine	JJ	PH
phosphate	NN	PH
in	IN	O
papillary	JJ	O
muscle	NN	O
.	.	O

Glycogen	NN	PH
levels	NNS	PH
were	VBD	O
also	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Myocardial	JJ	O
ultrastructure	NN	O
on	IN	O
septal	JJ	O
biopsies	NNS	O
,	,	O
obtained	VBD	O
within	IN	O
5	CD	O
min	NN	O
from	IN	O
weaning	VBG	O
from	IN	O
extracorporeal	JJ	O
circulation	NN	O
,	,	O
showed	VBD	O
better	JJR	O
preservation	NN	O
scores	NNS	O
for	IN	O
all	DT	O
considered	VBN	O
parameters	NNS	O
(	(	O
nucleus	NN	PH
,	,	PH
sarcoplasmic	JJ	PH
reticulum	NN	PH
,	,	PH
mitochondria	NN	PH
and	CC	PH
cellular	JJ	PH
oedema	NN	PH
)	)	O
in	IN	O
the	DT	O
treated	JJ	O
subjects	NNS	O
,	,	O
although	IN	O
the	DT	O
difference	NN	O
reached	VBD	O
statistical	JJ	O
significance	NN	O
only	RB	O
for	IN	O
nuclei	NN	O
.	.	O

When	WRB	O
biochemical	JJ	O
and	CC	O
ultrastructural	JJ	O
data	NNS	O
are	VBP	O
considered	VBN	O
,	,	O
these	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	O
improves	VBZ	O
myocardial	JJ	PH
metabolism	NN	PH
.	.	O

However	RB	O
,	,	O
it	PRP	O
can	MD	O
not	RB	O
be	VB	O
concluded	VBN	O
that	IN	O
L-carnitine	NNP	O
provides	VBZ	O
an	DT	O
advantageous	JJ	Ot
support	NN	Ot
therapy	NN	Ot
for	IN	O
well-compensated	JJ	O
patients	NNS	O
requiring	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
positive	JJ	O
effects	NNS	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
cardiac	JJ	PH
recovery	NN	PH
after	IN	O
bypass	NN	O
might	MD	O
become	VB	O
clinically	RB	O
relevant	JJ	O
in	IN	O
the	DT	O
surgical	JJ	O
setting	NN	O
for	IN	O
haemodynamically	RB	O
compromised	JJ	O
patients	NNS	O
,	,	O
in	IN	O
which	WDT	O
further	JJ	O
investigations	NNS	O
are	VBP	O
required	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
standardized	JJ	O
pamphlet	NN	O
on	IN	O
insomnia	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
Sleep	NNP	PH
difficulties	NNS	PH
are	VBP	O
common	JJ	O
reasons	NNS	O
why	WRB	O
parents	NNS	O
seek	VBP	O
medical	JJ	O
intervention	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASDs	NNP	O
)	)	O
.	.	O

We	PRP	O
determined	VBD	O
whether	IN	O
a	DT	O
pamphlet	NN	O
alone	RB	O
could	MD	O
be	VB	O
used	VBN	O
by	IN	O
parents	NNS	O
to	TO	O
help	VB	O
their	PRP$	O
child	NN	O
's	POS	O
insomnia	NN	PH
.	.	PH

METHODS	NNP	O
Thirty-six	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
ages	VBZ	O
2	CD	O
to	TO	O
10	CD	O
years	NNS	O
,	,	O
were	VBD	O
enrolled	VBN	O
.	.	O

All	DT	O
had	VBD	O
prolonged	VBN	O
sleep	JJ	PH
latency	NN	PH
confirmed	VBN	O
by	IN	O
actigraphy	NN	O
showing	VBG	O
a	DT	O
mean	JJ	O
sleep	JJ	PH
latency	NN	PH
of	IN	O
30	CD	O
minutes	NNS	O
or	CC	O
more	JJR	O
.	.	O

Parents	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
the	DT	O
sleep	JJ	O
education	NN	O
pamphlet	NN	O
or	CC	O
no	DT	O
intervention	NN	O
.	.	O

Children	NNP	O
wore	VBD	O
an	DT	O
actigraphy	NN	O
device	NN	O
to	TO	O
record	VB	O
baseline	NN	O
sleep	JJ	PH
parameters	NNS	PH
,	,	O
with	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
variable	JJ	O
being	VBG	O
change	NN	PH
in	IN	PH
sleep	JJ	PH
latency	NN	PH
.	.	PH

Actigraphy	NNP	O
data	NNS	O
were	VBD	O
collected	VBN	O
a	DT	O
second	JJ	O
time	NN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
parent	NN	O
received	VBD	O
the	DT	O
randomization	NN	O
assignment	NN	O
and	CC	O
analyzed	VBN	O
by	IN	O
using	VBG	O
Student	NNP	O
's	POS	O
t	JJ	O
test	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
also	RB	O
asked	VBN	O
a	DT	O
series	NN	O
of	IN	O
questions	NNS	O
to	TO	O
gather	VB	O
information	NN	O
about	IN	O
the	DT	O
pamphlet	NN	O
and	CC	O
its	PRP$	O
usefulness	NN	O
.	.	O

RESULTS	NNP	O
Although	IN	O
participants	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
2	CD	O
arms	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
statistically	RB	O
in	IN	O
age	NN	PH
,	,	PH
gender	NN	PH
,	,	PH
socioeconomic	JJ	PH
status	NN	PH
,	,	PH
total	JJ	PH
Children	NNP	PH
's	POS	PH
Sleep	NNP	PH
Habits	NNP	PH
Questionnaire	NNP	PH
score	NN	PH
,	,	PH
or	CC	PH
actigraphy	NN	PH
parameters	NNS	PH
,	,	O
some	DT	O
differences	NNS	O
may	MD	O
be	VB	O
large	JJ	O
enough	RB	O
to	TO	O
affect	VB	O
results	NNS	O
.	.	O

Mean	JJ	PH
change	NN	PH
in	IN	PH
sleep-onset	JJ	PH
latency	NN	PH
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
randomized	VBN	O
groups	NNS	O
(	(	O
pamphlet	VB	O
versus	NN	O
no	DT	O
pamphlet	NN	O
)	)	O
.	.	O

Parents	NNS	O
commented	VBD	O
that	IN	O
the	DT	O
pamphlet	NN	O
contained	VBD	O
good	JJ	O
information	NN	Ot
,	,	O
but	CC	O
indicated	VBD	O
that	IN	O
it	PRP	O
would	MD	O
have	VB	O
been	VBN	O
more	RBR	O
useful	JJ	O
to	TO	O
be	VB	O
given	VBN	O
specific	JJ	O
examples	NNS	O
of	IN	O
how	WRB	O
to	TO	O
take	VB	O
the	DT	O
information	NN	O
and	CC	O
put	VB	O
it	PRP	O
into	IN	O
practice	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
sleep	JJ	O
education	NN	O
pamphlet	NN	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
improve	VB	O
sleep	JJ	PH
latency	NN	PH
in	IN	O
children	NNS	O
with	IN	O
ASDs	NNP	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
alpha	JJ	O
dihydroergocryptine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
fibrocystic	JJ	O
breast	NN	O
disease	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
fibrocystic	JJ	O
mastopathy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
with	IN	O
diagnosis	NN	O
of	IN	O
fibrocystic	JJ	O
breast	NN	O
disease	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
longitudinal	JJ	O
blind	NN	O
double	NN	O
,	,	O
controlled	VBN	O
with	IN	O
placebo	NN	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
of	IN	O
treatment	NN	O
group	NN	O
A	DT	O
:	:	O
Alpha	NNP	O
dihidroergocriptine	VBP	O
tablets	NNS	O
of	IN	O
10	CD	O
mg	NNS	O
,	,	O
group	NN	O
B	NNP	O
:	:	O
Placebo	NN	O
,	,	O
during	IN	O
6	CD	O
months	NNS	O
.	.	O

After	IN	O
to	TO	O
basal	VB	O
evaluation	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
revised	VBN	O
in	IN	O
a	DT	O
monthly	JJ	O
way	NN	O
evaluating	VBG	O
the	DT	O
following	NN	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
:	:	O
mastalgia	NN	PH
,	,	O
mammary	JJ	PH
tension	NN	PH
,	,	O
presence	NN	PH
of	IN	PH
nodules	NNS	PH
,	,	O
nipple	JJ	PH
secretion	NN	PH
,	,	O
and	CC	O
the	DT	O
presence	NN	A
of	IN	A
adverse	JJ	A
events	NNS	A
.	.	O

RESULTS	NNP	O
39	CD	O
patients	NNS	O
with	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
and	CC	O
38	CD	O
with	IN	O
placebo	NN	O
.	.	O

Mastodinia	NNP	PH
,	,	O
a	DT	O
satisfactory	JJ	O
response	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
100	CD	O
%	NN	O
of	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
group	NN	O
vs	VBD	O
61.11	CD	O
%	NN	O
of	IN	O
placebo	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0002	CD	O
)	)	O
.	.	O

Mastalgia	NNP	PH
responded	VBD	O
in	IN	O
100	CD	O
%	NN	O
of	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
group	NN	O
vs	VBD	O
64.86	CD	O
%	NN	O
of	IN	O
placebo	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

Galactorrea	NNP	PH
responded	VBD	O
100	CD	O
%	NN	O
of	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
group	NN	O
vs	VBD	O
93.33	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
.	.	O

The	DT	O
nodules	NNS	PH
in	IN	O
the	DT	O
group	NN	O
alpha	VBZ	O
dihidroergocriptine	NN	O
disappeared	VBD	O
in	IN	O
23.1	CD	O
%	NN	O
and	CC	O
in	IN	O
21.1	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Ultrasound	IN	O
evaluation	NN	O
of	IN	O
the	DT	O
nodules	NNS	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
differences	NNS	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

Prolactin	NNP	PH
levels	NNS	PH
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
with	IN	O
an	DT	O
important	JJ	O
difference	NN	O
between	IN	O
both	DT	O
groups	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
6	CD	O
months	NNS	O
study	JJ	O
period	NN	O
.	.	O

There	EX	O
were	VBD	O
not	RB	O
differences	NNS	O
in	IN	O
the	DT	O
presence	NN	A
of	IN	A
adverse	JJ	A
events	NNS	A
between	IN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Alpha	NNP	O
dihidroergocriptine	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
fribrocystic	JJ	O
breast	NN	O
disease	NN	O
with	IN	O
minimum	JJ	O
adverse	JJ	O
events	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
similar	JJ	O
drugs	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
dalcetrapib	NN	O
on	IN	O
atherosclerotic	JJ	O
disease	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	NN	O
(	(	O
dal-PLAQUE	JJ	O
)	)	O
:	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Dalcetrapib	NNP	O
modulates	VBZ	O
cholesteryl	VBP	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
activity	NN	O
to	TO	O
raise	VB	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
HDL-C	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
failure	NN	O
of	IN	O
torcetrapib	NN	O
it	PRP	O
was	VBD	O
unknown	JJ	O
if	IN	O
HDL	NNP	O
produced	VBN	O
by	IN	O
interaction	NN	O
with	IN	O
CETP	NNP	O
had	VBD	O
pro-atherogenic	JJ	O
or	CC	O
pro-inflammatory	JJ	O
properties	NNS	O
.	.	O

dal-PLAQUE	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
multicentre	NN	O
study	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	VBG	O
to	TO	O
assess	VB	O
structural	JJ	O
and	CC	O
inflammatory	JJ	O
indices	NNS	O
of	IN	O
atherosclerosis	NN	O
as	IN	O
primary	JJ	O
endpoints	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
phase	NN	O
2b	CD	O
,	,	O
double-blind	NN	O
,	,	O
multicentre	JJ	O
trial	NN	O
,	,	O
patients	NNS	O
(	(	O
aged	VBN	O
18-75	CD	O
years	NNS	O
)	)	O
with	IN	O
,	,	O
or	CC	O
with	IN	O
high	JJ	O
risk	NN	O
of	IN	O
,	,	O
coronary	JJ	O
heart	NN	O
disease	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
(	(	O
1:1	CD	O
)	)	O
to	TO	O
dalcetrapib	VB	O
600	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
code	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
centre	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
treatment	NN	O
.	.	O

Coprimary	JJ	O
endpoints	NNS	O
were	VBD	O
MRI-assessed	JJ	Ot
indices	NNS	Ot
(	(	O
total	JJ	Ot
vessel	NN	Ot
area	NN	Ot
,	,	PH
wall	JJ	Ot
area	NN	Ot
,	,	PH
wall	NN	Ot
thickness	NN	Ot
,	,	PH
and	CC	PH
normalised	VBD	Ot
wall	NN	Ot
index	NN	Ot
[	JJ	O
average	JJ	O
carotid	NN	O
]	NN	O
)	)	O
after	IN	O
24	CD	O
months	NNS	O
and	CC	O
(	(	O
18	CD	O
)	)	O
F-fluorodeoxyglucose	NNP	O
(	(	O
(	(	O
18	CD	O
)	)	O
F-FDG	NN	O
)	)	O
PET/CT	NNP	O
assessment	NN	O
of	IN	O
arterial	JJ	O
inflammation	NN	O
within	IN	O
an	DT	O
index	NN	O
vessel	NN	O
(	(	O
right	JJ	O
carotid	NN	O
,	,	O
left	VBD	O
carotid	NN	O
,	,	O
or	CC	O
ascending	VBG	O
thoracic	JJ	O
aorta	NN	O
)	)	O
after	IN	O
6	CD	O
months	NNS	O
,	,	O
with	IN	O
no-harm	JJ	O
boundaries	NNS	O
established	VBN	O
before	IN	O
unblinding	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00655473	NNP	O
.	.	O

FINDINGS	NNP	O
189	CD	O
patients	NNS	O
were	VBD	O
screened	VBN	O
and	CC	O
130	CD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
(	(	O
66	CD	O
patients	NNS	O
)	)	O
or	CC	O
dalcetrapib	NN	O
(	(	O
64	CD	O
patients	NNS	O
)	)	O
.	.	O

For	IN	O
the	DT	O
coprimary	JJ	O
MRI	NNP	O
and	CC	O
PET/CT	NNP	O
endpoints	NNS	O
,	,	O
CIs	NNP	O
were	VBD	O
below	IN	O
the	DT	O
no-harm	JJ	O
boundary	NN	O
or	CC	O
the	DT	O
adverse	JJ	O
change	NN	O
was	VBD	O
numerically	RB	O
lower	JJR	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

MRI-derived	JJ	Ot
change	NN	Ot
in	IN	Ot
total	JJ	Ot
vessel	JJ	Ot
area	NN	Ot
was	VBD	O
reduced	VBN	O
in	IN	O
patients	NNS	O
given	VBN	O
dalcetrapib	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
given	VBN	O
placebo	NNS	O
after	IN	O
24	CD	O
months	NNS	O
;	:	O
absolute	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
relative	NN	O
to	TO	O
placebo	VB	O
was	VBD	O
-4?01	JJ	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
-7?23	NNP	O
to	TO	O
-0?80	VB	O
;	:	O
nominal	JJ	O
p=0?04	NN	O
)	)	O
.	.	O

The	DT	O
PET/CT	NNP	O
measure	NN	O
of	IN	O
index	NN	O
vessel	JJ	O
most-diseased-segment	JJ	O
target-to-background	NN	O
ratio	NN	O
(	(	O
TBR	NNP	O
)	)	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
,	,	O
but	CC	O
carotid	JJ	O
artery	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
7	CD	O
%	NN	O
reduction	NN	O
in	IN	O
most-diseased-segment	JJ	O
TBR	NNP	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
-7?3	NNP	O
[	RB	O
90	CD	O
%	NN	O
CI	NNP	O
-13?5	NNP	O
to	TO	O
-0?8	VB	O
]	NNP	O
;	:	O
nominal	JJ	O
p=0?07	NN	O
)	)	O
.	.	O

Dalcetrapib	NNP	O
did	VBD	O
not	RB	O
increase	VB	O
office	NN	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

INTERPRETATION	NNP	O
Dalcetrapib	NNP	O
showed	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
a	DT	O
pathological	JJ	O
effect	NN	O
related	VBN	O
to	TO	O
the	DT	O
arterial	JJ	O
wall	NN	O
over	IN	O
24	CD	O
months	NNS	O
.	.	O

Moreover	RB	O
,	,	O
this	DT	O
trial	NN	O
suggests	VBZ	O
possible	JJ	O
beneficial	JJ	O
vascular	JJ	O
effects	NNS	O
of	IN	O
dalcetrapib	NN	O
,	,	O
including	VBG	O
the	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
enlargement	NN	O
over	IN	O
24	CD	O
months	NNS	O
,	,	O
but	CC	O
long-term	JJ	O
safety	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
efficacy	NN	O
of	IN	O
dalcetrapib	NNS	O
need	VBP	O
to	TO	O
be	VB	O
analysed	VBN	O
.	.	O

FUNDING	NN	O
F	NNP	O
Hoffmann-La	NNP	O
Roche	NNP	O
Ltd	NNP	O
.	.	O

Effectiveness	NN	Ot
of	IN	O
norgestimate	NN	O
and	CC	O
ethinyl	NN	O
estradiol	NN	O
in	IN	O
treating	VBG	O
moderate	JJ	O
acne	NN	O
vulgaris	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
excess	NN	O
of	IN	O
androgen	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
development	NN	O
of	IN	O
acne	NN	O
in	IN	O
some	DT	O
patients	NNS	O
.	.	O

Because	IN	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OCs	NNP	O
)	)	O
may	MD	O
reduce	VB	O
the	DT	O
active	JJ	PH
androgen	NN	PH
level	NN	PH
,	,	O
hormonal	JJ	O
therapy	NN	O
with	IN	O
OCs	NNP	O
has	VBZ	O
been	VBN	O
used	VBN	O
successfully	RB	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
acne	NN	O
,	,	O
although	IN	O
this	DT	O
treatment	NN	O
has	VBZ	O
previously	RB	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
a	DT	O
triphasic	JJ	O
,	,	O
combination	NN	O
OC	NNP	O
(	(	O
ORTHO	NNP	O
TRI-CYCLEN	NNP	O
[	NNP	O
Ortho-McNeil	NNP	O
Pharmaceutical	NNP	O
,	,	O
Raritan	NNP	O
,	,	O
N.J.	NNP	O
]	NNP	O
,	,	O
norgestimate/ethinyl	RB	O
estradiol	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NN	O
vulgaris	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
fifty-seven	RB	O
healthy	JJ	O
female	NN	O
subjects	NNS	O
,	,	O
15	CD	O
to	TO	O
49	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
moderate	JJ	O
acne	NNS	O
vulgaris	NN	O
,	,	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Each	DT	O
month	NN	O
for	IN	O
6	CD	O
months	NNS	O
,	,	O
subjects	VBZ	O
received	VBN	O
either	RB	O
3	CD	O
consecutive	JJ	O
weeks	NNS	O
of	IN	O
the	DT	O
OC	NNP	O
(	(	O
i.e.	FW	O
,	,	O
tablets	NNS	O
containing	VBG	O
a	DT	O
fixed	VBN	O
dose	NN	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
[	VBD	O
0.035	CD	O
mg	NN	O
]	NN	O
and	CC	O
increasing	VBG	O
doses	NNS	O
of	IN	O
norgestimate	JJ	O
[	NNS	O
0.180	CD	O
mg	NNS	O
,	,	O
0.215	CD	O
mg	NN	O
,	,	O
0.250	CD	O
mg	NN	O
]	NN	O
)	)	O
followed	VBN	O
by	IN	O
7	CD	O
days	NNS	O
of	IN	O
inactive	JJ	O
drug	NN	O
or	CC	O
placebo	NN	O
(	(	O
color-matched	JJ	O
tablets	NNS	O
)	)	O
.	.	O

Efficacy	NN	Ot
was	VBD	O
assessed	VBN	O
by	IN	O
facial	JJ	PH
acne	JJ	PH
lesion	NN	PH
counts	NNS	PH
,	,	O
an	DT	O
investigator	NN	O
's	POS	O
global	JJ	PH
assessment	NN	PH
,	,	O
a	DT	O
subject	NN	Ot
's	POS	Ot
self-assessment	NN	Ot
,	,	O
and	CC	O
an	DT	O
analysis	NN	O
of	IN	O
within-cycle	JJ	PH
variation	NN	PH
(	(	PH
cycle	NN	PH
6	CD	PH
)	)	PH
in	IN	PH
lesion	NN	PH
counts	NNS	PH
.	.	PH

RESULTS	NNP	O
Of	IN	O
the	DT	O
160	CD	O
subjects	NNS	O
in	IN	O
whom	WP	O
efficacy	NN	O
could	MD	O
be	VB	O
evaluated	VBN	O
,	,	O
the	DT	O
OC	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	PH
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
for	IN	O
all	DT	O
primary	JJ	O
efficacy	NN	O
measures	NNS	O
.	.	O

The	DT	O
mean	JJ	PH
decrease	NN	PH
in	IN	PH
inflammatory	JJ	PH
lesion	NN	PH
count	NN	PH
from	IN	O
baseline	NN	O
to	TO	O
cycle	NN	O
6	CD	O
was	VBD	O
11.8	CD	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
versus	NN	O
7.6	CD	O
(	(	O
38.6	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	PH
decrease	NN	PH
in	IN	PH
total	JJ	PH
lesion	NN	PH
count	NN	PH
was	VBD	O
29.1	CD	O
(	(	O
53.1	CD	O
%	NN	O
)	)	O
versus	NN	O
14.1	CD	O
(	(	O
26.8	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
in	IN	O
the	DT	O
OC	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
investigator	NN	PH
's	POS	PH
global	JJ	PH
assessment	NN	PH
,	,	O
93.7	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
versus	VBD	O
65.4	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
improved	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
seven	CD	O
secondary	JJ	PH
efficacy	NN	PH
measures	NNS	PH
(	(	PH
total	JJ	PH
comedones	NNS	PH
,	,	PH
open	JJ	PH
comedones	NNS	PH
,	,	PH
closed	VBD	PH
comedones	NNS	PH
,	,	PH
papules	NNS	PH
,	,	PH
pustules	NNS	PH
,	,	PH
and	CC	PH
the	DT	PH
subject	NN	PH
's	POS	PH
self-assessment	NN	PH
of	IN	PH
study	NN	PH
treatment	NN	PH
)	)	PH
were	VBD	O
also	RB	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
in	IN	O
the	DT	O
OC	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
OC	NNP	O
containing	VBG	O
0.035	CD	O
mg	NN	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
combined	VBN	O
with	IN	O
the	DT	O
triphasic	JJ	O
regimen	NNS	O
of	IN	O
norgestimate	NN	O
is	VBZ	O
a	DT	O
safe	JJ	Ot
and	CC	Ot
effective	JJ	Ot
treatment	NN	Ot
of	IN	Ot
moderate	JJ	Ot
acne	NNS	Ot
vulgaris	VBP	Ot
in	IN	O
women	NNS	O
with	IN	O
no	DT	O
known	VBN	O
contraindication	NN	O
to	TO	O
OC	NNP	O
therapy	NN	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Intervention	NNP	O
Project	NNP	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
speech	NN	O
and	CC	O
language	NN	O
therapy	NN	O
for	IN	O
school-age	JJ	O
children	NNS	O
who	WP	O
have	VBP	O
pragmatic	JJ	O
and	CC	O
social	JJ	O
communication	NN	O
problems	NNS	O
with	IN	O
or	CC	O
without	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNPS	O
who	WP	O
show	VBP	O
disproportionate	JJ	O
difficulty	NN	O
with	IN	O
the	DT	O
pragmatic	JJ	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
structural	JJ	O
aspects	NNS	O
of	IN	O
language	NN	O
are	VBP	O
described	VBN	O
as	IN	O
having	VBG	O
pragmatic	JJ	O
language	NN	O
impairment	NN	O
(	(	O
PLI	NNP	O
)	)	O
or	CC	O
social	JJ	O
communication	NN	O
disorder	NN	O
(	(	O
SCD	NNP	O
)	)	O
.	.	O

Some	DT	O
children	NNS	O
who	WP	O
have	VBP	O
PLI	NNP	O
also	RB	O
show	VBP	O
mild	JJ	O
social	JJ	O
impairments	NNS	O
associated	VBN	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
or	CC	O
autism	NN	O
spectrum	JJ	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

There	EX	O
is	VBZ	O
little	JJ	O
robust	JJ	O
evidence	NN	O
of	IN	O
effectiveness	NN	O
of	IN	O
speech-language	NN	O
interventions	NNS	O
which	WDT	O
target	VBP	O
the	DT	O
language	NN	O
,	,	O
pragmatic	JJ	O
or	CC	O
social	JJ	O
communication	NN	O
needs	NNS	O
of	IN	O
these	DT	O
children	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
intensive	JJ	O
manualized	VBN	O
social	JJ	O
communication	NN	O
intervention	NN	O
(	(	O
SCIP	NNP	O
)	)	O
for	IN	O
children	NNS	O
who	WP	O
have	VBP	O
PLI	VBN	O
with	IN	O
or	CC	O
without	IN	O
features	NNS	O
of	IN	O
ASD	NNP	O
.	.	O

METHODS	NNP	O
&	CC	O
PROCEDURES	NNP	O
In	IN	O
a	DT	O
single-blind	JJ	O
RCT	NNP	O
design	NN	O
,	,	O
88	CD	O
children	NNS	O
with	IN	O
pragmatic	JJ	O
and	CC	O
social	JJ	O
communication	NN	O
needs	NNS	O
aged	VBD	O
5	CD	O
;	:	O
11-10	JJ	O
;	:	O
8	CD	O
,	,	O
recruited	VBN	O
from	IN	O
UK	NNP	O
speech	NN	O
and	CC	O
language	NN	O
therapy	NN	O
services	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
2:1	CD	O
ratio	NN	O
to	TO	O
SCIP	NNP	O
or	CC	O
to	TO	O
treatment-as-usual	JJ	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
SCIP	NNP	O
condition	NN	O
received	VBD	O
up	RB	O
to	TO	O
20	CD	O
sessions	NNS	O
of	IN	O
direct	JJ	O
intervention	NN	O
from	IN	O
a	DT	O
specialist	JJ	O
research	NN	O
speech	NN	O
and	CC	O
language	NN	O
therapist	NN	O
working	VBG	O
with	IN	O
supervised	JJ	O
assistants	NNS	O
.	.	O

All	DT	O
therapy	NN	O
content	NN	O
and	CC	O
methodology	NN	O
was	VBD	O
derived	VBN	O
from	IN	O
an	DT	O
intervention	NN	O
manual	NN	O
.	.	O

A	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
of	IN	O
structural	JJ	ME
language	NN	ME
and	CC	O
secondary	JJ	O
outcome	NN	O
measures	NNS	O
of	IN	O
narrative	JJ	ME
,	,	O
parent-reported	JJ	ME
pragmatic	JJ	ME
functioning	NN	ME
and	CC	ME
social	JJ	ME
communication	NN	ME
,	,	O
blind-rated	JJ	ME
perceptions	NNS	ME
of	IN	ME
conversational	JJ	ME
competence	NN	ME
and	CC	O
teacher-reported	JJ	ME
ratings	NNS	ME
of	IN	ME
classroom	NN	ME
learning	VBG	ME
skills	NNS	ME
were	VBD	O
taken	VBN	O
pre-intervention	NN	O
,	,	O
immediately	RB	O
post-intervention	NN	O
and	CC	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

OUTCOMES	NNP	O
&	CC	O
RESULTS	NNP	O
No	NNP	O
significant	JJ	O
treatment	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
the	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
of	IN	O
structural	JJ	ME
language	NN	ME
ability	NN	ME
or	CC	O
for	IN	O
a	DT	ME
measure	NN	ME
of	IN	ME
narrative	JJ	ME
ability	NN	ME
.	.	O

Significant	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
blind-rated	JJ	ME
perceptions	NNS	ME
of	IN	ME
conversational	JJ	ME
competence	NN	ME
,	,	O
for	IN	ME
parent-reported	JJ	ME
measures	NNS	ME
of	IN	ME
pragmatic	JJ	ME
functioning	NN	ME
and	CC	ME
social	JJ	ME
communication	NN	ME
,	,	O
and	CC	O
for	IN	ME
teacher-reported	JJ	ME
ratings	NNS	ME
of	IN	ME
classroom	NN	ME
learning	NN	ME
skills	NNS	ME
.	.	O

CONCLUSIONS	NNP	O
&	CC	O
IMPLICATIONS	NNP	O
There	EX	O
is	VBZ	O
some	DT	O
evidence	NN	O
of	IN	O
an	DT	O
intervention	NN	O
effect	NN	O
on	IN	O
blind	NN	O
and	CC	O
parent/teacher-reported	JJ	O
communication	NN	O
outcomes	NNS	O
,	,	O
but	CC	O
not	RB	O
standardized	JJ	O
language	NN	O
assessment	NN	O
outcomes	NNS	O
,	,	O
for	IN	O
6-11-year-old	JJ	O
children	NNS	O
who	WP	O
have	VBP	O
pragmatic	JJ	O
and	CC	O
social	JJ	O
communication	NN	O
needs	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
increasingly	RB	O
central	JJ	O
role	NN	O
of	IN	O
service	NN	O
user	NN	O
outcomes	NNS	O
in	IN	O
providing	VBG	O
evidence	NN	O
for	IN	O
an	DT	O
intervention	NN	O
.	.	O

The	DT	O
substantial	JJ	O
overlap	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
PLI	NNP	O
and	CC	O
ASD	NNP	O
(	(	O
75	CD	O
%	NN	O
)	)	O
across	IN	O
the	DT	O
whole	JJ	O
cohort	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
intervention	NN	O
may	MD	O
also	RB	O
be	VB	O
applicable	JJ	O
to	TO	O
some	DT	O
verbally	RB	O
able	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
have	VBP	O
pragmatic	JJ	O
communication	NN	O
needs	NNS	O
.	.	O

Rehabilitation	NNP	PH
outcomes	VBZ	PH
following	VBG	O
percutaneous	JJ	O
coronary	JJ	O
interventions	NNS	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
prospective	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
individualized	JJ	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
combining	NN	O
exercise	NN	O
training	NN	O
with	IN	O
risk	NN	O
factor	NN	O
modification	NN	O
and	CC	O
psychosocial	JJ	O
counseling	NN	O
on	IN	O
risk	NN	ME
factors	NNS	ME
,	,	O
psychological	JJ	ME
well-being	NN	ME
,	,	O
functional	JJ	ME
capacity	NN	ME
,	,	O
and	CC	O
work	NN	ME
resumption	NN	ME
in	IN	O
99	CD	O
post-percutaneous	JJ	O
coronary	JJ	O
interventions	NNS	O
(	(	O
PCI	NNP	O
)	)	O
patients	NNS	O
randomized	VBN	O
to	TO	O
control	VB	O
(	(	O
standard	JJ	O
care	NN	O
plus	CC	O
telephone	NN	O
follow-up	NN	O
,	,	O
n=49	NN	O
)	)	O
or	CC	O
intervention	NN	O
(	(	O
individualized	VBN	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
,	,	O
n=50	NN	O
)	)	O
groups	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
time	NN	O
1	CD	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
during	IN	O
hospital	JJ	O
admission	NN	O
,	,	O
time	NN	O
2	CD	O
(	(	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
approximately	RB	O
2	CD	O
months	NNS	O
post-PCI	JJ	O
,	,	O
and	CC	O
time	NN	O
3	CD	O
(	(	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
)	)	O
approximately	RB	O
12	CD	O
months	NNS	O
post-PCI	JJ	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
the	DT	O
allocation	NN	O
to	TO	O
an	DT	O
individualized	VBN	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
provided	VBD	O
more	RBR	O
advantageous	JJ	O
outcomes	NNS	O
.	.	O

At	IN	O
both	DT	O
follow-ups	NNS	O
,	,	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
within-group	JJ	O
improvement	NN	O
in	IN	O
serum	NN	PH
cholesterol	NN	PH
levels	NNS	PH
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
exercise	JJ	PH
participation	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
differences	NNS	O
in	IN	O
exercise	NN	PH
participation	NN	PH
favoring	VBG	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

Repeated	VBN	O
measures	NNS	O
ANOVA	NNP	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
over	IN	O
time	NN	O
in	IN	O
body	NN	PH
mass	NN	PH
index	NN	PH
(	(	PH
BMI	NNP	PH
)	)	PH
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
psychological	JJ	PH
well-being	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
functional	JJ	PH
capacity	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

More	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
had	VBD	O
returned	VBN	ME
to	TO	ME
work	VB	ME
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
did	VBD	O
so	RB	O
more	RBR	O
quickly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
an	DT	O
individualized	JJ	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
improves	VBZ	O
risk	NN	Ot
factor	NN	Ot
profiles	NNS	Ot
and	CC	Ot
work	NN	Ot
resumption	NN	Ot
patterns	NNS	Ot
for	IN	O
patients	NNS	O
following	VBG	O
PCI	NNP	O
.	.	O

Modulation	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

BACKGROUND	NNP	O
Free	JJ	O
radical-induced	JJ	O
oxidative	JJ	O
damage	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
diseases	NNS	O
associated	VBN	O
with	IN	O
cigarette	NN	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
production	NN	O
of	IN	O
8-epi-prostaglandin	JJ	O
(	(	O
PG	NNP	O
)	)	O
F2	NNP	O
alpha	NN	O
,	,	O
a	DT	O
stable	JJ	O
product	NN	O
of	IN	O
lipid	JJ	O
peroxidation	NN	O
in	IN	O
vivo	NN	O
,	,	O
and	CC	O
its	PRP$	O
modulation	NN	O
by	IN	O
aspirin	NN	O
and	CC	O
antioxidant	JJ	O
vitamins	NNS	O
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
studies	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
cross-sectional	JJ	O
comparison	NN	O
of	IN	O
smokers	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
an	DT	O
examination	NN	O
of	IN	O
the	DT	O
dose-response	JJ	O
relationship	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
an	DT	O
exploration	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
smoking	VBG	O
cessation	NN	O
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
nicotine	JJ	O
patch	NN	O
supplementation	NN	O
,	,	O
(	(	O
4	CD	O
)	)	O
the	DT	O
effect	NN	O
of	IN	O
aspirin	NN	O
consumption	NN	O
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
5	CD	O
days	NNS	O
'	POS	O
dosing	VBG	O
with	IN	O
vitamin	NN	O
E	NNP	O
(	(	O
100	CD	O
and	CC	O
800	CD	O
U	NNP	O
)	)	O
,	,	O
vitamin	FW	O
C	NNP	O
(	(	O
2	CD	O
g	NN	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
.	.	O

8-epi-PGF2	JJ	PH
alpha	JJ	PH
excretion	NN	PH
(	(	O
in	IN	O
pmol/mmol	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
)	)	O
was	VBD	O
176.5+/-30.6	JJ	O
in	IN	O
heavy	JJ	O
smokers	NNS	O
,	,	O
92.7+/-4.8	CD	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
in	IN	O
moderate	JJ	O
smokers	NNS	O
,	,	O
and	CC	O
54.1+/-2.7	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
in	IN	O
nonsmokers	NNS	O
.	.	O

Urinary	JJ	PH
levels	NNS	PH
fell	VBD	PH
from	IN	O
145.5+/-24.9	CD	O
to	TO	O
114.6+/-27.1	CD	O
(	(	O
week	NN	O
2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
112.6+/-24.9	JJ	O
(	(	O
week	NN	O
3	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
on	IN	O
cessation	NN	O
of	IN	O
smoking	NN	O
.	.	O

Aspirin	NNP	O
treatment	NN	O
failed	VBD	O
to	TO	O
suppress	VB	O
urinary	JJ	PH
levels	NNS	PH
of	IN	PH
8-epi-PGF2	JJ	PH
alpha	NN	PH
despite	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
urinary	JJ	PH
11-dehydro-TxB2	JJ	PH
production	NN	PH
and	CC	O
suppression	NN	PH
of	IN	PH
8-epi-PGF2	JJ	PH
alpha	NN	PH
and	CC	PH
TxB2	NNP	PH
in	IN	PH
serum	NN	PH
.	.	PH

Vitamin	NNP	O
C	NNP	O
(	(	O
pre	NN	O
,	,	O
194.6+/-40.9	JJ	O
;	:	O
post	NN	O
,	,	O
137.2+/-34.1	JJ	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
vitamin	JJ	O
C	NNP	O
and	CC	O
E	NNP	O
(	(	O
pre	NN	O
,	,	O
171.0+/-39.8	JJ	O
;	:	O
post	NN	O
,	,	O
133.5+/-29.6	JJ	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
suppressed	VBD	O
urinary	JJ	PH
8-epi-PGF2	JJ	PH
alpha	NN	PH
,	,	O
whereas	IN	O
vitamin	JJ	O
E	NNP	O
alone	RB	O
had	VBD	O
no	DT	O
effect	NN	O
.	.	O

CONCLUSIONS	NNP	O
Urinary	NNP	PH
8-epi-PGF2	JJ	PH
alpha	NN	PH
may	MD	O
represent	VB	O
a	DT	O
noninvasive	JJ	O
,	,	O
quantitative	JJ	O
index	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
.	.	O

Elevated	JJ	PH
levels	NNS	PH
of	IN	PH
8-epi-PGF2	JJ	PH
alpha	NN	PH
in	IN	PH
smokers	NNS	PH
may	MD	O
be	VB	O
modulated	VBN	O
by	IN	O
quitting	VBG	O
cigarettes	NNS	O
and	CC	O
switching	VBG	O
to	TO	O
nicotine	VB	O
patches	NNS	O
or	CC	O
by	IN	O
antioxidant	JJ	O
vitamin	NN	O
therapy	NN	O
.	.	O

Risperidone	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
serious	JJ	O
behavioral	JJ	O
problems	NNS	O
.	.	O

BACKGROUND	NNP	O
Atypical	NNP	O
antipsychotic	JJ	O
agents	NNS	O
,	,	O
which	WDT	O
block	VBP	O
postsynaptic	JJ	O
dopamine	NN	O
and	CC	O
serotonin	NN	O
receptors	NNS	O
,	,	O
have	VBP	O
advantages	NNS	O
over	IN	O
traditional	JJ	O
antipsychotic	JJ	O
medications	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adults	NNS	O
with	IN	O
schizophrenia	NN	O
and	CC	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
who	WP	O
have	VBP	O
serious	JJ	O
behavioral	JJ	O
disturbances	NNS	O
.	.	O

However	RB	O
,	,	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
atypical	JJ	O
antipsychotic	JJ	O
agents	NNS	O
in	IN	O
children	NNS	O
are	VBP	O
limited	VBN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
old	JJ	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
score	NN	O
on	IN	O
the	DT	O
Irritability	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
and	CC	O
the	DT	O
rating	NN	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
-	:	O
Improvement	NN	O
(	(	O
CGI-I	NNP	O
)	)	O
scale	NN	O
at	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
101	CD	O
children	NNS	O
(	(	O
82	CD	O
boys	NNS	O
and	CC	O
19	CD	O
girls	NNS	O
;	:	O
mean	VB	O
[	IN	O
+/-SD	JJ	O
]	NNP	O
age	NN	O
,	,	O
8.8+/-2.7	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
risperidone	NN	O
(	(	O
49	CD	O
children	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
52	CD	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
risperidone	NN	O
for	IN	O
eight	CD	O
weeks	NNS	O
(	(	O
dose	JJ	O
range	NN	O
,	,	O
0.5	CD	O
to	TO	O
3.5	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
resulted	VBD	O
in	IN	O
a	DT	O
56.9	CD	O
percent	NN	O
reduction	NN	O
in	IN	O
the	DT	O
Irritability	NNP	ME
score	NN	ME
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
a	DT	O
14.1	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
a	DT	O
positive	JJ	O
response	NN	O
,	,	O
defined	VBD	O
as	IN	O
at	IN	O
least	JJS	O
a	DT	O
25	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
the	DT	O
Irritability	NNP	ME
score	NN	ME
and	CC	O
a	DT	O
rating	NN	O
of	IN	O
much	JJ	O
improved	VBN	O
or	CC	O
very	RB	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
CGI-I	NNP	ME
scale	NN	ME
,	,	O
was	VBD	O
69	CD	O
percent	NN	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
(	(	O
34	CD	O
of	IN	O
49	CD	O
children	NNS	O
had	VBD	O
a	DT	O
positive	JJ	O
response	NN	O
)	)	O
and	CC	O
12	CD	O
percent	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
6	CD	O
of	IN	O
52	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Risperidone	NNP	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
average	JJ	PH
weight	JJ	PH
gain	NN	PH
of	IN	O
2.7+/-2.9	JJ	O
kg	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
0.8+/-2.2	JJ	O
kg	NN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Increased	VBN	O
appetite	RB	PH
,	,	PH
fatigue	NN	A
,	,	PH
drowsiness	NN	A
,	,	PH
dizziness	NN	A
,	,	PH
and	CC	PH
drooling	VBG	A
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
each	DT	O
comparison	NN	O
)	)	O
.	.	O

In	IN	O
two	CD	O
thirds	NNS	O
of	IN	O
the	DT	O
children	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
response	NN	O
to	TO	O
risperidone	VB	O
at	IN	O
eight	CD	O
weeks	NNS	O
(	(	O
23	CD	O
of	IN	O
34	CD	O
)	)	O
,	,	O
the	DT	O
benefit	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
six	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Risperidone	NNP	O
was	VBD	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

The	DT	O
short	JJ	O
period	NN	O
of	IN	O
this	DT	O
trial	NN	O
limits	VBZ	O
inferences	NNS	O
about	IN	O
adverse	JJ	O
effects	NNS	O
such	JJ	O
as	IN	O
tardive	JJ	O
dyskinesia	NN	O
.	.	O

Gastrointestinal	NNP	PH
safety	NN	PH
of	IN	O
NO-aspirin	NNP	O
(	(	O
NCX-4016	NNP	O
)	)	O
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
:	:	O
a	DT	O
proof	NN	O
of	IN	O
concept	NN	O
endoscopic	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
NCX-4016	NNP	O
is	VBZ	O
a	DT	O
nitric	JJ	O
oxide-releasing	JJ	O
derivative	NN	O
of	IN	O
aspirin	NN	O
with	IN	O
antiplatelet	NN	PH
activity	NN	PH
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NCX-4016	NNP	O
on	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
and	CC	O
platelet	NN	PH
functions	NNS	PH
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Forty	NNP	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
7	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
NCX-4016	NNP	O
(	(	O
400	CD	O
and	CC	O
800	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
,	,	O
equimolar	JJ	O
doses	NNS	O
of	IN	O
aspirin	NN	O
(	(	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Upper	IN	O
endoscopies	NNS	O
were	VBD	O
performed	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
gastroduodenal	JJ	PH
lesions	NNS	PH
were	VBD	O
graded	VBN	O
using	VBG	O
a	DT	O
predefined	VBN	PH
scoring	NN	PH
system	NN	PH
.	.	O

Basal	NNP	PH
and	CC	PH
posttreatment	JJ	PH
platelet	NN	PH
aggregation	NN	PH
in	IN	O
response	NN	O
to	TO	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
and	CC	O
serum	JJ	O
thromboxane	NN	O
(	(	O
TX	NNP	O
)	)	O
B	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
AA-stimulated	JJ	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
production	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

RESULTS	NNP	O
Mucosal	NNP	PH
endoscopic	JJ	PH
injury	NN	PH
score	NN	PH
on	IN	O
day	NN	O
7	CD	O
was	VBD	O
0.63	CD	O
+/-	JJ	O
0.16	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
11.0	CD	O
+/-	JJ	O
3.0	CD	O
and	CC	O
16.1	CD	O
+/-	JJ	O
1.6	CD	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
treated	VBD	O
with	IN	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
aspirin	JJ	O
twice	RB	O
daily	RB	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	NN	O
was	VBD	O
virtually	RB	O
devoid	JJ	O
of	IN	O
gastric	JJ	A
and	CC	A
duodenal	JJ	A
toxicity	NN	A
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
total	JJ	PH
gastric	NN	PH
and	CC	PH
duodenal	JJ	PH
endoscopic	NN	PH
score	NN	PH
of	IN	O
1.38	CD	O
+/-	JJ	O
0.3	CD	O
and	CC	O
1.25	CD	O
+/-	JJ	O
0.5	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	NN	O
aspirin	NN	O
,	,	O
not	RB	O
significant	JJ	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	JJ	O
inhibited	JJ	O
AA-induced	JJ	PH
platelet	NN	PH
aggregation	NN	PH
as	RB	O
well	RB	O
as	IN	O
serum	NN	PH
TXB	NNP	PH
(	(	PH
2	CD	PH
)	)	PH
and	CC	O
platelet	NN	PH
TXB	NNP	PH
(	(	PH
2	CD	PH
)	)	PH
generation	NN	PH
induced	VBN	O
by	IN	O
AA	NNP	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
aspirin	NN	O
(	(	O
not	RB	O
significant	JJ	O
vs.	FW	O
aspirin	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
have	VBP	O
proven	VBN	O
the	DT	O
concept	NN	O
that	IN	O
addition	NN	O
of	IN	O
an	DT	O
NO-donating	JJ	O
moiety	NN	O
to	TO	O
aspirin	VB	O
results	NNS	O
in	IN	O
a	DT	O
new	JJ	O
chemical	NN	O
entity	NN	O
that	WDT	O
maintains	VBZ	O
cyclooxygenase-1	NN	O
and	CC	O
platelet	VB	O
inhibitory	JJ	O
activity	NN	O
while	IN	O
nearly	RB	O
avoiding	VBG	O
gastrointestinal	JJ	PH
damage	NN	PH
.	.	O

Sucralfate	NNP	O
overcomes	VBZ	O
adverse	JJ	O
effect	NN	O
of	IN	O
cigarette	NN	O
smoking	NN	O
on	IN	O
duodenal	JJ	O
ulcer	NN	PH
healing	NN	PH
and	CC	O
prolongs	NNS	O
subsequent	JJ	O
remission	NN	O
.	.	O

A	DT	O
unicenter	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
283	CD	O
patients	NNS	O
with	IN	O
active	JJ	O
duodenal	JJ	O
ulcer	NN	O
to	TO	O
compare	VB	O
possible	JJ	O
factors	NNS	O
that	WDT	O
may	MD	O
affect	VB	O
healing	NN	O
and	CC	O
relapse	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
a	DT	O
potent	JJ	O
antisecretory	NN	O
agent	NN	O
,	,	O
cimetidine	NN	O
,	,	O
or	CC	O
a	DT	O
site-protective	JJ	O
and	CC	O
cytoprotective	JJ	O
agent	NN	O
,	,	O
sucralfate	NN	O
.	.	O

The	DT	O
endoscopic	NN	PH
healing	VBG	PH
rates	NNS	PH
at	IN	O
4	CD	O
wk	NNS	O
were	VBD	O
76	CD	O
%	NN	O
and	CC	O
79	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
cross-over	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
failures	NNS	O
for	IN	O
a	DT	O
further	JJ	O
4	CD	O
wk	NN	O
resulted	VBD	O
in	IN	O
68	CD	O
%	NN	O
healing	VBG	O
with	IN	O
cimetidine	NN	O
and	CC	O
69	CD	O
%	NN	O
healing	VBG	O
with	IN	O
sucralfate	NN	O
,	,	O
both	DT	O
differences	NNS	O
being	VBG	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

Unlike	IN	O
cimetidine	NN	O
,	,	O
healing	VBG	O
by	IN	O
sucralfate	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
cigarette	NN	O
smoking	NN	O
,	,	O
reluctance	NN	O
to	TO	O
give	VB	O
up	RP	O
smoking	NN	O
,	,	O
habitual	JJ	O
use	NN	O
of	IN	O
alcohol	NN	O
,	,	O
high	JJ	O
maximal	JJ	O
acid	NN	O
output	NN	O
,	,	O
and	CC	O
large	JJ	O
ulcer	JJ	O
diameter	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
healing	VBG	PH
rate	NN	PH
of	IN	O
smokers	NNS	O
treated	VBN	O
with	IN	O
sucralfate	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
of	IN	O
smokers	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	O
(	(	O
63	CD	O
%	NN	O
)	)	O
.	.	O

Duodenal	NNP	O
bulb	NN	O
deformity	NN	O
significantly	RB	O
affected	VBD	O
healing	NN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
was	VBD	O
the	DT	O
only	JJ	O
offsetting	VBG	O
factor	NN	O
identifiable	JJ	O
for	IN	O
sucralfate	NN	O
out	IN	O
of	IN	O
46	CD	O
factors	NNS	O
examined	VBD	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
healed	JJ	O
ulcers	NNS	O
,	,	O
238	CD	O
participated	VBN	O
in	IN	O
a	DT	O
24-mo	JJ	O
follow-up	NN	O
study	NN	O
consisting	VBG	O
of	IN	O
interviews	NNS	O
at	IN	O
2-mo	JJ	O
intervals	NNS	O
and	CC	O
endoscopy	NN	O
at	IN	O
4-mo	JJ	O
intervals	NNS	O
or	CC	O
whenever	WRB	O
symptoms	NNS	O
recurred	VBD	O
.	.	O

The	DT	O
cumulative	JJ	PH
relapse	NN	PH
rate	NN	PH
was	VBD	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.007	CD	O
)	)	O
greater	JJR	O
in	IN	O
patients	NNS	O
healed	VBN	O
with	IN	O
cimetidine	NN	O
than	IN	O
with	IN	O
sucralfate	NN	O
,	,	O
50	CD	O
%	NN	O
relapse	NN	O
occurring	VBG	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
mo	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
both	DT	O
,	,	O
the	DT	O
cumulative	JJ	PH
relapse	NN	PH
rate	NN	PH
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
cigarette	NN	O
smokers	NNS	O
than	IN	O
in	IN	O
nonsmokers	NNS	O
,	,	O
but	CC	O
smokers	NNS	O
and	CC	O
nonsmokers	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	O
relapsed	VBN	PH
(	(	O
50	CD	O
%	NN	O
at	IN	O
4	CD	O
and	CC	O
8	CD	O
mo	NN	O
,	,	O
respectively	RB	O
)	)	O
faster	RBR	O
than	IN	O
the	DT	O
corresponding	JJ	O
smokers	NNS	O
and	CC	O
nonsmokers	NNS	O
treated	VBN	O
with	IN	O
sucralfate	NN	O
(	(	O
50	CD	O
%	NN	O
at	IN	O
8	CD	O
and	CC	O
18	CD	O
mo	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
in	IN	O
cimetidine-	NN	O
but	CC	O
not	RB	O
sucralfate-healed	JJ	O
patients	NNS	O
,	,	O
early	JJ	O
ulcer	NN	O
relapse	NN	O
(	(	O
within	IN	O
6	CD	O
mo	NN	O
)	)	O
was	VBD	O
associated	VBN	O
with	IN	O
short	JJ	O
duration	NN	PH
of	IN	PH
illness	NN	PH
,	,	O
short	JJ	O
remission	NN	PH
period	NN	PH
,	,	PH
long	JJ	PH
symptomatic	JJ	PH
spell	NN	PH
,	,	PH
and	CC	PH
reluctance	NN	PH
to	TO	PH
give	VB	PH
up	RP	PH
smoking	VBG	PH
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
smoking	VBG	O
adversely	RB	O
affects	VBZ	O
duodenal	JJ	O
ulcer	NN	O
healing	NN	O
by	IN	O
cimetidine	NN	O
and	CC	O
hastens	VBZ	O
subsequent	JJ	O
relapse	NN	O
,	,	O
and	CC	O
that	IN	O
sucralfate	NN	O
overcomes	VBZ	O
the	DT	O
adverse	JJ	O
effect	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
healing	NN	O
as	IN	O
encountered	VBN	O
with	IN	O
cimetidine	NN	O
,	,	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
subsequent	JJ	O
remission	NN	O
period	NN	O
double	JJ	O
that	IN	O
of	IN	O
cimetidine	NN	O
.	.	O

Psychological	JJ	O
mediators	NNS	O
of	IN	O
bupropion	NN	O
sustained-release	NN	O
treatment	NN	O
for	IN	O
smoking	VBG	O
cessation	NN	O
.	.	O

AIM	IN	O
The	DT	O
study	NN	O
aimed	VBN	O
to	TO	O
test	VB	O
simultaneously	RB	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
bupropion	NN	O
sustained-release	NN	O
(	(	O
SR	NNP	O
)	)	O
treatment	NN	O
on	IN	O
putative	JJ	O
mediators	NNS	O
and	CC	O
our	PRP$	O
understanding	NN	O
of	IN	O
determinants	NNS	O
of	IN	O
post-quit	NN	O
abstinence	NN	O
,	,	O
including	VBG	O
withdrawal	NN	O
distress	NN	O
,	,	O
cigarette	NN	O
craving	NN	O
,	,	O
positive	JJ	O
affect	NN	O
and	CC	O
subjective	JJ	O
reactions	NNS	O
to	TO	O
cigarettes	NNS	O
smoked	VBN	O
during	IN	O
a	DT	O
lapse	NN	O
.	.	O

The	DT	O
specificity	NN	O
of	IN	O
bupropion	NN	O
SR	NNP	O
effects	NNS	O
was	VBD	O
also	RB	O
tested	VBN	O
in	IN	O
exploratory	JJ	O
analyses	NNS	O
.	.	O

DESIGN	NNP	O
Data	NNP	O
from	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
bupropion	NN	O
SR	NNP	O
were	VBD	O
submitted	VBN	O
to	TO	O
mediation	NN	O
analyses	NNS	O
.	.	O

SETTING	NN	O
Center	NNP	O
for	IN	O
Tobacco	NNP	O
Research	NNP	O
and	CC	O
Intervention	NNP	O
,	,	O
Madison	NNP	O
,	,	O
WI	NNP	O
,	,	O
USA	NNP	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
403	CD	O
adult	NN	O
,	,	O
daily	JJ	O
smokers	NNS	O
without	IN	O
contraindications	NNS	O
to	TO	O
bupropion	VB	O
SR	NNP	O
use	NN	O
.	.	O

INTERVENTION	NN	O
Participants	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
a	DT	O
9-week	JJ	O
course	NN	O
of	IN	O
bupropion	NN	O
SR	NNP	O
or	CC	O
placebo	NN	O
pill	NN	O
and	CC	O
to	TO	O
receive	VB	O
eight	CD	O
brief	JJ	O
individual	JJ	O
counseling	NN	O
sessions	NNS	O
or	CC	O
no	DT	O
counseling	NN	O
.	.	O

MEASUREMENTS	NNP	O
Ecological	NNP	ME
momentary	JJ	ME
assessment	NN	ME
ratings	NNS	ME
of	IN	ME
smoking	VBG	ME
behavior	NN	ME
and	CC	ME
putative	JJ	ME
mediators	NNS	ME
were	VBD	O
collected	VBN	O
pre-	JJ	O
and	CC	O
post-quit	NN	O
.	.	O

FINDINGS	NNP	O
Results	NNP	O
of	IN	O
structural	JJ	O
equation	NN	O
and	CC	O
hierarchical	JJ	O
linear	JJ	O
models	NNS	O
did	VBD	O
not	RB	O
support	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
bupropion	NN	O
SR	NNP	O
treatment	NN	O
improves	VBZ	O
short-term	JJ	ME
abstinence	NN	ME
by	IN	O
reducing	VBG	O
withdrawal	NN	O
distress	NN	O
or	CC	O
affecting	VBG	O
the	DT	O
subjective	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
lapse	NN	O
cigarette	NN	O
,	,	O
but	CC	O
provided	VBD	O
partial	JJ	O
support	NN	O
for	IN	O
mediation	NN	O
by	IN	O
cigarette	NN	ME
craving	VBG	ME
reduction	NN	ME
and	CC	ME
enhanced	VBD	ME
positive	JJ	ME
affect	NN	ME
.	.	ME

Bupropion	NNP	O
SR	NNP	O
effects	NNS	O
on	IN	O
point-prevalence	NN	O
abstinence	NN	ME
at	IN	O
1	CD	O
month	NN	O
post-quit	NN	O
were	VBD	O
also	RB	O
mediated	VBN	O
partially	RB	O
by	IN	O
enhanced	JJ	O
motivation	NN	O
to	TO	O
quit	VB	O
and	CC	O
self-efficacy	NN	O
.	.	O

CONCLUSIONS	NNP	O
Results	NNP	O
provided	VBD	O
some	DT	O
support	NN	O
for	IN	O
models	NNS	O
of	IN	O
bupropion	NN	O
SR	NNP	O
treatment	NN	O
and	CC	O
relapse	NN	O
and	CC	O
suggested	VBD	O
that	IN	O
motivational	JJ	O
processes	NNS	O
may	MD	O
partially	RB	O
account	VB	O
for	IN	O
bupropion	NN	O
SR	NNP	O
efficacy	NN	O
.	.	O

Parent	NNP	O
management	NN	O
training	NN	O
and	CC	O
Asperger	NNP	O
syndrome	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
a	DT	O
parent	NN	Ot
based	VBN	Ot
intervention	NN	Ot
.	.	O

This	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
a	DT	O
parent	NN	O
management	NN	O
intervention	NN	O
aimed	VBN	O
to	TO	O
increase	VB	O
parental	JJ	O
competence	NN	O
in	IN	O
management	NN	O
of	IN	O
problem	NN	O
behaviours	NNS	O
associated	VBN	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
.	.	O

The	DT	O
intervention	NN	O
compared	VBN	O
two	CD	O
formats	NNS	O
,	,	O
a	DT	O
1	CD	O
day	NN	O
workshop	NN	O
and	CC	O
six	CD	O
individual	JJ	O
sessions	NNS	O
.	.	O

Measures	NNS	O
were	VBD	O
taken	VBN	O
on	IN	O
three	CD	O
occasions	NNS	O
:	:	O
pre-intervention	NN	O
,	,	O
at	IN	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
month	NN	O
follow-up	NN	O
.	.	O

Variables	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
number	NN	ME
and	CC	ME
intensity	NN	ME
of	IN	ME
problem	NN	ME
behaviours	NN	ME
,	,	O
and	CC	O
parent	JJ	ME
evaluation	NN	ME
of	IN	ME
social	JJ	ME
interaction	NN	ME
skills	NNS	ME
.	.	O

Results	NNS	O
showed	VBD	O
parents	NNS	O
reporting	VBG	O
fewer	JJR	O
and	CC	O
lower	JJR	O
intensity	NN	ME
of	IN	ME
problem	NN	ME
behaviours	NNS	ME
and	CC	O
increased	VBD	ME
social	JJ	ME
interactions	NNS	ME
at	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
.	.	O

Results	NNS	O
held	VBD	O
across	IN	O
formats	NNS	O
and	CC	O
suggest	VBP	O
that	IN	O
parent	NN	O
management	NN	O
training	NN	O
can	MD	O
provide	VB	O
an	DT	O
effective	JJ	PH
intervention	NN	PH
for	IN	PH
parents	NNS	PH
of	IN	PH
a	DT	PH
child	NN	PH
with	IN	PH
Asperger	NNP	PH
syndrome	NN	PH
.	.	O

Group	NNP	O
differences	VBZ	O
on	IN	O
outcome	NN	O
measures	NNS	O
and	CC	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
strategies	NNS	O
are	VBP	O
discussed	VBN	O
along	IN	O
with	IN	O
limitations	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Improving	VBG	O
the	DT	O
transition	NN	O
from	IN	O
residential	JJ	O
to	TO	O
outpatient	JJ	O
addiction	NN	O
treatment	NN	O
:	:	O
gender	NN	O
differences	NNS	O
in	IN	O
response	NN	O
to	TO	O
supportive	VB	O
telephone	NN	O
calls	NNS	O
.	.	O

Substance	NN	O
use	NN	O
relapse	NN	O
rates	NNS	O
are	VBP	O
often	RB	O
high	JJ	O
in	IN	O
the	DT	O
first	JJ	O
months	NNS	O
after	IN	O
discharge	NN	O
from	IN	O
inpatient	JJ	O
substance	NN	O
abuse	NN	O
treatment	NN	O
,	,	O
and	CC	O
patient	JJ	ME
adherence	NN	ME
to	TO	ME
aftercare	VB	ME
plans	NNS	O
is	VBZ	O
often	RB	O
low	JJ	O
.	.	O

Four	CD	O
residential	JJ	O
addiction	NN	O
treatment	NN	O
centers	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
feasibility	NN	O
study	NN	O
designed	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
efficacy	NN	Ot
of	IN	O
a	DT	O
post-discharge	JJ	O
telephone	NN	O
intervention	NN	O
intended	VBN	O
to	TO	O
encourage	VB	O
compliance	NN	O
with	IN	O
aftercare	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
282	CD	O
participants	NNS	O
(	(	O
100	CD	O
women	NNS	O
,	,	O
182	CD	O
men	NNS	O
)	)	O
with	IN	O
substance	NN	O
use	NN	O
disorders	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
secondary	JJ	O
analysis	NN	O
.	.	O

The	DT	O
findings	NNS	O
revealed	VBD	O
that	IN	O
women	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
than	IN	O
men	NNS	O
to	TO	O
attend	VB	PH
aftercare	NN	PH
.	.	O

This	DT	O
gender	NN	O
effect	NN	O
persisted	VBN	O
after	IN	O
adjustment	NN	O
for	IN	O
a	DT	O
number	NN	O
of	IN	O
potential	JJ	O
mediators	NNS	O
.	.	O

Intra-operative	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
in	IN	O
neurosurgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
cefotiam	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
and	CC	O
controlled	VBN	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
cefotiam	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
wound	JJ	O
infections	NNS	O
following	VBG	O
trepanations	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
main	JJ	O
interest	NN	O
was	VBD	O
centered	VBN	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
post-operative	JJ	O
bone	NN	O
flap	NN	O
infections	NNS	O
requiring	VBG	O
operative	JJ	O
revision	NN	O
.	.	O

Administration	NNP	O
of	IN	O
cefotiam	NN	O
was	VBD	O
randomized	VBN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
major	JJ	O
craniotomies	NNS	O
.	.	O

The	DT	O
antibiotic	NN	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
in	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
2	CD	O
g	NN	O
with	IN	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
.	.	O

Only	JJ	O
clean	JJ	O
or	CC	O
clean	JJ	O
contaminated	VBN	O
cases	NNS	O
were	VBD	O
included	VBN	O
.	.	O

Excluded	VBN	O
were	VBD	O
contaminated	VBN	O
cases	NNS	O
,	,	O
operations	NNS	O
with	IN	O
a	DT	O
transnasal-transsphenoidal	JJ	O
approach	NN	O
,	,	O
shunt-operations	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
any	DT	O
other	JJ	O
preoperative	JJ	O
infection	NN	O
or	CC	O
antibiotic	JJ	O
therapy	NN	O
.	.	O

Outpatients	NNS	O
were	VBD	O
excluded	VBN	O
due	JJ	O
to	TO	O
difficulties	NNS	O
in	IN	O
obtaining	VBG	O
sufficient	JJ	O
clinical	JJ	O
information	NN	O
.	.	O

From	NNP	O
originally	RB	O
918	CD	O
consecutive	JJ	O
patients	NNS	O
operated	VBN	O
on	IN	O
711	CD	O
fulfilled	VBD	O
the	DT	O
entry	NN	O
criteria	NNS	O
.	.	O

With	IN	O
regard	NN	O
to	TO	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
diagnosis	NN	O
and	CC	O
the	DT	O
site	NN	O
of	IN	O
te	JJ	O
trepanation	NN	O
,	,	O
control	NN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
355	CD	O
)	)	O
and	CC	O
cefotiam	$	O
treated	VBN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
356	CD	O
)	)	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
.	.	O

In	IN	O
the	DT	O
various	JJ	O
subgroups	NNS	O
formed	VBN	O
for	IN	O
different	JJ	O
primary	JJ	O
diagnoses	NNS	O
,	,	O
concomitant	JJ	O
steroidal	NN	O
therapy	NN	O
and	CC	O
concomitant	NN	O
severe	JJ	O
internal	JJ	O
medical	JJ	O
diseases	NNS	O
cefotiam	VBP	O
treated	VBN	O
patients	NNS	O
and	CC	O
controls	NNS	O
were	VBD	O
comparable	JJ	O
as	RB	O
well	RB	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
difference	NN	O
for	IN	O
bone	NN	PH
flap	NN	PH
infection	NN	PH
could	MD	O
be	VB	O
shown	VBN	O
with	IN	O
0.3	CD	O
%	NN	O
in	IN	O
the	DT	O
cefotiam	NN	O
group	NN	O
versus	VBD	O
5.1	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	PH
rate	NN	PH
of	IN	PH
post-operative	JJ	PH
deep	JJ	PH
wound	NN	PH
infections	NNS	PH
including	VBG	PH
meningitis	NN	PH
and	CC	PH
abscesses	NNS	PH
was	VBD	O
also	RB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
different	JJ	O
with	IN	O
3.1	CD	O
%	NN	O
in	IN	O
the	DT	O
cefotiam	NN	O
versus	IN	O
9.0	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Thus	VB	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
cefotiam	NN	O
significantly	RB	O
reduces	VBZ	O
post-operative	JJ	PH
deep	JJ	PH
wound	NN	PH
infection	NN	PH
.	.	O

Intervention	NN	O
to	TO	O
lower	VB	O
household	NN	O
wood	NN	O
smoke	NN	O
exposure	NN	O
in	IN	O
Guatemala	NNP	O
reduces	NNS	O
ST-segment	NNP	PH
depression	NN	PH
on	IN	PH
electrocardiograms	NNS	PH
.	.	PH

BACKGROUND	VB	O
A	DT	O
large	JJ	O
body	NN	O
of	IN	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
fine	JJ	O
particulate	NN	O
matter	NN	O
(	(	O
PM	NNP	O
)	)	O
air	NN	O
pollution	NN	O
is	VBZ	O
a	DT	O
cause	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
but	CC	O
little	JJ	O
is	VBZ	O
known	VBN	O
in	IN	O
particular	JJ	O
about	IN	O
the	DT	O
cardiovascular	JJ	O
effects	NNS	Ot
of	IN	O
indoor	JJ	O
air	NN	O
pollution	NN	O
from	IN	O
household	NN	O
use	NN	O
of	IN	O
solid	JJ	O
fuels	NNS	O
in	IN	O
developing	VBG	O
countries	NNS	O
.	.	O

RESPIRE	NNP	O
(	(	O
Randomized	NNP	O
Exposure	NNP	O
Study	NNP	O
of	IN	O
Pollution	NNP	O
Indoors	NNP	O
and	CC	O
Respiratory	NNP	O
Effects	NNP	O
)	)	O
was	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
chimney	NN	O
woodstove	NN	O
that	WDT	O
reduces	VBZ	O
wood	NN	O
smoke	NN	O
exposure	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypotheses	NNS	O
that	IN	O
the	DT	O
stove	NN	O
intervention	NN	O
,	,	O
compared	VBN	O
with	IN	O
open	JJ	O
fire	NN	O
use	NN	O
,	,	O
would	MD	O
reduce	VB	O
ST-segment	NNP	PH
depression	NN	PH
and	CC	O
increase	VB	O
heart	NN	PH
rate	NN	PH
variability	NN	PH
(	(	PH
HRV	NNP	PH
)	)	PH
.	.	PH

METHODS	NNP	O
We	PRP	O
used	VBD	O
two	CD	O
complementary	JJ	O
study	NN	O
designs	NNS	O
:	:	O
a	DT	O
)	)	O
between-groups	NN	O
comparisons	NNS	O
based	VBN	O
on	IN	O
randomized	JJ	O
stove	NN	O
assignment	NN	O
,	,	O
and	CC	O
b	NN	O
)	)	O
before-and-after	NN	O
comparisons	NNS	O
within	IN	O
control	NN	O
subjects	NNS	O
who	WP	O
used	VBD	O
open	JJ	O
fires	NNS	O
during	IN	O
the	DT	O
trial	NN	O
and	CC	O
received	VBD	O
chimney	NN	O
stoves	NNS	O
after	IN	O
the	DT	O
trial	NN	O
.	.	O

Electrocardiogram	NNP	O
sessions	NNS	O
that	WDT	O
lasted	VBD	O
20	CD	O
hr	NNS	O
were	VBD	O
repeated	VBN	O
up	RP	O
to	TO	O
three	CD	O
times	NNS	O
among	IN	O
49	CD	O
intervention	NN	O
and	CC	O
70	CD	O
control	NN	O
women	NNS	O
38-84	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
and	CC	O
55	CD	O
control	NN	O
subjects	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
after	IN	O
receiving	VBG	O
stoves	NNS	O
.	.	O

HRV	NNP	PH
and	CC	O
ST-segment	JJ	PH
values	NNS	PH
were	VBD	O
assessed	VBN	O
for	IN	O
each	DT	O
30-min	JJ	O
period	NN	O
.	.	O

ST-segment	JJ	PH
depression	NN	PH
was	VBD	O
defined	VBN	O
as	IN	O
an	DT	O
average	JJ	O
value	NN	O
below	IN	O
-1.00	NNP	O
mm	NN	O
.	.	O

Personal	JJ	PH
fine	JJ	PH
PM	NNP	PH
[	NNP	O
aerodynamic	JJ	O
diameter	NN	O
?	.	O
2.5	CD	O
?m	NN	O
(	(	O
PM?.?	NNP	O
]	NNP	O
exposures	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
24	CD	O
hr	NN	O
before	IN	O
each	DT	O
electrocardiogram	NN	O
.	.	O

RESULTS	NNP	O
PM?.?	NNP	O
exposure	NN	O
means	NNS	O
were	VBD	O
266	CD	O
and	CC	O
102	CD	O
?g/m?	NN	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
intervention	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

During	IN	O
the	DT	O
trial	NN	O
,	,	O
the	DT	O
stove	NN	O
intervention	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
odds	NNS	O
ratio	NN	O
of	IN	O
0.26	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.08-0.90	NN	O
)	)	O
for	IN	O
ST-segment	JJ	O
depression	NN	O
.	.	O

We	PRP	O
found	VBD	O
similar	JJ	O
associations	NNS	O
with	IN	O
the	DT	O
before-and-after	JJ	O
comparison	NN	O
.	.	O

The	DT	O
intervention	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
associated	VBN	O
with	IN	O
HRV	NNP	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
stove	NN	O
intervention	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reduced	JJ	O
occurrence	NN	O
of	IN	O
nonspecific	JJ	O
ST-segment	JJ	O
depression	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
household	NN	O
wood	NN	O
smoke	NN	O
exposures	NNS	O
affect	VBP	O
ventricular	JJ	O
repolarization	NN	O
and	CC	O
potentially	RB	O
cardiovascular	JJ	O
health	NN	O
.	.	O

Endurance	NN	O
training	NN	O
has	VBZ	O
little	JJ	O
effect	NN	O
on	IN	O
active	JJ	O
muscle	NN	O
free	JJ	Ot
fatty	NN	Ot
acid	NN	Ot
,	,	O
lipoprotein	FW	PH
cholesterol	NN	PH
,	,	O
or	CC	O
triglyceride	JJ	PH
net	JJ	O
balances	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
net	JJ	PH
leg	NN	PH
total	JJ	PH
FFA	NNP	PH
,	,	O
LDL-C	NNP	PH
,	,	O
and	CC	O
TG	NNP	PH
uptake	JJ	PH
and	CC	O
HDL-C	JJ	PH
release	NN	PH
during	IN	O
moderate-intensity	NN	O
cycling	NN	O
exercise	NN	O
would	MD	O
be	VB	O
increased	VBN	O
following	VBG	O
endurance	NN	O
training	NN	O
.	.	O

Eight	NNP	O
sedentary	JJ	O
men	NNS	O
(	(	O
26	CD	O
+/-	JJ	O
1	CD	O
yr	NN	O
,	,	O
77.4	CD	O
+/-	JJ	O
3.7	CD	O
kg	NN	O
)	)	O
were	VBD	O
studied	VBN	O
in	IN	O
the	DT	O
postprandial	JJ	O
state	NN	O
during	IN	O
90	CD	O
min	NNS	O
of	IN	O
rest	NN	O
and	CC	O
60	CD	O
min	NN	O
of	IN	O
exercise	NN	O
twice	NN	O
before	IN	O
(	(	O
45	CD	O
%	NN	O
and	CC	O
65	CD	O
%	NN	O
V	NNP	O
(	(	O
O2	NNP	O
peak	NN	O
)	)	O
)	)	O
and	CC	O
twice	RB	O
after	IN	O
9	CD	O
wk	NN	O
of	IN	O
endurance	NN	O
training	NN	O
(	(	O
55	CD	O
%	NN	O
and	CC	O
65	CD	O
%	NN	O
posttraining	VBG	O
V	NNP	O
(	(	O
O2	NNP	O
peak	NN	O
)	)	O
)	)	O
.	.	O

Measurements	NNS	O
across	IN	O
an	DT	O
exercising	VBG	O
leg	NN	O
were	VBD	O
taken	VBN	O
to	TO	O
be	VB	O
a	DT	O
surrogate	NN	O
for	IN	O
active	JJ	O
skeletal	JJ	O
muscle	NN	O
.	.	O

To	TO	O
determine	VB	O
limb	NN	PH
lipid	JJ	PH
exchange	NN	PH
,	,	O
femoral	JJ	O
arterial	NN	O
and	CC	O
venous	JJ	O
blood	NN	O
samples	NNS	O
drawn	VBP	O
simultaneously	RB	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
total	JJ	O
and	CC	O
individual	JJ	O
FFA	NNP	O
(	(	O
e.g.	NN	O
,	,	O
palmitate	NN	O
,	,	O
oleate	NN	O
)	)	O
,	,	O
LDL-C	NNP	PH
,	,	O
HDL-C	NNP	PH
,	,	O
and	CC	O
TG	NNP	PH
concentrations	NNS	PH
,	,	O
and	CC	O
limb	NN	PH
blood	NN	PH
flow	NN	PH
was	VBD	O
determined	VBN	O
by	IN	O
thermodilution	NN	O
.	.	O

The	DT	O
transition	NN	O
from	IN	O
rest	NN	O
to	TO	O
exercise	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
shift	NN	O
from	IN	O
net	JJ	O
leg	NN	O
total	JJ	PH
FFA	NNP	PH
release	NN	PH
(	(	O
-44	JJ	O
+/-	JJ	O
16	CD	O
micromol/min	NN	O
)	)	O
to	TO	O
uptake	VB	O
(	(	O
193	CD	O
+/-	JJ	O
49	CD	O
micromol/min	NN	O
)	)	O
that	WDT	O
was	VBD	O
unaffected	VBN	O
by	IN	O
either	DT	O
exercise	NN	O
intensity	NN	O
or	CC	O
endurance	NN	O
training	NN	O
.	.	O

The	DT	O
relative	JJ	O
net	NN	O
leg	NN	O
release	NN	O
and	CC	O
uptake	NN	O
of	IN	O
individual	JJ	O
FFA	NNP	O
closely	RB	O
resembled	VBD	O
their	PRP$	O
relative	JJ	O
abundances	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
with	IN	O
approximately	RB	O
21	CD	O
and	CC	O
41	CD	O
%	NN	O
of	IN	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
uptake	NN	O
during	IN	O
exercise	NN	O
accounted	VBN	O
for	IN	O
by	IN	O
palmitate	NN	O
and	CC	O
oleate	NN	O
,	,	O
respectively	RB	O
.	.	O

Endurance	NNP	O
training	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
changes	NNS	O
in	IN	O
arterial	JJ	PH
concentrations	NNS	PH
of	IN	PH
HDL-C	NNP	PH
(	(	O
49	CD	O
+/-	JJ	O
5	CD	O
vs.	FW	O
52	CD	O
+/-	JJ	O
5	CD	O
mg/dl	NN	O
,	,	O
pre	NN	O
vs.	FW	O
post	NN	O
)	)	O
and	CC	O
LDL-C	NNP	PH
(	(	O
82	CD	O
+/-	JJ	O
9	CD	O
vs.	FW	O
76	CD	O
+/-	JJ	O
9	CD	O
mg/dl	NN	O
,	,	O
pre	NN	O
vs.	FW	O
post	NN	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
net	JJ	PH
TG	NN	PH
or	CC	PH
LDL-C	JJ	PH
uptake	NN	PH
or	CC	O
HDL-C	JJ	PH
release	NN	PH
across	IN	O
the	DT	O
resting	NN	O
or	CC	O
active	JJ	O
leg	NN	O
before	IN	O
or	CC	O
after	IN	O
endurance	JJ	O
training	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
endurance	NN	O
training	NN	O
favorably	RB	O
affects	VBZ	O
blood	NN	PH
lipoprotein	NN	PH
profiles	NNS	PH
,	,	O
even	RB	O
in	IN	O
young	JJ	O
,	,	O
healthy	JJ	O
normolipidemic	JJ	O
men	NNS	O
,	,	O
but	CC	O
muscle	NN	O
contractions	NNS	O
per	IN	O
se	NN	O
have	VBP	O
little	JJ	O
effect	NN	O
on	IN	O
net	JJ	O
leg	NN	PH
LDL-C	NNP	PH
,	,	O
or	CC	O
TG	NNP	PH
uptake	VBP	PH
or	CC	O
HDL-C	JJ	PH
release	NN	PH
during	IN	O
moderate-intensity	NN	O
cycling	NN	O
exercise	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
favorable	JJ	O
effects	NNS	O
of	IN	O
physical	JJ	O
activity	NN	O
on	IN	O
the	DT	O
lipid	JJ	O
profiles	NNS	O
of	IN	O
young	JJ	O
,	,	O
healthy	JJ	O
normolipidemic	JJ	O
men	NNS	O
in	IN	O
the	DT	O
postprandial	JJ	O
state	NN	O
are	VBP	O
not	RB	O
attributable	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
HDL-C	NNP	PH
or	CC	O
LDL-C	NNP	PH
exchange	NN	O
across	IN	O
active	JJ	O
skeletal	JJ	O
muscle	NN	O
.	.	O

Dexamethasone	NN	O
phosphate	NN	O
in	IN	O
antibiotic	JJ	O
ear	NN	O
drops	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bacterial	JJ	O
otitis	NN	O
externa	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
polymyxin	NN	O
sulfate	NN	O
7500	CD	O
IU/neomycin	NNP	O
sulfate	NN	O
3500	CD	O
IU/dexamethasone	NNP	O
phosphate	VB	O
0.1	CD	O
%	NN	O
(	(	O
PN+Dx	NNP	O
)	)	O
otic	JJ	O
solution	NN	O
with	IN	O
polymyxin	NN	O
sulfate	NN	O
7500	CD	O
IU/neomycin	NNP	O
sulfate	NN	O
3500	CD	O
IU	NNP	O
(	(	O
PN-Dx	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
bacterial	JJ	O
otitis	NN	O
externa	NN	O
(	(	O
AOE	NNP	O
)	)	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
the	DT	O
possible	JJ	O
benefit	NN	O
of	IN	O
the	DT	O
addition	NN	O
of	IN	O
dexamethasone	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Active	NNP	O
controlled	VBD	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel	JJ	O
group	NN	O
,	,	O
multi-center	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
ear	NN	O
,	,	O
nose	RB	O
,	,	O
and	CC	O
throat	NN	O
(	(	O
ENT	NNP	O
)	)	O
specialist	NN	O
practices	NNS	O
with	IN	O
a	DT	O
planned	VBN	O
interim	NN	O
analysis	NN	O
for	IN	O
sample	JJ	O
size	NN	O
adaptation	NN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
338	CD	O
patients	NNS	O
aged	VBN	O
18-76	NNS	O
who	WP	O
had	VBD	O
a	DT	O
previous	JJ	O
episode	NN	O
of	IN	O
otitis	NN	O
externa	NN	O
within	IN	O
the	DT	O
last	JJ	O
year	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
10	CD	O
+/-	JJ	O
2	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
two	CD	O
drops	NNS	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
,	,	O
of	IN	O
either	DT	O
PN+Dx	NNP	O
or	CC	O
PN-Dx	NNP	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Change	NNP	PH
in	IN	PH
the	DT	PH
clinical	JJ	PH
symptom	NN	PH
score	NN	PH
(	(	PH
consisting	VBG	PH
of	IN	PH
the	DT	PH
subscores	NNS	PH
redness	NN	PH
,	,	PH
swelling	VBG	PH
,	,	PH
pain	NN	PH
,	,	PH
and	CC	PH
secretion	NN	PH
)	)	PH
and	CC	O
of	IN	O
the	DT	O
visual	JJ	PA
analogue	NN	PA
scale	NN	PA
(	(	PA
VAS	NNP	PA
)	)	PA
rating	NN	PA
for	IN	PA
pain	NN	PA
from	IN	O
Visit	NNP	O
1	CD	O
(	(	O
Day	NNP	O
1	CD	O
)	)	O
to	TO	O
Visit	VB	O
2	CD	O
(	(	O
Day	NNP	O
4	CD	O
+/-	JJ	O
1	CD	O
)	)	O
,	,	O
patient	NN	Ot
's	POS	Ot
assessment	NN	Ot
of	IN	Ot
efficacy	NN	Ot
at	IN	O
Visit	NNP	O
3	CD	O
(	(	O
Day	NNP	O
10	CD	O
+/-	JJ	O
2	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
frequency	NN	A
and	CC	A
type	NN	A
of	IN	A
adverse	JJ	A
events	NNS	A
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
of	IN	O
swelling	VBG	PH
from	IN	O
Visit	NNP	O
1	CD	O
to	TO	O
Visit	VB	O
2	CD	O
with	IN	O
PN+Dx	NNP	O
,	,	O
and	CC	O
more	JJR	O
patients	NNS	O
rated	VBD	O
the	DT	O
efficacy	NN	Ot
of	IN	O
PN+Dx	NNP	O
as	IN	O
'very	RB	O
good	JJ	O
'	''	O
or	CC	O
'good	POS	O
'	''	O
at	IN	O
Visit	NNP	O
3	CD	O
(	(	O
p	NN	O
=	RB	O
0.03	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
the	DT	O
clinical	JJ	PH
symptom	NN	PH
score	NN	PH
from	IN	O
Visit	NNP	O
1	CD	O
to	TO	O
Visit	VB	O
2	CD	O
in	IN	O
the	DT	O
PN+Dx	NNP	O
group	NN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
at	IN	O
least	JJS	O
a	DT	O
moderately	RB	O
severe	JJ	PH
symptom	NN	PH
score	NN	PH
with	IN	O
more	JJR	O
than	IN	O
seven	CD	O
points	NNS	O
at	IN	O
Visit	NNP	O
1	CD	O
(	(	O
p	NN	O
=	RB	O
0.01	CD	O
)	)	O
and	CC	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
their	PRP$	O
current	JJ	O
episode	NN	O
of	IN	O
otitis	NN	O
externa	NN	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	O
days	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
14	CD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
with	IN	O
no	DT	O
related	JJ	O
adverse	JJ	A
drug	NN	A
reactions	NNS	A
for	IN	O
PN+Dx	NNP	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
addition	NN	O
of	IN	O
dexamethasone	NN	O
phosphate	NN	O
to	TO	O
polymyxin	VB	O
B/neomycin	NNP	O
significantly	RB	O
reduces	VBZ	O
swelling	VBG	O
in	IN	O
patients	NNS	O
with	IN	O
AOE	NNP	O
and	CC	O
leads	VBZ	O
to	TO	O
significantly	RB	O
higher	JJR	O
patient	NN	O
's	POS	O
ratings	NNS	O
of	IN	O
treatment	NN	O
efficacy	NN	O
.	.	O

It	PRP	O
especially	RB	O
leads	VBZ	O
to	TO	O
an	DT	O
overall	JJ	O
reduction	NN	O
of	IN	O
symptoms	NNS	O
in	IN	O
cases	NNS	O
of	IN	O
moderately	RB	O
or	CC	O
more	JJR	O
severe	JJ	O
otitis	NN	O
externa	NN	O
and	CC	O
cases	NNS	O
lasting	VBG	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	O
days	NNS	O
.	.	O

[	JJ	O
Impact	NNP	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
polymorphism	NN	O
on	IN	O
acute	JJ	A
adverse	JJ	A
events	NNS	A
in	IN	O
postoperative	JJ	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
adjuvant	JJ	O
concurrent	NN	O
chemoradiotherapy	NN	O
]	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
association	NN	O
between	IN	O
single	JJ	O
nucleotide	JJ	O
polymorphism	NN	O
(	(	O
SNP	NNP	O
)	)	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
and	CC	O
acute	JJ	A
adverse	JJ	A
events	NNS	A
(	(	A
AEs	NNP	A
)	)	A
in	IN	O
postoperative	JJ	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
who	WP	O
received	VBD	O
capecitabine-based	JJ	O
postoperative	JJ	O
chemoradiotherapy	NN	O
(	(	O
CRT	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Four	CD	O
hundred	VBD	O
patients	NNS	O
with	IN	O
stage	NN	O
II	NNP	O
and	CC	O
III	NNP	O
rectal	JJ	O
cancer	NN	O
received	VBD	O
postoperative	JJ	O
CRT	NNP	O
of	IN	O
capecitabine	NN	O
with	IN	O
or	CC	O
without	IN	O
oxaliplatin	NNS	O
were	VBD	O
accumulated	VBN	O
and	CC	O
prostectively	RB	O
studied	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Two	CD	O
hundred	CD	O
and	CC	O
twenty-eight	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
concurrent	JJ	O
capecitabine	NN	O
and	CC	O
radiotherapy	NN	O
(	(	O
Cap-CRT	NNP	O
)	)	O
,	,	O
and	CC	O
172	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
capecitabine	NN	O
and	CC	O
oxaliplatin	JJ	O
plus	CC	O
radiotherapy	JJ	O
(	(	O
Cap-Oxa-CRT	NNP	O
)	)	O
.	.	O

Adverse	JJ	A
events	NNS	A
were	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Common	NNP	Ot
Terminology	NNP	Ot
Criteria	NNP	Ot
for	IN	Ot
Adverse	NNP	Ot
Events	NNP	Ot
,	,	Ot
v.	NN	Ot
3.0	CD	O
(	(	O
CTCAE	NNP	O
v3.0	NN	O
)	)	O
.	.	O

The	DT	O
genotype	NN	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
in	IN	O
the	DT	O
patients	NNS	O
was	VBD	O
detected	VBN	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction-based	JJ	O
restriction	NN	O
fragment	NN	O
length	NN	O
polymorphism	NN	O
(	(	O
PCR-RFLP	NNP	O
)	)	O
analysis	NN	O
.	.	O

The	DT	O
associations	NNS	O
between	IN	O
the	DT	O
SNP	NNP	O
and	CC	O
acute	JJ	A
AEs	NNP	A
were	VBD	O
indicated	VBN	O
by	IN	O
odds	NNS	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
and	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
,	,	O
which	WDT	O
were	VBD	O
computed	VBN	O
with	IN	O
logistic	JJ	O
regression	NN	O
model	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
136	CD	O
patients	NNS	O
presented	VBN	O
severe	JJ	A
AEs	NNP	A
.	.	O

Among	IN	O
them	PRP	O
the	DT	O
frequencies	NNS	O
of	IN	O
the	DT	O
three	CD	O
genotypes	NNS	O
GG	NNP	O
,	,	O
GA	NNP	O
and	CC	O
AA	NNP	O
were	VBD	O
16.9	CD	O
%	NN	O
,	,	O
50.7	CD	O
%	NN	O
and	CC	O
32.4	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
24.6	CD	O
%	NN	O
,	,	O
48.1	CD	O
%	NN	O
and	CC	O
27.3	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
among	IN	O
the	DT	O
patients	NNS	O
without	IN	O
severe	JJ	A
AEs	NNP	A
.	.	O

Diarrhea	NNP	PH
was	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
AE	NNP	A
,	,	O
and	CC	O
severe	JJ	A
diarrhea	NN	A
occurred	VBD	O
in	IN	O
109	CD	O
patients	NNS	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
the	DT	O
three	CD	O
genotypes	NNS	O
GG	NNP	O
,	,	O
GA	NNP	O
and	CC	O
AA	NNP	O
were	VBD	O
15.6	CD	O
%	NN	O
,	,	O
47.7	CD	O
%	NN	O
and	CC	O
36.7	CD	O
%	NN	O
among	IN	O
these	DT	O
patients	NNS	O
,	,	O
compared	VBN	O
with	IN	O
24.4	CD	O
%	NN	O
,	,	O
49.5	CD	O
%	NN	O
and	CC	O
26.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
among	IN	O
patients	NNS	O
without	IN	O
severe	JJ	PH
diarrhea	NN	PH
.	.	O

Multivariate	NNP	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
1.66-fold	JJ	O
increased	JJ	O
risk	NN	O
for	IN	O
severe	JJ	PH
diarrhea	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
AA	NNP	O
genotype	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.03	CD	O
-	:	O
2.67	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
cases	NNS	O
with	IN	O
GG	NNP	O
or	CC	O
GA	NNP	O
genotypes	NNS	O
.	.	O

Stratified	VBN	O
analysis	NN	O
showed	VBD	O
that	IN	O
in	IN	O
the	DT	O
Cap-Oxa-CRT	NNP	O
group	NN	O
,	,	O
patients	NNS	O
with	IN	O
AA	NNP	O
genotype	NN	O
showed	VBD	O
a	DT	O
2.34-fold	JJ	O
increased	JJ	O
risk	NN	O
for	IN	O
severe	JJ	A
diarrhea	NN	A
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.16	CD	O
-	:	O
4.76	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
GG	NNP	O
or	CC	O
GA	NNP	O
genotypes	NNS	O
,	,	O
but	CC	O
in	IN	O
the	DT	O
Cap-CRT	NNP	O
group	NN	O
,	,	O
the	DT	O
SNP	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
the	DT	O
risk	NN	O
of	IN	O
severe	JJ	PH
diarrhea	NN	PH
.	.	O

CONCLUSIONS	VB	O
The	DT	O
genetic	JJ	O
polymorphism	NN	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
might	MD	O
be	VB	O
a	DT	O
potential	JJ	O
biomarker	NN	O
for	IN	O
predicting	VBG	O
acute	JJ	A
AEs	NNP	A
in	IN	O
postoperative	JJ	O
stage	NN	O
II	NNP	O
and	CC	O
III	NNP	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
adjuvant	JJ	O
concurrent	JJ	O
chemoradiotherapy	NN	O
of	IN	O
capecitabine	NN	O
and	CC	O
oxaliplatin	NN	O
.	.	O

Virtual	JJ	O
patients	NNS	O
design	NN	O
and	CC	O
its	PRP$	O
effect	NN	O
on	IN	O
clinical	JJ	ME
reasoning	NN	ME
and	CC	O
student	NN	Ot
experience	NN	Ot
:	:	Ot
a	DT	O
protocol	NN	O
for	IN	O
a	DT	O
randomised	JJ	O
factorial	JJ	O
multi-centre	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Virtual	JJ	O
Patients	NNP	O
(	(	O
VPs	NNP	O
)	)	O
are	VBP	O
web-based	JJ	O
representations	NNS	O
of	IN	O
realistic	JJ	O
clinical	JJ	O
cases	NNS	O
.	.	O

They	PRP	O
are	VBP	O
proposed	VBN	O
as	IN	O
being	VBG	O
an	DT	O
optimal	JJ	O
method	NN	O
for	IN	O
teaching	VBG	O
clinical	JJ	O
reasoning	NN	O
skills	NNS	O
.	.	O

International	NNP	O
standards	NNS	O
exist	VBP	O
which	WDT	O
define	VBP	O
precisely	RB	O
what	WP	O
constitutes	VBZ	O
a	DT	O
VP	NNP	O
.	.	O

There	EX	O
are	VBP	O
multiple	JJ	O
design	NN	O
possibilities	NNS	O
for	IN	O
VPs	NNP	O
,	,	O
however	RB	O
there	EX	O
is	VBZ	O
little	JJ	O
formal	JJ	O
evidence	NN	O
to	TO	O
support	VB	O
individual	JJ	O
design	NN	O
features	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
trial	NN	O
is	VBZ	O
to	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
different	JJ	O
potentially	RB	O
important	JJ	O
design	NN	O
features	NNS	O
on	IN	O
clinical	JJ	ME
reasoning	NN	ME
skills	NNS	ME
and	CC	O
the	DT	O
student	NN	Ot
experience	NN	Ot
.	.	ME

These	DT	O
are	VBP	O
the	DT	O
branching	VBG	O
case	NN	O
pathways	NNS	O
(	(	O
present	JJ	O
or	CC	O
absent	NN	O
)	)	O
and	CC	O
structured	JJ	O
clinical	JJ	O
reasoning	VBG	O
feedback	NN	O
(	(	O
present	JJ	O
or	CC	O
absent	NN	O
)	)	O
.	.	O

METHODS/DESIGN	NNP	O
This	DT	O
is	VBZ	O
a	DT	O
multi-centre	JJ	O
randomised	JJ	O
2	CD	O
x	JJ	O
2	CD	O
factorial	JJ	O
design	NN	O
study	NN	O
evaluating	VBG	O
two	CD	O
independent	JJ	O
variables	NNS	O
of	IN	O
VP	NNP	O
design	NN	O
,	,	O
branching	NN	O
(	(	O
present	JJ	O
or	CC	O
absent	NN	O
)	)	O
,	,	O
and	CC	O
structured	VBD	O
clinical	JJ	O
reasoning	NN	O
feedback	NN	O
(	(	O
present	JJ	O
or	CC	O
absent	NN	O
)	)	O
.The	NN	O
study	NN	O
will	MD	O
be	VB	O
carried	VBN	O
out	RP	O
in	IN	O
medical	JJ	O
student	NN	O
volunteers	NNS	O
in	IN	O
one	CD	O
year	NN	O
group	NN	O
from	IN	O
three	CD	O
university	NN	O
medical	JJ	O
schools	NNS	O
in	IN	O
the	DT	O
United	NNP	O
Kingdom	NNP	O
,	,	O
Warwick	NNP	O
,	,	O
Keele	NNP	O
and	CC	O
Birmingham	NNP	O
.	.	O

There	EX	O
are	VBP	O
four	CD	O
core	NN	O
musculoskeletal	NN	O
topics	NNS	O
.	.	O

Each	DT	O
case	NN	O
can	MD	O
be	VB	O
designed	VBN	O
in	IN	O
four	CD	O
different	JJ	O
ways	NNS	O
,	,	O
equating	VBG	O
to	TO	O
16	CD	O
VPs	NNP	O
required	VBN	O
for	IN	O
the	DT	O
research	NN	O
.	.	O

Students	NNS	O
will	MD	O
be	VB	O
randomised	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
,	,	O
completing	VBG	O
the	DT	O
four	CD	O
VP	NNP	O
topics	NNS	O
in	IN	O
the	DT	O
same	JJ	O
order	NN	O
,	,	O
but	CC	O
with	IN	O
each	DT	O
group	NN	O
exposed	VBD	O
to	TO	O
a	DT	O
different	JJ	O
VP	NNP	O
design	NN	O
sequentially	RB	O
.	.	O

All	DT	O
students	NNS	O
will	MD	O
be	VB	O
exposed	VBN	O
to	TO	O
the	DT	O
four	CD	O
designs	NNS	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
are	VBP	O
performance	NN	ME
for	IN	ME
each	DT	ME
case	NN	ME
design	NN	ME
in	IN	ME
a	DT	ME
standardized	JJ	ME
fifteen	JJ	ME
item	NN	ME
clinical	JJ	ME
reasoning	NN	ME
assessment	NN	ME
,	,	O
integrated	VBN	O
into	IN	O
each	DT	O
VP	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
identical	JJ	O
for	IN	O
each	DT	O
topic	NN	O
.	.	O

Additionally	RB	O
a	DT	O
15-item	JJ	Ot
self-reported	JJ	Ot
evaluation	NN	Ot
is	VBZ	O
completed	VBN	O
for	IN	O
each	DT	O
VP	NNP	O
,	,	O
based	VBN	O
on	IN	O
a	DT	O
widely	RB	O
used	VBN	O
EViP	NNP	O
tool	NN	O
.	.	O

Student	NN	O
patterns	NNS	O
of	IN	O
use	NN	O
of	IN	O
the	DT	O
VPs	NNP	O
will	MD	O
be	VB	O
recorded.In	JJ	O
one	CD	O
centre	NN	O
,	,	O
formative	JJ	O
clinical	JJ	O
and	CC	O
examination	NN	O
performance	NN	O
will	MD	O
be	VB	O
recorded	VBN	O
,	,	O
along	IN	O
with	IN	O
a	DT	O
self	NN	O
reported	VBN	O
pre	JJ	O
and	CC	O
post-intervention	NN	O
reasoning	NN	O
score	NN	O
,	,	O
the	DT	O
DTI	NNP	O
.	.	O

Our	PRP$	O
power	NN	O
calculations	NNS	O
indicate	VBP	O
a	DT	O
sample	JJ	O
size	NN	O
of	IN	O
112	CD	O
is	VBZ	O
required	VBN	O
for	IN	O
both	DT	O
primary	JJ	O
outcomes	NNS	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
trial	NN	O
will	MD	O
provide	VB	O
robust	JJ	O
evidence	NN	O
to	TO	O
support	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
different	JJ	O
designs	NNS	O
of	IN	O
virtual	JJ	O
patients	NNS	O
,	,	O
based	VBN	O
on	IN	O
student	NN	ME
performance	NN	ME
and	CC	O
evaluation	NN	Ot
.	.	O

The	DT	O
cases	NNS	O
and	CC	O
all	DT	O
learning	JJ	O
materials	NNS	O
will	MD	O
be	VB	O
open	JJ	O
access	NN	O
and	CC	O
available	JJ	O
on	IN	O
a	DT	O
Creative	JJ	O
Commons	NNP	O
Attribution-Share-Alike	NNP	O
license	NN	O
.	.	O

Paromomycin	NNP	O
for	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
effects	NNS	O
of	IN	O
paromomycin	NN	O
,	,	O
10	CD	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
and	CC	O
cryptosporidiosis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
paromomycin	VB	O
or	CC	O
placebo	VB	O
in	IN	O
a	DT	O
double-blind	JJ	O
trial	NN	O
.	.	O

After	IN	O
14	CD	O
days	NNS	O
,	,	O
patients	NNS	O
were	VBD	O
switched	VBN	O
to	TO	O
the	DT	O
other	JJ	O
treatment	NN	O
for	IN	O
14	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Measures	NNS	O
included	VBD	O
the	DT	O
number	NN	PH
and	CC	PH
character	NN	PH
of	IN	PH
each	DT	PH
stool	NN	PH
and	CC	O
weekly	JJ	O
24-h	JJ	O
stool	NN	PH
specimens	NNS	PH
for	IN	PH
weight	NN	PH
and	CC	O
oocyst	NN	PH
excretion	NN	PH
.	.	O

During	IN	O
the	DT	O
paromomycin	NN	O
treatment	NN	O
phase	NN	O
,	,	O
oocyst	JJ	PH
excretion	NN	PH
decreased	VBD	O
from	IN	O
314	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
to	TO	O
109	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
24	CD	O
h	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Oocyst	NNP	PH
excretion	NN	PH
increased	VBD	O
for	IN	O
the	DT	O
4	CD	O
patients	NNS	O
initially	RB	O
on	IN	O
placebo	NNS	O
compared	VBN	O
to	TO	O
a	DT	O
median	JJ	O
decrease	NN	O
of	IN	O
128	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/24	NN	O
h	NN	O
for	IN	O
the	DT	O
6	CD	O
initially	RB	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Stool	NNP	Ot
frequency	NN	Ot
also	RB	O
decreased	VBD	O
more	RBR	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
3.6	CD	O
fewer	JJR	O
vs.	NN	O
1.25	CD	O
fewer/24	NN	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Trends	NNS	O
favored	JJ	O
drug	NN	O
over	IN	O
placebo	NN	O
for	IN	O
stool	NN	PH
weight	NN	PH
,	,	PH
stool	JJ	PH
character	NN	PH
,	,	O
and	CC	O
Karnofsky	NNP	Ot
score	NN	Ot
.	.	O

Paromomycin	NNP	O
treatment	NN	O
resulted	VBD	O
in	IN	O
improvement	NN	O
in	IN	O
both	DT	O
clinical	JJ	O
and	CC	O
parasitologic	JJ	O
parameters	NNS	O
in	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
.	.	O

Anemia	NNP	O
and	CC	O
associated	VBN	O
clinical	JJ	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
due	JJ	O
to	TO	O
reduced	VB	O
left	JJ	O
ventricular	JJ	O
systolic	JJ	O
function	NN	O
.	.	O

BACKGROUND	NNP	O
Anemia	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
decreased	JJ	O
functional	JJ	O
capacity	NN	O
,	,	O
reduced	VBD	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
worsened	VBD	O
outcomes	NNS	O
among	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
(	(	O
HF	NNP	O
)	)	O
due	JJ	O
to	TO	O
reduced	VB	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
HFREF	NNP	O
)	)	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
independent	JJ	O
effect	NN	O
of	IN	O
anemia	NN	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
among	IN	O
those	DT	O
with	IN	O
HFREF	NNP	O
.	.	O

HYPOTHESIS	NNP	O
Anemia	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
.	.	O

METHODS	PDT	O
The	DT	O
HF-ACTION	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
exercise	NN	O
therapy	NN	O
vs	NN	O
usual	JJ	O
care	NN	O
in	IN	O
2331	CD	O
patients	NNS	O
with	IN	O
HFREF	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
class	NN	O
II	NNP	O
to	TO	O
IV	NNP	O
HF	NNP	O
and	CC	O
left	VBD	O
ventricular	JJ	O
ejection	NN	O
fractions	NNS	O
of	IN	O
?	.	O
35	CD	O
%	NN	O
were	VBD	O
recruited	VBN	O
.	.	O

Hemoglobin	NNP	O
(	(	O
Hb	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
up	RB	O
to	TO	O
1	CD	O
year	NN	O
prior	RB	O
to	TO	O
entry	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
quintile	NN	O
.	.	O

Anemia	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
baseline	NN	O
Hb	NNP	O
<	VBZ	O
13	CD	O
g/dL	NN	O
and	CC	O
<	$	O
12	CD	O
g/dL	NN	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
respectively	RB	O
.	.	O

Hemoglobin	NNP	O
was	VBD	O
assessed	VBN	O
in	IN	O
2	CD	O
models	NNS	O
:	:	O
a	DT	O
global	JJ	O
prediction	NN	O
model	NN	O
that	WDT	O
had	VBD	O
been	VBN	O
previously	RB	O
developed	VBN	O
,	,	O
and	CC	O
a	DT	O
modified	JJ	O
model	NN	O
including	VBG	O
variables	NNS	O
associated	VBN	O
with	IN	O
anemia	NN	O
and	CC	O
the	DT	O
studied	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Hemoglobin	NNP	O
was	VBD	O
available	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
1763	CD	O
subjects	NNS	O
(	(	O
76	CD	O
%	NN	O
of	IN	O
total	JJ	O
study	NN	O
population	NN	O
)	)	O
;	:	O
their	PRP$	O
median	JJ	O
age	NN	O
was	VBD	O
59.0	CD	O
years	NNS	O
,	,	O
73	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
and	CC	O
62	CD	O
%	NN	O
were	VBD	O
Caucasian	JJ	O
.	.	O

The	DT	O
prevalence	NN	O
of	IN	O
anemia	NN	O
was	VBD	O
515/1763	CD	O
(	(	O
29	CD	O
%	NN	O
)	)	O
.	.	O

Older	JJR	O
age	NN	O
,	,	O
female	JJ	O
sex	NN	O
,	,	O
African	JJ	O
American	NNP	O
race	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
hypertension	NN	O
,	,	O
and	CC	O
lower	JJR	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rates	NNS	O
were	VBD	O
all	DT	O
more	RBR	O
frequent	JJ	O
in	IN	O
lower	JJR	O
Hb	NNP	O
quintiles	NNS	O
.	.	O

Over	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
30	CD	O
months	NNS	O
,	,	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
or	CC	O
all-cause	JJ	O
hospitalization	NN	O
occurred	VBD	O
in	IN	O
78	CD	O
%	NN	O
of	IN	O
those	DT	O
with	IN	O
anemia	NN	O
and	CC	O
64	CD	O
%	NN	O
in	IN	O
those	DT	O
without	IN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
secondary	JJ	O
outcomes	NNS	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
alone	RB	O
,	,	O
cardiovascular	JJ	O
(	(	O
CV	NNP	O
)	)	O
mortality	NN	O
or	CC	O
CV	NNP	O
hospitalization	NN	O
,	,	O
and	CC	O
CV	NNP	O
mortality	NN	O
or	CC	O
HF	NNP	O
hospitalization	NN	O
occurred	VBD	O
in	IN	O
23	CD	O
%	NN	O
vs	JJ	O
15	CD	O
%	NN	O
,	,	O
67	CD	O
%	NN	O
vs	JJ	O
54	CD	O
%	NN	O
,	,	O
and	CC	O
44	CD	O
vs	NNS	O
29	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Heart	NNP	O
failure	NN	O
hospitalizations	NNS	O
occurred	VBD	O
in	IN	O
36	CD	O
%	NN	O
vs	JJ	O
22	CD	O
%	NN	O
,	,	O
and	CC	O
urgent	JJ	O
outpatient	NN	O
visits	NNS	O
for	IN	O
HF	NNP	O
exacerbations	NNS	O
occurred	VBD	O
in	IN	O
67	CD	O
%	NN	O
and	CC	O
55	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

For	IN	O
the	DT	O
global	JJ	O
model	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
association	NN	O
observed	VBD	O
for	IN	O
anemia	NN	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
or	CC	O
hospitalization	NN	O
(	(	O
adjusted	VBN	O
hazard	RB	O
ratio	JJ	O
[	NNP	O
HR	NNP	O
]	NN	O
:	:	O
1.15	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
1.01-1.32	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
but	CC	O
other	JJ	O
outcomes	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
at	IN	O
P	NNP	O
<	NNP	O
0.05	CD	O
.	.	O

In	IN	O
the	DT	O
modified	JJ	O
model	NN	O
,	,	O
the	DT	O
adjusted	JJ	O
HR	NNP	O
for	IN	O
anemia	NN	O
and	CC	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
or	CC	O
all-cause	JJ	O
hospitalization	NN	O
was	VBD	O
1.25	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.10-1.42	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
independent	JJ	O
associations	NNS	O
between	IN	O
anemia	NN	O
and	CC	O
all-cause	JJ	O
death	NN	O
(	(	O
HR	NNP	O
:	:	O
1.11	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.87-1.42	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
,	,	O
CV	NNP	O
death	NN	O
or	CC	O
CV	NNP	O
hospitalization	NN	O
(	(	O
HR	NNP	O
:	:	O
1.16	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.01-1.33	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
,	,	O
and	CC	O
CV	NNP	O
death	NN	O
and	CC	O
HF	NNP	O
hospitalization	NN	O
(	(	O
HR	NNP	O
:	:	O
1.27	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.06-1.51	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Anemia	NNP	O
modestly	RB	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
rates	NNS	O
of	IN	O
death	NN	O
,	,	O
hospitalization	NN	O
,	,	O
and	CC	O
HF	NNP	O
exacerbation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
HFREF	NNP	O
.	.	O

After	IN	O
adjusting	VBG	O
for	IN	O
other	JJ	O
important	JJ	O
covariates	NNS	O
,	,	O
anemia	NN	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
an	DT	O
excess	JJ	O
hazard	NN	O
for	IN	O
all-cause	JJ	O
mortality	NN	O
and	CC	O
all-cause	JJ	O
hospitalization	NN	O
.	.	O

Anemia	NNP	O
is	VBZ	O
also	RB	O
associated	VBN	O
with	IN	O
combinations	NNS	O
of	IN	O
CV	NNP	O
death	NN	O
and	CC	O
CV/HF	NNP	O
hospitalizations	NNS	O
as	IN	O
composite	JJ	O
endpoints	NNS	O
.	.	O

Myocardial	JJ	O
extracellular	JJ	O
volume	NN	O
by	IN	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
anthracycline-based	JJ	O
chemotherapy	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
myocardial	JJ	PH
extracellular	JJ	PH
volume	NN	PH
(	(	PH
ECV	NNP	PH
)	)	PH
,	,	O
measured	VBN	O
using	VBG	O
T1	NNP	PH
measurements	NNS	PH
obtained	VBD	O
during	IN	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
were	VBD	O
increased	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
anthracyclines	NNS	O
.	.	O

We	PRP	O
performed	VBD	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
and	CC	O
echocardiography	NN	O
and	CC	O
measured	VBD	O
the	DT	O
ECV	NNP	PH
in	IN	O
42	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
anthracyclines	NNS	O
.	.	O

The	DT	O
data	NN	O
from	IN	O
the	DT	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
study	NN	O
were	VBD	O
compared	VBN	O
to	TO	O
those	DT	O
from	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
anthracycline-treated	JJ	O
cohort	NN	O
consisted	VBD	O
of	IN	O
21	CD	O
men	NNS	O
and	CC	O
21	CD	O
women	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
55	CD	O
?	.	O
17	CD	O
years	NNS	O
,	,	O
who	WP	O
presented	VBD	O
a	DT	O
median	NN	O
of	IN	O
84	CD	O
months	NNS	O
after	IN	O
chemotherapy	NN	O
with	IN	O
a	DT	O
cumulative	JJ	O
anthracycline	NN	O
exposure	NN	O
of	IN	O
282	CD	O
?	.	O
65	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
and	CC	O
a	DT	O
mean	NN	O
left	VBD	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
of	IN	O
52	CD	O
?	.	O
12	CD	O
%	NN	O
.	.	O

The	DT	O
ECV	NNP	O
was	VBD	O
elevated	VBN	O
in	IN	O
the	DT	O
anthracycline-treated	JJ	O
patients	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
age-	JJ	O
and	CC	O
gender-matched	JJ	O
controls	NNS	O
(	(	O
0.36	CD	O
?	.	O
0.03	CD	O
vs	NN	O
0.28	CD	O
?	.	O
0.02	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	NNP	O
positive	JJ	O
association	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
ECV	NNP	O
and	CC	O
left	VBD	O
atrial	JJ	O
volume	NN	O
(	(	O
ECV	NNP	O
vs	RB	O
indexed	VBD	O
left	JJ	O
atrial	JJ	O
volume	NN	O
,	,	O
r	NN	O
=	VBD	O
0.65	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
negative	JJ	O
association	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
ECV	NNP	O
and	CC	O
diastolic	JJ	O
function	NN	O
(	(	O
E	NNP	O
'	POS	O
lateral	NN	O
,	,	O
r	NN	O
=	NNP	O
-0.64	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
myocardial	JJ	O
ECV	NNP	O
is	VBZ	O
elevated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
previous	JJ	O
anthracycline	NN	O
treatment	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
the	DT	O
diastolic	JJ	O
function	NN	O
and	CC	O
increased	VBD	O
atrial	JJ	O
volumes	NNS	O
.	.	O

Effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
antiviral	JJ	Ot
activity	NN	Ot
of	IN	O
didanosine	JJ	O
enteric-coated	JJ	O
capsules	NNS	O
:	:	O
a	DT	O
pilot	NN	O
comparative	NN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
enteric-coated	JJ	O
(	(	O
EC	NNP	O
)	)	O
capsules	NNS	O
of	IN	O
didanosine	NN	O
(	(	O
ddI	NN	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
pilot	NN	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
study	NN	O
of	IN	O
28-day	JJ	O
ddI-EC	JJ	O
capsules	NNS	O
monotherapy-administered	VBN	O
in	IN	O
a	DT	O
fasted	JJ	O
state	NN	O
(	(	O
group	NN	O
1	CD	O
,	,	O
n=11	NN	O
)	)	O
or	CC	O
with	IN	O
food	NN	O
(	(	O
group	NN	O
2	CD	O
,	,	O
n=10	RB	O
)	)	O
to	TO	O
treatment-na?ve	JJ	O
chronically	RB	O
HIV-1-infected	JJ	O
individuals	NNS	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
antiviral	JJ	O
efficacy	NN	O
,	,	O
HIV-1	NNP	O
RNA	NNP	O
was	VBD	O
determined	VBN	O
at	IN	O
baseline	NN	O
,	,	O
day	NN	O
3	CD	O
,	,	O
day	NN	O
7	CD	O
and	CC	O
weekly	JJ	O
thereafter	NN	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
HIV-1	NNP	O
RNA	NNP	O
curve	NN	O
minus	NN	O
baseline	NN	O
weighted	VBN	O
by	IN	O
time	NN	O
(	(	O
AUCMB/day	NNP	O
)	)	O
was	VBD	O
calculated	VBN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
baseline	JJ	O
HIV-1	NNP	O
RNA	NNP	O
was	VBD	O
4.2	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
3.8	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

After	IN	O
28	CD	O
days	NNS	O
,	,	O
the	DT	O
mean	JJ	O
HIV-1	NNP	O
RNA	NNP	O
reduction	NN	O
was	VBD	O
0.99	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
[	$	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.45-1.53	CD	O
]	NN	O
for	IN	O
group	NN	O
1	CD	O
and	CC	O
0.89	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.38-1.40	NN	O
)	)	O
for	IN	O
group	NN	O
2	CD	O
.	.	O

AUCMB/day	JJ	O
values	NNS	O
were	VBD	O
0.775	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.33-1.22	NN	O
)	)	O
and	CC	O
0.774	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.48-1.07	NN	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
showing	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
decrease	NN	O
of	IN	O
HIV-1	NNP	O
RNA	NNP	O
(	(	O
P=0.995	NNP	O
)	)	O
.	.	O

Mean	NNP	O
ddI	JJ	O
plasma	NN	O
levels	NNS	O
at	IN	O
day	NN	O
28	CD	O
were	VBD	O
0.0234	CD	O
mg/L	NN	O
for	IN	O
group	NN	O
1	CD	O
and	CC	O
0.0227	CD	O
mg/L	NN	O
for	IN	O
group	NN	O
2	CD	O
(	(	O
P=0.96	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
the	DT	O
administration	NN	O
of	IN	O
food	NN	O
did	VBD	O
not	RB	O
have	VB	O
any	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
ddI-EC	JJ	O
capsules	NNS	O
.	.	O

Contrast	NNP	O
,	,	O
motion	NN	O
,	,	O
perceptual	JJ	O
integration	NN	O
,	,	O
and	CC	O
neurocognition	NN	O
in	IN	O
schizophrenia	NN	O
:	:	O
the	DT	O
role	NN	O
of	IN	O
fragile-X	JJ	O
related	JJ	O
mechanisms	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
demonstrated	VBD	O
a	DT	O
reduced	JJ	O
expression	NN	O
of	IN	O
Fragile	NNP	O
X	NNP	O
Mental	NNP	O
Retardation	NNP	O
Protein	NNP	O
(	(	O
FMRP	NNP	O
)	)	O
,	,	O
an	DT	O
RNA	NNP	O
binding	NN	O
protein	NN	O
and	CC	O
translation	NN	O
regulator	NN	O
,	,	O
in	IN	O
the	DT	O
brain	NN	O
and	CC	O
peripheral	JJ	O
lymphocytes	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

Low	JJ	O
FMRP	NNP	O
levels	NNS	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
impaired	JJ	O
neurodevelopmental	JJ	O
processes	NNS	O
and	CC	O
synaptic	JJ	O
plasticity	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
studied	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
peripheral	JJ	O
FMRP	NNP	O
level	NN	O
,	,	O
visual	JJ	PH
perception	NN	PH
(	(	PH
contrast	JJ	PH
sensitivity	NN	PH
,	,	PH
perceptual	JJ	PH
integration	NN	PH
,	,	PH
motion/form	VB	PH
perception	NN	PH
)	)	PH
,	,	O
and	CC	O
neuropsychological	JJ	PH
functions	NNS	PH
in	IN	O
schizophrenia	NN	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
Repeatable	JJ	O
Battery	NN	O
for	IN	O
the	DT	O
Assessment	NNP	O
of	IN	O
Neuropsychological	NNP	O
Status	NNP	O
(	(	O
RBANS	NNP	O
)	)	O
.	.	O

Results	NNP	O
revealed	VBD	O
that	IN	O
patients	NNS	O
with	IN	O
schizophrenia	JJ	O
displayed	NNS	O
lower	JJR	O
FMRP	NNP	PH
levels	NNS	PH
in	IN	O
peripheral	JJ	O
lymphocytes	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
control	VB	O
individuals	NNS	O
.	.	O

We	PRP	O
found	VBD	O
significant	JJ	O
correlations	NNS	O
between	IN	O
FMRP	NNP	PH
levels	NNS	PH
and	CC	O
contrast	NN	O
sensitivity	NN	O
at	IN	O
low	JJ	O
spatial	NN	O
and	CC	O
high	JJ	O
temporal	JJ	O
frequencies	NNS	O
,	,	O
perceptual	JJ	O
integration	NN	O
,	,	O
and	CC	O
motion	NN	O
perception	NN	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
FMRP	NNP	PH
level	NN	PH
and	CC	PH
neuropsychological	JJ	PH
functions	NNS	PH
was	VBD	O
less	RBR	O
pronounced	JJ	O
than	IN	O
that	DT	O
seen	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
visual	JJ	O
perception	NN	O
,	,	O
with	IN	O
the	DT	O
greatest	JJS	O
effect	NN	O
for	IN	O
RBANS	NNP	O
attention	NN	O
.	.	O

FMRP	NNP	PH
level	NN	PH
was	VBD	O
not	RB	O
related	VBN	O
to	TO	O
contrast	VB	O
sensitivity	NN	O
at	IN	O
high	JJ	O
spatial	JJ	O
and	CC	O
low	JJ	O
temporal	JJ	O
frequencies	NNS	O
and	CC	O
form	JJ	O
perception	NN	O
.	.	O

This	DT	O
pattern	NN	O
of	IN	O
data	NNS	O
is	VBZ	O
reminiscent	JJ	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
Fragile	NNP	O
X	NNP	O
Syndrome	NNP	O
(	(	O
FXS	NNP	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
FMRP	NNP	O
may	MD	O
be	VB	O
implicated	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
schizophrenia	NN	O
,	,	O
possibly	RB	O
via	IN	O
the	DT	O
regulation	NN	O
of	IN	O
neurodevelopment	NN	PH
,	,	O
plasticity	NN	PH
,	,	O
GABA-ergic	NNP	PH
,	,	O
and	CC	O
glutamatergic	JJ	PH
neurotransmission	NN	PH
.	.	PH

Enhanced	NNP	Ot
bioavailability	NN	Ot
of	IN	Ot
zeaxanthin	NN	Ot
in	IN	O
a	DT	O
milk-based	JJ	O
formulation	NN	O
of	IN	O
wolfberry	NN	O
(	(	O
Gou	NNP	O
Qi	NNP	O
Zi	NNP	O
;	:	O
Fructus	NNP	O
barbarum	IN	O
L.	NNP	O
)	)	O
.	.	O

The	DT	O
carotenoid	NN	O
zeaxanthin	NN	O
is	VBZ	O
concentrated	VBN	O
within	IN	O
the	DT	O
macula	NN	O
.	.	O

Increased	VBD	O
macular	JJ	O
zeaxanthin	NN	O
is	VBZ	O
suggested	VBN	O
to	TO	O
lower	VB	O
the	DT	O
risk	NN	PH
of	IN	PH
age-related	JJ	PH
macular	JJ	PH
degeneration	NN	PH
.	.	PH

The	DT	O
small	JJ	O
red	JJ	O
berry	NN	O
,	,	O
wolfberry	NN	O
(	(	O
Fructus	NNP	O
barbarum	VBZ	O
L.	NNP	O
;	:	O
Gou	NNP	O
Qi	NNP	O
Zi	NNP	O
and	CC	O
Kei	NNP	O
Tze	NNP	O
)	)	O
,	,	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
richest	JJS	O
natural	JJ	O
sources	NNS	O
of	IN	O
zeaxanthin	NN	O
.	.	O

However	RB	O
,	,	O
carotenoid	JJ	PH
bioavailability	NN	PH
is	VBZ	O
low	JJ	O
,	,	O
and	CC	O
food-based	JJ	O
products	NNS	O
with	IN	O
enhanced	JJ	O
bioavailability	NN	PH
are	VBP	O
of	IN	O
interest	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
zeaxanthin	JJ	PH
bioavailability	NN	PH
from	IN	O
three	CD	O
wolfberry	NN	O
formulations	NNS	O
.	.	O

Berries	NNS	O
were	VBD	O
homogenised	VBN	O
in	IN	O
hot	JJ	O
(	(	O
80	CD	O
degrees	NNS	O
C	NNP	O
)	)	O
water	NN	O
,	,	O
warm	NN	O
(	(	O
40	CD	O
degrees	NNS	O
C	NNP	O
)	)	O
skimmed	VBD	O
milk	NN	O
and	CC	O
hot	JJ	O
(	(	O
80	CD	O
degrees	NNS	O
C	NNP	O
)	)	O
skimmed	VBD	O
milk	NN	O
,	,	O
with	IN	O
freeze	JJ	O
drying	NN	O
of	IN	O
each	DT	O
preparation	NN	O
into	IN	O
a	DT	O
powdered	JJ	O
form	NN	O
.	.	O

A	DT	O
zeaxanthin-standardised	JJ	O
dose	NN	O
(	(	O
15	CD	O
mg	NN	O
)	)	O
of	IN	O
each	DT	O
was	VBD	O
consumed	VBN	O
,	,	O
in	IN	O
randomised	JJ	O
order	NN	O
,	,	O
together	RB	O
with	IN	O
a	DT	O
standardised	VBN	O
breakfast	NN	O
by	IN	O
twelve	NN	O
healthy	JJ	O
,	,	O
consenting	VBG	O
subjects	NNS	O
in	IN	O
a	DT	O
cross-over	JJ	O
trial	NN	O
,	,	O
with	IN	O
a	DT	O
3-5-week	JJ	O
washout	NN	O
period	NN	O
between	IN	O
treatments	NNS	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
via	IN	O
a	DT	O
venous	JJ	O
cannula	NN	O
immediately	RB	O
before	IN	O
(	(	O
fasting	VBG	O
)	)	O
and	CC	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
and	CC	O
10	CD	O
h	JJ	O
post-ingestion	NN	O
.	.	O

Zeaxanthin	NNP	Ot
concentration	NN	Ot
in	IN	O
the	DT	O
triacylglycerol-rich	JJ	O
lipoprotein	JJ	O
fraction	NN	O
of	IN	O
plasma	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
HPLC	NNP	Ot
.	.	Ot

Results	NNP	O
showed	VBD	O
that	IN	O
triacylglycerol-rich	JJ	Ot
lipoprotein	NN	Ot
zeaxanthin	NN	Ot
peaked	VBD	Ot
at	IN	O
6	CD	O
h	JJ	O
post-ingestion	NN	O
for	IN	O
all	DT	O
formulations	NNS	O
.	.	O

Zeaxanthin	NNP	O
bioavailability	NN	O
from	IN	O
the	DT	O
hot	JJ	O
milk	NN	O
formulation	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
than	IN	O
from	IN	O
the	DT	O
others	NNS	O
.	.	O

Mean	JJ	Ot
area	NN	Ot
under	IN	Ot
the	DT	Ot
curve	NN	Ot
(	(	O
n	JJ	O
12	CD	O
)	)	O
results	NNS	O
were	VBD	O
9.73	CD	O
(	(	O
sem	VB	O
2.45	CD	O
)	)	O
,	,	O
3.24	CD	O
(	(	O
sem	VB	O
0.72	CD	O
)	)	O
and	CC	O
3.14	CD	O
(	(	O
sem	VB	O
1.09	CD	O
)	)	O
nmol	NN	O
x	NNP	O
h/l	NN	O
for	IN	O
the	DT	O
hot	JJ	O
milk	NN	O
,	,	O
warm	JJ	O
milk	NN	O
and	CC	O
hot	JJ	O
water	NN	O
formulations	NNS	O
,	,	O
respectively	RB	O
.	.	O

Results	NNS	O
showed	VBD	O
clearly	RB	O
that	DT	O
homogenisation	NN	O
of	IN	O
wolfberry	NN	O
in	IN	O
hot	JJ	O
skimmed	VBN	O
milk	NN	O
results	NNS	O
in	IN	O
a	DT	O
formulation	NN	O
that	WDT	O
has	VBZ	O
a	DT	O
3-fold	JJ	O
enhanced	JJ	O
bioavailability	NN	O
of	IN	O
zeaxanthin	NN	O
compared	VBN	O
with	IN	O
both	DT	O
the	DT	O
'classical	JJ	O
'	POS	O
hot	JJ	O
water	NN	O
and	CC	O
warm	NN	O
skimmed	VBD	O
milk	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
berries	NNS	O
.	.	O

Reduced	VBN	O
albuminuria	NNS	O
with	IN	O
sarpogrelate	NN	O
is	VBZ	O
accompanied	VBN	O
by	IN	O
a	DT	O
decrease	NN	O
in	IN	O
monocyte	JJ	O
chemoattractant	JJ	O
protein-1	NN	O
levels	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Sarpogrelate	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
albuminuria	NNS	O
in	IN	O
diabetic	JJ	O
nephropathy	NN	O
.	.	O

For	IN	O
examination	NN	O
of	IN	O
whether	IN	O
this	DT	O
is	VBZ	O
based	VBN	O
on	IN	O
the	DT	O
same	JJ	O
mechanisms	NN	O
as	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
or	CC	O
thiazolidinedione	NN	O
,	,	O
effects	NNS	O
of	IN	O
sarpogrelate	NN	O
on	IN	O
atherosclerotic	JJ	O
inflammatory	NN	O
molecules	NNS	O
and	CC	O
their	PRP$	O
relations	NNS	O
to	TO	O
albuminuria	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
diabetes	NNS	O
and	CC	O
had	VBD	O
already	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
and	CC	O
with	IN	O
or	CC	O
without	IN	O
thiazolidinedione	NN	O
were	VBD	O
examined	VBN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
PARTICIPANTS	NNP	O
,	,	O
&	CC	O
MEASUREMENTS	NNP	O
Forty	NNP	O
patients	NNS	O
who	WP	O
had	VBD	O
diabetes	NNS	O
with	IN	O
nephropathy	JJ	O
and	CC	O
arteriosclerosis	NN	O
obliterans	NNS	O
and	CC	O
had	VBD	O
already	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
sarpogrelate	VB	O
(	(	O
300	CD	O
mg/d	NN	O
;	:	O
n	CC	O
=	VB	O
20	CD	O
)	)	O
or	CC	O
aspirin	JJ	O
group	NN	O
(	(	O
100	CD	O
mg/d	NN	O
;	:	O
n	CC	O
=	VB	O
20	CD	O
)	)	O
.	.	O

Plasma	NNP	PH
monocyte	JJ	PH
chemoattractant	JJ	PH
protein-1	NN	PH
and	CC	PH
urinary	JJ	PH
albumin-to-creatinine	JJ	PH
ratio	NN	PH
and	CC	PH
monocyte	NN	PH
chemoattractant	JJ	PH
protein-1	NN	PH
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
16	CD	O
wk	NN	O
after	IN	O
administration	NN	O
.	.	O

RESULTS	NNP	O
Only	RB	O
the	DT	O
sarpogrelate	NN	O
group	NN	O
showed	VBD	O
increases	NNS	O
in	IN	O
plasma	NN	PH
adiponectin	NN	PH
and	CC	O
decreases	NNS	O
in	IN	O
both	DT	O
plasma	NN	PH
and	CC	PH
urinary	JJ	PH
monocyte	NN	PH
chemoattractant	JJ	PH
protein-1	JJ	PH
and	CC	PH
albumin-to-creatinine	JJ	PH
ratio	NN	PH
levels	NNS	PH
.	.	PH

Moreover	RB	O
,	,	O
percentage	NN	PH
change	NN	PH
of	IN	PH
monocyte	NN	PH
chemoattractant	JJ	PH
protein-1	JJ	PH
level	NN	PH
correlated	VBD	O
positively	RB	O
to	TO	O
that	DT	O
of	IN	O
albumin-to-creatinine	JJ	O
ratio	NN	O
.	.	O

Even	RB	O
when	WRB	O
the	DT	O
sarpogrelate	NN	O
group	NN	O
was	VBD	O
further	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
with	IN	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
or	CC	O
without	IN	O
thiazolidinedione	NN	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
,	,	O
changes	NNS	O
in	IN	O
monocyte	NN	PH
chemoattractant	JJ	PH
protein-1	JJ	PH
or	CC	PH
albumin-to-creatinine	JJ	PH
ratio	NN	PH
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

CONCLUSIONS	NNP	O
Sarpogrelate	NNP	O
can	MD	O
reduce	VB	O
albuminuria	NNS	O
and	CC	O
plasma	NN	O
and	CC	O
urinary	JJ	O
monocyte	NN	O
chemoattractant	JJ	O
protein-1	JJ	O
levels	NNS	O
while	IN	O
increasing	VBG	O
plasma	NN	O
adiponectin	NN	O
in	IN	O
diabetic	JJ	O
nephropathy	NN	O
.	.	O

These	DT	O
effects	NNS	O
seem	VBP	O
to	TO	O
be	VB	O
mediated	VBN	O
via	IN	O
mechanisms	NNS	O
that	WDT	O
are	VBP	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
angiotensin	JJ	O
II	NNP	O
receptor	NN	O
blocker	NN	O
or	CC	O
thiazolidinedione	NN	O
.	.	O

B-type	JJ	O
natriuretic	JJ	O
peptide	NN	O
for	IN	O
acute	JJ	O
dyspnea	NN	O
in	IN	O
patients	NNS	O
with	IN	O
kidney	JJ	O
disease	NN	O
:	:	O
insights	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
comparison	NN	O
.	.	O

BACKGROUND	NNP	O
B-type	NNP	PH
natriuretic	JJ	PH
peptide	NN	PH
(	(	PH
BNP	NNP	PH
)	)	PH
levels	NNS	PH
are	VBP	O
reliably	RB	O
elevated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
and	CC	O
therefore	RB	O
helpful	JJ	O
in	IN	O
its	PRP$	O
diagnosis	NN	O
.	.	O

However	RB	O
,	,	O
kidney	FW	O
disease	NN	O
results	NNS	O
in	IN	O
elevated	JJ	O
BNP	NNP	O
levels	NNS	O
independently	RB	O
of	IN	O
CHF	NNP	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
impact	NN	O
of	IN	O
kidney	NN	O
disease	NN	O
on	IN	O
the	DT	O
benefit	NN	O
of	IN	O
BNP	NNP	O
testing	VBG	O
needs	NNS	O
to	TO	O
be	VB	O
scrutinized	VBN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
kidney	NN	O
disease	NN	O
[	NNP	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
GFR	NNP	O
)	)	O
less	JJR	O
than	IN	O
60	CD	O
mL/min/1.73	JJ	O
m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
presenting	VBG	O
with	IN	O
acute	JJ	O
dyspnea	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
452	CD	O
consecutive	JJ	O
patients	NNS	O
(	(	O
240	CD	O
with	IN	O
kidney	NN	O
disease	NN	O
and	CC	O
212	CD	O
without	IN	O
kidney	NN	O
disease	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
diagnostic	JJ	O
strategy	NN	O
with	IN	O
(	(	O
BNP	NNP	O
group	NN	O
)	)	O
or	CC	O
without	IN	O
(	(	O
control	NN	O
group	NN	O
)	)	O
the	DT	O
use	NN	O
of	IN	O
BNP	NNP	O
levels	NNS	O
provided	VBN	O
by	IN	O
a	DT	O
rapid	JJ	O
bedside	NN	O
assay	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
with	IN	O
kidney	JJ	O
disease	NN	O
were	VBD	O
older	JJR	O
,	,	O
more	RBR	O
often	RB	O
had	VBD	O
CHF	NNP	PH
as	IN	PH
the	DT	PH
cause	NN	PH
of	IN	PH
acute	JJ	PH
dyspnea	NN	PH
,	,	O
and	CC	O
more	RBR	O
often	RB	O
died	JJ	O
in-hospital	JJ	O
or	CC	O
within	IN	O
30	CD	O
days	NNS	O
as	RB	O
compared	VBN	O
to	TO	O
patients	NNS	O
without	IN	O
kidney	NN	O
disease	NN	O
.	.	O

In	IN	O
patients	NNS	O
without	IN	O
kidney	NN	O
disease	NN	O
,	,	O
BNP	NNP	O
testing	VBG	O
significantly	RB	O
reduced	VBN	O
median	JJ	PH
time	NN	PH
to	TO	PH
discharge	VB	PH
(	(	O
from	IN	O
9.5	CD	O
days	NNS	O
to	TO	O
2.5	CD	O
days	NNS	O
)	)	O
(	(	O
P=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
total	JJ	Ot
cost	NN	Ot
of	IN	Ot
treatment	NN	Ot
(	(	O
from	IN	O
7184	CD	O
dollars	NNS	O
to	TO	O
4151	CD	O
dollars	NNS	O
)	)	O
(	(	O
P=	NNP	O
0.004	CD	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
kidney	NN	O
disease	NN	O
,	,	O
time	NN	O
to	TO	O
discharge	VB	O
and	CC	O
total	JJ	O
cost	NN	O
of	IN	O
treatment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
When	WRB	O
applying	VBG	O
BNP	NNP	O
cut-off	NN	O
values	NNS	O
without	IN	O
adjustment	NN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
kidney	NN	O
disease	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
BNP	NNP	PH
levels	NNS	PH
does	VBZ	O
significantly	RB	O
improve	VB	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
without	IN	O
kidney	NN	O
disease	NN	O
,	,	O
but	CC	O
not	RB	O
of	IN	O
those	DT	O
with	IN	O
kidney	JJ	O
disease	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
endocrine	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
in	IN	O
locally	RB	O
advanced	JJ	O
prostatic	JJ	O
cancer	NN	O
.	.	O

151	CD	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostatic	JJ	O
cancer	NN	O
(	(	O
T3-4	NNP	O
M0	NNP	O
)	)	O
,	,	O
representing	VBG	O
38	CD	O
%	NN	O
of	IN	O
the	DT	O
404	CD	O
cancer	NN	O
patients	NNS	O
in	IN	O
a	DT	O
Finnish	JJ	O
multicenter	NN	O
study	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
orchiectomy	NN	O
,	,	O
estrogens	VBZ	O
or	CC	O
radiotherapy	NN	O
.	.	O

During	IN	O
the	DT	O
4-year	JJ	O
follow-up	JJ	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
progression	NN	Ot
rates	NNS	Ot
(	(	PH
appearance	NN	PH
of	IN	PH
metastases	NNS	PH
in	IN	PH
bone	NN	PH
scan	NN	PH
)	)	PH
between	IN	O
the	DT	O
therapy	NN	O
groups	NNS	O
.	.	O

The	DT	O
frequency	NN	PH
of	IN	PH
thromboembolic	JJ	PH
and	CC	PH
other	JJ	PH
cardiovascular	JJ	PH
complications	NNS	PH
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
estrogen	NN	O
group	NN	O
(	(	O
13/50	CD	O
patients	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
radiotherapy	NN	O
group	NN	O
,	,	O
19	CD	O
of	IN	O
45	CD	O
patients	NNS	O
had	VBD	O
bowel	NN	PH
or	CC	PH
bladder	NN	PH
complications	NNS	PH
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
orchiectomy	NN	O
has	VBZ	O
few	JJ	O
,	,	O
if	IN	O
any	DT	O
,	,	O
complications	NNS	O
.	.	O

The	DT	O
high	JJ	O
risk	NN	O
of	IN	O
complications	NNS	O
associated	VBN	O
with	IN	O
estrogens	NNS	O
and	CC	O
radiotherapy	NN	O
has	VBZ	O
to	TO	O
be	VB	O
taken	VBN	O
into	IN	O
consideration	NN	O
in	IN	O
the	DT	O
selection	NN	O
of	IN	O
treatment	NN	O
.	.	O

Activator	NNP	O
protein-1	NN	O
(	(	O
AP-1	NNP	O
)	)	O
signalling	VBG	O
in	IN	O
human	JJ	O
atherosclerosis	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
systematic	JJ	O
evaluation	NN	O
and	CC	O
intervention	NN	O
study	NN	O
.	.	O

Animal	NNP	O
studies	NNS	O
implicate	VBP	O
the	DT	O
AP-1	NNP	O
(	(	O
activator	IN	O
protein-1	NN	O
)	)	O
pro-inflammatory	NN	O
pathway	NN	O
as	IN	O
a	DT	O
promising	NN	O
target	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
atherosclerotic	JJ	O
disease	NN	O
.	.	O

It	PRP	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
unclear	JJ	O
whether	IN	O
these	DT	O
observations	NNS	O
apply	VBP	O
to	TO	O
human	JJ	O
atherosclerosis	NN	O
.	.	O

Therefore	IN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
profile	NN	O
of	IN	O
AP-1	NNP	O
activation	NN	O
through	IN	O
histological	JJ	O
analysis	NN	O
and	CC	O
tested	VBD	O
the	DT	O
potential	JJ	O
benefit	NN	O
of	IN	O
AP-1	NNP	O
inhibition	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

AP-1	JJ	O
activation	NN	O
was	VBD	O
quantified	VBN	O
by	IN	O
phospho-c-Jun	JJ	O
nuclear	JJ	O
translocation	NN	O
(	(	O
immunohistochemistry	NN	O
)	)	O
on	IN	O
a	DT	O
biobank	NN	O
of	IN	O
aortic	JJ	O
wall	NN	O
samples	NNS	O
from	IN	O
organ	JJ	O
donors	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
AP-1	NNP	PH
inhibition	NN	PH
on	IN	O
vascular	JJ	O
parameters	NNS	O
was	VBD	O
tested	VBN	O
through	IN	O
a	DT	O
double	JJ	O
blind	JJ	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
of	IN	O
28	CD	O
days	NNS	O
doxycycline	NN	O
or	CC	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Vascular	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
brachial	JJ	O
dilation	NN	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
plasma	NN	O
samples	NNS	O
analysed	VBN	O
for	IN	O
hs-CRP	NN	O
(	(	O
high-sensitivity	JJ	O
C-reactive	NNP	O
protein	NN	O
)	)	O
,	,	O
IL-6	NNP	O
(	(	O
interleukin-6	NN	O
)	)	O
,	,	O
IL-8	NNP	O
,	,	O
ICAM-1	NNP	O
(	(	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
)	)	O
,	,	O
vWF	FW	O
(	(	O
von	FW	O
Willebrand	NNP	O
factor	NN	O
)	)	O
,	,	O
MCP-1	NNP	O
(	(	O
monocyte	JJ	O
chemoattractant	NN	O
protein-1	NN	O
)	)	O
,	,	O
PAI-1	NNP	O
(	(	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
)	)	O
and	CC	O
fibrinogen	NN	O
.	.	O

Histological	JJ	O
evaluation	NN	O
of	IN	O
human	JJ	O
atherosclerosis	NN	O
showed	VBD	O
minimal	JJ	O
AP-1	NNP	O
activation	NN	O
in	IN	O
non-diseased	JJ	O
arterial	JJ	O
wall	NN	O
(	(	O
i.e	JJ	O
.	.	O

vessel	NN	O
wall	NN	O
without	IN	O
any	DT	O
signs	NNS	O
of	IN	O
atherosclerotic	JJ	O
disease	NN	O
)	)	O
.	.	O

A	DT	O
gradual	JJ	O
increase	NN	O
of	IN	O
AP-1	NNP	O
activation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
non-progressive	JJ	O
and	CC	O
progressive	JJ	O
phases	NNS	O
of	IN	O
atherosclerosis	NN	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.044	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
progressive	JJ	O
and	CC	O
vulnerable	JJ	O
lesions	NNS	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
phospho-c-Jun	JJ	O
diminished	VBN	O
as	IN	O
the	DT	O
lesion	NN	O
stabilized	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.016	CD	O
)	)	O
and	CC	O
does	VBZ	O
not	RB	O
significantly	RB	O
differ	VBP	O
from	IN	O
the	DT	O
normal	JJ	O
aortic	JJ	O
wall	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.33	CD	O
)	)	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
doxycycline	NN	O
intervention	NN	O
only	RB	O
revealed	VBD	O
a	DT	O
borderline-significant	JJ	O
reduction	NN	O
of	IN	O
circulating	VBG	O
hs-CRP	JJ	O
levels	NNS	O
(	(	O
-0.51	NNP	O
?g/ml	NNP	O
,	,	O
P=0.05	NNP	O
)	)	O
and	CC	O
did	VBD	O
not	RB	O
affect	VB	O
any	DT	O
of	IN	O
the	DT	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
inflammation	NN	O
and	CC	O
vascular	JJ	O
function	NN	O
.	.	O

Our	PRP$	O
studies	NNS	O
do	VBP	O
not	RB	O
characterize	VB	O
AP-1	NNP	O
as	IN	O
a	DT	O
therapeutic	JJ	O
target	NN	O
for	IN	O
progressive	JJ	O
human	JJ	O
atherosclerotic	JJ	O
disease	NN	O
.	.	O

The	DT	O
additive	JJ	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	O
,	,	O
60	CD	O
mg	NN	O
,	,	O
in	IN	O
dental	JJ	O
pain	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
single-dose	JJ	O
trial	NN	O
the	DT	O
analgesic	JJ	O
contribution	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	O
,	,	O
60	CD	O
mg	NN	O
,	,	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
2	CD	O
X	NN	O
2	CD	O
factorial	JJ	O
experiment	NN	O
in	IN	O
which	WDT	O
120	CD	O
patients	NNS	O
suffering	VBG	O
from	IN	O
pain	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
oral	JJ	O
surgery	NN	O
rated	VBD	O
their	PRP$	O
pain	NN	PA
intensity	NN	PA
and	CC	O
pain	NN	PA
relief	NN	PA
for	IN	O
up	IN	O
to	TO	O
5	CD	O
hours	NNS	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
one	CD	O
of	IN	O
:	:	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
,	,	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
plus	CC	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
factorial	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
both	DT	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
and	CC	O
60	CD	O
mg	NN	O
codeine	NN	O
made	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
contribution	NN	O
to	TO	O
the	DT	O
analgesic	JJ	Ot
effectiveness	NN	Ot
of	IN	PA
the	DT	PA
combination	NN	PA
on	IN	PA
all	DT	PA
measures	NNS	PA
of	IN	PA
efficacy	NN	PA
(	(	O
sum	NN	PA
of	IN	PA
pain	NN	PA
intensity	NN	PA
differences	NNS	PA
,	,	O
largest	JJS	PA
pain	NN	PA
intensity	NN	PA
difference	NN	PA
,	,	O
total	JJ	PA
pain	NN	PA
relief	NN	PA
,	,	O
largest	JJS	PA
pain	NN	PA
relief	NN	PA
,	,	O
and	CC	O
time	NN	PA
to	TO	PA
remedication	NN	PA
)	)	O
.	.	O

The	DT	O
incidence	NN	A
of	IN	A
adverse	JJ	A
effects	NNS	A
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
differ	VB	O
among	IN	O
the	DT	O
treatments	NNS	O
,	,	O
including	VBG	O
placebo	NN	O
.	.	O

MSLT	NNP	O
in	IN	O
primary	JJ	O
insomnia	NN	ME
:	:	ME
stability	NN	O
and	CC	O
relation	NN	O
to	TO	O
nocturnal	JJ	PH
sleep	NN	PH
.	.	ME

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
assess	VB	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
multiple	JJ	O
sleep	JJ	O
latency	NN	O
test	NN	O
(	(	O
MSLT	NNP	O
)	)	O
in	IN	O
primary	JJ	PH
insomnia	NN	PH
and	CC	O
its	PRP$	O
relation	NN	O
to	TO	O
total	JJ	PH
sleep	JJ	PH
time	NN	PH
.	.	ME

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	NN	O
with	IN	O
sleep	JJ	O
laboratory	NN	O
assessments	NNS	O
in	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
of	IN	O
treatment	NN	O
.	.	O

PARTICIPANTS	VB	O
Ninety-five	JJ	O
primary	JJ	O
insomniacs	NN	O
,	,	O
32-64	CD	O
years	NNS	O
old	JJ	O
and	CC	O
55	CD	O
age-	JJ	O
and	CC	O
sex-matched	JJ	O
general	JJ	O
population-based	JJ	O
,	,	O
representative	JJ	O
controls	NNS	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
a	DT	O
screening	JJ	O
nocturnal	JJ	O
polysomnograms	NNS	O
(	(	O
NPSG	NNP	O
)	)	O
and	CC	O
MSLT	NNP	O
the	DT	O
following	JJ	O
day	NN	O
,	,	O
participants	NNS	O
with	IN	O
primary	JJ	O
insomnia	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
take	VB	O
zolpidem	NN	O
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
nightly	RB	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

During	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
,	,	O
while	IN	O
taking	VBG	O
their	PRP$	O
prescribed	JJ	O
treatments	NNS	O
,	,	O
NPSGs	NNP	O
and	CC	O
MSLTs	NNP	O
the	DT	O
following	JJ	O
day	NN	O
were	VBD	O
conducted	VBN	O
.	.	O

A	DT	O
population-based	JJ	O
sample	NN	O
served	VBD	O
as	IN	O
controls	NNS	O
and	CC	O
received	VBD	O
a	DT	O
single	JJ	O
NPSG	NNP	O
followed	VBN	O
by	IN	O
MSLT	NNP	O
.	.	O

RESULTS	NNP	O
Mean	NNP	PH
daily	JJ	PH
sleep	NN	PH
latency	NN	PH
on	IN	PH
the	DT	PH
screening	VBG	PH
MSLT	NNP	PH
of	IN	PH
insomniacs	NN	PH
was	VBD	O
normally	RB	O
distributed	VBN	O
across	IN	O
the	DT	O
full	JJ	O
range	NN	O
of	IN	O
MSLT	NNP	O
scores	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
a	DT	O
population-based	JJ	O
representative	NN	O
control	NN	O
sample	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.006	CD	O
)	)	O
.	.	O

The	DT	O
insomniacs	NN	O
with	IN	O
the	DT	O
highest	JJS	O
screening	NN	PH
MSLTs	NNP	PH
had	VBD	O
the	DT	O
shortest	JJS	O
screening	NN	PH
total	JJ	PH
sleep	JJ	PH
times	NNS	PH
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
MSLTs	NNP	O
of	IN	O
insomniacs	NN	O
during	IN	O
treatment	NN	O
in	IN	O
study	JJ	O
month	NN	O
1	CD	O
were	VBD	O
correlated	VBN	O
(	(	O
r	VB	O
=	RB	O
0.44	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
their	PRP$	O
month	NN	O
8	CD	O
MSLT	NNP	O
.	.	O

The	DT	O
mean	JJ	PH
MSLT	NNP	PH
score	NN	PH
of	IN	O
the	DT	O
zolpidem	NNP	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
stability	NN	O
within	IN	O
treatment	NN	O
groups	NNS	O
also	RB	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	IN	O
some	DT	O
insomniacs	NN	O
show	VBP	O
a	DT	O
reliable	JJ	O
disorder	NN	O
of	IN	O
hyperarousal	NN	PH
with	IN	O
increased	JJ	O
wake	NN	PH
drive	NN	PH
both	DT	O
at	IN	O
night	NN	O
and	CC	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

Can	MD	O
simvastatin	VB	O
improve	VB	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
?	.	O
Results	NNS	O
of	IN	O
the	DT	O
Erectile	NNP	O
Dysfunction	NNP	O
and	CC	O
Statins	NNP	O
Trial	NNP	O
[	NNP	O
ISRCTN66772971	NNP	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
simvastatin	NN	O
on	IN	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
ED	NNP	O
is	VBZ	O
common	JJ	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
and	CC	O
impacts	NNS	O
upon	VBP	O
their	PRP$	O
overall	JJ	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
that	IN	O
of	IN	O
their	PRP$	O
partners	NNS	O
.	.	O

Men	NNP	O
aged	VBD	O
?40	CD	O
years	NNS	O
who	WP	O
were	VBD	O
not	RB	O
receiving	VBG	O
lipid	JJ	O
lowering	NN	O
or	CC	O
anti-hypertensive	JJ	O
medication	NN	O
and	CC	O
not	RB	O
at	IN	O
high	JJ	O
cardiovascular	JJ	O
risk	NN	O
were	VBD	O
recruited	VBN	O
from	IN	O
10	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
the	DT	O
East	NNP	O
of	IN	O
England	NNP	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
173	CD	O
eligible	JJ	O
men	NNS	O
with	IN	O
untreated	JJ	O
ED	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
three	CD	O
points	NNS	O
over	IN	O
30	CD	O
weeks	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
erectile	JJ	PH
function	NN	PH
(	(	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function-5	NNP	O
score	NN	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
male	JJ	PH
ED-specific	JJ	PH
quality	NN	PH
of	IN	PH
life	NN	PH
(	(	PH
MED-QoL	NNP	PH
)	)	PH
,	,	O
quality-adjusted	JJ	O
life	NN	O
years	NNS	O
(	(	O
QALYs	NNP	O
)	)	O
using	VBG	O
the	DT	O
generic	JJ	O
Euroqol	NNP	O
measure	NN	O
(	(	O
EQ-5D	NNP	O
)	)	O
,	,	O
endothelial	JJ	PH
function	NN	PH
,	,	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
cholesterol	NN	PH
and	CC	O
health	NN	O
service	NN	O
costs	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
erectile	JJ	PH
function	NN	PH
between	IN	O
the	DT	O
simvastatin	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
(	(	O
mean	JJ	O
change	NN	O
,	,	O
1.28	CD	O
vs	NN	O
0.07	CD	O
,	,	O
z	NN	O
=	VBD	O
1.1	CD	O
,	,	O
p	NN	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
although	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
MED-QoL	NNP	PH
was	VBD	O
observed	VBN	O
(	(	O
5	CD	O
%	NN	O
vs	JJ	O
2	CD	O
%	NN	O
,	,	O
z	NN	O
=	VBD	O
2.09	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Both	DT	O
10-year	JJ	O
cardiovascular	NN	O
risk	NN	O
and	CC	O
low-density	NN	O
lipoprotein	NN	O
were	VBD	O
reduced	VBN	O
(	(	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
z	NN	O
=	NNP	O
-3.67	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
;	:	O
low-density	JJ	O
lipoprotein	NN	O
,	,	O
z	NN	O
=	NNP	O
-5.46	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
consistent	JJ	O
change	NN	O
in	IN	O
endothelial	JJ	O
function	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
sexual	JJ	O
encounters	NNS	O
is	VBZ	O
correlated	VBN	O
with	IN	O
improved	JJ	O
erectile	JJ	O
function	NN	O
.	.	O

The	DT	O
joint	JJ	O
distribution	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
probability	NN	O
of	IN	O
simvastatin	NN	O
being	VBG	O
cost-effective	JJ	O
for	IN	O
willingness-to-pay	JJ	O
thresholds	NNS	O
of	IN	O
?20,000	NN	O
and	CC	O
?30,000	NN	O
is	VBZ	O
86	CD	O
%	NN	O
and	CC	O
83	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Identifying	VBG	O
men	NNS	O
with	IN	O
ED	NNP	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
modify	VB	O
future	JJ	O
cardiovascular	JJ	O
risk	NN	O
and	CC	O
to	TO	O
improve	VB	O
MED-QoL	NNP	O
by	IN	O
treating	VBG	O
them	PRP	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
.	.	O

The	DT	O
joint	JJ	O
analysis	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
suggests	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
high	JJ	O
probability	NN	O
that	IN	O
simvastatin	NN	O
is	VBZ	O
a	DT	O
cost-effective	JJ	O
strategy	NN	O
in	IN	O
men	NNS	O
with	IN	O
ED	NNP	O
.	.	O

The	DT	O
findings	NNS	O
could	MD	O
influence	VB	O
urological	JJ	O
and	CC	O
primary	JJ	O
care	NN	O
practice	NN	O
by	IN	O
including	VBG	O
questions	NNS	O
on	IN	O
ED	NNP	O
during	IN	O
routine	JJ	O
consultations	NNS	O
and	CC	O
relevant	JJ	O
clinical	JJ	O
protocols	NNS	O
.	.	O

This	DT	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
impart	VB	O
lifestyle	JJ	O
advice	NN	O
.	.	O

[	RB	O
Accelerated	NNP	O
postoperative	JJ	O
radiotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
larynx	NN	O
cancer	NN	O
]	NNP	O
.	.	O

AIM	NNP	O
The	DT	O
aim	NN	O
of	IN	O
study	NN	O
was	VBD	O
test	JJ	O
efficacy	NN	Ot
of	IN	O
accelerated	JJ	O
postoperative	JJ	O
radiotherapy	NN	O
--	:	O
concomitant	JJ	O
boost	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
larynx	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
The	DT	O
prospective	JJ	O
study	NN	O
included	VBD	O
112	CD	O
patients	NNS	O
with	IN	O
advanced	JJ	O
larynx	NN	O
cancer	NN	O
after	IN	O
radical	JJ	O
surgical	JJ	O
treatment	NN	O
.	.	O

Patients	NNS	O
had	VBD	O
postoperative	JJ	O
radiation	NN	O
therapy	NN	O
,	,	O
conventional	JJ	O
(	(	O
C	NNP	O
)	)	O
or	CC	O
accelerated	VBN	O
(	(	O
CB	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
3-year	JJ	MO
overall	JJ	MO
survival	NN	MO
in	IN	O
CB	NNP	O
was	VBD	O
59	CD	O
%	NN	O
,	,	O
in	IN	O
C	NNP	O
--	:	O
58	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.2	CD	O
)	)	O
,	,	O
3-year	JJ	PH
locoregional	JJ	PH
control	NN	PH
in	IN	O
CB	NNP	O
--	:	O
83	CD	O
%	NN	O
,	,	O
in	IN	O
C	NNP	O
--	:	O
75	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
3-year	JJ	MO
disease	NN	MO
free	JJ	MO
survival	NN	MO
was	VBD	O
in	IN	O
CB	NNP	O
--	:	O
72	CD	O
%	NN	O
,	,	O
C	NNP	O
--	:	O
66	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.1	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Concomitant	NNP	O
boost	VBD	O
postoperative	JJ	O
radiation	NN	O
therapy	NN	O
did	VBD	O
not	RB	O
improve	VB	O
overall	JJ	MO
survival	NN	MO
,	,	O
loco-regional	JJ	Ot
control	NN	Ot
,	,	O
disease	NN	MO
free	JJ	MO
survival	NN	MO
.	.	O

Patients	NNS	O
with	IN	O
close	JJ	O
surgical	JJ	O
margins	NNS	O
,	,	O
longer	JJR	O
interval	NN	O
between	IN	O
surgery	NN	O
and	CC	O
radiation	NN	O
,	,	O
high	JJ	O
level	NN	O
of	IN	O
hemoglobin	NN	O
,	,	O
T4	NNP	O
had	VBD	O
benefit	VBN	O
from	IN	O
accelerated	VBN	O
radiotherapy	NN	O
.	.	O

Rehabilitation	NN	O
of	IN	O
therapy-related	JJ	O
cognitive	JJ	O
deficits	NNS	O
in	IN	O
patients	NNS	O
after	IN	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
.	.	O

Neuropsychological	JJ	O
deficits	NNS	O
are	VBP	O
potential	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
therapy	NN	O
(	(	O
HSCT	NNP	O
)	)	O
.	.	O

Systematic	JJ	O
data	NNS	O
on	IN	O
the	DT	O
long-term	JJ	O
course	NN	O
of	IN	O
and	CC	O
therapeutic	JJ	O
options	NNS	O
for	IN	O
these	DT	O
consequences	NNS	O
are	VBP	O
limited	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
fifty-seven	JJ	O
patients	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
cognitive	JJ	O
deficits	NNS	O
following	VBG	O
HSCT	NNP	O
for	IN	O
malignant	JJ	O
diseases	NNS	O
at	IN	O
an	DT	O
in-patient	JJ	O
oncologic	NN	O
rehabilitation	NN	O
clinic	NN	O
.	.	O

Patients	NNS	O
showing	VBG	O
evidence	NN	O
of	IN	O
impairment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
training	VBG	O
groups	NNS	O
:	:	O
individualized	VBN	O
PC-supported	JJ	O
training	NN	O
or	CC	O
neuropsychological	JJ	O
group	NN	O
therapy	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
no	DT	O
specific	JJ	O
training	NN	O
.	.	O

During	IN	O
in-patient	JJ	O
rehabilitation	NN	O
,	,	O
the	DT	O
results	NNS	ME
of	IN	ME
a	DT	ME
comprehensive	JJ	ME
neuropsychological	JJ	ME
test	NN	ME
battery	NN	ME
improved	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
,	,	O
and	CC	O
no	DT	O
specific	JJ	O
intervention	NN	O
effects	NNS	O
were	VBD	O
identified	VBN	O
.	.	O

Neuropsychological	JJ	ME
deficits	NNS	ME
were	VBD	O
still	RB	O
evident	JJ	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Correlation	NN	ME
between	IN	ME
neuropsychological	JJ	ME
testing	NN	ME
and	CC	ME
patients	NNS	ME
'	POS	ME
self-evaluation	NN	ME
of	IN	ME
cognitive	JJ	ME
functioning	NN	ME
in	IN	ME
daily	JJ	ME
life	NN	ME
was	VBD	O
generally	RB	O
low	JJ	O
.	.	O

Sustained	VBN	ME
attention	NN	ME
and	CC	O
verbal-semantic	JJ	ME
memory	NN	ME
played	VBD	O
the	DT	O
main	JJ	O
role	NN	O
for	IN	O
self-appraisal	JJ	O
and	CC	O
in	IN	O
the	DT	O
designation	NN	O
as	IN	O
'neuropsychologically	RB	O
impaired	VBN	O
'	''	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
a	DT	O
substantial	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
revealed	JJ	O
evidence	NN	O
of	IN	O
cognitive	JJ	O
deficits	NNS	O
a	DT	O
long	JJ	O
time	NN	O
after	IN	O
HSCT	NNP	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
need	NN	O
for	IN	O
more	JJR	O
studies	NNS	O
and	CC	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
differentiated	JJ	O
rehabilitative	JJ	O
measures	NNS	O
for	IN	O
such	JJ	O
therapeutic	JJ	O
consequences	NNS	O
.	.	O

Effect	NN	O
of	IN	O
two	CD	O
monophasic	JJ	O
oral	JJ	O
contraceptives	NNS	O
containing	VBG	O
gestodene	NN	O
or	CC	O
desogestrel	NN	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Forty-nine	NNP	O
healthy	JJ	O
women	NNS	O
aged	VBN	O
20-35	JJ	O
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
pregnant	JJ	O
or	CC	O
using	VBG	O
an	DT	O
oral	JJ	O
contraceptive	NN	O
(	(	O
OC	NNP	O
)	)	O
for	IN	O
the	DT	O
previous	JJ	O
3	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
group	NN	O
taking	VBG	O
an	DT	O
OC	NNP	O
containing	VBG	O
75	CD	O
micrograms	NNS	O
gestodene	NN	O
(	(	O
GTD	NNP	O
)	)	O
and	CC	O
30	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
(	(	O
EE	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
using	VBG	O
an	DT	O
OC	NNP	O
with	IN	O
150	CD	O
micrograms	NNS	O
desogestrel	NN	O
(	(	O
DSG	NNP	O
)	)	O
and	CC	O
30	CD	O
micrograms	NNS	O
EE	NNP	O
.	.	O

Fasting	VBG	PH
blood	NN	PH
samples	NNS	PH
were	VBD	O
taken	VBN	O
before	RB	O
treatment	NN	O
,	,	O
and	CC	O
after	IN	O
cycles	NNS	O
3	CD	O
and	CC	O
6	CD	O
,	,	O
between	IN	O
the	DT	O
18th	CD	O
and	CC	O
the	DT	O
22nd	CD	O
day	NN	O
of	IN	O
the	DT	O
cycle	NN	O
.	.	O

Blood	NNP	PH
lipoprotein	JJ	PH
lipid	JJ	PH
levels	NNS	PH
were	VBD	O
measured	VBN	O
.	.	O

Serum	NNP	PH
total	JJ	PH
cholesterol	NN	PH
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
first	JJ	O
three	CD	O
cycles	NNS	O
,	,	O
serum	JJ	PH
triglyceride	NN	PH
increased	VBN	PH
by	IN	O
46	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
and	CC	O
HDL-cholesterol	NNP	PH
by	IN	O
14	CD	O
%	NN	O
and	CC	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
GTD	NNP	PH
and	CC	PH
DSG	NNP	PH
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
serum	NN	PH
LDL	NNP	PH
level	NN	PH
decreased	VBN	O
by	IN	O
6.2	CD	O
%	NN	O
and	CC	O
11.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Between	VB	O
the	DT	O
third	JJ	O
and	CC	O
sixth	JJ	O
cycle	NN	O
,	,	O
no	DT	O
further	JJ	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
nor	CC	O
did	VBD	O
these	DT	O
changes	NNS	O
differ	VBP	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
both	DT	O
OC	NNP	O
preparations	NNS	O
exerted	VBD	O
small	JJ	O
and	CC	O
probably	RB	O
favorable	JJ	O
effects	NNS	O
on	IN	O
serum	NN	PH
lipoprotein	NN	PH
lipid	JJ	PH
levels	NNS	PH
.	.	O

Clozapine	NNP	O
versus	NN	O
placebo	NN	O
in	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
comparative	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
clozapine	NN	O
on	IN	O
chorea	NN	O
,	,	O
voluntary	JJ	O
motor	NN	O
performance	NN	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
three	CD	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
participated	VBD	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
trial	NN	O
.	.	O

A	DT	O
maximum	NN	O
of	IN	O
150	CD	O
mg/day	JJ	O
clozapine	NN	O
or	CC	O
placebo	NN	O
equivalent	NN	O
was	VBD	O
given	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
31	CD	O
days	NNS	O
.	.	O

Assessments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
week	NN	O
before	IN	O
and	CC	O
at	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Chorea	NNP	O
was	VBD	O
scored	VBN	O
using	VBG	O
the	DT	O
abnormal	JJ	O
involuntary	JJ	O
movement	NN	O
scale	NN	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
the	DT	O
chorea	NN	O
score	NN	O
of	IN	O
the	DT	O
unified	JJ	O
Huntington	NNP	O
's	POS	O
disease	NN	O
rating	NN	O
scale	NN	O
(	(	O
UHDRS	NNP	O
)	)	O
,	,	O
and	CC	O
judgement	NN	O
of	IN	O
video	JJ	O
recordings	NNS	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
UHDRS	NNP	O
motor	NN	O
scale	NN	O
.	.	O

Patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
completed	VBD	O
a	DT	O
questionnaire	NN	O
regarding	VBG	O
functional	JJ	O
disability	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
already	RB	O
used	VBD	O
other	JJ	O
neuroleptic	JJ	O
medication	NN	O
,	,	O
which	WDT	O
was	VBD	O
kept	FW	O
unchanged	JJ	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
.	.	O

Results	NNS	O
of	IN	O
neuroleptic	JJ	O
naive	JJ	O
and	CC	O
neuroleptic	JJ	O
treated	JJ	O
patients	NNS	O
were	VBD	O
analysed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
Clozapine	NNP	O
tended	VBD	O
to	TO	O
reduce	VB	O
chorea	NN	PH
in	IN	O
neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
only	RB	O
(	(	O
AIMS	NNP	O
)	)	O
;	:	O
improvement	NN	O
seemed	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
higher	JJR	O
doses	NNS	O
of	IN	O
clozapine	NN	O
.	.	O

Other	JJ	O
measures	NNS	PH
of	IN	PH
chorea	NN	PH
(	(	PH
UHDRS	NNP	PH
chorea	NN	PH
score	NN	PH
,	,	PH
video	JJ	PH
ratings	NNS	PH
)	)	PH
showed	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Clozapine	NNP	O
had	VBD	O
no	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
chorea	NN	PH
in	IN	O
patients	NNS	O
already	RB	O
receiving	VBG	O
neuroleptic	JJ	O
medication	NN	O
.	.	O

Voluntary	JJ	PH
motor	NN	PH
performance	NN	PH
did	VBD	O
not	RB	O
improve	VB	O
with	IN	O
clozapine	NN	O
.	.	O

Neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
reported	VBN	O
aggravation	NN	O
of	IN	O
functional	JJ	PH
disability	NN	PH
,	,	O
possibly	RB	O
reflecting	VBG	O
the	DT	O
frequent	JJ	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Adverse	JJ	O
reactions	NNS	O
forced	VBD	O
trial	NN	O
termination	NN	O
in	IN	O
six	CD	O
patients	NNS	O
and	CC	O
dose	JJ	O
reduction	NN	O
in	IN	O
another	DT	O
eight	CD	O
,	,	O
and	CC	O
consisted	VBD	O
mainly	RB	O
of	IN	O
drowsiness	NN	A
,	,	A
fatigue	NN	A
,	,	A
anticholinergic	NN	A
symptoms	NNS	A
,	,	A
and	CC	A
walking	VBG	A
difficulties	NNS	A
.	.	O

CONCLUSIONS	NNP	O
Clozapine	NNP	O
has	VBZ	O
little	JJ	O
beneficial	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
,	,	O
although	IN	O
individual	JJ	O
patients	NNS	O
may	MD	O
tolerate	VB	O
doses	NNS	O
high	JJ	O
enough	RB	O
to	TO	O
reduce	VB	O
chorea	NN	O
.	.	O

Because	IN	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
often	RB	O
encountered	VBN	O
,	,	O
clozapine	NN	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
restraint	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
laboratory	NN	O
stress	NN	O
testing	VBG	O
blood	NN	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

It	PRP	O
is	VBZ	O
the	DT	O
current	JJ	O
opinion	NN	O
that	IN	O
an	DT	O
ideal	JJ	O
antihypertensive	JJ	O
drug	NN	O
should	MD	O
reduce	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
not	RB	O
only	RB	O
at	IN	O
rest	NN	O
but	CC	O
also	RB	O
during	IN	O
stressful	JJ	O
situations	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
selective	JJ	O
alpha	NN	O
1-adrenergic	JJ	O
blocker	NN	O
terazosin	NN	O
(	(	O
5	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
)	)	O
and	CC	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
enalapril	NN	O
(	(	O
20	CD	O
mg	NN	O
once	RB	O
daily	RB	O
)	)	O
on	IN	O
cardiovascular	JJ	O
response	NN	O
to	TO	O
a	DT	O
set	NN	O
of	IN	O
standardized	JJ	O
laboratory	NN	O
stressors	NNS	O
,	,	O
such	JJ	O
as	IN	O
mental	JJ	O
arithmetic	JJ	O
,	,	O
handgrip	JJ	O
test	NN	O
and	CC	O
cycle	NN	O
ergometry	NN	O
,	,	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
16	CD	O
essential	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
preceded	VBN	O
by	IN	O
a	DT	O
placebo	JJ	O
run-in	JJ	O
period	NN	O
.	.	O

Terazosin	NNP	O
and	CC	O
enalapril	VB	O
had	VBD	O
a	DT	O
comparable	JJ	O
effect	NN	O
on	IN	O
resting	VBG	PH
BP	NNP	PH
,	,	PH
reducing	VBG	PH
systolic	JJ	PH
(	(	PH
SBP	NNP	PH
)	)	PH
and	CC	PH
diastolic	JJ	PH
(	(	PH
DBP	NNP	PH
)	)	PH
blood	NN	PH
pressure	NN	PH
from	IN	O
159.5	CD	O
+/-	JJ	O
13.9/101.6	CD	O
+/-	JJ	O
8.8	CD	O
mm	NN	O
Hg	NNP	O
during	IN	O
placebo	NN	O
by	IN	O
7.8	CD	O
%	NN	O
/6.7	CC	O
%	NN	O
and	CC	O
by	IN	O
11.3	CD	O
%	NN	O
/10.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
response	NN	Ot
rate	NN	Ot
to	TO	O
the	DT	O
two	CD	O
treatments	NNS	O
was	VBD	O
approximately	RB	O
the	DT	O
same	JJ	O
,	,	O
being	VBG	O
69	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
after	IN	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
,	,	O
respectively	RB	O
.	.	O

During	IN	O
mental	JJ	O
arithmetic	JJ	O
,	,	O
from	IN	O
an	DT	O
average	NN	O
of	IN	O
181.6	CD	O
+/-	JJ	O
17.8/118.6	CD	O
+/-	JJ	O
11.5	CD	O
mm	NN	O
Hg	NNP	O
during	IN	O
placebo	NN	O
,	,	O
BP	NNP	PH
was	VBD	O
reduced	VBN	O
by	IN	O
11.5	CD	O
%	NN	O
/7.9	CD	O
%	NN	O
after	IN	O
terazosin	NN	O
and	CC	O
by	IN	O
13.6	CD	O
%	NN	O
/8.5	CD	O
%	NN	O
after	IN	O
enalapril	NN	O
;	:	O
during	IN	O
handgrip	NN	O
test	NN	O
,	,	O
BP	NNP	PH
decreased	VBD	O
from	IN	O
207.2	CD	O
+/-	JJ	O
22.2/142.2	CD	O
+/-	JJ	O
13.6	CD	O
mm	NN	O
Hg	NNP	O
by	IN	O
7.3	CD	O
%	NN	O
/8.4	CD	O
%	NN	O
after	IN	O
terazosin	NN	O
and	CC	O
by	IN	O
7.7	CD	O
%	NN	O
/7.1	CD	O
%	NN	O
after	IN	O
enalapril	NN	O
;	:	O
finally	RB	O
,	,	O
during	IN	O
cycle	NN	O
ergometry	NN	O
,	,	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
lowered	VBN	O
BP	NNP	PH
by	IN	O
5.4	CD	O
%	NN	O
/6.7	CC	O
%	NN	O
and	CC	O
7	CD	O
%	NN	O
/3.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
from	IN	O
a	DT	O
placebo	NN	O
value	NN	O
of	IN	O
215.5	CD	O
+/-	JJ	O
17.3/127.6	CD	O
+/-	JJ	O
11.2	CD	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
antihypertensive	JJ	O
efficacy	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
,	,	O
either	RB	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
stress	JJ	O
testing	VBG	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Ciprofloxacin	NNP	O
,	,	O
lomefloxacin	NN	O
,	,	O
or	CC	O
levofloxacin	CC	O
as	IN	O
treatment	NN	O
for	IN	O
chronic	JJ	PH
osteomyelitis	NN	PH
.	.	PH

The	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
three	CD	O
oral	JJ	O
fluoroquinolones	NNS	O
(	(	O
lomefloxacin	NN	O
,	,	O
levofloxacin	NN	O
,	,	O
and	CC	O
ciprofloxacin	NN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
osteomyelitis	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
had	VBD	O
documented	VBN	O
infections	NNS	O
with	IN	O
quinolone-sensitive	JJ	O
organisms	NNS	O
and	CC	O
received	VBD	O
either	DT	O
lomefloxacin	NN	O
,	,	O
levofloxacin	NN	O
,	,	O
or	CC	O
ciprofloxacin	NN	O
.	.	O

Levofloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
9	CD	O
of	IN	O
15	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Lomefloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
five	CD	O
of	IN	O
seven	CD	O
(	(	O
71	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
and	CC	O
ciprofloxacin	NN	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
two	CD	O
of	IN	O
five	CD	O
patients	NNS	O
(	(	O
40	CD	O
%	NN	O
)	)	O
.	.	O

Average	JJ	O
follow-up	NN	O
was	VBD	O
11.8	CD	O
months	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
,	,	O
and	CC	O
the	DT	O
average	JJ	O
duration	NN	Ot
of	IN	Ot
therapy	NN	Ot
was	VBD	O
60.6	CD	O
days	NNS	O
.	.	O

Gram-positive	JJ	PH
bacteria	NNS	PH
were	VBD	O
isolated	VBN	O
from	IN	O
18	CD	O
patients	NNS	O
,	,	O
and	CC	O
11	CD	O
patients	NNS	O
were	VBD	O
cured	VBN	PH
.	.	O

Oral	JJ	O
fluoroquinolones	NNS	O
can	MD	O
be	VB	O
safe	JJ	Ot
,	,	Ot
effective	JJ	Ot
therapy	NN	O
if	IN	O
they	PRP	O
are	VBP	O
given	VBN	O
for	IN	O
a	DT	O
prolonged	JJ	O
course	NN	O
as	IN	O
treatment	NN	O
for	IN	O
infections	NNS	O
caused	VBN	O
by	IN	O
susceptible	JJ	O
gram-positive	JJ	O
as	RB	O
well	RB	O
as	IN	O
gram-negative	JJ	O
organisms	NNS	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
adequate	JJ	O
surgical	JJ	O
debridement	NN	O
.	.	O

Analysis	NN	Ot
of	IN	Ot
treatment	NN	Ot
in	IN	O
childhood	NN	O
leukaemia	NN	O
.	.	O

I.	NNP	O
Predisposition	NNP	O
to	TO	O
methotrexate-induced	JJ	O
neutropenia	NN	O
after	IN	O
craniospinal	JJ	O
irradiation	NN	O
.	.	O

Report	NNP	O
to	TO	O
the	DT	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
of	IN	O
the	DT	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	O
in	IN	O
Childhood	NNP	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
drug-induced	JJ	O
neutropenia	NNS	PH
resulting	VBG	O
from	IN	O
a	DT	O
controlled	VBN	O
trial	NN	O
(	(	O
UKALL	NNP	O
I	PRP	O
)	)	O
of	IN	O
treatment	NN	O
in	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
was	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
main	JJ	O
agent	NN	O
associated	VBN	O
with	IN	O
severe	JJ	O
neutropenia	NN	O
was	VBD	O
methotrexate	NN	O
,	,	O
and	CC	O
methotrexate-induced	JJ	PH
neutropenia	NN	PH
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
craniospinal	JJ	O
irradiation	NN	O
.	.	O

The	DT	O
synergistic	JJ	A
toxic	NN	A
effect	NN	A
of	IN	O
irradiation	NN	O
followed	VBN	O
by	IN	O
methotrexate	NN	O
treatment	NN	O
seems	VBZ	O
to	TO	O
have	VB	O
contributed	VBN	O
to	TO	O
three	CD	O
of	IN	O
the	DT	O
five	CD	O
deaths	NNS	O
which	WDT	O
occurred	VBD	O
in	IN	O
complete	JJ	O
remission	NN	PH
in	IN	O
this	DT	O
trial	NN	O
;	:	O
all	DT	O
deaths	NNS	O
in	IN	O
remission	NN	O
occurred	VBD	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
central	JJ	O
nervous	JJ	O
system	NN	O
prophylaxis	NN	O
.	.	O

Analysis	NN	O
of	IN	O
patients	NNS	O
who	WP	O
subsequently	RB	O
relapsed	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
still	RB	O
in	IN	O
remission	NN	O
after	IN	O
18	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
indicated	VBD	O
that	IN	O
the	DT	O
former	JJ	O
,	,	O
on	IN	O
average	NN	O
,	,	O
had	VBD	O
slightly	RB	O
lower	JJR	O
neutrophil	NN	PH
counts	NNS	PH
.	.	PH

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
children	NNS	O
who	WP	O
relapsed	VBD	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
less	RBR	O
aggressive	JJ	O
treatment	NN	O
than	IN	O
those	DT	O
who	WP	O
remained	VBD	O
in	IN	O
remission	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
succinylcholine	NN	O
with	IN	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	O
using	VBG	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
monitoring	VBG	O
neuromuscular	JJ	PH
block	NN	PH
at	IN	O
the	DT	O
laryngeal	NN	O
muscles	NNS	O
by	IN	O
surface	NN	O
laryngeal	NN	O
electromyography	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
onset	NN	PH
of	IN	PH
neuromuscular	JJ	PH
block	NN	PH
with	IN	O
succinylcholine	NN	O
(	(	O
1	CD	O
mg	RB	O
kg-1	NN	O
)	)	O
and	CC	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	O
(	(	O
0.6	CD	O
and	CC	O
0.9	CD	O
mg	JJ	O
kg-1	NN	O
)	)	O
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
muscle	NN	O
using	VBG	O
electromyography	NN	O
(	(	O
EMG	NNP	O
)	)	O
and	CC	O
acceleromyography	NN	O
(	(	O
AMG	NNP	O
)	)	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
adductor	NN	O
laryngeal	NN	O
muscles	NNS	O
with	IN	O
a	DT	O
new	JJ	O
electromyographic	JJ	O
method	NN	O
using	VBG	O
a	DT	O
disposable	JJ	O
surface	NN	O
electrode	NN	O
attached	VBN	O
to	TO	O
the	DT	O
cuff	NN	O
of	IN	O
a	DT	O
tracheal	JJ	O
tube	NN	O
.	.	O

At	IN	O
the	DT	O
larynx	NN	O
,	,	O
the	DT	O
mean	NN	PH
(	(	PH
+/-	JJ	PH
SD	NNP	PH
)	)	PH
time	NN	PH
to	TO	PH
90	CD	PH
%	NN	PH
block	NN	PH
and	CC	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
succinylcholine	NN	Ot
(	(	O
38	CD	O
+/-	JJ	O
15	CD	O
and	CC	O
47	CD	O
+/-	JJ	O
19	CD	O
s	NN	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	O
0.6	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
92	CD	O
+/-	JJ	O
42	CD	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
and	CC	O
rocuronium	$	O
0.9	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
52	CD	O
+/-	JJ	O
31	CD	O
and	CC	O
64	CD	O
+/-	JJ	O
30	CD	O
s	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
,	,	O
with	IN	O
comparable	JJ	O
degrees	NNS	O
of	IN	O
neuromuscular	JJ	PH
block	NN	PH
,	,	O
the	DT	O
onset	JJ	Ot
time	NN	Ot
of	IN	Ot
succinylcholine	NN	Ot
at	IN	Ot
the	DT	Ot
adductor	NN	Ot
pollicis	NN	Ot
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	O
0.6	CD	O
mg	NN	O
kg-1	NN	O
and	CC	O
0.9	CD	O
mg	NNS	O
kg-1	JJ	O
(	(	O
EMG	NNP	O
,	,	O
80	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
145	CD	O
+/-	JJ	O
48	CD	O
s	NN	O
and	CC	O
99	CD	O
+/-	JJ	O
31	CD	O
s	NN	O
;	:	O
AMG	NNP	O
,	,	O
90	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
124	CD	O
+/-	JJ	O
53	CD	O
s	NN	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
.	.	O

Clinical	JJ	Ot
duration	NN	Ot
at	IN	Ot
the	DT	Ot
adductor	NN	Ot
pollicis	NN	Ot
(	(	Ot
AMG	NNP	Ot
)	)	Ot
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
for	IN	O
both	DT	O
rocuronium	NN	O
groups	NNS	O
than	IN	O
for	IN	O
succinylcholine	NN	O
(	(	O
T4	NNP	O
:	:	O
T1	NNP	O
=	VBZ	O
0.7	CD	O
,	,	O
54	CD	O
+/-	JJ	O
18	CD	O
and	CC	O
77	CD	O
+/-	JJ	O
21	CD	O
vs	JJ	O
8	CD	O
+/-	JJ	O
6	CD	O
min	NN	O
)	)	O
.	.	O

The	DT	O
surface	NN	O
laryngeal	JJ	O
electrode	NN	O
proved	VBD	O
non-invasive	JJ	O
,	,	O
easy	JJ	O
to	TO	O
use	VB	O
and	CC	O
reliable	VB	O
in	IN	O
measuring	VBG	O
onset	NN	PH
of	IN	PH
the	DT	PH
neuromuscular	JJ	PH
block	NN	PH
at	IN	O
the	DT	O
larynx	NN	O
.	.	O

Preoperative	JJ	O
irradiation	NN	O
versus	IN	O
the	DT	O
use	NN	O
of	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	JJ	PH
ossification	NN	PH
following	VBG	O
total	JJ	O
hip	JJ	O
replacement	NN	O
:	:	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Previous	JJ	O
studies	NNS	O
showed	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
early	JJ	O
preoperative	NN	O
(	(	O
4	CD	O
h	NN	O
before	IN	O
operation	NN	O
)	)	O
irradiation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	NN	PH
ossification	NN	PH
(	(	PH
HO	NNP	PH
)	)	PH
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

This	DT	O
procedure	NN	O
can	MD	O
result	VB	O
in	IN	O
logistic	JJ	O
problems	NNS	O
,	,	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
great	JJ	O
distance	NN	O
between	IN	O
the	DT	O
department	NN	O
of	IN	O
radiotherapy	NN	O
and	CC	O
the	DT	O
orthopedic	JJ	O
clinic	NN	O
.	.	O

To	TO	O
avoid	VB	O
these	DT	O
organizational	JJ	O
problems	NNS	O
a	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	Ot
preoperative	JJ	Ot
irradiation	NN	Ot
on	IN	O
the	DT	O
day	NN	O
preceding	VBG	O
surgery	NN	O
(	(	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Between	NNP	O
1995	CD	O
and	CC	O
1996	CD	O
,	,	O
100	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
prophylactic	JJ	O
therapy	NN	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
.	.	O

Forty-six	JJ	O
patients	NNS	O
were	VBD	O
irradiated	VBN	O
with	IN	O
7	CD	O
Gy	NNP	O
single	JJ	O
dose	NN	O
within	IN	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
.	.	O

Fifty-four	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
(	(	O
NSAID	NNP	O
)	)	O
(	(	O
Voltaren	NNP	O
resinat	VBZ	O
2	CD	O
x	NN	O
75	CD	O
mg/day	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
)	)	O
.	.	O

Heterotopic	NNP	PH
ossification	NN	PH
was	VBD	O
scored	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Brooker	NNP	Ot
Grading	NNP	Ot
system	NN	Ot
.	.	Ot

One	CD	O
hundred	VBD	O
patients	NNS	O
receiving	VBG	O
no	DT	O
prophylactic	JJ	O
therapy	NN	O
after	IN	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
between	IN	O
1988	CD	O
and	CC	O
1992	CD	O
were	VBD	O
analyzed	VBN	O
and	CC	O
defined	VBN	O
as	IN	O
the	DT	O
historical	JJ	O
control	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
Incidence	NNP	O
of	IN	O
heterotopic	NN	PH
ossification	NN	PH
was	VBD	O
47.8	CD	O
%	NN	O
in	IN	O
the	DT	O
7	CD	O
Gy	NNP	O
preoperative	JJ	O
group	NN	O
(	(	O
Brooker	NNP	Ot
Score	NNP	Ot
I	PRP	O
:	:	O
36.9	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
8.7	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
2.2	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
11.1	CD	O
%	NN	O
in	IN	O
the	DT	O
NSAID	NNP	O
group	NN	O
(	(	O
Brooker	NNP	Ot
Score	NNP	Ot
I	PRP	O
:	:	O
9.3	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
1.8	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
0	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
0	CD	O
%	NN	O
)	)	O
.	.	O

Regarding	VBG	O
overall	JJ	O
heterotopic	NN	PH
ossification	NN	PH
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
NSAID	NNP	O
group	NN	O
and	CC	O
the	DT	O
7	CD	O
Gy	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Analyzing	VBG	O
the	DT	O
clinically	RB	O
significant	JJ	O
heterotopic	NN	PH
ossification	NN	PH
(	(	PH
Brooker	NNP	Ot
Score	NNP	Ot
III	NNP	Ot
and	CC	Ot
IV	NNP	Ot
)	)	PH
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
arms	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
untreated	JJ	O
historical	JJ	O
control	NN	O
group	NN	O
the	DT	O
incidence	NN	O
of	IN	O
heterotopic	NN	PH
ossification	NN	PH
was	VBD	O
65	CD	O
%	NN	O
(	(	O
Brooker	NNP	Ot
Score	NNP	Ot
I	PRP	O
:	:	O
26	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
15	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
19	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
5	CD	O
%	NN	O
)	)	O
.	.	O

Referring	VBG	O
to	TO	O
overall	JJ	O
and	CC	O
to	TO	O
clinically	RB	O
relevant	JJ	O
heterotopic	NN	PH
ossification	NN	PH
the	DT	O
incidence	NN	O
of	IN	O
HO	NNP	PH
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
prophylactically	RB	O
treated	VBN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiation	NNP	O
within	IN	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
and	CC	O
use	NN	O
of	IN	O
NSAID	NNP	O
(	(	O
Voltaren	NNP	O
resinat	NN	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
clinically	RB	O
relevant	JJ	O
heterotopic	NN	PH
ossification	NN	PH
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

Onset/offset	NNP	PH
characteristics	NNS	PH
and	CC	PH
intubating	VBG	PH
conditions	NNS	PH
of	IN	O
rapacuronium	NN	O
:	:	O
a	DT	O
comparison	NN	O
with	IN	O
rocuronium	NN	O
.	.	O

We	PRP	O
compared	VBN	O
onset	PRP	PH
and	CC	PH
offset	VB	PH
of	IN	PH
action	NN	PH
and	CC	PH
tracheal	JJ	PH
intubating	NN	PH
conditions	NNS	PH
after	IN	O
rapacuronium	NN	O
and	CC	O
rocuronium	NN	O
in	IN	O
60	CD	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
assessor-blinded	JJ	O
study	NN	O
.	.	O

Following	VBG	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
with	IN	O
propofol	JJ	O
2.5	CD	O
mg	JJ	O
kg-1	NN	O
,	,	O
either	CC	O
rapacuronium	NN	O
1.5	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
or	CC	O
rocuronium	$	O
0.6	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
was	VBD	O
administered	VBN	O
to	TO	O
facilitate	VB	O
tracheal	JJ	O
intubation	NN	O
.	.	O

Anaesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
either	CC	O
a	DT	O
propofol	JJ	O
infusion	NN	O
(	(	O
100	CD	O
micrograms	NNS	O
kg-1	JJ	O
min-1	JJ	O
)	)	O
or	CC	O
sevoflurane	NN	O
(	(	O
1	CD	O
%	NN	O
end-tidal	JJ	O
)	)	O
with	IN	O
66	CD	O
%	NN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
N2O	NNP	O
)	)	O
,	,	O
n	JJ	O
=	VBP	O
15	CD	O
in	IN	O
each	DT	O
subgroup	NN	O
.	.	O

Neuromuscular	JJ	Ot
monitoring	NN	Ot
was	VBD	O
performed	VBN	O
using	VBG	O
an	DT	O
electromyographic	JJ	O
(	(	O
EMG	NNP	O
)	)	O
device	NN	O
(	(	O
Datex	NNP	O
Relaxograph	NNP	O
)	)	O
.	.	O

The	DT	O
lag	NN	Ot
times	NNS	Ot
(	(	O
mean	JJ	O
42	CD	O
(	(	O
SD	NNP	O
11	CD	O
)	)	O
s	NN	O
and	CC	O
44	CD	O
(	(	O
16	CD	O
)	)	O
s	NN	O
)	)	O
,	,	O
maximum	JJ	Ot
block	NN	Ot
(	(	O
99	CD	O
(	(	O
2	CD	O
)	)	O
%	NN	O
and	CC	O
98	CD	O
(	(	O
3	CD	O
)	)	O
%	NN	O
)	)	O
and	CC	O
intubating	JJ	PH
conditions	NNS	PH
at	IN	PH
60	CD	PH
s	NN	PH
(	(	O
good-to-excellent	JJ	O
in	IN	O
86	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
of	IN	O
patients	NNS	O
)	)	O
were	VBD	O
similar	JJ	O
for	IN	O
rapacuronium	NN	O
and	CC	O
rocuronium	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
onset	JJ	Ot
time	NN	Ot
of	IN	O
rapacuronium	NN	O
was	VBD	O
shorter	JJR	O
than	IN	O
rocuronium	NN	O
(	(	O
87	CD	O
(	(	O
20	CD	O
)	)	O
vs	NN	O
141	CD	O
(	(	O
65	CD	O
)	)	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
degree	NN	PH
of	IN	PH
block	NN	PH
at	IN	PH
60	CD	PH
s	NN	PH
was	VBD	O
greater	JJR	O
(	(	O
69	CD	O
(	(	O
26	CD	O
)	)	O
vs	NN	O
50	CD	O
(	(	O
27	CD	O
)	)	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Twenty-five	JJ	O
per	IN	O
cent	NN	O
recovery	NN	PH
was	VBD	O
shorter	JJR	O
with	IN	O
rapacuronium	NN	O
than	IN	O
rocuronium	NN	O
during	IN	O
propofol	NN	O
(	(	O
15.0	CD	O
(	(	O
3.2	CD	O
)	)	O
vs	NN	O
39.1	CD	O
(	(	O
14.2	CD	O
)	)	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
sevoflurane	NN	O
(	(	O
15.1	CD	O
(	(	O
4.2	CD	O
)	)	O
vs	NN	O
47.8	CD	O
(	(	O
19.0	CD	O
)	)	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
anaesthesia	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
rapacuronium	NN	O
1.5	CD	O
mg	NN	O
kg-1	NN	O
had	VBD	O
a	DT	O
more	RBR	O
rapid	JJ	O
onset	NN	O
,	,	O
similar	JJ	O
intubating	NN	PH
conditions	NNS	PH
,	,	O
and	CC	O
shorter	JJR	O
recovery	NN	O
times	NNS	O
than	IN	O
rocuronium	NN	O
0.6	CD	O
mg	JJ	O
kg-1	NN	O
.	.	O

Single-needle	JJ	O
acupuncture	NN	O
alleviates	VBZ	O
gag	JJ	O
reflex	NN	O
during	IN	O
transesophageal	JJ	O
echocardiography	NN	O
:	:	O
a	DT	O
blinded	VBN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
pilot	NN	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
single-needle	JJ	O
acupuncture	NN	O
in	IN	O
suppressing	VBG	O
gag-reflex	JJ	O
in	IN	O
transesophageal	JJ	O
echocardiography	NN	O
(	(	O
TEE	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
blinded	VBD	O
trial	NN	O
.	.	O

Settings/locations	NNS	O
:	:	O
Patients	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
or	CC	O
transient	JJ	O
ischemic	JJ	O
attack	NN	O
undergoing	JJ	O
TEE	NNP	O
because	IN	O
of	IN	O
presumed	JJ	O
cardioembolic	JJ	O
origin	NN	O
in	IN	O
a	DT	O
specialized	JJ	O
stroke	NN	O
unit	NN	O
of	IN	O
the	DT	O
Johann	NNP	O
Wolfgang	NNP	O
Goethe-University	NNP	O
,	,	O
Frankfurt/Main	NNP	O
,	,	O
Germany	NNP	O
.	.	O

Subjects/Study	NNP	O
interventions	NNS	O
:	:	O
Forty-one	CD	O
(	(	O
41	CD	O
)	)	O
patients	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
single-needle	JJ	O
acupuncture	NN	O
with	IN	O
a	DT	O
0.2	CD	O
x	NN	O
13	CD	O
mm	NN	O
disposable	JJ	O
acupuncture	NN	O
needle	NN	O
(	(	O
Suzhou	NNP	O
Medical	NNP	O
Appliances	NNP	O
,	,	O
China	NNP	O
)	)	O
,	,	O
10-mm	JJ	O
deep	NN	O
either	NN	O
at	IN	O
Chengjiang	NNP	O
(	(	O
midline	NN	O
between	IN	O
lower	JJR	O
lip	NN	O
and	CC	O
chin	NN	O
)	)	O
or	CC	O
superficially	RB	O
at	IN	O
a	DT	O
sham	NN	O
point	NN	O
(	(	O
tip	NN	O
of	IN	O
the	DT	O
chin	NN	O
)	)	O
during	IN	O
TEE	NNP	O
or	CC	O
no	DT	O
acupuncture	NN	O
for	IN	O
alleviating	VBG	O
gag	NN	O
reflex	NN	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Severity	NNP	PH
of	IN	PH
gagging	NN	PH
was	VBD	O
rated	VBN	O
on	IN	O
a	DT	O
visual-analogue	JJ	O
scale	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
acupuncture	NN	O
group	NN	O
experienced	VBD	O
significantly	RB	O
less	RBR	PH
gagging	VBG	PH
than	IN	O
the	DT	O
sham	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.037	CD	O
)	)	O
or	CC	O
the	DT	O
nonacupuncture	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Acupuncture	NNP	O
of	IN	O
CV24	NNP	O
is	VBZ	O
an	DT	O
easy	JJ	O
to	TO	O
apply	VB	O
and	CC	O
effective	JJ	O
method	NN	O
to	TO	O
reduce	VB	O
gag	NN	Ot
reflex	NN	Ot
during	IN	O
TEE	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
is	VBZ	O
a	DT	O
severe	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
of	IN	O
unknown	JJ	O
etiology	NN	O
,	,	O
occurring	VBG	O
almost	RB	O
exclusively	RB	O
in	IN	O
female	JJ	O
patients	NNS	O
.	.	O

The	DT	O
etiology	NN	O
and	CC	O
functional	JJ	O
significance	NN	O
of	IN	O
plasma	JJ	O
carnitine	NN	O
deficiency	NN	O
seen	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
investigate	VB	O
whether	IN	O
L-carnitine	JJ	O
might	MD	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
Rett	NNP	O
syndrome	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
has	VBZ	O
been	VBN	O
completed	VBN	O
in	IN	O
35	CD	O
subjects	NNS	O
.	.	O

Eight-week	JJ	O
treatment	NN	O
phases	NNS	O
were	VBD	O
completed	VBN	O
for	IN	O
both	DT	O
a	DT	O
placebo	NN	O
and	CC	O
L-carnitine	NNP	O
.	.	O

Outcome	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
parents/caregivers	NNS	O
and	CC	O
at	IN	O
medical	JJ	O
follow-up	NN	O
using	VBG	O
three	CD	O
established	VBN	O
tools	NNS	O
:	:	O
the	DT	ME
Rett	NNP	ME
Syndrome	NNP	ME
Motor	NNP	ME
Behavioral	NNP	ME
Assessment	NNP	ME
,	,	O
the	DT	ME
Hand	NNP	ME
Apraxia	NNP	ME
Scale	NNP	ME
,	,	O
and	CC	O
the	DT	Ot
Patient	NNP	ME
Well-Being	NNP	ME
Index	NNP	ME
.	.	O

Analysis	NNP	O
comparing	VBG	O
change	NN	O
between	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
of	IN	O
treatment	NN	O
for	IN	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
placebo	NN	O
showed	VBD	O
that	IN	O
both	DT	O
parents/caregivers	NNS	O
and	CC	O
medical	JJ	O
follow-up	NN	O
detected	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
well-being	NN	ME
.	.	O

In	IN	O
addition	NN	O
,	,	O
medical	JJ	O
review	NN	O
showed	VBD	O
an	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Hand	NNP	ME
Apraxia	NNP	ME
Scale	NNP	ME
for	IN	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
girls	NNS	O
on	IN	O
L-carnitine	NNP	O
.	.	O

Identification	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
improvement	NN	O
has	VBZ	O
been	VBN	O
limited	VBN	O
by	IN	O
the	DT	O
power	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	O
is	VBZ	O
of	IN	O
benefit	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
.	.	O

While	IN	O
L-carnitine	NNP	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
major	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
ability	NN	O
,	,	O
the	DT	O
type	NN	O
of	IN	O
changes	NNS	O
reported	VBN	O
could	MD	O
still	RB	O
have	VB	O
a	DT	O
substantial	JJ	O
impact	NN	O
on	IN	O
the	DT	O
girls	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

Information	NN	O
is	VBZ	O
still	RB	O
needed	VBN	O
,	,	O
however	RB	O
,	,	O
to	TO	O
determine	VB	O
if	IN	O
only	RB	O
subgroups	NNS	O
of	IN	O
girls	NNS	O
with	IN	O
the	DT	O
disorder	NN	O
are	VBP	O
responsive	JJ	O
to	TO	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
appropriate	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
.	.	O

Memory	NN	ME
monitoring	NN	O
by	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
.	.	O

The	DT	O
authors	NNS	O
asked	VBD	O
whether	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
would	MD	O
use	VB	O
similarly	RB	O
an	DT	O
uncertain	JJ	O
response	NN	ME
to	TO	O
escape	VB	O
indeterminate	JJ	O
memories	NNS	O
.	.	O

Monkeys	NNS	O
and	CC	O
humans	NNS	O
performed	VBD	O
serial	JJ	O
probe	NN	O
recognition	NN	O
tasks	NNS	O
that	WDT	O
produced	VBD	O
differential	JJ	O
memory	NN	O
difficulty	NN	O
across	IN	O
serial	JJ	O
positions	NNS	O
(	(	O
e.g.	NN	O
,	,	O
primacy	NN	O
and	CC	O
recency	NN	O
effects	NNS	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
given	VBN	O
an	DT	O
escape	NN	O
option	NN	O
that	WDT	O
let	VBD	O
them	PRP	O
avoid	VB	O
any	DT	O
trials	NNS	O
they	PRP	O
wished	VBD	O
and	CC	O
receive	VB	O
a	DT	O
hint	NN	O
to	TO	O
the	DT	O
trial	NN	O
's	POS	O
answer	NN	O
.	.	O

Across	IN	O
species	NNS	O
,	,	O
across	IN	O
tasks	NNS	O
,	,	O
and	CC	O
even	RB	O
across	IN	O
conspecifics	NNS	O
with	IN	O
sharper	NN	O
or	CC	O
duller	NN	O
memories	NNS	O
,	,	O
monkeys	NNS	O
and	CC	O
humans	NNS	O
used	VBD	O
the	DT	O
escape	NN	ME
option	NN	ME
selectively	RB	O
when	WRB	O
more	RBR	O
indeterminate	JJ	O
memory	NN	O
traces	NNS	O
were	VBD	O
probed	VBN	O
.	.	O

Their	PRP$	O
pattern	NN	O
of	IN	O
escaping	VBG	O
always	RB	O
mirrored	VBN	O
the	DT	O
pattern	NN	O
of	IN	O
their	PRP$	O
primary	JJ	O
memory	NN	O
performance	NN	O
across	IN	O
serial	JJ	O
positions	NNS	O
.	.	O

Signal-detection	NN	Ot
analyses	NNS	Ot
confirm	VBP	O
the	DT	O
similarity	NN	O
of	IN	O
the	DT	O
animals	NNS	O
'	POS	O
and	CC	O
humans	NNS	O
'	POS	O
performances	NNS	O
.	.	O

Optimality	NNP	Ot
analyses	VBZ	Ot
assess	VB	O
their	PRP$	O
efficiency	NN	Ot
.	.	O

Several	JJ	O
aspects	NNS	O
of	IN	O
monkeys	NNS	O
'	POS	O
performance	NN	O
suggest	VBP	O
the	DT	O
cognitive	JJ	O
sophistication	NN	O
of	IN	O
their	PRP$	O
decisions	NNS	O
to	TO	O
escape	VB	O
.	.	O

FDA	NNP	O
review	NN	O
of	IN	O
a	DT	O
panitumumab	NN	O
(	(	O
Vectibix	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
for	IN	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

On	IN	O
September	NNP	O
27	CD	O
,	,	O
2006	CD	O
,	,	O
the	DT	O
U.S.	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
granted	VBD	O
accelerated	VBD	O
approval	NN	O
to	TO	O
panitumumab	VB	O
(	(	O
Vectibix	NNP	O
;	:	O
Amgen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Thousand	NNP	O
Oaks	NNP	O
,	,	O
CA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor-expressing	NN	O
,	,	O
metastatic	JJ	O
colorectal	NN	O
carcinoma	NN	O
with	IN	O
disease	JJ	O
progression	NN	O
on	IN	O
or	CC	O
following	VBG	O
fluoropyrimidine-	JJ	O
,	,	O
oxaliplatin-	JJ	O
,	,	O
and	CC	O
irinotecan-containing	JJ	O
chemotherapy	NN	O
regimens	NNS	O
.	.	O

Accelerated	NNP	O
approval	NN	O
was	VBD	O
based	VBN	O
on	IN	O
demonstration	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
submission	NN	O
summarizes	VBZ	O
a	DT	O
second	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
panitumumab	JJ	O
package	NN	O
insert	NN	O
in	IN	O
June	NNP	O
2008	CD	O
,	,	O
of	IN	O
chemotherapy	NN	O
and	CC	O
bevacizumab	NN	O
with	IN	O
and	CC	O
without	IN	O
panitumumab	NN	O
in	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
closed	VBN	O
when	WRB	O
inferior	JJ	O
PFS	NNP	O
and	CC	O
greater	JJR	O
toxicity	NN	O
were	VBD	O
demonstrated	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
planned	VBN	O
interim	NN	O
efficacy	NN	O
analysis	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
panitumumab	NN	O
in	IN	O
combination	NN	O
with	IN	O
bevacizumab	NN	O
and	CC	O
chemotherapy	NN	O
experienced	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
death	NN	MO
(	(	O
9	CD	O
%	NN	O
versus	IN	O
4	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
higher	JJR	O
risk	NN	O
for	IN	O
grade	NN	Ot
3	CD	Ot
and	CC	Ot
4	CD	Ot
toxicities	NNS	Ot
than	IN	O
patients	NNS	O
receiving	VBG	O
bevacizumab	NN	O
and	CC	O
chemotherapy	NN	O
alone	RB	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
any	DT	O
Common	NNP	A
Terminology	NNP	A
Criteria	NNP	A
for	IN	A
Adverse	NNP	A
Events	NNP	A
grade	VBD	A
3	CD	A
and	CC	A
4	CD	A
adverse	JJ	A
events	NNS	A
(	(	A
AEs	NNP	A
)	)	A
were	VBD	O
87	CD	O
%	NN	O
and	CC	O
72	CD	O
%	NN	O
in	IN	O
the	DT	O
panitumumab	NN	O
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	A
3	CD	A
and	CC	A
4	CD	A
AEs	NNP	A
occurring	VBG	O
more	JJR	O
commonly	RB	O
in	IN	O
panitumumab-treated	JJ	O
patients	NNS	O
included	VBD	O
rash/acneiform	NN	A
dermatitis	NN	A
,	,	O
diarrhea	NN	A
,	,	O
dehydration	NN	A
,	,	O
primarily	RB	O
resulting	VBG	O
from	IN	O
diarrhea	NN	A
,	,	O
hypokalemia	NN	A
,	,	O
stomatitis/mucositis	NN	A
,	,	O
and	CC	O
pulmonary	JJ	A
embolism	NN	A
.	.	O

The	DT	O
addition	NN	O
of	IN	O
panitumumab	NN	O
to	TO	O
bevacizumab	VB	O
and	CC	O
chemotherapy	VB	O
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	NN	O
cancer	NN	O
was	VBD	O
harmful	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
bevacizumab	NN	O
and	CC	O
chemotherapy	NN	O
alone	RB	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
panitumumab	NN	O
in	IN	O
this	DT	O
setting	NN	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
.	.	O

Gamma-hydroxybutyric	JJ	O
acid	NN	O
versus	NN	O
clomethiazole	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcohol	NN	PH
withdrawal	NN	PH
syndrome	NN	PH
in	IN	O
a	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
:	:	O
an	DT	O
open	JJ	O
,	,	O
single-center	JJ	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Clomethiazole	NNP	O
(	(	O
CLO	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
treating	VBG	PH
alcohol	NN	PH
withdrawal	NN	PH
syndrome	NN	PH
(	(	PH
AWS	NNP	PH
)	)	PH
.	.	O

Gamma-Hydroxybutyric	JJ	O
acid	NN	O
(	(	O
GHB	NNP	O
)	)	O
has	VBZ	O
also	RB	O
been	VBN	O
introduced	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcoholic	JJ	O
patients	NNS	O
and	CC	O
is	VBZ	O
effective	JJ	O
in	IN	O
surgical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
patients	NNS	O
in	IN	O
preventing	VBG	O
and	CC	O
treating	VBG	O
AWS	NNP	PH
.	.	O

There	EX	O
are	VBP	O
no	DT	O
comparative	JJ	O
studies	NNS	O
between	IN	O
CLO	NNP	O
and	CC	O
GHB	NNP	O
in	IN	O
a	DT	O
medical	JJ	O
ICU	NNP	O
setting	NN	O
.	.	O

METHODS	NNP	O
Twenty-six	NNP	O
alcoholic	JJ	O
patients	NNS	O
with	IN	O
severe	JJ	O
AWS	NNP	PH
and	CC	O
concomitant	JJ	O
medical	JJ	O
diseases	NNS	O
were	VBD	O
randomally	RB	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

CLO	NNP	O
was	VBD	O
given	VBN	O
orally	RB	O
to	TO	O
12	CD	O
patients	NNS	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
250	CD	O
mg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
a	DT	O
liquid	NN	O
;	:	O
GHB	NNP	O
(	(	O
initially	RB	O
30	CD	O
mg/kg	NNS	O
body	NN	O
weight	NN	O
(	(	O
BW	NNP	O
)	)	O
followed	VBN	O
by	IN	O
15	CD	O
mg/kg	NNS	O
BW	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
to	TO	O
14	CD	O
patients	NNS	O
.	.	O

Four	CD	O
major	JJ	O
AWS	NNP	PH
symptoms	NNS	PH
(	(	O
tremor	NN	PH
,	,	O
sweating	VBG	PH
,	,	O
nausea	NN	PH
,	,	O
restlessness	NN	PH
)	)	O
were	VBD	O
scored	VBN	O
,	,	O
and	CC	O
the	DT	O
administration	NN	O
of	IN	O
additional	JJ	Ot
medication	NN	Ot
was	VBD	O
registered	VBN	O
.	.	O

RESULTS	NNP	O
GHB	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
treating	VBG	O
AWS	NNP	O
symptoms	NNS	O
.	.	O

In	IN	O
the	DT	O
GHB	NNP	O
group	NN	O
,	,	O
AWS	NNP	PH
score	NN	O
dropped	VBD	O
from	IN	O
6.6	CD	O
+/-	JJ	O
2.6	CD	O
to	TO	O
1.8	CD	O
+/-	JJ	O
2.1	CD	O
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
while	IN	O
in	IN	O
the	DT	O
CLO	NNP	O
group	NN	O
,	,	O
the	DT	O
score	NN	O
dropped	VBD	O
from	IN	O
6	CD	O
+/-	JJ	O
2.5	CD	O
to	TO	O
4.1	CD	O
+/-	JJ	O
2.4	CD	O
(	(	O
n.	JJ	O
s.	NN	O
)	)	O
.	.	O

Differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=.021	NN	O
,	,	O
two-way	JJ	O
ANOVA	NNP	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
alter	VB	O
outcome	NN	PH
or	CC	O
the	DT	O
duration	NN	Ot
of	IN	Ot
ICU	NNP	Ot
stay	NN	Ot
.	.	O

No	DT	A
serious	JJ	A
side	NN	A
effects	NNS	A
were	VBD	O
detected	VBN	O
.	.	O

CONCLUSION	NNP	O
GHB	NNP	O
effectively	RB	O
controls	VBZ	O
AWS	NNP	PH
symptoms	NNS	PH
in	IN	O
medical	JJ	O
ICU	NNP	O
patients	NNS	O
.	.	O

The	DT	O
rapid	JJ	O
initial	JJ	O
treatment	NN	O
response	NN	O
of	IN	O
GHB	NNP	O
in	IN	O
contrast	NN	O
to	TO	O
CLO	NNP	O
has	VBZ	O
no	DT	O
influence	NN	O
on	IN	O
duration	NN	PH
of	IN	PH
patient	NN	PH
withdrawal	NN	PH
.	.	O

The	DT	O
impact	NN	O
of	IN	O
schizophrenic	JJ	O
patient	NN	O
functionality	NN	O
on	IN	O
service	NN	Ot
utilization	NN	Ot
and	CC	Ot
cost	NN	Ot
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
presentation	NN	O
by	IN	O
Sandra	NNP	O
L.	NNP	O
Tunis	NNP	O
,	,	O
PhD	NNP	O
.	.	O

With	IN	O
the	DT	O
advent	NN	O
of	IN	O
atypical	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	O
,	,	O
physicians	NNS	O
and	CC	O
policy	NN	O
makers	NNS	O
must	MD	O
consider	VB	O
the	DT	O
costs	NNS	O
that	WDT	O
may	MD	O
accompany	VB	O
greater	JJR	O
clinical	JJ	O
efficacy	NN	O
.	.	O

Analyses	VBZ	O
reveal	NN	O
that	WDT	O
olanzapine	NN	O
shows	VBZ	O
a	DT	O
greater	JJR	O
clinical	JJ	Ot
cost	NN	Ot
effectiveness	NN	Ot
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
greater	JJR	O
functional	JJ	Ot
cost	NN	Ot
effectiveness	NN	Ot
,	,	O
than	IN	O
haloperidol	NN	O
,	,	O
and	CC	O
that	IN	O
functional	JJ	O
outcomes	NNS	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
show	VBP	O
promise	NN	O
as	IN	O
important	JJ	O
measures	NNS	O
of	IN	O
effectiveness	NN	O
.	.	O

Functional	JJ	O
outcomes	NNS	O
can	MD	O
help	VB	O
differentiate	VB	O
medications	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
help	VB	O
demonstrate	VB	O
the	DT	O
cost	NN	Ot
effectiveness	NN	Ot
of	IN	O
atypical	JJ	O
agents	NNS	O
.	.	O

Mental	NNP	ME
health	NN	ME
and	CC	O
physical	JJ	PH
health	NN	PH
functioning	NN	PH
,	,	O
as	RB	O
well	RB	O
as	IN	O
work	NN	ME
status	NN	ME
,	,	O
are	VBP	O
all	DT	O
measures	NNS	O
of	IN	O
functioning	VBG	O
that	WDT	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
evaluate	VB	O
treatment	NN	O
strategies	NNS	O
.	.	O

When	WRB	O
comparing	VBG	O
olanzapine	NN	O
with	IN	O
haloperidol	NN	O
,	,	O
cost	NN	Ot
savings	NNS	Ot
are	VBP	O
seen	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
(	(	O
1	CD	O
year	NN	O
)	)	O
,	,	O
with	IN	O
physical	JJ	PH
functioning	VBG	PH
most	JJS	O
highly	RB	O
affected	VBN	O
over	IN	O
time	NN	O
.	.	O

Functional	JJ	O
outcomes	NNS	O
can	MD	O
therefore	VB	O
serve	VB	O
2	CD	O
purposes	NNS	O
:	:	O
to	TO	O
enhance	VB	O
compliance	NN	O
by	IN	O
improving	VBG	O
health-related	JJ	Ot
quality	NN	Ot
of	IN	Ot
life	NN	Ot
and	CC	O
to	TO	O
assist	VB	O
in	IN	O
making	VBG	O
both	DT	O
treatment	NN	O
and	CC	O
formulary	JJ	O
decisions	NNS	O
.	.	O

Eye	NNP	O
movements	NNS	O
affirm	NN	O
:	:	O
automatic	JJ	ME
overt	NN	ME
gaze	NN	ME
and	CC	PH
arrow	NN	ME
cueing	NN	ME
for	IN	O
typical	JJ	O
adults	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

People	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
show	NN	O
reduced	VBN	O
interest	NN	O
towards	NNS	O
social	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
environment	NN	O
and	CC	O
a	DT	O
lesser	JJR	O
tendency	NN	PH
to	TO	O
follow	VB	PH
other	JJ	PH
people	NNS	PH
's	POS	PH
gaze	NN	PH
in	IN	O
the	DT	O
real	JJ	O
world	NN	O
.	.	O

However	RB	O
,	,	O
most	JJS	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
people	NNS	O
with	IN	O
ASD	NNP	O
do	VBP	O
respond	VB	O
to	TO	O
eye-gaze	JJ	O
cues	NNS	O
in	IN	O
experimental	JJ	O
paradigms	NN	O
,	,	O
though	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
this	DT	O
behaviour	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
an	DT	O
atypical	JJ	O
strategy	NN	O
.	.	O

We	PRP	O
tested	VBD	O
this	DT	O
possibility	NN	O
in	IN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
using	VBG	O
a	DT	O
cueing	NN	O
task	NN	O
combined	VBN	O
with	IN	O
eye-movement	JJ	O
recording	NN	O
.	.	O

Both	DT	O
eye	NN	O
gaze	NN	O
and	CC	O
arrow	VB	O
pointing	VBG	O
distractors	NNS	O
resulted	VBD	O
in	IN	O
overt	JJ	ME
cueing	NN	ME
effects	NNS	ME
,	,	O
both	DT	O
in	IN	O
terms	NNS	O
of	IN	O
increased	VBN	PH
saccadic	JJ	ME
reaction	NN	ME
times	NNS	ME
,	,	O
and	CC	O
in	IN	O
proportions	NNS	ME
of	IN	ME
saccades	NNS	ME
executed	VBN	ME
to	TO	ME
the	DT	ME
cued	VBN	ME
direction	NN	ME
instead	RB	ME
of	IN	ME
to	TO	ME
the	DT	ME
target	NN	ME
,	,	O
for	IN	O
both	DT	O
participant	JJ	O
groups	NNS	O
.	.	O

Our	PRP$	O
results	NNS	O
confirm	VBP	O
previous	JJ	O
reports	NNS	O
that	IN	O
eye	NN	O
gaze	NN	O
cues	NNS	O
as	RB	O
well	RB	O
as	IN	O
arrow	NN	O
cues	NNS	O
result	VBP	O
in	IN	O
automatic	JJ	ME
orienting	NN	ME
of	IN	ME
overt	JJ	ME
attention	NN	ME
.	.	O

Moreover	RB	O
,	,	O
since	IN	O
there	EX	O
were	VBD	O
no	DT	O
group	NN	O
differences	VBZ	O
between	IN	O
arrow	NN	O
and	CC	O
eye	NN	O
gaze	NN	O
cues	NNS	O
,	,	O
we	PRP	O
conclude	VBP	O
that	IN	O
overt	JJ	ME
attentional	JJ	ME
orienting	NN	ME
in	IN	O
ASD	NNP	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
response	NN	O
to	TO	O
centrally	RB	O
presented	VBN	O
schematic	JJ	O
directional	JJ	O
distractors	NNS	O
,	,	O
is	VBZ	O
typical	JJ	O
.	.	O

Prevention	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
comparing	VBG	O
enoxaparin	NN	O
with	IN	O
warfarin	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
fixed-dose	JJ	O
enoxaparin	NN	O
and	CC	O
adjusted	VBD	O
dose	JJ	O
warfarin	NN	O
in	IN	O
preventing	VBG	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
8	CD	O
university	NN	O
hospitals	NNS	O
.	.	O

PATIENTS	VB	O
670	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
knee	VBN	O
arthroplasty	RB	O
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
enoxaparin	NN	O
(	(	O
30	CD	O
mg	NN	O
subcutaneously	RB	O
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
or	CC	O
adjusted-dose	JJ	O
warfarin	NN	O
(	(	O
international	JJ	O
normalized	VBN	O
ratio	NN	O
,	,	O
2.0	CD	O
to	TO	O
3.0	CD	O
)	)	O
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
started	VBN	O
after	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	PDT	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
incidence	NN	PH
of	IN	PH
deep	JJ	PH
venous	JJ	PH
thrombosis	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
adequate	JJ	O
bilateral	JJ	O
venograms	NNS	O
;	:	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
hemorrhage	NN	PH
.	.	PH

RESULTS	NNP	O
Among	IN	O
the	DT	O
417	CD	O
patients	NNS	O
with	IN	O
adequate	JJ	O
venograms	NNS	O
,	,	O
109	CD	O
of	IN	O
211	CD	O
warfarin	NN	O
recipients	NNS	O
(	(	O
51.7	CD	O
%	NN	O
)	)	O
had	VBD	O
deep	JJ	PH
venous	JJ	PH
thrombosis	NN	PH
compared	VBN	O
with	IN	O
76	CD	O
of	IN	O
206	CD	O
enoxaparin	NN	O
recipients	NNS	O
(	(	O
36.9	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	PH
risk	NN	PH
difference	NN	PH
was	VBD	O
14.8	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
enoxaparin	NN	O
(	(	O
95	CD	O
%	NN	O
Cl	NNP	O
,	,	O
5.3	CD	O
%	NN	O
to	TO	O
24.1	CD	O
%	NN	O
)	)	O
Twenty-two	NNP	O
warfarin	NN	O
recipients	NNS	O
(	(	O
10.4	CD	O
%	NN	O
)	)	O
and	CC	O
24	CD	O
enoxaparin	NN	O
recipients	NNS	O
(	(	O
11.7	CD	O
%	NN	O
)	)	O
had	VBD	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	PH
risk	NN	PH
difference	NN	PH
was	VBD	O
1.2	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	O
(	(	O
Cl	NNP	O
,	,	O
-7.2	NNP	O
%	NN	O
to	TO	O
4.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
major	JJ	PH
bleeding	NN	PH
was	VBD	O
1.8	CD	O
%	NN	O
(	(	O
6	CD	O
of	IN	O
334	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
and	CC	O
2.1	CD	O
%	NN	O
(	(	O
7	CD	O
of	IN	O
336	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
enoxaparin	NN	O
group	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	PH
risk	NN	PH
difference	NN	PH
was	VBD	O
0.3	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	O
(	(	O
Cl	NNP	O
,	,	O
-2.4	NNP	O
%	NN	O
to	TO	O
1.8	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
postoperative	JJ	O
,	,	O
fixed-dose	JJ	O
enoxaparin	NN	O
regimen	NNS	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
adjusted-dose	JJ	O
warfarin	NN	O
in	IN	O
preventing	VBG	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
or	CC	O
clinically	RB	O
overt	JJ	O
hemorrhage	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	O
to	TO	O
enhance	VB	O
immune	JJ	O
function	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

OBJECTIVE	NNP	O
We	PRP	O
collected	VBD	O
preliminary	JJ	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	O
to	TO	O
improve	VB	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
persons	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
and	CC	O
acquired	VBD	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
in	IN	O
an	DT	O
academic	JJ	O
medical	JJ	O
center-based	JJ	O
infectious	JJ	O
disease	NN	O
clinic	NN	O
,	,	O
11	CD	O
clinically	RB	O
stable	JJ	O
,	,	O
HIV-infected	JJ	O
adults	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
highly	RB	O
active	JJ	O
,	,	O
antiretroviral	JJ	O
therapy	NN	O
and	CC	O
had	VBD	O
HIV	NNP	O
plasma	NN	O
RNA	NNP	O
levels	NNS	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	O
000	CD	O
copies/mL	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
19.6	CD	O
g	NN	O
of	IN	O
arginine/d	NN	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
for	IN	O
14	CD	O
d.	NN	O
Plasma	NNP	PH
HIV	NNP	PH
RNA	NNP	PH
levels	NNS	PH
,	,	O
neuropsychologic	RB	PH
functioning	NN	PH
,	,	ME
and	CC	O
self-reported	JJ	A
adverse	JJ	A
events	NNS	A
were	VBD	O
analyzed	VBN	O
for	IN	O
safety	NN	O
of	IN	O
treatment	NN	O
.	.	O

Efficacy	NN	Ot
was	VBD	O
measured	VBN	O
by	IN	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
.	.	O

RESULTS	NNP	O
None	NN	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
any	DT	O
adverse	JJ	A
clinical	NN	A
,	,	A
virologic	NN	A
,	,	A
or	CC	A
neuropsychologic	JJ	A
events	NNS	A
that	WDT	O
necessitated	VBD	O
withdrawal	NN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
arginine-supplemented	JJ	O
group	NN	O
showed	VBD	O
a	DT	O
mean	JJ	PH
natural	JJ	PH
killer	NN	PH
cell	NN	PH
cytotoxicity	NN	PH
increase	NN	O
of	IN	O
18.9	CD	O
lytic	JJ	O
units	NNS	O
,	,	O
whereas	IN	O
the	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
0.3	CD	O
lytic	JJ	O
units	NNS	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.79	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
arginine	NN	O
supplementation	NN	O
is	VBZ	O
safe	JJ	O
for	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

Additional	NNP	O
studies	NNS	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
longer	JJR	O
periods	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
arginine	JJ	O
supplementation	NN	O
on	IN	O
other	JJ	O
indices	NNS	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
such	JJ	O
as	IN	O
intercurrent	JJ	O
illnesses	NNS	O
.	.	O

Satisfactory	JJ	O
sampling	NN	O
in	IN	O
cytological	JJ	O
cervical	JJ	O
diagnosis	NN	O
:	:	O
comparison	NN	O
between	IN	O
a	DT	O
conventional	JJ	O
and	CC	O
a	DT	O
new	JJ	O
sampling	NN	O
device	NN	O
.	.	O

AIM	NNP	O
Inadequate	NNP	O
cervical	JJ	O
sampling	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
frequent	JJ	O
cause	NN	O
of	IN	O
misdiagnosis	NN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
screening	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
ability	NN	O
of	IN	O
PapCone?	NNP	O
versus	IN	O
the	DT	O
conventional	JJ	O
sampling	NN	O
method	NN	O
(	(	O
Ayre	NNP	O
's	POS	O
spatula	NN	O
plus	CC	O
cytobrush	NN	O
)	)	O
to	TO	O
collect	VB	O
ectocervical	JJ	O
and	CC	O
glandular	JJ	O
cells	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
18	CD	O
healthy	JJ	O
women	NNS	O
,	,	O
two	CD	O
ecto-endocervical	JJ	O
samples	NNS	O
,	,	O
obtained	VBN	O
by	IN	O
two	CD	O
different	JJ	O
methods	NNS	O
,	,	O
were	VBD	O
obtained	VBN	O
at	IN	O
a	DT	O
three-month	JJ	O
interval	NN	O
.	.	O

Qualitative	JJ	O
and	CC	O
quantitative	JJ	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Ultrastructure	NN	O
features	NNS	O
of	IN	O
sampling	VBG	O
devices	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
scanning	VBG	O
electron	NN	O
microscopy	NN	O
(	(	O
SEM	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
sampling	VBG	O
.	.	O

RESULTS	VB	O
The	DT	O
?	.	O
(	(	O
2	CD	O
)	)	O
test	NN	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
:	:	O
PapCone?	NNP	O
caused	VBD	O
less	JJR	O
cell	NN	O
overlap	NN	O
and	CC	O
sampled	VBD	O
less	JJR	O
white	JJ	O
blood	NN	O
cells	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
more	RBR	O
metaplastic	JJ	O
cells	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

SEM	NNP	O
evaluation	NN	O
highlighted	VBD	O
the	DT	O
porous	JJ	O
and	CC	O
spongy	JJ	O
structure	NN	O
of	IN	O
PapCone?	NNP	O
that	WDT	O
was	VBD	O
responsible	JJ	O
for	IN	O
the	DT	O
large	JJ	O
number	NN	O
of	IN	O
glandular	JJ	O
cells	NNS	O
on	IN	O
its	PRP$	O
surface	NN	O
.	.	O

CONCLUSION	NNP	O
Cervical	NNP	O
smears	NNS	O
performed	VBN	O
by	IN	O
PapCone?	NNP	O
were	VBD	O
adequate	JJ	O
and	CC	O
generally	RB	O
easier	JJR	O
to	TO	O
screen	VB	O
than	IN	O
conventionally	RB	O
performed	VBN	O
ones	NNS	O
.	.	O

Phase	NNP	O
III	NNP	O
comparative	JJ	O
study	NN	O
of	IN	O
high-dose	JJ	O
cisplatin	NN	O
versus	IN	O
a	DT	O
combination	NN	O
of	IN	O
paclitaxel	NN	O
and	CC	O
cisplatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
New	NNP	O
effective	JJ	O
chemotherapy	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
improve	VB	O
the	DT	O
outcome	NN	O
of	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

Paclitaxel	NNP	O
administered	VBD	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
cisplatin	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
potentially	RB	O
new	JJ	O
useful	JJ	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1995	CD	O
and	CC	O
April	NNP	O
1996	CD	O
,	,	O
414	CD	O
patients	NNS	O
with	IN	O
stage	NN	O
IIIB	NNP	O
or	CC	O
IV	NNP	O
NSCLC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
received	VB	O
either	RB	O
a	DT	O
control	NN	O
arm	NN	O
of	IN	O
high-dose	JJ	O
cisplatin	NN	O
(	(	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
paclitaxel	NN	O
(	(	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
3-hour	JJ	O
infusion	NN	O
)	)	O
and	CC	O
cisplatin	NN	O
(	(	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
the	DT	O
cisplatin-only	JJ	O
arm	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
9	CD	O
%	NN	O
improvement	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0	CD	O
%	NN	O
to	TO	O
19	CD	O
%	NN	O
)	)	O
in	IN	O
overall	JJ	PH
response	NN	PH
rate	NN	PH
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
(	(	O
17	CD	O
%	NN	O
v	JJ	O
26	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P=.028	NNP	O
)	)	O
.	.	O

Median	JJ	Ot
time	NN	Ot
to	TO	Ot
progression	NN	Ot
was	VBD	O
2.7	CD	O
and	CC	O
4.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
respectively	RB	O
(	(	O
P=.026	NNP	O
)	)	O
.	.	O

The	DT	O
study	NN	O
,	,	O
however	RB	O
,	,	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
median	JJ	MO
survival	NN	MO
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
(	(	O
8.6	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
v	NN	O
8.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
P=.862	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
more	JJR	O
hematotoxicity	NN	PH
,	,	PH
peripheral	JJ	PH
neuropathy	NN	PH
,	,	PH
and	CC	PH
arthralgia/myalgia	NN	PH
on	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
whereas	IN	O
the	DT	O
high-dose	JJ	O
cisplatin	NN	O
arm	NN	O
produced	VBD	O
more	JJR	O
ototoxicity	NN	A
,	,	A
nausea	NN	A
,	,	A
vomiting	NN	A
,	,	A
and	CC	A
nephrotoxicity	NN	A
.	.	A

Quality	NN	Ot
of	IN	Ot
life	NN	Ot
(	(	Ot
QOL	NNP	Ot
)	)	Ot
was	VBD	O
similar	JJ	O
overall	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

CONCLUSION	NN	O
This	DT	O
large	JJ	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
combination	NN	O
compared	VBN	O
with	IN	O
high-dose	JJ	O
cisplatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
NSCLC	NNP	O
.	.	O

However	RB	O
,	,	O
the	DT	O
paclitaxel/cisplatin	NN	O
combination	NN	O
did	VBD	O
produce	VB	O
a	DT	O
better	JJR	O
clinical	JJ	O
response	NN	O
,	,	O
resulting	VBG	O
in	IN	O
an	DT	O
increased	JJ	O
time	NN	O
to	TO	O
progression	NN	O
while	IN	O
providing	VBG	O
a	DT	O
similar	JJ	O
QOL	NNP	O
.	.	O

Treatment	NN	O
of	IN	O
posterior	JJ	O
uveitis	NN	O
with	IN	O
a	DT	O
fluocinolone	NN	O
acetonide	NN	O
implant	NN	O
:	:	O
three-year	JJ	O
clinical	JJ	O
trial	NN	O
results	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
0.59-mg	JJ	O
and	CC	O
2.1-mg	JJ	O
fluocinolone	NN	O
acetonide	NN	O
(	(	O
FA	NNP	O
)	)	O
intravitreous	JJ	O
implants	NNS	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
3-year	JJ	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
historically	RB	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
0.59-mg	JJ	O
FA	NNP	O
intravitreous	JJ	O
implant	NN	O
in	IN	O
110	CD	O
patients	NNS	O
and	CC	O
the	DT	O
2.1-mg	JJ	O
FA	NNP	O
intravitreous	JJ	O
implant	NN	O
in	IN	O
168	CD	O
patients	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Recurrence	NNP	PH
rate	NN	PH
,	,	O
vision	NN	PH
,	,	O
and	CC	O
complications	NNS	A
.	.	O

RESULTS	NNP	O
Uveitis	NNP	PH
recurrence	NN	PH
was	VBD	PH
reduced	VBN	PH
in	IN	O
implanted	JJ	O
eyes	NNS	O
from	IN	O
62	CD	O
%	NN	O
(	(	O
during	IN	O
the	DT	O
1-year	JJ	O
preimplantation	NN	O
period	NN	O
)	)	O
to	TO	O
4	CD	O
%	NN	O
,	,	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
20	CD	O
%	NN	O
during	IN	O
the	DT	O
1-	JJ	O
,	,	O
2-	JJ	O
,	,	O
and	CC	O
3-year	JJ	O
postimplantation	NN	O
periods	NNS	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
0.59-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
from	IN	O
58	CD	O
%	NN	O
to	TO	O
7	CD	O
%	NN	O
,	,	O
17	CD	O
%	NN	O
,	,	O
and	CC	O
41	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
2.1-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

More	RBR	O
implanted	JJ	O
eyes	NNS	O
than	IN	O
nonimplanted	JJ	O
eyes	NNS	O
had	VBD	O
improved	VBN	PH
visual	JJ	PH
acuity	NN	PH
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Implanted	VBN	PH
eyes	NNS	PH
had	VBD	PH
higher	JJR	PH
incidences	NNS	PH
of	IN	PH
intraocular	JJ	PH
pressure	NN	PH
elevation	NN	PH
(	(	O
>	CD	O
or	CC	O
=	VB	O
10	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
than	IN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
and	CC	O
glaucoma	NN	PH
surgery	NN	PH
was	VBD	O
required	VBN	O
in	IN	O
40	CD	O
%	NN	O
of	IN	O
implanted	JJ	O
eyes	NNS	O
vs	VBP	O
2	CD	O
%	NN	O
of	IN	O
nonimplanted	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Cataracts	NNPS	PH
were	VBD	O
extracted	VBN	O
in	IN	O
93	CD	O
%	NN	O
of	IN	O
phakic	NN	O
implanted	VBN	O
eyes	NNS	O
vs	VBP	O
20	CD	O
%	NN	O
of	IN	O
phakic	NN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
FA	NNP	O
implant	NN	O
significantly	RB	O
reduced	VBN	PH
uveitis	JJ	PH
recurrence	NN	PH
and	CC	O
improved	VBD	PH
or	CC	PH
stabilized	VBN	PH
visual	JJ	PH
acuity	NN	PH
in	IN	O
subjects	NNS	O
with	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

Most	JJS	O
subjects	NNS	O
required	VBN	O
cataract	JJ	PH
extraction	NN	PH
,	,	O
and	CC	O
a	DT	O
significant	JJ	O
proportion	NN	O
required	VBN	O
intraocular	JJ	PH
pressure-lowering	JJ	PH
surgery	NN	PH
.	.	O

APPLICATION	NNP	O
TO	NNP	O
CLINICAL	NNP	O
PRACTICE	NNP	O
The	DT	O
FA	NNP	O
implant	NN	O
provides	VBZ	O
an	DT	O
alternative	JJ	O
therapy	NN	O
for	IN	O
prolonged	JJ	O
control	NN	O
of	IN	O
inflammation	NN	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00407082	NN	O
.	.	O

Chemotherapy	NN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
and	CC	O
prednisone	VB	O
alone	RB	O
or	CC	O
with	IN	O
levamisole	JJ	O
or	CC	O
with	IN	O
levamisole	JJ	O
plus	CC	O
BCG	NNP	O
for	IN	O
malignant	JJ	O
lymphoma	NN	O
:	:	O
a	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
Study	NNP	O
.	.	O

Between	NNP	O
1977	CD	O
and	CC	O
1983	CD	O
the	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
SWOG	NNP	O
)	)	O
evaluated	VBD	O
chemotherapy	NN	O
alone	RB	O
(	(	O
cyclophosphamide	JJ	O
,	,	O
doxorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
;	:	O
CHOP	NNP	O
)	)	O
or	CC	O
chemoimmunotherapy	NN	O
(	(	O
CHOP-levamisole	JJ	O
or	CC	O
CHOP-levamisole-BCG	JJ	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
715	CD	O
eligible	JJ	O
patients	NNS	O
with	IN	O
all	DT	O
types	NNS	O
of	IN	O
malignant	JJ	O
lymphoma	NN	O
(	(	O
ML	NNP	O
)	)	O
.	.	O

Of	IN	O
281	CD	O
evaluable	JJ	O
patients	NNS	O
with	IN	O
favorable	JJ	O
histologic	JJ	O
types	NNS	O
of	IN	O
ML	NNP	O
,	,	O
171	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
achieved	VBD	O
complete	JJ	PH
remission	NN	PH
(	(	PH
CR	NNP	PH
)	)	PH
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
CR	NNP	MO
rate	NN	MO
,	,	MO
CR	NNP	MO
duration	NN	MO
,	,	PH
or	CC	PH
survival	NN	MO
according	VBG	O
to	TO	O
the	DT	O
type	NN	O
of	IN	O
initial	JJ	O
treatment	NN	O
.	.	O

Of	IN	O
388	CD	O
evaluable	JJ	O
patients	NNS	O
with	IN	O
unfavorable	JJ	O
histologic	JJ	O
types	NNS	O
of	IN	O
ML	NNP	O
,	,	O
194	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
achieved	VBD	O
CR	NNP	PH
.	.	Ot

Levamisole	NNP	O
appeared	VBD	O
to	TO	O
adversely	RB	O
affect	VB	O
CR	NNP	MO
rates	NNS	MO
in	IN	O
nodular	JJ	O
mixed	JJ	O
and	CC	O
nodular	JJ	O
large-cell	NN	O
lymphoma	NN	O
and	CC	O
CR	NNP	PH
duration	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
unfavorable	JJ	O
histology	NN	O
ML	NNP	O
.	.	O

Chemoimmunotherapy	NNP	O
with	IN	O
levamisole	JJ	O
or	CC	O
levamisole-BCG	JJ	O
offers	NNS	O
no	DT	O
advantage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
CR	NNP	MO
rates	NNS	MO
,	,	A
CR	NNP	MO
duration	NN	MO
,	,	MO
or	CC	A
survival	NN	MO
compared	VBN	O
to	TO	O
CHOP	NNP	O
chemotherapy	NN	O
alone	RB	O
,	,	O
and	CC	O
levamisole	NN	O
may	MD	O
have	VB	O
had	VBD	O
an	DT	O
adverse	JJ	O
impact	NN	O
on	IN	O
outcome	NN	O
in	IN	O
certain	JJ	O
subtypes	NNS	O
of	IN	O
ML	NNP	O
.	.	O

Greater	NNP	O
knowledge	NN	ME
gain	NN	ME
with	IN	O
structured	VBN	O
than	IN	O
student-directed	JJ	O
learning	NN	O
in	IN	O
Child	NNP	O
Health	NNP	O
:	:	O
cluster	NN	O
randomized	VBD	O
trial	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
detect	VB	O
a	DT	O
difference	NN	O
in	IN	O
knowledge	NN	ME
gain	NN	ME
between	IN	O
students	NNS	O
receiving	VBG	O
structured	JJ	O
versus	NN	O
student-directed	JJ	O
learning	NN	O
for	IN	O
the	DT	O
two-week	JJ	O
Child	NNP	O
Health	NNP	O
outpatient	NN	O
module	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
138	CD	O
phase	NN	O
3	CD	O
(	(	O
year	NN	O
4	CD	O
)	)	O
medical	JJ	O
students	NNS	O
in	IN	O
10	CD	O
two-week	JJ	O
paediatric	JJ	O
outpatient	NN	O
blocks	NNS	O
at	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Child	NNP	O
Health	NNP	O
,	,	O
University	NNP	O
of	IN	O
Dundee	NNP	O
,	,	O
Scotland	NNP	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
student-directed	JJ	O
or	CC	O
structured	VBN	O
learning	NN	O
between	IN	O
January	NNP	O
and	CC	O
December	NNP	O
2002	CD	O
.	.	O

Pre-	JJ	Ot
and	CC	Ot
post-course	JJ	Ot
tests	NNS	Ot
were	VBD	O
administered	VBN	O
at	IN	O
the	DT	O
start	NN	O
and	CC	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
attachment	NN	O
;	:	O
129	CD	O
students	NNS	O
sat	VBD	O
both	DT	O
tests	NNS	O
.	.	O

Results	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
mean	JJ	O
scores	NNS	O
with	IN	O
standard	JJ	O
deviations	NNS	O
or	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CI	NNP	O
)	)	O
in	IN	O
parentheses	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
gain	NN	ME
in	IN	ME
knowledge	NN	ME
of	IN	O
the	DT	O
Child	NNP	O
Health	NNP	O
core	NN	O
curriculum	NN	O
that	WDT	O
is	VBZ	O
covered	VBN	O
in	IN	O
the	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

Although	IN	O
pre-course	JJ	ME
scores	NNS	ME
were	VBD	O
similar	JJ	O
(	(	O
student-directed	JJ	O
25.3	CD	O
(	(	O
7.3	CD	O
)	)	O
;	:	O
structured	VBN	O
24.8	CD	O
(	(	O
7.5	CD	O
)	)	O
)	)	O
the	DT	O
structured	JJ	O
approach	NN	O
resulted	VBD	O
in	IN	O
higher	JJR	O
post-course	NN	ME
scores	NNS	ME
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
student-directed	JJ	O
approach	NN	O
(	(	O
student-directed	JJ	O
41.8	CD	O
(	(	O
9.4	CD	O
)	)	O
;	:	O
structured	VBN	O
53.8	CD	O
(	(	O
8.8	CD	O
)	)	O
;	:	O
p	CC	O
<	VB	O
0.01	CD	O
)	)	O
.	.	O

Knowledge	NNP	ME
gain	NN	ME
showed	VBD	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
learning	NN	O
approaches	NNS	O
(	(	O
student-directed	JJ	O
16.5	CD	O
(	(	O
3.7	CD	O
)	)	O
;	:	O
structured	VBN	O
29.1	CD	O
(	(	O
3.8	CD	O
)	)	O
,	,	O
difference	NN	O
=	VBD	O
12.6	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
11.3	CD	O
to	TO	O
13.9	CD	O
)	)	O
)	)	O
.	.	O

Low	JJ	O
pre-course	JJ	ME
scores	NNS	ME
or	CC	O
gender	VB	O
did	VBD	O
not	RB	O
affect	VB	O
knowledge	NN	ME
gain	NN	ME
.	.	ME

In	IN	O
the	DT	O
Child	NNP	O
Health	NNP	O
outpatient	NN	O
setting	NN	O
,	,	O
the	DT	O
'traditional	NNP	O
'	POS	O
structured	JJ	O
approach	NN	O
led	VBD	O
to	TO	O
significantly	RB	O
greater	JJR	O
knowledge	NN	ME
gain	NN	ME
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
'novel	NNP	O
'	POS	O
student-directed	JJ	O
approach	NN	O
.	.	O

The	DT	O
findings	NNS	O
emphasize	VBP	O
the	DT	O
importance	NN	O
of	IN	O
careful	JJ	O
evaluation	NN	O
of	IN	O
novel	JJ	O
medical	JJ	O
education	NN	O
strategies	NNS	O
before	IN	O
their	PRP$	O
implementation	NN	O
in	IN	O
medical	JJ	O
schools	NNS	O
,	,	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
further	JJ	O
research	NN	O
to	TO	O
define	VB	O
the	DT	O
effective	JJ	O
methods	NNS	O
for	IN	O
delivering	VBG	O
medical	JJ	O
education	NN	O
in	IN	O
Child	NNP	O
Health	NNP	O
.	.	O

Randomized	VBN	O
Phase	NNP	O
II	NNP	O
trial	NN	O
assessing	VBG	O
estramustine	NN	O
and	CC	O
vinblastine	JJ	O
combination	NN	O
chemotherapy	NN	O
vs	JJ	O
estramustine	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	O
hormone-escaped	JJ	O
metastatic	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
combined	JJ	O
data	NNS	O
from	IN	O
three	CD	O
North	JJ	O
American	JJ	O
Phase	NNP	O
II	NNP	O
studies	NNS	O
,	,	O
a	DT	O
randomised	JJ	O
Phase	NNP	O
II	NNP	O
study	NN	O
in	IN	O
the	DT	O
same	JJ	O
patient	JJ	O
population	NN	O
was	VBD	O
performed	VBN	O
,	,	O
using	VBG	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
estramustine	JJ	O
phosphate	NN	O
(	(	O
EMP	NNP	O
)	)	O
and	CC	O
vinblastine	NN	O
(	(	O
VBL	NNP	O
)	)	O
in	IN	O
hormone	NN	O
refractory	NN	O
prostate	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

In	IN	O
all	DT	O
,	,	O
92	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
into	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
study	NN	O
of	IN	O
oral	JJ	O
EMP	NNP	O
(	(	O
10	CD	O
mg	NNS	O
kg	JJ	O
day	NN	O
continuously	RB	O
)	)	O
or	CC	O
oral	JJ	O
EMP	NNP	O
in	IN	O
combination	NN	O
with	IN	O
intravenous	JJ	O
VBL	NNP	O
(	(	O
4	CD	O
mg	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	O
weeks	NNS	O
rest	NN	O
)	)	O
.	.	O

The	DT	O
end	NN	O
points	NNS	O
were	VBD	O
toxicity	NN	A
and	CC	O
PSA	NNP	PH
response	NN	PH
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
the	DT	O
option	NN	O
to	TO	O
continue	VB	O
the	DT	O
trial	NN	O
as	IN	O
a	DT	O
Phase	NNP	O
III	NNP	O
study	NN	O
with	IN	O
time	NN	PH
to	TO	PH
progression	NN	PH
and	CC	O
survival	NN	MO
as	IN	O
end	NN	O
points	NNS	O
,	,	O
if	IN	O
sufficient	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Toxicity	NNP	A
was	VBD	O
unexpectedly	RB	O
high	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
and	CC	O
led	VBD	O
to	TO	O
treatment	NN	O
withdrawal	NN	O
or	CC	O
refusal	NN	O
in	IN	O
49	CD	O
%	NN	O
of	IN	O
all	DT	O
patients	NNS	O
,	,	O
predominantly	RB	O
already	RB	O
during	IN	O
the	DT	O
first	JJ	O
treatment	NN	O
cycle	NN	O
.	.	O

The	DT	O
mean	JJ	Ot
treatment	NN	Ot
duration	NN	Ot
was	VBD	O
10	CD	O
and	CC	O
14	CD	O
weeks	NNS	O
,	,	O
median	JJ	PH
time	NN	PH
to	TO	PH
PSA	NNP	PH
progression	NN	PH
was	VBD	O
27.2	CD	O
and	CC	O
30.8	CD	O
weeks	NNS	O
,	,	O
median	JJ	MO
survival	NN	MO
time	NN	MO
was	VBD	O
44	CD	O
and	CC	O
50.9	CD	O
weeks	NNS	O
,	,	O
and	CC	O
PSA	NNP	PH
response	NN	PH
rate	NN	PH
was	VBD	O
only	RB	O
24.6	CD	O
and	CC	O
28.9	CD	O
%	NN	O
in	IN	O
the	DT	O
EMP/VBL	NNP	O
and	CC	O
EMP	NNP	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
correlation	NN	O
between	IN	O
PSA	NNP	PH
response	NN	PH
and	CC	O
survival	NN	MO
.	.	O

While	IN	O
the	DT	O
PSA	NNP	PH
response	NN	PH
in	IN	O
the	DT	O
patients	NNS	O
tested	VBD	O
was	VBD	O
less	JJR	O
than	IN	O
half	NN	O
that	WDT	O
recorded	VBD	O
in	IN	O
the	DT	O
North	JJ	O
American	JJ	O
studies	NNS	O
,	,	O
the	DT	O
toxicity	NN	A
of	IN	A
EMP	NNP	A
monotherapy	NN	A
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
VBL	NNP	O
was	VBD	O
much	RB	O
higher	JJR	O
than	IN	O
expected	VBN	O
.	.	O

Further	NNP	O
research	NN	O
on	IN	O
more	RBR	O
effective	JJ	Ot
and	CC	O
less	RBR	O
toxic	JJ	A
treatment	NN	O
strategies	NNS	O
for	IN	O
hormone	NN	O
refractory	NN	O
prostate	NN	O
cancer	NN	O
is	VBZ	O
mandatory	JJ	O
.	.	O

[	IN	O
The	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
gastric	JJ	O
metaplasia	NN	O
in	IN	O
the	DT	O
duodenal	JJ	O
mucosa	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Helicobacter	NNP	O
pylori	VBP	O
positive	JJ	O
duodenal	JJ	O
bulb	NN	O
ulcer	NN	O
]	NNP	O
.	.	O

The	DT	O
predictive	JJ	O
value	NN	O
of	IN	O
gastric	JJ	O
metaplasia	NN	O
in	IN	O
the	DT	O
duodenal	JJ	O
mucosa	NN	O
in	IN	O
patients	NNS	O
Helicobacter	NNP	O
pylori-positive	JJ	O
patients	NNS	O
with	IN	O
duodenal	JJ	O
bulb	NN	O
ulcer	NN	O
(	(	O
DBU	NNP	O
)	)	O
was	VBD	O
investigated	VBN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
twenty	VB	O
four	CD	O
randomly	RB	O
selected	VBN	O
patients	NNS	O
with	IN	O
DBU	NNP	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
.	.	O

The	DT	O
detection	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	FW	O
(	(	O
HP	NNP	O
)	)	O
in	IN	O
the	DT	O
stomach	NN	O
and	CC	O
duodenum	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
with	IN	O
Giemsa	NNP	O
(	(	O
using	VBG	O
standard	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
)	)	O
,	,	O
rapid	JJ	O
urease	JJ	O
test	NN	O
(	(	O
standard	JJ	O
Jatrox-HP	NNP	O
test	NN	O
,	,	O
Rohm	NNP	O
Pharma	NNP	O
,	,	O
Germany	NNP	O
)	)	O
,	,	O
and	CC	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
to	TO	O
detect	VB	O
the	DT	O
specific	JJ	O
fragment	NN	O
of	IN	O
ureC	JJ	O
HP	NNP	O
gene	NN	O
(	(	O
Helicopol	NNP	O
II	NNP	O
,	,	O
Lytech	NNP	O
,	,	O
Russia	NNP	O
)	)	O
.	.	O

Regions	NNS	O
of	IN	O
gastric	JJ	O
metaplasia	NN	O
of	IN	O
the	DT	O
duodenum	NN	O
were	VBD	O
confirmed	VBN	O
by	IN	O
periodic	JJ	O
acid-Schiff	JJ	O
and	CC	O
alcian	JJ	O
blue	NN	O
(	(	O
Serva	NNP	O
)	)	O
staining	NN	O
(	(	O
pH	JJ	O
1.0	CD	O
;	:	O
2.5	CD	O
)	)	O
Duodenal	NNP	O
ulcer	NN	O
(	(	O
DU	NNP	O
)	)	O
complications	NNS	O
were	VBD	O
registered	VBN	O
within	IN	O
8	CD	O
to	TO	O
10	CD	O
years	NNS	O
.	.	O

Estimation	NN	O
of	IN	O
the	DT	O
predictive	JJ	O
factor	NN	O
(	(	PH
gastric	JJ	PH
metaplasia	NN	PH
in	IN	PH
the	DT	PH
duodenum	NN	PH
)	)	PH
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
patients	NNS	O
with	IN	O
non-complicated	JJ	O
DU	NNP	O
(	(	O
Group	NNP	O
1	CD	O
;	:	O
n	CC	O
=	VB	O
73	CD	O
)	)	O
,	,	O
and	CC	O
with	IN	O
such	JJ	O
complications	NNS	O
as	IN	O
bleeding	NN	O
,	,	O
perforation	NN	O
,	,	O
penetration	NN	O
,	,	O
pyloroduodenal	JJ	O
stenosis	NN	O
(	(	O
Group	NNP	O
2	CD	O
;	:	O
n	CC	O
=	VB	O
51	CD	O
)	)	O
which	WDT	O
were	VBD	O
revealed	VBN	O
within	IN	O
the	DT	O
8	CD	O
to	TO	O
10	CD	O
years	NNS	O
of	IN	O
observation	NN	O
.	.	O

Gastric	NNP	PH
metaplasia	NN	PH
in	IN	PH
the	DT	PH
duodenum	NN	PH
was	VBD	O
found	VBN	O
in	IN	O
64	CD	O
or	CC	O
87.7	CD	O
%	NN	O
of	IN	O
the	DT	O
73	CD	O
patients	NNS	O
with	IN	O
non-complicated	JJ	O
DU	NNP	O
and	CC	O
in	IN	O
5	CD	O
or	CC	O
9.8	CD	O
%	NN	O
of	IN	O
the	DT	O
51	CD	O
patients	NNS	O
with	IN	O
complicated	JJ	O
DU	NNP	O
within	IN	O
8	CD	O
to	TO	O
10	CD	O
years	NNS	O
of	IN	O
observation	NN	O
.	.	O

The	DT	O
following	JJ	O
facts	NNS	O
about	IN	O
the	DT	O
predictive	JJ	O
factor	NN	O
for	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
DU	NNP	O
complication	NN	O
were	VBD	O
found	VBN	O
:	:	O
the	DT	O
sensitivity	NN	Ot
of	IN	O
83.6	CD	O
%	NN	O
,	,	O
the	DT	O
specificity	NN	Ot
of	IN	O
92.8	CD	O
%	NN	O
,	,	O
the	DT	O
predictive	JJ	Ot
accuracy	NN	Ot
of	IN	O
88.7	CD	O
%	NN	O
,	,	O
the	DT	O
relative	JJ	PH
risk	NN	PH
of	IN	PH
the	DT	PH
predicted	JJ	PH
outcome	NN	PH
of	IN	O
7.5	CD	O
,	,	O
the	DT	O
relative	JJ	O
risk	NN	O
of	IN	O
a	DT	O
different	JJ	O
outcome	NN	O
of	IN	O
0.11	CD	O
,	,	O
the	DT	O
odds	NNS	O
ration	NN	O
of	IN	O
65.4	CD	O
.	.	O

The	DT	O
study	NN	O
revealed	VBD	O
a	DT	O
high	JJ	O
and	CC	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
predictive	JJ	O
value	NN	O
of	IN	O
gastric	JJ	PH
metaplasia	NN	PH
in	IN	O
the	DT	O
duodenum	NN	O
as	IN	O
a	DT	O
marker	NN	O
of	IN	O
non-complicated	JJ	O
clinical	JJ	O
course	NN	O
of	IN	O
DU	NNP	O
in	IN	O
HP-positive	JJ	O
patients	NNS	O
within	IN	O
an	DT	O
8	CD	O
to	TO	O
10-year	JJ	O
period	NN	O
.	.	O

Efficacy	NN	Ot
and	CC	O
tolerability	NN	Ot
of	IN	O
donepezil	NN	O
in	IN	O
vascular	JJ	O
dementia	NN	O
:	:	O
positive	JJ	O
results	NNS	O
of	IN	O
a	DT	O
24-week	JJ	O
,	,	O
multicenter	NN	O
,	,	O
international	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Clinical	NNP	O
observations	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
dementia	NN	O
(	(	O
VaD	NNP	O
)	)	O
may	MD	O
benefit	VB	O
from	IN	O
treatment	NN	O
with	IN	O
cholinesterase	NN	O
inhibitors	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	Ot
and	CC	O
safety	NN	Ot
of	IN	O
donepezil	NN	O
for	IN	O
relieving	VBG	O
symptoms	NNS	O
of	IN	O
dementia	NN	O
in	IN	O
VaD	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
(	(	O
n=603	JJ	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
73.9	CD	O
years	NNS	O
;	:	O
55.2	CD	O
%	NN	O
men	NNS	O
)	)	O
with	IN	O
probable	JJ	O
(	(	O
70.5	CD	O
%	NN	O
)	)	O
or	CC	O
possible	JJ	O
(	(	O
29.5	CD	O
%	NN	O
)	)	O
VaD	NNP	O
,	,	O
according	VBG	O
to	TO	O
criteria	NNS	O
of	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Neurological	NNP	O
Disorders	NNP	O
and	CC	O
Stroke	NNP	O
(	(	O
NINDS	NNP	O
)	)	O
and	CC	O
the	DT	O
Association	NNP	O
Internationale	NNP	O
pour	VBP	O
la	NN	O
Recherche	NNP	O
et	CC	O
l'Enseignement	JJ	O
en	NN	O
Neurosciences	NNP	O
(	(	O
AIREN	NNP	O
)	)	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
donepezil	JJ	O
5	CD	O
mg/d	NN	O
(	(	O
n=198	JJ	O
)	)	O
,	,	O
donepezil	$	O
10	CD	O
mg/d	NN	O
(	(	O
5	CD	O
mg/d	NN	O
for	IN	O
first	JJ	O
28	CD	O
days	NNS	O
;	:	O
n=206	CC	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n=199	JJ	O
)	)	O
.	.	O

Analyses	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
24	CD	O
,	,	O
both	DT	O
donepezil	NN	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
improvement	NN	ME
in	IN	ME
cognition	NN	ME
versus	NN	O
placebo	NN	O
on	IN	O
the	DT	O
Alzheimer	NNP	ME
's	POS	ME
Disease	NNP	ME
Assessment	NNP	ME
Scale-cognitive	JJ	ME
subscale	NN	ME
(	(	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
score	NN	O
effect	NN	O
size	NN	O
:	:	O
donepezil	NN	O
5	CD	O
mg/d	NN	O
,	,	O
-1.90	NNP	O
;	:	O
P=0.001	NNP	O
;	:	O
donepezil	VBZ	O
10	CD	O
mg/d	NN	O
,	,	O
-2.33	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significant	JJ	O
improvements	NNS	O
in	IN	O
patients	NNS	PH
'	POS	PH
global	JJ	PH
function	NN	PH
were	VBD	O
seen	VBN	O
versus	NN	O
placebo	NN	O
at	IN	O
week	NN	O
24	CD	O
(	(	O
observed	JJ	O
cases	NNS	O
)	)	O
,	,	O
on	IN	O
the	DT	O
Clinician	NNP	ME
's	POS	ME
Interview-Based	JJ	ME
Impression	NN	ME
of	IN	ME
Change-Plus	NNP	ME
version	NN	ME
only	RB	O
for	IN	O
patients	NNS	O
on	IN	O
donepezil	JJ	O
5	CD	O
mg/d	NN	O
(	(	O
P=0.014	NNP	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
Sum	NNP	PH
of	IN	PH
the	DT	PH
Boxes	NNP	PH
of	IN	PH
the	DT	PH
Clinical	NNP	PH
Dementia	NNP	PH
Rating	NNP	PH
only	RB	O
for	IN	O
patients	NNS	O
on	IN	O
10	CD	O
mg/d	NN	O
(	(	O
P=0.007	NNP	O
)	)	O
.	.	O

Donepezil-treated	JJ	O
patients	NNS	O
showed	VBD	O
significant	JJ	O
benefits	NNS	O
in	IN	O
activities	NNS	PH
of	IN	PH
daily	JJ	PH
living	NN	PH
over	IN	O
placebo	NN	O
on	IN	O
the	DT	O
Alzheimer	NNP	ME
's	POS	ME
Disease	NNP	ME
Functional	NNP	ME
Assessment	NNP	ME
and	CC	ME
Change	NNP	ME
Scale	NNP	ME
(	(	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
score	NN	O
effect	NN	O
size	NN	O
at	IN	O
week	NN	O
24	CD	O
:	:	O
donepezil	NN	O
5	CD	O
mg/d	NN	O
,	,	O
-1.31	NNP	O
,	,	O
P=0.02	NNP	O
;	:	O
donepezil	VBZ	O
10	CD	O
mg/d	NN	O
,	,	O
-1.31	NNP	O
,	,	O
P=0.02	NNP	O
)	)	O
.	.	O

Donepezil	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Withdrawal	NNP	Ot
rates	NNS	Ot
due	JJ	O
to	TO	O
adverse	JJ	A
events	NNS	A
were	VBD	O
relatively	RB	O
low	JJ	O
(	(	O
placebo	NN	O
,	,	O
11.1	CD	O
%	NN	O
;	:	O
donepezil	CC	O
5	CD	O
mg/d	NN	O
,	,	O
11.1	CD	O
%	NN	O
;	:	O
donepezil	CC	O
10	CD	O
mg/d	NN	O
,	,	O
21.8	CD	O
%	NN	O
;	:	O
P=0.005	NNP	O
versus	IN	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
donepezil	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
VaD	NNP	O
and	CC	O
show	VB	O
it	PRP	O
may	MD	O
have	VB	O
an	DT	O
important	JJ	O
place	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
this	DT	O
condition	NN	O
.	.	O

Efficiency	NN	Ot
of	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
following	VBG	O
curative	JJ	O
resection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
curative	JJ	O
resection	NN	O
,	,	O
50	CD	O
%	NN	O
-90	CD	O
%	NN	O
of	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
die	VBP	O
of	IN	O
disease	NN	PH
relapse	NN	PH
.	.	O

Although	IN	O
some	DT	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
chemotherapy	NN	O
and	CC	O
immunochemotherapy	NN	O
may	MD	O
be	VB	O
effective	JJ	O
modalities	NNS	O
,	,	O
more	RBR	O
recent	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
able	JJ	O
to	TO	O
define	VB	O
the	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
BCG	NNP	O
(	(	O
bacille	IN	O
Calmette-Guerin	NNP	O
)	)	O
and	CC	O
FAM	NNP	O
(	(	O
5-fluorouracil	JJ	O
,	,	O
adriamycin	JJ	O
,	,	O
mitomycin	JJ	O
C	NNP	O
)	)	O
chemotherapy	NN	O
on	IN	O
the	DT	O
survival	NN	MO
of	IN	MO
patients	NNS	MO
with	IN	O
locally	RB	O
advanced	VBN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
156	CD	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
gastric	JJ	O
cancer	NN	O
who	WP	O
had	VBD	O
undergone	JJ	O
curative	JJ	O
resection	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
(	(	O
immunochemotherapy	NN	O
)	)	O
,	,	O
FAM	NNP	O
(	(	O
chemotherapy	NN	O
)	)	O
,	,	O
and	CC	O
control	NN	O
(	(	O
surgery	NN	O
only	RB	O
)	)	O
.	.	O

Treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
2	CD	O
years	NNS	O
or	CC	O
until	IN	O
death	NN	O
.	.	O

Further	NNP	O
postsurgical	JJ	O
follow	VBP	O
up	RP	O
was	VBD	O
carried	VBN	O
on	IN	O
for	IN	O
up	IN	O
to	TO	O
10	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Overall	JJ	O
10-year	JJ	MO
survival	NN	MO
was	VBD	O
47.1	CD	O
%	NN	O
for	IN	O
the	DT	O
immunochemotherapy	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.037	CD	O
vs	NN	O
FAM	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.0006	CD	O
vs	NNS	O
control	NN	O
)	)	O
,	,	O
30	CD	O
%	NN	O
for	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
(	(	O
vs	FW	O
control	NN	O
,	,	O
NS	NNP	O
)	)	O
,	,	O
and	CC	O
15.2	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	O
primary	JJ	O
tumors	NNS	O
,	,	O
10-year	JJ	MO
survival	NN	MO
was	VBD	O
55.3	CD	O
%	NN	O
for	IN	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
vs	VBD	O
28.2	CD	O
%	NN	O
for	IN	O
FAM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
14.6	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.00018	CD	O
)	)	O
.	.	O

BCG	NNP	O
+	NNP	O
FAM	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
survival	NN	MO
of	IN	MO
patients	NNS	MO
with	IN	O
intestinal-type	JJ	O
but	CC	O
not	RB	O
diffuse-type	JJ	O
cancer	NN	O
.	.	O

Immunochemotherapy	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
,	,	O
based	VBN	O
on	IN	O
a	DT	O
limited	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
,	,	O
indicates	VBZ	O
that	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
(	(	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
)	)	O
may	MD	O
prolong	VB	O
the	DT	O
survival	NN	MO
of	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
after	IN	O
curative	JJ	O
gastrectomy	NN	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	O
tumors	NNS	O
and	CC	O
intestinal-type	JJ	O
primary	JJ	O
tumors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
survival	JJ	MO
benefit	NN	MO
from	IN	O
FAM	NNP	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

Prenatal	JJ	O
depression	NN	O
predicts	VBZ	O
postpartum	JJ	O
maternal	JJ	O
attachment	NN	O
in	IN	O
low-income	JJ	O
Latina	NNP	O
mothers	NNS	O
with	IN	O
infants	NNS	O
.	.	O

Although	IN	O
maternal	JJ	O
attachment	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
predictor	NN	O
of	IN	O
infant	JJ	O
attachment	JJ	O
security	NN	O
and	CC	O
other	JJ	O
developmental	JJ	O
outcomes	NNS	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
formation	NN	O
of	IN	O
maternal	JJ	O
attachment	NN	O
in	IN	O
the	DT	O
first	JJ	O
few	JJ	O
months	NNS	O
of	IN	O
the	DT	O
infant	NN	O
's	POS	O
life	NN	O
,	,	O
particularly	RB	O
among	IN	O
ethnic	JJ	O
minority	NN	O
mothers	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
predictors	NNS	O
of	IN	O
postpartum	JJ	O
maternal	JJ	O
attachment	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
217	CD	O
Latina	NNP	O
women	NNS	O
enrolled	VBD	O
in	IN	O
a	DT	O
perinatal	JJ	O
depression	NN	O
prevention	NN	O
trial	NN	O
.	.	O

Mothers	NNS	O
'	POS	O
attachment	NN	O
to	TO	O
their	PRP$	O
infants	NNS	O
was	VBD	O
measured	VBN	O
at	IN	O
6-8	JJ	O
weeks	NNS	O
postpartum	NN	O
using	VBG	O
the	DT	O
Maternal	NNP	ME
Postnatal	NNP	ME
Attachment	NNP	ME
Scale	NNP	ME
.	.	O

A	NNP	O
variety	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
early	JJ	O
attachment	NN	O
were	VBD	O
explored	VBN	O
including	VBG	O
:	:	O
depressive	JJ	ME
symptoms	NNS	ME
during	IN	ME
pregnancy	NN	ME
,	,	ME
pregnancy	NN	ME
intention	NN	ME
,	,	ME
feelings	NNS	ME
about	IN	ME
the	DT	ME
pregnancy	NN	ME
,	,	ME
and	CC	ME
the	DT	ME
quality	NN	ME
of	IN	ME
the	DT	ME
partner	NN	ME
relationship	NN	ME
.	.	O

The	DT	O
strongest	JJS	O
predictor	NN	O
of	IN	O
lower	JJR	Ot
maternal	JJ	Ot
attachment	NN	Ot
was	VBD	O
depressive	JJ	ME
symptoms	NNS	ME
late	RB	O
in	IN	O
pregnancy	NN	O
;	:	O
pregnancy	NN	O
intention	NN	O
was	VBD	O
marginally	RB	O
predictive	JJ	O
of	IN	O
attachment	NN	ME
,	,	O
with	IN	O
lower	JJR	O
scores	NNS	O
being	VBG	O
associated	VBN	O
with	IN	O
unwanted	JJ	O
pregnancies	NNS	O
.	.	O

The	DT	O
study	NN	O
fills	VBZ	O
a	DT	O
critical	JJ	O
gap	NN	O
in	IN	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
role	NN	O
of	IN	O
depressive	JJ	O
symptoms	NNS	O
during	IN	O
pregnancy	NN	O
in	IN	O
shaping	VBG	O
mothers	NNS	O
'	POS	O
early	JJ	O
attachment	NN	O
to	TO	O
their	PRP$	O
infants	NNS	O
.	.	O

Beneficial	JJ	O
effect	NN	O
of	IN	O
etidronate	NN	O
therapy	NN	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
,	,	O
disabled	JJ	O
patients	NNS	O
with	IN	O
stroke	NN	O
.	.	O

Incidence	NN	O
of	IN	O
hip	NN	O
fractures	NNS	O
is	VBZ	O
high	JJ	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
,	,	O
disabled	VBD	O
,	,	O
elderly	JJ	O
patients	NNS	O
after	IN	O
stroke	NN	O
.	.	O

Duration	NN	O
of	IN	O
hospitalization	NN	O
was	VBD	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
because	IN	O
of	IN	O
insufficiency	NN	O
of	IN	O
nursing	NN	O
homes	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
showed	VBD	O
that	IN	O
immobilization-induced	JJ	O
hypercalcemia	NN	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
deficiency	NN	O
contribute	NN	O
to	TO	O
reduced	VB	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
address	VB	O
the	DT	O
possibility	NN	O
that	WDT	O
treatment	NN	O
with	IN	O
etidronate	NN	O
may	MD	O
reduce	VB	O
the	DT	O
bone	NN	O
resorption	NN	O
and	CC	O
lower	JJR	O
the	DT	O
incidence	NN	O
of	IN	O
fractures	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
who	WP	O
are	VBP	O
chronically	RB	O
hospitalized	VBN	O
and	CC	O
disabled	VBN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
hemiparesis	NN	O
after	IN	O
stroke	NN	O
.	.	O

Patients	NNS	O
with	IN	O
stroke	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
daily	VB	O
treatment	NN	O
with	IN	O
400	CD	O
mg	NNS	O
of	IN	O
etidronate	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
,	,	O
and	CC	O
followed	VBD	O
up	RB	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
both	DT	O
groups	NNS	O
had	VBD	O
low	JJ	O
BMD	NNP	PH
with	IN	O
high	JJ	PH
levels	NNS	PH
of	IN	PH
serum	NN	PH
ionized	VBN	PH
calcium	NN	PH
and	CC	O
urinary	JJ	PH
deoxypyridinoline	NN	PH
.	.	O

In	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
,	,	O
serum	NN	PH
calcium	NN	PH
and	CC	O
urinary	JJ	PH
deoxypyridinoline	NN	PH
levels	NNS	PH
decreased	VBN	O
significantly	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
whereas	IN	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
increased	VBN	O
.	.	O

BMD	NNP	PH
on	IN	PH
the	DT	PH
hemiplegic	JJ	PH
side	NN	PH
increased	VBN	O
by	IN	O
1.4	CD	O
%	NN	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
and	CC	O
decreased	VBN	O
by	IN	O
2.2	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
sustained	VBD	O
hip	JJ	A
fractures	NNS	A
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
no	DT	O
hip	NN	A
fracture	NN	A
occurred	VBD	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
.	.	O

Treatment	NN	O
with	IN	O
etidronate	NN	O
increases	NNS	O
BMD	NNP	PH
in	IN	O
chronically	RB	O
hospitalized	VBN	O
patients	NNS	O
poststroke	VBD	O
,	,	O
and	CC	O
may	MD	O
prevent	VB	O
hip	NN	O
fracture	NN	O
.	.	O

An	DT	O
evaluation	NN	O
of	IN	O
an	DT	O
adaptive	JJ	O
automation	NN	O
system	NN	O
using	VBG	O
a	DT	O
cognitive	JJ	O
vigilance	NN	O
task	NN	O
.	.	O

The	DT	O
performance	NN	O
of	IN	O
an	DT	O
adaptive	JJ	O
automation	NN	O
system	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
cognitive	JJ	O
vigilance	NN	O
task	NN	O
.	.	O

Participants	NNS	O
responded	VBD	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
green	JJ	O
K	NNP	O
in	IN	O
an	DT	O
array	NN	O
of	IN	O
two	CD	O
,	,	O
five	CD	O
,	,	O
or	CC	O
nine	CD	O
distractor	NN	O
stimuli	NNS	O
during	IN	O
a	DT	O
40-min	JJ	O
vigil	NN	O
.	.	O

The	DT	O
array	NN	O
with	IN	O
the	DT	O
target	NN	O
stimulus	NN	O
was	VBD	O
presented	VBN	O
once	RB	O
each	DT	O
minute	NN	O
.	.	O

Participants	NNS	O
EEG	NNP	O
was	VBD	O
recorded	VBN	O
and	CC	O
an	DT	O
engagement	JJ	ME
index	NN	ME
(	(	O
EI	NNP	O
=	VBZ	O
20	CD	O
x	NN	O
beta/	NN	O
(	(	O
alpha	JJ	O
+	NNP	O
theta	NN	O
)	)	O
)	)	O
was	VBD	O
derived	VBN	O
.	.	O

In	IN	O
the	DT	O
negative	JJ	O
feedback	NN	O
condition	NN	O
,	,	O
increases	VBZ	O
in	IN	O
the	DT	O
EI	NNP	O
caused	VBD	O
the	DT	O
number	NN	ME
of	IN	ME
stimuli	NNS	ME
in	IN	ME
the	DT	ME
array	NN	ME
to	TO	O
decrease	VB	O
while	IN	O
decreases	NNS	O
in	IN	O
the	DT	O
EI	NNP	ME
caused	VBD	ME
the	DT	ME
number	NN	ME
of	IN	ME
stimuli	NNS	ME
to	TO	ME
increase	VB	ME
.	.	O

For	IN	O
the	DT	O
positive	JJ	O
feedback	NN	O
condition	NN	O
,	,	O
increases	VBZ	O
in	IN	O
the	DT	O
index	NN	O
caused	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
array	NN	O
size	NN	O
(	(	O
AS	IN	O
)	)	O
while	IN	O
decreases	NNS	O
caused	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
array	NN	O
size	NN	O
.	.	O

Each	DT	O
experimental	JJ	O
participant	NN	O
had	VBD	O
a	DT	O
yoked	VBN	O
control	NN	O
partner	NN	O
who	WP	O
received	VBD	O
the	DT	O
same	JJ	O
pattern	NN	O
of	IN	O
changes	NNS	O
in	IN	O
array	JJ	O
irrespective	NN	O
of	IN	O
their	PRP$	O
engagement	JJ	O
index	NN	O
.	.	O

A	DT	O
vigilance	NN	O
decrement	NN	O
was	VBD	O
seen	VBN	O
only	RB	O
for	IN	O
the	DT	O
positive	JJ	O
feedback	NN	O
,	,	O
experimental	JJ	O
group	NN	O
.	.	O

Chemoprevention	NN	O
of	IN	O
gastric	JJ	O
dysplasia	NN	O
:	:	O
randomized	JJ	O
trial	NN	O
of	IN	O
antioxidant	JJ	O
supplements	NNS	O
and	CC	O
anti-helicobacter	JJ	O
pylori	NN	O
therapy	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
research	NN	O
has	VBZ	O
identified	VBN	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
gastric	JJ	O
carcinoma	NN	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
cancer	NN	O
precursor	NN	O
lesions	NNS	O
in	IN	O
rural	JJ	O
populations	NNS	O
living	VBG	O
in	IN	O
the	DT	O
province	NN	O
of	IN	O
Nari?o	NNP	O
,	,	O
Colombia	NNP	O
,	,	O
in	IN	O
the	DT	O
Andes	NNP	O
Mountains	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
controlled	VBN	O
chemoprevention	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
subjects	NNS	O
with	IN	O
confirmed	JJ	O
histologic	JJ	O
diagnoses	NNS	O
of	IN	O
multifocal	JJ	O
nonmetaplastic	JJ	O
atrophy	NN	O
and/or	IN	O
intestinal	JJ	O
metaplasia	NN	O
,	,	O
two	CD	O
precancerous	JJ	O
lesions	NNS	O
.	.	O

Individuals	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
anti-Helicobacter	JJ	O
pylori	NN	O
triple	JJ	O
therapy	NN	O
and/or	NN	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
ascorbic	JJ	O
acid	NN	O
,	,	O
beta-carotene	JJ	O
,	,	O
or	CC	O
their	PRP$	O
corresponding	JJ	O
placebos	NN	O
.	.	O

Gastric	NNP	O
biopsy	NN	O
specimens	VBZ	O
taken	VBN	O
at	IN	O
baseline	NN	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
taken	VBN	O
at	IN	O
72	CD	O
months	NNS	O
.	.	O

Relative	JJ	O
risks	NNS	O
of	IN	O
progression	NN	O
,	,	O
no	DT	O
change	NN	O
,	,	O
and	CC	O
regression	NN	O
from	IN	O
multifocal	JJ	O
nonmetaplastic	JJ	O
atrophy	NN	O
and	CC	O
intestinal	JJ	O
metaplasia	NN	O
were	VBD	O
analyzed	VBN	O
with	IN	O
multivariate	NN	O
polytomous	JJ	O
logistic	JJ	O
regression	NN	O
models	NNS	O
to	TO	O
estimate	VB	O
treatment	NN	O
effects	NNS	O
.	.	O

All	DT	O
statistical	JJ	O
tests	NNS	O
were	VBD	O
two-sided	JJ	O
.	.	O

RESULTS	VB	O
All	DT	O
three	CD	O
basic	JJ	O
interventions	NNS	O
resulted	VBD	O
in	IN	O
statistically	RB	O
significant	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
rates	NNS	O
of	IN	O
regression	NN	O
:	:	O
Relative	JJ	O
risks	NNS	O
were	VBD	O
4.8	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	NNP	O
1.6-14.2	JJ	O
)	)	O
for	IN	O
anti-H.	JJ	O
pylori	NN	O
treatment	NN	O
,	,	O
5	CD	O
.	.	O

1	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.7-15.0	JJ	O
)	)	O
for	IN	O
beta-carotene	JJ	O
treatment	NN	O
,	,	O
and	CC	O
5.0	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.7-14.4	JJ	O
)	)	O
for	IN	O
ascorbic	JJ	O
acid	JJ	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
atrophy	NN	O
.	.	O

Corresponding	VBG	O
relative	JJ	O
risks	NNS	O
of	IN	O
regression	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
intestinal	JJ	O
metaplasia	NNS	O
were	VBD	O
3.1	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.0-9.3	JJ	O
)	)	O
,	,	O
3.4	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.1-9.8	JJ	O
)	)	O
,	,	O
and	CC	O
3.3	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.1-9.5	JJ	O
)	)	O
.	.	O

Combinations	NNS	O
of	IN	O
treatments	NNS	O
did	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
increase	VB	O
the	DT	O
regression	NN	O
rates	NNS	O
.	.	O

Curing	VBG	O
the	DT	O
H.	NNP	O
pylori	NN	O
infection	NN	O
(	(	O
which	WDT	O
occurred	VBD	O
in	IN	O
74	CD	O
%	NN	O
of	IN	O
the	DT	O
treated	JJ	O
subjects	NNS	O
)	)	O
produced	VBD	O
a	DT	O
marked	JJ	O
and	CC	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
regression	NN	O
of	IN	O
the	DT	O
precursor	NN	O
lesions	NNS	O
(	(	O
relative	JJ	O
risks	NNS	O
=	VBP	O
8.7	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
2.7-28.2	JJ	O
]	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
atrophy	NN	O
and	CC	O
5.4	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.7-17.6	JJ	O
]	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
intestinal	JJ	O
metaplasia	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
the	DT	O
very	RB	O
high-risk	JJ	O
population	NN	O
studied	VBN	O
,	,	O
effective	JJ	O
anti-H.	JJ	O
pylori	NN	O
treatment	NN	O
and	CC	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
antioxidant	JJ	O
micronutrients	NNS	O
may	MD	O
interfere	VB	O
with	IN	O
the	DT	O
precancerous	JJ	O
process	NN	O
,	,	O
mostly	RB	O
by	IN	O
increasing	VBG	O
the	DT	O
rate	NN	O
of	IN	O
regression	NN	O
of	IN	O
cancer	NN	O
precursor	NN	O
lesions	NNS	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
strategy	NN	O
to	TO	O
prevent	VB	O
gastric	JJ	O
carcinoma	NN	O
.	.	O

Processing	VBG	O
familiar	JJ	O
and	CC	O
unfamiliar	JJ	O
auditory	NN	O
stimuli	NN	O
during	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
tested	VBD	O
memory	NN	O
priming	NN	O
for	IN	O
auditory	JJ	O
stimuli	NNS	O
presented	VBN	O
during	IN	O
general	JJ	O
propofol-sufentanil	JJ	O
anesthesia	NN	O
in	IN	O
58	CD	O
patients	NNS	O
undergoing	JJ	O
day-case	JJ	O
arthroscopic	NN	O
surgery	NN	O
.	.	O

Stimuli	NNP	O
were	VBD	O
presented	VBN	O
via	IN	O
headphones	NNS	O
and	CC	O
consisted	VBN	O
of	IN	O
common	JJ	O
facts	NNS	O
(	(	O
Group	NNP	O
A	NNP	O
,	,	O
29	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
familiar	JJ	O
or	CC	O
unfamiliar	JJ	O
full	JJ	O
names	NNS	O
of	IN	O
fictitious	JJ	O
people	NNS	O
(	(	O
GRoup	NNP	O
B	NNP	O
,	,	O
29	CD	O
patients	NNS	O
)	)	O
.	.	O

Group	NNP	O
A	NNP	O
was	VBD	O
expected	VBN	O
to	TO	O
give	VB	O
more	JJR	O
correct	JJ	O
answers	NNS	O
to	TO	O
questions	NNS	O
about	IN	O
the	DT	O
common	JJ	O
facts	NNS	O
than	IN	O
Group	NNP	O
B	NNP	O
,	,	O
when	WRB	O
tested	VBN	O
postoperatively	RB	O
,	,	O
and	CC	O
Group	NNP	O
B	NNP	O
to	TO	O
attribute	VB	O
more	JJR	O
fame	NN	O
to	TO	O
presented	VBN	O
names	NNS	O
than	IN	O
Group	NNP	O
A	NNP	O
(	(	O
famous	JJ	O
names	RB	O
test	NN	O
)	)	O
.	.	O

Because	IN	O
the	DT	O
process	NN	O
for	IN	O
learning	VBG	O
new	JJ	O
or	CC	O
unfamiliar	JJ	O
stimuli	NNS	O
(	(	O
elaboration	NN	O
)	)	O
in	IN	O
particular	JJ	O
may	MD	O
be	VB	O
impaired	VBN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
more	JJR	O
memory	NN	O
priming	NN	O
was	VBD	O
expected	VBN	O
for	IN	O
familiar	JJ	O
than	IN	O
for	IN	O
unfamiliar	JJ	O
material	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
demonstrated	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
performance	NN	ME
on	IN	ME
common	JJ	ME
facts	NNS	ME
or	CC	O
in	IN	O
fame	NN	O
attributed	VBN	O
to	TO	O
the	DT	O
names	NNS	O
.	.	O

The	DT	O
amount	NN	ME
of	IN	ME
memory	NN	ME
priming	NN	ME
,	,	O
however	RB	O
,	,	O
was	VBD	O
positively	RB	ME
related	VBN	ME
to	TO	ME
one	CD	ME
of	IN	ME
two	CD	ME
measures	NNS	ME
of	IN	O
preoperative	JJ	ME
anxiety	NN	ME
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
secretin	NN	O
:	:	O
effects	NNS	O
on	IN	O
aberrant	JJ	ME
behavior	NN	ME
in	IN	ME
children	NNS	ME
with	IN	ME
autism	NN	ME
.	.	ME

Secretin	NNP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
treatment	NN	O
alternative	NN	O
for	IN	O
autistic	JJ	ME
spectrum	NN	ME
disorders	NNS	ME
,	,	O
but	CC	O
empirical	JJ	O
support	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
on	IN	O
aberrant	JJ	ME
behavior	NN	ME
.	.	ME

Parent	NN	O
and	CC	O
teacher	NN	O
data	NNS	O
from	IN	O
the	DT	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
for	IN	O
eight	CD	O
male	JJ	O
children	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
reliable	JJ	O
change	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
replication	NN	O
series	NN	O
.	.	O

By	IN	O
parent	NN	O
and	CC	O
teacher	NN	O
report	NN	O
,	,	O
the	DT	O
majority	NN	O
of	IN	O
change	NN	O
occurred	VBD	O
either	CC	O
on	IN	O
the	DT	O
placebo	NN	O
trial	NN	O
or	CC	O
reflected	VBN	O
deterioration	NN	O
subsequent	NN	O
to	TO	O
secretin	VB	O
infusion	NN	O
.	.	O

Repeated-measures	JJ	O
multivariate	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

Results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
other	JJ	O
studies	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
secretin	NN	O
may	MD	O
not	RB	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
option	NN	O
.	.	O

Efficacy	NN	Ot
of	IN	O
porcine	NN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

Secretin	NNP	O
,	,	O
a	DT	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
hormone	NN	O
,	,	O
was	VBD	O
reported	VBN	O
in	IN	O
a	DT	O
preliminary	JJ	O
study	NN	O
to	TO	O
improve	VB	O
language	NN	ME
and	CC	ME
behavior	NN	ME
in	IN	O
children	NNS	O
with	IN	O
autism/pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
and	CC	O
chronic	JJ	O
diarrhea	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
secretin	NN	O
,	,	O
we	PRP	O
completed	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
study	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism/PDD	NN	O
and	CC	O
various	JJ	O
GI	NNP	O
conditions	NNS	O
using	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intravenous	JJ	O
porcine	NN	O
secretin	NN	O
.	.	O

Children	NNP	O
with	IN	O
chronic	NN	O
,	,	O
active	JJ	O
diarrhea	NN	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
aberrant	JJ	ME
behaviors	NNS	ME
when	WRB	O
treated	VBN	O
with	IN	O
the	DT	O
secretin	NN	O
but	CC	O
not	RB	O
when	WRB	O
treated	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
.	.	O

Children	NNP	O
with	IN	O
no	DT	O
GI	NNP	O
problems	NNS	O
are	VBP	O
unaffected	VBN	O
by	IN	O
either	DT	O
secretin	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
improvement	NN	O
seen	VBN	O
with	IN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism/PDD	NN	O
and	CC	O
chronic	JJ	O
diarrhea	NN	O
suggests	VBZ	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
subtype	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism/PDD	NN	O
who	WP	O
respond	VBZ	O
to	TO	O
secretin	VB	O
.	.	O

Amphotericin	NNP	O
versus	NN	O
pentamidine	NN	O
in	IN	O
antimony-unresponsive	JJ	O
kala-azar	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
amphotericin	NN	O
B	NNP	O
and	CC	O
pentamidine	JJ	O
isethionate	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
trial	NN	O
in	IN	O
120	CD	O
uncomplicated	JJ	O
and	CC	O
parasitologically	RB	O
confirmed	VBN	O
cases	NNS	O
of	IN	O
antimony-unresponsive	JJ	O
kala-azar	NN	O
.	.	O

Doses	NNS	O
were	VBD	O
twenty	JJ	O
intramuscular	JJ	O
injections	NNS	O
of	IN	O
pentamidine	NN	O
4	CD	O
mg/kg	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
or	CC	O
fourteen	JJ	O
definitive	JJ	O
doses	NNS	O
of	IN	O
amphotericin	JJ	O
0.5	CD	O
mg/kg	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
.	.	O

48	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
patients	NNS	O
given	VBN	O
pentamidine	VBP	O
showed	VBN	O
initial	JJ	Ot
cure	NN	Ot
and	CC	O
46	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
showed	VBD	O
definitive	JJ	Ot
cure	NN	Ot
compared	VBN	O
with	IN	O
60	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
and	CC	O
59	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
cases	NNS	O
,	,	O
respectively	RB	O
,	,	O
on	IN	O
amphotericin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Amphotericin	NNP	O
also	RB	O
brought	VBD	O
about	RB	O
quicker	JJR	O
abatement	NN	PH
of	IN	PH
fever	NN	PH
and	CC	O
more	JJR	O
complete	JJ	A
spleen	JJ	A
regression	NN	A
.	.	PH

Arthroscopic	NNP	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
and	CC	O
without	IN	O
acromioplasty	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
full-thickness	JJ	O
rotator	NN	O
cuff	NN	O
tears	NNS	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
to	TO	O
compare	VB	O
functional	JJ	Ot
and	CC	Ot
quality-of-life	JJ	Ot
indices	NNS	Ot
and	CC	O
rates	NNS	PH
of	IN	PH
revision	NN	PH
surgery	NN	PH
in	IN	O
arthroscopic	NN	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
and	CC	O
without	IN	O
acromioplasty	JJ	O
.	.	O

METHODS	NNP	O
Eighty-six	JJ	O
patients	NNS	O
consented	VBN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
intraoperatively	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
,	,	O
and	CC	O
sixty-eight	NN	O
of	IN	O
them	PRP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
Western	JJ	Ot
Ontario	NNP	Ot
Rotator	NNP	Ot
Cuff	NNP	Ot
(	(	Ot
WORC	NNP	Ot
)	)	Ot
index	NN	Ot
.	.	PH

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
included	VBD	O
the	DT	O
American	JJ	Ot
Shoulder	NNP	Ot
and	CC	Ot
Elbow	NNP	Ot
Surgeons	NNP	Ot
(	(	Ot
ASES	NNP	Ot
)	)	Ot
shoulder	NN	Ot
assessment	JJ	Ot
form	NN	Ot
and	CC	PH
a	DT	PH
count	NN	Ot
of	IN	Ot
revisions	NNS	Ot
required	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
were	VBD	O
completed	VBN	O
preoperatively	RB	O
and	CC	O
at	IN	O
three	CD	O
,	,	O
six	CD	O
,	,	O
twelve	NN	O
,	,	O
eighteen	NN	O
,	,	O
and	CC	O
twenty-four	JJ	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
WORC	NNP	Ot
and	CC	O
ASES	NNP	Ot
scores	VBZ	Ot
improved	VBN	O
significantly	RB	O
in	IN	O
each	DT	O
group	NN	O
over	IN	O
time	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
WORC	NNP	Ot
or	CC	O
ASES	NNP	Ot
scores	NNS	Ot
between	IN	O
the	DT	O
groups	NNS	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
with	IN	O
or	CC	O
without	IN	O
acromioplasty	JJ	O
at	IN	O
any	DT	O
time	NN	O
point	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
scores	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
acromion	NN	O
type	NN	O
,	,	O
nor	CC	O
were	VBD	O
any	DT	O
interaction	NN	O
effects	NNS	O
identified	VBN	O
between	IN	O
group	NN	O
and	CC	O
acromion	NN	O
type	NN	O
.	.	O

Four	CD	O
participants	NNS	O
(	(	O
9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	Ot
alone	RB	O
,	,	O
one	CD	O
with	IN	O
a	DT	O
Type-2	JJ	O
and	CC	O
three	CD	O
with	IN	O
a	DT	O
Type-3	JJ	O
acromion	NN	O
,	,	O
required	VBN	O
additional	JJ	PH
surgery	NN	PH
by	IN	O
the	DT	O
twenty-four-month	JJ	O
time	NN	O
point	NN	O
.	.	O

The	DT	O
number	NN	Ot
of	IN	Ot
patients	NNS	Ot
who	WP	Ot
required	VBD	Ot
additional	JJ	Ot
surgery	NN	Ot
was	VBD	O
greater	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
alone	RB	O
than	IN	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
and	CC	O
acromioplasty	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
previous	JJ	O
research	NN	O
reports	NNS	O
in	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
functional	JJ	Ot
and	CC	Ot
quality-of-life	JJ	Ot
indices	NNS	Ot
for	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
or	CC	O
without	IN	O
acromioplasty	JJ	O
.	.	O

The	DT	O
higher	JJR	Ot
reoperation	NN	Ot
rate	NN	Ot
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
group	NN	O
without	IN	O
acromioplasty	NN	O
.	.	O

Further	CC	O
study	NN	O
that	WDT	O
includes	VBZ	O
follow-up	JJ	O
imaging	NN	O
and	CC	O
patient-reported	JJ	O
outcomes	NNS	O
over	IN	O
a	DT	O
greater	JJR	O
follow-up	JJ	O
period	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
(	(	O
gamma	NN	O
linolenic	RB	O
acid	NN	O
)	)	O
and	CC	O
fish	JJ	O
oil	NN	O
(	(	O
eicosapentaenoic	JJ	O
+	NNP	O
docahexaenoic	NN	O
acid	NN	O
)	)	O
versus	NN	O
magnesium	NN	O
,	,	O
and	CC	O
versus	NN	O
placebo	NN	O
in	IN	O
preventing	VBG	O
pre-eclampsia	NN	PH
.	.	PH

In	IN	O
a	DT	O
placebo	NN	O
controlled	VBN	O
,	,	O
partially	RB	O
double-blinded	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
,	,	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
and	CC	O
fish	JJ	O
oil	NN	O
was	VBD	O
compared	VBN	O
to	TO	O
Magnesium	NNP	O
Oxide	NNP	O
,	,	O
and	CC	O
to	TO	O
a	DT	O
Placebo	NNP	O
in	IN	O
preventing	VBG	O
Pre-Eclampsia	NNP	PH
of	IN	PH
Pregnancy	NNP	PH
.	.	PH

All	DT	O
were	VBD	O
given	VBN	O
as	IN	O
nutritional	JJ	O
supplements	NNS	O
for	IN	O
six	CD	O
months	NNS	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
primiparous	JJ	O
and	CC	O
multiparous	JJ	O
pregnant	JJ	O
women	NNS	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
women	NNS	O
had	VBD	O
personal	JJ	O
or	CC	O
family	NN	O
histories	NNS	O
of	IN	O
hypertension	NN	O
(	(	O
21	CD	O
%	NN	O
)	)	O
.	.	O

Only	RB	O
those	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
prenatal	JJ	O
care	NN	O
at	IN	O
the	DT	O
Central	NNP	O
Maternity	NNP	O
Hospital	NNP	O
for	IN	O
Luanda	NNP	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
Placebo	NNP	O
group	NN	O
(	(	O
29	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
mixture	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
and	CC	O
fish	JJ	O
oil	NN	O
containing	VBG	O
Gamma-linolenic	JJ	O
acid	NN	O
(	(	O
GLA	NNP	O
)	)	O
,	,	O
Eicosapentaenoic	NNP	O
acid	NN	O
(	(	O
EPA	NNP	O
)	)	O
,	,	O
and	CC	O
Docosahexaenoic	NNP	O
acid	NN	O
(	(	O
DHA	NNP	O
)	)	O
had	VBD	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	A
of	IN	A
edema	NN	PH
(	(	O
13	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
Magnesium	NNP	O
Oxide	NNP	O
had	VBD	O
statistically	RB	O
significant	JJ	O
fewer	JJR	O
subjects	NNS	O
who	WP	O
developed	VBD	O
hypertension	NN	PH
of	IN	PH
pregnancy	NN	PH
.	.	PH

There	EX	O
were	VBD	O
3	CD	O
cases	NNS	O
of	IN	O
eclampsia	NN	PH
,	,	O
all	DT	O
in	IN	O
the	DT	O
Placebo	NNP	O
group	NN	O
.	.	O

Successful	JJ	O
new	JJ	O
method	NN	O
of	IN	O
extracorporeal	JJ	O
percutaneous	JJ	O
endoscopic	NN	O
gastrostomy	NN	O
(	(	O
E-PEG	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
percutaneous	JJ	O
endoscopic	NNS	O
gastrostomy	NN	O
(	(	O
PEG	NNP	O
)	)	O
has	VBZ	O
become	VBN	O
popular	JJ	O
for	IN	O
patients	NNS	O
with	IN	O
swallowing	VBG	O
disorders	NNS	O
as	IN	O
a	DT	O
nutrition	NN	O
support	NN	O
or	CC	O
a	DT	O
decompressant	NN	O
of	IN	O
gastrointestine	NN	O
,	,	O
perioperative	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
PEG	NNP	O
have	VBP	O
not	RB	O
decreased	VBN	O
,	,	O
especially	RB	O
peristomal	JJ	O
infections	NNS	O
.	.	O

To	TO	O
reduce	VB	O
peristomal	JJ	O
infections	NNS	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
gastrostomy	NN	O
by	IN	O
extracorporeal	JJ	O
approach	NN	O
under	IN	O
endoscopic	JJ	O
observation	NN	O
,	,	O
named	VBN	O
as	IN	O
extra-corporeal	JJ	O
PEG	NNP	O
(	(	O
E-PEG	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Experimental	NNP	O
studies	NNS	O
for	IN	O
E-PEG	NNP	O
were	VBD	O
performed	VBN	O
repeatedly	RB	O
using	VBG	O
pigs	NNS	O
under	IN	O
general	JJ	O
anesthesia	NN	O
to	TO	O
confirm	VB	O
the	DT	O
safety	NN	O
of	IN	O
its	PRP$	O
procedure	NN	O
for	IN	O
human	JJ	O
use	NN	O
.	.	O

After	IN	O
approval	NN	O
of	IN	O
institutional	JJ	O
ethics	NNS	O
review	VBP	O
board	NN	O
in	IN	O
our	PRP$	O
university	NN	O
,	,	O
thirty	JJ	O
patients	NNS	O
with	IN	O
prior	JJ	O
consent	NN	O
participated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

The	DT	O
operation	NN	Ot
time	NN	Ot
,	,	O
the	DT	O
incidence	NN	Ot
rate	NN	Ot
of	IN	Ot
complications	NNS	Ot
and	CC	O
the	DT	O
hospital	NN	Ot
stay	NN	Ot
were	VBD	O
compared	VBN	O
between	IN	O
E-PEG	NNP	O
and	CC	O
ordinary	JJ	O
pull-method	JJ	O
PEG	NNP	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Two	CD	O
patients	NNS	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
in	IN	O
E-PEG	NNP	O
group	NN	O
had	VBD	O
postoperative	JJ	A
complications	NNS	A
,	,	O
i.e.	FW	O
,	,	O
aspiration	NN	A
pneumonia	NN	A
and	CC	O
surgical	JJ	A
site	NN	A
infection	NN	A
.	.	O

The	DT	O
operation	NN	Ot
time	NN	Ot
of	IN	O
E-PEG	NNP	O
group	NN	O
was	VBD	O
5-16	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
10.3	CD	O
+/-	JJ	O
2.96	CD	O
)	)	O
min	NN	O
as	IN	O
compared	VBN	O
to	TO	O
14-37	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
26.9	CD	O
+/-	JJ	O
8.39	CD	O
)	)	O
min	NN	O
with	IN	O
pull-method	JJ	O
PEG	NNP	O
.	.	O

The	DT	O
postoperative	JJ	Ot
hospital	NN	Ot
day	NN	Ot
of	IN	O
E-PEG	NNP	O
was	VBD	O
within	IN	O
two	CD	O
days	NNS	O
except	IN	O
for	IN	O
the	DT	O
two	CD	O
complicated	VBD	O
cases	NNS	O
.	.	O

Significance	NNP	O
differences	NNS	O
of	IN	O
operation	NN	Ot
time	NN	Ot
,	,	O
complication	NN	Ot
rate	NN	Ot
and	CC	O
postoperative	JJ	Ot
hospital	NN	Ot
stay	NN	Ot
between	IN	O
those	DT	O
groups	NNS	O
observed	VBD	O
statistically	RB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
E-PEG	NNP	O
was	VBD	O
safe	JJ	Ot
,	,	Ot
tolerable	JJ	Ot
and	CC	O
speedy	NN	O
when	WRB	O
compared	VBN	O
ordinary	JJ	O
pull-method	JJ	O
PEG	NNP	O
.	.	O

Sustained	JJ	O
effect	NN	O
of	IN	O
SQ-standardized	NNP	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
on	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
prevalence	NN	O
of	IN	O
allergic	JJ	O
rhinoconjunctivitis	NN	O
has	VBZ	O
increased	VBN	O
significantly	RB	O
over	IN	O
the	DT	O
past	JJ	O
decades	NNS	O
with	IN	O
grass	NN	O
pollen	NN	O
being	VBG	O
a	DT	O
common	JJ	O
trigger	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
allergy	NN	O
on	IN	O
patient	NN	O
's	POS	O
quality	NN	O
of	IN	O
life	NN	O
is	VBZ	O
substantial	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
sustained	JJ	O
effect	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
during	IN	O
the	DT	O
grass	NN	O
pollen	NN	O
season	NN	O
1	CD	O
year	NN	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
the	DT	O
SQ-standardized	JJ	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
(	(	O
AIT	NNP	O
)	)	O
,	,	O
Graza	NNP	O
(	(	O
Phleum	NNP	O
pratense	VBZ	O
75,000	CD	O
SQ-T/2800	JJ	O
BAU	NNP	O
;	:	O
ALK	NNP	O
,	,	O
Denmark	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
adult	NN	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
moderate-severe	JJ	O
grass	NN	O
pollen	NN	O
induced	VBD	O
rhinoconjunctivitis	NN	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
.	.	O

Subjects	NNS	O
received	VBD	O
3	CD	O
years	NNS	O
of	IN	O
grass	NN	O
AIT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
157	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
126	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Quality	NN	Ot
of	IN	Ot
life	NN	Ot
assessments	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
standardized	JJ	Ot
rhinoconjunctivitis	NN	Ot
quality	NN	Ot
of	IN	Ot
life	NN	Ot
questionnaire	NN	Ot
(	(	Ot
RQLQ	NNP	Ot
(	(	Ot
S	NNP	Ot
)	)	Ot
)	)	Ot
;	:	Ot
completed	VBN	O
weekly	JJ	O
during	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
follow-up	JJ	O
,	,	O
the	DT	O
overall	JJ	O
RQLQ	NNP	Ot
(	(	Ot
S	NNP	Ot
)	)	Ot
score	NN	Ot
for	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
relative	JJ	O
difference	NN	O
to	TO	O
placebo	VB	O
:	:	O
23	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
improvement	NN	O
was	VBD	O
higher	JJR	O
during	IN	O
the	DT	O
peak	NN	O
pollen	NN	O
season	NN	O
(	(	O
28	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
grass	NN	O
AIT	NNP	O
during	IN	O
the	DT	O
follow-up	JJ	O
year	NN	O
and	CC	O
the	DT	O
previous	JJ	O
three	CD	O
treatment	NN	O
years	NNS	O
was	VBD	O
similar	JJ	O
.	.	O

Improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
all	DT	O
seven	CD	O
RQLQ	NNP	Ot
(	(	Ot
S	NNP	Ot
)	)	Ot
domains	VBZ	Ot
.	.	O

The	DT	O
RQLQ	NNP	Ot
(	(	Ot
S	NNP	Ot
)	)	Ot
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
weekly	JJ	O
average	NN	O
pollen	NN	O
counts	VBZ	O
showed	VBD	O
a	DT	O
clear	JJ	O
separation	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
subjects	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
,	,	O
grass	NN	O
AIT	NNP	O
provided	VBD	O
sustained	VBN	O
and	CC	O
clinically	RB	O
relevant	JJ	O
improvements	NNS	O
in	IN	O
rhinoconjunctivitis	NN	PH
quality	NN	PH
of	IN	PH
life	NN	PH
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
effect	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
grass	NN	O
pollen	NN	O
exposure	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
duration	NN	O
on	IN	O
defibrillation	NN	Ot
efficacy	NN	Ot
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
prospectively	RB	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
(	(	O
VF	NNP	O
)	)	O
durations	NNS	O
of	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
on	IN	O
the	DT	O
defibrillation	NN	Ot
threshold	NN	Ot
(	(	Ot
DFT	NNP	Ot
)	)	Ot
during	IN	O
implantable	JJ	O
cardioverter-defibrillator	NN	O
(	(	O
ICD	NNP	O
)	)	O
implantation	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
the	DT	O
DFT	NNP	Ot
using	VBG	Ot
monophasic	JJ	Ot
waveforms	NNS	Ot
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
with	IN	O
VF	NNP	O
duration	NN	O
in	IN	O
humans	NNS	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
VF	NNP	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
primary	JJ	O
ICD	NNP	O
implantation	NN	O
or	CC	O
pulse	JJ	O
generator	NN	O
replacement	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
the	DT	O
DFT	NNP	O
determined	VBD	O
using	VBG	O
biphasic	JJ	O
shocks	NNS	O
at	IN	O
two	CD	O
durations	NNS	O
of	IN	O
VF	NNP	O
each	DT	O
(	(	O
5	CD	O
and	CC	O
10	CD	O
s	NN	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
or	CC	O
5	CD	O
and	CC	O
20	CD	O
s	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
mean	JJ	Ot
DFT	NNP	Ot
comparing	VBG	O
VF	NNP	O
durations	NNS	O
of	IN	O
5	CD	O
s	NNS	O
(	(	O
9.5+/-6.0	CD	O
J	NNP	O
)	)	O
and	CC	O
10	CD	O
s	NN	O
(	(	O
10.8+/-7.0	JJ	O
J	NNP	O
)	)	O
(	(	O
p=0.4	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
DFT	NNP	Ot
significantly	RB	O
increased	VBD	O
from	IN	O
10.9+/-6.1	JJ	O
J	NNP	O
at	IN	O
10	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
12.6+/-5.6	JJ	O
J	NNP	O
(	(	O
p=0.03	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
,	,	O
and	CC	O
from	IN	O
7.0+/-3.5	JJ	O
J	NNP	O
at	IN	O
5	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
10.5+/-6.3	JJ	O
J	NNP	O
(	(	O
p=0.04	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	Ot
was	VBD	O
observed	VBN	O
in	IN	O
14	CD	O
patients	NNS	O
as	IN	O
VF	NNP	O
duration	NN	O
increased	VBD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
clinical	JJ	O
characteristics	NNS	O
that	WDT	O
differentiated	VBD	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	Ot
.	.	O

CONCLUSIONS	NNP	O
Defibrillation	NNP	Ot
efficacy	NN	Ot
decreases	VBZ	O
with	IN	O
increasing	VBG	O
VF	NNP	O
duration	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

Ventricular	JJ	O
fibrillation	NN	O
durations	NNS	O
greater	JJR	O
than	IN	O
10	CD	O
s	NN	O
may	MD	O
negatively	RB	O
affect	VB	O
the	DT	O
effectiveness	NN	Ot
of	IN	Ot
ICD	NNP	Ot
therapy	NN	Ot
.	.	O

Intermittent	NNP	O
recombinant	JJ	O
growth	NN	O
hormone	NN	O
treatment	NN	O
in	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
:	:	O
four-year	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
two	CD	O
different	JJ	O
treatment	NN	O
regimens	NNS	O
.	.	O

BACKGROUND	NNP	O
Treatment	NNP	O
of	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
SGA	NNP	O
with	IN	O
recombinant	JJ	O
human	JJ	O
growth	NN	O
hormone	VBD	O
r-hGH	JJ	O
increases	NNS	O
growth	NN	PH
velocity	NN	PH
during	IN	O
childhood	NN	O
.	.	O

As	IN	O
in	IN	O
other	JJ	O
indications	NNS	O
,	,	O
the	DT	O
growth	NN	PH
velocity	NN	PH
in	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
more	JJR	O
marked	JJ	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
treatment	NN	O
and	CC	O
then	RB	O
decreases	VBZ	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
different	JJ	O
r-hGH	JJ	O
treatment	NN	O
schedules	NNS	O
(	(	O
67	CD	O
microg/kg/day	NN	O
in	IN	O
a	DT	O
discontinuous	JJ	O
or	CC	O
continuous	JJ	O
regimen	NNS	O
)	)	O
during	IN	O
the	DT	O
second	JJ	O
year	NN	O
of	IN	O
r-hGH	JJ	O
treatment	NN	O
by	IN	O
comparing	VBG	O
height	JJ	PH
velocity	NN	PH
changes	NNS	O
and	CC	O
total	JJ	PH
gain	NN	PH
of	IN	PH
height	NN	PH
over	IN	O
a	DT	O
4-year	JJ	O
period	NN	O
.	.	O

METHODS	$	O
58	CD	O
growth-retarded	JJ	O
SGA	NNP	O
children	NNS	O
aged	VBN	O
2-5	CD	O
years	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
TOTO	NNP	O
regimen	NN	O
(	(	O
4	CD	O
years	NNS	O
alternating	VBG	O
treatment	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
observation	NN	O
(	(	O
O	NNP	O
)	)	O
,	,	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
TTOO	JJ	O
regimen	NN	O
(	(	O
2	CD	O
years	NNS	O
'	POS	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	O
years	NNS	O
'	POS	O
observation	NN	O
,	,	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
.	.	O

Height	NNP	PH
velocity	NN	PH
HV	NNP	PH
and	CC	O
total	JJ	PH
height	NN	PH
gain	NN	PH
were	VBD	O
assessed	VBN	O
during	IN	O
the	DT	O
4-year	JJ	O
study	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
both	DT	O
groups	NNS	O
,	,	O
HV	NNP	PH
and	CC	O
HV	NNP	PH
standard	JJ	PH
deviation	NN	PH
score	VBD	PH
HV-SDSCA	NNP	PH
increased	VBD	O
during	IN	O
treatment	NN	O
and	CC	O
decreased	VBD	O
during	IN	O
observation	NN	O
periods	NNS	O
.	.	O

Interruption	NN	O
of	IN	O
treatment	NN	O
in	IN	O
the	DT	O
TOTO	NNP	O
group	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
better	JJR	O
gain	NN	PH
in	IN	PH
height	JJ	PH
standard	NN	PH
deviation	NN	PH
score	VBD	PH
H-SDSCA	NNP	PH
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
TTOO	NNP	O
group	NN	O
.	.	O

After	IN	O
4	CD	O
years	NNS	O
of	IN	O
study	NN	O
,	,	O
the	DT	O
gain	NN	PH
in	IN	PH
H-SDSCA	NNP	PH
was	VBD	O
1.4	CD	O
+	NN	O
or	CC	O
-	:	O
01	CD	O
in	IN	O
the	DT	O
TOTO	NNP	O
group	NN	O
and	CC	O
1.6	CD	O
+	NN	O
or	CC	O
-	:	O
0.2	CD	O
in	IN	O
the	DT	O
TTOO	NNP	O
group	NN	O
leading	VBG	O
to	TO	O
a	DT	O
mean	JJ	O
height	NN	PH
of	IN	O
-2.0	NNP	O
+	NNP	O
or	CC	O
-	:	O
1.0	CD	O
SDS	NNP	O
and	CC	O
-2.0	NNP	O
+	NNP	O
or	CC	O
-	:	O
0.8	CD	O
SDS	NNP	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
rate	NN	PH
of	IN	PH
bone	NN	PH
maturation	NN	PH
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
,	,	O
TOTO	NNP	O
and	CC	O
TTOO	NNP	O
regimens	NNS	O
produced	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
growth	NN	PH
during	IN	O
r-hGH	JJ	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
treatment	NN	O
interruption	NN	O
after	IN	O
1	CD	O
year	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
overall	JJ	PH
gain	NN	PH
in	IN	PH
height	NN	PH
SDS	NNP	PH
when	WRB	O
compared	VBN	O
with	IN	O
2	CD	O
years	NNS	O
'	POS	O
continuous	JJ	O
treatment	NN	O
.	.	O

Enhancing	VBG	O
implementation	NN	O
of	IN	O
tobacco	NN	O
use	NN	O
prevention	NN	O
and	CC	O
cessation	NN	O
counselling	VBG	O
guideline	NN	O
among	IN	O
dental	JJ	O
providers	NNS	O
:	:	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Tobacco	NNP	O
use	NN	O
adversely	RB	O
affects	VBZ	O
oral	JJ	O
health	NN	O
.	.	O

Tobacco	NNP	O
use	NN	O
prevention	NN	O
and	CC	O
cessation	NN	O
(	(	O
TUPAC	NNP	O
)	)	O
counselling	VBG	O
guidelines	NNS	O
recommend	VBP	O
that	IN	O
healthcare	NN	O
providers	NNS	O
ask	VBP	O
about	IN	O
each	DT	O
patient	NN	O
's	POS	O
tobacco	NN	O
use	NN	O
,	,	O
assess	IN	O
the	DT	O
patient	NN	O
's	POS	O
readiness	NN	O
and	CC	O
willingness	NN	O
to	TO	O
stop	VB	O
,	,	O
document	NN	O
tobacco	NN	O
use	NN	O
habits	NNS	O
,	,	O
advise	VBP	O
the	DT	O
patient	NN	O
to	TO	O
stop	VB	O
,	,	O
assist	NN	O
and	CC	O
help	NN	O
in	IN	O
quitting	NN	O
,	,	O
and	CC	O
arrange	JJ	O
monitoring	NN	O
of	IN	O
progress	NN	O
at	IN	O
follow-up	JJ	O
appointments	NNS	O
.	.	O

Adherence	NN	O
to	TO	O
such	JJ	O
guidelines	NNS	O
,	,	O
especially	RB	O
among	IN	O
dental	JJ	O
providers	NNS	O
,	,	O
is	VBZ	O
poor	JJ	O
.	.	O

To	TO	O
improve	VB	O
guideline	NN	O
implementation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
to	TO	O
understand	VB	O
factors	NNS	O
influencing	VBG	O
it	PRP	O
and	CC	O
find	VB	O
effective	JJ	O
ways	NNS	O
to	TO	O
influence	VB	O
those	DT	O
factors	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
protocol	NN	O
is	VBZ	O
to	TO	O
introduce	VB	O
a	DT	O
theory-based	JJ	O
approach	NN	O
to	TO	O
diagnose	VB	O
implementation	NN	O
difficulties	NNS	O
of	IN	O
TUPAC	NNP	O
counselling	VBG	O
guidelines	NNS	O
among	IN	O
dental	JJ	O
providers	NNS	O
.	.	O

METHODS	NNP	O
Theories	NNPS	ME
of	IN	ME
behaviour	NN	ME
change	NN	ME
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
identify	VB	O
key	JJ	O
theoretical	JJ	O
domains	NNS	O
relevant	VBP	O
to	TO	O
the	DT	O
behaviours	NN	O
of	IN	O
healthcare	JJ	O
providers	NNS	O
involved	VBN	O
in	IN	O
implementing	VBG	O
clinical	JJ	O
guidelines	NNS	O
.	.	O

These	DT	O
theoretical	JJ	O
domains	NNS	O
will	MD	O
inform	VB	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
questionnaire	NN	Ot
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
the	DT	O
TUPAC	NNP	O
counselling	VBG	O
guidelines	NNS	O
among	IN	O
Finnish	JJ	O
municipal	JJ	O
dental	JJ	O
providers	NNS	O
.	.	O

Specific	JJ	O
items	NNS	O
will	MD	O
be	VB	O
drawn	VBN	O
from	IN	O
the	DT	O
guidelines	NNS	O
and	CC	O
the	DT	O
literature	NN	O
on	IN	O
TUPAC	NNP	O
studies	NNS	O
.	.	O

After	IN	O
identifying	VBG	O
potential	JJ	O
implementation	NN	O
difficulties	NNS	O
,	,	O
we	PRP	O
will	MD	O
design	VB	O
two	CD	O
interventions	NNS	O
using	VBG	O
theories	NNS	O
of	IN	O
behaviour	JJ	O
change	NN	O
to	TO	O
link	VB	O
them	PRP	O
with	IN	O
relevant	JJ	O
behaviour	NN	O
change	NN	O
techniques	NNS	O
aiming	VBG	O
to	TO	O
improve	VB	O
guideline	NN	O
adherence	NN	O
.	.	O

For	IN	O
assessing	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
TUPAC	NNP	O
guidelines	NNS	O
,	,	O
the	DT	O
electronic	JJ	Ot
dental	NN	Ot
record	NN	Ot
audit	NN	Ot
and	CC	O
self-reported	JJ	Ot
questionnaires	NNS	Ot
will	MD	O
be	VB	O
used	VBN	O
.	.	O

DISCUSSION	NNP	O
To	TO	O
improve	VB	O
guideline	NN	O
adherence	NN	O
,	,	O
the	DT	O
theoretical-domains	NNS	O
approach	NN	O
could	MD	O
provide	VB	O
a	DT	O
comprehensive	JJ	O
basis	NN	O
for	IN	O
assessing	VBG	O
implementation	NN	O
difficulties	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
designing	VBG	O
and	CC	O
evaluating	VBG	O
interventions	NNS	O
.	.	O

After	IN	O
having	VBG	O
identified	VBN	O
implementation	NN	O
difficulties	NNS	O
,	,	O
we	PRP	O
will	MD	O
design	VB	O
and	CC	O
test	VB	O
two	CD	O
interventions	NNS	O
to	TO	O
enhance	VB	O
TUPAC	NNP	O
guideline	JJ	O
adherence	NN	O
.	.	O

Using	VBG	O
the	DT	O
cluster	NN	O
randomised	VBD	O
controlled	JJ	O
design	NN	O
,	,	O
we	PRP	O
aim	VBP	O
to	TO	O
provide	VB	O
further	JJ	O
evidence	NN	O
on	IN	O
intervention	NN	O
effects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
the	DT	O
validity	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
the	DT	O
theoretical-domain	JJ	O
approach	NN	O
.	.	O

The	DT	O
empirical	JJ	O
data	NNS	O
collected	VBN	O
within	IN	O
this	DT	O
trial	NN	O
will	MD	O
be	VB	O
useful	JJ	O
in	IN	O
testing	VBG	O
whether	IN	O
this	DT	O
theoretical-domain	JJ	O
approach	NN	O
can	MD	O
improve	VB	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
implementation	NN	O
of	IN	O
TUPAC	NNP	O
guidelines	NNS	O
among	IN	O
dental	JJ	O
providers	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN15427433	NNP	O
.	.	O

Impact	NN	O
of	IN	O
prior	JJ	O
pharmacotherapy	NN	O
on	IN	O
remission	NN	PH
of	IN	PH
psychotic	JJ	PH
depression	NN	PH
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Having	VBG	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
adequate	JJ	O
antidepressant	JJ	O
treatment	NN	O
course	NN	O
predicts	VBZ	O
poorer	JJR	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
impact	NN	O
of	IN	O
prior	JJ	O
treatment	NN	O
on	IN	O
the	DT	O
outcome	NN	O
of	IN	O
major	JJ	O
depression	NN	O
with	IN	O
psychotic	JJ	O
features	NNS	O
(	(	O
MDpsy	NNP	O
)	)	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
prior	JJ	O
treatment	NN	O
history	NN	O
on	IN	O
the	DT	O
outcome	NN	PH
of	IN	PH
pharmacotherapy	NN	PH
of	IN	O
MDpsy	NNP	O
in	IN	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
STOPD-PD	NNP	O
study	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
a	DT	O
combination	NN	O
of	IN	O
olanzapine	JJ	O
plus	CC	O
sertraline	JJ	O
vs.	FW	O
olanzapine	JJ	O
plus	CC	O
placebo	NN	O
.	.	O

The	DT	O
strength	NN	O
of	IN	O
treatment	NN	O
courses	NNS	O
received	VBD	O
prior	RB	O
to	TO	O
randomization	NN	O
was	VBD	O
classified	VBN	O
using	VBG	O
a	DT	O
validated	JJ	O
method	NN	O
.	.	O

A	DT	O
hierarchy	NN	O
of	IN	O
outcomes	NNS	O
was	VBD	O
hypothesized	VBN	O
based	VBN	O
on	IN	O
treatments	NNS	O
received	VBN	O
prior	RB	O
to	TO	O
randomization	NN	O
and	CC	O
randomized	JJ	O
treatment	NN	O
.	.	O

A	DT	O
high	JJ	PH
remission	NN	PH
rate	NN	PH
was	VBD	O
observed	VBN	O
in	IN	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
no	DT	O
prior	JJ	O
treatment	NN	O
or	CC	O
inadequate	JJ	O
treatment	NN	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
olanzapine	NN	O
and	CC	O
sertraline	NN	O
.	.	O

A	DT	O
low	JJ	PH
remission	NN	PH
rate	NN	PH
was	VBD	O
observed	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
antidepressant	JJ	O
alone	NN	O
and	CC	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
olanzapine	JJ	O
monotherapy	NN	O
.	.	O

A	DT	O
low	JJ	PH
remission	NN	PH
rate	NN	PH
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
a	DT	O
combination	NN	O
of	IN	O
an	DT	O
antipsychotic	JJ	O
and	CC	O
an	DT	O
antidepressant	NN	O
.	.	O

Similar	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
,	,	O
these	DT	O
results	NNS	O
emphasize	VBP	O
the	DT	O
impact	NN	PH
of	IN	PH
prior	JJ	PH
pharmacotherapy	NN	PH
on	IN	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
MDpsy	NNP	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
adjunctive	JJ	O
exenatide	NN	O
therapy	NN	O
in	IN	O
pediatric	JJ	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

OBJECTIVE	NNP	O
Exenatide	NNP	O
improves	VBZ	O
postprandial	JJ	O
glycemic	JJ	PH
excursions	NNS	PH
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

Exenatide	NNP	O
could	MD	O
benefit	VB	O
type	JJ	O
1	CD	O
diabetes	NNS	O
as	RB	O
well	RB	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
glucose-lowering	NN	PH
adjuvant	JJ	O
exenatide	NN	O
dose	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Eight	NNP	O
subjects	NNS	O
completed	VBD	O
a	DT	O
three-part	JJ	O
double-blinded	JJ	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
of	IN	O
premeal	JJ	O
exenatide	NN	O
.	.	O

Two	CD	O
doses	NNS	O
of	IN	O
exenatide	NN	O
(	(	O
1.25	CD	O
and	CC	O
2.5	CD	O
microg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
insulin	NN	O
monotherapy	NN	O
.	.	O

Prandial	JJ	O
insulin	NN	O
dose	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
20	CD	O
%	NN	O
.	.	O

Gastric	NNP	O
emptying	VBG	O
and	CC	O
hormones	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
300	CD	O
min	JJ	O
postmeal	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
exenatide	JJ	O
versus	NN	O
insulin	NN	O
monotherapy	NN	O
significantly	RB	O
reduced	VBD	PH
glucose	JJ	PH
excursions	NNS	PH
over	IN	O
300	CD	O
min	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Exenatide	NNP	O
administration	NN	O
failed	VBD	PH
to	TO	PH
suppress	VB	PH
glucagon	NN	PH
but	CC	PH
delayed	VBD	PH
gastric	JJ	PH
emptying	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.004	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Adjunctive	NNP	O
exenatide	NN	O
therapy	NN	O
reduces	VBZ	PH
postprandial	JJ	PH
hyperglycemia	NN	PH
in	IN	O
adolescents	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

This	DT	O
reduction	NN	O
in	IN	O
glucose	JJ	PH
excursion	NN	PH
occurs	VBZ	O
despite	IN	O
reduction	NN	O
in	IN	O
insulin	NN	O
dose	NN	O
.	.	O

We	PRP	O
suggest	VBP	O
that	DT	O
exenatide	NN	O
has	VBZ	O
therapeutic	JJ	O
potential	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
parallel	NN	O
study	NN	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
.	.	O

OBJECTIVES	CC	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
two	CD	O
cycled	VBD	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
imiquimod	JJ	O
5	CD	O
%	NN	O
cream	NN	O
for	IN	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
(	(	O
sBCC	NN	O
)	)	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
32	CD	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
regimens	NNS	O
:	:	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
once-daily	JJ	O
dosing	VBG	O
for	IN	O
alternate	JJ	O
weeks	NNS	O
(	(	O
R1	NNP	O
)	)	O
and	CC	O
5	CD	O
weeks	NNS	O
of	IN	O
once-daily	JJ	O
dosing	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
in	IN	O
the	DT	O
middle	NN	O
of	IN	O
the	DT	O
course	NN	O
(	(	O
R2	NNP	O
)	)	O
.	.	O

Efficacy	NN	O
measures	NNS	O
were	VBD	O
tumour	JJ	PH
clearance	NN	PH
at	IN	O
weeks	NNS	O
19	CD	O
and	CC	O
52	CD	O
and	CC	O
measures	NNS	Ot
of	IN	Ot
patients	NNS	Ot
'	POS	Ot
acceptability	NN	Ot
.	.	O

RESULTS	NNP	O
Data	NNP	O
from	IN	O
30	CD	O
patients	NNS	O
(	(	O
13	CD	O
females	NNS	O
)	)	O
,	,	O
14	CD	O
on	IN	O
R1	NNP	O
and	CC	O
16	CD	O
on	IN	O
R2	NNP	O
,	,	O
were	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
an	DT	O
initial	JJ	O
clearance	NN	PH
rate	NN	PH
of	IN	O
64	CD	O
%	NN	O
at	IN	O
week	NN	O
19	CD	O
for	IN	O
R1	NNP	O
and	CC	O
81	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
-14	NN	O
%	NN	O
to	TO	O
45	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
clearance	NN	PH
rates	NNS	PH
at	IN	O
week	NN	O
52	CD	O
were	VBD	O
significantly	RB	O
different	JJ	O
:	:	O
43	CD	O
%	NN	O
for	IN	O
R1	NNP	O
and	CC	O
88	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
11	CD	O
%	NN	O
to	TO	O
68	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
acceptability	NN	Ot
of	IN	Ot
treatment	NN	Ot
as	IN	O
measured	VBN	O
by	IN	O
composite	JJ	O
median	JJ	O
visual	JJ	O
analogue	NN	O
scores	NNS	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

CONCLUSION	NNP	O
Five	NNP	O
weeks	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
once	RB	O
daily	JJ	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
was	VBD	O
more	RBR	O
effective	JJ	Ot
but	CC	O
as	RB	O
well	RB	Ot
tolerated	VBN	Ot
as	IN	O
the	DT	O
8-week	JJ	O
alternate	NN	O
week	NN	O
regimen	NNS	O
for	IN	O
sBCC	NN	O
.	.	O

Utilization	NN	O
patterns	NNS	O
of	IN	O
conventional	JJ	O
and	CC	O
complementary/alternative	JJ	O
treatments	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
in	IN	O
a	DT	O
population-based	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
utilization	NN	O
of	IN	O
conventional	JJ	O
treatments	NNS	O
and	CC	O
utilization	NN	O
of	IN	O
complementary	JJ	O
and	CC	O
alternative	JJ	O
medicine	NN	O
in	IN	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
other	JJ	O
developmental	JJ	O
disabilities	NNS	O
(	(	O
DD	NNP	O
)	)	O
.	.	O

METHODS	JJ	O
Participants	NNS	O
were	VBD	O
578	CD	O
children	NNS	O
who	WP	O
were	VBD	O
part	NN	O
of	IN	O
an	DT	O
ongoing	JJ	O
population-based	JJ	O
,	,	O
case-control	JJ	O
study	NN	O
of	IN	O
2-	JJ	O
to	TO	O
5-year	JJ	O
olds	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
DD	NNP	O
,	,	O
and	CC	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

Parents	NNS	O
completed	VBD	O
an	DT	O
interview	NN	O
on	IN	O
past	JJ	O
and	CC	O
current	JJ	O
services	NNS	O
.	.	O

RESULTS	NNP	O
Four	CD	O
hundred	VBD	O
fifty-three	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
125	CD	O
DD	NNP	O
children	NNS	O
were	VBD	O
included	VBN	O
.	.	O

ASD	NNP	O
families	NNS	O
received	VBD	O
more	RBR	O
hours	NNS	O
of	IN	O
conventional	JJ	Ot
services	NNS	Ot
compared	VBN	O
with	IN	O
DD	NNP	O
families	NNS	O
(	(	O
17.8	CD	O
vs	RB	O
11	CD	O
;	:	O
p	NN	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
psychotropic	NN	O
medications	NNS	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
approximately	RB	O
3	CD	O
%	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
complementary	JJ	Ot
and	CC	Ot
alternative	JJ	Ot
medicine	NN	Ot
(	(	Ot
CAM	NNP	Ot
)	)	Ot
use	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
ASD	NNP	O
(	(	O
39	CD	O
%	NN	O
)	)	O
versus	NN	O
DD	NNP	O
(	(	O
30	CD	O
%	NN	O
)	)	O
.	.	O

Hispanic	JJ	O
families	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
used	VBD	O
CAM	NNP	Ot
less	RBR	O
often	RB	O
than	IN	O
non-Hispanic	JJ	O
families	NNS	O
.	.	O

Variables	NNS	O
such	JJ	O
as	IN	O
level	NN	PH
of	IN	PH
function	NN	PH
,	,	PH
immunization	NN	PH
status	NN	PH
,	,	PH
and	CC	PH
the	DT	PH
presence	NN	PH
of	IN	PH
an	DT	PH
identified	VBN	PH
neurogenetic	JJ	PH
disorder	NN	PH
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
CAM	NNP	O
use	NN	O
.	.	O

A	DT	O
higher	JJR	O
level	NN	Ot
of	IN	Ot
parental	JJ	Ot
education	NN	Ot
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
CAM	NNP	Ot
use	NN	O
in	IN	O
ASD	NNP	O
and	CC	O
DD	NNP	O
.	.	O

Families	NNS	O
who	WP	O
used	VBD	O
>	$	O
20	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
conventional	JJ	O
services	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	O
,	,	O
including	VBG	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	O
.	.	O

Underimmunized	VBN	O
children	NNS	O
were	VBD	O
marginally	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	O
but	CC	O
not	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
received	VBN	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
CAM	NNP	O
is	VBZ	O
common	JJ	O
in	IN	O
families	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
predicted	VBN	O
by	IN	O
higher	JJR	O
parental	JJ	O
education	NN	O
and	CC	O
non-Hispanic	JJ	O
ethnicity	NN	O
but	CC	O
not	RB	O
developmental	JJ	O
characteristics	NNS	O
.	.	O

Further	NNP	O
research	NN	O
should	MD	O
address	VB	O
how	WRB	O
health	NN	O
care	NN	O
providers	NNS	O
can	MD	O
support	VB	O
families	NNS	O
in	IN	O
making	VBG	O
decisions	NNS	O
about	IN	O
CAM	NNP	O
use	NN	O
.	.	O

Salmeterol	NNP	O
plus	CC	O
fluticasone	JJ	O
propionate	NN	O
versus	IN	O
fluticasone	NN	O
propionate	NN	O
plus	CC	O
montelukast	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
on	IN	O
airway	JJ	PH
inflammation	NN	PH
in	IN	O
asthma	NN	O
.	.	O

BACKGROUND	NNP	O
Few	NNP	O
studies	NNS	O
have	VBP	O
compared	VBN	O
treatment	NN	O
strategies	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
asthma	JJ	O
poorly	RB	O
controlled	VBN	O
on	IN	O
low	JJ	O
dose	NN	O
inhaled	JJ	O
corticosteroids	NNS	O
,	,	O
and	CC	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
different	JJ	O
treatments	NNS	O
on	IN	O
airway	JJ	O
inflammation	NN	O
.	.	O

In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
salmeterol	NN	O
plus	CC	O
fluticasone	NN	O
propionate	NN	O
(	(	O
FP	NNP	O
)	)	O
(	(	O
Seretide	NNP	O
;	:	O
SFC	NNP	O
)	)	O
and	CC	O
FP	NNP	O
plus	CC	O
montelukast	NN	O
(	(	O
FP/M	NNP	O
)	)	O
on	IN	O
sputum	NN	PH
inflammatory	NN	PH
markers	NNS	PH
,	,	O
airway	RB	PH
responsiveness	NN	PH
,	,	O
lung	NN	PH
function	NN	PH
,	,	O
and	CC	O
symptoms	NNS	PH
in	IN	O
adult	NN	O
asthmatics	NNS	O
.	.	O

METHODS	NNP	O
Sixty-six	JJ	O
subjects	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
SFC	NNP	O
or	CC	O
FP/M	NNP	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
changes	NNS	PH
in	IN	PH
neutrophil	NN	PH
,	,	PH
eosinophil	NN	PH
,	,	PH
macrophage	NN	PH
,	,	PH
lymphocyte	NN	PH
,	,	PH
and	CC	PH
epithelial	JJ	PH
cell	NN	PH
levels	NNS	PH
in	IN	PH
induced	JJ	PH
sputum	NN	PH
.	.	O

Additional	NNP	O
outcomes	NNS	O
included	VBD	O
the	DT	O
change	NN	O
in	IN	O
other	JJ	O
sputum	JJ	O
markers	NNS	O
of	IN	O
airway	JJ	PH
inflammation	NN	PH
,	,	O
airway	RB	PH
responsiveness	NN	PH
,	,	O
symptom	NN	PH
control	NN	PH
,	,	O
and	CC	O
lung	NN	PH
function	NN	PH
.	.	O

RESULTS	NNP	O
Both	NNP	O
treatments	NNS	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
induced	JJ	O
sputum	NN	PH
inflammatory	NN	PH
cells	NNS	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
a	DT	O
reduction	NN	O
in	IN	O
sputum	NN	PH
eosinophils	NNS	PH
.	.	O

Both	DT	O
treatments	NNS	O
significantly	RB	O
improved	VBN	O
airway	RB	PH
responsiveness	NN	PH
,	,	O
whereas	WP	O
SFC	NNP	O
generally	RB	O
led	VBD	O
to	TO	O
greater	JJR	O
improvements	NNS	O
in	IN	O
symptom	JJ	PH
control	NN	PH
and	CC	O
lung	NN	PH
function	NN	PH
than	IN	O
FP/M	NNP	O
.	.	O

FP/M	NNP	O
led	VBD	O
to	TO	O
significantly	RB	O
greater	JJR	O
reductions	NNS	O
in	IN	O
sputum	NN	PH
cysteinyl	NN	PH
leukotrienes	NNS	PH
than	IN	O
SFC	NNP	O
(	(	O
treatment	NN	O
ratio	NN	O
1.80	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.09	CD	O
,	,	O
2.94	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	DT	O
treatments	NNS	O
led	VBD	O
to	TO	O
similar	JJ	O
control	NN	O
of	IN	O
eosinophilic	JJ	PH
airway	NN	PH
inflammation	NN	PH
,	,	O
although	IN	O
PEF	NNP	O
and	CC	O
symptom	VB	O
control	NN	O
were	VBD	O
better	JJR	O
with	IN	O
SFC	NNP	O
.	.	O

STUDY	NNP	O
NUMBER	NNP	O
:	:	O
SAM40030	NNP	O
(	(	O
SOLTA	NNP	O
)	)	O
.	.	O

Long-term	JJ	O
outcome	NN	O
of	IN	O
migraine	JJ	O
therapy	NN	O
:	:	O
predictive	JJ	O
value	NN	O
of	IN	O
the	DT	O
frontotemporal	JJ	O
nitroglycerin	JJ	O
test	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
whether	IN	O
type	NN	O
of	IN	O
response	NN	O
to	TO	O
the	DT	O
migraine-induction	JJ	O
test	NN	O
with	IN	O
a	DT	O
nitroglycerin	JJ	O
ointment	NN	O
applied	VBN	O
to	TO	O
the	DT	O
frontotemporal	JJ	O
head	NN	O
region	NN	O
could	MD	O
predict	VB	Ot
the	DT	Ot
efficacy	NN	Ot
of	IN	Ot
antimigraine	JJ	Ot
therapy	NN	Ot
.	.	O

Forty-two	JJ	O
patients	NNS	O
with	IN	O
migraine	NN	O
without	IN	O
aura	JJ	O
underwent	NN	O
the	DT	O
test	NN	O
before	IN	O
and	CC	O
2	CD	O
months	NNS	O
after	IN	O
antimigraine	JJ	O
therapy	NN	O
.	.	O

Two	CD	O
and	CC	O
4	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
withdrawal	NN	O
,	,	O
most	RBS	O
subjects	NNS	O
with	IN	O
a	DT	O
negative	JJ	O
response	NN	O
to	TO	O
the	DT	O
post-treatment	JJ	O
test	NN	O
maintained	VBD	Ot
treatment	NN	Ot
benefit	NN	Ot
,	,	O
whereas	JJ	O
benefit	NN	O
was	VBD	O
lost	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
an	DT	O
early	JJ	PH
onset	NN	PH
migraine	NN	PH
response	NN	PH
.	.	ME

Treatment	NN	O
of	IN	O
renal	JJ	PH
failure	NN	PH
associated	VBN	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Plasmapheresis	NN	O
,	,	O
hemodialysis	NN	O
,	,	O
and	CC	O
chemotherapy	NN	O
.	.	O

The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
examine	VB	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
plasmapheresis	NN	O
in	IN	O
preventing	VBG	O
irreversible	JJ	PH
renal	JJ	PH
failure	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
and	CC	O
to	TO	O
study	VB	O
the	DT	O
renal	JJ	O
biopsy	NN	O
tissues	NNS	O
from	IN	O
such	JJ	O
patients	NNS	O
.	.	O

Twenty-one	CD	O
patients	NNS	O
with	IN	O
active	JJ	O
myeloma	NN	O
and	CC	O
progressive	JJ	O
renal	JJ	O
failure	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
,	,	O
forced	VBN	O
diuresis	NN	O
and	CC	O
chemotherapy	NN	O
(	(	O
10	CD	O
patients	NNS	O
)	)	O
,	,	O
and	CC	O
group	NN	O
2	CD	O
,	,	O
forced	VBN	O
diuresis	NN	O
,	,	O
chemotherapy	NN	O
,	,	O
and	CC	O
plasmapheresis	NN	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

Plasmapheresis	NN	O
and	CC	O
chemotherapy	NN	O
lowered	VBD	O
the	DT	O
serum	NN	PH
myeloma	NN	PH
protein	IN	PH
value	NN	PH
much	RB	O
more	RBR	O
rapidly	RB	O
than	IN	O
chemotherapy	VB	O
alone	JJ	O
.	.	O

Of	IN	O
5	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
oliguric	JJ	O
and	CC	O
undergoing	JJ	O
dialysis	NN	O
at	IN	O
presentation	NN	O
,	,	O
only	RB	O
3	CD	O
who	WP	O
were	VBD	O
treated	VBN	O
by	IN	O
plasmapheresis	NN	O
recovered	VBN	O
.	.	O

Of	IN	O
16	CD	O
polyuric	JJ	O
patients	NNS	O
,	,	O
5	CD	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
7	CD	O
in	IN	O
group	NN	O
2	CD	O
showed	VBD	O
improvement	NN	O
in	IN	O
renal	JJ	PH
function	NN	PH
.	.	O

The	DT	O
main	JJ	O
factor	NN	O
that	WDT	O
determined	VBD	O
irreversibility	NN	O
of	IN	O
renal	JJ	O
failure	NN	O
was	VBD	O
the	DT	O
severity	NN	O
of	IN	O
myeloma	NN	O
cast	NN	O
formation	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
a	DT	O
spiritually	RB	O
based	VBN	O
and	CC	O
non-spiritually	RB	O
based	VBN	O
educational	JJ	O
intervention	NN	O
for	IN	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
church-attending	JJ	O
African-American	JJ	O
men	NNS	O
.	.	O

INTRODUCTION	NNP	O
Health	NNP	O
communication	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
modestly	RB	O
effective	JJ	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
African-American	JJ	O
men	NNS	O
;	:	O
however	RB	O
,	,	O
knowledge	NN	O
and	CC	O
informed	JJ	O
decision	NN	O
making	NN	O
is	VBZ	O
still	RB	O
questionable	JJ	O
even	RB	O
with	IN	O
screening	VBG	O
.	.	O

Church-based	JJ	O
programs	NNS	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
if	IN	O
they	PRP	O
are	VBP	O
spiritually	RB	O
based	VBN	O
in	IN	O
nature	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aims	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
were	VBD	O
to	TO	O
implement	VB	O
and	CC	O
provide	VB	O
an	DT	O
initial	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
spiritually	RB	O
based	VBN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
informed	JJ	O
decision	NN	O
making	VBG	O
intervention	NN	O
for	IN	O
African-American	JJ	O
men	NNS	O
who	WP	O
attend	VBP	O
church	NN	O
,	,	O
and	CC	O
determine	VB	O
its	PRP$	O
efficacy	NN	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHOD	NNP	O
Churches	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
spiritually	RB	O
based	VBN	O
or	CC	O
the	DT	O
non-spiritual	JJ	O
intervention	NN	O
.	.	O

Trained	NNP	O
community	NN	O
health	NN	O
advisors	NNS	O
,	,	O
who	WP	O
were	VBD	O
African-American	JJ	O
male	JJ	O
church	NN	O
members	NNS	O
,	,	O
led	VBD	O
an	DT	O
educational	JJ	O
session	NN	O
and	CC	O
distributed	VBD	O
educational	JJ	O
print	NN	O
materials	NNS	O
.	.	O

Participants	NNS	O
completed	VBD	O
baseline	NN	O
and	CC	O
immediate	JJ	O
follow-up	JJ	O
surveys	NNS	O
to	TO	O
assess	VB	O
the	DT	O
intervention	NN	O
impact	NN	O
on	IN	O
study	NN	O
outcomes	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
spiritually	RB	O
based	VBN	O
intervention	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
areas	NNS	O
such	JJ	O
as	IN	O
knowledge	NN	O
,	,	O
and	CC	O
men	NNS	O
read	VBP	O
more	JJR	O
of	IN	O
their	PRP$	O
materials	NNS	Ot
in	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
non-spiritual	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Further	NNP	O
examination	NN	O
of	IN	O
the	DT	O
efficacy	NN	Ot
of	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
approach	NN	O
to	TO	O
health	NN	O
communication	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
mild	JJ	O
physical	JJ	O
exercise	NN	O
on	IN	O
serum	NN	PH
lipoproteins	NNS	PH
and	CC	O
metabolites	NNS	PH
of	IN	PH
arachidonic	JJ	PH
acid	NN	PH
:	:	O
a	DT	O
controlled	VBN	O
randomised	JJ	O
trial	NN	O
in	IN	O
middle	JJ	O
aged	VBN	O
men	NNS	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
exercise	NN	O
on	IN	O
biochemical	JJ	PH
risk	NN	PH
factors	NNS	PH
for	IN	PH
ischaemic	JJ	PH
heart	NN	PH
disease	NN	PH
31	CD	O
healthy	JJ	O
middle	NNS	O
aged	VBN	O
men	NNS	O
undertook	IN	O
regular	JJ	O
physical	JJ	O
exercise	NN	O
for	IN	O
two	CD	O
months	NNS	O
and	CC	O
29	CD	O
served	VBD	O
as	IN	O
controls	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

In	IN	O
the	DT	O
men	NNS	O
taking	VBG	O
regular	JJ	O
exercise	NN	O
serum	NN	PH
cholesterol	NN	PH
concentrations	NNS	PH
increased	VBD	O
26	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
high	JJ	PH
density	NN	PH
lipoprotein	VBP	PH
subfraction	NN	PH
two	CD	PH
(	(	PH
HDL2	NNP	PH
)	)	PH
and	CC	O
decreased	VBD	O
31	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
subfraction	NN	PH
three	CD	PH
(	(	PH
HDL3	NNP	PH
)	)	PH
and	CC	O
9	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
low	JJ	PH
density	NN	PH
lipoprotein	NN	PH
fraction	NN	PH
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
tendency	NN	O
towards	NNS	O
increased	VBD	O
plasma	JJ	PH
6-keto-prostaglandin	JJ	PH
F1	NNP	PH
alpha	NN	PH
concentration	NN	PH
and	CC	O
decreased	VBD	O
serum	NN	PH
thromboxane	NN	PH
B2	NNP	PH
concentration	NN	PH
was	VBD	O
found	VBN	O
during	IN	O
the	DT	O
period	NN	O
of	IN	O
regular	JJ	O
exercise	NN	O
,	,	O
but	CC	O
prostaglandin	VBP	PH
E2	NNP	PH
concentrations	NNS	PH
remained	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
plasma	JJ	PH
6-keto-prostaglandin	JJ	PH
F1	NNP	PH
alpha	NN	PH
concentration	NN	PH
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	PH
HDL2	NNP	PH
cholesterol	NN	PH
concentration	NN	PH
in	IN	O
the	DT	O
group	NN	O
taking	VBG	O
regular	JJ	O
exercise	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
mild	JJ	O
regular	JJ	O
physical	JJ	O
exercise	NN	O
favourably	RB	O
influences	VBZ	O
cholesterol	NN	PH
distribution	NN	PH
in	IN	O
serum	NN	PH
lipoproteins	NNS	PH
in	IN	O
healthy	JJ	O
middle	NN	O
aged	VBN	O
men	NNS	O
and	CC	O
may	MD	O
have	VB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
circulating	VBG	PH
metabolites	NNS	PH
of	IN	PH
arachidonic	JJ	PH
acid	NN	PH
.	.	O

Naltrexone	NN	O
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
naltrexone	NN	O
,	,	O
an	DT	O
opiate	NN	O
blocker	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Thirteen	NNP	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBD	O
3.4	CD	O
to	TO	O
8.3	CD	O
years	NNS	O
(	(	O
mean	VB	O
5.4	CD	O
)	)	O
,	,	O
were	VBD	O
studied	VBN	O
in	IN	O
home	NN	O
,	,	O
school	NN	O
,	,	O
and	CC	O
outpatient	JJ	O
laboratory	NN	O
.	.	O

Naltrexone	NNP	O
,	,	O
1.0	CD	O
mg/kg	NN	O
,	,	O
was	VBD	O
given	VBN	O
daily	RB	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Dependent	JJ	O
measures	NNS	O
included	VBD	O
parent	NN	O
and	CC	O
teacher	RB	O
Clinical	JJ	ME
Global	NNP	ME
Impressions	NNP	ME
(	(	ME
CGI	NNP	ME
)	)	ME
,	,	O
Conners	NNPS	ME
Rating	NNP	ME
Scales	NNP	ME
,	,	O
and	CC	O
Naltrexone	NNP	Ot
Side-Effects	NNP	Ot
(	(	Ot
SE	NNP	Ot
)	)	Ot
Rating	NNP	Ot
Scale	NNP	Ot
;	:	O
laboratory	NN	ME
CGI	NNP	ME
,	,	O
movement	NN	ME
actometer	NN	ME
readings	NNS	ME
,	,	O
and	CC	O
a	DT	ME
10-second	JJ	ME
interval	NN	ME
recording	VBG	ME
system	NN	ME
analysis	NN	ME
of	IN	ME
on-task	NN	ME
,	,	O
communication	NN	ME
initiations	NNS	ME
,	,	O
disruptive	JJ	ME
behavior	NN	ME
,	,	O
and	CC	O
self-stimulation	NN	ME
.	.	O

RESULTS	NNP	O
Eight	NNP	O
of	IN	O
13	CD	O
subjects	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
parent	NN	ME
measures	NNS	ME
(	(	ME
CGI	NNP	ME
,	,	O
Conners	NNP	ME
Impulsivity-Hyperactivity	NNP	ME
Factor	NNP	ME
,	,	O
and	CC	O
SE-Restlessness	NNP	ME
)	)	O
and	CC	O
Teacher	NNP	ME
CGI	NNP	ME
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

Teacher	CC	ME
SE-Restlessness	JJ	ME
and	CC	O
initiation	NN	ME
of	IN	ME
communication	NN	ME
in	IN	O
the	DT	O
clinic	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
.	.	O

Actometer	NNP	PH
readings	NNS	PH
improved	VBN	O
in	IN	O
two	CD	O
children	NNS	O
who	WP	O
were	VBD	O
very	RB	O
active	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Adverse	JJ	A
side	NN	A
effects	NNS	A
were	VBD	O
behavioral	JJ	O
,	,	O
mild	JJ	O
,	,	O
and	CC	O
transient	NN	O
.	.	O

Administering	VBG	O
the	DT	O
bitter	JJ	O
tablet	NN	O
was	VBD	O
a	DT	O
challenge	NN	O
.	.	O

CONCLUSIONS	NNP	O
Naltrexone	NNP	O
offers	VBZ	O
promise	RB	O
as	IN	O
an	DT	O
agent	NN	O
for	IN	O
modest	JJ	O
improvement	NN	O
of	IN	O
behavior	NN	O
and	CC	O
social	JJ	ME
communication	NN	ME
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Parent	NN	O
and	CC	O
teacher	NN	O
measures	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
outpatient	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
change	NN	O
.	.	O

Cardiovascular	JJ	Ot
safety	NN	Ot
and	CC	Ot
gastrointestinal	JJ	Ot
tolerability	NN	Ot
of	IN	O
etoricoxib	JJ	O
vs	NN	O
diclofenac	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
The	DT	O
MEDAL	NNP	O
study	NN	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
cardiovascular	JJ	Ot
(	(	Ot
CV	NNP	Ot
)	)	Ot
and	CC	Ot
other	JJ	Ot
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
parameters	NNS	Ot
of	IN	O
etoricoxib	JJ	O
60	CD	O
and	CC	O
90	CD	O
mg	NN	O
,	,	O
and	CC	O
diclofenac	VBZ	O
150	CD	O
mg.	NN	O
METHODS	NNP	O
This	DT	O
double-blind	NN	O
study	NN	O
randomized	VBD	O
OA	NNP	O
patients	NNS	O
to	TO	O
etoricoxib	VB	O
90	CD	O
mg	NN	O
,	,	O
then	RB	O
to	TO	O
60	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
vs	NNS	O
diclofenac	VBP	O
75	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
;	:	O
RA	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
etoricoxib	VB	O
90	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
or	CC	O
diclofenac	JJ	O
75	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
non-inferiority	NN	O
of	IN	O
etoricoxib	JJ	O
vs	NN	O
diclofenac	NN	O
for	IN	O
thrombotic	JJ	O
CV	NNP	O
events	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
upper	JJ	O
bound	NN	O
of	IN	O
hazard	NN	O
ratio	NN	O
<	NNP	O
1.30	CD	O
)	)	O
.	.	O

Other	JJ	Ot
safety	NN	Ot
and	CC	Ot
efficacy	NN	Ot
parameters	NNS	Ot
were	VBD	O
evaluated	VBN	O
in	IN	O
cohorts	NNS	O
of	IN	O
patients	NNS	O
based	VBN	O
on	IN	O
etoricoxib	NN	O
dose	NN	O
and	CC	O
disease	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
23	CD	O
504	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
with	IN	O
mean	JJ	O
treatment	NN	O
duration	NN	O
from	IN	O
19.4	CD	O
to	TO	O
20.8	CD	O
months	NNS	O
.	.	O

The	DT	O
thrombotic	JJ	Ot
CV	NNP	Ot
risk	NN	Ot
hazard	NN	Ot
ratio	NN	Ot
(	(	PH
HR	NNP	PH
)	)	PH
(	(	O
etoricoxib	UH	O
to	TO	O
diclofenac	VB	O
)	)	O
was	VBD	O
0.96	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.81	CD	O
,	,	O
1.15	CD	O
)	)	O
,	,	O
consistent	JJ	O
with	IN	O
non-inferiority	NN	O
of	IN	O
etoricoxib	NN	O
to	TO	O
diclofenac	VB	O
.	.	O

The	DT	O
cumulative	JJ	A
gastrointestinal	NN	A
(	(	A
GI	NNP	A
)	)	A
/liver	VBP	A
adverse	JJ	A
events	NNS	A
(	(	A
AEs	NNP	A
)	)	A
discontinuation	NN	A
rate	NN	A
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
etoricoxib	JJR	O
than	IN	O
diclofenac	NN	O
in	IN	O
each	DT	O
patient	NN	O
cohort	NN	O
;	:	O
HR	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
of	IN	O
0.46	CD	O
(	(	O
0.39	CD	O
,	,	O
0.54	CD	O
)	)	O
,	,	O
0.52	CD	O
(	(	O
0.42	CD	O
,	,	O
0.63	CD	O
)	)	O
and	CC	O
0.49	CD	O
(	(	O
0.39	CD	O
,	,	O
0.62	CD	O
)	)	O
for	IN	O
the	DT	O
60	CD	O
mg	NN	O
OA	NNP	O
,	,	O
90	CD	O
mg	NN	O
OA	NNP	O
and	CC	O
RA	NNP	O
cohorts	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
average	JJ	O
change	NN	O
in	IN	O
systolic	JJ	PH
blood	NN	PH
pressure	NN	PH
(	(	O
BP	NNP	O
)	)	O
with	IN	O
etoricoxib	NN	O
was	VBD	O
3.4-3.6	JJ	O
mmHg	NN	O
(	(	O
diastolic	JJ	O
BP	NNP	O
:	:	O
1.0-1.5	JJ	O
mmHg	NN	O
)	)	O
,	,	O
while	IN	O
diclofenac	NN	O
produced	VBD	O
a	DT	O
maximum	JJ	O
average	JJ	O
change	NN	O
of	IN	O
0.9-1.9	JJ	O
mmHg	NN	O
(	(	O
diastolic	JJ	O
BP	NNP	O
:	:	O
0.0-0.5	JJ	O
mmHg	NN	O
)	)	O
.	.	O

Both	DT	O
agents	NNS	O
resulted	VBD	O
in	IN	O
similar	JJ	O
efficacy	NN	Ot
regardless	NN	O
of	IN	O
etoricoxib	NN	O
dose	NN	O
.	.	O

CONCLUSION	NNP	O
Long-term	NNP	O
etoricoxib	NN	O
use	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
risk	NN	PH
of	IN	PH
thrombotic	JJ	PH
CV	NNP	PH
events	NNS	PH
comparable	JJ	O
with	IN	O
that	DT	O
of	IN	O
diclofenac	NN	O
.	.	O

Compared	VBN	O
with	IN	O
diclofenac	NN	O
,	,	O
etoricoxib	RB	O
demonstrated	VBD	O
a	DT	O
greater	JJR	O
risk	NN	O
of	IN	O
renovascular	JJ	PH
AEs	NNP	PH
,	,	O
but	CC	O
a	DT	O
more	RBR	O
favourable	JJ	O
GI/liver	NNP	Ot
tolerability	NN	Ot
profile	NN	Ot
.	.	Ot

Treating	VBG	O
the	DT	O
substance-abusing	JJ	O
suicidal	JJ	O
patient	NN	O
.	.	O

Studies	NNPS	O
concerning	VBG	O
the	DT	O
treatment	NN	O
of	IN	O
substance-abusing	JJ	O
suicidal	NN	O
patients	NNS	O
are	VBP	O
scarce	JJ	O
despite	IN	O
the	DT	O
frequent	JJ	O
presence	NN	O
of	IN	O
suicidal	JJ	O
behavior	NN	O
among	IN	O
this	DT	O
population	NN	O
.	.	O

Indeed	RB	O
,	,	O
suicidality	NN	O
(	(	O
ideation	NN	O
or	CC	O
behavior	NN	O
)	)	O
is	VBZ	O
generally	RB	O
an	DT	O
exclusion	NN	O
criterion	NN	O
for	IN	O
participation	NN	O
in	IN	O
treatment	NN	O
studies	NNS	O
of	IN	O
subjects	NNS	O
with	IN	O
alcohol	NN	O
or	CC	O
drug	NN	O
abuse	NN	O
.	.	O

Consequently	RB	O
,	,	O
to	TO	O
date	NN	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
optimal	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
population	NN	O
.	.	O

The	DT	O
first	JJ	O
study	NN	O
involving	VBG	O
substance-abusing	JJ	O
suicidal	JJ	O
patients	NNS	O
was	VBD	O
an	DT	O
open-label	JJ	O
trial	NN	O
conducted	VBN	O
in	IN	O
the	DT	O
early	JJ	O
1990s	CD	O
.	.	O

This	DT	O
study	NN	O
involved	VBD	O
12	CD	O
patients	NNS	O
,	,	O
all	DT	O
of	IN	O
whom	WP	O
demonstrated	VBD	O
recent	JJ	O
suicidal	JJ	MO
ideations	NNS	MO
and	CC	O
had	VBD	O
made	VBN	O
a	DT	O
lifetime	NN	O
suicide	NN	O
attempt	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
that	DT	O
open-label	JJ	O
study	NN	O
demonstrated	VBD	O
significant	JJ	O
within-group	JJ	O
improvement	NN	O
in	IN	O
both	DT	O
depressive	JJ	MO
symptoms	NNS	MO
(	(	MO
including	VBG	MO
suicidal	JJ	MO
ideations	NNS	MO
)	)	MO
and	CC	MO
level	NN	MO
of	IN	MO
drinking	NN	MO
.	.	MO

However	RB	O
,	,	O
substantial	JJ	O
residual	JJ	O
depressive	NN	ME
symptoms	NNS	ME
and	CC	ME
drinking	NN	ME
persisted	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Also	RB	O
,	,	O
because	IN	O
no	DT	O
placebo	NN	O
control	NN	O
group	NN	O
was	VBD	O
utilized	VBN	O
,	,	O
the	DT	O
authors	NNS	O
of	IN	O
that	DT	O
study	NN	O
could	MD	O
not	RB	O
rule	VB	O
out	IN	O
the	DT	O
possibility	NN	O
that	IN	O
the	DT	O
apparent	JJ	O
therapeutic	JJ	O
effect	NN	O
from	IN	O
fluoxetine	NN	O
was	VBD	O
the	DT	O
result	NN	O
of	IN	O
the	DT	O
placebo	NN	O
effect	NN	O
.	.	O

To	TO	O
date	NN	O
,	,	O
only	RB	O
one	CD	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
alcohol	NN	O
or	CC	O
substance	NN	O
abuse	NN	O
has	VBZ	O
included	VBN	O
substantial	JJ	O
numbers	NNS	O
of	IN	O
suicidal	JJ	O
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
involved	VBD	O
51	CD	O
subjects	NNS	O
,	,	O
of	IN	O
whom	WP	O
20	CD	O
(	(	O
39	CD	O
%	NN	O
)	)	O
had	VBD	O
made	VBN	O
a	DT	O
suicide	JJ	O
attempt	NN	O
in	IN	O
the	DT	O
current	JJ	O
depressive	JJ	O
episode	NN	O
,	,	O
31	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
had	VBD	O
made	VBN	O
a	DT	O
suicide	JJ	O
attempt	NN	O
in	IN	O
their	PRP$	O
lifetime	NN	O
,	,	O
and	CC	O
46	CD	O
(	(	O
90	CD	O
%	NN	O
)	)	O
had	VBD	O
reported	VBN	O
suicidal	JJ	O
ideations	NNS	O
in	IN	O
the	DT	O
week	NN	O
before	IN	O
hospitalization	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
that	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
suggest	VBP	O
that	IN	O
fluoxetine	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
but	CC	O
not	RB	O
eliminating	VBG	O
both	CC	O
the	DT	O
depressive	NN	ME
symptoms	NNS	ME
(	(	ME
including	VBG	ME
suicidal	JJ	ME
ideations	NNS	ME
)	)	ME
and	CC	ME
the	DT	ME
level	NN	ME
of	IN	ME
alcohol	JJ	ME
consumption	NN	ME
among	IN	O
a	DT	O
study	NN	O
group	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
comorbid	NN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
and	CC	O
alcohol	NN	O
dependence	NN	O
,	,	O
many	JJ	O
of	IN	O
whom	WP	O
displayed	VBD	O
suicidal	JJ	O
ideations	NNS	O
.	.	O

A	DT	O
secondary	JJ	O
data	NN	O
analysis	NN	O
from	IN	O
that	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
cigarette	NN	ME
smoking	NN	ME
is	VBZ	O
also	RB	O
significantly	RB	O
decreased	VBN	O
by	IN	O
fluoxetine	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
decrease	NN	O
is	VBZ	O
limited	JJ	O
and	CC	O
few	JJ	O
of	IN	O
these	DT	O
patients	NNS	O
totally	RB	O
quit	VBP	O
smoking	VBG	O
with	IN	O
fluoxetine	JJ	O
treatment	NN	O
alone	RB	O
.	.	O

Another	DT	O
secondary	JJ	O
data	NN	O
analysis	NN	O
from	IN	O
that	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
marijuana	NN	ME
smoking	NN	ME
was	VBD	O
also	RB	O
significantly	RB	O
decreased	VBN	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
subjects	NNS	O
who	WP	O
demonstrated	VBD	O
cannabis	NN	O
abuse	NN	O
and	CC	O
that	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
this	DT	O
improvement	NN	O
was	VBD	O
robust	JJ	O
.	.	O

A	DT	O
third	JJ	O
secondary	JJ	O
data	NNS	O
analysis	NN	O
from	IN	O
that	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
cocaine	NN	ME
abuse	NN	ME
acts	VBZ	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
poor	JJ	O
outcome	NN	O
for	IN	O
both	DT	O
depressive	JJ	ME
symptoms	NNS	ME
(	(	ME
including	VBG	ME
suicidality	NN	ME
)	)	ME
and	CC	ME
level	NN	ME
of	IN	ME
alcohol	NN	ME
use	NN	ME
in	IN	O
this	DT	O
population	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
naturalistic	JJ	O
follow-up	NN	O
study	NN	O
involving	VBG	O
the	DT	O
patients	NNS	O
from	IN	O
that	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
fluoxetine	NN	O
in	IN	O
decreasing	VBG	O
depressive	JJ	O
symptoms	NNS	O
and	CC	O
level	NN	O
of	IN	O
drinking	VBG	O
persist	NN	O
1	CD	O
year	NN	O
after	IN	O
entering	VBG	O
the	DT	O
treatment	NN	O
program	NN	O
.	.	O

To	TO	O
date	NN	O
,	,	O
no	DT	O
other	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
studies	NNS	O
involving	VBG	O
substantial	JJ	O
numbers	NNS	O
of	IN	O
substance-abusing	JJ	O
suicidal	NN	O
patients	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
either	DT	O
confirm	NN	O
or	CC	O
refute	VB	O
these	DT	O
findings	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
clearly	RB	O
warranted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
various	JJ	O
pharmacotherapeutic	JJ	O
agents	NNS	O
and	CC	O
various	JJ	O
psychotherapies	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
substance-abusing	JJ	O
suicidal	JJ	O
patients	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
peer	NN	O
counseling	VBG	O
on	IN	O
smoking	VBG	O
cessation	NN	ME
and	CC	O
reduction	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
a	DT	O
peer	NN	O
counseling	VBG	O
intervention	NN	O
for	IN	O
pregnant	JJ	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
forty-two	NN	O
pregnant	NN	O
,	,	O
predominantly	RB	O
Hispanic	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
peer-led	JJ	O
smoking	NN	O
cessation	NN	O
program	NN	O
or	CC	O
to	TO	O
usual	JJ	O
care	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
usual	JJ	O
care	NN	O
,	,	O
peer	NN	O
counseling	NN	O
reduced	VBN	O
smoking	NN	O
(	(	O
-9.1	JJ	O
versus	NN	O
-4.5	NNP	O
cigarettes	VBZ	O
daily	RB	O
,	,	O
P	NNP	O
=.03	NNP	O
)	)	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
absolute	JJ	O
quit	NN	ME
rates	NNS	ME
(	(	O
24	CD	O
%	NN	O
versus	IN	O
21	CD	O
%	NN	O
)	)	O
at	IN	O
36	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
.	.	O

Infant	NNP	PH
birth	NN	PH
weight	VBD	PH
negatively	RB	O
correlated	VBN	O
with	IN	O
cigarettes	NNS	O
smoked	VBN	O
per	IN	O
day	NN	O
(	(	O
r	VB	O
=	NNP	O
-0.29	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
expired	JJ	O
carbon	NN	O
monoxide	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.39	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
at	IN	O
delivery	NN	O
.	.	O

Birth	NNP	PH
weight	VBD	PH
for	IN	PH
infants	NNS	PH
born	VBN	PH
to	TO	PH
women	NNS	PH
who	WP	PH
quit	VBP	PH
smoking	VBG	PH
averaged	VBD	O
7.2	CD	O
lb	JJ	O
versus	NN	O
6.8	CD	O
and	CC	O
6.3	CD	O
lb	NN	O
for	IN	O
mothers	NNS	O
smoking	VBG	O
one	CD	O
to	TO	O
six	CD	O
and	CC	O
more	JJR	O
than	IN	O
six	CD	O
cigarettes	NNS	O
per	IN	O
day	NN	O
at	IN	O
delivery	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Peer	NNP	Ot
counseling	NN	Ot
reduced	VBD	O
the	DT	O
number	NN	ME
of	IN	ME
cigarettes	NNS	ME
smoked	VBN	ME
daily	RB	ME
but	CC	O
did	VBD	O
not	RB	O
increase	VB	O
cigarette	NN	ME
abstinence	NN	ME
rates	NNS	ME
.	.	O

Infant	NNP	PH
birth	NN	PH
weight	NN	PH
increases	NNS	O
with	IN	O
both	DT	O
smoking	VBG	O
cessation	NN	O
and	CC	O
smoking	NN	O
reduction	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
peer	NN	O
counseling	VBG	O
intervention	NN	O
programs	NNS	O
may	MD	O
improve	VB	O
newborn	JJR	PH
health	NN	PH
despite	IN	O
their	PRP$	O
failure	NN	O
to	TO	O
affect	VB	O
smoking	VBG	O
cessation	NN	O
.	.	O

Roles	NNS	O
of	IN	O
adapalene	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

BACKGROUND	NNP	O
Ketoconazole	NNP	O
is	VBZ	O
a	DT	O
typical	JJ	O
treatment	NN	O
available	JJ	O
for	IN	O
pityriasis	NN	O
versicolor	NN	O
;	:	O
tretinoin	CC	O
cream	NN	O
is	VBZ	O
effective	JJ	O
,	,	O
too	RB	O
.	.	O

Adapalene	NNP	O
gel	NN	O
is	VBZ	O
a	DT	O
tretinoin	JJ	O
derivative	NN	O
and	CC	O
has	VBZ	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
irritation	NN	A
compared	VBN	O
with	IN	O
other	JJ	O
topical	JJ	O
retinoid	NN	O
products	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
reports	NNS	O
on	IN	O
adapalene	NN	O
gel	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
adapalene	NN	O
gel	NN	O
comparing	VBG	O
the	DT	O
treatment	NN	O
with	IN	O
adapalene	JJ	O
gel	NNS	O
and	CC	O
2	CD	O
%	NN	O
ketoconazole	JJ	O
cream	NN	O
in	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
patients	NNS	O
suffering	VBG	O
from	IN	O
pityriasis	NN	O
versicolor	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
one	CD	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
2	CD	O
%	NN	O
ketoconazole	JJ	O
cream	NN	O
topically	RB	O
twice	JJ	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
adapalene	JJ	O
gel	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
other	JJ	O
group	NN	O
in	IN	O
a	DT	O
similar	JJ	O
fashion	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
efficacy	NN	Ot
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

No	DT	O
major	JJ	O
side	NN	A
effects	NNS	A
were	VBD	O
noted	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
either	CC	O
.	.	O

CONCLUSION	NNP	O
Adapalene	NNP	O
was	VBD	O
the	DT	O
favorable	JJ	O
option	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

The	DT	O
probable	JJ	O
therapeutic	JJ	O
mechanism	NN	O
of	IN	O
adapalene	NN	O
is	VBZ	O
also	RB	O
discussed	VBN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
soy-based	JJ	O
dietary	JJ	O
supplement	NN	O
on	IN	O
lipid	JJ	PH
levels	NNS	PH
and	CC	O
cardiovascular	JJ	PH
risk	NN	PH
markers	NNS	PH
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVE	NNP	O
Consumption	NNP	O
of	IN	O
soy	NN	O
protein	NN	O
has	VBZ	O
recently	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
the	DT	O
blood	NN	PH
lipid	JJ	PH
levels	NNS	PH
in	IN	O
nondiabetic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
if	IN	O
a	DT	O
dietary	JJ	O
supplement	NN	O
of	IN	O
soy	NN	O
protein	NN	O
,	,	O
isoflavones	NNS	O
,	,	O
and	CC	O
cotyledon	VB	O
fiber	NN	O
(	(	O
Abalon	NNP	O
)	)	O
affects	VBZ	O
cardiovascular	JJ	PH
risk	NN	PH
markers	NNS	PH
,	,	O
blood	NN	PH
glucose	NN	PH
,	,	O
and	CC	O
insulin	NN	PH
levels	NNS	PH
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Twenty	NNP	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
crossover	NN	O
trial	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	JJ	O
supplementation	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
Abalon	NNP	O
(	(	O
soy	JJ	O
protein	NN	O
[	VBD	O
50	CD	O
g/day	JJ	O
]	NNP	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
isoflavones	NNS	O
[	NNP	O
minimum	VBD	O
165	CD	O
mg/day	NN	O
]	NNP	O
and	CC	O
cotyledon	VB	O
fiber	NN	O
[	$	O
20	CD	O
g/day	JJ	O
]	NNPS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
casein	JJ	O
[	VBZ	O
50	CD	O
g/day	NN	O
]	NNP	O
and	CC	O
cellulose	VB	O
[	JJ	O
20	CD	O
g/day	JJ	O
]	NNP	O
)	)	O
,	,	O
separated	VBN	O
by	IN	O
a	DT	O
3-week	JJ	O
wash-out	JJ	O
period	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
means	NNS	O
+/-	JJ	O
SD	NNP	O
.	.	O

The	DT	O
percentage	NN	O
mean	JJ	O
treatment	NN	O
difference	NN	O
between	IN	O
Abalon	NNP	O
and	CC	O
placebo	NN	O
demonstrated	VBD	O
significantly	RB	O
lower	JJR	O
mean	NN	O
values	NNS	O
after	IN	O
Abalon	NNP	O
for	IN	O
LDL	NNP	PH
cholesterol	NN	PH
(	(	O
10	CD	O
+/-	JJ	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
LDL/UHDL	NNP	PH
ratio	NN	PH
(	(	O
12	CD	O
+/-	JJ	O
18	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
apolipoprotein	RB	PH
(	(	O
apo	NN	O
)	)	O
B100	NNP	O
(	(	O
30	CD	O
+/-	JJ	O
38	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
triglycerides	NNS	PH
(	(	O
22	CD	O
+/-	JJ	O
10	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
homocysteine	NN	PH
(	(	O
14	CD	O
+/-	JJ	O
21	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
whereas	VBD	O
the	DT	O
total	JJ	PH
cholesterol	NN	PH
value	NN	PH
tended	VBD	O
to	TO	O
be	VB	O
less	RBR	O
significant	JJ	O
but	CC	O
still	RB	O
lower	JJR	O
(	(	O
8	CD	O
+/-	JJ	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.08	CD	O
)	)	O
.	.	O

No	UH	O
change	NN	O
occurred	VBD	O
in	IN	O
HDL	NNP	PH
cholesterol	NN	PH
,	,	O
apo	JJ	PH
B100/apo	NNP	PH
A1	NNP	PH
ratio	NN	PH
,	,	O
plasminogen	NN	PH
activator	NN	PH
inhibitor	NN	PH
1	CD	PH
,	,	O
factor	NN	PH
VIIc	NNP	PH
,	,	O
von	NNP	PH
Willebrand	NNP	PH
factor	NN	PH
,	,	O
fibrinogen	NN	PH
,	,	O
lipoprotein	NN	PH
(	(	PH
a	DT	PH
)	)	PH
,	,	O
glucose	JJ	PH
,	,	O
HbA1c	NNP	PH
,	,	O
or	CC	O
24-h	JJ	PH
blood	NN	PH
pressure	NN	PH
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
Abalon	NNP	O
on	IN	O
cardiovascular	JJ	PH
risk	NN	PH
markers	NNS	PH
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

This	DT	O
improvement	NN	O
is	VBZ	O
seen	VBN	O
even	RB	O
in	IN	O
individuals	NNS	O
with	IN	O
near-normal	JJ	O
lipid	JJ	O
values	NNS	O
.	.	O

Efficacy	NN	Ot
of	IN	O
amantadine	NN	O
on	IN	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
treated	VBD	O
with	IN	O
interferon-alpha	JJ	O
and	CC	O
ribavirin	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

AIM	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
amantadine	JJ	O
reduces	NNS	O
deterioration	NN	Ot
of	IN	Ot
quality	NN	Ot
of	IN	Ot
life	NN	Ot
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
during	IN	O
and	CC	O
after	IN	O
treatment	NN	O
with	IN	O
interferon-alpha	JJ	O
(	(	O
IFN-alpha	NNP	O
)	)	O
and	CC	O
ribavirin	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
,	,	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
IFN-alpha	NNP	O
plus	CC	O
ribavirin	JJ	O
[	NN	O
17	CD	O
]	NN	O
and	CC	O
randomized	VBN	O
for	IN	O
treatment	NN	O
with	IN	O
amantadine	NN	O
(	(	O
200	CD	O
mg/day	NN	O
,	,	O
orally	RB	O
,	,	O
n=136	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=131	JJ	O
)	)	O
.	.	O

Quality	NN	Ot
of	IN	Ot
life	NN	Ot
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
'Profile	NN	ME
of	IN	ME
Mood	NNP	ME
States	NNPS	ME
'	POS	ME
scale	NN	ME
and	CC	Ot
the	DT	Ot
'Everyday	JJ	Ot
Life	NNP	Ot
'	POS	Ot
questionnaire	NN	Ot
at	IN	O
baseline	NN	O
,	,	O
treatment	NN	O
week	NN	O
(	(	O
TW	NNP	O
)	)	O
8	CD	O
,	,	O
TW24	NNP	O
,	,	O
TW48	NNP	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
.	.	O

RESULTS	VB	O
Early	JJ	O
during	IN	O
treatment	NN	O
at	IN	O
TW8	NNP	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
amantadine	NN	O
group	NN	O
.	.	O

At	IN	O
TW24	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
amantadine	NN	O
group	NN	O
,	,	O
however	RB	O
,	,	O
showed	VBD	O
significant	JJ	O
deterioration	NN	O
of	IN	O
the	DT	O
modalities	NNS	PH
depression	NN	PH
,	,	O
fatigue	NN	PH
,	,	PH
and	CC	PH
vigor	NN	PH
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

Especially	RB	O
,	,	O
nonresponders	NNS	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
lower	JJR	PH
deterioration	NN	PH
of	IN	PH
depression	NN	PH
,	,	O
anger	NN	PH
,	,	ME
mind	NN	PH
function	NN	PH
,	,	ME
everyday	JJ	ME
life	NN	ME
,	,	ME
and	CC	ME
zest	JJS	ME
for	IN	ME
life	NN	ME
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
beneficial	JJ	Ot
effects	NNS	Ot
of	IN	O
amantadine	NN	O
disappeared	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
addition	NN	O
of	IN	O
amantadine	NN	O
to	TO	O
IFN-alpha	NNP	O
plus	CC	O
ribavirin	JJ	O
combination	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
deterioration	NN	PH
of	IN	PH
depression	NN	PH
,	,	O
fatigue	NN	PH
,	,	O
and	CC	O
vigor	NN	PH
during	IN	O
treatment	NN	O
but	CC	O
does	VBZ	O
not	RB	O
affect	JJ	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
after	IN	O
treatment	NN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
videotape	NN	O
information	NN	O
intervention	NN	O
at	IN	O
discharge	NN	O
on	IN	O
diet	JJ	O
and	CC	O
exercise	NN	O
compliance	NN	O
after	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
relative	JJ	O
effects	NNS	O
on	IN	O
compliance	NN	O
with	IN	O
recommended	JJ	O
lifestyle	JJ	O
changes	NNS	O
of	IN	O
two	CD	O
experimental	JJ	O
videotapes	NNS	O
that	WDT	O
involved	VBD	O
different	JJ	O
approaches	NNS	O
for	IN	O
preparing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
(	(	O
CABG	NNP	O
)	)	O
patients	NNS	O
for	IN	O
the	DT	O
posthospital	JJ	O
recovery	NN	O
period	NN	O
.	.	O

The	DT	O
tapes	NNS	O
differed	VBN	O
in	IN	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
they	PRP	O
portrayed	VBD	O
the	DT	O
recovery	NN	O
period	NN	O
as	IN	O
a	DT	O
steady	JJ	O
,	,	O
forward	JJ	O
progression	NN	O
versus	IN	O
a	DT	O
series	NN	O
of	IN	O
ups	NNS	O
and	CC	O
downs	NNS	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
sixteen	JJ	O
male	NN	O
and	CC	O
female	JJ	O
CABG	NNP	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
either	DT	O
to	TO	O
view	VB	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
videotapes	NNS	O
before	IN	O
discharge	NN	O
from	IN	O
the	DT	O
hospital	NN	O
or	CC	O
to	TO	O
receive	VB	O
only	RB	O
the	DT	O
standard	JJ	O
discharge	NN	O
preparation	NN	O
provided	VBN	O
by	IN	O
the	DT	O
hospital	NN	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBN	O
measures	NNS	Ot
of	IN	Ot
anxiety	NN	Ot
and	CC	Ot
self-efficacy	NN	Ot
at	IN	O
discharge	NN	O
,	,	O
1	CD	O
month	NN	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
from	IN	O
the	DT	O
hospital	NN	O
.	.	O

Patients	NNS	O
also	RB	O
completed	VBD	O
measures	NNS	O
of	IN	O
dietary	JJ	ME
fat	JJ	ME
consumption	NN	ME
and	CC	O
activity	NN	ME
level	NN	ME
1	CD	ME
and	CC	ME
3	CD	ME
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

RESULTS	NNP	O
Relative	NNP	O
to	TO	O
controls	NNS	O
,	,	O
patients	NNS	O
who	WP	O
viewed	VBD	O
either	DT	O
of	IN	O
the	DT	O
videotapes	NNS	O
before	IN	O
hospital	NN	O
release	NN	O
reported	VBD	O
higher	JJR	O
self-efficacy	NN	ME
for	IN	ME
adhering	VBG	ME
to	TO	ME
the	DT	ME
recommended	VBN	ME
low-fat	NN	ME
diet	JJ	ME
both	DT	O
at	IN	O
discharge	NN	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
surgery	NN	O
.	.	O

Viewing	VBG	O
either	DT	O
of	IN	O
the	DT	O
videotapes	NNS	O
also	RB	O
resulted	VBD	O
in	IN	O
significantly	RB	ME
less	JJR	ME
dietary	JJ	ME
fat	NN	ME
intake	NN	ME
1	CD	ME
month	NN	ME
after	IN	ME
hospital	NN	ME
release	NN	ME
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
viewed	VBD	O
the	DT	O
tape	NN	O
that	WDT	O
portrayed	VBD	O
the	DT	O
recovery	NN	O
period	NN	O
as	IN	O
consisting	NN	O
of	IN	O
ups	NNS	O
and	CC	O
downs	NNS	O
also	RB	O
reported	VBD	O
significantly	RB	O
more	RBR	O
frequent	JJ	O
moderate	JJ	ME
exercise	NN	ME
at	IN	ME
1	CD	ME
month	NN	ME
and	CC	O
more	RBR	O
frequent	JJ	O
strenuous	JJ	ME
exercise	NN	ME
3	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
experimental	JJ	O
videotapes	NNS	O
proved	VBD	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
method	NN	O
for	IN	O
increasing	VBG	O
dietary	JJ	ME
and	CC	ME
exercise	NN	ME
compliance	NN	ME
during	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
after	IN	O
CABG	NNP	O
.	.	O

Determinants	NNS	O
of	IN	O
improvement	NN	O
in	IN	O
walking	VBG	PH
capacity	NN	PH
among	IN	O
individuals	NNS	O
with	IN	O
chronic	JJ	O
stroke	NN	O
following	VBG	O
a	DT	O
multi-dimensional	JJ	O
exercise	NN	O
program	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
identify	VB	O
the	DT	O
determinants	NNS	O
of	IN	O
improvement	NN	O
in	IN	O
walking	VBG	PH
capacity	NN	PH
following	VBG	O
therapeutic	JJ	O
exercise	NN	O
in	IN	O
chronic	JJ	O
stroke	NN	O
survivors	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
secondary	JJ	O
analysis	NN	O
of	IN	O
data	NNS	O
obtained	VBN	O
from	IN	O
a	DT	O
prospective	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
randomized	VBN	O
controlled	VBN	O
intervention	NN	O
trial	NN	O
.	.	O

SUBJECTS	JJ	O
Sixty-three	JJ	O
community-dwelling	JJ	O
individuals	NNS	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
65	CD	O
years	NNS	O
,	,	O
age	NN	O
range	NN	O
=	NNP	O
50-87	CD	O
years	NNS	O
)	)	O
with	IN	O
a	DT	O
chronic	JJ	O
stroke	NN	O
(	(	O
post-stroke	JJ	O
duration	NN	O
:	:	O
mean	JJ	O
=	VBP	O
5.5	CD	O
years	NNS	O
,	,	O
range	NN	O
=	NNP	O
1-28	CD	O
years	NNS	O
)	)	O
.	.	O

METHODS	JJ	O
Subjects	NNPS	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
leg	JJ	O
exercise	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
32	CD	O
)	)	O
or	CC	O
an	DT	O
arm	JJ	O
exercise	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
31	CD	O
)	)	O
.	.	O

Subjects	NNS	O
in	IN	O
each	DT	O
group	NN	O
underwent	VBD	O
3	CD	O
1-hour	JJ	O
exercise	NN	O
sessions	NNS	O
per	IN	O
week	NN	O
for	IN	O
19	CD	O
weeks	NNS	O
.	.	O

Walking	VBG	PH
capacity	NN	PH
,	,	PH
cardiorespiratory	NN	PH
fitness	NN	PH
,	,	PH
isometric	JJ	PH
knee	NN	PH
extensor	NN	PH
muscle	NN	PH
strength	NN	PH
,	,	PH
balance	NN	PH
ability	NN	PH
,	,	PH
and	CC	PH
balance	NN	PH
confidence	NN	PH
were	VBD	O
evaluated	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
interventions	NNS	O
.	.	O

Multiple	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
the	DT	O
determinants	NNS	O
of	IN	O
improvement	NN	O
in	IN	O
walking	VBG	O
capacity	NN	O
.	.	O

RESULTS	VB	O
After	IN	O
controlling	VBG	O
for	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
post-stroke	JJ	O
duration	NN	O
,	,	O
and	CC	O
baseline	NN	O
walking	NN	PH
capacity	NN	PH
,	,	O
gain	NN	PH
in	IN	PH
paretic	JJ	PH
leg	NN	PH
muscle	NN	PH
strength	NN	PH
and	CC	PH
peak	NN	PH
oxygen	NN	PH
consumption	NN	PH
remained	VBD	PH
independently	RB	PH
associated	VBN	O
with	IN	O
gain	NN	PH
in	IN	PH
walking	VBG	PH
capacity	NN	PH
(	(	O
R2	NNP	O
=	NNP	O
0.229	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Enhancement	NNP	O
of	IN	O
cardiorespiratory	NN	O
fitness	NN	O
and	CC	O
paretic	JJ	O
leg	NN	O
muscle	NN	O
strength	NN	O
are	VBP	O
both	DT	O
significant	JJ	O
determinants	NNS	O
in	IN	O
improving	VBG	O
walking	JJ	O
capacity	NN	O
among	IN	O
chronic	JJ	O
stroke	NN	O
survivors	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
rather	RB	O
weak	JJ	O
relationship	NN	O
(	(	O
R2	NNP	O
=	NNP	O
0.229	CD	O
)	)	O
indicates	VBZ	O
that	IN	O
other	JJ	O
factors	NNS	O
not	RB	O
measured	VBN	O
in	IN	O
this	DT	O
study	NN	O
may	MD	O
also	RB	O
contribute	VB	O
to	TO	O
the	DT	O
improvement	NN	O
in	IN	O
walking	VBG	O
capacity	NN	O
.	.	O

Nasal	NNP	O
oxytocin	MD	O
for	IN	O
social	JJ	O
deficits	NNS	O
in	IN	O
childhood	NN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

The	DT	O
last	JJ	O
two	CD	O
decades	NNS	O
have	VBP	O
witnessed	VBN	O
a	DT	O
surge	NN	O
in	IN	O
research	NN	O
investigating	VBG	O
the	DT	O
application	NN	O
of	IN	O
oxytocin	NN	O
as	IN	O
a	DT	O
method	NN	O
of	IN	O
enhancing	VBG	O
social	JJ	O
behaviour	NN	O
in	IN	O
humans	NNS	O
.	.	O

Preliminary	JJ	O
evidence	NN	O
suggests	VBZ	O
oxytocin	NN	O
may	MD	O
have	VB	O
potential	NN	O
as	IN	O
an	DT	O
intervention	NN	O
for	IN	O
autism	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
a	DT	O
5-day	JJ	O
'live-in	NN	O
'	POS	O
intervention	NN	O
using	VBG	O
a	DT	O
double-blind	JJ	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

38	CD	O
male	JJ	O
youths	NNS	O
(	(	O
7-16	CD	O
years	NNS	O
old	JJ	O
)	)	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
were	VBD	O
administered	VBN	O
24	CD	O
or	CC	O
12	CD	O
international	JJ	O
units	NNS	O
(	(	O
depending	VBG	O
on	IN	O
weight	NN	O
)	)	O
intranasal	NN	O
placebo	NN	O
or	CC	O
oxytocin	JJ	O
once	RB	O
daily	RB	O
over	IN	O
four	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
oxytocin	NN	O
or	CC	O
placebo	NN	O
was	VBD	O
administered	VBN	O
during	IN	O
parent-child	JJ	O
interaction	NN	O
training	NN	O
sessions	NNS	O
.	.	O

Parent	NN	O
and	CC	O
child	NN	O
behaviours	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
parent	NN	ME
reports	NNS	ME
,	,	ME
clinician	JJ	ME
ratings	NNS	ME
,	,	ME
and	CC	ME
independent	JJ	ME
observations	NNS	ME
,	,	O
at	IN	O
multiple	JJ	O
time	NN	O
points	NNS	O
to	TO	O
measure	VB	ME
side-effects	NNS	A
;	:	ME
social	JJ	ME
interaction	NN	ME
skills	NNS	ME
;	:	ME
repetitive	JJ	ME
behaviours	NNS	ME
;	:	ME
emotion	NN	ME
recognition	NN	ME
and	CC	ME
diagnostic	JJ	ME
status	NN	ME
.	.	O

Compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
intranasal	VB	O
oxytocin	RB	O
did	VBD	O
not	RB	O
significantly	RB	O
improve	VB	O
emotion	NN	ME
recognition	NN	ME
,	,	ME
social	JJ	ME
interaction	NN	ME
skills	NNS	ME
,	,	ME
or	CC	ME
general	JJ	ME
behavioral	JJ	ME
adjustment	NN	ME
in	IN	O
male	JJ	O
youths	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
nasal	JJ	O
oxytocin	NN	O
for	IN	O
young	JJ	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
may	MD	O
be	VB	O
more	JJR	O
circumscribed	JJ	O
than	IN	O
suggested	VBN	O
by	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
and	CC	O
suggest	JJS	O
caution	NN	O
in	IN	O
recommending	VBG	O
it	PRP	O
as	IN	O
an	DT	O
intervention	NN	O
that	WDT	O
is	VBZ	O
broadly	RB	O
effective	JJ	O
.	.	O

Weight	NNP	PH
and	CC	O
leptin	JJ	PH
changes	NNS	PH
among	IN	O
risperidone-treated	JJ	O
youths	NNS	O
with	IN	O
autism	NN	O
:	:	O
6-month	JJ	O
prospective	JJ	O
data	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
authors	NNS	O
examined	VBD	O
the	DT	O
developmental	JJ	O
impact	NN	O
and	CC	O
temporal	JJ	O
characteristics	NNS	O
of	IN	O
risperidone-associated	JJ	O
weight	NN	PH
change	NN	PH
.	.	O

METHOD	NNP	O
Weight	NNP	PH
change	NN	PH
was	VBD	O
measured	VBN	O
for	IN	O
63	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
treated	VBN	O
with	IN	O
risperidone	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Change	NNP	PH
in	IN	PH
serum	NN	PH
leptin	NN	PH
levels	NNS	PH
after	IN	O
2	CD	O
months	NNS	O
was	VBD	O
examined	VBN	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
final	JJ	PH
weight	NN	PH
gain	NN	PH
in	IN	O
mixed	JJ	O
regression	NN	O
models	NNS	O
that	WDT	O
controlled	VBD	O
for	IN	O
site	NN	O
,	,	O
gender	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
risperidone	NN	O
dose	NN	O
.	.	O

RESULTS	NNP	O
Age-	JJ	O
and	CC	O
gender-standardized	JJ	O
weight	NN	PH
increased	VBD	PH
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
gross	JJ	O
:	:	O
mean=5.6	NN	O
kg	NN	O
[	NNP	O
SD=3.9	NNP	O
]	NNP	O
;	:	O
standardized	VBN	O
:	:	O
mean=0.6	NN	O
z	NN	O
[	NNP	O
SD=0.5	NNP	O
]	NNP	O
)	)	O
and	CC	O
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
weight	NN	PH
gained	VBN	PH
after	IN	O
1	CD	O
month	NN	O
.	.	O

Change	NN	PH
in	IN	PH
leptin	NN	PH
levels	NNS	PH
after	IN	O
2	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean=-0.3	JJ	O
ng/ml	NN	O
,	,	O
SD=6.2	NNP	O
)	)	O
(	(	O
N=48	NNP	O
)	)	O
did	VBD	O
not	RB	O
predict	JJ	O
final	JJ	PH
weight	NN	PH
gain	NN	PH
.	.	O

CONCLUSIONS	NNP	O
Chronic	NNP	O
risperidone	NN	O
exposure	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
causes	NNS	O
weight	VBD	PH
gain	NN	PH
in	IN	O
excess	NN	O
of	IN	O
developmentally	RB	O
expected	VBN	O
norms	NNS	O
that	WDT	O
follows	VBZ	O
a	DT	O
curvilinear	JJ	O
trajectory	NN	O
and	CC	O
decelerates	VBZ	O
over	IN	O
time	NN	O
.	.	O

Serum	NNP	PH
leptin	JJ	PH
change	NN	PH
does	VBZ	O
not	RB	O
reliably	VB	O
predict	JJ	O
risperidone-associated	JJ	O
weight	NN	PH
gain	NN	PH
.	.	O

Effect	NN	O
of	IN	O
phenylephrine	NN	O
on	IN	O
the	DT	O
haemodynamic	JJ	PH
state	NN	PH
and	CC	PH
cerebral	JJ	PH
oxygen	NN	PH
saturation	NN	PH
during	IN	O
anaesthesia	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
upright	JJ	O
sitting	NN	O
or	CC	O
beachchair	NN	O
position	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
hypotension	NN	PH
,	,	PH
risk	NN	PH
of	IN	PH
cerebral	JJ	PH
hypoperfusion	NN	PH
,	,	PH
and	CC	PH
cerebral	JJ	PH
injury	NN	PH
.	.	PH

We	PRP	O
hypothesized	VBD	O
that	IN	O
by	IN	O
increasing	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	JJ	O
administration	NN	O
,	,	O
cerebral	JJ	PH
perfusion	NN	PH
,	,	O
and	CC	O
postoperative	JJ	PH
recovery	NN	PH
would	MD	O
be	VB	O
improved	VBN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
shoulder	NN	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
saline	NN	O
or	CC	O
phenylephrine	NN	O
infusion	NN	O
(	(	O
PE	NNP	O
)	)	O
5	CD	O
min	NN	O
before	IN	O
being	VBG	O
placed	VBN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

Simultaneous	JJ	O
measurements	NNS	O
of	IN	O
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
,	,	PH
cerebral	JJ	PH
oxygen	NN	PH
saturation	NN	PH
,	,	PH
middle	JJ	PH
cerebral	JJ	PH
artery	NN	PH
velocity	NN	PH
,	,	PH
and	CC	PH
cardiac	JJ	PH
function	NN	PH
using	VBG	PH
transthoracic	JJ	PH
echocardiography	NN	PH
were	VBD	O
made	VBN	O
.	.	O

Postoperative	JJ	O
neurocognitive	JJ	ME
function	NN	ME
was	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
commencement	NN	O
of	IN	O
PE	NNP	O
,	,	O
mean	NN	PH
(	(	PH
SD	NNP	PH
)	)	PH
cerebral	JJ	PH
oxygen	NN	PH
saturation	NN	PH
significantly	RB	O
decreased	VBN	O
from	IN	O
77	CD	O
(	(	O
10	CD	O
)	)	O
to	TO	O
67	CD	O
(	(	O
13	CD	O
)	)	O
%	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
further	RB	O
to	TO	O
59	CD	O
(	(	O
11	CD	O
)	)	O
%	NN	O
on	IN	O
upright	JJ	O
positioning	NN	O
.	.	O

The	DT	O
level	NN	PH
of	IN	PH
cerebral	JJ	PH
saturation	NN	PH
upright	NN	PH
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
to	TO	O
patients	NNS	O
receiving	VBG	O
saline	NN	O
(	(	O
P=0.07	NNP	O
)	)	O
,	,	O
with	IN	O
values	NNS	O
remaining	VBG	O
at	IN	O
room-air	JJ	O
levels	NNS	O
.	.	O

Middle	NNP	PH
cerebral	JJ	PH
artery	RB	PH
blood	NN	PH
velocity	NN	PH
increased	VBN	O
by	IN	O
20	CD	O
%	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
.	.	O

Phenylephrine	NNP	O
prevented	VBD	O
hypotension	NN	PH
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
primarily	RB	O
by	IN	O
maintaining	VBG	O
preload	NN	O
and	CC	O
increasing	VBG	O
systemic	JJ	PH
vascular	NN	PH
resistance	NN	PH
(	(	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	PH
output	NN	PH
.	.	PH

No	DT	O
postoperative	JJ	ME
neurocognitive	JJ	ME
dysfunction	NN	ME
was	VBD	O
identified	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
maintaining	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	NN	O
,	,	O
cerebral	JJ	PH
desaturation	NN	PH
occurred	VBD	O
with	IN	O
upright	JJ	O
positioning	VBG	O
.	.	O

Cerebral	NNP	PH
oxygen	IN	PH
saturation	NN	PH
can	MD	O
provide	VB	O
a	DT	O
valuable	JJ	O
endpoint	NN	O
when	WRB	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
vasopressor	NN	O
therapy	NN	O
on	IN	O
cerebral	JJ	O
perfusion	NN	O
.	.	O

Effects	NNS	O
of	IN	O
skin-to-skin	JJ	O
contact	NN	O
on	IN	O
autonomic	JJ	PA
pain	NN	PA
responses	NNS	PA
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

UNLABELLED	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
crossover	NN	O
trial	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
on	IN	O
autonomic	JJ	O
responses	NNS	O
in	IN	O
preterm	JJ	O
infants	NNS	O
of	IN	O
longer	JJR	O
Kangaroo	NNP	O
Care	NNP	O
(	(	O
30	CD	O
minutes	NNS	O
,	,	O
KC30	NNP	O
)	)	O
and	CC	O
shorter	JJR	O
KC	NNP	O
(	(	O
15	CD	O
minutes	NNS	O
,	,	O
KC15	NNP	O
)	)	O
before	IN	O
and	CC	O
throughout	IN	O
heel	NN	O
stick	NNS	O
compared	VBN	O
with	IN	O
incubator	NN	O
care	NN	O
(	(	O
IC	NNP	O
)	)	O
.	.	O

Beat-to-beat	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
and	CC	O
spectral	JJ	O
power	NN	O
analysis	NN	O
of	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
,	,	O
low	JJ	O
frequency	NN	O
power	NN	O
(	(	O
LF	NNP	O
)	)	O
,	,	O
high	JJ	O
frequency	NN	O
power	NN	O
(	(	O
HF	NNP	O
)	)	O
,	,	O
and	CC	O
LF/HF	NNP	O
ratio	NN	O
were	VBD	O
measured	VBN	O
in	IN	O
26	CD	O
infants	NNS	O
.	.	O

HR	NNP	PH
changes	NNS	O
from	IN	O
Baseline	NNP	O
to	TO	O
Heel	NNP	O
Stick	NNP	O
were	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
KC30	NNP	O
and	CC	O
KC15	NNP	O
than	IN	O
in	IN	O
IC	NNP	O
,	,	O
and	CC	O
more	JJR	O
infants	NNS	O
had	VBD	O
HR	NNP	PH
decrease	NN	O
in	IN	O
IC	NNP	O
than	IN	O
in	IN	O
2	CD	O
KC	NNP	O
conditions	NNS	O
.	.	O

In	IN	O
IC	NNP	O
,	,	O
LF	NNP	PH
and	CC	O
HF	NNP	PH
significantly	RB	O
increased	VBD	O
from	IN	O
Baseline	NNP	O
to	TO	O
Heel	NNP	O
Stick	NNP	O
and	CC	O
dropped	VBD	O
from	IN	O
Heel	NNP	O
Stick	NNP	O
to	TO	O
Recovery	NNP	O
;	:	O
in	IN	O
2	CD	O
KC	NNP	O
conditions	NNS	O
,	,	O
no	DT	O
changes	NNS	O
across	IN	O
study	NN	O
phases	NNS	O
were	VBD	O
found	VBN	O
.	.	O

During	IN	O
Heel	NNP	O
Stick	NNP	O
,	,	O
LF	NNP	PH
and	CC	O
HF	NNP	PH
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
IC	NNP	O
than	IN	O
in	IN	O
KC30	NNP	O
.	.	O

In	IN	O
all	DT	O
3	CD	O
conditions	NNS	O
,	,	O
LF/HF	NNP	PH
ratio	NN	PH
decreased	VBD	O
from	IN	O
Baseline	NNP	O
to	TO	O
Heel	NNP	O
Stick	NNP	O
and	CC	O
increased	VBD	O
to	TO	O
Recovery	NNP	O
;	:	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
IC	NNP	O
and	CC	O
two	CD	O
KC	NNP	O
conditions	NNS	O
.	.	O

Both	NNP	O
longer	JJR	O
and	CC	O
shorter	JJR	O
KC	NNP	O
before	IN	O
and	CC	O
throughout	IN	O
heel	NN	O
stick	NN	O
can	MD	O
stabilize	VB	O
HR	NNP	PH
response	NN	PH
in	IN	O
preterm	JJ	O
infants	NNS	O
,	,	O
and	CC	O
longer	JJR	O
KC	NNP	O
significantly	RB	O
affected	VBD	O
infants	NNS	O
'	POS	O
sympathetic	JJ	O
and	CC	O
parasympathetic	JJ	O
responses	NNS	O
during	IN	O
heel	NN	O
stick	NNS	O
compared	VBN	O
with	IN	O
incubator	NN	O
care	NN	O
.	.	O

PERSPECTIVE	VB	O
This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
KC	NNP	O
has	VBZ	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
reducing	VBG	O
autonomic	JJ	O
pain	NN	O
responses	NNS	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

The	DT	O
findings	NNS	O
support	NN	O
that	IN	O
KC	NNP	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
pain	NN	O
intervention	NN	O
in	IN	O
the	DT	O
neonatal	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
.	.	O

Lung	NNP	O
function	NN	O
and	CC	O
respiratory	NN	O
symptoms	NNS	O
in	IN	O
a	DT	O
1-year	JJ	O
randomized	JJ	O
smoking	NN	O
cessation	NN	O
trial	NN	O
of	IN	O
varenicline	NN	O
in	IN	O
COPD	NNP	O
patients	NNS	O
.	.	O

UNLABELLED	IN	O
There	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
concerning	VBG	O
changes	NNS	O
in	IN	O
lung	NN	O
function	NN	O
and	CC	O
respiratory	NN	O
symptoms	NNS	O
in	IN	O
smokers	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
weeks	NNS	O
to	TO	O
months	NNS	O
after	IN	O
quitting	VBG	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
serial	JJ	O
changes	NNS	O
in	IN	O
spirometry	NN	O
and	CC	O
Clinical	NNP	O
COPD	NNP	O
Questionnaire	NNP	O
(	(	O
CCQ	NNP	O
)	)	O
scores	VBZ	O
(	(	O
measuring	VBG	O
respiratory	NN	O
symptoms	NNS	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
)	)	O
in	IN	O
COPD	NNP	O
participants	NNS	O
by	IN	O
smoking	VBG	O
status	NN	O
during	IN	O
a	DT	O
smoking	NN	O
cessation	NN	O
trial	NN	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
,	,	O
smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
varenicline	JJ	O
1	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

or	CC	O
placebo	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
followed	VBD	O
to	TO	O
Week	VB	O
52	CD	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
of	IN	O
abstinence	NN	ME
were	VBD	O
previously	RB	O
reported	VBN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mean	JJ	Ot
changes	NNS	Ot
from	IN	Ot
baseline	NN	Ot
in	IN	O
post-bronchodilator	NN	PH
forced	VBN	PH
expired	JJ	PH
volume	NN	PH
in	IN	PH
1	CD	PH
s	NN	PH
(	(	PH
FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	PH
)	)	PH
and	CC	Ot
CCQ	NNP	PH
scores	NNS	PH
.	.	Ot

Change	NN	Ot
from	IN	Ot
baseline	NN	Ot
in	IN	O
post-bronchodilator	NN	O
FEV	NNP	PH
(	(	PH
1	CD	PH
)	)	Ot
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
continuous	JJ	O
abstainers	NNS	O
(	(	O
121.8	CD	O
mL	NN	O
)	)	O
vs.	FW	O
continuous	JJ	O
smokers	NNS	O
(	(	O
37.9	CD	O
mL	NN	O
)	)	O
at	IN	O
Week	$	O
12	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.0069	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
Weeks	NNP	O
24	CD	O
or	CC	O
52	CD	O
.	.	O

Mean	JJ	Ot
change	NN	Ot
from	IN	Ot
baseline	NN	Ot
at	IN	Ot
Week	NNP	Ot
12	CD	Ot
in	IN	Ot
CCQ	NNP	PH
Total	NNP	PH
Score	NNP	PH
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
continuous	JJ	O
abstainers	NNS	O
(	(	O
-1.04	NN	O
)	)	O
vs.	FW	O
continuous	JJ	O
smokers	NNS	O
(	(	O
-0.53	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
:	:	O
this	DT	O
improvement	NN	O
was	VBD	O
sustained	VBN	O
at	IN	O
Weeks	NNP	O
24	CD	O
and	CC	O
52	CD	O
.	.	O

In	IN	O
a	DT	O
1-year	JJ	O
cessation	NN	O
trial	NN	O
of	IN	O
smokers	NNS	O
with	IN	O
COPD	NNP	O
,	,	O
continuous	JJ	ME
abstinence	NN	ME
compared	VBN	O
with	IN	O
continuous	JJ	O
smoking	VBG	O
significantly	RB	O
improved	VBN	O
post-bronchodilator	NN	Ot
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
at	IN	O
Week	$	O
12	CD	O
(	(	O
although	IN	O
the	DT	O
difference	NN	O
narrowed	VBD	O
subsequently	RB	O
)	)	O
and	CC	O
CCQ	NNP	PH
Total	NNP	PH
Scores	NNP	PH
at	IN	O
Week	NNP	O
12	CD	O
,	,	O
with	IN	O
sustained	JJ	O
improvement	NN	O
thereafter	RB	O
.	.	O

(	(	O
TRIAL	NNP	O
REGISTRY	NNP	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
;	:	O
trial	NN	O
identifier	NN	O
:	:	O
NCT00285012	NNP	O
)	)	O
.	.	O

[	IN	O
The	DT	O
application	NN	O
of	IN	O
naphcon	JJ	O
eye	NN	O
drops	NNS	O
during	IN	O
Lasik	NNP	O
surgery	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
for	IN	O
preventing	VBG	O
conjunctival	JJ	O
bleeding	NN	O
during	IN	O
Lasik	NNP	O
surgery	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBN	O
cases	NNS	O
(	(	O
200	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
divided	VBN	O
into	IN	O
treating	VBG	O
group	NN	O
and	CC	O
control	NN	O
group	NN	O
randomly	RB	O
according	VBG	O
to	TO	O
using	VBG	O
and	CC	O
not	RB	O
using	VBG	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
before	IN	O
Lasik	NNP	O
surgery	NN	O
.	.	O

Treating	VBG	O
group	NN	O
patients	NNS	O
received	VBD	O
three	CD	O
times	NNS	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
during	IN	O
15	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
incidence	NN	PH
of	IN	PH
conjunctival	JJ	PH
bleeding	VBG	PH
from	IN	O
treating	VBG	O
and	CC	O
control	VB	O
group	NN	O
were	VBD	O
8	CD	O
%	NN	O
and	CC	O
15	CD	O
%	NN	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
between	IN	O
them	PRP	O
.	.	O

CONCLUSION	NNP	O
Naphcon	NNP	O
eye	NN	O
drop	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
agent	NN	O
to	TO	O
prevent	VB	O
conjunctival	JJ	O
bleeding	NN	O
.	.	O

Determination	NN	O
of	IN	O
vital	JJ	O
status	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
DIG	NNP	O
trial	NN	O
.	.	O

The	DT	O
Digitalis	NNP	O
Investigation	NNP	O
Group	NNP	O
(	(	O
DIG	NNP	O
)	)	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
whose	WP$	O
primary	JJ	O
objective	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
digoxin	NN	O
had	VBD	O
beneficial	JJ	O
,	,	O
harmful	JJ	O
,	,	O
or	CC	O
no	DT	O
effect	NN	O
on	IN	O
total	JJ	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
who	WP	O
were	VBD	O
in	IN	O
sinus	NN	O
rhythm	NN	O
and	CC	O
whose	WP$	O
ejection	NN	O
fraction	NN	O
was	VBD	O
<	JJ	O
/=0.45	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
large	JJ	O
simple	JJ	O
trial	NN	O
with	IN	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
centers	NNS	O
(	(	O
302	CD	O
)	)	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
Canada	NNP	O
,	,	O
many	JJ	O
of	IN	O
which	WDT	O
were	VBD	O
inexperienced	VBN	O
in	IN	O
research	NN	O
.	.	O

To	TO	O
ensure	VB	O
that	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
trial	NN	O
would	MD	O
be	VB	O
reported	VBN	O
accurately	RB	O
without	IN	O
possible	JJ	O
bias	NN	O
due	JJ	O
to	TO	O
missing	VBG	O
data	NNS	O
,	,	O
the	DT	O
study	NN	O
leadership	NN	O
decided	VBD	O
that	IN	O
no	DT	O
outcome	NN	O
results	NNS	O
would	MD	O
be	VB	O
reported	VBN	O
until	IN	O
the	DT	O
vital	JJ	O
status	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
known	VBN	O
for	IN	O
at	IN	O
least	JJS	O
97	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
participants	NNS	O
.	.	O

Planning	VBG	O
for	IN	O
closeout	NN	O
of	IN	O
the	DT	O
study	NN	O
began	VBD	O
a	DT	O
year	NN	O
prior	RB	O
to	TO	O
the	DT	O
common	JJ	O
end	NN	O
date	NN	O
of	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
and	CC	O
included	VBD	O
plans	NNS	O
for	IN	O
obtaining	VBG	O
vital	JJ	O
status	NN	O
on	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
.	.	O

Participants	NNS	O
were	VBD	O
given	VBN	O
postcards	NNS	O
at	IN	O
their	PRP$	O
final	JJ	O
study	NN	O
visit	NN	O
to	TO	O
be	VB	O
completed	VBN	O
and	CC	O
mailed	VBN	O
on	IN	O
or	CC	O
after	IN	O
January	NNP	O
1	CD	O
,	,	O
1996	CD	O
.	.	O

Of	IN	O
5602	CD	O
postcards	NNS	O
distributed	VBN	O
,	,	O
5070	CD	O
(	(	O
90.5	CD	O
%	NN	O
)	)	O
were	VBD	O
completed	VBN	O
and	CC	O
returned	VBN	O
.	.	O

A	DT	O
contract	NN	O
search	NN	O
agency	NN	O
was	VBD	O
hired	VBN	O
to	TO	O
locate	VB	O
the	DT	O
remaining	VBG	O
participants	NNS	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
7788	CD	O
participants	NNS	O
entered	VBD	O
into	IN	O
the	DT	O
DIG	NNP	O
trial	NN	O
,	,	O
only	RB	O
97	CD	O
participants	NNS	O
(	(	O
1.2	CD	O
%	NN	O
)	)	O
could	MD	O
not	RB	O
have	VB	O
their	PRP$	O
vital	JJ	PH
status	NN	PH
as	IN	O
of	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
determined	VBD	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
investigators	NNS	O
having	VBG	O
an	DT	O
outcome	NN	O
measure	NN	O
with	IN	O
a	DT	O
common	JJ	O
end	NN	O
date	NN	O
include	VBP	O
plans	NNS	O
in	IN	O
their	PRP$	O
protocols	NNS	O
for	IN	O
obtaining	VBG	O
their	PRP$	O
measures	NNS	O
and	CC	O
activate	VBP	O
those	DT	O
plans	NNS	O
as	RB	O
early	RB	O
as	IN	O
possible	JJ	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Interferential	JJ	O
therapy	NN	O
electrode	NN	O
placement	NN	O
technique	NN	O
in	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
preliminary	JJ	O
investigation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
interferential	JJ	O
therapy	NN	O
(	(	O
IFT	NNP	O
)	)	O
electrode	VBP	O
placement	NN	O
technique	NN	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
LBP	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single-blind	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

SETTING	NN	O
Outpatient	NNP	O
physiotherapy	NN	O
departments	NNS	O
in	IN	O
hospital	NN	O
and	CC	O
university	NN	O
settings	NNS	O
.	.	O

PATIENTS	VB	O
A	DT	O
random	JJ	O
sample	NN	O
of	IN	O
60	CD	O
eligible	JJ	O
patients	NNS	O
with	IN	O
back	JJ	O
pain	NN	O
(	(	O
28	CD	O
men	NNS	O
,	,	O
32	CD	O
women	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
by	IN	O
general	JJ	O
practitioners	NNS	O
and	CC	O
self-referral	JJ	O
for	IN	O
physiotherapy	NN	O
treatment	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

INTERVENTIONS	NNP	O
(	(	O
1	CD	O
)	)	O
IFT	NNP	O
painful	JJ	O
area	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
,	,	O
(	(	O
2	CD	O
)	)	O
IFT	NNP	O
spinal	JJ	O
nerve	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
Control	NN	O
,	,	O
The	DT	O
Back	NNP	O
Book	NNP	O
only	RB	O
.	.	O

Standardized	VBN	O
IFT	NNP	O
stimulation	NN	O
parameters	NNS	O
were	VBD	O
used	VBN	O
:	:	O
carrier	NN	O
frequency	NN	O
3.85	CD	O
kHz	NN	O
;	:	O
140	CD	O
Hz	NNP	O
constant	NN	O
;	:	O
pulse	JJ	O
duration	NN	O
130	CD	O
micros	NN	O
;	:	O
30	CD	O
minutes	NNS	O
'	POS	O
duration	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Pain	NNP	PH
Rating	NNP	PH
Index	NNP	PH
,	,	PH
Roland-Morris	NNP	PH
Disability	NNP	PH
Questionnaire	NNP	PH
(	(	PH
RMDQ	NNP	PH
)	)	PH
,	,	PH
and	CC	PH
EuroQol	NNP	PH
were	VBD	O
completed	VBN	O
by	IN	O
subjects	NNS	O
pretreatment	JJ	O
,	,	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
groups	NNS	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
all	DT	O
outcomes	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

Subjects	NNS	O
managed	VBN	O
by	IN	O
IFT	NNP	O
spinal	JJ	O
nerve	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
displayed	VBD	O
both	DT	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
.030	NNP	O
)	)	O
and	CC	O
clinically	RB	O
meaningful	JJ	O
reduction	NN	PH
in	IN	PH
functional	JJ	PH
disability	NN	PH
(	(	PH
RMDQ	NNP	PH
)	)	PH
,	,	O
compared	VBN	O
with	IN	O
management	NN	O
via	IN	O
IFT	NNP	O
painful	JJ	O
area	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
combined	VBD	O
or	CC	O
The	DT	O
Back	JJ	O
Book	NNP	O
alone	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
showed	VBD	O
that	IN	O
IFT	NNP	O
electrode	FW	O
placement	NN	O
technique	NN	O
affects	VBZ	O
LBP-specific	JJ	O
functional	JJ	O
disability	NN	O
,	,	O
providing	VBG	O
preliminary	JJ	O
implications	NNS	O
for	IN	O
future	JJ	O
clinical	JJ	O
studies	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
short-term	JJ	O
aromatase	NN	O
inhibitor	NN	O
(	(	O
letrozole	JJ	O
)	)	O
and	CC	O
GnRH	NNP	O
agonist	NN	O
(	(	O
triptorelin	NN	O
)	)	O
versus	NN	O
case	NN	O
control	NN	O
on	IN	O
pregnancy	NN	PH
rate	NN	PH
and	CC	O
symptom	NN	PH
and	CC	PH
sign	NN	PH
recurrence	NN	PH
after	IN	O
laparoscopic	JJ	O
treatment	NN	O
of	IN	O
endometriosis	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
role	NN	O
of	IN	O
an	DT	O
aromatase	NN	O
inhibitor	NN	O
(	(	O
letrozole	JJ	O
)	)	O
with	IN	O
a	DT	O
GnRH	NNP	O
agonist	NN	O
(	(	O
triptorelin	NN	O
)	)	O
versus	NN	O
case	NN	O
control	NN	O
on	IN	O
the	DT	O
pregnancy	NN	PH
rate	NN	PH
and	CC	O
recurrence	NN	PH
of	IN	PH
symptoms	NNS	PH
and	CC	PH
signs	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
endometriosis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
,	,	O
after	IN	O
treatment	NN	O
of	IN	O
144	CD	O
infertile	JJ	O
women	NNS	O
in	IN	O
their	PRP$	O
reproductive	JJ	O
age	NN	O
by	IN	O
laparoscopy	NN	O
(	(	O
whose	WP$	O
endometriosis	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
prior	JJ	O
laparoscopy	NN	O
)	)	O
,	,	O
they	PRP	O
were	VBD	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
(	(	O
47	CD	O
cases	NNS	O
)	)	O
who	WP	O
received	VBD	O
letrozole	NN	O
for	IN	O
2	CD	O
months	NNS	O
,	,	O
group	NN	O
2	CD	O
(	(	O
40	CD	O
patients	NNS	O
)	)	O
who	WP	O
were	VBD	O
prescribed	VBN	O
triptorelin	NN	O
for	IN	O
2	CD	O
months	NNS	O
and	CC	O
group	NN	O
3	CD	O
who	WP	O
were	VBD	O
57	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
medication	NN	O
.	.	O

We	PRP	O
followed	VBD	O
up	RP	O
each	DT	O
group	NN	O
at	IN	O
least	JJS	O
for	IN	O
12	CD	O
months	NNS	O
after	IN	O
their	PRP$	O
restoration	NN	O
of	IN	O
regular	JJ	O
cycle	NN	O
.	.	O

RESULTS	JJ	O
Pregnancy	NNP	PH
rate	NN	PH
was	VBD	O
23.4	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
27.5	CD	O
%	NN	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
and	CC	O
28.1	CD	O
%	NN	O
in	IN	O
group	NN	O
3	CD	O
.	.	O

The	DT	O
results	NNS	O
did	VBD	Ot
not	RB	Ot
show	VB	Ot
significant	JJ	Ot
differences	NNS	Ot
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

Recurrence	NNP	PH
rate	NN	PH
of	IN	PH
endometriosis	NN	PH
was	VBD	O
6.4	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
5	CD	O
%	NN	O
group	NN	O
2	CD	O
and	CC	O
5.3	CD	O
%	NN	O
in	IN	O
group	NN	O
3	CD	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	Ot
statistically	RB	Ot
significantly	RB	Ot
different	JJ	Ot
as	RB	O
well	RB	O
.	.	O

CONCLUSION	NNP	O
Pregnancy	NNP	PH
rate	NN	PH
and	CC	O
endometriosis	NN	PH
recurrence	NN	PH
rate	NN	PH
are	VBP	O
comparable	JJ	O
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
motor	NN	O
cortex	NN	O
excitability	NN	O
associated	VBN	O
with	IN	O
temporal	JJ	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
in	IN	O
tinnitus	NN	O
:	:	O
hints	NNS	O
for	IN	O
cross-modal	JJ	O
plasticity	NN	O
?	.	O
BACKGROUND	NNP	O
Motor	NNP	O
cortex	VBP	O
excitability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
changed	VBN	O
after	IN	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
rTMS	NN	O
)	)	O
of	IN	O
the	DT	O
temporal	JJ	O
cortex	NN	O
highlighting	VBG	O
the	DT	O
occurrence	NN	O
of	IN	O
cross-modal	JJ	O
plasticity	NN	O
in	IN	O
non-invasive	JJ	O
brain	NN	O
stimulation	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
temporal	JJ	O
low-frequency	NN	O
rTMS	NN	O
on	IN	O
motor	NN	O
cortex	NN	O
plasticity	NN	O
in	IN	O
a	DT	O
large	JJ	O
sample	NN	O
of	IN	O
tinnitus	NN	O
patients	NNS	O
.	.	O

In	IN	O
116	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
tinnitus	NN	O
different	JJ	O
parameters	NNS	O
of	IN	O
cortical	JJ	O
excitability	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
ten	JJ	O
rTMS	JJ	O
treatment	NN	O
sessions	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
one	CD	O
of	IN	O
three	CD	O
different	JJ	O
protocols	NNS	O
all	DT	O
including	VBG	O
1	CD	O
Hz	NNP	O
rTMS	NN	O
over	IN	O
the	DT	O
left	JJ	O
temporal	JJ	O
cortex	NN	O
.	.	O

Treatment	NNP	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
improvement	NN	O
by	IN	O
at	IN	O
least	JJS	O
five	CD	O
points	NNS	O
in	IN	O
the	DT	O
tinnitus	NN	O
questionnaire	NN	O
(	(	O
TQ	NNP	O
)	)	O
.	.	O

Variables	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
resting	VBG	PH
motor	NN	PH
threshold	NN	PH
(	(	PH
RMT	NNP	PH
)	)	PH
,	,	O
short-interval	JJ	PH
intra-cortical	JJ	PH
inhibition	NN	PH
(	(	PH
SICI	NNP	PH
)	)	PH
,	,	O
intracortical	JJ	PH
facilitation	NN	PH
(	(	PH
ICF	NNP	PH
)	)	PH
,	,	O
and	CC	O
cortical	JJ	PH
silent	JJ	PH
period	NN	PH
(	(	PH
CSP	NNP	PH
)	)	PH
.	.	O

RESULTS	NNP	O
After	IN	O
rTMS	JJ	O
treatment	NN	O
RMT	NNP	PH
was	VBD	PH
decreased	VBN	PH
by	IN	O
about	IN	O
1	CD	O
%	NN	O
of	IN	O
stimulator	NN	O
output	NN	O
near-significantly	RB	O
in	IN	O
the	DT	O
whole	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

SICI	NNP	PH
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
changes	NNS	O
with	IN	O
respect	NN	O
to	TO	O
treatment	NN	O
response	NN	O
.	.	O

The	DT	O
group	NN	O
of	IN	O
treatment	NN	O
responders	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	PH
of	IN	PH
SICI	NNP	PH
over	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
group	NN	O
of	IN	O
non-responders	NNS	O
the	DT	O
reverse	NN	O
pattern	NN	O
.	.	O

CONCLUSIONS	NNP	O
Minor	NNP	PH
RMT	NNP	PH
changes	NNS	PH
during	IN	O
rTMS	NN	O
treatment	NN	O
do	VBP	O
not	RB	O
necessarily	RB	O
suggest	VB	O
the	DT	O
need	NN	O
for	IN	O
systematic	JJ	O
re-examination	NN	O
of	IN	O
the	DT	O
RMT	NNP	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
issues	NNS	O
.	.	O

Treatment	NNP	O
response	NN	O
to	TO	O
rTMS	VB	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
SICI	NNP	O
that	WDT	O
might	MD	O
reflect	VB	O
modulation	NN	O
of	IN	O
GABAergic	NNP	O
mechanisms	FW	O
directly	RB	O
or	CC	O
indirectly	RB	O
related	VBN	O
to	TO	O
rTMS	VB	O
treatment	NN	O
effects	NNS	O
.	.	O

Benzodiazepine	NNP	O
and	CC	O
opioid	JJ	O
sedation	NN	O
attenuate	IN	O
the	DT	O
sympathetic	JJ	O
response	NN	O
to	TO	O
fiberoptic	JJ	Ot
bronchoscopy	NN	Ot
.	.	O

Prophylactic	JJ	O
labetalol	NN	O
gave	VBD	O
no	DT	O
additional	JJ	O
benefit	NN	O
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Hypertension	NNP	O
and	CC	O
tachycardia	NN	O
are	VBP	O
common	JJ	O
during	IN	O
fiber-optic	JJ	O
bronchoscopy	NN	O
(	(	O
FOB	NNP	O
)	)	O
,	,	O
and	CC	O
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
cardiac	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
addition	NN	O
of	IN	O
a	DT	O
beta-adrenergic	JJ	O
anatagonist	NN	O
might	MD	O
mask	VB	O
this	DT	O
response	NN	O
and	CC	O
prevent	VB	O
the	DT	O
deleterious	JJ	O
cardiovascular	JJ	PH
effects	NNS	PH
of	IN	PH
FOB	NNP	PH
.	.	PH

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
labetalol	$	O
10mg	CD	O
iv	NN	O
given	VBN	O
with	IN	O
midazolam-alfentanil	JJ	O
sedation	NN	O
.	.	O

We	PRP	O
monitored	VBD	O
heart	NN	PH
rate	NN	PH
(	(	PH
HR	NNP	PH
)	)	PH
and	CC	PH
systolic/diastolic	JJ	PH
blood	NN	PH
pressure	NN	PH
(	(	PH
SBP/DBP	NNP	PH
)	)	PH
throughout	IN	O
the	DT	O
bronchoscopy	NN	O
and	CC	O
calculated	VBD	O
the	DT	O
rate-pressure	JJ	O
product	NN	O
(	(	O
RPP=	NNP	O
(	(	O
HRxSBP	NNP	O
)	)	O
/100	NN	O
)	)	O
.	.	O

One-hundred	JJ	O
twenty	NN	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
rise	NN	O
in	IN	O
HR	NNP	PH
,	,	O
SBP	NNP	PH
,	,	PH
DBP	NNP	PH
or	CC	O
RPP	NNP	PH
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
placebo	NN	O
and	CC	O
labetalol	NN	O
groups	NNS	O
.	.	O

Adverse	JJ	A
events	NNS	A
during	IN	A
bronchoscopy	NN	A
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
interventional	JJ	O
bronchoscopy	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
SBP	NNP	PH
(	(	O
p=0.06	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
undergoing	VBG	O
FOB	NNP	O
under	IN	O
adequate	JJ	O
midazolam-alfentanil	JJ	O
sedation	NN	O
do	VBP	O
not	RB	O
develop	VB	O
excessive	JJ	O
sympathetic	JJ	O
drive	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
cardiac	JJ	O
stress	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
labetalol	NN	O
did	VBD	O
not	RB	O
confer	VB	O
additional	JJ	O
benefit	NN	O
or	CC	O
risk	NN	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00394537	NNP	O
)	)	O
.	.	O

Accuracy	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
contrast	NN	O
echocardiography	NN	O
for	IN	O
detection	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
in	IN	O
routine	JJ	O
practice	NN	O
:	:	O
comparison	NN	O
with	IN	O
wall	JJ	O
motion	NN	O
and	CC	O
technetium-99m	JJ	O
sestamibi	NN	O
single-photon	JJ	O
emission	NN	O
computed	VBD	O
tomography	NN	O
.	.	O

The	DT	O
Nycomed	NNP	O
NC100100	NNP	O
Investigators	NNP	O
.	.	O

OBJECTIVES	NNP	O
We	PRP	O
sought	VBD	O
to	TO	O
assess	VB	O
the	DT	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
myocardial	JJ	O
contrast	NN	O
echocardiography	NN	O
(	(	O
MCE	NNP	O
)	)	O
using	VBG	O
standard	JJ	O
imaging	NN	O
approaches	NNS	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Myocardial	NNP	O
contrast	NN	O
echocardiography	NN	O
may	MD	O
be	VB	O
more	JJR	O
versatile	JJ	O
than	IN	O
perfusion	NN	O
scintigraphy	NN	O
for	IN	O
identifying	VBG	O
the	DT	O
presence	NN	O
and	CC	O
extent	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
after	IN	O
MI	NNP	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
reliability	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
Fundamental	NNP	O
or	CC	O
harmonic	JJ	O
MCE	NNP	O
was	VBD	O
performed	VBN	O
with	IN	O
continuous	JJ	O
or	CC	O
triggered	JJ	O
imaging	NN	O
in	IN	O
203	CD	O
patients	NNS	O
with	IN	O
a	DT	O
previous	JJ	O
MI	NNP	O
using	VBG	O
bolus	JJ	O
doses	NNS	O
of	IN	O
a	DT	O
perfluorocarbon-filled	JJ	O
contrast	NN	O
agent	NN	O
(	(	O
NC100100	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
underwent	JJ	O
single-photon	JJ	O
emission	NN	O
computed	VBN	O
tomography	NN	O
(	(	O
SPECT	NNP	O
)	)	O
after	IN	O
the	DT	O
injection	NN	O
of	IN	O
technetium-99m	JJ	O
(	(	O
Tc-99m	NNP	O
)	)	O
sestamibi	NN	O
at	IN	O
rest	NN	O
.	.	O

Quantitative	NNP	O
and	CC	O
semiquantitative	JJ	O
SPECT	NNP	O
,	,	O
wall	NN	O
motion	NN	O
and	CC	O
digitized	JJ	O
echocardiographic	JJ	O
data	NNS	O
were	VBD	O
interpreted	VBN	O
independently	RB	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
MCE	NNP	O
was	VBD	O
assessed	VBN	O
for	IN	O
detection	NN	O
of	IN	O
segments	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
moderate	JJ	O
and	CC	O
severe	JJ	O
sestamibi-SPECT	JJ	O
defects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
detection	NN	O
of	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
perfusion	NN	O
defects	NNS	O
(	(	O
>	VB	O
12	CD	O
%	NN	O
of	IN	O
left	JJ	O
ventricle	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
segments	NNS	O
with	IN	O
diagnostic	JJ	O
MCE	NNP	O
,	,	O
the	DT	O
segmental	JJ	PH
sensitivity	NN	PH
ranged	VBD	O
from	IN	O
14	CD	O
%	NN	O
to	TO	O
65	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
specificity	NN	Ot
varied	VBD	O
from	IN	O
78	CD	O
%	NN	O
to	TO	O
95	CD	O
%	NN	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
dose	NN	O
of	IN	O
contrast	NN	O
agent	NN	O
.	.	O

Using	VBG	O
both	DT	O
segment-	JJ	O
and	CC	O
patient-based	JJ	O
analysis	NN	O
,	,	O
the	DT	O
greatest	JJS	O
accuracy	NN	O
and	CC	O
proportion	NN	O
of	IN	O
interpretable	JJ	O
images	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
harmonic	JJ	O
imaging	NN	O
in	IN	O
the	DT	O
triggered	JJ	O
mode	NN	O
.	.	O

For	IN	O
the	DT	O
detection	NN	O
of	IN	O
extensive	JJ	O
defects	NNS	O
,	,	O
the	DT	O
sensitivity	NN	PH
varied	VBD	O
from	IN	O
13	CD	O
%	NN	O
to	TO	O
48	CD	O
%	NN	O
,	,	O
with	IN	O
specificity	NN	O
from	IN	O
63	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
.	.	O

Harmonic	NNP	O
imaging	NN	O
remained	VBD	O
the	DT	O
most	RBS	O
accurate	JJ	O
approach	NN	O
.	.	O

Time	NNP	Ot
since	IN	Ot
MI	NNP	Ot
and	CC	O
SPECT	NNP	Ot
defect	VBP	Ot
location	NN	Ot
and	CC	Ot
intensity	NN	Ot
were	VBD	O
all	DT	O
determinants	NNS	O
of	IN	O
the	DT	O
MCE	NNP	O
response	NN	O
.	.	O

The	DT	O
extent	NN	A
of	IN	A
defects	NNS	A
on	IN	A
MCE	NNP	A
was	VBD	O
less	JJR	O
than	IN	O
the	DT	O
extent	NN	O
of	IN	O
either	DT	O
abnormal	JJ	O
wall	NN	O
motion	NN	O
or	CC	O
SPECT	NNP	O
abnormalities	NNS	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
wall	JJ	O
motion	NN	O
and	CC	O
MCE	NNP	O
assessment	NN	O
gave	VBD	O
the	DT	O
best	JJS	O
balance	NN	O
of	IN	O
sensitivity	NN	O
(	(	O
46	CD	O
%	NN	O
to	TO	O
55	CD	O
%	NN	O
)	)	O
and	CC	O
specificity	NN	O
(	(	O
82	CD	O
%	NN	O
to	TO	O
83	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
MCE	NNP	O
is	VBZ	O
specific	JJ	O
,	,	O
it	PRP	O
has	VBZ	O
limited	VBN	O
sensitivity	NN	O
for	IN	O
detection	NN	O
of	IN	O
moderate	JJ	A
or	CC	A
severe	JJ	A
perfusion	NN	A
defects	NNS	A
,	,	O
and	CC	O
it	PRP	O
underestimates	VBZ	O
the	DT	O
extent	NN	O
of	IN	O
SPECT	NNP	A
defects	NNS	A
.	.	O

The	DT	O
best	JJS	O
results	NNS	O
are	VBP	O
obtained	VBN	O
by	IN	O
integration	NN	O
with	IN	O
wall	DT	O
motion	NN	O
.	.	O

More	RBR	O
sophisticated	JJ	O
methods	NNS	O
of	IN	O
acquisition	NN	O
and	CC	O
interpretation	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
this	DT	O
technique	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
.	.	O

Validation	NN	O
of	IN	O
an	DT	O
FFQ	NNP	O
for	IN	O
evaluation	NN	O
of	IN	O
EPA	NNP	ME
and	CC	ME
DHA	NNP	ME
intake	VBP	ME
.	.	PH

OBJECTIVE	NNP	O
To	TO	O
validate	VB	O
an	DT	O
FFQ	NNP	O
for	IN	O
the	DT	O
assessment	NN	O
of	IN	O
dietary	JJ	O
EPA	NNP	PH
and	CC	PH
DHA	NNP	PH
against	IN	O
their	PRP$	O
relative	JJ	PH
concentrations	NNS	PH
in	IN	PH
red	JJ	PH
blood	NN	PH
cells	NNS	PH
(	(	PH
RBC	NNP	PH
)	)	PH
.	.	PH

DESIGN	NNP	O
Cross-sectional	JJ	O
analysis	NN	O
of	IN	O
baseline	NN	O
data	NNS	O
.	.	O

Intakes	NNS	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
and	CC	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
were	VBD	O
estimated	VBN	O
by	IN	O
FFQ	NNP	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
consumption	NN	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
in	IN	O
the	DT	O
last	JJ	O
month	NN	O
.	.	O

Fatty	NNP	O
acid	JJ	O
composition	NN	O
of	IN	O
RBC	NNP	O
membranes	NNS	O
was	VBD	O
quantified	VBN	O
by	IN	O
GC	NNP	O
.	.	O

SETTING	NNP	O
Saint-Fran?ois	JJ	O
d'Assise	NN	O
Hospital	NNP	O
,	,	O
Qu?bec	NNP	O
,	,	O
Canada	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
sixty-five	JJ	O
middle-aged	JJ	O
women	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

RESULTS	NNP	O
Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficient	NN	O
between	IN	O
intake	NN	O
of	IN	O
EPA	NNP	O
,	,	O
DHA	NNP	O
and	CC	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
and	CC	O
their	PRP$	O
corresponding	JJ	O
concentration	NN	O
in	IN	O
RBC	NNP	O
was	VBD	O
0.46	CD	O
,	,	O
0.40	CD	O
and	CC	O
0.42	CD	O
,	,	O
respectively	RB	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Multiple	JJ	O
regression	NN	O
analysis	NN	O
of	IN	O
EPA+DHA	NNP	O
intake	NN	O
and	CC	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentration	NN	O
indicated	VBD	O
positive	JJ	O
and	CC	O
significant	JJ	O
correlations	NNS	O
for	IN	O
oily	RB	O
fish	JJ	O
(	(	O
beta	JJ	O
=	NN	O
0.44	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.16	CD	O
,	,	O
0.72	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0027	CD	O
)	)	O
,	,	O
total	JJ	O
fish	NN	O
(	(	O
beta	JJ	O
=	NN	O
0.42	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.19	CD	O
,	,	O
0.64	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0005	CD	O
)	)	O
and	CC	O
marine	VB	O
food	NN	O
products	NNS	O
(	(	O
beta	NN	O
=	RB	O
0.42	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.20	CD	O
,	,	O
0.64	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

No	UH	O
other	JJ	O
marine	VB	O
food	NN	O
products	NNS	O
significantly	RB	O
predicted	VBD	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentration	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
present	JJ	O
validation	NN	O
study	NN	O
was	VBD	O
undertaken	VBN	O
among	IN	O
middle-aged	JJ	O
women	NNS	O
with	IN	O
low	JJ	O
consumption	NN	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
(	(	O
<	$	O
3	CD	O
servings/week	NN	O
)	)	O
,	,	O
our	PRP$	O
FFQ	NNP	O
provided	VBD	O
estimates	NNS	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
intakes	NNS	O
that	WDT	O
correlated	VBD	O
fairly	RB	O
well	RB	O
with	IN	O
their	PRP$	O
RBC	NNP	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
absence	NN	O
of	IN	O
correlations	NNS	O
between	IN	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
intakes	NNS	O
from	IN	O
different	JJ	O
marine	NN	O
species	NNS	O
suggests	VBZ	O
that	IN	O
a	DT	O
minimum	JJ	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
intake	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
observe	VB	O
a	DT	O
relationship	NN	O
with	IN	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentrations	NNS	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
,	,	O
fixed-dose	JJ	O
study	NN	O
of	IN	O
aripiprazole	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	Ot
and	CC	O
safety	NN	Ot
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
Two	CD	O
hundred	VBD	O
eighteen	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
aged	VBN	O
6-17	CD	O
years	NNS	O
)	)	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
and	CC	O
with	IN	O
behaviors	NNS	O
such	JJ	O
as	IN	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
self-injurious	JJ	O
behavior	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
symptoms	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
1:1:1:1	CD	O
to	TO	O
aripiprazole	VB	O
(	(	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
this	DT	O
8-week	JJ	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Efficacy	NNP	Ot
was	VBD	O
evaluated	VBN	O
using	VBG	O
the	DT	O
caregiver-rated	JJ	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
Irritability	NNP	ME
subscale	NN	ME
(	(	ME
primary	JJ	ME
efficacy	NN	ME
measure	NN	ME
)	)	ME
and	CC	O
the	DT	O
clinician-rated	JJ	ME
Clinical	JJ	ME
Global	NNP	ME
Impressions-Improvement	NNP	ME
score	NN	ME
.	.	O

Safety	NNP	Ot
and	CC	Ot
tolerability	NN	Ot
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
8	CD	O
,	,	O
all	DT	O
aripiprazole	JJ	O
doses	NNS	O
produced	VBN	O
significantly	RB	O
greater	JJR	O
improvement	NN	Ot
than	IN	O
placebo	NN	O
in	IN	O
mean	JJ	O
Aberrant	NNP	ME
Behavior	NNP	ME
Checklist	NNP	ME
Irritability	NNP	ME
subscale	NN	ME
scores	NNS	ME
(	(	O
5	CD	O
mg/day	NN	O
,	,	O
-12.4	NNP	O
;	:	O
10	CD	O
mg/day	NN	O
,	,	O
-13.2	NNP	O
;	:	O
15	CD	O
mg/day	NN	O
,	,	O
-14.4	NNP	O
;	:	O
versus	NN	O
placebo	NN	O
,	,	O
-8.4	NNP	O
;	:	O
all	DT	O
p	VBP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

All	DT	O
aripiprazole	JJ	O
doses	NNS	O
demonstrated	VBN	O
significantly	RB	O
greater	JJR	O
improvements	NNS	ME
in	IN	ME
mean	JJ	ME
Clinical	JJ	ME
Global	NNP	ME
Impressions-Improvement	NNP	ME
score	NN	ME
than	IN	O
placebo	NN	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

Discontinuation	NN	O
rates	NNS	O
due	JJ	O
to	TO	O
adverse	JJ	A
events	NNS	A
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	VB	O
7.7	CD	O
%	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
9.4	CD	O
%	NN	O
,	,	O
10	CD	O
mg/day	JJ	O
13.6	CD	O
%	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	JJ	O
7.4	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	A
event	NN	A
leading	VBG	O
to	TO	O
discontinuation	NN	O
was	VBD	O
sedation	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
serious	JJ	A
adverse	JJ	A
events	NNS	A
:	:	O
presyncope	NN	A
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
and	CC	O
aggression	NN	A
(	(	O
10	CD	O
mg/day	NN	O
)	)	O
.	.	O

At	IN	O
week	NN	O
8	CD	O
,	,	O
mean	JJ	O
weight	NN	PH
change	NN	PH
(	(	O
last	JJ	O
observation	NN	O
carried	VBD	O
forward	RB	O
)	)	O
was	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	NN	O
+0.3	NNP	O
kg	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
+1.3	NNP	O
kg	NN	O
,	,	O
10	CD	O
mg/day	NN	O
+1.3	NNP	O
kg	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	NN	O
+1.5	NNP	O
kg	NN	O
;	:	O
all	DT	O
p	VBP	O
<	JJ	O
.05	NNP	O
versus	NN	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	O
was	VBD	O
efficacious	JJ	Ot
and	CC	O
generally	RB	O
safe	JJ	Ot
and	CC	O
well	RB	Ot
tolerated	VBN	Ot
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Comparison	NNP	O
with	IN	O
computed	JJ	O
tomography	NN	O
of	IN	O
two	CD	O
ultrasound	JJ	O
devices	NNS	O
for	IN	O
diagnosis	NN	O
of	IN	O
abdominal	JJ	O
aortic	JJ	O
aneurysm	NN	O
.	.	O

Screening	VBG	O
for	IN	O
abdominal	JJ	O
aortic	JJ	O
aneurysms	NNS	O
(	(	O
AAAs	NNP	O
)	)	O
in	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
will	MD	O
become	VB	O
more	RBR	O
cost	JJ	O
effective	JJ	O
if	IN	O
a	DT	O
simple	NN	O
,	,	O
inexpensive	JJ	O
,	,	O
and	CC	O
reliable	JJ	O
ultrasound	JJ	O
device	NN	O
is	VBZ	O
available	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
2-dimensional	JJ	O
,	,	O
handheld	JJ	O
ultrasound	JJ	O
device	NN	O
and	CC	O
a	DT	O
newly	RB	O
developed	VBN	O
ultrasound	JJ	O
volume	NN	O
scanner	NN	O
(	(	O
based	VBN	O
on	IN	O
bladder	NN	O
scan	JJ	O
technology	NN	O
)	)	O
with	IN	O
computed	VBN	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
for	IN	O
diagnosing	VBG	O
AAA	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
146	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
69	CD	O
+/-	JJ	O
10	CD	O
years	NNS	O
;	:	O
127	CD	O
men	NNS	O
)	)	O
were	VBD	O
screened	VBN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
AAAs	NNP	O
(	(	O
diameter	NN	O
>	VBZ	O
3	CD	O
cm	NN	O
)	)	O
using	VBG	O
CT.	NNP	O
All	NNP	O
patients	NNS	O
were	VBD	O
examined	VBN	O
with	IN	O
the	DT	O
handheld	NN	O
ultrasound	JJ	O
device	NN	O
and	CC	O
the	DT	O
volume	NN	O
scanner	NN	O
.	.	O

Maximal	JJ	PH
diameters	NNS	PH
and	CC	PH
volumes	NNS	PH
were	VBD	O
used	VBN	O
for	IN	O
the	DT	O
analyses	NNS	O
.	.	O

AAAs	NNP	O
were	VBD	O
diagnosed	VBN	O
by	IN	O
CT	NNP	O
in	IN	O
116	CD	O
patients	NNS	O
(	(	O
80	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
absolute	JJ	PH
difference	NN	PH
of	IN	PH
aortic	JJ	PH
diameter	NN	PH
between	IN	O
ultrasound	NN	O
and	CC	O
CT	NNP	O
was	VBD	O
<	JJ	O
5	CD	O
mm	NN	O
in	IN	O
88	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Limits	NNS	O
of	IN	O
agreement	NN	O
between	IN	O
ultrasound	NN	O
and	CC	O
CT	NNP	O
(	(	O
-6.6	NNP	O
to	TO	O
9.4	CD	O
mm	NN	O
)	)	O
exceeded	VBD	O
the	DT	O
limits	NNS	O
of	IN	O
clinical	JJ	O
acceptability	NN	O
(	(	O
+/-5	JJ	O
mm	NN	O
)	)	O
.	.	O

An	DT	O
excellent	JJ	O
correlation	NN	O
between	IN	O
ultrasound	NN	O
and	CC	O
CT	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
r	JJ	O
=	NNP	O
0.98	CD	O
)	)	O
.	.	O

The	DT	O
correlation	NN	O
coefficient	NN	O
between	IN	O
the	DT	O
volume	NN	O
scanner	NN	O
and	CC	O
CT	NNP	O
was	VBD	O
0.86	CD	O
,	,	O
with	IN	O
agreement	NN	O
of	IN	O
90	CD	O
%	NN	O
and	CC	O
kappa	JJ	O
value	NN	O
of	IN	O
0.73	CD	O
.	.	O

Using	VBG	O
an	DT	O
optimal	JJ	O
cut-off	NN	O
value	NN	O
of	IN	O
>	$	O
56	CD	O
ml	NN	O
,	,	O
defined	VBN	O
by	IN	O
receiver-operating	JJ	O
characteristic	JJ	O
curve	NN	O
analysis	NN	O
,	,	O
sensitivity	NN	O
,	,	O
specificity	NN	O
,	,	O
and	CC	O
the	DT	O
positive	JJ	O
and	CC	O
negative	JJ	O
predictive	JJ	O
values	NNS	O
of	IN	O
the	DT	O
volume	NN	O
scanner	NN	O
for	IN	O
detecting	VBG	O
AAA	NNP	O
were	VBD	O
90	CD	O
%	NN	O
,	,	O
90	CD	O
%	NN	O
,	,	O
97	CD	O
%	NN	O
,	,	O
and	CC	O
71	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
this	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
a	DT	O
2-dimensional	JJ	O
,	,	O
handheld	JJ	O
ultrasound	JJ	O
device	NN	O
and	CC	O
a	DT	O
newly	RB	O
developed	VBN	O
ultrasound	JJ	O
volume	NN	O
scanner	NN	O
can	MD	O
effectively	RB	O
identify	VB	O
patients	NNS	O
with	IN	O
AAAs	NNP	O
confirmed	VBN	O
by	IN	O
CT	NNP	O
.	.	O

Bilateral	NNP	O
transversus	NN	O
abdominis	NN	O
plane	NN	O
block	NN	O
does	VBZ	O
not	RB	O
decrease	VB	O
postoperative	JJ	O
pain	NN	O
after	IN	O
laparoscopic	NN	O
cholecystectomy	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
of	IN	O
trocar	NN	O
insertion	NN	O
sites	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Transversus	NNP	O
abdominis	NN	O
plane	NN	O
(	(	O
TAP	NNP	O
)	)	O
block	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
pain	NN	O
and	CC	O
analgesic	JJ	O
requirements	NNS	O
after	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Our	PRP$	O
hypothesis	NN	O
was	VBD	O
that	IN	O
bilateral	JJ	O
TAP	NNP	O
blocks	NNS	O
decrease	NN	O
pain	NN	O
after	IN	O
laparoscopic	NN	O
cholecystectomy	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
of	IN	O
trocar	NN	O
insertion	NN	O
sites	NNS	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
bilateral	JJ	O
TAP	NNP	O
blocks	NNS	O
or	CC	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
of	IN	O
trocar	NN	O
insertion	NN	O
sites	VBZ	O
with	IN	O
ropivacaine	JJ	O
0.5	CD	O
%	NN	O
.	.	O

Postoperative	JJ	PA
pain	NN	PA
scores	NNS	O
and	CC	O
analgesic	JJ	O
use	NN	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Eighty	NNP	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
exclusions	NNS	O
,	,	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
on	IN	O
39	CD	O
patients	NNS	O
in	IN	O
group	NN	O
T	NNP	O
(	(	O
bilateral	JJ	O
TAP	NNP	O
block	NN	O
)	)	O
and	CC	O
35	CD	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
infiltration	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	PH
significant	JJ	PH
difference	NN	PH
in	IN	O
pain	NN	PA
scores	NNS	PA
on	IN	PA
the	DT	PA
numeric	JJ	PA
analog	NN	PA
scale	NN	PA
(	(	O
0-10	JJ	O
)	)	O
between	IN	O
the	DT	O
groups	NNS	O
at	IN	O
4	CD	O
hrs	NN	O
after	IN	O
surgery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.18	CD	O
)	)	O
or	CC	O
during	IN	O
the	DT	O
24	CD	O
hrs	NN	O
after	IN	O
surgery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.23	CD	O
)	)	O
.	.	O

The	DT	O
time	NN	Ot
interval	NN	Ot
from	IN	Ot
anesthesia	JJ	Ot
start	NN	Ot
to	TO	Ot
surgery	VB	Ot
start	NN	Ot
was	VBD	O
greater	JJR	O
in	IN	O
group	NN	O
T	NNP	O
than	IN	O
group	NN	O
I	PRP	O
(	(	O
48	CD	O
vs	RB	O
35	CD	O
mins	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	PH
difference	NN	PH
found	VBD	O
in	IN	O
analgesic	JJ	Ot
use	NN	Ot
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
after	IN	O
surgery	NN	O
.	.	O

CONCLUSIONS	NNP	O
Bilateral	NNP	O
ultrasound-guided	JJ	O
TAP	NNP	O
block	NN	O
is	VBZ	O
equivalent	JJ	O
to	TO	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
of	IN	O
trocar	NN	O
insertion	NN	O
sites	VBZ	O
for	IN	O
overall	JJ	O
postoperative	JJ	PA
pain	NN	PA
in	IN	O
a	DT	O
heterogeneous	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

Low-intensity	NNP	O
exercise	NN	O
and	CC	O
reduction	NN	O
of	IN	O
the	DT	O
risk	NN	PH
for	IN	PH
falls	NNS	PH
among	IN	O
at-risk	JJ	O
elders	NNS	O
.	.	O

BACKGROUND	NNP	O
Among	IN	O
elderly	JJ	O
persons	NNS	O
,	,	O
falls	VBZ	PH
account	NN	O
for	IN	O
87	CD	O
%	NN	O
of	IN	O
all	DT	O
fractures	NNS	O
and	CC	O
are	VBP	O
contributing	VBG	O
factors	NNS	O
in	IN	O
many	JJ	O
nursing	NN	O
home	NN	O
admissions	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
easily	RB	O
implemented	VBN	O
,	,	O
low-intensity	JJ	O
exercise	NN	O
program	NN	O
on	IN	O
the	DT	O
incidence	NN	PH
of	IN	PH
falls	NNS	PH
and	CC	O
the	DT	O
time	NN	PH
to	TO	PH
first	VB	PH
fall	NN	PH
among	IN	O
a	DT	O
clinically	RB	O
defined	JJ	O
population	NN	O
of	IN	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

METHODS	VB	O
This	DT	O
community-based	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
exercise	NN	O
intervention	NN	O
with	IN	O
a	DT	O
no-intervention	JJ	O
control	NN	O
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
294	CD	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
aged	VBD	O
60	CD	O
years	NNS	O
or	CC	O
older	JJR	O
,	,	O
who	WP	O
had	VBD	O
either	CC	O
a	DT	O
hospital	JJ	O
admission	NN	O
or	CC	O
bed	NN	O
rest	NN	O
for	IN	O
2	CD	O
days	NNS	O
or	CC	O
more	JJR	O
within	IN	O
the	DT	O
previous	JJ	O
month	NN	O
.	.	O

Exercise	NN	O
participants	NNS	O
were	VBD	O
scheduled	VBN	O
to	TO	O
attend	VB	O
exercise	NN	O
sessions	NNS	O
lasting	VBG	O
45	CD	O
minutes	NNS	O
,	,	O
including	VBG	O
warm-up	JJ	O
and	CC	O
cool-down	JJ	O
,	,	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
(	(	O
24	CD	O
sessions	NNS	O
)	)	O
.	.	O

Assessments	NNS	O
included	VBD	O
gait	NN	PH
and	CC	PH
balance	NN	PH
measures	NNS	PH
,	,	O
self-reported	JJ	PH
physical	JJ	PH
function	NN	PH
,	,	O
the	DT	O
number	NN	ME
of	IN	ME
medications	NNS	ME
being	VBG	ME
taking	VBG	ME
at	IN	ME
baseline	NN	ME
,	,	O
participant	JJ	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
and	CC	O
history	NN	Ot
of	IN	Ot
falling	VBG	Ot
.	.	O

Falls	NNS	PH
were	VBD	O
tracked	VBN	O
for	IN	O
1	CD	O
year	NN	O
after	IN	O
each	DT	O
participant	NN	O
's	POS	O
baseline	JJ	O
assessment	NN	O
.	.	O

RESULTS	VB	O
29	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
participants	NNS	O
reported	VBD	O
a	DT	O
fall	NN	PH
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
in	IN	O
preventing	VBG	Ot
falls	NNS	Ot
varied	VBN	O
significantly	RB	O
by	IN	O
baseline	JJ	O
physical	JJ	O
function	NN	O
level	NN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=.002	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	PH
for	IN	PH
falls	NNS	PH
decreased	VBN	O
for	IN	O
exercise	NN	O
participants	NNS	O
with	IN	O
low	JJ	O
baseline	NN	O
physical	JJ	O
functioning	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
.51	NN	O
)	)	O
but	CC	O
increased	VBD	O
for	IN	O
exercise	NN	O
participants	NNS	O
with	IN	O
high	JJ	O
baseline	NN	O
physical	JJ	O
functioning	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
3.51	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
easily	RB	O
implemented	VBN	O
,	,	O
low-intensity	JJ	O
exercise	NN	O
program	NN	O
appears	VBZ	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	PH
for	IN	PH
falls	NNS	PH
among	IN	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
recovering	VBG	O
from	IN	O
recent	JJ	O
hospitalizations	NNS	O
,	,	O
bed	VBD	O
rest	NN	O
,	,	O
or	CC	O
both	DT	O
who	WP	O
have	VBP	O
low	JJ	O
levels	NNS	O
of	IN	O
physical	JJ	O
functioning	NN	O
.	.	O

[	NN	O
Mitoxantrone	NNP	O
(	(	O
MTX	NNP	O
)	)	O
versus	NN	O
mitomycin	NN	O
C	NNP	O
(	(	O
MMC	NNP	O
)	)	O
in	IN	O
the	DT	O
ablative	JJ	O
treatment	NN	O
of	IN	O
Ta	NNP	O
,	,	O
T1	NNP	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
.	.	O

Phase	NNP	O
III	NNP	O
,	,	O
randomized	VBD	O
prospective	JJ	O
study	NN	O
]	NNP	O
.	.	O

A	NNP	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
ablation	NN	PH
capacity	NN	PH
of	IN	O
mitoxantrone	NN	O
in	IN	O
Ta-T1	NNP	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
versus	VBP	O
mitomycin	JJ	O
C	NNP	O
,	,	O
a	DT	O
drug	NN	O
whose	WP$	O
intravesical	JJ	O
ablation	NN	O
properties	NNS	O
are	VBP	O
well-known	JJ	O
.	.	O

Fifty-seven	JJ	O
patients	NNS	O
comprised	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
tumor	NN	O
was	VBD	O
not	RB	O
completely	RB	O
resected	VBN	O
when	WRB	O
the	DT	O
patient	NN	O
underwent	JJ	O
TUR	NNP	O
.	.	O

This	DT	O
residual	JJ	O
tumor	NN	O
was	VBD	O
used	VBN	O
as	IN	O
control	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
either	DT	O
20	CD	O
mg	NN	O
Mitoxantrone	NNP	O
or	CC	O
40	CD	O
mg	NNS	O
mitomycin	JJ	O
C	NNP	O
weekly	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
and	CC	O
two	CD	O
other	JJ	O
instillations	NNS	O
every	DT	O
15	CD	O
days	NNS	O
in	IN	O
50	CD	O
ml	NNS	O
saline	JJ	O
solution	NN	O
.	.	O

Response	NNP	Ot
to	TO	Ot
therapy	NN	Ot
was	VBD	O
evaluated	VBN	O
between	IN	O
the	DT	O
4th	CD	O
and	CC	O
8th	CD	O
week	NN	O
and	CC	O
classified	VBD	O
as	IN	O
complete	JJ	Ot
response	NN	Ot
(	(	Ot
CR	NNP	Ot
)	)	Ot
,	,	O
defined	VBD	O
as	IN	O
no	DT	O
gross	JJ	PH
and	CC	PH
microscopic	JJ	PH
evidence	NN	PH
of	IN	PH
residual	JJ	PH
tumor	NN	PH
,	,	O
or	CC	O
no	DT	Ot
response	NN	Ot
(	(	Ot
NR	NNP	Ot
)	)	Ot
or	CC	O
therapeutic	JJ	Ot
failure	NN	Ot
.	.	O

CR	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
77.7	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
and	CC	O
in	IN	O
50	CD	O
%	NN	O
in	IN	O
those	DT	O
that	WDT	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
Mitoxantrone	NNP	O
.	.	O

Treatment	NNP	O
was	VBD	O
discontinued	VBN	O
because	IN	O
of	IN	O
side	NN	A
effects	NNS	A
in	IN	O
15	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
and	CC	O
in	IN	O
63.4	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
Mitoxantrone	NNP	O
.	.	O

We	PRP	O
can	MD	O
conclude	VB	O
from	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
that	IN	O
Mitoxantrone	NNP	O
is	VBZ	O
a	DT	O
useful	JJ	O
agent	NN	O
for	IN	O
ablation	NN	O
therapy	NN	O
of	IN	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
,	,	O
although	IN	O
the	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	O
side	NN	A
effects	NNS	A
warrants	NNS	O
its	PRP$	O
limited	JJ	O
use	NN	O
and	CC	O
at	IN	O
high	JJ	O
dilutions	NNS	O
.	.	O

Insular	JJ	O
and	CC	O
anterior	JJ	O
cingulate	NN	O
circuits	NNS	O
in	IN	O
smokers	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

Schizophrenia	NNP	O
(	(	O
SZ	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
high	JJ	O
rates	NNS	O
of	IN	O
smoking	NN	O
.	.	O

We	PRP	O
previously	RB	O
found	VBD	O
that	IN	O
resting	VBG	O
state	NN	O
functional	JJ	O
connectivity	NN	O
(	(	O
rsFC	NN	O
)	)	O
between	IN	O
the	DT	O
dorsal	NN	O
anterior	JJ	O
cingulate	NN	O
(	(	O
dACC	NN	O
)	)	O
and	CC	O
striatum	NN	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
nicotine	JJ	O
addiction	NN	O
and	CC	O
psychiatric	JJ	O
illness	NN	O
.	.	O

Since	IN	O
the	DT	O
insula	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
nicotine	JJ	O
dependence	NN	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
SZ	NNP	O
smokers	NNS	O
will	MD	O
have	VB	O
greater	JJR	O
dysfunction	NN	O
in	IN	O
smoking-related	JJ	O
insular	NN	O
and	CC	O
dACC	NN	O
circuits	NNS	O
than	IN	O
normal	JJ	O
control	NN	O
smokers	NNS	O
(	(	O
NC	NNP	O
)	)	O
independent	JJ	O
of	IN	O
smoking	VBG	O
severity	NN	O
,	,	O
consistent	NN	O
with	IN	O
an	DT	O
inherent	JJ	O
disease-related	JJ	O
weakening	NN	O
of	IN	O
smoking-related	JJ	O
circuits	NNS	O
.	.	O

Nicotine	NNP	O
challenge	NN	O
was	VBD	O
used	VBN	O
to	TO	O
demonstrate	VB	O
that	DT	O
decreased	VBD	O
rsFC	NN	O
in	IN	O
identified	JJ	O
circuits	NNS	O
reflects	VBZ	O
addiction	JJ	O
trait	NN	O
and	CC	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
pharmacological	JJ	O
state	NN	O
.	.	O

Twenty-four	CD	O
NC	NNP	O
smokers	NNS	O
and	CC	O
20	CD	O
smokers	NNS	O
with	IN	O
SZ	NNP	O
matched	VBD	O
on	IN	O
nicotine	JJ	O
addiction	NN	O
severity	NN	O
participated	VBN	O
in	IN	O
a	DT	O
resting	NN	O
state	NN	O
fMRI	NN	O
study	NN	O
and	CC	O
were	VBD	O
scanned	VBN	O
during	IN	O
two	CD	O
separate	JJ	O
sessions	NNS	O
while	IN	O
receiving	VBG	O
a	DT	O
placebo	NN	O
or	CC	O
nicotine	JJ	O
patch	NN	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
cross-over	JJ	O
design	NN	O
.	.	O

Using	VBG	O
individualized	JJ	O
,	,	O
anatomically	RB	O
defined	VBN	O
anterior	JJ	O
and	CC	O
posterior	JJ	O
insula	NN	O
and	CC	O
dACC	NN	O
as	IN	O
regions	NNS	O
of	IN	O
interest	NN	O
(	(	O
ROI	NNP	O
)	)	O
,	,	O
whole	JJ	O
brain	NN	O
rsFC	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
each	DT	O
ROI	NNP	O
as	IN	O
a	DT	O
seed	NN	O
.	.	O

Significant	NNP	O
negative	JJ	O
correlations	NNS	O
between	IN	O
smoking	VBG	ME
severity	NN	ME
and	CC	O
rsFC	NN	PH
between	IN	PH
insula	NN	PH
,	,	O
dACC	NN	O
and	CC	O
striatum	NN	O
were	VBD	O
found	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
smokers	NNS	O
with	IN	O
SZ	NNP	O
demonstrated	VBD	O
additive	JJ	O
reductions	NNS	O
in	IN	O
circuit	NN	O
strength	NN	O
between	IN	O
the	DT	O
dACC	NN	O
and	CC	O
insula	NN	O
compared	VBN	O
to	TO	O
NC	NNP	O
smokers	NNS	O
independent	JJ	O
of	IN	O
smoking	VBG	O
severity	NN	O
.	.	O

Nicotine	NNP	Ot
challenge	NN	Ot
did	VBD	O
not	RB	O
significantly	RB	O
alter	VB	PH
rsFC	NN	PH
in	IN	PH
insula-dACC-striatal	JJ	PH
circuits	NNS	PH
.	.	PH

Reduced	VBN	O
rsFC	JJ	PH
strength	NN	PH
between	IN	O
the	DT	O
insula	NN	O
,	,	O
dACC	NN	O
and	CC	O
striatum	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
nicotine	JJ	O
addiction	NN	O
severity	NN	O
in	IN	O
both	DT	O
non-psychiatrically	RB	O
ill	NN	O
and	CC	O
in	IN	O
SZ	NNP	O
smokers	NNS	O
.	.	O

Decreased	VBN	O
insula-dACC	JJ	O
rsFC	NN	O
may	MD	O
index	NN	O
overlapping	VBG	O
circuitry	NN	O
associated	VBN	O
with	IN	O
smoking	NN	O
and	CC	O
SZ	NNP	O
.	.	O

Relationship	NN	O
between	IN	O
endogenous	JJ	O
estrogen	NN	O
concentrations	NNS	O
and	CC	O
serum	NN	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
concentrations	NNS	O
in	IN	O
Chinese	JJ	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
CETP	NNP	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
HDL	NNP	O
metabolism	NN	O
and	CC	O
in	IN	O
the	DT	O
reverse	NN	O
cholesterol	NN	O
transport	NN	O
pathway	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
changes	NNS	O
of	IN	O
endogenous	JJ	O
estrogen	NN	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
Chinese	JJ	O
women	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

Serum	NNP	PH
concentrations	NNS	PH
of	IN	PH
estradiol	NN	PH
(	(	PH
E	NNP	PH
(	(	PH
2	CD	PH
)	)	PH
)	)	PH
,	,	O
follicle-stimulating	JJ	PH
hormone	NN	PH
(	(	PH
FSH	NNP	PH
)	)	PH
,	,	O
CETP	NNP	PH
and	CC	O
lipid	JJ	PH
profile	NN	PH
were	VBD	O
determined	VBN	O
in	IN	O
196	CD	O
Chinese	JJ	O
women	NNS	O
(	(	O
52	CD	O
premenopausal	NN	O
with	IN	O
ages	NNS	O
ranging	VBG	O
from	IN	O
18	CD	O
to	TO	O
40	CD	O
years	NNS	O
,	,	O
57	CD	O
perimenopausal	NN	O
from	IN	O
41	CD	O
to	TO	O
60	CD	O
years	NNS	O
,	,	O
and	CC	O
87	CD	O
postmenopausal	NN	O
from	IN	O
61	CD	O
to	TO	O
81	CD	O
years	NNS	O
)	)	O
.	.	O

RESULTS	NNP	O
Serum	NNP	PH
CETP	NNP	PH
concentration	NN	PH
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
perimenopausal	NN	O
and	CC	O
premenopausal	JJ	O
women	NNS	O
(	(	O
1.39+/-1.06	JJ	O
,	,	O
2.36+/-1.50	JJ	O
and	CC	O
2.31+/-1.25	JJ	O
mg/l	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Even	RB	O
in	IN	O
the	DT	O
women	NNS	O
around	IN	O
the	DT	O
menopausal	NN	O
,	,	O
CETP	NNP	PH
concentration	NN	PH
in	IN	O
postmenopause	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
premenopause	NN	O
(	(	O
1.93+/-1.33	JJ	O
vs.	IN	O
3.42+/-1.35	JJ	O
mg/l	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
CETP	NNP	O
concentration	NN	O
had	VBD	O
a	DT	O
highly	RB	O
positive	JJ	O
correlation	NN	O
with	IN	O
serum	JJ	PH
concentration	NN	PH
of	IN	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
r=0.243	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
while	IN	O
negative	JJ	O
correlation	NN	O
of	IN	O
CETP	NNP	PH
concentration	NN	PH
with	IN	O
serum	JJ	PH
concentration	NN	PH
of	IN	PH
FSH	NNP	PH
was	VBD	O
found	VBN	O
(	(	O
r=-0.273	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Estrogen	NNP	O
may	MD	O
affect	VB	O
the	DT	O
concentration	NN	PH
of	IN	PH
CETP	NNP	PH
.	.	O

Line-item	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
:	:	O
results	NNS	O
from	IN	O
two	CD	O
studies	NNS	O
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
discrete	JJ	O
symptoms	NNS	O
of	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
symptoms	NNS	O
captured	VBN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
two	CD	O
8-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
multicenter	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	O
dosed	VBN	O
flexibly	RB	O
(	(	O
2-15	JJ	O
mg/day	NN	O
,	,	O
n=47	NN	O
)	)	O
or	CC	O
fixed	VBN	O
(	(	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
mg/day	NN	O
,	,	O
n	JJ	O
=	NNP	O
166	CD	O
)	)	O
versus	NN	O
placebo	NN	O
(	(	O
flexibly	RB	O
dosed	VBN	O
,	,	O
n	JJ	O
=	VBP	O
51	CD	O
;	:	O
fixed	VBN	O
dose	NN	O
,	,	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
on	IN	O
the	DT	O
58	CD	O
ABC	NNP	O
items	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Statistically	NNP	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
was	VBD	O
seen	VBN	O
with	IN	O
aripiprazole	JJ	O
versus	NN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
all	DT	O
arms	NNS	O
in	IN	O
both	DT	O
trials	NNS	O
on	IN	O
the	DT	O
ABC-Irritability	NNP	ME
total	JJ	ME
subscale	NN	ME
score	NN	ME
and	CC	ME
on	IN	ME
the	DT	ME
following	JJ	ME
individual	JJ	ME
ABC-Irritability	NNP	ME
items	NNS	ME
:	:	O
Mood	NNP	ME
changes	NNS	ME
quickly	RB	ME
,	,	O
cries/screams	NNS	ME
inappropriately	RB	ME
,	,	O
and	CC	O
stamps	JJ	ME
feet/bangs	NNS	ME
objects	NNS	ME
.	.	O

Several	JJ	O
additional	JJ	O
items	NNS	O
measuring	VBG	O
tantrum-like	JJ	ME
behaviors	NNS	ME
improved	VBN	O
in	IN	O
the	DT	O
flexibly	RB	O
dosed	VBN	O
trial	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
arm	NN	O
of	IN	O
the	DT	O
fixed-dose	JJ	O
trial	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Measures	NNS	ME
of	IN	ME
self-injurious	JJ	ME
behavior	NN	ME
,	,	O
which	WDT	O
had	VBD	O
low	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
demonstrated	VBD	O
numerical	JJ	O
,	,	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
,	,	O
improvement	NN	O
in	IN	O
both	DT	O
trials	NNS	O
.	.	O

Statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
ABC	NNP	ME
Stereotypic	NNP	ME
Behavior	NNP	ME
and	CC	ME
Hyperactivity	NNP	ME
total	JJ	ME
subscale	NN	ME
scores	NNS	ME
was	VBD	O
also	RB	O
consistent	JJ	O
across	IN	O
all	DT	O
arms	NNS	O
in	IN	O
both	DT	O
trials	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
cluster	NN	O
of	IN	O
items	NNS	O
related	VBN	O
to	TO	O
hyperkinesis	VB	ME
that	WDT	O
were	VBD	O
consistently	RB	O
sensitive	JJ	O
to	TO	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	O
is	VBZ	O
efficacious	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
particularly	RB	O
with	IN	O
respect	NN	O
to	TO	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
tantrum	JJ	O
behavior	NN	O
.	.	O

A	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
tamoxifen	NN	O
with	IN	O
surgical	JJ	O
oophorectomy	NN	O
in	IN	O
premenopausal	NN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

We	PRP	O
randomized	VBD	O
122	CD	O
premenopausal	JJ	O
women	NNS	O
to	TO	O
receive	VB	O
tamoxifen	NN	O
or	CC	O
to	TO	O
undergo	VB	O
a	DT	O
surgical	JJ	O
oophorectomy	NN	O
.	.	O

Of	IN	O
54	CD	O
evaluable	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
tamoxifen	NN	O
,	,	O
24	CD	O
%	NN	O
had	VBD	O
an	DT	O
objective	JJ	Ot
response	NN	Ot
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
21	CD	O
%	NN	O
of	IN	O
53	CD	O
women	NNS	O
having	VBG	O
an	DT	O
oophorectomy	NN	O
.	.	O

The	DT	O
median	JJ	Ot
duration	NN	Ot
of	IN	Ot
response	NN	Ot
for	IN	O
tamoxifen	NN	O
(	(	O
20	CD	O
months	NNS	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
for	IN	O
surgical	JJ	O
oophorectomy	NN	O
(	(	O
7	CD	O
months	NNS	O
)	)	O
,	,	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
achieve	VB	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
.056	NNP	O
)	)	O
.	.	O

Overall	JJ	MO
median	JJ	MO
survival	NN	MO
was	VBD	O
15	CD	O
months	NNS	O
for	IN	O
58	CD	O
patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
and	CC	O
25	CD	O
months	NNS	O
for	IN	O
53	CD	O
patients	NNS	O
undergoing	JJ	O
oophorectomy	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.18	NNP	O
)	)	O
.	.	O

Toxicity	NN	A
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
undergoing	JJ	O
oophorectomy	NN	O
,	,	O
though	IN	O
both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	Ot
tolerated	VBN	Ot
.	.	Ot

In	IN	O
those	DT	O
premenopausal	JJ	O
women	NNS	O
for	IN	O
whom	WP	O
hormonal	JJ	O
therapy	NN	O
is	VBZ	O
indicated	VBN	O
,	,	O
tamoxifen	EX	O
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
surgical	JJ	O
oophorectomy	NN	O
.	.	O

Efficacy	NN	Ot
and	CC	Ot
safety	NN	Ot
of	IN	O
mizolastine	JJ	O
10	CD	O
mg	NN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
comparison	NN	O
with	IN	O
loratadine	NN	O
in	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NNS	O
:	:	O
results	NNS	O
of	IN	O
the	DT	O
MILOR	NNP	O
Study	NNP	O
.	.	O

BACKGROUND	NNP	O
Mizolastine	NNP	O
is	VBZ	O
a	DT	O
novel	JJ	O
histamine	NN	O
H1-antagonist	NN	O
registered	VBD	O
in	IN	O
Europe	NNP	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
and	CC	O
urticaria	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
mizolastine	NN	O
with	IN	O
loratadine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
(	(	O
CIU	NNP	O
)	)	O
.	.	O

METHODS	CC	O
A	DT	O
multicentre	NN	O
,	,	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
in	IN	O
which	WDT	O
247	CD	O
patients	NNS	O
with	IN	O
CIU	NNP	O
were	VBD	O
randomised	VBN	O
after	IN	O
a	DT	O
1-week	JJ	O
placebo	NN	O
run-in	JJ	O
period	NN	O
to	TO	O
10	CD	O
mg	NNS	O
daily	JJ	O
mizolastine	NN	O
(	(	O
n	JJ	O
=	NNP	O
88	CD	O
)	)	O
,	,	O
10	CD	O
mg	JJ	O
daily	JJ	O
loratadine	NN	O
(	(	O
n	JJ	O
=	NNP	O
79	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
80	CD	O
)	)	O
for	IN	O
a	DT	O
4-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
Mizolastine	NNP	O
and	CC	O
loratadine	VB	O
both	DT	O
relieved	JJ	PH
symptoms	NNS	PH
of	IN	PH
CIU	NNP	PH
.	.	O

After	IN	O
2	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
,	,	O
the	DT	O
severity	NN	PH
of	IN	PH
pruritus	NN	PH
(	(	PH
visual	JJ	PH
analogue	NN	PH
score	NN	PH
(	(	PH
VAS	NNP	PH
)	)	PH
assessed	VBN	PH
by	IN	PH
patients	NNS	PH
)	)	PH
decreased	VBD	O
significantly	RB	O
in	IN	O
both	CC	O
the	DT	O
mizolastine	NN	O
and	CC	O
loratadine	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
mizolastine	NN	O
:	:	O
-36.7	NN	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
;	:	O
loratadine	NN	O
:	:	O
-29.8	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0071	CD	O
;	:	O
placebo	NN	O
:	:	O
-16.3	NN	O
)	)	O
;	:	O
this	DT	O
improvement	NN	O
with	IN	O
both	DT	O
active	JJ	O
treatments	NNS	O
was	VBD	O
maintained	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
mizolastine	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0090	CD	O
)	)	O
.	.	O

Both	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
reduced	JJ	O
weekly	JJ	O
episodes	NNS	PH
of	IN	PH
urticaria	NNS	PH
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
which	WDT	O
was	VBD	O
significant	JJ	O
after	IN	O
2	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
(	(	O
mizolastine	NN	O
:	:	O
7.9	CD	O
episodes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0061	CD	O
;	:	O
loratadine	NN	O
:	:	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0221	CD	O
;	:	O
placebo	NN	O
:	:	O
13.3	CD	O
)	)	O
.	.	O

Angioedema	NNP	PH
was	VBD	O
improved	VBN	O
to	TO	O
a	DT	O
clinically	RB	O
significant	JJ	O
extent	NN	O
with	IN	O
mizolastine	NN	O
,	,	O
and	CC	O
loratadine	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
this	DT	O
symptom	NN	O
before	IN	O
treatment	NN	O
.	.	O

Overall	JJ	Ot
tolerability	NN	Ot
of	IN	O
both	DT	O
treatments	NNS	O
was	VBD	O
similar	JJ	O
to	TO	O
placebo	VB	O
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
relevant	JJ	O
effects	NNS	PH
on	IN	PH
cardiac	JJ	PH
repolarisation	NN	PH
with	IN	O
either	DT	O
mizolastine	NN	O
or	CC	O
loratadine	NN	O
.	.	O

CONCLUSION	NNP	O
Mizolastine	NNP	O
(	(	O
10	CD	O
mg	NNS	O
daily	RB	O
)	)	O
is	VBZ	O
confirmed	VBN	O
as	IN	O
an	DT	O
effective	JJ	Ot
and	CC	Ot
well	RB	Ot
tolerated	JJ	Ot
agent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
loratadine	VB	O
and	CC	O
superior	VB	O
to	TO	O
placebo	VB	O
,	,	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
CIU	NNP	O
.	.	O

Mizolastine	NNP	O
acted	VBD	O
as	RB	O
rapidly	RB	O
as	IN	O
loratadine	NN	O
in	IN	O
improving	VBG	O
urticarial	JJ	PH
symptoms	NNS	PH
from	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
.	.	O

Antibiotic	JJ	O
therapy	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
using	VBG	O
tetracycline	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
40	CD	O
patients	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
antibiotics	NNS	O
in	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
sufficiently	RB	O
ill	VBN	O
to	TO	O
require	VB	O
hospitalization	NN	O
although	IN	O
none	NN	O
needed	VBD	O
ventilatory	JJ	O
support	NN	O
;	:	O
the	DT	O
presence	NN	O
of	IN	O
pneumonia	NN	O
was	VBD	O
excluded	VBN	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
bronchodilators	NNS	O
,	,	O
corticosteroids	NNS	O
,	,	O
and	CC	O
either	DT	O
tetracycline	NN	O
,	,	O
500	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	O
by	IN	O
mouth	NN	O
every	DT	O
6	CD	O
hours	NNS	O
for	IN	O
1	CD	O
week	NN	O
.	.	O

Arterial	JJ	PH
blood	NN	PH
gases	NNS	PH
,	,	O
spirometric	JJ	Ot
tests	NNS	Ot
,	,	O
bacteriologic	JJ	PH
evaluation	NN	PH
of	IN	PH
sputum	NN	PH
,	,	O
and	CC	O
patient	NN	Ot
and	CC	Ot
physician	JJ	Ot
evaluation	NN	Ot
of	IN	Ot
the	DT	Ot
severity	NN	PH
of	IN	PH
illness	NN	PH
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
improved	VBN	O
both	DT	O
symptomatically	RB	O
and	CC	O
by	IN	O
objective	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
those	DT	O
patients	NNS	O
receiving	VBG	O
tetracycline	NN	O
and	CC	O
those	DT	O
receiving	VBG	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
antibiotic	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
needed	VBN	O
in	IN	O
moderately	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

An	DT	O
interactive	JJ	O
computer	NN	O
program	NN	O
can	MD	O
effectively	RB	O
educate	VB	O
potential	JJ	O
users	NNS	O
of	IN	O
cystic	JJ	O
fibrosis	NN	O
carrier	NN	O
tests	NNS	O
.	.	O

The	DT	O
demand	NN	O
for	IN	O
cystic	JJ	O
fibrosis	NN	O
(	(	O
CF	NNP	O
)	)	O
carrier	NN	O
testing	VBG	O
is	VBZ	O
steadily	RB	O
growing	VBG	O
,	,	O
not	RB	O
only	RB	O
from	IN	O
individuals	NNS	O
with	IN	O
raised	VBN	O
a	DT	O
priori	FW	O
carrier	NN	O
risk	NN	O
,	,	O
but	CC	O
also	RB	O
from	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

This	DT	O
trend	NN	O
will	MD	O
likely	RB	O
exceed	VB	O
the	DT	O
availability	NN	O
of	IN	O
genetic	JJ	O
counselors	NNS	O
,	,	O
making	VBG	O
it	PRP	O
impossible	JJ	O
to	TO	O
provide	VB	O
standard	JJ	O
face-to-face	JJ	O
genetic	JJ	O
counseling	NN	O
to	TO	O
all	PDT	O
those	DT	O
asking	VBG	O
for	IN	O
the	DT	O
test	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
time	NN	O
needed	VBN	O
to	TO	O
educate	VB	O
individuals	NNS	O
on	IN	O
the	DT	O
basics	NNS	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
its	PRP$	O
genetic	JJ	O
transmission	NN	O
,	,	O
and	CC	O
carrier	NN	O
testing	VBG	O
peculiarities	NNS	O
,	,	O
we	PRP	O
developed	VBD	O
an	DT	O
educational	JJ	O
method	NN	O
based	VBN	O
on	IN	O
an	DT	O
interactive	JJ	O
computer	NN	O
program	NN	O
(	(	O
IC	NNP	O
)	)	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
this	DT	O
program	NN	O
and	CC	O
to	TO	O
compare	VB	O
it	PRP	O
to	TO	O
a	DT	O
classical	JJ	O
genetic	JJ	O
counseling	NN	O
session	NN	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
comparative	JJ	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
population	NN	O
setting	NN	O
of	IN	O
people	NNS	O
undergoing	VBG	O
assisted	JJ	O
reproduction	NN	O
,	,	O
44	CD	O
individuals	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
receiving	VBG	O
standard	JJ	O
one-on-one	JJ	O
genetic	JJ	O
counseling	NN	O
or	CC	O
education	NN	O
by	IN	O
the	DT	O
IC	NNP	O
program	NN	O
.	.	O

We	PRP	O
measured	VBD	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
knowledge	NN	O
about	IN	O
CF	NNP	O
genetic	JJ	O
transmission	NN	O
and	CC	O
carrier	NN	O
testing	NN	O
.	.	O

Starting	VBG	O
from	IN	O
an	DT	O
equivalent	JJ	O
baseline	NN	O
of	IN	O
correct	JJ	O
answers	NNS	O
to	TO	O
a	DT	O
specially	RB	O
designed	VBN	O
multiple-choice	NN	O
questionnaire	NN	O
(	(	O
47	CD	O
%	NN	O
in	IN	O
the	DT	O
counselor	NN	O
group	NN	O
and	CC	O
45	CD	O
%	NN	O
in	IN	O
the	DT	O
computer	NN	O
group	NN	O
)	)	O
both	DT	O
groups	NNS	O
showed	VBD	O
a	DT	O
highly	RB	O
significant	JJ	O
and	CC	O
similar	JJ	O
increase	NN	O
(	(	O
reaching	VBG	O
84	CD	O
%	NN	O
in	IN	O
the	DT	O
counselor	NN	O
group	NN	O
and	CC	O
85	CD	O
%	NN	O
in	IN	O
the	DT	O
computer	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
computer	NN	O
program	NN	O
under	IN	O
evaluation	NN	O
can	MD	O
successfully	RB	O
educate	VB	O
individuals	NNS	O
considering	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
CF	NNP	O
.	.	O

Dentists	NNS	O
United	NNP	O
to	TO	O
Extinguish	VB	O
Tobacco	NNP	O
(	(	O
DUET	NNP	O
)	)	O
:	:	O
a	DT	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
cluster	NN	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
for	IN	O
enhancing	VBG	O
implementation	NN	O
of	IN	O
clinical	JJ	O
practice	NN	O
guidelines	NNS	O
for	IN	O
treating	VBG	O
tobacco	NN	O
dependence	NN	O
in	IN	O
dental	JJ	O
care	NN	O
settings	NNS	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
dental	JJ	O
care	NN	O
settings	NNS	O
provide	VBP	O
an	DT	O
exceptional	JJ	O
opportunity	NN	O
to	TO	O
reach	VB	O
smokers	NNS	O
and	CC	O
provide	VB	O
brief	JJ	O
cessation	NN	O
advice	NN	O
and	CC	O
treatment	NN	O
to	TO	O
reduce	VB	O
oral	JJ	O
and	CC	O
other	JJ	O
tobacco-related	JJ	O
health	NN	O
conditions	NNS	O
,	,	O
dental	JJ	O
care	NN	O
providers	NNS	O
demonstrate	VBP	O
limited	JJ	O
adherence	NN	O
to	TO	O
evidence-based	JJ	O
guidelines	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
tobacco	NN	O
use	NN	O
and	CC	O
dependence	NN	O
.	.	O

METHODS/DESIGN	NNP	O
Guided	VBN	O
by	IN	O
a	DT	O
multi-level	NN	O
,	,	O
conceptual	JJ	O
framework	NN	O
that	WDT	O
emphasizes	VBZ	O
changes	NNS	O
in	IN	O
provider	NN	O
beliefs	NNS	O
and	CC	O
organizational	JJ	O
characteristics	NNS	O
as	IN	O
drivers	NNS	O
of	IN	O
improvement	NN	O
in	IN	O
tobacco	NN	O
treatment	NN	O
delivery	NN	O
,	,	O
the	DT	O
current	JJ	O
protocol	NN	O
will	MD	O
use	VB	O
a	DT	O
cluster	NN	O
,	,	O
randomized	VBN	O
design	NN	O
and	CC	O
multiple	JJ	O
data	NNS	O
sources	NNS	O
(	(	O
patient	JJ	O
exit	NN	O
interviews	NNS	O
,	,	O
provider	NN	O
surveys	NNS	O
,	,	O
site	NN	O
observations	NNS	O
,	,	O
chart	JJ	O
audits	NN	O
,	,	O
and	CC	O
semi-structured	JJ	O
provider	NN	O
interviews	NNS	O
)	)	O
to	TO	O
study	VB	O
the	DT	O
process	NN	O
of	IN	O
implementing	VBG	O
clinical	JJ	O
practice	NN	O
guidelines	NNS	O
for	IN	O
treating	VBG	O
tobacco	NN	O
dependence	NN	O
in	IN	O
18	CD	O
public	JJ	O
dental	NN	O
care	NN	O
clinics	NNS	O
in	IN	O
New	NNP	O
York	NNP	O
City	NNP	O
.	.	O

The	DT	O
specific	JJ	O
aims	NNS	O
of	IN	O
this	DT	O
comparative-effectiveness	JJ	Ot
research	NN	O
trial	NN	O
are	VBP	O
to	TO	O
:	:	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
three	CD	O
promising	VBG	O
strategies	NNS	O
for	IN	O
implementation	NN	O
of	IN	O
tobacco	NN	O
use	NN	O
treatment	NN	O
guidelines-staff	JJ	O
training	NN	O
and	CC	O
current	JJ	O
best	JJS	O
practices	NNS	O
(	(	O
CBP	NNP	O
)	)	O
,	,	O
CBP	NNP	O
+	NNP	O
provider	NN	O
performance	NN	O
feedback	NN	O
(	(	O
PF	NNP	O
)	)	O
,	,	O
and	CC	O
CBP	NNP	O
+	NNP	O
PF	NNP	O
+	NNP	O
provider	NN	O
reimbursement	NN	O
for	IN	O
delivery	NN	O
of	IN	O
tobacco	NN	O
cessation	NN	O
treatment	NN	O
(	(	O
pay-for-performance	NN	O
,	,	O
or	CC	O
P4P	NNP	O
)	)	O
;	:	O
examine	JJ	O
potential	JJ	O
theory-driven	JJ	O
mechanisms	NNS	O
hypothesized	VBN	O
to	TO	O
explain	VB	O
the	DT	O
comparative	JJ	O
effectiveness	NN	O
of	IN	O
three	CD	O
strategies	NNS	O
for	IN	O
implementation	NN	O
;	:	O
and	CC	O
identify	VB	O
baseline	JJ	O
organizational	JJ	O
factors	NNS	O
that	WDT	O
influence	VBP	O
the	DT	O
implementation	NN	O
of	IN	O
evidence-based	JJ	O
tobacco	NN	O
use	NN	O
treatment	NN	O
practices	NNS	O
in	IN	O
dental	JJ	O
clinics	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
is	VBZ	O
change	VBN	O
in	IN	O
providers	NNS	O
'	POS	O
tobacco	NN	O
treatment	NN	O
practices	NNS	O
and	CC	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
are	VBP	O
cost	VBN	O
per	IN	O
quit	NN	O
,	,	O
use	NN	O
of	IN	O
tobacco	NN	O
cessation	NN	O
treatments	NNS	O
,	,	O
quit	NN	O
attempts	NNS	O
,	,	O
and	CC	O
smoking	VBG	O
abstinence	NN	O
.	.	O

DISCUSSION	NNP	O
We	PRP	O
hypothesize	VBP	O
that	IN	O
the	DT	O
value	NN	O
of	IN	O
these	DT	O
promising	JJ	O
implementation	NN	O
strategies	NNS	O
is	VBZ	O
additive	JJ	O
and	CC	O
that	IN	O
incorporating	VBG	O
all	DT	O
three	CD	O
strategies	NNS	O
(	(	O
CBP	NNP	O
,	,	O
PF	NNP	O
,	,	O
and	CC	O
P4P	NNP	O
)	)	O
will	MD	O
be	VB	O
superior	JJ	O
to	TO	O
CBP	VB	O
alone	RB	O
and	CC	O
CBP	NNP	O
+	NNP	O
PF	NNP	O
in	IN	O
improving	VBG	O
delivery	NN	O
of	IN	O
cessation	NN	O
assistance	NN	O
to	TO	O
smokers	NNS	O
.	.	O

The	DT	O
findings	NNS	O
will	MD	O
improve	VB	O
knowledge	NN	O
pertinent	NN	O
to	TO	O
the	DT	O
implementation	NN	O
,	,	O
dissemination	NN	O
,	,	O
and	CC	O
sustained	VBD	O
utilization	NN	O
of	IN	O
evidence-based	JJ	O
tobacco	NN	O
use	NN	O
treatment	NN	O
in	IN	O
dental	JJ	O
practices	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NCT01615237	NNP	O
.	.	O

Treatment	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
with	IN	O
low-dose	JJ	O
antacids	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
investigation	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
low-dose	JJ	O
antacid	NN	O
(	(	O
Maalox	NNP	O
70	CD	O
,	,	O
280	CD	O
mmol/day	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
H2-receptor	NNP	O
antagonist	NN	O
cimetidine	NN	O
(	(	O
Tagamet	NNP	O
,	,	O
200	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
and	CC	O
400	CD	O
mg/day	NN	O
)	)	O
after	IN	O
14	CD	O
and	CC	O
28	CD	O
days	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

The	DT	O
prospective	JJ	O
multicentre	NN	O
study	NN	O
included	VBD	O
171	CD	O
patients	NNS	O
with	IN	O
endoscopically	RB	O
confirmed	VBN	O
duodenal	JJ	O
ulcers	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
antacid	JJ	O
containing	VBG	O
Mg	NNP	O
and	CC	O
Al	NNP	O
hydroxide	NN	O
(	(	O
M	NNP	O
)	)	O
(	(	O
4	CD	O
X	RB	O
70	CD	O
mmol/day	NN	O
;	:	O
n	CC	O
=	VB	O
86	CD	O
)	)	O
or	CC	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
cimetidine	NN	O
(	(	O
T	NNP	O
)	)	O
(	(	O
1000	CD	O
mg/day	NN	O
;	:	O
n	CC	O
=	VB	O
85	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
matched	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
drinking	NN	O
and	CC	O
smoking	NN	O
habits	NNS	O
,	,	O
and	CC	O
drug	NN	O
use	NN	O
.	.	O

Endoscopic	JJ	O
examinations	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
and	CC	O
14	CD	O
days	NNS	O
later	RB	O
.	.	O

If	IN	O
the	DT	O
ulcer	NN	O
was	VBD	O
still	RB	O
present	JJ	O
at	IN	O
this	DT	O
time	NN	O
,	,	O
the	DT	O
second	JJ	O
endoscopic	NN	O
examination	NN	O
was	VBD	O
done	VBN	O
after	IN	O
a	DT	O
further	JJ	O
14	CD	O
days	NNS	O
.	.	O

Endoscopically	RB	O
,	,	O
the	DT	O
ulcer	NN	O
had	VBD	O
healed	VBN	PH
at	IN	O
14	CD	O
days	NNS	O
in	IN	O
38.8	CD	O
%	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
in	IN	O
34.9	CD	O
%	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
at	IN	O
28	CD	O
days	NNS	O
in	IN	O
80.0	CD	O
%	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
74.7	CD	O
%	NN	O
(	(	O
T	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
healing	VBG	PH
rate	NN	PH
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Complaints	NNS	Ot
,	,	O
measured	VBN	O
as	IN	O
percentage	NN	O
of	IN	O
days	NNS	O
per	IN	O
week	NN	O
with	IN	O
upper	JJ	PA
abdominal	JJ	PA
pain	NN	PA
,	,	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
pain	VB	PA
relief	NN	PA
or	CC	O
side	NN	A
effects	NNS	A
.	.	O

Treatment	NN	O
had	VBD	O
to	TO	O
be	VB	O
abandoned	VBN	O
in	IN	O
one	CD	O
patient	NN	O
receiving	VBG	O
antacid	NN	O
because	IN	O
of	IN	O
diarrhoea	NN	O
and	CC	O
in	IN	O
one	CD	O
patient	NN	O
receiving	VBG	O
cimetidine	NN	O
because	IN	O
of	IN	O
the	DT	O
absence	NN	O
of	IN	O
any	DT	O
response	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Effect	NN	O
of	IN	O
ischemic	JJ	PH
postconditioning	NN	PH
in	IN	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

Inappropriate	NNP	O
myocardial	JJ	O
protection	NN	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
main	JJ	O
causes	NNS	O
of	IN	O
mortality	NN	O
and	CC	O
morbidity	NN	O
in	IN	O
the	DT	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
(	(	O
TOF	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
previous	JJ	O
reports	NNS	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ischemic	JJ	O
postconditioning	NN	O
on	IN	O
myocardial	JJ	PH
protection	NN	PH
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
are	VBP	O
very	RB	O
encouraging	JJ	O
.	.	O

This	DT	O
randomized	JJ	O
and	CC	O
controlled	JJ	O
trial	NN	O
aimed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ischemic	JJ	PH
postconditioning	VBG	PH
on	IN	O
protection	NN	PH
against	IN	PH
myocardial	JJ	PH
ischemia	NN	PH
reperfusion	NN	O
injury	NN	O
in	IN	O
TOF	NNP	O
patients	NNS	O
receiving	VBG	O
cardioplegia	NN	O
.	.	O

From	IN	O
January	NNP	O
2008	CD	O
to	TO	O
June	NNP	O
2010	CD	O
,	,	O
80	CD	O
consecutive	JJ	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
TOF	NNP	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
postconditioning	NN	O
group	NN	O
(	(	O
three	CD	O
cycles	NNS	O
of	IN	O
30	CD	O
seconds	NNS	O
of	IN	O
ischemia	NN	O
and	CC	O
30	CD	O
seconds	NNS	O
of	IN	O
reperfusion	NN	O
using	VBG	O
re-clamping	JJ	O
and	CC	O
de-clamping	JJ	O
starting	VBG	O
30	CD	O
seconds	NNS	O
after	IN	O
the	DT	O
initial	JJ	O
de-clamping	NN	O
of	IN	O
the	DT	O
aorta	NN	O
,	,	O
n	JJ	O
=	NNP	O
41	CD	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
.	.	O

Cardiac	NNP	PH
troponin	NN	PH
I	PRP	PH
(	(	O
cTnI	NN	O
)	)	O
was	VBD	O
assayed	VBN	O
preoperatively	RB	O
,	,	O
and	CC	O
then	RB	O
4	CD	O
hours	NNS	O
,	,	O
8	CD	O
hours	NNS	O
,	,	O
12	CD	O
hours	NNS	O
,	,	O
20	CD	O
hours	NNS	O
,	,	O
and	CC	O
48	CD	O
hours	NNS	O
after	IN	O
persistent	JJ	O
reperfusion	NN	O
.	.	O

The	DT	O
pre-	JJ	O
,	,	O
intra-	JJ	O
and	CC	O
postoperative	JJ	O
relevant	JJ	O
data	NNS	O
of	IN	O
all	DT	O
selected	VBN	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
reduced	VBD	O
postoperative	JJ	Ot
peak	NN	Ot
release	NN	Ot
by	IN	O
45	CD	O
%	NN	O
for	IN	O
cTnI	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
0.43	CD	O
?	.	O
0.18	CD	O
ng/mL	JJ	O
versus	NN	O
0.78	CD	O
?	.	O
0.15	CD	O
ng/mL	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Ischemic	NNP	O
postconditioned	VBD	O
patients	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
peak	NN	O
inotropic	NN	O
score	NN	O
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
(	(	O
5.6	CD	O
?	.	O
2.2	CD	O
?g/kg/minute	JJ	O
versus	NN	O
8.6	CD	O
?	.	O
3.6	CD	O
?g/kg/minute	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
extubation	JJ	O
time	NN	O
(	(	O
21.5	CD	O
?	.	O
7.3	CD	O
hours	NNS	O
versus	IN	O
30.2	CD	O
?	.	O
12.4	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
and	CC	O
length	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
(	(	O
43.4	CD	O
?	.	O
12.6	CD	O
hours	NNS	O
versus	IN	O
56.3	CD	O
?	.	O
17.8	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
while	IN	O
they	PRP	O
had	VBD	O
a	DT	O
higher	JJR	O
cardiac	JJ	O
output	NN	O
on	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
(	(	O
1.41	CD	O
?	.	O
0.26	CD	O
L/minute	NNP	O
versus	NN	O
1.28	CD	O
?	.	O
0.25	CD	O
L/minute	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.0255	CD	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
may	MD	O
to	TO	O
some	DT	O
extent	NN	O
provide	VBP	O
myocardial	JJ	O
protection	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

The	DT	O
Randomised	JJ	O
Intervention	NNP	O
Treatment	NNP	O
of	IN	O
Angina	NNP	O
(	(	O
RITA	NNP	O
)	)	O
Trial	NNP	O
protocol	NN	O
:	:	O
a	DT	O
long	JJ	O
term	NN	O
study	NN	O
of	IN	O
coronary	JJ	O
angioplasty	NN	O
and	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
in	IN	O
patients	NNS	O
with	IN	O
angina	NN	O
.	.	O

The	DT	O
Randomised	JJ	O
Intervention	NNP	O
Treatment	NNP	O
of	IN	O
Angina	NNP	O
(	(	O
RITA	NNP	O
)	)	O
Trial	NNP	O
is	VBZ	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
to	TO	O
compare	VB	O
the	DT	O
short	JJ	O
term	NN	O
and	CC	O
long	JJ	O
term	NN	O
effects	NNS	O
of	IN	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	NN	O
angioplasty	NN	O
and	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
.	.	O

During	IN	O
the	DT	O
study	NN	O
a	DT	O
register	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
arteriography	NN	O
at	IN	O
the	DT	O
fourteen	JJ	O
participating	VBG	O
centres	NNS	O
is	VBZ	O
being	VBG	O
maintained	VBN	O
to	TO	O
assess	VB	O
the	DT	O
overall	JJ	O
context	NN	O
of	IN	O
patient	JJ	O
recruitment	NN	O
.	.	O

Patients	NNS	O
with	IN	O
arteriographically	RB	O
proven	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
are	VBP	O
considered	VBN	O
for	IN	O
the	DT	O
trial	NN	O
if	IN	O
the	DT	O
participating	VBG	O
cardiologist	NN	O
and	CC	O
surgeon	NN	O
agree	VBP	O
that	IN	O
equivalent	JJ	O
revascularisation	NN	O
could	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
method	NN	O
.	.	O

Patients	NNS	O
who	WP	O
satisfy	VBP	O
the	DT	O
trial	NN	O
entry	NN	O
criteria	NNS	O
are	VBP	O
randomised	VBN	O
to	TO	O
treatment	NN	O
by	IN	O
coronary	JJ	O
angioplasty	NN	O
or	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
,	,	O
with	IN	O
prospective	JJ	O
stratification	NN	O
into	IN	O
groups	NNS	O
with	IN	O
one	CD	O
,	,	O
two	CD	O
,	,	O
or	CC	O
three	CD	O
treatment	NN	O
vessels	NNS	O
.	.	O

Randomisation	NNP	O
implies	VBZ	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
the	DT	O
patient	NN	O
by	IN	O
the	DT	O
assigned	JJ	O
procedure	NN	O
and	CC	O
the	DT	O
analysis	NN	O
of	IN	O
long	JJ	O
term	NN	O
results	NNS	O
will	MD	O
include	VB	O
all	DT	O
randomised	JJ	O
cases	NNS	O
.	.	O

The	DT	O
trial	NN	O
will	MD	O
recruit	VB	O
at	IN	O
least	JJS	O
1000	CD	O
patients	NNS	O
who	WP	O
will	MD	O
be	VB	O
followed	VBN	O
for	IN	O
five	CD	O
years	NNS	O
.	.	O

The	DT	O
major	JJ	O
trial	NN	O
end	NN	O
points	NNS	O
include	VBP	O
death	NN	MO
,	,	O
new	JJ	PH
myocardial	JJ	PH
infarction	NN	PH
,	,	O
and	CC	O
new	JJ	PH
coronary	JJ	PH
angioplasty	NN	PH
or	CC	O
coronary	JJ	PH
artery	NN	PH
bypass	NN	PH
procedures	NNS	PH
.	.	O

Other	JJ	O
outcome	JJ	O
measures	NNS	O
include	VBP	O
symptom	NN	Ot
and	CC	Ot
employment	NN	Ot
status	NN	Ot
,	,	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
,	,	O
exercise	NN	PH
tolerance	NN	PH
,	,	O
and	CC	O
left	VBD	PH
ventricular	JJ	PH
function	NN	PH
.	.	O

Effects	NNS	O
of	IN	O
monotherapy	NN	O
and	CC	O
combination	NN	O
therapy	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
control	NN	O
and	CC	O
target	NN	O
organ	JJ	O
damage	NN	O
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
intervention	NN	O
study	NN	O
in	IN	O
a	DT	O
large	JJ	O
population	NN	O
of	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
monotherapy	NN	O
and	CC	O
different	JJ	O
combination	NN	O
therapies	NNS	O
on	IN	O
cardiovascular	JJ	O
target	NN	O
organ	JJ	O
damage	NN	O
and	CC	O
metabolic	JJ	O
profile	NN	O
in	IN	O
520	CD	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
a	DT	O
single	JJ	O
agent	NN	O
:	:	O
carvedilol	NN	O
25	CD	O
mg	NN	O
,	,	O
amlodipine	VBP	O
10	CD	O
mg	NN	O
,	,	O
enalapril	VBZ	O
20	CD	O
mg	NN	O
,	,	O
or	CC	O
losartan	VBZ	O
50	CD	O
mg	NN	O
(	(	O
groups	NNS	O
C	NNP	O
,	,	O
A	NNP	O
,	,	O
E	NNP	O
,	,	O
and	CC	O
L	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

After	IN	O
2	CD	O
months	NNS	O
(	(	O
level	JJ	O
2	CD	O
)	)	O
,	,	O
nonresponders	NNS	O
received	VBD	O
a	DT	O
low-dose	JJ	O
thiazide	NN	O
diuretic	NN	O
,	,	O
and	CC	O
after	IN	O
4	CD	O
months	NNS	O
(	(	O
level	JJ	O
3	CD	O
)	)	O
,	,	O
amlodipine	JJ	O
(	(	O
groups	NNS	O
E	NNP	O
,	,	O
C	NNP	O
,	,	O
and	CC	O
L	NNP	O
)	)	O
and	CC	O
carvedilol	NN	O
(	(	O
group	NN	O
A	DT	O
)	)	O
.	.	O

Twenty-four-hour	JJ	PH
blood	NN	PH
pressure	NN	PH
was	VBD	O
significantly	RB	O
lowered	VBN	O
in	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Blood	NNP	PH
pressure	NN	PH
control	NN	PH
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
two	CD	O
or	CC	O
three	CD	O
drugs	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
carotid	JJ	PH
intima-media	JJ	PH
thickness	NN	PH
decreased	VBN	O
in	IN	O
group	NN	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
left	VBD	PH
ventricular	JJ	PH
mass	NN	PH
index	NN	PH
in	IN	O
groups	NNS	O
E	NNP	O
and	CC	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
.001	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
with	IN	O
a	DT	O
concomitant	JJ	O
reduction	NN	O
in	IN	O
cholesterol	NN	PH
in	IN	O
group	NN	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.03	NNP	O
)	)	O
.	.	O

Diastolic	NNP	PH
function	NN	PH
improved	VBD	O
significantly	RB	O
in	IN	O
group	NN	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
describes	VBZ	O
the	DT	O
need	NN	O
to	TO	O
control	VB	O
blood	NN	PH
pressure	NN	PH
with	IN	O
two	CD	O
or	CC	O
more	JJR	O
drugs	NNS	O
in	IN	O
most	JJS	O
hypertensive	JJ	O
patients	NNS	O
and	CC	O
illustrates	NNS	O
good	JJ	O
clinical	JJ	O
outcomes	NNS	O
,	,	O
independent	JJ	O
of	IN	O
blood	NN	O
pressure	NN	O
lowering	NN	O
,	,	O
using	VBG	O
combination	NN	O
therapy	NN	O
with	IN	O
losartan	JJ	O
,	,	O
low-dose	JJ	O
thiazide	NN	O
,	,	O
and	CC	O
amlodipine	NN	O
.	.	O

Pharmacokinetic	NNP	O
study	NN	O
of	IN	O
RU	NNP	O
486	CD	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
after	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
single	JJ	O
doses	NNS	O
to	TO	O
pregnant	VB	O
and	CC	O
non-pregnant	JJ	O
women	NNS	O
.	.	O

RU	NNP	O
486	CD	O
and	CC	O
three	CD	O
of	IN	O
its	PRP$	O
metabolites	NNS	O
(	(	O
RU	NNP	O
42633-monodemethyl	CD	O
,	,	O
RU	NNP	O
42848-didemethyl	CD	O
,	,	O
and	CC	O
RU	NNP	O
42698-hydroxymetabolite	JJ	O
)	)	O
were	VBD	O
determined	VBN	O
by	IN	O
HPLC	NNP	O
in	IN	O
plasma	NN	O
from	IN	O
nine	CD	O
non-pregnant	JJ	O
and	CC	O
36	CD	O
pregnant	JJ	O
women	NNS	O
.	.	O

Each	DT	O
non-pregnant	JJ	O
subject	NN	O
took	VBD	O
an	DT	O
oral	JJ	O
dose	NN	O
of	IN	O
RU	NNP	O
486	CD	O
(	(	O
25	CD	O
,	,	O
100	CD	O
,	,	O
400	CD	O
and	CC	O
600	CD	O
mg	NNS	O
consecutively	RB	O
)	)	O
once	RB	O
per	IN	O
menstrual	JJ	O
cycle	NN	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
nine	CD	O
women	NNS	O
also	RB	O
received	VBD	O
a	DT	O
dose	NN	O
of	IN	O
200	CD	O
mg	NN	O
.	.	O

The	DT	O
36	CD	O
pregnant	JJ	O
women	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
which	WDT	O
were	VBD	O
given	VBN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
25	CD	O
,	,	O
100	CD	O
,	,	O
400	CD	O
or	CC	O
600	CD	O
mg	NNS	O
RU	NNP	O
486	CD	O
.	.	O

Blood	NN	PH
samples	NNS	PH
were	VBD	O
taken	VBN	O
up	RB	O
to	TO	O
120	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
.	.	O

Peak	NNP	PH
concentrations	NNS	PH
of	IN	PH
RU	NNP	PH
486	CD	PH
occurred	VBD	O
on	IN	O
most	JJS	O
occasions	NNS	O
within	IN	O
2	CD	O
h.	NN	O
Plasma	NNP	PH
concentrations	NNS	PH
at	IN	O
1	CD	O
h	NN	O
and	CC	O
at	IN	O
24	CD	O
h	NN	O
increased	VBN	O
in	IN	O
proportion	NN	O
to	TO	O
log	VB	O
dose	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
wide	JJ	O
variability	NN	O
(	(	O
up	IN	O
to	TO	O
ten-fold	JJ	O
)	)	O
in	IN	O
the	DT	O
pharmacokinetic	JJ	O
parameters	NNS	O
within	IN	O
each	DT	O
dose	NN	O
group	NN	O
.	.	O

Plasma	NNP	PH
concentrations	NNS	PH
of	IN	PH
RU	NNP	PH
42633	CD	PH
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
of	IN	O
RU	NNP	O
486	CD	O
but	CC	O
concentrations	NNS	O
of	IN	O
RU	NNP	O
42848	CD	O
and	CC	O
RU	NNP	O
42698	CD	O
were	VBD	O
much	JJ	O
lower	JJR	O
.	.	O

As	IN	O
with	IN	O
RU	NNP	O
486	CD	O
,	,	O
the	DT	O
plasma	JJ	PH
concentrations	NNS	PH
of	IN	PH
the	DT	PH
metabolites	NNS	PH
were	VBD	O
maintained	VBN	O
at	IN	O
high	JJ	O
levels	NNS	O
for	IN	O
up	IN	O
to	TO	O
48-72	JJ	O
h	NN	O
after	IN	O
dosing	VBG	O
.	.	O

The	DT	O
findings	NNS	O
were	VBD	O
consistent	JJ	O
with	IN	O
a	DT	O
rapid	JJ	O
metabolism	NN	O
of	IN	O
RU	NNP	PH
486	CD	PH
to	TO	PH
RU	NNP	PH
42633	CD	PH
;	:	O
removal	NN	O
of	IN	O
the	DT	O
second	JJ	O
methyl	NN	O
group	NN	O
leading	VBG	O
to	TO	O
RU	NNP	O
42698	CD	O
occurred	VBD	O
much	RB	O
more	RBR	O
slowly	RB	O
and	CC	O
to	TO	O
a	DT	O
much	RB	O
less	RBR	O
extent	JJ	O
than	IN	O
removal	NN	O
of	IN	O
the	DT	O
first	JJ	O
.	.	O

There	EX	O
appeared	VBD	O
to	TO	O
be	VB	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
non-pregnant	JJ	O
and	CC	O
pregnant	JJ	O
women	NNS	O
in	IN	O
either	CC	O
the	DT	O
plasma	JJ	O
concentrations	NNS	O
or	CC	O
pharmacokinetic	JJ	O
parameters	NNS	O
of	IN	O
RU	NNP	O
486	CD	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
fidelity	NN	Ot
of	IN	Ot
implementation	NN	Ot
on	IN	O
teacher-student	JJ	ME
interaction	NN	ME
quality	NN	ME
in	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
the	DT	O
Responsive	NNP	O
Classroom	NNP	O
approach	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
direct	JJ	Ot
and	CC	Ot
indirect	JJ	Ot
effects	NNS	Ot
between	IN	O
training	NN	O
in	IN	O
the	DT	O
Responsive	NNP	O
Classroom?	NNP	O
(	(	O
RC	NNP	O
)	)	O
approach	NN	O
,	,	O
teachers	NNS	O
'	POS	O
uptake	NN	O
of	IN	O
RC	NNP	O
practices	NNS	O
,	,	O
and	CC	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
,	,	O
using	VBG	O
a	DT	O
structural	JJ	O
equation	NN	O
modeling	VBG	O
framework	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
24	CD	O
schools	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
experimental	VB	O
or	CC	O
control	VB	O
conditions	NNS	O
.	.	O

Third-	CD	O
and	CC	O
fourth-grade	JJ	O
teachers	NNS	O
in	IN	O
treatment	NN	O
schools	NNS	O
(	(	O
n=132	NN	O
)	)	O
received	VBD	O
training	NN	O
in	IN	O
the	DT	O
RC	NNP	O
approach	NN	O
,	,	O
whereas	JJ	O
teachers	NNS	O
in	IN	O
control	NN	O
schools	NNS	O
(	(	O
n=107	NN	O
)	)	O
continued	VBD	O
business	NN	O
as	IN	O
usual	JJ	O
.	.	O

Observers	NNS	O
rated	VBD	O
teachers	NNS	O
'	POS	O
fidelity	NN	O
of	IN	O
implementation	NN	O
(	(	O
FOI	NNP	O
)	)	O
of	IN	O
RC	NNP	O
practices	NNS	O
5	CD	O
times	NNS	O
throughout	IN	O
the	DT	O
year	NN	O
using	VBG	O
the	DT	O
Classroom	NNP	O
Practices	NNPS	O
Observation	NNP	O
Measure	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
teachers	NNS	O
completed	VBD	O
self-report	JJ	O
measures	NNS	O
of	IN	O
FOI	NNP	O
,	,	O
the	DT	O
Classroom	NNP	O
Practices	NNPS	O
Teacher	NNP	O
Survey	NNP	O
and	CC	O
Classroom	NNP	O
Practices	NNP	O
Frequency	NNP	O
Survey	NNP	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
school	NN	O
year	NN	O
.	.	O

Teacher-student	JJ	O
interactions	NNS	O
were	VBD	O
rated	VBN	O
during	IN	O
classroom	NN	O
observations	NNS	O
using	VBG	O
the	DT	O
Classroom	NNP	O
Assessment	NNP	O
Scoring	NNP	O
System	NNP	O
.	.	O

Controlling	VBG	O
for	IN	O
teachers	NNS	O
'	POS	O
grade	NN	O
level	NN	O
and	CC	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
at	IN	O
pretest	JJS	O
,	,	O
RC	NNP	O
training	NN	O
was	VBD	O
expected	VBN	O
to	TO	O
predict	VB	O
posttest	JJS	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
directly	RB	O
and	CC	O
indirectly	RB	O
through	IN	O
FOI	NNP	O
.	.	O

Results	NNP	O
supported	VBD	O
only	RB	O
a	DT	O
significant	JJ	O
indirect	JJ	O
effect	NN	O
,	,	O
?=0.85	NNP	O
,	,	O
p=.002	NN	O
.	.	O

Specifically	RB	O
,	,	O
RC	NNP	O
teachers	NNS	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
FOI	NNP	O
of	IN	O
RC	NNP	O
practices	NNS	O
,	,	O
?=1.62	NNP	O
,	,	O
p	NN	O
<	NNP	O
.001	NNP	O
,	,	O
R2=.69	NNP	O
.	.	O

In	IN	O
turn	NN	O
,	,	O
FOI	NNP	O
related	VBD	O
to	TO	O
greater	JJR	O
improvement	NN	O
in	IN	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
,	,	O
?=0.52	NNP	O
,	,	O
p=.001	NN	O
,	,	O
R2=.32	NNP	O
.	.	O

Discussion	NNP	O
highlights	NNS	O
factors	NNS	O
contributing	VBG	O
to	TO	O
variability	NN	O
in	IN	O
FOI	NNP	O
and	CC	O
school	NN	O
administrators	NNS	O
roles	NNS	O
in	IN	O
supporting	VBG	O
FOI	NNP	O
.	.	O

Fluoroscopic	NNP	O
functional	JJ	O
evaluation	NN	O
of	IN	O
bileaflet	NN	O
prostheses	NNS	O
:	:	O
effect	NN	O
of	IN	O
different	JJ	O
intraoperative	JJ	O
valve	NN	O
orientation	NN	O
.	.	O

Fluoroscopy	NNP	O
is	VBZ	O
a	DT	O
reliable	JJ	O
,	,	O
easy	JJ	O
,	,	O
and	CC	O
readily	RB	O
available	JJ	O
technique	NN	O
to	TO	O
follow-up	JJ	O
prosthesis	NN	O
functioning	NN	O
after	IN	O
heart	NN	O
valve	NN	O
surgery	NN	O
.	.	O

The	DT	O
different	JJ	O
orientation	NN	O
given	VBN	O
to	TO	O
the	DT	O
prosthesis	NN	O
may	MD	O
represent	VB	O
a	DT	O
limitation	NN	O
of	IN	O
the	DT	O
technique	NN	O
accounting	NN	O
for	IN	O
unsatisfactory	JJ	O
results	NNS	O
in	IN	O
10	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
and	CC	O
to	TO	O
what	WP	O
extent	VB	O
different	JJ	O
intraoperative	JJ	O
valve	NN	O
orientation	NN	O
influence	NN	O
feasibility	NN	Ot
and	CC	Ot
accuracy	NN	Ot
of	IN	O
postoperative	JJ	O
fluoroscopic	JJ	O
evaluation	NN	O
of	IN	O
bileaflet	NN	O
prostheses	NNS	O
.	.	O

We	PRP	O
prospectively	RB	O
evaluated	VBD	O
90	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
aortic	JJ	O
,	,	O
mitral	JJ	O
,	,	O
and/or	JJ	O
tricuspid	JJ	O
valve	FW	O
replacement	NN	O
with	IN	O
Sorin	NNP	O
Bicarbon	NNP	O
or	CC	O
CarboMedics	NNPS	O
bileaflet	NN	O
prostheses	NNS	O
.	.	O

Fifty	NNP	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
prostheses	NNS	O
oriented	VBN	O
in	IN	O
a	DT	O
perpendicular	NN	O
or	CC	O
a	DT	O
parallel	JJ	O
position	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
ventricular	JJ	O
septum	NN	O
.	.	O

Fluoroscopic	NNP	O
evaluation	NN	O
was	VBD	O
considered	VBN	O
appropriate	JJ	O
when	WRB	O
the	DT	O
prosthesis	NN	O
'	POS	O
tilting	VBG	O
disk	NN	O
projection	NN	O
was	VBD	O
obtained	VBN	O
.	.	O

The	DT	O
valve	NN	O
's	POS	O
hemodynamic	JJ	PH
performance	NN	PH
was	VBD	O
investigated	VBN	O
through	IN	O
Doppler	NNP	O
study	NN	O
.	.	O

A	DT	O
proper	JJ	Ot
fluoroscopic	NN	Ot
evaluation	NN	Ot
was	VBD	O
rapidly	RB	O
(	(	O
15	CD	O
+/-	JJ	O
5	CD	O
seconds	NNS	O
)	)	O
achieved	VBN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
the	DT	O
former	JJ	O
orientation	NN	O
,	,	O
whereas	IN	O
it	PRP	O
was	VBD	O
impossible	JJ	O
to	TO	O
obtain	VB	O
it	PRP	O
in	IN	O
8	CD	O
of	IN	O
20	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
,	,	O
19	CD	O
of	IN	O
20	CD	O
(	(	O
95	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
4	CD	O
of	IN	O
5	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
latter	JJ	O
orientation	NN	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
extremely	RB	O
angulated	VBN	O
,	,	O
uneasy	JJ	O
projection	NN	O
was	VBD	O
often	RB	O
required	VBN	O
to	TO	O
get	VB	O
a	DT	O
correct	JJ	O
fluoroscopic	NN	PH
image	NN	PH
.	.	PH

The	DT	O
Doppler	NNP	O
study	NN	O
showed	VBD	O
a	DT	O
similarly	RB	O
favorable	JJ	O
hemodynamic	JJ	PH
performance	NN	PH
regardless	NN	O
of	IN	O
valve	JJ	O
orientation	NN	O
.	.	O

Prosthesis	NNP	O
orientation	NN	O
crucially	RB	O
affects	VBZ	O
the	DT	O
rate	NN	Ot
of	IN	Ot
success	NN	Ot
of	IN	Ot
the	DT	Ot
fluoroscopic	JJ	Ot
evaluation	NN	Ot
.	.	PH

The	DT	O
orientation	NN	O
perpendicular	NN	O
to	TO	O
the	DT	O
ventricular	JJ	O
septum	NN	O
greatly	RB	O
facilitates	VBZ	O
the	DT	O
postoperative	JJ	Ot
feasibility	NN	Ot
and	CC	Ot
accuracy	NN	Ot
of	IN	Ot
fluoroscopy	NN	Ot
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
detrimental	JJ	O
to	TO	O
the	DT	O
valve	NN	PH
's	POS	PH
hemodynamic	JJ	PH
performance	NN	PH
.	.	PH

This	DT	O
valve	JJ	O
orientation	NN	O
may	MD	O
provide	VB	O
a	DT	O
better	JJR	O
fluoroscopic	NN	PH
window	NN	PH
whenever	WRB	O
a	DT	O
valve	NN	O
dysfunction	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

Microbiologic	JJ	O
yields	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
of	IN	O
vitreous	JJ	O
needle	JJ	O
aspiration	NN	O
versus	IN	O
mechanized	VBN	O
vitreous	JJ	O
biopsy	NN	O
in	IN	O
the	DT	O
Endophthalmitis	NNP	O
Vitrectomy	NNP	O
Study	NNP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
microbiologic	JJ	O
yields	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
associated	VBN	O
with	IN	O
vitreous	JJ	O
needle	JJ	O
tap	NN	O
and	CC	O
vitreous	JJ	O
biopsy	NN	O
in	IN	O
the	DT	O
Endophthalmitis	NNP	O
Vitrectomy	NNP	O
Study	NNP	O
(	(	O
EVS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Of	IN	O
420	CD	O
EVS	NNP	O
patients	NNS	O
with	IN	O
postoperative	JJ	O
endophthalmitis	NN	O
,	,	O
201	CD	O
received	VBD	O
immediate	JJ	O
vitreous	JJ	O
tap	NN	O
or	CC	O
biopsy	NN	O
(	(	O
without	IN	O
pars	NNS	O
plana	VBP	O
vitrectomy	NN	O
)	)	O
by	IN	O
random	JJ	O
assignment	NN	O
and	CC	O
193	CD	O
completed	VBN	O
9-12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Vitreous	JJ	O
specimens	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
biopsy	NN	O
with	IN	O
a	DT	O
20-gauge	JJ	O
vitrectomy	NN	O
cutting	VBG	O
instrument	NN	O
or	CC	O
by	IN	O
needle	JJ	O
tap	NN	O
with	IN	O
a	DT	O
22-27-gauge	JJ	O
needle	NN	O
.	.	O

If	IN	O
resistance	NN	O
to	TO	O
aspiration	NN	O
by	IN	O
needle	JJ	O
tap	NN	O
was	VBD	O
noted	VBN	O
,	,	O
a	DT	O
vitreous	JJ	O
biopsy	NN	O
was	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
201	CD	O
patients	NNS	O
undergoing	JJ	O
tap	NN	O
or	CC	O
biopsy	NN	O
,	,	O
70	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
had	VBD	O
needle	JJ	O
tap	NN	O
,	,	O
127	CD	O
(	(	O
63	CD	O
%	NN	O
)	)	O
had	VBD	O
mechanized	VBN	O
biopsy	NN	O
,	,	O
and	CC	O
4	CD	O
(	(	O
2	CD	O
%	NN	O
)	)	O
had	VBD	O
initial	JJ	O
needle	JJ	O
tap	NN	O
that	WDT	O
was	VBD	O
aborted	VBN	O
to	TO	O
mechanized	VBN	O
biopsy	NN	O
(	(	O
abort	JJ	O
eyes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	PH
hyphema	NN	PH
occurred	VBD	O
in	IN	O
2	CD	O
tap	JJ	O
eyes	NNS	O
(	(	O
3	CD	O
%	NN	O
)	)	O
,	,	O
3	CD	O
biopsy	NN	O
eyes	NNS	O
(	(	O
2	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
abort	NN	O
eyes	NNS	O
.	.	O

Postoperative	JJ	PH
retinal	JJ	PH
detachment	NN	PH
developed	VBD	O
in	IN	O
8	CD	O
(	(	O
11	CD	O
%	NN	O
)	)	O
tap	NN	O
eyes	NNS	O
,	,	O
10	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
biopsy	NN	O
eyes	NNS	O
,	,	O
and	CC	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
abort	NN	O
eyes	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Respective	JJ	PH
rates	NNS	PH
of	IN	PH
culture	NN	PH
and	CC	PH
gram	NN	PH
stain	VBP	PH
positivity	NN	PH
were	VBD	O
69	CD	O
%	NN	O
and	CC	O
42	CD	O
%	NN	O
in	IN	O
tap	JJ	O
eyes	NNS	O
and	CC	O
66	CD	O
%	NN	O
and	CC	O
41	CD	O
%	NN	O
in	IN	O
biopsy	JJ	O
eyes	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
rate	NN	PH
of	IN	PH
severe	JJ	PH
visual	JJ	PH
loss	NN	PH
(	(	O
final	JJ	O
acuity	NN	O
<	NNP	O
5/200	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
tap	JJ	O
eyes	NNS	O
(	(	O
16	CD	O
eyes	NNS	O
,	,	O
24	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
biopsy	JJ	O
eyes	NNS	O
(	(	O
13	CD	O
eyes	NNS	O
,	,	O
11	CD	O
%	NN	O
)	)	O
and	CC	O
abort	JJ	O
eyes	NNS	O
(	(	O
0	CD	O
eyes	NNS	O
,	,	O
0	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
largely	RB	O
explained	VBN	O
by	IN	O
the	DT	O
greater	JJR	O
proportion	NN	PH
of	IN	PH
virulent	JJ	PH
organisms	NNS	PH
in	IN	PH
the	DT	PH
tap	JJ	PH
eyes	NNS	PH
compared	VBN	O
with	IN	O
biopsy	JJ	O
eyes	NNS	O
.	.	O

When	WRB	O
visual	JJ	PH
acuity	NN	PH
outcome	NN	PH
was	VBD	O
defined	VBN	O
by	IN	O
other	JJ	O
thresholds	NNS	O
(	(	O
20/40	CD	O
and	CC	O
20/100	CD	O
)	)	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
mechanized	VBN	O
vitreous	JJ	O
biopsy	NN	O
and	CC	O
needle	JJ	O
tap	NN	O
with	IN	O
respect	NN	O
to	TO	O
microbiologic	JJ	O
yield	NN	O
,	,	O
operative	JJ	O
complications	NNS	O
,	,	O
short-term	JJ	O
(	(	O
9-12	JJ	O
months	NNS	O
)	)	O
retinal	JJ	O
detachment	NN	O
risk	NN	O
,	,	O
or	CC	O
visual	JJ	O
outcome	NN	O
.	.	O

Choice	NNP	O
of	IN	O
vitreous	JJ	O
sampling	VBG	O
procedure	NN	O
must	MD	O
depend	VB	O
on	IN	O
the	DT	O
clinical	JJ	O
judgment	NN	O
of	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Walking	VBG	O
trials	NNS	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
:	:	O
effect	NN	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
on	IN	O
aerobic	JJ	PH
fitness	NN	PH
.	.	PH

We	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
of	IN	O
walking	VBG	O
on	IN	O
aerobic	JJ	PH
fitness	NN	PH
and	CC	O
body	NN	PH
composition	NN	PH
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
thirty-four	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
exercise	NN	O
groups	NNS	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
and	CC	O
130	CD	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
subjects	NNS	O
walked	VBD	O
5	CD	O
d/week	NN	O
for	IN	O
15	CD	O
weeks	NNS	O
at	IN	O
65	CD	O
%	NN	O
of	IN	O
their	PRP$	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
expending	VBG	O
300	CD	O
kcal	JJ	O
(	(	O
1255	CD	O
kJ	NN	O
)	)	O
in	IN	O
exercise	NN	O
in	IN	O
one	CD	O
(	(	O
Group	NNP	O
S1	NNP	O
)	)	O
or	CC	O
two	CD	O
daily	JJ	O
sessions	NNS	O
(	(	O
Group	NNP	O
S2	NNP	O
)	)	O
.	.	O

VO	NNP	PH
(	(	PH
2max	CD	PH
)	)	PH
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
direct	JJ	O
maximal	NN	O
treadmill	NN	O
test	NN	O
.	.	O

Body	NNP	PH
mass	NN	PH
index	NN	PH
(	(	PH
BMI	NNP	PH
)	)	PH
was	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
body	NN	O
fat	NN	O
(	(	O
fat	JJ	O
%	NN	O
)	)	O
estimated	VBN	O
using	VBG	O
skinfold	JJ	O
measurements	NNS	O
.	.	O

The	DT	O
net	JJ	O
change	NN	O
in	IN	O
the	DT	O
VO	NNP	PH
(	(	PH
2max	CD	PH
)	)	PH
was	VBD	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	PH
change	NN	PH
in	IN	PH
body	NN	PH
mass	NN	PH
was	VBD	O
-1.2	JJ	O
kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.9	NNP	O
,	,	O
-0.5	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.1	NNP	O
kg	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.8	NNP	O
,	,	O
-0.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	PH
fat	NN	PH
%	NN	PH
change	NN	PH
was	VBD	O
-2.1	JJ	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.7	NNP	O
,	,	O
-1.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.7	NNP	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.3	NNP	O
,	,	O
-1.0	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

Exercise	NN	O
improved	VBD	O
the	DT	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
and	CC	O
body	NN	O
composition	NN	O
equally	RB	O
when	WRB	O
walking	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
one	CD	O
or	CC	O
two	CD	O
daily	JJ	O
bouts	NNS	O
.	.	O

Comparison	NNP	O
between	IN	O
the	DT	O
central	JJ	O
effects	NNS	O
of	IN	O
camazepam	NN	O
and	CC	O
temazepam	NN	O
.	.	O

Computerized	JJ	O
analysis	NN	O
of	IN	O
sleep	JJ	O
recordings	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
acute	JJ	O
administration	NN	O
per	IN	O
os	NN	O
of	IN	O
30	CD	O
mg	NNS	O
camazepam	NN	O
and	CC	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
temazepam	NN	O
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
8	CD	O
young	JJ	O
male	NN	O
volunteers	NNS	O
,	,	O
fully	RB	O
adapted	VBN	O
to	TO	O
the	DT	O
laboratory	NN	O
environment	NN	O
by	IN	O
6	CD	O
nights	NNS	O
of	IN	O
adaptation	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
double-blind	JJ	O
,	,	O
in	IN	O
a	DT	O
random	NN	O
order	NN	O
,	,	O
10	CD	O
days	NNS	O
separating	VBG	O
each	DT	O
session	NN	O
.	.	O

Spectral	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
the	DT	O
all-night	JJ	O
records	NNS	O
(	(	O
1-min	JJ	O
epochs	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
relative	JJ	O
power	NN	O
of	IN	O
six	CD	O
frequency	NN	O
bands	NNS	O
calculated	VBN	O
.	.	O

Concerning	VBG	O
sleep	JJ	PH
parameters	NNS	PH
,	,	O
temazepam	NN	O
induces	NNS	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
:	:	O
phase	NN	O
shifts	NNS	O
;	:	O
number	NN	O
of	IN	O
awakenings	NNS	O
;	:	O
percent	JJ	O
duration	NN	O
of	IN	O
sleep	JJ	O
stages	NNS	O
I	PRP	O
and	CC	O
IV	NNP	O
.	.	O

A	NNP	O
significant	JJ	O
increase	NN	O
of	IN	O
the	DT	O
percent	NN	PH
duration	NN	PH
of	IN	PH
stage	NN	PH
II	NNP	PH
and	CC	O
sleep	JJ	Ot
efficiency	NN	Ot
was	VBD	O
also	RB	O
found	VBN	O
.	.	O

Camazepam	NNP	Ot
shows	VBZ	Ot
modification	NN	Ot
,	,	O
with	IN	O
the	DT	O
same	JJ	O
trend	NN	O
,	,	O
but	CC	O
not	RB	O
reaching	VBG	O
statistical	JJ	O
significance	NN	O
.	.	O

Concerning	VBG	O
spectral	JJ	O
analysis	NN	O
,	,	O
temazepam	NN	Ot
induces	NNS	O
a	DT	O
light	JJ	O
increase	NN	O
of	IN	O
the	DT	O
relative	JJ	O
power	NN	O
of	IN	O
the	DT	O
slowest	JJS	O
frequencies	NNS	O
,	,	O
paralleled	VBN	O
by	IN	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
fast	JJ	O
bands	NNS	O
,	,	O
while	IN	O
major	JJ	O
effects	NNS	O
are	VBP	O
found	VBN	O
on	IN	O
the	DT	O
characteristic	JJ	O
periodicity	NN	O
of	IN	O
delta	NN	O
activities	NNS	O
,	,	O
which	WDT	O
appear	VBP	O
disrupted	VBN	O
by	IN	O
the	DT	O
drug	NN	O
.	.	O

These	DT	O
effects	NNS	O
are	VBP	O
not	RB	O
evident	JJ	O
with	IN	O
camazepam	NN	O
,	,	O
which	WDT	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
distort	VB	O
the	DT	O
normal	JJ	O
sleep	JJ	O
pattern	NN	O
.	.	O

Infrared	NNP	O
LED	NNP	O
irradiation	NN	O
applied	VBD	O
during	IN	O
high-intensity	NN	O
treadmill	NN	O
training	VBG	O
improves	NNS	O
maximal	JJ	PH
exercise	NN	PH
tolerance	NN	PH
in	IN	O
postmenopausal	JJ	O
women	NNS	O
:	:	O
a	DT	O
6-month	JJ	O
longitudinal	JJ	O
study	NN	O
.	.	O

Reduced	NNP	O
aerobic	JJ	O
fitness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
among	IN	O
the	DT	O
older	JJR	O
population	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	Ot
of	IN	O
LED	NNP	O
irradiation	NN	O
(	(	O
850	CD	O
nm	RB	O
)	)	O
applied	VBD	O
during	IN	O
treadmill	JJ	O
training	VBG	O
on	IN	O
the	DT	O
maximal	JJ	PH
exercise	NN	PH
tolerance	NN	PH
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

At	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
45	CD	O
postmenopausal	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
three	CD	O
groups	NNS	O
,	,	O
and	CC	O
30	CD	O
women	NNS	O
completed	VBD	O
the	DT	O
entire	JJ	O
6	CD	O
months	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
LED	NNP	O
group	NN	O
(	(	O
treadmill	IN	O
training	VBG	O
associated	VBN	O
with	IN	O
phototherapy	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
(	(	O
2	CD	O
)	)	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
treadmill	IN	O
training	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
sedentary	JJ	O
group	NN	O
(	(	O
neither	DT	O
physical	JJ	O
training	NN	O
nor	CC	O
phototherapy	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

The	DT	O
training	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
45	CD	O
min	NN	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
months	NNS	O
at	IN	O
intensities	NNS	O
between	IN	O
85	CD	O
%	NN	O
and	CC	O
90	CD	O
%	NN	O
maximal	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HRmax	NNP	O
)	)	O
.	.	O

The	DT	O
irradiation	NN	O
parameters	NNS	O
were	VBD	O
39	CD	O
mW/cm	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
45	CD	O
min	NN	O
and	CC	O
108	CD	O
J/cm	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
sedentary	JJ	O
group	NN	O
(	(	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
time	NN	O
of	IN	O
tolerance	NN	O
(	(	O
Tlim	NNP	O
)	)	O
,	,	O
metabolic	JJ	O
equivalents	NNS	O
(	(	O
METs	NNP	O
)	)	O
and	CC	O
Bruce	NNP	O
stage	NN	O
reached	VBD	O
significantly	RB	O
higher	JJR	O
values	NNS	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
and	CC	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
the	DT	O
HR	NNP	O
,	,	O
double	JJ	O
product	NN	O
and	CC	O
Borg	NNP	O
score	NN	O
at	IN	O
isotime	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
and	CC	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
time	NN	O
of	IN	O
recovery	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
only	RB	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
differences	NNS	O
between	IN	O
before	IN	O
and	CC	O
after	IN	O
training	NN	O
(	(	O
delta	JJ	O
values	NNS	O
)	)	O
for	IN	O
the	DT	O
Tlim	NNP	O
,	,	O
METs	NNP	O
and	CC	O
HR	NNP	O
at	IN	O
isotime	NN	O
were	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
intergroup	NN	O
difference	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
infrared	JJ	O
LED	NNP	O
irradiation	NN	O
during	IN	O
treadmill	JJ	O
training	NN	O
can	MD	O
improve	VB	O
maximal	JJ	O
performance	NN	O
and	CC	O
post-exercise	JJ	O
recovery	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

Boosting	VBG	O
uptake	NN	PH
of	IN	O
influenza	JJ	O
immunisation	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
telephone	NN	O
appointing	VBG	O
in	IN	O
general	JJ	O
practice	NN	O
.	.	O

BACKGROUND	NNP	O
Immunisation	NNP	O
against	IN	O
influenza	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
intervention	NN	O
that	WDT	O
reduces	VBZ	O
serologically	RB	O
confirmed	VBN	O
cases	NNS	O
by	IN	O
between	IN	O
60	CD	O
%	NN	O
and	CC	O
70	CD	O
%	NN	O
.	.	O

Almost	NNP	O
all	DT	O
influenza	JJ	O
immunisation	NN	O
in	IN	O
the	DT	O
UK	NNP	O
is	VBZ	O
done	VBN	O
within	IN	O
general	JJ	O
practice	NN	O
.	.	O

Current	JJ	O
evidence	NN	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
patient	JJ	O
reminders	NNS	O
for	IN	O
all	DT	O
types	NNS	O
of	IN	O
immunisation	NN	O
programmes	NNS	O
is	VBZ	O
largely	RB	O
based	VBN	O
on	IN	O
North	JJ	O
American	JJ	O
studies	NNS	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
telephone	NN	O
appointments	NNS	O
offered	VBD	O
bygeneral	JJ	O
practice	NN	O
receptionists	NNS	O
increase	VBP	O
the	DT	O
uptake	NN	Ot
of	IN	Ot
irfluenza	JJ	Ot
immunisation	NN	Ot
among	IN	O
the	DT	O
registered	JJ	O
population	NN	O
aged	VBD	O
over	IN	O
65	CD	O
years	NNS	O
in	IN	O
east	JJ	O
London	NNP	O
practices	NNS	O
.	.	O

DESIGN	NNP	O
OF	NNP	O
STUDY	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	NNP	O
research	NN	O
general	JJ	O
practices	NNS	O
within	IN	O
the	DT	O
East	NNP	O
London	NNP	O
and	CC	O
Essex	NNP	O
network	NN	O
of	IN	O
researchers	NNS	O
(	(	O
ELENoR	NNP	O
)	)	O
.	.	O

METHOD	JJ	O
Participants	NNS	O
were	VBD	O
1,820	CD	O
low-risk	JJ	O
patients	NNS	O
aged	VBD	O
65	CD	O
to	TO	O
74	CD	O
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
previously	RB	O
been	VBN	O
in	IN	O
a	DT	O
recall	NN	O
system	NN	O
for	IN	O
influenza	JJ	O
immunisation	NN	O
at	IN	O
their	PRP$	O
general	JJ	O
practice	NN	O
.	.	O

The	DT	O
intervention	NN	O
,	,	O
during	IN	O
October	NNP	O
2000	CD	O
,	,	O
was	VBD	O
a	DT	O
telephone	NN	O
call	NN	O
from	IN	O
the	DT	O
practice	NN	O
receptionist	NN	O
to	TO	O
intervention	NN	O
group	NN	O
households	NNS	O
,	,	O
offering	VBG	O
an	DT	O
appointment	NN	O
for	IN	O
influenza	JJ	O
immunisation	NN	O
at	IN	O
a	DT	O
nurse-run	JJ	O
.	.	O

clinic	JJ	O
Main	NNP	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
numbers	NNS	ME
of	IN	ME
individuals	NNS	ME
in	IN	ME
each	DT	ME
group	NN	ME
receiving	VBG	ME
immunisation	NN	ME
,	,	PH
and	CC	PH
practice	NN	Ot
costs	NNS	Ot
of	IN	Ot
a	DT	Ot
telephone-appointing	JJ	Ot
programme	NN	Ot
.	.	PH

RESULTS	NNP	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
showed	VBD	O
an	DT	O
immunisation	NN	ME
rate	NN	ME
in	IN	O
the	DT	O
control	NN	O
group	NN	O
of	IN	O
44	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
50	CD	O
%	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
1.29	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
=	VBD	O
1.03	CD	O
to	TO	O
1.63	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
making	VBG	O
a	DT	O
telephone	NN	O
appointment	NN	O
,	,	O
88	CD	O
%	NN	O
recieved	JJ	O
immunisation	NN	ME
,	,	O
while	IN	O
22	CD	O
%	NN	O
of	IN	O
those	DT	O
not	RB	O
wanting	VBG	O
an	DT	O
appointment	NN	O
went	VBD	O
on	IN	O
to	TO	O
be	VB	O
immunised	VBN	O
.	.	O

In	IN	O
the	DT	O
controlgroup	NN	O
,	,	O
income	NN	Ot
generated	VBD	Ot
was	VBD	O
11.35	CD	O
pounds	NNS	O
per	IN	O
immunisation	NN	O
,	,	O
for	IN	O
each	DT	O
additional	JJ	O
immunisation	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
the	DT	O
income	NN	O
was	VBD	O
5.20	CD	O
pounds	NNS	O
.	.	O

The	DT	O
'number	NNP	Ot
needed	VBD	Ot
to	TO	Ot
telephone	NN	Ot
'	''	O
was	VBD	O
17	CD	O
.	.	O

CONCLUSION	NNP	O
Uptake	NNP	O
of	IN	O
influenza	JJ	O
immunisation	NN	PH
among	IN	O
the	DT	O
low-risk	JJ	O
older	JJR	O
population	NN	O
in	IN	O
inner-city	JJ	O
areas	NNS	O
can	MD	O
be	VB	O
boosted	VBN	O
by	IN	O
around	IN	O
6	CD	O
%	NN	O
using	VBG	O
a	DT	O
simple	JJ	O
intervention	NN	O
by	IN	O
receptionists	NNS	O
.	.	O

Immunisation	NN	ME
rates	NNS	ME
in	IN	O
this	DT	O
low-risk	JJ	O
group	NN	O
fell	VBD	O
well	RB	O
short	RB	O
of	IN	O
the	DT	O
60	CD	O
%	NN	O
government	NN	O
target	NN	O
.	.	O

Improving	VBG	O
immunisation	NN	ME
rates	NNS	ME
will	MD	O
require	VB	O
a	DT	O
sustained	JJ	O
public	JJ	O
health	NN	O
campaign	NN	O
.	.	O

Retaining	VBG	O
the	DT	O
item-of-service	JJ	O
payments	NNS	O
to	TO	O
practices	NNS	O
should	MD	O
support	VB	O
costs	NNS	O
of	IN	O
practice-based	JJ	O
interventions	NNS	O
.	.	O

Losartan	NNP	O
vs.	FW	O
amlodipine	NN	O
treatment	NN	O
in	IN	O
elderly	JJ	O
oncologic	JJ	O
hypertensive	JJ	O
patients	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Elderly	JJ	O
neoplastic	JJ	O
patients	NNS	O
frequently	RB	O
may	MD	O
show	VB	O
hypertension	NN	O
and	CC	O
hyperuricemia	NN	O
,	,	O
before	IN	O
and	CC	O
after	IN	O
chemotherapeutic	JJ	O
treatments	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
losartan	NN	O
which	WDT	O
is	VBZ	O
an	DT	O
antihypertensive	JJ	O
drug	NN	O
with	IN	O
uricosuric	JJ	O
properties	NNS	O
vs.	FW	O
amlodipine	NN	O
in	IN	O
hypertensive	JJ	O
neoplastic	JJ	O
elderly	JJ	O
patients	NNS	O
.	.	O

This	DT	O
was	VBD	O
an	DT	O
open-labeled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
comparative	JJ	O
trial	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
a	DT	O
30-day	JJ	O
study	NN	O
.	.	O

Seventy	NNP	O
patients	NNS	O
with	IN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
losartan	NN	O
or	CC	O
amlodipine	NN	O
.	.	O

Blood	NNP	PH
pressure	NN	PH
(	(	PH
BP	NNP	PH
)	)	PH
,	,	PH
blood	VBD	PH
urea	JJ	PH
nitrogen	NN	PH
(	(	PH
BUN	NNP	PH
)	)	PH
levels	NNS	PH
,	,	PH
creatinine	NN	PH
,	,	PH
serum	NN	PH
and	CC	PH
urinary	JJ	PH
uric	JJ	PH
acid	NN	PH
,	,	PH
creatinine	NN	PH
and	CC	PH
uric	JJ	PH
acid	JJ	PH
clearance	NN	PH
were	VBD	O
determined	VBN	O
before	IN	O
and	CC	O
after	IN	O
chemotherapy	NN	O
.	.	O

One	CD	O
day	NN	O
after	IN	O
chemotherapy	NN	O
in	IN	O
losartan	JJ	O
group	NN	O
vs.	FW	O
amlodipine	NN	O
group	NN	O
we	PRP	O
observed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
urinary	JJ	PH
uric	JJ	PH
acid	NN	PH
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
of	IN	O
18	CD	O
mg/24	NNS	O
h	VBD	O
vs.	FW	O
40	CD	O
mg/24	NN	O
h.	NN	O
Thirty	NNP	O
days	NNS	O
after	IN	O
chemotherapy	NN	O
we	PRP	O
observed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
azotemia	NN	PH
of	IN	O
0.0	CD	O
mg/dl	NNS	O
vs.	FW	O
3.8	CD	O
mg/dl	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
serum	JJ	PH
uric	JJ	PH
acid	NN	PH
of	IN	O
0.05	CD	O
mg/dl	NNS	O
vs.	FW	O
0.49	CD	O
mg/dl	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
urinary	JJ	PH
uric	JJ	PH
acid	NN	PH
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
of	IN	O
23	CD	O
mg/24	NNS	O
h	VBD	O
vs.	FW	O
0.0	CD	O
mg/24	NN	O
h	NN	O
,	,	O
GFR	NNP	O
of	IN	O
2	CD	O
ml/min/1.73	NNS	O
m	NN	O
(	(	O
2	CD	O
)	)	O
vs.	FW	O
-8	FW	O
ml/min/1.73	FW	O
m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
systolic	JJ	PH
BP	NNP	PH
(	(	O
SBP	NNP	O
)	)	O
of	IN	O
3.6	CD	O
mmHg	NNS	O
vs.	FW	O
0.8	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
support	VBD	O
the	DT	O
effective	JJ	O
role	NN	O
of	IN	O
losartan	JJ	O
compared	VBN	O
to	TO	O
amlodipine	VB	O
in	IN	O
treating	VBG	O
hypertension	NN	O
and	CC	O
hyperuricemia	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
under	IN	O
chemotherapeutic	JJ	O
treatment	NN	O
.	.	O

Effectiveness	NN	Ot
of	IN	O
the	DT	O
school	NN	O
dental	JJ	O
screening	VBG	O
programme	NN	O
in	IN	O
stimulating	VBG	Ot
dental	JJ	Ot
attendance	NN	Ot
for	IN	O
children	NNS	O
in	IN	O
need	NN	O
of	IN	O
treatment	NN	O
in	IN	O
Northern	NNP	O
Ireland	NNP	O
.	.	O

UNLABELLED	IN	O
The	DT	O
school	NN	O
dental	JJ	O
screening	NN	O
programme	NN	O
has	VBZ	O
been	VBN	O
in	IN	O
existence	NN	O
from	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
20th	JJ	O
century	NN	O
yet	RB	O
its	PRP$	O
value	NN	O
in	IN	O
encouraging	JJ	O
attendance	NN	O
among	IN	O
children	NNS	O
with	IN	O
a	DT	O
dental	JJ	O
health	NN	O
need	NN	O
is	VBZ	O
not	RB	O
fully	RB	O
established	VBN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
school	NN	O
dental	JJ	O
screening	NN	O
in	IN	O
promoting	VBG	O
dental	JJ	Ot
attendance	NN	Ot
among	IN	O
children	NNS	O
with	IN	O
a	DT	O
treatment	NN	O
need	NN	O
and	CC	O
to	TO	O
examine	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
screening	NN	O
,	,	O
social	JJ	O
class	NN	O
and	CC	O
other	JJ	O
factors	NNS	O
in	IN	O
dental	JJ	Ot
attendance	NN	Ot
.	.	O

METHODS	NNP	O
Sixty-four	JJ	O
participating	NN	O
schools	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
study	VB	O
and	CC	O
control	VB	O
groups	NNS	O
using	VBG	O
a	DT	O
stratified	JJ	O
,	,	O
blocked	JJ	O
randomisation	NN	O
technique	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
children	NNS	O
received	VBD	O
the	DT	O
standard	JJ	O
school	NN	O
dental	JJ	O
screening	NN	O
and	CC	O
the	DT	O
dental	JJ	Ot
attendance	NN	Ot
of	IN	O
those	DT	O
with	IN	O
a	DT	O
positive	JJ	O
screening	NN	O
result	NN	O
was	VBD	O
assessed	VBN	O
after	IN	O
2	CD	O
months	NNS	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
questionnaire	NN	O
issued	VBN	O
to	TO	O
the	DT	O
children	NNS	O
's	POS	O
parents	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
children	NNS	O
were	VBD	O
not	RB	O
,	,	O
at	IN	O
this	DT	O
stage	NN	O
,	,	O
screened	VBD	O
,	,	O
yet	CC	O
their	PRP$	O
parents	NNS	O
received	VBD	O
the	DT	O
same	JJ	O
questionnaire	NN	O
assessing	VBG	O
dental	JJ	Ot
attendance	NN	Ot
over	IN	O
the	DT	O
2-month	JJ	O
period	NN	O
.	.	O

However	RB	O
,	,	O
only	RB	O
questionnaires	VBZ	O
from	IN	O
control	NN	O
group	NN	O
children	NNS	O
who	WP	O
had	VBD	O
a	DT	O
positive	JJ	O
result	NN	O
at	IN	O
a	DT	O
subsequent	JJ	O
screening	NN	O
were	VBD	O
retained	VBN	O
for	IN	O
analysis	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
2,321	CD	O
children	NNS	O
were	VBD	O
screened	VBN	O
,	,	O
with	IN	O
980	CD	O
having	VBG	O
a	DT	O
positive	JJ	O
result	NN	O
.	.	O

The	DT	O
mean	JJ	O
dmft	NN	O
of	IN	O
those	DT	O
screening	VBG	O
positive	JJ	O
was	VBD	O
4.85	CD	O
.	.	O

In	IN	O
all	DT	O
,	,	O
664	CD	O
completed	VBN	O
questionnaires	NNS	O
were	VBD	O
returned	VBN	O
,	,	O
giving	VBG	O
a	DT	O
response	NN	O
rate	NN	O
of	IN	O
67.8	CD	O
%	NN	O
.	.	O

Dental	JJ	Ot
attendance	NN	Ot
was	VBD	O
reported	VBN	O
among	IN	O
45.5	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
group	NN	O
(	(	O
n=352	NN	O
)	)	O
in	IN	O
the	DT	O
2	CD	O
months	NNS	O
following	VBG	O
screening	NN	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
period	NN	O
,	,	O
27.6	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n=312	RB	O
)	)	O
claimed	VBD	O
attendance	NN	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significant	JJ	O
among	IN	O
the	DT	O
high	JJ	O
employed	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
the	DT	O
unemployed	JJ	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
School	NNP	O
dental	JJ	O
screening	NN	O
was	VBD	O
capable	JJ	O
of	IN	O
stimulating	VBG	O
dental	JJ	Ot
attendance	NN	Ot
.	.	O

The	DT	O
strong	JJ	O
effect	NN	O
among	IN	O
the	DT	O
lowest	JJS	O
socio-economic	JJ	O
group	NN	O
shows	VBZ	O
that	IN	O
school	NN	O
dental	JJ	O
screening	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
decrease	VB	O
dental	JJ	Ot
health	NN	Ot
inequalities	NNS	Ot
.	.	O

Effect	NN	O
of	IN	O
spinal	JJ	O
versus	NN	O
general	JJ	O
anesthesia	NN	O
on	IN	O
bladder	NN	PH
compliance	NN	PH
and	CC	O
intraabdominal	JJ	PH
pressure	NN	PH
during	IN	O
transurethral	JJ	O
procedures	NNS	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
influence	NN	O
of	IN	O
spinal	JJ	O
versus	NN	O
general	JJ	O
anesthesia	NN	O
on	IN	O
bladder	NN	PH
compliance	NN	PH
and	CC	O
intraabdominal	JJ	PH
pressure	NN	PH
in	IN	O
elderly	JJ	O
males	NNS	O
undergoing	VBG	O
elective	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
open-label	JJ	O
study	NN	O
.	.	O

SETTING	NN	O
Teaching	NNP	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
21	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
and	CC	O
III	NNP	O
patients	NNS	O
at	IN	O
least	JJS	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
undergoing	VBG	O
transurethral	JJ	O
surgery	NN	O
.	.	O

INTERVENTIONS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
computer-generated	JJ	O
randomization	NN	O
schedule	NN	O
,	,	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
Group	NNP	O
Spinal	NNP	O
(	(	O
S	NNP	O
)	)	O
,	,	O
10	CD	O
mg	NN	O
of	IN	O
hyperbaric	JJ	O
tetracaine	NN	O
was	VBD	O
administered	VBN	O
intrathecally	RB	O
.	.	O

In	IN	O
Group	NNP	O
General	NNP	O
Anesthesia	NNP	O
(	(	O
GA	NNP	O
)	)	O
,	,	O
patients	NNS	O
received	VBD	O
,	,	O
fentanyl	RB	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

1	CD	O
to	TO	O
2	CD	O
micrograms/kg	NNS	O
and	CC	O
propofol	NN	O
i.v	NN	O
.	.	O

1.0	CD	O
to	TO	O
2.0	CD	O
mg/kg	NN	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

Thereafter	NNP	O
,	,	O
a	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
was	VBD	O
inserted	VBN	O
and	CC	O
,	,	O
with	IN	O
spontaneous	JJ	O
ventilation	NN	O
,	,	O
anesthesia	NN	O
was	VBD	O
maintained	VBN	O
by	IN	O
administering	VBG	O
isoflurane	NN	O
(	(	O
end-tidal	JJ	O
0.7	CD	O
%	NN	O
to	TO	O
1.2	CD	O
%	NN	O
)	)	O
and	CC	O
70	CD	O
%	NN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
N2O	NNP	O
)	)	O
in	IN	O
oxygen	NN	O
.	.	O

Intraabdominal	JJ	O
pressure	NN	O
and	CC	O
bladder	NN	O
compliance	NN	O
were	VBD	O
recorded	VBN	O
prior	RB	O
to	TO	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
and	CC	O
immediately	RB	O
before	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
demographically	RB	O
comparable	JJ	O
.	.	O

In	IN	O
Group	NNP	O
S	NNP	O
,	,	O
mean	JJ	O
bladder	NN	O
compliance	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
higher	JJR	O
and	CC	O
mean	JJ	O
intraabdominal	JJ	PH
pressure	NN	PH
significantly	RB	O
lower	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.007	CD	O
)	)	O
when	WRB	O
compared	VBN	O
to	TO	O
baseline	VB	O
preanesthetic	JJ	O
values	NNS	O
.	.	O

In	IN	O
Group	NNP	O
GA	NNP	O
,	,	O
mean	JJ	PH
intraabdominal	JJ	PH
pressure	NN	PH
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
decreased	VBD	O
when	WRB	O
compared	VBN	O
to	TO	O
baseline	VB	O
preanesthetic	JJ	O
recordings	NNS	O
.	.	O

Following	VBG	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
a	DT	O
small	JJ	O
change	NN	O
in	IN	O
bladder	NN	PH
compliance	NN	PH
was	VBD	O
noted	VBN	O
.	.	O

However	RB	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
and	CC	O
compared	VBN	O
using	VBG	O
Student	NNP	O
's	POS	O
t-test	NN	O
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
spinal	JJ	O
and	CC	O
general	JJ	O
anesthesia	NN	O
induced	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
intraabdominal	JJ	O
pressure	NN	O
.	.	O

While	IN	O
both	DT	O
techniques	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
bladder	NN	O
compliance	NN	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
demonstrated	VBN	O
only	RB	O
in	IN	O
the	DT	O
spinal	JJ	O
anesthesia	NN	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
single-dose	JJ	O
metronidazole	JJ	O
therapy	NN	O
for	IN	O
patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
a	DT	O
2-g	JJ	O
single	JJ	O
dose	NN	O
of	IN	O
metronidazole	NN	O
for	IN	O
male	JJ	O
partners	NNS	O
of	IN	O
women	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
improving	VBG	O
cure	NN	O
rate	NN	O
and	CC	O
decreasing	VBG	O
recurrence	NN	O
rate	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
2-g	JJ	O
single	JJ	O
dose	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
500	CD	O
mg	NN	O
of	IN	O
metronidazole	JJ	O
twice	NN	O
a	DT	O
day	NN	O
in	IN	O
patients	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
benefits	NNS	O
of	IN	O
partner	NN	O
treatment	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
cure	NN	O
rate	NN	O
by	IN	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.01	NN	O
)	)	O
and	CC	O
in	IN	O
percentage	NN	O
of	IN	O
women	NNS	O
with	IN	O
symptoms	NNS	O
eight	CD	O
weeks	NNS	O
after	IN	O
initiating	VBG	O
therapy	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.05	NN	O
)	)	O
.	.	O

The	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
single-dose	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
clue	JJ	O
cells	NNS	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
sniff	NN	O
test	NN	O
at	IN	O
the	DT	O
first	JJ	O
follow-up	JJ	O
visit	NN	O
;	:	O
however	RB	O
,	,	O
differences	NNS	O
in	IN	O
the	DT	O
initial	JJ	PH
cure	NN	PH
rate	NN	PH
assessed	VBN	PH
by	IN	PH
clinical	JJ	PH
criteria	NNS	PH
and	CC	PH
Gram-stained	JJ	PH
smear	JJ	PH
criteria	NNS	PH
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
between	IN	O
the	DT	O
two	CD	O
patient	NN	O
treatment	NN	O
regimens	NNS	O
.	.	O

Recurrence	NN	PH
rates	NNS	PH
by	IN	PH
Gram-stained	JJ	PH
smear	JJ	PH
criteria	NNS	PH
between	IN	O
patient	NN	O
and	CC	O
partner	NN	O
treatment	NN	O
groups	NNS	O
at	IN	O
five	CD	O
and	CC	O
eight	CD	O
weeks	NNS	O
after	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
were	VBD	O
also	RB	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
patient	NN	O
regimens	NNS	O
.	.	O

Single-dose	JJ	O
metronidazole	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
sexual	JJ	O
partner	NN	O
of	IN	O
women	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
improves	VBZ	O
initial	JJ	O
bacterial	JJ	PH
vaginosis	NN	PH
cure	NN	PH
rates	NNS	PH
.	.	O

The	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
not	RB	O
found	VBN	O
by	IN	O
statistical	JJ	O
analysis	NN	O
to	TO	O
be	VB	O
significantly	RB	O
superior	JJ	O
to	TO	O
single-dose	JJ	O
therapy	NN	O
when	WRB	O
considering	VBG	O
initial	JJ	O
cure	NN	O
rates	NNS	O
by	IN	O
clinical	JJ	O
or	CC	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
or	CC	O
recurrence	NN	O
rates	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Improved	NNP	O
responsiveness	NN	O
of	IN	O
PCOS	NNP	O
patients	NNS	O
to	TO	O
clomiphene	VB	O
after	IN	O
CYP17a	NNP	O
inhibitor	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
CYP17a	NNP	O
inhibitor	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
on	IN	O
clomiphene	NN	O
responsiveness	NN	O
in	IN	O
PCOS	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Prospective	JJ	O
analysis	NN	O
was	VBD	O
employed	VBN	O
with	IN	O
the	DT	O
setup	NN	O
at	IN	O
Alexandria	NNP	O
IVF/ICSI	NNP	O
center	NN	O
.	.	O

Ninety-seven	JJ	O
insulin-resistant	JJ	O
PCOS	NNP	O
patients	NNS	O
undergoing	VBG	O
ovulation	NN	O
induction	NN	O
using	VBG	O
clomiphene	JJ	O
citrate	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
,	,	O
by	IN	O
random	JJ	O
number	NN	O
table	NN	O
,	,	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
first	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
received	VBN	O
ketoconazole	NN	O
(	(	O
400	CD	O
mg	NNS	O
daily	RB	O
)	)	O
till	NN	O
correction	NN	O
of	IN	O
metabolic	JJ	O
syndrome	NN	O
followed	VBN	O
by	IN	O
clomiphene	NN	O
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
;	:	O
the	DT	O
second	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
receiving	VBG	O
clomiphene	NN	O
without	IN	O
ketoconazole	JJ	O
pretreatment	NN	O
.	.	O

Main	NNP	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
incidence	NN	PH
of	IN	PH
clomiphene	NN	PH
resistance	NN	PH
,	,	PH
monofollicular	JJ	PH
response	NN	PH
,	,	PH
fasting	VBG	PH
insulin/glucose	JJ	PH
ratio	NN	PH
,	,	PH
serum	NN	PH
testosterone	NN	PH
,	,	PH
and	CC	PH
pregnancy	NN	PH
rates	NNS	PH
.	.	PH

RESULTS	VB	O
The	DT	O
ketoconazole	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
incidence	NN	PH
of	IN	PH
monofollicular	JJ	PH
response	NN	PH
(	(	O
38	CD	O
%	NN	O
)	)	O
,	,	O
higher	JJR	PH
pregnancy	NN	PH
rates	NNS	PH
,	,	O
and	CC	O
significantly	RB	PH
less	JJR	PH
marked	JJ	PH
antiestrogenic	NN	PH
manifestations	NNS	PH
than	IN	O
did	VBD	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

They	PRP	O
also	RB	O
had	VBD	O
significantly	RB	O
lower	JJR	O
incidence	NN	PH
of	IN	PH
clomiphene	NN	PH
resistance	NN	PH
(	(	O
11.6	CD	O
%	NN	O
)	)	O
,	,	O
lower	JJR	PH
serum	NN	PH
testosterone	NN	PH
levels	NNS	PH
,	,	O
less	JJR	O
hyperinsulinaemia	NN	PH
,	,	O
than	IN	O
did	VBD	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Ketoconazole	NNP	O
improved	VBD	O
clomiphene	JJ	PH
responsivenss	NN	PH
in	IN	PH
PCOS	NNP	PH
patients	NNS	PH
and	CC	O
attenuated	VBD	O
its	PRP$	O
untoward	JJ	PH
biological	JJ	PH
effects	NNS	PH
.	.	PH

Laser-aided	JJ	O
external	JJ	O
drainage	NN	O
of	IN	O
subretinal	JJ	O
fluid	NN	O
:	:	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
with	IN	O
needle	JJ	O
drainage	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
50	CD	O
consecutive	JJ	O
eyes	NNS	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
safety	NN	Ot
and	CC	O
efficacy	NN	Ot
of	IN	O
draining	VBG	O
subretinal	JJ	O
fluid	NN	O
transchoroidally	RB	O
in	IN	O
primary	JJ	O
scleral	JJ	O
buckling	NN	O
for	IN	O
rhegmatogenous	JJ	O
retinal	JJ	O
detachment	NN	O
using	VBG	O
a	DT	O
needle	JJ	O
,	,	O
with	IN	O
the	DT	O
safety	NN	PH
and	CC	O
efficacy	NN	PH
of	IN	O
the	DT	O
same	JJ	O
procedure	NN	O
using	VBG	O
an	DT	O
angulated	VBN	O
endolaser	NN	O
probe	NN	O
set	VBN	O
at	IN	O
1	CD	O
W	NNP	O
for	IN	O
0.2	CD	O
seconds	NNS	O
,	,	O
using	VBG	O
an	DT	O
average	NN	O
of	IN	O
2.4	CD	O
laser	NN	O
burns	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
complications	NNS	A
associated	VBN	O
with	IN	O
the	DT	O
laser-aided	JJ	O
drainage	NN	O
procedures	NNS	O
(	(	O
25	CD	O
eyes	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
transchoroidal	NN	O
needle	JJ	O
drainage	NN	O
procedures	NNS	O
(	(	O
25	CD	O
eyes	NNS	O
)	)	O
,	,	O
subretinal	JJ	PH
hemorrhage	NN	PH
occurred	VBD	O
in	IN	O
three	CD	O
eyes	NNS	O
and	CC	O
retinal	JJ	O
incarceration	NN	O
in	IN	O
one	CD	O
.	.	O

Thus	VB	O
,	,	O
though	IN	O
our	PRP$	O
numbers	NNS	O
are	VBP	O
small	JJ	O
,	,	O
there	EX	O
appears	VBZ	O
to	TO	O
be	VB	O
some	DT	O
advantage	NN	O
of	IN	O
laser-assisted	JJ	O
drainage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
a	DT	O
lower	JJR	O
incidence	NN	A
of	IN	A
complications	NNS	A
.	.	O

Blockade	NN	O
of	IN	O
cytotoxic	JJ	O
T-lymphocyte	JJ	O
antigen-4	NN	O
by	IN	O
ipilimumab	JJ	O
results	NNS	O
in	IN	O
dysregulation	NN	O
of	IN	O
gastrointestinal	JJ	O
immunity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NN	O
.	.	O

Blockade	NNP	O
of	IN	O
cytotoxic	JJ	O
T-lymphocyte	JJ	O
antigen-4	NN	O
(	(	O
CTLA-4	NNP	O
)	)	O
by	IN	O
ipilimumab	NN	O
leads	NNS	O
to	TO	O
immune-mediated	JJ	O
tumor	NN	O
regression	NN	O
and	CC	O
immune-related	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
irAEs	NN	O
)	)	O
,	,	O
including	VBG	O
diarrhea	NN	O
and	CC	O
colitis	NN	O
.	.	O

The	DT	O
current	JJ	O
analyses	NNS	O
were	VBD	O
undertaken	JJ	O
to	TO	O
promote	VB	O
an	DT	O
understanding	NN	O
of	IN	O
the	DT	O
underlying	VBG	O
mechanism	NN	O
of	IN	O
action	NN	O
and	CC	O
to	TO	O
identify	VB	O
potential	JJ	O
biomarkers	NNS	O
that	WDT	O
could	MD	O
help	VB	O
in	IN	O
the	DT	O
prediction	NN	O
and	CC	O
management	NN	O
of	IN	O
ipilimumab-induced	JJ	O
gastrointestinal	JJ	O
irAEs	NN	O
.	.	O

Treatment-na?ve	CD	O
or	CC	O
previously	RB	O
treated	VBN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
stage	NN	O
III/IV	NNP	O
melanoma	NN	O
(	(	O
n	JJ	O
=	NNP	O
115	CD	O
)	)	O
received	VBD	O
open-label	JJ	O
ipilimumab	NN	O
(	(	O
10	CD	O
mg/kg	NN	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
four	CD	O
doses	NNS	O
)	)	O
and	CC	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
concomitant	NN	O
blinded	VBN	O
prophylactic	JJ	O
oral	JJ	O
budesonide	NN	O
(	(	O
9	CD	O
mg/d	NN	O
with	IN	O
gradual	JJ	O
taper	NN	O
through	IN	O
week	NN	O
16	CD	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
histologic	JJ	PH
assessment	NN	PH
of	IN	PH
bowel	NN	PH
biopsies	NNS	PH
and	CC	O
assessment	NN	PH
of	IN	PH
serologic	JJ	PH
markers	NNS	PH
of	IN	PH
inflammatory	JJ	PH
bowel	NN	PH
disease	NN	PH
(	(	PH
IBD	NNP	PH
)	)	PH
,	,	O
fecal	JJ	PH
calprotectin	NN	PH
levels	NNS	PH
,	,	O
and	CC	O
polymorphisms	NNS	PH
in	IN	PH
immune-related	JJ	PH
genes	NNS	PH
.	.	O

Ipilimumab	NNP	O
resulted	VBD	O
in	IN	O
dysregulation	NN	O
of	IN	O
gastrointestinal	JJ	O
mucosal	NN	O
immunity	NN	O
as	IN	O
evidenced	VBN	O
by	IN	O
altered	JJ	O
antibody	NN	O
levels	NNS	O
to	TO	O
enteric	VB	O
flora	NNS	O
,	,	O
inflammatory	NN	PH
cell	NN	PH
infiltration	NN	PH
into	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
,	,	O
and	CC	O
increased	VBD	O
fecal	JJ	PH
calprotectin	NN	PH
associated	VBN	O
with	IN	O
diarrhea	NN	PH
and	CC	O
clinical	JJ	O
evidence	NN	O
of	IN	O
colitis	NN	PH
.	.	O

The	DT	O
pattern	NN	O
of	IN	O
ipilimumab-induced	JJ	O
antibody	NN	O
titers	NNS	O
to	TO	O
microbial	JJ	O
flora	NN	O
and	CC	O
the	DT	O
histologic	NN	O
features	NNS	O
and	CC	O
location	NN	O
of	IN	O
the	DT	O
inflammation	NN	O
were	VBD	O
distinct	JJ	O
from	IN	O
classic	JJ	O
IBD	NNP	O
.	.	O

Prophylactic	NNP	O
budesonide	NN	O
did	VBD	O
not	RB	O
prevent	VB	O
ipilimumab-induced	JJ	O
bowel	NN	O
inflammation	NN	O
.	.	O

Despite	IN	O
an	DT	O
observed	JJ	O
association	NN	O
between	IN	O
colonic	JJ	O
inflammation	NN	O
and	CC	O
grade	VB	O
2	CD	O
or	CC	O
higher	JJR	O
diarrhea	NN	O
,	,	O
no	DT	O
baseline	NN	O
biomarkers	NNS	O
could	MD	O
reliably	RB	O
predict	VB	O
development	NN	O
of	IN	O
gastrointestinal	JJ	O
toxicity	NN	O
.	.	O

Although	IN	O
classic	JJ	O
IBD	NNP	O
and	CC	O
ipilimumab-related	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
are	VBP	O
both	DT	O
immune	JJ	O
mediated	VBN	O
,	,	O
the	DT	O
observed	JJ	O
pattern	NN	O
of	IN	O
biomarkers	NNS	O
suggests	VBZ	O
ipilimumab-related	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
may	MD	O
be	VB	O
a	DT	O
distinct	JJ	O
clinicopathologic	NN	O
entity	NN	O
.	.	O

Clofibrate	NNP	Ot
and	CC	O
diabetes	VBZ	Ot
control	NN	Ot
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
.	.	O

1	CD	O
.	.	O

Twenty-two	JJ	O
maturity-onset	JJ	O
type	NN	O
diabetics	NNS	O
treated	VBD	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
entered	VBD	O
a	DT	O
single-blind	JJ	O
crossover	NN	O
study	NN	O
using	VBG	O
placebo	NN	O
(	(	O
periods	VB	O
A	DT	O
and	CC	O
C	NNP	O
,	,	O
2	CD	O
months	NNS	O
each	DT	O
)	)	O
and	CC	O
clofibrate	NN	O
(	(	O
2	CD	O
g/day	NN	O
;	:	O
period	NN	O
B	NNP	O
;	:	O
2	CD	O
months	NNS	O
)	)	O
.	.	O

2	CD	O
.	.	O

In	IN	O
thirteen	JJ	O
patients	NNS	O
,	,	O
under	IN	O
reasonably	RB	O
good	JJ	O
control	NN	O
,	,	O
clofibrate	NN	O
did	VBD	O
not	RB	O
reduce	VB	Ot
fasting	VBG	PH
or	CC	PH
post-prandial	JJ	PH
blood	NN	PH
glucose	NN	PH
,	,	O
nor	CC	O
24	CD	PH
h	NN	PH
glycosuria	NN	PH
;	:	O
no	DT	O
improvement	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
M-value	NNP	PH
,	,	O
an	DT	O
index	NN	PH
of	IN	PH
diabetes	NNS	PH
control	NN	PH
.	.	O

3	CD	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
nine	CD	O
patients	NNS	O
,	,	O
with	IN	O
poor	JJ	O
diabetes	NNS	PH
control	NN	PH
,	,	O
clofibrate	NN	O
reduced	VBD	O
24	CD	PH
h	NN	PH
glycosuria	NN	PH
and	CC	O
significantly	RB	O
improved	VBD	O
the	DT	O
M-value	NNP	PH
.	.	O

4	CD	O
.	.	O

In	IN	O
all	DT	O
patients	NNS	O
,	,	O
clofibrate	JJ	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
19-23	JJ	O
%	NN	O
reduction	NN	O
in	IN	O
plasma	NN	PH
fibrinogen	NN	PH
.	.	O

5	CD	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
addition	NN	O
of	IN	O
clofibrate	NN	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
maturity-onset	JJ	O
diabetics	NNS	O
not	RB	O
adequately	RB	O
controlled	VBN	O
by	IN	O
diet	NN	O
combined	VBN	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
.	.	O

Trachoma	NNP	O
prevalence	NN	O
and	CC	O
associated	VBN	O
risk	NN	O
factors	NNS	O
in	IN	O
the	DT	O
gambia	NN	O
and	CC	O
Tanzania	NNP	O
:	:	O
baseline	NN	O
results	NNS	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Blinding	NNP	O
trachoma	NN	O
,	,	O
caused	VBN	O
by	IN	O
ocular	JJ	O
infection	NN	O
with	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
,	,	O
is	VBZ	O
targeted	VBN	O
for	IN	O
global	JJ	O
elimination	NN	O
by	IN	O
2020	CD	O
.	.	O

Knowledge	NNP	O
of	IN	O
risk	NN	O
factors	NNS	O
can	MD	O
help	VB	O
target	VB	O
control	JJ	O
interventions	NNS	O
.	.	O

METHODOLOGY/PRINCIPAL	NNP	O
FINDINGS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
baseline	NN	O
prevalence	NN	O
of	IN	O
,	,	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
,	,	O
active	JJ	O
trachoma	NN	PH
and	CC	O
ocular	JJ	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
randomly	RB	O
selected	VBN	O
children	NNS	O
aged	VBN	O
0-5	CD	O
years	NNS	O
from	IN	O
48	CD	O
Gambian	JJ	O
and	CC	O
36	CD	O
Tanzanian	JJ	O
communities	NNS	O
.	.	O

Both	DT	O
children	NNS	O
's	POS	O
eyes	NNS	O
were	VBD	O
examined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
World	NNP	PH
Health	NNP	PH
Organization	NNP	PH
(	(	PH
WHO	NNP	PH
)	)	PH
simplified	VBD	PH
grading	VBG	PH
system	NN	PH
,	,	O
and	CC	O
an	DT	O
ocular	JJ	PH
swab	NN	PH
was	VBD	O
taken	VBN	O
from	IN	O
each	DT	O
child	NN	O
's	POS	O
right	JJ	O
eye	NN	O
and	CC	O
processed	VBN	O
by	IN	O
Amplicor	NNP	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
to	TO	O
test	VB	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
DNA	NNP	O
.	.	O

Prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
was	VBD	O
6.7	CD	O
%	NN	O
(	(	O
335/5033	CD	O
)	)	O
in	IN	O
The	DT	O
Gambia	NNP	O
and	CC	O
32.3	CD	O
%	NN	O
(	(	O
1008/3122	CD	O
)	)	O
in	IN	O
Tanzania	NNP	O
.	.	O

The	DT	O
countries	NNS	O
'	POS	O
corresponding	VBG	O
Amplicor	NNP	PH
positive	JJ	PH
prevalences	NNS	PH
were	VBD	O
0.8	CD	O
%	NN	O
and	CC	O
21.9	CD	O
%	NN	O
.	.	O

After	IN	O
adjustment	NN	O
,	,	O
risk	NN	O
factors	NNS	O
for	IN	O
follicular	JJ	O
trachoma	NN	O
(	(	O
TF	NNP	O
)	)	O
in	IN	O
both	DT	O
countries	NNS	O
were	VBD	O
ocular	JJ	PH
or	CC	PH
nasal	JJ	PH
discharge	NN	PH
,	,	O
a	DT	O
low	JJ	ME
level	NN	ME
of	IN	ME
household	NN	ME
head	NN	ME
education	NN	ME
,	,	O
and	CC	O
being	VBG	O
aged	VBN	O
?	.	O
1	CD	O
year	NN	O
.	.	O

Additional	NNP	O
risk	NN	O
factors	NNS	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
flies	NNS	O
on	IN	O
the	DT	O
child	NN	O
's	POS	O
face	NN	O
,	,	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
,	,	O
and	CC	O
crowding	NN	O
(	(	O
the	DT	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
household	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
for	IN	O
TF	NNP	O
,	,	O
with	IN	O
the	DT	O
exclusion	NN	O
of	IN	O
flies	NNS	O
and	CC	O
crowding	VBG	O
.	.	O

In	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
.	.	O

CONCLUSIONS/SIGNIFICANCE	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
and	CC	O
Amplicor	NNP	O
positives	NNS	O
were	VBD	O
very	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
countries	NNS	O
,	,	O
the	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
active	JJ	O
trachoma	NN	O
were	VBD	O
similar	JJ	O
but	CC	O
those	DT	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
were	VBD	O
different	JJ	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
an	DT	O
association	NN	O
between	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
and	CC	O
TF	NNP	O
in	IN	O
The	DT	O
Gambia	NNP	O
highlights	VBZ	O
the	DT	O
poor	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
trachoma	JJ	O
clinical	JJ	O
signs	NNS	O
and	CC	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

Only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
DNA	NN	O
in	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
suggesting	VBG	O
that	IN	O
at	IN	O
this	DT	O
low	JJ	O
endemicity	NN	O
,	,	O
this	DT	O
may	MD	O
be	VB	O
the	DT	O
most	RBS	O
important	JJ	O
risk	NN	O
factor	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
NCT00792922	NNP	O
.	.	O

[	RB	O
Clinical	JJ	O
trial	NN	O
of	IN	O
2	CD	O
tobacco	NN	O
use	NN	O
cessation	NN	O
interventions	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
two	CD	O
types	NNS	O
of	IN	O
intervention	NN	O
to	TO	O
stop	VB	O
tobacco	NN	ME
dependency	NN	ME
.	.	ME

DESIGN	NNP	O
Randomised	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Primary	NNP	O
care	NN	O
centre	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
OTHER	NNP	O
PARTICIPANTS	NNP	O
Smokers	NNP	O
recruited	VBD	O
from	IN	O
among	IN	O
the	DT	O
health	NN	O
centre	NN	O
users	NNS	O
through	IN	O
the	DT	O
preventive	JJ	O
activities	NNS	O
and	CC	O
health	NN	O
promotion	NN	O
programme	NN	O
.	.	O

INTERVENTIONS	NNP	O
INDEPENDENT	NNP	O
VARIABLE	NNP	O
type	NN	O
of	IN	O
intervention	NN	O
.	.	O

General	JJ	O
variables	NNS	O
:	:	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
marital	JJ	O
status	NN	O
,	,	O
educational	JJ	O
level	NN	O
,	,	O
work	NN	O
situation	NN	O
,	,	O
cohabitation	NN	O
with	IN	O
children	NNS	O
,	,	O
smokers	NNS	O
at	IN	O
home	NN	O
,	,	O
number	NN	O
of	IN	O
years	NNS	O
smoking	VBG	O
,	,	O
type	NN	O
of	IN	O
tobacco	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
types	NNS	O
of	IN	O
intervention	NN	O
:	:	O
a	DT	O
)	)	O
Minimal	NNP	O
Intervention	NNP	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

b	NN	O
)	)	O
Advanced	NNP	O
Intervention	NNP	O
(	(	O
AI	NNP	O
)	)	O
.	.	O

54	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
with	IN	O
6	CD	O
losses	NNS	O
.	.	O

21	CD	O
were	VBD	O
assigned	VBN	O
at	IN	O
random	NN	O
to	TO	O
the	DT	O
MI	NNP	O
group	NN	O
and	CC	O
27	CD	O
to	TO	O
the	DT	O
AI	NNP	O
group	NN	O
.	.	O

Progress	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
15	CD	O
days	NNS	O
,	,	O
1	CD	O
month	NN	O
,	,	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
and	CC	O
a	DT	O
year	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
MI	NNP	O
,	,	O
23.8	CD	O
%	NN	O
were	VBD	O
abstinent	JJ	ME
at	IN	O
15	CD	O
days	NNS	O
;	:	O
the	DT	O
same	JJ	O
percentage	NN	O
at	IN	O
one	CD	O
month	NN	O
and	CC	O
3	CD	O
months	NNS	O
;	:	O
19	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
;	:	O
and	CC	O
14.3	CD	O
%	NN	O
remained	VBD	O
abstinent	JJ	ME
after	IN	ME
a	DT	ME
year	NN	ME
.	.	ME

In	IN	O
the	DT	O
AI	NNP	O
,	,	O
51.9	CD	O
%	NN	O
were	VBD	O
abstinent	JJ	O
at	IN	O
15	CD	O
days	NNS	O
;	:	O
48.1	CD	O
%	NN	O
at	IN	O
both	DT	O
one	CD	O
and	CC	O
3	CD	O
months	NNS	O
;	:	O
25.9	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
;	:	O
and	CC	O
22.2	CD	O
%	NN	O
were	VBD	O
still	RB	O
not	RB	ME
smoking	VBG	ME
after	IN	ME
a	DT	ME
year	NN	ME
.	.	ME

No	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
interventions	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
observations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
do	VBP	O
not	RB	O
show	VB	O
that	IN	O
one	CD	O
intervention	NN	O
is	VBZ	O
better	RBR	O
than	IN	O
the	DT	O
other	JJ	O
.	.	O

With	IN	O
the	DT	O
passage	NN	O
of	IN	O
time	NN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
decreased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Obesity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
:	:	O
analysis	NN	O
of	IN	O
RTOG	NNP	O
85-31	JJ	O
.	.	O

BACKGROUND	NNP	O
Greater	NNP	O
body	NN	PH
mass	NN	PH
index	NN	PH
(	(	PH
BMI	NNP	PH
)	)	PH
is	VBZ	O
associated	VBN	O
with	IN	O
shorter	JJR	O
time	NN	O
to	TO	O
prostate-specific	JJ	O
antigen	NN	O
(	(	O
PSA	NNP	O
)	)	O
failure	NN	O
following	VBG	O
radical	JJ	O
prostatectomy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
(	(	O
RT	NNP	O
)	)	O
.	.	O

Whether	NNP	O
BMI	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
prostate	JJ	O
cancer-specific	JJ	O
mortality	NN	O
(	(	O
PCSM	NNP	O
)	)	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
RT	NNP	O
and	CC	O
androgen	JJ	O
deprivation	NN	O
therapy	NN	O
(	(	O
ADT	NNP	O
)	)	O
for	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1987	CD	O
and	CC	O
1992	CD	O
,	,	O
945	CD	O
eligible	JJ	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
phase	NN	O
3	CD	O
trial	NN	O
(	(	O
RTOG	NNP	O
85-31	CD	O
)	)	O
and	CC	O
randomized	VBN	O
to	TO	O
RT	NNP	O
and	CC	O
immediate	JJ	O
goserelin	NN	O
or	CC	O
RT	NNP	O
alone	RB	O
followed	VBD	O
by	IN	O
goserelin	NN	O
at	IN	O
recurrence	NN	O
.	.	O

Height	NNP	O
and	CC	O
weight	VBN	O
data	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
baseline	NN	O
for	IN	O
788	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
.	.	O

Cox	NNP	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
relations	NNS	O
between	IN	O
BMI	NNP	PH
and	CC	O
all-cause	JJ	MO
mortality	NN	MO
,	,	O
PCSM	NNP	MO
,	,	O
and	CC	O
nonprostate	JJ	MO
cancer	NN	MO
mortality	NN	MO
.	.	O

Covariates	NNS	O
included	VBD	O
age	NN	O
,	,	O
race	NN	O
,	,	O
treatment	NN	O
arm	NN	O
,	,	O
history	NN	O
of	IN	O
prostatectomy	NN	O
,	,	O
nodal	JJ	O
involvement	NN	O
,	,	O
Gleason	NNP	O
score	NN	O
,	,	O
clinical	JJ	O
stage	NN	O
,	,	O
and	CC	O
BMI	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
5-year	JJ	MO
PCSM	NNP	MO
rate	NN	MO
for	IN	O
men	NNS	O
with	IN	O
BMI	NNP	PH
<	NNP	O
25	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
was	VBD	O
6.5	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
13.1	CD	O
%	NN	O
and	CC	O
12.2	CD	O
%	NN	O
in	IN	O
men	NNS	O
with	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=25	VB	O
to	TO	O
<	VB	O
30	CD	O
and	CC	O
BMI	NNP	O
>	NNP	O
or	CC	O
=30	NNP	O
,	,	O
respectively	RB	O
(	(	O
Gray	NNP	O
's	POS	O
P	NNP	O
=	NNP	O
.005	NNP	O
)	)	O
.	.	O

In	IN	O
multivariate	NN	O
analyses	NNS	O
,	,	O
greater	JJR	O
BMI	NNP	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
higher	JJR	MO
PCSM	NNP	MO
(	(	O
for	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=25	VB	O
to	TO	O
<	VB	O
30	CD	O
,	,	O
hazard	RB	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
1.52	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.02-2.27	JJ	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
;	:	O
for	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=30	NNP	O
,	,	O
HR	NNP	O
1.64	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-2.66	JJ	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
.	.	O

BMI	NNP	PH
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
nonprostate	JJ	O
cancer	NN	O
or	CC	O
all-cause	JJ	MO
mortality	NN	MO
.	.	O

CONCLUSIONS	NNP	O
Greater	NNP	O
baseline	NN	PH
BMI	NNP	PH
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
PCSM	NN	MO
in	IN	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
mechanism	NN	O
(	(	O
s	NN	O
)	)	O
for	IN	O
increased	VBN	O
cancer-specific	JJ	MO
mortality	NN	MO
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
weight	JJ	PH
loss	NN	PH
after	IN	O
prostate	JJ	O
cancer	NN	O
diagnosis	NN	O
alters	NNS	O
disease	VBP	O
course	NN	O
.	.	O

Parenteral	JJ	O
nutrition	NN	O
and	CC	O
protein	NN	O
sparing	NN	O
after	IN	O
surgery	NN	O
:	:	O
do	VBP	O
we	PRP	O
need	VB	O
glucose	RB	O
?	.	O
Although	IN	O
capable	JJ	O
of	IN	O
inducing	VBG	O
an	DT	O
anabolic	JJ	O
state	NN	O
after	IN	O
surgery	NN	O
,	,	O
parenteral	JJ	O
nutrition	NN	O
,	,	O
including	VBG	O
glucose	NN	O
,	,	O
leads	VBZ	O
to	TO	O
hyperglycemia	VB	O
.	.	O

Even	RB	O
moderate	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
poor	JJ	O
surgical	JJ	O
outcome	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
amino	NN	O
acids	NNS	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
glucose	JJ	O
supply	NN	O
,	,	O
spare	JJ	O
protein	NN	O
while	IN	O
preventing	VBG	O
hyperglycemia	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
,	,	O
14	CD	O
patients	NNS	O
with	IN	O
colonic	JJ	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
a	DT	O
6-hour	JJ	O
stable	JJ	O
isotope	NN	O
infusion	NN	O
study	NN	O
(	(	O
3	CD	O
hours	NNS	O
of	IN	O
fasting	VBG	O
followed	VBN	O
by	IN	O
3-hour	JJ	O
infusions	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
,	,	O
Travasol	NNP	O
[	NNP	O
Baxter	NNP	O
,	,	O
Montreal	NNP	O
,	,	O
Canada	NNP	O
]	VBD	O
10	CD	O
%	NN	O
at	IN	O
0.02	CD	O
mL.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
glucose	JJ	O
at	IN	O
4	CD	O
mg.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
on	IN	O
the	DT	O
second	JJ	O
day	NN	O
after	IN	O
colorectal	JJ	O
surgery	NN	O
.	.	O

Protein	NNP	PH
breakdown	NN	PH
,	,	O
protein	JJ	PH
oxidation	NN	PH
,	,	O
protein	JJ	PH
balance	NN	PH
,	,	O
and	CC	O
glucose	JJ	PH
production	NN	PH
were	VBD	O
assessed	VBN	O
by	IN	O
stable	JJ	O
isotope	NN	O
tracer	NN	O
kinetics	NNS	O
using	VBG	O
l-	JJ	O
[	JJ	O
1-	JJ	O
(	(	O
13	CD	O
)	)	O
C	NNP	O
]	NNP	O
leucine	NN	O
and	CC	O
[	JJ	O
6,6-	JJ	O
(	(	O
2	CD	O
)	)	O
H2	NNP	O
]	NNP	O
glucose	NN	O
.	.	O

Circulating	VBG	PH
concentrations	NNS	PH
of	IN	PH
glucose	NN	PH
,	,	O
cortisol	NN	PH
,	,	O
insulin	NN	PH
,	,	O
and	CC	O
glucagon	NN	PH
were	VBD	O
determined	VBN	O
.	.	O

The	DT	O
administration	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
increased	VBD	O
protein	JJ	PH
balance	NN	PH
from	IN	O
-16+/-4	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
in	IN	O
the	DT	O
fasted	JJ	O
state	NN	O
to	TO	O
16+/-3	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

Combined	VBN	O
infusion	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
glucose	VB	O
increased	JJ	O
protein	NN	PH
balance	NN	PH
from	IN	O
-17+/-7	JJ	O
to	TO	O
7+/-5	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
protein	JJ	PH
balance	NN	PH
during	IN	O
nutrition	NN	O
was	VBD	O
comparable	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P=.07	NNP	O
)	)	O
.	.	O

Combined	VBN	O
administration	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
glucose	VB	O
decreased	VBN	O
endogenous	JJ	PH
glucose	JJ	PH
production	NN	PH
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
stimulated	VBN	O
insulin	NN	PH
secretion	NN	PH
(	(	O
P=.001	NNP	O
)	)	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
the	DT	O
administration	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
alone	RB	O
.	.	O

Hyperglycemia	NNP	PH
(	(	O
blood	NN	O
glucose	NN	O
,	,	O
10.1+/-1.9	JJ	O
micromol/L	NN	O
)	)	O
occurred	VBD	O
only	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
glucose	JJ	O
infusion	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
excluding	VBG	O
glucose	NN	O
from	IN	O
a	DT	O
short-term	JJ	O
feeding	NN	O
protocol	NN	O
does	VBZ	O
not	RB	O
diminish	VB	O
the	DT	O
protein-sparing	JJ	PH
effect	NN	PH
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
avoids	NNS	O
hyperglycemia	NN	PH
.	.	O

Severe	NNP	O
enteropathy	NN	O
among	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
II/III	NNP	O
colon	NN	O
cancer	NN	O
treated	VBN	O
on	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
bolus	JJ	O
5-fluorouracil/leucovorin	JJ	O
plus	CC	O
or	CC	O
minus	CC	O
oxaliplatin	NN	O
:	:	O
a	DT	O
prospective	JJ	O
analysis	NN	O
.	.	O

BACKGROUND	NNP	O
Cases	NNP	O
of	IN	O
severe	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
were	VBD	O
monitored	VBN	O
prospectively	RB	O
during	IN	O
NSABP	NNP	O
C-07	NNP	O
,	,	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
II/III	NNP	O
colon	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
treated	VBN	O
with	IN	O
weekly	JJ	O
bolus	NN	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
and	CC	O
leucovorin	$	O
(	(	O
FL	NNP	O
;	:	O
Roswell	NNP	O
Park	NNP	O
Regimen	NNP	O
)	)	O
or	CC	O
the	DT	O
same	JJ	O
regimen	NNS	O
plus	CC	O
oxaliplatin	NN	O
(	(	O
FLOX	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
1857	CD	O
patients	NNS	O
,	,	O
79	CD	O
(	(	O
4.3	CD	O
%	NN	O
)	)	O
developed	VBD	O
a	DT	O
syndrome	NN	PH
of	IN	PH
bowel	NN	PH
wall	NN	PH
injury	NN	PH
(	(	PH
BWI	NNP	PH
,	,	PH
small	JJ	PH
or	CC	PH
large	JJ	PH
)	)	PH
characterized	VBN	O
by	IN	O
hospitalization	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
severe	JJ	PH
diarrhea	NN	PH
or	CC	PH
dehydration	NN	PH
and	CC	PH
radiographic	JJ	PH
or	CC	PH
endoscopic	JJ	PH
evidence	NN	PH
of	IN	PH
bowel	NN	PH
wall	NN	PH
thickening	NN	PH
or	CC	PH
ulceration	NN	PH
.	.	O

Fifty-one	CD	O
(	(	O
64.6	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
adverse	JJ	A
events	NNS	A
occurred	VBD	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
FLOX	NNP	O
and	CC	O
28	CD	O
(	(	O
35.4	CD	O
%	NN	O
)	)	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
FL	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Enteric	JJ	PH
sepsis	NN	PH
(	(	PH
ES	NNP	PH
)	)	PH
,	,	O
characterized	VBN	O
by	IN	O
grade	NN	PH
3	CD	PH
or	CC	PH
greater	JJR	PH
diarrhea	NN	PH
and	CC	PH
grade	VBD	PH
4	CD	PH
neutropenia	NN	PH
with	IN	PH
or	CC	PH
without	IN	PH
proven	JJ	PH
bacteremia	NN	PH
occurred	VBD	O
in	IN	O
22	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
FLOX	NNP	O
,	,	O
versus	NN	O
8	CD	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
FL	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Patients	NNPS	O
>	JJ	O
60	CD	O
years	NNS	O
were	VBD	O
at	IN	O
higher	JJR	PH
risk	NN	PH
for	IN	PH
BWI	NNP	PH
after	IN	O
treatment	NN	O
with	IN	O
FLOX	NNP	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
versus	NN	O
treatment	NN	O
with	IN	O
FL	NNP	O
(	(	O
2.9	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Female	JJ	O
patients	NNS	O
had	VBD	O
a	DT	O
higher	JJR	PH
incidence	NN	PH
of	IN	PH
BWI	NNP	PH
with	IN	O
FLOX	NNP	O
(	(	O
9.1	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
FL	NNP	O
(	(	O
3.9	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Severe	JJ	PH
gastrointestinal	JJ	PH
toxicity	NN	PH
usually	RB	O
occurred	VBD	O
during	IN	O
the	DT	O
third	JJ	O
or	CC	O
fourth	JJ	O
week	NN	O
on	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
of	IN	O
therapy	NN	O
,	,	O
required	VBN	O
hospitalization	NN	O
,	,	O
and	CC	O
was	VBD	O
managed	VBN	O
with	IN	O
fluids	NNS	O
,	,	O
antidiarrheals	NNS	O
,	,	O
and	CC	O
antibiotics	NNS	O
.	.	O

There	EX	O
were	VBD	O
5	CD	O
deaths	NNS	MO
(	(	O
0.3	CD	O
%	NN	O
)	)	O
due	JJ	O
to	TO	O
enteropathy	VB	O
,	,	O
2	CD	O
related	VBN	O
to	TO	O
ES	NNP	O
and	CC	O
3	CD	O
related	VBN	O
to	TO	O
both	DT	O
BWI	NNP	O
and	CC	O
ES	NNP	O
.	.	O

Seventy-one	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
resumed	VBN	O
treatment	NN	O
with	IN	O
FL	NNP	O
after	IN	O
recovery	NN	O
.	.	O

CONCLUSIONS	NNP	O
Patients	NNPS	O
treated	VBD	O
with	IN	O
adjuvant	JJ	O
FL	NNP	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
for	IN	O
diarrhea	NN	A
and	CC	O
aggressively	RB	O
managed	VBN	O
,	,	O
especially	RB	O
if	IN	O
oxaliplatin	VBN	O
has	VBZ	O
been	VBN	O
added	VBN	O
to	TO	O
the	DT	O
regimen	NNS	O
.	.	O

Society	NN	O
.	.	O

Pre-operative	JJ	O
radiochemotherapy	NN	O
for	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
pre-operative	JJ	O
vs.	FW	O
postoperative	JJ	O
radiochemotherapy	NN	O
in	IN	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
out	RP	O
whether	IN	O
pre-operative	JJ	O
radiochemotherapy	NN	O
had	VBD	O
any	DT	O
survival	JJ	PH
advantage	NN	PH
over	IN	O
postoperative	JJ	O
radiochemotherapy	NN	O
for	IN	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
without	IN	O
distant	JJ	O
metastasis	NN	O
or	CC	O
peritoneal	JJ	O
carcinomatosis	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1998	CD	O
and	CC	O
December	NNP	O
2003	CD	O
,	,	O
51	CD	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
without	IN	O
distant	JJ	O
metastasis	NN	O
or	CC	O
peritoneal	JJ	O
carcinomatosis	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
pre-operative	JJ	O
(	(	O
PRE	NNP	O
)	)	O
and	CC	O
postoperative	JJ	O
(	(	O
POST	NNP	O
)	)	O
radiochemotherapy	NN	O
groups	NNS	O
.	.	O

Twenty-six	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
PRE	NNP	O
group	NN	O
and	CC	O
were	VBD	O
operated	VBN	O
on	IN	O
5	CD	O
to	TO	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
completion	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

The	DT	O
other	JJ	O
25	CD	O
patients	NNS	O
were	VBD	O
operated	VBN	O
on	IN	O
immediately	RB	O
and	CC	O
received	VBD	O
radiotherapy	NN	O
postoperatively	RB	O
2	CD	O
to	TO	O
4	CD	O
weeks	NNS	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
between	IN	O
4	CD	O
to	TO	O
51	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
the	DT	O
rates	NNS	PH
of	IN	PH
disease-free	JJ	PH
survival	NN	PH
were	VBD	O
92	CD	O
%	NN	O
,	,	O
70	CD	O
%	NN	O
,	,	O
56	CD	O
%	NN	O
and	CC	O
56	CD	O
%	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
3rd	CD	O
and	CC	O
4th	CD	O
years	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
POST	NNP	O
group	NN	O
those	DT	O
percentages	NNS	O
were	VBD	O
83	CD	O
%	NN	O
,	,	O
68	CD	O
%	NN	O
,	,	O
51	CD	O
%	NN	O
and	CC	O
51	CD	O
%	NN	O
at	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
3rd	CD	O
and	CC	O
4th	CD	O
years	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.707	CD	O
)	)	O
.	.	O

One-year	JJ	MO
and	CC	MO
4-year	JJ	MO
overall	JJ	MO
survival	NN	MO
rates	NNS	MO
in	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
were	VBD	O
100	CD	O
%	NN	O
and	CC	O
86	CD	O
%	NN	O
respectively	RB	O
and	CC	O
100	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
in	IN	O
the	DT	O
POST	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.520	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
statistical	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
survival	JJ	MO
rates	NNS	MO
of	IN	O
the	DT	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
either	CC	O
pre-operatively	RB	O
or	CC	O
postoperatively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
disease-free	JJ	MO
survival	NN	MO
rates	NNS	MO
of	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
were	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
POST	NNP	O
group	NN	O
's	POS	O
during	IN	O
each	DT	O
year	NN	O
and	CC	O
overall	JJ	MO
survival	NN	MO
rates	NNS	MO
were	VBD	O
higher	JJR	O
after	IN	O
the	DT	O
third	JJ	O
and	CC	O
fourth	JJ	O
years	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
pre-operative	JJ	O
radiotherapy	NN	O
is	VBZ	O
at	IN	Ot
least	JJS	Ot
as	RB	Ot
effective	JJ	Ot
as	IN	Ot
postoperative	JJ	O
radiotherapy	NN	O
.	.	O

Effect	NN	O
of	IN	O
negative	JJ	O
air	NN	O
ionization	NN	O
on	IN	O
hyperactive	JJ	O
and	CC	O
autistic	JJ	O
children	NNS	O
.	.	O

Twenty-one	CD	O
attention	NN	O
deficit	NN	O
disorder	NN	O
with	IN	O
hyperactivity	NN	O
and	CC	O
seven	CD	O
autistic	JJ	O
children	NNS	O
were	VBD	O
randomly	RB	O
exposed	VBN	O
to	TO	O
negatively	RB	O
ionized	JJ	O
and	CC	O
ambient	JJ	O
atmospheres	NNS	O
under	IN	O
rigorously	RB	O
controlled	VBN	O
experimental	JJ	O
conditions	NNS	O
.	.	O

The	DT	O
negatively	RB	O
ionized	JJ	O
condition	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
affect	JJ	O
measurements	NNS	O
of	IN	O
activity	NN	ME
level	NN	ME
,	,	O
impulsivity	NN	ME
,	,	O
reality	NN	ME
orientation	NN	ME
,	,	O
destructive/constructiveness	NN	ME
,	,	O
attention	NN	ME
,	,	O
or	CC	O
task	NN	ME
performance	NN	ME
.	.	O

Significant	JJ	O
results	NNS	O
might	MD	O
be	VB	O
obtained	VBN	O
if	IN	O
subgroups	NNS	O
of	IN	O
known	JJ	O
hyperserotoninemic	JJ	O
autistic	NN	O
and	CC	O
attention	NN	O
deficit	NN	O
disorder	NN	O
children	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
negatively	RB	O
ionized	JJ	O
conditions	NNS	O
.	.	O

Sinemet	NNP	O
CR	NNP	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Sinemet	NNP	O
CR	NNP	O
,	,	O
a	DT	O
controlled	JJ	O
release	NN	O
carbidopa/levodopa	NN	O
preparation	NN	O
,	,	O
was	VBD	O
compared	VBN	O
to	TO	O
conventional	JJ	O
carbidopa/levodopa	NN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Comparable	JJ	Ot
clinical	JJ	Ot
benefits	NNS	Ot
and	CC	O
adverse	JJ	A
effects	NNS	A
were	VBD	O
noted	VBN	O
with	IN	O
the	DT	O
two	CD	O
medications	NNS	O
.	.	O

However	RB	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
dosing	NN	O
was	VBD	O
necessary	JJ	O
with	IN	O
Sinemet	NNP	O
CR	NNP	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
improves	VBZ	O
parasympathetic	JJ	O
function	NN	O
in	IN	O
diabetes	NNS	O
.	.	O

AIM	VB	O
The	DT	O
renin-angiotensin-aldosterone	NN	O
system	NN	O
(	(	O
RAAS	NNP	O
)	)	O
and	CC	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
regulate	VB	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
.	.	O

Blockade	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
may	MD	O
slow	VB	O
the	DT	O
progression	NN	O
of	IN	O
end-organ	JJ	O
damage	NN	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
offers	VBZ	O
a	DT	O
means	NN	O
for	IN	O
blocking	VBG	O
the	DT	O
RAAS	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
direct	JJ	O
renin	NN	O
inhibition	NN	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
,	,	O
60	CD	O
individuals	NNS	O
with	IN	O
diabetes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
300	CD	O
mg	NN	O
of	IN	O
aliskiren	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
change	NN	PH
in	IN	PH
tests	NNS	PH
of	IN	PH
cardiovascular	JJ	PH
autonomic	JJ	PH
function	NN	PH
.	.	PH

Autonomic	NNP	PH
function	NN	PH
was	VBD	O
assessed	VBN	O
by	IN	O
power	NN	O
spectral	JJ	O
analysis	NN	O
and	CC	O
RR-variation	NNP	O
during	IN	O
deep	JJ	O
breathing	NN	O
[	JJ	O
i.e	NN	O
.	.	O

mean	VB	O
circular	JJ	O
resultant	NN	O
(	(	O
MCR	NNP	O
)	)	O
,	,	O
expiration/inspiration	NN	O
(	(	O
E/I	NNP	O
)	)	O
ratio	NN	O
]	NN	O
.	.	O

The	DT	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
assess	NN	O
parasympathetic	JJ	O
function	NN	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
change	NN	PH
in	IN	PH
biochemical	JJ	PH
parameters	NNS	PH
[	VBP	PH
e.g	NN	PH
.	.	PH

plasma	JJ	PH
renin	NN	PH
activity	NN	PH
,	,	PH
leptin	NN	PH
and	CC	PH
interleukin-6	JJ	PH
]	NN	PH
.	.	PH

Change	NN	PH
in	IN	PH
cardiovascular	JJ	PH
autonomic	JJ	PH
function	NN	PH
and	CC	PH
blood	NN	PH
analytes	NNS	PH
were	VBD	O
analysed	VBN	O
by	IN	O
a	DT	O
mixed	JJ	O
effects	NNS	O
model	NN	O
for	IN	O
repeated	JJ	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
aliskiren	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
blood	NN	PH
pressure	NN	PH
was	VBD	O
reduced	VBN	O
as	RB	O
well	RB	O
as	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
[	VBP	O
from	IN	O
2.4	CD	O
?	.	O
3.8	CD	O
(	(	O
mean	VB	O
?	.	O
standard	JJ	O
deviation	NN	O
)	)	O
to	TO	O
0.5	CD	O
?	.	O
0.4	CD	O
?g/l/h	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
]	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
(	(	O
aliskiren	VB	O
?	.	O
visit	NN	O
)	)	O
for	IN	O
MCR	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
E/I	NNP	O
ratio	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
indicating	VBG	O
improvement	NN	O
in	IN	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
for	IN	O
those	DT	O
on	IN	O
aliskiren	NNS	O
.	.	O

MCR	NNP	O
means	VBZ	O
,	,	O
baseline	VB	O
vs.	IN	O
follow-up	JJ	O
,	,	O
were	VBD	O
41.8	CD	O
?	.	O
19.7	CD	O
vs.	IN	O
50.8	CD	O
?	.	O
26.1	CD	O
(	(	O
aliskiren	NN	O
)	)	O
and	CC	O
38.2	CD	O
?	.	O
23.6	CD	O
vs.	IN	O
37.5	CD	O
?	.	O
24.1	CD	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Parasympathetic	NNP	O
function	NN	O
(	(	O
i.e	JJ	O
.	.	O

MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
)	)	O
was	VBD	O
enhanced	VBN	O
by	IN	O
downregulation	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
.	.	O

[	JJ	O
Hemostatic	NNP	O
balance	NN	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
newest	JJS	O
contraceptives	NNS	O
]	RB	O
.	.	O

Thirty-four	CD	O
healthy	JJ	O
young	JJ	O
women	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
12	CD	O
consecutive	JJ	O
cycles	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
monophasic	JJ	O
combinations	NNS	O
of	IN	O
:	:	O
20	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
and	CC	O
150	CD	O
micrograms	NNS	O
desogestrel	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
30	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
and	CC	O
75	CD	O
micrograms	NNS	O
gestodene	NN	O
(	(	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
plasma	VBP	PH
levels	NNS	PH
of	IN	PH
fibrinogen	NN	PH
and	CC	PH
factor	NN	PH
VII	NNP	PH
increased	VBD	O
while	IN	O
the	DT	O
capacity	NN	O
of	IN	O
coagulation	NN	O
inhibition	NN	O
was	VBD	O
affected	VBN	O
by	IN	O
increased	JJ	PH
protein	NN	PH
C	NNP	PH
and	CC	PH
decreased	VBN	PH
protein	NN	PH
S	NNP	PH
levels	NNS	PH
.	.	PH

Increased	VBN	O
fibrinolytic	JJ	PH
capacity	NN	PH
was	VBD	O
indicated	VBN	O
by	IN	O
elevated	JJ	O
activity	NN	O
and	CC	O
reduced	JJ	O
antigen	NN	PH
levels	NNS	PH
of	IN	PH
tissue	NN	PH
plasminogen	NN	PH
activator	NN	PH
and	CC	O
reduced	JJ	O
activity	NN	O
and	CC	O
concentration	NN	PH
of	IN	PH
tissue	NN	PH
plasminogen	NN	PH
activator	NN	PH
inhibitor	NN	PH
.	.	PH

The	DT	O
ratio	NN	PH
between	IN	PH
thrombin-antithrombin-III-complexes	NNS	PH
and	CC	PH
fibrin	JJ	PH
degradation	NN	PH
products	NNS	PH
were	VBD	O
unchanged	JJ	O
signifying	VBG	O
no	DT	O
effect	NN	O
of	IN	O
hormonal	JJ	O
intake	NN	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
thrombin	JJ	O
formation	NN	O
and	CC	O
fibrin	JJ	O
resolution	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
dynamic	JJ	O
balance	NN	O
between	IN	O
generation	NN	O
and	CC	O
resolution	NN	O
of	IN	O
fibrin	NN	O
was	VBD	O
undisturbed	JJ	O
during	IN	O
treatment	NN	O
with	IN	O
both	DT	O
hormonal	JJ	O
compounds	NNS	O
and	CC	O
our	PRP$	O
findings	NNS	O
do	VBP	O
not	RB	O
provide	VB	O
evidence	NN	O
for	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
thrombosis	NN	O
in	IN	O
normal	JJ	O
women	NNS	O
.	.	O

Effect	NN	O
of	IN	O
sulfasalazine	NN	O
on	IN	O
inflammation	NN	PH
and	CC	PH
endothelial	JJ	PH
function	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
established	VBN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Inflammation	NNP	O
is	VBZ	O
critical	JJ	O
for	IN	O
atherosclerosis	NN	O
development	NN	O
and	CC	O
may	MD	O
be	VB	O
a	DT	O
target	NN	O
for	IN	O
risk-reduction	NN	O
therapy	NN	O
.	.	O

In	IN	O
experimental	JJ	O
studies	NNS	O
,	,	O
activation	NN	O
of	IN	O
the	DT	O
inflammatory	JJ	O
regulator	NN	O
,	,	O
nuclear	JJ	O
factor	NN	O
kappa	NN	O
B	NNP	O
(	(	O
NFlB	NNP	O
)	)	O
,	,	O
contributes	VBZ	O
to	TO	O
endothelial	JJ	O
activation	NN	O
and	CC	O
reduced	JJ	O
nitric	JJ	O
oxide	NN	O
production	NN	O
.	.	O

We	PRP	O
treated	VBD	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
with	IN	O
sulfasalazine	NN	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
NF?B	NNP	O
,	,	O
and	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	NN	O
study	NN	O
design	NN	O
.	.	O

Brachial	JJ	O
artery	JJ	O
flow-mediated	JJ	O
dilation	NN	O
(	(	O
FMD	NNP	O
)	)	O
and	CC	O
digital	JJ	O
vascular	JJ	O
function	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
each	DT	O
6-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

Of	IN	O
the	DT	O
53	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
crossover	NN	O
study	NN	O
,	,	O
32	CD	O
(	(	O
age	NN	O
60	CD	O
?	.	O
10	CD	O
,	,	O
22	CD	O
%	NN	O
female	NN	O
)	)	O
completed	VBD	O
all	PDT	O
the	DT	O
visits	NNS	O
,	,	O
with	IN	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
study	NN	O
withdrawal	NN	O
due	JJ	O
to	TO	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

In	IN	O
a	DT	O
subset	NN	O
of	IN	O
10	CD	O
participants	NNS	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
4	CD	O
days	NNS	O
of	IN	O
sulfasalazine	JJ	O
treatment	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
to	TO	O
no	DT	O
treatment	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
on	IN	O
NF?B-regulated	JJ	O
gene	NN	O
expression	NN	O
in	IN	O
peripheral	JJ	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
.	.	O

Tumor	NNP	O
necrosis	JJ	O
factor	NN	O
?-stimulated	JJ	O
expression	NN	O
of	IN	O
CD69	NNP	O
and	CC	O
NFlB	NNP	O
subunit	VBD	O
p50	NN	O
was	VBD	O
significantly	RB	O
blunted	VBN	O
after	IN	O
4	CD	O
days	NNS	O
of	IN	O
sulfasalazine	JJ	O
treatment	NN	O
but	CC	O
not	RB	O
after	IN	O
no	DT	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
FMD	NNP	O
and	CC	O
digital	JJ	O
vasodilator	NN	O
response	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
from	IN	O
baseline	NN	O
with	IN	O
long-term	JJ	O
sulfasalazine	NN	O
treatment	NN	O
.	.	O

Short-term	JJ	O
sulfasalazine	NN	O
inhibited	VBN	O
NFlB	NNP	O
activity	NN	O
;	:	O
however	RB	O
,	,	O
long-term	JJ	O
treatment	NN	O
was	VBD	O
poorly	RB	O
tolerated	VBN	O
and	CC	O
did	VBD	O
not	RB	O
improve	VB	O
endothelial	JJ	O
function	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
sulfasalazine	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
the	DT	O
optimal	JJ	O
anti-inflammatory	JJ	O
treatment	NN	O
for	IN	O
reversing	VBG	O
endothelial	JJ	O
dysfunction	NN	O
in	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
potential	NN	O
for	IN	O
NFlB	NNP	O
inhibition	NN	O
to	TO	O
reduce	VB	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

[	JJ	O
Radiotherapy	NNP	O
for	IN	O
choroidal	JJ	O
neovascularization	NN	O
in	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
using	VBG	O
low-	JJ	O
versus	NN	O
high-dose	JJ	O
photon	NN	O
bean	NN	O
radiation	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
Several	JJ	O
pilot	NN	O
studies	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
low-dose	JJ	O
radiation	NN	O
therapy	NN	O
might	MD	O
have	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
choroidal	JJ	O
neovascularization	NN	O
(	(	O
CNV	NNP	O
)	)	O
in	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
(	(	O
AMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
ascertain	VB	O
whether	IN	O
such	JJ	O
treatment	NN	O
might	MD	O
halt	VB	O
the	DT	O
progression	NN	O
of	IN	O
neovascular	JJ	O
AMD	NNP	O
and	CC	O
whether	IN	O
a	DT	O
low	JJ	O
or	CC	O
a	DT	O
high	JJ	O
radiation	NN	O
dose	NN	O
should	MD	O
be	VB	O
applied	VBN	O
.	.	O

PATIENTS	VB	O
The	DT	O
patients	NNS	O
comprised	VBD	O
some	DT	O
randomized	VBN	O
to	TO	O
0	CD	O
vs	NNS	O
10	CD	O
vs	NNS	O
36	CD	O
Gy	NNP	O
of	IN	O
radiation	NN	O
and	CC	O
(	(	O
after	IN	O
a	DT	O
change	NN	O
of	IN	O
the	DT	O
study	NN	O
protocol	NN	O
became	VBD	O
necessary	JJ	O
)	)	O
others	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
non-randomized	JJ	O
pilot	NN	O
study	NN	O
.	.	O

Enclosed	VBN	O
were	VBD	O
eyes	NNS	O
with	IN	O
visual	JJ	O
acuity	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
0.1	CD	O
and	CC	O
<	NNP	O
or	CC	O
=	$	O
0.6	CD	O
revealing	VBG	O
a	DT	O
juxta-subfoveal	JJ	O
CNV	NNP	O
either	NN	O
of	IN	O
the	DT	O
occult	NN	O
type	NN	O
(	(	O
type	JJ	O
1	CD	O
)	)	O
or	CC	O
the	DT	O
classic	JJ	O
type	NN	O
(	(	O
isolated	JJ	O
or	CC	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
predominantly	RB	O
occult	JJ	O
lesion	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Eyes	NNP	O
treated	VBD	O
with	IN	O
10	CD	O
Gy	NNP	O
for	IN	O
occult	NN	O
CNV	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
were	VBD	O
subject	JJ	O
to	TO	O
severe	JJ	PH
visual	JJ	PH
loss	NN	PH
in	IN	O
41.6	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
compared	VBN	O
to	TO	O
38.5	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
at	IN	O
12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

For	IN	O
eyes	NNS	O
treated	VBN	O
with	IN	O
10	CD	O
Gy	NNP	O
because	IN	O
of	IN	O
classic	JJ	O
CNV	NNP	O
,	,	O
the	DT	O
corresponding	JJ	O
figures	NNS	O
were	VBD	O
33	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
and	CC	O
57	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
respectively	RB	O
.	.	O

At	IN	O
18	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
the	DT	O
percentages	NNS	O
were	VBD	O
63	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
respectively	RB	O
.	.	O

Fluorescein	NNP	PH
angiographic	JJ	PH
growth	NN	PH
of	IN	PH
classic	JJ	PH
and	CC	PH
occult	NN	PH
CNV	NNP	PH
could	MD	O
not	RB	O
be	VB	O
halted	VBN	O
by	IN	O
10	CD	O
Gy	NNP	O
,	,	O
while	IN	O
a	DT	O
temporary	JJ	PH
growth	NN	PH
retardation	NN	PH
was	VBD	O
observed	VBN	O
in	IN	O
cases	NNS	O
irradiated	VBN	O
with	IN	O
36	CD	O
Gy	NNP	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
the	DT	O
study	NN	O
presented	VBD	O
,	,	O
the	DT	O
natural	JJ	O
course	NN	O
of	IN	O
occult	NN	O
CNV	NNP	O
could	MD	O
not	RB	O
be	VB	O
improved	VBN	O
by	IN	O
irradiation	NN	O
with	IN	O
10	CD	O
or	CC	O
36	CD	O
Gy	NNP	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
classic	JJ	O
CNV	NNP	O
,	,	O
low-dose	JJ	O
irradiation	NN	O
with	IN	O
10	CD	O
Gy	NNP	O
postponed	VBD	O
severe	JJ	PH
visual	JJ	PH
loss	NN	PH
by	IN	O
a	DT	O
maximum	NN	O
of	IN	O
18	CD	O
months	NNS	O
.	.	O

A	DT	O
positive	JJ	O
treatment	NN	O
effect	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
cases	NNS	O
irradiated	VBN	O
with	IN	O
36	CD	O
Gy	NNP	O
;	:	O
however	RB	O
,	,	O
a	DT	O
25	CD	O
%	NN	O
incidence	NN	O
of	IN	O
radiation	NN	O
retinopathy	NN	O
seems	VBZ	O
unacceptable	JJ	O
.	.	O

Preschoolers	NNS	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	O
in	IN	O
pretense	NN	O
.	.	O

Children	NNP	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
about	IN	O
many	JJ	O
kinds	NNS	O
of	IN	O
things	NNS	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
known	VBN	O
means	NNS	O
by	IN	O
which	WDT	O
this	DT	O
knowledge	NN	O
is	VBZ	O
acquired	VBN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
children	NNS	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	O
in	IN	O
pretend	JJ	O
play	NN	O
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
twenty-two	JJ	O
3-	JJ	O
to	TO	O
4-year-olds	NNS	O
watched	VBN	O
pretense	NN	O
in	IN	O
which	WDT	O
a	DT	O
puppet	NN	O
represented	VBD	O
a	DT	O
nerp	NN	O
(	(	O
an	DT	O
unfamiliar	JJ	O
kind	NN	O
of	IN	O
animal	NN	O
)	)	O
.	.	O

For	IN	O
instance	NN	O
,	,	O
in	IN	O
one	CD	O
scenario	NN	O
,	,	O
the	DT	O
nerp	JJ	O
ate	NN	O
and	CC	O
disliked	VBD	O
a	DT	O
carrot	NN	O
.	.	O

When	WRB	O
subsequently	RB	O
asked	VBD	O
generic	JJ	O
questions	NNS	O
about	IN	O
real	JJ	O
nerps	NNS	O
,	,	O
children	NNS	O
's	POS	O
responses	NNS	ME
suggested	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
learned	VBN	ME
general	JJ	ME
facts	NNS	ME
(	(	O
e.g.	NN	O
,	,	O
nerps	RB	O
dislike	JJ	O
carrots	NNS	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
thirty-two	JJ	O
4-	JJ	O
to	TO	O
5-year-olds	NNS	O
learned	VBN	O
from	IN	O
scenarios	NNS	ME
lacking	VBG	ME
pretend	JJ	ME
speech	NN	ME
or	CC	ME
sound	JJ	ME
effects	NNS	ME
.	.	ME

The	DT	O
findings	NNS	O
reveal	VBP	O
a	DT	O
long	JJ	O
overlooked	JJ	O
means	NNS	O
by	IN	O
which	WDT	O
children	NNS	O
can	MD	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
.	.	O

Stress	NNP	O
reduction	NN	O
prolongs	NNS	O
life	NN	O
in	IN	O
women	NNS	O
with	IN	O
coronary	JJ	O
disease	NN	O
:	:	O
the	DT	O
Stockholm	NNP	O
Women	NNP	O
's	POS	O
Intervention	NNP	O
Trial	NNP	O
for	IN	O
Coronary	NNP	O
Heart	NNP	O
Disease	NNP	O
(	(	O
SWITCHD	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Psychosocial	NNP	O
stress	NN	O
may	MD	O
increase	VB	O
risk	NN	O
and	CC	O
worsen	JJ	O
prognosis	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
in	IN	O
women	NNS	O
.	.	O

Interventions	NNS	O
that	IN	O
counteract	JJ	O
women	NNS	O
's	POS	O
psychosocial	JJ	O
stress	NN	O
have	VBP	O
not	RB	O
previously	RB	O
been	VBN	O
presented	VBN	O
.	.	O

This	DT	O
study	NN	O
implemented	VBD	O
a	DT	O
stress	JJ	O
reduction	NN	O
program	NN	O
for	IN	O
women	NNS	O
and	CC	O
investigated	VBD	O
its	PRP$	O
ability	NN	O
to	TO	O
improve	VB	O
survival	NN	MO
in	IN	MO
women	NNS	MO
coronary	JJ	MO
patients	NNS	MO
.	.	MO

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Two	CD	O
hundred	VBD	O
thirty-seven	JJ	O
consecutive	JJ	O
women	NNS	O
patients	NNS	O
,	,	O
aged	VBD	O
75	CD	O
years	NNS	O
or	CC	O
younger	JJR	O
,	,	O
hospitalized	VBN	O
for	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
,	,	O
or	CC	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
group-based	JJ	O
psychosocial	JJ	O
intervention	NN	O
program	NN	O
or	CC	O
usual	JJ	O
care	NN	O
.	.	O

Initiated	VBN	O
4	CD	O
months	NNS	O
after	IN	O
hospitalization	NN	O
,	,	O
intervention	NN	O
groups	NNS	O
of	IN	O
4	CD	O
to	TO	O
8	CD	O
women	NNS	O
met	VBD	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
20	CD	O
sessions	NNS	O
that	WDT	O
were	VBD	O
spread	VBN	O
over	IN	O
a	DT	O
year	NN	O
.	.	O

We	PRP	O
provided	VBD	O
education	NN	O
about	IN	O
risk	NN	O
factors	NNS	O
,	,	O
relaxation	NN	O
training	NN	O
techniques	NNS	O
,	,	O
methods	NNS	O
for	IN	O
self-monitoring	NN	O
and	CC	O
cognitive	JJ	O
restructuring	NN	O
,	,	O
with	IN	O
an	DT	O
emphasis	NN	O
on	IN	O
coping	VBG	O
with	IN	O
stress	JJ	O
exposure	NN	O
from	IN	O
family	NN	O
and	CC	O
work	NN	O
,	,	O
and	CC	O
self-care	NN	O
and	CC	O
compliance	NN	O
with	IN	O
clinical	JJ	O
advice	NN	O
.	.	O

From	IN	O
randomization	NN	O
until	IN	O
end	NN	O
of	IN	O
follow-up	NN	O
(	(	O
mean	JJ	O
duration	NN	O
,	,	O
7.1	CD	O
years	NNS	O
)	)	O
,	,	O
25	CD	O
women	NNS	O
(	(	O
20	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
usual	JJ	O
care	NN	O
and	CC	O
8	CD	O
women	NNS	O
(	(	O
7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
stress	NN	PH
reduction	NN	PH
died	VBD	O
,	,	O
yielding	VBG	O
an	DT	O
almost	RB	O
3-fold	JJ	O
protective	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.15	CD	O
to	TO	O
0.74	CD	O
;	:	O
P=0.007	NNP	O
)	)	O
.	.	O

Introducing	VBG	O
baseline	JJ	O
measures	NNS	O
of	IN	O
clinical	JJ	O
prognostic	JJ	O
factors	NNS	O
,	,	O
including	VBG	O
use	NN	PH
of	IN	PH
aspirin	NN	PH
,	,	PH
beta-blockers	NNS	PH
,	,	PH
angiotensin-converting	JJ	PH
enzyme	NN	PH
inhibitors	NNS	PH
,	,	PH
calcium-channel	JJ	PH
blockers	NNS	PH
,	,	PH
and	CC	PH
statins	VBZ	PH
into	IN	O
multivariate	NN	O
models	NNS	O
confirmed	VBD	O
the	DT	O
unadjusted	JJ	O
results	NNS	O
(	(	O
P=0.009	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
mechanisms	NN	O
remain	VBP	O
unclear	JJ	O
,	,	O
a	DT	O
group-based	JJ	O
psychosocial	JJ	O
intervention	NN	O
program	NN	O
for	IN	O
women	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
may	MD	O
prolong	VB	O
lives	NNS	O
independent	JJ	O
of	IN	O
other	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Opioid-immune	JJ	O
interactions	NNS	O
in	IN	O
autism	NN	O
:	:	O
behavioural	JJ	O
and	CC	O
immunological	JJ	O
assessment	NN	O
during	IN	O
a	DT	O
double-blind	JJ	O
treatment	NN	O
with	IN	O
naltrexone	NN	O
.	.	O

The	DT	O
emerging	VBG	O
concept	NN	O
of	IN	O
opioid	JJ	O
peptides	NNS	O
as	IN	O
a	DT	O
new	JJ	O
class	NN	O
of	IN	O
chemical	JJ	O
messengers	NNS	O
of	IN	O
the	DT	O
neuroimmune	JJ	O
axis	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
immunological	JJ	O
abnormalities	NNS	O
in	IN	O
infantile	JJ	O
autism	NN	O
prompted	VBD	O
us	PRP	O
to	TO	O
correlate	VB	O
biological	JJ	O
(	(	O
hormonal	JJ	O
and	CC	O
immunological	JJ	O
)	)	O
determinations	NNS	O
and	CC	O
behavioural	JJ	O
performances	NNS	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
potent	NN	O
opiate	JJ	O
antagonist	NN	O
,	,	O
naltrexone	NN	O
(	(	O
NAL	NNP	O
)	)	O
.	.	O

Twelve	NNP	O
autistic	JJ	O
patients	NNS	O
ranging	VBG	O
from	IN	O
7	CD	O
to	TO	O
15	CD	O
years	NNS	O
,	,	O
diagnosed	VBD	O
according	VBG	O
to	TO	O
DSM-III-R	NNP	O
,	,	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
with	IN	O
NAL	NNP	O
at	IN	O
the	DT	O
doses	NNS	O
of	IN	O
0.5	CD	O
,	,	O
1.0	CD	O
and	CC	O
1.5	CD	O
mg/kg	NN	O
every	DT	O
48	CD	O
hours	NNS	O
.	.	O

The	DT	O
behavioural	JJ	O
evaluation	NN	O
was	VBD	O
conducted	VBN	O
using	VBG	O
the	DT	O
specific	JJ	O
BSE	NNP	ME
and	CC	ME
CARS	NNP	ME
rating	NN	ME
scales	NNS	ME
NAL	NNP	O
treatment	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
autistic	JJ	ME
symptomatology	NN	ME
in	IN	O
seven	CD	O
(	(	O
responders	NNS	O
)	)	O
out	IN	O
of	IN	O
12	CD	O
children	NNS	O
.	.	O

The	DT	O
behavioural	JJ	O
improvement	NN	O
was	VBD	O
accompanied	VBN	O
by	IN	O
alterations	NNS	O
in	IN	O
the	DT	O
distribution	NN	O
of	IN	O
the	DT	O
major	JJ	O
lymphocyte	NN	O
subsets	NNS	O
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
the	DT	O
T-helper-inducers	NNP	PH
(	(	PH
CD4+CD8-	NNP	PH
)	)	PH
and	CC	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
T-cytotoxic-suppressor	NNP	PH
(	(	PH
CD4-CD8+	NNP	PH
)	)	PH
resulting	VBG	O
in	IN	O
a	DT	O
normalization	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	PH
ratio	NN	PH
.	.	PH

Changes	NNS	O
in	IN	O
natural	JJ	PH
killer	NN	PH
cells	NNS	PH
and	CC	PH
activity	NN	PH
were	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
plasma	VB	O
beta-endorphin	JJ	O
levels	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
mechanisms	NNS	O
underlying	VBG	O
opioid-immune	JJ	O
interactions	NNS	O
are	VBP	O
altered	VBN	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
autistic	JJ	O
children	NNS	O
and	CC	O
that	DT	O
an	DT	O
immunological	JJ	O
screening	NN	O
may	MD	O
have	VB	O
prognostic	JJ	O
value	NN	O
for	IN	O
the	DT	O
pharmacological	JJ	O
therapy	NN	O
with	IN	O
opiate	JJ	O
antagonists	NNS	O
.	.	O

Superior	JJ	O
survival	NN	MO
with	IN	O
capecitabine	JJ	O
plus	CC	O
docetaxel	JJ	O
combination	NN	O
therapy	NN	O
in	IN	O
anthracycline-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
phase	NN	O
III	NNP	O
trial	NN	O
results	NNS	O
.	.	O

PURPOSE	NNP	O
Docetaxel	NNP	O
and	CC	O
capecitabine	NN	O
,	,	O
a	DT	O
tumor-activated	JJ	O
oral	JJ	O
fluoropyrimidine	NN	O
,	,	O
show	VBP	O
high	JJ	O
single-agent	JJ	O
efficacy	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
and	CC	O
synergy	NN	O
in	IN	O
preclinical	JJ	O
studies	NNS	O
.	.	O

This	DT	O
international	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
compared	VBN	O
efficacy	NN	Ot
and	CC	Ot
tolerability	NN	Ot
of	IN	O
capecitabine/docetaxel	JJ	O
therapy	NN	O
with	IN	O
single-agent	JJ	O
docetaxel	NN	O
in	IN	O
anthracycline-pretreated	JJ	O
patients	NNS	O
with	IN	O
MBC	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
21-day	JJ	O
cycles	NNS	O
of	IN	O
oral	JJ	O
capecitabine	NN	O
1,250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
on	IN	O
days	NNS	O
1	CD	O
to	TO	O
14	CD	O
plus	CC	O
docetaxel	JJ	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
255	CD	O
)	)	O
or	CC	O
to	TO	O
docetaxel	VB	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
256	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Capecitabine/docetaxel	NNP	O
resulted	VBD	O
in	IN	O
significantly	RB	O
superior	JJ	O
efficacy	NN	Ot
in	IN	O
time	NN	PH
to	TO	PH
disease	VB	PH
progression	NN	PH
(	(	PH
TTP	NNP	PH
)	)	PH
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.652	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.545	CD	O
to	TO	O
0.780	CD	O
;	:	O
P	NNP	O
=.0001	NNP	O
;	:	O
median	JJ	O
,	,	O
6.1	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
)	)	O
,	,	O
overall	JJ	MO
survival	NN	MO
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.775	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.634	CD	O
to	TO	O
0.947	CD	O
;	:	O
P	NNP	O
=.0126	NNP	O
;	:	O
median	JJ	O
,	,	O
14.5	CD	O
v	NN	O
11.5	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
objective	JJ	PH
tumor	NN	PH
response	NN	PH
rate	NN	PH
(	(	O
42	CD	O
%	NN	O
v	JJ	O
30	CD	O
%	NN	O
,	,	O
P	NNP	O
=.006	NNP	O
)	)	O
compared	VBN	O
with	IN	O
docetaxel	NN	O
.	.	O

Gastrointestinal	JJ	A
side	NN	A
effects	NNS	A
and	CC	A
hand-foot	JJ	A
syndrome	NN	A
were	VBD	O
more	JJR	O
common	JJ	O
with	IN	O
combination	NN	O
therapy	NN	O
,	,	O
whereas	JJ	O
myalgia	NN	A
,	,	A
arthralgia	NN	A
,	,	O
and	CC	O
neutropenic	JJ	A
fever/sepsis	NN	A
were	VBD	O
more	JJR	O
common	JJ	O
with	IN	O
single-agent	JJ	O
docetaxel	NN	O
.	.	O

More	JJR	O
grade	JJ	A
3	CD	A
adverse	JJ	A
events	NNS	A
occurred	VBD	O
with	IN	O
combination	NN	O
therapy	NN	O
(	(	O
71	CD	O
%	NN	O
v	JJ	O
49	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
whereas	JJ	O
grade	VBP	A
4	CD	A
events	NNS	A
were	VBD	O
slightly	RB	O
more	RBR	O
common	JJ	O
with	IN	O
docetaxel	NN	O
(	(	O
31	CD	O
%	NN	O
v	JJ	O
25	CD	O
%	NN	O
with	IN	O
combination	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
significantly	RB	O
superior	JJ	O
TTP	NNP	MO
and	CC	MO
survival	NN	MO
achieved	VBN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
capecitabine	NN	O
to	TO	O
docetaxel	VB	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
manageable	JJ	O
toxicity	NN	PH
profile	NN	PH
,	,	O
indicate	VBP	O
that	IN	O
this	DT	O
combination	NN	O
provides	VBZ	O
clear	JJ	O
benefits	NNS	O
over	IN	O
single-agent	JJ	O
docetaxel	NN	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Docetaxel/capecitabine	NNP	O
therapy	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
women	NNS	O
with	IN	O
anthracycline-pretreated	JJ	O
MBC	NNP	O
.	.	O

Fake	NNP	O
bad	JJ	O
test	NN	O
response	NN	O
bias	NN	O
effects	NNS	O
on	IN	O
the	DT	O
test	NN	ME
of	IN	ME
variables	NNS	ME
of	IN	ME
attention	NN	ME
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
faking	VBG	O
bad	JJ	O
(	(	O
FB	NNP	O
)	)	O
on	IN	O
the	DT	O
Test	NNP	O
of	IN	O
Variables	NNP	O
of	IN	O
Attention	NNP	O
(	(	O
TOVA	NNP	O
)	)	O
using	VBG	O
subjects	NNS	O
randomly	RB	O
placed	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
took	VBD	O
the	DT	O
TOVA	NNP	O
under	IN	O
normal	JJ	O
conditions	NNS	O
(	(	O
NC	NNP	O
)	)	O
first	RB	O
;	:	O
they	PRP	O
were	VBD	O
then	RB	O
requested	VBN	O
to	TO	O
subtly	RB	O
fake	VB	O
bad	JJ	O
.	.	O

Group	NNP	O
2	CD	O
subjects	NNS	O
took	VBD	O
the	DT	O
TOVA	NNP	O
under	IN	O
the	DT	O
same	JJ	O
fake	JJ	O
bad	JJ	O
instructions	NNS	O
first	RB	O
,	,	O
then	RB	O
took	VBD	O
the	DT	O
test	NN	O
under	IN	O
normal	JJ	O
conditions	NNS	O
the	DT	O
second	JJ	O
time	NN	O
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
test	NN	O
order	NN	O
yielded	VBN	O
non-significant	JJ	O
differences	NNS	O
for	IN	O
basic	JJ	O
TOVA	NNP	ME
variables	NNS	ME
across	IN	O
all	DT	O
four	CD	O
quarters	NNS	O
,	,	O
both	DT	O
halves	NNS	O
and	CC	O
the	DT	O
total	JJ	O
score	NN	O
.	.	O

An	DT	O
analysis	NN	O
for	IN	O
group	NN	O
mean	NN	O
differences	NNS	O
between	IN	O
the	DT	O
NC	NNP	O
and	CC	O
the	DT	O
FB	NNP	O
instructions	NNS	O
yielded	VBD	O
significant	JJ	O
differences	NNS	O
across	IN	O
the	DT	O
basic	JJ	ME
TOVA	NNP	ME
variables	NNS	ME
across	IN	O
the	DT	O
four	CD	O
quarters	NNS	O
,	,	O
two	CD	O
halves	NNS	O
and	CC	O
total	JJ	O
score	NN	O
.	.	O

The	DT	O
FB	NNP	O
group	NN	O
had	VBD	O
excessive	JJ	O
amounts	NNS	ME
of	IN	ME
omission	NN	ME
and	CC	ME
commission	NN	ME
errors	NNS	ME
,	,	O
a	DT	O
greater	JJR	O
response	NN	ME
time	NN	ME
mean	NN	ME
(	(	O
i.e.	FW	O
,	,	O
slower	JJR	O
to	TO	O
respond	VB	O
)	)	O
and	CC	O
had	VBD	O
greater	JJR	O
variance	NN	ME
around	IN	ME
their	PRP$	ME
mean	JJ	ME
response	NN	ME
time	NN	ME
.	.	O

The	DT	O
study	NN	O
affirms	VBZ	O
that	IN	O
the	DT	O
professional	JJ	O
using	VBG	O
the	DT	O
TOVA	NNP	O
needs	VBZ	O
to	TO	O
carefully	RB	O
eliminate	VB	O
a	DT	O
fake	JJ	O
bad	JJ	O
test-taking	NN	O
bias	NN	O
when	WRB	O
subjects	NNS	O
produce	VBP	O
excessive	JJ	O
test	NN	O
results	NNS	O
.	.	O

Changes	NNS	O
of	IN	O
activated	JJ	O
circulating	VBG	O
endothelial	JJ	O
cells	NNS	O
and	CC	O
survivin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
after	IN	O
antiangiogenesis	NN	O
therapy	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
antiangiogenesis	NN	O
therapy	NN	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
anti-neoplastic	JJ	O
treatment	NN	O
with	IN	O
its	PRP$	O
recognized	VBN	O
efficacy	NN	O
and	CC	O
slight	JJ	O
adverse	JJ	O
effect	NN	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
define	VB	O
ideal	JJ	O
markers	NNS	O
for	IN	O
predicting	VBG	O
efficacy	NN	O
of	IN	O
antiangiogenic	JJ	O
therapy	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
changes	NNS	O
of	IN	O
activated	JJ	O
circulating	VBG	O
endothelial	JJ	O
cells	NNS	O
(	(	O
aCECs	NN	O
)	)	O
and	CC	O
survivin	JJ	O
after	IN	O
anti-angiogenesis	JJ	O
therapy	NN	O
and	CC	O
their	PRP$	O
significance	NN	O
in	IN	O
predicting	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
therapy	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
of	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
treated	VBD	O
with	IN	O
chemotherapy	NN	O
with	IN	O
or	CC	O
without	IN	O
Endostar	NNP	O
were	VBD	O
observed	VBN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
activated	JJ	O
CECs	NNP	O
was	VBD	O
detected	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
,	,	O
and	CC	O
the	DT	O
expression	NN	O
of	IN	O
survivin	NN	O
mRNA	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
real-time	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
activated	JJ	PH
CECs	NNP	PH
decreased	VBD	O
significantly	RB	O
in	IN	O
clinical	JJ	O
benefit	NN	O
cases	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0.021	CD	O
in	IN	O
chemotherapy	NN	O
alone	RB	O
,	,	O
P	NNP	O
=	VBZ	O
0.001	CD	O
in	IN	O
chemotherapy	NN	O
plus	CC	O
Endostar	NNP	O
)	)	O
,	,	O
increased	VBN	O
in	IN	O
disease	NN	PH
progressive	JJ	PH
cases	NNS	PH
(	(	O
P	NNP	O
=	VBZ	O
0.015	CD	O
in	IN	O
chemotherapy	NN	O
alone	RB	O
,	,	O
but	CC	O
P	NNP	O
=	NNP	O
0.293	CD	O
in	IN	O
chemotherapy	NN	O
with	IN	O
Endotatar	NNP	O
)	)	O
.	.	O

After	IN	O
therapy	NN	O
,	,	O
the	DT	O
expression	NN	PH
of	IN	PH
survivin	JJ	PH
mRNA	NN	PH
decreased	VBN	O
in	IN	O
clinical	JJ	O
benefit	NN	O
cases	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
and	CC	O
increased	VBN	O
in	IN	O
disease	NN	PH
progressive	JJ	PH
cases	NNS	PH
(	(	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
activated	VBN	PH
CECs	NNP	PH
and	CC	O
survivin	NN	O
in	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
pre-	JJ	O
and	CC	O
post-therapy	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
and	CC	O
0.021	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
only	RB	O
in	IN	O
the	DT	O
chemotherapy	NN	O
with	IN	O
Endostar	NNP	O
group	NN	O
pre-therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.030	CD	O
)	)	O
rather	RB	O
than	IN	O
post-therapy	NN	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
decreased	VBN	O
activated	VBN	PH
CECs	NNP	PH
after	IN	O
therapy	NN	O
and	CC	O
time	NN	PH
to	TO	PH
progression	NN	PH
(	(	PH
TTP	NNP	PH
)	)	PH
(	(	O
r	JJ	O
=	NN	O
0.322	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.012	CD	O
)	)	O
;	:	O
a	DT	O
negative	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
amount	NN	PH
of	IN	PH
survivin	NN	PH
mRNA	NN	PH
in	IN	PH
serum	JJ	PH
post-therapy	NN	PH
and	CC	PH
TTP	NNP	PH
(	(	O
r	NN	O
=	NNP	O
-0.291	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.048	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Activated	NNP	O
CECs	NNP	O
and	CC	O
survivin	NN	O
may	MD	O
be	VB	O
ideal	JJ	O
markers	NNS	O
forecasting	VBG	O
efficacy	NN	O
and	CC	O
prognosis	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

The	DT	O
former	JJ	O
can	MD	O
reflect	VB	O
more	RBR	O
sensitively	RB	O
antiangiogenic	JJ	O
efficacy	NN	O
and	CC	O
the	DT	O
latter	NN	O
is	VBZ	O
more	RBR	O
sensitive	JJ	O
to	TO	O
shrinkage	VB	O
or	CC	O
swelling	VBG	O
of	IN	O
tumors	NNS	O
.	.	O

Their	PRP$	O
combination	NN	O
can	MD	O
evaluate	VB	O
more	RBR	O
accurately	RB	O
the	DT	O
efficacy	NN	O
of	IN	O
antiangiogenic	JJ	O
therapy	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

Dexamethasone	NN	O
in	IN	O
salbutamol-treated	JJ	O
inpatients	NNS	O
with	IN	O
acute	JJ	O
bronchiolitis	NN	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
clinical	JJ	Ot
benefit	NN	Ot
of	IN	O
oral	JJ	O
dexamethasone	NN	O
in	IN	O
children	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
hospital	NN	O
with	IN	O
bronchiolitis	NN	O
treated	VBN	O
with	IN	O
nebulized	JJ	O
salbutamol	NN	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
the	DT	O
inpatient	JJ	O
wards	NNS	O
of	IN	O
a	DT	O
pediatric	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

The	DT	O
participants	NNS	O
,	,	O
children	NNS	O
aged	VBD	O
6	CD	O
weeks	NNS	O
to	TO	O
15	CD	O
months	NNS	O
,	,	O
admitted	VBN	O
with	IN	O
first-time	JJ	O
wheezing	NN	O
,	,	O
were	VBD	O
eligible	JJ	O
if	IN	O
their	PRP$	O
oxygen	NN	O
saturation	NN	O
was	VBD	O
less	JJR	O
than	IN	O
95	CD	O
%	NN	O
on	IN	O
admission	NN	O
to	TO	O
the	DT	O
hospital	NN	O
and	CC	O
their	PRP$	O
Respiratory	NNP	PH
Distress	NNP	PH
Assessment	NNP	PH
Instrument	NNP	PH
(	(	PH
RDAI	NNP	PH
)	)	PH
score	NN	PH
was	VBD	O
greater	JJR	O
than	IN	O
6	CD	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
an	DT	O
underlying	JJ	O
disease	NN	O
that	WDT	O
might	MD	O
affect	VB	O
cardiopulmonary	JJ	O
status	NN	O
,	,	O
asthma	NN	O
,	,	O
recent	JJ	O
treatment	NN	O
with	IN	O
steroids	NNS	O
(	(	O
within	IN	O
2	CD	O
weeks	NNS	O
)	)	O
,	,	O
or	CC	O
any	DT	O
history	NN	O
of	IN	O
adverse	JJ	O
reaction	NN	O
to	TO	O
steroids	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
orally	RB	O
administered	VBN	O
dexamethasone	NN	O
with	IN	O
0.5	CD	O
mg/kg	NNS	O
as	IN	O
the	DT	O
first	JJ	O
dose	NN	O
and	CC	O
0.3	CD	O
mg/kg	NN	O
for	IN	O
the	DT	O
next	JJ	O
2	CD	O
mornings	NNS	O
,	,	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
an	DT	O
orally	RB	O
administered	VBN	O
placebo	NN	O
with	IN	O
an	DT	O
identical	JJ	O
appearance	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
nebulized	JJ	O
salbutamol	NN	O
at	IN	O
0.15	CD	O
mg/kg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
RDAI	NNP	PH
score	NN	PH
at	IN	O
24	CD	O
hours	NNS	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
oxygen	JJ	PH
saturation	NN	PH
,	,	O
respiratory	NN	PH
rate	NN	PH
,	,	O
RDAI	NNP	PH
measurement	NN	PH
twice	RB	PH
daily	RB	PH
for	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
length	NN	Ot
of	IN	Ot
hospitalization	NN	Ot
.	.	O

RESULTS	NNP	O
At	IN	O
24	CD	O
hours	NNS	O
the	DT	O
mean	JJ	Ot
change	NN	Ot
(	(	Ot
SD	NNP	Ot
)	)	Ot
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
RDAI	NNP	PH
score	NN	PH
was	VBD	O
1.6	CD	O
(	(	O
2.3	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
and	CC	O
1.4	CD	O
(	(	O
2.0	CD	O
)	)	O
in	IN	O
the	DT	O
dexamethasone	NN	O
group	NN	O
(	(	O
n	JJ	O
=	VBZ	O
33	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.74	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
change	NN	O
in	IN	O
oxygen	NN	PH
saturation	NN	PH
,	,	O
respiratory	NN	PH
rate	NN	PH
,	,	O
and	CC	O
RDAI	NNP	PH
score	NN	PH
at	IN	O
any	DT	O
assessment	JJ	O
period	NN	O
.	.	O

The	DT	O
median	JJ	Ot
length	NN	Ot
of	IN	Ot
stay	NN	Ot
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
was	VBD	O
48	CD	O
(	(	O
42	CD	O
,	,	O
54	CD	O
)	)	O
hours	NNS	O
compared	VBN	O
with	IN	O
57	CD	O
(	(	O
38	CD	O
,	,	O
76	CD	O
)	)	O
hours	NNS	O
in	IN	O
the	DT	O
dexamethasone	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.19	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
dexamethasone	NN	O
therapy	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
children	NNS	O
hospitalized	VBN	O
with	IN	O
bronchiolitis	NN	O
and	CC	O
therefore	RB	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
in	IN	O
this	DT	O
clinical	JJ	O
situation	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomised	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
dynamic	JJ	O
hip	NN	O
screw	NN	O
and	CC	O
the	DT	O
gamma	NN	O
locking	VBG	O
nail	NN	O
.	.	O

We	PRP	O
made	VBD	O
a	DT	O
randomised	JJ	O
prospective	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
Dynamic	NNP	O
Hip	NNP	O
Screw	NNP	O
and	CC	O
the	DT	O
Gamma	NNP	O
locking	VBG	O
nail	NN	O
for	IN	O
the	DT	O
internal	JJ	O
fixation	NN	O
of	IN	O
200	CD	O
petrochanteric	JJ	O
femoral	JJ	O
fractures	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
less	RBR	O
intraoperative	JJ	PH
blood	NN	PH
loss	NN	PH
and	CC	PH
a	DT	PH
lower	JJR	PH
rate	NN	PH
of	IN	PH
wound	NN	PH
complications	NNS	PH
in	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
by	IN	O
the	DT	O
Gamma	NNP	O
nail	NN	O
.	.	O

They	PRP	O
had	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
femoral	JJ	PH
shaft	NN	PH
fracture	NN	PH
which	WDT	O
we	PRP	O
relate	VBP	O
in	IN	O
part	NN	O
to	TO	O
implant	VB	O
design	NN	O
.	.	O

We	PRP	O
do	VBP	O
not	RB	O
recommend	VB	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Gamma	NNP	O
nail	NN	O
for	IN	O
these	DT	O
fractures	NNS	O
.	.	O

Management	NN	O
of	IN	O
unstable	JJ	O
angina	NN	O
at	IN	O
rest	NN	O
by	IN	O
verapamil	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
coronary	JJ	O
care	NN	O
unit	NN	O
.	.	O

A	NNP	O
therapeutic	JJ	O
trial	NN	O
with	IN	O
verapamil	NN	O
,	,	O
a	DT	O
calcium-antagonist	JJ	O
drug	NN	O
,	,	O
was	VBD	O
performed	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
admitted	VBN	O
to	TO	O
our	PRP$	O
coronary	JJ	O
care	NN	O
unit	NN	O
because	IN	O
of	IN	O
frequent	JJ	O
daily	JJ	O
attacks	NNS	O
of	IN	O
angina	NN	O
at	IN	O
rest	NN	O
attributed	VBN	O
to	TO	O
coronary	JJ	O
vasospasm	NN	O
.	.	O

After	IN	O
a	DT	O
48-hour	JJ	O
run-in	JJ	O
period	NN	O
,	,	O
oral	JJ	O
verapamil	NN	O
480	CD	O
mg/day	NN	O
and	CC	O
placebo	NN	O
were	VBD	O
administered	VBN	O
alternately	RB	O
during	IN	O
4	CD	O
randomised	VBD	O
48-hour	CD	O
periods	NNS	O
.	.	O

Transient	NNP	PH
ischaemic	JJ	PH
attacks	NNS	PH
with	IN	PH
ST	NNP	PH
segment	NN	PH
elevation	NN	PH
or	CC	PH
depression	NN	PH
,	,	PH
with	IN	PH
or	CC	PH
without	IN	PH
pain	NN	PH
,	,	O
were	VBD	O
documented	VBN	O
by	IN	O
continuous	JJ	Ot
electrocardiographic	JJ	Ot
monitoring	NN	Ot
.	.	O

The	DT	O
number	NN	PH
of	IN	PH
attacks	NNS	PH
during	IN	O
the	DT	O
run-in	JJ	O
and	CC	O
2	CD	O
placebo	NN	O
periods	NNS	O
were	VBD	O
128	CD	O
,	,	O
123	CD	O
,	,	O
and	CC	O
130	CD	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
31	CD	O
and	CC	O
23	CD	O
during	IN	O
the	DT	O
2	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.006	CD	O
and	CC	O
P	NNP	O
less	JJR	O
than	IN	O
0.003	CD	O
)	)	O
.	.	O

This	DT	O
drug	NN	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
frequent	JJ	O
attacks	NNS	PH
of	IN	PH
angina	NN	PH
at	IN	PH
rest	NN	PH
.	.	O

Rizatriptan	NNP	O
5	CD	O
mg	NN	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	PH
in	IN	O
adolescents	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
tolerability	NN	Ot
and	CC	Ot
efficacy	NN	Ot
of	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
in	IN	O
adolescent	JJ	O
migraineurs	NNS	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
12	CD	O
to	TO	O
17	CD	O
years	NNS	O
received	VBD	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
149	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
for	IN	O
a	DT	O
moderate	JJ	O
or	CC	O
severe	JJ	O
headache	NN	O
and	CC	O
for	IN	O
up	RB	O
to	TO	O
two	CD	O
recurrences	NNS	O
.	.	O

Headache	NNP	PH
severity	NN	PH
,	,	O
presence	NN	PH
or	CC	PH
absence	NN	PH
of	IN	PH
associated	VBN	PH
symptoms	NNS	PH
,	,	O
and	CC	O
functional	JJ	PH
disability	NN	PH
were	VBD	O
assessed	VBN	O
over	IN	O
a	DT	O
4-hour	JJ	O
postdose	JJ	O
period	NN	O
,	,	O
and	CC	O
any	DT	O
adverse	JJ	A
events	NNS	A
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
measure	NN	O
was	VBD	O
pain-free	JJ	PA
status	NN	PA
at	IN	PA
2	CD	PA
hours	NNS	PA
postdose	RB	PA
.	.	O

RESULTS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
adverse	JJ	A
events	NNS	A
(	(	O
all	DT	O
with	IN	O
incidence	NN	O
of	IN	O
5	CD	O
%	NN	O
or	CC	O
less	JJR	O
)	)	O
among	IN	O
patients	NNS	O
receiving	VBG	O
rizatriptan	NNS	O
were	VBD	O
dry	JJ	A
mouth	NN	A
,	,	A
dizziness	NN	A
,	,	A
asthenia/fatigue	NN	A
,	,	A
nausea	NN	A
,	,	A
and	CC	A
somnolence	NN	A
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
pain-free	JJ	PA
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
32	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
versus	NN	O
28	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.474	NNP	O
)	)	O
.	.	O

The	DT	O
percentage	NN	PA
of	IN	PA
patients	NNS	PA
with	IN	PA
pain	NN	PA
relief	NN	PA
(	(	O
reduction	NN	O
of	IN	O
predose	JJ	PA
pain	NN	PA
intensity	NN	PA
to	TO	O
mild	VB	O
or	CC	O
none	NN	O
)	)	O
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
66	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
versus	NN	O
56	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.079	NNP	O
)	)	O
.	.	O

Placebo	NNP	PH
response	NN	PH
rates	NNS	PH
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
typically	RB	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
of	IN	O
rizatriptan	NN	O
in	IN	O
adults	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
rizatriptan	VBP	O
significantly	RB	O
improved	VBN	O
functional	JJ	PH
disability	NN	PH
at	IN	O
1.5	CD	O
and	CC	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
nausea	NN	A
at	IN	O
1	CD	O
and	CC	O
1.5	CD	O
hours	NNS	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
benefit	NN	O
of	IN	O
rizatriptan	JJ	O
versus	NN	O
placebo	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
pain	NN	PA
relief	NN	PA
when	WRB	O
their	PRP$	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
weekends	NNS	O
(	(	O
65	CD	O
%	NN	O
versus	IN	O
36	CD	O
%	NN	O
,	,	O
P=.046	NNP	O
)	)	O
compared	VBN	O
with	IN	O
weekdays	NNS	O
(	(	O
66	CD	O
%	NN	O
versus	IN	O
61	CD	O
%	NN	O
,	,	O
P=.365	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
weekend	NN	O
placebo	NN	O
response	NN	PH
rate	NN	PH
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
seen	VBN	O
in	IN	O
adults	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Ot
and	CC	Ot
effective	JJ	Ot
on	IN	O
some	DT	O
measures	NNS	O
when	WRB	O
used	VBN	O
in	IN	O
adolescents	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
.	.	O

Cholesterol-lowering	JJ	O
effect	NN	O
of	IN	O
stanol	NN	O
ester	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
of	IN	O
mildly	RB	O
hypercholesterolemic	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
stanol	NN	O
esters	NNS	O
in	IN	O
lowering	VBG	O
cholesterol	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
After	IN	O
a	DT	O
run-in	JJ	O
phase	NN	O
,	,	O
318	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
margarine-like	JJ	O
spreads	NNS	O
containing	VBG	O
stanol	JJ	O
ester	NN	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
:	:	O
EU	NNP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
European	JJ	O
formula	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
2	CD	O
G	NNP	O
:	:	O
0.67	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
or	CC	O
placebo	VB	O
spread	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	PH
+/-	JJ	PH
SD	NNP	PH
baseline	NN	PH
total	NN	PH
cholesterol	NN	PH
(	(	PH
TC	NNP	PH
)	)	PH
and	CC	O
low-density	JJ	PH
lipoprotein	NN	PH
cholesterol	NN	PH
(	(	PH
LDL-C	NNP	PH
)	)	PH
levels	NNS	PH
were	VBD	O
233+/-20	JJ	O
and	CC	O
153+21	CD	O
mg+/-dL	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
US	NNP	O
3	CD	O
G	NNP	O
group	NN	O
,	,	O
3	CD	O
g	JJ	O
daily	NN	O
of	IN	O
stanol	JJ	O
esters	NNS	O
lowered	VBD	O
TC	NNP	PH
and	CC	O
LDL-C	NNP	PH
levels	NNS	PH
by	IN	O
6.4	CD	O
%	NN	O
and	CC	O
10.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
response	NN	O
compared	VBN	O
with	IN	O
2	CD	O
g	NNS	O
daily	RB	O
(	(	O
US	PRP	O
2	CD	O
G	NNP	O
)	)	O
.	.	O

Triglyceride	NNP	PH
and	CC	PH
high-density	NN	PH
lipoprotein	NNS	PH
cholesterol	NN	PH
levels	NNS	PH
were	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	A
effects	NNS	A
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	O
.	.	O

Serum	NNP	PH
vitamin	VBD	PH
A	DT	PH
and	CC	PH
25-hydroxyvitamin	JJ	PH
D	NNP	PH
levels	NNS	PH
were	VBD	O
not	RB	O
affected	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Stanol	NNP	O
esters	NNS	O
lowered	VBD	O
TC	NNP	PH
and	CC	O
LDL-C	NNP	PH
levels	NNS	PH
in	IN	O
a	DT	O
mildly	RB	O
hypercholesterolemic	JJ	O
US	NNP	O
population	NN	O
without	IN	O
evidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
dietary	JJ	O
adjunct	NN	O
to	TO	O
lower	VB	O
cholesterol	NN	O
.	.	O

[	JJ	O
Rapidity	NNP	PA
of	IN	PA
pain	NN	PA
relief	NN	PA
,	,	O
medication	NN	Ot
requirement	NN	Ot
and	CC	O
patient	JJ	Ot
satisfaction	NN	Ot
with	IN	O
reflux	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
physician	NN	O
's	POS	O
office	NN	O
]	NN	O
.	.	O

Treatment	NN	O
of	IN	O
gastroesophageal	NN	PH
reflux	NN	PH
disease	NN	PH
(	(	PH
GERD	NNP	PH
)	)	PH
with	IN	O
proton	NN	O
pump	NN	O
inhibitors	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
three	CD	O
controlled	VBD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
open	JJ	O
studies	NNS	O
.	.	O

Lansoprazole	NNP	O
,	,	O
omeprazole	JJ	O
MUPS	NNP	O
and	CC	O
esomeprazole	NN	O
were	VBD	O
compared	VBN	O
under	IN	O
doctor	NN	O
's	POS	O
office	NN	O
conditions	NNS	O
.	.	O

The	DT	O
outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
the	DT	O
rapidity	NN	PA
of	IN	PA
pain	NN	PA
relief	NN	PA
achieved	VBN	O
with	IN	O
a	DT	O
single	JJ	Ot
dose	NN	Ot
,	,	O
effectiveness	NN	Ot
and	CC	O
patient	JJ	Ot
satisfaction	NN	Ot
with	IN	O
on	IN	O
demand	NN	O
therapy	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
180	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
and	CC	O
prolonged	JJ	O
episodes	NNS	O
of	IN	O
reflux	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

Time	NN	O
to	TO	O
pain	VB	PA
relief	NN	PA
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
was	VBD	O
1.1	CD	O
+/-	JJ	O
0.8	CD	O
hours	NNS	O
with	IN	O
30	CD	O
mg	NNS	O
lansoprazole	JJ	O
,	,	O
3.0	CD	O
+/-	JJ	O
2.5	CD	O
hours	NNS	O
with	IN	O
20	CD	O
mgomeprazole	JJ	O
MUPS	NNP	O
and	CC	O
2.1	CD	O
+/-	JJ	O
1.2	CD	O
hours	NNS	O
with	IN	O
40	CD	O
mg	NNS	O
esomeprazole	JJ	O
.	.	O

Studies	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
designed	VBN	O
as	IN	O
cross-over	NN	O
studies	NNS	O
intended	VBN	O
to	TO	O
investigate	VB	O
drug	NN	PH
consumption	NN	PH
.	.	O

In	IN	O
study	NN	O
2	CD	O
,	,	O
the	DT	O
amount	NN	Ot
of	IN	Ot
lansoprazole	NN	Ot
consumed	VBN	Ot
was	VBD	O
approximately	RB	O
50	CD	O
%	NN	O
less	JJR	O
than	IN	O
that	DT	O
of	IN	O
omeprazole	NN	O
,	,	O
and	CC	O
this	DT	O
translated	VBN	O
to	TO	O
81	CD	O
%	NN	O
patient	JJ	Ot
satisfaction	NN	Ot
with	IN	O
lansoprazole	JJ	O
compared	VBN	O
with	IN	O
only	RB	O
9.5	CD	O
%	NN	O
for	IN	O
omeprazole	NN	O
.	.	O

In	IN	O
study	NN	O
3	CD	O
comparing	VBG	O
lansoprazole	NN	O
and	CC	O
esomeprazole	NN	O
,	,	O
consumption	NN	Ot
of	IN	O
the	DT	O
former	JJ	O
was	VBD	O
85	CD	O
%	NN	O
that	WDT	O
of	IN	O
the	DT	O
latter	NN	O
.	.	O

58	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
opted	VBD	O
to	TO	O
continuetreatment	VB	Ot
with	IN	O
lansoprazole	NN	O
,	,	O
compared	VBN	O
with	IN	O
only	RB	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
esomeprazole	NN	O
.	.	O

The	DT	O
appreciably	RB	O
greater	JJR	O
patient	JJ	Ot
satisfaction	NN	Ot
with	IN	O
lansoprazole	NN	O
was	VBD	O
due	JJ	O
tothe	NN	O
faster	RBR	PA
pain	NN	PA
relief	NN	PA
achieved	VBN	O
with	IN	O
this	DT	O
drug	NN	O
.	.	O

Phase	NNP	O
III	NNP	O
trial	NN	O
comparing	VBG	O
whole-pelvic	JJ	O
versus	NN	O
prostate-only	JJ	O
radiotherapy	NN	O
and	CC	O
neoadjuvant	JJ	O
versus	NN	O
adjuvant	NN	O
combined	VBN	O
androgen	JJ	O
suppression	NN	O
:	:	O
Radiation	NN	O
Therapy	NNP	O
Oncology	NNP	O
Group	NNP	O
9413	CD	O
.	.	O

PURPOSE	VB	O
This	DT	O
trial	NN	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
combined	VBD	O
androgen	DT	O
suppression	NN	O
(	(	O
CAS	NNP	O
)	)	O
and	CC	O
whole-pelvic	JJ	O
(	(	O
WP	NNP	O
)	)	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
boost	NN	O
to	TO	O
the	DT	O
prostate	NN	O
improves	VBZ	O
progression-free	JJ	MO
survival	NN	MO
(	(	MO
PFS	NNP	MO
)	)	MO
by	IN	O
10	CD	O
%	NN	O
compared	VBN	O
with	IN	O
CAS	NNP	O
and	CC	O
prostate-only	RB	O
(	(	O
PO	NNP	O
)	)	O
RT	NNP	O
.	.	O

This	DT	O
trial	NN	O
also	RB	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
neoadjuvant	JJ	O
and	CC	O
concurrent	JJ	O
hormonal	JJ	O
therapy	NN	O
(	(	O
NCHT	NNP	O
)	)	O
improves	VBZ	O
PFS	NNP	O
compared	VBN	O
with	IN	O
adjuvant	JJ	O
hormonal	JJ	O
therapy	NN	O
(	(	O
AHT	NNP	O
)	)	O
by	IN	O
10	CD	O
%	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Eligibility	NNP	O
included	VBD	O
localized	JJ	O
prostate	NN	O
cancer	NN	O
with	IN	O
an	DT	O
elevated	JJ	O
prostate-specific	JJ	O
antigen	NN	O
(	(	O
PSA	NNP	O
)	)	O
<	VBD	O
or	CC	O
=	$	O
100	CD	O
ng/mL	NN	O
and	CC	O
an	DT	O
estimated	VBN	O
risk	NN	O
of	IN	O
lymph	JJ	O
node	NN	O
(	(	O
LN	NNP	O
)	)	O
involvement	NN	O
of	IN	O
15	CD	O
%	NN	O
.	.	O

Between	NNP	O
April	NNP	O
1	CD	O
,	,	O
1995	CD	O
,	,	O
and	CC	O
June	NNP	O
1	CD	O
,	,	O
1999	CD	O
,	,	O
1,323	CD	O
patients	NNS	O
were	VBD	O
accrued	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
WP	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
PO	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
WP	NNP	O
+	NNP	O
AHT	NNP	O
,	,	O
or	CC	O
PO	NNP	O
+	NNP	O
AHT	NNP	O
.	.	O

Failure	NN	MO
for	IN	MO
PFS	NNP	MO
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
first	JJ	O
occurrence	NN	O
of	IN	O
local	JJ	PH
,	,	PH
regional	JJ	PH
,	,	PH
or	CC	PH
distant	JJ	PH
disease	NN	PH
;	:	PH
PSA	NNP	PH
failure	NN	PH
;	:	O
or	CC	O
death	NN	MO
for	IN	O
any	DT	O
cause	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
59.5	CD	O
months	NNS	O
,	,	O
WP	NNP	O
RT	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
4-year	JJ	MO
PFS	NNP	MO
of	IN	O
54	CD	O
%	NN	O
compared	VBN	O
with	IN	O
47	CD	O
%	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
PO	NNP	O
RT	NNP	O
(	(	O
P	NNP	O
=.022	NNP	O
)	)	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
NCHT	NNP	O
experienced	VBD	O
a	DT	O
4-year	JJ	MO
PFS	NNP	MO
of	IN	O
52	CD	O
%	NN	O
versus	IN	O
49	CD	O
%	NN	O
for	IN	O
AHT	NNP	O
(	(	O
P	NNP	O
=.56	NNP	O
)	)	O
.	.	O

When	WRB	O
comparing	VBG	O
all	DT	O
four	CD	O
arms	NNS	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
progression-free	JJ	MO
difference	NN	MO
among	IN	O
WP	NNP	O
RT	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
PO	NNP	O
RT	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
WP	NNP	O
RT	NNP	O
+	NNP	O
AHT	NNP	O
,	,	O
and	CC	O
PO	NNP	O
RT	NNP	O
+	NNP	O
AHT	NNP	O
(	(	O
60	CD	O
%	NN	O
v	JJ	O
44	CD	O
%	NN	O
v	JJ	O
49	CD	O
%	NN	O
v	JJ	O
50	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.008	NNP	O
)	)	O
.	.	O

No	UH	O
survival	JJ	MO
advantage	NN	MO
has	VBZ	O
yet	RB	O
been	VBN	O
seen	VBN	O
.	.	O

CONCLUSION	NNP	O
WP	NNP	O
RT	NNP	O
+	NNP	O
NCHT	NNP	O
improves	VBZ	O
PFS	NNP	MO
compared	VBN	O
with	IN	O
PO	NNP	O
RT	NNP	O
and	CC	O
NCHT	NNP	O
or	CC	O
PO	NNP	O
RT	NNP	O
and	CC	O
AHT	NNP	O
,	,	O
and	CC	O
compared	VBN	O
with	IN	O
WP	NNP	O
RT	NNP	O
+	NNP	O
AHT	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
risk	NN	O
of	IN	O
LN	NNP	O
involvement	NN	O
of	IN	O
15	CD	O
%	NN	O
.	.	O

Scaling	VBG	O
clinical	JJ	O
judgments	NNS	O
of	IN	O
symptom	JJ	O
pathology	NN	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
psychophysiological	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

Summing	VBG	O
scores	NNS	O
across	IN	O
heterogeneous	JJ	O
symptom	NN	O
items	NNS	O
without	IN	O
consideration	NN	O
of	IN	O
their	PRP$	O
differing	JJ	O
psychopathological	JJ	O
significance	NN	O
has	VBZ	O
been	VBN	O
criticized	VBN	O
as	IN	O
producing	VBG	O
an	DT	O
inadequate	JJ	O
picture	NN	O
of	IN	O
an	DT	O
individual	NN	O
's	POS	O
clinical	JJ	O
status	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
derive	JJ	O
symptom	JJ	O
item	NN	O
weights	NNS	O
representing	VBG	O
clinically	RB	O
judged	VBN	O
seriousness	NN	O
of	IN	O
each	DT	O
symptom	NN	O
through	IN	O
the	DT	O
application	NN	O
of	IN	O
Steven	NNP	O
's	POS	O
psychophysical	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

A	DT	O
nationwide	JJ	O
sample	NN	O
of	IN	O
129	CD	O
clinicians	NNS	O
rated	VBD	O
the	DT	O
pathological	JJ	O
significance	NN	O
of	IN	O
221	CD	O
symptom	JJ	O
items	NNS	O
in	IN	O
a	DT	O
design	NN	O
such	JJ	O
that	IN	O
every	DT	O
rater	NN	O
rated	VBD	O
121	CD	O
items	NNS	O
,	,	O
21	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
by	IN	O
all	DT	O
raters	NNS	O
and	CC	O
100	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
only	RB	O
by	IN	O
the	DT	O
A	NNP	O
or	CC	O
B	NNP	O
subgroup	NN	O
to	TO	O
which	WDT	O
each	DT	O
rater	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

Each	DT	O
item	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
to	TO	O
the	DT	O
seriousness	NN	O
of	IN	O
the	DT	O
pathology	NN	O
it	PRP	O
would	MD	O
represent	VB	O
if	IN	O
manifested	VBN	O
by	IN	O
either	CC	O
a	DT	O
boy	NN	O
child	NN	O
,	,	O
girl	JJ	O
child	NN	O
,	,	O
boy	JJ	O
adolescent	NN	O
,	,	O
or	CC	O
girl	JJ	O
adolescent	NN	O
,	,	O
with	IN	O
one-fourth	NN	O
of	IN	O
the	DT	O
raters	NNS	O
assigned	VBD	O
to	TO	O
each	DT	O
condition	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
211	CD	O
two-way	JJ	O
analyses	NNS	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
age	NN	O
and	CC	O
age	NN	ME
and	CC	ME
sex	NN	ME
in	IN	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
sex	VB	O
alone	RB	O
,	,	O
significantly	RB	O
influenced	VBD	O
the	DT	O
clinical	JJ	O
ratings	NNS	O
.	.	O

The	DT	O
resulting	VBG	O
magnitude	JJ	ME
estimation	NN	ME
ratings	NNS	ME
of	IN	ME
symptom	JJ	ME
pathology	NN	ME
ranged	VBD	O
from	IN	O
1.0	CD	O
to	TO	O
9.9	CD	O
.	.	O

They	PRP	O
were	VBD	O
demonstrated	VBN	O
to	TO	O
have	VB	O
satisfactoy	VBN	O
reliability	NN	O
and	CC	O
convergent	NN	O
validity	NN	O
and	CC	O
to	TO	O
have	VB	O
the	DT	O
psychophysical	JJ	O
characteristics	NNS	O
of	IN	O
a	DT	O
prothetic	JJ	O
continuum	NN	O
.	.	O

Pethidine	NNP	O
versus	NN	O
tramadol	NN	O
for	IN	O
pain	NN	O
relief	NN	O
during	IN	O
labor	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
analgesic	JJ	Ot
efficacy	NN	Ot
and	CC	O
adverse	JJ	A
effects	NNS	A
of	IN	O
tramadol	NN	O
and	CC	O
pethidine	NN	O
in	IN	O
labor	NN	O
.	.	O

METHOD	NNP	O
Fifty-nine	NNP	O
full	JJ	O
term	NN	O
parturients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
in	IN	O
active	JJ	O
labor	NN	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
100	CD	O
mg	NNS	O
pethidine	VBP	O
;	:	O
group	NN	O
2	CD	O
,	,	O
100	CD	O
mg	NN	O
tramadol	NN	O
,	,	O
intramuscularly	RB	O
.	.	O

Analgesic	JJ	Ot
efficacy	NN	Ot
,	,	O
maternal	JJ	A
side	NN	A
effects	NNS	A
,	,	O
changes	NNS	PH
in	IN	PH
the	DT	PH
blood	NN	PH
pressure	NN	PH
,	,	O
heart	NN	PH
rate	NN	PH
,	,	O
and	CC	O
duration	NN	PH
of	IN	PH
labor	NN	PH
were	VBD	O
assessed	VBN	O
.	.	O

RESULT	NNP	O
At	IN	O
30	CD	O
and	CC	O
60	CD	O
min	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
pain	VBP	PA
relief	NN	PA
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
pethidine	NN	O
group	NN	O
than	IN	O
in	IN	O
tramadol	JJ	O
group	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	A
and	CC	A
fatigue	NN	A
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
tramadol	NN	O
group	NN	O
.	.	O

Following	VBG	O
drug	NN	O
administration	NN	O
the	DT	O
decrease	NN	PH
in	IN	PH
systolic	JJ	PH
and	CC	PH
diastolic	JJ	PH
blood	NN	PH
pressure	NN	PH
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
heart	NN	PH
rate	NN	PH
were	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
when	WRB	O
compared	VBN	O
for	IN	O
duration	NN	PH
of	IN	PH
labor	NN	PH
and	CC	PH
Apgar	NNP	PH
scores	NNS	PH
.	.	O

None	NN	O
of	IN	O
the	DT	O
neonates	NNS	O
developed	VBD	O
respiratory	JJ	PH
depression	NN	PH
.	.	O

CONCLUSION	NNP	O
Pethidine	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
better	RBR	O
alternative	JJ	O
than	IN	O
tramadol	NN	O
in	IN	O
obstetric	JJ	O
analgesia	NN	O
because	IN	O
of	IN	O
its	PRP$	O
superiority	NN	O
in	IN	O
analgesic	JJ	Ot
efficacy	NN	Ot
and	CC	O
low	JJ	O
incidence	NN	O
of	IN	O
maternal	JJ	A
side	NN	A
effects	NNS	A
.	.	O

Effects	NNS	O
of	IN	O
short-term	JJ	O
isotonic	JJ	O
&	CC	O
isometric	JJ	O
training	NN	O
on	IN	O
cardiovascular	JJ	PH
&	CC	PH
pulmonary	JJ	PH
function	NN	PH
.	.	PH

A	DT	O
randomised	JJ	O
control	NN	O
trial	NN	O
of	IN	O
short-term	JJ	O
exercises	NNS	O
on	IN	O
specific	JJ	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
parameters	NNS	O
was	VBD	O
undertaken	VBN	O
in	IN	O
normal	JJ	O
male	JJ	O
college	NN	O
students	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
isotonic	JJ	O
training	NN	O
(	(	O
5BX	CD	O
programme	NN	O
)	)	O
and	CC	O
isometric	JJ	O
training	NN	O
(	(	O
a	DT	O
programme	NN	O
of	IN	O
isometric	JJ	O
exercises	NNS	O
working	VBG	O
all	DT	O
major	JJ	O
groups	NNS	O
of	IN	O
muscles	NNS	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
with	IN	O
no	DT	O
specific	JJ	O
workout	NN	O
.	.	O

Both	DT	O
isotonic	JJ	O
and	CC	O
isometric	JJ	O
training	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	PH
cardiovascular	JJ	PH
improvement	NN	PH
but	CC	O
seemed	VBD	O
inadequate	JJ	O
to	TO	O
improve	VB	O
vital	JJ	PH
capacity	NN	PH
and	CC	PH
flow	NN	PH
rates	NNS	PH
.	.	PH

Isotonic	JJ	O
training	NN	O
in	IN	O
addition	NN	O
,	,	O
improved	JJ	O
ventilatory	NN	Ot
efficiency	NN	Ot
.	.	PH

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
such	JJ	O
isotonic	JJ	O
or	CC	O
isometric	JJ	O
training	NN	O
of	IN	O
thrice	NN	O
a	DT	O
week	NN	O
for	IN	O
ten	JJ	O
weeks	NNS	O
,	,	O
requiring	VBG	O
no	DT	O
equipment	NN	O
,	,	O
less	JJR	O
time	NN	O
and	CC	O
space	NN	O
can	MD	O
be	VB	O
promoted	VBN	O
to	TO	O
improve	VB	O
physical	JJ	PH
fitness	NN	PH
.	.	PH

Attenuation	NN	O
of	IN	O
hemodynamic	JJ	O
responses	NNS	O
to	TO	O
laryngoscopy	VB	O
and	CC	O
tracheal	VB	O
intubation	NN	O
during	IN	O
rapid	JJ	O
sequence	NN	O
induction	NN	O
:	:	O
remifentanil	NN	O
vs.	FW	O
lidocaine	NN	O
with	IN	O
esmolol	NN	O
.	.	O

AIM	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
remifentanil	NN	O
vs.	FW	O
a	DT	O
lidocaine-esmolol	JJ	O
combination	NN	O
in	IN	O
blunting	VBG	O
the	DT	O
hemodynamic	JJ	PH
response	NN	PH
to	TO	O
laryngoscopy	VB	O
and	CC	O
intubation	NN	O
during	IN	O
rapid	JJ	O
sequence	NN	O
induction	NN	O
using	VBG	O
thiopental	JJ	O
and	CC	O
rocuronium	NN	O
in	IN	O
normotensive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Sixty-six	JJ	O
patients	NNS	O
with	IN	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
(	(	O
ASA	NNP	O
)	)	O
physical	JJ	O
status	NN	O
class	NN	O
I	PRP	O
who	WP	O
required	VBD	O
tracheal	JJ	O
intubation	NN	O
for	IN	O
elective	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
R	NNP	O
received	VBD	O
0.9	CD	O
%	NN	O
saline	NN	O
10	CD	O
ml	NN	O
and	CC	O
remifentanil	VB	O
1	CD	O
microg/kg	NN	O
.	.	O

Group	NNP	O
LE	NNP	O
received	VBD	O
lidocaine	JJ	O
1.5	CD	O
mg/kg	NN	O
and	CC	O
esmolol	$	O
1.0	CD	O
mg/kg	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	O
sodium	NN	O
5	CD	O
mg/kg	NN	O
,	,	O
followed	VBN	O
by	IN	O
rocuronium	NN	O
1.0	CD	O
mg/kg	NN	O
.	.	O

Mean	NNP	PH
arterial	JJ	PH
pressure	NN	PH
and	CC	PH
heart	NN	PH
rate	NN	PH
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
induction	NN	O
,	,	O
immediately	RB	O
after	IN	O
intubation	NN	O
and	CC	O
every	DT	O
minute	NN	O
for	IN	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

RESULTS	NNP	O
Changes	NNP	O
in	IN	O
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
over	IN	PH
time	NN	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
maximum	JJ	PH
pressor	NN	PH
response	NN	PH
was	VBD	O
observed	VBN	O
immediately	RB	O
after	IN	O
intubation	NN	O
,	,	O
at	IN	O
which	WDT	O
time	NN	O
the	DT	O
mean	JJ	PH
arterial	JJ	PH
pressure	NN	PH
change	NN	PH
from	IN	O
baseline	NN	O
in	IN	O
group	NN	O
LE	NNP	O
(	(	O
29.7	CD	O
%	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
116.1	CD	O
,	,	O
121.9	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
R	NNP	O
(	(	O
4.4	CD	O
%	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
92.9	CD	O
,	,	O
98.5	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
R	NNP	O
and	CC	O
15	CD	O
patients	NNS	O
in	IN	O
group	NN	O
LE	NNP	O
developed	VBD	O
hypertension	NN	PH
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NN	O
:	:	O
0.064	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
heart	NN	PH
rate	NN	PH
over	IN	PH
time	NN	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P=0.465	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
remifentanil	VBZ	O
1	CD	O
mg/kg	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
combination	NN	O
of	IN	O
lidocaine	JJ	O
1.5	CD	O
mg/kg	NN	O
and	CC	O
esmolol	$	O
1	CD	O
mg/kg	NN	O
for	IN	O
attenuating	VBG	O
the	DT	O
hemodynamic	JJ	PH
responses	NNS	PH
to	TO	O
rapid	JJ	O
sequence	NN	O
intubation	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
dujieqing	VBG	O
oral	JJ	O
liquid	NN	O
on	IN	O
the	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
the	DT	O
MGMT	NNP	O
gene	NN	O
in	IN	O
middle-and-late	JJ	O
stage	NN	O
tumor	NN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effects	NNS	O
of	IN	O
Dujieqing	VBG	O
Oral	NNP	O
Liquid	NNP	O
(	(	O
DJQ	NNP	O
)	)	O
on	IN	O
the	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
the	DT	O
O6-methylguanine-DNA	JJ	O
methyltransferase	NN	O
(	(	O
MGMT	NNP	O
)	)	O
gene	NN	O
in	IN	O
the	DT	O
plasma	NN	O
DNA	NNP	O
samples	NNS	O
from	IN	O
middle-and-late	JJ	O
stage	NN	O
tumor	NN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
.	.	O

METHODS	NNP	O
Recruited	VBD	O
60	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
treated	VBN	O
by	IN	O
conventional	JJ	O
chemotherapy	NN	O
combined	VBN	O
DJQ	NNP	O
,	,	O
20	CD	O
mL	NN	O
each	DT	O
time	NN	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
treated	VBN	O
by	IN	O
chemotherapy	NN	O
alone	RB	O
)	)	O
,	,	O
30	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
therapeutic	JJ	O
course	NN	O
was	VBD	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
the	DT	O
MGMT	NNP	O
gene	NN	O
in	IN	O
the	DT	O
plasma	NN	O
DNA	NNP	O
samples	VBZ	O
form	VB	O
middle-and-late	JJ	O
stage	NN	O
tumor	NN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
was	VBD	O
detected	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
using	VBG	O
nested	JJ	O
methylation-specific	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
MSP	NNP	O
)	)	O
.	.	O

Meanwhile	RB	O
,	,	O
the	DT	O
peripheral	JJ	O
hemogram	NN	O
was	VBD	O
detected	VBN	O
.	.	O

The	DT	O
clinical	JJ	PH
efficacy	NN	PH
and	CC	PH
toxic/adverse	JJ	A
reactions	NNS	A
were	VBD	O
assessed	VBN	O
using	VBG	O
Karnofsky	NNP	O
performance	NN	O
scale	NN	O
(	(	O
KPS	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Results	NNP	O
of	IN	O
the	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
MGMT	NNP	O
genes	NNS	O
showed	VBD	O
that	IN	O
methylation	NN	O
rate	NN	O
was	VBD	O
20.00	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
46.67	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
before	RB	O
treatment	NN	O
,	,	O
the	DT	O
KPS	NNP	PH
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
after	IN	O
treatment	NN	O
,	,	O
while	IN	O
it	PRP	O
significantly	RB	O
decreased	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
after	IN	O
treatment	NN	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
statistical	JJ	O
difference	NN	O
in	IN	O
the	DT	O
KPS	NNP	PH
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
after	IN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
toxic/adverse	JJ	A
reactions	NNS	A
were	VBD	O
milder	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
DJQ	NNP	O
showed	VBD	O
efficiency	NN	O
synergism	NN	O
and	CC	O
toxicity	NN	O
reducing	NN	O
effects	NNS	O
,	,	O
but	CC	O
with	IN	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
hematopoietic	JJ	O
function	NN	O
of	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
.	.	O

MGMT	NNP	O
gene	NN	O
was	VBD	O
indicated	VBN	O
as	IN	O
DJQ	NNP	O
's	POS	O
target	NN	O
point	NN	O
for	IN	O
efficiency	NN	O
synergism	NN	O
and	CC	O
toxicity	NN	O
reducing	NN	O
.	.	O

The	DT	O
efficiency	NN	O
synergism	NN	O
and	CC	O
toxicity	NN	O
reducing	VBG	O
effects	NNS	O
were	VBD	O
achieved	VBN	O
by	IN	O
regulating	VBG	O
the	DT	O
activities	NNS	O
of	IN	O
MGMT	NNP	O
gene	NN	O
.	.	O

Effect	NN	O
of	IN	O
cervical	JJ	O
spine	NN	O
manipulative	JJ	O
therapy	NN	O
on	IN	O
judo	NN	O
athletes	NNS	O
'	POS	O
grip	NN	O
strength	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
perform	VB	O
an	DT	O
investigation	NN	O
evaluating	VBG	O
if	IN	O
cervical	JJ	O
spinal	JJ	O
manipulative	JJ	O
therapy	NN	O
(	(	O
SMT	NNP	O
)	)	O
can	MD	O
increase	VB	O
grip	JJ	O
strength	NN	O
on	IN	O
judo	NN	O
athletes	NNS	O
in	IN	O
a	DT	O
top	JJ	O
10	CD	O
national-ranked	JJ	O
team	NN	O
.	.	O

METHODS	VB	O
A	DT	O
single-blinded	JJ	O
,	,	O
prospective	JJ	O
,	,	O
comparative	JJ	O
,	,	O
pilot	NN	O
,	,	O
randomized	VBN	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
18	CD	O
athletes	NNS	O
of	IN	O
both	DT	O
sexes	NNS	O
from	IN	O
a	DT	O
judo	NN	O
team	NN	O
currently	RB	O
competing	VBG	O
on	IN	O
a	DT	O
national	JJ	O
level	NN	O
.	.	O

The	DT	O
athletes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
chiropractic	JJ	O
SMT	NNP	O
and	CC	O
sham	NN	O
.	.	O

Three	CD	O
interventions	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
of	IN	O
the	DT	O
athletes	NNS	O
at	IN	O
different	JJ	O
time	NN	O
points	NNS	O
.	.	O

Force	NN	O
measurements	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
a	DT	O
hydraulic	JJ	O
dynamometer	NN	O
immediately	RB	O
before	IN	O
and	CC	O
after	IN	O
each	DT	O
intervention	NN	O
at	IN	O
the	DT	O
same	JJ	O
period	NN	O
before	IN	O
training	VBG	O
up	RP	O
to	TO	O
3	CD	O
weeks	NNS	O
with	IN	O
at	IN	O
least	JJS	O
36	CD	O
hours	NNS	O
between	IN	O
interventions	NNS	O
.	.	O

RESULTS	NNP	O
Analysis	NNP	O
of	IN	O
grip	NN	PH
strength	NN	PH
data	NNS	Ot
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
strength	NN	Ot
within	IN	O
the	DT	O
treatment	NN	O
group	NN	O
after	IN	O
the	DT	O
first	JJ	O
intervention	NN	O
(	(	O
6.95	CD	O
%	NN	O
right	NN	O
,	,	O
12.61	CD	O
%	NN	O
left	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
second	JJ	O
(	(	O
11.53	CD	O
%	NN	O
right	NN	O
,	,	O
17.02	CD	O
%	NN	O
left	NN	O
)	)	O
and	CC	O
the	DT	O
third	JJ	O
interventions	NNS	O
(	(	O
10.53	CD	O
%	NN	O
right	NN	O
,	,	O
16.81	CD	O
%	NN	O
left	VBD	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
grip	JJ	Ot
strength	NN	Ot
comparison	NN	Ot
within	IN	O
the	DT	O
sham	NN	O
group	NN	O
.	.	O

Overall	JJ	O
differences	NNS	Ot
in	IN	Ot
strength	NN	PH
were	VBD	O
consistently	RB	O
significant	JJ	O
between	IN	O
the	DT	O
study	NN	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.0025	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
grip	NN	O
strength	NN	O
of	IN	O
national	JJ	O
level	NN	O
judo	NN	O
athletes	NNS	O
receiving	VBG	O
chiropractic	JJ	O
SMT	NNP	O
improved	VBD	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
sham	NN	O
.	.	O

Levobunolol	NNP	O
compared	VBN	O
with	IN	O
timolol	NN	O
:	:	O
a	DT	O
four-year	JJ	O
study	NN	O
.	.	O

Fifty-one	CD	O
patients	NNS	O
with	IN	O
raised	VBN	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
were	VBD	O
treated	VBN	O
for	IN	O
up	IN	O
to	TO	O
four	CD	O
years	NNS	O
with	IN	O
one	CD	O
of	IN	O
three	CD	O
ophthalmic	JJ	O
solutions	NNS	O
:	:	O
0.5	CD	O
%	NN	O
levobunolol	NN	O
,	,	O
1	CD	O
%	NN	O
levobunolol	NN	O
,	,	O
or	CC	O
0.5	CD	O
%	NN	O
timolol	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
as	IN	O
a	DT	O
double-masked	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
medications	NNS	O
were	VBD	O
administered	VBN	O
twice	RB	O
daily	RB	O
to	TO	O
both	DT	O
eyes	NNS	O
.	.	O

Levobunolol	NNP	O
and	CC	O
timolol	NN	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
overall	JJ	PH
mean	JJ	PH
IOP	NNP	PH
;	:	O
reductions	NNS	O
were	VBD	O
greater	JJR	O
than	IN	O
8.8	CD	O
mmHg	NNS	O
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
study	NN	O
showed	VBD	O
levobunolol	NNS	O
to	TO	O
be	VB	O
as	IN	O
safe	JJ	O
and	CC	O
effective	JJ	O
as	IN	O
timolol	NN	O
in	IN	O
the	DT	O
long-term	JJ	O
control	NN	O
of	IN	O
raised	VBN	O
IOP	NNP	PH
.	.	O

Acute	NNP	O
pressor	NN	O
and	CC	O
hormonal	JJ	O
effects	NNS	O
of	IN	O
beta-endorphin	NN	O
at	IN	O
high	JJ	O
doses	NNS	O
in	IN	O
healthy	JJ	O
and	CC	O
hypertensive	JJ	O
subjects	NNS	O
:	:	O
role	NN	O
of	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

CONTEXT	VB	O
The	DT	O
opioid	NN	O
system	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
regulation	NN	O
in	IN	O
both	DT	O
normal	JJ	O
humans	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high-dose	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	NN	O
,	,	O
an	DT	O
opioid	JJ	O
peptide	NN	O
,	,	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
on	IN	O
the	DT	O
hormonal	JJ	O
profile	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
and	CC	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
and	CC	O
the	DT	O
mediation	NN	O
played	VBN	O
by	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
randomized	VBN	O
double-blind	NN	O
design	NN	O
,	,	O
11	CD	O
healthy	JJ	O
subjects	NNS	O
(	(	O
controls	NNS	O
)	)	O
and	CC	O
12	CD	O
hypertensive	JJ	O
inpatients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
38.9	CD	O
and	CC	O
40.4	CD	O
yr	NN	O
,	,	O
respectively	RB	O
)	)	O
received	VBD	O
1-h	JJ	O
iv	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	JJ	O
(	(	O
250	CD	O
mug/h	NN	O
)	)	O
and	CC	O
,	,	O
on	IN	O
another	DT	O
occasion	NN	O
,	,	O
the	DT	O
same	JJ	O
infusion	NN	O
protocol	NN	O
preceded	VBN	O
by	IN	O
the	DT	O
opioid	JJ	O
antagonist	NN	O
naloxone	NN	O
(	(	O
8	CD	O
mg	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Hemodynamic	NNP	PH
and	CC	PH
hormonal	JJ	PH
measurements	NNS	PH
were	VBD	O
performed	VBN	O
at	IN	O
established	VBN	O
times	NNS	O
during	IN	O
the	DT	O
infusion	NN	O
protocols	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
circulating	VBG	PH
beta-endorphin	JJ	PH
,	,	PH
norepinephrine	JJ	PH
,	,	PH
and	CC	PH
endothelin-1	NN	PH
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

In	IN	O
controls	NNS	O
,	,	O
beta-endorphin	JJ	O
reduced	VBD	O
blood	NN	PH
pressure	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
circulating	VBG	PH
norepinephrine	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
and	CC	O
increased	VBD	O
plasma	JJ	PH
atrial	JJ	PH
natriuretic	JJ	PH
factor	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.003	CD	O
)	)	O
and	CC	O
GH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
hypertensive	JJ	O
patients	NNS	O
,	,	O
beta-endorphin	JJ	O
decreased	JJ	O
systemic	JJ	PH
vascular	NN	PH
resistance	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
blood	NN	PH
pressure	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
plasma	JJ	PH
norepinephrine	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
endothelin-1	JJ	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
raised	VBD	O
circulating	VBG	PH
atrial	JJ	PH
natriuretic	JJ	PH
factor	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
GH	NNP	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
IGF-I	NNP	PH
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

These	DT	O
hemodynamic	JJ	PH
and	CC	PH
hormonal	JJ	PH
responses	NNS	PH
to	TO	O
beta-endorphin	JJ	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
greater	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
but	CC	O
were	VBD	O
annulled	VBN	O
in	IN	O
all	DT	O
individuals	NNS	O
when	WRB	O
naloxone	NN	O
preceded	VBD	O
beta-endorphin	JJ	O
infusion	NN	O
.	.	O

CONCLUSIONS	NNP	O
High	NNP	O
doses	NNS	O
of	IN	O
beta-endorphin	JJ	O
induce	NN	O
hypotensive	NN	O
and	CC	O
beneficial	JJ	O
hormonal	JJ	O
effects	NNS	O
in	IN	O
humans	NNS	O
,	,	O
which	WDT	O
are	VBP	O
enhanced	VBN	O
in	IN	O
essential	JJ	O
hypertension	NN	O
and	CC	O
are	VBP	O
mediated	VBN	O
by	IN	O
opioid	JJ	O
receptors	NNS	O
.	.	O

Four-year	JJ	O
outcomes	NNS	O
from	IN	O
adolescent	JJ	O
alcohol	NN	O
and	CC	O
drug	NN	O
treatment	NN	O
.	.	O

OBJECTIVE	NNP	O
Knowledge	NNP	O
of	IN	O
treatment	NN	O
response	NN	O
for	IN	O
alcohol	NN	O
and	CC	O
drug	NN	O
problems	NNS	O
among	IN	O
adults	NNS	O
is	VBZ	O
mounting	VBG	O
;	:	O
less	CC	O
is	VBZ	O
known	VBN	O
about	IN	O
long-term	JJ	O
outcome	NN	O
for	IN	O
adolescents	NNS	O
who	WP	O
receive	VBP	O
treatment	NN	O
for	IN	O
alcohol	NN	O
and	CC	O
drug	NN	O
problems	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
examined	VBD	O
youth	JJR	O
substance	NN	O
involvement	NN	O
over	IN	O
4	CD	O
years	NNS	O
(	(	O
using	VBG	O
five	CD	O
waves	NNS	O
of	IN	O
data	NNS	O
collection	NN	O
)	)	O
following	VBG	O
treatment	NN	O
for	IN	O
alcohol	NN	O
and	CC	O
drug	NN	O
abuse	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
youth	NN	O
(	(	O
N	NNP	O
=	NNP	O
162	CD	O
,	,	O
60	CD	O
%	NN	O
male	NN	O
)	)	O
treated	VBD	O
during	IN	O
adolescence	NN	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
16	CD	O
years	NNS	O
)	)	O
was	VBD	O
followed	VBN	O
into	IN	O
young	JJ	O
adulthood	NN	O
,	,	O
a	DT	O
period	NN	O
associated	VBN	O
with	IN	O
stabilization	NN	O
of	IN	O
alcohol	NN	O
use	NN	O
patterns	NNS	O
and	CC	O
elevated	VBN	O
risk	NN	O
for	IN	O
life	NN	O
problems	NNS	O
secondary	JJ	O
to	TO	O
both	DT	O
alcohol	NN	O
and	CC	O
drug	NN	O
use	NN	O
.	.	O

Participants	NNS	O
(	(	O
14-18	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
consecutive	JJ	O
admissions	NNS	O
to	TO	O
inpatient	VB	O
adolescent	JJ	O
alcohol	NN	O
and	CC	O
drug	NN	O
treatment	NN	O
centers	NNS	O
in	IN	O
San	NNP	O
Diego	NNP	O
that	WDT	O
were	VBD	O
abstinence	NN	O
focused	VBN	O
and	CC	O
based	VBN	O
on	IN	O
the	DT	O
12-step	JJ	O
approach	NN	O
.	.	O

RESULTS	NNP	O
Alcohol	NNP	A
and	CC	A
other	JJ	A
drug	NN	A
use	NN	A
were	VBD	O
reduced	VBN	O
during	IN	O
the	DT	O
4	CD	O
years	NNS	O
posttreatment	JJ	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
nicotine	NN	O
.	.	O

The	DT	O
greatest	JJS	O
prevalence	NN	PH
reduction	NN	PH
occurred	VBD	O
for	IN	O
stimulants	NNS	O
;	:	O
modest	JJ	O
changes	NNS	O
were	VBD	O
evident	JJ	O
in	IN	O
alcohol	NN	O
and	CC	O
marijuana	NN	O
use	NN	O
.	.	O

Nicotine	NN	O
was	VBD	O
the	DT	O
most	RBS	O
commonly	RB	O
used	VBN	O
substance	NN	O
throughout	IN	O
the	DT	O
4	CD	O
years	NNS	O
after	IN	O
treatment	NN	O
.	.	O

Several	JJ	O
distinct	JJ	O
substance	NN	O
involvement	NN	O
trajectories	NNS	O
were	VBD	O
evident	JJ	O
during	IN	O
the	DT	O
4	CD	O
years	NNS	O
following	VBG	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Alcohol	NNP	O
and	CC	O
drug	NN	O
use	NN	O
patterns	NNS	O
during	IN	O
the	DT	O
4	CD	O
years	NNS	O
following	VBG	O
treatment	NN	O
highlight	VBD	O
both	DT	O
changes	NNS	O
and	CC	O
diversity	NN	O
in	IN	O
substance	NN	O
involvement	NN	O
as	IN	O
youth	NN	O
make	VBP	O
the	DT	O
transitions	NNS	O
from	IN	O
middle	JJ	O
to	TO	O
late	JJ	O
adolescence	NN	O
and	CC	O
into	IN	O
young	JJ	O
adulthood	NN	O
.	.	O

Findings	NNS	O
demonstrate	VBP	O
the	DT	O
importance	NN	O
of	IN	O
identifying	VBG	O
transitional	JJ	O
periods	NNS	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
alternative	JJ	O
intervention	NN	O
strategies	NNS	O
that	WDT	O
may	MD	O
help	VB	O
the	DT	O
progression	NN	O
of	IN	O
this	DT	O
population	NN	O
into	IN	O
young	JJ	O
adulthood	NN	O
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
's	POS	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

The	DT	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
is	VBZ	O
the	DT	O
largest	JJS	O
breast	NN	O
cancer	NN	O
prevention	NN	O
study	NN	O
ever	RB	O
undertaken	RB	O
.	.	O

Administered	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
,	,	O
it	PRP	O
is	VBZ	O
the	DT	O
first	JJ	O
trial	NN	O
seeking	VBG	O
to	TO	O
demonstrate	VB	O
whether	IN	O
a	DT	O
drug	NN	O
,	,	O
tamoxifen	NN	O
,	,	O
can	MD	O
prevent	VB	O
breast	NN	O
cancer	NN	O
in	IN	O
high-risk	JJ	O
women	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
trial	NN	O
are	VBP	O
to	TO	O
determine	VB	O
whether	IN	O
tamoxifen	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
1	CD	O
)	)	O
reducing	VBG	PH
the	DT	PH
incidence	NN	PH
of	IN	PH
invasive	JJ	PH
breast	NN	PH
cancer	NN	PH
,	,	O
2	CD	O
)	)	O
reducing	VBG	MO
breast	NN	MO
cancer	NN	MO
mortality	NN	MO
,	,	O
3	CD	O
)	)	O
reducing	VBG	MO
deaths	NNS	MO
from	IN	MO
cardiovascular	JJ	MO
disease	NN	MO
,	,	O
and	CC	O
4	CD	O
)	)	O
reducing	VBG	PH
bone	NN	PH
fractures	NNS	PH
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
study	NN	O
will	MD	O
evaluate	VB	O
side	NN	A
effects	NNS	A
,	,	O
toxicity	NN	MO
,	,	O
and	CC	O
the	DT	O
quality	NN	Ot
of	IN	Ot
life	NN	Ot
of	IN	O
all	DT	O
study	NN	O
participants	NNS	O
.	.	O

A	DT	O
good	JJ	O
response	NN	O
to	TO	O
oil	NN	O
with	IN	O
medium-	NN	O
and	CC	O
long-chain	JJ	O
fatty	JJ	O
acids	NNS	O
in	IN	O
body	NN	PH
fat	JJ	PH
and	CC	O
blood	NN	PH
lipid	JJ	PH
profiles	NNS	PH
of	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

A	DT	O
double	JJ	O
blind	NN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
clarify	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oil	NN	O
with	IN	O
medium-	NN	O
and	CC	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
MLCT	NNP	O
)	)	O
on	IN	O
body	NN	PH
fat	JJ	PH
and	CC	O
blood	NN	PH
lipid	JJ	PH
profiles	NNS	PH
in	IN	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

One-hundred-and-twelve	JJ	O
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
those	DT	O
that	IN	O
consumed	VBD	O
MLCT	NNP	O
oil	NN	O
and	CC	O
those	DT	O
that	WDT	O
consumed	VBD	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
LCT	NNP	O
)	)	O
oil	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
requested	VBN	O
to	TO	O
consume	VB	O
25-30	JJ	O
g	NN	O
of	IN	O
the	DT	O
oils	NNS	O
daily	RB	O
and	CC	O
maintain	VB	O
a	DT	O
fixed	JJ	O
level	NN	O
of	IN	O
energy	NN	O
intake	NN	O
and	CC	O
exercise	NN	O
.	.	O

Anthropometric	NNP	PH
and	CC	PH
blood	NN	PH
biochemical	JJ	PH
parameters	NNS	PH
were	VBD	O
measured	VBN	O
when	WRB	O
the	DT	O
study	NN	O
was	VBD	O
initiated	VBN	O
and	CC	O
completed	VBN	O
.	.	O

The	DT	O
LCT	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
50	CD	O
subjects	NNS	O
(	(	O
34	CD	O
men	NNS	O
and	CC	O
16	CD	O
women	NNS	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MLCT	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
51	CD	O
subjects	NNS	O
(	(	O
33	CD	O
men	NNS	O
and	CC	O
18	CD	O
women	NNS	O
)	)	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Larger	NNP	O
decreases	VBZ	O
in	IN	O
body	NN	PH
weight	NN	PH
,	,	PH
body	NN	PH
mass	NN	PH
index	NN	PH
,	,	PH
waist	NN	PH
circumference	NN	PH
,	,	PH
body	NN	PH
fat	NN	PH
,	,	PH
total	JJ	PH
fat	JJ	PH
area	NN	PH
and	CC	PH
subcutaneous	JJ	PH
fat	JJ	PH
area	NN	PH
in	IN	PH
the	DT	PH
abdomen	NNS	PH
and	CC	PH
serum	NN	PH
triglycerides	NNS	PH
,	,	PH
low-density	NN	PH
lipoprotein	NN	PH
cholesterol	NN	PH
,	,	PH
apolipoprotein	NN	PH
B	NNP	PH
,	,	PH
C2	NNP	PH
,	,	PH
C3	NNP	PH
and	CC	PH
E	NNP	PH
were	VBD	O
observed	VBN	O
in	IN	O
male	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
MLCT	NNP	O
group	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
LCT	NNP	O
group	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
these	DT	Ot
parameters	NNS	Ot
between	IN	O
the	DT	O
female	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
consumption	NN	O
of	IN	O
medium-and	JJ	O
long-chain	JJ	O
triglycerides	NNS	O
can	MD	O
reduce	VB	O
body	NN	PH
weight	NN	PH
and	CC	O
body	NN	PH
fat	NN	PH
and	CC	O
improve	VB	O
blood	NN	PH
lipid	JJ	PH
profiles	NNS	Ot
in	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
sequencing	NN	O
of	IN	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
after	IN	O
conservative	JJ	O
surgery	NN	O
for	IN	O
early-stage	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Patients	NNPS	O
with	IN	O
early-stage	JJ	O
breast	NN	O
cancer	NN	O
who	WP	O
are	VBP	O
at	IN	O
substantial	JJ	O
risk	NN	O
for	IN	O
systemic	JJ	O
metastases	NNS	O
are	VBP	O
increasingly	RB	O
treated	VBN	O
with	IN	O
breast-conserving	JJ	O
therapy	NN	O
and	CC	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
optimal	JJ	O
sequencing	NN	O
of	IN	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
is	VBZ	O
not	RB	O
clear	JJ	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
forty-four	JJ	O
patients	NNS	O
with	IN	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
breast	NN	O
cancer	NN	O
who	WP	O
were	VBD	O
at	IN	O
substantial	JJ	O
risk	NN	O
for	IN	O
distant	JJ	O
metastases	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
12-week	JJ	O
course	NN	O
of	IN	O
chemotherapy	NN	O
either	CC	O
before	IN	O
or	CC	O
after	IN	O
radiation	NN	O
therapy	NN	O
.	.	O

All	DT	O
had	VBD	O
had	VBN	O
breast-conserving	JJ	O
surgery	NN	O
.	.	O

The	DT	O
median	JJ	O
length	NN	O
of	IN	O
follow-up	NN	O
in	IN	O
surviving	VBG	O
patients	NNS	O
was	VBD	O
58	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
10	CD	O
to	TO	O
124	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
five-year	JJ	PH
actuarial	JJ	PH
rates	NNS	PH
of	IN	PH
cancer	NN	PH
recurrence	NN	PH
at	IN	O
any	DT	O
site	NN	O
and	CC	O
of	IN	O
distant	JJ	O
metastases	NNS	O
in	IN	O
the	DT	O
radiotherapy-first	JJ	O
group	NN	O
and	CC	O
the	DT	O
chemotherapy-first	JJ	O
group	NN	O
were	VBD	O
38	CD	O
percent	NN	O
and	CC	O
31	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.17	CD	O
)	)	O
and	CC	O
36	CD	O
percent	NN	O
and	CC	O
25	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Overall	JJ	MO
survival	NN	MO
was	VBD	O
73	CD	O
percent	NN	O
and	CC	O
81	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.11	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
five-year	JJ	PH
crude	NN	PH
rates	NNS	PH
of	IN	PH
first	JJ	PH
recurrence	NN	PH
according	VBG	O
to	TO	O
site	NN	O
in	IN	O
the	DT	O
radiotherapy-first	JJ	O
and	CC	O
chemotherapy-first	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
5	CD	O
percent	NN	O
and	CC	O
14	CD	O
percent	NN	O
for	IN	O
local	JJ	O
recurrence	NN	O
and	CC	O
32	CD	O
percent	NN	O
and	CC	O
20	CD	O
percent	NN	O
for	IN	O
distant	NN	O
or	CC	O
regional	JJ	O
recurrence	NN	O
or	CC	O
both	DT	O
.	.	O

This	DT	O
difference	NN	O
in	IN	O
the	DT	O
pattern	NN	PH
of	IN	PH
recurrence	NN	PH
was	VBD	O
of	IN	O
borderline	JJ	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
for	IN	O
patients	NNS	O
ar	VBP	O
substantial	JJ	O
risk	NN	O
for	IN	O
systemic	JJ	O
metastases	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
preferable	JJ	O
to	TO	O
give	VB	O
a	DT	O
12-week	JJ	O
course	NN	O
of	IN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiation	NN	O
therapy	NN	O
,	,	O
rather	RB	O
than	IN	O
radiation	NN	O
therapy	NN	O
followed	VBN	O
by	IN	O
chemotherapy	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	O
heel	NN	O
lifts	NNS	O
on	IN	O
Achilles	NNP	PH
tendon	NNP	PH
force	NN	PH
and	CC	PH
strain	NN	PH
during	IN	O
running	VBG	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	O
heel	NN	O
lifts	NNS	O
on	IN	O
Achilles	NNP	PH
tendon	NN	PH
(	(	PH
AT	NNP	PH
)	)	PH
force	NN	PH
and	CC	PH
strain	NN	PH
during	IN	O
running	VBG	O
.	.	O

Ten	CD	O
females	NNS	O
ran	VBD	O
barefoot	NN	O
over	IN	O
a	DT	O
force	NN	O
plate	NN	O
in	IN	O
three	CD	O
conditions	NNS	O
:	:	O
no	DT	O
heel	NN	O
lifts	NNS	O
(	(	O
NHL	NNP	O
)	)	O
,	,	O
with	IN	O
12	CD	O
mm	NNS	O
heel	JJ	O
lifts	NNS	O
(	(	O
12HL	CD	O
)	)	O
and	CC	O
with	IN	O
18	CD	O
mm	NNS	O
heel	JJ	O
lifts	NNS	O
(	(	O
18HL	CD	O
)	)	O
.	.	O

Kinematics	NNS	PH
for	IN	PH
the	DT	PH
right	JJ	PH
lower	JJR	PH
limb	NN	PH
were	VBD	O
collected	VBN	O
(	(	O
200	CD	O
Hz	NNP	O
)	)	O
.	.	O

AT	NNP	PH
force	NN	PH
was	VBD	O
calculated	VBN	O
from	IN	O
inverse	JJ	O
dynamics	NNS	O
.	.	O

AT	NNP	PH
strain	NN	PH
was	VBD	O
determined	VBN	O
from	IN	O
kinematics	NNS	O
and	CC	O
ultrasound	JJ	O
images	NNS	O
of	IN	O
medial	JJ	O
gastrocnemius	NN	O
(	(	O
50	CD	O
Hz	NNP	O
)	)	O
.	.	O

Peak	NNP	PH
AT	NNP	PH
strain	NN	PH
was	VBD	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
5.5	CD	O
?	.	O
4.4	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
7.4	CD	O
?	.	O
4.2	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
.029	NNP	O
,	,	O
effect	NN	O
size	NN	O
[	NNP	O
ES	NNP	O
]	NNP	O
=	NNP	O
0.44	CD	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
5.8	CD	O
?	.	O
4.8	CD	O
%	NN	O
)	)	O
versus	NN	O
NHL	NNP	O
(	(	O
ES	NNP	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
force	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
.024	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
2382	CD	O
?	.	O
717	CD	O
N	NNP	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
2710	CD	O
?	.	O
830	CD	O
N	NNP	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
2538	CD	O
?	.	O
823	CD	O
N	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

The	DT	O
18HL	CD	O
reduced	VBD	O
ankle	JJ	PH
dorsiflexion	NN	PH
but	CC	O
not	RB	O
flexion-extension	JJ	O
ankle	NN	O
moments	NNS	O
and	CC	O
increased	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
NHL	NNP	O
.	.	O

Thus	NNP	O
,	,	O
18HL	CD	O
reduced	VBN	O
force	NN	O
and	CC	O
strain	NN	O
on	IN	O
the	DT	O
AT	NNP	O
during	IN	O
running	VBG	O
via	IN	O
a	DT	O
reduction	NN	O
in	IN	O
dorsiflexion	NN	O
,	,	O
which	WDT	O
lengthened	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
.	.	O

Therefore	RB	O
,	,	O
heel	NN	O
lifts	NNS	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
reduce	VB	O
AT	NNP	O
loading	NN	O
and	CC	O
strain	NN	O
during	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
AT	NNP	O
injuries	NNS	O
.	.	O

Etanercept	NNP	O
treatment	NN	O
in	IN	O
adults	NNS	O
with	IN	O
established	VBN	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
7	CD	O
years	NNS	O
of	IN	O
clinical	JJ	O
experience	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
safety	NN	Ot
and	CC	O
efficacy	NN	Ot
of	IN	O
longterm	JJ	O
etanercept	FW	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
disease	NN	O
modifying	VBG	O
antirheumatic	JJ	O
drug	NN	O
(	(	O
DMARD	NNP	O
)	)	O
refractory	NN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Safety	NNP	O
results	NNS	O
are	VBP	O
reported	VBN	O
for	IN	O
714	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
etanercept	RB	O
in	IN	O
one	CD	O
of	IN	O
7	CD	O
initial	JJ	O
trials	NNS	O
or	CC	O
a	DT	O
longterm	JJ	O
extension	NN	O
.	.	O

Efficacy	NN	O
results	NNS	O
are	VBP	O
reported	VBN	O
for	IN	O
581	CD	O
patients	NNS	O
who	WP	O
enrolled	VBD	O
in	IN	O
the	DT	O
extension	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
714	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
trials	NNS	O
,	,	O
581	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
enrolled	VBN	O
in	IN	O
the	DT	O
extension	NN	O
,	,	O
and	CC	O
388	CD	O
(	(	O
54	CD	O
%	NN	O
)	)	O
patients	NNS	O
are	VBP	O
continuing	VBG	O
to	TO	O
receive	VB	O
etanercept	JJ	O
therapy	NN	O
.	.	O

The	DT	O
longest	JJS	O
individual	JJ	O
treatment	NN	O
was	VBD	O
8.2	CD	O
years	NNS	O
,	,	O
with	IN	O
3139	CD	O
total	JJ	O
patient-years	NNS	O
of	IN	O
etanercept	JJ	O
exposure	NN	O
.	.	O

Rates	NNS	A
of	IN	A
serious	JJ	A
adverse	JJ	A
events	NNS	A
(	(	O
overall	JJ	O
rate=14.8	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
serious	JJ	A
infections	NNS	A
(	(	O
overall	JJ	O
rate=4.2	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
cancer	NN	PH
(	(	O
overall	JJ	O
rate=1.0	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
and	CC	O
deaths	NNS	MO
(	(	O
overall	JJ	O
rate=0.7	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
were	VBD	O
stable	JJ	O
each	DT	O
year	NN	O
,	,	O
through	IN	O
8	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	O
exposure	NN	O
.	.	O

For	IN	O
356	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
6	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	O
treatment	NN	O
,	,	O
response	NN	Ot
rates	NNS	Ot
were	VBD	O
ACR20=73	NNP	O
%	NN	O
,	,	O
ACR50=52	NNP	O
%	NN	O
,	,	O
ACR70=27	NNP	O
%	NN	O
,	,	O
DAS28	NNP	O
CRP	NNP	O
good	JJ	O
response=52	NN	O
%	NN	O
,	,	O
and	CC	O
DAS28	NNP	O
CRP	NNP	O
remission=37	VBZ	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Similar	JJ	O
responses	NNS	O
occurred	VBD	O
in	IN	O
167	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
Year	NNP	O
7	CD	O
.	.	O

Doses	NNS	Ot
of	IN	O
concomitant	JJ	O
methotrexate	NN	O
or	CC	O
corticosteroids	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
many	JJ	O
patients	NNS	O
who	WP	O
maintained	VBD	O
clinical	JJ	O
responses	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
safety	NN	Ot
profile	NN	Ot
of	IN	O
etanercept	NN	O
was	VBD	O
consistent	JJ	O
over	IN	O
time	NN	O
,	,	O
with	IN	O
rates	NNS	A
of	IN	A
adverse	JJ	A
events	NNS	A
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
for	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
in	IN	O
general	JJ	O
.	.	O

Durable	JJ	O
clinical	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
for	IN	O
7	CD	O
years	NNS	O
or	CC	O
more	JJR	O
.	.	O

The	DT	O
benefit-to-risk	JJ	O
ratio	NN	O
for	IN	O
longterm	JJ	O
etanercept	JJ	O
treatment	NN	O
remains	VBZ	O
highly	RB	O
favorable	JJ	O
.	.	O

LEGO	NNP	O
therapy	NN	O
and	CC	O
the	DT	O
social	JJ	O
use	NN	O
of	IN	O
language	NN	O
programme	NN	O
:	:	O
an	DT	O
evaluation	NN	O
of	IN	O
two	CD	O
social	JJ	ME
skills	NNS	ME
interventions	NNS	O
for	IN	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
and	CC	O
Asperger	NNP	O
Syndrome	NNP	O
.	.	O

LEGO	NNP	O
therapy	NN	O
and	CC	O
the	DT	O
Social	NNP	O
Use	NNP	O
of	IN	O
Language	NNP	O
Programme	NNP	O
(	(	O
SULP	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
as	IN	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
for	IN	O
6-11	JJ	O
year	NN	O
olds	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
and	CC	O
Asperger	NNP	O
Syndrome	NNP	O
.	.	O

Children	NNP	O
were	VBD	O
matched	VBN	O
on	IN	O
CA	NNP	O
,	,	O
IQ	NNP	O
,	,	O
and	CC	O
autistic	JJ	O
symptoms	NNS	O
before	IN	O
being	VBG	O
randomly	RB	O
assigned	VBN	O
to	TO	O
LEGO	NNP	O
or	CC	O
SULP	NNP	O
.	.	O

Therapy	NNP	O
occurred	VBD	O
for	IN	O
1	CD	O
h/week	NN	O
over	IN	O
18	CD	O
weeks	NNS	O
.	.	O

A	DT	O
no-intervention	JJ	O
control	NN	O
group	NN	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
LEGO	NNP	O
therapy	NN	O
group	NN	O
improved	VBD	O
more	JJR	O
than	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
on	IN	O
autism-specific	JJ	ME
social	JJ	ME
interaction	NN	ME
scores	NNS	ME
(	(	ME
Gilliam	NNP	ME
Autism	NNP	ME
Rating	NNP	ME
Scale	NNP	ME
)	)	ME
.	.	O

Maladaptive	JJ	ME
behaviour	NN	ME
decreased	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
LEGO	NNP	O
and	CC	O
SULP	NNP	O
groups	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
non-significant	JJ	O
trend	NN	O
for	IN	O
SULP	NNP	O
and	CC	O
LEGO	NNP	O
groups	NNS	O
to	TO	O
improve	VB	O
more	JJR	O
than	IN	O
the	DT	O
no-intervention	JJ	O
group	NN	O
in	IN	O
communication	NN	ME
and	CC	ME
socialisation	NN	ME
skills	NNS	ME
.	.	O

[	JJ	O
Comparison	NNP	O
of	IN	O
fracture	NN	PH
resistance	NN	PH
of	IN	O
pulpless	NN	O
teeth	NNS	O
restored	VBD	O
with	IN	O
fiber	NN	O
reinforced	VBN	O
composite	JJ	O
posts	NNS	O
and	CC	O
three	CD	O
kinds	NNS	O
of	IN	O
resin	NN	O
core	NN	O
material	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
fracture	NN	PH
resistances	NNS	PH
of	IN	O
pulpless	NN	O
teeth	NNS	O
restored	VBD	O
with	IN	O
FRC	NNP	O
(	(	O
Fiber	NNP	O
Reinforced	NNP	O
Composite	NNP	O
)	)	O
posts	NNS	O
and	CC	O
three	CD	O
kinds	NNS	O
of	IN	O
resin	NN	O
core	NN	O
material	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
42	CD	O
recently	RB	O
extracted	VBN	O
upper	JJ	O
incisors	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
A	NNP	O
was	VBD	O
restored	VBN	O
with	IN	O
prefabricated	JJ	O
glass-fiber	JJ	O
posts	NNS	O
and	CC	O
Artglass	NNP	O
polymer	NN	O
core	NN	O
;	:	O
group	NN	O
B	NNP	O
with	IN	O
prefabricated	JJ	O
glass-fiber	JJ	O
posts	NNS	O
and	CC	O
Charisma	NNP	O
composite	JJ	O
resin	NN	O
core	NN	O
;	:	O
and	CC	O
group	NN	O
C	NNP	O
with	IN	O
prefabricated	JJ	O
glass-fiber	JJ	O
posts	NNS	O
and	CC	O
AB	NNP	O
composite	JJ	O
resin	NN	O
core	NN	O
.	.	O

In	IN	O
every	DT	O
group	NN	O
,	,	O
the	DT	O
core	NN	O
material	NN	O
was	VBD	O
processed	VBN	O
by	IN	O
hot-press	NN	O
and	CC	O
non	JJ	O
hot-press	NN	O
respectively	RB	O
.	.	O

The	DT	O
posts	NNS	O
size	NN	O
and	CC	O
shape	NN	O
were	VBD	O
identical	JJ	O
in	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

All	DT	O
teeth	NNS	O
were	VBD	O
fully	RB	O
covered	VBN	O
with	IN	O
polycarbonate	JJ	O
resin	NN	O
crowns	NNS	O
.	.	O

Fracture	NN	PH
resistance	NN	PH
was	VBD	O
measured	VBN	O
by	IN	O
applying	VBG	O
point	NN	O
force	NN	O
at	IN	O
130	CD	O
degrees	NNS	O
to	TO	O
the	DT	O
long	JJ	O
axis	NN	O
of	IN	O
the	DT	O
teeth	NN	O
on	IN	O
an	DT	O
universal	JJ	O
testing	NN	O
machine	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	PH
fracture	NN	PH
threshold	NN	PH
was	VBD	O
505.4	CD	O
N	NNP	O
+/-	JJ	O
42.0	CD	O
N	NNP	O
and	CC	O
564.1	CD	O
N	NNP	O
+/-	JJ	O
41.7	CD	O
N	NNP	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
411.3	CD	O
N	NNP	O
+/-	JJ	O
23.3	CD	O
N	NNP	O
and	CC	O
315.3	CD	O
N	NNP	O
+/-	JJ	O
19.1	CD	O
N	NNP	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
358.4	CD	O
N	NNP	O
+/-	JJ	O
36.1	CD	O
N	NNP	O
and	CC	O
423.4	CD	O
N	NNP	O
+/-	JJ	O
47.5	CD	O
N	NNP	O
in	IN	O
group	NN	O
C.	NNP	O
In	IN	O
all	DT	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	PH
posts	NNS	PH
fracture	NN	PH
and	CC	PH
polycarbonate	NN	PH
resin	NN	PH
crowns	NNS	PH
fragmentation	NN	PH
.	.	O

CONCLUSION	VB	O
The	DT	O
composite	JJ	O
restoration	NN	O
of	IN	O
FRC	NNP	O
posts	NNS	O
combined	VBD	O
with	IN	O
resin	NN	O
core	NN	O
and	CC	O
resin	VB	O
crown	NN	O
can	MD	O
improve	VB	O
the	DT	O
fracture	NN	PH
resistance	NN	PH
of	IN	O
the	DT	O
pulpless	JJ	O
roots	NNS	O
.	.	O

The	DT	O
strength	NN	O
of	IN	O
resin	NN	O
core	NN	O
material	NN	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
hot-press	JJ	O
methods	NNS	O
.	.	O

Warfarin	NNP	O
versus	NN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
thromboembolism	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
II	NNP	O
Study	NNP	O
.	.	O

Warfarin	NNP	O
is	VBZ	O
an	DT	O
established	JJ	O
treatment	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
value	NN	O
of	IN	O
this	DT	O
agent	JJ	O
relative	NN	O
to	TO	O
aspirin	VB	O
in	IN	O
unclear	JJ	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
(	(	O
SPAF-I	NNP	O
)	)	O
study	NN	O
,	,	O
direct	JJ	O
comparison	NN	O
of	IN	O
warfarin	NN	O
with	IN	O
aspirin	NN	O
was	VBD	O
limited	VBN	O
by	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
thromboembolic	JJ	O
events	NNS	O
.	.	O

SPAF-II	JJ	O
aims	NNS	O
to	TO	O
address	VB	O
this	DT	O
issue	NN	O
and	CC	O
also	RB	O
to	TO	O
assess	VB	O
the	DT	O
differential	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
according	VBG	O
to	TO	O
age	NN	O
.	.	O

We	PRP	O
compared	VBN	O
warfarin	NN	O
(	(	O
prothrombin	JJ	O
time	NN	O
ratio	JJ	O
1.3-1.8	JJ	O
,	,	O
international	JJ	O
normalised	JJ	O
ratio	NN	O
2.0-4.5	JJ	O
)	)	O
with	IN	O
aspirin	$	O
325	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
and	CC	O
systemic	JJ	O
embolism	NN	O
(	(	O
primary	JJ	O
events	NNS	O
)	)	O
in	IN	O
two	CD	O
parallel	NNS	O
randomised	VBD	O
trials	NNS	O
involving	VBG	O
715	CD	O
patients	NNS	O
aged	VBN	O
75	CD	O
years	NNS	O
or	CC	O
less	JJR	O
and	CC	O
385	CD	O
patients	NNS	O
older	JJR	O
than	IN	O
75	CD	O
;	:	O
we	PRP	O
sought	VBD	O
reductions	NNS	O
in	IN	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
warfarin	NNS	O
compared	VBN	O
with	IN	O
aspirin	NN	O
of	IN	O
2	CD	O
%	NN	O
per	IN	O
year	NN	O
and	CC	O
4	CD	O
%	NN	O
per	IN	O
year	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
younger	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	O
decreased	VBD	O
the	DT	O
absolute	JJ	PH
rate	NN	PH
of	IN	PH
primary	JJ	PH
events	NNS	PH
by	IN	O
0.7	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-0.4	NNP	O
to	TO	O
1.7	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	PH
event	NN	PH
rate	NN	PH
per	IN	PH
year	NN	PH
was	VBD	O
1.3	CD	O
%	NN	O
with	IN	O
warfarin	NN	O
and	CC	O
1.9	CD	O
%	NN	O
with	IN	O
aspirin	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
0.67	CD	O
,	,	O
p	NN	O
=	NNP	O
0.24	CD	O
)	)	O
.	.	O

The	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
in	IN	O
low-risk	JJ	O
younger	NN	O
patients	NNS	O
(	(	O
without	IN	O
hypertension	NN	O
,	,	O
recent	JJ	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
previous	JJ	O
thromboembolism	NN	O
)	)	O
on	IN	O
aspirin	NN	O
was	VBD	O
0.5	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.1	CD	O
to	TO	O
1.9	CD	O
)	)	O
.	.	O

Among	IN	O
older	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	O
decreased	VBD	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
1.2	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.7	NNP	O
to	TO	O
4.1	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
event	NN	O
rate	NN	O
per	IN	O
year	NN	O
was	VBD	O
3.6	CD	O
%	NN	O
with	IN	O
warfarin	NN	O
and	CC	O
4.8	CD	O
%	NN	O
with	IN	O
aspirin	NN	O
(	(	O
RR	NNP	O
0.73	CD	O
,	,	O
p	NN	O
=	NNP	O
0.39	CD	O
)	)	O
.	.	O

In	IN	O
this	DT	O
older	JJR	O
group	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
all	DT	O
stroke	NN	O
with	IN	O
residual	JJ	O
deficit	NN	O
(	(	O
ischaemic	JJ	O
or	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
4.3	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
aspirin	NN	O
and	CC	O
4.6	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
warfarin	NN	O
(	(	O
RR	NNP	O
1.1	CD	O
)	)	O
.	.	O

Warfarin	NNP	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
absolute	JJ	O
reduction	NN	O
in	IN	O
stroke	NN	O
rate	NN	O
by	IN	O
warfarin	NN	O
is	VBZ	O
small	JJ	O
.	.	O

Younger	JJR	O
patients	NNS	O
without	IN	O
risk	NN	O
factors	NNS	O
had	VBD	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
stroke	NN	O
when	WRB	O
treated	VBN	O
with	IN	O
aspirin	NN	O
.	.	O

In	IN	O
older	JJR	O
patients	NNS	O
the	DT	O
rate	NN	O
of	IN	O
stroke	NN	O
(	(	O
ischaemic	JJ	O
and	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
substantial	JJ	O
,	,	O
irrespective	NN	O
of	IN	O
which	WDT	O
agent	NN	O
was	VBD	O
given	VBN	O
.	.	O

Patient	JJ	O
age	NN	O
and	CC	O
the	DT	O
inherent	JJ	O
risk	NN	O
of	IN	O
thromboembolism	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
the	DT	O
choice	NN	O
of	IN	O
antithrombotic	JJ	O
prophylaxis	NN	O
for	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Effects	NNS	O
of	IN	O
an	DT	O
Internet-based	JJ	O
intervention	NN	O
on	IN	O
plasma	NNS	PH
glucose	JJ	PH
levels	NNS	PH
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

This	DT	O
study	NN	O
applied	VBD	O
a	DT	O
12-week	JJ	O
educational	JJ	O
intervention	NN	O
that	WDT	O
used	VBD	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
to	TO	O
send	VB	O
short	JJ	O
message	NN	O
service	NN	O
.	.	O

Forty-two	NNP	O
diabetic	JJ	O
patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
access	NN	O
a	DT	O
Web	NNP	O
site	NN	O
by	IN	O
using	VBG	O
a	DT	O
cellular	JJ	O
phone	NN	O
or	CC	O
wire	NN	O
Internet	NNP	O
and	CC	O
input	VB	O
their	PRP$	O
blood	NN	PH
glucose	NN	PH
levels	NNS	PH
every	DT	O
day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
sent	VBN	O
the	DT	O
optimal	JJ	O
recommendations	NNS	O
by	IN	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
28.6	CD	O
mg/dL	NNS	O
in	IN	O
fasting	VBG	PH
plasma	NN	PH
glucose	NN	PH
and	CC	O
78.4	CD	O
mg/dL	NN	O
in	IN	O
2-hour	JJ	PH
postprandial	JJ	PH
blood	NN	PH
sugar	NN	PH
levels	NNS	PH
and	CC	O
a	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
the	DT	O
care	NN	Ot
satisfaction	NN	Ot
score	NN	Ot
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
serologic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
and	CC	O
injectable	JJ	O
trivalent	NN	O
poliovirus	NN	O
vaccines	NNS	O
.	.	O

United	NNP	O
States	NNPS	O
children	NNS	O
two	CD	O
months	NNS	O
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
the	DT	O
commercially	RB	O
available	JJ	O
oral	JJ	O
trivalent	NN	O
poliovirus	NN	O
vaccine	NN	O
(	(	O
OPV	NNP	O
)	)	O
or	CC	O
an	DT	O
injectable	JJ	O
(	(	O
inactivated	VBN	O
)	)	O
trivalent	NN	O
poliovirus	NN	O
vaccine	NN	O
(	(	O
IPV	NNP	O
)	)	O
with	IN	O
a	DT	O
confirmed	JJ	O
minimum	JJ	O
D-antigen	NNP	O
content	NN	O
of	IN	O
27	CD	O
,	,	O
3.5	CD	O
,	,	O
and	CC	O
29	CD	O
units	NNS	O
for	IN	O
poliovirus	NN	O
types	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
.	.	O

Vaccine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
two	CD	O
,	,	O
four	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Sera	NN	O
obtained	VBN	O
from	IN	O
439	CD	O
children	NNS	O
at	IN	O
two	CD	O
,	,	O
four	CD	O
,	,	O
and	CC	O
six	CD	O
months	NNS	O
of	IN	O
age	NN	O
and	CC	O
from	IN	O
85	CD	O
children	NNS	O
at	IN	O
18	CD	O
and	CC	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
neutralizing	VBG	PH
antibodies	NNS	PH
.	.	O

The	DT	O
percentage	NN	PH
of	IN	PH
children	NNS	PH
with	IN	PH
detectable	JJ	PH
antibodies	NNS	PH
and	CC	PH
the	DT	PH
reciprocal	JJ	PH
geometric	JJ	PH
mean	NN	PH
titers	NNS	PH
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
at	IN	O
two	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

At	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
all	DT	O
children	NNS	O
but	CC	O
one	CD	O
had	VBD	O
detectable	JJ	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

Significantly	RB	O
higher	JJR	O
geometric	JJ	PH
mean	NN	PH
titers	NNS	PH
against	IN	PH
types	NNS	PH
2	CD	PH
and	CC	PH
3	CD	PH
were	VBD	O
noted	VBN	O
at	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
the	DT	O
IPV	NNP	O
group	NN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
L-carnosine	NNP	O
supplementation	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

L-Carnosine	NNP	O
,	,	O
a	DT	O
dipeptide	NN	O
,	,	O
can	MD	O
enhance	VB	O
frontal	JJ	O
lobe	NN	O
function	NN	O
or	CC	O
be	VB	O
neuroprotective	JJ	O
.	.	O

It	PRP	O
can	MD	O
also	RB	O
correlate	VB	O
with	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
-homocarnosine	NN	O
interaction	NN	O
,	,	O
with	IN	O
possible	JJ	O
anticonvulsive	JJ	O
effects	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
31	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blinded	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
800	CD	O
mg	JJ	O
L-carnosine	JJ	O
daily	NN	O
would	MD	O
result	VB	O
in	IN	O
observable	JJ	O
changes	NNS	O
versus	VBP	O
placebo	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
Childhood	NNP	PH
Autism	NNP	PH
Rating	NNP	PH
Scale	NNP	PH
,	,	PH
the	DT	PH
Gilliam	NNP	PH
Autism	NNP	PH
Rating	NNP	PH
Scale	NNP	PH
,	,	PH
the	DT	PH
Expressive	NNP	PH
and	CC	PH
Receptive	NNP	PH
One-Word	NNP	PH
Picture	NNP	PH
Vocabulary	NNP	PH
tests	NNS	PH
,	,	O
and	CC	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
of	IN	O
Change	NNP	O
.	.	O

Children	NNP	O
on	IN	O
placebo	NN	O
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
on	IN	O
L-carnosine	NNP	O
,	,	O
children	NNS	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
on	IN	O
the	DT	O
Gilliam	NNP	PH
Autism	NNP	PH
Rating	NNP	PH
Scale	NNP	PH
(	(	PH
total	JJ	PH
score	NN	PH
and	CC	PH
the	DT	PH
Behavior	NNP	PH
,	,	PH
Socialization	NNP	PH
,	,	PH
and	CC	PH
Communication	NNP	PH
subscales	NNS	PH
)	)	PH
and	CC	PH
the	DT	PH
Receptive	JJ	PH
One-Word	NNP	PH
Picture	NNP	PH
Vocabulary	NNP	PH
test	NN	PH
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Improved	VBN	O
trends	NNS	O
were	VBD	O
noted	VBN	O
on	IN	O
other	JJ	O
outcome	JJ	O
measures	NNS	O
.	.	O

Although	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
L-carnosine	NNP	O
is	VBZ	O
not	RB	O
well	RB	O
understood	RB	O
,	,	O
it	PRP	O
may	MD	O
enhance	VB	O
neurologic	JJ	O
function	NN	O
,	,	O
perhaps	RB	O
in	IN	O
the	DT	O
enterorhinal	JJ	O
or	CC	O
temporal	JJ	O
cortex	NN	O
.	.	O

An	DT	O
evaluation	NN	O
of	IN	O
chemical	JJ	O
arthrodesis	NN	O
of	IN	O
the	DT	O
proximal	JJ	O
interphalangeal	NN	O
joint	NN	O
in	IN	O
the	DT	O
horse	NN	O
by	IN	O
using	VBG	O
monoiodoacetate	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
monoiodoacetate	NN	O
(	(	O
MIA	NNP	O
)	)	O
for	IN	O
arthrodesis	NN	O
of	IN	O
the	DT	O
proximal	JJ	O
interphalangeal	NN	O
joint	NN	O
(	(	O
PIJ	NNP	O
)	)	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
on	IN	O
the	DT	O
degree	NN	O
of	IN	O
fusion	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

Eight	JJ	O
horses	NNS	O
received	VBD	O
3	CD	O
injections	NNS	O
(	(	O
Weeks	NNP	O
0	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
)	)	O
of	IN	O
MIA	NNP	O
(	(	O
2	CD	O
mL	NN	O
;	:	O
60	CD	O
mg/mL	NN	O
)	)	O
into	IN	O
the	DT	O
right	NN	O
or	CC	O
left	VBD	O
front	JJ	O
PIJ	NNP	O
.	.	O

Peri-operatively	RB	O
,	,	O
the	DT	O
horses	NNS	O
received	VBD	O
phenylbutazone	NN	O
,	,	O
butorphanol	NN	O
,	,	O
and	CC	O
abaxial	JJ	O
sesamoidean	NN	O
nerve	NN	O
blocks	NNS	O
to	TO	O
relieve	VB	O
pain	NN	O
.	.	O

During	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
horses	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
general	JJ	O
health	NN	O
,	,	O
lameness	NN	O
,	,	O
and	CC	O
swelling	VBG	O
around	IN	O
the	DT	O
injection	NN	O
area	NN	O
.	.	O

Radiographs	NNP	O
were	VBD	O
taken	VBN	O
biweekly	RB	O
to	TO	O
evaluate	VB	O
bony	NN	O
fusion	NN	O
.	.	O

Horses	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
non-exercised	JJ	O
and	CC	O
exercised	JJ	O
groups	NNS	O
.	.	O

Exercise	NNP	O
consisted	VBD	O
of	IN	O
20	CD	O
minutes	NNS	O
of	IN	O
trotting	VBG	O
on	IN	O
a	DT	O
treadmill	NN	O
(	(	O
4	CD	O
m/s	NN	O
)	)	O
,	,	O
3	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
13	CD	O
weeks	NNS	O
.	.	O

The	DT	O
horses	NNS	O
were	VBD	O
euthanized	VBN	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Slab	NNP	O
sections	NNS	O
of	IN	O
the	DT	O
PIJ	NNP	O
were	VBD	O
evaluated	VBN	O
grossly	RB	O
and	CC	O
radiographically	RB	O
for	IN	O
bony	NN	O
fusion	NN	O
.	.	O

Histologic	JJ	O
examinations	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
articular	JJ	O
cartilage	NN	O
.	.	O

Three	CD	O
horses	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
after	IN	O
developing	VBG	O
soft	JJ	O
tissue	NN	O
necrosis	NN	O
around	IN	O
the	DT	O
injection	NN	O
site	NN	O
,	,	O
septic	JJ	O
arthritis	NN	O
,	,	O
and	CC	O
necrotic	JJ	O
tendinitis	NN	O
.	.	O

The	DT	O
remaining	VBG	O
horses	NNS	O
remained	VBD	O
healthy	JJ	O
,	,	O
developed	VBD	O
a	DT	O
grade	NN	O
1	CD	O
to	TO	O
4	CD	O
lameness	NN	O
with	IN	O
minimal	JJ	O
to	TO	O
severe	VB	O
swelling	VBG	O
in	IN	O
the	DT	O
PIJ	NNP	O
region	NN	O
.	.	O

All	DT	O
5	CD	O
horses	NNS	O
showed	VBD	O
radiographic	JJ	PH
evidence	NN	PH
of	IN	PH
bony	NN	PH
fusion	NN	PH
,	,	O
however	RB	O
,	,	O
no	DT	O
fusion	NN	O
was	VBD	O
present	JJ	O
when	WRB	O
injected	JJ	O
joints	NNS	O
were	VBD	O
examined	VBN	O
on	IN	O
postmortem	NN	O
examination	NN	O
.	.	O

Histologic	NNP	PH
examination	NN	PH
revealed	VBD	PH
thinning	NN	PH
of	IN	PH
the	DT	PH
cartilage	NN	PH
,	,	PH
diffuse	VBP	PH
necrosis	NN	PH
of	IN	PH
chondrocytes	NNS	PH
,	,	PH
with	IN	PH
the	DT	PH
calcified	JJ	PH
zone	NN	PH
intact	JJ	PH
.	.	PH

Subjectively	RB	O
,	,	O
exercise	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
degree	NN	PH
of	IN	PH
cartilage	NN	PH
destruction	NN	PH
.	.	O

Based	VBN	O
on	IN	O
this	DT	O
study	NN	O
,	,	O
chemical	JJ	O
arthrodesis	NN	O
can	MD	O
not	RB	O
be	VB	O
advocated	VBN	O
in	IN	O
clinical	JJ	O
cases	NNS	O
because	IN	O
of	IN	O
the	DT	O
high	JJ	O
complication	NN	A
rate	NN	A
and	CC	O
lack	NN	O
of	IN	O
bony	NN	PH
fusion	NN	PH
.	.	O

Modest	NNP	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
epanolol	NN	O
,	,	O
a	DT	O
beta	NN	O
1-selective	JJ	O
receptor	NN	O
blocker	NN	O
with	IN	O
beta	NN	O
1	CD	O
agonist	NN	O
activity	NN	O
:	:	O
an	DT	O
acute	NN	O
and	CC	O
long-term	JJ	O
hemodynamic	NN	O
study	NN	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
and	CC	O
double	JJ	O
crossover	NN	O
comparison	NN	O
with	IN	O
atenolol	NN	O
on	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Beta-blockers	NNS	O
with	IN	O
less	JJR	O
cardiodepressive	JJ	O
effect	NN	O
than	IN	O
traditional	JJ	O
nonselective	JJ	O
beta	NN	O
(	(	O
1+2	CD	O
)	)	O
-blocking	VBG	O
agents	NNS	O
could	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
provided	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
was	VBD	O
satisfactory	JJ	O
.	.	O

Epanolol	NNP	O
,	,	O
a	DT	O
selective	JJ	O
beta	NN	O
1-receptor	JJ	O
blocker	NN	O
with	IN	O
intrinsic	JJ	O
sympathomimetic	JJ	O
activity	NN	O
,	,	O
induced	VBD	O
a	DT	O
fall	NN	O
in	IN	O
intraarterial	JJ	PH
pressure	NN	PH
of	IN	O
8	CD	O
%	NN	O
at	IN	O
rest	NN	O
sitting	VBG	O
and	CC	O
11	CD	O
%	NN	O
during	IN	O
100	CD	O
W	NNP	O
bicycle	NN	O
exercise	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Heart	NNP	PH
rate	NN	PH
,	,	PH
stroke	VBD	PH
index	NN	PH
,	,	PH
and	CC	PH
cardiac	JJ	PH
index	NN	PH
initially	RB	O
fell	VBD	O
by	IN	O
14	CD	O
%	NN	O
,	,	O
11	CD	O
%	NN	O
,	,	O
and	CC	O
23	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
total	JJ	PH
peripheral	JJ	PH
resistance	NN	PH
index	NN	PH
increased	VBD	O
by	IN	O
21	CD	O
%	NN	O
after	IN	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
then	RB	O
reverted	VBD	O
towards	IN	O
the	DT	O
pretreatment	NN	O
level	NN	O
.	.	O

After	IN	O
10	CD	O
months	NNS	O
of	IN	O
epanolol	JJ	O
treatment	NN	O
(	(	O
mean	JJ	O
300	CD	O
mg/day	NN	O
)	)	O
,	,	O
the	DT	O
reduction	NN	O
in	IN	O
arterial	JJ	PH
pressure	NN	PH
was	VBD	O
5	CD	O
%	NN	O
at	IN	O
rest	NN	O
and	CC	O
10	CD	O
%	NN	O
during	IN	O
exercise	NN	O
.	.	O

Cardiac	NNP	PH
index	NN	PH
and	CC	PH
heart	NN	PH
rate	NN	PH
were	VBD	O
still	RB	O
reduced	VBN	O
14-21	CD	O
%	NN	O
,	,	O
while	IN	O
total	JJ	PH
peripheral	JJ	PH
resistance	NN	PH
was	VBD	O
unchanged	JJ	O
or	CC	O
slightly	RB	O
increased	VBN	O
(	(	O
2-10	CD	O
%	NN	O
)	)	O
.	.	O

Twenty-four	JJ	PH
hour	NN	PH
ambulatory	NN	PH
blood	NN	PH
pressure	NN	PH
was	VBD	O
higher	JJR	O
on	IN	O
epanolol	NN	O
(	(	O
300	CD	O
mg/day	NN	O
)	)	O
than	IN	O
on	IN	O
atenolol	NN	O
(	(	O
150	CD	O
mg/day	NN	O
)	)	O
treatment	NN	O
(	(	O
137/97	CD	O
vs.	FW	O
128/91	CD	O
mmHg	NN	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
achieved	VBN	O
blood	NN	PH
pressure	NN	PH
reduction	NN	O
induced	VBN	O
by	IN	O
epanolol	NN	O
was	VBD	O
moderate	JJ	O
,	,	O
while	IN	O
other	JJ	O
characteristics	NNS	O
of	IN	O
beta-receptor	NN	O
blockade	NN	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
heart	NN	PH
rate	NN	PH
and	CC	PH
cardiac	JJ	PH
output	NN	PH
,	,	O
were	VBD	O
maintained	VBN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
compound	NN	O
may	MD	O
be	VB	O
useful	JJ	O
for	IN	O
other	JJ	O
cardiovascular	JJ	O
disorders	NNS	O
,	,	O
e.g.	NN	O
,	,	O
angina	JJ	O
pectoris	NN	O
in	IN	O
patients	NNS	O
without	IN	O
hypertension	NN	O
or	CC	O
cardiac	JJ	O
arrhythmia	NN	O
.	.	O

Assessment	NN	O
in	IN	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
autistic	JJ	PH
disorder	NN	PH
:	:	PH
the	DT	O
Autism	NNP	O
RUPP	NNP	O
Network	NNP	O
.	.	O

Research	NNP	O
Units	VBZ	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
.	.	O

Assessment	NNP	O
of	IN	O
autistic	JJ	PH
disorder	NN	PH
(	(	PH
autism	NN	PH
)	)	PH
symptoms	NNS	PH
,	,	PH
primary	JJ	PH
and	CC	PH
secondary	JJ	PH
,	,	O
poses	VBZ	O
more	RBR	O
challenging	JJ	O
problems	NNS	O
than	IN	O
ordinarily	RB	O
found	VBN	O
in	IN	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
assessments	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
subjects	NNS	O
may	MD	O
be	VB	O
uncommunicative	JJ	O
and	CC	O
extremely	RB	O
heterogeneous	JJ	O
in	IN	O
problem	NN	O
presentation	NN	O
,	,	O
and	CC	O
current	JJ	O
pharmacological	JJ	O
treatments	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
alter	VB	O
most	JJS	O
core	NN	O
features	NNS	O
of	IN	O
autism	NN	O
.	.	O

The	DT	O
Autism	NNP	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
Autism	NNP	O
Network	NNP	O
)	)	O
resolved	VBD	O
some	DT	O
of	IN	O
these	DT	O
problems	NNS	O
during	IN	O
the	DT	O
design	NN	O
of	IN	O
a	DT	O
risperidone	NN	O
RCT	NNP	O
in	IN	O
children/adolescents	NNS	O
.	.	O

The	DT	O
inappropriateness	NN	O
of	IN	O
the	DT	O
usual	JJ	O
anchors	NNS	O
for	IN	O
a	DT	O
Clinical	JJ	O
Global	NNP	O
Impression	NNP	O
of	IN	O
Severity	NNP	O
(	(	O
CGI-S	NNP	O
)	)	O
was	VBD	O
resolved	VBN	O
by	IN	O
defining	VBG	O
uncomplicated	JJ	O
autism	NN	O
without	IN	O
secondary	JJ	O
symptoms	NNS	O
as	IN	O
a	DT	O
CGI-S	NNP	O
of	IN	O
3	CD	O
,	,	O
mildly	RB	O
ill	JJ	O
.	.	O

The	DT	O
communication	NN	PH
problems	NNS	PH
,	,	O
compromising	VBG	O
use	NN	O
of	IN	O
the	DT	O
patient	NN	O
as	IN	O
an	DT	O
informant	NN	O
,	,	O
were	VBD	O
addressed	VBN	O
by	IN	O
several	JJ	O
strategies	NNS	O
,	,	O
including	VBG	O
careful	JJ	PH
questioning	NN	PH
of	IN	PH
care	NN	PH
providers	NNS	PH
,	,	PH
rating	NN	Ot
scales	NNS	Ot
,	,	PH
laboratory	NN	Ot
tests	NNS	Ot
,	,	O
and	CC	O
physical	JJ	Ot
exams	NN	Ot
.	.	Ot

The	DT	O
broad	JJ	O
subject	JJ	O
heterogeneity	NN	O
requires	VBZ	O
outcome	JJ	O
measures	NNS	O
sensitive	JJ	O
to	TO	O
individual	JJ	O
change	NN	O
over	IN	O
a	DT	O
wide	JJ	O
spectrum	NN	O
of	IN	O
treatment	NN	O
response	NN	Ot
and	CC	O
side	NN	A
effects	NNS	A
.	.	A

The	DT	O
problems	NNS	O
of	IN	O
neuropsychologically	RB	O
testing	VBG	O
nonverbal	JJ	O
,	,	O
lower	JJR	O
functioning	NN	O
,	,	O
sometimes	RB	O
noncompliant	JJ	O
subjects	NNS	O
requires	VBZ	O
careful	JJ	O
instrument	JJ	O
selection/adaptation	NN	O
and	CC	O
flexible	JJ	O
administration	NN	O
techniques	NNS	O
.	.	O

The	DT	O
problems	NNS	O
of	IN	O
assessing	VBG	O
low-end	JJ	PH
IQs	NNP	PH
,	,	O
neglected	VBN	O
by	IN	O
most	JJS	O
standardized	JJ	O
test	NN	O
developers	NNS	O
,	,	O
was	VBD	O
resolved	VBN	O
by	IN	O
an	DT	O
algorithm	NN	O
of	IN	O
test	NN	O
hierarchy	NN	O
.	.	O

Scarcity	NN	O
of	IN	O
other	JJ	O
autism-adapted	JJ	O
cognitive	NN	O
and	CC	O
neuropsychological	JJ	O
tests	NNS	O
and	CC	O
lack	NN	O
of	IN	O
standardization	NN	O
required	VBN	O
development	NN	O
of	IN	O
a	DT	O
new	JJ	O
,	,	O
specially	RB	O
adapted	VBN	O
battery	NN	O
.	.	O

Reliability	NN	O
on	IN	O
the	DT	O
Autism	NNP	PH
Diagnostic	NNP	PH
Interview	NNP	PH
(	(	O
currently	RB	O
the	DT	O
most	RBS	O
valid	JJ	O
diagnostic	JJ	O
instrument	NN	O
)	)	O
and	CC	O
other	JJ	O
clinician	JJ	O
instruments	NNS	O
required	VBN	O
extensive	JJ	O
cross-site	JJ	O
training	NN	O
(	(	O
in-person	JJ	O
,	,	O
videotape	NN	O
,	,	O
and	CC	O
teleconference	NN	O
sessions	NNS	O
)	)	O
.	.	O

Definition	NN	O
of	IN	O
a	DT	O
treatment	NN	O
responder	NN	O
required	VBN	O
focus	NN	O
on	IN	O
individually	RB	O
relevant	JJ	O
target	NN	O
symptoms	NNS	O
,	,	O
synthesis	NN	O
of	IN	O
possible	JJ	O
modest	JJ	O
improvements	NNS	O
in	IN	O
many	JJ	O
domains	NNS	O
,	,	O
and	CC	O
acceptance	NN	O
of	IN	O
attainable	JJ	O
though	IN	O
imperfect	JJ	O
goals	NNS	O
.	.	O

The	DT	O
assessment	NN	O
strategy	NN	O
developed	VBD	O
is	VBZ	O
implemented	VBN	O
in	IN	O
a	DT	O
RCT	NNP	O
of	IN	O
risperidone	NN	O
(	(	O
McDougle	NNP	O
et	RB	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
for	IN	O
which	WDT	O
the	DT	O
design	NN	O
and	CC	O
other	JJ	O
methodological	JJ	O
challenges	NNS	O
are	VBP	O
described	VBN	O
elsewhere	RB	O
(	(	O
Scahill	NNP	O
et	VBZ	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
problems	NNS	O
and	CC	O
solutions	NNS	O
are	VBP	O
partially	RB	O
shared	VBN	O
with	IN	O
RCTs	NNP	O
of	IN	O
other	JJ	O
treatments	NNS	O
and	CC	O
other	JJ	O
disorders	NNS	O
.	.	O

Dietary	NNP	O
lignan	NN	O
and	CC	O
proanthocyanidin	NN	O
consumption	NN	O
and	CC	O
colorectal	JJ	PH
adenoma	NN	PH
recurrence	NN	PH
in	IN	O
the	DT	O
Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

Lignans	NNPS	O
and	CC	O
proanthocyanidins	NNS	O
are	VBP	O
plant	NN	O
polyphenols	NNS	O
that	WDT	O
have	VBP	O
shown	VBN	O
protective	JJ	O
properties	NNS	O
against	IN	O
colorectal	JJ	PH
neoplasms	NNS	PH
in	IN	O
some	DT	O
human	JJ	O
studies	NNS	O
.	.	O

Using	VBG	O
logistic	JJ	O
regression	NN	O
,	,	O
we	PRP	O
estimated	VBD	O
odds	NNS	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
and	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
to	TO	O
prospectively	RB	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
lignan	NN	O
and	CC	O
proanthocyanidin	JJ	O
intake	NN	O
,	,	O
estimated	VBN	O
from	IN	O
databases	NNS	O
linked	VBN	O
to	TO	O
a	DT	O
food	NN	O
frequency	NN	O
questionnaire	NN	O
,	,	O
and	CC	O
adenoma	JJ	PH
recurrence	NN	PH
in	IN	O
1,859	CD	O
participants	NNS	O
of	IN	O
the	DT	O
Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

Overall	NNP	O
,	,	O
individual	NN	O
or	CC	O
total	JJ	O
lignans	NNS	O
or	CC	O
proanthocyanidins	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
colorectal	JJ	PH
adenoma	NN	PH
recurrence	NN	PH
.	.	O

However	RB	O
,	,	O
in	IN	O
sex-specific	JJ	O
analyses	NNS	O
,	,	O
total	JJ	O
lignan	JJ	O
intake	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
any	DT	O
adenoma	JJ	PH
recurrence	NN	PH
in	IN	O
women	NNS	O
(	(	O
highest	JJS	O
vs.	NN	O
lowest	JJS	O
lignan	JJ	O
intake	NN	O
quartile	NN	O
OR	NNP	O
=	VBZ	O
2.07	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.22-3.52	JJ	O
,	,	O
p	JJ	O
trend	NN	O
=	VBZ	O
0.004	CD	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
men	NNS	O
(	(	O
p	JJ	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

To	TO	O
conclude	VB	O
,	,	O
dietary	JJ	O
lignan	NN	O
and	CC	O
proanthocyanidin	NN	O
consumption	NN	O
were	VBD	O
not	RB	O
generally	RB	O
related	VBN	O
to	TO	O
colorectal	JJ	PH
adenoma	JJ	PH
recurrence	NN	PH
;	:	O
however	RB	O
,	,	O
high	JJ	O
lignan	NNS	O
intake	VBP	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	PH
of	IN	PH
adenoma	JJ	PH
recurrence	NN	PH
in	IN	O
women	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
analgesic	JJ	O
effect	NN	O
of	IN	O
locally	RB	O
and	CC	O
systemically	RB	O
administered	VBN	O
ketorolac	NN	O
in	IN	O
mastectomy	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Ketorolac	NNP	O
is	VBZ	O
a	DT	O
parenteral	JJ	O
nonsteroidal	JJ	O
antiinflammatory	JJ	O
drug	NN	O
(	(	O
NSAID	NNP	O
)	)	O
.	.	O

Two	CD	O
features	NNS	O
have	VBP	O
limited	VBN	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
:	:	O
tendency	NN	O
to	TO	O
elicit	VB	O
kidney	NN	O
failure	NN	O
and	CC	O
inability	NN	O
to	TO	O
produce	VB	O
complete	JJ	O
analgesia	NN	O
.	.	O

Because	IN	O
most	JJS	O
NSAIDs	NNP	O
are	VBP	O
weak	JJ	O
acids	NNS	O
(	(	O
pKa	IN	O
3-5	NNP	O
)	)	O
and	CC	O
become	VBN	O
concentrated	JJ	O
in	IN	O
acidic	JJ	O
tissues	NNS	O
,	,	O
such	JJ	O
as	IN	O
injured	JJ	O
and	CC	O
inflamed	JJ	O
tissues	NNS	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
local	JJ	O
administration	NN	O
may	MD	O
enhance	VB	O
its	PRP$	O
analgesic	JJ	O
efficacy	NN	O
while	IN	O
lowering	VBG	O
the	DT	O
potential	NN	O
for	IN	O
systemic	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
60	CD	O
group	NN	O
I-II	NNP	O
(	(	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiology	NNP	O
criteria	NNS	O
)	)	O
mastectomy	NN	O
patients	NNS	O
,	,	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Near	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
and	CC	O
every	DT	O
6	CD	O
h	NN	O
postoperatively	RB	O
,	,	O
20	CD	O
ml	NN	O
of	IN	O
the	DT	O
study	NN	O
solution	NN	O
containing	VBG	O
normal	JJ	O
saline	NN	O
with	IN	O
or	CC	O
without	IN	O
30	CD	O
mg	NN	O
of	IN	O
ketorolac	NN	O
were	VBD	O
administered	VBN	O
simultaneously	RB	O
either	CC	O
via	IN	O
a	DT	O
Jackson-Pratt	JJ	O
drain	NN	O
or	CC	O
intravenously	RB	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
.	.	O

The	DT	O
quality	NN	PH
of	IN	PH
pain	NN	PH
control	NN	PH
,	,	PH
the	DT	PH
amount	NN	PH
and	CC	PH
character	NN	PH
of	IN	PH
the	DT	PH
drain	NN	PH
fluid	NN	PH
,	,	PH
incidence	NN	PH
of	IN	PH
nausea	NN	PH
and	CC	PH
vomiting	NN	PH
,	,	PH
length	NN	PH
of	IN	PH
stay	NN	PH
in	IN	PH
the	DT	PH
postoperative	JJ	PH
care	NN	PH
unit	NN	PH
,	,	PH
and	CC	PH
amount	NN	PH
of	IN	PH
morphine	NN	PH
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
break-through	JJ	O
pain	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Intraoperative	NNP	O
administration	NN	O
of	IN	O
ketorolac	NN	O
resulted	VBD	O
in	IN	O
better	JJR	O
quality	NN	PA
of	IN	PA
pain	NN	PA
control	NN	PA
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
regardless	NN	O
of	IN	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
incidence	NN	PH
of	IN	PH
nausea	NN	PH
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
drain	NN	PH
output	NN	PH
in	IN	O
the	DT	O
ketorolac	NN	O
groups	NNS	O
did	VBD	O
not	RB	O
exceed	VB	O
the	DT	O
output	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Analgesic	NNP	O
of	IN	O
the	DT	O
locally	RB	O
administered	VBN	O
ketorolac	NN	O
is	VBZ	O
equally	RB	O
effective	JJ	Ot
to	TO	O
the	DT	O
efficacy	NN	Ot
of	IN	O
ketorolac	NN	O
administered	VBN	O
intravenously	RB	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
ketazolam	NN	O
,	,	O
diazepam	NN	O
and	CC	O
placebo	NN	O
in	IN	O
once-a-day	JJ	O
vs	NN	O
t.i.d	NN	O
.	.	O

dosing	VBG	O
.	.	O

Comparison	NNP	O
of	IN	O
ketazolam	NNP	O
given	VBN	O
once-a-day	JJ	O
with	IN	O
diazepam	NN	O
given	VBN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
and	CC	O
placebo	VB	O
given	VBN	O
either	DT	O
once	RB	O
or	CC	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
in	IN	O
101	CD	O
anxious	JJ	O
outpatients	NNS	O
showed	VBD	O
ketazolam	NNS	O
to	TO	O
be	VB	O
significantly	RB	O
better	JJR	O
than	IN	O
placebo	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
anxiety	NN	O
and	CC	O
,	,	O
on	IN	O
several	JJ	O
measures	NNS	O
of	IN	O
efficacy	NN	O
,	,	O
better	JJR	O
than	IN	O
diazepam	NN	O
as	IN	O
well	RB	O
.	.	O

Significantly	RB	O
fewer	JJR	O
patients	NNS	O
on	IN	O
ketazolam	NN	O
dropped	VBD	O
out	IN	O
of	IN	O
the	DT	O
study	NN	O
due	JJ	O
to	TO	O
ineffective	JJ	O
medication	NN	O
than	IN	O
on	IN	O
the	DT	O
other	JJ	O
3	CD	O
treatments	NNS	O
.	.	O

The	DT	O
incidence	NN	A
of	IN	A
side	NN	A
effects	NNS	A
was	VBD	A
lowest	JJS	A
in	IN	O
the	DT	O
ketazolam	NN	O
group	NN	O
.	.	O

Of	IN	O
particular	JJ	O
note	NN	O
,	,	O
drowsiness	NN	A
was	VBD	O
reported	VBN	O
twice	RB	O
as	RB	O
often	RB	O
by	IN	O
diazepam	JJ	O
patients	NNS	O
as	IN	O
by	IN	O
ketazolam	NN	O
patients	NNS	O
.	.	O

